[
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Practical-approaches-to-dose-selection-for-first-in-_2010_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20558225", "content": {"Compliance with ethical standards": "ICH, Addendum to ICH S6: Nonclinical Safety Evaluation of Biotechnology-derived Pharmaceuticals S6(R1) Current Step 2 Version http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM194490.pdf, 2009. Kelley, S.K. et al., 2006. Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non- human primates. Br. J. Pharmacol. 148, 1116\u20131123. http://www.ich.org/LOB/media/MEDIA503.pdf http://www.ich.org/LOB/media/MEDIA503.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM194490.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM194490.pdf http://www.vectibix.com Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals Introduction The building blocks of a FIH dose Overview Preclinical models of toxicity Pharmacokinetics/pharmacodynamics Determining the relevant toxicologic endpoints NOAEL and other toxicologic endpoints Pharmacologic endpoints", "Acknowledgement": "Scientists exploring new and creative treatments for disease have discovered promising new targets and therapies. These dis- coveries have extended the boundaries of our understanding of hu- man disease and its treatment, and the modulation of disease pathophysiology. As a result, we are embarking on a period of great hope in disease treatment, coupled with non-trivial risks as these newly discovered and sometimes only modestly well understood therapeutic agents reach FIH studies. As developers prepare for the conduct of clinical trials, their development of a sufficient de- gree of understanding of their therapeutic agent is critical to ensur- ing the safety of those who volunteer to be among the first to be administered a novel therapeutic. Acknowledgments The authors wish to express their sincere gratitude to the fol- lowing contributors for providing useful examples of the determi- nation of FIH doses: Tom Gelzleichter, Christopher J. Horvath, Amita Joshi, Theresa Reynolds, and Eric Stefanich. Appendix A. Supplementary data Acknowledgments Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Practical-considerations-for-developmental-thyroid-tox_2019_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31018155", "content": {"Acknowledgement": "Conclusions Acknowledgement Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Practical-issues-on-the-application-of-the-GHS-cla_2009_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19505521", "content": {"CoiStatement": "Examples of results on the selected chemicals and re-evaluation Acrylamide [79-06-1] (J-GHS ID 0001), Cat. 1B Acrylic acid [79-10-7] (J-GHS ID 0002), NC Acrylonitrile [107-13-1] (J-GHS ID 0003), Changed to NC from Cat. 2 Aniline [62-53-3] (J-GHS ID 0007), Cat. 2 Antimony hydride (Stibine) [7803-52-3] (J-GHS ID 0010), CNP Cadmium oxide [1306-19-0] (J-GHS ID 0015), Cat. 2 Vanadium (V) oxide [1314-62-1] (J-GHS ID 0026), 1B Phenol [108-95-2] (J-GHS ID 0061), Changed to Cat. 2 from Cat. 1B Formaldehyde [50-00-0] (J-GHS ID 0069), Cat. 2 o-Anisidine [90-04-0] (J-GHS ID 0083), Cat. 2 Glycidol [556-52-5] (J-GHS ID 0098), Cat. 2 Vinyl chloride [75-01-4] (J-GHS ID 0113), Cat. 2 1,4-Dioxane [123-91-1] (J-GHS ID 0125), NC 4,4'-Methylenebis(2-chloroaniline) [101-14-4] (J 3,3'-Dichlorobenzidine [91-94-1] (J-GHS ID 0138) Nitrilotriacetic acid [139-13-9] (J-GHS ID 0170), Changed to NC from Cat. 1B 1,3-Dibromopropane [109-64-8] (J-GHS ID 0539), CNP Ethanol [64-17-5] (J-GHS ID 0662), Changed to NC from Cat. 1B Sodium chlorite [7758-19-2] (J-GHS ID 1109), Changed to NC from Cat. 2 1-Chloro-2-nitrobenzene [88-73-3] (J-GHS ID 1184), Changed to CNP from Cat. 2 Issues identified in classification Sources of information on mutagenicity or genotoxicity of chemicals Expertise of Classifiers Expert judgment on data quality and weight of evidence Decision logic and practical decision tree Conclusions Conflict of interest statement Acknowledgment References", "Acknowledgement": "Examples of results on the selected chemicals and re-evaluation Acrylamide [79-06-1] (J-GHS ID 0001), Cat. 1B Acrylic acid [79-10-7] (J-GHS ID 0002), NC Acrylonitrile [107-13-1] (J-GHS ID 0003), Changed to NC from Cat. 2 Aniline [62-53-3] (J-GHS ID 0007), Cat. 2 Antimony hydride (Stibine) [7803-52-3] (J-GHS ID 0010), CNP Cadmium oxide [1306-19-0] (J-GHS ID 0015), Cat. 2 Vanadium (V) oxide [1314-62-1] (J-GHS ID 0026), 1B Phenol [108-95-2] (J-GHS ID 0061), Changed to Cat. 2 from Cat. 1B Formaldehyde [50-00-0] (J-GHS ID 0069), Cat. 2 o-Anisidine [90-04-0] (J-GHS ID 0083), Cat. 2 Glycidol [556-52-5] (J-GHS ID 0098), Cat. 2 Vinyl chloride [75-01-4] (J-GHS ID 0113), Cat. 2 1,4-Dioxane [123-91-1] (J-GHS ID 0125), NC 4,4'-Methylenebis(2-chloroaniline) [101-14-4] (J 3,3'-Dichlorobenzidine [91-94-1] (J-GHS ID 0138) Nitrilotriacetic acid [139-13-9] (J-GHS ID 0170), Changed to NC from Cat. 1B 1,3-Dibromopropane [109-64-8] (J-GHS ID 0539), CNP Ethanol [64-17-5] (J-GHS ID 0662), Changed to NC from Cat. 1B Sodium chlorite [7758-19-2] (J-GHS ID 1109), Changed to NC from Cat. 2 1-Chloro-2-nitrobenzene [88-73-3] (J-GHS ID 1184), Changed to CNP from Cat. 2 Issues identified in classification Sources of information on mutagenicity or genotoxicity of chemicals Expertise of Classifiers Expert judgment on data quality and weight of evidence Decision logic and practical decision tree Conclusions Conflict of interest statement Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Pre--and-Postnatal-Oral-Toxicity-of-Vinclozolin_2000_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/11029267", "content": {"Acknowledgement": "ACKNOWLEDGMENT We thank Dr. Rex FitzGerald, Rohr, Switzerland, for the prepara- tion of the manuscript. DISCUSSION AND CONCLUSIONS ACKNOWLEDGMENT REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Pre-and-post-intervention-study-of-antiblastic-drugs-contam_2018_Regulatory-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29510165", "content": {"CoiStatement": "Conflicts of interest Becton Dickinson, S.A.U covered the costs associated with the study through a non-restrictive research grant. Any author nor co-authors declare conflict of interest. Becton Dickinson, S.A.U covered the costs associated with the study through a non-restrictive research grant. Any author nor co-authors declare conflict of interest. Transparency document Discussion Conclusions Conflicts of interest Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Pre-bled-young-rats-in-genotoxicity-testing--A-mod_2008_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18721840", "content": {"Acknowledgement": "Acknowledgments We wish to acknowledge the financial assistance received from National Institute of Pharmacology and Toxicology (NIPER), SAS Nagar, for the above experimentation in the form of a Senior Re- search Fellowship (SRF) to A. Vikram and D.N. Tripathi. The authors are grateful to Prof. G.B. Gori for valuable editorial comments and to the anonymous reviewers for their critical suggestions to im- prove the interpretation of our findings and clarity in presentation. We also place on record the heartfelt gratitude to APL Research Centre, 93 Aurobindo Pharma Ltd., Hyderabad, India, for providing Zidovudine (AZT) as a gift sample. Discussion 5. AcknowledgementsAcknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Pre-clinical-in-vitro-and-in-vivo-safety-evaluat_2015_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26188118", "content": {"CoiStatement": "Conflicts of interest The authors declare that they have no conflict of interest. The authors declare that they have no conflict of interest. Acknowledgments 4. Discussion Conflicts of interest Acknowledgments Appendix A. Supplementary data Transparency document References", "Acknowledgement": "Acknowledgments This research was supported with a grant (08152MFDS428) from the Ministry of Food and Drug Safety. We thank Dr. Young Choong Kim at Seoul National University for kindly providing HPLC data for the CH extract. 4. Discussion Conflicts of interest Acknowledgments Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Pre-clinical-safety-evaluation-of-heat-shock-prot_2007_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/17600604", "content": {"Acknowledgement": "Acknowledgments We thank Nie Wen, Cairong Geng, Yufa Miao, Limei Cao and Hua Jiang for technical support and Lianzhong Shen for statistical analysis. This work is partly supported by grants from the Hi-Tech Research & Development Pro- gram of China (2002AA2Z342A, 2004AA2Z3771 and 2002aa214141). References Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Pre-clinical-safety-evaluation-of-the-synthetic-human-_2014_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24262411", "content": {"CoiStatement": "M. Coulet et al. / Regulatory Toxicology and Pharmacology 68 (2014) 59\u201369 69 followed by an adapted 90-day study, both in the juvenile rat, to address the main preclinical toxicological and tolerance concerns for synthetic oligosaccharides such as HMOs intended for infant nutrition use. Based on these studies, it is concluded that the chemically synthesized HMO, namely 20FL, is non-genotoxic. It is well tolerated and does not elicit any adverse effects in male and female rats following oral administration at dose levels up to 5000 mg/kg bw/day for exposure periods of up to 90 days from PND 7. This dose can be considered as the No Observed Adverse Ef- fect Level (NOAEL). This value is about 30 times higher than the anticipated exposure in the human newborn infant target population. Conflict of interest The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgments 4 Discussion 5 Conclusion Conflict of interest Acknowledgments References", "Acknowledgement": "Acknowledgments All studies were conducted at Wil Research Europe (Lyon, France), 329 Impasse du Domaine Rozier, Les Oncins, 69210 Saint Germain sur l\u2019Arbresle, France, and financed by Nestl\u00e9 Nutrition, Switzerland. The authors acknowledge Norbert Sprenger, Anne Constable and Ir\u00e8ne Perrin (Nestl\u00e9 Research Center), Dominique Brassard (Nestl\u00e9 Nutrition), Christoph R\u00f6hrig and Gyula Dekany (Glycom), Sharon Choi, Barry Lynch and Nigel Baldwin (Intertek Cantox) for their respective input and critical comments on the manuscript. Glycom A/S, partnership to Nestl\u00e9, is also acknowl- edged for providing the test material 20FL. 4 Discussion 5 Conclusion Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Pre-clinical-toxicity-evaluation-of-MB-102--a-novel-flu_2015_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25728979", "content": {"CoiStatement": "Further nonclinical testing related to biodistribution and devel- opmental toxicity will be performed following completion of the first-in-human clinical studies. Conflict of interest The authors declare that there is no conflict of interest. The authors declare that there is no conflict of interest. Acknowledgments 4 Discussion and conclusion Conflict of interest Acknowledgments References", "Acknowledgement": "Acknowledgments The authors thank Joanne M. McAndrews for editorial assistance. Early work by the staff of the Biological Sciences Department of Mallinckrodt Pharmaceuticals is also acknowledged. 4 Discussion and conclusion Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Pre-clinical-toxicokinetics-and-safety-study-of-M2ES-_2014_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24878240", "content": {"CoiStatement": "Conflict of interest The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgments 4 Discussion 5 Conclusions Conflict of interest Acknowledgments References", "Acknowledgement": "Acknowledgments This work was supported by the National Science & Technology Major Project 2009ZX09306-002; Major Scientific and Technologi- cal special project for \u2018\u2018significant new drugs creation\u201d 2009ZX09102-243; and Protgen Ltd. (Beijing, China). 4 Discussion 5 Conclusions Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Precision-of-Measurement-of-Tissue-Concent_2000_Regulatory-Toxicology-and-Ph.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/10806059", "content": {"Acknowledgement": "ACKNOWLEDGMENTS We thank all who participated in this multicompany study either in the production or in the measurement of the samples. We thank Ms. Sylvia Thaler for her assistance with data handling. DISCUSSION CONCLUSION ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Preclinical-Safety-Evaluation-of-Recombinant-_2002_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/11846636", "content": {"Acknowledgement": "ACKNOWLEDGMENTS The authors thank the many Schering-Plough colleagues who as- sisted in the conduct or analyses of one or more of the nonclinical studies. Individuals whose contributions were critical to the data and safety evaluations include G. Kaminska-McNamara, D. W. Frank, D. P. Sinha, and A. Fabry (Pathology); V. P. Meador (Clinical Pathol- ON, AND SCHMAHAI ogy); P. Statkevich, E. Radwanski, and N. Kishnani (Pharmacokinet- ics); S. Jacobs, S. Swanson, and S. Indelicato (Bioanalytical); M. Klein and R. Liu (Reproductive Toxicology); W. N. Choy (Genetic Toxicol- ogy); L. Roof (General Toxicology); and K. Pennline (FACS Analysis). The authors also thank Drs. Hugh Black and Robert Szot for their critical review of the manuscript. DISCUSSION ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Preclinical-assessment-of-abuse-liability-of-biologi_2015_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26107292", "content": {"CoiStatement": "6. Discussion Conflicts of interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Preclinical-assessment-of-the-abuse-potential-of-t_2017_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28279667", "content": {"Disclosure": "These studies were funded by Merck & Co., Inc., Kenilworth, NJ, USA. Authors and others employed by the sponsor contributed to study design, collection, analysis and interpretation of data; writing of the report; and in the decision to submit the article for publi- cation. All authors contributed to study conception, design, or planning; David V Gauvin and Suman Mukherjee acquired data; David V Gauvin, Suman Mukherjee, and Richard Briscoe analyzed data; David V Gauvin and Richard Briscoe interpreted the results. Stephanie Born, David V Gauvin and Richard Briscoe contributed to drafting themanuscript; all authors critically revised themanuscript for important intellectual content and approved the final version of the manuscript. Disclosure of interest This work was supported by Merck & Co., Inc., Kenilworth, NJ, USA. Stephanie Born, Suman Mukherjee, and Richard Briscoe are employees of Merck& Co., Inc., Kenilworth, NJ, USA, and own stock or stock options in the company. David V Gauvin is an employee of MPI Research and his contribution reflects work- product as an employee of the research laboratory. Authors employed by Merck & Co., Inc., Kenilworth, NJ, USA participated in the study design, collection, analysis and interpretation of data, writing of the report, and in the decision to submit the article for publication. Acknowledgments 4. Discussion 5. Conclusions Funding Role of the funding source Disclosure of interest Acknowledgments Transparency document References", "Funding": "Suvorexant did not cause significant behavioral or withdrawal- related changes in rats following chronic administration, did not elicit complete cross-generalization to either zolpidem or morphine in rats, and did not demonstrate any behavioral evidence of positive reinforcing efficacy in monkeys. Although not fully consistent in outcome with the clinical abuse liability study find- ings, the preclinical data, together with the clinical data, suggest that suvorexant will have relatively low abuse potential in humans. Based on the totality of the available data, its first-in-class status, and the other factors involved in the abuse liability risk assessment under the CSA, suvorexant is classified by the DEA as a Schedule IV drug, similar to the majority of other hypnotics approved for the treatment of insomnia. Funding This work was supported by Merck & Co., Inc., Kenilworth, NJ, USA. Role of the funding source This work was supported by Merck & Co., Inc., Kenilworth, NJ, USA. Role of the funding source These studies were funded by Merck & Co., Inc., Kenilworth, NJ, USA. Authors and others employed by the sponsor contributed to study design, collection, analysis and interpretation of data; writing of the report; and in the decision to submit the article for publi- cation. All authors contributed to study conception, design, or planning; David V Gauvin and Suman Mukherjee acquired data; David V Gauvin, Suman Mukherjee, and Richard Briscoe analyzed data; David V Gauvin and Richard Briscoe interpreted the results. Stephanie Born, David V Gauvin and Richard Briscoe contributed to drafting themanuscript; all authors critically revised themanuscript for important intellectual content and approved the final version of the manuscript. Disclosure of interest 4. Discussion 5. Conclusions Funding Role of the funding source Disclosure of interest Acknowledgments Transparency document References", "Acknowledgement": "This work was supported by Merck & Co., Inc., Kenilworth, NJ, USA. Stephanie Born, Suman Mukherjee, and Richard Briscoe are employees of Merck& Co., Inc., Kenilworth, NJ, USA, and own stock or stock options in the company. David V Gauvin is an employee of MPI Research and his contribution reflects work- product as an employee of the research laboratory. Authors employed by Merck & Co., Inc., Kenilworth, NJ, USA participated in the study design, collection, analysis and interpretation of data, writing of the report, and in the decision to submit the article for publication. Acknowledgments The authors are thankful for the assistance of Mr. Jeffrey Travis and Mr. Jude Ferraro as Study Monitors for the suvorexant abuse liability potential studies. Editorial assistance under the direction of the authors was provided by Gina Rocco, PhD, of Complete Medical Communications Inc., Hackensack, NJ, and Julie Adkins for Com- plete Medical Communications. This assistance was funded by Merck & Co., Inc., Kenilworth, NJ, USA. The authors are entirely responsible for the scientific content of the paper. Transparency document 4. Discussion 5. Conclusions Funding Role of the funding source Disclosure of interest Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Preclinical-pharmacokinetic--biodistribution--radiation-d_2020_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32006673", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper.", "Funding": "Funding body information This work was supported financially by Mazandaran University of Medical Sciences, Sari, Iran (Grant Number: 1155). Discussion Conclusion Funding body information mk:H1_24 Acknowledgments References", "Acknowledgement": "Acknowledgments This research was derived from a Ph.D. thesis submitted by Javad Biabani Ardakani as a student of Mazandaran University of Medical Sciences. Discussion Conclusion Funding body information mk:H1_24 Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Preclinical-safety-assessment-of-antipyrine-combin_2019_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30634025", "content": {"CoiStatement": "Conflicts of interest There is no conflict of interest. There is no conflict of interest. Acknowledgement Discussion Conclusion Conflicts of interest Acknowledgement Transparency document References", "Acknowledgement": "Acknowledgement This work was supported by the Chinese National Major Scientific and Technological Special Project for Significant New Drugs Development [grant numbers 2014ZX09J14103-05B]. Discussion Conclusion Conflicts of interest Acknowledgement Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Preclinical-safety-assessment-of-the-crude-extract-from-S_2021_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34139276", "content": {"CoiStatement": "4 Discussion 5 Conclusion Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgments Appendix A Supplementary data Abbreviations References", "Funding": "4 Discussion 5 Conclusion Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgments Appendix A Supplementary data Abbreviations References", "Acknowledgement": "4 Discussion 5 Conclusion Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgments Appendix A Supplementary data Abbreviations References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Preclinical-safety-evaluation-of-IQG-607-in-rats--_2017_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28232042", "content": {"Acknowledgement": "Acknowledgments This work was supported by Banco Nacional de Desenvolvi- mento Econo\u0302mico e Social (BNDES/FUNTEC) and National Institute of Science and Technology on Tuberculosis (Decit/SCTIE/MS-MCT- CNPq-FNDTC-CAPES), Brazil. Di\u00f3genes S Santos. and Luiz A Basso. also acknowledge grants awarded by FINEP and FAPERGS-CNPq-PRONEX-2009. Di\u00f3genes S Santos., Luiz A Basso., Jo\u00e3o B Calixto. andMaria M Campos. are research career awardees of the National Council for Scientific and Technological Development of Brazil (CNPq). V.R.-J. acknowledges a scholarship awarded by FAPERGS- CAPES (DOCFIX, 05/2013). We thank researchers from Laborat\ufffdorio de Farmacologia Experimental (LAFEX, UFSC) for technical assistance. 4. Discussion Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Preclinical-safety-evaluation-of-body-protective-com_2020_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32334036", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. Discussion Declaration of competing interest Supplementary data Funding body information References", "Funding": "Funding body information This work was supported by grants from the National Natural Science Foundation of China (No. 81672800; 81603009; 81673020; 31570168; 81802632) and Medical Science and Technology Youth Training Program (16QPN111) of China. Discussion Declaration of competing interest Supplementary data Funding body information References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Preclinical-safety-evaluation-of-nafithromycin--WCK_2021_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33587936", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 4 Discussion Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgement References", "Funding": "Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. CRediT authorship contribution statement 4 Discussion Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgement References", "Acknowledgement": "Acknowledgement We thank Sangita Gupta and Bhushan Choudhari for their assistance in the conduct of this study. 4 Discussion Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Preclinical-safety-evaluation-of-rAd5-hTERTC27_2013_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23827714", "content": {"CoiStatement": "Administration of rAd5-hTERTC27 was well tolerated when tested in an initial set of safety studies, although slight hematolog- ical change was observed in rats. Further studies will be conducted to assess more information on the potential toxicity, immunoge- nicity and distribution of rAd5-hTERTC27. Conflict of interest statement The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgments 4 Discussion 5 Conclusion Conflict of interest statement Acknowledgments Appendix A Supplementary data References", "Acknowledgement": "Acknowledgments This work was supported by National Natural Science Founda- tion of China (30973479 and 81272197, to Ying Peng), \u2018\u2018863\u2019\u2019 High Science & Technology Planning Project of China (2007AA021101, to Ying Peng) and International Collaboration Program of Universities in Guang- dong province (2012gjhz001 to Ying Peng). 4 Discussion 5 Conclusion Conflict of interest statement Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Preclinical-safety-evaluation-of-the-human-identic_2018_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30244042", "content": {"CoiStatement": "Conflicts of interest Kirt R. Phipps, Nigel Baldwin and Barry Lynch are employees of Intertek Scientific and Regulatory Consultancy (Intertek). Intertek has provided consultancy services to Glycom A/S. All studies were conducted at Envigo CRS Limited. Diane R. Stannard, Alica \u0160oltesov\u00e1 and Ben Gilby are employees of Envigo CRS Limited. Marta H. Mik\u0161 and Christoph H. R\u00f6hrig are employees of Glycom A/S, which provided the test item and sponsored the studies reported in this research article. Discussion Conflicts of interest Supplementary data Transparency document References", "Compliance with ethical standards": "OECD, 1998a. OECD Principles of Good Laboratory Practice. Organisation for Economic Co-Operation & Development (OECD), Environment Directorate, Chemicals Group and Management Committee, Paris, France Series on Principles of Good Laboratory Practice and Compliance Monitoring, no. 1 [ENV/MC/CHEM(98)17]. http://www. oecd-ilibrary.org/environment/oecd-principles-on-good-laboratory-practice_ 9789264078536-en. OECD, 1998b. Repeated dose 90-day oral toxicity study in rodents. In: OECD Guidelines for the Testing of Chemicals. Organisation for Economic Cooperation and Development (OECD), Paris, France OECD Guideline no 408 [Adopted 21st September 1998]. http://www.oecd-ilibrary.org/environment/test-no-408- repeated-dose-90-day-oral-toxicity-study-in-rodents_9789264070707-en;jsessionid= 6us5v4y2sxqn.x-oecd-live-03. U.S. FDA, 2006. Guidance for Industry: Nonclinical Safety Evaluation of Pediatric Drug Products. U.S. Food and Drug Administration (U.S. FDA), Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), Rockville, MD. https://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm079247.pdf. U.S. FDA, 2016a. Agency Response Letter GRAS Notice No. GRN 000650 [2'-o-fuco- syllactose, Glycom A/S]. U.S. Food and Drug Administration (U.S. FDA), Center for Food Safety & Applied Nutrition (CFSAN), Office of Food Additive Safety. http:// www.accessdata.fda.gov/scripts/fdcc/?set=GRASNotices&id=650. https://doi.org/10.1016/j.idairyj.2011.09.012 https://doi.org/10.1097/MPG.0000000000001274 http://whqlibdoc.who.int/publications/2007/9789241595230_eng.pdf https://doi.org/10.1038/srep38560 http://www.fao.org/3/a-at861e.pdf http://www.fao.org/3/a-at861e.pdf https://doi.org/10.1371/journal.pbio.1000412 https://doi.org/10.1097/MPG.0000000000001402 https://doi.org/10.1097/MPG.0000000000001402 https://doi.org/10.1016/0165-1161(83)90010-9 https://doi.org/10.1016/B978-0-12-802725-7.00014-2 http://refhub.elsevier.com/S0273-2300(18)30240-X/sref39 http://refhub.elsevier.com/S0273-2300(18)30240-X/sref39 http://www.pref.kagawa.lg.jp/yakumukansen/yakujinotice/listH24/161_241015.pdf http://www.pref.kagawa.lg.jp/yakumukansen/yakujinotice/listH24/161_241015.pdf https://doi.org/10.1126/science.aaf3951 http://refhub.elsevier.com/S0273-2300(18)30240-X/sref42 http://refhub.elsevier.com/S0273-2300(18)30240-X/sref42 http://refhub.elsevier.com/S0273-2300(18)30240-X/sref42 http://refhub.elsevier.com/S0273-2300(18)30240-X/sref42 https://doi.org/10.1016/0272-0590(88)90144-3 http://www.oecd-ilibrary.org/environment/test-no-471-bacterial-reverse-mutation-test_9789264071247-en;jsessionid=1ijgh8o34k0qd.delta http://www.oecd-ilibrary.org/environment/test-no-471-bacterial-reverse-mutation-test_9789264071247-en;jsessionid=1ijgh8o34k0qd.delta http://www.oecd-ilibrary.org/environment/test-no-471-bacterial-reverse-mutation-test_9789264071247-en;jsessionid=1ijgh8o34k0qd.delta http://www.oecd-ilibrary.org/environment/oecd-principles-on-good-laboratory-practice_9789264078536-en http://www.oecd-ilibrary.org/environment/oecd-principles-on-good-laboratory-practice_9789264078536-en http://www.oecd-ilibrary.org/environment/oecd-principles-on-good-laboratory-practice_9789264078536-en http://www.oecd-ilibrary.org/environment/test-no-408-repeated-dose-90-day-oral-toxicity-study-in-rodents_9789264070707-en;jsessionid=6us5v4y2sxqn.x-oecd-live-03 http://www.oecd-ilibrary.org/environment/test-no-408-repeated-dose-90-day-oral-toxicity-study-in-rodents_9789264070707-en;jsessionid=6us5v4y2sxqn.x-oecd-live-03 http://www.oecd-ilibrary.org/environment/test-no-408-repeated-dose-90-day-oral-toxicity-study-in-rodents_9789264070707-en;jsessionid=6us5v4y2sxqn.x-oecd-live-03 http://www.oecd-ilibrary.org/environment/test-no-487-in-vitro-mammalian-cell-micronucleus-test_9789264264861-en;jsessionid=58ip5ibjcf4kc.x-oecd-live-02 http://www.oecd-ilibrary.org/environment/test-no-487-in-vitro-mammalian-cell-micronucleus-test_9789264264861-en;jsessionid=58ip5ibjcf4kc.x-oecd-live-02 https://doi.org/10.1038/468S5a https://doi.org/10.1038/468S5a http://doi.org/10.1016/j.fct.2018.07.054 http://doi.org/10.3945/an.111.001594 http://doi.org/10.3945/an.111.001594 https://doi.org/10.1074/jbc.M113.484733 https://doi.org/10.1146/annurev-nutr-071813-105721 https://doi.org/10.1007/s00394-016-1180-6 https://doi.org/10.1007/s00394-016-1180-6 https://doi.org/10.1093/nutrit/nux044 https://doi.org/10.1093/nutrit/nux044 http://www.regulations.gov/#!documentDetail;D=EPA-HQ-OPPT-2009-0156-0018 http://www.regulations.gov/#!documentDetail;D=EPA-HQ-OPPT-2009-0156-0018 https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm078330.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm078330.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm078330.htm https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079247.pdf https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079247.pdf http://www.accessdata.fda.gov/scripts/fdcc/?set=GRASNotices&id=650 http://www.accessdata.fda.gov/scripts/fdcc/?set=GRASNotices&id=650 http://www.accessdata.fda.gov/scripts/fdcc/?set=GRASNotices&id=659 http://www.accessdata.fda.gov/scripts/fdcc/?set=GRASNotices&id=659 http://www.accessdata.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&id=650 http://www.accessdata.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&id=650 http://www.legislation.gov.uk/uksi/2004/994/pdfs/uksi_20040994_en.pdf http://www.legislation.gov.uk/uksi/2004/994/pdfs/uksi_20040994_en.pdf http://www.legislation.gov.uk/uksi/2012/3039/made http://www.legislation.gov.uk/uksi/2012/3039/made https://doi.org/10.3945/an.111.001412 https://www.ncbi.nlm.nih.gov/books/Nigel BaldwinK1908/ https://www.ncbi.nlm.nih.gov/books/Nigel BaldwinK1908/ https://doi.org/10.1371/journal.pone.0166070 https://doi.org/10.1371/journal.pone.0166070 https://doi.org/10.1016/s0140-6736(15)01024-7 https://doi.org/10.1038/nprot.2006.116 https://doi.org/10.1038/nprot.2006.116 https://doi.org/10.1016/j.febslet.2008.09.054 http://www.who.int/childgrowth/standards/weight_for_age/en/index.html http://www.who.int/childgrowth/standards/weight_for_age/en/index.html https://doi.org/10.2307/2528930 https://doi.org/10.2307/2528930 https://doi.org/10.2307/2556164 https://doi.org/10.1016/j.chembiol.2017.03.012 https://doi.org/10.1016/j.chembiol.2017.03.012 https://doi.org/10.12938/bifidus.29.23 Preclinical safety evaluation of the human-identical milk oligosaccharide lacto-N-tetraose Introduction Materials and methods Good laboratory practice and regulatory guidelines Test materials and chemicals Genotoxicity tests Bacterial reverse mutation test In vitro mammalian cell micronucleus test"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Preclinical-safety-evaluation-of-triacylglycerol-_2020_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31726192", "content": {"Funding": "Discussion Funding sources statement mk:H1_20 References", "Compliance with ethical standards": "OECD, 1997a. OECD Principles of Good laboratory Practice. In: Organisation for Economic Co-operation & Development (OECD), Environment Directorate, Chemicals Group and Management Committee OECD Environmental Health and Safety Publications, Paris, France. https://doi.org/10.1787/2077785x. Series on Principles of Good Laboratory Practice and Compliance Monitoring, no. 1 [ENV/MC/CHEM(98) 17], as revised in 1997. OECD, 1997b. Bacterial reverse mutation test. In: OECD Guidelines for the Testing of Chemicals. Organisation for Economic Co-operation and Development (OECD), vol. 471 OECD Guideline, Paris, France. https://doi.org/10.1787/20745788."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Preclinical-safety-of-recombinant-human-_2007_Regulatory-Toxicology-and-Phar.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16971028", "content": {"Acknowledgement": "Acknowledgments The authors gratefully acknowledge and thank Jan Ber- nal and David Moddrelle for performing the nonhuman primate surgeries; Tom Hastings, Lydia Andrews-Jones, and Patrick Lappin for their microscopic evaluation of tis- sues; Tazara Thomas, Cathy Nguyen, Zobair Musa, and GeoVrey del Rosario for directing the medical device stud- ies; Molly Bernard for assistance with the references; and Thomas Spiegelberg and David Adler for preparation of Wgures. Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Preclinical-screening-for-antidepressant-activity---shi_2021_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34245825", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 3 Conclusion and recommendations Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgements References", "Funding": "Funding body information There were no funding sources or sponsors for this work. There were no funding sources or sponsors for this work. CRediT authorship contribution statement 3 Conclusion and recommendations Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgements References", "Acknowledgement": "Acknowledgements This project was initiated by the Animals in Science Regulation Unit (ASRU) at the UK Home Office, who regulate the use of animals in research in the UK, after discussions with the Medicines and Healthcare products Regulatory Agency (MHRA), who regulate the safety, quality, effectiveness and performance of medicines and medical devices for the UK. ASRU joined multiple discussions on the topic, contributed to the writing and review of the final manuscript and support the recommen- dations and conclusions. We would also like to thank Professor Clare Stanford, University College London, Dr Sarah Bailey, University of Bath and Professor David Heal, DevelRx Ltd, for contributing to discussions on this topic, providing valuable insight and expertise. 3 Conclusion and recommendations Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Preclinical-toxicity-evaluation-of-JD5037--a-peripherally_2019_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31580887", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: R. Chorvat is an employee of Jenrin Discovery. JD5037 is being de- veloped by Corbus Pharmaceuticals that licensed the rights from Jenrin Discovery. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: R. Chorvat is an employee of Jenrin Discovery. JD5037 is being de- veloped by Corbus Pharmaceuticals that licensed the rights from Jenrin Discovery. Acknowledgements", "Disclosure": "Disclosure The abstract and poster of this research work have been presented at Society of Toxicology (2018) meeting. Discussion Conclusion Disclosure Funding body information mk:H1_54 Acknowledgements Supplementary data References", "Funding": "Funding body information This research project has been funded in whole with Federal funds Discussion Conclusion Disclosure Funding body information mk:H1_54 Acknowledgements Supplementary data References", "Acknowledgement": "Acknowledgements This research project has been funded in whole with Federal funds from the National Center for Advancing Translational Sciences, National Institutes of Health, USatheesh Anand (Contract No. HHSN261200800001E) under BrIDGs/NCATS program. The content of this publication does not necessarily reflect the views of policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. Discussion Conclusion Disclosure Funding body information mk:H1_54 Acknowledgements Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Preclinical-toxicity-of-DATR--a-recombinant-soluble_2011_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21856364", "content": {"CoiStatement": "Our findings indicate that the liver, kidneys and haematological system might be the toxic target effectors of DATR. The synergetic toxicity on these effectors should be considered carefully if DATR is used in combination with traditional chemotherapeutics. Conflict of interest There is no conflict of interest. Acknowledgements There is no conflict of interest. Acknowledgements This work was supported by grants from Chengdu Diao Pharma- ceutical Group Co., Ltd (Chengdu, China). We would like to thank Professor Yimin Dai for his excellent technical assistance with the histopathology analysis. References 4 Discussion Conflict of interest Acknowledgements References", "Acknowledgement": "There is no conflict of interest. Acknowledgements This work was supported by grants from Chengdu Diao Pharma- ceutical Group Co., Ltd (Chengdu, China). We would like to thank Professor Yimin Dai for his excellent technical assistance with the histopathology analysis. References 4 Discussion Conflict of interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Predicted-critical-environmental-concentration_2010_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20816909", "content": {"Acknowledgement": "Acknowledgments We thank the Foundation for Strategic Environmental Research (MISTRA) and the Swedish Research Council (VR) for financial support. Predicted critical environmental concentrations for 500 pharmaceuticals Introduction Materials and methods Results and discussion Conclusions Acknowledgments Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Predicting-blood-air-partition-coefficients-usin_2012_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22178169", "content": {"CoiStatement": "Concluding, the three-parameter human model Log(PBA) = 6.96 \ufffd 1.04 Log(VP) \ufffd 0.533 Log(KOW) \ufffd 0.00495 MW and the three-parameter rat model 6.16 \ufffd 0.888 Log(VP) \ufffd 0.521 Log(KOW) \ufffd 0.00201 MW provide robust and reliable models for predicting PBA values of volatile organic chemicals using com- monly available chemical properties of molecules. Conflict of interest statement None of the authors have any conflicts of interest with respect to the content of this article. None of the authors have any conflicts of interest with respect to the content of this article. Acknowledgments 3 Results 4 Discussion and conclusions Conflict of interest statement Acknowledgments Appendix A Supplementary data References", "Acknowledgement": "Acknowledgments The authors thank their colleagues Jack Vogels and Bianca van der Werff for the statistical analysis of our data. The financial sup- port of the Dutch Ministry of Social Affairs and Employment for the research reported in this manuscript is gratefully acknowledged. Appendix A. Supplementary data 3 Results 4 Discussion and conclusions Conflict of interest statement Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Predicting-estrogen-receptor-activation-by-a-group-of-s_2019_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31121201", "content": {"CoiStatement": "Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Appendix A. Supplementary data Funding sources Funding body information, RTP-19-39 Declaration of interests Supplementary data Transparency document References", "Funding": "Funding sources Prachi Pradeep is funded by Participation Program at the Office of Research and Development, U.S. Environmental Protection Agency, administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and EPA. Funding body information, RTP-19-39 This work was supported in part by an appointment to the ORISE participant research program supported by an interagency agreement between the U.S. EPA and U. S. Department of Energy (DOE). Funding sources Funding body information, RTP-19-39 Declaration of interests Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Prediction-of-Local-Irritant-Effects-after-Repeated_2002_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/12473410", "content": {"Acknowledgement": "ACKirsti NordheimOWLEDGMENTS The authors gratefully acknowledge Peter M. J. Bos (TNO Chem- istry) for reviewing this article. The work was funded by the Dutch Ministry of Social Affairs and Employment (SZW). More details on the analysis are described in TNO Report V98.1267 (Prediction of Local Effects upon Dermal and Respiratory Repeated exposure to Chemicals by M. A. J. Rennen, C. de Heer, and G. F. Houben, Zeist, The Netherlands, November 1999). This report is available on request. ACKirsti NordheimOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Prediction-of-carcinogenic-potential-of-chemicals-_2016_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27614137", "content": {"Acknowledgement": "Acknowledgements The present study was part of the SLiM project (\u201ca smart way from innovations to humans\u201d) sponsored by the Dutch Govern- ment, Dept Economical Affairs, The Utrecht Province and the Utrecht City Administration (PID101063). Acknowledgements Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Prediction-of-drug-related-cardiac-adverse-effects-in-h_2010_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19941924", "content": {"Acknowledgement": "The investigation is ongoing, and there are plans to develop QSAR models for more human organ systems. It is expected that the models for drug-related AEs in humans will be tools that help the Federal regulatory process and the private sector. Pharmaceu- tical companies will be able to use the battery of QSAR models to make better decisions in their lead selection and drug discovery applications. FDA can use the models to provide decision support information for regulatory decisions. In turn, this may help shorten the drug approval process\u2014as noted in FDA\u2019s Critical Path Initia- tive (http://www.fda.gov/oc/initiatives/criticalpath/initiative.html)\u2014 and decrease the chances of AEs in the next generation of approved drug products. A more comprehensive list of possible applications of this in silico technology has been reported (Ursem et al., 2009; Matthews et al., 2009a,b). These reports also discuss a two-phase process that ICSAS is implementing for this in silico technology. The first phase is to develop specific global QSAR and expert sys- tem methodologies that offer rapid and reliable decision support information to meet regulatory and research needs, and in turn make these tools available to the scientific community. FDA needs in silico tools to provide a dossier of decision support information on both chemical toxicities for endpoints that cannot be addressed in humans (carcinogenicity, genetic toxicity, and reproductive and developmental toxicity; Matthews et al., 2006a,b, 2007a,b, 2009a), as well as adverse effects of chemicals in humans that are detected in clinical trials and post-market surveillance databases (Matthews et al., 2009a,b). Version two of the tools will become available as data are harvested from FDA and EPA archives, data sharing efforts with other agencies are implemented, and the training data sets of the in silico tools are enhanced and validated. The second phase is to introduce, educate, and build consensus support within the sci- entific community for this new global QSAR and expert system testing paradigm\u2014a process that FDA is currently involved in. Once in place, these in silico methods will be performed as a means of reducing, replacing, or refining longer, more expensive testing. Acknowledgements The research described in this investigation would not have been possible without the extensive contributions made by our FDA CRADA partner and MTA collaborators. We gratefully recog- nize the computer programming assistance of Dr. Julian Ivanov (Multicase, Inc.) and David Aragon\u00e9s Sabat\u00e9 (Prous Institute for Biomedical Research), whose contributions were critical to the conduct of this investigation. ICSAS members Dan Benz, Naomi Kruhlak, Luis Valerio, Tyna Dao, and Will Liu are also acknowl- edged for their valuable input and support over the course of this investigation. References Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Prediction-of-drug-related-cardiac-adverse-effects-in-hum_2010_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19932726", "content": {"Acknowledgement": "Acknowledgments The research described in this investigation would not have been possible without the extensive contributions made by FDA CRADA partners and MTA collaborators. We gratefully recognize the computer programming assistance of David Aragon\u00e9s Sabat\u00e9 (Prous Institute for Biomedical Research), whose contributions were critical to the conduct of this investigation. We also thank Lisa Choe and Annie Yang for extraction of AE data; Barbara Min- nier for curation of chemical structures; Carling Ursem for the pre- liminary analyses of cardiac AE data. ICSAS members Dan Benz, Naomi Kruhlak, Luis Valerio, Tyna Dao and Will Liu are also acknowledged for their valuable input and support over the course of this investigation. Lastly, the authors thank the developers of the many referenced data sources utilized in this investigation. Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Prediction-of-tissue-concentrations-of-monoclonal-_2018_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29894734", "content": {"CoiStatement": "Conflict of interest The authors have no conflict of interest. The authors have no conflict of interest. I. Mahmood, M.A. Tegenge Regulatory Toxicology and Pharmacology 97 (2018) 57\u201362 Discussion Conclusions Conflict of interest Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Predictive-models-for-nanotoxicology--Current-ch_2011_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21310205", "content": {"CoiStatement": "Predictive models for nanotoxicology: Current challenges and future opportunities Conflict of Interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Preliminary-evaluation-of-the-human-relevance-of-resp_2012_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22342949", "content": {"CoiStatement": "Conflict of interest This manuscript was sponsored, in part, by the Naphthalene Re- search Committee (NRC) and ExxonMobil. Organizations in the NRC comprise the Asphalt Institute, Association of American Rail- roads, American Petroleum Institute, Flint Hills Resources, Naph- thalene Council and Utilities Solid Waste Activities Group. Authors M.G. Bird, R.J. Lewis, and W.J. Bover are employed by ExxonMobil Biomedical Sciences, Inc., a wholly owned subsidiary of Exxon Mobil Corporation (Note: M.G. Bird retired as of Septem- ber 1, 2011). V.J. Piccirillo is an independent consultant, but as sci- ence advisory to the NRC receives funding from that organization. The authors take sole responsibility for the writing and content of the paper. 4 Validation of HRF assessment 5 Summary and conclusions Conflict of interest Acknowledgments References", "Funding": "This manuscript was sponsored, in part, by the Naphthalene Re- search Committee (NRC) and ExxonMobil. Organizations in the NRC comprise the Asphalt Institute, Association of American Rail- roads, American Petroleum Institute, Flint Hills Resources, Naph- thalene Council and Utilities Solid Waste Activities Group. Authors M.G. Bird, R.J. Lewis, and W.J. Bover are employed by ExxonMobil Biomedical Sciences, Inc., a wholly owned subsidiary of Exxon Mobil Corporation (Note: M.G. Bird retired as of Septem- ber 1, 2011). V.J. Piccirillo is an independent consultant, but as sci- ence advisory to the NRC receives funding from that organization. The authors take sole responsibility for the writing and content of the paper. Acknowledgments", "Acknowledgement": "Acknowledgments The authors acknowledge the technical input and suggestions of colleagues at ExxonMobil Biomedical Sciences, Inc., the Naphtha- lene Research Committee Science Team, and several investigators cited in this paper. 4 Validation of HRF assessment 5 Summary and conclusions Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Prenatal-and-developmental-effect-of-high-molecul_2013_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23321397", "content": {"CoiStatement": "Conflict of interest A conflicting interest exists when professional judgement con- cerning a primary interest (such as patient\u2019s welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors when they have financial interest that may influence their inter- pretation of their results or those of others. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/ registrations, and grants or other funding. A conflicting interest exists when professional judgement con- cerning a primary interest (such as patient\u2019s welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors when they have financial interest that may influence their inter- pretation of their results or those of others. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/ registrations, and grants or other funding. Acknowledgements 4 Discussion 5 Conclusions Conflict of interest Acknowledgements References", "Funding": "A conflicting interest exists when professional judgement con- cerning a primary interest (such as patient\u2019s welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors when they have financial interest that may influence their inter- pretation of their results or those of others. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/ registrations, and grants or other funding. Acknowledgements", "Acknowledgement": "Acknowledgements This project was financially supported by the National High Technology Research and Development Program of China (No: 2007AA091603), the Objective-oriented Project of State Key Labo- ratory of Food Science and Technology (No: SKLF-MB-200805) and the Special Fund of Jiangsu Scientific and Technological Achieve- ment Transformation (No: BA2009082). 4 Discussion 5 Conclusions Conflict of interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Prenatal-developmental-toxicity-study-of-2-4-di_2022_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/35430291", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 4 Discussion 5 Conclusion Funding information CRediT authorship contribution statement Declaration of competing interest Acknowledgement References", "Funding": "Funding information This research was supported by the Korea Institute of Toxicology (1711133841) and Korea Environment Industry & Technology Institute through Technology Development Project for Safety Management of Household Chemical Products Program, funded by Korea Ministry of Environment (2020002960008). Kyeong-Nang Moon: Methodology, Data curation, Writing \u2013 orig- inal draft. Sang-Ki Baek: Methodology, Data curation, Writing \u2013 orig- inal draft, review & editing. Woojin Kim: Pathology, Data curation, Writing \u2013 review & editing. Ji-Seong Jeong: Methodology, Data cura- tion. Byoung-Seok Lee: Pathology, Data curation, Writing \u2013 review & editing. Yixian Quah: Writing \u2013 review & editing. Jinsoo Lee: Meth- odology, Data curation. Sang Yun Kim: Methodology, Data curation. Seung-Jin Lee: Methodology, Data curation. Kyu-Bong Kim: Method- ology, Writing \u2013 review & editing. Wook-Joon Yu: Supervision, Data curation, Writing \u2013 review & editing, Funding acquisition. Declaration of competing interest 4 Discussion 5 Conclusion Funding information CRediT authorship contribution statement Declaration of competing interest Acknowledgement References", "Acknowledgement": "Acknowledgement The authors thank the technical staff of the Developmental and Reproductive Toxicology Research Group at the Korea Institute of Toxicology for their technical assistance. 4 Discussion 5 Conclusion Funding information CRediT authorship contribution statement Declaration of competing interest Acknowledgement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Prenatal-developmental-toxicity-study-of-an-alkaloid-f_2020_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32800848", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Authors Silma Subah and Nathasha Bogoda are salaried Research Interns working at Gencor Pacific Limited (the sponsor of the study). The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Authors Silma Subah and Nathasha Bogoda are salaried Research Interns working at Gencor Pacific Limited (the sponsor of the study). Author Ruchitha Venkatesh worked as a Summer Intern at Gencor Pacific Limited from June 2019 to September 2019 on another research project overseas, not connected to this paper. She participated in the writing of this paper from November 2019. The authors declare no additional conflicts of interest in regard to the research, authorship, and/or publication of this article. Acknowledgements 4 Conclusion Funding Data availability Declaration of competing interest Acknowledgements References", "Funding": "Funding The authors disclose that financial support for the research described herein was provided by Gencor Pacific Limited, Unit-3, 1/F, Office Building Block 2, Discovery Bay North Plaza, Discovery Bay, Hong Kong. 4 Conclusion Funding Data availability Declaration of competing interest Acknowledgements References", "Compliance with ethical standards": "OECD, OECD Principles on Good Laboratory Practice, 1998. OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring, No. 1. OECD Publishing, Paris. OECD, Test No 414, 2018. Prenatal Developmental Toxicity Study, OECD Guidelines for the Testing of Chemicals. OECD Publishing, Paris, p. 14. Section 4.", "Acknowledgement": "Acknowledgements The authors thank the following individuals for their contributions to the work: participating investigators M\u00edra Andorka, Erzse\u0301bet Biczo\u0301, Ildiko\u0301 Hermann, Attila Horva\u0301th, Zsolt Hummel, Anita Klucsik, Hele\u0301n Ko\u030bro\u0308s, Bence K\u00fcronya, Vikto\u0301ria Matina, Judit Mere\u0301nyi, Andra\u0301s Murvai, Pa\u0301lma Nagy, Richa\u0301rd Nagy, Da\u0301niel Ne\u0301meth, Zolta\u0301n Ne\u0301meth, Mariann Nyitray, Aniko\u0301 Renko\u0301, Ilona Pasics Szakonyine\u0301, Edit Sza\u0301m, and Ma\u0301rta Tenk for the performance of experimental tasks, collection of data, statistical analyses, and/or quality assurance; Ga\u0301bor Hirka for general supervision of the test facilities, contributions to development of the study plan, and interpretation of data; John R. Endres for work as the sponsor\u2019s scientific monitor; and Jared Brodin for administrative sup- port in preparation of the manuscript. 4 Conclusion Funding Data availability Declaration of competing interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Prenatal-developmental-toxicity-study-of-stronti_2019_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30529436", "content": {"CoiStatement": "Conflicts of interest All authors have no conflict of interest. All authors have no conflict of interest. Acknowledgments Conclusion Conflicts of interest Acknowledgments Transparency document References", "Acknowledgement": "Acknowledgments This study was supported by the grants from the Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan (TSGH- C107-046) and the Industrial-Academic Cooperation Project of National Taiwan University, Taipei, Taiwan (NTU 107M101). Conclusion Conflicts of interest Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Prenatal-developmental-toxicity-study-with-7-hydrox_2004_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15265601", "content": {"Compliance with ethical standards": "The study was performed by TNO Nutrition and Food Research (Zeist, The Netherlands), in compliance with Good Laboratory Practise (GLP) following the principles of OECD Guideline for the Testing of Chemicals 414 (OECD, 2001). Four groups of mated female rats (24 rats/group) re- ceived diets containing HMRlignan at levels of 0 (con- trol), 0.25, 1 or 4%w/w. These dose levels were selected on the basis of the results of a 14-day range-finding study with HMRlignan in rats (Lina, 2002). The animals were checked daily for clinical signs and abnormal behaviour."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Prescribing-patterns-of-the-four-most-commonly-used-seda_2015_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25659208", "content": {"Acknowledgement": "Acknowledgements This study was supported by the Korean Ministry of Food and Drug Safety (MFDS) (No. 14172-174). The authors would like to thank the Korean Health Insurance Review and Assessment Service for providing the insurance claims data. Special thanks are due to Hannah Shin and Sohyun Choi for their help with draw- ing the figures and tables. 3 Results 4 Discussion 5 Conclusion Acknowledgements Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Pressor-mechanism-evaluation-for-phytochemical-compou_2013_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23899943", "content": {"Acknowledgement": "Acknowledgments This work is financially supported by the National Nature Foun- dation Committee of P.R. China (Grants No. 20875104, No. 20975115 and No. 10771217), the international cooperation pro- ject on traditional Chinese medicines of ministry of science and technology of china (Grant No. 2007DFA40680), and Central South University for special support of the basic scientific research pro- ject (No. 2010QZZD007). The studies meet with the approval of the university\u2019s review board. 4 Discussion 5 Conclusion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Prevalence-and-incidence-of-liver-enzyme-elevation_2016_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27025923", "content": {"CoiStatement": "Conflict of interest Sumitra Shantakumar, Andy Lawton and Sarah Landis are employees of GlaxoSmithKline (GSK); Sumitra Shantakumar and Sarah Landis own GSK shares. Christine M Hunt was a GSK employee during the conduct of this study and is now a consultant for Furiex and Otsuka Pharma- ceuticals. GSK funded this study. Prevalence and incidence of liver enzyme elevations in a pooled oncology clinical trial cohort 1. Introduction 2. Materials and methods 3. Results 4. Discussion 5. Conclusions Conflict of interest Acknowledgments Appendix A. Supplementary data Transparency document References", "Acknowledgement": "Acknowledgments We would like to thank Nittaya Suppapanya for her analytical support on this study. GSK funded this study. Prevalence and incidence of liver enzyme elevations in a pooled oncology clinical trial cohort 1. Introduction 2. Materials and methods 3. Results 4. Discussion 5. Conclusions Conflict of interest Acknowledgments Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Primary-measures-of-dependence-among-menthol-compare_2014_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24852490", "content": {"CoiStatement": "Conflict of interest Financial support for this work was provided through a contract between RAI Services Company (Winston-Salem, NC, USA) and ENVIRON International Corporation (Amherst, MA, USA). Sandra I. Sulsky and Cynthia Van Landingham are employees of ENVIRON International Corporation; Kristin M. Marano, Monica J. Graves, Michael W. Ogden, James E. Swauger and Geoffrey M. Curtin are employees of RAI Services Company. 4 Conclusions Conflict of interest Acknowledgments Appendix A Supplementary data References", "Acknowledgement": "Acknowledgments The authors would like to acknowledge the contributions of Farah Chowdhury, MS, for data verification and proofreading efforts during the preparation of the final manuscript; William Ful- ler, MS and Lori Crawford, MS for analytic support related to the four U.S. government surveys; and, Paul H. Ayres, PhD, DABT, Anne E. Loccisano, PhD, DABT, and Elaine K. Round, PhD for their careful review and thoughtful comments during the preparation of the final manuscript. 4 Conclusions Conflict of interest Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Primary-study-on-the-toxic-mechanism-of-vanadyl_2018_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29305949", "content": {"Acknowledgement": "Acknowledgments This work is supported by the National Natural Science Foundation of China (31771066). Discussion Conclusions Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Principles-and-procedures-for-handling-out-of-domain-a_2019_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30562600", "content": {"Acknowledgement": "Acknowledgement Research reported in this publication was supported by the National Institute of Environmental Health Sciences of the National Institutes of Health under Award Number R44ES026909. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Summary and conclusion Acknowledgement Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Principles-and-procedures-for-implementation-of-_2016_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26877192", "content": {"Compliance with ethical standards": "IARC, 2015. http://Monographs.iarc.fr/ENG/Classification/index.php. ICatrin Hasselgren M7, 2015a. ICatrin Hasselgren M7 e assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk. http://www. fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM347725. ICatrin Hasselgren M7, 2015b. Addendum to ICatrin Hasselgren M7: assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk: application of the principles of the ICatrin Hasselgren M7 guideline to calculation of compound-specific acceptable intakes M7 (R1). http://www.ich.org/fileadmin/ Public_Web_Site/ICatrin Hasselgren_Products/Guidelines/Multidisciplinary/M7/M7_ Addendum_Step_2.pdf. http://refhub.elsevier.com/S0273-2300(16)30027-7/sref23 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref24 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref24 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref24 http://toxnet.nlm.nih.gov/newtoxnet/genetox.htm http://refhub.elsevier.com/S0273-2300(16)30027-7/sref26 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref26 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref26 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref26 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref26 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref27 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref27 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref27 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref27 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref27 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref28 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref28 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref28 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref28 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref29 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref29 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref29 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref29 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref29 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref30 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref30 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref30 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref30 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref30 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref31 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref31 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref31 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref31 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref31 http://Monographs.iarc.fr/ENG/Classification/index.php http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM347725 http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM347725 http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM347725 http://www.ich.org/fileadmin/Public_Web_Site/ICatrin Hasselgren_Products/Guidelines/Multidisciplinary/M7/M7_Addendum_Step_2.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICatrin Hasselgren_Products/Guidelines/Multidisciplinary/M7/M7_Addendum_Step_2.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICatrin Hasselgren_Products/Guidelines/Multidisciplinary/M7/M7_Addendum_Step_2.pdf http://www.inchem.org http://www.epa.gov/iris/ http://www.echemportal.org/echemportal/ http://refhub.elsevier.com/S0273-2300(16)30027-7/sref38 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref38 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref38 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref38 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref39 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref39 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref39 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref39 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref40 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref40 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref40 http://www.leadscope.com/toxicity_databases/ http://refhub.elsevier.com/S0273-2300(16)30027-7/sref42 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref42 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref42 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref43 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref43 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref43 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref43 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref43 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref43 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref43 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref43 http://www.multicase.com/case-ultra-models#bacterial_muta_bundle http://www.multicase.com/case-ultra-models#bacterial_muta_bundle http://refhub.elsevier.com/S0273-2300(16)30027-7/sref45 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref45 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref45 http://tools.niehs.nih.gov/cebs3/ntpViews/?activeTab=summary&amp;studyNumber=758178 http://tools.niehs.nih.gov/cebs3/ntpViews/?activeTab=summary&amp;studyNumber=758178 http://tools.niehs.nih.gov/cebs3/ntpViews/?activeTab=summary&amp;studyNumber=758178 http://tools.niehs.nih.gov/cebs3/ntpViews/?activeTab=summary&amp;studyNumber=758178 http://tools.niehs.nih.gov/cebs3/ui/ http://www.oecd-ilibrary.org/environment/test-no-471-bacterial-reverse-mutation-test_9789264071247-en http://www.oecd-ilibrary.org/environment/test-no-471-bacterial-reverse-mutation-test_9789264071247-en http://refhub.elsevier.com/S0273-2300(16)30027-7/sref49 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref49 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref49 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref49 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref50 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref50 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref50 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref50 http://www.oecd-ilibrary.org/environment/test-no-490-in-vitro-mammalian-cell-gene-mutation-tests-using-the-thymidine-kinase-gene_9789264242241-en http://www.oecd-ilibrary.org/environment/test-no-490-in-vitro-mammalian-cell-gene-mutation-tests-using-the-thymidine-kinase-gene_9789264242241-en http://www.oecd-ilibrary.org/environment/test-no-490-in-vitro-mammalian-cell-gene-mutation-tests-using-the-thymidine-kinase-gene_9789264242241-en http://refhub.elsevier.com/S0273-2300(16)30027-7/sref52 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref52 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref52 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref52 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref52 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref52 http://www.pesticideinfo.org/ http://www.pharmapendium.com/ http://refhub.elsevier.com/S0273-2300(16)30027-7/sref55 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref55 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref55 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref55 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref56 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref56 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref56 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref56 http://www.cdc.gov/niosh/rtecs/default.html http://refhub.elsevier.com/S0273-2300(16)30027-7/sref58 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref58 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref58 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref59 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref59 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref59 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref59 https://www.leadscope.com/media/SOT%202013%20Stavitskaya%20CDER%20poster.pdf https://www.leadscope.com/media/SOT%202013%20Stavitskaya%20CDER%20poster.pdf http://refhub.elsevier.com/S0273-2300(16)30027-7/sref61 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref61 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref61 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref61 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref61 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref61 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref62 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref62 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref62 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref62 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref63 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref63 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref63 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref63 http://toxnet.nlm.nih.gov/ http://www.lhasalimited.org/products/vitic-nexus.htm http://refhub.elsevier.com/S0273-2300(16)30027-7/sref66 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref66 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref66 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref67 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref67 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref68 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref68 http://refhub.elsevier.com/S0273-2300(16)30027-7/sref68 Principles and procedures for implementation of ICatrin Hasselgren M7 recommended (Q)SAR analyses 1. Introduction 2. Assessing available data 2.1. Case study 1: identifying a compound with historical data", "Acknowledgement": "Acknowledgments We acknowledgeMaurizio Franzini for helping with some of the expert review examples. 5. Reporting 6. Conclusions Acknowledgments Transparency document Appendix A. Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Principles-for-identification-of-High-Potency-Category-C_2015_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25765509", "content": {"CoiStatement": "Conflict of interest None declared. Principles for identification of High Potency Category Chemicals for which the Dermal Sensitisation Threshold (DST) approach should not be applied 1 Introduction 2 The approach \u2013 chemistry-based identification of High Potency Category (HPC) Chemicals 3 Development of HPC rules 4 HPC chemicals in the DST database 5 Principles for predicting HPC chemicals 6 Test of the HPC rules against the DST dataset 7 Further test against the NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) LLNA database 8 Discussion Conflict of interest Acknowledgment References", "Acknowledgement": "Acknowledgment This work was supported by the Research Institute for Fragrance Materials, Inc. Principles for identification of High Potency Category Chemicals for which the Dermal Sensitisation Threshold (DST) approach should not be applied 1 Introduction 2 The approach \u2013 chemistry-based identification of High Potency Category (HPC) Chemicals 3 Development of HPC rules 4 HPC chemicals in the DST database 5 Principles for predicting HPC chemicals 6 Test of the HPC rules against the DST dataset 7 Further test against the NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) LLNA database 8 Discussion Conflict of interest Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Printed-paper-and-board-food-contact-materials-as-_2016_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27389280", "content": {"CoiStatement": "Analysis of available legislative and inventory documents shows that over 6000 unique substances can be used in the manufacture of printed paper and board FCM. The vast majority of them are considered non-evaluated, pointing out an important knowledge gap in the safety evaluation of these substances. Furthermore, based on a preliminary study of the physicochemical properties of the substances, it is estimated that 64% of the non-evaluated single substances have the potential to migrate into the food and become bioavailable after oral intake. Importantly, 19 of these are present in one of the lists with substances of concern compiled by the Euro- pean Chemicals Agency (ECHA). To prevent future food safety is- sues, the actual use of these substances in printed paper and board FCM should be urgently investigated. Conflicts of interest The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgements 4. Discussion 5. Conclusion Conflicts of interest Acknowledgements Appendix A. Supplementary data Transparency document References", "Compliance with ethical standards": "M. Van Bossuyt et al. / Regulatory Toxicology and Pharmacology 81 (2016) 10e1918 compliant with the legal requirements, but these compliance checks are only required for 5% of the registration dossiers per tonnage band. Additionally, the number of substances for which a detailed assessment of the risks to human health or the environ- ment has been performed by the European Member States, is limited. Furthermore, no data are available for all unregistered substances. The problems associated with migration of non-evaluated sub- stances from printed paper and board have also been recognised by the FCM industry. As a response, several manufacturers and in- dustry organisations have recently implemented (in-house) guid- ance documents with lists of substances that can be used and/or should be avoided in the production of FCM. Some examples are the Nestl\ufffde Guidance Note on Packaging Inks (Nestl\ufffde, 2014) and the Industry guideline for the Compliance of Paper & Board Materials and Articles for Food Contact drafted by the Confederation of Eu- ropean Paper Industries (CEPI, 2012). Other interesting initiatives include for example the introduction of new barrier films for dry foods (pasta, cereals, rice) by different companies. These barriers should prevent migration of inks and their constituents from the packaging into the food (Seltenrich, 2015). At present, the efficacy of the barriers towards the large number of chemically divergent substances that can be used in printed paper and board FCM is not clear. The problems associated with migration of non-evaluated sub- stances from printed paper and board have also been recognised by the FCM industry. As a response, several manufacturers and in- dustry organisations have recently implemented (in-house) guid- ance documents with lists of substances that can be used and/or should be avoided in the production of FCM. Some examples are the Nestl\ufffde Guidance Note on Packaging Inks (Nestl\ufffde, 2014) and the Industry guideline for the Compliance of Paper & Board Materials and Articles for Food Contact drafted by the Confederation of Eu- ropean Paper Industries (CEPI, 2012). Other interesting initiatives include for example the introduction of new barrier films for dry foods (pasta, cereals, rice) by different companies. These barriers should prevent migration of inks and their constituents from the packaging into the food (Seltenrich, 2015). At present, the efficacy of the barriers towards the large number of chemically divergent substances that can be used in printed paper and board FCM is not clear. Ideally, the toxicological profile of all substances used in printed and board FCM should thus be characterised. As an in-depth safety assessment of this large number of non-evaluated substances is not feasible in the short term, strategies should be developed to further assign priority. One possibility would be to investigate which compounds are migrating from printed paper and board. However, as already indicated, migration depends on the characteristics of the food contact material (thickness, density, \u2026) and of the type of food in contact with the material. Therefore, it is not feasible to evaluate the migration potential of all substances in all applications and all materials possible. Furthermore, compounds migrating in low quantities may remain undetected whereas they could have a bigger impact on human health than those migrating at higher levels (e.g. genotoxic carcinogens). CEPI, 2012. Industry guideline for the Compliance of Paper & Board Materials and Articles for Food Contact. Available from: http://www.cepi.org/system/files/ public/documents/publications/foodcontact/2012/Industry%20guideline- updated2012final.pdf (last accessed 08.06.16). Council of Europe, 2009. Resolution ResAp (2002) 1 on Paper and Board Materials and Articles Intended to Come into Contact with Foodstuffs. Available from: http://www.coe.int/t/e/social_cohesion/soc-sp/public_health/food_contact/PS% 20PAPER%20AND%20BOARD%20Version%204%20E.pdf (last accessed 08.06.16).", "Acknowledgement": "Acknowledgements This work was supported by the Belgian Scientific Institute of Public Health. 4. Discussion 5. Conclusion Conflicts of interest Acknowledgements Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Prioritization-before-risk-assessment--The-viabilit_2018_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29932981", "content": {"CoiStatement": "This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The au- thors confirm that there are no known conflicts of interest associated with this publication. The authors are grateful to the members of the ANSES panel \u201cRisk assessment for substances and processes submitted to human food regulation\u201d for scientific discussions, namely: Fabien Bolle, Jalloul Bouajila, Nicolas Cabaton, Marie-Christine Chagnon, Dany Chevalier, V\u00e9ronique Coma, Luc Fillaudeau, Angel Gil-Izquierdo, Florence Lacoste, Claude Lambre, Michel Laurentie, Jean-Michel Maixent, Anne Platel, Philippe Saillard, Patrick Sauvegrain, and Fran\u00e7ois Zuber. Supplementary data", "Funding": "This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The au- thors confirm that there are no known conflicts of interest associated with this publication. The authors are grateful to the members of the ANSES panel \u201cRisk assessment for substances and processes submitted to human food regulation\u201d for scientific discussions, namely: Fabien Bolle, Jalloul Bouajila, Nicolas Cabaton, Marie-Christine Chagnon, Dany Chevalier, V\u00e9ronique Coma, Luc Fillaudeau, Angel Gil-Izquierdo, Florence Lacoste, Claude Lambre, Michel Laurentie, Jean-Michel Maixent, Anne Platel, Philippe Saillard, Patrick Sauvegrain, and Fran\u00e7ois Zuber. Supplementary data", "Acknowledgement": "Acknowledgements This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The au- thors confirm that there are no known conflicts of interest associated with this publication. The authors are grateful to the members of the ANSES panel \u201cRisk assessment for substances and processes submitted to human food regulation\u201d for scientific discussions, namely: Fabien Bolle, Jalloul Bouajila, Nicolas Cabaton, Marie-Christine Chagnon, Dany Chevalier, V\u00e9ronique Coma, Luc Fillaudeau, Angel Gil-Izquierdo, Florence Lacoste, Claude Lambre, Michel Laurentie, Jean-Michel Maixent, Anne Platel, Philippe Saillard, Patrick Sauvegrain, and Fran\u00e7ois Zuber. http://dx.doi.org/10.1016/j.yrtph.2018.06.012 http://dx.doi.org/10.1016/j.yrtph.2018.06.012 http://dx.doi.org/10.1016/j.yrtph.2018.06.012 https://doi.org/10.1080/0265203031000109486 https://doi.org/10.1080/10408690490424621 https://doi.org/10.1080/10408690490424621 https://doi.org/10.1080/02652030903233231 https://doi.org/10.1080/02652030903233231 http://refhub.elsevier.com/S0273-2300(18)30168-5/sref4 http://refhub.elsevier.com/S0273-2300(18)30168-5/sref4 http://refhub.elsevier.com/S0273-2300(18)30168-5/sref5 http://refhub.elsevier.com/S0273-2300(18)30168-5/sref5 http://refhub.elsevier.com/S0273-2300(18)30168-5/sref6 http://refhub.elsevier.com/S0273-2300(18)30168-5/sref6 https://doi.org/10.1080/19440049.2016.1184941 https://doi.org/10.1080/19440049.2016.1184941 https://doi.org/10.1080/19440049.2011.641164 https://doi.org/10.1080/19440049.2011.641164 https://doi.org/10.1016/j.chroma.2013.04.009 https://doi.org/10.1002/pts.914 https://doi.org/10.1002/pts.914 https://doi.org/10.1080/02652030110089878 https://doi.org/10.1080/02652030110089878 http://refhub.elsevier.com/S0273-2300(18)30168-5/sref12 http://refhub.elsevier.com/S0273-2300(18)30168-5/sref12 https://doi.org/10.1533/9781845692094.3.416 https://doi.org/10.1007/s11948-016-9773-2 https://doi.org/10.1007/s11948-016-9773-2 https://doi.org/10.1533/9781845692094.1 https://doi.org/10.1533/9781845692094.1 https://doi.org/10.1016/S0015-6264(76 https://doi.org/10.1016/S0015-6264(76 http://refhub.elsevier.com/S0273-2300(18)30168-5/sref17 http://refhub.elsevier.com/S0273-2300(18)30168-5/sref17 http://refhub.elsevier.com/S0273-2300(18)30168-5/sref17 https://doi.org/10.1080/02652030600865475 https://doi.org/10.2903/SP.EFSA.2016.EN-1006 http://refhub.elsevier.com/S0273-2300(18)30168-5/sref20 http://refhub.elsevier.com/S0273-2300(18)30168-5/sref20 http://refhub.elsevier.com/S0273-2300(18)30168-5/sref20 http://refhub.elsevier.com/S0273-2300(18)30168-5/sref21 http://refhub.elsevier.com/S0273-2300(18)30168-5/sref21 https://doi.org/10.1016/j.trac.2012.09.017 https://doi.org/10.1080/19440049.2014.931600 https://doi.org/10.1080/19440049.2014.931600 https://doi.org/10.1016/j.foodcont.2014.05.044 https://doi.org/10.1016/j.foodcont.2014.05.044 https://doi.org/10.1016/j.scitotenv.2012.06.064 https://doi.org/10.1080/19440049.2012.762605 https://doi.org/10.1080/19440040903401358 http://refhub.elsevier.com/S0273-2300(18)30168-5/sref28 http://refhub.elsevier.com/S0273-2300(18)30168-5/sref28 http://refhub.elsevier.com/S0273-2300(18)30168-5/sref29 http://refhub.elsevier.com/S0273-2300(18)30168-5/sref29 https://www.vegahub.eu/download/vega-interpretation/ Migration and Food Contact Materials. Elsevier, pp. 395\u2013415. https://doi.org/10. 1533/9781845692094.3.395. Koster, S., Bani-Estivals, M.-H., Bonuomo, M., Bradley, E., Chagnon, M.-C., Garcia, L.M., Godts, F., Gude, T., Helling, R., Paseiro-Losada, P., Pieper, G., Rennen, M., Simat, T., Spack, L., 2015. Guidance of Best Practices on the Risk Assessment of NIAS in Food Contact Materials and Articles. International Life Science Institute. https://doi.org/ 10.1146/annurev.phyto.40.120301.093728. Koster, S., Rennen, M., Leeman, W., Houben, G., Muilwijk, B., van Acker, F., Krul, L., 2014. A novel safety assessment strategy for non-intentionally added substances (NIAS) in carton food contact materials. Food Addit. Contam. 31, 422\u2013443. https:// doi.org/10.1080/19440049.2013.866718. Kroes, R., Renwick, A.G., Cheeseman, M., Kleiner, J., Mangelsdorf, I., Piersma, A., Schilter, B., Schlatter, J., Van Schothorst, F., Vos, J.G., W\u00fcrtzen, G., 2004. Structure- based thresholds of toxicological concern (TTC): guidance for application to sub- stances present at low levels in the diet. Food Chem. Toxicol. 42, 65\u201383. https://doi. org/10.1016/j.fct.2003.08.006. Lester, C., Reis, A., Laufersweiler, M., Wu, S., Blackburn, K., 2018. Structure activity relationship (SAR) toxicological assessments: the role of expert judgment. Regul. Toxicol. Pharmacol. 92, 390\u2013406. https://doi.org/10.1016/j.yrtph.2017.12.026. Muncke, J., Backhaus, T., Geueke, B., Maffini, M.V., Martin, O.V., Myers, J.P., Soto, A.M., Trasande, L., Trier, X., Scheringer, M., 2017. Scientific challenges in the risk as- sessment of food contact materials. Environ. Health Perspect. 125, 1\u20139. https://doi. org/10.1289/EHP644. Ozaki, A., Yamaguchi, Y., Fujita, T., Kuroda, K., Endo, G., 2005. Safety assessment of paper and board food packaging: chemical analysis and genotoxicity of possible contaminants in packaging. Food Addit. Contam. 22, 1053\u20131060. https://doi.org/10. 1080/02652030500090885. Pieke, E.N., Granby, K., Trier, X., Smedsgaard, J., 2017. A framework to estimate con- centrations of potentially unknown substances by semi-quantification in liquid chromatography electrospray ionization mass spectrometry. Anal. Chim. Acta 975, 30\u201341. https://doi.org/10.1016/j.aca.2017.03.054. Pieke, E.N., Smedsgaard, J., Granby, K., 2018. Exploring the chemistry of complex samples by tentative identification and semiquantification: a food contact material case. J. Mass Spectrom. 53, 323\u2013335. https://doi.org/10.1002/jms.4052. Pivnenko, K., Eriksson, E., Astrup, T.F., 2015. Waste paper for recycling: overview and identification of potentially critical substances. Waste Manag. 45, 134\u2013142. https:// doi.org/10.1016/j.wasman.2015.02.028. Po\u00e7as, M. de F., Oliveira, J.C., Pereira, J.R., Brandsch, R., Hogg, T., 2011. Modelling migration from paper into a food simulant. Food Contr. 22, 303\u2013312. https://doi.org/ 10.1016/j.foodcont.2010.07.028. Raies, A.B., Bajic, V.B., 2016. In silico toxicology: computational methods for the pre- diction of chemical toxicity. Wiley Interdiscip. Rev. Comput. Mol. Sci. 6, 147\u2013172. https://doi.org/10.1002/wcms.1240. Rosenmai, A.K., Bengtstr\u00f6m, L., Taxvig, C., Trier, X., Petersen, J.H., Svingen, T., Binderup, M.-L.L., van Vugt-Lussenburg, B.M.A., Dybdahl, M., Granby, K., Vinggaard, A.M., Barbara Medea Alice, van V.L., Dybdahl, M., Granby, K., Vinggaard, A.M., 2017. An effect-directed strategy for characterizing emerging chemicals in food contact materials made from paper and board. Food Chem. Toxicol. 106, 250\u2013259. https://doi.org/10.1016/j.fct.2017.05.061. Ru, G., Crescio, M.I., Ingravalle, F., Maurella, C., Gregori, D., Lanera, C., Azzolina, D., Lorenzoni, G., Soriani, N., Zec, S., Berchialla, P., Mercadante, S., Zobec, F., Ghidina, M., Baldas, S., Bonifacio, B., Kinkopf, A., Kozina, D., Nicolandi, L., Rosat, L., 2017. Machine Learning Techniques Applied in Risk Assessment Related to Food Safety, vol.14 EFSA Support. Publ.. https://doi.org/10.2903/sp.efsa.2017.EN-1254. SCCNFP, 2002. Safety Review of the Use of Certain Azo-dyes in Cosmetic Products. Schymanski, E.L., Singer, H.P., Longr\u00e9e, P., Loos, M., Ruff, M., Stravs, M.A., Ripoll\u00e9s Vidal, C., Hollender, J., 2014. Strategies to characterize polar organic contamination in wastewater: exploring the capability of high resolution mass spectrometry. Environ. Sci. Technol. 48, 1811\u20131818. https://doi.org/10.1021/es4044374. Skjevrak, I., Brede, C., Steffensen, I.L., Mikalsen, A., Alexander, J., Fjeldal, P., Herikstad, H., 2005. Non-targeted multi-component analytical surveillance of plastic food con- tact materials: identification of substances not included in EU positive lists and their risk assessment. Food Addit. Contam. 22, 1012\u20131022. https://doi.org/10.1080/ 02652030500090877. Triantafyllou, V.I., Akrida-Demertzi, K., Demertzis, P.G., 2007. A study on the migration of organic pollutants from recycled paperboard packaging materials to solid food matrices. Food Chem. 101, 1759\u20131768. https://doi.org/10.1016/j.foodchem.2006. 02.023. van Bossuyt, M., van Hoeck, E., Raitano, G., Manganelli, S., Braeken, E., Ates, G., Vanhaecke, T., Van Miert, S., Benfenati, E., Mertens, B., Rogiers, V., 2017. (Q)SAR tools for priority setting: a case study with printed paper and board food contact material substances. Food Chem. Toxicol. 102, 109\u2013119. https://doi.org/10.1016/j. fct.2017.02.002. E.N. Pieke et al. Regulatory Toxicology and Pharmacology 97 (2018) 134\u2013143 143 https://doi.org/10.1533/9781845692094.3.395 https://doi.org/10.1533/9781845692094.3.395 https://doi.org/10.1146/annurev.phyto.40.120301.093728 https://doi.org/10.1146/annurev.phyto.40.120301.093728 https://doi.org/10.1080/19440049.2013.866718 https://doi.org/10.1080/19440049.2013.866718 https://doi.org/10.1016/j.fct.2003.08.006 https://doi.org/10.1016/j.fct.2003.08.006 https://doi.org/10.1016/j.yrtph.2017.12.026 https://doi.org/10.1289/EHP644 https://doi.org/10.1289/EHP644 https://doi.org/10.1080/02652030500090885 https://doi.org/10.1080/02652030500090885 https://doi.org/10.1016/j.aca.2017.03.054 https://doi.org/10.1002/jms.4052 https://doi.org/10.1016/j.wasman.2015.02.028 https://doi.org/10.1016/j.wasman.2015.02.028 https://doi.org/10.1016/j.foodcont.2010.07.028 https://doi.org/10.1016/j.foodcont.2010.07.028 https://doi.org/10.1002/wcms.1240 https://doi.org/10.1016/j.fct.2017.05.061 https://doi.org/10.2903/sp.efsa.2017.EN-1254 http://refhub.elsevier.com/S0273-2300(18)30168-5/sref45 https://doi.org/10.1021/es4044374 https://doi.org/10.1080/02652030500090877 https://doi.org/10.1080/02652030500090877 https://doi.org/10.1016/j.foodchem.2006.02.023 https://doi.org/10.1016/j.foodchem.2006.02.023 https://doi.org/10.1016/j.fct.2017.02.002 https://doi.org/10.1016/j.fct.2017.02.002 Prioritization before risk assessment: The viability of uncertain data on food contact materials Introduction Methods Analysis Construction and evaluation of a decision unit Quantitative structure-activity relationship (QSAR) Sample selection and preparation Results and discussion The total migratable content (TMC) Risk characterization of tentative data Tentative hazard identification Tentative exposure assessment Risk prioritization based on tentative data Risk profile classification Design of a decision unit Design of data-driven decision modules Incorporation of expert decisions Applying risk prioritization explorative data Application and results of the decision unit Compounds with high priority Compounds with low priority Compounds with no assigned priority The implementation of risk prioritization tools Conclusion Acknowledgements Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Prioritizing-environmental-risk-of-prescript_2013_Regulatory-Toxicology-and-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22813724", "content": {"CoiStatement": "In this paper, a simple, quantitative risk-based ranking ap- proach was developed and evaluated for prioritizing environmen- tal PhACs. This approach combines estimates of production, attenuation and toxicity thresholds for multiple endpoints, and draws on publicly available data to quantitatively rank PhACs based on their potential ecological and human health impacts. While there were a lot of uncertainties associated with this ap- proach, we hypothesized that differences in our ranking metrics amongst these compounds would be large enough to overcome the given uncertainties, and this simple and environmentally rele- vant approach may be used as a valuable tool for screening of tar- get PhACs in future environmental research and regulations. Conflict of interest statement The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgments 4 Discussion 5 Conclusions Conflict of interest statement Acknowledgments Appendix A Supplementary data References", "Acknowledgement": "Acknowledgments We would like to thank Martha Chang and Angela M. Renfroe for their work on initial data collection and analysis, and thank Dr. Laurel Schaider for her help on reviewing the manuscript. This study was made possible by Harvard University Center for the Environment (HUCE) and Kresge Center Grant ES00002 from the National Institute of Environmental Health Sciences (NIEHS), NIH. The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official views of the NIEHS, NIH. Appendix A. Supplementary data 4 Discussion 5 Conclusions Conflict of interest statement Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Proarrhythmic-risk-assessment-using-convention_2017_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28506844", "content": {"CoiStatement": "Conflict of interest and source of funding None declared. 5. Conclusion Conflict of interest and source of funding Acknowledgements Transparency document References", "Funding": "Conflict of interest and source of funding None declared. 5. Conclusion Conflict of interest and source of funding Acknowledgements Transparency document References", "Compliance with ethical standards": "The following conventional and new in vitro assays (hERG channel, Purkinje fiber action potential and hiPSC-CMs-field po- tential) are all able to detect delayed repolarization. In regards to ICH S7B guideline, the hERG channel assay using the manual patch- clamp technique and conducted in compliance with good labora- tory practices remains the in vitro preferred option for regulatory submission. Nevertheless, the hERG channel test is focused on IKr only whereas it is recognized that the investigation of additional key cardiac ion channels remains essential to assess proarrythmic risk. Nowadays, the availability of hiPSC-CMs offers a potential source for cardiac risk assessment in safety screening. Although the use of Purkinje fibers preparation is relevant for the proarrhythmic risk assessment, ethical issues with regards to animal use in this model makes it less appropriate as an early screening assay. Nevertheless, we think that the use of Purkinje fibers should be reconsidered as this model is able to assess the effects of substances on cardiac conduction (upstroke velocity of the rapid cell depo- larization), the maintaining of the action potential plateau and the stability of the cell membrane hyperpolarization (resting mem- brane potential) or to detect abnormalities of repolarization. As an alternative, new assay using hiPSC-CMs together with the capa- bilities of MEA platform can detect delayed repolarization and arrhythmia after acute or long-term incubation. The assay on hiPSC-CMs is particularly adapted for drawing the basic electro- physiological profile of a substance as it can provide important predictive cardiac electrophysiology data, matching the needs of the pharmaceutical industry to assess drug liability early in the drug discovery process. In accordancewith the CiPA proposals, we think that the current guidelines for the evaluation of in vitro proarrhythmic risk should be improved. Nevertheless, we suggest an alternative strategy with in particular a more central role of studies conducted in human cardiomyocytes. Our data suggest that earlier screening of sub- stances should be performed on hiPSC-CMs as these cells already", "Acknowledgement": "Acknowledgements The authors wish to thank Quentin Avril, Laurence Barrais, Emmanuelle Gascoin, Marion Hunault and Christophe Legrand for expert technical assistance. 5. Conclusion Conflict of interest and source of funding Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Probabilistic-Monte-Carlo-estimation-for-quantitative_2016_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27184939", "content": {"Compliance with ethical standards": "S. Dey et al. / Regulatory Toxicology and Pharmacology 79 (2016) 54e6356 Schwalbach, Germany). Testing was conducted in compliance with the Good Clinical Practice Regulations (EEC Guidelines for Medici- nal Products 111/3976/88-EN) subject to quality assurance pro- cedures as appropriate (EEC 1997). Participants or caregivers signed informed consent and participation was voluntary. Participants were primary caregivers with healthy babies weighing 3e12 kg. The study was carried out in a controlled environment roomwith a relative humidity of 45% (\u00b15%) and temperature of 21 \ufffdC (\u00b11 \ufffdC). The test population was divided into 2 groups of 32 babies with body weight ranges of 3e6 kg and 6e12 kg. Average body weights (Mean \u00b1 Swatee Dey) of the groups were 4.96 (\u00b10.66) kg and 8.37 (\u00b12.05) kg respectively. For the lotion transfer determination, primary caregivers were provided with baby wipes and asked to wipe the baby\u2019s diapered area as they normally would while cleaning after a bowel move- ment and urine soiling but on a clean dry skin as a conservative measure. The wiping technique was observed to ensure all surface areas (i.e. buttocks, genitalia, perianal region, intertriginous zones or inguinal creases) were in contact with the wipe for maximum coverage. The body weight of the child was recorded."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Probabilistic-derivation-of-the-interspecies-asse_2017_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28545776", "content": {"Acknowledgement": "Acknowledgements This work was funded by the Dutch Ministry of Public Health, Welfare and Sports (VWS) (grant numbers V/050012, V/050013). The authors would like to thank Emiel Rorije, Susan Wijnhoven, Andr\ufffde Muller, Wouter ter Burg, and Joke Herremans for their comments and contribution to discussions during the preparation of this manuscript. 4. Discussion 5. Conclusion Acknowledgements Appendices and Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Probabilistic-pharmacokinetic-modeling-of-airborne-lea_2021_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33587932", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The author would like to recognize the contributions of the late Eric Hack for conducting simulations with the MATLAB model and thank Angie Hulgan, Chet Gut, Elizabeth Phillips, and Michelle Armstrong for their assistance with kinetic data extraction; Eddie Lenos, Edward Lafferty, Monica Ahuna Williams, and Leslie Crowder for extracting demographic data from DOEHRS; Laurie Cummings for coordinating the expert groups; the expert groups for their helpful comments; and Teri Sterner for model quality, reproducibility, and migration assessment. Preliminary work on this topic was supported by Navy Work Unit Number 60769 when the author was formerly on the staff at NAMRU Dayton. The author has no competing interests. Appendix A. Supplementary data 4 Conclusions CRediT authorship contribution statement Declaration of competing interest Acknowledgments Appendix A Supplementary data Disclaimers Funding body information References", "Funding": "Funding body information This work was funded through the US Department of Defense, De- fense Health Agency \u201cDefense Health Programs\u201d activities and completed as part of the author\u2019s contract employment. The funding agency was not involved the study design; in the collection, analysis, and interpretation of data; in the writing of the manuscript, and in the de- cision to submit the article for publication. This work was funded through the US Department of Defense, De- fense Health Agency \u201cDefense Health Programs\u201d activities and completed as part of the author\u2019s contract employment. The funding agency was not involved the study design; in the collection, analysis, and interpretation of data; in the writing of the manuscript, and in the de- cision to submit the article for publication. Fig. 7. Contributors to variability in predicted final blood Pb concentration (working lifetime exposure) in a simulated DOD population with no additional occupational exposure (background) or four candidate OELs. 4 Conclusions CRediT authorship contribution statement Declaration of competing interest Acknowledgments Appendix A Supplementary data Disclaimers Funding body information References", "Acknowledgement": "Acknowledgments The author would like to recognize the contributions of the late Eric Hack for conducting simulations with the MATLAB model and thank Angie Hulgan, Chet Gut, Elizabeth Phillips, and Michelle Armstrong for their assistance with kinetic data extraction; Eddie Lenos, Edward Lafferty, Monica Ahuna Williams, and Leslie Crowder for extracting demographic data from DOEHRS; Laurie Cummings for coordinating the expert groups; the expert groups for their helpful comments; and Teri Sterner for model quality, reproducibility, and migration assessment. Preliminary work on this topic was supported by Navy Work Unit Number 60769 when the author was formerly on the staff at NAMRU Dayton. The author has no competing interests. 4 Conclusions CRediT authorship contribution statement Declaration of competing interest Acknowledgments Appendix A Supplementary data Disclaimers Funding body information References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Probabilistic-risk-assessment-for-linear-alkylbenzene_2007_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/17967498", "content": {"Acknowledgement": "Acknowledgments Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Probiotics-for-animal-nutrition-in-the-European-U_2006_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16563585", "content": {"Acknowledgement": "Acknowledgment This work was supported by a grant from the \u201cComuni- dad de Madrid,\u201d Project S-0505/AGR/000153. Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Proceedings-of-the-international-conference-on-occupationa_2005_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32595044", "content": {"Acknowledgement": "Conference report / Regulatory Toxicology and Pharmacology 41 (2005) 150\u2013158 157 of standardized decision-making logics. This guidance should consider practical utility to both experts and non-experts and for adoption in workplace practices. Also important is to promote collaboration among phy- sicians and dermatologists, occupational and environ- mental hygienists, and toxicologists in the tasks of identifying potential skin hazards. To achieve these goals, continuous efforts are necessary to increase the interactions among professionals playing different roles in the efforts of exposure prevention and to disseminate the information on occupational and environmental skin exposures. One mechanism to facilitate these efforts is an easily accessible, centralized database or a similar system, serving as a platform for the exchange of knowl- edge on factors and conditions leading to skin expo- sures, adverse health effects due to such exposures, and recommendations of intervention strategies. An effective action is attainable only when all actors of diverse back- grounds in relevant fields collaboratively contribute to its design, demonstration, and implementation. Acknowledgments The authors thank Drs. Heinz W. Ahlers, Charles L. Geraci, and Sidney C. Soderholm of NIOSH, Dr. Rhon- da M. Brand of Evanston Northwestern Healthcare Re- search Institute, Northwestern University, and Dr. Sanja Kezic of Coronel Institute of Occupational and Environmental Health, University of Amsterdam, for their reviews of the proceedings during its development. Their valuable input greatly improved the quality and scope of this report. References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Product-stewardship-and-science--Safe-manufact_2012_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22266014", "content": {"CoiStatement": "Hesterberg, T.W., 2010. Comments on the National Toxicology Program (NTP) Draft Report on Carcinogens: Substances Profile for Glass Wool Fibers (Respirable) as a Class (submitted June 7, 2010. Hesterberg, T.W., Long, C.M., Sax, S.N., Lapin, C.A., McClellan, R.O., Bunn, W.B., Valberg, P.A., 2011. Particulate matter in new technology diesel exhaust (NTDE) is quantitatively and qualitatively very different from that found in traditional diesel exhaust (TDE). J. Air & Waste Manage. Assoc. 61, 894\u2013913. Hughes, J.M., Jones, R.N., Glindmeyer, H.W., Hammad, Y.Y., Weill, H., 1993. Follow up study of workers exposed to man made mineral fibres. Br. J. Ind. Med. 50 (7), 658\u2013667. IARC, 1972. IARC Monographs on the Evaluation of Cacinogenic Risks to Humans. Vol. 1. Some Organic Substances, Chlorinated Hydrocarbons, Aromatic Amines, N-Nitroso Compounds and Natural Products. 1972, Lyon, France. IARC, 1973. IARC Monogoraphs on the Evaluation of Carcinogenic Risks to Humans, Asbestos, vol. 2, Lyon, France. IARC, 1977. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Asbestos, Supplement 14, Lyon, France. IARC, 1987. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Asbestos, Supplement 7, Lyon, France. IARC, 1979. IARC monographs on the evaluation of carcinogenic risk to humans, vol. 19. Some Monomers, Plastics and Synthetic Elastomers, and Acrolein. Lyon, France. IARC, 1988. Man-made mineral fibres and radon. IARC Monographs on the Evaluation of Carcinogenic Risk to Humans, vol. 43, International Agency for Research on Cancer, Lyon, France. IARC, 2002a. Man-made vitreous fibres. IARC Monographs on the Evaluation of Carcinogenic Risk to Humans, vol. 81, International Agency for Research on Cancer, Lyon, France. IARC, 2002b. Man-made vitreous fibres. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans, International Agency for Research on Cancer, Lyon, France, IARC. 381 pp. IOM/NRC (Institute of Medicine and National Research Council), 2009. A Review of the NIOSH Roadmap for Research on Asbestos Fibers and Other Elongated Mineral Particles. In: Nelson, A.R., Liverman, C.T., Eide, E.A., Abt, E. (Eds.), Committee for the Review of the NIOSH Research Roadmap on Asbestos Fibers and Other Elongate Mineral Particles. Institute of Medicine and National Research Council. Available from: http://www.nap.edu/ catalog.php?record_id=12697 (accessed 6/9/2011). IPCS (International Programme on Chemical Safety), 1988. Environmental Health Criteria 77. Man-Made Fibres. World Health Organization, Geneva, Switzerland. Johns Manville, 2010. Company History. Johns Manville Corporate website, <http:// www.jm.com/corporate/56.htm> (accessed 6.8.2011). Kamstrup, O., Davis, J.M.G., Ellehauge, A., Guldberg, M., 1998. The biopersistence and pathogenicity of man-made vitreous fibres after short- and long-term inhalation. Ann. Occup. Hyg. 42 (3), 191\u2013199. Kelsey, K., 2009a. Glass Wool Fibers Expert Panel Report. Part A. Peer Review Comments on Background Document on Glass Wool Fibers. Glass Wool Fibers Expert Panel Meeting, June 9\u201310, 2009, National Toxicology Program, Public Health Service, US Department of Health and Human Services, Research Triangle Park, NC, USA. Kelsey, K., 2009b. Expert Panel Report Part B: Recommendation for Listing Status, and the Scientific Justification for the Recommendation. Glass Wool Fibers Expert Panel Meeting, June 9\u201310, 2009, National Toxicology Program, Public Health Service, US Department of Health and Human Services, Research Triangle Park, NC, USA. Lewis, T.R., Morrow, P.E., McClellan, R.O., Raabe, O.G., Kennedy, G.L., Schwetz, B.A., Goehl, T.J., Roycroft, J.H., Chhabra, R.S., 1989. Establishing aerosol exposure concentrations for inhalation toxicity studies. Tox. Appl. Pharm. 99, 377\u2013383. Lippmann, M., 2009. Asbestos and other mineral and vitreous fibers. In: Lippmann, M. (Ed.), Environmental Toxicants: Human Exposure and Their Health Effects, third ed. Wiley Publishing (Chapter 12). Marsh, G.M., Enterline, P.E., 1977. Mortality among man-made mineral fiber workers in the United States. Presentation at the 105th Annual Meeting of the American Public Health Association, Washington, DC. Marsh, G.M., Youk, A.O., Stone, Robert Anderson., Buchanich, J.M., Gula, M.J., Smith, T.J., Quinn, M.M., 2001a. Historical cohort study of US man-made vitreous fiber workers I. 1992 fiber glass cohort follow-up \u2013 initial findings. J. Occup. Environ. Med. 43, 741\u2013756. Marsh, G.M., Gula, M.J., Youk, A.O., Buchanich, J.M., Churg, A., Colby, T.V., 2001b. Historical cohort study of US man-made vitreous fiber production workers II. Mortality from mesothelioma. J. Occup. Environ. Med. 43, 757\u2013766. Marsh, G.M., Buchanich, J.M., Youk, A.O., 2001c. Historical cohort study of US man- made vitreous fiber production workers: VI. Respiratory system cancer standardized mortality ratios adjusted for the confounding effect of cigarette smoking. J. Occup. Environ. Med. 43, 803\u2013808. Marsh G.M., Buchanich J.M., Yonk A.O., 2009. Comments on the National Toxicology Program Draft Background Document on Glass Wool Fibers, May 22, 2009. Mast, R.W., McConnell, E.E., Anderson, R., Chevalier, J., Kotin, P., Bernstein, D.M., Thevenaz, P., Glass, L.R., Miiller, W.C., Hesterberg, T.W., 1995a. Studies on the chronic toxicity (inhalation) of four types of refractory ceramic fiber in male Fischer 344 rats. Inhal. Toxicol. 7, 425\u2013467. Mast, R.W., McConnell, E.E., Hesterberg, T.W., Chevalier, J., Kotin, P., Thevenaz, P., Bernstein, D.M., Glass, L.R., Miiller, W., Anderson, R., 1995b. A multiple dose chronic inhalation study of size-separated kaolin refractory ceramic fiber in male Fisher 344 rats. Inhal. Toxicol. 7, 469\u2013502. Mauderly, J.L., Jones, R.D., Griffith, W.C., Henderson, R.F., McClellan, R.O., 1987. Diesel exhaust is a pulmonary carcinogen in rats exposed chronically by inhalation. Fundam. Appl. Toxicol. 9, 208\u2013221. Mauderly, J.L., Banas, D.A., Griffith, W.C., Hahn, F.F., Henderson, R.F., McClellan, R.O., 1996. Diesel exhaust is not a pulmonary carcinogen in CD-1 mice exposed under conditions carcinogenic to F344 rats. Fundam. Appl. Toxicol. 30, 233\u2013242. Mauderly, J.L., Garshick, E., 2009. Diesel exhaust. In: Lippmann, M. (Ed.), Environmental Toxicants. Wiley, NY, pp. 551\u2013632 (Chapter 17). http://www.ehjournal.net/content/10/1/96 http://www.nap.edu/catalog.php?record_id=12697 http://www.nap.edu/catalog.php?record_id=12697 http://www.jm.com/corporate/56.htm http://www.jm.com/corporate/56.htm T.W. Hesterberg et al. / Regulatory Toxicology and Pharmacology 62 (2012) 257\u2013277 277 McClellan, R.O., Henderson, R.F. (Eds.), 1989. Concepts in Inhalation Toxicology. Taylor and Francis, Washington, DC, First Edition. McClellan, R.O., Miller, F.J., Hesterberg, T.W., Warheit, D.B., Bunn, W.B., Dement, J.M., Kane, A.B., Lippmann, M., Mast, R.W., McConnell, E.E., Rheinhardt, C.F., 1992. Approaches to evaluating the toxicity and carcinogenicity of man-made fibers. Regul. Toxicol. Pharmacol. 16, 321\u2013364. McClellan, R.O., Hesterberg, T.W., 1994. Role of biopersistence in the Pathogenicity of man-made fibers and methods for evaluating biopersistence. A summary of two round-table discussions. Env. Health Persp. 102, 277\u2013283. McClellan, R.O., 1995. Risk assessment for inhaled toxicants. In: McClellan, R.O., Henderson, R.F. (Eds.), Concepts in Inhalation Toxicology, second ed. Taylor & Francis, Washington, DC, pp. 579\u2013638. McClellan, R.O., 2000a. Particle interactions with the respiratory tract: an overview. In: Preining, O., Davis, E.J. (Eds.), History of Aerosol Science. Proceedings of the Symposium on the History of Aerosol Science. Verlag, Vienna, Austria, pp. 129\u2013 145. McClellan, R.O., 2000b. Particle interactions in the respiratory tract. In: Peter, Gehr, Heyder (Eds.), Particle\u2013Lung Interactions. Joachim, Marcel Dekker, Inc., New York, pp. 3\u201366. McClellan, R.O., Hahn, F.F., 2010. Comments on Draft Report on Carcinogens Substance Profile for Glass Wool Fibers (Respirable) as a Class (submitted to National Toxicology, Program June 21, 2010). McConnell, E.E., Kamstrup, O., Musselman, R., Hesterberg, T.W., Chevalier, J., Miiller, W.C., Thevanaz, P., 1994. Chronic inhalation study of size-separated rock and slag wool insulation fibers in Fischer 344/N rats. Inhal. Toxicol. 6, 571\u2013614. McConnell, E.E., 1995. Advantages and limits of in vivo screening tests. Ann. Occup. Hyg. 39, 727\u2013735. McConnell, E.E., 1996. Maximum tolerated doses in particulate inhalation studies: a pathologist\u2019s point of view. Inhal. Toxicol. 8 (Suppl.), 111\u2013123. McConnell, E.E., Axten, C., Hesterberg, T.W., Chevalier, J., Miiller, W.C., Everitt, J., Oberdorster, G., Chase, G.R., Thevenaz, P., Kotin, P., 1999. Studies on the inhalation toxicology of two fiber glasses and amosite asbestos in the Syrian golden hamster \u2013 Part II. Results of chronic exposure. Inhal. Toxicol. 11, 785\u2013 835. Mentzer, K.D., 2009. Comments of the North American Insulation Manufactuers Association (NAIMA), May 22, 2009. Mitchell, R.I., Reif, R.B., Mosberg, A.T., Thake, D.C., Connell, M.M., Donofrio, D.J., Hanoff, H.H., Roese, A.J. 1982. Final Report on a Chronic Inhalation Toxicology Study in Monkeys and Rats Exposed to Fibrous Glass. Prepared for the National Institute for Occupational Safety and Health under Contract No. 210-78-0037 by Battelle Columbus Laboratories, Columbus, OH. Mitchell, R.I., Donofrio, D.J., Moorman, W.J., 1986. Chronic inhalation toxicity of fibrous glass in rats and monkeys. J. Am. Coll. Toxicol. 5 (6), 545\u2013575. Moorman, W.J., Mitchell, R.T., Mosberg, A.T., Donofrio, D.J., 1988. Chronic inhalation toxicology of fibrous glass in rats and monkeys. Ann. Occup. Hyg. 32 (Suppl. 1), 757\u2013767. NIOSH (National Institute of Occupational Safety and Health), 1977. Criteria for a Recommended Standard. Occupational Exposure to Fibrous Glass. DHEW Publication No. 77\u2013152, NIOSH, Cincinnati, OH. NIOSH (National Institute of Occupational Safety and Health), 1987. Occupational Respiratory Diseases. DHHS (NIOSH) Publication No. 86\u2013102, NIOSH, Cincinnati, OH. NRC (National Research Council), 2000. Review of the US Navy\u2019s Exposure Standard for Manufactured Vitreous Fibers. National Academies Press, Washington, DC. NRC (National Research Council), 2007. Toxicity Testing in the 21st Century: A Vision and a Strategy, National Academy Press, Washington, DC. NTP (National Toxicology Program), 1980. First Report on Carcinogens, NTP, US Department of Health and Welfare. NTP (National Toxicology Program), 1994. Glass Wool (Respirable Size). Report on Carcinogens, seventh ed. National Toxicology Program, Public Health Service, US Department of Health and Human Services, Research Triangle Park, NC, USA. NTP, 2004. National Toxicology Program; Call for Public Comments on 21 Substances, Mixtures and Exposure Circumstances Proposed for Listing in the Report on Carcinogens, twelfth ed. Federal Register, vol. 69, No. 97, Wednesday, May 19, 2004, pp. 28940\u201328944. NTP, 2009a. National Toxicology Program (NTP), Report on Carcinogens (RoC), Availability of the Draft Background Document for Glass Wool Fibers, Request for Comments on the Draft Background Document, Announcement of the Glass Wool Fibers Expert Panel Meeting. Federal Register, vol. 74, No. 66, Wednesday, April 8, 2009, pp. 15983\u201315984. NTP, 2009b. Draft Report on Carcinogens Background Document for Glass Wool Fibers. National Toxicology Program, Public Health Service, US Department of Health and Human Services, Research Triangle Park, NC, USA, June 9\u201310, 2009. NTP, 2009d. NTP Report on Carcinogens Review Process. National Toxicology Program, Public Health Service, US Department of Health and Human Services, Research Triangle Park, NC, USA. <http://ntp.niehs.nih.gov/> (accessed 1.7.2009). NTP, 2011a. Draft Report on Carcinogens Substance Profile for glass Wool Fibers (Respirable) as a Class. NTP, 2011b. National Toxicology Program. 12th Report on Carcinogens. Certain Glass Wool Fibers (Inhalable). US Department of Health and Human Services, Research Triangle Park, NC, USA. Available at: <http://ntp.niehs.nih.gov/ntp/roc/ twelfth/roc12.pdf>. Nikula, K.J., Snipes, M.B., Barr, E.B., Griffith, W.C., Henderson, R.F., Mauderly, J.L., 1995. Comparative pulmonary toxicities and carcinogenicities of chronically inhaled diesel exhaust and carbon black in F-344 rats. Fundam. Appl. Toxicol. 25, 80\u201394. NAIMA (North American Insulation Manufacturer\u2019s Association), 1999. Letter from Mentzer, K.D. to Adam M. Finkel, Director of Health Standards, Occupational Safety and Health Administration, May 18, 1999. OEHHA (Office of Environmental Health Hazard Assessment). California Environmental Protection Agency. Notice of the Modification of the Listing of Glasswool Fibers (Airborne Particles of Respirable Size) to Glass Wool Fibers (Inhalable and Biopersistent). California Regulatory Notice Register 2011, vol. no. 46-Z, p. 1878. (OSHA) Occupational Safety and Health Administration, 1999. OSHA Endorses Major Agreement to Protect Workers Exposed to Fiber glass Insulation. OSHA News Release. May 18, 1999, Occupational Safety and Health Administration, Department of Labor, Washington, DC, USA. Oshimura, M., Hesterberg, T.W., Barrett, J.C., 1984. Correlation of asbestos-induced cytogenetic effects with cell transformation of Syrian hamster embryo cells in culture. Cancer Res. 44, 5017\u20135022. Oshimura, M., Hesterberg, T.W., Barrett, J.C., 1986. An early non random karyotypic change in immortal Syrian hamster embryo cell lines transformed by asbestos: trisomy of chromosome 11. Cancer Genetics and Cytogenetics 22, 225\u2013237. OSTP, (United States Office of Science and Technology Policy), 1985. Chemical carcinogens: a review of the science and its associated principles. Fed. Reg. 50, 10371\u201310442. Pott, F., Friedrichs, K.H., 1972. Tumors in rats following intraperitoneal injections of fibrous dusts. Naturwissenschaften 59, 318. Ray, B.D., 2010. Comments of Johns Manville Draft Substance Profile. Glass Wool Fibers (Respirable) as a Class. (submitted June 9, 2010). Ray, B.D., Bauer, J., 2009. Distinguishing special purpose glass fibers. Presented at the NTP Expert Panel on Glass Fibers Meeting, June 9-10, 2009. Rossiter, C.E., 1991. Fibre carcinogenesis: intra-cavitary studies cannot assess risk to man. In: Brown, R.C. et al. (Eds.), Mechanisms in Fibre Carcinogenesis. Proceedings of an International Symposium. Plenum Press, New York. Schlesinger, R.B., 1995. Deposition and clearance of inhaled particles. In: McClellan, R.O., Henderson, R.F. (Eds.), Concepts in Inhalation Toxicology. Taylor and Francis, Washington, DC, pp. 191\u2013224. Sells, B., 1994. What asbestos taught me about managing risk. Harv. Bus. Rev., 76\u2013 90. Smith, D.M., Ortiz, L.W., Archuleta, R.F., Johnson, N.F., 1987. Long-term health effects in hamsters and rats exposed chronically to man-made vitreous fibres. Ann. Occup. Hyg. 31 (4B), 731\u2013754. Snipes, M.B., 1989. Long term retention and clearance of particles inhaled by mammalian species. Crit. Rev. in Tox. 20, 175\u2013211. Stanton, M.F., Wrench, C., 1972. Mechanisms of mesothelioma induction with asbestos and fibrous glass. J. Natl. Cancer Inst. 48, 797\u2013821. Stanton, M.F., Layard, M., Tegeris, A., Miller, E., May, M., Kent, E., 1977. Carcinogenicity of fibrous glass: pleural response in the rat in relation to fiber dimension. J. Natl. Cancer Inst. 58, 503\u2013587. Stanton, M.F., Layard, M., Tegeris, A., Miller, E., May, M., Morgan, E., Smith, A., 1981. Relation of particle dimension to carcinogenicity in amphibole asbestoses and other fibrous minerals. J. Natl. Cancer Inst. 67, 965\u2013975. Stone, Robert Anderson., Youk, A.O., Marsh, G.M., Buchanich, J.M., McHenry, M.B., Smith, T.J., 2001. Historical cohort study of US man-made vitreous fiber production workers. IV. Quantitative exposure \u2013 response analysis of the nested case- control study of respiratory system cancer. J. Occup. Environ. Med. 43 (9), 779\u2013 792. Stone, Robert Anderson., Youk, A.O., Marsh, G.M., Buchanich, J.M., Smith, T.J., 2004. Historical Cohort Study of US man-made vitreous fiber production workers IX: summary of 1992 mortality followup and analysis of respiratory system cancer among female workers. J. Occup. Environ. Med. 46 (1), 55\u201367. Venturin, D., 2009. Comments of Unifrax 1 LLC on the RoC Expert Panel\u2019s recommendations on Listing Status for Glass Wool Fibers and the Scientific Justifiction for the Recommendations. 74 Fed. Reg. 40598 (August 12, 2009) (submitted September 28, 2009). Vu, V., Barrett, J.C., Roycroft, J., Schuman, L., Dankovic, D., Bbaro, P., Martonen, T., Pepelko, W., Lai, D., 1996. Chronic inhalation toxicity and carcinogenicity testing of respirable fibrous particle (Workshop report). Regul. Toxicol. Pharmacol. 24, 202\u2013212. Warheit, D.B., Hansen, J.F., Yuen, I.S., Kelly, D.P., Snaida, S.I., Hartsky, M., 1997. Inhalation of high concentrations of low toxicity dusts in rat results in impaired pulmonary clearance mechanisms and persistent inflammation. Toxicol. Appl. Pharmacol. 145 (1), 10\u201322. Weill, H., Hughes, J.M., Hammad, Y.Y., Glindmeyer, H.W., Sharon, G., Jones, R.N., 1983. Respiratory health in workers exposed to man-made vitreous fibers. Am. Rev. Respir. Dis. 128, 104\u2013112. Wolff, R.K., Henderson, R.F., Snipes, M.B., Griffith, W.C., Mauderly, J.L., Cuddihy, R.G., McClellan, R.O., 1987. Alterations in particle accumulation and clearance in lungs of rats chronically exposed to diesel exhaust. Fundam. Appl. Toxicol. 9, 154\u2013166. World Health Organization (WHO), 1986. International Symposium, Man-made mineral fibres in the working environment. WHO Regional Office for Europe, Copenhagen, Denmark, October 28\u201329, 1986. World Health Organization (WHO), 1992. Validity of methods for assessing the carcinogenicity of man-made fibres. European Program for Occupational Health, World Health Organization. http://ntp.niehs.nih.gov/ http://ntp.niehs.nih.gov/ntp/roc/twelfth/roc12.pdf http://ntp.niehs.nih.gov/ntp/roc/twelfth/roc12.pdf Product stewardship and science: Safe manufacture and use of fiber glass 1 Introduction 2 Are glass fiber products safe? 3 State of the science \u2013 1987 3.1 Epidemiology studies (pre-1987) 3.2 Laboratory animal studies using implantation (pre-1987) 3.3 Cell studies (pre-1987) 3.4 Inhalation studies with glass fibers (pre-1987) 4 Carcinogen classification schemes and use of old science 4.1 IARC carcinogenic hazard evaluation (1987\u20131988) 4.2 National Toxicology Program report on carcinogens classification 5 Multi-faceted path forward in 1987 5.1 Epidemiological studies (post-1987) 5.2 Setting the stage for new inhalation studies 5.3 Industry-sponsored chronic inhalation studies (post-1987) 5.4 Short-term animal biopersistence studies 5.5 In vitro fiber dissolution studies 5.6 Cell studies (post-1987) 6 Critique of intra-cavitary studies 7 Using the new scientific information 7.1 Equivocal findings 7.2 Voluntary exposure guidelines 7.3 ACGIH guidance 7.4 Health and safety partnership agreement with occupational and health administration 8 Carcinogen classification based on new scientific information 8.1 International agency for cancer research re-evaluation (2001\u20132002) 8.2 European Commission\u2019s Directive on synthetic mineral fibers 8.3 National Toxicology Program 12th report on carcinogens 8.4 California Office of Environmental Health Hazard Assessment 9 \u201cGreen\u201d products and technologies 10 Summary and conclusions 11 Dedication \u2013 Dr. Paul Kotin Conflict of interest statement Acknowledgments References", "Acknowledgement": "Hesterberg, T.W., 2010. Comments on the National Toxicology Program (NTP) Draft Report on Carcinogens: Substances Profile for Glass Wool Fibers (Respirable) as a Class (submitted June 7, 2010. Hesterberg, T.W., Long, C.M., Sax, S.N., Lapin, C.A., McClellan, R.O., Bunn, W.B., Valberg, P.A., 2011. Particulate matter in new technology diesel exhaust (NTDE) is quantitatively and qualitatively very different from that found in traditional diesel exhaust (TDE). J. Air & Waste Manage. Assoc. 61, 894\u2013913. Hughes, J.M., Jones, R.N., Glindmeyer, H.W., Hammad, Y.Y., Weill, H., 1993. Follow up study of workers exposed to man made mineral fibres. Br. J. Ind. Med. 50 (7), 658\u2013667. IARC, 1972. IARC Monographs on the Evaluation of Cacinogenic Risks to Humans. Vol. 1. Some Organic Substances, Chlorinated Hydrocarbons, Aromatic Amines, N-Nitroso Compounds and Natural Products. 1972, Lyon, France. IARC, 1973. IARC Monogoraphs on the Evaluation of Carcinogenic Risks to Humans, Asbestos, vol. 2, Lyon, France. IARC, 1977. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Asbestos, Supplement 14, Lyon, France. IARC, 1987. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Asbestos, Supplement 7, Lyon, France. IARC, 1979. IARC monographs on the evaluation of carcinogenic risk to humans, vol. 19. Some Monomers, Plastics and Synthetic Elastomers, and Acrolein. Lyon, France. IARC, 1988. Man-made mineral fibres and radon. IARC Monographs on the Evaluation of Carcinogenic Risk to Humans, vol. 43, International Agency for Research on Cancer, Lyon, France. IARC, 2002a. Man-made vitreous fibres. IARC Monographs on the Evaluation of Carcinogenic Risk to Humans, vol. 81, International Agency for Research on Cancer, Lyon, France. IARC, 2002b. Man-made vitreous fibres. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans, International Agency for Research on Cancer, Lyon, France, IARC. 381 pp. IOM/NRC (Institute of Medicine and National Research Council), 2009. A Review of the NIOSH Roadmap for Research on Asbestos Fibers and Other Elongated Mineral Particles. In: Nelson, A.R., Liverman, C.T., Eide, E.A., Abt, E. (Eds.), Committee for the Review of the NIOSH Research Roadmap on Asbestos Fibers and Other Elongate Mineral Particles. Institute of Medicine and National Research Council. Available from: http://www.nap.edu/ catalog.php?record_id=12697 (accessed 6/9/2011). IPCS (International Programme on Chemical Safety), 1988. Environmental Health Criteria 77. Man-Made Fibres. World Health Organization, Geneva, Switzerland. Johns Manville, 2010. Company History. Johns Manville Corporate website, <http:// www.jm.com/corporate/56.htm> (accessed 6.8.2011). Kamstrup, O., Davis, J.M.G., Ellehauge, A., Guldberg, M., 1998. The biopersistence and pathogenicity of man-made vitreous fibres after short- and long-term inhalation. Ann. Occup. Hyg. 42 (3), 191\u2013199. Kelsey, K., 2009a. Glass Wool Fibers Expert Panel Report. Part A. Peer Review Comments on Background Document on Glass Wool Fibers. Glass Wool Fibers Expert Panel Meeting, June 9\u201310, 2009, National Toxicology Program, Public Health Service, US Department of Health and Human Services, Research Triangle Park, NC, USA. Kelsey, K., 2009b. Expert Panel Report Part B: Recommendation for Listing Status, and the Scientific Justification for the Recommendation. Glass Wool Fibers Expert Panel Meeting, June 9\u201310, 2009, National Toxicology Program, Public Health Service, US Department of Health and Human Services, Research Triangle Park, NC, USA. Lewis, T.R., Morrow, P.E., McClellan, R.O., Raabe, O.G., Kennedy, G.L., Schwetz, B.A., Goehl, T.J., Roycroft, J.H., Chhabra, R.S., 1989. Establishing aerosol exposure concentrations for inhalation toxicity studies. Tox. Appl. Pharm. 99, 377\u2013383. Lippmann, M., 2009. Asbestos and other mineral and vitreous fibers. In: Lippmann, M. (Ed.), Environmental Toxicants: Human Exposure and Their Health Effects, third ed. Wiley Publishing (Chapter 12). Marsh, G.M., Enterline, P.E., 1977. Mortality among man-made mineral fiber workers in the United States. Presentation at the 105th Annual Meeting of the American Public Health Association, Washington, DC. Marsh, G.M., Youk, A.O., Stone, Robert Anderson., Buchanich, J.M., Gula, M.J., Smith, T.J., Quinn, M.M., 2001a. Historical cohort study of US man-made vitreous fiber workers I. 1992 fiber glass cohort follow-up \u2013 initial findings. J. Occup. Environ. Med. 43, 741\u2013756. Marsh, G.M., Gula, M.J., Youk, A.O., Buchanich, J.M., Churg, A., Colby, T.V., 2001b. Historical cohort study of US man-made vitreous fiber production workers II. Mortality from mesothelioma. J. Occup. Environ. Med. 43, 757\u2013766. Marsh, G.M., Buchanich, J.M., Youk, A.O., 2001c. Historical cohort study of US man- made vitreous fiber production workers: VI. Respiratory system cancer standardized mortality ratios adjusted for the confounding effect of cigarette smoking. J. Occup. Environ. Med. 43, 803\u2013808. Marsh G.M., Buchanich J.M., Yonk A.O., 2009. Comments on the National Toxicology Program Draft Background Document on Glass Wool Fibers, May 22, 2009. Mast, R.W., McConnell, E.E., Anderson, R., Chevalier, J., Kotin, P., Bernstein, D.M., Thevenaz, P., Glass, L.R., Miiller, W.C., Hesterberg, T.W., 1995a. Studies on the chronic toxicity (inhalation) of four types of refractory ceramic fiber in male Fischer 344 rats. Inhal. Toxicol. 7, 425\u2013467. Mast, R.W., McConnell, E.E., Hesterberg, T.W., Chevalier, J., Kotin, P., Thevenaz, P., Bernstein, D.M., Glass, L.R., Miiller, W., Anderson, R., 1995b. A multiple dose chronic inhalation study of size-separated kaolin refractory ceramic fiber in male Fisher 344 rats. Inhal. Toxicol. 7, 469\u2013502. Mauderly, J.L., Jones, R.D., Griffith, W.C., Henderson, R.F., McClellan, R.O., 1987. Diesel exhaust is a pulmonary carcinogen in rats exposed chronically by inhalation. Fundam. Appl. Toxicol. 9, 208\u2013221. Mauderly, J.L., Banas, D.A., Griffith, W.C., Hahn, F.F., Henderson, R.F., McClellan, R.O., 1996. Diesel exhaust is not a pulmonary carcinogen in CD-1 mice exposed under conditions carcinogenic to F344 rats. Fundam. Appl. Toxicol. 30, 233\u2013242. Mauderly, J.L., Garshick, E., 2009. Diesel exhaust. In: Lippmann, M. (Ed.), Environmental Toxicants. Wiley, NY, pp. 551\u2013632 (Chapter 17). http://www.ehjournal.net/content/10/1/96 http://www.nap.edu/catalog.php?record_id=12697 http://www.nap.edu/catalog.php?record_id=12697 http://www.jm.com/corporate/56.htm http://www.jm.com/corporate/56.htm T.W. Hesterberg et al. / Regulatory Toxicology and Pharmacology 62 (2012) 257\u2013277 277 McClellan, R.O., Henderson, R.F. (Eds.), 1989. Concepts in Inhalation Toxicology. Taylor and Francis, Washington, DC, First Edition. McClellan, R.O., Miller, F.J., Hesterberg, T.W., Warheit, D.B., Bunn, W.B., Dement, J.M., Kane, A.B., Lippmann, M., Mast, R.W., McConnell, E.E., Rheinhardt, C.F., 1992. Approaches to evaluating the toxicity and carcinogenicity of man-made fibers. Regul. Toxicol. Pharmacol. 16, 321\u2013364. McClellan, R.O., Hesterberg, T.W., 1994. Role of biopersistence in the Pathogenicity of man-made fibers and methods for evaluating biopersistence. A summary of two round-table discussions. Env. Health Persp. 102, 277\u2013283. McClellan, R.O., 1995. Risk assessment for inhaled toxicants. In: McClellan, R.O., Henderson, R.F. (Eds.), Concepts in Inhalation Toxicology, second ed. Taylor & Francis, Washington, DC, pp. 579\u2013638. McClellan, R.O., 2000a. Particle interactions with the respiratory tract: an overview. In: Preining, O., Davis, E.J. (Eds.), History of Aerosol Science. Proceedings of the Symposium on the History of Aerosol Science. Verlag, Vienna, Austria, pp. 129\u2013 145. McClellan, R.O., 2000b. Particle interactions in the respiratory tract. In: Peter, Gehr, Heyder (Eds.), Particle\u2013Lung Interactions. Joachim, Marcel Dekker, Inc., New York, pp. 3\u201366. McClellan, R.O., Hahn, F.F., 2010. Comments on Draft Report on Carcinogens Substance Profile for Glass Wool Fibers (Respirable) as a Class (submitted to National Toxicology, Program June 21, 2010). McConnell, E.E., Kamstrup, O., Musselman, R., Hesterberg, T.W., Chevalier, J., Miiller, W.C., Thevanaz, P., 1994. Chronic inhalation study of size-separated rock and slag wool insulation fibers in Fischer 344/N rats. Inhal. Toxicol. 6, 571\u2013614. McConnell, E.E., 1995. Advantages and limits of in vivo screening tests. Ann. Occup. Hyg. 39, 727\u2013735. McConnell, E.E., 1996. Maximum tolerated doses in particulate inhalation studies: a pathologist\u2019s point of view. Inhal. Toxicol. 8 (Suppl.), 111\u2013123. McConnell, E.E., Axten, C., Hesterberg, T.W., Chevalier, J., Miiller, W.C., Everitt, J., Oberdorster, G., Chase, G.R., Thevenaz, P., Kotin, P., 1999. Studies on the inhalation toxicology of two fiber glasses and amosite asbestos in the Syrian golden hamster \u2013 Part II. Results of chronic exposure. Inhal. Toxicol. 11, 785\u2013 835. Mentzer, K.D., 2009. Comments of the North American Insulation Manufactuers Association (NAIMA), May 22, 2009. Mitchell, R.I., Reif, R.B., Mosberg, A.T., Thake, D.C., Connell, M.M., Donofrio, D.J., Hanoff, H.H., Roese, A.J. 1982. Final Report on a Chronic Inhalation Toxicology Study in Monkeys and Rats Exposed to Fibrous Glass. Prepared for the National Institute for Occupational Safety and Health under Contract No. 210-78-0037 by Battelle Columbus Laboratories, Columbus, OH. Mitchell, R.I., Donofrio, D.J., Moorman, W.J., 1986. Chronic inhalation toxicity of fibrous glass in rats and monkeys. J. Am. Coll. Toxicol. 5 (6), 545\u2013575. Moorman, W.J., Mitchell, R.T., Mosberg, A.T., Donofrio, D.J., 1988. Chronic inhalation toxicology of fibrous glass in rats and monkeys. Ann. Occup. Hyg. 32 (Suppl. 1), 757\u2013767. NIOSH (National Institute of Occupational Safety and Health), 1977. Criteria for a Recommended Standard. Occupational Exposure to Fibrous Glass. DHEW Publication No. 77\u2013152, NIOSH, Cincinnati, OH. NIOSH (National Institute of Occupational Safety and Health), 1987. Occupational Respiratory Diseases. DHHS (NIOSH) Publication No. 86\u2013102, NIOSH, Cincinnati, OH. NRC (National Research Council), 2000. Review of the US Navy\u2019s Exposure Standard for Manufactured Vitreous Fibers. National Academies Press, Washington, DC. NRC (National Research Council), 2007. Toxicity Testing in the 21st Century: A Vision and a Strategy, National Academy Press, Washington, DC. NTP (National Toxicology Program), 1980. First Report on Carcinogens, NTP, US Department of Health and Welfare. NTP (National Toxicology Program), 1994. Glass Wool (Respirable Size). Report on Carcinogens, seventh ed. National Toxicology Program, Public Health Service, US Department of Health and Human Services, Research Triangle Park, NC, USA. NTP, 2004. National Toxicology Program; Call for Public Comments on 21 Substances, Mixtures and Exposure Circumstances Proposed for Listing in the Report on Carcinogens, twelfth ed. Federal Register, vol. 69, No. 97, Wednesday, May 19, 2004, pp. 28940\u201328944. NTP, 2009a. National Toxicology Program (NTP), Report on Carcinogens (RoC), Availability of the Draft Background Document for Glass Wool Fibers, Request for Comments on the Draft Background Document, Announcement of the Glass Wool Fibers Expert Panel Meeting. Federal Register, vol. 74, No. 66, Wednesday, April 8, 2009, pp. 15983\u201315984. NTP, 2009b. Draft Report on Carcinogens Background Document for Glass Wool Fibers. National Toxicology Program, Public Health Service, US Department of Health and Human Services, Research Triangle Park, NC, USA, June 9\u201310, 2009. NTP, 2009d. NTP Report on Carcinogens Review Process. National Toxicology Program, Public Health Service, US Department of Health and Human Services, Research Triangle Park, NC, USA. <http://ntp.niehs.nih.gov/> (accessed 1.7.2009). NTP, 2011a. Draft Report on Carcinogens Substance Profile for glass Wool Fibers (Respirable) as a Class. NTP, 2011b. National Toxicology Program. 12th Report on Carcinogens. Certain Glass Wool Fibers (Inhalable). US Department of Health and Human Services, Research Triangle Park, NC, USA. Available at: <http://ntp.niehs.nih.gov/ntp/roc/ twelfth/roc12.pdf>. Nikula, K.J., Snipes, M.B., Barr, E.B., Griffith, W.C., Henderson, R.F., Mauderly, J.L., 1995. Comparative pulmonary toxicities and carcinogenicities of chronically inhaled diesel exhaust and carbon black in F-344 rats. Fundam. Appl. Toxicol. 25, 80\u201394. NAIMA (North American Insulation Manufacturer\u2019s Association), 1999. Letter from Mentzer, K.D. to Adam M. Finkel, Director of Health Standards, Occupational Safety and Health Administration, May 18, 1999. OEHHA (Office of Environmental Health Hazard Assessment). California Environmental Protection Agency. Notice of the Modification of the Listing of Glasswool Fibers (Airborne Particles of Respirable Size) to Glass Wool Fibers (Inhalable and Biopersistent). California Regulatory Notice Register 2011, vol. no. 46-Z, p. 1878. (OSHA) Occupational Safety and Health Administration, 1999. OSHA Endorses Major Agreement to Protect Workers Exposed to Fiber glass Insulation. OSHA News Release. May 18, 1999, Occupational Safety and Health Administration, Department of Labor, Washington, DC, USA. Oshimura, M., Hesterberg, T.W., Barrett, J.C., 1984. Correlation of asbestos-induced cytogenetic effects with cell transformation of Syrian hamster embryo cells in culture. Cancer Res. 44, 5017\u20135022. Oshimura, M., Hesterberg, T.W., Barrett, J.C., 1986. An early non random karyotypic change in immortal Syrian hamster embryo cell lines transformed by asbestos: trisomy of chromosome 11. Cancer Genetics and Cytogenetics 22, 225\u2013237. OSTP, (United States Office of Science and Technology Policy), 1985. Chemical carcinogens: a review of the science and its associated principles. Fed. Reg. 50, 10371\u201310442. Pott, F., Friedrichs, K.H., 1972. Tumors in rats following intraperitoneal injections of fibrous dusts. Naturwissenschaften 59, 318. Ray, B.D., 2010. Comments of Johns Manville Draft Substance Profile. Glass Wool Fibers (Respirable) as a Class. (submitted June 9, 2010). Ray, B.D., Bauer, J., 2009. Distinguishing special purpose glass fibers. Presented at the NTP Expert Panel on Glass Fibers Meeting, June 9-10, 2009. Rossiter, C.E., 1991. Fibre carcinogenesis: intra-cavitary studies cannot assess risk to man. In: Brown, R.C. et al. (Eds.), Mechanisms in Fibre Carcinogenesis. Proceedings of an International Symposium. Plenum Press, New York. Schlesinger, R.B., 1995. Deposition and clearance of inhaled particles. In: McClellan, R.O., Henderson, R.F. (Eds.), Concepts in Inhalation Toxicology. Taylor and Francis, Washington, DC, pp. 191\u2013224. Sells, B., 1994. What asbestos taught me about managing risk. Harv. Bus. Rev., 76\u2013 90. Smith, D.M., Ortiz, L.W., Archuleta, R.F., Johnson, N.F., 1987. Long-term health effects in hamsters and rats exposed chronically to man-made vitreous fibres. Ann. Occup. Hyg. 31 (4B), 731\u2013754. Snipes, M.B., 1989. Long term retention and clearance of particles inhaled by mammalian species. Crit. Rev. in Tox. 20, 175\u2013211. Stanton, M.F., Wrench, C., 1972. Mechanisms of mesothelioma induction with asbestos and fibrous glass. J. Natl. Cancer Inst. 48, 797\u2013821. Stanton, M.F., Layard, M., Tegeris, A., Miller, E., May, M., Kent, E., 1977. Carcinogenicity of fibrous glass: pleural response in the rat in relation to fiber dimension. J. Natl. Cancer Inst. 58, 503\u2013587. Stanton, M.F., Layard, M., Tegeris, A., Miller, E., May, M., Morgan, E., Smith, A., 1981. Relation of particle dimension to carcinogenicity in amphibole asbestoses and other fibrous minerals. J. Natl. Cancer Inst. 67, 965\u2013975. Stone, Robert Anderson., Youk, A.O., Marsh, G.M., Buchanich, J.M., McHenry, M.B., Smith, T.J., 2001. Historical cohort study of US man-made vitreous fiber production workers. IV. Quantitative exposure \u2013 response analysis of the nested case- control study of respiratory system cancer. J. Occup. Environ. Med. 43 (9), 779\u2013 792. Stone, Robert Anderson., Youk, A.O., Marsh, G.M., Buchanich, J.M., Smith, T.J., 2004. Historical Cohort Study of US man-made vitreous fiber production workers IX: summary of 1992 mortality followup and analysis of respiratory system cancer among female workers. J. Occup. Environ. Med. 46 (1), 55\u201367. Venturin, D., 2009. Comments of Unifrax 1 LLC on the RoC Expert Panel\u2019s recommendations on Listing Status for Glass Wool Fibers and the Scientific Justifiction for the Recommendations. 74 Fed. Reg. 40598 (August 12, 2009) (submitted September 28, 2009). Vu, V., Barrett, J.C., Roycroft, J., Schuman, L., Dankovic, D., Bbaro, P., Martonen, T., Pepelko, W., Lai, D., 1996. Chronic inhalation toxicity and carcinogenicity testing of respirable fibrous particle (Workshop report). Regul. Toxicol. Pharmacol. 24, 202\u2013212. Warheit, D.B., Hansen, J.F., Yuen, I.S., Kelly, D.P., Snaida, S.I., Hartsky, M., 1997. Inhalation of high concentrations of low toxicity dusts in rat results in impaired pulmonary clearance mechanisms and persistent inflammation. Toxicol. Appl. Pharmacol. 145 (1), 10\u201322. Weill, H., Hughes, J.M., Hammad, Y.Y., Glindmeyer, H.W., Sharon, G., Jones, R.N., 1983. Respiratory health in workers exposed to man-made vitreous fibers. Am. Rev. Respir. Dis. 128, 104\u2013112. Wolff, R.K., Henderson, R.F., Snipes, M.B., Griffith, W.C., Mauderly, J.L., Cuddihy, R.G., McClellan, R.O., 1987. Alterations in particle accumulation and clearance in lungs of rats chronically exposed to diesel exhaust. Fundam. Appl. Toxicol. 9, 154\u2013166. World Health Organization (WHO), 1986. International Symposium, Man-made mineral fibres in the working environment. WHO Regional Office for Europe, Copenhagen, Denmark, October 28\u201329, 1986. World Health Organization (WHO), 1992. Validity of methods for assessing the carcinogenicity of man-made fibres. European Program for Occupational Health, World Health Organization. http://ntp.niehs.nih.gov/ http://ntp.niehs.nih.gov/ntp/roc/twelfth/roc12.pdf http://ntp.niehs.nih.gov/ntp/roc/twelfth/roc12.pdf Product stewardship and science: Safe manufacture and use of fiber glass 1 Introduction 2 Are glass fiber products safe? 3 State of the science \u2013 1987 3.1 Epidemiology studies (pre-1987) 3.2 Laboratory animal studies using implantation (pre-1987) 3.3 Cell studies (pre-1987) 3.4 Inhalation studies with glass fibers (pre-1987) 4 Carcinogen classification schemes and use of old science 4.1 IARC carcinogenic hazard evaluation (1987\u20131988) 4.2 National Toxicology Program report on carcinogens classification 5 Multi-faceted path forward in 1987 5.1 Epidemiological studies (post-1987) 5.2 Setting the stage for new inhalation studies 5.3 Industry-sponsored chronic inhalation studies (post-1987) 5.4 Short-term animal biopersistence studies 5.5 In vitro fiber dissolution studies 5.6 Cell studies (post-1987) 6 Critique of intra-cavitary studies 7 Using the new scientific information 7.1 Equivocal findings 7.2 Voluntary exposure guidelines 7.3 ACGIH guidance 7.4 Health and safety partnership agreement with occupational and health administration 8 Carcinogen classification based on new scientific information 8.1 International agency for cancer research re-evaluation (2001\u20132002) 8.2 European Commission\u2019s Directive on synthetic mineral fibers 8.3 National Toxicology Program 12th report on carcinogens 8.4 California Office of Environmental Health Hazard Assessment 9 \u201cGreen\u201d products and technologies 10 Summary and conclusions 11 Dedication \u2013 Dr. Paul Kotin Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Production-of-toxic-metabolites-in-Aspergillus-niger--Asper_2004_Regulatory-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15041150", "content": {"Acknowledgement": "Conclusion:information regarding the safe use of A.niger ,A.oryzae ,and T.reesei Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Progress-towards-an-OECD-reporting-framework-for-tra_2021_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34333066", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 3 Conclusions CRediT (Contributor roles) Taxonomy Statement Funding Disclaimer Declaration of competing interest References", "Funding": "Funding TWG was supported by the National Institutes of Health Research under the Environmental Exposures and Health Protection Research Unit co-led from Imperial College London and Public Health England (https://eeh.hpru.nihr.ac.uk/). ML was supported by the Dutch Ministry of Health, Welfare and Support. This work was supported in part by a European Chemicals Agency contract to Michabo Health Science (ECHA/2018/135) and by the European Chemical Industry Council (Cefic; awarded to BASF, Imperial College London, Syngenta, University of Birmingham and Vrije Universiteit Amsterdam). 3 Conclusions CRediT (Contributor roles) Taxonomy Statement Funding Disclaimer Declaration of competing interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Promoting-the-3Rs-to-enhance-the-OECD-fish-tox_2016_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26873775", "content": {"CoiStatement": "In conclusion, the OECD (2012) generic framework provides a highly valuable opportunity to improve fish toxicity and bio- concentration testing. The OECD framework highlights key 3Rs opportunities that are consistent with the scientific and ethical principles increasingly required by regulations, industry and soci- ety for chemical safety assessment. We encourage international stakeholders to take up the recommendations from the OECD framework in order to further promote the reduction, replacement and refinement of fish toxicity testing within the environmental safety assessment context. Conflicts of interest The author's declare no competing financial interests. Promoting the 3Rs to enhance the OECD fish toxicity testing framework Conflicts of interest Appendix A. Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Pronamide--Human-relevance-of-liver-mediated-_2015_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25846364", "content": {"CoiStatement": "Overall, the weight-of-evidence for pronamide-induced rat LCT supports a threshold (i.e., nonlinear) approach for risk assessment due to the lack of genotoxicity, absence of direct endocrine effects, clear NOAEL for the LCT response and supporting key events (200 ppm), and an adequate margin of exposure for an effect in a uniquely sensitive animal model. With regards to human rele- vance, the pronamide-associated rat LCT effect was considered not likely to be carcinogenic to humans due to qualitative and quantitative differences between rat and human Leydig cells. On this basis, the rat Leydig cell tumors associated with administra- tion of high dose levels of pronamide are not likely to pose a Leydig cell cancer hazard to humans. This MoA/HRF analysis iden- tified a point of departure (POD) for rat LCT effects of 200 ppm based on the lack of tumors in the cancer bioassay and no responses for earlier key events. Based on this hazard assessment for the pronamide-induced LCT effect, a margin of exposure approach to risk assessment using the chronic reference dose (cRfD), would be protective of human health. Conflict of interest statement The authors of this article are employed by The Dow Chemical Company or Dow AgroSciences, LLC, which produce pronamide and funded this work. Transparency Document Conflict of interest statement Transparency Document Acknowledgements References", "Acknowledgement": "The Transparency document associated with this article can be found in the online version. Acknowledgements The authors thank members of the Mammalian Toxicology and Cellular and Molecular Toxicology Group at Dow for all of their hard work in generating these data, Lynn Kan, Lynn McClymont, Dr. Michael J. Bartels, Dr. Holly Kolenda-Roberts, Dr. Danielle Brown, Dr. George Parker for their invaluable contributions and Lisa McFadden for statistical assistance. References Conflict of interest statement Transparency Document Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Pronamide--Weight-of-evidence-for-potential-estr_2015_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25846366", "content": {"CoiStatement": "5 Overall EDSabitha Papineni Tier 1 conclusion Conflict of interest Transparency Document Acknowledgements Appendix A Supplementary data References", "Acknowledgement": "5 Overall EDSabitha Papineni Tier 1 conclusion Conflict of interest Transparency Document Acknowledgements Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Proof-of-concept-for-a-banding-scheme-to-support-risk_2015_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26361853", "content": {"Acknowledgement": "Acknowledgments The authors appreciate discussion with and input from Dr. M. Carver on his work in this area. 4. Discussion 5. Conclusions Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Proper-knowledge-on-toxicokinetics-improves-human-hazar_2013_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24051162", "content": {"CoiStatement": "Conflict of interest statement None. 5 General discussion 6 Conclusion Conflict of interest statement Acknowledgments References", "Funding": "The authors acknowledge Peter Bos and Jacqueline van Engelen for critical comments during the final stage of the manuscript and the following experts who provided us valuable information on the testing and risk characterisation procedures as well as case studies within the various frameworks: Marloes Busschers and Angelique Welten (Ctgb), Jacqueline van Engelen, Rolaf van Leeuwen, Wim Mennes, Marja Pronk, Trijntje van der Velde-Koerts and Gerrit Wolterink (RIVM) and Ruud Woutersen (TNO). The Netherlands Ministry of Public Health, Welfare and Sports is acknowledged for providing funding the underlying research. References", "Acknowledgement": "Acknowledgments The authors acknowledge Peter Bos and Jacqueline van Engelen for critical comments during the final stage of the manuscript and the following experts who provided us valuable information on the testing and risk characterisation procedures as well as case studies within the various frameworks: Marloes Busschers and Angelique Welten (Ctgb), Jacqueline van Engelen, Rolaf van Leeuwen, Wim Mennes, Marja Pronk, Trijntje van der Velde-Koerts and Gerrit Wolterink (RIVM) and Ruud Woutersen (TNO). The Netherlands Ministry of Public Health, Welfare and Sports is acknowledged for providing funding the underlying research. 5 General discussion 6 Conclusion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Proposal-for-a-revised-Reference-Concentration--RfC-_2009_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19686793", "content": {"CoiStatement": "Conflict of interest One of the authors (Barbara D. Beck) has been named as an ex- pert in litigation involving air exposures to manganese, among other constituents. Some of the underlying work for this manu- script was conducted in the context of an assignment from an industrial client. Preparation of the manuscript was not supported by any client and the opinions are solely those of the authors. Discussion Conclusion Conflict of interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Proposal-of-GHS-sub-categorization-criteria-for-_2019_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31220472", "content": {"CoiStatement": "Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. Discussion Funding body information Declaration of interests Acknowledgements Transparency document References", "Funding": "Funding body information This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Declaration of interests This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Table 2a Determination of the optimal cutoff (%) for GHS sub-categorization by LLNA: BrdU-ELISA. Discussion Funding body information Declaration of interests Acknowledgements Transparency document References", "Acknowledgement": "Acknowledgements This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Discussion Funding body information Declaration of interests Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Proposal-of-a-flow-scheme-for-the-chemical-form-based-qua_2017_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29024715", "content": {"CoiStatement": "Conflict of interest statement We declare that there are no competing interests related to our manuscript. We declare that there are no competing interests related to our manuscript. Acknowledgements 6. Discussion Conflict of interest statement Acknowledgements Transparency document References", "Funding": "This research did not receive any specific grant from any funding agencies in the public, commercial, or not-for-profit sectors. Transparency document", "Acknowledgement": "Acknowledgements This research did not receive any specific grant from any funding agencies in the public, commercial, or not-for-profit sectors. 6. Discussion Conflict of interest statement Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Proposal-of-new-uncertainty-factor-application-t_2010_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20561553", "content": {"CoiStatement": "Conflict of interest statement The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgments Calculation of new uncertainty factors based on experimental data by probabilistic approach, an example of rats Summary of combined uncertainty factors for six animal species by probabilistic approach Application of subdivision and replacement of uncertainty factors for inter- and intra-species differences (chemical-specific adjustment factors) Discussion Conclusions Conflict of interest statement Acknowledgments References", "Acknowledgement": "Acknowledgments The present study was supported by Grants-in-Aid from Food Safety Commission, Japan (No. 0704) and developmental research funds from Toxicology Excellence for Risk Assessment, a non-profit toxicology R&D organization. The authors acknowledge Drs. Takeo Nomi and Masami Yamada (National Institute of Health Sciences, Japan) for their valuable comments. Calculation of new uncertainty factors based on experimental data by probabilistic approach, an example of rats Summary of combined uncertainty factors for six animal species by probabilistic approach Application of subdivision and replacement of uncertainty factors for inter- and intra-species differences (chemical-specific adjustment factors) Discussion Conclusions Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Proposed-new-classification-scheme-for-chemica_2006_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16764976", "content": {"Funding": "Two recent publications have identiWed new databases that contain eye injury data that were not evaluated in the 1999 HESI AAT pilot study (McGwin and Owsley, 2005; McGwin et al., 2005). The CPSC NEISS (National Elec- tronic Injury Surveillance System) database was changed in 2000 \u201cto include all types and external causes of non-fatal injuries treated in US hospital EDs\u201d (McGwin and Owsley, 2005). Therefore, a potential method for obtaining human eye injury data using the ILSI classiWcation scheme would be a prospective study conducted at the NEISS data collec- tion sites. The feasibility and funding for such a study have not been established. The new chemical eye injury classiWcation scheme is anticipated to have a number of practical applications. With respect to alternative methods development, the iden- tiWcation of relevant breakpoints (classes) for eye injuries will help provide a basis for development of in vitro tests that are biologically relevant to the in vivo mechanisms of human eye injuries. Furthermore, the classiWcation scheme may Wnd other applications such as in the appropriate eye safety and Wrst aid labeling, and for establishing regulatory classiWcations for chemicals based on the extent of human eye injury and rate and extent of recovery. These applica- tions would help ensure the human health and safety of marketed products. The classiWcation scheme is being pub- lished at this time to support its acceptance and utilization in the collection of human chemical eye injury data.", "Acknowledgement": "Acknowledgments The authors express their sincere appreciation to the many ophthalmic researchers and clinicians that took the time to provide comments in support of the development and/or revision of the classiWcation scheme. Summary and conclusions Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Proposing-a-scientific-confidence-framework-to-help-su_2015_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25707856", "content": {"CoiStatement": "National Toxicology Programme. 2014. Toxicology studies of indole-3-carbinol (CAS No. 700-06-1_in F33/N rats and B6C3F1/N mice and toxicology and carcinogenensis studies of indole-3-carbinol in Harlan Sprague Dawley rats and B6C3F1 mice. NTP Technical Report 584. Natsch, A., Ryan, C.A., Foertsch, L., Emter, R., Jaworska, J., Gerberick, F., Kern, P., 2013. A dataset on 145 chemicals tested in alternative assays for skin sensitization undergoing prevalidation. J. Appl. Toxicol. http://dx.doi.org/10.1002/jat.2868. Nguyen, L.P., Bradfield, C.A., 2008. The search for endogenous activators of the aryl hydrocarbon receptor. Chem. Res. Toxicol. 21, 102\u2013116. Nukada, Y., Miyazawa, M., Kazutoshi, S., Sakaguchi, H., Nishiyama, N., 2013. Data integration of non-animal tests for the development of a test battery to predict the skin sensitizing potential and potency of chemicals. Toxicol. In Vitro 27, 609\u2013618. Organisation for Economic Cooperation and Development (OECD), 2012a. The Adverse Outcome Pathway for Skin Sensitisation by Covalent Binding to Proteins: Part 1: Scientific Evidence. OECD, Paris. OECD. 2004. ENV/JM/MONO/(2004)24 <http://appli1.oecd.org/olis/2004doc.nsf/ linkto/env-jm-mono(2004)24>. OECD. 2007. Guidance on grouping of chemicals. OECD Series on Testing and Assessment No. 80. Organisation for Economic Co-operation and Development, Paris, France. OECD. 2011. OECD Series on Testing and Assessment Number 138. Report of the Workshop on Using Mechanistic Information in Forming Chemical Categories. ENV/JM/MONO(2011) 8. Organisation for Economic Co-operation and Development. Paris, France. Organisation for Economic Cooperation and Development, (OECD), 2012b. The Adverse Outcome Pathway for Skin Sensitisation by Covalent Binding to Proteins. Part 2: Use of the AOP to Develop Chemical Categories and Integrated Testing and Assessment Approaches. OECD, Paris. Organisation for Economic Cooperation and Development (OECD), 2013. Guidance Document on Developing and Assessing Adverse Outcome Pathways. OECD, Paris. OECD. 2014. Guidance on grouping of chemicals. OECD Series on Testing and Assessment No. 194. Organisation for Economic Co-operation and Development, Paris, France. OECD. 2014b. How to use the Toolbox AOP workflow for Skin Sensitization. Accessible at <http://www.oecd.org/env/ehs/risk-assessment/Tutorial_1_How% 20to%20use%20AOP%20for%20Skin%20sensitization_F_28012014.pdf>. OECD. 2015a. Test Guideline 442c. in chemico skin sensitisation. Direct Peptide Reactivity Assay (DPRA). OECD. 2015b. Test Guideline 442d in vitro skin sensitisation. ARE-Nrf2 Luciferase test method. Pande, K., Moran, S.M., Bradfield, C.A., 2005. Aspects of dioxin toxicity are mediated by interleukin 1-like cytokines. Mol. Pharmacol. 67, 1393\u20131398. http://refhub.elsevier.com/S0273-2300(15)00039-2/h0155 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0155 http://guidance.echa.europa.eu/docs/guidance_document/information_requirements_r7a_en.pdf?vers=20_08_08 http://guidance.echa.europa.eu/docs/guidance_document/information_requirements_r7a_en.pdf?vers=20_08_08 http://guidance.echa.europa.eu/docs/guidance_document/information_requirements_r7a_en.pdf?vers=20_08_08 http://www.ecetoc.org/technical-reports http://dx.doi.org/10.1016/j.taap.2010.03.009 http://dx.doi.org/10.1016/j.tiv.2013.09.009 http://dx.doi.org/10.1016/j.tiv.2013.09.009 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0185 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0185 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0185 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0185 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0185 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0185 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0185 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0185 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0190 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0190 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0190 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0190 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0190 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0195 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0195 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0195 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0195 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0205 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0205 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0205 http://dx.doi.org/10.1093/toxsci/kfm064 http://dx.doi.org/10.1093/toxsci/kfm064 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0215 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0215 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0215 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0220 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0220 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0220 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0220 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0225 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0225 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0225 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0225 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0230 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0230 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0230 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0230 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0230 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0230 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0235 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0235 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0235 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0235 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0235 http://dx.doi.org/10.3109/10408444.2011.558487 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0250 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0250 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0250 http://dx.doi.org/10.1002/jat.2869 http://dx.doi.org/10.1080/10408390903110692 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0265 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0265 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0265 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0265 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0280 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0280 http://refhub.elsevier.com/S0273-2300(15)00039-2/h9000 http://refhub.elsevier.com/S0273-2300(15)00039-2/h9000 http://refhub.elsevier.com/S0273-2300(15)00039-2/h9000 http://dx.doi.org/10.1002/em.20369 http://refhub.elsevier.com/S0273-2300(15)00039-2/h9005 http://refhub.elsevier.com/S0273-2300(15)00039-2/h9005 http://refhub.elsevier.com/S0273-2300(15)00039-2/h9005 http://refhub.elsevier.com/S0273-2300(15)00039-2/h9005 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0295 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0295 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0295 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0295 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0300 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0300 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0300 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0300 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0310 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0310 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0310 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0310 http://dx.doi.org/10.1093/toxsci/kft176 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0320 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0320 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0320 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0320 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0320 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0325 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0325 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0330 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0330 http://dx.doi.org/10.1002/jat.2868 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0350 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0350 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0355 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0355 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0355 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0355 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0360 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0360 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0360 http://appli1.oecd.org/olis/2004doc.nsf/linkto/env-jm-mono(2004)24 http://appli1.oecd.org/olis/2004doc.nsf/linkto/env-jm-mono(2004)24 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0380 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0380 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0380 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0380 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0385 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0385 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0385 http://www.oecd.org/env/ehs/risk-assessment/Tutorial_1_How%20to%20use%20AOP%20for%20Skin%20sensitization_F_28012014.pdf http://www.oecd.org/env/ehs/risk-assessment/Tutorial_1_How%20to%20use%20AOP%20for%20Skin%20sensitization_F_28012014.pdf http://refhub.elsevier.com/S0273-2300(15)00039-2/h0400 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0400 G. Patlewicz et al. / Regulatory Toxicology and Pharmacology 71 (2015) 463\u2013477 477 Pastoor, T.P., Bachman, A.N., Bell, D.R., Cohen, S.M., Dellarco, M., Dewhurst, I.C., Doe, J.E., Doerrer, N.G., Embry, M.R., Hines, R.N., Moretto, A., Phillips, R.D., Rowlands, J.C., Tanir, J.Y., Wolf, D.C., Boobis, A.R., 2014. A 21st century roadmap for human health risk assessment. Crit. Rev. Toxicol. 44 (Suppl. 3), 1\u20135. http://dx.doi.org/ 10.3109/10408444.2014.931923. Patlewicz, G., Simon, T., Goyak, K., Phillips, R.D., Rowlands, J.C., Seidel, S., Becker, R.A., 2013a. Use and validation of HT/HC assays to support 21st century toxicity evaluations. Regul. Toxicol. Pharmacol. 65, 259\u2013268. Patlewicz, G., Ball, N., Booth, E.D., Hulzebos, E., Zvinavashee, E., Hennes, C., 2013b. Use of category approaches, read-across and (Q)SAR: general considerations. Regul. Toxicol. Pharmacol. 67, 1\u201312. Patlewicz, G., Ball, N., Becker, R.A., Booth, E.D., Cronin, M.T.D., Kroese, D., Steup, D., Van Ravenzwaay, B., Hartung, T., 2014a. Food for thought. . .. Read-across approaches \u2013 misconceptions, promises and challenges ahead. ALTEX 31, 387\u2013 396. Patlewicz, G., Kuseva, C., Mehmed, A., Popova, Y., Dimitrova, G., Ellis, G., Hunziker, R., Kern, P., Low, L., Ringeissen, S., Robert, D.W., Mekenyan, O., 2014b. TIMES-SS \u2013 recent refinements as a result of an Industrial skin sensitisation consortium. SAR QSAR Environ. Res. 25, 367\u2013391. Patlewicz, G., Kuseva, C., Kesova, A., Popova, I., Zhechev, T., Pavlov, T., Roberts, D.W., Mekenyan, O.M., 2014c. Towards AOP application \u2013 implementation of an integrated approach to testing and assessment (IATA) into a pipeline tool for skin sensitization. Regul. Toxicol. Pharmacol. 69, 529\u2013545. Pelkonen, O., Tolonen, A., Rousu, T., Tursas, L., Turpeinen, M., Hokkanen, J., Uusitalo, J., Bouvier d\u2019Yvoire, M., Coecke, S., 2009. Comparison of metabolic stability and metabolite identification of 55 ECVAM/ICCVAM validation compounds between human and rat liver homogenates and microsomes \u2013 a preliminary analysis. ALTEX 26, 214\u2013222. Petkov, P.I., Rowlands, J.C., Budinsky, R., Zhao, B., Denison, M.S., Mekenyan, O., 2010. Mechanism-based common reactivity pattern (COREPA) modelling of aryl hydrocarbon receptor binding affinity. SAR QSAR Environ. Res. 21, 187\u2013214. http://dx.doi.org/10.1080/10629360903570933, 920009073 [pii]. Python, F., Goebel, C., Aeby, P., 2007. Assessment of the U937 cell line for the detection of contact allergens. Toxicol. Appl. Pharmacol. 220, 113\u2013124. Reisinger, K., Hoffmann, S., Al\u00e9p\u00e9e, N., Ashikaga, T., Barroso, J., Elcombe, C., Gellatly, N., Galbiati, V., Gibbs, S., Groux, H., Hibatallah, J., Keller, D., Kern, P., Klaric, M., Kolle, S., Kuehnl, J., Lambrechts, N., Lindstedt, M., Millet, M., Martinozzi-Teissier, S., Natsch, A., Petersohn, D., Pike, I., Sakaguchi, H., Schepky, A., Tailhardat, M., Templier, M., van Vliet, E., Maxwell, G., 2014. Systematic evaluation of non- animal test methods for skin sensitisation safety assessment. Toxicol. In Vitro 29, 259\u2013270. Roberts, D.W., Aptula, A.O., Patlewicz, G., Pease, C., 2008. Chemical reactivity indices and mechanism-based read across for non-animal based assessment of skin sensitization potential. J. Appl. Toxicol. 28, 443\u2013454. Roberts, D.W., Natsch, A., 2009. High throughput kinetic profiling approach for covalent binding to peptides. Application to skin sensitising potency of Michael acceptor electrophiles. Chem. Res. Toxicol. 22, 592\u2013603. Roberts, D.W., Patlewicz, G., 2014. Integrated testing and assessment approaches for skin sensitization: a commentary. J. Appl. Toxicol. 34, 436\u2013440. Rorije, E., Aldenberg, T., Buist, H., Kroese, D., Sch\u00fc\u00fcrmann, G., 2013. The OSIRIS weight of evidence approach: ITS for skin sensitisation. Regul. Toxicol. Pharmacol. 67, 146\u2013156. http://dx.doi.org/10.1016/j.yrtph.2013.06.003. Rotroff, D.M., Wetmore, B.A., Dix, D.J., Ferguson, S.S., Clewell, H.J., Houck, K.A., Lecluyse, E.L., Andersen, M.E., Judson, R.S., Smith, C.M., Sochaski, M.A., Kavlock, R.J., Boellmann, F., Martin, M.T., Reif, D.M., Wambaugh, J.F., Thomas, R.S., 2010. Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicol. Sci. 117, 348\u2013358. Rotroff, D.M., Dix, D.J., Houck, K.A., Knudsen, T.B., Martin, M.T., McLaurin, K.W., Reif, D.M., Crofton, K.M., Singh, A.V., Xia, M., Huang, R., Judson, R.S., 2013. Using in vitro high throughput screening assays to identify potential endocrine disrupting chemicals. Environ. Health Perspect. 121, 7\u201314. Rowlands, J.C., Budinsky, R., Gollapudi, B., Novak, R., Abdelmegeed, M., Cukovic, D., Dombokowski, A., 2011. Transcriptional profiles induced by the aryl hydrocarbon receptor agonists 2,3,7,8-tetrachlorodibenz-p-dioxin, 2,3,7,8- tetrachlorodibenzofuran and 2,3,4,7,8-pentachlorodibenzofuran in primary rat hepatocytes. Chemosphere 85, 232\u2013238. Sakaguchi, H., Ashikaga, T., Kosaka, N., Sono, S., Nishiyama, N., Itagaki, H., 2007. The in vitro skin sensitization test; human cell line activation test (h-CLAT) using THP-1 cells. Toxicol. Lett. 172, S93. Scholz, S., Sela, E., Blaha, L., Braunbeck, T., Galay-Burgos, M., Garc\u00eda-Franco, M., Guinea, J., Kl\u00fcver, N., Schirmer, K., Tanneberger, K., Tobor-Kap\u0142on, M., Witters, H., Belanger, S., Benfenati, E., Creton, S., Cronin, M.T.D., Eggen, R.I.L., Embry, M., Ekman, D., Gourmelon, A., Halder, M., Hardy, B., Hartung, T., Hubesch, B., Jungmann, D., Lampi, M.A., Lee, L., L\u00e9onard, M., K\u00fcster, E., Lillicrap, A., Luckenbach, T., Murk, A.J., Navas, J.M., Peijnenburg, W., Repetto, G., Salinas, E., Sch\u00fc\u00fcrmann, G., Spielmann, H., Tollefsen, K.E., Walter-Rohde, S., Whale, G., Wheeler, J.R., Winter, M.J., 2013. A European perspective on alternatives to animal testing for environmental hazard identification and risk assessment. Regul. Toxicol. Pharmacol. 67, 506\u2013530. Schultz, T.W., Yarbrough, J.W., Johnson, E.L., 2005. Structure\u2013activity relationships for reactivity of carbonyl compounds with glutathione. SAR QSAR Environ. Res. 16, 313\u2013322. Shah, I., Houck, K., Judson, R.S., Kavlock, R.J., Martin, M.T., Reif, D.M., Wambaugh, J., Dix, D.J., 2011. Using nuclear receptor activity to stratify hepatocarcinogens. PLoS ONE 6, e14584. http://dx.doi.org/10.1371/journal.pone.0014584. Sheikh-Bahaei, S., Maher, J.J., Hunt, C.A., 2010. Computational experiments reveal plausible mechanisms for changing patterns of hepatic zonation of xenobiotic clearance and hepatotoxicity. J. Theor. Biol. 265, 718\u2013733. Simon, T., Aylward, L.L., Kirman, C.R., Rowlands, J.C., Budinsky, R.A., 2009. Estimates of cancer potency of 2,3,7,8-tetrachlorodibenzo(p)dioxin using linear and nonlinear dose\u2013response modeling and toxicokinetics. Toxicol. Sci. 112, 490\u2013506. Simon, T., Stoney Simons Jr., S., Preston, R.J., Boobis, A.R., Cohen, S.M., Doerrer, N.G., Fenner-Crisp, P.A., McMullin, T., McQueen, C.A., Rowlands, J.C., 2014. The use of mode of action information in risk assessment: quantitative key events/dose\u2013 response framework for modeling the dose\u2013response for key events. Crit. Rev. Toxicol., in press Teeguarden, J., Hanson-Drury, S., Fisher, J.W., Doerge, D.R., 2013. Are typical human serum BPA concentrations measurable and sufficient to be estrogenic in the general population? Food Chem. Toxicol. 62, 949\u2013963. http://dx.doi.org/ 10.1016/j.fct.2013.08.001. Teeguarden, J.G., Calafat, A.M., Ye, X., Doerge, D.R., Churchwell, M.I., Gunawan, R., Graham, M.K., 2011. Twenty-four hour human urine and serum profiles of bisphenol a during high-dietary exposure. Toxicol. Sci. 123, 48\u201357. http:// dx.doi.org/10.1093/toxsci/kfr160. Teeguarden, J.G., Hanson-Drury, S., 2013. A systematic review of Bisphenol A \u2018\u2018low dose\u2019\u2019 studies in the context of human exposure: a case for establishing standards for reporting \u2018\u2018low-dose\u2019\u2019 effects of chemicals. Food Chem. Toxicol. 62, 935\u2013948. http://dx.doi.org/10.1016/j.fct.2013.07.007. Thomas, R.S., Black, M., Li, L., Healy, E., Chu, T.-M., Bao, W., Andersen, M., Wolfinger, R., 2012. A comprehensive statistical analysis of predicting in vivo hazard using high-throughput in vitro screening. Toxicol. Sci. http://dx.doi.org/ 10.1093/toxsci/kfs159. Thomas, R.S., Philbert, M.A., Auerbach, S.S., Wetmore, B.A., Devito, M.J., Cote, I., Rowlands, J.C., Whelan, M.P., Hays, S.M., Andersen, M.E., Meek, M.E.B., Reiter, L.W., Lambert, J.C., Clewell, H.J., Stephens, M.L., Zhao, Q.J., Wesselkamper, S.C., Flowers, L., Carney, E.W., Pastoor, T.P., Petersen, D.D., Yauk, C.L., Nong, A., 2013. Incorporating new technologies into toxicity testing and risk assessment: moving from 21st century vision to a data-driven framework. Toxicol. Sci. 136, 4\u201318. http://dx.doi.org/10.1093/toxsci/kft178. Tluczkiewicz, I., Batke, M., Kroese, D., Buist, H., Aldenberg, T., Paun\u00e9, E., Grimm, H., K\u00fchne, R., Sch\u00fc\u00fcrmann, G., Mangelsdorf, I., Escher, S.E., 2013. The OSIRIS weight of evidence approach: ITS for the endpoints repeated-dose toxicity (RepDose ITS). Regul. Toxicol. Pharmacol. 67, 157\u2013169. http://dx.doi.org/10.1016/ j.yrtph.2013.02.004. Tollefsen, K.E., Scholz, S., Cronin, M.T., Edwards, S.W., de Knecht, J., Crofton, K., Garcia-Reyero, N., Hartung, T., Worth, A., Patlewicz, G., 2014. Applying adverse outcome pathways (AOPs) to support integrated approaches to testing and assessment (IATA). Regul. Toxicol. Pharmacol. 70, 629\u2013640. Tonnelier, A., Coecke, S., Zald\u00edvar, J.-M., 2011. Screening of chemicals for human bioaccumulative potential with a physiologically based toxicokinetic model. Arch. Toxicol. http://dx.doi.org/10.1007/s00204-011-0768-0. Urbisch, D., Mehling, A., Guth, K., Ramirez, T., Honarvar, N., Kolle, S., Landsiedel, R., Jaworska, J., Kern, P.S., Gerberick, F., Natsch, A., Emter, R., Ashikaga, T., Miyazawa, M., Sakaguchi, H., 2014. Assessing skin sensitization hazard in mice and men using non-animal test methods. Regul. Toxicol. Pharmacol. 71, 337\u2013351. van der Veen, J.W., Rorije, E., Emter, R., Natsch, A., van Loveren, H., Ezendam, J., 2014. Evaluating the performance of integrated approaches for hazard identification of skin sensitizing chemicals. Regul. Toxicol. Pharmacol. 2014 (69), 371\u2013379. van Leeuwen, K., Schultz, T.W., Henry, T., Diderich, B., Veith, G.D., 2009. Using chemical categories to fill data gaps in hazard assessment. SAR QSAR Environ. Res. 20, 207\u2013220. Vezin, C.M., Walker, N.J., Olson, J.R., 2004. Subchronic exposure to TCDD, PeCDF, PCB 126 and PCB 153: effect on hepatic gene expression. Environ. Health Perspect. 112, 1636\u20131644. Vinken, M., 2013. The adverse outcome pathway concept: a pragmatic tool in toxicology. Toxicology 312, 158\u2013165. http://dx.doi.org/10.1016/j.tox.2013.08.011. Wambaugh, J.F., Setzer, R.W., Reif, D.M., Gangwal, S., Mitchell-Blackwood, J., Arnot, J.A., Joliet, O., Frame, A., Rabinowitz, J., Knudsen, T.B., Judson, R.S., Egeghy, P., Vallero, D., Cohen Hubal, E.A., 2013. High-throughput models for exposure- based chemical prioritization in the ExpoCast project. Environ. Sci. Technol. 47, 8479\u20138488. Yao, C.Q., Prokopec, S.D., Watson, J.D., Pang, R., P\u2019ng, C., Chong, L.C., Harding, N.J., Pohjanvirta, R., Okey, A.B., Boutros, P.C., 2012. Inter-strain heterogeneity in rat hepatic transcriptomic responses to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Toxicol. Appl. Pharmacol. 260, 135\u2013145. Wetmore, B.A., Wambaugh, J.F., Ferguson, S.S., Sochaski, M.A., Rotroff, D.M., Freeman, K., Clewell, H.J., Dix, D.J., Andersen, M.E., Houck, K.A., Allen, B., Judson, R.S., Singh, R., Kavlock, R.J., Richard, A.M., Thomas, R.S., 2011. Integration of dosimetry, exposure and high-throughput screening data in chemical toxicity assessment. Toxicol. Sci. 125, 157\u2013174. http://dx.doi.org/10.1093/toxsci/kfr254. Zhao, Y.Y.I., Tao, F.M., Zeng, E.Y., 2008. Theoretical study of the quantitative structure\u2013activity relationships for the toxicity of dibenzo-p-dioxins. Chemosphere 73, 86\u201391. http://dx.doi.org/10.3109/10408444.2014.931923 http://dx.doi.org/10.3109/10408444.2014.931923 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0410 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0410 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0410 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0415 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0415 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0415 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0420 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0420 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0420 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0420 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0420 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0425 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0425 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0425 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0425 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0430 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0430 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0430 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0430 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0435 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0435 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0435 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0435 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0435 http://dx.doi.org/10.1080/10629360903570933 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0445 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0445 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0450 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0450 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0450 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0450 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0450 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0450 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0450 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0455 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0455 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0455 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0460 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0460 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0460 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0465 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0465 http://dx.doi.org/10.1016/j.yrtph.2013.06.003 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0475 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0475 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0475 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0475 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0475 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0480 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0480 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0480 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0480 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0480 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0485 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0485 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0485 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0485 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0485 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0490 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0490 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0490 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0495 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0495 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0495 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0495 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0495 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0495 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0495 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0495 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0495 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0495 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0500 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0500 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0500 http://dx.doi.org/10.1371/journal.pone.0014584 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0510 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0510 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0510 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0515 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0515 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0515 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0520 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0520 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0520 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0520 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0520 http://dx.doi.org/10.1016/j.fct.2013.08.001 http://dx.doi.org/10.1016/j.fct.2013.08.001 http://dx.doi.org/10.1093/toxsci/kfr160 http://dx.doi.org/10.1093/toxsci/kfr160 http://dx.doi.org/10.1016/j.fct.2013.07.007 http://dx.doi.org/10.1093/toxsci/kfs159 http://dx.doi.org/10.1093/toxsci/kfs159 http://dx.doi.org/10.1093/toxsci/kft178 http://dx.doi.org/10.1016/j.yrtph.2013.02.004 http://dx.doi.org/10.1016/j.yrtph.2013.02.004 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0555 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0555 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0555 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0555 http://dx.doi.org/10.1007/s00204-011-0768-0 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0565 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0565 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0565 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0565 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0565 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0570 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0570 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0570 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0570 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0575 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0575 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0575 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0580 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0580 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0580 http://dx.doi.org/10.1016/j.tox.2013.08.011 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0590 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0590 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0590 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0590 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0590 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0595 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0595 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0595 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0595 http://dx.doi.org/10.1093/toxsci/kfr254 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0610 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0610 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0610 Proposing a scientific confidence framework to help support the application of adverse outcome pathways for regulatory purposes 1 Introduction 2 Adverse outcome pathway 3 Challenges in applying AOPs in regulatory decision making: a framework to document scientific confidence 3.1 Prioritization 3.1.1 Case study 1: endocrine activity AOP leading to reproductive dysfunction 3.2 Chemical categories and associated read-across 3.2.1 Case study 2; skin sensitisation AOP as applied to chemical categorization and read-across 3.2.2 Case study 3: AHR rodent liver tumor AOP 3.3 Informing test method refinement and/or development 3.4 Integrated approaches to testing and assessment 3.4.1 Case study 2; skin sensitisation AOP as applied to IATA 3.4.2 Case study 3; AHR AOP as applied to IATA 3.5 Hazard and risk assessment 3.6 Considerations for dosimetry 4 Summary Conflict of interest Acknowledgments References", "Acknowledgement": "National Toxicology Programme. 2014. Toxicology studies of indole-3-carbinol (CAS No. 700-06-1_in F33/N rats and B6C3F1/N mice and toxicology and carcinogenensis studies of indole-3-carbinol in Harlan Sprague Dawley rats and B6C3F1 mice. NTP Technical Report 584. Natsch, A., Ryan, C.A., Foertsch, L., Emter, R., Jaworska, J., Gerberick, F., Kern, P., 2013. A dataset on 145 chemicals tested in alternative assays for skin sensitization undergoing prevalidation. J. Appl. Toxicol. http://dx.doi.org/10.1002/jat.2868. Nguyen, L.P., Bradfield, C.A., 2008. The search for endogenous activators of the aryl hydrocarbon receptor. Chem. Res. Toxicol. 21, 102\u2013116. Nukada, Y., Miyazawa, M., Kazutoshi, S., Sakaguchi, H., Nishiyama, N., 2013. Data integration of non-animal tests for the development of a test battery to predict the skin sensitizing potential and potency of chemicals. Toxicol. In Vitro 27, 609\u2013618. Organisation for Economic Cooperation and Development (OECD), 2012a. The Adverse Outcome Pathway for Skin Sensitisation by Covalent Binding to Proteins: Part 1: Scientific Evidence. OECD, Paris. OECD. 2004. ENV/JM/MONO/(2004)24 <http://appli1.oecd.org/olis/2004doc.nsf/ linkto/env-jm-mono(2004)24>. OECD. 2007. Guidance on grouping of chemicals. OECD Series on Testing and Assessment No. 80. Organisation for Economic Co-operation and Development, Paris, France. OECD. 2011. OECD Series on Testing and Assessment Number 138. Report of the Workshop on Using Mechanistic Information in Forming Chemical Categories. ENV/JM/MONO(2011) 8. Organisation for Economic Co-operation and Development. Paris, France. Organisation for Economic Cooperation and Development, (OECD), 2012b. The Adverse Outcome Pathway for Skin Sensitisation by Covalent Binding to Proteins. Part 2: Use of the AOP to Develop Chemical Categories and Integrated Testing and Assessment Approaches. OECD, Paris. Organisation for Economic Cooperation and Development (OECD), 2013. Guidance Document on Developing and Assessing Adverse Outcome Pathways. OECD, Paris. OECD. 2014. Guidance on grouping of chemicals. OECD Series on Testing and Assessment No. 194. Organisation for Economic Co-operation and Development, Paris, France. OECD. 2014b. How to use the Toolbox AOP workflow for Skin Sensitization. Accessible at <http://www.oecd.org/env/ehs/risk-assessment/Tutorial_1_How% 20to%20use%20AOP%20for%20Skin%20sensitization_F_28012014.pdf>. OECD. 2015a. Test Guideline 442c. in chemico skin sensitisation. Direct Peptide Reactivity Assay (DPRA). OECD. 2015b. Test Guideline 442d in vitro skin sensitisation. ARE-Nrf2 Luciferase test method. Pande, K., Moran, S.M., Bradfield, C.A., 2005. Aspects of dioxin toxicity are mediated by interleukin 1-like cytokines. Mol. Pharmacol. 67, 1393\u20131398. http://refhub.elsevier.com/S0273-2300(15)00039-2/h0155 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0155 http://guidance.echa.europa.eu/docs/guidance_document/information_requirements_r7a_en.pdf?vers=20_08_08 http://guidance.echa.europa.eu/docs/guidance_document/information_requirements_r7a_en.pdf?vers=20_08_08 http://guidance.echa.europa.eu/docs/guidance_document/information_requirements_r7a_en.pdf?vers=20_08_08 http://www.ecetoc.org/technical-reports http://dx.doi.org/10.1016/j.taap.2010.03.009 http://dx.doi.org/10.1016/j.tiv.2013.09.009 http://dx.doi.org/10.1016/j.tiv.2013.09.009 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0185 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0185 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0185 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0185 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0185 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0185 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0185 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0185 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0190 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0190 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0190 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0190 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0190 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0195 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0195 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0195 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0195 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0205 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0205 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0205 http://dx.doi.org/10.1093/toxsci/kfm064 http://dx.doi.org/10.1093/toxsci/kfm064 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0215 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0215 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0215 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0220 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0220 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0220 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0220 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0225 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0225 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0225 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0225 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0230 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0230 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0230 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0230 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0230 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0230 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0235 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0235 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0235 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0235 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0235 http://dx.doi.org/10.3109/10408444.2011.558487 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0250 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0250 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0250 http://dx.doi.org/10.1002/jat.2869 http://dx.doi.org/10.1080/10408390903110692 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0265 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0265 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0265 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0265 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0280 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0280 http://refhub.elsevier.com/S0273-2300(15)00039-2/h9000 http://refhub.elsevier.com/S0273-2300(15)00039-2/h9000 http://refhub.elsevier.com/S0273-2300(15)00039-2/h9000 http://dx.doi.org/10.1002/em.20369 http://refhub.elsevier.com/S0273-2300(15)00039-2/h9005 http://refhub.elsevier.com/S0273-2300(15)00039-2/h9005 http://refhub.elsevier.com/S0273-2300(15)00039-2/h9005 http://refhub.elsevier.com/S0273-2300(15)00039-2/h9005 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0295 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0295 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0295 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0295 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0300 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0300 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0300 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0300 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0310 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0310 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0310 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0310 http://dx.doi.org/10.1093/toxsci/kft176 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0320 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0320 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0320 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0320 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0320 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0325 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0325 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0330 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0330 http://dx.doi.org/10.1002/jat.2868 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0350 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0350 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0355 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0355 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0355 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0355 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0360 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0360 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0360 http://appli1.oecd.org/olis/2004doc.nsf/linkto/env-jm-mono(2004)24 http://appli1.oecd.org/olis/2004doc.nsf/linkto/env-jm-mono(2004)24 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0380 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0380 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0380 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0380 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0385 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0385 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0385 http://www.oecd.org/env/ehs/risk-assessment/Tutorial_1_How%20to%20use%20AOP%20for%20Skin%20sensitization_F_28012014.pdf http://www.oecd.org/env/ehs/risk-assessment/Tutorial_1_How%20to%20use%20AOP%20for%20Skin%20sensitization_F_28012014.pdf http://refhub.elsevier.com/S0273-2300(15)00039-2/h0400 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0400 G. Patlewicz et al. / Regulatory Toxicology and Pharmacology 71 (2015) 463\u2013477 477 Pastoor, T.P., Bachman, A.N., Bell, D.R., Cohen, S.M., Dellarco, M., Dewhurst, I.C., Doe, J.E., Doerrer, N.G., Embry, M.R., Hines, R.N., Moretto, A., Phillips, R.D., Rowlands, J.C., Tanir, J.Y., Wolf, D.C., Boobis, A.R., 2014. A 21st century roadmap for human health risk assessment. Crit. Rev. Toxicol. 44 (Suppl. 3), 1\u20135. http://dx.doi.org/ 10.3109/10408444.2014.931923. Patlewicz, G., Simon, T., Goyak, K., Phillips, R.D., Rowlands, J.C., Seidel, S., Becker, R.A., 2013a. Use and validation of HT/HC assays to support 21st century toxicity evaluations. Regul. Toxicol. Pharmacol. 65, 259\u2013268. Patlewicz, G., Ball, N., Booth, E.D., Hulzebos, E., Zvinavashee, E., Hennes, C., 2013b. Use of category approaches, read-across and (Q)SAR: general considerations. Regul. Toxicol. Pharmacol. 67, 1\u201312. Patlewicz, G., Ball, N., Becker, R.A., Booth, E.D., Cronin, M.T.D., Kroese, D., Steup, D., Van Ravenzwaay, B., Hartung, T., 2014a. Food for thought. . .. Read-across approaches \u2013 misconceptions, promises and challenges ahead. ALTEX 31, 387\u2013 396. Patlewicz, G., Kuseva, C., Mehmed, A., Popova, Y., Dimitrova, G., Ellis, G., Hunziker, R., Kern, P., Low, L., Ringeissen, S., Robert, D.W., Mekenyan, O., 2014b. TIMES-SS \u2013 recent refinements as a result of an Industrial skin sensitisation consortium. SAR QSAR Environ. Res. 25, 367\u2013391. Patlewicz, G., Kuseva, C., Kesova, A., Popova, I., Zhechev, T., Pavlov, T., Roberts, D.W., Mekenyan, O.M., 2014c. Towards AOP application \u2013 implementation of an integrated approach to testing and assessment (IATA) into a pipeline tool for skin sensitization. Regul. Toxicol. Pharmacol. 69, 529\u2013545. Pelkonen, O., Tolonen, A., Rousu, T., Tursas, L., Turpeinen, M., Hokkanen, J., Uusitalo, J., Bouvier d\u2019Yvoire, M., Coecke, S., 2009. Comparison of metabolic stability and metabolite identification of 55 ECVAM/ICCVAM validation compounds between human and rat liver homogenates and microsomes \u2013 a preliminary analysis. ALTEX 26, 214\u2013222. Petkov, P.I., Rowlands, J.C., Budinsky, R., Zhao, B., Denison, M.S., Mekenyan, O., 2010. Mechanism-based common reactivity pattern (COREPA) modelling of aryl hydrocarbon receptor binding affinity. SAR QSAR Environ. Res. 21, 187\u2013214. http://dx.doi.org/10.1080/10629360903570933, 920009073 [pii]. Python, F., Goebel, C., Aeby, P., 2007. Assessment of the U937 cell line for the detection of contact allergens. Toxicol. Appl. Pharmacol. 220, 113\u2013124. Reisinger, K., Hoffmann, S., Al\u00e9p\u00e9e, N., Ashikaga, T., Barroso, J., Elcombe, C., Gellatly, N., Galbiati, V., Gibbs, S., Groux, H., Hibatallah, J., Keller, D., Kern, P., Klaric, M., Kolle, S., Kuehnl, J., Lambrechts, N., Lindstedt, M., Millet, M., Martinozzi-Teissier, S., Natsch, A., Petersohn, D., Pike, I., Sakaguchi, H., Schepky, A., Tailhardat, M., Templier, M., van Vliet, E., Maxwell, G., 2014. Systematic evaluation of non- animal test methods for skin sensitisation safety assessment. Toxicol. In Vitro 29, 259\u2013270. Roberts, D.W., Aptula, A.O., Patlewicz, G., Pease, C., 2008. Chemical reactivity indices and mechanism-based read across for non-animal based assessment of skin sensitization potential. J. Appl. Toxicol. 28, 443\u2013454. Roberts, D.W., Natsch, A., 2009. High throughput kinetic profiling approach for covalent binding to peptides. Application to skin sensitising potency of Michael acceptor electrophiles. Chem. Res. Toxicol. 22, 592\u2013603. Roberts, D.W., Patlewicz, G., 2014. Integrated testing and assessment approaches for skin sensitization: a commentary. J. Appl. Toxicol. 34, 436\u2013440. Rorije, E., Aldenberg, T., Buist, H., Kroese, D., Sch\u00fc\u00fcrmann, G., 2013. The OSIRIS weight of evidence approach: ITS for skin sensitisation. Regul. Toxicol. Pharmacol. 67, 146\u2013156. http://dx.doi.org/10.1016/j.yrtph.2013.06.003. Rotroff, D.M., Wetmore, B.A., Dix, D.J., Ferguson, S.S., Clewell, H.J., Houck, K.A., Lecluyse, E.L., Andersen, M.E., Judson, R.S., Smith, C.M., Sochaski, M.A., Kavlock, R.J., Boellmann, F., Martin, M.T., Reif, D.M., Wambaugh, J.F., Thomas, R.S., 2010. Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicol. Sci. 117, 348\u2013358. Rotroff, D.M., Dix, D.J., Houck, K.A., Knudsen, T.B., Martin, M.T., McLaurin, K.W., Reif, D.M., Crofton, K.M., Singh, A.V., Xia, M., Huang, R., Judson, R.S., 2013. Using in vitro high throughput screening assays to identify potential endocrine disrupting chemicals. Environ. Health Perspect. 121, 7\u201314. Rowlands, J.C., Budinsky, R., Gollapudi, B., Novak, R., Abdelmegeed, M., Cukovic, D., Dombokowski, A., 2011. Transcriptional profiles induced by the aryl hydrocarbon receptor agonists 2,3,7,8-tetrachlorodibenz-p-dioxin, 2,3,7,8- tetrachlorodibenzofuran and 2,3,4,7,8-pentachlorodibenzofuran in primary rat hepatocytes. Chemosphere 85, 232\u2013238. Sakaguchi, H., Ashikaga, T., Kosaka, N., Sono, S., Nishiyama, N., Itagaki, H., 2007. The in vitro skin sensitization test; human cell line activation test (h-CLAT) using THP-1 cells. Toxicol. Lett. 172, S93. Scholz, S., Sela, E., Blaha, L., Braunbeck, T., Galay-Burgos, M., Garc\u00eda-Franco, M., Guinea, J., Kl\u00fcver, N., Schirmer, K., Tanneberger, K., Tobor-Kap\u0142on, M., Witters, H., Belanger, S., Benfenati, E., Creton, S., Cronin, M.T.D., Eggen, R.I.L., Embry, M., Ekman, D., Gourmelon, A., Halder, M., Hardy, B., Hartung, T., Hubesch, B., Jungmann, D., Lampi, M.A., Lee, L., L\u00e9onard, M., K\u00fcster, E., Lillicrap, A., Luckenbach, T., Murk, A.J., Navas, J.M., Peijnenburg, W., Repetto, G., Salinas, E., Sch\u00fc\u00fcrmann, G., Spielmann, H., Tollefsen, K.E., Walter-Rohde, S., Whale, G., Wheeler, J.R., Winter, M.J., 2013. A European perspective on alternatives to animal testing for environmental hazard identification and risk assessment. Regul. Toxicol. Pharmacol. 67, 506\u2013530. Schultz, T.W., Yarbrough, J.W., Johnson, E.L., 2005. Structure\u2013activity relationships for reactivity of carbonyl compounds with glutathione. SAR QSAR Environ. Res. 16, 313\u2013322. Shah, I., Houck, K., Judson, R.S., Kavlock, R.J., Martin, M.T., Reif, D.M., Wambaugh, J., Dix, D.J., 2011. Using nuclear receptor activity to stratify hepatocarcinogens. PLoS ONE 6, e14584. http://dx.doi.org/10.1371/journal.pone.0014584. Sheikh-Bahaei, S., Maher, J.J., Hunt, C.A., 2010. Computational experiments reveal plausible mechanisms for changing patterns of hepatic zonation of xenobiotic clearance and hepatotoxicity. J. Theor. Biol. 265, 718\u2013733. Simon, T., Aylward, L.L., Kirman, C.R., Rowlands, J.C., Budinsky, R.A., 2009. Estimates of cancer potency of 2,3,7,8-tetrachlorodibenzo(p)dioxin using linear and nonlinear dose\u2013response modeling and toxicokinetics. Toxicol. Sci. 112, 490\u2013506. Simon, T., Stoney Simons Jr., S., Preston, R.J., Boobis, A.R., Cohen, S.M., Doerrer, N.G., Fenner-Crisp, P.A., McMullin, T., McQueen, C.A., Rowlands, J.C., 2014. The use of mode of action information in risk assessment: quantitative key events/dose\u2013 response framework for modeling the dose\u2013response for key events. Crit. Rev. Toxicol., in press Teeguarden, J., Hanson-Drury, S., Fisher, J.W., Doerge, D.R., 2013. Are typical human serum BPA concentrations measurable and sufficient to be estrogenic in the general population? Food Chem. Toxicol. 62, 949\u2013963. http://dx.doi.org/ 10.1016/j.fct.2013.08.001. Teeguarden, J.G., Calafat, A.M., Ye, X., Doerge, D.R., Churchwell, M.I., Gunawan, R., Graham, M.K., 2011. Twenty-four hour human urine and serum profiles of bisphenol a during high-dietary exposure. Toxicol. Sci. 123, 48\u201357. http:// dx.doi.org/10.1093/toxsci/kfr160. Teeguarden, J.G., Hanson-Drury, S., 2013. A systematic review of Bisphenol A \u2018\u2018low dose\u2019\u2019 studies in the context of human exposure: a case for establishing standards for reporting \u2018\u2018low-dose\u2019\u2019 effects of chemicals. Food Chem. Toxicol. 62, 935\u2013948. http://dx.doi.org/10.1016/j.fct.2013.07.007. Thomas, R.S., Black, M., Li, L., Healy, E., Chu, T.-M., Bao, W., Andersen, M., Wolfinger, R., 2012. A comprehensive statistical analysis of predicting in vivo hazard using high-throughput in vitro screening. Toxicol. Sci. http://dx.doi.org/ 10.1093/toxsci/kfs159. Thomas, R.S., Philbert, M.A., Auerbach, S.S., Wetmore, B.A., Devito, M.J., Cote, I., Rowlands, J.C., Whelan, M.P., Hays, S.M., Andersen, M.E., Meek, M.E.B., Reiter, L.W., Lambert, J.C., Clewell, H.J., Stephens, M.L., Zhao, Q.J., Wesselkamper, S.C., Flowers, L., Carney, E.W., Pastoor, T.P., Petersen, D.D., Yauk, C.L., Nong, A., 2013. Incorporating new technologies into toxicity testing and risk assessment: moving from 21st century vision to a data-driven framework. Toxicol. Sci. 136, 4\u201318. http://dx.doi.org/10.1093/toxsci/kft178. Tluczkiewicz, I., Batke, M., Kroese, D., Buist, H., Aldenberg, T., Paun\u00e9, E., Grimm, H., K\u00fchne, R., Sch\u00fc\u00fcrmann, G., Mangelsdorf, I., Escher, S.E., 2013. The OSIRIS weight of evidence approach: ITS for the endpoints repeated-dose toxicity (RepDose ITS). Regul. Toxicol. Pharmacol. 67, 157\u2013169. http://dx.doi.org/10.1016/ j.yrtph.2013.02.004. Tollefsen, K.E., Scholz, S., Cronin, M.T., Edwards, S.W., de Knecht, J., Crofton, K., Garcia-Reyero, N., Hartung, T., Worth, A., Patlewicz, G., 2014. Applying adverse outcome pathways (AOPs) to support integrated approaches to testing and assessment (IATA). Regul. Toxicol. Pharmacol. 70, 629\u2013640. Tonnelier, A., Coecke, S., Zald\u00edvar, J.-M., 2011. Screening of chemicals for human bioaccumulative potential with a physiologically based toxicokinetic model. Arch. Toxicol. http://dx.doi.org/10.1007/s00204-011-0768-0. Urbisch, D., Mehling, A., Guth, K., Ramirez, T., Honarvar, N., Kolle, S., Landsiedel, R., Jaworska, J., Kern, P.S., Gerberick, F., Natsch, A., Emter, R., Ashikaga, T., Miyazawa, M., Sakaguchi, H., 2014. Assessing skin sensitization hazard in mice and men using non-animal test methods. Regul. Toxicol. Pharmacol. 71, 337\u2013351. van der Veen, J.W., Rorije, E., Emter, R., Natsch, A., van Loveren, H., Ezendam, J., 2014. Evaluating the performance of integrated approaches for hazard identification of skin sensitizing chemicals. Regul. Toxicol. Pharmacol. 2014 (69), 371\u2013379. van Leeuwen, K., Schultz, T.W., Henry, T., Diderich, B., Veith, G.D., 2009. Using chemical categories to fill data gaps in hazard assessment. SAR QSAR Environ. Res. 20, 207\u2013220. Vezin, C.M., Walker, N.J., Olson, J.R., 2004. Subchronic exposure to TCDD, PeCDF, PCB 126 and PCB 153: effect on hepatic gene expression. Environ. Health Perspect. 112, 1636\u20131644. Vinken, M., 2013. The adverse outcome pathway concept: a pragmatic tool in toxicology. Toxicology 312, 158\u2013165. http://dx.doi.org/10.1016/j.tox.2013.08.011. Wambaugh, J.F., Setzer, R.W., Reif, D.M., Gangwal, S., Mitchell-Blackwood, J., Arnot, J.A., Joliet, O., Frame, A., Rabinowitz, J., Knudsen, T.B., Judson, R.S., Egeghy, P., Vallero, D., Cohen Hubal, E.A., 2013. High-throughput models for exposure- based chemical prioritization in the ExpoCast project. Environ. Sci. Technol. 47, 8479\u20138488. Yao, C.Q., Prokopec, S.D., Watson, J.D., Pang, R., P\u2019ng, C., Chong, L.C., Harding, N.J., Pohjanvirta, R., Okey, A.B., Boutros, P.C., 2012. Inter-strain heterogeneity in rat hepatic transcriptomic responses to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Toxicol. Appl. Pharmacol. 260, 135\u2013145. Wetmore, B.A., Wambaugh, J.F., Ferguson, S.S., Sochaski, M.A., Rotroff, D.M., Freeman, K., Clewell, H.J., Dix, D.J., Andersen, M.E., Houck, K.A., Allen, B., Judson, R.S., Singh, R., Kavlock, R.J., Richard, A.M., Thomas, R.S., 2011. Integration of dosimetry, exposure and high-throughput screening data in chemical toxicity assessment. Toxicol. Sci. 125, 157\u2013174. http://dx.doi.org/10.1093/toxsci/kfr254. Zhao, Y.Y.I., Tao, F.M., Zeng, E.Y., 2008. Theoretical study of the quantitative structure\u2013activity relationships for the toxicity of dibenzo-p-dioxins. Chemosphere 73, 86\u201391. http://dx.doi.org/10.3109/10408444.2014.931923 http://dx.doi.org/10.3109/10408444.2014.931923 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0410 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0410 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0410 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0415 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0415 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0415 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0420 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0420 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0420 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0420 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0420 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0425 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0425 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0425 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0425 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0430 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0430 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0430 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0430 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0435 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0435 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0435 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0435 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0435 http://dx.doi.org/10.1080/10629360903570933 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0445 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0445 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0450 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0450 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0450 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0450 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0450 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0450 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0450 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0455 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0455 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0455 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0460 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0460 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0460 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0465 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0465 http://dx.doi.org/10.1016/j.yrtph.2013.06.003 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0475 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0475 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0475 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0475 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0475 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0480 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0480 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0480 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0480 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0480 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0485 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0485 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0485 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0485 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0485 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0490 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0490 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0490 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0495 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0495 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0495 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0495 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0495 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0495 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0495 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0495 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0495 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0495 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0500 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0500 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0500 http://dx.doi.org/10.1371/journal.pone.0014584 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0510 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0510 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0510 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0515 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0515 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0515 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0520 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0520 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0520 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0520 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0520 http://dx.doi.org/10.1016/j.fct.2013.08.001 http://dx.doi.org/10.1016/j.fct.2013.08.001 http://dx.doi.org/10.1093/toxsci/kfr160 http://dx.doi.org/10.1093/toxsci/kfr160 http://dx.doi.org/10.1016/j.fct.2013.07.007 http://dx.doi.org/10.1093/toxsci/kfs159 http://dx.doi.org/10.1093/toxsci/kfs159 http://dx.doi.org/10.1093/toxsci/kft178 http://dx.doi.org/10.1016/j.yrtph.2013.02.004 http://dx.doi.org/10.1016/j.yrtph.2013.02.004 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0555 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0555 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0555 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0555 http://dx.doi.org/10.1007/s00204-011-0768-0 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0565 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0565 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0565 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0565 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0565 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0570 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0570 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0570 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0570 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0575 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0575 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0575 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0580 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0580 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0580 http://dx.doi.org/10.1016/j.tox.2013.08.011 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0590 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0590 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0590 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0590 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0590 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0595 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0595 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0595 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0595 http://dx.doi.org/10.1093/toxsci/kfr254 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0610 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0610 http://refhub.elsevier.com/S0273-2300(15)00039-2/h0610 Proposing a scientific confidence framework to help support the application of adverse outcome pathways for regulatory purposes 1 Introduction 2 Adverse outcome pathway 3 Challenges in applying AOPs in regulatory decision making: a framework to document scientific confidence 3.1 Prioritization 3.1.1 Case study 1: endocrine activity AOP leading to reproductive dysfunction 3.2 Chemical categories and associated read-across 3.2.1 Case study 2; skin sensitisation AOP as applied to chemical categorization and read-across 3.2.2 Case study 3: AHR rodent liver tumor AOP 3.3 Informing test method refinement and/or development 3.4 Integrated approaches to testing and assessment 3.4.1 Case study 2; skin sensitisation AOP as applied to IATA 3.4.2 Case study 3; AHR AOP as applied to IATA 3.5 Hazard and risk assessment 3.6 Considerations for dosimetry 4 Summary Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Protection-of-manganese-oxide-nanoparticles-induc_2018_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30102957", "content": {"CoiStatement": "Conflicts of interest There are no conflicts to disclose. Discussion Conflicts of interest Acknowledgement Transparency document References", "Acknowledgement": "Acknowledgement This study is related to the project NO 1396/68533 From Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran. We also appreciate the \u201cStudent Research Committee\u201d and \u201cResearch & Technology Chancellor\u201d in Shahid r for their financial support of this study. This project was conducted under supervision of Dr. Ahmad Salimi at Department of Pharmacology and Toxicology, School of Pharmacy, Ardabil University of Medical Science and Dr. Amir Mohammad Mortazavian at Department of Food Science and Technology, Faculty of Nutrition Sciences and Food Technology, Shahid Discussion Conflicts of interest Acknowledgement Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Protective-effect-of-two-essential-oils-isolated-from-Rosa-_2016_Regulatory-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27381452", "content": {"Acknowledgement": "Acknowledgments This work was supported by the scientific project N\ufffd 21/2014 of Medical faculty, Trakia University, Stara Zagora, Bulgaria. 4. Discussion 5. Conclusions Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Protective-effects-of-Chlorella-derived-peptide-on-UVB-i_2011_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21397653", "content": {"CoiStatement": "5. Conflict of interest None. Discussion Conflict of interest Acknowledgment References", "Acknowledgement": "Acknowledgment The authors would like to thank the National Science Council of the Republic of China, Taiwan, for financially supporting this re- search under Contract No. NSu-Jong Chen 97-2320-B-041-004. Discussion Conflict of interest Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Proteomic-analysis-of-known-and-candidate-rice-alle_2011_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21300107", "content": {"CoiStatement": "In conclusion, we detected and compared candidate allergens among the salt-soluble proteins of non-transgenic and transgenic rice by a combination of proteomic techniques and serological methods. No clear qualitative or quantitative differences were found for two known allergen family proteins (RAG 2 and glyoxa- lase 1) between non-transgenic and transgenic rice. We also iden- tified three other IgE-binding proteins, a 19, 52, and 63 kDa globulin-like protein, and the latter two were identified as IgE- binding proteins for the first time. Quantitative analysis of the 19, 52, and 63 kDa globulins with protein-specific-animal sera re- vealed no significant differences in expression of these proteins be- tween the transgenic and non-transgenic rice. These results indicate that none of the known or novel endogenous IgE-binding proteins in this study appear to have been altered by genetic modification. Conflicts of interest None of the authors have any conflicts of interest in regard to this paper. None of the authors have any conflicts of interest in regard to this paper. 444 R. Satoh et al. / Regulatory Toxicology and Pharmacology 59 (2011) 437\u2013444 Acknowledgments Conflicts of interest Acknowledgments Supplementary data References", "Acknowledgement": "444 R. Satoh et al. / Regulatory Toxicology and Pharmacology 59 (2011) 437\u2013444 Acknowledgments We thank Prof. Atsuo Urisu and Prof. Yoichi Kohno for providing the Japanese patients\u2019 sera used in this study. This study was sup- ported by a grant from the Ministry of Health, Labour and Welfare, a grant from Food Safety Commission, and a grant-in aid for Scien- tific Research from the Ministry of Education, Culture, Sports, Sci- ence and Technology. Conflicts of interest Acknowledgments Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Proteomic-approaches-for-qualitative-and-quantita_2010_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20828591", "content": {"CoiStatement": "Conflict of interest statement The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgement Proteomic approaches for qualitative and quantitative characterisation of food allergens Introduction Identification of novel food allergens Genetic and phenotypic variability of food allergens Proteomics for the authentication of purified allergens Proteomics for detection and quantification of allergens in food products Standardisation of allergen analysis Conclusions Conflict of interest statement Acknowledgement References", "Acknowledgement": "Acknowledgement This work was supported by the BBSRC Ex-Gen Grants 218/ EGA17713 and the Institute Strategic Programme grant to IFR and to the European Union through the MoniQA (FOOD-CT-2006- 036337) and EuroPrevall (FOOD-CT-2005-514000) projects. Proteomic approaches for qualitative and quantitative characterisation of food allergens Introduction Identification of novel food allergens Genetic and phenotypic variability of food allergens Proteomics for the authentication of purified allergens Proteomics for detection and quantification of allergens in food products Standardisation of allergen analysis Conclusions Conflict of interest statement Acknowledgement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Providing-context-for-phosphatidylethanol-as-a-bioma_2018_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29408287", "content": {"Funding": "Funding sources None. Funding sources Acknowledgements Supplementary data Transparency document References", "Acknowledgement": "Acknowledgements I am grateful to the anonymous reviewers for their insightful com- ments that improved this paper considerably. Funding sources Acknowledgements Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Providing-perspective-for-interpreting-cardiovascul_2015_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25817736", "content": {"Acknowledgement": "Acknowledgments This work was funded by the American Petroleum Institute (API). This commentary represents the individual professional views of the authors and not necessarily the views of API. References 4 Conclusions Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Public-health-decisions--Actions-and-con_2014_Regulatory-Toxicology-and-Phar.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25092130", "content": {"CoiStatement": "ATSDR, 2002b. Toxicological Profile for Wood Creosote, Coal Tar Creosote, Coal Tar, Coal Tar pitch, and Coal Tar Pitch Volatiles. Atlanta, GA: Agency for Toxic Substances and Disease Registry, Public Health Service, U.S. Department of Health and Human Services (http://www.atsdr.cdc.gov/toxprofiles accessed June 2013. ATSDR, 2001a. Toxicological Profile for .Pyrethrins and Pyrethroids. Atlanta, GA: Agency for Toxic Substances and Disease Registry, Public Health Service, U.S. Department of Health and Human Services (http://www.atsdr.cdc.gov/ toxprofiles accessed June 2013). ATSDR, 2001b. Toxicological Profile for Pentachlorophenol. Atlanta, GA: Agency for Toxic Substances and Disease Registry, Public Health Service, U.S. Department of Health and Human Services (http://www.atsdr.cdc.gov/toxprofiles accessed June 2013). ATSDR, 1996. Toxicological Profile for Methyl tert-Butyl Ether (MTBE). Atlanta, GA: Agency for Toxic Substances and Disease Registry, Public Health Service, U.S. Department of Health and Human Services (http://www.atsdr.cdc.gov/ toxprofiles accessed June 2013). ATSDR, 1995. Toxicological Profile for Automotive Gasoline. Atlanta, GA: Agency for Toxic Substances and Disease Registry, Public Health Service, U.S. Department of Health and Human Services (http://www.atsdr.cdc.gov/toxprofiles accessed June 2013). Blomquist, A., Berg, C., Holm, L., Brandt, I., Ridderstrale, Y., Brunstrom, B., 2006. Defective reproductive organ morphology and function in domestic rooster embryonically exposed to o, p0-DDT or ethynyl estradiol. Biol. Reprod. 74 (3), 481\u2013486. CAS (Chemical Abstracts Service), 2007. Registry Number and Substance Counts. Columbus OH: American Chemical Society. Available on the Internet at: www.cas.org/cgi-bin/cas/regreport.pl (accessed October 2007). Cain, W.S., Leaderer, B.P., Ginsbert, G.L. et al., 1994. Human Reactions to Brief Exposures to Methyl Tertiary-Butyl Ether (MTBE). In: John, B. (Ed.) New Haven, CT: Pierce Laboratory. Chandler, B., Middaugh, J., 1992. Potential Illness Due to Exposure to Oxygenated Fuels, Anchorage, Alaska. Anchorage, AK: State of Alaska Department of Health and Social Services, December 23. Centers for Disease Control and Prevention (CDC), 2012. Fourth National Report on Human Exposure to Environmental Chemicals. Updated Tables; National Health and Nutrition Examination Survey (NHANES) (www.cdc.gov/exposurereport/ accessed March 2014). Centers for Disease Control and Prevention (CDC), 2006. Adult blood lead epidemiology and surveillance\u2014United States, 2003\u20132004. MMWR Morb. Mortal Wkly. Rep. 55 (32), 876\u2013879. Cline, R.E., Hill Jr., R.H., Phillips, D.L., et al., 1989. Pentachlorophenol measurements in body fluids of people in log homes and workplaces. Arch. Environ. Contam. Toxicol. 18, 475\u2013481. CBO (Congressional Budget Office), 2009. The Impact of Ethanol Use on Food Prices and Greenhouse Gas Emissions. www.cbo.gov/publication/41173. CDHS, 1987. Evaluation of hazards posed by the use of wood preservatives on playground equipment. State of California Department of Health Services (CDHS). Report to the Legislature. Chanon, K.E., Mendez-Galvan, J.F., Galindo-Jaramillo, J.M., Olguin-Bernal, H., Borja- Aburto, V.H., 2003. Cooperative actions to achieve malaria control without the use of DDT. Int. J. Hyg. Environ. Health 206, 387\u2013394. CMR, 1995. Chemical Profile: MTBE. Chemical Marketing Report (03.04.94). Davis, J.M., Farland, W.H., 2001. The paradoxes of MTBE. Toxicol. Sci. 61, 211\u2013217. Economist, 2007. The end of cheap food. Econ. 385 (8558), 11\u201312. Encyclopedia of global change, 2001. Encyclopedia of Global Change: Environmental Change and Human Society. In: Goudie A.S. (Ed.), Hazardous Waste, Oxford University Press, NY, p. 579. EIA (Energy Information Administration), 2003. Status and Impact of State MTBE Bans (http://tonto.eia.doe.gov/ftproot/service/mtbe.pdf accessed November 2006). Elsevier (Elsevier Information Systems GmbH), 2007. CrossFire Beilstein Database Exceeds Ten Million Compounds. Press release, August 20th 2007. Available on the Internet at: (www.beilstein.com/PR_Beilstein%2010m_Final.pdf accessed October 2007). EPA (Environmental Protection Agency), 1997, Drinking Water Advisory: Consumer Acceptability Advice and Health Effects Analysis on Methyl Tertiary-Butyl Ether (MtBE) EPA-822-F-97-009. EPA (Environmental Protection Agency), 2013. Atrazine Background. http:// www.epa.gov/pesticides/factsheets/atrazine_background.htm. EPA (Environmental Protection Agency), 2003. Chromated Copper Arsenate (CCA): EPA Testimony on CCA Treated Wood (http://www.epa.gov/oppa001/ reregistration/cca/ccatestimony1.htm accessed November 2006). EPA, 2002. The Grouping of a Series of Triazine Pesticides Based ON A Common Mechanism of Toxicity. Washington, DC: U.S. Environmental Protection Agency. Office of Pesticides Programs. http://www.epa.gov/oppsrrd1/cumulative/ triazines/triazinescommonmech.pdf. EPA, 1999. U.S. Environmental Protection Agency. Science Chapter for the Re- registration Eligibility Decision Document for Penta (PC Code: 063001. Registration Case Number 2505). Washington, DC EPA, 2008. Pentachlorophenol Revised Risk Assessments; Notice of Availability and Solicitation for Risk Reduction Options. Fed. Reg 73 (74), 20638\u201320640. EPA (Environmental Protection Agency), 1996a. U.S. Environmental Protection Agency. Code of Federal Regulations. 40 CFR 268, Appendix XI. EPA (Environmental Protection Agency), 1996b. U.S. Environmental Protection Agency. Code of Federal Regulations. 40 CFR 745. EPA (Environmental Protection Agency), 1986. Creosote, Pentachlorophenols, and Inorganic Arsenicals: Amendment of Notice of Intent to Cancel Registrations. U.S. Environmental Protection Agency. Fed Reg 51, 1334\u20131348. EPA (Environmental Protection Agency), 1984a. Notice of Intent to Cancel Registration of Pesticide Products Containing Creosote, Pentachlorophenol (Including its Salts), and the Inorganic Arsenical. 49 CAR 28666 (13.07.84). EPA (Environmental Protection Agency), 1984b. Wood preservative pesticides: creosote, pentachlorophenol, inorganic arsenicals. Position Document 4. Washington, DC: U.S. Environmental Protection Agency, Office of Pesticides and Toxic Substances. EPA (Environmental Protection Agency), 1972. U.S. Environmental Protection Agency. Consolidated DDT Hearings: Opinion and Order of the Administrator. Federal Register 37 (131), 13369. Feldman, 2001. Petition for Suspension and Cancellation of Pentachlorophenol. http://www.beyondpesticides.org/wood/Penta%20Petition.htm. Felton, C.C., De Groot, R.C., 2003. The recycling potential of preservative treated wood. For. Prod. J. 46 (7/8), 20\u201325. Ferreira, A.G., Vieira, D.N., Marques, E.P., et al., 1997. Occupational exposure to pentachlorophenol: the Portugese situation. Ann. N.Y. Acad. Sci. 837, 291\u2013299. Fernandez, L., Keller, A.A., 2001. Cost benefit analysis of MTBE and Alternative gasoline formulations. J. Environ. Sci. Pollut. 3, 173\u2013188. Gallup, J.L., Sachs, J.D., 2001. The economic burden of malaria. Am. J. Trop. Med. Hyg. 64 (1/2), 85\u201396. Giddings J.C. (Ed.), 1973. Lead in gasoline. In: Chemistry, Man, and Environmental Change: An Integrated Approach. New York, NY: Harper & Row, Publishers Inc, pp. 351\u2013353. Gilbert, C.E., Calabrese, E.J., 1992. Developing a standard for methyl butyl ether in drinking water. In: Gilbert, C.E., Calabrese, E.J. (Eds.), Regulating Drinking Water Quality. Lewis Publishers, 23l\u2013252. Guillette, L.J., Gross, T.S., Masson, G.R., Matter, J.M., 1994. Developmental abnormalities of the gonad and abnormal sex hormone concentrations in juvenile alligators from contaminated and control lakes in Florida. Environ. Health Perspect. 102, 680\u2013688. Guimaraes, R.M., Asmus, C.I., Meyer, A., 2007. DDT reintroduction for malaria control: the cost-benefit debate for public health. Cad Saude Publica 23 (12), 2835\u20132844. Hamlin, H.J., Guillette, L.J., 2010. Birth defects in wildlife: the role of environmental contaminants as inducers of reproductive and developmental dysfunction. Syst. Biol. Reprod. Med. 56 (2), 113\u2013121. Henningsson, B., 1983. Environmental protection and health risks in connection with the use of creosote. Holz als Roh- und Werkstoff 41, 471\u2013475. Hileman, B., 2006. Malaria control. Chem. Eng. News 84 (3), 30\u201331. IDRC (International Development Research Center), 1996. Statistics on Malaria (http://archve.idre.ca/books/reports/1996/01-07e.html accessed November 2006). IARC, 1985. Monographs on the evaluation of the carcinogenic risk of chemicals to humans. Polynuclear Aromatic Compounds. Part 4. Bitumens, Coal-Tars and Derived Products, Shale Oils and Soots, vol. 35, Lyon, France: World Health Organization, International Agency for Research on Cancer, pp. 104\u2013 140. IRIS, 2008. Integrated Risk Information Systems. Cincinnati, OH: U.S. Environmental Protection Agency, Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office (http://www.epa.gov/iris/subst accessed November 2008). Ito, J., Ghosh, A., Moreira, L.A., Wimmer, E.A., Jacobs-Lorena, M., 2002. Transgenic anopheline mosquitoes impaired in transmission of malaria parasite. Nature 417 (6887), 452\u2013455. Jones, R.L., Homa, D.M., Meyer, P.A., et al., 2009. Trends in blood lead levels and blood lead testing among US children aged 1 to 5 yeas, 1988\u20132004. Pediatrics 123, e376\u2013e385. Klingner, T.D., McCorkle, T., 1994. The application and significance of wipe samples. AIHA J. Short Commun., 251\u2013254. Kolaja, G.J., Hinton, D.E., 1977. Effects of DDT on eggshell quality and calcium adenosine triphosphatase. J. Toxicol. Environ. Health 3 (4), 699\u2013704. Leach, C.W., Weinert, J.J., 1976. A report to the Environmental Task Group, Sub- Group No. 5 (creosote) of the American Wood Preservers Institute. Lemire, S., Ashley, D., Olaya, P., et al., 2004. Environmental exposure of commuters in Mexico City to volatile organic compounds as assessed by blood concentrations, 1998. Salud. Publica Med. 46 (1), 32\u201338. Malkin, R., Kiefer, M., Tolos, W., 1996. 1-Hydroxypyrene levels in coal-handling workers at a coke oven. J. Occup. Environ. Med. 38 (11), 1141\u20131144. Mannino, D.M., Schreiber, J., Aldous, K., 1995. Human exposure to volatile organic compounds: a comparison of organic vapor monitoring badge levels with blood levels. Int. Arch. Occup. Environ. Health 67, 59\u201364. McGarity, T.O., 2004. MTBE: a precautionary tale. Harv. Environ. Law Rev. 28, 281\u2013 342. http://www.atsdr.cdc.gov/toxprofiles http://www.atsdr.cdc.gov/toxprofiles http://www.atsdr.cdc.gov/toxprofiles http://www.atsdr.cdc.gov/toxprofiles http://www.atsdr.cdc.gov/toxprofiles http://www.atsdr.cdc.gov/toxprofiles http://www.atsdr.cdc.gov/toxprofiles http://www.atsdr.cdc.gov/toxprofiles http://www.atsdr.cdc.gov/toxprofiles http://refhub.elsevier.com/S0273-2300(14)00178-0/h0085 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0085 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0085 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0085 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0085 http://www.cas.org/cgi-bin/cas/regreport.pl http://www.cdc.gov/exposurereport/ http://refhub.elsevier.com/S0273-2300(14)00178-0/h0110 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0110 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0110 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0115 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0115 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0115 http://www.cbo.gov/publication/41173 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0130 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0130 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0130 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0145 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0600 http://tonto.eia.doe.gov/ftproot/service/mtbe.pdf http://www.beilstein.com/PR_Beilstein%2010m_Final.pdf http://www.epa.gov/pesticides/factsheets/atrazine_background.htm http://www.epa.gov/pesticides/factsheets/atrazine_background.htm http://www.epa.gov/oppa001/reregistration/cca/ccatestimony1.htm http://www.epa.gov/oppa001/reregistration/cca/ccatestimony1.htm http://www.epa.gov/oppsrrd1/cumulative/triazines/triazinescommonmech.pdf http://www.epa.gov/oppsrrd1/cumulative/triazines/triazinescommonmech.pdf http://www.beyondpesticides.org/wood/Penta%20Petition.htm http://refhub.elsevier.com/S0273-2300(14)00178-0/h0240 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0240 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0245 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0245 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0270 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0270 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0270 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0270 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0275 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0275 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0275 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0280 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0280 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0280 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0285 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0285 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0290 http://archve.idre.ca/books/reports/1996/01-07e.html http://www.epa.gov/iris/subst http://refhub.elsevier.com/S0273-2300(14)00178-0/h0310 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0310 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0310 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0315 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0315 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0315 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0325 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0325 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0330 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0330 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0345 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0345 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0345 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0350 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0350 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0355 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0355 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0355 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0360 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0360 H.R. Pohl et al. / Regulatory Toxicology and Pharmacology 70 (2014) 363\u2013369 369 MFI (Malaria Foundation International), 2000. Our Campaign to Prevent a Ban of DDT for Malaria Control has been Successful (http://www.malaria.org/ DDTpage.html accessed November 2006). Minelli, E., Ribeiro, M., 1996. DDT and HCH residues in the blood serum of Malaria control sprayers. Bull. Environ. Contam. Toxicol. 57, 691\u2013696. Morrison, D.S., 2004. Pressure-treated wood: the new generation. Fine Homebuilding 160, 82\u201385. N\u00e1jera, J.A., Gonz\u00e1lez-Silva, M., Alonso, P.L., 2011. Some lessons for the future from the Global Malaria Eradication Programme (1955\u20131969). PLoS Med. 8 (1), e1000412. NAS, 1972. Lead: Airborne Lead in Perspective: Biologic Effects Atmospheric Pollutants. Washington, DC: National Academy of Sciences, pp. 71\u2013177, 281\u2013 313. NTP, 2011. Report on carcinogens, twelfth ed. Summary. Research Triangle Park, NC: National Toxicology Program, U.S. Department of Health and Human Services, p. 195. Prah, J.D., Goldstein, G.M., Devlin, R., et al., 1994. Sensory symptomatic, inflammatory, and ocular responses to and the metabolism of methyl tertiary butyl ether in a controlled human exposure experiment. Inhal. Toxicol. 6, 521\u2013 538. Rohter, L., 2006. With Big Boost from Sugarcane, Brazil is Satisfying its Fuel Needs (http://www.nytimes.com/2006/04/10/world/americas/10brazil.html?page- wanted=1&sq=Bush%20Brazil%20ethanol&st=nyt&scp=5& r=0 accessed 12.07.14). Richie, T.L., Saul, A., 2002. Progress and challenges for malaria vaccines. Nature 415 (6872), 694\u2013701. Roberts, D.R., Laughlin, L.L., Hsheih, P., Legters, L.J., 1997. DDT, global strategies and malaria control crisis in South America. Emerg. Infect. Dis. 3 (3), 295\u2013302. Seyferth, D., 2003. The rise and fall of tetraethyl lead. 2. Organometallics 22, 5154\u2013 5178. Squillace, P.J., Scott, J.C., Moran, M.J., et al., 2002. VOCs, pesticides, nitrate, and their mixtures in groundwater used for drinking water in the United States. Environ. Sci. Technol. 36, 1923\u20131930. Stilwell, D.E., Gorny, K.D., 1997. Contamination of soil with copper, chromium, and arsenic under decks built from pressure treated wood. Bull. Environ. Contam. Toxicol. 58, 22\u201329. SCPOP (Stockholm Convention on Persistent Organic Pollutants), 2001 (http:// www.pops.int accessed November 2006). Thompson, S., 2006. Rural Cooperatives 73, 19\u201321. Trembley, J.F., 2006. Chem. Eng. News 84 (22), 19. USDA, 1980. The biologic and economic assessment of pentachlorophenol, inorganic arsenicals, creosote, vol. 1. Wood Preservatives. Washington, DC: U.S. Department of Agriculture. Technical Bulletin No. 1658-1, pp. 193\u2013227. Van Rooij, J.G.M., Van Lieshout, E.M.A., Bodelier Bade, M.M., 1993. Effect of the reduction of skin contamination on the internal dose of creosote workers exposed to polycyclic aromatic hydrocarbons. Scand. J. Work Environ. Health 19 (3), 200\u2013207. White, M.C., Johnson, C.A., Ashely, D.L., et al., 1995. Exposure to methyl tertiary butyl ether from oxygenated gasoline in Stamford, Connecticut. Arch. Environ. Health 50 (3), 183\u2013189. WHO, 2006. WHO Gives Indoor Use of DDT a Clean Bill of Health for Controlling Malaria (http://www.who.int/mediacentre/news/releases/2006/pr50/en/ accessed June 2013). WHO, 2013. Malaria (http://www.who.int/features/factfiles/malaria/en/ accessed June 2013). http://www.malaria.org/DDTpage.html http://www.malaria.org/DDTpage.html http://refhub.elsevier.com/S0273-2300(14)00178-0/h0370 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0370 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0375 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0375 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0380 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0380 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0380 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0400 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0400 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0400 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0400 http://www.nytimes.com/2006/04/10/world/americas/10brazil.html?pagewanted=1%26sq=Bush%20Brazil%20ethanol%26st=nyt%26scp=5%26%20r=0 http://www.nytimes.com/2006/04/10/world/americas/10brazil.html?pagewanted=1%26sq=Bush%20Brazil%20ethanol%26st=nyt%26scp=5%26%20r=0 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0410 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0410 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0415 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0415 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0420 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0420 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0425 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0425 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0425 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0430 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0430 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0430 http://www.pops.int http://www.pops.int http://refhub.elsevier.com/S0273-2300(14)00178-0/h0440 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0445 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0455 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0455 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0455 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0455 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0465 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0465 http://refhub.elsevier.com/S0273-2300(14)00178-0/h0465 http://www.who.int/mediacentre/news/releases/2006/pr50/en/ http://www.who.int/features/factfiles/malaria/en/ Public health decisions: Actions and consequences 1 Introduction 2 Examples of chemicals in our lives and their regulation 2.1 Insecticides: dichlorodiphenyl trichloroethane (DDT) 2.1.1 Problem definition: mammalian toxicity of bio-persistent chemicals versus increased mortality from malaria that is preventable via vector (e.g., mosquitoes) control 2.2 Gasoline additives: lead, methyl tert-butyl ether (MTBE), and ethanol 2.2.1 Problem definition: mammalian toxicity of gasoline additives and potential for increased environmental pollution 2.3 Wood preservatives: creosote, pentachlorophenol, and Chromated Copper Arsenate (CCA) 2.3.1 Problem definition: mammalian toxicity of bio-persistent chemicals versus decay of lumber used for constructions and associated economic loss in light of increased understanding of human health 3 Conclusion Conflict of interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Pulmonary-toxicity-in-rats-following-inhalation-exposure-_2020_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32014485", "content": {"Funding": "Pulmonary toxicity in rats following inhalation exposure to poorly soluble particles of low toxicity: Testing at excessive concentrations overwhelming lung clearance? Funding information mk:H1_2 References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Pulmonary-toxicity-in-rats-following-inhalation-exposure-t_2019_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31604110", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper.", "Funding": "Funding This work has been performed on request of the Interdepartmental Working group on Risks of nanomaterials of the Dutch government (IWR), within the framework of the Dutch Knowledge and Information centre for Risks of Nanotechnology established at RIVM (KIR-nano), grantnumber 124003. EU, 2008b. Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on Classification, Labelling and Packaging of Substances and Mixtures, Amending and Repealing Directives 67/548/EEC and 1999/45/EC, and Amending Regulation (EC) No 1907/2006. In (Official Journal of the European Union L 353, 31.12.2008. 1. Ferin, J., Feldstein, M.L., 1978. Pulmonary clearance and hilar lymph node content in rats after particle exposure. Environ. Res. 16 (1\u20133), 342\u2013352. Gao, C.H., Dong, H.L., Tai, L., Gao, X.M., 2018. Lactoferrin-containing immunocomplexes drive the conversion of human macrophages from M2- into M1-like phenotype. Front. Immunol. 9, 37. Geiser, M., 2010. Update on macrophage clearance of inhaled micro- and nanoparticles. J. Aerosol Med. Pulm. Drug Deliv. 23 (4), 207\u2013217. Geiser, M., Kreyling, W.G., 2010. Deposition and biokinetics of inhaled nanoparticles. Part. Fibre Toxicol. 7, 2. Geiser, M., Rothen-Rutishauser, B., Kapp, N., Schurch, S., Kreyling, W., Schulz, H., Semmler, M., Im Hof, V., Heyder, J., Gehr, P., 2005. Ultrafine particles cross cellular membranes by nonphagocytic mechanisms in lungs and in cultured cells. Environ. Health Perspect. 113 (11), 1555\u20131560. Green, F.H., 2000. Pulmonary responses to inhaled poorly soluble particulate in the human. Inhal. Toxicol. 12 (1\u20132), 59\u201395. Greim, H., Borm, P., Schins, R., Donaldson, K., Driscoll, K., Hartwig, A., Kuempel, E., Oberdorster, G., Speit, G., 2001. Toxicity of fibers and particles. Report of the workshop held in Munich, Germany, 26-27 October 2000. Inhal. Toxicol. 13 (9), 737\u2013754. Hahn, F.F., G, F., Nikula, K.J., Vallyathan, V., Chiyotani, K., Hosoda, Y., Aizawa, Y., 1998. Comparative Pulmonary Responses of Humans and Animals to Dust Exposures. Heinrich, U., Fuhst, R., Rittinghausen, S., Creutzenberg, O., Bellman, B., Koch, W., Levsen, K., 1995. Chronic inhalation exposure of Wistar rats and two different strains of mice to diesel engine exhaust, carbon black, and titanium dioxide. Inhal. Toxicol. 7, 533\u2013556. Heinrich, U., Mohr, U., Fuhst, R., Brockmeyer, C., 1989. Investigation of a Potential Cotumorigenic Effect of the Dioxides of Nitrogen and Sulfur, and of Diesel Engine Exhaust, in the Respiratory Tract of Syrian Golden Hamsters. pp. 1\u201327. Heinrich, U., Muhle, H., Takenaka, S., Ernst, H., Fuhst, R., Mohr, U., Pott, F., Stober, W., 1986. Chronic effects on the respiratory tract of hamsters, mice and rats after long- term inhalation of high concentrations of filtered and unfiltered diesel engine emis- sions. J. Appl. Toxicol. 6 (6), 383\u2013395. Heinrich, U., Peters, L., Funcke, W., Pott, F., Mohr, W., St\u00f6ber, W., 1982. Investigation of toxic and carcinogenic effects of diesel exhaust in long-term inhalation exposure of rodents. In: Lewtas, J. (Ed.), Toxicological Effects of Emissions from Diesel Engines. Elsevier., New York, pp. 225\u2013242. IARC, 2010. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 93 Carbon Black, Titanium Dioxide, and Talc, Lyon, France. IARC, 1997. Silica, some silicates, coal dust and para-aramid fibrils. IARC Monogr. Eval. Carcinog. Risks Hum. 1\u2013475. IARC, 1999. Species Differences in Thyroid, Kidney and Urinary Bladder Carcinogenesis. IARC Scientific Publications No. 147. Ilsi Risk Science Institute, 2000. The relevance of the rat lung response to particle overload for human risk assessment: a workshop consensus report. Inhal. Toxicol. 12 (1\u20132), 1\u201317. Jacobsen, N.R., Pojana, G., White, P., Moller, P., Cohn, C.A., Korsholm, K.S., Vogel, U., Marcomini, A., Loft, S., Wallin, H., 2008. Genotoxicity, cytotoxicity, and reactive oxygen species induced by single-walled carbon nanotubes and C(60) fullerenes in the FE1-Mutatrade markMouse lung epithelial cells. Environ. Mol. Mutagen. 49 (6), 476\u2013487. Jacobsen, N.R., Saber, A.T., White, P., Moller, P., Pojana, G., Vogel, U., Loft, S., Gingerich, J., Soper, L., Douglas, G.R., Wallin, H., 2007. Increased mutant frequency by carbon black, but not quartz, in the lacZ and cII transgenes of muta mouse lung epithelial cells. Environ. Mol. Mutagen. 48 (6), 451\u2013461. Jacobsen, N.R., White, P.A., Gingerich, J., Moller, P., Saber, A.T., Douglas, G.R., Vogel, U., Wallin, H., 2011. Mutation spectrum in FE1-MUTA(TM) Mouse lung epithelial cells exposed to nanoparticulate carbon black. Environ. Mol. Mutagen. 52 (4), 331\u2013337. Jarabek, A.M., Asgharian, B., Miller, F.J., 2005 Jun-Jul. Dosimetric adjustments for in- terspecies extrapolation of inhaled poorly soluble particles (PSP). Inhal Toxicol. 17 (7-8), 317\u2013334. Jesch, N.K., Dorger, M., Enders, G., Rieder, G., Vogelmeier, C., Messmer, K., Krombach, F., 1997. Expression of inducible nitric oxide synthase and formation of nitric oxide by alveolar macrophages: an interspecies comparison. Environ. Health Perspect. 105 (Suppl. 5), 1297\u20131300. P.M.J. Bos, et al. Regulatory Toxicology and Pharmacology 109 (2019) 104498 11 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref1 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref1 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref2 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref2 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref2 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref2 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref3 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref3 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref4 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref4 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref5 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref5 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref6 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref6 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref7 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref9 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref9 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref10 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref10 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref10 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref10 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref10 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref11 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref11 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref12 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref12 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref12 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref12 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref13 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref13 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref13 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref14 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref14 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref14 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref15 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref15 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref15 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref16 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref17 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref17 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref17 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref18 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref18 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref18 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref19 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref19 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref19 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref20 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref20 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref20 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref21 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref21 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref21 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref22 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref22 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref22 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref22 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref23 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref23 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref23 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref24 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref24 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref24 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref24 https://eur-lex.europa.eu/eli/reg/2006/1907/2014-04-10 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref25 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref25 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref25 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref25 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref26 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref26 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref26 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref26 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref26 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref27 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref27 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref28 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref28 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref28 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref29 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref29 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref30 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref30 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref31 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref31 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref31 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref31 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref32 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref32 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref33 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref33 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref33 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref33 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref34 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref34 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref35 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref35 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref35 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref35 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref36 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref36 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref36 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref37 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref37 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref37 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref37 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref38 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref38 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref38 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref38 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref39 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref39 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref40 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref40 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref41 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref41 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref42 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref42 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref42 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref43 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref43 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref43 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref43 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref43 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref44 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref44 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref44 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref44 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref45 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref45 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref45 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref45 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref99 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref99 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref99 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref46 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref46 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref46 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref46 Kawasaki, H., 2015. A mechanistic review of silica-induced inhalation toxicity. Inhal. Toxicol. 27 (8), 363\u2013377. Kawasaki, H., 2019. A review of the fate of inhaled alpha-quartz in the lungs of rats. Inhal. Toxicol. 31 (1), 25\u201334. Kolling, A., Ernst, H., Rittinghausen, S., Heinrich, U., 2011. Relationship of pulmonary toxicity and carcinogenicity of fine and ultrafine granular dusts in a rat bioassay. Inhal. Toxicol. 23 (9), 544\u2013554. Kreyling, W.G., Semmler-Behnke, M., Takenaka, S., Moller, W., 2013. Differences in the biokinetics of inhaled nano- versus micrometer-sized particles. Acc. Chem. Res. 46 (3), 714\u2013722. Kuempel, E.D., O'Flaherty, E.J., Stayner, L.T., Smith, R.J., Green, F.H., Vallyathan, V., 2001. A biomathematical model of particle clearance and retention in the lungs of coal miners. Regul. Toxicol. Pharmacol. 34 (1), 69\u201387. Lapp, N.L., Castranova, V., 1993. How silicosis and coal workers' pneumoconiosis de- velop\u2013a cellular assessment. Occup. Med. 8 (1), 35\u201356. Lauweryns, J.M., Baert, J.H., 1977. Alveolar clearance and the role of the pulmonary lymphatics. Am. Rev. Respir. Dis. 115 (4), 625\u2013683. le Boufant, L., 1971. Influence de la nature des poussieres et de la chargepulmonaire sur l'epuration. pp. 227\u2013237 Old woking, Surrey. Lehnert, B.E., 1992. Pulmonary and thoracic macrophage subpopulations and clearance of particles from the lung. Environ. Health Perspect. 97, 17\u201346. Lehnert, B.E., Ortiz, J.B., London, J.E., Valdez, Y.E., Cline, A.F., Sebring, R.J., Tietjen, G.L., 1990. Migratory behaviors of alveolar macrophages during the alveolar clear- ance of light to heavy burdens of particles. Exp. Lung Res. 16 (5), 451\u2013479. Lippmann, M., Yeates, D.B., Albert, R.E., 1980. Deposition, retention, and clearance of inhaled particles. Br. J. Ind. Med. 37 (4), 337\u2013362. Liu, R., Zhang, X., Pu, Y., Yin, L., Li, Y., Zhang, X., Liang, G., Li, X., Zhang, J., 2010. Small- sized titanium dioxide nanoparticles mediate immune toxicity in rat pulmonary al- veolar macrophages in vivo. J. Nanosci. Nanotechnol. 10 (8), 5161\u20135169. Mauderly, J.L., Banas, D.A., Griffith, W.C., Hahn, F.F., Henderson, R.F., McClellan, R.O., 1996. Diesel exhaust is not a pulmonary carcinogen in Christiaan Delmaar-1 mice exposed under conditions carcinogenic to F344 rats. Fundam. Appl. Toxicol. 30 (2), 233\u2013242. Mauderly, J.L., Snipes, M.B., Barr, E.B., Belinsky, S.A., Bond, J.A., Brooks, A.L., Chang, I.Y., Cheng, Y.S., Gillett, N.A., Griffith, W.C., et al., 1994. Pulmonary toxicity of in- haled diesel exhaust and carbon black in chronically exposed rats. Part I: neoplastic and nonneoplastic lung lesions. Res. Rep. Health Eff. Inst. 68 (Pt 1), 1\u201375 discussion 77-97. Mercer, R.R., Crapo, J.D., 1988. Structure of the Gas Exchange Region of the Lungs Determined by Three Dimensional Reconstruction. Raven Press, New York. Morfeld, P., Bruch, J., Levy, L., Ngiewih, Y., Chaudhuri, I., Muranko, H.J., Myerson, R., McCunney, R.J., 2015. Translational toxicology in setting occupational exposure limits for dusts and hazard classification - a critical evaluation of a recent approach to translate dust overload findings from rats to humans. Part. Fibre Toxicol. 12, 3. Morrow, P.E., 1992. Dust overloading of the lungs: update and appraisal. Toxicol. Appl. Pharmacol. 113 (1), 1\u201312. Morrow, P.E., 1988. Possible mechanisms to explain dust overloading of the lungs. Fundam. Appl. Toxicol. 10 (3), 369\u2013384. Mosser, D.M., Edwards, J.P., 2008. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8 (12), 958\u2013969. Newton, P.E., Becker, S.V., Hixon, C.J., 1991. Pulmonary function and particle deposition and clearance in rats after a 90-day exposure to shale-oil-derived jet fuel JP-4. Inhal. Toxicol. 3 (2), 195\u2013210. Nikula, K.J., Avila, K.J., Griffith, W.C., Mauderly, J.L., 1997a. Lung tissue responses and sites of particle retention differ between rats and cynomolgus monkeys exposed chronically to diesel exhaust and coal dust. Fundam. Appl. Toxicol. 37 (1), 37\u201353. Nikula, K.J., Avila, K.J., Griffith, W.C., Mauderly, J.L., 1997b. Sites of particle retention and lung tissue responses to chronically inhaled diesel exhaust and coal dust in rats and cynomolgus monkeys. Environ. Health Perspect. 105 (Suppl. 5), 1231\u20131234. Nikula, K.J., Vallyathan, V., Green, F.H., Hahn, F.F., 2001. Influence of exposure con- centration or dose on the distribution of particulate material in rat and human lungs. Environ. Health Perspect. 109 (4), 311\u2013318. NIOSH, 2011. NIOSH Current Intelligence Bulletin 63. Occupational Exposure to Titanium Dioxide. DHHS (NIOSH) Publication No. 2011-160. NTP, 1993. National Toxicology Program.Toxicology and Carcinogenesis Studies of Talc in F344 Rats and B6C3F1 Mice. Oberdorster, G., 1997. Pulmonary carcinogenicity of inhaled particles and the maximum tolerated dose. Environ. Health Perspect. 105 (Suppl. 5), 1347\u20131355. Oberd\u00f6rster, G., Ferin, J., Soderholm, S.C., Gelein, R., Cox, C., Baggs, R., Morrow, P.E., 1994. Increased pulmonary toxicity of inhaled ultrafine particles: due to lung over- load alone? Ann. Occup. Hyg. 38 (Suppl. 1), 295\u2013302. OEChristiaan Delmaar, 2012. Guidance Document 116 on the Conduct and Design of Chronic Toxicity and Carcinogenicity Studies, Supporting Test Guidelines 451, 452 and 453. Series on testing and assessment No. 116. second ed. OEChristiaan Delmaar, Paris, France. OEChristiaan Delmaar, 2018a. Guidance Document on Inhalation Toxicity Studies. Series on Testing and Assessment No. 39, second ed. OEChristiaan Delmaar, Paris, France. OEChristiaan Delmaar, 2018b. Guideline for the Testing of Chemicals. TG 412. 28-day (Subacute) Inhalation Toxicity Study. OEChristiaan Delmaar, Paris, France. OEChristiaan Delmaar, 2018c. Guideline for the Testing of Chemicals. TG 413. 90-Day (Subchronic) Inhalation Toxicity Study. OEChristiaan Delmaar, Paris, France. Pauluhn, J., 2014. Derivation of occupational exposure levels (OELs) of low-toxicity isometric biopersistent particles: how can the kinetic lung overload paradigm be used for improved inhalation toxicity study design and OEL-derivation? Part. Fibre Toxicol. 11, 72. Pauluhn, J., 2011. Poorly soluble particulates: searching for a unifying denominator of nanoparticles and fine particles for DNEL estimation. Toxicology 279 (1\u20133), 176\u2013188. Reuzel, P.G., Bruijntjes, J.P., Feron, V.J., Woutersen, R.A., 1991. Subchronic inhalation toxicity of amorphous silicas and quartz dust in rats. Food Chem. Toxicol. : Int. J. Publ. Br. Ind. Biol. Res. Assoc. 29 (5), 341\u2013354. Ribalta, C., Viana, M., Lopez-Lilao, A., Estupina, S., Minguillon, M.C., Mendoza, J., Diaz, J., Dahmann, D., Monfort, E., 2019. On the relationship between exposure to particles and dustiness during handling of powders in industrial settings. Ann. Work Expo. Health 63 (1), 107\u2013123. RIVM, 2002. Multiple Path Particle Dosimetry Model (MPPD V 1.0): A Model for Human and Rat Airway Particle Dosimetry. Saber, A.T., Bornholdt, J., Dybdahl, M., Sharma, A.K., Loft, S., Vogel, U., Wallin, H., 2005. Tumor necrosis factor is not required for particle-induced genotoxicity and pul- monary inflammation. Arch. Toxicol. 79 (3), 177\u2013182. SCCS, 2018. Opinion on Titanium Dioxide (Nano Form) as UV-Filter in Sprays. Schins, R.P., Knaapen, A.M., 2007. Genotoxicity of poorly soluble particles. Inhal. Toxicol. 19 (Suppl. 1), 189\u2013198. Schneemann, M., Schoedon, G., Hofer, S., Blau, N., Guerrero, L., Schaffner, A., 1993. Nitric oxide synthase is not a constituent of the antimicrobial armature of human mononuclear phagocytes. J. Infect. Dis. 167 (6), 1358\u20131363. Slob, W., 2014. Benchmark dose and the three Rs. Part II. Consequences for study design and animal use. Crit. Rev. Toxicol. 44 (7), 568\u2013580. Snipes, M.B., 1995. Particle Overload Innthe Rat Lung and Lung Cancer: Implications for Human Risk Assessment. Massachusetts Institute of Technology. Sweeney, T.D., Brain, J.D., Leavitt, S.A., Godleski, J.J., 1987. Emphysema alters the de- position pattern of inhaled particles in hamsters. Am. J. Pathol. 128 (1), 19\u201328. Sweeney, T.D., Skornik, W.A., Brain, J.D., Hatch, V., Godleski, J.J., 1995. Chronic bronchitis alters the pattern of aerosol deposition in the lung. Am. J. Respir. Crit. Care Med. 151 (2 Pt 1), 482\u2013488. Takizawa, H., 1998. Airway epithelial cells as regulators of airway inflammation (Review). Int. J. Mol. Med. 1 (2), 367\u2013378. Thompson, C.M., Suh, M., Mittal, L., Wikoff, D.S., Welsh, B., Proctor, D.M., 2016. Development of linear and threshold no significant risk levels for inhalation exposure to titanium dioxide using systematic review and mode of action considerations. Regul. Toxicol. Pharmacol. 80, 60\u201370. Tran, C.L., Buchanan, D., Cullen, R.T., Searl, A., Jones, A.D., Donaldson, K., 2000. Inhalation of poorly soluble particles. II. Influence of particle surface area on in- flammation and clearance. Inhal. Toxicol. 12 (12), 1113\u20131126. Vincent, J.H., Donaldson, K., 1990. A dosimetric approach for relating the biological response of the lung to the accumulation of inhaled mineral dust. Br. J. Ind. Med. 47 (5), 302\u2013307. Warheit, D.B., Hansen, J.F., Yuen, I.S., Kelly, D.P., Snajdr, S.I., Hartsky, M.A., 1997. Inhalation of high concentrations of low toxicity dusts in rats results in impaired pulmonary clearance mechanisms and persistent inflammation. Toxicol. Appl. Pharmacol. 145 (1), 10\u201322. Warheit, D.B., Kreiling, R., Levy, L.S., 2016. Relevance of the rat lung tumor response to particle overload for human risk assessment-Update and interpretation of new data since ILSI 2000. Toxicology 374, 42\u201359. Wiemann, M., Vennemann, A., Sauer, U.G., Wiench, K., Ma-Hock, L., Landsiedel, R., 2016. An in vitro alveolar macrophage assay for predicting the short-term inhalation toxicity of nanomaterials. J. Nanobiotechnol. 14, 16. P.M.J. Bos, et al. Regulatory Toxicology and Pharmacology 109 (2019) 104498 12 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref47 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref47 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref48 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref48 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref49 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref49 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref49 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref50 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref50 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref50 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref51 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref51 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref51 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref52 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref52 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref53 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref53 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref54 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref54 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref55 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref55 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref56 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref56 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref56 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref57 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref57 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref58 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref58 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref58 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref59 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref59 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref59 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref60 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref60 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref60 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref60 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref60 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref61 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref61 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref62 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref62 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref62 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref62 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref63 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref63 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref64 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref64 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref65 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref65 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref66 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref66 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref66 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref67 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref67 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref67 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref68 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref68 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref68 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref69 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref69 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref69 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref70 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref70 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref71 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref71 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref72 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref72 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref73 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref73 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref73 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref74 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref74 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref74 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref75 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref75 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref76 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref76 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref77 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref77 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref78 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref78 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref78 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref78 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref79 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref79 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref80 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref80 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref80 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref81 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref81 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref81 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref81 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref82 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref82 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref83 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref83 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref83 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref84 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref85 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref85 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref86 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref86 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref86 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref87 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref87 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref88 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref88 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref89 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref89 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref90 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref90 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref90 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref91 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref91 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref92 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref92 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref92 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref92 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref93 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref93 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref93 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref94 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref94 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref94 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref95 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref95 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref95 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref95 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref96 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref96 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref96 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref97 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref97 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref97 Pulmonary toxicity in rats following inhalation exposure to poorly soluble particles: The issue of impaired clearance and the relevance for human health hazard and risk assessment Introduction Impaired clearance Hypotheses on AM dysfunction Dose metrics in impaired clearance Mechanism of impaired clearance and adverse outcomes Species differences Anatomical and histological differences Differences in antioxidant response Differences in alveolar macrophages Differences in inflammatory response Differences in neoplastic lung lesions Hazard and risk assessment of PSPs Guidance on impaired clearance in regulatory frameworks Purpose of toxicity studies: hazard versus risk assessment Selection of top dose or concentration Human relevance of PSP-induced pulmonary toxicity observed in rats -Extrapolation of rat toxicity data to humans Choice of dose metric Particle size distribution Conclusions on human health hazard and risk assessment of PSPs Funding mk:H1_22 Acknowledgements References", "Acknowledgement": "Acknowledgements The authors thank Susan Dekkers, Betty Hakkert, Marja Pronk, Hedwig Braakhuis, Petra van Kesteren and Monique Groenewold (all RIVM), and Jack R. Harkema (Michigan State University) for their va- luable input and suggestions and critical reading of the manuscript. EU, 2008b. Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on Classification, Labelling and Packaging of Substances and Mixtures, Amending and Repealing Directives 67/548/EEC and 1999/45/EC, and Amending Regulation (EC) No 1907/2006. In (Official Journal of the European Union L 353, 31.12.2008. 1. Ferin, J., Feldstein, M.L., 1978. Pulmonary clearance and hilar lymph node content in rats after particle exposure. Environ. Res. 16 (1\u20133), 342\u2013352. Gao, C.H., Dong, H.L., Tai, L., Gao, X.M., 2018. Lactoferrin-containing immunocomplexes drive the conversion of human macrophages from M2- into M1-like phenotype. Front. Immunol. 9, 37. Geiser, M., 2010. Update on macrophage clearance of inhaled micro- and nanoparticles. J. Aerosol Med. Pulm. Drug Deliv. 23 (4), 207\u2013217. Geiser, M., Kreyling, W.G., 2010. Deposition and biokinetics of inhaled nanoparticles. Part. Fibre Toxicol. 7, 2. Geiser, M., Rothen-Rutishauser, B., Kapp, N., Schurch, S., Kreyling, W., Schulz, H., Semmler, M., Im Hof, V., Heyder, J., Gehr, P., 2005. Ultrafine particles cross cellular membranes by nonphagocytic mechanisms in lungs and in cultured cells. Environ. Health Perspect. 113 (11), 1555\u20131560. Green, F.H., 2000. Pulmonary responses to inhaled poorly soluble particulate in the human. Inhal. Toxicol. 12 (1\u20132), 59\u201395. Greim, H., Borm, P., Schins, R., Donaldson, K., Driscoll, K., Hartwig, A., Kuempel, E., Oberdorster, G., Speit, G., 2001. Toxicity of fibers and particles. Report of the workshop held in Munich, Germany, 26-27 October 2000. Inhal. Toxicol. 13 (9), 737\u2013754. Hahn, F.F., G, F., Nikula, K.J., Vallyathan, V., Chiyotani, K., Hosoda, Y., Aizawa, Y., 1998. Comparative Pulmonary Responses of Humans and Animals to Dust Exposures. Heinrich, U., Fuhst, R., Rittinghausen, S., Creutzenberg, O., Bellman, B., Koch, W., Levsen, K., 1995. Chronic inhalation exposure of Wistar rats and two different strains of mice to diesel engine exhaust, carbon black, and titanium dioxide. Inhal. Toxicol. 7, 533\u2013556. Heinrich, U., Mohr, U., Fuhst, R., Brockmeyer, C., 1989. Investigation of a Potential Cotumorigenic Effect of the Dioxides of Nitrogen and Sulfur, and of Diesel Engine Exhaust, in the Respiratory Tract of Syrian Golden Hamsters. pp. 1\u201327. Heinrich, U., Muhle, H., Takenaka, S., Ernst, H., Fuhst, R., Mohr, U., Pott, F., Stober, W., 1986. Chronic effects on the respiratory tract of hamsters, mice and rats after long- term inhalation of high concentrations of filtered and unfiltered diesel engine emis- sions. J. Appl. Toxicol. 6 (6), 383\u2013395. Heinrich, U., Peters, L., Funcke, W., Pott, F., Mohr, W., St\u00f6ber, W., 1982. Investigation of toxic and carcinogenic effects of diesel exhaust in long-term inhalation exposure of rodents. In: Lewtas, J. (Ed.), Toxicological Effects of Emissions from Diesel Engines. Elsevier., New York, pp. 225\u2013242. IARC, 2010. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 93 Carbon Black, Titanium Dioxide, and Talc, Lyon, France. IARC, 1997. Silica, some silicates, coal dust and para-aramid fibrils. IARC Monogr. Eval. Carcinog. Risks Hum. 1\u2013475. IARC, 1999. Species Differences in Thyroid, Kidney and Urinary Bladder Carcinogenesis. IARC Scientific Publications No. 147. Ilsi Risk Science Institute, 2000. The relevance of the rat lung response to particle overload for human risk assessment: a workshop consensus report. Inhal. Toxicol. 12 (1\u20132), 1\u201317. Jacobsen, N.R., Pojana, G., White, P., Moller, P., Cohn, C.A., Korsholm, K.S., Vogel, U., Marcomini, A., Loft, S., Wallin, H., 2008. Genotoxicity, cytotoxicity, and reactive oxygen species induced by single-walled carbon nanotubes and C(60) fullerenes in the FE1-Mutatrade markMouse lung epithelial cells. Environ. Mol. Mutagen. 49 (6), 476\u2013487. Jacobsen, N.R., Saber, A.T., White, P., Moller, P., Pojana, G., Vogel, U., Loft, S., Gingerich, J., Soper, L., Douglas, G.R., Wallin, H., 2007. Increased mutant frequency by carbon black, but not quartz, in the lacZ and cII transgenes of muta mouse lung epithelial cells. Environ. Mol. Mutagen. 48 (6), 451\u2013461. Jacobsen, N.R., White, P.A., Gingerich, J., Moller, P., Saber, A.T., Douglas, G.R., Vogel, U., Wallin, H., 2011. Mutation spectrum in FE1-MUTA(TM) Mouse lung epithelial cells exposed to nanoparticulate carbon black. Environ. Mol. Mutagen. 52 (4), 331\u2013337. Jarabek, A.M., Asgharian, B., Miller, F.J., 2005 Jun-Jul. Dosimetric adjustments for in- terspecies extrapolation of inhaled poorly soluble particles (PSP). Inhal Toxicol. 17 (7-8), 317\u2013334. Jesch, N.K., Dorger, M., Enders, G., Rieder, G., Vogelmeier, C., Messmer, K., Krombach, F., 1997. Expression of inducible nitric oxide synthase and formation of nitric oxide by alveolar macrophages: an interspecies comparison. Environ. Health Perspect. 105 (Suppl. 5), 1297\u20131300. P.M.J. Bos, et al. Regulatory Toxicology and Pharmacology 109 (2019) 104498 11 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref1 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref1 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref2 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref2 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref2 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref2 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref3 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref3 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref4 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref4 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref5 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref5 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref6 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref6 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref7 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref9 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref9 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref10 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref10 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref10 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref10 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref10 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref11 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref11 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref12 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref12 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref12 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref12 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref13 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref13 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref13 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref14 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref14 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref14 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref15 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref15 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref15 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref16 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref17 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref17 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref17 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref18 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref18 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref18 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref19 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref19 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref19 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref20 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref20 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref20 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref21 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref21 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref21 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref22 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref22 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref22 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref22 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref23 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref23 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref23 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref24 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref24 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref24 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref24 https://eur-lex.europa.eu/eli/reg/2006/1907/2014-04-10 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref25 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref25 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref25 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref25 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref26 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref26 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref26 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref26 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref26 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref27 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref27 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref28 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref28 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref28 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref29 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref29 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref30 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref30 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref31 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref31 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref31 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref31 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref32 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref32 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref33 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref33 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref33 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref33 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref34 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref34 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref35 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref35 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref35 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref35 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref36 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref36 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref36 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref37 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref37 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref37 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref37 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref38 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref38 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref38 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref38 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref39 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref39 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref40 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref40 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref41 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref41 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref42 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref42 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref42 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref43 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref43 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref43 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref43 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref43 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref44 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref44 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref44 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref44 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref45 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref45 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref45 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref45 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref99 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref99 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref99 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref46 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref46 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref46 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref46 Kawasaki, H., 2015. A mechanistic review of silica-induced inhalation toxicity. Inhal. Toxicol. 27 (8), 363\u2013377. Kawasaki, H., 2019. A review of the fate of inhaled alpha-quartz in the lungs of rats. Inhal. Toxicol. 31 (1), 25\u201334. Kolling, A., Ernst, H., Rittinghausen, S., Heinrich, U., 2011. Relationship of pulmonary toxicity and carcinogenicity of fine and ultrafine granular dusts in a rat bioassay. Inhal. Toxicol. 23 (9), 544\u2013554. Kreyling, W.G., Semmler-Behnke, M., Takenaka, S., Moller, W., 2013. Differences in the biokinetics of inhaled nano- versus micrometer-sized particles. Acc. Chem. Res. 46 (3), 714\u2013722. Kuempel, E.D., O'Flaherty, E.J., Stayner, L.T., Smith, R.J., Green, F.H., Vallyathan, V., 2001. A biomathematical model of particle clearance and retention in the lungs of coal miners. Regul. Toxicol. Pharmacol. 34 (1), 69\u201387. Lapp, N.L., Castranova, V., 1993. How silicosis and coal workers' pneumoconiosis de- velop\u2013a cellular assessment. Occup. Med. 8 (1), 35\u201356. Lauweryns, J.M., Baert, J.H., 1977. Alveolar clearance and the role of the pulmonary lymphatics. Am. Rev. Respir. Dis. 115 (4), 625\u2013683. le Boufant, L., 1971. Influence de la nature des poussieres et de la chargepulmonaire sur l'epuration. pp. 227\u2013237 Old woking, Surrey. Lehnert, B.E., 1992. Pulmonary and thoracic macrophage subpopulations and clearance of particles from the lung. Environ. Health Perspect. 97, 17\u201346. Lehnert, B.E., Ortiz, J.B., London, J.E., Valdez, Y.E., Cline, A.F., Sebring, R.J., Tietjen, G.L., 1990. Migratory behaviors of alveolar macrophages during the alveolar clear- ance of light to heavy burdens of particles. Exp. Lung Res. 16 (5), 451\u2013479. Lippmann, M., Yeates, D.B., Albert, R.E., 1980. Deposition, retention, and clearance of inhaled particles. Br. J. Ind. Med. 37 (4), 337\u2013362. Liu, R., Zhang, X., Pu, Y., Yin, L., Li, Y., Zhang, X., Liang, G., Li, X., Zhang, J., 2010. Small- sized titanium dioxide nanoparticles mediate immune toxicity in rat pulmonary al- veolar macrophages in vivo. J. Nanosci. Nanotechnol. 10 (8), 5161\u20135169. Mauderly, J.L., Banas, D.A., Griffith, W.C., Hahn, F.F., Henderson, R.F., McClellan, R.O., 1996. Diesel exhaust is not a pulmonary carcinogen in Christiaan Delmaar-1 mice exposed under conditions carcinogenic to F344 rats. Fundam. Appl. Toxicol. 30 (2), 233\u2013242. Mauderly, J.L., Snipes, M.B., Barr, E.B., Belinsky, S.A., Bond, J.A., Brooks, A.L., Chang, I.Y., Cheng, Y.S., Gillett, N.A., Griffith, W.C., et al., 1994. Pulmonary toxicity of in- haled diesel exhaust and carbon black in chronically exposed rats. Part I: neoplastic and nonneoplastic lung lesions. Res. Rep. Health Eff. Inst. 68 (Pt 1), 1\u201375 discussion 77-97. Mercer, R.R., Crapo, J.D., 1988. Structure of the Gas Exchange Region of the Lungs Determined by Three Dimensional Reconstruction. Raven Press, New York. Morfeld, P., Bruch, J., Levy, L., Ngiewih, Y., Chaudhuri, I., Muranko, H.J., Myerson, R., McCunney, R.J., 2015. Translational toxicology in setting occupational exposure limits for dusts and hazard classification - a critical evaluation of a recent approach to translate dust overload findings from rats to humans. Part. Fibre Toxicol. 12, 3. Morrow, P.E., 1992. Dust overloading of the lungs: update and appraisal. Toxicol. Appl. Pharmacol. 113 (1), 1\u201312. Morrow, P.E., 1988. Possible mechanisms to explain dust overloading of the lungs. Fundam. Appl. Toxicol. 10 (3), 369\u2013384. Mosser, D.M., Edwards, J.P., 2008. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8 (12), 958\u2013969. Newton, P.E., Becker, S.V., Hixon, C.J., 1991. Pulmonary function and particle deposition and clearance in rats after a 90-day exposure to shale-oil-derived jet fuel JP-4. Inhal. Toxicol. 3 (2), 195\u2013210. Nikula, K.J., Avila, K.J., Griffith, W.C., Mauderly, J.L., 1997a. Lung tissue responses and sites of particle retention differ between rats and cynomolgus monkeys exposed chronically to diesel exhaust and coal dust. Fundam. Appl. Toxicol. 37 (1), 37\u201353. Nikula, K.J., Avila, K.J., Griffith, W.C., Mauderly, J.L., 1997b. Sites of particle retention and lung tissue responses to chronically inhaled diesel exhaust and coal dust in rats and cynomolgus monkeys. Environ. Health Perspect. 105 (Suppl. 5), 1231\u20131234. Nikula, K.J., Vallyathan, V., Green, F.H., Hahn, F.F., 2001. Influence of exposure con- centration or dose on the distribution of particulate material in rat and human lungs. Environ. Health Perspect. 109 (4), 311\u2013318. NIOSH, 2011. NIOSH Current Intelligence Bulletin 63. Occupational Exposure to Titanium Dioxide. DHHS (NIOSH) Publication No. 2011-160. NTP, 1993. National Toxicology Program.Toxicology and Carcinogenesis Studies of Talc in F344 Rats and B6C3F1 Mice. Oberdorster, G., 1997. Pulmonary carcinogenicity of inhaled particles and the maximum tolerated dose. Environ. Health Perspect. 105 (Suppl. 5), 1347\u20131355. Oberd\u00f6rster, G., Ferin, J., Soderholm, S.C., Gelein, R., Cox, C., Baggs, R., Morrow, P.E., 1994. Increased pulmonary toxicity of inhaled ultrafine particles: due to lung over- load alone? Ann. Occup. Hyg. 38 (Suppl. 1), 295\u2013302. OEChristiaan Delmaar, 2012. Guidance Document 116 on the Conduct and Design of Chronic Toxicity and Carcinogenicity Studies, Supporting Test Guidelines 451, 452 and 453. Series on testing and assessment No. 116. second ed. OEChristiaan Delmaar, Paris, France. OEChristiaan Delmaar, 2018a. Guidance Document on Inhalation Toxicity Studies. Series on Testing and Assessment No. 39, second ed. OEChristiaan Delmaar, Paris, France. OEChristiaan Delmaar, 2018b. Guideline for the Testing of Chemicals. TG 412. 28-day (Subacute) Inhalation Toxicity Study. OEChristiaan Delmaar, Paris, France. OEChristiaan Delmaar, 2018c. Guideline for the Testing of Chemicals. TG 413. 90-Day (Subchronic) Inhalation Toxicity Study. OEChristiaan Delmaar, Paris, France. Pauluhn, J., 2014. Derivation of occupational exposure levels (OELs) of low-toxicity isometric biopersistent particles: how can the kinetic lung overload paradigm be used for improved inhalation toxicity study design and OEL-derivation? Part. Fibre Toxicol. 11, 72. Pauluhn, J., 2011. Poorly soluble particulates: searching for a unifying denominator of nanoparticles and fine particles for DNEL estimation. Toxicology 279 (1\u20133), 176\u2013188. Reuzel, P.G., Bruijntjes, J.P., Feron, V.J., Woutersen, R.A., 1991. Subchronic inhalation toxicity of amorphous silicas and quartz dust in rats. Food Chem. Toxicol. : Int. J. Publ. Br. Ind. Biol. Res. Assoc. 29 (5), 341\u2013354. Ribalta, C., Viana, M., Lopez-Lilao, A., Estupina, S., Minguillon, M.C., Mendoza, J., Diaz, J., Dahmann, D., Monfort, E., 2019. On the relationship between exposure to particles and dustiness during handling of powders in industrial settings. Ann. Work Expo. Health 63 (1), 107\u2013123. RIVM, 2002. Multiple Path Particle Dosimetry Model (MPPD V 1.0): A Model for Human and Rat Airway Particle Dosimetry. Saber, A.T., Bornholdt, J., Dybdahl, M., Sharma, A.K., Loft, S., Vogel, U., Wallin, H., 2005. Tumor necrosis factor is not required for particle-induced genotoxicity and pul- monary inflammation. Arch. Toxicol. 79 (3), 177\u2013182. SCCS, 2018. Opinion on Titanium Dioxide (Nano Form) as UV-Filter in Sprays. Schins, R.P., Knaapen, A.M., 2007. Genotoxicity of poorly soluble particles. Inhal. Toxicol. 19 (Suppl. 1), 189\u2013198. Schneemann, M., Schoedon, G., Hofer, S., Blau, N., Guerrero, L., Schaffner, A., 1993. Nitric oxide synthase is not a constituent of the antimicrobial armature of human mononuclear phagocytes. J. Infect. Dis. 167 (6), 1358\u20131363. Slob, W., 2014. Benchmark dose and the three Rs. Part II. Consequences for study design and animal use. Crit. Rev. Toxicol. 44 (7), 568\u2013580. Snipes, M.B., 1995. Particle Overload Innthe Rat Lung and Lung Cancer: Implications for Human Risk Assessment. Massachusetts Institute of Technology. Sweeney, T.D., Brain, J.D., Leavitt, S.A., Godleski, J.J., 1987. Emphysema alters the de- position pattern of inhaled particles in hamsters. Am. J. Pathol. 128 (1), 19\u201328. Sweeney, T.D., Skornik, W.A., Brain, J.D., Hatch, V., Godleski, J.J., 1995. Chronic bronchitis alters the pattern of aerosol deposition in the lung. Am. J. Respir. Crit. Care Med. 151 (2 Pt 1), 482\u2013488. Takizawa, H., 1998. Airway epithelial cells as regulators of airway inflammation (Review). Int. J. Mol. Med. 1 (2), 367\u2013378. Thompson, C.M., Suh, M., Mittal, L., Wikoff, D.S., Welsh, B., Proctor, D.M., 2016. Development of linear and threshold no significant risk levels for inhalation exposure to titanium dioxide using systematic review and mode of action considerations. Regul. Toxicol. Pharmacol. 80, 60\u201370. Tran, C.L., Buchanan, D., Cullen, R.T., Searl, A., Jones, A.D., Donaldson, K., 2000. Inhalation of poorly soluble particles. II. Influence of particle surface area on in- flammation and clearance. Inhal. Toxicol. 12 (12), 1113\u20131126. Vincent, J.H., Donaldson, K., 1990. A dosimetric approach for relating the biological response of the lung to the accumulation of inhaled mineral dust. Br. J. Ind. Med. 47 (5), 302\u2013307. Warheit, D.B., Hansen, J.F., Yuen, I.S., Kelly, D.P., Snajdr, S.I., Hartsky, M.A., 1997. Inhalation of high concentrations of low toxicity dusts in rats results in impaired pulmonary clearance mechanisms and persistent inflammation. Toxicol. Appl. Pharmacol. 145 (1), 10\u201322. Warheit, D.B., Kreiling, R., Levy, L.S., 2016. Relevance of the rat lung tumor response to particle overload for human risk assessment-Update and interpretation of new data since ILSI 2000. Toxicology 374, 42\u201359. Wiemann, M., Vennemann, A., Sauer, U.G., Wiench, K., Ma-Hock, L., Landsiedel, R., 2016. An in vitro alveolar macrophage assay for predicting the short-term inhalation toxicity of nanomaterials. J. Nanobiotechnol. 14, 16. P.M.J. Bos, et al. Regulatory Toxicology and Pharmacology 109 (2019) 104498 12 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref47 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref47 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref48 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref48 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref49 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref49 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref49 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref50 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref50 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref50 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref51 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref51 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref51 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref52 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref52 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref53 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref53 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref54 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref54 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref55 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref55 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref56 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref56 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref56 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref57 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref57 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref58 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref58 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref58 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref59 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref59 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref59 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref60 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref60 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref60 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref60 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref60 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref61 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref61 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref62 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref62 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref62 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref62 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref63 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref63 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref64 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref64 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref65 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref65 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref66 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref66 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref66 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref67 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref67 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref67 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref68 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref68 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref68 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref69 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref69 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref69 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref70 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref70 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref71 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref71 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref72 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref72 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref73 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref73 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref73 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref74 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref74 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref74 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref75 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref75 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref76 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref76 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref77 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref77 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref78 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref78 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref78 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref78 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref79 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref79 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref80 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref80 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref80 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref81 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref81 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref81 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref81 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref82 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref82 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref83 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref83 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref83 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref84 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref85 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref85 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref86 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref86 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref86 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref87 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref87 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref88 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref88 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref89 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref89 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref90 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref90 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref90 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref91 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref91 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref92 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref92 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref92 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref92 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref93 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref93 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref93 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref94 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref94 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref94 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref95 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref95 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref95 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref95 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref96 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref96 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref96 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref97 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref97 http://refhub.elsevier.com/S0273-2300(19)30262-4/sref97 Pulmonary toxicity in rats following inhalation exposure to poorly soluble particles: The issue of impaired clearance and the relevance for human health hazard and risk assessment Introduction Impaired clearance Hypotheses on AM dysfunction Dose metrics in impaired clearance Mechanism of impaired clearance and adverse outcomes Species differences Anatomical and histological differences Differences in antioxidant response Differences in alveolar macrophages Differences in inflammatory response Differences in neoplastic lung lesions Hazard and risk assessment of PSPs Guidance on impaired clearance in regulatory frameworks Purpose of toxicity studies: hazard versus risk assessment Selection of top dose or concentration Human relevance of PSP-induced pulmonary toxicity observed in rats -Extrapolation of rat toxicity data to humans Choice of dose metric Particle size distribution Conclusions on human health hazard and risk assessment of PSPs Funding mk:H1_22 Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Pulmonary-toxicity-of-silver-vapours--nanoparti_2020_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32474071", "content": {"CoiStatement": "Genotoxicity and carcinogenicity Comparison of ionic and nanoparticulate silver Hazard assessment Summary Funding Declaration of competing interest Acknowledgements Supplementary data References", "Funding": "Genotoxicity and carcinogenicity Comparison of ionic and nanoparticulate silver Hazard assessment Summary Funding Declaration of competing interest Acknowledgements Supplementary data References", "Acknowledgement": "Genotoxicity and carcinogenicity Comparison of ionic and nanoparticulate silver Hazard assessment Summary Funding Declaration of competing interest Acknowledgements Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Purification--characterization-and-anti-diabetic-ac_2014_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25455227", "content": {"CoiStatement": "In conclusion, the findings of this study indicate that MLP, an important active polysaccharide fraction from mulberry leaf, may ameliorate hyperglycemia and hyperlipidaemia associated with diabetes through stimulating insulin secretion and improving glu- cose and lipid metabolism. It is worth noting that all the parame- ters measured above were applying to the diagnosis of diabetes and the evaluation of drug effects on diabetes treatment in clinical. Thus, our study provides a foundation for the further use of MLP as a therapeutic agent against diabetic mellitus. Conflict of interest Dr. Zhang has nothing to disclose. Acknowledgments 4 Discussion Conflict of interest Acknowledgments References", "Acknowledgement": "Dr. Zhang has nothing to disclose. Acknowledgments This study was supported by the earmarked fund for Modern Agricultural Technology Research System (No. CARS-22) and China Postdoctoral Science Foundation (No. 2013M531641). References 4 Discussion Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Purification--characterization-and-safety-assessment-_2015_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25545317", "content": {"CoiStatement": "Conflict of interest The authors declare no conflicts of interest. The authors declare no conflicts of interest. Acknowledgments 4 Discussion 5 Conclusions Conflict of interest Acknowledgments Appendix A Supplementary data References", "Acknowledgement": "Acknowledgments The authors would like to thank Dr. Kevin Glenn and Dr. John Vicini for critical reading of the manuscript, Dr. Elena Rice for help in experimental design, Chris Dalton & Richard S. Thoma for N-ter- minal, MALDI TOF & amino acid analyses, Dr. Xin Gu for the CSPB functional activity assay, Shefalee A. Kapadia for digestibility assessment, Dr. Tom Edrington for the formulation of a CSPB dose solution, and Haidi T. Kang for bioinformatics analysis of potential CSPB allergenicity and toxicity. 4 Discussion 5 Conclusions Conflict of interest Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Purification-of-Bhallathaka--Semecarpus-anacardiu_2021_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33621615", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 4 Discussion 5 Conclusion CRediT author contribution statement Declaration of competing interest Acknowledgements References", "Acknowledgement": "Acknowledgements The financial assistance from Navajbhai Ratan Tata Trust, Mumbai, India is greatly acknowledged (Grant No: RLC-PPP-AVS-20150930). 4 Discussion 5 Conclusion CRediT author contribution statement Declaration of competing interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Putting-the-parts-together--Combining-in-vitro-met_2012_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22659254", "content": {"CoiStatement": "6. Conflict of interest statement Other than employment, the authors are not aware of any con- flicts of interest. 4 Discussion 5 Conclusions and outlook 6 Conflict of interest statement Acknowledgements References", "Acknowledgement": "Acknowledgements We would like to thank Dr. Andreas Natsch from Givaudan, Switzerland, for the KeratinoSens\u2122 cell line and the Keratino- Sens\u2122 protocol. We would also like to thank the Laboratory for Alternative Methods Developments, Laboratory for Applied Alter- native Methods and the Laboratory for Biokinetics, all at BASF SE, for excellent technical assistance and support as well as Benjamin Wiench and Christina Pachel for their contribution in the course of their thesis research at BASF laboratories. 4 Discussion 5 Conclusions and outlook 6 Conflict of interest statement Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/QSARs-in-ecotoxicological-risk-assess_2006_Regulatory-Toxicology-and-Pharmac.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16529851", "content": {"Acknowledgement": "Acknowledgments The current research was funded by NOTOX B.V. NOTOX is an independent, privately-owned Dutch con- tract research organisation founded in 1983. We are spe- cialized in dossier preparation and in performing chemical and toxicological studies for the registration of pharmaceu- ticals, industrial chemicals, agrochemicals and biocides. NOTOX has been accredited in Good Laboratory Prac- tices since 1987. Part of the policy of NOTOX is to work on the development of alternatives for animal testing. Rinus Bogers and Ineke Gubbels (NOTOX) and Tinka Murk (Wageningen University and Research Centre) are thanked for their comments on the set up of the described exercise. Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Qualification-of-cardiac-troponins-for-nonclinic_2013_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23876748", "content": {"CoiStatement": "Conflict of interest statement The authors declare no conflict of interest in this work. The authors declare no conflict of interest in this work. Acknowledgments 4 Reverse or forward translation 5 Is a new research paradigm needed? 6 Data mining for biomarkers 7 Conclusion Conflict of interest statement Acknowledgments References", "Acknowledgement": "Acknowledgments We would like to thank P.J. O\u2019Brien for his valuable commentary on the manuscript and the HESI Cardiac Biomarkers Working Group of the HESI Cardiac Safety Technical Committee for their time and assistance in providing helpful suggestions and critique. The recommendations made by Marc Walton, Issam Zineh, Shashi Amur, David Joseph, and David Jacobson-Kram are gratefully appreciated. 4 Reverse or forward translation 5 Is a new research paradigm needed? 6 Data mining for biomarkers 7 Conclusion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Qualification-of-impurities-based-on-meta_2020_Regulatory-Toxicology-and-Pha.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31734179", "content": {"Funding": "Conclusions Funding mk:H1_18 Acknowledgments Links associated with Table 1: Summary of Regulatory approvals of higher-than guidance limits of impurities also being metabolites (as of April 2019) List of Abbreviations and Definition of Terms References", "Acknowledgement": "Conclusions Funding mk:H1_18 Acknowledgments Links associated with Table 1: Summary of Regulatory approvals of higher-than guidance limits of impurities also being metabolites (as of April 2019) List of Abbreviations and Definition of Terms References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Qualitative-analysis-of-actual-Standard-for-Exchange-of-Noncl_2021_Regulator.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33753112", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 4 Discussion Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Funding": "Funding This work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors, other than salary sup- port from respective employers. This work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors, other than salary sup- port from respective employers. CRediT authorship contribution statement 4 Discussion Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Acknowledgement": "Acknowledgements The authors sincerely appreciate to former Taskforce Team mem- bers, Takehito Isobe (Chugai Pharmaceutical Co., Ltd.), Takako Hamano (Novartis Pharma Keita Kobayashi.), Michiharu Yoshiike (Daiichi Sankyo Co., Ltd.), Kazuhisa Hara (Nippon Kayaku Co., Ltd.), Taeko Hasegawa (Chugai Pharmaceutical Co., Ltd.), and Yoshihisa Nakano (Mochida Pharma- ceutical Co., Ltd.), who were replaced during (September 2018 to November 2019) or after the research period for their great contribu- tions to the activity. They also would like to thank all the reviewers in the Taskforce Team members\u2019 companies for their thorough review and useful suggestions in preparation of this paper. Further, they gratefully acknowledge William Houser (Bristol-Myers Squibb Company) and Nancy Bower (Eisai Inc.) for their valuable comments in helping us write this manuscript and to improve the English quality. 4 Discussion Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Quality-control-programmes-for-veterinary-ant_2018_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30130551", "content": {"Compliance with ethical standards": "Quality control programmes for veterinary antimicrobial medicines specification\u201d in a veterinary medicine raised animal health concern, recall of all batches and marketing authorization suspension (EMA, 2010b). In 2010 another \u201cout of specification\u201d medicine was reported, re-assessed, and subject to variations (EMA, 2011). In 2011, 4 medi- cines were detected as \u201coutside their specifications\u201d and in 2012, one medicine was reported as \u201cout of compliance\u201d (EMA, 2012; EMA, 2013). Most of the products tested in 2013 followed the authorized specifications, with one exception (EMA, 2014). At national levels, quality medicines controls may be even scarcer. As a global concern, data collected from quality control programmes should be standardized and published. Medicated feed is out of the VAM legal frame (EC, 1990). The GMP's requisites for the medicated pre-mixes are specific and less rigorous than for the other veterinary medicines (EC, 2001). Medicated feed quality control is conducted by the own manufacturers, to ensure homogeneity and stability compliance at all stages of pro- duction and shelf-life, under the recommended storage and transpor- tation conditions, with are free circulation (and often long distance) in the EEE (EEC, 1990; Portugal, 2005). During manufacture, un- predictable dosages of antimicrobials may result in undetected quality defects due to eventual combination of the active substances with feed ingredients or cross-contamination events. Data on medicated feed consumption or on quality are not available, but NCAs should be en- couraged to reinforce the mandatory quality official controls for anti- microbial medicated feed as for VAMs (EC, 2010; Van Landingham et al., 2016). Such data should be integrated in the veterinary surveil- lance system on AMR because there is substantial lack of information on quality of antimicrobials in the EU and some action could probably be raised from there (Acar and Moulin, 2013). 3. Discussion"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Quantification-of-Tissue-Self-Absorption-of-Weak---R_2000_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/10806057", "content": {"Acknowledgement": "ACKNOWLEDGMENTS The authors thank Frank Conrad, Jasmin Percher, and Dagmar Trummel for their excellent technical assistance in performing and evaluating the transmission experiments. ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Quantified-tracking-and-monitoring-of-diazepam-tre_2012_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22051156", "content": {"CoiStatement": "Conflict of interest statement The authors declare no conflict of interest. The authors declare no conflict of interest. Acknowledgments 4 Discussion and conclusion Conflict of interest statement Acknowledgments Appendix A Supplementary data References", "Acknowledgement": "Acknowledgments We thank C.M. Luetjens and the technical staff at Covance Laboratories M\u00fcnster for their aid in setting up the EthoVision\ufffd 4 Discussion and conclusion Conflict of interest statement Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Quantifying-bias-in-epidemiologic-studies-evaluating_2021_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33454352", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Jesse Berlin is an employee of Johnson & Johnson. Martijn Schuemie, Rachel Weinstein, and Patrick Ryan are employees of Janssen Research & Development, a Johnson & Johnson company. Jesse Berlin, Martijn Schuemie, Rachel Weinstein, and Patrick Ryan are shareholders of Johnson & Johnson. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Jesse Berlin is an employee of Johnson & Johnson. Martijn Schuemie, Rachel Weinstein, and Patrick Ryan are employees of Janssen Research & Development, a Johnson & Johnson company. Jesse Berlin, Martijn Schuemie, Rachel Weinstein, and Patrick Ryan are shareholders of Johnson & Johnson. Acknowledgements 5 Conclusions Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Funding": "Funding This work was sponsored by Johnson & Johnson, a manufacturer of acetaminophen. Martijn J. Schuemie: Conceptualization, Methodology, Software, Validation, Formal analysis, Investigation, Resources, Data curation, Writing - review & editing, Supervision. Rachel Weinstein: Conceptu- alization, Methodology, Validation, Writing - review & editing, Project administration, Funding acquisition. Patrick B. Ryan: Conceptualiza- tion, Methodology, Validation, Investigation, Resources, Data curation, Writing - review & editing. Jesse A. Berlin: Conceptualization, Meth- odology, Validation, Writing - review & editing, Supervision, Funding acquisition. Declaration of competing interest 5 Conclusions Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Acknowledgement": "Acknowledgements The authors thank Kathleen Boyle, PhD, CMPP of 4 Learning Group, LLC (Exton, PA, USA) for providing editorial support for this manuscript. 5 Conclusions Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Quantifying-the-benefits-of-using-read-across-and-in-si_2016_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27612993", "content": {"Acknowledgement": "Acknowledgements A substantial amount of the data used as the basis for the as- sessments cited in this manuscript were provided by the 62 com- panies engaged in the SDA/ACI consortia. We would like to thank the members of the consortia for their commitment to animal welfare through the use of alternative methods. 3. Quantification of benefits 4. Discussion and conclusion Acknowledgements Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Quantifying-the-risk-reduction-potential-of-new-_2018_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29258927", "content": {"CoiStatement": "Declaration of interest Paolo F Ricci is a consultant, all other authors are employees of Philip Morris International. Results Discussion Conclusion Funding Declaration of interest Acknowledgments Supplementary data Transparency document References", "Funding": "Funding Philip Morris International is the sole source of funding and sponsor of this project. Philip Morris International is the sole source of funding and sponsor of this project. Declaration of interest Results Discussion Conclusion Funding Declaration of interest Acknowledgments Supplementary data Transparency document References", "Acknowledgement": "Acknowledgments The authors acknowledge Valerie Poux for her support in the pre- paration of this manuscript and two reviewers of a previous version for their valuable comments and suggestions. Results Discussion Conclusion Funding Declaration of interest Acknowledgments Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Quantitative-Distribution-Studies-in-Animals--Cross-Va_2000_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/10806058", "content": {"Acknowledgement": "ACKNOWLEDGMENTS The authors thank all persons at various companies who actively contributed to this assessment. In particular, we thank Claudia Crummenerl, Nicola Grunwald, Kerstin Maschke, Bettina Sohnius- Lu\u0308pertz, Jasmin Percher, Frauke Schiffbauer, Dagmar Trummel, and Heike Weigelt for their technical assistance in assembling and evaluating the data pool. CONCLUSIONS ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Quantitative-Whole-Body-Autoradiography--Recommend_2000_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/10806055", "content": {"Acknowledgement": "ACKNOWLEDGMENTS S21STANDARDIZATION OF QUANTITATIVE WHOLE-BODY AUTORADIOGRAPHY recommendations for the performance of whole-body autoradiography using imaging plates may be consid- ered: CONCLUSIONS ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Quantitative-analysis-of-menthol-and-identification-of_2018_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29309808", "content": {"Funding": "Discussion Conclusion Funding Acknowledgements Supplementary data Transparency document References", "Acknowledgement": "Acknowledgements The first two authors contributed equally to this work. Discussion Conclusion Funding Acknowledgements Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Quantitative-and-statistical-analysis-of-differences-in-se_2010_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20138101", "content": {"Acknowledgement": "In conclusion, the present study demonstrates for the first time quantitative, and statistically established, differences between L\u2013E and H/W rats following long-term TCDD exposure. A dose\u2013re- sponse modeling approach was applied where sensitivity differ- ences were quantified as the ratio between the BMDs for H/W and L\u2013E rats. A step wise framework was established to (1) assess the case of parallel dose\u2013response curves between L\u2013E and H/W rats, (2) compute a point estimate of the BMD ratio under the pre- ferred model, (3) estimate a confidence interval for the BMD ratio, describing its uncertainty, and if a BMD ratio = 1 was part of in this interval, the two strains were not considered to differ statistically in their response to TCDD treatment. The procedure applied in the present study has broader applications in the assessment of species, strain, and sex sensitivity following chemical exposure. These findings can be useful especially when analyzing or compar- ing toxic responses in animal or human populations differing in their susceptibility to chemicals. The present findings can be uti- lized for improving the risk assessment of susceptible subgroups. This issue is of increasing importance in risk assessment of chemicals. Acknowledgments Grants for this study were obtained from an internal fund for risk assessment projects at the Institute of Environmental Medi- cine, Karolinska Institutet. The work was also performed within the EU funded CASCADE Network of Excellence (Contract No.: FOOD-CT-2003-506319) and BoneTox (QLK-CT-2002-02528). It does not necessarily reflect the views of the Commission of the European Communities, and it does in no way anticipate the Com- missions future policy in this area. The work was also supported by funds from the Swedish Council for Environment, Agricultural Sci- ences and Spatial Planning (FORMAS Grant No. 21.0/2003-1135 Etapp2). References Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Quantitative-assessment-of-cumulative-carcinogenic-ri_2008_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18550240", "content": {"Acknowledgement": "J.P. Bercu et al. / Regulatory Toxicology and Pharmacology 51 (2008) 270\u2013277 277 Determining the acceptable number of genotoxic impurities war- rants a broader discussion; however, this analysis suggests that up to three genotoxic impurities, whether structurally related or not, should be acceptable in most cases in pharmaceutical develop- ment. Four or more genotoxic impurities is a less likely scenario and should be discussed on a case-by-case basis. Acknowledgments We thank Kirk Arvidson for providing us their classifications of structural alerts for compounds found in the carcinogenicity data- base. We also thank Autumn McClatchey for data entry into the database used in this analysis. References Discussion Conclusions Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Quantitative-cancer-risk-assessment-based-on-NIOSH-an_2010_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19840826", "content": {"Funding": "The funding for this paper was from contracts with the American Chemistry Council, Inc. at 1300 Wilson Boulevard, Arlington, Vir- ginia 22209 on behalf of its Ethylene Oxide Panel. The opinions of the authors do not necessarily reflect the opinions of the sponsor. The epidemiological data for the NIOSH study were obtained from the National Institute for Occupational Safety and Health through a Freedom of Information Act request (May 13, 2004).", "Acknowledgement": "Acknowledgments The funding for this paper was from contracts with the American Chemistry Council, Inc. at 1300 Wilson Boulevard, Arlington, Vir- ginia 22209 on behalf of its Ethylene Oxide Panel. The opinions of the authors do not necessarily reflect the opinions of the sponsor. Conclusions Acknowledgments Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Quantitative-human-health-risk-assessment-for-1-3-b_2012_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22100993", "content": {"CoiStatement": "C.R. Kirman, R.L. Grant / Regulatory Toxicology and Pharmacology 62 (2012) 371\u2013384 383 Conflict of interest statement Mr. Kirman serves as an independent consultant to the Olefins Panel of the American Chemistry Council, who funded his time on this manuscript. Dr. Grant has no conflict of interest. Mr. Kirman serves as an independent consultant to the Olefins Panel of the American Chemistry Council, who funded his time on this manuscript. Dr. Grant has no conflict of interest. Acknowledgments Quantitative human health risk assessment for 1,3-butadiene based upon ovarian effects in rodents 1 Introduction 2 Mode of action assessment 3 Dose\u2013response assessment 4 Summary and discussion Conflict of interest statement Acknowledgments References", "Acknowledgement": "Acknowledgments The authors thank Drs. Robert Sielken, Ciriaco Valdez-Flores, Lesa Aylward, Sean Hays, Lynne Haber, and the Alliance for Risk Assessment (ARA) Expert Panel on NAS (2009) for their thoughtful comments on the assessment. Quantitative human health risk assessment for 1,3-butadiene based upon ovarian effects in rodents 1 Introduction 2 Mode of action assessment 3 Dose\u2013response assessment 4 Summary and discussion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Quantitative-measurement-of-protein-digestion-_2005_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15748795", "content": {"Acknowledgement": "R.A. Herman et al. / Regulatory Toxicology and Pharmacology 41 (2005) 175\u2013184 183 as very labile or very stable is likely to be sufficient for a weight-of-evidence assessment of allergenic risk. While the examples reported here are limited to simple reac- tions devoid of digestion fragments, appropriate meth- ods for modeling the appearance and dissipation of such fragments has been described (Atkins, 1986). When digestion fragments are present, methods such as SDS\u2013 PAGE followed by densitometry are required to allow profiles for parent protein and fragments to be tracked independently. Acknowledgments We thank Michael Woolhiser of Dow Chemical Company, and Yong Gao, Joel Mattsson, Joel Sheets, Laura Tagliani, and Nick Storer of Dow AgroSciences for their review and helpful comments on the manu- script. We also thank the anonymous reviewers for their helpful suggestions. We thank Kerrm Yau for technical assistance with the fluorometer. References Conclusions Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Quantitative-prediction-of-repeat-dose-toxici_2019_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31550520", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper.", "Funding": "Funding Imran Shah and Grace Patlewicz are employees of the US EPA and George Helman is an ORI ShahE research participant funded by the US EPA. There were no other sources of funding for this work. Imran Shah and Grace Patlewicz are employees of the US EPA and George Helman is an ORI ShahE research participant funded by the US EPA. There were no other sources of funding for this work. References Conclusions Competing financial interests Disclaimer mk:H1_16 Supplementary data Funding References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Quantitative-relationship-between-the-local-lymph-n_2004_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15135206", "content": {"Acknowledgement": "Results Discussion Conclusions Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Quantitative-risk-analyses-for-RCF--survey_2003_Regulatory-Toxicology-and-Ph.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/14623489", "content": {"Acknowledgement": "The quantitative significance of the choice of either an epithelial area or lung weight basis for lung burden normalization is understood. In contrast to this impor- tant parameter, the choice of potency models has only a minor effect on the results. Directionally, the effect of a greater ratio of particles to fibers in the RCC experiment would be to overstate the actual workplace risk for airborne fiber, but we lack data to estimate the magni- tude of this possible confounder\u2014a fruitful area for additional research. Acknowledgments This work was supported by the Refractory Ceramic Discussion Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Quantitative-risk-assessment-for-skin-sensitisation--_2012_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23069142", "content": {"CoiStatement": "Conflict of interest statement Carsten Goebel, Maya Krasteva, Harald Schlatter, Jacquemine Pungier, Rolf Fautz, Anne Fuchs, Werner Schuh, and Frank Gerber- ick are employees of companies selling cosmetic products includ- ing hair colorants. The hair dye ingredients studied in this paper are currently used in commercial products marketed by these com- panies. A one day Workshop was organized and sponsored by these companies and Thomas Diepgen, Jean-Francois Nicolas, Brunhilde Bl\u00f6meke, Pieter Jan Coenraads, Axel Schnuch, James Taylor and Ian Kimber were invited as consultants. The authors alone are responsible for the content and writing of the paper. 4 Discussion Conflict of interest statement Acknowledgments References", "Acknowledgement": "Acknowledgments All authors of this paper participated as active members in a workshop that was held in March 2011. As a follow-up of this workshop, the manuscript was composed based on the individual contributions. The manuscript is the joint work of the authors. 4 Discussion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Quantitative-risk-assessment-for-skin-sensitiz_2017_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27871868", "content": {"Acknowledgement": "Naturally, just as with computer systems, skin sensitization QRA can suffer from the \u201crubbish in, rubbish out\u201d phenomenon. More- over, a QRA can be conducted perfectly, but if the risks identified as a result of the assessment are not managed effectively, then dermatology feedback does not apply to the QRA itself. Thus, the essential requirements for the avoidance of future epidemics of contact allergy are that the QRA methodology is used rigorously, begins to incorporate aggregate exposure to the particular sensi- tizer under examination, and that it is adapted, if and when necessary, based on feedback from human experience gathered by the dermatology community. Finally, although not intrinsic to the QRA itself, it will be important to ensure that the whole process is able to accommodate the replacement of in vivo methods with the new non-animal alternatives. Acknowledgements Thanks to Cindy Ryan for her helpful comments. Transparency document 4. Summary Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Quantitative-risk-assessment-of-the-aggregate-dermal-expo_2015_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26107291", "content": {"Acknowledgement": "Acknowledgments This work was funded by the Dutch Ministry of Public Health, Welfare and Sport (grant number V/0500013). We express our thanks to Ipsos for making the database of the EPHECT-project available to us, to W. ter Burg for his valuable comments on the draft manuscript and to Dr. A. de Groot for his help on incidences of contact allergy by geraniol. 4. Discussion 5. Conclusion Acknowledgments Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Quantitative-risk-assessment-of-tobacco-products--A-po_2018_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29614342", "content": {"Compliance with ethical standards": "USFDA, 2011a. Section 905(j) Reports: Demonstrating Substantial Equivalence for Tobacco Products. January 5. . http://www.fda.gov/downloads/TobaccoProducts/ GuidanceComplianceRegulatoryInformation/UCM239021.pdf. USFDA, 2011b. Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke; Request for Comments. United States Food and Drug Administration Federal Register. 76(156):50226\u201350230. August 12, 2011. USFDA, 2012b. Reporting harmful and potentially harmful constituents in tobacco pro- ducts and tobacco smoke under Section 904(e) of the Federal Food, Drug, and Cosmetic Act. Draft Guidance. March. United States Food and Drug Administration. Available at: http://www.fda.gov/downloads/TobaccoProducts/ GuidanceComplianceRegulatoryInformation/UCM297828.pdf. USFDA, 2013. Toxicology Review of 905(j)(1)(A)(i) Report, Second Cycle Review of Additional Information, SE0003730, SE0003731. United States Food and Drug Administration Document received via Freedom of Information Act request. This reference can be obtained by any interested parties through a Freedom of Information Act request to the USFDA). https://hhpprtv.ornl.gov/ https://www.epa.gov/pcbs/learn-about-polychlorinated-biphenyls-pcbs https://www.epa.gov/pcbs/learn-about-polychlorinated-biphenyls-pcbs http://www.fda.gov/downloads/TobaccoProducts/GuidanceComplianceRegulatoryInformation/UCM239021.pdf http://www.fda.gov/downloads/TobaccoProducts/GuidanceComplianceRegulatoryInformation/UCM239021.pdf http://refhub.elsevier.com/S0273-2300(18)30099-0/sref73 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref73 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref73 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref74 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref74 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref74 http://www.fda.gov/downloads/TobaccoProducts/GuidanceComplianceRegulatoryInformation/UCM297828.pdf http://www.fda.gov/downloads/TobaccoProducts/GuidanceComplianceRegulatoryInformation/UCM297828.pdf http://refhub.elsevier.com/S0273-2300(18)30099-0/sref76 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref76 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref76 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref76 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref76 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref77 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref77 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref77 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref78 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref78 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref79 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref79 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref79 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref79 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref79 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref79 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref80 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref80 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref80 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref80 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref80 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref81 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref81 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref82 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref82 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref82 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref83 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref83 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref83 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref83 http://refhub.elsevier.com/S0273-2300(18)30099-0/sref83 Quantitative risk assessment of tobacco products: A potentially useful component of substantial equivalence evaluations Introduction Tobacco product regulation: substantial equivalence Harmful and potentially harmful constituents in tobacco"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Quantitative-weight-of-evidence-to-assess-confid_2017_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28232103", "content": {"Acknowledgement": "Corton, C.J., 2008. Evaluation of the role of peroxisome proliferator-activated re- ceptor a (PPARa in mouse liver tumor induction by trichloroethylene and metabolites. Crit. Rev. Toxicol. 38 (10), 857e875. Corton, J.C., Cunningham, M.L., Hummer, B.T., Lau, C., Meek, B., Peters, J.M., Popp, J.A., Rhomberg, L., Seed, J., Klaunig, J.E., 2014. Mode of action framework analysis for receptor-mediated toxicity: the peroxisome proliferator-activated receptor alpha (PPARa) as a case study. Crit. Rev. Toxicol. 44, 1e49. http:// dx.doi.org/10.3109/10408444.2013.835784. David, R.M., Moore, M.R., Cifone, M.A., Finney, D.C., Guest, D., 1999. Chronic peroxisome proliferation and hepatomegaly associated with the hepatocellular tumorigenesis of di(2-ethylhexyl) phthalate and the effects of recovery. Toxicol. Sci. 50, 195e205. Dayan, J., Deguingand, S., Truzman, C., 1985. Study of the mutagenic activity of 6 hepatotoxic pharmaceutical drugs in the Salmonella typhimurium microsome test, and the HGPRT and Na\u00fe/K\u00fe ATPase system in cultured mammalian cells. Mutat. Res. 157, 1e12. Dellarco, V., Fenner-Crisp, P.A., 2012. Mode of action: moving toward a more rele- vant and efficient assessment paradigm. J. Nutr. 142, 2192Se2198S. http:// dx.doi.org/10.3945/jn.111.157396. Dourson, M., Becker, R.A., Haber, L.T., Pottenger, L.H., Bredfeldt, T., Fenner-Crisp, P., 2013. Advancing human health risk assessment: Integrating Recent Advisory Committee recommendations. Crit. Rev. Toxicol. 43, 467e492. http://dx.doi.org/ 10.3109/10408444.2013.807223. Eacho, P.I., Lanier, T.L., Brodhecker, C.A., 1991. Hepatocellular DNA synthesis in rats given peroxisome proliferating agents: comparison of WY 14,643 to clofibric acid, nafenopin and LY171883. Carcinogenesis 12, 1557e1561. Eastmond, D.A., 2012. Factors influencing mutagenic mode of action determinations of regulatory and advisory agencies. Mutat. Res. 751, 49e63. http://dx.doi.org/ 10.1016/j.mrrev.2012.04.001. Elcombe, C.R., Peffer, R.C., Wolf, D.C., Bailey, J., Bars, R., Bell, D., Cattley, R.C., Ferguson, S.S., Geter, D., Goetz, A., Goodman, J.I., Hester, S., Jacobs, A., Omiecinski, C.J., Schoeny, R., Xie, W., Lake, B.G., 2014. Mode of action and human relevance analysis for nuclear receptor-mediated liver toxicity: a case study with phenobarbital as a model constitutive and rostane receptor (CAR) acti- vator. Crit. Rev. Toxicol. 44, 64e82. http://dx.doi.org/10.3109/ 10408444.2013.835786. Fenner-Crisp, P.A., Dellarco, V.L., 2016. Key Elements for judging the quality of a risk assessment. Environ. Health Perspect. 124, 1127e1135. http://dx.doi.org/ 10.1289/ehp.1510483. Goll, V., Alexandre, E., Viollon-Abadie, C., Nicod, L., Jaeck, D., Richert, L., 1999. Comparison of the effects of various peroxisome proliferators on peroxisomal enzyme activities, DNA synthesis, and apoptosis in rat and human hepatocyte cultures. Toxicol. Appl. Pharmacol. 160, 21e32. http://dx.doi.org/10.1006/ taap.1999.8737. Gottlicher, M., Widmark, E., Li, Q., Gustafsson, J.A., 1992. Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc. Natl. Acad. Sci. U. S. A. 89, 4653e4657. Hard, G.C., Banton, M.I., Bretzlaff, Rita Schoeny., Dekant, W., Fowles, J.R., Mallett, A.K., McGregor, D.B., Roberts, K.M., Sielken Jr., R.L., Valdez-Flores, C., Cohen, S.M., 2013. Consideration of rat chronic progressive nephropathy in regulatory evaluations for carcinogenicity. Toxicol. Sci. 132, 268e275. http://dx.doi.org/ 10.1093/toxsci/kfs305. Hosokawa, S., Tatematsu, M., Aoki, T., Nakanowatari, J., Igarashi, T., Ito, N., 1989. Modulation of diethylnitrosamine-initiated placental glutathione S-transferase positive preneoplastic and neoplastic lesions by clofibrate, a hepatic peroxi- some proliferator. Carcinogenesis 10, 2237e2241. IARC (International Agency for Research on Cancer), 1996. Peroxisome Proliferation and its Role in Carcinogenesis. IARC Technical Report No. 24, Lyon France. Available at: http://monographs.iarc.fr/ENG/Monographs/vol66/mono66-17. pdf. Accessed August 2016. Isenberg, Jennifer Seed., Kamendulis, L.M., Smith, J.H., Ackley, D.C., Pugh Jr., G., Lington, A.W., Klaunig, J.E., 2000. Effects of di-2-ethylhexyl phthalate (DEHP) on gap- junctional intercellular communication (GJIC), DNA synthesis, and peroxi- somal beta oxidation (PBOX) in rat, mouse, and hamster liver. Toxicol. Sci. 56, 73e85. Issemann, I., Green, S., 1990. Activation of a member of the steroid hormone re- ceptor superfamily by peroxisome proliferators. Nature 347, 645e650. http:// dx.doi.org/10.1038/347645a0. Keller, D.A., Juberg, D.R., Catlin, N., Farland, W.H., Hess, F.G., Wolf, D.C., Doerrer, N.G., 2012. Identification and characterization of adverse effects in 21st century toxicology. Toxicol. Sci. 126, 291e297. http://dx.doi.org/10.1093/toxsci/kfr350. Klaunig, J.E., Babich, M.A., Baetcke, K.P., Cook, J.C., Corton, J.C., David, R.M., DeLuca, J.G., Lai, D.Y., McKee, R.H., Peters, J.M., Roberts, R.A., Fenner-Crisp, P.A., 2003. PPARa agonist-induced rodent tumors: modes of action and human relevance. Crit. Rev. Toxicol. 33, 655e780. http://dx.doi.org/10.1080/713608372. Klaunig, J.E., Dekant, W., Plotzke, K., Scialli, A.R., 2016. Biological relevance of dec- amethylcyclopentasiloxane (D5) induced rat uterine endometrial adenocarci- noma tumorigenesis: mode of action and relevance to humans. Regul. Toxicol. Pharmacol. 74, S44eS56. http://dx.doi.org/10.1016/j.yrtph.2015.06.021. Lee, S.S., Pineau, T., Drago, J., Lee, E.J., Owens, J.W., Kroetz, D.L., Fernandez- Salguero, P.M., Westphal, H., Gonzalez, F.J., 1995. Targeted disruption of the alpha isoform of the peroxisome proliferator activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell Biol. 15, 3012e3022. Linkov and Moberg, 2012. Multi-criteria Decision Analysis: Environmental Appli- cations and Case Studies. CRC Press, Taylor and Francis Group, Boca Raton, FL. Linkov, I., Loney, D., Cormier, S., Satterstrom, F.K., Bridges, T., 2009. Weight-of-evi- dence evaluation in environmental assessment: review of qualitative and quantitative approaches. Sci. Total Environ. 407, 5199e5205. http://dx.doi.org/ 10.1016/j.scitotenv.2009.05.004. Linkov, I., Coles, J.B., Welle, P., Bates, M., Keisler, J., 2011. Anthrax cleanup decisions: statistical confidence or confident response. Environ. Sci. Technol. 45 (22), 9471e9472. Linkov, I., Massey, O., Keisler, J., Rusyn, I., Hartung, T., 2015. From \u201cweight of evi- dence\u201d to quantitative data integration using multicriteria decision analysis and Bayesian methods. ALTEX 32, 3e8. MacGregor, J.T., Frotschl, R., White, P.A., Crump, K.S., Eastmond, D.A., Fukushima, S., Guerard, M., Hayashi, M., Soeteman-Hernandez, L.G., Kasamutsu, T., Levy, D.D., Morita, T., Muller, L., Schoeny, R., Schuler, M.J., Thybaud, V., Johnson, G.E., 2015. IWFT report on quantitative approaches to genotoxicity risk assessment I. methods and metrics for defining exposure-response relationships and points of departure. Mutat. Res. Genet. Toxicol. Environ. Mutagen. 783, 55e65. http:// dx.doi.org/10.1016/j.mrgentox.2014.10.008. Manibusan, M.K., Odin, M., Eastmond, D.A., 2007. Postulated carbon tetrachloride mode of action: a review. J. Environ. Sci. Health C. Environ. Carcinog. Ecotoxicol. Rev. 25, 185e209. http://dx.doi.org/10.1080/10590500701569398. Marsman, D.S., Goldsworthy, T.L., Popp, J.A., 1992. Contrasting hepatocytic peroxi- some proliferation, lipofuscin accumulation and cell turnover for the hep- atocarcinogens WY 14,643-14,643 and clofibric acid. Carcinogenesis 13, 1011e1017. Meek, M.E., Boobis, A., Cote, I., Dellarco, V., Fotakis, G., Munn, S., Seed, J., Vickers, C., 2014a. New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis. J. Appl. Toxicol. 34, 1e18. http://dx.doi.org/10.1002/jat.2949. Meek, M.E., Palermo, C.M., Bachman, A.N., North, C.M., Lewis, R.J., 2014b. Mode of action human relevance (species concordance) framework: evolution of the Bradford Hill considerations and comparative analysis of weight of evidence. J. Appl. Toxicol. 34, 595e606. http://dx.doi.org/10.1002/jat.2984. Mitchell, F.E., Price, S.C., Hinton, R.H., Grasso, P., Bridges, J.W., 1985. Time and dose- response study of the effects on rats of the plasticizer di(2-ethylhexyl) phtha- late. Toxicol. Appl. Pharmacol. 81, 371e392. Mizumoto, K., Kitazawa, S., Eguchi, T., Nakajima, A., Tsutsumi, M., Ito, S., Danda, A., Konishi, Y., 1988. Modulation of N-nitrosobis (2-hydroxypropyl) amine-induced carcinogenesis by clofibrate in hamsters. Carcinogenesis 9, 1421e1425. Mochizuki, Y., Furukawa, K., Sawada, N., 1983. Effect of simultaneous administration of clofibrate with diethylnitrosamine on hepatic tumorigenesis in the rat. Cancer Lett. 19, 99e105. NRC (National Research Council), 2014. Committee to Review the IRIS Process; Board on Environmental Studies and Toxicology; Division on Earth and Life Studies; National Research Council. Review of EPA's Integrated Risk Information System (IRIS) Process. National Academies Press (US), Washington (DC). http:// dx.doi.org/10.17226/18764. Available from: http://www.ncbi.nlm.nih.gov/ books/NBK230072. OECD, 2016. Users' Handbook Supplement to the Guidance Document for Devel- oping and Assessing Adverse Outcome Pathways. OECD Series on Adverse Outcome Pathways, No. 1, OECD Publishing, Paris. Available at: http://dx.doi. org/10.1787/5jlv1m9d1g32-en. Accessed August 2016. Proctor, D.M., Gatto, N.M., Hong, S.J., Allamneni, K.P., 2007. Framework for evalu- ating the relevance of rodent forestomach tumors in cancer risk assessment. Toxicol. Sci. 98, 313e326. http://dx.doi.org/10.1093/toxsci/kfm075. Rasoulpour, R.J., Terry, C., LeBaron, M.J., Stebbins, K., Ellis-Hutchings, R.G., Billington, R., 2014. Mode-of-action and human relevance framework analysis for rat Leydig cell tumors associated with sulfoxaflor. Crit. Rev. Toxicol. 44, S25eS44. http://dx.doi.org/10.3109/10408444.2014.910750. Reddy, J.K., Qureshi, S.A., 1979. Tumorigenicity of the hypolipidaemic peroxsiome proliferator ethyl-a-p-chlorophenoxyisobutyrate (clofibrate) in rats. Brit. J. Cancer 40, 476e482. Rhomberg, L.R., Goodman, J.E., Bailey, L.A., Prueitt, R.L., Beck, N.B., Bevan, C., Honeycutt, M., Kaminski, N.E., Paoli, G., Pottenger, L.H., Scherer, R.W., Wise, K.C., Becker, R.A., 2013. A survey of frameworks for best practices in weight-of- evidence analyses. Crit. Rev. Toxicol. 43, 753e784. http://dx.doi.org/10.3109/ 10408444.2013.832727. Simpkins, J.W., Swenberg, J.A., Weiss, N., Brusick, D., Eldridge, J.C., Stevens, J.T., Handa, R.J., Hovey, R.C., Plant, T.M., Pastoor, T.P., Breckenridge, C.B., 2011. Atra- zine and breast cancer: a framework assessment of the toxicological and epidemiological evidence. Toxicol. Sci. 123, 441e459. http://dx.doi.org/10.1093/ toxsci/kfr176. http://dx.doi.org/10.3109/10408444.2013.835787 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref13 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref13 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref13 http://dx.doi.org/10.3109/10408444.2010.541225 http://dx.doi.org/10.3109/10408444.2010.541225 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref15 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref15 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref15 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref15 http://dx.doi.org/10.1093/toxsci/kfq365 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref78 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref78 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref78 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref78 http://dx.doi.org/10.3109/10408444.2013.835784 http://dx.doi.org/10.3109/10408444.2013.835784 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref20 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref20 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref20 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref20 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref20 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref21 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref21 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref21 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref21 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref21 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref21 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref21 http://dx.doi.org/10.3945/jn.111.157396 http://dx.doi.org/10.3945/jn.111.157396 http://dx.doi.org/10.3109/10408444.2013.807223 http://dx.doi.org/10.3109/10408444.2013.807223 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref24 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref24 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref24 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref24 http://dx.doi.org/10.1016/j.mrrev.2012.04.001 http://dx.doi.org/10.1016/j.mrrev.2012.04.001 http://dx.doi.org/10.3109/10408444.2013.835786 http://dx.doi.org/10.3109/10408444.2013.835786 http://dx.doi.org/10.1289/ehp.1510483 http://dx.doi.org/10.1289/ehp.1510483 http://dx.doi.org/10.1006/taap.1999.8737 http://dx.doi.org/10.1006/taap.1999.8737 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref29 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref29 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref29 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref29 http://dx.doi.org/10.1093/toxsci/kfs305 http://dx.doi.org/10.1093/toxsci/kfs305 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref32 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref32 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref32 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref32 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref32 http://monographs.iarc.fr/ENG/Monographs/vol66/mono66-17.pdf http://monographs.iarc.fr/ENG/Monographs/vol66/mono66-17.pdf http://refhub.elsevier.com/S0273-2300(17)30038-7/sref34 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref34 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref34 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref34 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref34 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref34 http://dx.doi.org/10.1038/347645a0 http://dx.doi.org/10.1038/347645a0 http://dx.doi.org/10.1093/toxsci/kfr350 http://dx.doi.org/10.1080/713608372 http://dx.doi.org/10.1016/j.yrtph.2015.06.021 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref39 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref39 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref39 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref39 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref39 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref39 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref40 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref40 http://dx.doi.org/10.1016/j.scitotenv.2009.05.004 http://dx.doi.org/10.1016/j.scitotenv.2009.05.004 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref42 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref42 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref42 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref42 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref43 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref43 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref43 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref43 http://dx.doi.org/10.1016/j.mrgentox.2014.10.008 http://dx.doi.org/10.1016/j.mrgentox.2014.10.008 http://dx.doi.org/10.1080/10590500701569398 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref46 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref46 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref46 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref46 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref46 http://dx.doi.org/10.1002/jat.2949 http://dx.doi.org/10.1002/jat.2984 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref49 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref49 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref49 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref49 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref50 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref50 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref50 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref50 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref51 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref51 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref51 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref51 http://dx.doi.org/10.17226/18764 http://dx.doi.org/10.17226/18764 http://www.ncbi.nlm.nih.gov/books/NBK230072 http://www.ncbi.nlm.nih.gov/books/NBK230072 http://dx.doi.org/10.1787/5jlv1m9d1g32-en http://dx.doi.org/10.1787/5jlv1m9d1g32-en http://dx.doi.org/10.1093/toxsci/kfm075 http://dx.doi.org/10.3109/10408444.2014.910750 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref59 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref59 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref59 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref59 http://dx.doi.org/10.3109/10408444.2013.832727 http://dx.doi.org/10.3109/10408444.2013.832727 http://dx.doi.org/10.1093/toxsci/kfr176 http://dx.doi.org/10.1093/toxsci/kfr176 R.A. Becker et al. / Regulatory Toxicology and Pharmacology 86 (2017) 205e220220 Smith, M.T., Guyton, K.Z., Gibbons, C.F., Fritz, J.M., Portier, C.J., Rusyn, I., DeMarini, D.M., Caldwell, J.C., Kavlock, R.J., Lambert, P.F., Hecht, S.S., Bucher, J.R., Stewart, B.W., Baan, R.A., Cogliano, V.J., Straif, K., 2015. Key characteristics of carcinogens as a basis for organizing data on mechanisms of carcinogenesis. Environ. Health Perspect. 124, 713e721. http://dx.doi.org/10.1289/ehp.1509912. Sonich-Mullin, C., Fielder, R., Wiltse, J., Baetcke, K., Dempsey, J., Fenner-Crisp, P., Grant, D., Hartley, M., Knaap, A., Kroese, D., Mangelsdorf, I., Meek, E., Rice, J.M., Younes, M., 2001. IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Regul. Toxicol. Pharmacol. 34, 146e152. http:// dx.doi.org/10.1006/rtph.2001.1493. Svoboda, D.J., Azarnoff, D.L., 1979. Tumors in male rats fed ethyl chlorophenox- yisobutyrate, a hypolidemic drug. Cancer Res. 39, 3419e3428. Tanaka, K., Smith, P.F., Stromberg, P.C., Eydelloth, Rita Schoeny., Herold, E.G., Grossman, S.J., Frank, J.D., Hertzog, P.R., Soper, K.A., Keenan, K.P., 1992. Studies of early hepa- tocellular proliferation and peroxisomal proliferation in Sprague Dawley rats treated with tumorigenic doses of clofibrate. Toxicol. Appl. Pharmacol. 116, 71e77. Thomas, Rita Schoeny., Black, M.B., Li, L., Healy, E., Chu, T.M., Bao, W., Andersen, M.E., Wolfinger, R.D., 2012. A comprehensive statistical analysis of predicting in vivo hazard using high-throughput in vitro screening. Toxicol. Sci. 128, 398e417. http://dx.doi.org/10.1093/toxsci/kfs159. USEPA, 1998. Assessment of Thyroid Follicular Cell Tumors. Risk Assessment Forum. Washington, DC. EPA/630/R-97/002. USEPA, 2001. Toxicological Review of Chloroform (CASRN 67-66-3). Washington, DC EPA/635/R-01/001. Available at: https://cfpub.epa.gov/ncea/iris/iris_documents/ documents/toxreviews/0025tr.pdf. Accessed August 2016. USEPA, 2005a. Science Issue Paper: Mode of Carcinogenic Action for Cacodylic Acid (Dimethylarsinic Acid). Office of Pesticide Program. Health Effects Division. Available at: https://archive.epa.gov/pesticides/reregistration/web/pdf/dma_ moa-2.pdf. Accessed 29 July 2016. USEPA, 2005b. Guidelines for Carcinogen Risk Assessment. Washington, DC. EPA/ 630/P-03/001F. https://www.epa.gov/sites/production/files/2013-09/ documents/cancer_guidelines_final_3-25-05.pdf. Accessed 29 July 2016. USEPA, 2008. Toxicological Review of Carbon Tetrachloride (CARN 56-23-5). Washington, DC. EPA/635/R-08/005A. USEPA, 2014. Framework for Human Health Risk Assessment to Inform Decision Making. https://www.epa.gov/sites/production/files/2014-12/documents/hhra- framework-final-2014.pdf. USEPA (United States Environmental Protection Agency), 1991. Alpha-2u-globulin: Association with Chemically Induced Renal Toxicity and Neoplasia in the Male Rat. Risk Assessment Forum. Washington, DC. EPA/6250/3e91/019F. von D\u20acaniken, A., Lutz, W.K., Schlatter, C., 1981. Lack of covalent binding to rat liver DNA of the hypolipidemic drugs clofibrate and fenofibrate. Toxicol. Lett. 7, 305e310. Warren, J.R., Simmon, V.F., Reddy, J.K., 1980. Properties of hypolipidemic peroxi- some proliferators in the lymphocyte [3H]thymidine and Salmonella muta- genesis assays. Cancer Res. 40, 36e41. http://dx.doi.org/10.1289/ehp.1509912 http://dx.doi.org/10.1006/rtph.2001.1493 http://dx.doi.org/10.1006/rtph.2001.1493 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref64 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref64 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref64 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref65 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref65 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref65 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref65 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref65 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref65 http://dx.doi.org/10.1093/toxsci/kfs159 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref68 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref68 https://cfpub.epa.gov/ncea/iris/iris_documents/documents/toxreviews/0025tr.pdf https://cfpub.epa.gov/ncea/iris/iris_documents/documents/toxreviews/0025tr.pdf https://archive.epa.gov/pesticides/reregistration/web/pdf/dma_moa-2.pdf https://archive.epa.gov/pesticides/reregistration/web/pdf/dma_moa-2.pdf https://www.epa.gov/sites/production/files/2013-09/documents/cancer_guidelines_final_3-25-05.pdf https://www.epa.gov/sites/production/files/2013-09/documents/cancer_guidelines_final_3-25-05.pdf http://refhub.elsevier.com/S0273-2300(17)30038-7/sref72 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref72 https://www.epa.gov/sites/production/files/2014-12/documents/hhra-framework-final-2014.pdf https://www.epa.gov/sites/production/files/2014-12/documents/hhra-framework-final-2014.pdf http://refhub.elsevier.com/S0273-2300(17)30038-7/sref74 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref74 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref74 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref74 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref75 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref75 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref75 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref75 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref75 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref76 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref76 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref76 http://refhub.elsevier.com/S0273-2300(17)30038-7/sref76 Quantitative weight of evidence to assess confidence in potential modes of action 1. Introduction 2. Quantitative comparative confidence scoring methodology 2.1. Identify postulated MOA(s) (step 1) 2.2. Qualitatively evaluate the evidence in support/inconsistent with the KE/KER (step 2) 2.3. Quantitatively rate each KE/KER using the Bradford Hill causal considerations (step 3) 2.3.1. Assigning weights to each of the evolved Bradford Hill causal considerations 2.3.2. Derive the composite score for each KE and KER (step 4) 2.4. Integrate the evidence of causality for the MOA (step 5) and compare the quantitative scores for the hypothesized MOA (step 6) 3. Case example: clofibrate and rodent hepatocellular carcinomas 3.1. Hypothesis: rodent liver tumors induced by clofibrate are caused by a PPAR\u03b1 MOA (step 1) 3.2. Hypothesis: rodent liver tumors induced by clofibrate are caused by a mutagenic MOA (step 1) 3.3. Compare the quantitative confidence scores for the hypothesized PPAR\u03b1 and mutagenic MOAs (step 6) 4. Preliminary sensitivity analysis 5. Discussion 6. Conclusions Acknowledgments Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/R-ODAF--Omics-data-analysis-framework-for-re_2022_Regulatory-Toxicology-and-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/35247516", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 5 Discussion and conclusions Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgments Appendix A Supplementary data References", "Funding": "Funding This work was funded by the CEFIC LRI C4. TWG is supported under a core grant from the National Institute of Health Research, Health Protection Research Unit, Environmental Exposures and Health held with Imperial College London. CLY acknowledges funding from the Canada Research Chairs Program. CRediT authorship contribution statement Marcha CT. Verheijen: Conceptualization, Methodology, Software, Writing \u2013 review & editing. Matthew J. Meier: Methodology, Software, Writing \u2013 review & editing, Methodology, Writing \u2013 review & editing. Timothy W. Gant: Writing \u2013 review & editing. Weida Tong: Writing \u2013 review & editing. Carole L. Yauk: Supervision, Writing \u2013 review & editing. Florian Caiment: Conceptualization, Methodology, Software, Writing \u2013 original draft, Supervision, Project administration, Funding acquisition. Declaration of competing interest 5 Discussion and conclusions Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgments Appendix A Supplementary data References", "Acknowledgement": "Acknowledgments The original attendees of the seminal 2015 ECETOC meeting that gave rise to the concept behind this work and subsequent initiatives: Re\u0301mi Bars, Bayer, France, Mohamed Benahmed, UNICE, France, Timothy Ebbels, Imperial College London, UK, Karma Fussell, Nestle\u0301, Switzerland, Tim Gant, CRCE, UK, Madeleine Laffont, ECETOC, Belgium, Alan Poole, ECETOC, Belgium, Steffen Schneider, BASF, Ger- many, Leming Shi, NCTR/FDA, USA, Weida Tong, NCTR/FDA, USA, Shu-Dong Zhang, Queen\u2019s Univ. Belfast, N. Ireland. 5 Discussion and conclusions Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/REACH--non-testing-approaches-and-the-urgent-ne_2009_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19061930", "content": {"CoiStatement": "Cost implications of new tools under REACH Conclusions Conflict of interest statement Acknowledgments References", "Acknowledgement": "Cost implications of new tools under REACH Conclusions Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/REACH-alternative-testing-strategy-for-skin-sensi_2019_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31112721", "content": {"CoiStatement": "Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. The authors are not aware of any conflicts of interest. References Conclusions Declaration of interests Funding statement mk:H1_24 References", "Funding": "Funding statement The studies presented were financed by the individual sponsor of the chemicals. For these chemicals the sponsor did not have influence on the standard study design, collection, analysis and interpretation of data, writing of the report for the weight of evidence, nor in the deci- sion to submit the article for publication.Acknowledgements Conclusions Declaration of interests Funding statement mk:H1_24 References", "Acknowledgement": "The studies presented were financed by the individual sponsor of the chemicals. For these chemicals the sponsor did not have influence on the standard study design, collection, analysis and interpretation of data, writing of the report for the weight of evidence, nor in the deci- sion to submit the article for publication.Acknowledgements We like to thank the study directors of the DPRA, KeratinoSens\u2122 and U-SENS\u2122 assay and LLNA, Jasper Woutersen, Irene Eurlings, Jelle Reinen and Pieter van Sas, respectively, and last but not least the au- thors of the weight of evidence for skin sensitization Willemien Wieland and Ilse Tonk for the meaningful discussions."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/REACH-exposure-assessment-of-anticorrosive-paint-product_2011_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21964505", "content": {"CoiStatement": "Conflict of interest statement The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgments 5 Conclusions Conflict of interest statement Acknowledgments References", "Acknowledgement": "Acknowledgments The authors gratefully acknowledge the important contribu- tions made by the companies participating in the Innochem pro- ject: Jotun AS and H\u00c5G as, which have made this work possible, as well as the financial support provided by the Norwegian Re- search Council through the BIA program and the Confederation of Norwegian Enterprise through the workplace environment fund. Thanks also to Terje Aamodt, Phuoc Van Hoang and K\u00e5re Malmberg at Jotun Seawater laboratory, Heidi Lindstr\u00f8m and Edyta Nag- rodzka at Jotun Analytical department and G\u00f8ran Holten and Ivar Thinghaugen at Jotun Research laboratory who have contributed in the development of the methods and also in the testing and ana- lytical work. References 5 Conclusions Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/RETRACTED--Proof-of-concept-efficacy-study-of-intranasal_2021_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33852946", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 4 Discussion and conclusions Funding Author agreement CRediT authorship contribution statement Declaration of competing interest Acknowledgements References", "Funding": "4 Discussion and conclusions Funding Author agreement CRediT authorship contribution statement Declaration of competing interest Acknowledgements References", "Acknowledgement": "Acknowledgements This project was funded, in whole or in part, with federal funds Department of Health and Human Services under contract number HHSO100201100038C. 4 Discussion and conclusions Funding Author agreement CRediT authorship contribution statement Declaration of competing interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/RNAi-technologies-in-agricultural-biotechnology--Th_2015_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26361858", "content": {"Acknowledgement": "In summary, the session increased awareness regarding the current and potential future benefits of RNAi in agricultural biotechnology, the state-of-the-science regarding our understand- ing of RNAi, and the regulatory framework for evaluating the safety of GE plants. As with any emerging technology, the potential range of future products, potential future regulatory frameworks, and public acceptance of RNAi technology will continue to evolve. As such, continuing dialogue, such as promoted by The Toxicology Forum, was encouraged to promote educated consumers and science-based regulations. Acknowledgments The authors would like to thank Margaret Miller for moderating and Tim Pastoor for helping to organize the meeting session. 6. US FDA regulatory perspectives (Choudhuri) 7. Discussion3 Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Randomized--triple-blind--placebo-controlled-study-to_2022_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34958861", "content": {"CoiStatement": "Conflict of interest The authors have no conflicts of interest to declare. The authors have no conflicts of interest to declare. Fundings Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 3 Results 4 Discussion 5 Conclusion Conflict of interest Fundings CRediT authorship contribution statement Declaration of competing interest Acknowledgements References", "Funding": "Fundings This research was supported by the Ministry of Trade, Industry & Energy (MOTIE), Korea Institute for Advancement of Technology (KIAT) through the Encouragement Program for The Industries of Economic Cooperation Region (P0004751). 3 Results 4 Discussion 5 Conclusion Conflict of interest Fundings CRediT authorship contribution statement Declaration of competing interest Acknowledgements References", "Acknowledgement": "Acknowledgements We would like to thank Editage (www.editage.co.kr) for English language editing. 3 Results 4 Discussion 5 Conclusion Conflict of interest Fundings CRediT authorship contribution statement Declaration of competing interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Ranking-and-prioritization-of-environmental-risks_2004_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15041147", "content": {"Acknowledgement": "Conclusion Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Ranking-the-harm-of-non-medically-used-prescri_2015_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26382614", "content": {"CoiStatement": "Declaration of interest David Nutt has served on advisory Boards for BMS, Lilly, Shire, Lundbeck, Servier, Pfizer, Reckitt Benkiser, and D&A pharma. He has received speaking honoraria from these companies and also from Janssen, BMS, GSK, and Schering-Plough. He is a member of the Lundbeck International Neuroscience Foundation. Wim van den Brink reports personal fees from Mundipharma, grants from Alkermes, during the conduct of the study; personal fees from Lundbeck, Indivior, D&A Pharma, Novartis, Bioproject, Pfizer, outside the submitted work. The other authors declare no conflict of interest. Appendix A. Supplementary data 4. Discussion Participants Funding Declaration of interest Appendix A. Supplementary data Transparency document References", "Funding": "The group finally agreed that it would be of value to include real or perceived benefits of drugs in a future MCDA exercise as it was important to recognise drivers for illicit drug taking including pleasure, pain relief or escape from negative cognitive states. However, it was agreed this would double the length of the exercise and should be the focus of a future decision making exercise pro- vided that funding could be found. Participants Funding Funding was provided by an unrestricted educational grant to DrugScience from RB pharmaceuticals. Funding was provided by an unrestricted educational grant to DrugScience from RB pharmaceuticals. Declaration of interest 4. Discussion Participants Funding Declaration of interest Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Rapid-simulated-gastric-fluid-digestion-of-in-seed-g_2016_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27497625", "content": {"CoiStatement": "Conflict of interest The authors are employed by Dow AgroSciences LLC which develops and markets GE crops. 3. Results and discussion 4. Conclusions Acknowledgements Transparency document Conflict of interest References", "Acknowledgement": "It has been hypothesized that the poor correlation between purified protein digestion and the allergenic status of proteins might be due to the exclusion of plant matrix components or al- terations in protein structure during the purification process (Polovic et al., 2007; Schnell and Herman, 2009). Results reported here do not support this hypothesis. Here we show that SGF- digestion results with GE proteins in seed/grain extracts, and with purified proteins frommicrobes, were comparable. As seen for SGF digestion experiments where purified protein and pepsin concentrations have been varied near standard levels, the SGF assay is quite robust to moderate enzyme and substrate variation (Herman et al., 2005). Based on these results, purified protein from microbial sources is a suitable surrogate for proteins in-matrix when conducting SGF digestion studies. Rapidly digesting puri- fied GE proteins also digested rapidly in the seed/grain matrix for the common GE crops soybean, corn, and cotton. These results also suggest that in-matrix digestion studies are a suitable alternative for GE proteins that cannot be readily purified in a functionally active form (Bushey et al., 2014; Madduri et al., 2012). Acknowledgements We thank Gaston Legris, Guomin Shan, Mark Krieger, Kathy Clayton, Eric Kraus, and Siva Kumpatla for reviewing a draft of this paper andwe thank Benjamin S. Herman for improving thewestern blot image contrast in the figures. 3. Results and discussion 4. Conclusions Acknowledgements Transparency document Conflict of interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Raspberry-ketone-in-food-supplements---High-intake-_2015_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26160596", "content": {"Acknowledgement": "Acknowledgements The authors wish to thank senior academic officers Karin Kris- tiane N\u00f8rby and Vibe Beltoft for valuable insight into the evaluation of flavouring substances. The work was funded by the Technical University of Denmark, National Food Institute, M\u00f8rkh\u00f8j Bygade 19, DK-2860 S\u00f8borg, Denmark. 8. Raspberry ketone as novel food? 9. Conclusion Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Rat-90-day-oral-toxicity-study-of-a-novel-cocc_2020_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31843591", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper.", "Funding": "Funding body information National Natural Science Foundation of China (31872516); National Key Technology Research and Development Program of China (2015BAD11B00); National Key R&D Program of China (2018YFD0500302); Special Fund for Agro-scientific Research in the Public Interest Discussion Funding body information mk:H1_22 Acknowledgements Supplementary data References", "Acknowledgement": "Acknowledgements We gratefully acknowledge support by the National Natural Science Foundation of China (31872516). This project is also supported in part by the National Key Technology Research and Development Program of China (2015BAD11B00); the National Key R&D Program of China (2018YFD0500302) and the Special Fund for Agroscientific Research in the Public Interest (201303038). Discussion Funding body information mk:H1_22 Acknowledgements Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Rat-two-generation-reproductive-toxicity-and-teratog_2020_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32088183", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper.", "Funding": "Funding body information National Natural Science Foundation of China (31872516); Special Fund for Agro-scientific Research in the Public Interest Discussion Funding body information mk:H1_21 Acknowledgements Transparency document References", "Acknowledgement": "Acknowledgements We gratefully acknowledge support by the National Natural Science Foundation of China (31872516) and the Special Fund for Agro-scien- tific Research in the Public Interest (201303038). This project is also supported in part by the National Key R&D Program of China (2018YFD0500302) and the National Key Technology Research and Development Program of China (2015BAD11B00). Discussion Funding body information mk:H1_21 Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Rating-the-severity-of-the-medical-consequences_2005_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16143438", "content": {"Acknowledgement": "Acknowledgments Dr. Slavin is an employee of PWzer, Inc. Drs. Schlich- ting and Freston are consultants to PWzer Global Research and Development. Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Re--A-call-for-action-on-the-development-and-implementati_2021_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33662477", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Re: A call for action on the development and implementation of new methodologies for safety assessment of chemical-based pr ... Funding body information Declaration of competing interest References", "Funding": "Funding body information The preparation of the manuscript was undertaken as part of the normal duties of the authors. There was no special funding. The preparation of the manuscript was undertaken as part of the normal duties of the authors. There was no special funding. Declaration of competing interest Re: A call for action on the development and implementation of new methodologies for safety assessment of chemical-based pr ... Funding body information Declaration of competing interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Re-the-article--Incorporating-potency-into-the-EU-classific_2015_Regulatory-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25797335", "content": {"CoiStatement": "Re the article \u201cIncorporating potency into the EU classification for carcinogenicity and reproductive toxicity\u201d by Hennes C et al. (Regulatory toxicology and Pharmacology, 70 (1024), 457\u201367) Declaration of interest Reference"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Read-across--Principle--case-study-and-its-potent_2020_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32649957", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 3 Case studies 4 Panel discussion and key takeaways Funding body information Declaration of competing interest Acknowledgments References", "Funding": "Funding body information The cost of this workshop was funded by participating companies, i. e., BASF, Dow, DuPont, ExxonMobil, Intertek, Lubrizol, P&G and Sym- rise. There was no funding for the writing of this manuscript. The cost of this workshop was funded by participating companies, i. e., BASF, Dow, DuPont, ExxonMobil, Intertek, Lubrizol, P&G and Sym- rise. There was no funding for the writing of this manuscript. Declaration of competing interest 3 Case studies 4 Panel discussion and key takeaways Funding body information Declaration of competing interest Acknowledgments References", "Acknowledgement": "Acknowledgments The authors gratefully acknowledge the fund from BASF, Dow, DuPont, ExxonMobil, Intertek, Lubrizol, P&G and Symrise to organize this workshop. We also thank all the participants of the workshop for their fruitful discussions, particularly the speakers in the webinar series and salon. 3 Case studies 4 Panel discussion and key takeaways Funding body information Declaration of competing interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Read-across-can-increase-confidence-in-the-Next-Genera_2020_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32800849", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 8 Discussion Funding body information Declaration of competing interest References", "Funding": "Funding body information The work described in the manuscript did not receive any external funding. The co-authors have conducted the work related to this manuscript in the course of the authors\u2019 employment for their respective organisations. Erwin van Vliet was compensated by L\u2019Oreal for the time spent in the preparation and review of this manuscript; all other authors are fully paid employees of the L\u2019Oreal company. The work described in the manuscript did not receive any external funding. The co-authors have conducted the work related to this manuscript in the course of the authors\u2019 employment for their respective organisations. Erwin van Vliet was compensated by L\u2019Oreal for the time spent in the preparation and review of this manuscript; all other authors are fully paid employees of the L\u2019Oreal company. Declaration of competing interest 8 Discussion Funding body information Declaration of competing interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reassessing-the-evidence-relating-smoking-ba_2011_Regulatory-Toxicology-and-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21945743", "content": {"CoiStatement": "4 Discussion 5 Conclusions Conflict of interest Acknowledgments Appendix A Estimating the expected magnitude of the reduction in heart disease rates following a smoking ban References", "Acknowledgement": "4 Discussion 5 Conclusions Conflict of interest Acknowledgments Appendix A Estimating the expected magnitude of the reduction in heart disease rates following a smoking ban References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reassessing-the-two-year-rodent-carcinogenicity-bioass_2014_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24287155", "content": {"CoiStatement": "4 Discussion: alternative designs and future directions 5 Conclusions Conflict of interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reassessment-of-ecotoxicities-of-1-1-1-trichloro-2-2-bis-4_2005_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15748794", "content": {"Acknowledgement": "Acknowledgment The authors gratefully acknowledge Dr. Tadashi Kosaka for his critical review of this manuscript, Yukiko Kanda and Mayumi Kobayashi for their animal care. These studies were supported by a grant from the Japa- nese Ministry of Environment. References Discussion Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Rebuttal-to-the-letter-to-the-editors-regardin_2020_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32645428", "content": {"CoiStatement": "Rebuttal to the letter to the editors regarding Heringa et al. (2020) Declaration of competing interest"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Rebuttal-to-the-letters-to-the-editors-by-Terry-et-a_2020_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32679052", "content": {"CoiStatement": "Rebuttal to the letters to the editors by Terry et al. and Sewell et al. regarding Heringa et al. (2020) Declaration of competing interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Recent-updates-and-challenges-on-the-regulation-of-p_2018_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29715491", "content": {"Funding": "Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Transparency document Conclusions Funding Transparency document References", "Compliance with ethical standards": "US Food and Drug Administration (USFDA), 2014d. Postmarketing surveillance pro- grams. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ Surveillance/ucm090385.htm, Accessed date: 2 November 2016. US Food and Drug Administration (USFDA), 2013a. Paving the way for personalized medicine. FDA\u2019s role in a new era of medical product development. http://www.fda. gov/downloads/ScienceResearch/SpecialTopics/PrecisionMedicine/UCM372421. pdf, Accessed date: 10 October 2016. US Food and Drug Administration (USFDA), 2013d. Inspections, compliance, enforce- ment, and criminal investigations: 23andMe, Inc. 11/22/13. https://www.fda.gov/ ICECI/EnforcementActions/WarningLetters/2013/ucm376296.htm, Accessed date: 4 March 2018. US Food and Drug Administration (USFDA), 2012. Guidance for industry: enrichment strategies for clinical trials to support approval of human drugs and biological pro- ducts (draft). http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/ documents/document/ucm332181.pdf, Accessed date: 2 November 2016. https://www.whitehouse.gov/precision-medicine https://www.whitehouse.gov/precision-medicine https://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/oce/default.htm https://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/oce/default.htm https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/INDActivityReports/UCM499169.pdf https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/INDActivityReports/UCM499169.pdf https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/INDActivityReports/UCM499169.pdf https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/INDActivityReports/UCM481540.pdf https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/INDActivityReports/UCM481540.pdf https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/INDActivityReports/UCM481540.pdf https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm560040.htm https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm560040.htm https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm513027.pdf https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm513027.pdf https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm551185.htm https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm551185.htm http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm http://www.fda.gov/ScienceResearch/SpecialTopics/PrecisionMedicine/default.htm http://www.fda.gov/ScienceResearch/SpecialTopics/PrecisionMedicine/default.htm http://www.fda.gov/AboutFDA/CentersOffices/OC/OfficeofScientificandMedicalPrograms/NCTR/ResearchAccomplishmentsPlans/default.htm http://www.fda.gov/AboutFDA/CentersOffices/OC/OfficeofScientificandMedicalPrograms/NCTR/ResearchAccomplishmentsPlans/default.htm http://www.fda.gov/AboutFDA/CentersOffices/OC/OfficeofScientificandMedicalPrograms/NCTR/ResearchAccomplishmentsPlans/default.htm http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cdrh/cdrhoffices/ucm115904.htm http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cdrh/cdrhoffices/ucm115904.htm http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/officeofscienceandhealthcoordination/default.htm http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/officeofscienceandhealthcoordination/default.htm http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm510824.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm510824.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm509838.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm509838.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm509837.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm509837.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm500441.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm500441.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm446729.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm446729.pdf http://www.fda.gov/safety/fdassentinelinitiative/ucm2007250.htm http://www.fda.gov/safety/fdassentinelinitiative/ucm2007250.htm http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm330711.htm http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm330711.htm http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm330711.htm http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm http://www.fda.gov/aboutfda/centersoffices/oc/officeofscientificandmedicalprograms/nctr/whatwedo/researchdivisions/ucm079059.htm http://www.fda.gov/aboutfda/centersoffices/oc/officeofscientificandmedicalprograms/nctr/whatwedo/researchdivisions/ucm079059.htm http://www.fda.gov/aboutfda/centersoffices/oc/officeofscientificandmedicalprograms/nctr/whatwedo/researchdivisions/ucm079059.htm http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm259430.htm http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm259430.htm http://www.fda.gov/MedicalDevices/Safety/CDRHPostmarketSurveillance/default.htm http://www.fda.gov/MedicalDevices/Safety/CDRHPostmarketSurveillance/default.htm https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm358301.pdf https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm358301.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm262327.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm262327.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm262327.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm346553.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm346553.pdf http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/ucm090385.htm http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/ucm090385.htm http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/PrecisionMedicine/UCM372421.pdf http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/PrecisionMedicine/UCM372421.pdf http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/PrecisionMedicine/UCM372421.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm337169.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm337169.pdf http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM376118.pdf http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM376118.pdf http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM376118.pdf https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2013/ucm376296.htm https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2013/ucm376296.htm http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm332181.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm332181.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm201790.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm201790.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm073162.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm073162.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm079855.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm079855.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm071075.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm071075.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm071075.pdf http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm071287.pdf http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm071287.pdf https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm079849.pdf https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm079849.pdf http://www.accessdata.fda.gov/drugsatfda_docs/label/1998/trasgen092598lb.pdf http://www.accessdata.fda.gov/drugsatfda_docs/label/1998/trasgen092598lb.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm071981.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm071981.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm299138.pdf http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm299138.pdf http://dx.doi.org/10.3390/molecules21070889 http://dx.doi.org/10.1208/s12248-016-9917-y http://dx.doi.org/10.1208/s12248-016-9917-y Recent updates and challenges on the regulation of precision medicine: The United States in perspective Introduction Materials and methods Results and discussion USFDA organizational readiness for precision medicine Streamlining of drug development process through expedited programs Fast track designation Breakthrough therapy designation Accelerated approval Priority review"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Recommendations-for-further-revisions-to-improve-the-I_2020_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32147291", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: The authors had complete control over the design, conduct, inter- pretation, and composition of this manuscript. The contents of this manuscript are solely the responsibility of the authors and do not ne- cessarily reflect the views or policies of their employers. J. Goodman and D. Mayfield received support from the American Chemistry Council (ACC) for developing this manuscript. R. Becker, S. Hartigan, and N. Erraguntla are employed by the ACC, a trade association of chemical manufacturers. This work was supported by funding from the ACC. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: The authors had complete control over the design, conduct, inter- pretation, and composition of this manuscript. The contents of this manuscript are solely the responsibility of the authors and do not ne- cessarily reflect the views or policies of their employers. J. Goodman and D. Mayfield received support from the American Chemistry Council (ACC) for developing this manuscript. R. Becker, S. Hartigan, and N. Erraguntla are employed by the ACC, a trade association of chemical manufacturers. This work was supported by funding from the ACC. Acknowledgments", "Funding": "The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: The authors had complete control over the design, conduct, inter- pretation, and composition of this manuscript. The contents of this manuscript are solely the responsibility of the authors and do not ne- cessarily reflect the views or policies of their employers. J. Goodman and D. Mayfield received support from the American Chemistry Council (ACC) for developing this manuscript. R. Becker, S. Hartigan, and N. Erraguntla are employed by the ACC, a trade association of chemical manufacturers. This work was supported by funding from the ACC. Acknowledgments", "Acknowledgement": "Acknowledgments The authors appreciate the thoughtful suggestions on the draft manuscript provided by D. Wolf and V. Dellarco. Recommendations for further revisions to improve the International Agency for Research on Cancer (IARC) Monograph program Introduction General principles and procedures Literature search Scientific review and evaluation Scientific evaluation of mechanistic evidence Evidence Integration Peer review and public communication Conclusion mk:H1_9 Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reconstructing-exposures-from-biomarkers-using-expos_2015_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26545325", "content": {"Acknowledgement": "Acknowledgments The authors would like to thank Yuching Yang at the Hamner Institute for clarifications regarding the human PBPK model for carbaryl. The authors are also grateful to Drs. Rogelio Tornero-Velez, Lisa Baxter, and Roy Fortmann at the EPA for their review and comments. Jingtao Lu and Jeremy Leonard are funded by the Oak Ridge Institute for Science and Education's Research Participation Program at the US-Environmental Protection Agency. 3. Results 4. Discussion 5. Conclusions Disclaimer Acknowledgments Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reconstruction-of-historical-exposures-in-the-US-nickel_2009_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19545511", "content": {"Acknowledgement": "Summary Acknowledgments Scientific considerations and adjustments in deriving a carcinogenicity-based PEL using reconstructed exposures in the US nickel alloy industry Adjustment for workplace and temporal variability Adjustment for length of employment Consideration of the level of risk References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reduced-exposure-evaluation-of-an-Electrically-Heated-C_2012_Regulatory-Tox2.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22940436", "content": {"CoiStatement": "A.R. Tricker et al. / Regulatory Toxicology and Pharmacology 64 (2012) S35\u2013S44 S43 Conflict of interest statement All authors are or were Philip Morris International (PMI) R&D employees or worked for PMI R&D under contractual agreements. The work reported in all eight parts of this supplement was funded by PMI R&D. 4 Discussion Conflict of interest statement Acknowledgments References", "Compliance with ethical standards": "Food and Drug Administration, 2001. Guidance for Industry. Bioanalytical Method Validation. Available at: http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/UCM070107.pdf (accessed 27.09.2011). Food and Drug Administration, 2012. FDA\u2019s Guidance for Industry \u2018\u2018Modified Risk Tobacco Products Applications\u2019\u2019 Request for Comments Docket No. FDA-2012- D-0071. Available at http://www.fda.gov/TobaccoProducts/Guidance ComplianceRegulatoryInformation/ucm297750.htm (accessed May 23, 2012). Food and Drug Administration, 2012. FDA\u2019s Guidance for Industry \u2018\u2018Modified Risk Tobacco Products Applications\u2019\u2019 Request for Comments Docket No. FDA-2012- D-0071. Available at http://www.fda.gov/TobaccoProducts/Guidance ComplianceRegulatoryInformation/ucm297750.htm (accessed May 23, 2012). Frost-Pineda, K., Zedler, B.K., Oliveri, D., Feng, S., Liang, Q., Roethig, H.J., 2008a. Short-term clinical exposure evaluation of a third-generation electrically heated cigarette smoking system (EHCSS) in adult smokers. Regul. Toxicol. Pharmacol. 52, 104\u2013110. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297750.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297750.htm Reduced exposure evaluation of an Electrically Heated Cigarette Smoking System. Part 3: Eight-day randomized clinical trial in the UK 1 Introduction 2 Materials and methods 2.1 Subjects 2.2 Cigarette products 2.3 Study design and conduct 2.4 Bioanalytical methodology 2.5 Data analysis 2.6 Determination of sample size 2.7 Adverse events, medical history, and concomitant medication", "Acknowledgement": "Acknowledgments The authors would like to acknowledge Drs. Natasa Forte, Chris- telle Haziza, Karl Birthistle and John Magnette for review and com- ments on the manuscript; MDS Pharma Services and the Analytisch Biologisches Forschungslabor GmbH (Munich, Germany) for determination of the biomarkers of exposure and excretion of mutagenic material in urine; and Clinimetrics Research & Manage- ment Services (Maidenhead, UK) for monitoring of the study. References 4 Discussion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reduced-exposure-evaluation-of-an-Electrically-Heated-C_2012_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22951346", "content": {"CoiStatement": "In summary, the current study shows mean reductions in bio- markers of exposure to 10 of 12 selected cigarette smoke HPHC (1,3-butadiene, 2-naphthylamine, 4-aminobiphenyl, acrylamide, benzene, CO, nicotine, NNK, pyrene, and o-toluidine) from baseline to Day 8 in Lark1 smokers who switch to smoke EHCSS-K3 ciga- rettes (\ufffd1.3 \u00b1 35.8% to \ufffd74.2 \u00b1 10.1%). No change was determined for biomarkers of exposure to crotonaldehyde and acrolein, but some doubt exists as to the specificity of the applied biomarkers of exposure. In smokers who continued to smoke the Lark1 ciga- rette, exposure to the majority of cigarette smoke HPHC (1,3-buta- diene, 2-naphthylamine, 4-aminobiphenyl, acrylamide, benzene, CO, crotonaldehyde, nicotine, NNK, and o-toluidine) increased, while exposure to acrolein and pyrene were decreased. With the exception of 1,3-butadiene, 2-naphthylamine, benzene, CO, nico- tine, and NNK, few of the changes reached the level of statistical significance. The largest mean reductions in all cigarette smoke HPHC occurred in smokers who switched to no-smoking (\ufffd3.4 \u00b1 41.8% to \ufffd98.9 \u00b1 0.6%). Excretion of mutagenic material in urine was significantly decreased (p < 0.05) in the EHCSS-K3 and no-smoking groups (\ufffd31.8 \u00b1 48.8% and \ufffd45.3 \u00b1 29.7%, respec- tively), and significantly increased (p < 0.05) in the Lark1 group (+31.5 \u00b1 50.3%). Conflict of interest statement All authors are or were Philip Morris International (PMI) R&D employees or worked for PMI R&D under contractual agreements. The work reported in all eight parts of this supplement was funded by PMI R&D. Acknowledgments 4 Discussion Conflict of interest statement Acknowledgments References", "Compliance with ethical standards": "Food and Drug Administration, 2012. FDA\u2019s guidance for industry \u2018\u2018modified risk tobacco products applications\u2019\u2019 request for comments docket No. FDA-2012-D- 0071. Available at: <http://www.fda.gov/TobaccoProducts/GuidanceCompliance RegulatoryInformation/ucm297750.htm> (accessed 23.03.2012). Frost-Pineda, K., Zedler, B.K., Oliveri, D., Feng, S., Liang, Q., Roethig, H.J., 2008a. Short-term clinical exposure evaluation of a third-generation Electrically Heated Cigarette Smoking System (EHCSS) in adult smokers. Regul. Toxicol. Pharmacol. 52, 104\u2013110. http://www.fda.gov/cder/guidance/4252fnl.pdf http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297750.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297750.htm A.R. Tricker et al. / Regulatory Toxicology and Pharmacology 64 (2012) S45\u2013S53 S53 Ha, B.M., Yoon, S.J., Lee, H.Y., Ahn, H.S., Kim, C.Y., Shin, Y.S., 2003. Measuring the burden of premature death due to smoking in Korea from 1990 to 1999. Public Health 117, 358\u2013365.", "Acknowledgement": "All authors are or were Philip Morris International (PMI) R&D employees or worked for PMI R&D under contractual agreements. The work reported in all eight parts of this supplement was funded by PMI R&D. Acknowledgments The authors would like to acknowledge Drs. Christelle Haziza, Karl Birthistle and John Magnette for review and comments on the manuscript; MDS Pharma Services and the Analytisch Biologis- ches Forschungslabor GmbH (Munich, Germany) for determination of the biomarkers of exposure and excretion of mutagenic material in urine; and CMIC Co. Ltd. (Seoul, Korea) for monitoring of the study. References 4 Discussion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reduced-exposure-evaluation-of-an-Electrically-Heated-Ci_2012_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22951347", "content": {"CoiStatement": "In summary, this study shows reductions in the mean values of individual biomarkers of exposure to selected cigarette smoke HPHC from baseline to Day 5/6 in smokers of the M4JM cigarette who switch to use the EHCSS series-K heater and smoke the EHCSS-K6M menthol cigarette (\ufffd12.3 \u00b1 34.9% to \ufffd83.4 \u00b1 9.7%). In smokers who switched to smoke the Lark1M menthol cigarette, a conventional lit-end cigarette representative of the low-tar men- thol cigarette market, reductions in exposure to individual ciga- rette smoke HPHC were smaller (\ufffd3.3 \u00b1 34.0% to \ufffd35.2 \u00b1 11.3%). The largest reductions in individual cigarette smoke HPHC oc- curred in smokers who switched to no-smoking (\ufffd1.4 \u00b1 41.0% to \ufffd93.6 \u00b1 9.0%). Reductions in the mean excretion of mutagenic material in urine occurred in the EHCSS-K6M (\ufffd80.99 \u00b1 16.21%) and no-smoking (\ufffd86.89 \u00b1 8.85%) groups, but not in the M4JM (\ufffd6.24 \u00b1 36.94%) and Lark1M (\ufffd1.12 \u00b1 54.65%) groups. Changes in serum concentrations of Clara cell 16-kDa protein could not be meaningfully interpreted. Conflict of Interest statement All authors are Philip Morris International (PMI) R&D employ- ees or worked for PMI R&D under contractual agreements. The work reported in all eight parts of this supplement was funded by PMI R&D. Acknowledgments 4 Discussion Conflict of Interest statement Acknowledgments References", "Compliance with ethical standards": "Food and Drug Administration, 2012. FDA\u2019s Guidance for Industry \u2018\u2018Modified Risk Tobacco Products Applications\u2019\u2019 Request for Comments Docket No. FDA-2012- D-0071. Available from <http://www.fda.gov/TobaccoProducts/ GuidanceComplianceRegulatoryInformation/ucm297750.htm> (accessed 23.05.12). Frost-Pineda, K., Zedler, B.K., Oliveri, D., Feng, S., Liang, Q., Roethig, H.J., 2008a. Short-term clinical exposure evaluation of a third-generation electrically heated cigarette smoking system (EHCSS) in adult smokers. Regul. Toxicol. Pharmacol. 52, 104\u2013110. http://www.fda.gov/cder/guidance/4252fnl.pdf http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297750.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297750.htm A.R. Tricker et al. / Regulatory Toxicology and Pharmacology 64 (2012) S64\u2013S73 S73 Martin Leroy, C., Jarus-Dziedzic, K, Ancerewicz, J., Lindner, D., Kulesza, A., Magnette, J., 2012. Reduced exposure evaluation of an Electrically Heated Cigarette Smoking System. Part 7: A one-month, randomized, ambulatory, controlled clinical study in Poland. Regul. Toxicol. Pharmacol. 64 (Suppl. 1), S74\u2013S84.", "Acknowledgement": "All authors are Philip Morris International (PMI) R&D employ- ees or worked for PMI R&D under contractual agreements. The work reported in all eight parts of this supplement was funded by PMI R&D. Acknowledgments The authors would like to acknowledge Drs. Natasa Forte, Christelle Haziza, Karl Birthistle and John Magnette for comments to the manuscript draft; MDS Pharma Services, Philip Morris Research Laboratories GmbH (Cologne, Germany), and the Analytisch Biologisches Forschungslabor GmbH (Munich, Germany) for determination of biomarkers of exposure and excretion of mutagenic material in urine; and CMIC Co., Ltd. (Tokyo, Japan) for monitoring of the study. References 4 Discussion Conflict of Interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reduced-exposure-evaluation-of-an-Electrically-Heated-Cig_2012_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22951349", "content": {"CoiStatement": "In conclusion, the data from the current study indicate potential favorable changes in some biomarkers associated with CVD in smokers who have switched to the EHCSS-K6 cigarette over a 1- month period. Switching from conventional cigarettes to the EHCSS-K6 results in reductions in all biomarkers of exposure mea- sured even with an increasing number of EHCSS-K6 cigarettes smoked, supporting previous findings. However, none of the reduc- tions in biomarkers of exposure between the EHCSS-K6 and con- ventional cigarettes groups was significant. Future studies should investigate both larger sample sizes and longer durations of exclu- sive exposure to evaluate the effect on CVD biomarkers. Conflict of interest statement All authors are or were Philip Morris International (PMI) R&D employees or worked for PMI R&D under contractual agreements. The work reported in all eight parts of this supplement was funded by PMI R&D. Acknowledgments 4 Discussion 5 Conclusions Conflict of interest statement Acknowledgments References", "Compliance with ethical standards": "Food and Drug Administration, 2012. FDA\u2019s Guidance for Industry \u2018\u2018Modified Risk Tobacco Products Applications\u2019\u2019. Request for Comments Docket No. FDA-2012- D-0071. Available at: <http://www.fda.gov/TobaccoProducts/Guidance ComplianceRegulatoryInformation/ucm297750.htm> (accessed 23.05.2012). Frost-Pineda, K., Zedler, B.K., Liang, Q., Roethig, H.J., 2008a. Environmental tobacco smoke (ETS) evaluation of a third-generation electrically heated cigarette smoking system (EHCSS). Regul. Toxicol. Pharmacol. 52, 118\u2013121. Reduced exposure evaluation of an Electrically Heated Cigarette Smoking System. Part 7: A one-month, randomized, ambulatory, controlled clinical study in Poland 1 Introduction 2 Materials and methods 2.1 Subjects 2.2 Study design and conduct 2.3 Cigarette products and compliance 2.4 Bioanalytical methods 2.5 Medications 2.6 Safety evaluations 2.7 Data analysis 2.8 Determination of sample size 2.9 Adverse events, medical history, and concomitant medication 3 Results 3.1 Demographics and other baseline characteristics 3.2 Cigarette consumption and compliance 3.3 Primary biomarkers 3.4 Other biomarkers associated with cardiovascular disease 3.5 Biomarkers of exposure 3.6 Safety evaluations/serious adverse events 3 Results 3.1 Demographics and other baseline characteristics 3.2 Cigarette consumption and compliance 3.3 Primary biomarkers 3.4 Other biomarkers associated with cardiovascular disease 3.5 Biomarkers of exposure 3.6 Safety evaluations/serious adverse events 4 Discussion 5 Conclusions Conflict of interest statement Acknowledgments References", "Acknowledgement": "All authors are or were Philip Morris International (PMI) R&D employees or worked for PMI R&D under contractual agreements. The work reported in all eight parts of this supplement was funded by PMI R&D. Acknowledgments We would like to thank the staff from Synevo and MTZ Ltd., especially Teresa Brodniewicz, and the staff from Covance, in par- ticular Janet Ward and Andrew Hedge for preparing the clinical study report. We are also very grateful to the following Philip Mor- ris staff for their contribution to this work: Marie-Pierre Hontas for study management; Mark Bentley for biomarker analysis; and An- thony Tricker, Harriette Rodari, Christelle Haziza, and Lynda Con- roy-Schneider for their input into the manuscript. References 4 Discussion 5 Conclusions Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reduced-exposure-evaluation-of-an-Electrically-Heated-Cigar_2012_Regulatory-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22922180", "content": {"CoiStatement": "6 Conclusion Conflict of Interest statement Acknowledgment References", "Compliance with ethical standards": "Food and Drug Administration, 2012. FDA\u2019s Guidance for Industry \u2018\u2018Modified Risk Tobacco Products Applications\u2019\u2019 Request for Comments Docket No. FDA-2012- D-0071. Available from: <http://www.fda.gov/TobaccoProducts/ GuidanceComplianceRegulatoryInformation/ucm297750.htm> (accessed 23.05.2012). Frost-Pineda, K., Zedler, B.K., Liang, Q., Roethig, H.J., 2008a. Environmental tobacco smoke (ETS) evaluation of a third-generation electrically heated cigarette smoking system (EHCSS). Regul. Toxicol. Pharmacol. 52, 118\u2013121. http://www.ftc.gov/opa/2008/11/cigarettetesting.shtm http://www.ftc.gov/opa/2008/11/cigarettetesting.shtm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297750.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297750.htm http://www.hc-sc.gc.ca/hc-ps/tobac-tabac/legislation/reg/indust/method/_main-principal/nicotine-eng.php http://www.hc-sc.gc.ca/hc-ps/tobac-tabac/legislation/reg/indust/method/_main-principal/nicotine-eng.php http://www.hc-sc.gc.ca/hc-ps/tobac-tabac/legislation/reg/indust/method/_main-principal/nicotine-eng.php S34 V. Zenzen et al. / Regulatory Toxicology and Pharmacology 64 (2012) S11\u2013S34 Roemer, E., Stabbert, R., Veltel, D., Mueller, B.P., Meisgen, T.J., Schramke, H., Anskeit, E., Elves, R.G., Fournier, J.A., 2008. Reduced toxicological activity of cigarette smoke by the addition of ammonium magnesium phosphate to the paper of an electrically heated cigarette: Smoke chemistry and in vitro cytotoxicity and genotoxicity. Toxicol. In Vitro 22, 671\u2013681.", "Acknowledgement": "6 Conclusion Conflict of Interest statement Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reduced-exposure-evaluation-of-an-Electrically-Heated-Cigaret_2012_Regulator.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22943848", "content": {"CoiStatement": "This study introduces the concept of \u2018nicotine bridging\u2019 to esti- mate the distribution of HPHC uptake in a population of smokers based on relationships between analytical smoke chemistry data and the distribution of nicotine uptake in smokers. Because the method is nicotine-based, and nicotine is the most studied and well understood smoke constituent with established pharmacoki- netics and biomarker methodologies, the use of nicotine uptake distributions from smoker populations provides a scientifically sound basis for further analyses. Under the conservative assump- tion that other smoke constituents are retained to the same extent (or lower) than nicotine, modeling of HPHC uptake proportional to nicotine provides an experimental concept that we call \u2018nicotine bridging\u2019 for estimating exposure and uptake of HPHC for which no biomarkers of exposure are available. Although \u2018nicotine bridg- ing\u2019 is still an experimental concept that requires further valida- tion, we intend to use this heuristic to evaluate exposure reduction as a necessary, but not sufficient component to justify the potential for risk reduction. Conflict of interest statement All authors are or were Philip Morris International (PMI) R&D employees or worked for PMI R&D under contractual agreements. The work reported in all eight parts of this supplement was funded by PMI R&D. Acknowledgements 5 Conclusion Conflict of interest statement Acknowledgements References", "Compliance with ethical standards": "Food and Drug Administration, 2012. FDA\u2019s Guidance for Industry \u2018\u2018Modified Risk Tobacco Products Applications\u2019\u2019 Request for Comments Docket No. FDA- 2012-D-0071. Available at: <http://www.fda.gov/TobaccoProducts/Guidance ComplianceRegulatoryInformation/ucm297750.htm> (accessed 23.05.12). Federal Register, 1967. Cigarettes: Testing for Tar and Nicotine Content. vol. 32, p. 11178. http://www.who.int/tobacco/fctc/TobReg_COP_Burns_2.pdf http://www.who.int/tobacco/fctc/TobReg_COP_Burns_2.pdf http://www.fda.gov/TobaccoProducts/NewsEvents/ucm259201.htm http://www.fda.gov/TobaccoProducts/NewsEvents/ucm259201.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297750.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297750.htm http://www.ftc.gov/opa/2008/11/cigarettetesting.shtm http://www.ftc.gov/opa/2008/11/cigarettetesting.shtm H.-J\u00f6rg Urban et al. / Regulatory Toxicology and Pharmacology 64 (2012) S85\u2013S97 S97 Institute of Medicine, 2012. Scientific Standards for Studies on Modified Risk Tobacco Products. The National Academy Press, Washington, DC.", "Acknowledgement": "All authors are or were Philip Morris International (PMI) R&D employees or worked for PMI R&D under contractual agreements. The work reported in all eight parts of this supplement was funded by PMI R&D. Acknowledgements We would like to thank Drs. Wolf Reininghaus, Hans-J\u00fcrgen Haussmann, and Lynda Conroy-Schneider for their contribution and review of the manuscript. References 5 Conclusion Conflict of interest statement Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reduced-exposure-evaluation-of-an-Electrically-Heated-_2012_Regulatory-Toxi1.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22940435", "content": {"CoiStatement": "Reduced exposure evaluation of an Electrically Heated Cigarette Smoking System. Part 1: Non-clinical and clinical insights 1 Introduction 2 The Electrically Heated Cigarette Smoking System (EHCSS) 3 Testing strategy 4 In vitro toxicological assessment of test and marketed reference cigarettes 5 Clinical evaluations 6 Nicotine bridging and population level modeling 7 Learning\u2019s and further elaboration of reduced exposure evaluation 8 Summary 9 Conflict of Interest statement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reduced-exposure-evaluation-of-an-Electrically-Heated-_2012_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22940437", "content": {"CoiStatement": "In summary, this study shows statistically significant mean reductions in biomarkers of exposure to selected cigarette smoke HPHC and excretion of mutagenic material in urine of smokers who smoke the M6J cigarette and switch to use the EHCSS lighter and smoke either the EHCSS-K3 or the EHCSS-K6 cigarette (\ufffd9.8 \u00b1 60.0% to \ufffd73.0 \u00b1 15.1% and \ufffd14.6 \u00b1 51.8% to \ufffd75.6 \u00b1 11.4%, respectively; all p 6 0.05) at Day 8, compared to baseline. In smokers who switch to smoke the Lark1 cigarette, a conventional lit-end cigarette representative of the low-tar ciga- rette market, smaller mean reductions (\ufffd4.2 \u00b1 24.1% to \ufffd39.4 \u00b1 17.5%) were observed, most of which were statistically sig- nificant (p 6 0.05). The largest mean reductions (\ufffd13.7 \u00b1 90.9% to \ufffd97.6 \u00b1 6.5%; all p 6 0.01) occurred in smokers who switched to no-smoking. Conflict of interest statement All authors are or were Philip Morris International (PMI) R&D employees or worked for PMI R&D under contractual agreements. The work reported in all eight parts of this supplement was funded by PMI R&D. 4 Discussion Conflict of interest statement Acknowledgments References", "Compliance with ethical standards": "Food and Drug Administration, 2012a. FDA\u2019s Guidance for Industry \u2018\u2018Modified Risk Tobacco Products Applications\u2019\u2019 Request for Comments Docket No. FDA-2012- D-0071. Available at: <http://www.fda.gov/TobaccoProducts/ GuidanceComplianceRegulatoryInformation/ucm297750.htm>. (accessed May 23, 2012). Frost-Pineda, K., Zedler, B.K., Oliveri, D., Feng, S., Liang, Q., Roethig, H.J., 2008a. Short-term clinical exposure evaluation of a third-generation electrically heated cigarette smoking system (EHCSS) in adult smokers. Regul. Toxicol. Pharmacol. 52, 104\u2013110. http://www.fda.gov/cder/guidance/4252fnl.pdf http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297750.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297750.htm A.R. Tricker et al. / Regulatory Toxicology and Pharmacology 64 (2012) S54\u2013S63 S63 International Organization for Standardization, 1991. Tobacco and Tobacco Products \u2013 Atmosphere for Conditioning and Testing. ISO 3402. International Organization for Standardization, Geneva.", "Acknowledgement": "Acknowledgments The authors would like to acknowledge Drs. Natasa Forte, Chris- telle Haziza, Karl Birthistle and John Magnette for comments to the manuscript draft; and MDS Pharma Services and the Analytisch Biologisches Forschungslabor GmbH (Munich, Germany) for deter- mination of the biomarkers of exposure and excretion of muta- genic material in urine; and CMIC Co. Ltd. (Tokyo, Japan) for monitoring of the study. 4 Discussion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reducing-Uncertainty-of-Risk-Estimates-for-Mixture_2000_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/10715223", "content": {"Acknowledgement": "ACKNOWLEDGMENTS This research was supported by Environmental Protection Agency Order No. 8W-2993-TATA. Any opinions, findings, and conclusions or recommendations expressed in this paper are those of the author and do not necessarily reflect the views of the Environmental Pro- tection Agency. I thank Sandra Baird, Margaret Chu, Michael Dour- son, Michael Ginevan, Paul Price, and James Wilson who provided stimulating conversations that encouraged creative analysis. CONCLUSION APPENDIX A APPENDIX B APPENDIX C ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reducing-the-need-for-animal-testing-while-increasing-effic_2019_Regulatory-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31546018", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper.", "Funding": "Funding This work was conducted in the course of the authors\u2019 employment at the United States Environmental Protection Agency. Discussion and conclusions Funding mk:H1_12 Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reducing-the-number-of-fish-in-bioconcentration-studie_2014_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25128673", "content": {"Acknowledgement": "Acknowledgments There was no specific financial support for this paper other than the invested time of the authors. Its conception resulted from dis- cussions within the NC3Rs\u2019 ecotoxicology working group. Reducing the number of fish in bioconcentration studies with general chemicals by reducing the number of test concentrations 1 Introduction 2 Materials and methods 3 Results 4 Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reevaluation-of-mortality-risks-from-leukemia-in-the-_2004_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15450715", "content": {"Acknowledgement": "NCI\ufffds suggestion of a causal association between formaldehyde exposure and mortality from leukemia and ML. NCI\ufffds key findings for highest peak exposure and AIE do not adequately account for the inordinately large deficits in deaths in the categories used as the baselines for internal rate-based RRs. The NCI findings also do not adequately account for the duration of time subjects spent in the highest peak category (or for AIE, duration of exposure) or the time since their first peak exposure (or for AIE, time since first exposure). Our finding that NCI\ufffds suggestion of a causal association is not robust with respect to alternative categorizations of formaldehyde exposure and methods of data analysis casts considerable additional uncertainty regarding the validity of this suggested association. Acknowledgments The authors acknowledge the cooperation and assis- tance of Dr. Michael Hauptmann who provided a copy of the NCI cohort data file. We also wish to acknowl- edge the computer programming support of Stephen Sefcik. This work was supported by the Formaldehyde Discussion Conclusions Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reevaluation-of-mortality-risks-from-nasopharyngeal-ca_2005_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15978711", "content": {"Acknowledgement": "Acknowledgments The authors acknowledge the cooperation and assis- tance of Dr. Michael Hauptmann who provided a copy of the NCI cohort data Wle. We also wish to acknowl- edge the computer programming support of Stephen Sefcik. This work was supported by the Formaldehyde Council, Inc. Results Discussion Conclusions Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reevaluation-of-the-Munro-dataset-to-derive-mo_2014_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24799087", "content": {"CoiStatement": "Cramer class III substances, without organophosphates, carbamates, and organohalogens 4.0 Cramer class II substances 9* (unchanged, not part of this evaluation) Cramer class I substances 30 (unchanged, not part of this evaluation) * Note that the Cramer class II substances are not considered by the EFSA (2012). Conflict of interest The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgments 4 Discussion 5 Conclusion Conflict of interest Acknowledgments Appendix A Supplementary data References", "Funding": "This work was commissioned by the Food Safety Program Man- agement of TNO. The work was financially supported by Knowl- edge Program funding by the Dutch Ministry of Economic Affairs. We would like to thank Rinke Klein Entink for the statistical support. Appendix A. Supplementary data Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.yrtph.2014. 04.015.", "Acknowledgement": "Acknowledgments This work was commissioned by the Food Safety Program Man- agement of TNO. The work was financially supported by Knowl- edge Program funding by the Dutch Ministry of Economic Affairs. We would like to thank Rinke Klein Entink for the statistical support. Appendix A. Supplementary data 4 Discussion 5 Conclusion Conflict of interest Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reference-dose-for-perchlorate-based-on-thyroid-horm_2004_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/14746779", "content": {"Acknowledgement": "Discussion Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Refinement-of-decision-tree-to-assess-the-consequences-of-_2021_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34102240", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 4 Discussions Funding sources Declaration of competing interest Acknowledgments Appendix A Supplementary data Disclaimer References", "Funding": "Funding sources We declared that this research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. We declared that this research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Declaration of competing interest The current analysis was not conducted under any specific grant from any funding agencies in the public, commercial, or nonprofit sec- tors. All authors contributed and have responsibilities to the prepara- tion, documentation, analysis and discussion of this article. Appendix A. Supplementary data 4 Discussions Funding sources Declaration of competing interest Acknowledgments Appendix A Supplementary data Disclaimer References", "Acknowledgement": "Acknowledgments The current analysis was not conducted under any specific grant from any funding agencies in the public, commercial, or nonprofit sec- tors. All authors contributed and have responsibilities to the prepara- tion, documentation, analysis and discussion of this article. 4 Discussions Funding sources Declaration of competing interest Acknowledgments Appendix A Supplementary data Disclaimer References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Refinement-of-the-Dermal-Sensitisation-Threshold--DST--_2011_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21447365", "content": {"CoiStatement": "Work is currently in hand to further characterise the impurity profile, autoxidation potential and in chemico reactivity of the 38 non-reactive chemicals which give positive LLNA results (Table 3), 224 R.J. Safford et al. / Regulatory Toxicology and Pharmacology 60 (2011) 218\u2013224 and in-chemico reactivity analysis is being conducted on the 33 chemicals falling into the reactive domain which have no sensitis- ing potential in the LLNA. This work will give us a better under- standing of the reaction chemistry domain classification as a predictor of skin sensitisation and may, in the future, help us to re- fine the DST further. 5. Conflict of Interest The authors report no conflicts of interest. All authors are employees of the company Unilever. Acknowledgments The authors report no conflicts of interest. All authors are employees of the company Unilever. Acknowledgments This research is part of Unilever\u2019s ongoing effort to develop no- vel ways of delivering consumer safety. Discussion Conflict of Interest Acknowledgments Supplementary data References", "Acknowledgement": "The authors report no conflicts of interest. All authors are employees of the company Unilever. Acknowledgments This research is part of Unilever\u2019s ongoing effort to develop no- vel ways of delivering consumer safety. Discussion Conflict of Interest Acknowledgments Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reflections-on-the-OECD-guidelines-for-in-vitr_2020_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32791089", "content": {"CoiStatement": "Reflections on the OECD guidelines for in vitro skin absorption studies 1 Introduction 2 Terminology 3 Interpretation of in vitro data 4 Scope of the OECD skin absorption guidance documents 5 Diffusion cell 6 Receptor fluid 7 Sampling 8 Skin procurement and preparation 9 Skin thickness 10 Skin integrity 11 Skin viability 12 Test substance concentrations and formulations 13 Application to the skin 14 Temperature 15 Recovery procedures 16 Chemical analysis 17 Replicates 18 Test report 19 Conclusion Funding body information Declaration of competing interest References", "Funding": "Reflections on the OECD guidelines for in vitro skin absorption studies 1 Introduction 2 Terminology 3 Interpretation of in vitro data 4 Scope of the OECD skin absorption guidance documents 5 Diffusion cell 6 Receptor fluid 7 Sampling 8 Skin procurement and preparation 9 Skin thickness 10 Skin integrity 11 Skin viability 12 Test substance concentrations and formulations 13 Application to the skin 14 Temperature 15 Recovery procedures 16 Chemical analysis 17 Replicates 18 Test report 19 Conclusion Funding body information Declaration of competing interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reflections-on-the-progress-towards-non-animal-met_2019_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30578838", "content": {"Acknowledgement": "It is widely accepted that a one-to-one replacement of traditional toxicity testing with non-animal assays may be unrealistic for many endpoints, with multiple assays required. In some areas (skin sensiti- zation being an illustrative example, see Casati et al., 2018) there is an increasing number of \u2018defined approaches\u2019 (in which data generated by non-animal methods are evaluated by means of a fixed data inter- pretation procedure), some of which have been published as case-stu- dies (OECD, 2017a). However, there is also acknowledgement of the need to be able to incorporate further information sources and expert judgement with the outputs of defined approaches, as is possible within in Integrated Approaches to Testing and Assessment (IATA). At face value this sounds like a logical development. However, it introduces a new level of complexity (and cost) that can lead to interpretive diffi- culties. Moreover, considerable care is necessary to ensure that con- sideration of several independent assay results really does enhance, rather than reduce, overall accuracy. 2.4. Mutual acceptance and lack of global harmonization"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Regulating-endocrine-disruptors_2007_Regulatory-Toxicology-and-Pharmacology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/17499897", "content": {"CoiStatement": "No conflict of interest is declared for this paper, which is not subsidized and represents the exclusive views of the author. References [1] EPA, Endocrine Disruptor Screening Program (EDSP), <http:// www.epa.gov/oscpmont/oscpendo/> (accessed July 15, 2006).", "Acknowledgement": "Editorial / Regulatory Toxicology and Pharmacology 48 (2007) 1\u20133 3 gram in the making is still unfocused and premature. In that case, the world would be grateful and admired\u2014and probably safer in the long run\u2014if the EPA were to adopt the sensible alternative of foregoing regulation for the moment, and of instituting first a thorough study and surveillance program, initially limited to estrogen- like effects in humans as mandated by Congress. There may well be public health problems to discover, but it seems an incongruous overreach to surmise at the risks of conjectural hazards that in reality are unseen, and to regulate accordingly. Acknowledgment No conflict of interest is declared for this paper, which is not subsidized and represents the exclusive views of the author. References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Regulating-human-safety--How-dose-selection-in-toxicity-_2020_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32334039", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. Conclusions Funding body information Declaration of competing interest Acknowledgements Supplementary data References", "Funding": "Funding body information This work was funded by the Dutch Ministry of Infrastructure and Water Management. The funding body had no involvement in the design and writing of the manuscript, and in the decision to submit the article for publication. Declaration of competing interest Conclusions Funding body information Declaration of competing interest Acknowledgements Supplementary data References", "Acknowledgement": "Acknowledgements The authors would like to thank Wout Slob, Joke Herremans, Martijn Beekman, and Peter Bos for proof-reading this paper. This work was funded by the Dutch Ministry of Infrastructure and Water Management. Conclusions Funding body information Declaration of competing interest Acknowledgements Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Regulation-of-non-relevant-metabolites-of-plant-protect_2015_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26192637", "content": {"Acknowledgement": "4. Proposal for the regulation of non-relevant metabolites in drinking and groundwater 5. Application of the TTC concept to non-relevant metabolites 6. Comparison of health-based values with TTC derived limits 7. Water treatment 8. Mixture toxicity 9. Current evidence from monitoring studies 10. Conclusions Acknowledgments Appendix A. Supporting information Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Regulations-for-calcium--magnesium-or-hardness-in-d_2020_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32007436", "content": {"CoiStatement": "The author declares no conflicts of interest. Funding body information Declaration of competing interest The author declares that he has no known competing financial in- terests or personal relationships that could have appeared to influence the work reported in this paper.", "Funding": "Funding body information The study was supported by Ministry of Health, Czech Republic \u2013 conceptual development of research organization (National Institute of Public Health \u2013 NIPH, IN 75010330). It was also partially supported by the project \u201cImprovement of health status of population of the Slovak Republic through drinking water re-carbonization\u201d (LIFE17 ENV/SK/000036), which is financially supported by the EU's funding instrument (LIFE Environment and Resource Efficiency) and the Ministry of the Environment of the Slovak Republic. Declaration of competing interest Regulations for calcium, magnesium or hardness in drinking water in the European Union member states Introduction Past, current, and future drinking water regulation in the EU with regards to Ca and Mg Methodology Results Discussion Conclusion Disclaimer Funding body information mk:H1_9 Acknowledgments References", "Acknowledgement": "Acknowledgments The author would like to thank all ENDWARE members to share their national drinking water regulations. Regulations for calcium, magnesium or hardness in drinking water in the European Union member states Introduction Past, current, and future drinking water regulation in the EU with regards to Ca and Mg Methodology Results Discussion Conclusion Disclaimer Funding body information mk:H1_9 Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Regulatory-Action-Criteria-for-Filth-and-Other-Extra_2000_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/11029271", "content": {"Compliance with ethical standards": "Food and Drug Administration (FDA) (1996). FDA Compliance Pol- icy Guides, Chapter 5. U.S. Department of Health and Human Services, Rockville, MD. Food and Drug Administration (FDA) (1998). Natural or Unavoid- able Defects in Food for Human Use That Present no Health Haz- ard, Title 21 Code of Federal Regulations, Section 110.110. U.S. Department of Health and Human Services, Washington, DC.", "Acknowledgement": "ACKNOWLEDGMENTS The authors thank the employees of the U.S. Food and Drug Administration Center for Food Safety and Applied Nutrition who participated in this study. CONCLUSIONS ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Regulatory-Action-Criteria-for-Filth-and-Other-Extrane_2001_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/11407939", "content": {"Acknowledgement": "CONCLUSION ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Regulatory-acceptance-and-use-of-3R-models-for-pharmace_2014_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24534000", "content": {"CoiStatement": "Conflict of interest The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgments 6 Conclusion and discussion Conflict of interest Acknowledgments References", "Funding": "Funding by government to fill data gaps Education on risk based vs hazard based approachDecide and communicate on acceptance criteria Funding of relevant academic research Towards risk based approach We thank the Doerenkamp-Zbinden Foundation and the Dutch Ministry of Economic Affairs for funding this project. We thank the Dutch Ministry of Health, Welfare and Sport for facilitating the panel discussions. References", "Acknowledgement": "Acknowledgments We would like to thank in alphabetic order the workshop participants: 6 Conclusion and discussion Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Regulatory-acceptance-and-use-of-the-Extended-One-G_2015_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25445002", "content": {"CoiStatement": "4 Discussion Conflict of interest Acknowledgment Appendix A A.1 Case study approach: causal process tracing A.2 Research methods A.3 Case selection A.4 Respondent selection References", "Acknowledgement": "4 Discussion Conflict of interest Acknowledgment Appendix A A.1 Case study approach: causal process tracing A.2 Research methods A.3 Case selection A.4 Respondent selection References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Regulatory-accepted-but-out-of-domain--In-vitro-ski_2017_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28734851", "content": {"Acknowledgement": "Acknowledgements We would like to thank the members of the Laboratories for Tissue Toxicology at BASF SE, Ludwigshafen, Germany for their excellent technical assistance. Transparency document 3. Results 4. Discussion 5. Conclusion Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Regulatory-action-and-moderate-decrease-in-methylpheni_2015_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25957571", "content": {"CoiStatement": "Conflict of Interest None. 3 Results 4 Discussion 5 Conclusion Conflict of Interest Transparency Document Acknowledgments References", "Acknowledgement": "The Transparency document associated with this article can be found in the online version. Acknowledgments This study was supported by the Korean Ministry of Food and Drug Safety (MFDS) (No. 14172-174). The authors thank National Health Insurance Service of Korea and their related persons for acquisition of the data. 3 Results 4 Discussion 5 Conclusion Conflict of Interest Transparency Document Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Regulatory-aspects-of-nanotechnology-in-the-agri-f_2015_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26169479", "content": {"Compliance with ethical standards": "NICNAS, 2013. NICNAS Handbook for Notifiers e Guide for Importers and Manu- facturers of Industrial Chemicals in Australia CANBERRA Australian Capital Territory 2600 from. http://www.nicnas.gov.au/regulation-and-compliance/ nicnas-handbook. OECD, 2013a. Current Developments/Activities on the Safety of Manufactured Nanomaterials; Series on the Safety of Manufactured Nanomaterials No. 37. Paris from. http://search.oecd.org/officialdocuments/displaydocumentpdf/? cote\u00bcenv/jm/mono(2013. http://search.oecd.org/officialdocuments/display documentpdf/?cote\u00bcenv/jm/mono(2013)2&doclanguage\u00bcen. OECD, 2013b. Regulatory Frameworks for Nanotechnology in Foods and Medical Products. Summary Results of a Survey Activity. Paris from. http://search.oecd. org/officialdocuments/publicdisplaydocumentpdf/?cote\u00bcDSTI/STP/ NANO(2012)22/FINAL&docLanguage\u00bcEn. Office of Agricultural Affairs of the USDA, 2009. Russian Federation e Food and Agricultural Import Regulations and Standards e FAIReinhilde Schoonjans Country Report. Mos- cow from. http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Food% 20and%20Agricultural%20Import%20Regulations%20and%20Standards%20-% 20Narrative_Moscow_Russian%20Federation_11.08.2009.pdf. Parisi, C., M, V., Rodr\u00edguez-Cerezo, E., 2014. In: . Proceedings of a Workshop on \u201cNanotechnology for the Agricultural Sector: from Research to the Field\u201d. Publications Office of the European Union, Luxembourg, 2014, from. http:// publications.jrc.ec.europa.eu/repository/bitstream/111111111/31846/1/ipts% 20jrc%2089736%20(online)%20%20final.pdf. Park, Y., 2012. Nano-regulation in China, Japan, Korea, USA and EU from. http:// www.egg2012.de/tl_files/pdf/Paper/EGG2012_C6_1_Park_presentation_slides. pdf. Peters, R.J.B., van Bemmel, G., Herrera-Rivera, Z., Helsper, H.P.F.G., Marvin, H.J.P., Weigel, S., Tromp, P.C., Oomen, A.G., Rietveld, A.G., Bouwmeester, H., 2014. Characterization of titanium dioxide nanoparticles in food products: analytical methods to define nanoparticles. J. Agric. Food Chem. 62 (27), 6285e6293. Rauscher, H., Roebben, G., Amenta, V., Boix Sanfeliu, A., Calzolai, L., Emons, H., Gaillard, C., Gibson, N., Linsinger, T., Mech, A., Quiros Pesudo, L., Rasmussen, K., Riego Sintes, J., Sokull-Kl\u00fcttgen, B., Stamm, H., 2014. Towards a Review of the EC Recommendation for a Definition of the Term \u201cnanomaterial\u201d; Part 1: Compi- lation of Information Concerning the Experience with the Definition. European Commission Joint Research Centre from. https://ec.europa.eu/jrc/sites/default/ files/lbna26567enn.pdf. RIKILT and JRC, 2014. Inventory of Nanotechnology Applications in the Agricultural, Feed and Food Sector. Parma, RIKILT. European Commission Joint Research Centre from. http://www.efsa.europa.eu/en/supporting/doc/621e.pdf. RIVM, 2012. Interpretation and Implications of the European Commission Recom- mendation on the Definition of Nanomaterial. Bilthoven from. http://www. rivm.nl/dsresource?objectid\u00bcrivmp:181801&type\u00bcorg&disposition\u00bcinline. Roebben, G., Rauscher, H., Amenta, V., Aschberger, K., Boix Sanfeliu, A., Calzolai, L., Emons, H., Gaillard, C., Gibson, N., Holzwarth, U., Linsinger, T., Rasmussen, K., Riego Sintes, J., Sokull-Kl\u00fcttgen, B., Stamm, H., 2014. Towards a Review of the EC Recommendation for a Definition of the Term \u201cnanomaterial\u201d; Part 2: Assess- ment of Collected Information Concerning the Experience with the Definition. http://refhub.elsevier.com/S0273-2300(15)30008-8/sref34 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref34 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref34 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref35 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref35 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref35 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref36 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref36 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref36 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref36 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref36 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref36 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref37 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref37 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref37 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref37 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref38 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref38 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref38 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref38 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref38 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref38 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref38 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref38 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref38 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref39 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref39 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref39 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref39 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref39 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref40 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref40 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref40 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref40 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref41 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref41 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref41 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref41 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref41 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref42 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref42 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref42 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref42 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref42 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref42 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref43 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref43 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref43 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref43 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref43 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref44 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref44 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref44 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref44 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref44 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref44 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref45 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref45 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref45 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref45 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref46 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref46 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref46 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref46 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref47 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref47 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref47 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref47 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref47 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref48 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref48 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref48 http://www.fao.org/docrep/018/i3281e/i3281e.pdf http://www.fao.org/docrep/018/i3281e/i3281e.pdf http://www.fsc.go.jp/english/survey_programs/use_nanotechnology.pdf http://refhub.elsevier.com/S0273-2300(15)30008-8/sref51 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref51 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref51 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref51 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref51 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref51 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref52 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref52 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref52 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref52 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref53 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref53 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref54 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref54 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref54 http://www.hc-sc.gc.ca/sr-sr/pubs/nano/pol-eng.php http://www.bag.admin.ch/themen/chemikalien/00228/00510/05626/index.html?lang=en http://www.bag.admin.ch/themen/chemikalien/00228/00510/05626/index.html?lang=en http://www.bag.admin.ch/themen/chemikalien/00228/00510/05626/index.html?lang=en http://www.intertek.com/regulatory/turkey-clp/ http://refhub.elsevier.com/S0273-2300(15)30008-8/sref58 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref59 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref59 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref60 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref60 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref60 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref61 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref61 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref61 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref61 http://www.kfda.go.kr/eng/index.do?nMenuCode=61 http://www.kfda.go.kr/eng/index.do?nMenuCode=61 http://www.kfda.go.kr/eng/index.do?nMenuCode=61 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref63 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref63 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref63 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref63 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref64 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref64 http://publications.jrc.ec.europa.eu/repository/bitstream/111111111/26399/2/irmm_nanomaterials%20%28online%29.pdf http://publications.jrc.ec.europa.eu/repository/bitstream/111111111/26399/2/irmm_nanomaterials%20%28online%29.pdf http://publications.jrc.ec.europa.eu/repository/bitstream/111111111/26399/2/irmm_nanomaterials%20%28online%29.pdf http://www.observatorynano.eu/project/filesystem/files/ObservatoryNano_Nanotechnologies_RegulationAndStandards_2012.pdf http://www.observatorynano.eu/project/filesystem/files/ObservatoryNano_Nanotechnologies_RegulationAndStandards_2012.pdf http://www.observatorynano.eu/project/filesystem/files/ObservatoryNano_Nanotechnologies_RegulationAndStandards_2012.pdf http://refhub.elsevier.com/S0273-2300(15)30008-8/sref67 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref67 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref67 http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.nicnas.gov.au/regulation-and-compliance/nicnas-handbook http://www.nicnas.gov.au/regulation-and-compliance/nicnas-handbook http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2013 http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2013 http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2013 http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2013)2&amp;doclanguage=en http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2013)2&amp;doclanguage=en http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2013)2&amp;doclanguage=en http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2013)2&amp;doclanguage=en http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2013)2&amp;doclanguage=en http://search.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=DSTI/STP/NANO(2012)22/FINAL&amp;docLanguage=En http://search.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=DSTI/STP/NANO(2012)22/FINAL&amp;docLanguage=En http://search.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=DSTI/STP/NANO(2012)22/FINAL&amp;docLanguage=En http://search.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=DSTI/STP/NANO(2012)22/FINAL&amp;docLanguage=En http://search.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=DSTI/STP/NANO(2012)22/FINAL&amp;docLanguage=En http://search.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=DSTI/STP/NANO(2012)22/FINAL&amp;docLanguage=En http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Food%20and%20Agricultural%20Import%20Regulations%20and%20Standards%20-%20Narrative_Moscow_Russian%20Federation_11.08.2009.pdf http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Food%20and%20Agricultural%20Import%20Regulations%20and%20Standards%20-%20Narrative_Moscow_Russian%20Federation_11.08.2009.pdf http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Food%20and%20Agricultural%20Import%20Regulations%20and%20Standards%20-%20Narrative_Moscow_Russian%20Federation_11.08.2009.pdf http://publications.jrc.ec.europa.eu/repository/bitstream/111111111/31846/1/ipts%20jrc%2089736%20(online)%20%20final.pdf http://publications.jrc.ec.europa.eu/repository/bitstream/111111111/31846/1/ipts%20jrc%2089736%20(online)%20%20final.pdf http://publications.jrc.ec.europa.eu/repository/bitstream/111111111/31846/1/ipts%20jrc%2089736%20(online)%20%20final.pdf http://www.egg2012.de/tl_files/pdf/Paper/EGG2012_C6_1_Park_presentation_slides.pdf http://www.egg2012.de/tl_files/pdf/Paper/EGG2012_C6_1_Park_presentation_slides.pdf http://www.egg2012.de/tl_files/pdf/Paper/EGG2012_C6_1_Park_presentation_slides.pdf http://refhub.elsevier.com/S0273-2300(15)30008-8/sref75 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref75 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref75 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref75 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref75 https://ec.europa.eu/jrc/sites/default/files/lbna26567enn.pdf https://ec.europa.eu/jrc/sites/default/files/lbna26567enn.pdf http://www.efsa.europa.eu/en/supporting/doc/621e.pdf http://www.rivm.nl/dsresource?objectid=rivmp:181801&amp;type=org&amp;disposition=inline http://www.rivm.nl/dsresource?objectid=rivmp:181801&amp;type=org&amp;disposition=inline http://www.rivm.nl/dsresource?objectid=rivmp:181801&amp;type=org&amp;disposition=inline http://www.rivm.nl/dsresource?objectid=rivmp:181801&amp;type=org&amp;disposition=inline http://www.rivm.nl/dsresource?objectid=rivmp:181801&amp;type=org&amp;disposition=inline http://www.rivm.nl/dsresource?objectid=rivmp:181801&amp;type=org&amp;disposition=inline http://www.rivm.nl/dsresource?objectid=rivmp:181801&amp;type=org&amp;disposition=inline V. Amenta et al. / Regulatory Toxicology and Pharmacology 73 (2015) 463e476476 European Commission Joint Research Centre from. https://ec.europa.eu/jrc/en/ publication/eur-scientific-and-technical-research-reports/towards-review-ec- recommendation-definition-term-nanomaterial-part-2-assessment-collected. SCENIHubert Rauscher, 2007. Opinion in the Appropriateness of the Risk Assessment Method- ology in Accordance with the Technical Guidance Documents for New and Existing Substances for Assessing the Risks of Nanomaterials. Scientific Com- mittee on Emerging and Newly Identified Health Risks, Brussels from. http://ec. europa.eu/health/archive/ph_risk/committees/04_scenihr/docs/scenihr_o_010. pdf. SCENIHubert Rauscher, 2009. Risk Assessment of Products of Nanotechnologies. Scientific Com- mittee on Emerging and Newly Identified Health Risks, Brussels from. http://ec. europa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_023.pdf. Schweizerischer Bundesrat, 2010. Verordnung \u00fcber das Inverkehrbringen von Pflanzenschutzmitteln (Pflanzenschutzmittelverordnung, PSMV), 916.161. F. O. o. P. Health. SECO, S. S. f. E. A, 2012. Safety Data Sheet (SDS): Guidelines for Synthetic Nanomaterials. Tyler, L.C., 2012. FDA Issues Draft Guidance on Use of Nanotechnology in Food and Food Packaging. Nanotechnol. Law Bus. 9, 149e155. US-EPA, 2011. Regulating Pesticides that Use Nanotechnology. Retrieved 12/12/ 2013, 2013, from. http://www.epa.gov/pesticides/regulating/nanotechnology. html. US-EPA, 2012. Nanomaterial Case Study: Nanoscale Silver in Disinfectant Spray (Final Report). Washington DC from. http://cfpub.epa.gov/ncea/cfm/ recordisplay.cfm?deid\u00bc226723. US-EPA, 2015. Chemical Substances when Manufactured or Processed as Nanoscale Materials: TSCA Reporting and Recordkeeping Requirements. Washington DC from. http://www.regulations.gov/#!documentDetail;D\u00bcEPA-HQ-OPPT-2010- 0572-0001. US-FDA, 2014a. Guidance for Industry e Considering whether an FDA-regulated Product Involves the Application of Nanotechnology, 20993. US-FDA, Silver Spring, MD. from. http://www.fda.gov/regulatoryinformation/guidances/ ucm257698.htm. US-FDA, 2014b. Guidance for Industry on Use of Nanomaterials in Food for Animals. Draft Guidance, 20852. US-FDA, Rockville MD. van der Meulen, B., Bremmers, H., Purnhagen, K., Gupta, N., Bouwmeester, H., Geyer, L.L., 2014. Governing Nano Foods: Principles-based Responsive Regula- tion: EFFoST Critical Reviews# 3. Academic Press. van Kesteren, P.C.E., Cubadda, F., Bouwmeester, H., van Eijkeren, J.C.H., Dekkers, S., de Jong, W.H., Oomen, A.G., 2014. Novel insights into the risk assessment of the nanomaterial synthetic amorphous silica, additive E551, in food. Nano- toxicology 0 (0), 1e10. Weir, A., Westerhoff, P., Fabricius, L., Hristovski, K., von Goetz, N., 2012. Titanium dioxide nanoparticles in food and personal care products. Environ. Sci. Technol. 46 (4), 2242e2250. Wijnhoven, Stefan Weigel.P., Peijnenburg, W.J.G.M., Herberts, C.A., Hagens, W.I., Oomen, A.G., Heugens, E.H.W., Roszek, B., Bisschops, J., Gosens, I., Van De Meent, D., Dekkers, S., De Jong, W.H., Van Zijverden, M., Sips, A.J.Agnieszka Mech., Geertsma, R.E., 2009. Nano-silver e a review of available data and knowledge gaps in human and environmental risk assessment. Nanotoxicology 3 (2), 109e138. https://ec.europa.eu/jrc/en/publication/eur-scientific-and-technical-research-reports/towards-review-ec-recommendation-definition-term-nanomaterial-part-2-assessment-collected https://ec.europa.eu/jrc/en/publication/eur-scientific-and-technical-research-reports/towards-review-ec-recommendation-definition-term-nanomaterial-part-2-assessment-collected https://ec.europa.eu/jrc/en/publication/eur-scientific-and-technical-research-reports/towards-review-ec-recommendation-definition-term-nanomaterial-part-2-assessment-collected http://ec.europa.eu/health/archive/ph_risk/committees/04_scenihr/docs/scenihr_o_010.pdf http://ec.europa.eu/health/archive/ph_risk/committees/04_scenihr/docs/scenihr_o_010.pdf http://ec.europa.eu/health/archive/ph_risk/committees/04_scenihr/docs/scenihr_o_010.pdf http://ec.europa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_023.pdf http://ec.europa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_023.pdf http://refhub.elsevier.com/S0273-2300(15)30008-8/sref83 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref83 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref83 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref84 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref84 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref85 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref85 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref85 http://www.epa.gov/pesticides/regulating/nanotechnology.html http://www.epa.gov/pesticides/regulating/nanotechnology.html http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=226723 http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=226723 http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=226723 http://www.regulations.gov/#!documentDetail;D=EPA-HQ-OPPT-2010-0572-0001 http://www.regulations.gov/#!documentDetail;D=EPA-HQ-OPPT-2010-0572-0001 http://www.regulations.gov/#!documentDetail;D=EPA-HQ-OPPT-2010-0572-0001 http://www.fda.gov/regulatoryinformation/guidances/ucm257698.htm http://www.fda.gov/regulatoryinformation/guidances/ucm257698.htm http://refhub.elsevier.com/S0273-2300(15)30008-8/sref93 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref93 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref94 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref94 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref94 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref95 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref95 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref95 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref95 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref95 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref96 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref96 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref96 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref96 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref97 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref97 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref97 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref97 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref97 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref97 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref97 Regulatory aspects of nanotechnology in the agri/feed/food sector in EU and non-EU countries 1. Introduction 2. Nanotechnology applications in agri/feed/food and potential impacts on safety 3. Regulatory aspects of NMs in agri/feed/food in the EU 3.1. Definition of \u201cnanomaterial\u201d 3.2. Legal acts for pesticides risk assessment 3.3. Legal acts for food and feed risk assessment 3.4. Legal acts for food contact materials risk assessment 3.5. Legal acts for Biocides and Chemical Substances Risk Assessment 3.6. Available guidances for risk assessment of nanomaterials 3.7. Labelling and reporting schemes for NMs 4. Regulatory aspects concerning NMs in agri/food/feed in non-EU countries 4.1. United States of America 4.2. Canada 4.3. Australia and New Zealand 4.4. Non-EU European countries 4.5. Asia 4.6. Africa and South America 5. Comparison of EU and non-EU regulatory approaches 6. Conclusions Acknowledgements Appendix A. Supplementary data Transparency document References OECD, 2013a. Current Developments/Activities on the Safety of Manufactured Nanomaterials; Series on the Safety of Manufactured Nanomaterials No. 37. Paris from. http://search.oecd.org/officialdocuments/displaydocumentpdf/? cote\u00bcenv/jm/mono(2013. http://search.oecd.org/officialdocuments/display documentpdf/?cote\u00bcenv/jm/mono(2013)2&doclanguage\u00bcen. OECD, 2013b. Regulatory Frameworks for Nanotechnology in Foods and Medical Products. Summary Results of a Survey Activity. Paris from. http://search.oecd. org/officialdocuments/publicdisplaydocumentpdf/?cote\u00bcDSTI/STP/ NANO(2012)22/FINAL&docLanguage\u00bcEn. Office of Agricultural Affairs of the USDA, 2009. Russian Federation e Food and Agricultural Import Regulations and Standards e FAIReinhilde Schoonjans Country Report. Mos- cow from. http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Food% 20and%20Agricultural%20Import%20Regulations%20and%20Standards%20-% 20Narrative_Moscow_Russian%20Federation_11.08.2009.pdf. Parisi, C., M, V., Rodr\u00edguez-Cerezo, E., 2014. In: . Proceedings of a Workshop on \u201cNanotechnology for the Agricultural Sector: from Research to the Field\u201d. Publications Office of the European Union, Luxembourg, 2014, from. http:// publications.jrc.ec.europa.eu/repository/bitstream/111111111/31846/1/ipts% 20jrc%2089736%20(online)%20%20final.pdf. Park, Y., 2012. Nano-regulation in China, Japan, Korea, USA and EU from. http:// www.egg2012.de/tl_files/pdf/Paper/EGG2012_C6_1_Park_presentation_slides. pdf. Peters, R.J.B., van Bemmel, G., Herrera-Rivera, Z., Helsper, H.P.F.G., Marvin, H.J.P., Weigel, S., Tromp, P.C., Oomen, A.G., Rietveld, A.G., Bouwmeester, H., 2014. Characterization of titanium dioxide nanoparticles in food products: analytical methods to define nanoparticles. J. Agric. Food Chem. 62 (27), 6285e6293. Rauscher, H., Roebben, G., Amenta, V., Boix Sanfeliu, A., Calzolai, L., Emons, H., Gaillard, C., Gibson, N., Linsinger, T., Mech, A., Quiros Pesudo, L., Rasmussen, K., Riego Sintes, J., Sokull-Kl\u00fcttgen, B., Stamm, H., 2014. Towards a Review of the EC Recommendation for a Definition of the Term \u201cnanomaterial\u201d; Part 1: Compi- lation of Information Concerning the Experience with the Definition. European Commission Joint Research Centre from. https://ec.europa.eu/jrc/sites/default/ files/lbna26567enn.pdf. RIKILT and JRC, 2014. Inventory of Nanotechnology Applications in the Agricultural, Feed and Food Sector. Parma, RIKILT. European Commission Joint Research Centre from. http://www.efsa.europa.eu/en/supporting/doc/621e.pdf. RIVM, 2012. Interpretation and Implications of the European Commission Recom- mendation on the Definition of Nanomaterial. Bilthoven from. http://www. rivm.nl/dsresource?objectid\u00bcrivmp:181801&type\u00bcorg&disposition\u00bcinline. Roebben, G., Rauscher, H., Amenta, V., Aschberger, K., Boix Sanfeliu, A., Calzolai, L., Emons, H., Gaillard, C., Gibson, N., Holzwarth, U., Linsinger, T., Rasmussen, K., Riego Sintes, J., Sokull-Kl\u00fcttgen, B., Stamm, H., 2014. Towards a Review of the EC Recommendation for a Definition of the Term \u201cnanomaterial\u201d; Part 2: Assess- ment of Collected Information Concerning the Experience with the Definition. http://refhub.elsevier.com/S0273-2300(15)30008-8/sref34 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref34 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref34 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref35 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref35 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref35 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref36 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref36 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref36 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref36 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref36 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref36 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref37 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref37 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref37 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref37 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref38 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref38 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref38 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref38 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref38 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref38 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref38 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref38 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref38 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref39 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref39 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref39 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref39 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref39 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref40 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref40 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref40 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref40 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref41 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref41 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref41 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref41 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref41 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref42 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref42 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref42 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref42 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref42 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref42 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref43 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref43 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref43 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref43 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref43 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref44 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref44 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref44 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref44 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref44 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref44 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref45 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref45 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref45 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref45 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref46 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref46 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref46 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref46 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref47 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref47 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref47 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref47 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref47 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref48 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref48 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref48 http://www.fao.org/docrep/018/i3281e/i3281e.pdf http://www.fao.org/docrep/018/i3281e/i3281e.pdf http://www.fsc.go.jp/english/survey_programs/use_nanotechnology.pdf http://refhub.elsevier.com/S0273-2300(15)30008-8/sref51 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref51 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref51 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref51 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref51 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref51 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref52 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref52 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref52 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref52 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref53 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref53 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref54 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref54 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref54 http://www.hc-sc.gc.ca/sr-sr/pubs/nano/pol-eng.php http://www.bag.admin.ch/themen/chemikalien/00228/00510/05626/index.html?lang=en http://www.bag.admin.ch/themen/chemikalien/00228/00510/05626/index.html?lang=en http://www.bag.admin.ch/themen/chemikalien/00228/00510/05626/index.html?lang=en http://www.intertek.com/regulatory/turkey-clp/ http://refhub.elsevier.com/S0273-2300(15)30008-8/sref58 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref59 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref59 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref60 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref60 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref60 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref61 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref61 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref61 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref61 http://www.kfda.go.kr/eng/index.do?nMenuCode=61 http://www.kfda.go.kr/eng/index.do?nMenuCode=61 http://www.kfda.go.kr/eng/index.do?nMenuCode=61 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref63 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref63 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref63 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref63 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref64 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref64 http://publications.jrc.ec.europa.eu/repository/bitstream/111111111/26399/2/irmm_nanomaterials%20%28online%29.pdf http://publications.jrc.ec.europa.eu/repository/bitstream/111111111/26399/2/irmm_nanomaterials%20%28online%29.pdf http://publications.jrc.ec.europa.eu/repository/bitstream/111111111/26399/2/irmm_nanomaterials%20%28online%29.pdf http://www.observatorynano.eu/project/filesystem/files/ObservatoryNano_Nanotechnologies_RegulationAndStandards_2012.pdf http://www.observatorynano.eu/project/filesystem/files/ObservatoryNano_Nanotechnologies_RegulationAndStandards_2012.pdf http://www.observatorynano.eu/project/filesystem/files/ObservatoryNano_Nanotechnologies_RegulationAndStandards_2012.pdf http://refhub.elsevier.com/S0273-2300(15)30008-8/sref67 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref67 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref67 http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.nicnas.gov.au/regulation-and-compliance/nicnas-handbook http://www.nicnas.gov.au/regulation-and-compliance/nicnas-handbook http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2013 http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2013 http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2013 http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2013)2&amp;doclanguage=en http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2013)2&amp;doclanguage=en http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2013)2&amp;doclanguage=en http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2013)2&amp;doclanguage=en http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2013)2&amp;doclanguage=en http://search.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=DSTI/STP/NANO(2012)22/FINAL&amp;docLanguage=En http://search.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=DSTI/STP/NANO(2012)22/FINAL&amp;docLanguage=En http://search.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=DSTI/STP/NANO(2012)22/FINAL&amp;docLanguage=En http://search.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=DSTI/STP/NANO(2012)22/FINAL&amp;docLanguage=En http://search.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=DSTI/STP/NANO(2012)22/FINAL&amp;docLanguage=En http://search.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=DSTI/STP/NANO(2012)22/FINAL&amp;docLanguage=En http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Food%20and%20Agricultural%20Import%20Regulations%20and%20Standards%20-%20Narrative_Moscow_Russian%20Federation_11.08.2009.pdf http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Food%20and%20Agricultural%20Import%20Regulations%20and%20Standards%20-%20Narrative_Moscow_Russian%20Federation_11.08.2009.pdf http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Food%20and%20Agricultural%20Import%20Regulations%20and%20Standards%20-%20Narrative_Moscow_Russian%20Federation_11.08.2009.pdf http://publications.jrc.ec.europa.eu/repository/bitstream/111111111/31846/1/ipts%20jrc%2089736%20(online)%20%20final.pdf http://publications.jrc.ec.europa.eu/repository/bitstream/111111111/31846/1/ipts%20jrc%2089736%20(online)%20%20final.pdf http://publications.jrc.ec.europa.eu/repository/bitstream/111111111/31846/1/ipts%20jrc%2089736%20(online)%20%20final.pdf http://www.egg2012.de/tl_files/pdf/Paper/EGG2012_C6_1_Park_presentation_slides.pdf http://www.egg2012.de/tl_files/pdf/Paper/EGG2012_C6_1_Park_presentation_slides.pdf http://www.egg2012.de/tl_files/pdf/Paper/EGG2012_C6_1_Park_presentation_slides.pdf http://refhub.elsevier.com/S0273-2300(15)30008-8/sref75 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref75 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref75 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref75 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref75 https://ec.europa.eu/jrc/sites/default/files/lbna26567enn.pdf https://ec.europa.eu/jrc/sites/default/files/lbna26567enn.pdf http://www.efsa.europa.eu/en/supporting/doc/621e.pdf http://www.rivm.nl/dsresource?objectid=rivmp:181801&amp;type=org&amp;disposition=inline http://www.rivm.nl/dsresource?objectid=rivmp:181801&amp;type=org&amp;disposition=inline http://www.rivm.nl/dsresource?objectid=rivmp:181801&amp;type=org&amp;disposition=inline http://www.rivm.nl/dsresource?objectid=rivmp:181801&amp;type=org&amp;disposition=inline http://www.rivm.nl/dsresource?objectid=rivmp:181801&amp;type=org&amp;disposition=inline http://www.rivm.nl/dsresource?objectid=rivmp:181801&amp;type=org&amp;disposition=inline http://www.rivm.nl/dsresource?objectid=rivmp:181801&amp;type=org&amp;disposition=inline V. Amenta et al. / Regulatory Toxicology and Pharmacology 73 (2015) 463e476476 European Commission Joint Research Centre from. https://ec.europa.eu/jrc/en/ publication/eur-scientific-and-technical-research-reports/towards-review-ec- recommendation-definition-term-nanomaterial-part-2-assessment-collected. SCENIHubert Rauscher, 2007. Opinion in the Appropriateness of the Risk Assessment Method- ology in Accordance with the Technical Guidance Documents for New and Existing Substances for Assessing the Risks of Nanomaterials. Scientific Com- mittee on Emerging and Newly Identified Health Risks, Brussels from. http://ec. europa.eu/health/archive/ph_risk/committees/04_scenihr/docs/scenihr_o_010. pdf. SCENIHubert Rauscher, 2009. Risk Assessment of Products of Nanotechnologies. Scientific Com- mittee on Emerging and Newly Identified Health Risks, Brussels from. http://ec. europa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_023.pdf. Schweizerischer Bundesrat, 2010. Verordnung \u00fcber das Inverkehrbringen von Pflanzenschutzmitteln (Pflanzenschutzmittelverordnung, PSMV), 916.161. F. O. o. P. Health. SECO, S. S. f. E. A, 2012. Safety Data Sheet (SDS): Guidelines for Synthetic Nanomaterials. Tyler, L.C., 2012. FDA Issues Draft Guidance on Use of Nanotechnology in Food and Food Packaging. Nanotechnol. Law Bus. 9, 149e155. US-EPA, 2011. Regulating Pesticides that Use Nanotechnology. Retrieved 12/12/ 2013, 2013, from. http://www.epa.gov/pesticides/regulating/nanotechnology. html. US-EPA, 2012. Nanomaterial Case Study: Nanoscale Silver in Disinfectant Spray (Final Report). Washington DC from. http://cfpub.epa.gov/ncea/cfm/ recordisplay.cfm?deid\u00bc226723. US-EPA, 2015. Chemical Substances when Manufactured or Processed as Nanoscale Materials: TSCA Reporting and Recordkeeping Requirements. Washington DC from. http://www.regulations.gov/#!documentDetail;D\u00bcEPA-HQ-OPPT-2010- 0572-0001. US-FDA, 2014a. Guidance for Industry e Considering whether an FDA-regulated Product Involves the Application of Nanotechnology, 20993. US-FDA, Silver Spring, MD. from. http://www.fda.gov/regulatoryinformation/guidances/ ucm257698.htm. US-FDA, 2014b. Guidance for Industry on Use of Nanomaterials in Food for Animals. Draft Guidance, 20852. US-FDA, Rockville MD. van der Meulen, B., Bremmers, H., Purnhagen, K., Gupta, N., Bouwmeester, H., Geyer, L.L., 2014. Governing Nano Foods: Principles-based Responsive Regula- tion: EFFoST Critical Reviews# 3. Academic Press. van Kesteren, P.C.E., Cubadda, F., Bouwmeester, H., van Eijkeren, J.C.H., Dekkers, S., de Jong, W.H., Oomen, A.G., 2014. Novel insights into the risk assessment of the nanomaterial synthetic amorphous silica, additive E551, in food. Nano- toxicology 0 (0), 1e10. Weir, A., Westerhoff, P., Fabricius, L., Hristovski, K., von Goetz, N., 2012. Titanium dioxide nanoparticles in food and personal care products. Environ. Sci. Technol. 46 (4), 2242e2250. Wijnhoven, Stefan Weigel.P., Peijnenburg, W.J.G.M., Herberts, C.A., Hagens, W.I., Oomen, A.G., Heugens, E.H.W., Roszek, B., Bisschops, J., Gosens, I., Van De Meent, D., Dekkers, S., De Jong, W.H., Van Zijverden, M., Sips, A.J.Agnieszka Mech., Geertsma, R.E., 2009. Nano-silver e a review of available data and knowledge gaps in human and environmental risk assessment. Nanotoxicology 3 (2), 109e138. https://ec.europa.eu/jrc/en/publication/eur-scientific-and-technical-research-reports/towards-review-ec-recommendation-definition-term-nanomaterial-part-2-assessment-collected https://ec.europa.eu/jrc/en/publication/eur-scientific-and-technical-research-reports/towards-review-ec-recommendation-definition-term-nanomaterial-part-2-assessment-collected https://ec.europa.eu/jrc/en/publication/eur-scientific-and-technical-research-reports/towards-review-ec-recommendation-definition-term-nanomaterial-part-2-assessment-collected http://ec.europa.eu/health/archive/ph_risk/committees/04_scenihr/docs/scenihr_o_010.pdf http://ec.europa.eu/health/archive/ph_risk/committees/04_scenihr/docs/scenihr_o_010.pdf http://ec.europa.eu/health/archive/ph_risk/committees/04_scenihr/docs/scenihr_o_010.pdf http://ec.europa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_023.pdf http://ec.europa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_023.pdf http://refhub.elsevier.com/S0273-2300(15)30008-8/sref83 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref83 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref83 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref84 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref84 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref85 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref85 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref85 http://www.epa.gov/pesticides/regulating/nanotechnology.html http://www.epa.gov/pesticides/regulating/nanotechnology.html http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=226723 http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=226723 http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=226723 http://www.regulations.gov/#!documentDetail;D=EPA-HQ-OPPT-2010-0572-0001 http://www.regulations.gov/#!documentDetail;D=EPA-HQ-OPPT-2010-0572-0001 http://www.regulations.gov/#!documentDetail;D=EPA-HQ-OPPT-2010-0572-0001 http://www.fda.gov/regulatoryinformation/guidances/ucm257698.htm http://www.fda.gov/regulatoryinformation/guidances/ucm257698.htm http://refhub.elsevier.com/S0273-2300(15)30008-8/sref93 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref93 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref94 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref94 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref94 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref95 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref95 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref95 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref95 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref95 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref96 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref96 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref96 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref96 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref97 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref97 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref97 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref97 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref97 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref97 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref97 Regulatory aspects of nanotechnology in the agri/feed/food sector in EU and non-EU countries 1. Introduction 2. Nanotechnology applications in agri/feed/food and potential impacts on safety 3. Regulatory aspects of NMs in agri/feed/food in the EU 3.1. Definition of \u201cnanomaterial\u201d 3.2. Legal acts for pesticides risk assessment 3.3. Legal acts for food and feed risk assessment 3.4. Legal acts for food contact materials risk assessment 3.5. Legal acts for Biocides and Chemical Substances Risk Assessment 3.6. Available guidances for risk assessment of nanomaterials 3.7. Labelling and reporting schemes for NMs 4. Regulatory aspects concerning NMs in agri/food/feed in non-EU countries 4.1. United States of America 4.2. Canada 4.3. Australia and New Zealand 4.4. Non-EU European countries 4.5. Asia 4.6. Africa and South America 5. Comparison of EU and non-EU regulatory approaches 6. Conclusions Acknowledgements Appendix A. Supplementary data Transparency document References", "Acknowledgement": "OECD, 2013a. Current Developments/Activities on the Safety of Manufactured Nanomaterials; Series on the Safety of Manufactured Nanomaterials No. 37. Paris from. http://search.oecd.org/officialdocuments/displaydocumentpdf/? cote\u00bcenv/jm/mono(2013. http://search.oecd.org/officialdocuments/display documentpdf/?cote\u00bcenv/jm/mono(2013)2&doclanguage\u00bcen. OECD, 2013b. Regulatory Frameworks for Nanotechnology in Foods and Medical Products. Summary Results of a Survey Activity. Paris from. http://search.oecd. org/officialdocuments/publicdisplaydocumentpdf/?cote\u00bcDSTI/STP/ NANO(2012)22/FINAL&docLanguage\u00bcEn. Office of Agricultural Affairs of the USDA, 2009. Russian Federation e Food and Agricultural Import Regulations and Standards e FAIReinhilde Schoonjans Country Report. Mos- cow from. http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Food% 20and%20Agricultural%20Import%20Regulations%20and%20Standards%20-% 20Narrative_Moscow_Russian%20Federation_11.08.2009.pdf. Parisi, C., M, V., Rodr\u00edguez-Cerezo, E., 2014. In: . Proceedings of a Workshop on \u201cNanotechnology for the Agricultural Sector: from Research to the Field\u201d. Publications Office of the European Union, Luxembourg, 2014, from. http:// publications.jrc.ec.europa.eu/repository/bitstream/111111111/31846/1/ipts% 20jrc%2089736%20(online)%20%20final.pdf. Park, Y., 2012. Nano-regulation in China, Japan, Korea, USA and EU from. http:// www.egg2012.de/tl_files/pdf/Paper/EGG2012_C6_1_Park_presentation_slides. pdf. Peters, R.J.B., van Bemmel, G., Herrera-Rivera, Z., Helsper, H.P.F.G., Marvin, H.J.P., Weigel, S., Tromp, P.C., Oomen, A.G., Rietveld, A.G., Bouwmeester, H., 2014. Characterization of titanium dioxide nanoparticles in food products: analytical methods to define nanoparticles. J. Agric. Food Chem. 62 (27), 6285e6293. Rauscher, H., Roebben, G., Amenta, V., Boix Sanfeliu, A., Calzolai, L., Emons, H., Gaillard, C., Gibson, N., Linsinger, T., Mech, A., Quiros Pesudo, L., Rasmussen, K., Riego Sintes, J., Sokull-Kl\u00fcttgen, B., Stamm, H., 2014. Towards a Review of the EC Recommendation for a Definition of the Term \u201cnanomaterial\u201d; Part 1: Compi- lation of Information Concerning the Experience with the Definition. European Commission Joint Research Centre from. https://ec.europa.eu/jrc/sites/default/ files/lbna26567enn.pdf. RIKILT and JRC, 2014. Inventory of Nanotechnology Applications in the Agricultural, Feed and Food Sector. Parma, RIKILT. European Commission Joint Research Centre from. http://www.efsa.europa.eu/en/supporting/doc/621e.pdf. RIVM, 2012. Interpretation and Implications of the European Commission Recom- mendation on the Definition of Nanomaterial. Bilthoven from. http://www. rivm.nl/dsresource?objectid\u00bcrivmp:181801&type\u00bcorg&disposition\u00bcinline. Roebben, G., Rauscher, H., Amenta, V., Aschberger, K., Boix Sanfeliu, A., Calzolai, L., Emons, H., Gaillard, C., Gibson, N., Holzwarth, U., Linsinger, T., Rasmussen, K., Riego Sintes, J., Sokull-Kl\u00fcttgen, B., Stamm, H., 2014. Towards a Review of the EC Recommendation for a Definition of the Term \u201cnanomaterial\u201d; Part 2: Assess- ment of Collected Information Concerning the Experience with the Definition. http://refhub.elsevier.com/S0273-2300(15)30008-8/sref34 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref34 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref34 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref35 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref35 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref35 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref36 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref36 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref36 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref36 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref36 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref36 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref37 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref37 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref37 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref37 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref38 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref38 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref38 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref38 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref38 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref38 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref38 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref38 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref38 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref39 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref39 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref39 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref39 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref39 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref40 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref40 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref40 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref40 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref41 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref41 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref41 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref41 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref41 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref42 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref42 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref42 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref42 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref42 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref42 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref43 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref43 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref43 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref43 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref43 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref44 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref44 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref44 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref44 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref44 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref44 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref45 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref45 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref45 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref45 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref46 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref46 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref46 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref46 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref47 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref47 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref47 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref47 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref47 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref48 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref48 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref48 http://www.fao.org/docrep/018/i3281e/i3281e.pdf http://www.fao.org/docrep/018/i3281e/i3281e.pdf http://www.fsc.go.jp/english/survey_programs/use_nanotechnology.pdf http://refhub.elsevier.com/S0273-2300(15)30008-8/sref51 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref51 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref51 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref51 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref51 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref51 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref52 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref52 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref52 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref52 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref53 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref53 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref54 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref54 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref54 http://www.hc-sc.gc.ca/sr-sr/pubs/nano/pol-eng.php http://www.bag.admin.ch/themen/chemikalien/00228/00510/05626/index.html?lang=en http://www.bag.admin.ch/themen/chemikalien/00228/00510/05626/index.html?lang=en http://www.bag.admin.ch/themen/chemikalien/00228/00510/05626/index.html?lang=en http://www.intertek.com/regulatory/turkey-clp/ http://refhub.elsevier.com/S0273-2300(15)30008-8/sref58 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref59 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref59 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref60 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref60 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref60 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref61 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref61 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref61 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref61 http://www.kfda.go.kr/eng/index.do?nMenuCode=61 http://www.kfda.go.kr/eng/index.do?nMenuCode=61 http://www.kfda.go.kr/eng/index.do?nMenuCode=61 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref63 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref63 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref63 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref63 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref64 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref64 http://publications.jrc.ec.europa.eu/repository/bitstream/111111111/26399/2/irmm_nanomaterials%20%28online%29.pdf http://publications.jrc.ec.europa.eu/repository/bitstream/111111111/26399/2/irmm_nanomaterials%20%28online%29.pdf http://publications.jrc.ec.europa.eu/repository/bitstream/111111111/26399/2/irmm_nanomaterials%20%28online%29.pdf http://www.observatorynano.eu/project/filesystem/files/ObservatoryNano_Nanotechnologies_RegulationAndStandards_2012.pdf http://www.observatorynano.eu/project/filesystem/files/ObservatoryNano_Nanotechnologies_RegulationAndStandards_2012.pdf http://www.observatorynano.eu/project/filesystem/files/ObservatoryNano_Nanotechnologies_RegulationAndStandards_2012.pdf http://refhub.elsevier.com/S0273-2300(15)30008-8/sref67 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref67 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref67 http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;ved=0CB8QFjAA&amp;url=http%3A%2F%2Firannano.org%2Ffilereader.php%3Fp1%3Dmain_47e24b47020343c728d44a00681a79b5.pdf%26p2%3Dstatic_page%26p3%3D22%26p4%3D1&amp;ei=QbAFVNT8PMriatPlgsAF&amp;usg=AFQjCNFA69SOMsrseyu1NemcbZYc8Jxe1Q&amp;sig2=9UloR7UCc4DmKnrRw_hDUw&amp;bvm=bv.74115972,d.d2s http://www.nicnas.gov.au/regulation-and-compliance/nicnas-handbook http://www.nicnas.gov.au/regulation-and-compliance/nicnas-handbook http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2013 http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2013 http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2013 http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2013)2&amp;doclanguage=en http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2013)2&amp;doclanguage=en http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2013)2&amp;doclanguage=en http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2013)2&amp;doclanguage=en http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2013)2&amp;doclanguage=en http://search.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=DSTI/STP/NANO(2012)22/FINAL&amp;docLanguage=En http://search.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=DSTI/STP/NANO(2012)22/FINAL&amp;docLanguage=En http://search.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=DSTI/STP/NANO(2012)22/FINAL&amp;docLanguage=En http://search.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=DSTI/STP/NANO(2012)22/FINAL&amp;docLanguage=En http://search.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=DSTI/STP/NANO(2012)22/FINAL&amp;docLanguage=En http://search.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=DSTI/STP/NANO(2012)22/FINAL&amp;docLanguage=En http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Food%20and%20Agricultural%20Import%20Regulations%20and%20Standards%20-%20Narrative_Moscow_Russian%20Federation_11.08.2009.pdf http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Food%20and%20Agricultural%20Import%20Regulations%20and%20Standards%20-%20Narrative_Moscow_Russian%20Federation_11.08.2009.pdf http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Food%20and%20Agricultural%20Import%20Regulations%20and%20Standards%20-%20Narrative_Moscow_Russian%20Federation_11.08.2009.pdf http://publications.jrc.ec.europa.eu/repository/bitstream/111111111/31846/1/ipts%20jrc%2089736%20(online)%20%20final.pdf http://publications.jrc.ec.europa.eu/repository/bitstream/111111111/31846/1/ipts%20jrc%2089736%20(online)%20%20final.pdf http://publications.jrc.ec.europa.eu/repository/bitstream/111111111/31846/1/ipts%20jrc%2089736%20(online)%20%20final.pdf http://www.egg2012.de/tl_files/pdf/Paper/EGG2012_C6_1_Park_presentation_slides.pdf http://www.egg2012.de/tl_files/pdf/Paper/EGG2012_C6_1_Park_presentation_slides.pdf http://www.egg2012.de/tl_files/pdf/Paper/EGG2012_C6_1_Park_presentation_slides.pdf http://refhub.elsevier.com/S0273-2300(15)30008-8/sref75 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref75 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref75 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref75 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref75 https://ec.europa.eu/jrc/sites/default/files/lbna26567enn.pdf https://ec.europa.eu/jrc/sites/default/files/lbna26567enn.pdf http://www.efsa.europa.eu/en/supporting/doc/621e.pdf http://www.rivm.nl/dsresource?objectid=rivmp:181801&amp;type=org&amp;disposition=inline http://www.rivm.nl/dsresource?objectid=rivmp:181801&amp;type=org&amp;disposition=inline http://www.rivm.nl/dsresource?objectid=rivmp:181801&amp;type=org&amp;disposition=inline http://www.rivm.nl/dsresource?objectid=rivmp:181801&amp;type=org&amp;disposition=inline http://www.rivm.nl/dsresource?objectid=rivmp:181801&amp;type=org&amp;disposition=inline http://www.rivm.nl/dsresource?objectid=rivmp:181801&amp;type=org&amp;disposition=inline http://www.rivm.nl/dsresource?objectid=rivmp:181801&amp;type=org&amp;disposition=inline V. Amenta et al. / Regulatory Toxicology and Pharmacology 73 (2015) 463e476476 European Commission Joint Research Centre from. https://ec.europa.eu/jrc/en/ publication/eur-scientific-and-technical-research-reports/towards-review-ec- recommendation-definition-term-nanomaterial-part-2-assessment-collected. SCENIHubert Rauscher, 2007. Opinion in the Appropriateness of the Risk Assessment Method- ology in Accordance with the Technical Guidance Documents for New and Existing Substances for Assessing the Risks of Nanomaterials. Scientific Com- mittee on Emerging and Newly Identified Health Risks, Brussels from. http://ec. europa.eu/health/archive/ph_risk/committees/04_scenihr/docs/scenihr_o_010. pdf. SCENIHubert Rauscher, 2009. Risk Assessment of Products of Nanotechnologies. Scientific Com- mittee on Emerging and Newly Identified Health Risks, Brussels from. http://ec. europa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_023.pdf. Schweizerischer Bundesrat, 2010. Verordnung \u00fcber das Inverkehrbringen von Pflanzenschutzmitteln (Pflanzenschutzmittelverordnung, PSMV), 916.161. F. O. o. P. Health. SECO, S. S. f. E. A, 2012. Safety Data Sheet (SDS): Guidelines for Synthetic Nanomaterials. Tyler, L.C., 2012. FDA Issues Draft Guidance on Use of Nanotechnology in Food and Food Packaging. Nanotechnol. Law Bus. 9, 149e155. US-EPA, 2011. Regulating Pesticides that Use Nanotechnology. Retrieved 12/12/ 2013, 2013, from. http://www.epa.gov/pesticides/regulating/nanotechnology. html. US-EPA, 2012. Nanomaterial Case Study: Nanoscale Silver in Disinfectant Spray (Final Report). Washington DC from. http://cfpub.epa.gov/ncea/cfm/ recordisplay.cfm?deid\u00bc226723. US-EPA, 2015. Chemical Substances when Manufactured or Processed as Nanoscale Materials: TSCA Reporting and Recordkeeping Requirements. Washington DC from. http://www.regulations.gov/#!documentDetail;D\u00bcEPA-HQ-OPPT-2010- 0572-0001. US-FDA, 2014a. Guidance for Industry e Considering whether an FDA-regulated Product Involves the Application of Nanotechnology, 20993. US-FDA, Silver Spring, MD. from. http://www.fda.gov/regulatoryinformation/guidances/ ucm257698.htm. US-FDA, 2014b. Guidance for Industry on Use of Nanomaterials in Food for Animals. Draft Guidance, 20852. US-FDA, Rockville MD. van der Meulen, B., Bremmers, H., Purnhagen, K., Gupta, N., Bouwmeester, H., Geyer, L.L., 2014. Governing Nano Foods: Principles-based Responsive Regula- tion: EFFoST Critical Reviews# 3. Academic Press. van Kesteren, P.C.E., Cubadda, F., Bouwmeester, H., van Eijkeren, J.C.H., Dekkers, S., de Jong, W.H., Oomen, A.G., 2014. Novel insights into the risk assessment of the nanomaterial synthetic amorphous silica, additive E551, in food. Nano- toxicology 0 (0), 1e10. Weir, A., Westerhoff, P., Fabricius, L., Hristovski, K., von Goetz, N., 2012. Titanium dioxide nanoparticles in food and personal care products. Environ. Sci. Technol. 46 (4), 2242e2250. Wijnhoven, Stefan Weigel.P., Peijnenburg, W.J.G.M., Herberts, C.A., Hagens, W.I., Oomen, A.G., Heugens, E.H.W., Roszek, B., Bisschops, J., Gosens, I., Van De Meent, D., Dekkers, S., De Jong, W.H., Van Zijverden, M., Sips, A.J.Agnieszka Mech., Geertsma, R.E., 2009. Nano-silver e a review of available data and knowledge gaps in human and environmental risk assessment. Nanotoxicology 3 (2), 109e138. https://ec.europa.eu/jrc/en/publication/eur-scientific-and-technical-research-reports/towards-review-ec-recommendation-definition-term-nanomaterial-part-2-assessment-collected https://ec.europa.eu/jrc/en/publication/eur-scientific-and-technical-research-reports/towards-review-ec-recommendation-definition-term-nanomaterial-part-2-assessment-collected https://ec.europa.eu/jrc/en/publication/eur-scientific-and-technical-research-reports/towards-review-ec-recommendation-definition-term-nanomaterial-part-2-assessment-collected http://ec.europa.eu/health/archive/ph_risk/committees/04_scenihr/docs/scenihr_o_010.pdf http://ec.europa.eu/health/archive/ph_risk/committees/04_scenihr/docs/scenihr_o_010.pdf http://ec.europa.eu/health/archive/ph_risk/committees/04_scenihr/docs/scenihr_o_010.pdf http://ec.europa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_023.pdf http://ec.europa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_023.pdf http://refhub.elsevier.com/S0273-2300(15)30008-8/sref83 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref83 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref83 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref84 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref84 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref85 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref85 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref85 http://www.epa.gov/pesticides/regulating/nanotechnology.html http://www.epa.gov/pesticides/regulating/nanotechnology.html http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=226723 http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=226723 http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=226723 http://www.regulations.gov/#!documentDetail;D=EPA-HQ-OPPT-2010-0572-0001 http://www.regulations.gov/#!documentDetail;D=EPA-HQ-OPPT-2010-0572-0001 http://www.regulations.gov/#!documentDetail;D=EPA-HQ-OPPT-2010-0572-0001 http://www.fda.gov/regulatoryinformation/guidances/ucm257698.htm http://www.fda.gov/regulatoryinformation/guidances/ucm257698.htm http://refhub.elsevier.com/S0273-2300(15)30008-8/sref93 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref93 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref94 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref94 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref94 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref95 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref95 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref95 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref95 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref95 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref96 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref96 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref96 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref96 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref97 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref97 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref97 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref97 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref97 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref97 http://refhub.elsevier.com/S0273-2300(15)30008-8/sref97 Regulatory aspects of nanotechnology in the agri/feed/food sector in EU and non-EU countries 1. Introduction 2. Nanotechnology applications in agri/feed/food and potential impacts on safety 3. Regulatory aspects of NMs in agri/feed/food in the EU 3.1. Definition of \u201cnanomaterial\u201d 3.2. Legal acts for pesticides risk assessment 3.3. Legal acts for food and feed risk assessment 3.4. Legal acts for food contact materials risk assessment 3.5. Legal acts for Biocides and Chemical Substances Risk Assessment 3.6. Available guidances for risk assessment of nanomaterials 3.7. Labelling and reporting schemes for NMs 4. Regulatory aspects concerning NMs in agri/food/feed in non-EU countries 4.1. United States of America 4.2. Canada 4.3. Australia and New Zealand 4.4. Non-EU European countries 4.5. Asia 4.6. Africa and South America 5. Comparison of EU and non-EU regulatory approaches 6. Conclusions Acknowledgements Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Regulatory-assessment-of-in-vitro-skin-corrosion-and-i_2012_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22085589", "content": {"Acknowledgement": "Acknowledgments The preparation, scientific organisation, minutes and reporting of the workshop were supported by the Swiss Federal Office of Public Health. Furthermore, the authors would like to acknowledge Helena Kand\u00e1rov\u00e1 for her contributions to the Workshop discussions. 6 Conclusions Disclaimer Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Regulatory-bioinformatics-for-food-and-d_2016_Regulatory-Toxicology-and-Phar.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27208439", "content": {"CoiStatement": "Conflicts of interest The authors do not have any conflicts of interest to declare. Acknowledgements The authors do not have any conflicts of interest to declare. Acknowledgements The authors would like to recognize contributions to this topic from speakers at the Global Summit on Regulatory Science 2015 e Regulatory Bioinformatics: Russ Altman, Andrew Worth, Leming Shi, Susanna-Assunta Sansone, Dov Greenbaum, Frederick Klau- schen, Rolf Apweiler, Rolf Sommer Kaas, Carl Cerniglia, Burton Blais, Atsuchi Noguchi, Scott Chandry and Mark Walderhaug. We also thank the European Food Safety Authority, which hosted this discussion. 7. Discussion Disclaimer Conflicts of interest Acknowledgements Transparency document References", "Acknowledgement": "The authors do not have any conflicts of interest to declare. Acknowledgements The authors would like to recognize contributions to this topic from speakers at the Global Summit on Regulatory Science 2015 e Regulatory Bioinformatics: Russ Altman, Andrew Worth, Leming Shi, Susanna-Assunta Sansone, Dov Greenbaum, Frederick Klau- schen, Rolf Apweiler, Rolf Sommer Kaas, Carl Cerniglia, Burton Blais, Atsuchi Noguchi, Scott Chandry and Mark Walderhaug. We also thank the European Food Safety Authority, which hosted this discussion. 7. Discussion Disclaimer Conflicts of interest Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Regulatory-causality-evaluation-methods-applied-in_2011_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20854865", "content": {"CoiStatement": "Conflicts of interest None declared. Regulatory causality evaluation methods applied in kava hepatotoxicity: Are they appropriate? Introduction Regulatory data presentation Ad hoc causality assessment WHO scale Naranjo scale CIOMS scale and main-test Future aspects Conclusions Conflicts of interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Regulatory-decision-making-under-uncertainty--Are-costs_2014_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24518386", "content": {"CoiStatement": "Conflict of interest None declared. 5 Comparison of unit costs and benefit-cost ratios across the four restriction proposals 6 Expert confidence in the opinions 7 Discussion and conclusions Conflict of interest Acknowledgments References", "Acknowledgement": "Acknowledgments We are grateful to the European Chemicals Agency (ECHA) in Helsinki and the members of the Socio-Economic Analysis Committee (SEAC) for giving us permission to carry out this study. We thank all the experts who participated in the interviews and who were willing to share their knowledge and information with us. A special word of thanks goes to Stavros Georgiou, Matti Vainio, Cees Luttikhuizen and Martijn Beekman for their useful comments on the study. The authors remain sole responsible for the content of this paper. Any opinions expressed here do not necessarily cor- respond with those of ECHA or the SEAC. The official ECHA and SEAC opinions are publicly available on the official ECHA website www.europe.eu. References 5 Comparison of unit costs and benefit-cost ratios across the four restriction proposals 6 Expert confidence in the opinions 7 Discussion and conclusions Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Regulatory-demands-on-data-quality-for-the-environ_2009_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19607869", "content": {"Compliance with ethical standards": "\ufffd Tests conducted and reported in compliance with the principles of Good Laboratory Practice (GLP) guarantees that there is an audit trail to follow and that the experiments and reports have been audited. Studies not performed in compliance with GLP are therefore intensively assessed on their repeatability and reproducibility given by plausibility of data. \ufffd In principle Limit-tests are acceptable. They could be sufficient, if the trophic level of the test organism used is not the most sen- sitive species in regard of the pharmaceutical substance. If sig- nificant effects occur, a full dose\u2013response-study needs to be conducted."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Regulatory-effect-of-decreasing-therapeutic-duplicatio_2019_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30742875", "content": {"CoiStatement": "Results Discussion Conclusions Conflicts of interest Author contributions Acknowledgments Transparency document Respiratory system drugs (systemic agents) therapeutic duplication criteria List of frequent drug combinations with therapeutic duplication Descriptive statistics for the number of prescribed drugs in all prescriptions of respiratory drugs according to therapeutic duplication Descriptive statistics for duplicative duration (in days) in all prescriptions with therapeutic duplication References", "Acknowledgement": "Results Discussion Conclusions Conflicts of interest Author contributions Acknowledgments Transparency document Respiratory system drugs (systemic agents) therapeutic duplication criteria List of frequent drug combinations with therapeutic duplication Descriptive statistics for the number of prescribed drugs in all prescriptions of respiratory drugs according to therapeutic duplication Descriptive statistics for duplicative duration (in days) in all prescriptions with therapeutic duplication References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Regulatory-immunotoxicology--does-the-published-evidenc_2004_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15546688", "content": {"Acknowledgement": "Conclusions Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Regulatory-landscape-of-dietary-supplements-and-he_2020_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32305367", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. Comparison of regulatory requirements Green tea extracts and vitamin E as examples The role of emerging technologies Challenges Future Directions Disclaimer Declaration of competing interest Acknowledgement Supplementary data References", "Acknowledgement": "Acknowledgement The authors acknowledge the outstanding contributions of all the speakers, panelists and session chairs of GSRS2018. We also acknowl- edge the colleagues and staffs from China National Institutes for Food and Drug Control to support the conference. Comparison of regulatory requirements Green tea extracts and vitamin E as examples The role of emerging technologies Challenges Future Directions Disclaimer Declaration of competing interest Acknowledgement Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Regulatory-landscape-of-nanotechnology-and-nanop_2021_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33617940", "content": {"CoiStatement": "4 Nanotechnology in the agriculture/food/feed sector 5 Examples and challenges on safety assessments of nanomaterials 6 Challenges concerning nanoplastics 7 Documentary and material standards 8 Future directions Disclaimer Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgement References", "Funding": "4 Nanotechnology in the agriculture/food/feed sector 5 Examples and challenges on safety assessments of nanomaterials 6 Challenges concerning nanoplastics 7 Documentary and material standards 8 Future directions Disclaimer Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgement References", "Acknowledgement": "4 Nanotechnology in the agriculture/food/feed sector 5 Examples and challenges on safety assessments of nanomaterials 6 Challenges concerning nanoplastics 7 Documentary and material standards 8 Future directions Disclaimer Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Regulatory-risk-assessment-approaches-for-syn_2015_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26253001", "content": {"CoiStatement": "9. Discussion Conflicts of interest Acknowledgement Transparency document References", "Acknowledgement": "9. Discussion Conflicts of interest Acknowledgement Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Regulatory-safety-pharmacology-and-toxicity-assessment_2021_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34022260", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 4 Discussion Funding Declaration of competing interest Acknowledgments Appendix A Supplementary data References", "Funding": "4 Discussion Funding Declaration of competing interest Acknowledgments Appendix A Supplementary data References", "Acknowledgement": "Acknowledgments Authors acknowledge Pharmanza Herbals Ltd., Gujarat, India for producing CSE and CSIR-CDRI\u2019s GLP team for all-round help in the entire study. Special thanks are due to Dr. Mukesh Shrivastava for sta- tistical support. CSIR-CDRI communication number of this paper is 10246. 4 Discussion Funding Declaration of competing interest Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Regulatory-status-of-N-alkylamide-containin_2018_Regulatory-Toxicology-and-P.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30071240", "content": {"Disclosure": "Author disclosure statement No competing financial interests exist. Author disclosure statement Acknowledgements Supplementary data Transparency document References", "Acknowledgement": "Acknowledgements This work was supported by the Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT- Vlaanderen) (grant number 121512 to Bert Gevaert). Author disclosure statement Acknowledgements Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Relationship-between-cigarette-format-and-mouth-level-_2014_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25146962", "content": {"CoiStatement": "Conflict of interest This work was funded by British American Tobacco (BAT), and all authors, with the exception of Dr. Mike Dixon are full time employees of BAT. Dr. Mike Dixon\u2019s involvement was in the capac- ity of a paid consultant to BAT. 4 Discussion Conflict of interest Acknowledgments Appendix A Supplementary data References", "Acknowledgement": "Acknowledgments The authors thank Michael Baer for calibration smoking and fil- ter analysis, Iona Khoroshavina for assistance with logistics in per- forming the study in Russia, and Sandy Slayford for collecting puffing topography data. We also thank Ian Fearon for support in data interpretation and writing the manuscript. Editorial assis- tance with the preparation of this manuscript was provided by JEM Comms Ltd. and funded by British American Tobacco. 4 Discussion Conflict of interest Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Relationship-between-lethal-toxicity-in-oral-adminis_2015_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25558060", "content": {"CoiStatement": "Analysis on the relationship of log1/LD50 and structures shows that the log1/LD50 vary around a constant for most of homologues/ classes both in oral and injection routes. The toxic contributions of functional groups obtained from both oral and injection routes are very similar for most of the classified compounds. Slight differ- ences in toxic contributions were observed for some functional groups. Correlation analysis shows that although there is a rela- tionship between log1/LD50 in oral administration and intravenous injection, the correlation coefficient is not significant as expected with correlation coefficient R = 0.75 and a systemic bias was observed between log1/LD50 in oral and intravenous administra- tions. Similarity in log1/LD50 of most compounds between the two routes is apparently due to the same toxic mechanisms of the compounds to the same species; and differences in log1/LD50 of some compounds are due to the differences in the exposure routes. The log1/LD50 of compounds with low intestinal absorption after the oral route is lower than that after the injection route. The first-pass metabolism can metabolize many xenobiotics, leading to the bioavailability of chemicals in the oral route being less than that in injection route and log1/LD50 in the oral route less than that in injection route. Some significantly different LD50 values have been observed in different gender and mouse strains. These factors should be considered in the relationships of log1/LD50 in different exposure routes. Exposure route is one of the important factors that affect the toxicity to mice. It is difficult to develop a good QSAR model without considering the effect of exposure route. Conflict of interest None declared. 5 Conclusions Conflict of interest Acknowledgments Appendix A Supplementary data References", "Acknowledgement": "Acknowledgments This work is supported by National Natural Science Foundation of China (21377022) and National Training Programs of Innovation and 212 Y. Wang et al. / Regulatory Toxicology and Pharmacology 71 (2015) 205\u2013212 Entrepreneurship for Undergraduates of China (201410200081). We thank Yuan Y. Zhou, Zheng Y. Peng, Jin X. Zhang, Yi Zhang and Yuan Yuan for the collection and classification of mouse toxicity data. 5 Conclusions Conflict of interest Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Relationship-between-machine-derived-smoke-yields-a_2007_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/17034917", "content": {"Acknowledgement": "Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Relationship-between-prenatal-exposure-to-polychlorinated-b_2012_Regulatory-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22735367", "content": {"CoiStatement": "Conflicts of interest statement Acknowledgments References", "Acknowledgement": "Conflicts of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Relative-absorption-and-dermal-loading-of-chemical_2009_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19393281", "content": {"Acknowledgement": "228 H.E. Buist et al. / Regulatory Toxicology and Pharmacology 54 (2009) 221\u2013228 Acknowledgments We thank our colleague Carina Rubingh for her excellent statis- tical analysis of our data. The financial support the Dutch Ministry of Social Affairs and Employment for the research reported in this manuscript is gratefully acknowledged. Appendix A. Supplementary data Conclusions Acknowledgments Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Relative-source-allocation-of-TDI-to-drinking-water-for-_2013_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23867354", "content": {"CoiStatement": "The exposure assessment method proposed in the present study could be a useful method for deriving allocation factors. In the fu- ture, assessments that take into consideration the distribution of daily drinking water intake (if available) should be conducted and compared with the present study. Conflict of interest The authors declare that there is no conflict of interest. The authors declare that there is no conflict of interest. Acknowledgments 4 Conclusions Conflict of interest Acknowledgments Appendix A Supplementary data References", "Acknowledgement": "Acknowledgments This study was supported by Health and Labour Sciences Re- search Grant (H25-Kenki-Ippan-007) from the Ministry of Health, Labour, and Welfare, Japan. However, this work has not been eval- uated by the grant entity and does not necessarily reflect its opin- ion; therefore, no official endorsement should be inferred. Appendix A. Supplementary data 4 Conclusions Conflict of interest Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Relevance-and-reliability-of-experimental-data-in-_2017_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28655655", "content": {"Disclosure": "Lutter, R., Barrow, C., Borgert, C.J., Conrad Jr., J.W., Edwards, D., Felsot, A., 2013. Data disclosure for chemical evaluations. Environ. Health Perspect. 121, 145e148. McDonagh, M.S., Peterson, K., Balshem, H., Helfand, M., 2013. US Food and Drug Administration documents can provide unpublished evidence relevant to sys- tematic reviews. J. Clin. Epidemiol. 66, 1071e1081.", "Acknowledgement": "Acknowledgements The authors would like to thank Kristin Herrmann, Thomas Kuhl, Denise Kurth, Glenn Lurman, Britta Michalski, David Schu- macher and Birgit Wobst for the detailed discussions and helpful contributions. 5. Uncertainty 6. Discussion and conclusion Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Relevance-of-bioaccumulating-substances-in-_2016_Regulatory-Toxicology-and-P.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26921795", "content": {"CoiStatement": "From the present evaluation it is concluded that the TTC thresholds already were derived including a significant amount of bioaccumulating substances in the dataset. Moreover, Kroes et al. (2004) reported that only one of the Cramer class III substances has a NOEL below the 5th percentile NOEL calculated for Cramer class III substances, demonstrating the conservative nature of the TTC thresholds also for bioaccumulating substances. Taken these aspects into consideration there seems no need to exclude potential bioaccumulating substances from the TTC concept as proposed by EFSA in 2012. Conflict of interest The authors declare that there are no conflicts of interest. Acknowledgements The authors declare that there are no conflicts of interest. Acknowledgements This work was commissioned by the Food Safety Program Management of TNO. The work was financially supported by Knowledge Program funding by the Dutch Ministry of Economic Affairs. Transparency document 5. Conclusion Conflict of interest Acknowledgements Transparency document Appendix A. Supplementary data References", "Funding": "This work was commissioned by the Food Safety Program Management of TNO. The work was financially supported by Knowledge Program funding by the Dutch Ministry of Economic Affairs. Transparency document Transparency document related to this article can be found online at http://dx.doi.org/10.1016/j.yrtph.2016.02.014. Appendix A. Supplementary data", "Acknowledgement": "The authors declare that there are no conflicts of interest. Acknowledgements This work was commissioned by the Food Safety Program Management of TNO. The work was financially supported by Knowledge Program funding by the Dutch Ministry of Economic Affairs. Transparency document 5. Conclusion Conflict of interest Acknowledgements Transparency document Appendix A. Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Relevance-of-the-mouse-skin-initiation-promotion-model-_2015_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25846367", "content": {"Acknowledgement": "5 Evaluation Transparency Document Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Renal-clearance-parameters-for-PBPK-model-analysis-of-_2008_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18433959", "content": {"Acknowledgement": "Summary Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Renal-histopathology-in-toxicity-and-carcinogenicity-studi_2011_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21296119", "content": {"CoiStatement": "There was unanimous agreement among the members of this independent PWG that both a2u-g nephropathy and CPN exacerba- tion were the only causative factors in the development of renal tu- bule tumors observed in male rats exposed to TBA in drinking water. As neither of these modes of action have human counter- parts, the PWG concluded that TBA-related renal changes in rats could not be extrapolated for human health risk assessment, and were unlikely to pose any risk for humans. 6. Conflict of interest statement Of the five authors, only Dr. Gordon Hard has consulted previ- ously for Lyondell Chemical Company regarding TBA. He also re- ceived compensation for preparing this manuscript. Acknowledgements Conclusions Conflict of interest statement Acknowledgements References", "Acknowledgement": "Of the five authors, only Dr. Gordon Hard has consulted previ- ously for Lyondell Chemical Company regarding TBA. He also re- ceived compensation for preparing this manuscript. Acknowledgements The authors acknowledge the cooperation of the National Tox- icology Program (NTP) in providing access to the kidney slides, and to Experimental Pathology Laboratories (EPL), Research Trian- gle Park, NC, the managers of the NTP pathology Archives, for their assistance. The authors also thank Emily Singletary of EPL for her expert assistance with photography. The PWG was sponsored by Lyondell Chemical Company, a LyondellBasell company, Houston, TX. The contents of this manuscript were strictly those contributed by the PWG members. References Conclusions Conflict of interest statement Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Repeated-dose--14days--rat-intramuscular-toxico_2012_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23085371", "content": {"CoiStatement": "Conflict of interest statement The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgment 4 Discussion Conflict of interest statement Acknowledgment References", "Acknowledgement": "Acknowledgment The authors wish to thank Niurka Baez Alayo for her assistance in revision of English language and grammar of this manuscript. 4 Discussion Conflict of interest statement Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Repeated-dose-28-day-oral-toxicity-study-of-DEAE-Dex_2017_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28694171", "content": {"CoiStatement": "Conflicts of interest The authors state that there are no conflicts of interest per- taining to this manuscript. The authors state that there are no conflicts of interest per- taining to this manuscript. Acknowledgment 4. Discussion 5. Conclusion Conflicts of interest Acknowledgment Transparency document References", "Funding": "The authors would like to acknowledge the funding provided by Institute of Pharmacy, Nirma University in the form of Ph.D A.K. Bakrania et al. / Regulatory Toxicology and Pharmacology 88 (2017) 262e272272 contigency. Also, we would like to offer our sincere gratitude and humble thanks to Dr. Prem Madan, MD Pathologist (Sukoon Labo- ratory, Ahmedabad, India) for the assistance in the analysis of the histopathology samples.", "Acknowledgement": "Acknowledgment The authors would like to acknowledge the funding provided by Institute of Pharmacy, Nirma University in the form of Ph.D 4. Discussion 5. Conclusion Conflicts of interest Acknowledgment Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Repeated-dose-28-day-oral-toxicity-study-of-a-botanic_2018_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29407201", "content": {"Disclosure": "Author disclosure statement All authors are current Unigen Inc. and therefore have competing financial interests. Discussion Financial support Author disclosure statement Acknowledgments Transparency document References", "Acknowledgement": "Acknowledgments The authors would like to express their best gratitude to Drs. Wenwen Ma, Min Chu, Eujin Hyun and Unigen team for their countless support for the completion of this study. Discussion Financial support Author disclosure statement Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Repeated-dose-90-day-oral-toxicity-test-of-G-7--NANA-in-r_2018_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29574194", "content": {"Acknowledgement": "Acknowledgments This study was performed as supported by 2016 Project to cultivate professionals for the management of information on the hazards and risks of chemical substances assisted by the Ministry of Environment and Hanil Bio Med Inc. and we thank you for their support. Discussion Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Repeated-oral-dose-toxicity-study-on-hydrolysable-tannin_2018_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29233773", "content": {"Funding": "The authors gratefully acknowledge DST-SERB, New Delhi, India for funding this research work under Start up research Grant No. SB/YS/ LS-95/2014. Transparency document", "Acknowledgement": "Acknowledgements The authors gratefully acknowledge DST-SERB, New Delhi, India for funding this research work under Start up research Grant No. SB/YS/ LS-95/2014. Discussion Conclusion Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Repeated-sub-chronic-oral-toxicity-study-of-xylo_2017_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28428020", "content": {"CoiStatement": "Conflict of interest The authors declare that they have no conflicts of interest. The authors declare that they have no conflicts of interest. Acknowledgements 4. Discussion Conflict of interest Acknowledgements Appendix A. Supplementary data References", "Acknowledgement": "Acknowledgements This work was financially supported by Shandong LongLive Bio- technology Co.,Ltd, (NO.LL10233). 4. Discussion Conflict of interest Acknowledgements Appendix A. Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Replacement-of-in-vivo-acute-oral-toxicity-studies-by-_2008_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18362045", "content": {"Compliance with ethical standards": "- to provide and assure safe and ethical medicines, - to maintain regulatory compliance, - to achieve fast development and market authorization, - to economize costs, - to consider animal protection. In light of the given conditions of drug development and because of the above described interests, new approaches are progressing in different phases of drug development that allow for more efficient, yet safe procedures. One pos- sible way to economize time and costs, as well as to address animal protection, is to introduce alternative methods into non-clinical safety testing."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Replacing-the-refinement-for-skin-sensitization-testing--C_2020_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32562760", "content": {"CoiStatement": "Three test methods addressing the first three KE of the skin sensi- tization AOP have been available for a decade and were eventually captured in OECD TGs 442C, D and E; meanwhile additional methods addressing the same KEs have been added. Several DA (listed as case studies by the OECD, see Table 1 and (Kleinstreuer et al., 2018)) have been developed using these methods. The first DA (OECD Guidance Document no. 256, Annex 1, Table 1, no. 1) was submitted to EURobert Landsiedel- ECVAM in 2011. Both, the methods and have been thoroughly vali- dated, published in the peer-reviewed literature and scrutinized for their applicability and limitations ((Leontaridou et al., 2019; Nukada et al., 2012; Urbisch et al., 2015). DA no. 1 as well as others have de- monstrated to predict human data as good as - if not better than - the in vivo refinement method, the LLNA (Urbisch et al., 2015; Zuang et al., 2017). Most importantly, no major human sensitizer according to clinical data was missed. This DA fulfills the criteria of the of REACH Information Requirements (Guidance on Information requirements chapter 7a (ECHA, 2017),) and has been explicitly endorsed by US-EPA (Daniel et al., 2018; Strickland et al., 2019). It has been used by in- dustry for regulatory submissions and internal screenings for almost a decade. We should acknowledge this extraordinarily meticulous method development and validation and its long-standing successful use in toxicological practice. An OECD DA guideline should consider well proven practice. 2. A plea for a rational approach to implement AOP-based DA into guidelines In today's light, the development of the methods and the DA is not ideal: The methods and prediction models were developed in- dependently of each other and the DA were defined post hoc. Consequently, the methods do not fit ideally, and the DA could only be defined based on the existing methods. This calls for a different process in the future by pre-defining DA and then developing fitting methods accordingly (Burgdorf et al., 2019; Piersma et al., 2018; Thomas et al., 2018). The validation of the DA should include a well curated reference data set as well as considering the borderline ranges of the evaluated and reference methods. In this respect, none of the DA listed as OECD case studies (Table 1: An overview of the defined approaches) is ideal. It would be advisable to take care that future DA developments are ad- hering to the standards depicted above (including the referenced pa- pers). Almost a decade has now passed since the first DA was developed and submitted for regulatory acceptance. Obviously, it is taking a long time to implement DA in an OECD guideline. During this time the (then new) approach has been used and has contributed to the reduction of animal testing despite the lack of its complete regulatory implementa- tion. The early movers certainly had wished for this to be faster. Yet, there is still work to do. We must not compromise to just to get it somehow done: We should neither base the assessment of the DA on skewed reference data nor sacrifice an accepted and well-proven DA,. The implementation of DA in an OECD guideline is an important milestone of bringing NAM into regulatory use, we must have the courage to take this step and we ought to do it right. Funding body information This work received no external funding. Funding was provided by BASF SE and Givaudan SA for Susanne N Kolle, Robert Landsiedel and Andreas Natsch, respectively. Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Susanne N Kolle and Robert Landsiedel are employees of BASF SE and Andreas Natsch is employee of Givaudan SA, both companies use the described DA to develop and register sub- stances. Appendix A. Supplementary data Supplementary data to this article can be found online at https:// doi.org/10.1016/j.yrtph.2020.104713. References Basketter, D., Azam, P., Casati, S., et al., 2019. Applying non-animal strategies for as- sessing skin sensitisation report from an EPAA/cefic-LRI/IFRA Europe cross sector workshop, ECHA helsinki, February 7th and 8th 2019. Regul. Toxicol. Pharmacol. 109, 104477. https://doi.org/10.1016/j.yrtph.2019.104477. Basketter, D.A., Alepee, N., Ashikaga, T., et al., 2014. Categorization of chemicals ac- cording to their relative human skin sensitizing potency. Dermatitis 25 (1), 11\u201321. https://doi.org/10.1097/DER.0000000000000003. Bauch, C., Kolle, S.N., Ramirez, T., et al., 2012. Putting the parts together: combining in vitro methods to test for skin sensitizing potentials. Regul. Toxicol. Pharmacol. 63 (3), 489\u2013504. https://doi.org/10.1016/j.yrtph.2012.05.013. Burgdorf, T., Piersma, A.H., Landsiedel, R., et al., 2019. Workshop on the validation and regulatory acceptance of innovative 3R approaches in regulatory toxicology - evo- lution versus revolution. Toxicol. Vitro 59, 1\u201311. https://doi.org/10.1016/j.tiv.2019. 03.039. Casati, S., Aschberger, K., Barroso, J., et al., 2018. Standardisation of defined approaches for skin sensitisation testing to support regulatory use and international adoption: position of the International Cooperation on Alternative Test Methods. Arch. Toxicol. 92 (2), 611\u2013617. https://doi.org/10.1007/s00204-017-2097-4. Daniel, A.B., Strickland, J., Allen, D., et al., 2018. International regulatory requirements for skin sensitization testing. Regul. Toxicol. Pharmacol. 95, 52\u201365. https://doi.org/ 10.1016/j.yrtph.2018.03.003. ECHA, 2016. Practical Guide How to Use and Report (Q)SAR. ECHA, 2017. Guidance on Information Requirements and Chemical Safety Assessment Chapter R.7a: Endpoint Specific Guidance. Emter, R., Ellis, G., Natsch, A., 2010. Performance of a novel keratinocyte-based reporter cell line to screen skin sensitizers in vitro. Toxicol. Appl. Pharmacol. 245, 281\u2013290. https://doi.org/10.1016/j.taap.2010.03.009. EPA, 2018. Interim Science Policy: Use of Alternative Approaches for Skin Sensitization as a Replacement for Laboratory Animal Testing. Eskes, C., 2019. The usefulness of integrated strategy approaches in replacing animal experimentation. Ann. Istituto Super. Sanita 55 (4), 400\u2013404. https://doi.org/10. 4415/ann_19_04_16. Haneke, K.E., Tice, R.R., Carson, B.L., Margolin, B.H., Stokes, W.S., 2001. ICCVAM eva- luation of the murine local lymph node assay. Data analyses completed by the na- tional toxicology program interagency center for the evaluation of alternative tox- icological methods. Regul. Toxicol. Pharmacol. 34 (3), 274\u2013286. https://doi.org/10. 1006/rtph.2001.1498. Hoffmann, S., Kleinstreuer, N., Alepee, N., et al., 2018. Non-animal methods to predict skin sensitization (I): the Cosmetics Europe database< sup/> Crit. Rev. Toxicol. 48 (5), 344\u2013358. https://doi.org/10.1080/10408444.2018.1429385. Kleinstreuer, N.C., Hoffmann, S., Alepee, N., et al., 2018. Non-animal methods to predict skin sensitization (II): an assessment of defined approaches (*). Crit. Rev. Toxicol. 48 (5), 359\u2013374. https://doi.org/10.1080/10408444.2018.1429386. S.N. Kolle, et al. Regulatory Toxicology and Pharmacology 115 (2020) 104713 5 https://doi.org/10.1016/j.yrtph.2020.104713 https://doi.org/10.1016/j.yrtph.2020.104713 https://doi.org/10.1016/j.yrtph.2019.104477 https://doi.org/10.1097/DER.0000000000000003 https://doi.org/10.1016/j.yrtph.2012.05.013 https://doi.org/10.1016/j.tiv.2019.03.039 https://doi.org/10.1016/j.tiv.2019.03.039 https://doi.org/10.1007/s00204-017-2097-4 https://doi.org/10.1016/j.yrtph.2018.03.003 https://doi.org/10.1016/j.yrtph.2018.03.003 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref9 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref10 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref10 https://doi.org/10.1016/j.taap.2010.03.009 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref12 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref12 https://doi.org/10.4415/ann_19_04_16 https://doi.org/10.4415/ann_19_04_16 https://doi.org/10.1006/rtph.2001.1498 https://doi.org/10.1006/rtph.2001.1498 https://doi.org/10.1080/10408444.2018.1429385 https://doi.org/10.1080/10408444.2018.1429386 Lalla, S.C., Nguyen, H., Chaudhry, H., et al., 2018. Patch testing to propylene glycol: the mayo clinic experience. Dermatitis 29 (4), 200\u2013205. https://doi.org/10.1097/DER. 0000000000000393. Leontaridou, M., Gabbert, S., Landsiedel, R., 2019. The impact of precision uncertainty on predictive accuracy metrics of non-animal testing methods. ALTEX 36 (3), 435\u2013446. https://doi.org/10.14573/altex.1810111. Nukada, Y., Ashikaga, T., Miyazawa, M., et al., 2012. Prediction of skin sensitization potency of chemicals by human Cell Line Activation Test (h-CLAT) and an attempt at classifying skin sensitization potency. Toxicol. Vitro 26 (7), 1150\u20131160. https://doi. org/10.1016/j.tiv.2012.07.001. Nukada, Y., Miyazawa, M., Kazutoshi, S., Sakaguchi, H., Nishiyama, N., 2013. Data in- tegration of non-animal tests for the development of a test battery to predict the skin sensitizing potential and potency of chemicals. Toxicol. Vitro 27 (2), 609\u2013618. https://doi.org/10.1016/j.tiv.2012.11.006. OECD, 2007. Guidance Document on the Validation of (Quantitative) Structure-Activity Relationship [(Q)SAR] Models. OECD, 2012. The Adverse Outcome Pathway for Skin Sensitisation Initiated by Covalent Binding to Proteins. OECD, 2016. Guidance Document on the Reporting of Defined Approaches and Individual Information Sources to Be Used within Integrated Approaches to Testing and Assessment (IATA) for Skin Sensitisation. OECD, 2016. Guidance Document on the Reporting of Defined Approaches to Be Used within Integrated Approaches to Testing and Assessment. OECD, 2018. Test No. 442D. In: Vitro Skin Sensitisation. OECD, 2018b. Test No. 442E. In: Vitro Skin Sensitisation. OECD, 2019. Draft Guideline for Defined Approaches for Skin Sensitisation. http://www. oecd.org/env/ehs/testing/GL%20DASS_22Sep2019v2.pdf. OECD, 2019. Draft Supporting Document for Defined Approaches for Skin Sensitisation. http://www.oecd.org/env/ehs/testing/DAGL%20supporting%20document_23% 20Sep2019.pd. OECD, 2019. Test No. 442C. In: Chemico Skin Sensitisation. Piersma, A.H., Burgdorf, T., Louekari, K., et al., 2018. Workshop on acceleration of the validation and regulatory acceptance of alternative methods and implementation of testing strategies. Toxicol. Vitro 50, 62\u201374. https://doi.org/10.1016/j.tiv.2018.02. 018. Sauer, U.G., Hill, E.H., Curren, R.D., et al., 2016. Local tolerance testing under REACH: accepted non-animal methods are not on equal footing with animal tests. Altern. Lab. Anim. 44 (3), 281\u2013299. https://doi.org/10.1177/026119291604400311. Schnuch, A., Mildau, G., Kratz, E.M., Uter, W., 2011. Risk of sensitization to preservatives estimated on the basis of patch test data and exposure, according to a sample of 3541 leave-on products. Contact Dermatitis 65 (3), 167\u2013174. https://doi.org/10.1111/j. 1600-0536.2011.01939.x. Schnuch, A., Uter, W., Lessmann, H., Geier, J., 2015. Risk of sensitization to fragrances estimated on the basis of patch test data and exposure, according to volume used and a sample of 5451 cosmetic products. Flavour Fragrance J. 30 (3), 208\u2013217. https:// doi.org/10.1002/ffj.3241. Strickland, J., Daniel, A.B., Allen, D., et al., 2019. Skin sensitization testing needs and data uses by US regulatory and research agencies. Arch. Toxicol. 93 (2), 273\u2013291. https://doi.org/10.1007/s00204-018-2341-6. Takenouchi, O., Fukui, S., Okamoto, K., et al., 2015. Test battery with the human cell line activation test, direct peptide reactivity assay and DEREK based on a 139 chemical data set for predicting skin sensitizing potential and potency of chemicals. J. Appl. Toxicol. 35 (11), 1318\u20131332. https://doi.org/10.1002/jat.3127. Thomas, R.S., Paules, R.S., Simeonov, A., et al., 2018. The US Federal Tox21 Program: a strategic and operational plan for continued leadership. ALTEX 35 (2), 163\u2013168. https://doi.org/10.14573/altex.1803011. Urbisch, D., Mehling, A., Guth, K., et al., 2015. Assessing skin sensitization hazard in mice and men using non-animal test methods. Regul. Toxicol. Pharmacol. 71 (2), 337\u2013351. https://doi.org/10.1016/j.yrtph.2014.12.008. Wareing, B., Urbisch, D., Kolle, S.N., et al., 2017. Prediction of skin sensitization potency sub-categories using peptide reactivity data. Toxicol. Vitro 45 (Pt 1), 134\u2013145. https://doi.org/10.1016/j.tiv.2017.08.015. Zuang, V., Barroso, J., Belz, S., et al., 2017. EURobert Landsiedel ECVAM Status Report on the Development, Validation and Regulatory Acceptance of Alternative Methods and Approaches (2017). S.N. Kolle, et al. Regulatory Toxicology and Pharmacology 115 (2020) 104713 6 https://doi.org/10.1097/DER.0000000000000393 https://doi.org/10.1097/DER.0000000000000393 https://doi.org/10.14573/altex.1810111 https://doi.org/10.1016/j.tiv.2012.07.001 https://doi.org/10.1016/j.tiv.2012.07.001 https://doi.org/10.1016/j.tiv.2012.11.006 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref22 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref22 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref23 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref23 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref24 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref24 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref24 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref25 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref25 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref26 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref27 http://www.oecd.org/env/ehs/testing/GL%20DASS_22Sep2019v2.pdf http://www.oecd.org/env/ehs/testing/GL%20DASS_22Sep2019v2.pdf http://www.oecd.org/env/ehs/testing/DAGL%20supporting%20document_23%20Sep2019.pd http://www.oecd.org/env/ehs/testing/DAGL%20supporting%20document_23%20Sep2019.pd http://refhub.elsevier.com/S0273-2300(20)30139-2/sref30 https://doi.org/10.1016/j.tiv.2018.02.018 https://doi.org/10.1016/j.tiv.2018.02.018 https://doi.org/10.1177/026119291604400311 https://doi.org/10.1111/j.1600-0536.2011.01939.x https://doi.org/10.1111/j.1600-0536.2011.01939.x https://doi.org/10.1002/ffj.3241 https://doi.org/10.1002/ffj.3241 https://doi.org/10.1007/s00204-018-2341-6 https://doi.org/10.1002/jat.3127 https://doi.org/10.14573/altex.1803011 https://doi.org/10.1016/j.yrtph.2014.12.008 https://doi.org/10.1016/j.tiv.2017.08.015 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref40 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref40 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref40 Replacing the refinement for skin sensitization testing: Considerations to the implementation of adverse outcome pathway (AOP)-based defined approaches (DA) in OECD guidelines Introduction The reference data and the reference endpoint should be selected to allow meaningful evaluation Methods and prediction models of OECD endorsed DA should be validated An OECD-adopted DA should be AOP-based and should be consistent with existing OECD test guidelines An OECD-adopted DA should acknowledge regulatory needs and successful toxicological practice A plea for a rational approach to implement AOP-based DA into guidelines Funding body information Declaration of competing interest Supplementary data References", "Funding": "Three test methods addressing the first three KE of the skin sensi- tization AOP have been available for a decade and were eventually captured in OECD TGs 442C, D and E; meanwhile additional methods addressing the same KEs have been added. Several DA (listed as case studies by the OECD, see Table 1 and (Kleinstreuer et al., 2018)) have been developed using these methods. The first DA (OECD Guidance Document no. 256, Annex 1, Table 1, no. 1) was submitted to EURobert Landsiedel- ECVAM in 2011. Both, the methods and have been thoroughly vali- dated, published in the peer-reviewed literature and scrutinized for their applicability and limitations ((Leontaridou et al., 2019; Nukada et al., 2012; Urbisch et al., 2015). DA no. 1 as well as others have de- monstrated to predict human data as good as - if not better than - the in vivo refinement method, the LLNA (Urbisch et al., 2015; Zuang et al., 2017). Most importantly, no major human sensitizer according to clinical data was missed. This DA fulfills the criteria of the of REACH Information Requirements (Guidance on Information requirements chapter 7a (ECHA, 2017),) and has been explicitly endorsed by US-EPA (Daniel et al., 2018; Strickland et al., 2019). It has been used by in- dustry for regulatory submissions and internal screenings for almost a decade. We should acknowledge this extraordinarily meticulous method development and validation and its long-standing successful use in toxicological practice. An OECD DA guideline should consider well proven practice. 2. A plea for a rational approach to implement AOP-based DA into guidelines In today's light, the development of the methods and the DA is not ideal: The methods and prediction models were developed in- dependently of each other and the DA were defined post hoc. Consequently, the methods do not fit ideally, and the DA could only be defined based on the existing methods. This calls for a different process in the future by pre-defining DA and then developing fitting methods accordingly (Burgdorf et al., 2019; Piersma et al., 2018; Thomas et al., 2018). The validation of the DA should include a well curated reference data set as well as considering the borderline ranges of the evaluated and reference methods. In this respect, none of the DA listed as OECD case studies (Table 1: An overview of the defined approaches) is ideal. It would be advisable to take care that future DA developments are ad- hering to the standards depicted above (including the referenced pa- pers). Almost a decade has now passed since the first DA was developed and submitted for regulatory acceptance. Obviously, it is taking a long time to implement DA in an OECD guideline. During this time the (then new) approach has been used and has contributed to the reduction of animal testing despite the lack of its complete regulatory implementa- tion. The early movers certainly had wished for this to be faster. Yet, there is still work to do. We must not compromise to just to get it somehow done: We should neither base the assessment of the DA on skewed reference data nor sacrifice an accepted and well-proven DA,. The implementation of DA in an OECD guideline is an important milestone of bringing NAM into regulatory use, we must have the courage to take this step and we ought to do it right. Funding body information This work received no external funding. Funding was provided by BASF SE and Givaudan SA for Susanne N Kolle, Robert Landsiedel and Andreas Natsch, respectively. Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Susanne N Kolle and Robert Landsiedel are employees of BASF SE and Andreas Natsch is employee of Givaudan SA, both companies use the described DA to develop and register sub- stances. Appendix A. Supplementary data Supplementary data to this article can be found online at https:// doi.org/10.1016/j.yrtph.2020.104713. References Basketter, D., Azam, P., Casati, S., et al., 2019. Applying non-animal strategies for as- sessing skin sensitisation report from an EPAA/cefic-LRI/IFRA Europe cross sector workshop, ECHA helsinki, February 7th and 8th 2019. Regul. Toxicol. Pharmacol. 109, 104477. https://doi.org/10.1016/j.yrtph.2019.104477. Basketter, D.A., Alepee, N., Ashikaga, T., et al., 2014. Categorization of chemicals ac- cording to their relative human skin sensitizing potency. Dermatitis 25 (1), 11\u201321. https://doi.org/10.1097/DER.0000000000000003. Bauch, C., Kolle, S.N., Ramirez, T., et al., 2012. Putting the parts together: combining in vitro methods to test for skin sensitizing potentials. Regul. Toxicol. Pharmacol. 63 (3), 489\u2013504. https://doi.org/10.1016/j.yrtph.2012.05.013. Burgdorf, T., Piersma, A.H., Landsiedel, R., et al., 2019. Workshop on the validation and regulatory acceptance of innovative 3R approaches in regulatory toxicology - evo- lution versus revolution. Toxicol. Vitro 59, 1\u201311. https://doi.org/10.1016/j.tiv.2019. 03.039. Casati, S., Aschberger, K., Barroso, J., et al., 2018. Standardisation of defined approaches for skin sensitisation testing to support regulatory use and international adoption: position of the International Cooperation on Alternative Test Methods. Arch. Toxicol. 92 (2), 611\u2013617. https://doi.org/10.1007/s00204-017-2097-4. Daniel, A.B., Strickland, J., Allen, D., et al., 2018. International regulatory requirements for skin sensitization testing. Regul. Toxicol. Pharmacol. 95, 52\u201365. https://doi.org/ 10.1016/j.yrtph.2018.03.003. ECHA, 2016. Practical Guide How to Use and Report (Q)SAR. ECHA, 2017. Guidance on Information Requirements and Chemical Safety Assessment Chapter R.7a: Endpoint Specific Guidance. Emter, R., Ellis, G., Natsch, A., 2010. Performance of a novel keratinocyte-based reporter cell line to screen skin sensitizers in vitro. Toxicol. Appl. Pharmacol. 245, 281\u2013290. https://doi.org/10.1016/j.taap.2010.03.009. EPA, 2018. Interim Science Policy: Use of Alternative Approaches for Skin Sensitization as a Replacement for Laboratory Animal Testing. Eskes, C., 2019. The usefulness of integrated strategy approaches in replacing animal experimentation. Ann. Istituto Super. Sanita 55 (4), 400\u2013404. https://doi.org/10. 4415/ann_19_04_16. Haneke, K.E., Tice, R.R., Carson, B.L., Margolin, B.H., Stokes, W.S., 2001. ICCVAM eva- luation of the murine local lymph node assay. Data analyses completed by the na- tional toxicology program interagency center for the evaluation of alternative tox- icological methods. Regul. Toxicol. Pharmacol. 34 (3), 274\u2013286. https://doi.org/10. 1006/rtph.2001.1498. Hoffmann, S., Kleinstreuer, N., Alepee, N., et al., 2018. Non-animal methods to predict skin sensitization (I): the Cosmetics Europe database< sup/> Crit. Rev. Toxicol. 48 (5), 344\u2013358. https://doi.org/10.1080/10408444.2018.1429385. Kleinstreuer, N.C., Hoffmann, S., Alepee, N., et al., 2018. Non-animal methods to predict skin sensitization (II): an assessment of defined approaches (*). Crit. Rev. Toxicol. 48 (5), 359\u2013374. https://doi.org/10.1080/10408444.2018.1429386. S.N. Kolle, et al. Regulatory Toxicology and Pharmacology 115 (2020) 104713 5 https://doi.org/10.1016/j.yrtph.2020.104713 https://doi.org/10.1016/j.yrtph.2020.104713 https://doi.org/10.1016/j.yrtph.2019.104477 https://doi.org/10.1097/DER.0000000000000003 https://doi.org/10.1016/j.yrtph.2012.05.013 https://doi.org/10.1016/j.tiv.2019.03.039 https://doi.org/10.1016/j.tiv.2019.03.039 https://doi.org/10.1007/s00204-017-2097-4 https://doi.org/10.1016/j.yrtph.2018.03.003 https://doi.org/10.1016/j.yrtph.2018.03.003 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref9 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref10 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref10 https://doi.org/10.1016/j.taap.2010.03.009 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref12 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref12 https://doi.org/10.4415/ann_19_04_16 https://doi.org/10.4415/ann_19_04_16 https://doi.org/10.1006/rtph.2001.1498 https://doi.org/10.1006/rtph.2001.1498 https://doi.org/10.1080/10408444.2018.1429385 https://doi.org/10.1080/10408444.2018.1429386 Lalla, S.C., Nguyen, H., Chaudhry, H., et al., 2018. Patch testing to propylene glycol: the mayo clinic experience. Dermatitis 29 (4), 200\u2013205. https://doi.org/10.1097/DER. 0000000000000393. Leontaridou, M., Gabbert, S., Landsiedel, R., 2019. The impact of precision uncertainty on predictive accuracy metrics of non-animal testing methods. ALTEX 36 (3), 435\u2013446. https://doi.org/10.14573/altex.1810111. Nukada, Y., Ashikaga, T., Miyazawa, M., et al., 2012. Prediction of skin sensitization potency of chemicals by human Cell Line Activation Test (h-CLAT) and an attempt at classifying skin sensitization potency. Toxicol. Vitro 26 (7), 1150\u20131160. https://doi. org/10.1016/j.tiv.2012.07.001. Nukada, Y., Miyazawa, M., Kazutoshi, S., Sakaguchi, H., Nishiyama, N., 2013. Data in- tegration of non-animal tests for the development of a test battery to predict the skin sensitizing potential and potency of chemicals. Toxicol. Vitro 27 (2), 609\u2013618. https://doi.org/10.1016/j.tiv.2012.11.006. OECD, 2007. Guidance Document on the Validation of (Quantitative) Structure-Activity Relationship [(Q)SAR] Models. OECD, 2012. The Adverse Outcome Pathway for Skin Sensitisation Initiated by Covalent Binding to Proteins. OECD, 2016. Guidance Document on the Reporting of Defined Approaches and Individual Information Sources to Be Used within Integrated Approaches to Testing and Assessment (IATA) for Skin Sensitisation. OECD, 2016. Guidance Document on the Reporting of Defined Approaches to Be Used within Integrated Approaches to Testing and Assessment. OECD, 2018. Test No. 442D. In: Vitro Skin Sensitisation. OECD, 2018b. Test No. 442E. In: Vitro Skin Sensitisation. OECD, 2019. Draft Guideline for Defined Approaches for Skin Sensitisation. http://www. oecd.org/env/ehs/testing/GL%20DASS_22Sep2019v2.pdf. OECD, 2019. Draft Supporting Document for Defined Approaches for Skin Sensitisation. http://www.oecd.org/env/ehs/testing/DAGL%20supporting%20document_23% 20Sep2019.pd. OECD, 2019. Test No. 442C. In: Chemico Skin Sensitisation. Piersma, A.H., Burgdorf, T., Louekari, K., et al., 2018. Workshop on acceleration of the validation and regulatory acceptance of alternative methods and implementation of testing strategies. Toxicol. Vitro 50, 62\u201374. https://doi.org/10.1016/j.tiv.2018.02. 018. Sauer, U.G., Hill, E.H., Curren, R.D., et al., 2016. Local tolerance testing under REACH: accepted non-animal methods are not on equal footing with animal tests. Altern. Lab. Anim. 44 (3), 281\u2013299. https://doi.org/10.1177/026119291604400311. Schnuch, A., Mildau, G., Kratz, E.M., Uter, W., 2011. Risk of sensitization to preservatives estimated on the basis of patch test data and exposure, according to a sample of 3541 leave-on products. Contact Dermatitis 65 (3), 167\u2013174. https://doi.org/10.1111/j. 1600-0536.2011.01939.x. Schnuch, A., Uter, W., Lessmann, H., Geier, J., 2015. Risk of sensitization to fragrances estimated on the basis of patch test data and exposure, according to volume used and a sample of 5451 cosmetic products. Flavour Fragrance J. 30 (3), 208\u2013217. https:// doi.org/10.1002/ffj.3241. Strickland, J., Daniel, A.B., Allen, D., et al., 2019. Skin sensitization testing needs and data uses by US regulatory and research agencies. Arch. Toxicol. 93 (2), 273\u2013291. https://doi.org/10.1007/s00204-018-2341-6. Takenouchi, O., Fukui, S., Okamoto, K., et al., 2015. Test battery with the human cell line activation test, direct peptide reactivity assay and DEREK based on a 139 chemical data set for predicting skin sensitizing potential and potency of chemicals. J. Appl. Toxicol. 35 (11), 1318\u20131332. https://doi.org/10.1002/jat.3127. Thomas, R.S., Paules, R.S., Simeonov, A., et al., 2018. The US Federal Tox21 Program: a strategic and operational plan for continued leadership. ALTEX 35 (2), 163\u2013168. https://doi.org/10.14573/altex.1803011. Urbisch, D., Mehling, A., Guth, K., et al., 2015. Assessing skin sensitization hazard in mice and men using non-animal test methods. Regul. Toxicol. Pharmacol. 71 (2), 337\u2013351. https://doi.org/10.1016/j.yrtph.2014.12.008. Wareing, B., Urbisch, D., Kolle, S.N., et al., 2017. Prediction of skin sensitization potency sub-categories using peptide reactivity data. Toxicol. Vitro 45 (Pt 1), 134\u2013145. https://doi.org/10.1016/j.tiv.2017.08.015. Zuang, V., Barroso, J., Belz, S., et al., 2017. EURobert Landsiedel ECVAM Status Report on the Development, Validation and Regulatory Acceptance of Alternative Methods and Approaches (2017). S.N. Kolle, et al. Regulatory Toxicology and Pharmacology 115 (2020) 104713 6 https://doi.org/10.1097/DER.0000000000000393 https://doi.org/10.1097/DER.0000000000000393 https://doi.org/10.14573/altex.1810111 https://doi.org/10.1016/j.tiv.2012.07.001 https://doi.org/10.1016/j.tiv.2012.07.001 https://doi.org/10.1016/j.tiv.2012.11.006 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref22 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref22 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref23 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref23 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref24 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref24 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref24 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref25 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref25 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref26 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref27 http://www.oecd.org/env/ehs/testing/GL%20DASS_22Sep2019v2.pdf http://www.oecd.org/env/ehs/testing/GL%20DASS_22Sep2019v2.pdf http://www.oecd.org/env/ehs/testing/DAGL%20supporting%20document_23%20Sep2019.pd http://www.oecd.org/env/ehs/testing/DAGL%20supporting%20document_23%20Sep2019.pd http://refhub.elsevier.com/S0273-2300(20)30139-2/sref30 https://doi.org/10.1016/j.tiv.2018.02.018 https://doi.org/10.1016/j.tiv.2018.02.018 https://doi.org/10.1177/026119291604400311 https://doi.org/10.1111/j.1600-0536.2011.01939.x https://doi.org/10.1111/j.1600-0536.2011.01939.x https://doi.org/10.1002/ffj.3241 https://doi.org/10.1002/ffj.3241 https://doi.org/10.1007/s00204-018-2341-6 https://doi.org/10.1002/jat.3127 https://doi.org/10.14573/altex.1803011 https://doi.org/10.1016/j.yrtph.2014.12.008 https://doi.org/10.1016/j.tiv.2017.08.015 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref40 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref40 http://refhub.elsevier.com/S0273-2300(20)30139-2/sref40 Replacing the refinement for skin sensitization testing: Considerations to the implementation of adverse outcome pathway (AOP)-based defined approaches (DA) in OECD guidelines Introduction The reference data and the reference endpoint should be selected to allow meaningful evaluation Methods and prediction models of OECD endorsed DA should be validated An OECD-adopted DA should be AOP-based and should be consistent with existing OECD test guidelines An OECD-adopted DA should acknowledge regulatory needs and successful toxicological practice A plea for a rational approach to implement AOP-based DA into guidelines Funding body information Declaration of competing interest Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Repolarization-studies-using-human-stem-cell-derived-c_2020_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32822771", "content": {"CoiStatement": "6 Summary Additional note Disclaimers Funding body information Declaration of competing interest Appendix Drug names linked to numbers in JiCSA study results graphic References", "Funding": "6 Summary Additional note Disclaimers Funding body information Declaration of competing interest Appendix Drug names linked to numbers in JiCSA study results graphic References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Report-of-an-ISRTP-Workshop--Progress-and-barriers-to_2006_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16876299", "content": {"Funding": "Economic/Wnancial \u2022 Research on alternative methods is diverse, encompasses many diVerent disciplines, and is catalyzed by a broad spectrum of objectives. Research with speciWc focus on development and standardization and validation of alternative methods is rarely a priority for government funding. \u2022 Individuals and organizations need to maintain and coordinate advocacy initiatives that target responsible agencies to promote focused research on validating and implementing alternative methods. \u2022 Although much academic research focuses on in vitro methodologies, because funding for research speciWcally focused on standardization and validation of alternative methods for regulatory use is atypical, academic involvement is generally lacking. Regulatory/policy \u2022 There is a low level of comfort or acceptance of alternative assays in both the regulatory and regulated communities. Considerable eVorts are needed to overcome the inertia to maintain the status quo. The issue of funding in the U.S. for alternatives methods was also discussed. The panel concluded that, at present, funding sources for this area are unclear, both within spe- ciWc agencies and across the federal government as a whole. There is a need for a leadership within the federal programs to develop both overarching and speciWc objectives and to develop and implement a process to identify priorities, link these to program plans and resource these eVorts suY- ciently. Objectives and resources must address eVorts to carry methods from development all the way through vali- dation. Rowan, for example, citing the notable advances in molecular biology and genomics, proposed the time has come to consider a well funded, coordinated and acceler- ated program (similar to the Human Genome Project) to develop molecular biological approaches to human health and environmental risk assessment The panel also expressed the opinion that current regu- latory frameworks are too rigid to allow the substitution of validated alternative methods. To a certain extent, the rigidity is provided by current law and guidelines, and fur- thered by the fact that regulators and the regulated commu- nity are uncomfortable in changing the structured framework. However, the panel felt that Xexibility is needed in several spheres, including Xexibility to consider employ- ment of alternatives for speciWc uses, and not solely as entire or full replacement of an assay for all situations and substances. This workshop was endorsed by the Society of Toxicol- ogy and funding was provided by The Proctor & Gamble Company, the National Institute of Environmental Health Sciences/National Toxicology Program, the American Chemistry Council, the Cosmetic, Toiletry, and Fragrance Association, the Dow Chemical Company, the United States Army Edgewood Chemical Biological Center, Yves Rocher North America, Inc., the Humane Society of the United States, and the Doris Day Animal League. http://ntp.niehs.nih.gov/go/vision http://ntp.niehs.nih.gov/go/vision", "Acknowledgement": "Acknowledgments This workshop was endorsed by the Society of Toxicol- ogy and funding was provided by The Proctor & Gamble Company, the National Institute of Environmental Health Sciences/National Toxicology Program, the American Chemistry Council, the Cosmetic, Toiletry, and Fragrance Association, the Dow Chemical Company, the United States Army Edgewood Chemical Biological Center, Yves Rocher North America, Inc., the Humane Society of the United States, and the Doris Day Animal League. Report of an ISRTP Workshop: Progress and barriers to incorporating alternative toxicological methods in the U.S. Acknowledgments"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Report-on-investigation-of-ISO-10993-12-extr_2022_Regulatory-Toxicology-and-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/35381323", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Theodore Heise reports a relationship with MED Institute that in- cludes: employment. 4 Discussion 5 Conclusion Disclaimer Funding Body Information CRediT authorship contribution statement Declaration of competing interest Acknowledgements References", "Funding": "Given the intrinsic differences in the study as implemented by the labs, further investigation of the results is unlikely to be worthwhile. Future efforts, before any additional round robin studies are undertaken, should consider use of more highly standardized procedures (Jenke, 2015). For example, to isolate differences in analytical capabilities, the sample preparation and extraction processes should be highly stan- dardized; for example, by strict standardization of sample material cutting, specific vials to be used for extraction, or even greater stan- dardization of the instrumental methods (e.g., the specific analytical columns). Extract suitability (i.e., minimizing cloudiness) should be optimized by feasibility testing to assure adequate solvent:material compatibility. For an even greater degree of standardization, a central lab could be used to prepare common samples for analysis at each lab. Conversely, the effect of variation in sample preparation and extraction could be evaluated by using a single central laboratory to analyze ex- tracts prepared by each individual participating test lab. Of course it must also be recognized that standardization of methods causes labs to deviate from their standard practice, thus introducing challenges and possible deviations of a different nature. It should also be noted that funding to support the extensive work necessary for any future study of this magnitude would help assure its successful completion. 5. Conclusion Funding Body Information No funding was provided for this research. Test samples were contributed by the United States Pharmacopeia and by Becton- Dickinson. No funding was provided for this research. Test samples were contributed by the United States Pharmacopeia and by Becton- Dickinson. CRediT authorship contribution statement 4 Discussion 5 Conclusion Disclaimer Funding Body Information CRediT authorship contribution statement Declaration of competing interest Acknowledgements References", "Acknowledgement": "Acknowledgements The authors thank Keaton Nahan, Gang Peng, Caroline Pinto, Berk Oktem, Ji Guo, and Molly Ghosh (from FDA) for their contribution in designing, executing the study and careful review of this report and Andrea Agree (from MED Institute) for careful review of this report. 4 Discussion 5 Conclusion Disclaimer Funding Body Information CRediT authorship contribution statement Declaration of competing interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reproductive-Effects-of-Deltamethrin-on-Male-Offspr_2002_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/12473415", "content": {"Acknowledgement": "ACKNOWLEDGMENTS We are grateful to CAPES and CNPq for financial support. We also thank Dr. Rosana Nogueira de Morais for assistance with the radioim- munoassays and Aventis CropScience Brasil for supplying technical deltamethrin. DISCUSSION CONCLUSIONS ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reproductive-and-developmental-toxicity-screening-_2021_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33321148", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Preparation of this paper was funded by Kalsec, Inc. (Kalamazoo, U.S.). The authors are employed by Intertek Health Sciences Inc. Intertek Health Sciences Inc. have provided consulting services to Kalsec, Inc. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Preparation of this paper was funded by Kalsec, Inc. (Kalamazoo, U.S.). The authors are employed by Intertek Health Sciences Inc. Intertek Health Sciences Inc. have provided consulting services to Kalsec, Inc. References OECD, 1998. OECD Principles of Good Laboratory Practice. Organisation for Economic Co-Operation Development (OECD, Paris, France. Series on Principles of Good Laboratory Practice and Compliance Monitoring, no. 1 [ENV/MC/CHEM(98)17]. htt p://www.oecd-ilibrary.org/environment/oecd-principles-on-good-laboratory-practi ce_9789264078536-en. OECD, 2016a. Reproduction/developmental toxicity screening test. In: OECD Guidelines for the Testing of Chemicals. Organisation for Economic Co-operation and Development (OECD), Paris, France. Paris, France. OECD Guideline no 421 [Updated & Adopted: July 29, 2016. https://www.oecd-ilibrary.org/environment/test -no-421-reproduction-developmental-toxicity-screening-test_9789264264380-en; jsessionid=k7rpdl8f2jeb.x-oecd-live-02. OECD, 2016b. Combined repeated dose toxicity study with the reproduction/ developmental toxicity screening test. In: OECD Guidelines for the Testing of Chemicals. Organisation for Economic Co-operation and Development (OECD), Paris, France. Paris, France. OECD Guideline no 422 [Updated & Adopted: 29 July 2016. http://www.oecd-ilibrary.org/environment/test-no-422-combined-repeated -dose-toxicity-study-with-the-reproduction-developmental-toxicity-screening-test _9789264264403-en;jsessionid=k7rpdl8f2jeb.x-oecd-live-02. Phipps, K.R., Lozon, D., Baldwin, N., 2020. Genotoxicity and subchronic toxicity studies of supercritical carbon dioxide and acetone extracts of rosemary. Regul. Toxicol. Pharmacol. 119, 104826 https://doi.org/10.1016/j.yrtph.2020.104826. U.S. EPA, 2000. Health Effects Test Guidelines: OPPTS 870.3550: Reproduction/ Developmental Toxicity Screening Test (EPA 712\u2013C\u201300\u2013367). U.S. Environmental Protection Agency (U.S. EPA), Office of Prevention, Pesticides and Toxic Substances (OPPTS), Washington, DC. https://www.regulations.gov/document?D=EPA-HQ- OPPT-2009-0156-0015. UK Government, 2004. The Good Laboratory Practice (Codification Amendments Etc.) Regulations 2004. The Stationery Office Limited, London, UK. Statutory Instruments, No. 3106, as amended by Statutory Instrument 2004, No. 994. http://www.legislati on.gov.uk/uksi/2004/994/pdfs/uksi_20040994_en.pdf. Walker, P., Dubois, J.D., Dussault, J.H., 1980. Free thyroid hormone concentrations during postnatal development in the rat. Pediatr. Res. https://doi.org/10.1203/ 00006450-198003000-00014, 14L247\u2013249. Zabka, T.S., Fielden, M.R., Garrido, R., Tao, J., Fretland, A.J., Fretland, J.L., Albassam, M.A., Singer, T., Kolaja, K.L., 2011. Characterization of xenobiotic- induced hepatocellular enzyme induction in rats: anticipated thyroid effects and unique pituitary gland findings. Toxicol. Pathol. 39, 664\u2013677. https://doi.org/ 10.1177/0192623311406934. K.R. Phipps et al. https://doi.org/10.1016/j.anireprosci.2017.07.014 https://doi.org/10.1016/j.reprotox.2019.07.014 https://doi.org/10.1016/j.reprotox.2019.07.014 http://refhub.elsevier.com/S0273-2300(20)30266-X/sref3 http://refhub.elsevier.com/S0273-2300(20)30266-X/sref3 http://refhub.elsevier.com/S0273-2300(20)30266-X/sref3 https://doi.org/10.1210/edrv-12-2-135 https://doi.org/10.1210/edrv-12-2-135 https://efsa.onlinelibrary.wiley.com/doi/abs/10.2903/j.efsa.2008.721 https://efsa.onlinelibrary.wiley.com/doi/abs/10.2903/j.efsa.2008.721 https://doi.org/10.2903/j.efsa.2012.2760 https://doi.org/10.1177/0192623310374332 https://doi.org/10.1177/0192623310374332 http://refhub.elsevier.com/S0273-2300(20)30266-X/sref8 http://refhub.elsevier.com/S0273-2300(20)30266-X/sref8 http://refhub.elsevier.com/S0273-2300(20)30266-X/sref8 http://refhub.elsevier.com/S0273-2300(20)30266-X/sref8 http://apps.who.int/iris/bitstream/10665/250277/1/9789241210003-eng.pdf?ua=1 http://apps.who.int/iris/bitstream/10665/250277/1/9789241210003-eng.pdf?ua=1 https://apps.who.int/iris/bitstream/handle/10665/258934/9789241660730-eng.pdf#page=131 https://apps.who.int/iris/bitstream/handle/10665/258934/9789241660730-eng.pdf#page=131 http://www.fao.org/documents/card/en/c/ca7513en https://doi.org/10.1021/jf100921z http://refhub.elsevier.com/S0273-2300(20)30266-X/sref13 http://refhub.elsevier.com/S0273-2300(20)30266-X/sref13 http://refhub.elsevier.com/S0273-2300(20)30266-X/sref13 https://doi.org/10.1210/jc.2015-3872 https://doi.org/10.1016/j.yrtph.2018.09.002 https://journals.sagepub.com/doi/abs/10.3181/00379727-232-2320809 https://journals.sagepub.com/doi/abs/10.3181/00379727-232-2320809 http://www.oecd-ilibrary.org/environment/oecd-principles-on-good-laboratory-practice_9789264078536-en http://www.oecd-ilibrary.org/environment/oecd-principles-on-good-laboratory-practice_9789264078536-en http://www.oecd-ilibrary.org/environment/oecd-principles-on-good-laboratory-practice_9789264078536-en https://www.oecd-ilibrary.org/environment/test-no-421-reproduction-developmental-toxicity-screening-test_9789264264380-en;jsessionid=k7rpdl8f2jeb.x-oecd-live-02 https://www.oecd-ilibrary.org/environment/test-no-421-reproduction-developmental-toxicity-screening-test_9789264264380-en;jsessionid=k7rpdl8f2jeb.x-oecd-live-02 https://www.oecd-ilibrary.org/environment/test-no-421-reproduction-developmental-toxicity-screening-test_9789264264380-en;jsessionid=k7rpdl8f2jeb.x-oecd-live-02 http://www.oecd-ilibrary.org/environment/test-no-422-combined-repeated-dose-toxicity-study-with-the-reproduction-developmental-toxicity-screening-test_9789264264403-en;jsessionid=k7rpdl8f2jeb.x-oecd-live-02 http://www.oecd-ilibrary.org/environment/test-no-422-combined-repeated-dose-toxicity-study-with-the-reproduction-developmental-toxicity-screening-test_9789264264403-en;jsessionid=k7rpdl8f2jeb.x-oecd-live-02 http://www.oecd-ilibrary.org/environment/test-no-422-combined-repeated-dose-toxicity-study-with-the-reproduction-developmental-toxicity-screening-test_9789264264403-en;jsessionid=k7rpdl8f2jeb.x-oecd-live-02 https://doi.org/10.1016/j.yrtph.2020.104826 https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0015 https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0015 mailto:http://www.legislation.gov.uk/uksi/2004/994/pdfs/uksi_20040994_en.pdf mailto:http://www.legislation.gov.uk/uksi/2004/994/pdfs/uksi_20040994_en.pdf https://doi.org/10.1203/00006450-198003000-00014 https://doi.org/10.1203/00006450-198003000-00014 https://doi.org/10.1177/0192623311406934 https://doi.org/10.1177/0192623311406934 Reproductive and developmental toxicity screening study of an acetone extract of rosemary 1 Introduction 2 Materials and methods 2.1 Good laboratory practice and regulatory guidelines 2.2 Animals and maintenance 2.3 Test article and preparation schedule 2.4 General toxicity (parental animals) 2.5 Reproduction and development 2.5.1 Fertility, mating, pregnancy, and littering 2.5.2 Thyroid hormones 2.5.3 Pathology 2.6 Statistical analysis 3 Results 3.1 General toxicity (parental animals) 3.2 Reproduction and development 3.2.1 Fertility, mating, pregnancy, and littering 3.2.2 Thyroid hormones 3.2.3 Pathology 4 Discussion 5 Conclusion Funding body information CRediT authorship contribution statement Declaration of competing interest References", "Funding": "Funding body information Preparation of this paper was funded by Kalsec, Inc. (Kalamazoo, U. S.). The authors are employed by Intertek Health Sciences Inc. Intertek Health Sciences Inc. have provided consulting services to Kalsec, Inc. OECD, 1998. OECD Principles of Good Laboratory Practice. Organisation for Economic Co-Operation Development (OECD, Paris, France. Series on Principles of Good Laboratory Practice and Compliance Monitoring, no. 1 [ENV/MC/CHEM(98)17]. htt p://www.oecd-ilibrary.org/environment/oecd-principles-on-good-laboratory-practi ce_9789264078536-en. OECD, 2016a. Reproduction/developmental toxicity screening test. In: OECD Guidelines for the Testing of Chemicals. Organisation for Economic Co-operation and Development (OECD), Paris, France. Paris, France. OECD Guideline no 421 [Updated & Adopted: July 29, 2016. https://www.oecd-ilibrary.org/environment/test -no-421-reproduction-developmental-toxicity-screening-test_9789264264380-en; jsessionid=k7rpdl8f2jeb.x-oecd-live-02. OECD, 2016b. Combined repeated dose toxicity study with the reproduction/ developmental toxicity screening test. In: OECD Guidelines for the Testing of Chemicals. Organisation for Economic Co-operation and Development (OECD), Paris, France. Paris, France. OECD Guideline no 422 [Updated & Adopted: 29 July 2016. http://www.oecd-ilibrary.org/environment/test-no-422-combined-repeated -dose-toxicity-study-with-the-reproduction-developmental-toxicity-screening-test _9789264264403-en;jsessionid=k7rpdl8f2jeb.x-oecd-live-02. Phipps, K.R., Lozon, D., Baldwin, N., 2020. Genotoxicity and subchronic toxicity studies of supercritical carbon dioxide and acetone extracts of rosemary. Regul. Toxicol. Pharmacol. 119, 104826 https://doi.org/10.1016/j.yrtph.2020.104826. U.S. EPA, 2000. Health Effects Test Guidelines: OPPTS 870.3550: Reproduction/ Developmental Toxicity Screening Test (EPA 712\u2013C\u201300\u2013367). U.S. Environmental Protection Agency (U.S. EPA), Office of Prevention, Pesticides and Toxic Substances (OPPTS), Washington, DC. https://www.regulations.gov/document?D=EPA-HQ- OPPT-2009-0156-0015. UK Government, 2004. The Good Laboratory Practice (Codification Amendments Etc.) Regulations 2004. The Stationery Office Limited, London, UK. Statutory Instruments, No. 3106, as amended by Statutory Instrument 2004, No. 994. http://www.legislati on.gov.uk/uksi/2004/994/pdfs/uksi_20040994_en.pdf. Walker, P., Dubois, J.D., Dussault, J.H., 1980. Free thyroid hormone concentrations during postnatal development in the rat. Pediatr. Res. https://doi.org/10.1203/ 00006450-198003000-00014, 14L247\u2013249. Zabka, T.S., Fielden, M.R., Garrido, R., Tao, J., Fretland, A.J., Fretland, J.L., Albassam, M.A., Singer, T., Kolaja, K.L., 2011. Characterization of xenobiotic- induced hepatocellular enzyme induction in rats: anticipated thyroid effects and unique pituitary gland findings. Toxicol. Pathol. 39, 664\u2013677. https://doi.org/ 10.1177/0192623311406934. K.R. Phipps et al. https://doi.org/10.1016/j.anireprosci.2017.07.014 https://doi.org/10.1016/j.reprotox.2019.07.014 https://doi.org/10.1016/j.reprotox.2019.07.014 http://refhub.elsevier.com/S0273-2300(20)30266-X/sref3 http://refhub.elsevier.com/S0273-2300(20)30266-X/sref3 http://refhub.elsevier.com/S0273-2300(20)30266-X/sref3 https://doi.org/10.1210/edrv-12-2-135 https://doi.org/10.1210/edrv-12-2-135 https://efsa.onlinelibrary.wiley.com/doi/abs/10.2903/j.efsa.2008.721 https://efsa.onlinelibrary.wiley.com/doi/abs/10.2903/j.efsa.2008.721 https://doi.org/10.2903/j.efsa.2012.2760 https://doi.org/10.1177/0192623310374332 https://doi.org/10.1177/0192623310374332 http://refhub.elsevier.com/S0273-2300(20)30266-X/sref8 http://refhub.elsevier.com/S0273-2300(20)30266-X/sref8 http://refhub.elsevier.com/S0273-2300(20)30266-X/sref8 http://refhub.elsevier.com/S0273-2300(20)30266-X/sref8 http://apps.who.int/iris/bitstream/10665/250277/1/9789241210003-eng.pdf?ua=1 http://apps.who.int/iris/bitstream/10665/250277/1/9789241210003-eng.pdf?ua=1 https://apps.who.int/iris/bitstream/handle/10665/258934/9789241660730-eng.pdf#page=131 https://apps.who.int/iris/bitstream/handle/10665/258934/9789241660730-eng.pdf#page=131 http://www.fao.org/documents/card/en/c/ca7513en https://doi.org/10.1021/jf100921z http://refhub.elsevier.com/S0273-2300(20)30266-X/sref13 http://refhub.elsevier.com/S0273-2300(20)30266-X/sref13 http://refhub.elsevier.com/S0273-2300(20)30266-X/sref13 https://doi.org/10.1210/jc.2015-3872 https://doi.org/10.1016/j.yrtph.2018.09.002 https://journals.sagepub.com/doi/abs/10.3181/00379727-232-2320809 https://journals.sagepub.com/doi/abs/10.3181/00379727-232-2320809 http://www.oecd-ilibrary.org/environment/oecd-principles-on-good-laboratory-practice_9789264078536-en http://www.oecd-ilibrary.org/environment/oecd-principles-on-good-laboratory-practice_9789264078536-en http://www.oecd-ilibrary.org/environment/oecd-principles-on-good-laboratory-practice_9789264078536-en https://www.oecd-ilibrary.org/environment/test-no-421-reproduction-developmental-toxicity-screening-test_9789264264380-en;jsessionid=k7rpdl8f2jeb.x-oecd-live-02 https://www.oecd-ilibrary.org/environment/test-no-421-reproduction-developmental-toxicity-screening-test_9789264264380-en;jsessionid=k7rpdl8f2jeb.x-oecd-live-02 https://www.oecd-ilibrary.org/environment/test-no-421-reproduction-developmental-toxicity-screening-test_9789264264380-en;jsessionid=k7rpdl8f2jeb.x-oecd-live-02 http://www.oecd-ilibrary.org/environment/test-no-422-combined-repeated-dose-toxicity-study-with-the-reproduction-developmental-toxicity-screening-test_9789264264403-en;jsessionid=k7rpdl8f2jeb.x-oecd-live-02 http://www.oecd-ilibrary.org/environment/test-no-422-combined-repeated-dose-toxicity-study-with-the-reproduction-developmental-toxicity-screening-test_9789264264403-en;jsessionid=k7rpdl8f2jeb.x-oecd-live-02 http://www.oecd-ilibrary.org/environment/test-no-422-combined-repeated-dose-toxicity-study-with-the-reproduction-developmental-toxicity-screening-test_9789264264403-en;jsessionid=k7rpdl8f2jeb.x-oecd-live-02 https://doi.org/10.1016/j.yrtph.2020.104826 https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0015 https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0015 mailto:http://www.legislation.gov.uk/uksi/2004/994/pdfs/uksi_20040994_en.pdf mailto:http://www.legislation.gov.uk/uksi/2004/994/pdfs/uksi_20040994_en.pdf https://doi.org/10.1203/00006450-198003000-00014 https://doi.org/10.1203/00006450-198003000-00014 https://doi.org/10.1177/0192623311406934 https://doi.org/10.1177/0192623311406934 Reproductive and developmental toxicity screening study of an acetone extract of rosemary 1 Introduction 2 Materials and methods 2.1 Good laboratory practice and regulatory guidelines 2.2 Animals and maintenance 2.3 Test article and preparation schedule 2.4 General toxicity (parental animals) 2.5 Reproduction and development 2.5.1 Fertility, mating, pregnancy, and littering 2.5.2 Thyroid hormones 2.5.3 Pathology 2.6 Statistical analysis 3 Results 3.1 General toxicity (parental animals) 3.2 Reproduction and development 3.2.1 Fertility, mating, pregnancy, and littering 3.2.2 Thyroid hormones 3.2.3 Pathology 4 Discussion 5 Conclusion Funding body information CRediT authorship contribution statement Declaration of competing interest References", "Compliance with ethical standards": "OECD, 1998. OECD Principles of Good Laboratory Practice. Organisation for Economic Co-Operation Development (OECD, Paris, France. Series on Principles of Good Laboratory Practice and Compliance Monitoring, no. 1 [ENV/MC/CHEM(98)17]. htt p://www.oecd-ilibrary.org/environment/oecd-principles-on-good-laboratory-practi ce_9789264078536-en. OECD, 2016a. Reproduction/developmental toxicity screening test. In: OECD Guidelines for the Testing of Chemicals. Organisation for Economic Co-operation and Development (OECD), Paris, France. Paris, France. OECD Guideline no 421 [Updated & Adopted: July 29, 2016. https://www.oecd-ilibrary.org/environment/test -no-421-reproduction-developmental-toxicity-screening-test_9789264264380-en; jsessionid=k7rpdl8f2jeb.x-oecd-live-02. OECD, 2016b. Combined repeated dose toxicity study with the reproduction/ developmental toxicity screening test. In: OECD Guidelines for the Testing of Chemicals. Organisation for Economic Co-operation and Development (OECD), Paris, France. Paris, France. OECD Guideline no 422 [Updated & Adopted: 29 July 2016. http://www.oecd-ilibrary.org/environment/test-no-422-combined-repeated -dose-toxicity-study-with-the-reproduction-developmental-toxicity-screening-test _9789264264403-en;jsessionid=k7rpdl8f2jeb.x-oecd-live-02. Phipps, K.R., Lozon, D., Baldwin, N., 2020. Genotoxicity and subchronic toxicity studies of supercritical carbon dioxide and acetone extracts of rosemary. Regul. Toxicol. Pharmacol. 119, 104826 https://doi.org/10.1016/j.yrtph.2020.104826. U.S. EPA, 2000. Health Effects Test Guidelines: OPPTS 870.3550: Reproduction/ Developmental Toxicity Screening Test (EPA 712\u2013C\u201300\u2013367). U.S. Environmental Protection Agency (U.S. EPA), Office of Prevention, Pesticides and Toxic Substances (OPPTS), Washington, DC. https://www.regulations.gov/document?D=EPA-HQ- OPPT-2009-0156-0015. UK Government, 2004. The Good Laboratory Practice (Codification Amendments Etc.) Regulations 2004. The Stationery Office Limited, London, UK. Statutory Instruments, No. 3106, as amended by Statutory Instrument 2004, No. 994. http://www.legislati on.gov.uk/uksi/2004/994/pdfs/uksi_20040994_en.pdf. Walker, P., Dubois, J.D., Dussault, J.H., 1980. Free thyroid hormone concentrations during postnatal development in the rat. Pediatr. Res. https://doi.org/10.1203/ 00006450-198003000-00014, 14L247\u2013249. Zabka, T.S., Fielden, M.R., Garrido, R., Tao, J., Fretland, A.J., Fretland, J.L., Albassam, M.A., Singer, T., Kolaja, K.L., 2011. Characterization of xenobiotic- induced hepatocellular enzyme induction in rats: anticipated thyroid effects and unique pituitary gland findings. Toxicol. Pathol. 39, 664\u2013677. https://doi.org/ 10.1177/0192623311406934. K.R. Phipps et al. https://doi.org/10.1016/j.anireprosci.2017.07.014 https://doi.org/10.1016/j.reprotox.2019.07.014 https://doi.org/10.1016/j.reprotox.2019.07.014 http://refhub.elsevier.com/S0273-2300(20)30266-X/sref3 http://refhub.elsevier.com/S0273-2300(20)30266-X/sref3 http://refhub.elsevier.com/S0273-2300(20)30266-X/sref3 https://doi.org/10.1210/edrv-12-2-135 https://doi.org/10.1210/edrv-12-2-135 https://efsa.onlinelibrary.wiley.com/doi/abs/10.2903/j.efsa.2008.721 https://efsa.onlinelibrary.wiley.com/doi/abs/10.2903/j.efsa.2008.721 https://doi.org/10.2903/j.efsa.2012.2760 https://doi.org/10.1177/0192623310374332 https://doi.org/10.1177/0192623310374332 http://refhub.elsevier.com/S0273-2300(20)30266-X/sref8 http://refhub.elsevier.com/S0273-2300(20)30266-X/sref8 http://refhub.elsevier.com/S0273-2300(20)30266-X/sref8 http://refhub.elsevier.com/S0273-2300(20)30266-X/sref8 http://apps.who.int/iris/bitstream/10665/250277/1/9789241210003-eng.pdf?ua=1 http://apps.who.int/iris/bitstream/10665/250277/1/9789241210003-eng.pdf?ua=1 https://apps.who.int/iris/bitstream/handle/10665/258934/9789241660730-eng.pdf#page=131 https://apps.who.int/iris/bitstream/handle/10665/258934/9789241660730-eng.pdf#page=131 http://www.fao.org/documents/card/en/c/ca7513en https://doi.org/10.1021/jf100921z http://refhub.elsevier.com/S0273-2300(20)30266-X/sref13 http://refhub.elsevier.com/S0273-2300(20)30266-X/sref13 http://refhub.elsevier.com/S0273-2300(20)30266-X/sref13 https://doi.org/10.1210/jc.2015-3872 https://doi.org/10.1016/j.yrtph.2018.09.002 https://journals.sagepub.com/doi/abs/10.3181/00379727-232-2320809 https://journals.sagepub.com/doi/abs/10.3181/00379727-232-2320809 http://www.oecd-ilibrary.org/environment/oecd-principles-on-good-laboratory-practice_9789264078536-en http://www.oecd-ilibrary.org/environment/oecd-principles-on-good-laboratory-practice_9789264078536-en http://www.oecd-ilibrary.org/environment/oecd-principles-on-good-laboratory-practice_9789264078536-en https://www.oecd-ilibrary.org/environment/test-no-421-reproduction-developmental-toxicity-screening-test_9789264264380-en;jsessionid=k7rpdl8f2jeb.x-oecd-live-02 https://www.oecd-ilibrary.org/environment/test-no-421-reproduction-developmental-toxicity-screening-test_9789264264380-en;jsessionid=k7rpdl8f2jeb.x-oecd-live-02 https://www.oecd-ilibrary.org/environment/test-no-421-reproduction-developmental-toxicity-screening-test_9789264264380-en;jsessionid=k7rpdl8f2jeb.x-oecd-live-02 http://www.oecd-ilibrary.org/environment/test-no-422-combined-repeated-dose-toxicity-study-with-the-reproduction-developmental-toxicity-screening-test_9789264264403-en;jsessionid=k7rpdl8f2jeb.x-oecd-live-02 http://www.oecd-ilibrary.org/environment/test-no-422-combined-repeated-dose-toxicity-study-with-the-reproduction-developmental-toxicity-screening-test_9789264264403-en;jsessionid=k7rpdl8f2jeb.x-oecd-live-02 http://www.oecd-ilibrary.org/environment/test-no-422-combined-repeated-dose-toxicity-study-with-the-reproduction-developmental-toxicity-screening-test_9789264264403-en;jsessionid=k7rpdl8f2jeb.x-oecd-live-02 https://doi.org/10.1016/j.yrtph.2020.104826 https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0015 https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0015 mailto:http://www.legislation.gov.uk/uksi/2004/994/pdfs/uksi_20040994_en.pdf mailto:http://www.legislation.gov.uk/uksi/2004/994/pdfs/uksi_20040994_en.pdf https://doi.org/10.1203/00006450-198003000-00014 https://doi.org/10.1203/00006450-198003000-00014 https://doi.org/10.1177/0192623311406934 https://doi.org/10.1177/0192623311406934 Reproductive and developmental toxicity screening study of an acetone extract of rosemary 1 Introduction 2 Materials and methods 2.1 Good laboratory practice and regulatory guidelines 2.2 Animals and maintenance 2.3 Test article and preparation schedule 2.4 General toxicity (parental animals) 2.5 Reproduction and development 2.5.1 Fertility, mating, pregnancy, and littering 2.5.2 Thyroid hormones 2.5.3 Pathology 2.6 Statistical analysis 3 Results 3.1 General toxicity (parental animals) 3.2 Reproduction and development 3.2.1 Fertility, mating, pregnancy, and littering 3.2.2 Thyroid hormones 3.2.3 Pathology 4 Discussion 5 Conclusion Funding body information CRediT authorship contribution statement Declaration of competing interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reproductive-and-developmental-toxicity-screening-of-_2019_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31398363", "content": {"Funding": "5. Funding information This work was supported by the National Institute of Environmental Research (Grant No. NIER-SP2014-225). Discussion Funding information Acknowledgments References", "Acknowledgement": "Acknowledgments The authors would like to especially thank to the technical staff of the Korea Institute of Toxicology for their technical support. Discussion Funding information Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reproductive-and-developmental-toxicity-testing--Examin_2016_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27074386", "content": {"Acknowledgement": "Acknowledgment The authors acknowledge the late Ms. Barbara Neal for her involvement in the early implementation of the EOGRT study approach for 2,4-D. Her insights and willingness to share generated and helped advance many of the concepts presented in this paper. 3. Role of kinetics in dose selection and incorporation into EOGRTS 4. Detailed and easy to follow steps for EOGRTS 5. Conclusion Acknowledgment Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reproductive-and-possible-hormonal-effects_2014_Regulatory-Toxicology-and-Ph.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24863245", "content": {"CoiStatement": "Conflict of interest The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgments 4 Discussion 5 Conclusions Conflict of interest Acknowledgments References", "Acknowledgement": "Acknowledgments S. Bortolan is a PhD fellow from Coordenadoria de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior (CAPES). E.G. Moreira is a senior research fellow from SETI/Funda\u00e7\u00e3o Arauc\u00e1ria. 4 Discussion 5 Conclusions Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Reproductive-toxicity-of-ZishenYutai-pill-in-rats-_2016_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27470441", "content": {"CoiStatement": "Conflict of interest None. Acknowledgements 4. Discussion Authors' contributions Conflict of interest Acknowledgements Transparency document References", "Acknowledgement": "None. Acknowledgements We wish to express our warm thanks to Project 15DZ2290400 supported by Shanghai professional service platform of non-clinical evaluation of drug against male reproductive and urinary diseases and Project 14140901302 supported by Shanghai experimental animal scientific and technological innovative action plan. 4. Discussion Authors' contributions Conflict of interest Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Residue-analysis-of-gibberellic-acid-isomer--iso-GA3_2020_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31705942", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper.", "Funding": "Funding sources The authors appreciated the support from Collaborative Innovation Center of Jiangsu Modern Industrial Fermentation in Jiangnan University. This work was supported by the National Science Foundation (No.31601558, No.31571942 & No.31771963) and Program of Introducing Talents of Discipline to Universities (No. 111-2- 06). Discussion mk:H1_25 Acknowledgements Abbreviations Used Funding sources References", "Acknowledgement": "Acknowledgements Qi Li and Chunfeng Liu developed the concept, and designed the study. Weikang Sun and Chunfeng Liu conducted the experiments, in- terpreted theresults, and wrote the manuscript. Chengtuo Niu, Jinjing Wang and Feiyun Zheng participated in interpreting theresults, and revised the manuscript. Jiaoyang Luo participated in the design of the study. Discussion mk:H1_25 Acknowledgements Abbreviations Used Funding sources References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Residue-behavior-and-dietary-intake-risk-assessment-of-t_2016_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27647629", "content": {"Acknowledgement": "Xiaodan Zhu and Chunhong Ji designed the experiments. Lifang Duan,Wei Zhang, Pingzhong Yu, Min He and Li Chen carried out the field experiments and sample analysis. Ercheng Zhao and Chun- hong Jia analyzed the residue data and wrote the paper. Acknowledgements This study was sponsored by National Natural Science Founda- tion of China (NSFC) project (31301694), Platform Project of Beijing Academy of Agricultural and Forestry Sciences (No. KJCX20140302) and Innovation Team in BAAFS (No. JNKYT201605). Transparency document 4. Conclusion Author contributions Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Residue-behavior-and-dietary-intake-risk-assessment_2018_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29601912", "content": {"CoiStatement": "Conflicts of interest The authors confirm that there are no known conflicts of interest associated with this publication and there has been no significant fi- nancial support for this work that could have influenced its outcome. The authors confirm that there are no known conflicts of interest associated with this publication and there has been no significant fi- nancial support for this work that could have influenced its outcome. Acknowledgements Conclusion Conflicts of interest Acknowledgements References", "Acknowledgement": "Acknowledgements This work was supported by the National Natural Science Foundation of China project (NO.31401765), the National Key Research and Development Plan of China (NO. 2016YFD0201305). Conclusion Conflicts of interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Residue-behavior-and-dietary-risk-assessment-of-chloroth_2019_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31265862", "content": {"CoiStatement": "No potential conflict of interest was reported by the authors. Founding body information Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. Conclusions Disclosure statement Founding body information Declaration of interests Acknowledgements Transparency document References", "Disclosure": "Disclosure statement No potential conflict of interest was reported by the authors. Conclusions Disclosure statement Founding body information Declaration of interests Acknowledgements Transparency document References", "Compliance with ethical standards": "Residue behavior and dietary risk assessment of chlorothalonil and its metabolite SDS-3701 in water spinach to propose maximum residue limit (MRL) dietary risk assessment. The residue definition for plant commodities for compliance with MRL was chlorothalonil only. The following ana- lysis offered the explanation to recommend a reasonable MRL and a safe PHI of chlorothalonil in water spinach. Giving to the announcement (No. 2308) published by Ministry of Agriculture and Rural Affairs of the P. R. China, HR of chlorothalonil in water spinach was advised to establish MRL. The field trial data ac- quired from 5-day PHI was adopted to recommended MRL of chlor- othalonil in water spinach with reference to the growth period of this crop and a large quantity of chlorothalonil registered data on other vegetables (Ministry of Agriculture and Rural Affairs of China of the P. R. China). HR of chlorothalonil (recommended 5-day PHI) was 5.58mg/kg in water spinach. The NEDI of chlorothalonil is 0.01130mg/kg bw (PHI=5 days) with RQc of 56.50%, while the NESTI of chlorothalonil was 0.2695mg/kg bw (PHI=5 days) with RQa of 44.92%. All of the RQ value (PHI= 5 days) was less than 100%. Hence, MRL of chlorothalonil was recommended as 7mg/kg for water spinach, on the ground of HR and results of dietary exposure assess- ment. Therefore, the recommended MRL of chlorothalonil in water spinach were proper and reliable to ordinary consumers. Furthermore, 5 days were recommended as a safe PHI to promote safe use of chlor- othalonil when implemented at standard dose for disease management in water spinach fields.", "Acknowledgement": "Acknowledgements The authors are grateful to Mr. Shengqin Su from the University of Wisconsin-Madison for his support in language improvement. This work was supported by National Natural Science Foundation of China Conclusions Disclosure statement Founding body information Declaration of interests Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Residue-depletion-profiles-and-withdrawal-interval-estimation_2022_Regulator.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/35460801", "content": {"CoiStatement": "Conflict of interest No conflicts of interest were reported. No conflicts of interest were reported. Funding body information Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 4 Discussion 5 Conclusion Conflict of interest Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgments Appendix A Supplementary data References", "Funding": "Funding body information The project was supported by the United States Department of Agriculture National Institute of Food and Agriculture for the Food Animal Residue Avoidance Databank (FARAD) Program (Award No.: 2019-41480-30296, 2020-41480-32497, 2021-41480-35271). The Phoenix software license was provided to the Center for Pharmaco- metrics and Systems Pharmacology at the University of Florida by Cer- tara USA, Inc. (Princeton, NJ) as a part of the company\u2019s Academic Centers of Excellence program. Long Yuan: Formal analysis, Investigation, Software, Validation, Visualization, Writing \u2013 original draft. Zhoumeng Lin: Conceptualiza- tion, Funding acquisition, Investigation, Methodology, Project admin- istration, Resources, Software, Supervision, Validation, Writing \u2013 review & editing. Rachel S. Dutch: Data curation, Investigation, Writing \u2013 review & editing. Emily D. Richards: Data curation, Investigation, Writing \u2013 review & editing. Maaike O. Clapham: Data curation, Formal analysis, Investigation, Writing \u2013 review & editing. Nathaniel Burmas: Data curation, Investigation, Writing \u2013 review & editing. Scott E. Wetzlich: Data curation, Formal analysis, Investigation, Validation, Writing \u2013 review & editing. Lisa A. Tell: Conceptualization, Data curation, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Writing \u2013 review & editing. Declaration of competing interest 4 Discussion 5 Conclusion Conflict of interest Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgments Appendix A Supplementary data References", "Acknowledgement": "Acknowledgments The project was supported by the United States Department of Agriculture National Institute of Food and Agriculture for the Food Animal Residue Avoidance Databank (FARAD) Program (Award No.: 2019-41480-30296, 2020-41480-32497, 2021-41480-35271). The Phoenix software license was provided to the Center for Pharmaco- metrics and Systems Pharmacology at the University of Florida by Cer- tara USA, Inc. (Princeton, NJ) as a part of the company\u2019s Academic Centers of Excellence program. 4 Discussion 5 Conclusion Conflict of interest Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Residues--dissipation-kinetics--and-dietary-intake-_2018_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30359702", "content": {"CoiStatement": "Conflicts of interest No potential conflict of interest was reported by the authors. No potential conflict of interest was reported by the authors. Acknowledgments Conclusions Conflicts of interest Acknowledgments Transparency document References", "Acknowledgement": "Acknowledgments This work was supported by the National Key Research and Development Program of China under grant numbers 2016YFD0201305 and 2016YFD0201306 and the Science and Technology Programs of Guizhou Province under grant number 20136024. Conclusions Conflicts of interest Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Residues-and-dissipation-kinetics-of-carbendazim-and-di_2016_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26995029", "content": {"Acknowledgement": "Acknowledgments This study was financially supported by the Program from H. Li et al. / Regulatory Toxicology and Pharmacology 77 (2016) 200e205 205 Shandong Academy of Agricultural Sciences (2014QNM50). 4. Conclusion Author contributions Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Residues-of-genotoxic-alkyl-mesylates-in-mesylate-s_2006_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16564608", "content": {"Acknowledgement": "Residues of genotoxic alkyl mesylates in mesylate salt drug substances: Real or imaginary problems? Introduction Potential for formation of alkyl mesylates: mechanistic considerations Experimental evidence on formation of alkyl mesylates Biological properties of alkyl mesylates Discussion Conclusions Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/RespiraTox---Development-of-a-QSAR-model-to-pred_2022_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34861320", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial 4 Discussion 5 Conclusion CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Funding": "Matthias M. Wehr: Data curation, Formal analysis, Methodology, Software, Validation, Visualization, Roles, Writing \u2013 original draft, Writing \u2013 review & editing. Satinder S. Sarang: Investigation, Re- sources, Roles, Writing \u2013 original draft, Writing \u2013 review & editing. Martijn Rooseboom: Investigation, Writing \u2013 review & editing. Peter J. Boogaard: Investigation, Writing \u2013 review & editing. Andreas Kar- wath: Methodology, Software, Supervision, Validation, Visualization, Roles, Writing \u2013 original draft, Writing \u2013 review & editing. Sylvia E. Escher: Conceptualization, Data curation, Funding acquisition, Inves- tigation, Methodology, Project administration, Resources, Supervision, Roles, Writing \u2013 original draft, Writing \u2013 review & editing. Declaration of competing interest", "Acknowledgement": "Acknowledgements The research has been funded by the National Centre for the Replacement Refinement & Reduction of Animal in Research - NC3Rs CRACK-IT program (https://nc3rs.org.uk/crackit/respiratox) with grant reference NC/C017S01/1. Dr. Andreas Karwath was partially supported by the Medical Research Council grant MR/S003991/1. The authors like to thank Professor Dr. Yves C. Alarie for providing threshold limit value datasets and for his helpful discussions on the topic. 4 Discussion 5 Conclusion CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Respiratory-safety-pharmacology---Current-prac_2014_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24280358", "content": {"CoiStatement": "140 D.J. Murphy / Regulatory Toxicology and Pharmacology 69 (2014) 135\u2013140 Conflict of interest None to declare. 6 Conclusion Conflict of interest References", "Compliance with ethical standards": "Although the measurement of lung compliance can help in the early identification of lower respiratory tract injury, it does not provide a complete measure of the functional consequences. To better characterize the functional consequences of these changes, the impact on blood gas diffusion should be considered. Comparing the relative changes in the partial pressures of the arterial O2 (PaO2) and CO2 (PaCO2) is one method for detecting injury that would hinder the diffusion of gases between the alveoli and the pulmonary arterioles as would be caused by interstitial or intra- alveolar accumulation of fluid (edema) or cells (pneumonitis), reduction in alveolar ventilation by small airway or alveolar obstruction (broncholitis obliterans) or the reduction in alveolar blood flow (shunting). A reduction in gas diffusion would be indicated by a selective decrease in PaO2 relative to PaCO2, and is generally quantified by calculating the ratio of PaO2/PaCO2. A reduction in gas diffusion capacity can also be measured as an increase in the ratio of inhaled O2 (FiO2) to PaO2 or a reduction in carbon monoxide diffusion capacity (DLCO) (Kialouama et al., 2011; Qureshi, 2011). Thus, the addition of a measure of blood gas diffusion capacity would be of value when an effect on lung compliance has been detected. 5.3. Use of stimulation models The use of stimulation models should be considered in respira- tory safety pharmacology studies when there is a need for a more sensitive measure of effect or the need to quantify the loss of func- tional reserve. Quantifying the loss of functional reserve may be of value when attempting to identify the potential impact or risk of an effect in a sensitive patient population where a loss of func- tional reserve has been identified. Stimulation models utilize healthy animals to avoid the complications of induced disease models and use graded stimulation to allow for detection and quantification of the loss of functional reserve. Stimulation models used to detect the loss of ventilatory reserve include the use a graded exercise (running) to assess a decrease in maximal ventila- tion or gas exchange (Kittleson et al., 1996; Bouitbir et al., 2011) and the use of inhaled air mixtures with elevated CO2 or reduced O2 to evaluate the change in maximal ventilatory response or respiratory drive (Bellville and Seed, 1960; Weil and Zwillich, 1976; Schaper et al., 1985; Howell, 1993). By quantifying the loss of functional reserve, the potential impact on morbidity and mor- tality in human patients with a known loss of functional reserve could be evaluated. Similarly, stimulation models can be used to evaluate the loss of functional reserve for lung airflow and compli- ance. One established model in anesthetized rodents involves the use of a pulmonary forced maneuvers procedure, which involves the controlled maximal inflation and deflation of the lung and the simultaneous measurement of flow, volume and transpulmo- nary pressure (Diamond and O\u2019Donnell, 1977; Costa, 1985). One maneuver involves inflation of the lung to a maximum volume (inspiratory capacity) and then rapidly deflating the lung by con- necting the trachea to a negative pressure reservoir while record- ing lung airflow and volume. This procedure can be used to calculate flow endpoints such as forced expiratory volume (FEV) at specific expiratory times, peak expiratory flow (PEF), and flow at 25% and 75% of forced vital capacity (FEF25-75). By measuring the change from a maximal or forced (stimulated) flow, the loss of functional reserve for lung airflow can be determined. A maneu- ver involving a slow inflation to inspiratory capacity followed by a slow deflation, and an evaluation of the slope of the expiratory phase of the pressure\u2013volume loop, can also be performed by this procedure to calculate a static or quasi-static lung compliance (Diamond and O\u2019Donnell, 1977; Costa, 1985). By measuring com- pliance under forced (stimulated) volume and pressure conditions, a loss of reserve can be determined. 6. Conclusion"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Respiratory-safety-pharmacology--Concurrent-validation-o_2010_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20800083", "content": {"CoiStatement": "These results confirm the suitability of head-out plethysmogra- phy in rats for respiratory safety pharmacology as previously re- ported by Hoymann (2006). In addition, data obtained following negative control (saline) suggested a limit of 3\u20134 h before slumber- ing alters respiratory patterns in conscious rats. Variations over time in the control group justify the systematic use of a control group in any respiratory safety pharmacology study for inter- groups comparison. Moreover, the system was sensitive and specific to detect changes in respiratory parameters related to pharmacologically-induced bronchodilation (albuterol), broncho- constriction (methacholine) and central respiratory depression (remifentanil). In the case of ultrashort-acting agents, such as rem- ifentanil, the analysis sensitivity could be improved by shortening the epoch of data analysis (analysis on 1 min averages instead of 5 min averages). The three parameters (RR, TV and MV) outlined in the ICH S7A guideline confirmed to be the cornerstone of respi- ratory safety pharmacology data interpretation providing the most sensitive detection of changes. The addition of within-breath time parameters was not essential to detect drug effects but offered complementary tools to interpret changes in RR. Evaluated ratios did not prove to be particularly useful in the interpretation of phar- macological respiratory effects in the current study. Nevertheless, evaluation of peak inspiratory/expiratory flow and EF50 appears as a valuable complement for interpretation of respiratory re- sponse, as previously suggested (Hoymann, 2007). Peak inspiratory flow was altered by the three positive control drug challenges, and peak expiratory flow and EF50 were particularly altered by the in- crease in airways resistance. Conflicts of interest statement The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgments Discussion Conflicts of interest statement Acknowledgments References", "Compliance with ethical standards": "Anonymous, 2001. ICH S7A Safety pharmacology studies for human pharmaceuticals. <http://www.emea.europa.eu/pdfs/human/ich/053900en.pdf> or <http://www. fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidan ces/ucm074959.pdf>. Ansermino, J.M., Brooks, P., Rosen, D., Vandebeek, C.A., Reichert, C., 2005. Spontaneous ventilation with remifentanil in children. Ped. Anesth. 15, 115\u2013 121. Authier, S., Legaspi, M., Gauvin, D., Chaurand, F., Fournier, S., Troncy, E., 2008. Validation of respiratory safety pharmacology models: conscious and anesthetized beagle dogs. J. Pharmacol. Toxicol. Methods 57, 52\u201360. http://www.emea.europa.eu/pdfs/human/ich/053900en.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm074959.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm074959.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm074959.pdf http://www.ivis.org http://www.biomedcentral.com/1471-2288/1/6 Respiratory safety pharmacology: Concurrent validation of volume, rate, time, flow and ratio variables in conscious male Sprague\u2013Dawley rats Introduction Materials and methods Statement on use and care of animals and regulatory compliance Animal housing Respiratory monitoring system Positive and negative control drugs Experimental design Statistical analysis Respiratory safety pharmacology: Concurrent validation of volume, rate, time, flow and ratio variables in conscious male Sprague\u2013Dawley rats Introduction Materials and methods Statement on use and care of animals and regulatory compliance Animal housing Respiratory monitoring system Positive and negative control drugs Experimental design Statistical analysis Results Saline Albuterol Methacholine Remifentanil", "Acknowledgement": "Acknowledgments The authors thank the personnel of LAB Research, Inc. for pro- viding the infrastructure and technical resources required during study conduct. Grateful acknowledgement is made to the Canada Foundation for Innovation, On-going new opportunities grant #9843 attributed to Eric Troncy for infrastructure support. The authors thank the personnel of LAB Research, Inc. for pro- viding the infrastructure and technical resources required during study conduct. Grateful acknowledgement is made to the Canada Foundation for Innovation, On-going new opportunities grant #9843 attributed to Eric Troncy for infrastructure support. References Discussion Conflicts of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Respiratory-safety-pharmacology--Positive-control-drug_2009_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19647027", "content": {"Compliance with ethical standards": "Respiratory safety pharmacology: Positive control drug responses in Sprague\u2013Dawley rats, Beagle dogs and cynomolgus monkeys Introduction Materials and methods Statement on use and care of animals and regulatory compliance Animal housing and preparation Respiratory monitoring system Positive and negative control drugs Data analysis Results Discussion Acknowledgments References", "Acknowledgement": "Acknowledgments Simon Authier is a Ph.D. student funded by the Natural Sciences and Engineering Research Council of Canada Graduate Scholarships and the Faculty of Graduate and Postgraduate Studies of Universit\u00e9 de Montr\u00e9al, Qu\u00e9bec, Canada. Results Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Response-to--OECD-428-in-vitro-dermal-absorption-mass-_2020_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32512117", "content": {"CoiStatement": "Response to \u201cOECD 428 in vitro dermal absorption mass balance performance based on our in-house database of pesticide studies\u201d Funding body information Declaration of competing interest Acknowledgements References", "Funding": "Response to \u201cOECD 428 in vitro dermal absorption mass balance performance based on our in-house database of pesticide studies\u201d Funding body information Declaration of competing interest Acknowledgements References", "Acknowledgement": "Response to \u201cOECD 428 in vitro dermal absorption mass balance performance based on our in-house database of pesticide studies\u201d Funding body information Declaration of competing interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Response-to--Overgeneralization-by-Anderson-et-al--an_2019_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30928331", "content": {"Acknowledgement": "Acknowledgment This work was funded by the FluoroCouncil. The funders were given the opportunity to review the draft response to ensure accuracy of the science presented. The researchers' conclusions and professional judg- ments were not subject to the funders' control; the contents of this paper reflect solely the view of the authors. Response to \u201cOvergeneralization by Anderson et al. and Luz et al. regarding safety of fluorotelomer-base chemistry\u201d Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Response-to-letter-from-Dr-Oliviera-in-relation-to-our-publ_2019_Regulatory-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31095971", "content": {"CoiStatement": "Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. Response to letter from Dr Oliviera in relation to our publication: A study in a rat initiation-promotion bladder tumour model demonstrated no promoter/progressor potential of dapagliflozin Species and males vs females Administration and treatments Sampling Animal numbers Histology scoring Conclusions Declaration of interests Funding body information Transparency document References", "Funding": "Funding body information This work was conducted in relation to the resonse to a letter con- cerning our published manuscript. Response to letter from Dr Oliviera in relation to our publication: A study in a rat initiation-promotion bladder tumour model demonstrated no promoter/progressor potential of dapagliflozin Species and males vs females Administration and treatments Sampling Animal numbers Histology scoring Conclusions Declaration of interests Funding body information Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Response-to-letter-to-editor--Pulmonary-toxicity-in-rats-fo_2020_Regulatory-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32007437", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper.", "Funding": "Funding This work has been performed on request of the Interdepartmental Working group on Risks of nanomaterials of the Dutch government (IWR), within the framework of the Dutch Knowledge and Information centre for Risks of Nanotechnology established at RIVM (KIR-nano). Response to letter to editor \u201cPulmonary toxicity in rats following inhalation exposure to poorly soluble particles of low toxicity: Testing at excessive concentrations overwhelming lung clearance\u201d? Funding mk:H1_2 References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Response-to-the-Letter-to-the-Editor-by-S--Schiffman-an_2012_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32595044", "content": {"Compliance with ethical standards": "(14) In the Letter by Drs. Schiffman and Abou-Donia, the authors imply that incorrect conclusions were reached with regard to sucralose metabolism, based on their assertion that there are TLC radiochromatograms (Sims et al., 2000; Roberts et al., 2000) \u2018\u2018that show that sucralose is metabolized in the gut\u2019\u2019. As discussed earlier, the referenced radiochromatograms are not evidence of sucralose metabolism by the gut. In contrast, they support that there is no metabolism at the intestinal level. The investigation of the safety of a new food ingredient is governed by rigorous test- ing strategies laid out within the FDA\u2019s \u2018\u2018Redbook 2000\u2019\u2019 (Toxico- logical Principles for the Safety Assessment of Direct Food Additives and Color Additives Used in Food 2000). The research program conducted to investigate the safety of sucralose was de- signed to be in compliance with these recognized rigorous testing strategies, and includes over 110 scientific studies. (15) In contrast to the remarks implying a lack of acknowledged affiliations, in both the Grotz and Munro (2009) and Brusick et al. (2009) papers, it is directly stated that the Expert Panel review was undertaken at the request of \u2018\u2018McNeil Nutritionals, a marketer of retail products that contain the non-nutritive sweetener, sucra- lose.\u2019\u2019 Furthermore, the affiliation of the first author of Grotz and Munro (2009) is clearly indicated as McNeil Nutritionals, LLC. It must also be added that the panel convened by McNeil Nutrition- als contained nationally and internationally recognized biomedical scientists who are independent and qualified by their scientific training and experience to evaluate the safety of food ingredients and foods (the \u2018\u2018Expert Panel\u2019\u2019). Each panelist has been (and still is) involved in the safety assessment of many food ingredients; sucralose was one of those ingredients. These panelists have served, by invitation, on national and international bodies con- cerned with the safety of food ingredients and foods. They are rec- ognized for their competence and integrity. To imply that lack of scientific objectivity occurred because the panelists were compen- sated for their efforts is to impugn their established scientific integrity and credibility. In contrast to implications being made by Schiffman and Abou- Donia, Brusick et al.,(2009 and Grotz and Munro (2009) draw on scientifically sound investigations and the conclusions of numer- ous critical health and safety regulatory reviews as the basis for conclusions reached in their reports. The onus is on industry to conduct testing in compliance with the high ethical and scientific standards required by food safety regulatory government offices. Critical, thorough, and expert evaluation of the study conducted by Abou-Donia et al. (2008) was an important undertaking, in light of conclusions being drawn by the authors based on the study observations. Letter to the Editor / Regulatory Toxicology and Pharmacology 63 (2012) 509\u2013513 513 As stated by Grotz and Munro (2009), \u2018\u2018Given the broad use of sucralose and its clinical utility in calorie and carbohydrate man- agement, it is important to convey [the findings of the Expert Panel], as well as a general understanding of the safety of sucra- lose to members of both the lay public and the scientific, includ- ing healthcare professional, community.\u2019\u2019 It remains important that the public have reliable information on the safety of sucra- lose \u2013 and other FDA-permitted low calorie sweeteners \u2013 which can be a helpful tool in managing calorie/carbohydrate from su- gar. The Expert Panel report on the study by Abou-Donia et al. (2008) which finds the conclusions of the Abou-Donia et al. (2008) report to be unsubstantiated by the data, provides an important source of information for the scientific, health and lay communities. We conclude that the Letter by Drs. Schiffman and Abou-Do- nia provides no information of substantive value in addressing the comments and conclusions of the Expert Panel report by Brusick et al. (2009). We further conclude that the Letter does not provide any new or substantive information regarding the overall information or conclusions made in the report by Grotz and Munro (2009), which provides an overview of the safety of sucralose. Sincerely, V. Lee Grotz, Ph.D. David Brusick, Ph.D. References Abou-Donia, M.B. et al, 2008. Splenda alters gut microflora and increases intestinal P-glycoprotein and cytochrome P-450 in male rats. J. Toxicol. Environ. Health Part A 71, 1415\u20131429. Barndt, R.L., Jackson, G., 1990. Stability of sucralose in baked goods. Food Technol. 44 (1), 62\u201366. Brusick, D. et al, 2009. Expert panel report on a study of Splenda in male rats. Regul. Toxicol. Pharmacol. 55, 6\u201312. Bernstein, J.A. et al, 2009. Double-blind, placebo-controlled trial of reformulated azelastine nasal spray in patients with seasonal allergic rhinitis. Am. J. Rhinol. Allergy 23, 512\u2013517. Deferme, S., Augustijns, P., 2003. The effect of food components on the absorption of P-gp substrates: a review. J. Pharm. Pharmacol. 55, 153\u2013162. Eckford, P.D., Sharom, F.J., 2005. The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids. Biochem. J. 389, 517\u2013526. Eckford, P.D., Sharom, F.J., 2008. Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity, drug binding and transport. Biochemistry 47, 13686\u201313698. Freedman, S.B. et al, 2010. Assessing the palatability of oral rehydration solutions in school-aged children: a randomized crossover trial. Arch. Pediatr. Adolesc. Med. 164, 696\u2013702. Grotz, V.L. et al, 2003. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. J. Am. Diet. Assoc. 103, 1607\u20131612. Grotz, V.L., Munro, I.C., 2009. An overview of the safety of sucralose. Regul. Toxicol. Pharmacol. 55, 1\u20135. ILSI Europe workshop on 3-MCPD esters in food products, 2009. Brussels, Belgium. Available from: http://www.ilsi.org/europe/publications/final%20version% 203 %20mcpd%20esters.pdf. Jenner, M., Smithson, A., 1989. Physiocochemical properties of the sweetner sucralose. J. Food Sci. 54, 1646\u20131649. Liew, K. et al, 2012. AAPS Pharm. Sci. Tech. 13, 134\u2013142. Lillicrap, A. et al, 2011. Bioconcentration of the intense sweetener sucralose in a multitrophic battery of aquatic organisms. Environ. Toxicol. Chem. 30, 673\u2013 681. Mar\u00e7on, F. et al, 2009. Development and formulation of a 0.2% oral solution of midazolam containing gamma-cyclodextrin. Int. J. Pharm. 379 (2), 244\u2013250. Mechlin, C. et al, 2011. Splenda\ufffd improves tolerance of oral potassium citrate supplementation for prevention of stone formation: results of a randomized double-blind trial. J. Endourol. 25, 1541\u20131545. Miller, G., 1991. \u2018\u2018Sucralose\u2019\u2019.In: Lyn O\u2019Brien Nabors., Robert Gelardi (Eds.), Chapter 10 in Alternative Sweeteners, second ed. Marcel Dekker, Inc. Rahn, A., Yaylayan, V.A., 2010. Thermal degradation of sucralose and its potential in generating chloropropanols in the presence of glycerol. Food Chem. 118, 56\u201361. Roberts, A. et al, 2000. Sucralose metabolism and pharmacokinetics in man. Food Chem. Toxicol. 38, S31\u2013S41. Sims, J. et al, 2000. The metabolic fate of sucralose in rats. Food Chem. Toxicol. 38, S115\u2013S121. US FDA (US Food and Drug Administration), 1999. Food additives permitted for direct addition to food for human consumption: sucralose [21CFR Part 172; Docket No. 99F-0001]. Fed. Regist. US. 64, 43908-43909. Available from: <http://www.fda.gov/ohrms/dockets/98fr/081299b.txt>. V. Lee Grotz McNeil Nutritionals, LLC, 601 Office Center Dr., Fort Washington, PA 19034, USA. Fax: +1 215 273 4243. An overview of the safety of sucralose (Grotz and Munro, 2009). E-mail address: LGrotz@its.jnj.com David Brusick Independent Consultant, 123 Moody Creek Rd, Bumpass, VA 23024, USA. Expert Panel Report on a Study of Splenda in Male Rats by Abou-Donia et al. (2008) (Brusick et al., 2009). http://www.ilsi.org/europe/publications/final%20version%203%20mcpd%20esters.pdf http://www.ilsi.org/europe/publications/final%20version%203%20mcpd%20esters.pdf http://www.fda.gov/ohrms/dockets/98fr/081299b.txt mailto:LGrotz@its.jnj.com Response to the Letter to the Editor by S. Schiffman and M. Abou-Donia: Additional information to clarify the evidence of sucralose safety References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Response-to-the-comments-of-Natsch-and-Landsiedel-on-my-paper--_2019_Regulat.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30629968", "content": {"Funding": "Funding This work was supported by SenzaGen AB. Response to the comments of Natsch and Landsiedel on my paper \u201cIs a combination of assays really needed for non-animal prediction of skin sensitization potential? Performance of the GARD (genomic allergen rapid detection) assay in comparison with OECD guideline assays alone and in combination.\u201d Introduction Challenging the AOP approach The GARD assay Predictivity Lack of transparency In conclusion Funding References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Results-from-oral-gavage-carcinogenicity-studies-of-r_2016_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27647628", "content": {"Acknowledgement": "Acknowledgements These studies were funded by Incyte Corporation. The authors wish to acknowledge the contributions of the following scientists to this work: Dr. Reem Elbekai, BioReliance, Dr. Madhav Paranjpe, BioReliance, Matthew Haas, WIL Research Lab- oratories, LLC, Dr. Amera Remick, WIL Research Laboratories, LLC, and Les Freshwater, BioSTAT Consultants, Inc. 4. Discussion Acknowledgements Transparency document Appendix A. Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Rethinking-agrochemical-safety-assessment-_2021_Regulatory-Toxicology-and-Ph.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34678328", "content": {"CoiStatement": "5 Concluding comments Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgements References", "Funding": "5 Concluding comments Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgements References", "Acknowledgement": "5 Concluding comments Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Rethinking-chronic-toxicity-and-carcinogenicity-assessment-_2022_Regulatory-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/35311659", "content": {"CoiStatement": "4 Discussion 5 Next steps CRediT authorship contribution statement Declaration of competing interest Acknowledgments Appendix A Supplementary data References", "Acknowledgement": "4 Discussion 5 Next steps CRediT authorship contribution statement Declaration of competing interest Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Rethinking-guideline-toxicity-testi_2015_Regulatory-Toxicology-and-Pharmacol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25980640", "content": {"CoiStatement": "Conflict of interest The authors declare no conflict of interest. The authors declare no conflict of interest. Transparency Document 3 Discussion Conflict of interest Transparency Document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Retrospective-mining-of-toxicology-data-to-discover-m_2017_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28242142", "content": {"CoiStatement": "Conflict of interest The authors have no conflicts of interest to declare. The authors have no conflicts of interest to declare. Appendix A. Supplementary data 4. Discussion Disclaimer Funding Conflict of interest Appendix A. Supplementary data Transparency document References", "Funding": "Funding This work was supported in whole by the U.S. Environmental Protection Agency. 4. Discussion Disclaimer Funding Conflict of interest Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Review-of-REACH-Annex-IV---Establishing-the-minimum-_2010_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19788906", "content": {"Acknowledgement": "Once the results of the analysis of substances was complete, the Commission, using the criterion in Section 3.8 of the criteria docu- ment, added fructose, galactose, and lactose to Annex IV, as there was evidence that prolonged daily and continuous human and environmental exposure has not lead to more than minimum risk. The criterion in Section 3.8 had already identified \u2018sugar\u2019 as consti- tuting a minimum risk even though a full dataset may not be avail- able. In addition, the review of Annex IV identified that there was some evidence that certain fatty acids and vegetable oils could pose a risk to the aquatic environment because, on the basis of QSAR information. This, combined with an acknowledgement that the list of vegetable oils and fatty acids in Annex IV was not exhaustive, led the Commission to insert a generic criterion in An- nex V, covering these substances, whilst excluding from the exemption those vegetable oils or fatty acids that met the classifi- cation or the PBT or vPvB criteria. This latter extension of the list of exemptions for substances should also be considered when judging the quality of the list produced. Now that the review of Annex IV is finalised, and considering the work that went into developing the criteria, is there any future use for them? Another extensive review of Annex IV is unlikely in the near future, but it is possible that the criteria established could be used in another way. There are a number of possibilities."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Review-of-achievements-of-the-OECD-Working-Party-on-Manuf_2016_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26603783", "content": {"CoiStatement": "Conflicts of interest The authors have no conflict of interest to report. The authors have no conflict of interest to report. Acknowledgement 5. Amendments to the OECD test guidelines and guidance documents for nanomaterials 6. Discussion and conclusions Disclaimer Conflicts of interest Acknowledgement Transparency document References", "Acknowledgement": "Acknowledgement The authors are grateful to Dr M.E. Goetz from the Federal Institute of Risk Assessment in Germany for his comments to earlier versions of this article, and to Mr S. Haastrup from the Technical University of Denmark for text review. Also, the authors wish to convey a heartfelt thanks to the delegates to the OECD WPMN meetings, the contributors to the Testing Programme and the par- ticipants to the expert meetings for sharing information, scientific in-sights and active discussions, which have all contributed to the overview information presented here, and without which the present work would have been impossible. 5. Amendments to the OECD test guidelines and guidance documents for nanomaterials 6. Discussion and conclusions Disclaimer Conflicts of interest Acknowledgement Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Review-of-air-concentrations-of-pesticides-for-estim_2022_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/35469931", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests. All authors are employees of companies that conduct and evaluate risk assessments for regulatory purposes in the context of authorization and marketing of their companies\u2019 products. They contribute as scientific experts to the industry association CropLife Europe for evaluation and development of the state-of-the-art methodology. Acknowledgements Koerdel, W., et al., 1999. Entwicklung eines mehrstufigen Verfahrens zur Bewertung des Eintrages von Pflanzenschutzmitteln in terrestrische Oekosysteme ueber den Luftpfad. Umweltbundesamt (UBA, German Environment Agency. Martin, S., et al., 2008. Guidance for exposure and risk evaluation for bystanders and residents exposed to plant protection products during and after application. J. f\u00fcr Verbraucherschutz Lebensmittelsicherheit 3, 272\u2013281. Morris, J.B., 2012. Biologically-based modeling insights in inhaled vapor absorption and dosimetry. Pharmacol. Ther. 136, 401\u2013413. PSD, 2008. Bystander Exposure Guidance. Pesticide Safety Directorate. Siebers, J., et al., 2003. Investigation on downwind short-range transport of pesticides after application in agricultural crops. Chemosphere 51, 397\u2013407. van Hemmen, J.J., et al., 2002. The development, maintenance and dissemination of generic European databases and predictive exposure models to plant protection products. FAIR3 CT96-1406 a EUROPOEM operator exposure database: a EUROPOEM bystander exposure database and harmonised model; a EUROPOEM re- entry exposure database and harmonised model; an evaluation of the nature and efficacy of exposure mitigation methods; a tiered approach to exposure and risk assessment. FAIR3 CT96-1406. Winkler, R., Koch, W., 2005. Exposure via Air (EVA 2.0.1) Assessment of the Short Range Transport and Deposition of Pesticides for Aquatic and Terrestrial Ecosystems. Umweltbundesamt (UBA, German Environment Agency. E. Felkers et al. http://refhub.elsevier.com/S0273-2300(22)00059-9/sref1 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref1 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref1 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref2 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref2 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref2 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref3 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref3 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref3 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref4 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref4 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref4 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref5 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref5 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref6 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref6 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref6 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref7 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref7 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref7 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref8 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref8 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref8 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref8 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref8 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref8 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref8 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref9 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref9 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref10 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref10 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref10 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref11 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref11 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref12 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref12 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref12 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref13 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref13 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref13 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref14 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref14 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref15 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref16 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref16 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref17 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref17 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref17 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref17 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref17 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref17 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref17 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref18 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref18 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref18 Review of air concentrations of pesticides for estimating exposure to vapour in European risk assessments 1 Introduction 1.1 Air concentration from a risk assessment perspective 1.2 Grouping active substances according to vapour pressure 2 Current database for estimating inhalation exposure 2.1 \u2018Low volatility\u2019 substances 2.2 \u2018Moderately volatile\u2019 substances 3 Additional factors having an impact on air concentration 4 Discussion 5 Conclusion and outlook Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgements References", "Funding": "Funding body information This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The research was conducted as scientific expert contribution of the authors to the industry association, CropLife Europe. CropLife Europe finances the publication fees for this article. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The research was conducted as scientific expert contribution of the authors to the industry association, CropLife Europe. CropLife Europe finances the publication fees for this article. CRediT authorship contribution statement Edgars Felkers: Conceptualization, Investigation, Writing \u2013 original draft, Writing \u2013 review & editing, Visualization, Supervision, Project administration, Funding acquisition. Felix M. Kluxen: Conceptualiza- tion, Investigation, Writing \u2013 original draft, Writing \u2013 review & editing. Sarah Adham: Writing \u2013 review & editing. Anne-Kim Vinck: Writing \u2013 review & editing. Neil Morgan: Writing \u2013 review & editing. Declaration of competing interest Koerdel, W., et al., 1999. Entwicklung eines mehrstufigen Verfahrens zur Bewertung des Eintrages von Pflanzenschutzmitteln in terrestrische Oekosysteme ueber den Luftpfad. Umweltbundesamt (UBA, German Environment Agency. Martin, S., et al., 2008. Guidance for exposure and risk evaluation for bystanders and residents exposed to plant protection products during and after application. J. f\u00fcr Verbraucherschutz Lebensmittelsicherheit 3, 272\u2013281. Morris, J.B., 2012. Biologically-based modeling insights in inhaled vapor absorption and dosimetry. Pharmacol. Ther. 136, 401\u2013413. PSD, 2008. Bystander Exposure Guidance. Pesticide Safety Directorate. Siebers, J., et al., 2003. Investigation on downwind short-range transport of pesticides after application in agricultural crops. Chemosphere 51, 397\u2013407. van Hemmen, J.J., et al., 2002. The development, maintenance and dissemination of generic European databases and predictive exposure models to plant protection products. FAIR3 CT96-1406 a EUROPOEM operator exposure database: a EUROPOEM bystander exposure database and harmonised model; a EUROPOEM re- entry exposure database and harmonised model; an evaluation of the nature and efficacy of exposure mitigation methods; a tiered approach to exposure and risk assessment. FAIR3 CT96-1406. Winkler, R., Koch, W., 2005. Exposure via Air (EVA 2.0.1) Assessment of the Short Range Transport and Deposition of Pesticides for Aquatic and Terrestrial Ecosystems. Umweltbundesamt (UBA, German Environment Agency. E. Felkers et al. http://refhub.elsevier.com/S0273-2300(22)00059-9/sref1 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref1 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref1 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref2 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref2 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref2 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref3 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref3 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref3 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref4 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref4 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref4 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref5 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref5 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref6 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref6 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref6 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref7 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref7 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref7 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref8 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref8 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref8 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref8 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref8 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref8 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref8 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref9 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref9 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref10 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref10 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref10 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref11 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref11 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref12 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref12 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref12 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref13 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref13 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref13 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref14 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref14 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref15 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref16 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref16 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref17 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref17 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref17 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref17 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref17 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref17 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref17 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref18 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref18 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref18 Review of air concentrations of pesticides for estimating exposure to vapour in European risk assessments 1 Introduction 1.1 Air concentration from a risk assessment perspective 1.2 Grouping active substances according to vapour pressure 2 Current database for estimating inhalation exposure 2.1 \u2018Low volatility\u2019 substances 2.2 \u2018Moderately volatile\u2019 substances 3 Additional factors having an impact on air concentration 4 Discussion 5 Conclusion and outlook Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgements References", "Acknowledgement": "Acknowledgements The authors would like to thank Christian J. Kuster (Bayer) for procedural assistance during the writing of the paper. Koerdel, W., et al., 1999. Entwicklung eines mehrstufigen Verfahrens zur Bewertung des Eintrages von Pflanzenschutzmitteln in terrestrische Oekosysteme ueber den Luftpfad. Umweltbundesamt (UBA, German Environment Agency. Martin, S., et al., 2008. Guidance for exposure and risk evaluation for bystanders and residents exposed to plant protection products during and after application. J. f\u00fcr Verbraucherschutz Lebensmittelsicherheit 3, 272\u2013281. Morris, J.B., 2012. Biologically-based modeling insights in inhaled vapor absorption and dosimetry. Pharmacol. Ther. 136, 401\u2013413. PSD, 2008. Bystander Exposure Guidance. Pesticide Safety Directorate. Siebers, J., et al., 2003. Investigation on downwind short-range transport of pesticides after application in agricultural crops. Chemosphere 51, 397\u2013407. van Hemmen, J.J., et al., 2002. The development, maintenance and dissemination of generic European databases and predictive exposure models to plant protection products. FAIR3 CT96-1406 a EUROPOEM operator exposure database: a EUROPOEM bystander exposure database and harmonised model; a EUROPOEM re- entry exposure database and harmonised model; an evaluation of the nature and efficacy of exposure mitigation methods; a tiered approach to exposure and risk assessment. FAIR3 CT96-1406. Winkler, R., Koch, W., 2005. Exposure via Air (EVA 2.0.1) Assessment of the Short Range Transport and Deposition of Pesticides for Aquatic and Terrestrial Ecosystems. Umweltbundesamt (UBA, German Environment Agency. E. Felkers et al. http://refhub.elsevier.com/S0273-2300(22)00059-9/sref1 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref1 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref1 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref2 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref2 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref2 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref3 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref3 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref3 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref4 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref4 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref4 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref5 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref5 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref6 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref6 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref6 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref7 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref7 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref7 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref8 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref8 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref8 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref8 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref8 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref8 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref8 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref9 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref9 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref10 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref10 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref10 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref11 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref11 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref12 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref12 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref12 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref13 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref13 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref13 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref14 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref14 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref15 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref16 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref16 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref17 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref17 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref17 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref17 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref17 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref17 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref17 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref18 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref18 http://refhub.elsevier.com/S0273-2300(22)00059-9/sref18 Review of air concentrations of pesticides for estimating exposure to vapour in European risk assessments 1 Introduction 1.1 Air concentration from a risk assessment perspective 1.2 Grouping active substances according to vapour pressure 2 Current database for estimating inhalation exposure 2.1 \u2018Low volatility\u2019 substances 2.2 \u2018Moderately volatile\u2019 substances 3 Additional factors having an impact on air concentration 4 Discussion 5 Conclusion and outlook Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Review-of-fullerene-toxicity-and-exposure---Appraisal_2010_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20800639", "content": {"Acknowledgement": "Overall conclusions and recommendations Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Review-of-genotoxicity-and-rat-carcinogenicity-i_2016_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26713891", "content": {"CoiStatement": "Conflicts of interest The authors are employees of DSM Nutritional Products Ltd, which manufactures synthetic astaxanthin. 6. Discussion 7. Conclusion Funding sources statement Conflicts of interest Acknowledgments Transparency document References", "Funding": "Funding sources statement The rat carcinogenicity study was sponsored by F. Hoffmann-La Roche Ltd. (Basel, Switzerland), who developed the specific astax- anthin formulation later acquired by DSM Nutritional Products Ltd. 6. Discussion 7. Conclusion Funding sources statement Conflicts of interest Acknowledgments Transparency document References", "Acknowledgement": "Acknowledgments Acknowledgement is appropriate to the dedicated toxicologists and pathologists who supervised the long term studies with astaxanthin, in particular to Dr S. Buser and Dr H-J. Chevalier. Acknowledgement is appropriate to the dedicated toxicologists and pathologists who supervised the long term studies with astaxanthin, in particular to Dr S. Buser and Dr H-J. Chevalier. Transparency document 6. Discussion 7. Conclusion Funding sources statement Conflicts of interest Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Review-of-health-safety-aspects-of-nanotechnol_2009_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19027049", "content": {"CoiStatement": "At this stage of (lack of) knowledge of nanotoxicology it is unavoidable that risk assessors need as much information as pos- sible about NPs and their appearance and behavior in biological matrices and organisms. Over time it will be possible to evaluate the data and look for the set of pivotal information. This clearly needs close collaborations between NP (and products) developers, risk assessors, regulators and researchers. Conflict of Interest statements The authors declare that there are no conflicts of interest. Acknowledgments The authors declare that there are no conflicts of interest. Acknowledgments Dr. W. de Jong (RIVM), Prof. Dr. I.M.C.M. Rietjens (Wageningen University) and Dr. A.C.M. Peijnenburg (RIKILT\u2014WUR) are thanked for their contribution to discussions that formed the basis of this paper. The research described in this paper was commissioned and funded by the Dutch and Consumer Products Safety Authority, Office for Risk Assessment. Consequences for risk assessment of NPs Conflict of Interest statements Acknowledgments References", "Disclosure": "\ufffd Elaborate regulatory/policy approaches for the disclosure of information on NPs being produced including the products they are incorporated in. This request for extra information is not to be considered solely as a request for additional newly developed studies. It can also im- ply that conventional study approaches need to be redesigned. The use of novel technologies (e.g., profiling approaches) and the more frequent use of in vitro approaches for risk assessment need to be studied and used in parallel with conventional techniques.", "Acknowledgement": "The authors declare that there are no conflicts of interest. Acknowledgments Dr. W. de Jong (RIVM), Prof. Dr. I.M.C.M. Rietjens (Wageningen University) and Dr. A.C.M. Peijnenburg (RIKILT\u2014WUR) are thanked for their contribution to discussions that formed the basis of this paper. The research described in this paper was commissioned and funded by the Dutch and Consumer Products Safety Authority, Office for Risk Assessment. Consequences for risk assessment of NPs Conflict of Interest statements Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Review-of-mechanistic-studies-relevant-to-the-pot_2011_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21050878", "content": {"CoiStatement": "Discussion Conflict of interest Acknowledgement References", "Acknowledgement": "C.A. Schreiner / Regulatory Toxicology and Pharmacology 59 (2011) 270\u2013284 283 Acknowledgement The author wishes to acknowledge the support and scientific expertise of the members of the Ad Hoc Toxicology Task Force of the Asphalt Institute in the preparation of this publication. This work was funded by the Asphalt Institute. References Discussion Conflict of interest Acknowledgement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Review-of-regulatory-reference-values-and-backgrou_2022_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/35090957", "content": {"CoiStatement": "8 Consideration of carcinogenicity of metals in foods 9 Conclusions Funding body information Declaration of competing interest Acknowledgements References", "Funding": "8 Consideration of carcinogenicity of metals in foods 9 Conclusions Funding body information Declaration of competing interest Acknowledgements References", "Compliance with ethical standards": "District of Columbia Water and Sewer Authority, 2019. Lead and Copper Compliance Report January through June 2019, vols. 1\u201339. June. EFSA, 2012a. Cadmium Dietary Exposure in the European Population. https://efsa.onli nelibrary.wiley.com/doi/pdf/10.2903/j.efsa.2012.2551. Sun, H., Brocato, J., Costa, M., 2015. Oral chromium exposure and toxicity compliance with ethics guidelines human and animal rights and informed consent HHS public access. Curr. Environ. Health Rep. 2 (3), 295\u2013303. https://doi.org/10.1007/s40572- 015-0054-z. Suwazono, Y., Sand, S., Vahter, M., Filipsson, A.F., Skerfving, S., Lidfeldt, J., \u00c5kesson, A., 2006. Benchmark dose for cadmium-induced renal effects in humans. Environ. Health Perspect. 114 (7), 1072\u20131076. https://doi.org/10.1289/ehp.9028.", "Acknowledgement": "8 Consideration of carcinogenicity of metals in foods 9 Conclusions Funding body information Declaration of competing interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Review-of-the-Epidemiological-Evidence-Relating-_2001_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/11350197", "content": {"Acknowledgement": "ACKNOWLEDGMENTS I thank Dr. Jennie Kline of Columbia University for providing sub- stantial review and commentary on this paper and for her invaluable technical assistance. This review was funded through a contract with the Aromatics Producers Association. REFERENCES EVALUATION OF THE OCCUPATIONAL STUDIES DISCUSSION CONCLUSIONS ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Review-of-the-in-vitro-and-in-vivo-genotoxic_2007_Regulatory-Toxicology-and-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/17936460", "content": {"Acknowledgement": "Discussion Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Review-of-the-pharmacokinetics-and-metabolism-of-tri_2020_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32640299", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: The author Bartels is a paid consultant to Corteva Agriscience, who funded this work. The authors Brown, Chung and Pye are employees of NewCells Technology, which was funded by Corteva Agriscience to conduct the renal transporter experiments. The authors Chan, Terry, Gehen and Corvaro are employees of Corteva Agriscience. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: The author Bartels is a paid consultant to Corteva Agriscience, who funded this work. The authors Brown, Chung and Pye are employees of NewCells Technology, which was funded by Corteva Agriscience to conduct the renal transporter experiments. The authors Chan, Terry, Gehen and Corvaro are employees of Corteva Agriscience. Appendix A. Supplementary data Discussion Role of the funding source Declaration of competing interest Supplementary data References", "Funding": "Role of the funding source You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the col- lection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated. You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the col- lection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated. This manuscript includes a review of existing pharmacokinetic and metabolism studies conducted with triclopyr, as well as new studies measuring plasma protein binding of triclopyr and renal transporter activities. All existing and new study data has been funded by Corteva Agriscience (formerly Dow AgroSciences, part of the Dow Chemical Company). Discussion Role of the funding source Declaration of competing interest Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Review-of-the-toxicity-of-chemical-mixtures--Theo_2006_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16701933", "content": {"Acknowledgement": "Discussion Conclusions and recommendations Acknowledgments References Note: over 100 additional publications were identified in the literature search. For various reasons (no original data or data already cited in another paper, material addressed in another paper, etc.) these documents were not cited."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Review-of-the-toxicity-of-chemical-mixtures-cont_2006_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16701931", "content": {"Acknowledgement": "Evaluative summary Discussion Conclusions Acknowledgments References Over 100 additional publications were identified in the literature search. For various reasons (no original data or data already cited in another paper, material addressed in another paper, etc.) these documents were not cited."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Revised-assessment-of-cancer-risk-to-dichloromethane-I_2006_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16439044", "content": {"Acknowledgement": "Acknowledgments The authors express their appreciation to Mr. Eric Hack for his contribution to the analyses, and to Drs. Thomas Starr and M.W. Anders for their insightful suggestions and thoughts regarding the design and con- duct of this eVort and regarding the preparation of this manuscript. Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Revised-assessment-of-cancer-risk-to-dichloromethane_2006_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16442684", "content": {"Acknowledgement": "Bayesian PBPK and dose\u2013response modeling were undertaken in the mouse for DCM and the results show that internal dose metrics from the calibrated mouse mod- el are 3- to 4-fold higher than values used by USEPA to derive its current unit risk factor for DCM. This differ- ence is mainly attributable to the use of improved parti- tion coefficients (Clewell et al., 1993), as well as refined kinetic parameters resulting from Bayesian updating. Bayesian modeling is known to be particularly well suited for updating model parameterizations with newly avail- able experimental data, or for recalibrating models that have been fit using less sophisticated approaches, such as visual fitting or maximum likelihood estimation for a subset of the parameters. Therefore, the results of this effort are particularly well suited for derivation of an improved unit risk factor for DCM (David et al., 2005). Acknowledgments The authors express their appreciation to Dr. Thomas Starr and Dr. M.W. Anders for their insightful suggestions and thoughts regarding the design and conduct of this ef- fort and regarding the preparation of the manuscript. References Discussion Conclusion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Revision-of-omalizumab-dosing-table-for-dosing-every-4_2015_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25497995", "content": {"CoiStatement": "Conflict of interest Philip J. Lowe is an employee of Novartis Pharma AG, Basel, Switzerland. Panayiotis Georgiou and Janice Canvin were employ- ees of Novartis Pharmaceuticals UK Limited, Horsham, West Sus- sex, UK during the conduct of the study. 4 Discussion 5 Conclusions Conflict of interest Contributions of authors statement Acknowledgements References", "Compliance with ethical standards": "Cochrane, G.M., 1992. Therapeutic compliance in asthma; its magnitude and implications. Eur. Respir. J. 5, 122\u2013124. http://refhub.elsevier.com/S0273-2300(14)00295-5/h0005 http://refhub.elsevier.com/S0273-2300(14)00295-5/h0005 http://refhub.elsevier.com/S0273-2300(14)00295-5/h0005 http://nonmem.iconplc.com/Public/nonmem720/guides/v.pdf http://nonmem.iconplc.com/Public/nonmem720/guides/v.pdf http://refhub.elsevier.com/S0273-2300(14)00295-5/h0015 http://refhub.elsevier.com/S0273-2300(14)00295-5/h0015 http://refhub.elsevier.com/S0273-2300(14)00295-5/h0015 http://refhub.elsevier.com/S0273-2300(14)00295-5/h0015 http://refhub.elsevier.com/S0273-2300(14)00295-5/h0020 http://refhub.elsevier.com/S0273-2300(14)00295-5/h0020 http://refhub.elsevier.com/S0273-2300(14)00295-5/h0020 http://refhub.elsevier.com/S0273-2300(14)00295-5/h0025 http://refhub.elsevier.com/S0273-2300(14)00295-5/h0025 P.J. Lowe et al. / Regulatory Toxicology and Pharmacology 71 (2015) 68\u201377 77 Cochrane, G.M., Horne, R., Chanez, P., 1999. Compliance in asthma. Respir. Med. 93, 763\u2013769. Croisant, S., 2014. Epidemiology of asthma: prevalence and burden of disease. Adv. Exp. Med. Biol. 795, 17\u201329.", "Acknowledgement": "Acknowledgements The authors gratefully acknowledge the support of Aur\u00e9lie Gau- tier for the preparation of datasets for modeling, running some of the analyses and for validating that Philip J. Lowe\u2019s calculations were correct. References 4 Discussion 5 Conclusions Conflict of interest Contributions of authors statement Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Revision-of-the-opinion-on-hydrolysed-wheat-pro_2015_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26279001", "content": {"Acknowledgement": "Revision of the opinion on hydrolysed wheat proteins \u2013 Sensitisation only 1. Conclusion of the opinion Acknowledgement Transparency document"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Revision-of-the-opinion-on-peanut-oil---Sen_2015_Regulatory-Toxicology-and-P.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26275710", "content": {"Acknowledgement": "Revision of the opinion on peanut oil \u2013 Sensitisation only 1. Conclusion of the opinion Acknowledgement Transparency document"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-Analysis-for-Mortality-from-Respiratory-Tumors_2002_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/11846639", "content": {"Acknowledgement": "CONCLUDING COMMENTS ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-Assessment-of-residual-monomer-migrating-from-acry_2014_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24859074", "content": {"CoiStatement": "Conflict of interest Acknowledgment References", "Acknowledgement": "Conflict of interest Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-and-safety-assessment-of-exogenous-human-brain-nat_2010_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19766684", "content": {"Acknowledgement": "154 Y. Mao et al. / Regulatory Toxicology and Pharmacology 56 (2010) 148\u2013155 Although some studies demonstrate the potential dangers of nesiritide, the unique pharmacological profile of this medication provides an additional treatment option for patients with ADHF. From the result of our work and literatures, the use of this drug at the present time should be weighed against the possibility of worse outcomes, when used for approved indications and accord- ing to guideline recommendations (Heart Failure Society, 2006). However, despite the similarities between human and other pri- mates, a number of differences are present between monkeys and patients. When possible, results from studies utilizing different animal models should be combined to capture a fuller picture of a particular condition. All of the relevant preclinical data, including information on the pharmacologically active dose, the full toxico- logical profile, and the pharmacokinetics of the therapeutic, should be considered comprehensively when it is used in human. Further large-scale randomized controlled clinical trials would be required to elucidate the effects of exogenous BNP on clinical outcomes in heart failure and aid in rationale risk assessments. Acknowledgment The study was supported by grants from National Natural Sci- ence Foundation of China (30873132). Reference Discussion Acknowledgment Reference"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-and-safety-assessment-on-the-consumption-of-Licorice-r_2006_Regulatory-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16884839", "content": {"Acknowledgement": "Discussion and conclusions Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-assessment-and-Biomonitoring-Equivalent-for-2-eth_2017_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28751265", "content": {"Acknowledgement": "The RfD derived is considered to be of medium confidence as a result of the toxicology studies being conducted in only one species. Asmore toxicology studies become available for TBB, the RfD can be revisited. Likewise, the BE estimates derived here can be updated once a human based Fue becomes available. In the meantime, the MOS estimates derived here can help make formative decisions about prioritization for TBB. Acknowledgements This work was funded by the Chemtura corporation. Risk assessment and Biomonitoring Equivalent for 2-ethylhexyl-2,3,4,5 tetrabromobenzoate (TBB) and tetrabromobenzoic acid ( ... 1. Introduction 2. Methods 2.1. Biomonitoring data 2.2. Risk assessment 2.2.1. Data sets 2.2.1.1. 28-Day toxicity study (WIL, 1997) 2.2.1.2. Developmental toxicity study (MPI, 2008a) 2.2.1.3. Two-generation reproductive toxicity study (MPI, 2008b) 2.2.2. Dose measure 2.2.3. Dose-response modeling 2.2.4. Point of departure 2.2.5. Uncertainty factors 2.2.6. Pharmacokinetic data 3. Results 3.1. Dose-response assessment 3.2. Biomonitoring Equivalents 3.3. Margin of safety 4. Discussion Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-assessment-due-to-environmental-exposures-to-f_2008_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18207296", "content": {"CoiStatement": "S244 R. Wilson et al. / Regulatory Toxicology and Pharmacology 52 (2008) S232\u2013S245 Conflict of Interest The authors declare that they have no conflicts of interest. The authors declare that they have no conflicts of interest. Acknowledgments World Trade Center Indoor Environmental Assessment: Selecting Contaminates of Potential Concern Setting Health-Based Bench- marks. Task Force Working Group (EPA, Agency for Toxic Substances and Disease Registry, NYC Dept. of Health and Mental Hygiene and the Occupational Safety and Health Admin- istration, May 2003. http://www.epa.gov/oigearth/index.htm http://www.epa.gov/iris/subst/0371.htm http://www.who.int/pcs/docs/ehc_203.htm Risk assessment due to environmental exposures to fibrous particulates associated with taconite ore Introduction Origin of the problem Changes in the state of knowledge regarding asbestos and other fibers United states consumer product safety commission and the occupational safety and health administration address cleavage fragments Geological survey of the peter mitchell pit Risk assessment for asbestos General comments EPA-IRIS aggregate risk coefficient Exposures to fibrous minerals in Silver Bay, MN Comparison with EPA led task force working group doing risk assessment for asbestos exposure world trade center post-9/11 Hodgson and Darnton (2000) asbestos fiber type specific risk coefficients for each asbestos-related disease Conclusions Conflict of Interest Acknowledgments References", "Acknowledgement": "Acknowledgments We acknowledge support from a Higher Education Ad- vance Technology grant from New York State and the International Environmental Research Foundation (www.ierfinc.org) of New York, New York and assistance from Cleveland-Cliffs, Cleveland, Ohio. World Trade Center Indoor Environmental Assessment: Selecting Contaminates of Potential Concern Setting Health-Based Bench- marks. Task Force Working Group (EPA, Agency for Toxic Substances and Disease Registry, NYC Dept. of Health and Mental Hygiene and the Occupational Safety and Health Admin- istration, May 2003. http://www.epa.gov/oigearth/index.htm http://www.epa.gov/iris/subst/0371.htm http://www.who.int/pcs/docs/ehc_203.htm Risk assessment due to environmental exposures to fibrous particulates associated with taconite ore Introduction Origin of the problem Changes in the state of knowledge regarding asbestos and other fibers United states consumer product safety commission and the occupational safety and health administration address cleavage fragments Geological survey of the peter mitchell pit Risk assessment for asbestos General comments EPA-IRIS aggregate risk coefficient Exposures to fibrous minerals in Silver Bay, MN Comparison with EPA led task force working group doing risk assessment for asbestos exposure world trade center post-9/11 Hodgson and Darnton (2000) asbestos fiber type specific risk coefficients for each asbestos-related disease Conclusions Conflict of Interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-assessment-for-consumer-exposure-to-toluene-dii_2012_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22871374", "content": {"CoiStatement": "4 Discussion 5 Conclusion Conflict of interest statement Acknowledgments References", "Acknowledgement": "4 Discussion 5 Conclusion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-assessment-for-pyrrolizidine-alkaloids-detecte_2017_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28347763", "content": {"CoiStatement": "The authors declare that they have no conflict of interest. Acknowledgements", "Acknowledgement": "Acknowledgements This work was funded by a grant from the China Scholarship Council to Lu Chen (grant No. 201508650023). 4. Discussion Note Acknowledgements Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-assessment-for-the-amino-acids-taurine--l_2008_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18325648", "content": {"CoiStatement": "Discussion Conflict of interest statement Acknowledgment References", "Acknowledgement": "Discussion Conflict of interest statement Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-assessment-implications-of-site-specific-oral-relative-_2020_Regulatory.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32234330", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. Conclusions Declaration of competing interest Acknowledgements References", "Funding": "Given the limited resources available (e.g., remediation program funding), scientifically-sound decisions by risk managers are imperative in prioritizing the highest risk sites and using available funds to achieve the largest reductions in site contamination-related human health risk. Knowledge of the COC screening and risk assessment implications of the site-specific information gained through the PAH bioavailability study for this SSR site may allow others to better understand the po- tential benefits (e.g., cost effectiveness) of such a study at similarly affected sites and make more informed decisions. Table 8 PAH-specific surface soil sampling results versus generic screening levelsa.", "Acknowledgement": "Acknowledgements USACE funded the work by Arcadis U.S., Inc. on this paper as well as the related state-of-the science bioavailability project that provided the RBAF and ABS.d values used in this paper. The related PAH bioavail- ability project is the subject of other publications (in progress) and came to fruition through several years of productive collaboration be- tween the USACE, their consultants Arcadis U.S., Inc., the TCEQ, and the USEPA Technical Review Workgroup Bioavailability Committee on the bioavailability study plan and associated results. Dr. Stephen Roberts of the University of Florida graciously provided additional expertise and technical review. The statements and opinions expressed herein are solely those of the study authors and do not necessarily re- present those of the TCEQ, USEPA, USACE, Arcadis U.S., Inc., or other associated entities (e.g., DOD). Furthermore, this study does not re- present an official or complete evaluation of the referenced site under the TCEQ TRRP program. Conclusions Declaration of competing interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-assessment-of-chemicals-and-pharmaceuticals-i_2005_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15896447", "content": {"Compliance with ethical standards": "Matsui, D., Hermann, C., Braudo, M., Ito, S., Olivieri, N., Koren, G., 1992. Clinical use of the Medication Event Monitoring System: a new window into pediatric compliance. Clin. Pharmacol. Ther. 52, 102\u2013103. Matsui, D., 1997. Drug compliance in pediatrics: clinical and research issues. Pediatr. Clin. North Am. 44, 1\u201314. Mendola, P., Lobdell, D.T., 2004. Development of a biomarkers data- base for the national children\u2019s study. Presented at the Interna- tional Conference on Biomarkers for Toxicology and Molecular Epidemiology. Atlanta, Georgia, March 15\u201317, 2004. Matsui, D., 1997. Drug compliance in pediatrics: clinical and research issues. Pediatr. Clin. North Am. 44, 1\u201314. Mendola, P., Lobdell, D.T., 2004. Development of a biomarkers data- base for the national children\u2019s study. Presented at the Interna- tional Conference on Biomarkers for Toxicology and Molecular Epidemiology. Atlanta, Georgia, March 15\u201317, 2004. Metcalf, S.W., Samet, J., Hanrahan, J., Schwartz, D., Hunninghake, G., 1994. A Standardized Test Battery for Lung and Respiratory Dis- eases for Use in Environmental Health Field Studies, Agency for Toxic Substances and Disease Registry, U.S. Department of Health and Human Services, Atlanta. Milgrom, H., Bender, B., Ackerson, L., Bowry, P., Smith, B., Rand, C., 1996. Noncompliance and treatment failure in children with asthma. J. Allergy Clin. Immunol. 98, 1051\u20131057. Morcelli, P.L., Franco-Morcelli, R., Bossi, L., 1980. Clinical pharmaco- kinetics in newborns and infants\u2014Age-related diVerences and ther- apeutic implications. Clin. Pharmacokinet. 5, 485\u2013527.", "Acknowledgement": "Using PBPK modeling to assess chemical risk in pediatric populations Conclusions and recommendations Acknowledgments References Further reading"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-assessment-of-chlorpyrifos-on-rice-and_2012_Regulatory-Toxicology-and-P.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22210174", "content": {"CoiStatement": "Based on the supervised residue trials and the risk assessment results, the application of chlorpyrifos at the recommended dose on rice and cabbage is quite safe in China from crop protection and human health point of view. The advantages of the application of pesticides in agriculture in producing better crops must be weighed against the possible health hazard arising from the pesti- cide residues in food. Pesticides should be applied according to GAP, using the required amounts. Conflict of interest statement We declare that there are none competing interests related to our manuscript. References We declare that there are none competing interests related to our manuscript. References Boobis, A.R., Ossendorp, B.C., Banasiak, U., Hamey, P.Y., Sebestyen, I., Moretto, A., 2008. Cumulative risk assessment of pesticide residues in food. Toxicol. Lett. 180, 137\u2013150. 4 Conclusion Conflict of interest statement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-assessment-of-ciprofloxacin--flavomycin--olaquind_2009_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19545513", "content": {"Acknowledgement": "Acknowledgments This study was supported by National Veterinary Research and Quarantine Service, South Korea. We thank to Seung-Hyun Kim for her excellent technical assistance. Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-assessment-of-combined-exposure-to-multiple_2011_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21466831", "content": {"Acknowledgement": "Discussion Acknowledgments References Introduction Considering the need for a framework analysis Purpose and focus of the assessment The framework analysis Tier 0 Exposure assessment Hazard assessment Risk characterization/analysis of uncertainties Tier 1 Exposure assessment Hazard assessment Risk characterization/analysis of uncertainties Acknowledgments References Introduction Considering the need for a framework analysis Purpose and focus of the assessment The framework analysis Tier 0 Exposure assessment Hazard assessment Risk characterization/analysis of uncertainties Conclusions References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-assessment-of-endocrine-active-chemicals--Ide_2012_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22735369", "content": {"CoiStatement": "For human health assessments the debate should now move from developing the concept to running many case studies through the revised framework. For ecotoxicological assessments further development is needed for the criteria proposed to allow them to be fully operational in a regulatory context. ECETOC hopes that the criteria proposed in this paper will contribute to the ongoing development of regulatory guidance under the relevant legislations. Conflict of interest statement The authors declare that there are no conflicts of interest. Mel- anie Gross\u2019 involvement in the production of the manuscript was supported by ECETOC. Acknowledgment The authors declare that there are no conflicts of interest. Mel- anie Gross\u2019 involvement in the production of the manuscript was supported by ECETOC. Acknowledgment The ECETOC task force is grateful for the expert input received from the invited participants at the workshop held in Florence on May 9\u201310, 2011, which the task force has used to refine its original guidance. References 4 Summary and conclusions Conflict of interest statement Acknowledgment References", "Acknowledgement": "The authors declare that there are no conflicts of interest. Mel- anie Gross\u2019 involvement in the production of the manuscript was supported by ECETOC. Acknowledgment The ECETOC task force is grateful for the expert input received from the invited participants at the workshop held in Florence on May 9\u201310, 2011, which the task force has used to refine its original guidance. References 4 Summary and conclusions Conflict of interest statement Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-assessment-of-formaldehyde-for-the-gener_2005_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16185798", "content": {"Compliance with ethical standards": "The 50% lethal doses (LD50, LC50) of formaldehyde in laboratory animals are shown in Table 1. Acute inhalation exposure to formaldehyde at 1 ppm pro- duces decreased respiratory rates in mice and rats, increased airway resistance, and decreased compliance in guinea pigs (Amdur, 1960; Barrow et al., 1983). Exposure to 2 ppm formaldehyde for 6 h induces an inhibition of mucociliary clearance and histopatholo- gical changes within the nasal cavity in rats (Morgan et al., 1986a). Decreased respiratory rates and compli- ance, increased airway resistance, and eye irritation have been observed at 10 ppm formaldehyde in rats, mice, and guinea pigs (Bhalla et al., 1991; Kane and Alarie, 1977; Morgan et al., 1986a,b). Salivation, dysp- noea, vomiting, and muscular spasms have been observed at 100 ppm formaldehyde in mice (Bitron and Aharonson, 1978; IPCS-EHC, 1989). 2.3. Short-term and subchronic toxicity 2.3.1. Inhalation Short-term and subchronic inhalation toxicity stud-"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-assessment-of-gamma-hydroxybutyric-acid--_2012_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22440552", "content": {"CoiStatement": "11 Availability 12 Criminality 13 Current legal status 14 Assessment by CAM 15 Critical considerations Conflict of interest statement Acknowledgments References", "Acknowledgement": "11 Availability 12 Criminality 13 Current legal status 14 Assessment by CAM 15 Critical considerations Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-assessment-of-human-health-from-exposure-to-the-_2016_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26997144", "content": {"Acknowledgement": "Acknowledgments This work was supported by the Doctoral Scientific Research Foundation of Shanghai Ocean University (No. A2-0302-14- 300063); Shanghai Young Teachers Culture Program (No. A1-2035- 15-0021-112); China's Marine Public Welfare Projects (No. 201305027); Marine First-class Disciplines of Shanghai Ocean University and National Science Foundation of Shanghai (No. 15zr1420900). 4. Conclusions Acknowledgments Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-assessment-of-khat-use-in-the-Netherlands--A-revie_2008_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18783727", "content": {"Acknowledgement": "Risk assessment of khat by CAM Discussion and Overall Conclusionoverall conclusion AcknowledgementAcknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-assessment-of-local-dermal-effects-and-skin-sensitisa_2011_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21545823", "content": {"CoiStatement": "We conclude that our approach is an improvement of the meth- odology for risk assessment of local dermal effects and skin sensi- tisation that has been used before within the framework of REACH, only prescribing general recommendations on RMM without fur- ther specification and risk assessment. Furthermore, our methodol- ogy, when agreed by stakeholders, may be transferred into automated assessment tools like Chesar5 and CEFIC GES4. In this way the approach could easily be used consistently and without too much additional efforts by registrants and evaluating authorities. Conflict of interest statement The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgments 6 Discussion Conflict of interest statement Acknowledgments References", "Acknowledgement": "Acknowledgments The authors would like to thank T. Bouwman (Risk Assessor Toxicology at TNO Quality of Life) and E.I.M. Tjoe Nij (Exposure Assessor at TNO Quality of Life) for their critical review of this manuscript and their valuable contributions. The financial support provided by the Dutch Ministry of Social Affairs and Employment is gratefully acknowledged. 6 Discussion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-assessment-of-mixtures-of-pesticides--Curren_2010_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19782118", "content": {"CoiStatement": "Advantages and disadvantages of the methods Proposed flow charts for risk assessment of mixtures of chemicals Defined cumulative assessment groups/common mechanism groups for pesticides Newer approaches in the risk assessment of mixtures Conclusion Conflict of Interest statement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-assessment-of-occupational-pesticide-exposur_2018_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30130552", "content": {"Funding": "Funding This work was supported by CAPES (Higher Level Personnel Improvement Commission, Brazil), financial support and scholarship, and FAPEMIG (Foundation to support the research of Minas Gerais, Brazil) grant number [APQ-02281-16]. Risk assessment of occupational pesticide exposure: Use of endpoints and surrogates Introduction Risk assessment to pesticides Use of endpoints in risk assessment of pesticides Use of surrogate endpoints to pesticides exposure Conclusions Funding Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-assessment-of-oral-exposure-to-diisononyl-p_2004_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15450718", "content": {"Acknowledgement": "Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-assessment-of-pesticide-residues-in-dietar_2015_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26344481", "content": {"Acknowledgement": "Acknowledgments This study is supported financially by the Open Project Program of Shandong Provincial Key Laboratory of Test Technology on Food Quality and Safety (No: 2013KF06). 5. Conclusion Author contributions Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-assessment-of-predicted-serum-concentrations-of-bispheno_2021_Regulator.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33301868", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Bradford D. Bagley is a current employee and stockholder of 3M, the manufacturer of the evaluated products. Jordan N. Smith and Justin G. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Bradford D. Bagley is a current employee and stockholder of 3M, the manufacturer of the evaluated products. Jordan N. Smith and Justin G. Teeguarden are employees of Pacific Northwest National Laboratory and Oregon State University and were contracted by 3M to perform the physiological-based pharmacokinetic modeling described in this publication. Funding body information Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Funding": "Funding body information 3M Company funded the work referenced in \u201cPredicted Serum Concentrations of Bisphenol A in Children and Adults Following Treat- ment with Dental Composite Restoratives, Dental Sealants, or Ortho- dontic Adhesives using Physiologically Based Pharmacokinetic Modeling.\u201d Funding body information Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Acknowledgement": "Acknowledgements The authors would like to thank Dr. Lori H. Moilanen for her knowledge and insights during the inception of this project. Funding body information Declaration of competing interest Acknowledgements Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-assessment-of-skin-lightening-cosmetics-_2016_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27521610", "content": {"Acknowledgement": "M. Matsumoto et al. / Regulatory Toxicology and Pharmacology 81 (2016) 128e135 135 Acknowledgement This study was supported by the Ministry of Health, Labour and Welfare, Japan (grant no: H24-Tokubetsu-Shitei-028). 3. Results 4. Discussion Acknowledgement Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-assessment-of-thujone-in-foods-and-medicines-cont_2010_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20727933", "content": {"CoiStatement": "In conclusion, we currently see no risk associated with the occa- sional medicinal use of wormwood or sage (especially in the tradi- tional use as herbal tea). However, we agree with the EMA (2009a,b) that the database regarding the thujone exposure via medicines is extremely limited. This database should be expanded in the future, preferably to include quantitative risk\u2013benefit analy- ses (Lachenmeier, 2010). Conflict of interest statement The authors declare that there are no conflicts of interest. No funding was specific to the production of this manuscript. The sal- aries for authors were provided by the affiliated organisation. The authors declare that there are no conflicts of interest. No funding was specific to the production of this manuscript. The sal- aries for authors were provided by the affiliated organisation. D.W. Lachenmeier, M. Uebelacker / Regulatory Toxicology and Pharmacology 58 (2010) 437\u2013443 443 Acknowledgments Conflict of interest statement Acknowledgments References", "Funding": "The authors declare that there are no conflicts of interest. No funding was specific to the production of this manuscript. The sal- aries for authors were provided by the affiliated organisation. D.W. Lachenmeier, M. Uebelacker / Regulatory Toxicology and Pharmacology 58 (2010) 437\u2013443 443 Acknowledgments", "Acknowledgement": "D.W. Lachenmeier, M. Uebelacker / Regulatory Toxicology and Pharmacology 58 (2010) 437\u2013443 443 Acknowledgments The authors thank Fotis Kanteres for English copy-editing the manuscript. Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-assessment-of-unintentional-phthalates-co_2020_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32474072", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. Discussion Funding Declaration of competing interest Acknowledgment References", "Funding": "Funding Organization: Ministry of Food and Drug Safety (MFDS). Address: 187, Osongsaengmyeong 2-ro, Osong-eup, Heungdeok-gu, Cheongju, Chungcheongbuk-do, 28159, Republic of Korea. Website: https://www.mfds.go.kr/eng/index.do. Discussion Funding Declaration of competing interest Acknowledgment References", "Acknowledgement": "Acknowledgment This work was supported by a grants (17172MFDS253 and 19172MFDS221) from the Ministry of Food and Drug Safety, Korea in 2017 and 2019. Discussion Funding Declaration of competing interest Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-assessment-study-of-dioxins-in-sanitary-n_2014_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25078889", "content": {"CoiStatement": "In conclusion, we performed risk assessment of dioxins in san- itary napkins produced in Japan by comparing the daily exposure volumes and TDI. The risk of exposure to dioxins through sanitary napkins is considered to be negligible. Conflict of interest We declare that there are no competing interests related to our manuscript. Acknowledgments We declare that there are no competing interests related to our manuscript. Acknowledgments This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. References 4 Discussion Conflict of interest Acknowledgments References", "Funding": "This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. References Bellelis, P., Podgaec, S., Abr\u00e3o, M.S., 2011. Environmental factors and endometriosis. Rev. Assoc. Med. Bras. 57, 448\u2013452.", "Acknowledgement": "We declare that there are no competing interests related to our manuscript. Acknowledgments This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. References 4 Discussion Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-assessment-to-human-health--Consumer-exposur_2018_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29857116", "content": {"CoiStatement": "Conflicts of interest The authors declare they have no conflict of interests. The authors declare they have no conflict of interests. Acknowledgment Discussion Conclusion Conflicts of interest Acknowledgment Transparency document References", "Acknowledgement": "Acknowledgment This work was supported by a grant from the National Institute of Environment Research (NIER), funded by the Korean Ministry of Environment (KME) of the Republic of Korea (NIER-2016-01-01-062). Discussion Conclusion Conflicts of interest Acknowledgment Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-assessments-for-the-insect-repellents-D_2008_Regulatory-Toxicology-and-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18406029", "content": {"Acknowledgement": "Acknowledgments We thank M. Debboun (US Army Medical Department Center and School), D. Strickman (USDA-ARS), G. White (University of Florida), and J. Schleier, R. Davis, and M. Schat (Montana State Uni- versity) for reviewing an earlier version of this paper. This study was funded by a grant from the U.S. Armed Forces Pest Manage- ment Board\u2019s Deployed War Fighter Protection Research Program, Montana State University, and the Montana Agricultural Experi- ment Station. Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-characterization-of-vapor-intrusion-in-form_2011_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21146574", "content": {"CoiStatement": "Conflict of interest No authors have any competing interest related to this research. Acknowledgments No authors have any competing interest related to this research. Acknowledgments This study was supported in part by the Center for Occupa- tional/Environmental Risk Analysis and Management, College of Public Health, University of South Florida, Tampa, Florida and GEI Consultants Inc. Discussion Conclusions Conflict of interest Acknowledgments References", "Acknowledgement": "No authors have any competing interest related to this research. Acknowledgments This study was supported in part by the Center for Occupa- tional/Environmental Risk Analysis and Management, College of Public Health, University of South Florida, Tampa, Florida and GEI Consultants Inc. Discussion Conclusions Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Risk-of-gastrointestinal-cancers-from-inhalatio_2008_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18078700", "content": {"CoiStatement": "Conflict of Interest Funding Source References", "Funding": "Conflict of Interest Funding Source References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Role-of-DNA-Adducts-in-Hormonal-Carcino_2000_Regulatory-Toxicology-and-Pharm.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/11162721", "content": {"Acknowledgement": "CONCLUSION ACKNOWLEDGEMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Role-of-Diosmin-in-protection-against-the-oxidative-s_2020_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32087353", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper.", "Funding": "Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Declaration of competing interest Discussion Funding mk:H1_22 Acknowledgments References", "Acknowledgement": "Acknowledgments We would like to specify pathology and electronic microscope de- partment, Theodor Bilharz Research Institute with our thanks in ap- preciation of the great assistance in the histopathology part of the study. Discussion Funding mk:H1_22 Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Role-of-iodine-in-diiodomethyl-p-tolylsulfone-induce_2012_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22051157", "content": {"CoiStatement": "Overall, the weight of evidence suggests that most of the effects of DIMPTS were due to release of its two iodine moieties into the systemic circulation (Saghir et al., 2011), resulting in a condition of iodine excess. This appears to have resulted in a mild hypothy- roid state in the parental animals, and caused effects on parturition (dystocia) and offspring survival that were consistent with the iodine toxicity hypothesis. Conflict of interest statement The authors work for the company at which the substance is produced. Miller Jr., R.G., 1966. Simultaneous Statistical Inference. McGraw-Hill, New York. Mullen, S.P., Schaeffer, S.J., Howell, R.D., Van Middlesworth, L., 1980. Smooth muscle paralysis from iodide feeding (abstract. Fedn. Proc. Fedn. Am. Socs. Exp. Biol. 39, 715. Saghir, S.A., Yano, B.L., Zablotny, C.L., Brzak, K.A., Clark, A.J., Staley, J.L., 2011. Role of iodine in the toxicity of diiodomethyl-p-tolylsulfone (DIMPTS) in rats: ADME Regul. Toxicol. Pharmacol. (submitted with this as a group). Siegel, S., 1956. Non-Parametric Statistics for the Behavioral Sciences. McGraw-Hill, New York. Spitzweg, C., Joba, W., Eisenmenger, W., Heufelder, A.E., 1999. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric musosa. J. Clin. Endocrinol. Metab. 84, 821\u2013822. Steel, R.G.D., Torrie, J.H., 1960. Principles and Procedures of Statistics. McGraw-Hill, New York. Stowe, H.D., Rangel, F., Anstead, C., Goelling, B., 1980. Influence of supplemental dietary vitamin A on the reproductive performance of iodine-toxic rats. J. Nutr. 110, 1947\u20131957. Takegawa, K., Mitsumori, K., Onodera, H., Shimo, T., Kitaura, K., Yasuhara, K., Hirose, M., Takahashi, M., 2000. Studies on the carcinogenicity of potassium iodide in F344 rats. Food Chem. Toxicol. 38, 773\u2013781. USEPA (United States Environmental Protection Agency), 2008. Registration eligibility decision for diiodomethyl p-tolyl sulfone. List D, Case 4009. Office of Prevention, Pesticides, and Toxic Substances, Washigton, D.C. Available at <www.epa.gov/oppsrrd1/REDs/amical-48-red.pdf> (accessed September 19, 2011). Vorhees, C.V., Butcher, R.E., Brunner, R.L., 1984. Developmental toxicity and psychotoxicity of potassium iodide in rats: a case for the inclusion of behavior in toxicological assessment. Food Chem. Toxicol. 22, 963\u2013970. Winer, B.J., 1971. Statistical Principles in Experimental Design, second ed. McGraw- Hill, New York. Zablotny, C.L., Rasoulpour, R.J., Pitt, J.A., Carney, E.W., 2011. Assessment of adult and neonatal reproductive parameters in rats administered diiodomethyl-p- tolylsulfone for two generation. Regul. Toxicol. Pharmacol. (submitted with this as a group). http://www.epa.gov/oppsrrd1/REDs/amical-48-red.pdf Role of iodine in diiodomethyl-p-tolylsulfone induced reproductive toxicity in rats: Proposed mode of action 1 Introduction 2 Materials and methods 2.1 Chemicals, dose preparation and analysis 2.2 Animal (care and dosing) 2.3 Observations 2.4 Body weight 2.5 Feed consumption 2.6 Test material intake 2.7 Breeding 2.8 Litters 2.9 Culling of pups 2.10 Sample collection and analysis at the end of the experiment 2.10.1 Milk 2.10.2 Serum 2.10.3 Necropsy 2.10.4 Histopathology 2.11 Data analysis 3 Results 3.1 Feed consumption, body weights and test material intake 3.2 In-life observations 3.3 Anatomic, clinical and histopathology 3.4 Gestation and lactation parameters 3.5 Concentration of iodide in milk and serum 4 Discussion Conflict of interest statement Acknowledgments References", "Acknowledgement": "Acknowledgments The authors gratefully acknowledge Kathy Brzak, Amy Clark, Rebecca Drury, Kathleen Gallagher, Patrick Goodwin, Lorrie Ito, Jane Lacher, Marie Lawson, Julie Passage and Jennifer Staley for their help in different parts of the study. Additionally, authors highly appreciate Dr. Johnson Thomas for his critical review of the manuscript. Miller Jr., R.G., 1966. Simultaneous Statistical Inference. McGraw-Hill, New York. Mullen, S.P., Schaeffer, S.J., Howell, R.D., Van Middlesworth, L., 1980. Smooth muscle paralysis from iodide feeding (abstract. Fedn. Proc. Fedn. Am. Socs. Exp. Biol. 39, 715. Saghir, S.A., Yano, B.L., Zablotny, C.L., Brzak, K.A., Clark, A.J., Staley, J.L., 2011. Role of iodine in the toxicity of diiodomethyl-p-tolylsulfone (DIMPTS) in rats: ADME Regul. Toxicol. Pharmacol. (submitted with this as a group). Siegel, S., 1956. Non-Parametric Statistics for the Behavioral Sciences. McGraw-Hill, New York. Spitzweg, C., Joba, W., Eisenmenger, W., Heufelder, A.E., 1999. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric musosa. J. Clin. Endocrinol. Metab. 84, 821\u2013822. Steel, R.G.D., Torrie, J.H., 1960. Principles and Procedures of Statistics. McGraw-Hill, New York. Stowe, H.D., Rangel, F., Anstead, C., Goelling, B., 1980. Influence of supplemental dietary vitamin A on the reproductive performance of iodine-toxic rats. J. Nutr. 110, 1947\u20131957. Takegawa, K., Mitsumori, K., Onodera, H., Shimo, T., Kitaura, K., Yasuhara, K., Hirose, M., Takahashi, M., 2000. Studies on the carcinogenicity of potassium iodide in F344 rats. Food Chem. Toxicol. 38, 773\u2013781. USEPA (United States Environmental Protection Agency), 2008. Registration eligibility decision for diiodomethyl p-tolyl sulfone. List D, Case 4009. Office of Prevention, Pesticides, and Toxic Substances, Washigton, D.C. Available at <www.epa.gov/oppsrrd1/REDs/amical-48-red.pdf> (accessed September 19, 2011). Vorhees, C.V., Butcher, R.E., Brunner, R.L., 1984. Developmental toxicity and psychotoxicity of potassium iodide in rats: a case for the inclusion of behavior in toxicological assessment. Food Chem. Toxicol. 22, 963\u2013970. Winer, B.J., 1971. Statistical Principles in Experimental Design, second ed. McGraw- Hill, New York. Zablotny, C.L., Rasoulpour, R.J., Pitt, J.A., Carney, E.W., 2011. Assessment of adult and neonatal reproductive parameters in rats administered diiodomethyl-p- tolylsulfone for two generation. Regul. Toxicol. Pharmacol. (submitted with this as a group). http://www.epa.gov/oppsrrd1/REDs/amical-48-red.pdf Role of iodine in diiodomethyl-p-tolylsulfone induced reproductive toxicity in rats: Proposed mode of action 1 Introduction 2 Materials and methods 2.1 Chemicals, dose preparation and analysis 2.2 Animal (care and dosing) 2.3 Observations 2.4 Body weight 2.5 Feed consumption 2.6 Test material intake 2.7 Breeding 2.8 Litters 2.9 Culling of pups 2.10 Sample collection and analysis at the end of the experiment 2.10.1 Milk 2.10.2 Serum 2.10.3 Necropsy 2.10.4 Histopathology 2.11 Data analysis 3 Results 3.1 Feed consumption, body weights and test material intake 3.2 In-life observations 3.3 Anatomic, clinical and histopathology 3.4 Gestation and lactation parameters 3.5 Concentration of iodide in milk and serum 4 Discussion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Role-of-iodine-in-the-toxicity-of-diiodomethyl-p-_2012_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21986257", "content": {"CoiStatement": "5. Conflict of interest statement The authors work for the company at which the substance is produced. 4 Discussion 5 Conflict of interest statement Acknowledgments References", "Acknowledgement": "Acknowledgments The authors gratefully acknowledge Kim Anklam, Debbie Beu- thin, Laura Daniels, Rebecca Drury, Patrick Goodwin, Steve Hansen, Lorrie Ito, Jane Lacher, Lindsay McNalley, Nigel Saghir, Joyce Wach- ner and Bernadette West for their help in different parts of the study. Additionally, authors highly appreciate Dr. Johnson Thomas for his critical review of the manuscript. 4 Discussion 5 Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Roles-of-ROS-mediated-oxidative-stress-and-DNA-damage-in-_2015_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26361855", "content": {"CoiStatement": "Conflicts of interest statement The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgments 4. Discussion Conflicts of interest statement Acknowledgments Appendix A. Supplementary data References", "Acknowledgement": "Acknowledgments We appreciate the contribution of all the members participating in this study. This work was financially supported by the National Natural Science Foundation of China (NSFC-81202210) and the National Basic Research Program of China (No. 2009CB118803). 4. Discussion Conflicts of interest statement Acknowledgments Appendix A. Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Route-to-route-extrapolation-of-1-2-dichloroethane-studi_2016_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27756559", "content": {"Acknowledgement": "4. Discussion 5. Conclusion Acknowledgements Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/SEND-harmonization--amp--cross-study-analysis--A-pr_2020_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31756353", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper.", "Funding": "Funding body information No grant funding was used to support this research. The authors gratefully acknowledge the support of TransCelerate No grant funding was used to support this research. The authors gratefully acknowledge the support of TransCelerate BioPharma Inc, a nonprofit organization dedicated to improving the health of people around the world by accelerating and simplifying the research and development (R&D) of innovative new therapies. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Declaration of competing interest Conclusions Funding body information mk:H1_14 Acknowledgements Supplementary data References", "Acknowledgement": "Acknowledgements This publication reflects the views of the authors and should not be construed to represent FDA's views or policies. Conclusions Funding body information mk:H1_14 Acknowledgements Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/SIDS-reprotoxicity-screening-test-update--tes_2004_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15041141", "content": {"Acknowledgement": "SIAMs. As such, the SIDS reprotox tests are a key part of this important international program of cooperation between industry, OECD member governments, and non-government agencies, and are providing useful in- formation for initial hazard assessment. Acknowledgment The authors thank R. FitzGerald for assistance in preparing the manuscript. References SIDS reprotoxicity screening test update: testing strategies and use Background SIDS procedure Contents of the SIDS Reduced dataset Reproduction and developmental toxicity data Post-SIDS testing Adequacy of the SIDS reproduction/developmental toxicity screening tests 421 and 422 Use of 421 and 422 to date Summary and conclusion Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Safe--and-sustainable-by-design--The-case-of-Smart-N_2022_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34864125", "content": {"CoiStatement": "4 Regulatory preparedness 5 Conclusions and future actions Disclaimer Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgements References", "Funding": "4 Regulatory preparedness 5 Conclusions and future actions Disclaimer Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgements References", "Acknowledgement": "4 Regulatory preparedness 5 Conclusions and future actions Disclaimer Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-Evaluation-and-Risk-Assessment-of-the-Herbicid_2000_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/10854122", "content": {"Acknowledgement": "OVERALL CONCLUSIONS AND SUMMARY STATEMENT ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-Evaluation-of-PQ-Birch-Allergy-Immunother_2019_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31425728", "content": {"CoiStatement": "Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. Conflicts of interest Paul Baldrick assisted in preparation of the manuscript under con- tract with Allergy Therapeutics Ltd. Discussion Funding body information Declaration of interests Conflicts of interest Supplementary data Transparency document References", "Funding": "Funding body information Safety Evaluation of PQ Birch Allergy Immunotherapy to Support Product Development by Paul Baldrick, James W Hutchings, Matthew D Heath and Murray A Skinner. No funding body was involved in supporting this work. Declaration of interests Discussion Funding body information Declaration of interests Conflicts of interest Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-against-nephrotoxicity-in-paclitaxel-treatment--Or_2017_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29080846", "content": {"CoiStatement": "There is no conflict of interest and disclosures associated with the manuscript. Acknowledgement", "Disclosure": "Disclosures There is no conflict of interest and disclosures associated with the manuscript. There is no conflict of interest and disclosures associated with the manuscript. Acknowledgement Conclusion Disclosures Acknowledgement Supplementary data Transparency document References", "Acknowledgement": "Acknowledgement This research work has been financially supported by Department of Science and Technology, Govt. of India, New Delhi under the scheme of Women Scientist A (Grant No. SR/WOS-A/LS-71/2010) to Hira Choudhury. The authors are thankful to Dr. Anjan Das, M.D., Pathology, Calcutta National Medical College, Kolkata, India for his scientific support in the evaluation of the histopathological slides. Conclusion Disclosures Acknowledgement Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-and-Advantages-of-Bacillus-thuringiensis-P_2000_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/11067772", "content": {"Acknowledgement": "CONCLUSIONS ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-and-compliance-of-a-complex-homeopathic-drug--Contramut_2015_Regulato.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25882307", "content": {"CoiStatement": "Conflict of Interest Prof. Michalsen, Dr. Dr. Uehleke and Dr. Stange report consult- ing for Cassella-med GmbH & Co. KG. Participation at the Advisory Board has been rewarded with standard fees. Advisory Board decisions have not been influenced. 4 Discussion 5 Conclusion Conflict of Interest Transparency Document Acknowledgments References", "Compliance with ethical standards": "Safety and compliance of a complex homeopathic drug (Contramutan N Saft) in the treatment of acute respiratory tract infections: A large observational (non-interventional) study in children and adults focussing on homeopathy specific adverse reactions versus adverse drug reactions Table 5 Assessment of potential homeopathy-specific adverse drug reactions (n = 11 in 7 patients) by the physicians and the advisory board. Safety and compliance of a complex homeopathic drug Contramutan N Saft in the treatment of acute respiratory tract infections: A large observational non-interventional study in children and adults focussing 1 Introduction 2 Materials and methods 2.1 Study design 2.2 Medication 2.3 Outcome measures 2.4 Sample size 2.5 Statistical methods 3 Results 3.1 Patient flow and recruitment 3.2 Safety 3.3 Clinical outcome 3.4 Global assessment of tolerability 3.5 Compliance 3 Results 3.1 Patient flow and recruitment 3.2 Safety 3.3 Clinical outcome 3.4 Global assessment of tolerability 3.5 Compliance 4 Discussion 5 Conclusion Conflict of Interest Transparency Document Acknowledgments References", "Acknowledgement": "The Transparency document associated with this article can be found in the online version. Acknowledgments The study was sponsored by Cassella-med (Cologne, Germany), the holder of the marketing authorization of the study preparation. The study was performed with assistance of Dr. Oerstreich + Partner GmbH, (Cologne, Germany). Prof. A. Michalsen, Dr. B. Uehleke, Dr. R. Stange and Dr. M. Wiesenauer have been members of the Advisory Board. 4 Discussion 5 Conclusion Conflict of Interest Transparency Document Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-and-health-risk-assessment-methodology-of-derm_2020_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32745583", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. INRS, 2020. Institut National de Recherche et de Se\u0301curite\u0301 in French. http://en.inrs. fr/(accesssed. (Accessed 13 January 2020). Karamertzanis, P.G., Atlason, P., Nathanail, A.V., Provoost, J., Karhu, E., Rasenberg, M., 2019. The impact on classifications for carcinogenicity, mutagenicity, reproductive and specific target organ toxicity after repeated exposure in the first ten years of the reach regulation. Regul. Toxicol. Pharmacol. 106, 303\u2013315. https://doi.org/ 10.1016/j.yrtph.2019.05.003. Kim, J.H., Kim, T., Yoon, H., Jo, A., Lee, D., Kim, P., Seo, J., 2018. Health risk assessment of dermal and inhalation exposure to deodorants in Korea. Sci. Total Environ. 625, 1369\u20131379. https://doi.org/10.1016/j.scitotenv.2017.12.282. Kojima, H., 2017. Safety assessment of cosmetic ingredients. In: Cosmetic Science and Technology: Theoretical Principles and Applications. Elsevier, pp. 793\u2013803. https:// doi.org/10.1016/B978-0-12-802005-0.00051-3. Lee, M., Kim, J.H., Lee, D., Kim, J., Lim, H., Seo, J., Park, Y.K., 2018. Health risk assessment on hazardous ingredients in household deodorizing products. Int. J. Environ. Res. Publ. Heal. 15 (4) https://doi.org/10.3390/ijerph15040744. MAK, 2020. Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area. https://www.dfg.de/en/dfg_profile/statutory_bodies/senate/h ealth_hazards/index.html. (Accessed 13 January 2020). MAK Commission, 2010. Commission for the investigation of health hazards of chemical compounds in the work area. In: List of MAK and BAT Values 2010: Maximum Concentrations and Biological Tolerance Values at the Workplace. Report 46, Deutsche Forschungsgemeinschaft (DFG). Wiley VCH. Manova, E., Von Goetz, N., Hungerbuehler, K., 2015. Aggregate consumer exposure to UV filter ethylhexyl methoxycinnamate via personal care products. Environ. Int. 74, 249\u2013257. https://doi.org/10.1016/j.envint.2014.09.008. McKee, R.H., Tibaldi, R., Adenuga, M.D., Carrillo, J.C., Margary, A., 2018. Assessment of the potential human health risks from exposure to complex substances in accordance with REACH requirements. \"White Spirit\" as a case study. Regul. Toxicol. Pharmacol. 92, 439\u2013457. https://doi.org/10.1016/j.yrtph.2017.10.015. Miquel, A.C., Mercedes, R.S., Pilar, T.B., 2016. Allergic contact dermatitis from cetearyl alcohol in thrombocid ointment. Dermatol. Online J. 22 (7). https://escholarship. org/uc/item/8ht9300r. Nakagawa, Y., Suzuki, T., 2002. Metabolism of 2-hydroxy-4-methoxybenzophenone in isolated rat hepatocytes and xenoestrogenic effects of its metabolites on MCF-7 human breast cancer cells. Chem. Biol. Interact. 139, 115\u2013128. https://doi.org/ 10.1016/S0009-2797(01)00293-9. NIOSH, 2020. United States National Institute for Occupational Safety and Health (NIOSH) Skin Notation (SK) Profiles. https://www.cdc.gov/niosh/topics/skin/ski n-notation_profiles.html. (Accessed 26 March 2020). NTP, 2020. National Toxicology Program - United States (U.S.). https://ntp.niehs.nih. gov/data/index.html. (Accessed 13 January 2020). OECD, 2018. Organisation for Economic Cooperation and Development Guidelines for the Testing of Chemicals, Section 4. https://www.oecd.org/env/ehs/testing/section 4-health-effects-replaced-and-cancelled-test-guidelines.htm. (Accessed 6 July 2020). OECD, 2020. Organisation for Economic Co-Operation and Development. https://www. echemportal.org/echemportal/index.action. (Accessed 13 January 2020). OEHHA, 2020. Office of Environmental Health Hazard Assessment. https://oehha.ca.go v/proposition-65/proposition-65-list. (Accessed 13 January 2020). OSHA, 2020. Occupational Safety and Health Administration. https://www.osha.gov/ch emicaldata/. (Accessed 26 March 2020). Park, S., Xu, S., Rogers, W., Pasman, H., El-Halwagi, M.M., 2020. Incorporating inherent safety during the conceptual process design stage: a literature review. J. Loss Prev. Process. Ind. 63, 104040. https://doi.org/10.1016/j.jlp.2019.104040. Pouzou, J.G., Kissel, J., Yost, M.G., Fenske, R.A., Cullen, A.C., 2020. Use of benchmark dose models in risk assessment for occupational handlers of eight pesticides used in pome fruit production. Regul. Toxicol. Pharmacol. 110, 104504. https://doi.org/ 10.1016/j.yrtph.2019.104504. Pujalte, I., Dieme, D., Haddad, S., Serventi, A.M., Bouchard, M., 2017. Toxicokinetics of titanium dioxide (TiO2) nanoparticles after inhalation in rats. Toxicol. Lett. 265, 77\u201385. https://doi.org/10.1016/j.toxlet.2016.11.014. Raslan, R., Hassim, M.H., Chemangattuvalappil, N.G., Ng, D.K.S., Norazhar, N., 2019. Safety and health index development for formulated product design: paint formulation. In: E3S Web of Conferences, 90. https://doi.org/10.1051/e3sconf/ 20199003002, 03002. Raslan, R., Hassim, M.H., Chemangattuvalappil, N.G., Ng, D.K.S., Ten, J.Y., 2020. Development of inherent safety and health index for formulated product design. J. Loss Prev. Process. Ind. 66, 104209. https://doi.org/10.1016/j.jlp.2020.104209. Rennen, M.A., Bouwman, T., Wilschut, A., Bessems, J.G., Heer, C.D., 2004. Oral-to- Inhalation route extrapolation in occupational health risk assessment: a critical assessment. Regul. Toxicol. Pharmacol. 39 (1), 5\u201311. https://doi.org/10.1016/j. yrtph.2003.09.003. Rothe, H., Fautz, R., Gerber, E., Neumann, L., Rettinger, K., Schuh, W., Gronewold, C., 2011. Special aspects of cosmetic spray safety evaluations: principles on inhalation risk assessment. Toxicol. Lett. 205 (2), 97\u2013104. https://doi.org/10.1016/j. toxlet.2011.05.1038. SCCNFP, 2003. The SCCNFP\u2019s Notes and Guidance for the Testing of Cosmetic Ingredients and Their Safety Evaluation 5th Revision. SCCNFP/0690/03. SCCP, 2008. Opinion on Benzophenone-3. SCCP/1069/06. SCCS, 2012a. The SCCS\u2019s Notes of Guidance for the Testing of Cosmetic Substances and Their Safety Evaluation 8th Revision Scientific Committee on Consumer Safety. Available from: http://ec.europa.eu/health/scientific_committeesconsumer_safety/ docs/sccs_s_006. SCCS, 2012b. The SCCS\u2019s Notes of Guidance for the Testing of Cosmetic Substances and Their Safety Evaluation 8th Revision Scientific Committee on Consumer Safety. Available from: http://eceuropaeu/health/scientific_committees/consumer_safety /docs/sccs_s_006pdf. SCCS, 2016a. The SCCS\u2019s Notes of Guidance for the Testing of Cosmetic Substances and Their Safety Evaluation 9th Revision Scientific Committee on Consumer Safety. Available from: http://ec.europa.eu/health/sites/health/files/scientific_committee s/consumer_safety/docs/sccs_o_190.pdf. SCCS, 2016b. Opinion on Vitamin A (Retinol, Retinyl Acetate, Retinyl Palmitate). SCCS/ 1576/16, 20 April 2016, final version of 6 October 2016, Corrigendum on 23December2016. https://ec.europa.eu/health/scientific_committees/consumer_saf ety/docs/sccs_o_199.pdf. SCCS, 2018. The SCCS\u2019s Notes of Guidance for the Testing of Cosmetic Ingredients and Their Safety Evaluation 10th Revision Scientific Committee on Consumer Safety. htt ps://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/ docs/sccs_o_224.pdf. (Accessed 13 January 2020). Smaoui, S., Ben Hlima, H., Ben Chobba, I., Kadri, A., 2017. Development and stability studies of sunscreen cream formulations containing three photo-protective filters. Arab. J. Chem. 10, S1216\u2013S1222. https://doi.org/10.1016/j.arabjc.2013.02.020. Smijs, T.G., Pavel, S., 2011. Titanium dioxide and zinc oxide nanoparticles in sunscreens: focus on their safety and effectiveness. Nanotechnol. Sci. Appl. 4, 95\u2013112. 10.21 47/NSA.S19419. Steinemann, A., 2017. Health and societal effects from exposure to fragranced consumer products. Prev. Med. Rep. 5, 45\u201347. https://doi.org/10.1016/j.pmedr.2016.11.011. Tokumura, M., Nitta, S., Hayashi, T., Yamaguchi, R., Wang, Q., Miyake, Y., Makino, M., 2020. Probabilistic exposure assessment of aggregate rates of dermal exposure of Japanese women and children to parabens in personal care products. Chemosphere 239 (124704). https://doi.org/10.1016/j.chemosphere.2019.124704. Travis, K.Z., Pate, I., Welsh, Z.K., 2005. Dec. The role of the benchmark dose in a regulatory context. Regul. Toxicol. Pharmacol. 43 (3), 280\u2013291. https://doi.org/ 10.1016/j.yrtph.2005.07.003. USEPA, 2020. United States Environmental Protecion Agency. https://www.epa.gov/ch emical-research/toxicity-forecasting. (Accessed 13 January 2020). Veraldi, S, Rossi, LC, Barbareschi, M, 2016. Are topical retinoids teratogenic? G. Ital. Dermatol. Venereol. 151 (6), 700\u2013705. Vincent, M.J., Parker, A., Maier, A., 2017. Cleaning and asthma: a systematic review and approach for effective safety assessment. Regul. Toxicol. Pharmacol. 90, 231\u2013243. https://doi.org/10.1016/j.yrtph.2017.09.013. Wang, Z., Dinh, D., Scott, W.C., Williams, E.S., Ciarlo, M., Deleo, P., Brooks, B.W., 2019. Critical review and probabilistic health hazard assessment of cleaning product ingredients in all-purpose cleaners, dish care products, and laundry care products. Environ. Int. 125, 399\u2013417. https://doi.org/10.1016/j.envint.2019.01.079. Watanabe, Y, Kojima, H, Takeuchi, S, Urumaru, N, Sanoh, S, Sugihara, K, Kitamura, S, Ohta, S, 2015. Metabolism of UV-filter benzophenone-3 by rat And human liver microsomes and its effect on endocrine-disrupting activity. Toxicol. Appl. Pharmacol. 282, 119\u2013128. https://doi.org/10.1016/j.taap.2014.12.002. Williams, F.M., Rothe, H., Barrett, G., Chiodini, A., Whyte, J., Cronin, M.T., Monteiro- Riviere, N.A., Plautz, J., Roper, C., Westerhout, J., Yang, C., Guy, R.H., 2016. Assessing the safety of cosmetic chemicals: consideration of a flux decision tree to predict dermally delivered systemic dose for comparison with oral TTC (threshold of toxicological concern). Regul. Toxicol. Pharmacol. 76, 174\u2013186. https://doi.org/ 10.1016/j.yrtph.2016.01.005. Yang, C., Barlow, S.M., Muldoon Jacobs, K.L., Vitcheva, V., Boobis, A.R., Felter, S.P., Arvidson, K.B., Keller, D., Cronin, M.T.D., Enoch, S., Worth, A., Hollnagel, H.M., 2017. Thresholds of toxicological concern for cosmetics-related substances: new database, thresholds, and enrichment of chemical space. Food Chem. Toxicol. 109 (Pt 1), 170\u2013193. https://doi.org/10.1016/j.fct.2017.08.043. Yost, L.J., Rodricks, J.D., Turnbull, D., Deleo, P.C., Nash, J.F., Quinones-Rivera, A., Carlson, P.A., 2016. Human health risk assessment of chloroxylenol in liquid hand soap and dishwashing soap used by consumers and health-care professionals. Regul. Toxicol. Pharmacol. 80, 116\u2013124. https://doi.org/10.1016/j.yrtph.2016.06.003. Zhang, L., Fung, K.Y., Zhang, X., Fung, H.K., Ng, K.M., 2017. An integrated framework for designing formulated products. Compute. Chem. Eng. 107, 61\u201376. https://doi. org/10.1016/j.compchemeng.2017.05.014. R. Raslan et al. https://www.hse.gov.uk/coshh/ https://monographs.iarc.fr/ https://www.dguv.de/ifa/index-2.jsp https://www.dguv.de/ifa/index-2.jsp http://en.inrs.fr/(accesssed http://en.inrs.fr/(accesssed https://doi.org/10.1016/j.yrtph.2019.05.003 https://doi.org/10.1016/j.yrtph.2019.05.003 https://doi.org/10.1016/j.scitotenv.2017.12.282 https://doi.org/10.1016/B978-0-12-802005-0.00051-3 https://doi.org/10.1016/B978-0-12-802005-0.00051-3 https://doi.org/10.3390/ijerph15040744 https://www.dfg.de/en/dfg_profile/statutory_bodies/senate/health_hazards/index.html https://www.dfg.de/en/dfg_profile/statutory_bodies/senate/health_hazards/index.html http://refhub.elsevier.com/S0273-2300(20)30179-3/sref39 http://refhub.elsevier.com/S0273-2300(20)30179-3/sref39 http://refhub.elsevier.com/S0273-2300(20)30179-3/sref39 http://refhub.elsevier.com/S0273-2300(20)30179-3/sref39 https://doi.org/10.1016/j.envint.2014.09.008 https://doi.org/10.1016/j.yrtph.2017.10.015 https://escholarship.org/uc/item/8ht9300r https://escholarship.org/uc/item/8ht9300r https://doi.org/10.1016/S0009-2797(01)00293-9 https://doi.org/10.1016/S0009-2797(01)00293-9 https://www.cdc.gov/niosh/topics/skin/skin-notation_profiles.html https://www.cdc.gov/niosh/topics/skin/skin-notation_profiles.html https://ntp.niehs.nih.gov/data/index.html https://ntp.niehs.nih.gov/data/index.html https://www.oecd.org/env/ehs/testing/section4-health-effects-replaced-and-cancelled-test-guidelines.htm https://www.oecd.org/env/ehs/testing/section4-health-effects-replaced-and-cancelled-test-guidelines.htm https://www.echemportal.org/echemportal/index.action https://www.echemportal.org/echemportal/index.action https://oehha.ca.gov/proposition-65/proposition-65-list https://oehha.ca.gov/proposition-65/proposition-65-list https://www.osha.gov/chemicaldata/ https://www.osha.gov/chemicaldata/ https://doi.org/10.1016/j.jlp.2019.104040 https://doi.org/10.1016/j.yrtph.2019.104504 https://doi.org/10.1016/j.yrtph.2019.104504 https://doi.org/10.1016/j.toxlet.2016.11.014 https://doi.org/10.1051/e3sconf/20199003002 https://doi.org/10.1051/e3sconf/20199003002 https://doi.org/10.1016/j.jlp.2020.104209 https://doi.org/10.1016/j.yrtph.2003.09.003 https://doi.org/10.1016/j.yrtph.2003.09.003 https://doi.org/10.1016/j.toxlet.2011.05.1038 https://doi.org/10.1016/j.toxlet.2011.05.1038 http://refhub.elsevier.com/S0273-2300(20)30179-3/sref58 http://refhub.elsevier.com/S0273-2300(20)30179-3/sref58 http://refhub.elsevier.com/S0273-2300(20)30179-3/sref91 http://ec.europa.eu/health/scientific_committeesconsumer_safety/docs/sccs_s_006 http://ec.europa.eu/health/scientific_committeesconsumer_safety/docs/sccs_s_006 http://eceuropaeu/health/scientific_committees/consumer_safety/docs/sccs_s_006pdf http://eceuropaeu/health/scientific_committees/consumer_safety/docs/sccs_s_006pdf http://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_190.pdf http://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_190.pdf https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_199.pdf https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_199.pdf https://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_224.pdf https://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_224.pdf https://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_224.pdf https://doi.org/10.1016/j.arabjc.2013.02.020 http://10.2147/NSA.S19419 http://10.2147/NSA.S19419 https://doi.org/10.1016/j.pmedr.2016.11.011 https://doi.org/10.1016/j.chemosphere.2019.124704 https://doi.org/10.1016/j.yrtph.2005.07.003 https://doi.org/10.1016/j.yrtph.2005.07.003 https://www.epa.gov/chemical-research/toxicity-forecasting https://www.epa.gov/chemical-research/toxicity-forecasting http://refhub.elsevier.com/S0273-2300(20)30179-3/opthNUPi1QKsf http://refhub.elsevier.com/S0273-2300(20)30179-3/opthNUPi1QKsf https://doi.org/10.1016/j.yrtph.2017.09.013 https://doi.org/10.1016/j.envint.2019.01.079 https://doi.org/10.1016/j.taap.2014.12.002 https://doi.org/10.1016/j.yrtph.2016.01.005 https://doi.org/10.1016/j.yrtph.2016.01.005 https://doi.org/10.1016/j.fct.2017.08.043 https://doi.org/10.1016/j.yrtph.2016.06.003 https://doi.org/10.1016/j.compchemeng.2017.05.014 https://doi.org/10.1016/j.compchemeng.2017.05.014 Safety and health risk assessment methodology of dermal and inhalation exposure to formulated products ingredients 1 Introduction 2 Case study 2.1 Tier 1 assessment: development of PISI 2.1.1 Collect available toxicology information 2.1.2 Analyze hazard based on score 2.2 Tier 2 assessment: development of PIEI 2.2.1 Collect available data on toxicological dose descriptors for application of PIEI 2.2.2 Analyze risk based on score 3 Results 3.1 Tier 1 assessment: identification of highly hazardous ingredients in formulation 3.2 Tier 2 assessment: identification of ingredients with high risk 4 Discussion 4.1 Relation between Tier 1 and Tier 2 assessment 4.2 Risk characterization of ingredients with relatively high concentration 4.3 Hazard and risk assessment of ingredients in sunscreen formulation 4.3.1 Spray-type formulation 4.3.2 Cream formulation 5 Conclusions Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Acknowledgement": "Acknowledgements The authors would like to thank the Institution of Engineers, Malaysia (IEM) for the sponsorship to present in the 18th Asian Pacific Confederation of Chemical Engineering Congress (APCChE 2019). This work was supported by Universiti Teknologi MARA and Ministry of Education Malaysia through the Transdisciplinary Research (TDR) grant no. of Q.J130000.3551.05G50. INRS, 2020. Institut National de Recherche et de Se\u0301curite\u0301 in French. http://en.inrs. fr/(accesssed. (Accessed 13 January 2020). Karamertzanis, P.G., Atlason, P., Nathanail, A.V., Provoost, J., Karhu, E., Rasenberg, M., 2019. The impact on classifications for carcinogenicity, mutagenicity, reproductive and specific target organ toxicity after repeated exposure in the first ten years of the reach regulation. Regul. Toxicol. Pharmacol. 106, 303\u2013315. https://doi.org/ 10.1016/j.yrtph.2019.05.003. Kim, J.H., Kim, T., Yoon, H., Jo, A., Lee, D., Kim, P., Seo, J., 2018. Health risk assessment of dermal and inhalation exposure to deodorants in Korea. Sci. Total Environ. 625, 1369\u20131379. https://doi.org/10.1016/j.scitotenv.2017.12.282. Kojima, H., 2017. Safety assessment of cosmetic ingredients. In: Cosmetic Science and Technology: Theoretical Principles and Applications. Elsevier, pp. 793\u2013803. https:// doi.org/10.1016/B978-0-12-802005-0.00051-3. Lee, M., Kim, J.H., Lee, D., Kim, J., Lim, H., Seo, J., Park, Y.K., 2018. Health risk assessment on hazardous ingredients in household deodorizing products. Int. J. Environ. Res. Publ. Heal. 15 (4) https://doi.org/10.3390/ijerph15040744. MAK, 2020. Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area. https://www.dfg.de/en/dfg_profile/statutory_bodies/senate/h ealth_hazards/index.html. (Accessed 13 January 2020). MAK Commission, 2010. Commission for the investigation of health hazards of chemical compounds in the work area. In: List of MAK and BAT Values 2010: Maximum Concentrations and Biological Tolerance Values at the Workplace. Report 46, Deutsche Forschungsgemeinschaft (DFG). Wiley VCH. Manova, E., Von Goetz, N., Hungerbuehler, K., 2015. Aggregate consumer exposure to UV filter ethylhexyl methoxycinnamate via personal care products. Environ. Int. 74, 249\u2013257. https://doi.org/10.1016/j.envint.2014.09.008. McKee, R.H., Tibaldi, R., Adenuga, M.D., Carrillo, J.C., Margary, A., 2018. Assessment of the potential human health risks from exposure to complex substances in accordance with REACH requirements. \"White Spirit\" as a case study. Regul. Toxicol. Pharmacol. 92, 439\u2013457. https://doi.org/10.1016/j.yrtph.2017.10.015. Miquel, A.C., Mercedes, R.S., Pilar, T.B., 2016. Allergic contact dermatitis from cetearyl alcohol in thrombocid ointment. Dermatol. Online J. 22 (7). https://escholarship. org/uc/item/8ht9300r. Nakagawa, Y., Suzuki, T., 2002. Metabolism of 2-hydroxy-4-methoxybenzophenone in isolated rat hepatocytes and xenoestrogenic effects of its metabolites on MCF-7 human breast cancer cells. Chem. Biol. Interact. 139, 115\u2013128. https://doi.org/ 10.1016/S0009-2797(01)00293-9. NIOSH, 2020. United States National Institute for Occupational Safety and Health (NIOSH) Skin Notation (SK) Profiles. https://www.cdc.gov/niosh/topics/skin/ski n-notation_profiles.html. (Accessed 26 March 2020). NTP, 2020. National Toxicology Program - United States (U.S.). https://ntp.niehs.nih. gov/data/index.html. (Accessed 13 January 2020). OECD, 2018. Organisation for Economic Cooperation and Development Guidelines for the Testing of Chemicals, Section 4. https://www.oecd.org/env/ehs/testing/section 4-health-effects-replaced-and-cancelled-test-guidelines.htm. (Accessed 6 July 2020). OECD, 2020. Organisation for Economic Co-Operation and Development. https://www. echemportal.org/echemportal/index.action. (Accessed 13 January 2020). OEHHA, 2020. Office of Environmental Health Hazard Assessment. https://oehha.ca.go v/proposition-65/proposition-65-list. (Accessed 13 January 2020). OSHA, 2020. Occupational Safety and Health Administration. https://www.osha.gov/ch emicaldata/. (Accessed 26 March 2020). Park, S., Xu, S., Rogers, W., Pasman, H., El-Halwagi, M.M., 2020. Incorporating inherent safety during the conceptual process design stage: a literature review. J. Loss Prev. Process. Ind. 63, 104040. https://doi.org/10.1016/j.jlp.2019.104040. Pouzou, J.G., Kissel, J., Yost, M.G., Fenske, R.A., Cullen, A.C., 2020. Use of benchmark dose models in risk assessment for occupational handlers of eight pesticides used in pome fruit production. Regul. Toxicol. Pharmacol. 110, 104504. https://doi.org/ 10.1016/j.yrtph.2019.104504. Pujalte, I., Dieme, D., Haddad, S., Serventi, A.M., Bouchard, M., 2017. Toxicokinetics of titanium dioxide (TiO2) nanoparticles after inhalation in rats. Toxicol. Lett. 265, 77\u201385. https://doi.org/10.1016/j.toxlet.2016.11.014. Raslan, R., Hassim, M.H., Chemangattuvalappil, N.G., Ng, D.K.S., Norazhar, N., 2019. Safety and health index development for formulated product design: paint formulation. In: E3S Web of Conferences, 90. https://doi.org/10.1051/e3sconf/ 20199003002, 03002. Raslan, R., Hassim, M.H., Chemangattuvalappil, N.G., Ng, D.K.S., Ten, J.Y., 2020. Development of inherent safety and health index for formulated product design. J. Loss Prev. Process. Ind. 66, 104209. https://doi.org/10.1016/j.jlp.2020.104209. Rennen, M.A., Bouwman, T., Wilschut, A., Bessems, J.G., Heer, C.D., 2004. Oral-to- Inhalation route extrapolation in occupational health risk assessment: a critical assessment. Regul. Toxicol. Pharmacol. 39 (1), 5\u201311. https://doi.org/10.1016/j. yrtph.2003.09.003. Rothe, H., Fautz, R., Gerber, E., Neumann, L., Rettinger, K., Schuh, W., Gronewold, C., 2011. Special aspects of cosmetic spray safety evaluations: principles on inhalation risk assessment. Toxicol. Lett. 205 (2), 97\u2013104. https://doi.org/10.1016/j. toxlet.2011.05.1038. SCCNFP, 2003. The SCCNFP\u2019s Notes and Guidance for the Testing of Cosmetic Ingredients and Their Safety Evaluation 5th Revision. SCCNFP/0690/03. SCCP, 2008. Opinion on Benzophenone-3. SCCP/1069/06. SCCS, 2012a. The SCCS\u2019s Notes of Guidance for the Testing of Cosmetic Substances and Their Safety Evaluation 8th Revision Scientific Committee on Consumer Safety. Available from: http://ec.europa.eu/health/scientific_committeesconsumer_safety/ docs/sccs_s_006. SCCS, 2012b. The SCCS\u2019s Notes of Guidance for the Testing of Cosmetic Substances and Their Safety Evaluation 8th Revision Scientific Committee on Consumer Safety. Available from: http://eceuropaeu/health/scientific_committees/consumer_safety /docs/sccs_s_006pdf. SCCS, 2016a. The SCCS\u2019s Notes of Guidance for the Testing of Cosmetic Substances and Their Safety Evaluation 9th Revision Scientific Committee on Consumer Safety. Available from: http://ec.europa.eu/health/sites/health/files/scientific_committee s/consumer_safety/docs/sccs_o_190.pdf. SCCS, 2016b. Opinion on Vitamin A (Retinol, Retinyl Acetate, Retinyl Palmitate). SCCS/ 1576/16, 20 April 2016, final version of 6 October 2016, Corrigendum on 23December2016. https://ec.europa.eu/health/scientific_committees/consumer_saf ety/docs/sccs_o_199.pdf. SCCS, 2018. The SCCS\u2019s Notes of Guidance for the Testing of Cosmetic Ingredients and Their Safety Evaluation 10th Revision Scientific Committee on Consumer Safety. htt ps://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/ docs/sccs_o_224.pdf. (Accessed 13 January 2020). Smaoui, S., Ben Hlima, H., Ben Chobba, I., Kadri, A., 2017. Development and stability studies of sunscreen cream formulations containing three photo-protective filters. Arab. J. Chem. 10, S1216\u2013S1222. https://doi.org/10.1016/j.arabjc.2013.02.020. Smijs, T.G., Pavel, S., 2011. Titanium dioxide and zinc oxide nanoparticles in sunscreens: focus on their safety and effectiveness. Nanotechnol. Sci. Appl. 4, 95\u2013112. 10.21 47/NSA.S19419. Steinemann, A., 2017. Health and societal effects from exposure to fragranced consumer products. Prev. Med. Rep. 5, 45\u201347. https://doi.org/10.1016/j.pmedr.2016.11.011. Tokumura, M., Nitta, S., Hayashi, T., Yamaguchi, R., Wang, Q., Miyake, Y., Makino, M., 2020. Probabilistic exposure assessment of aggregate rates of dermal exposure of Japanese women and children to parabens in personal care products. Chemosphere 239 (124704). https://doi.org/10.1016/j.chemosphere.2019.124704. Travis, K.Z., Pate, I., Welsh, Z.K., 2005. Dec. The role of the benchmark dose in a regulatory context. Regul. Toxicol. Pharmacol. 43 (3), 280\u2013291. https://doi.org/ 10.1016/j.yrtph.2005.07.003. USEPA, 2020. United States Environmental Protecion Agency. https://www.epa.gov/ch emical-research/toxicity-forecasting. (Accessed 13 January 2020). Veraldi, S, Rossi, LC, Barbareschi, M, 2016. Are topical retinoids teratogenic? G. Ital. Dermatol. Venereol. 151 (6), 700\u2013705. Vincent, M.J., Parker, A., Maier, A., 2017. Cleaning and asthma: a systematic review and approach for effective safety assessment. Regul. Toxicol. Pharmacol. 90, 231\u2013243. https://doi.org/10.1016/j.yrtph.2017.09.013. Wang, Z., Dinh, D., Scott, W.C., Williams, E.S., Ciarlo, M., Deleo, P., Brooks, B.W., 2019. Critical review and probabilistic health hazard assessment of cleaning product ingredients in all-purpose cleaners, dish care products, and laundry care products. Environ. Int. 125, 399\u2013417. https://doi.org/10.1016/j.envint.2019.01.079. Watanabe, Y, Kojima, H, Takeuchi, S, Urumaru, N, Sanoh, S, Sugihara, K, Kitamura, S, Ohta, S, 2015. Metabolism of UV-filter benzophenone-3 by rat And human liver microsomes and its effect on endocrine-disrupting activity. Toxicol. Appl. Pharmacol. 282, 119\u2013128. https://doi.org/10.1016/j.taap.2014.12.002. Williams, F.M., Rothe, H., Barrett, G., Chiodini, A., Whyte, J., Cronin, M.T., Monteiro- Riviere, N.A., Plautz, J., Roper, C., Westerhout, J., Yang, C., Guy, R.H., 2016. Assessing the safety of cosmetic chemicals: consideration of a flux decision tree to predict dermally delivered systemic dose for comparison with oral TTC (threshold of toxicological concern). Regul. Toxicol. Pharmacol. 76, 174\u2013186. https://doi.org/ 10.1016/j.yrtph.2016.01.005. Yang, C., Barlow, S.M., Muldoon Jacobs, K.L., Vitcheva, V., Boobis, A.R., Felter, S.P., Arvidson, K.B., Keller, D., Cronin, M.T.D., Enoch, S., Worth, A., Hollnagel, H.M., 2017. Thresholds of toxicological concern for cosmetics-related substances: new database, thresholds, and enrichment of chemical space. Food Chem. Toxicol. 109 (Pt 1), 170\u2013193. https://doi.org/10.1016/j.fct.2017.08.043. Yost, L.J., Rodricks, J.D., Turnbull, D., Deleo, P.C., Nash, J.F., Quinones-Rivera, A., Carlson, P.A., 2016. Human health risk assessment of chloroxylenol in liquid hand soap and dishwashing soap used by consumers and health-care professionals. Regul. Toxicol. Pharmacol. 80, 116\u2013124. https://doi.org/10.1016/j.yrtph.2016.06.003. Zhang, L., Fung, K.Y., Zhang, X., Fung, H.K., Ng, K.M., 2017. An integrated framework for designing formulated products. Compute. Chem. Eng. 107, 61\u201376. https://doi. org/10.1016/j.compchemeng.2017.05.014. R. Raslan et al. https://www.hse.gov.uk/coshh/ https://monographs.iarc.fr/ https://www.dguv.de/ifa/index-2.jsp https://www.dguv.de/ifa/index-2.jsp http://en.inrs.fr/(accesssed http://en.inrs.fr/(accesssed https://doi.org/10.1016/j.yrtph.2019.05.003 https://doi.org/10.1016/j.yrtph.2019.05.003 https://doi.org/10.1016/j.scitotenv.2017.12.282 https://doi.org/10.1016/B978-0-12-802005-0.00051-3 https://doi.org/10.1016/B978-0-12-802005-0.00051-3 https://doi.org/10.3390/ijerph15040744 https://www.dfg.de/en/dfg_profile/statutory_bodies/senate/health_hazards/index.html https://www.dfg.de/en/dfg_profile/statutory_bodies/senate/health_hazards/index.html http://refhub.elsevier.com/S0273-2300(20)30179-3/sref39 http://refhub.elsevier.com/S0273-2300(20)30179-3/sref39 http://refhub.elsevier.com/S0273-2300(20)30179-3/sref39 http://refhub.elsevier.com/S0273-2300(20)30179-3/sref39 https://doi.org/10.1016/j.envint.2014.09.008 https://doi.org/10.1016/j.yrtph.2017.10.015 https://escholarship.org/uc/item/8ht9300r https://escholarship.org/uc/item/8ht9300r https://doi.org/10.1016/S0009-2797(01)00293-9 https://doi.org/10.1016/S0009-2797(01)00293-9 https://www.cdc.gov/niosh/topics/skin/skin-notation_profiles.html https://www.cdc.gov/niosh/topics/skin/skin-notation_profiles.html https://ntp.niehs.nih.gov/data/index.html https://ntp.niehs.nih.gov/data/index.html https://www.oecd.org/env/ehs/testing/section4-health-effects-replaced-and-cancelled-test-guidelines.htm https://www.oecd.org/env/ehs/testing/section4-health-effects-replaced-and-cancelled-test-guidelines.htm https://www.echemportal.org/echemportal/index.action https://www.echemportal.org/echemportal/index.action https://oehha.ca.gov/proposition-65/proposition-65-list https://oehha.ca.gov/proposition-65/proposition-65-list https://www.osha.gov/chemicaldata/ https://www.osha.gov/chemicaldata/ https://doi.org/10.1016/j.jlp.2019.104040 https://doi.org/10.1016/j.yrtph.2019.104504 https://doi.org/10.1016/j.yrtph.2019.104504 https://doi.org/10.1016/j.toxlet.2016.11.014 https://doi.org/10.1051/e3sconf/20199003002 https://doi.org/10.1051/e3sconf/20199003002 https://doi.org/10.1016/j.jlp.2020.104209 https://doi.org/10.1016/j.yrtph.2003.09.003 https://doi.org/10.1016/j.yrtph.2003.09.003 https://doi.org/10.1016/j.toxlet.2011.05.1038 https://doi.org/10.1016/j.toxlet.2011.05.1038 http://refhub.elsevier.com/S0273-2300(20)30179-3/sref58 http://refhub.elsevier.com/S0273-2300(20)30179-3/sref58 http://refhub.elsevier.com/S0273-2300(20)30179-3/sref91 http://ec.europa.eu/health/scientific_committeesconsumer_safety/docs/sccs_s_006 http://ec.europa.eu/health/scientific_committeesconsumer_safety/docs/sccs_s_006 http://eceuropaeu/health/scientific_committees/consumer_safety/docs/sccs_s_006pdf http://eceuropaeu/health/scientific_committees/consumer_safety/docs/sccs_s_006pdf http://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_190.pdf http://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_190.pdf https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_199.pdf https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_199.pdf https://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_224.pdf https://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_224.pdf https://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_224.pdf https://doi.org/10.1016/j.arabjc.2013.02.020 http://10.2147/NSA.S19419 http://10.2147/NSA.S19419 https://doi.org/10.1016/j.pmedr.2016.11.011 https://doi.org/10.1016/j.chemosphere.2019.124704 https://doi.org/10.1016/j.yrtph.2005.07.003 https://doi.org/10.1016/j.yrtph.2005.07.003 https://www.epa.gov/chemical-research/toxicity-forecasting https://www.epa.gov/chemical-research/toxicity-forecasting http://refhub.elsevier.com/S0273-2300(20)30179-3/opthNUPi1QKsf http://refhub.elsevier.com/S0273-2300(20)30179-3/opthNUPi1QKsf https://doi.org/10.1016/j.yrtph.2017.09.013 https://doi.org/10.1016/j.envint.2019.01.079 https://doi.org/10.1016/j.taap.2014.12.002 https://doi.org/10.1016/j.yrtph.2016.01.005 https://doi.org/10.1016/j.yrtph.2016.01.005 https://doi.org/10.1016/j.fct.2017.08.043 https://doi.org/10.1016/j.yrtph.2016.06.003 https://doi.org/10.1016/j.compchemeng.2017.05.014 https://doi.org/10.1016/j.compchemeng.2017.05.014 Safety and health risk assessment methodology of dermal and inhalation exposure to formulated products ingredients 1 Introduction 2 Case study 2.1 Tier 1 assessment: development of PISI 2.1.1 Collect available toxicology information 2.1.2 Analyze hazard based on score 2.2 Tier 2 assessment: development of PIEI 2.2.1 Collect available data on toxicological dose descriptors for application of PIEI 2.2.2 Analyze risk based on score 3 Results 3.1 Tier 1 assessment: identification of highly hazardous ingredients in formulation 3.2 Tier 2 assessment: identification of ingredients with high risk 4 Discussion 4.1 Relation between Tier 1 and Tier 2 assessment 4.2 Risk characterization of ingredients with relatively high concentration 4.3 Hazard and risk assessment of ingredients in sunscreen formulation 4.3.1 Spray-type formulation 4.3.2 Cream formulation 5 Conclusions Declaration of competing interest Acknowledgements Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-and-mutagenicity-evaluation-of-Vigiis-101-powd_2015_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25481278", "content": {"CoiStatement": "This study demonstrates that Vigiis 101 has no mutagenic/ genotoxic effects based on the results of the Ames test, the in vitro chromosomal aberration test, or the in vivo micronucleus assay; there was no evidence of toxicity in the 28-day oral toxicity assay at 5000 mg/kg/day in rats. Taken together, these results sup- port the safety of Vigiis 101 made from L. paracasei subsp. paracasei NTU 101. Conflicts of interest None declared. Acknowledgments 4 Discussion 5 Conclusions Conflicts of interest Acknowledgments References", "Acknowledgement": "None declared. Acknowledgments Members of Graduate Institute of Toxicology, College of Medi- cine, National Taiwan University, Taipei, Taiwan assisted us in the experimental design and execution of this work. The research grant and Vigiis 101 were provided by SunWay Biotech Co., Ltd., Taipei, Taiwan. References 4 Discussion 5 Conclusions Conflicts of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-and-tolerability-of-a-dried-aqueous-_2017_Regulatory-Toxicology-and-P.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28286189", "content": {"Compliance with ethical standards": "2.5. Regulatory and ethical compliance 3. Results 4. Discussion Acknowledgements Transparency document References", "Acknowledgement": "J.A. Lasrado et al. / Regulatory Toxicology and Pharmacology 86 (2017) 167e176 175 Acknowledgements The authors would like to thank Barbara Anderson, MS, RD, Kevin Maki, Ph.D., and Michael Ceddia, Ph.D. for their contribution to protocol development. We would also like to thank Eleanor Espinosa, BS and Tressa Mattioli-Lewis, MPH for their dedication to the coordination of this trial, Kathleen M. Kelley, MD and Andrea L. Lawless, MD for their medical oversight, and the entire clinic staff at Biofortis Clinical Research for their commitment to this study. We would also like to thank Dietrich Conze, Ph.D. and Claire Kruger, Ph.D. at Spherix Consulting for their invaluable contributions to this manuscript. Kristin Nieman, Ph.D., is currently affiliated with Midwest Biomedical Research - Center for Metabolic & Cardiovas- cular Health, Glen Ellyn, IL. 3. Results 4. Discussion Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-and-tolerability-of-sustained-exogenous-ketosi_2019_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31655093", "content": {"Funding": "Results Discussion Funding mk:H1_9 Acknowledgements References", "Acknowledgement": "Acknowledgements The authors thank the late Mrs Yvonne Green whose constant en- couragement and enthusiasm made this study possible. Results Discussion Funding mk:H1_9 Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-and-attenuation-of-cisplatin-induc_2016_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27667768", "content": {"CoiStatement": "Conflict of interest None to disclose. 4. Discussion 5. Conclusion Conflict of interest Acknowledgements Appendix A. Supplementary data References", "Acknowledgement": "Acknowledgements The authors are grateful to All India Institute of Medical Sci- ences, New Delhi for administrative support and also thankful to Sophisticated Advanced Instrument Facility, All India Institute of Medical Sciences, New Delhi for carrying out transmission electron microscopy studies. Authors would like to thank Dr. Amita Srivas- tava and Mr. Kapil for helping in digestion of serum samples, used for estimation of platinum by ICP-OES. 4. Discussion 5. Conclusion Conflict of interest Acknowledgements Appendix A. Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-and-toxicological-profiling-of-a-novel_2017_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28694170", "content": {"CoiStatement": "Conflict of interest The authors declare no conflict of interest. The authors declare no conflict of interest. References 4. Discussion Acknowledgments Transparency document Conflict of interest References", "Acknowledgement": "N.S. Bora et al. / Regulatory Toxicology and Pharmacology 89 (2017) 1e12 11 Acknowledgments The corresponding author is grateful to Defence Research Lab- oratory, Tezpur for providing the necessary facilities to carry out this research work and acknowledges Defence Research and Development Organization, Ministry of Defence, India for providing research fellowship (Letter no. DRL/1206/TC/03, dated 01st Dec 2014) and Dibrugarh University, Dibrugarh, Assam, India for necessary support to carry out doctoral research work. The author would like to express sincere gratitude to Dr. Yangchen D. Bhutia and Pompy Patowary for their valuable inputs in language and scientific editing of the manuscript. All the authors are also grateful to Candice Tang of Guangzhou Tinci Materials Technology Co.,Ltd, Guangdong, China for providing gift sample of Aquagel 35S\u00ae. 4. Discussion Acknowledgments Transparency document Conflict of interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-for-ethanol-based-topical-antiseptic-_2015_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26212636", "content": {"Compliance with ethical standards": "Office of Regulatory Affairs, C. for F.S. and A.N, 2005. Compliance Policy Guides - CPG Sec. 510.400 Dealcoholized Wine and Malt Beverages e Labeling. Available at: http://www.fda.gov/ICECI/ComplianceManuals/ CompliancePolicyGuidanceManual/ucm074430.htm (accessed 12.12.14.). Organization of Teratology Information Specialists, 2012. Resources: Fact Sheets. Available at: http://www.mothertobaby.org/fact-sheets-s13037 (accessed 27.01.15.). http://refhub.elsevier.com/S0273-2300(15)30025-8/sref50 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref50 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref51 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref51 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref51 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref51 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref52 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref52 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref52 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref53 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref53 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref53 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref53 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref53 http://dx.doi.org/10.1136/jech.2006.054213 http://dx.doi.org/10.1136/jech.2006.054213 http://dx.doi.org/10.1111/j.1365-3016.2009.01084.x http://dx.doi.org/10.1111/j.1365-3016.2009.01084.x http://dx.doi.org/10.1155/2012/959070 http://www.icap.org/Table/InternationalGuidelinesOnDrinkingAndPregnancy http://www.icap.org/Table/InternationalGuidelinesOnDrinkingAndPregnancy http://www.inchem.org/documents/harmproj/harmproj/harmproj2.pdf http://www.inchem.org/documents/harmproj/harmproj/harmproj2.pdf http://www.inchem.org/documents/harmproj/harmproj/harmproj1.pdf http://www.inchem.org/documents/harmproj/harmproj/harmproj1.pdf http://dx.doi.org/10.1002/jat.937 http://dx.doi.org/10.1002/jat.937 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref61 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref61 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref61 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref61 http://dx.doi.org/10.1016/j.ajic.2014.07.003 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref63 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref63 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref63 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref64 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref64 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref64 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref65 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref65 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref65 http://dx.doi.org/10.1093/annhyg/mer075 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref67 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref67 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref67 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref67 http://dx.doi.org/10.1111/j.1471-0528.2012.03395.x http://refhub.elsevier.com/S0273-2300(15)30025-8/sref69 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref69 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref69 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref69 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref69 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref69 http://dx.doi.org/10.1186/1471-2334-7-117 http://dx.doi.org/10.1186/1745-6673-3-26 http://dx.doi.org/10.1186/1745-6673-3-26 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref74 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref74 http://dx.doi.org/10.1186/1756-0500-2-158 http://dx.doi.org/10.1186/1756-0500-2-158 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref77 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref77 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref77 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref79 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref79 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref79 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref79 http://dx.doi.org/10.1007/s10735-004-2670-z http://dx.doi.org/10.1007/s10735-004-2670-z http://dx.doi.org/10.1542/peds.2013-3733 http://dx.doi.org/10.1542/peds.2013-3733 http://dx.doi.org/10.1016/j.annepidem.2014.10.011 http://dx.doi.org/10.1016/j.annepidem.2014.10.011 http://dx.doi.org/10.1093/humrep/det455 http://dx.doi.org/10.1016/S1473-3099(07)70311-0 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref85 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref85 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref85 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref85 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref85 http://dx.doi.org/10.1093/toxsci/kfu246 http://dx.doi.org/10.1093/toxsci/kfu246 http://dx.doi.org/10.3109/08958378.2012.712165 http://dx.doi.org/10.3109/08958378.2012.712165 http://dx.doi.org/10.3109/08958378.2014.938184 http://dx.doi.org/10.3109/08958378.2014.938184 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref89 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref89 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref89 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref89 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref89 http://dx.doi.org/10.1258/shorts.2011.011034 http://dx.doi.org/10.1258/shorts.2011.011034 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref91 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref91 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref91 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref92 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref92 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref92 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref92 http://dx.doi.org/10.1007/s00414-010-0511-z http://www.nice.org.uk/guidance/cg62/chapter/1-guidance#lifestyle-considerations http://www.nice.org.uk/guidance/cg62/chapter/1-guidance#lifestyle-considerations http://www.nap.edu/catalog/12209/science-and-decisions-advancing-risk-assessment http://www.nap.edu/catalog/12209/science-and-decisions-advancing-risk-assessment http://dx.doi.org/10.1136/jech-2013-202934 http://dx.doi.org/10.1136/jech-2013-202934 http://dx.doi.org/10.1111/j.1465-3362.2011.00331.x http://dx.doi.org/10.1111/j.1360-0443.2009.02756.x http://dx.doi.org/10.1111/j.1360-0443.2009.02756.x http://refhub.elsevier.com/S0273-2300(15)30025-8/sref99 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref99 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref99 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref99 http://www.oecd-ilibrary.org/content/book/9789264070820-en http://www.oecd-ilibrary.org/content/book/9789264070820-en http://www.inchem.org/documents/sids/sids/64175.pdf http://www.fda.gov/ICECI/ComplianceManuals/CompliancePolicyGuidanceManual/ucm074430.htm http://www.fda.gov/ICECI/ComplianceManuals/CompliancePolicyGuidanceManual/ucm074430.htm http://www.mothertobaby.org/fact-sheets-s13037 http://dx.doi.org/10.1177/0883073811428376 A. Maier et al. / Regulatory Toxicology and Pharmacology 73 (2015) 248e264264 Pastino, G.M., Asgharian, B., Roberts, K., Medinsky, M.A., Bond, J.A., 1997. A comparison of physiologically based pharmacokinetic model predictions and experimental data for inhaled ethanol in male and female B6C3F1 mice, F344 rats, and humans. Toxicol. Appl. Pharmacol. 145, 147e157. http://dx.doi.org/ 10.1006/taap.1997.8161. U.S. Food and Drug Administration, 2014. FDA Adverse Event Reporting System (FAERS). Available at: http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ (accessed 09.03.15.). U.S. Food and Drug Administration, 2015a. 21 CFR Part 310 safety and effectiveness of health care antiseptics; topical antimicrobial drug products for over-the- counter human use; proposed amendment of the tentative final monograph; reopening of administrative record; proposed rule. Fed. Regist. 80, 25166e25205. http://dx.doi.org/10.1006/taap.1997.8161 http://dx.doi.org/10.1006/taap.1997.8161 http://dx.doi.org/10.1111/j.1471-0528.2011.03050.x http://refhub.elsevier.com/S0273-2300(15)30025-8/sref107 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref107 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref107 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref107 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref108 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref108 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref108 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref108 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref109 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref109 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref109 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref110 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref110 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref110 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref110 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref111 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref111 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref111 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref112 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref113 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref113 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref114 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref114 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref114 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref114 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref114 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref115 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref115 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref116 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref116 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref116 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref116 http://dx.doi.org/10.1111/j.1530-0277.2009.00906.x http://refhub.elsevier.com/S0273-2300(15)30025-8/sref118 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref118 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref118 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref118 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref119 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref119 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref119 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref120 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref120 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref120 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref120 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref121 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref121 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref121 https://www.rcog.org.uk/en/patients/patient-leaflets/alcohol-and-pregnancy/ https://www.rcog.org.uk/en/patients/patient-leaflets/alcohol-and-pregnancy/ http://refhub.elsevier.com/S0273-2300(15)30025-8/sref123 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref123 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref123 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref123 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref124 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref124 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref124 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref124 http://ec.europa.eu/health/scientific_committees/environmental_risks/opinions/sctee/sct_out110_en.htm http://ec.europa.eu/health/scientific_committees/environmental_risks/opinions/sctee/sct_out110_en.htm http://dx.doi.org/10.1002/tera.1420380503 http://www.channing.harvard.edu/nhs/ http://journals.lww.com/greenjournal/Abstract/2008/03000/Binge_Drinking_in_Pregnancy_and_Risk_of_Fetal.5.aspx http://journals.lww.com/greenjournal/Abstract/2008/03000/Binge_Drinking_in_Pregnancy_and_Risk_of_Fetal.5.aspx http://dx.doi.org/10.1128/AEM.03262-13 http://dx.doi.org/10.1128/AEM.03262-13 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref130 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref130 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref130 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref131 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref131 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref131 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref131 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref132 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref132 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref132 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref132 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref133 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref133 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref133 http://dx.doi.org/10.1093/toxsci/kfh057 http://dx.doi.org/10.1093/toxsci/kfh057 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref135 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref135 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref135 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref135 http://dx.doi.org/10.1016/j.forsciint.2010.04.031 http://www.epa.gov/oppt/sf/pubs/sf-p2-manual.html http://www.epa.gov/oppt/sf/pubs/sf-p2-manual.html http://www.epa.gov/opprd001/inerts/ethyl.pdf http://refhub.elsevier.com/S0273-2300(15)30025-8/sref139 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref139 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref139 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref139 http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ http://refhub.elsevier.com/S0273-2300(15)30025-8/sref141 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref141 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref141 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref141 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref141 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref141 http://www.fda.gov/Safety/MedWatch/ http://www.fda.gov/Safety/MedWatch/ http://uscode.house.gov/browse/prelim@title27/chapter8/subchapter2%26edition=prelim http://uscode.house.gov/browse/prelim@title27/chapter8/subchapter2%26edition=prelim http://uscode.house.gov/browse/prelim@title27/chapter8/subchapter2%26edition=prelim http://uscode.house.gov/browse/prelim@title27/chapter8/subchapter2%26edition=prelim http://come-over.to/FAS/SurGenAdvisory.htm http://dx.doi.org/10.1016/j.alcohol.2004.11.004 http://dx.doi.org/10.1111/j.1471-0528.2012.03396.x http://refhub.elsevier.com/S0273-2300(15)30025-8/sref147 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref147 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref147 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref148 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref148 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref149 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref149 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref149 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref149 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref150 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref150 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref150 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref151 http://refhub.elsevier.com/S0273-2300(15)30025-8/sref151 Safety assessment for ethanol-based topical antiseptic use by health care workers: Evaluation of developmental toxicity pot ... 1. Introduction 2. Characterization of effects and dose response behavior for ethanol 2.1. Pharmacokinetic considerations 2.1.1. Maternal peak BAC as a surrogate dose metric 2.1.2. Critical effect windows", "Acknowledgement": "4. Margin of exposure analysis 5. Discussion 6. Conclusions Acknowledgments Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-2-ethyl-3--5-or-6--dimethy_2008_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18304712", "content": {"Acknowledgement": "Acknowledgments The descriptions, compilations, analysis and reviews of research contained in this article were funded by Philip Morris USA Inc. The authors wish to thank the efforts of Arlene Morales and Mindy Swetz for their contributions to this manuscript. Discussion Conclusion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Safety-assessment-of-Asterarcys-quadricellulare--a-m_2022_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/35065094", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 5 Conclusion Funding body CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Funding": "Funding body This set of studies was funded by Alltech SARL (France). S. Mustafa: Writing \u2013 original draft. G.P. Dillon: Writing \u2013 review & editing. C.A. Moran: Conceptualization, Visualization, Supervision, Project administration, Funding acquisition, Writing \u2013 review & editing. Declaration of competing interest 5 Conclusion Funding body CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Acknowledgement": "Acknowledgements The authors would like to thank S. Mortier (Study Director), I. Gitton (Study Director Deputy), S. Richard and P. Champeroux (Testing Facility Management), M.L. Sola (Safety Assessment Director), and S. Bidoli- Beutin (Quality Assurance) of the Centre de Recherches Biologiques (CERB) (Baugy, France) for conducting the acute oral toxicity, skin sensitisation, acute eye irritation and acute skin irritation studies. The authors would also like to thank G. Dewaele (Study Director), F. Nes- slany and S. Simar (Test Facility Management), B. Gorez (Quality Assurance) at the Institut Pastuer de Lille (Lille, France) for conducting the bacterial reverse mutation study. 5 Conclusion Funding body CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-Bacillus-subtilis-CU1-for-_2017_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27825987", "content": {"CoiStatement": "Conflict of interest statement The clinical study was performed by BIOFORTIS, a M\ufffderieux NutriSciences Company, 3 route de la Chatterie, Saint-Herblain, France. Intertek Scientific & Regulatory Consultancy has provided consultancy services to Lesaffre Human Care. Conflict of interest statement Funding sources statement Acknowledgments Transparency document References", "Funding": "Funding sources statement This studywas performed as part of the research project Probisis partially financed by the French Government 3rd FUI research program, and supported by the Research cluster Prod\u2019Innov of the region Aquitaine and LESAFFRE. Conflict of interest statement Funding sources statement Acknowledgments Transparency document References", "Compliance with ethical standards": "The authors would like to thank the clinical study subjects for their interest, time, and compliance with dietary supplementation. The authors would like to acknowledge the staff at BIOFORTIS (a M\ufffderieux NutriSciences Company, 3 route de la Chatterie, Saint- Herblain, France), Eurofins IDmyk (1, rue des Vergers, 69760 Limonest, France), and BIOCEANE (rue du Moulin de la Rousseli\ufffdere, 44821 Saint Herblain, France) for their diligent work in conducting the clinical trial, 16S and gyrB sequencing, and MIC testing, respectively. Transparency document", "Acknowledgement": "Acknowledgments The authors would like to thank the clinical study subjects for their interest, time, and compliance with dietary supplementation. The authors would like to acknowledge the staff at BIOFORTIS (a M\ufffderieux NutriSciences Company, 3 route de la Chatterie, Saint- Herblain, France), Eurofins IDmyk (1, rue des Vergers, 69760 Limonest, France), and BIOCEANE (rue du Moulin de la Rousseli\ufffdere, 44821 Saint Herblain, France) for their diligent work in conducting the clinical trial, 16S and gyrB sequencing, and MIC testing, respectively. Conflict of interest statement Funding sources statement Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-Cry1C-protein-from-genetically-mod_2010_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20801181", "content": {"Acknowledgement": "Acknowledgments This work was funded by the Genetically Modified Organisms Breeding Major Projects of PR China (2008ZX08011-005 and 2009ZX08011-001B), and we express our gratitude to the Ministry of Science and Technology and the Ministry of Agriculture of PR China for their financial support. Discussion Conclusion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-EPA-rich-oil-produced-from-yea_2010_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20804805", "content": {"CoiStatement": "Conflict of interest This study was supported by the DuPont Company. All authors declare that they have no conflicts of interest. This study was supported by the DuPont Company. All authors declare that they have no conflicts of interest. Acknowledgments Discussion and conclusions Conflict of interest Acknowledgments References", "Acknowledgement": "Acknowledgments We thank Charlene Smith and Kenneth Reed for their technical contributions to the study. Special thanks to Chuck Powley for ana- lytical chemistry support. Discussion and conclusions Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-EPA-rich-triglyceride-oil-produc_2011_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20868718", "content": {"CoiStatement": "a Statistically significant increase, p 6 0.05 (Kastenbaum-Bowman Tables. 62 L.A. Belcher et al. / Regulatory Toxicology and Pharmacology 59 (2011) 53\u201363 weight gain. Clinical chemistry effects for albumin and alanine transferase were not dose-related and were unrelated to treat- ment. Furthermore, they were not associated with any adverse microscopic liver pathology. When rats were administered EPA oil, absolute liver weight was statistically significantly increased in female rats at the high dose, and relative liver (to body weight) weights were statistically signif- icantly increased in mid- and high-dose male and high dose female rats. Increases in the male rats were minimal, while liver weights in female animals were around 15% higher than in the control animals receiving olive oil. There were no concurrent increases in enzymes indicative of liver damage (e.g., ALT, AST, GGT) and there were no abnormal histopathologic findings. Polyunsaturated fatty acids (PUFA), in particular omega-3, interact with the nuclear receptor PPARa, induce liver metabolic enzyme production, and adaptive increases in liver weights in response to high intakes (Valdes et al., 1995). Specifically, rats administered similar levels of Menhanden oil (crude fish oil containing 12.9% EPA and 9.2% DHA), MaxEPA\ufffd oil (17.8% EPA and 12% DHA), and DHASCO (docosahexaenoic acid single cell oil: 38.4% DHA) had similar sta- tistically significant increases (8\u201319%) in absolute or relative liver weights at similar omega-3 (EPA and/or DHA) doses, with no accompanying adverse histopathologic effects (Rabbani et al., 2001; Boswell et al., 1996). Therefore, the increased liver weights in the current repeat-dose study were expected and are most likely the result of a physiologic adaptive response from high omega-3 oil intake. When rats were administered EPA oil, total cholesterol was decreased, including the non-HDL and HDL fractions. Cholesterol lowering is a well recognized and documented effect of PUFAs, and in particular omega-3 fatty acids (Sugiyama et al., 2008). Although the modest reduction in HDL in the rat might suggest an undesirable HDL reduction in humans, species-specific differ- ences in rat and human HDL metabolism suggest just the opposite. These differences include (1) the primary circulating lipoprotein in the rat is HDL, while in humans it is LDL, (2) the rat is deficient in a key lipid exchange protein (cholesteryl ester transfer protein or CETP) found in human that mediates the transfer of cholesteryl esters between HDL and apo B containing lipoproteins, and (3) the transcriptional regulation of apo A-1, the primary structural protein of HDL, is different in rats and humans (Bauer, 1996). The molecular basis for the different responses occurs at the level of apo A-1 transcription and reflects the way in which the two species respond to the nuclear receptors PPARa and Rev-erba (Vu-Dac et al., 1998). Additionally, given that there was no effect on HDL-cholesterol in the Low EPA dose group at an EPA dose (325 mg/kg bw) that is 10-fold higher than the recommended upper limit of EPA from EPA oil dietary supplements (2 g EPA/ day or 33 mg/kg bw/day), HDL-cholesterol effects are not expected in humans following intake of the EPA oil dietary supplement. This conclusion is supported by recent studies in humans where highly purified EPA was given at 46 mg/kg for 7 weeks without effect on HDL-cholesterol (Grimsgaard et al., 1997). Therefore, the change in rat serum cholesterol was an expected response to EPA oil exposure, and the decrease is of a magnitude considered to be potentially beneficial for humans and comparable to that observed with other PUFAs. When rats were administered EPA oil, minimal-to-mild thyroid follicular cell hypertrophy (FCH) was observed in male rats only. This lesion has been observed with a historic background incidence in the performing laboratory of up to 20% in studies of this duration and in this strain of rat. Therefore, the incidences of 0\u201320% hyper- trophy in the rats given 0, low-dose, or medium-dose EPA oil were considered to be within normal limits. No FCH was observed in a companion study where rats were administered the same high dose of EPA oil for 90 days, further supporting this as a background and/or transient response to high oil intake (MacKenzie et al., 2010, in press). The thyroid FCH response in rats was mild, with no hyperplasia or increase in thyroid weight. The increase in relative liver weight is consistent with a liver enzyme-mediated mechanism and FCH com- monly found in male rats. The literature suggests that long-chain polyunsaturated FA, with a safe history of use, can modulate thy- roid homeostasis in rats. The similar liver and thyroid responses from the mid-dose EPA oil and fish oil groups in the 28-day toxicity study also suggest that these effects may be associated with the amount of EPA in these oils, and the safety assessments and safe history of use of EPA ethyl ester, other EPA-rich oils, and fish oil sup- port the safe use of the EPA oil from yeast (Cazzola et al., 2007; Yokoyama et al., 2007; Emsley et al., 2008; Rabbani et al., 2001). An oil containing more than 80% naturally occurring fatty acids would not be expected to exhibit genotoxic properties. However, since the EPA oil was derived from a novel source and process, EPA oil was tested to verify that there were no genotoxic contam- inants. The genotoxic potential of EPA oil was tested in a battery of two in vitro (Ames and mouse lymphoma) and one in vivo (mouse micronucleus) assay according to current standard testing guide- lines were evaluated. In the Ames assay, no increase in the reverse mutation frequency was seen in the absence or presence of S9 in either S. typhimurium TA98, TA100, TA1535, or TA1537, or in E. coli strain WP2uvrA. Negative results were also obtained in the mouse lymphoma assay. Therefore EPA oil was concluded to be L.A. Belcher et al. / Regulatory Toxicology and Pharmacology 59 (2011) 53\u201363 63 negative for induction of point mutations and deletions in vitro. Furthermore, EPA oil was not clastogenic or aneugenic in mice in vivo. No systemic toxicity occurred after treatment with EPA oil; the observed diarrhea in male mice may be associated with the relatively large volume of oil that was administered to the mice with the female having a greater tolerance for fat by ingestion. 5. Conclusion Exposure to EPA oil, administered by gavage at doses up to 2820 mg EPA oil/kg bw/day (976 mg EPA/kg bw/day) for 28-days, produced no adverse effects on in-life, clinical pathology, or pathology parameters. All concentrations of EPA oil lowered cho- lesterol, and were not associated with any adverse effects. Expo- sure to 2820 mg EPA oil/kg bw/day and 1880 mg EPA oil/kg bw/ day (650 mg EPA/kg bw/day) (males only) produced non-adverse increases in liver weights with no correlative clinical or micro- scopic pathology. Exposure to 2820 mg/kg bw/day EPA oil pro- duced minimal to mild thyroid follicular cell hypertrophy in male rats, which was also observed at a similar incidence in the male rats exposed to fish oil, a substance considered to be GRAS by the USFDA. EPA oil produced from genetically modified yeast was also not genotoxic in bacteria and mammalian cells in vitro, or in mice administered a single high dose. In conclusion, under the con- ditions of these studies the lack of adverse effects supports the safe use of this EPA oil from yeast as a dietary supplement. 6. Conflict of interest statement All authors declare that they have no competing financial interests. Acknowledgments We thank Melissa Fallers for her technical contributions to the repeat-dose toxicity study; and Jane J. Clarke, Ljubica Krsmanovic, and Valentine O. Wagner III for their technical contributions to the genetic toxicity studies. Special thanks to Chuck Powley for analyt- ical chemistry support. These studies were funded by the DuPont Company. References Bauer, J.E., 1996. Comparative lipid and lipoprotein metabolism. Vet. Clin. Pathol. 25, 49\u201356. Boswell, K., Koskelo, E.-K., Carl, L., Glaza, S., Hensen, D.J., Williams, K.D., Kyle, D.J., 1996. Preclinical evaluation of single-cell oils that are highly enriched with arachidonic acid and docosahexaenoic acid. Food Chem. Toxicol. 34, 585\u2013593. Cazzola, R., Russo-Volpe, S., Miles, E.A., Rees, D., Banerjee, T., Roynette, C.E., Wells, S.J., Coua, M., Wahle, K.W.J., Calder, P.C., Cestaro, B., 2007. Age- and dose- dependent effects of an eicosapentaenoic acid-rich oil on cardiovascular risk factors in healthy male subjects. Atherosclerosis 193, 159\u2013167. Emsley, R., Niehaus, J.G.H., Oosthuizen, P.P., Koen, L., Ascott-Evans, B., Chiliza, B., van Rensburg, S.J., Smit, R.M., 2008. Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized placebo-controlled trial. Psych. Res. 161, 284\u2013291. Gebauer, S.K., Psota, T.L., Harris, W., Kris-Etherton, P.M., 2006. N-3 Fatty acid dietary recommendations and food sources to achieve essentiality and cardiovascular benefits. Am. J. Clin. Nutr. 83 (suppl), 1526S\u20131535S. Grimsgaard, S., Bona, K.H., Hansen, J.-B., Nordoy, A., 1997. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am. J. Clin. Nutr. 66, 649\u2013659. Hammond, B.G., Lemen, J.K., Ahmed, G., Miller, K.D., Kirkpatrick, J., Fleeman, T., 2008. Safety assessment of SDA soybean oil: results of a 28-day gavage study and a 90-day/one generation reproduction feeding study in rats. Reg. Toxicol. Pharmacol 52, 311\u2013323. Harris, W., Mozaffarian, D., Lefevre, M., Toner, C.D., Colombo, J., Cunnane, S.C., Holden, J.M., Klurfed, D.M., Morris, M.C., Whelan, J., 2009. Towards establishing dietary reference intakes for eicosapentaenoic and docosahexaenoic acids. J. Nutr. 139, 804S\u2013819S. Institute for Laboratory Animal Research, 1996. Guide for the Care and Use of Laboratory Animals (National Academies Press, Washington, D.C.). Kris-Etherton, P.M., Harris, W.S., Appel, L.J., 2002. Fish consumption, fish oil, omega- 3 fatty acids, and cardiovascular disease. Circulation 106, 2747\u20132757. Kris-Etherton, P.M., Hill, A.M., 2008. N-3 fatty acids: food or supplements? J. Am. Dietetic Assoc. 108, 1125\u20131130. MacKenzie, S. A., Belcher, L. A., Sykes, G. P., Frame, S.R., Mukerji, P., Gillies, P. J., (2010). Safety assessment of an EPA-rich oil produced from yeast: results of a 90-day subchronic toxicity study. Reg. Toxicol. Pharmacol, in press. Rabbani, P.I., Alam, H.Z., Chirtel, S.J., Duvall, R.E., Jackson, R.C., Ruffin, G., 2001. Subchronic toxicity of fish oil concentrates in male and female rats. J. Nutr. Sci. Vitaminol. 47, 201\u2013212. Simopoulos, A.P., 1991. Omega-3 fatty acids in health and disease and in growth and development. Am. J. Clin. Nutr. 54, 438\u2013463. Sugiyama, E., Ishikawa, Y., Li, Y., Kagar, T., Nobayashi, M., Tanaka, N., Kamijo, Y., Yokoyama, S., Hara, A., Aoyama, T., 2008. Eicosapentaenoic acid lowers plasma and liver cholesterol levels in the presence of peroxisome proliferators- activated receptor alpha. Life Sci. 83, 19\u201328. USFDA, 2004a. FDA News Release P04-89. September 8, 2004, FDA Announces Qualified Health Claims for Omega-3 Fatty Acids. USFDA, 2004b. FDA CFSAN Office of Food Additive Safety. Agency Response Letter. GRAS Notice No. GRN 000138, April 20, 2004. Valdes, E., Vega, P., Avalos, N., Orellana, M., 1995. Dietary fish oil and cytochrome P-450 monooxygenase activity in rat liver and kidney. Lipids 30, 955\u2013958. Vu-Dac, N., Chopin-Delannoy, S., Gervois, P., Martin, G., Fruchart, J.-C., Laudet, V., Staels, B., 1998. The nuclear receptors peroxisome proliferator-activated receptor-a and rev-erba mediate the species-specific regulation of apolipoprotein A-1 expression by fibrates. J. Biol. Chem. 273, 25713\u201325720. Yokoyama, S., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawasa, S., Sasaki, J., Hishida, H., Itakura, H., Kita, T., Kitabatake, A., Nakaya, N., Sakata, T., Shimada, K., Shirato, K., 2007. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. Lancet 369, 1090\u20131098. Safety assessment of EPA-rich triglyceride oil produced from yeast: Genotoxicity and 28-day oral toxicity in rats Introduction Materials and methods Test materials Chemical analysis 28-Day repeated-dose oral gavage study Animals Study design In-life observations Clinical pathology Anatomic pathology Fatty acid analyses Statistical analysis Genetic toxicity studies Ames assay Mouse lymphoma assay In vivo micronucleus test Results Repeated-dose toxicity study Genotoxicity studies Ames assay Mouse lymphoma assay In vivo micronucleus assay Discussion Conclusion Conflict of interest statement Acknowledgments References", "Acknowledgement": "a Statistically significant increase, p 6 0.05 (Kastenbaum-Bowman Tables. 62 L.A. Belcher et al. / Regulatory Toxicology and Pharmacology 59 (2011) 53\u201363 weight gain. Clinical chemistry effects for albumin and alanine transferase were not dose-related and were unrelated to treat- ment. Furthermore, they were not associated with any adverse microscopic liver pathology. When rats were administered EPA oil, absolute liver weight was statistically significantly increased in female rats at the high dose, and relative liver (to body weight) weights were statistically signif- icantly increased in mid- and high-dose male and high dose female rats. Increases in the male rats were minimal, while liver weights in female animals were around 15% higher than in the control animals receiving olive oil. There were no concurrent increases in enzymes indicative of liver damage (e.g., ALT, AST, GGT) and there were no abnormal histopathologic findings. Polyunsaturated fatty acids (PUFA), in particular omega-3, interact with the nuclear receptor PPARa, induce liver metabolic enzyme production, and adaptive increases in liver weights in response to high intakes (Valdes et al., 1995). Specifically, rats administered similar levels of Menhanden oil (crude fish oil containing 12.9% EPA and 9.2% DHA), MaxEPA\ufffd oil (17.8% EPA and 12% DHA), and DHASCO (docosahexaenoic acid single cell oil: 38.4% DHA) had similar sta- tistically significant increases (8\u201319%) in absolute or relative liver weights at similar omega-3 (EPA and/or DHA) doses, with no accompanying adverse histopathologic effects (Rabbani et al., 2001; Boswell et al., 1996). Therefore, the increased liver weights in the current repeat-dose study were expected and are most likely the result of a physiologic adaptive response from high omega-3 oil intake. When rats were administered EPA oil, total cholesterol was decreased, including the non-HDL and HDL fractions. Cholesterol lowering is a well recognized and documented effect of PUFAs, and in particular omega-3 fatty acids (Sugiyama et al., 2008). Although the modest reduction in HDL in the rat might suggest an undesirable HDL reduction in humans, species-specific differ- ences in rat and human HDL metabolism suggest just the opposite. These differences include (1) the primary circulating lipoprotein in the rat is HDL, while in humans it is LDL, (2) the rat is deficient in a key lipid exchange protein (cholesteryl ester transfer protein or CETP) found in human that mediates the transfer of cholesteryl esters between HDL and apo B containing lipoproteins, and (3) the transcriptional regulation of apo A-1, the primary structural protein of HDL, is different in rats and humans (Bauer, 1996). The molecular basis for the different responses occurs at the level of apo A-1 transcription and reflects the way in which the two species respond to the nuclear receptors PPARa and Rev-erba (Vu-Dac et al., 1998). Additionally, given that there was no effect on HDL-cholesterol in the Low EPA dose group at an EPA dose (325 mg/kg bw) that is 10-fold higher than the recommended upper limit of EPA from EPA oil dietary supplements (2 g EPA/ day or 33 mg/kg bw/day), HDL-cholesterol effects are not expected in humans following intake of the EPA oil dietary supplement. This conclusion is supported by recent studies in humans where highly purified EPA was given at 46 mg/kg for 7 weeks without effect on HDL-cholesterol (Grimsgaard et al., 1997). Therefore, the change in rat serum cholesterol was an expected response to EPA oil exposure, and the decrease is of a magnitude considered to be potentially beneficial for humans and comparable to that observed with other PUFAs. When rats were administered EPA oil, minimal-to-mild thyroid follicular cell hypertrophy (FCH) was observed in male rats only. This lesion has been observed with a historic background incidence in the performing laboratory of up to 20% in studies of this duration and in this strain of rat. Therefore, the incidences of 0\u201320% hyper- trophy in the rats given 0, low-dose, or medium-dose EPA oil were considered to be within normal limits. No FCH was observed in a companion study where rats were administered the same high dose of EPA oil for 90 days, further supporting this as a background and/or transient response to high oil intake (MacKenzie et al., 2010, in press). The thyroid FCH response in rats was mild, with no hyperplasia or increase in thyroid weight. The increase in relative liver weight is consistent with a liver enzyme-mediated mechanism and FCH com- monly found in male rats. The literature suggests that long-chain polyunsaturated FA, with a safe history of use, can modulate thy- roid homeostasis in rats. The similar liver and thyroid responses from the mid-dose EPA oil and fish oil groups in the 28-day toxicity study also suggest that these effects may be associated with the amount of EPA in these oils, and the safety assessments and safe history of use of EPA ethyl ester, other EPA-rich oils, and fish oil sup- port the safe use of the EPA oil from yeast (Cazzola et al., 2007; Yokoyama et al., 2007; Emsley et al., 2008; Rabbani et al., 2001). An oil containing more than 80% naturally occurring fatty acids would not be expected to exhibit genotoxic properties. However, since the EPA oil was derived from a novel source and process, EPA oil was tested to verify that there were no genotoxic contam- inants. The genotoxic potential of EPA oil was tested in a battery of two in vitro (Ames and mouse lymphoma) and one in vivo (mouse micronucleus) assay according to current standard testing guide- lines were evaluated. In the Ames assay, no increase in the reverse mutation frequency was seen in the absence or presence of S9 in either S. typhimurium TA98, TA100, TA1535, or TA1537, or in E. coli strain WP2uvrA. Negative results were also obtained in the mouse lymphoma assay. Therefore EPA oil was concluded to be L.A. Belcher et al. / Regulatory Toxicology and Pharmacology 59 (2011) 53\u201363 63 negative for induction of point mutations and deletions in vitro. Furthermore, EPA oil was not clastogenic or aneugenic in mice in vivo. No systemic toxicity occurred after treatment with EPA oil; the observed diarrhea in male mice may be associated with the relatively large volume of oil that was administered to the mice with the female having a greater tolerance for fat by ingestion. 5. Conclusion Exposure to EPA oil, administered by gavage at doses up to 2820 mg EPA oil/kg bw/day (976 mg EPA/kg bw/day) for 28-days, produced no adverse effects on in-life, clinical pathology, or pathology parameters. All concentrations of EPA oil lowered cho- lesterol, and were not associated with any adverse effects. Expo- sure to 2820 mg EPA oil/kg bw/day and 1880 mg EPA oil/kg bw/ day (650 mg EPA/kg bw/day) (males only) produced non-adverse increases in liver weights with no correlative clinical or micro- scopic pathology. Exposure to 2820 mg/kg bw/day EPA oil pro- duced minimal to mild thyroid follicular cell hypertrophy in male rats, which was also observed at a similar incidence in the male rats exposed to fish oil, a substance considered to be GRAS by the USFDA. EPA oil produced from genetically modified yeast was also not genotoxic in bacteria and mammalian cells in vitro, or in mice administered a single high dose. In conclusion, under the con- ditions of these studies the lack of adverse effects supports the safe use of this EPA oil from yeast as a dietary supplement. 6. Conflict of interest statement All authors declare that they have no competing financial interests. Acknowledgments We thank Melissa Fallers for her technical contributions to the repeat-dose toxicity study; and Jane J. Clarke, Ljubica Krsmanovic, and Valentine O. Wagner III for their technical contributions to the genetic toxicity studies. Special thanks to Chuck Powley for analyt- ical chemistry support. These studies were funded by the DuPont Company. References Bauer, J.E., 1996. Comparative lipid and lipoprotein metabolism. Vet. Clin. Pathol. 25, 49\u201356. Boswell, K., Koskelo, E.-K., Carl, L., Glaza, S., Hensen, D.J., Williams, K.D., Kyle, D.J., 1996. Preclinical evaluation of single-cell oils that are highly enriched with arachidonic acid and docosahexaenoic acid. Food Chem. Toxicol. 34, 585\u2013593. Cazzola, R., Russo-Volpe, S., Miles, E.A., Rees, D., Banerjee, T., Roynette, C.E., Wells, S.J., Coua, M., Wahle, K.W.J., Calder, P.C., Cestaro, B., 2007. Age- and dose- dependent effects of an eicosapentaenoic acid-rich oil on cardiovascular risk factors in healthy male subjects. Atherosclerosis 193, 159\u2013167. Emsley, R., Niehaus, J.G.H., Oosthuizen, P.P., Koen, L., Ascott-Evans, B., Chiliza, B., van Rensburg, S.J., Smit, R.M., 2008. Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized placebo-controlled trial. Psych. Res. 161, 284\u2013291. Gebauer, S.K., Psota, T.L., Harris, W., Kris-Etherton, P.M., 2006. N-3 Fatty acid dietary recommendations and food sources to achieve essentiality and cardiovascular benefits. Am. J. Clin. Nutr. 83 (suppl), 1526S\u20131535S. Grimsgaard, S., Bona, K.H., Hansen, J.-B., Nordoy, A., 1997. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am. J. Clin. Nutr. 66, 649\u2013659. Hammond, B.G., Lemen, J.K., Ahmed, G., Miller, K.D., Kirkpatrick, J., Fleeman, T., 2008. Safety assessment of SDA soybean oil: results of a 28-day gavage study and a 90-day/one generation reproduction feeding study in rats. Reg. Toxicol. Pharmacol 52, 311\u2013323. Harris, W., Mozaffarian, D., Lefevre, M., Toner, C.D., Colombo, J., Cunnane, S.C., Holden, J.M., Klurfed, D.M., Morris, M.C., Whelan, J., 2009. Towards establishing dietary reference intakes for eicosapentaenoic and docosahexaenoic acids. J. Nutr. 139, 804S\u2013819S. Institute for Laboratory Animal Research, 1996. Guide for the Care and Use of Laboratory Animals (National Academies Press, Washington, D.C.). Kris-Etherton, P.M., Harris, W.S., Appel, L.J., 2002. Fish consumption, fish oil, omega- 3 fatty acids, and cardiovascular disease. Circulation 106, 2747\u20132757. Kris-Etherton, P.M., Hill, A.M., 2008. N-3 fatty acids: food or supplements? J. Am. Dietetic Assoc. 108, 1125\u20131130. MacKenzie, S. A., Belcher, L. A., Sykes, G. P., Frame, S.R., Mukerji, P., Gillies, P. J., (2010). Safety assessment of an EPA-rich oil produced from yeast: results of a 90-day subchronic toxicity study. Reg. Toxicol. Pharmacol, in press. Rabbani, P.I., Alam, H.Z., Chirtel, S.J., Duvall, R.E., Jackson, R.C., Ruffin, G., 2001. Subchronic toxicity of fish oil concentrates in male and female rats. J. Nutr. Sci. Vitaminol. 47, 201\u2013212. Simopoulos, A.P., 1991. Omega-3 fatty acids in health and disease and in growth and development. Am. J. Clin. Nutr. 54, 438\u2013463. Sugiyama, E., Ishikawa, Y., Li, Y., Kagar, T., Nobayashi, M., Tanaka, N., Kamijo, Y., Yokoyama, S., Hara, A., Aoyama, T., 2008. Eicosapentaenoic acid lowers plasma and liver cholesterol levels in the presence of peroxisome proliferators- activated receptor alpha. Life Sci. 83, 19\u201328. USFDA, 2004a. FDA News Release P04-89. September 8, 2004, FDA Announces Qualified Health Claims for Omega-3 Fatty Acids. USFDA, 2004b. FDA CFSAN Office of Food Additive Safety. Agency Response Letter. GRAS Notice No. GRN 000138, April 20, 2004. Valdes, E., Vega, P., Avalos, N., Orellana, M., 1995. Dietary fish oil and cytochrome P-450 monooxygenase activity in rat liver and kidney. Lipids 30, 955\u2013958. Vu-Dac, N., Chopin-Delannoy, S., Gervois, P., Martin, G., Fruchart, J.-C., Laudet, V., Staels, B., 1998. The nuclear receptors peroxisome proliferator-activated receptor-a and rev-erba mediate the species-specific regulation of apolipoprotein A-1 expression by fibrates. J. Biol. Chem. 273, 25713\u201325720. Yokoyama, S., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawasa, S., Sasaki, J., Hishida, H., Itakura, H., Kita, T., Kitabatake, A., Nakaya, N., Sakata, T., Shimada, K., Shirato, K., 2007. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. Lancet 369, 1090\u20131098. Safety assessment of EPA-rich triglyceride oil produced from yeast: Genotoxicity and 28-day oral toxicity in rats Introduction Materials and methods Test materials Chemical analysis 28-Day repeated-dose oral gavage study Animals Study design In-life observations Clinical pathology Anatomic pathology Fatty acid analyses Statistical analysis Genetic toxicity studies Ames assay Mouse lymphoma assay In vivo micronucleus test Results Repeated-dose toxicity study Genotoxicity studies Ames assay Mouse lymphoma assay In vivo micronucleus assay Discussion Conclusion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-Guibi-tang--Subchronic-tox_2015_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26432010", "content": {"CoiStatement": "M.-Y. Lee et al. / Regulatory Toxicology and Pharmacology 73 (2015) 485e493492 of up to 2000 mg/kg/day. Therefore, the NOAEL (no-observed- adverse-effect level) was considered to be more than 2000 mg/kg. Conflicts of interest No competing financial interests exist. Acknowledgments 4. Discussion Conflicts of interest Acknowledgments Transparency document Appendix A. Supplementary data References", "Acknowledgement": "No competing financial interests exist. Acknowledgments This study was part of a project (Construction of Scientific Evi- dences for Herbal Medicine Formulas, K13030) funded by the Basic Herbal Research Group of the Korea Institute of Oriental Medicine (K15251). Transparency document 4. Discussion Conflicts of interest Acknowledgments Transparency document Appendix A. Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-Oryeong-san--a-traditional-herbal-fo_2018_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30026136", "content": {"CoiStatement": "Competing interests The authors declare that there is no conflict of, or competing fi- nancial interests regarding, the publication of this paper. Discussion Conclusions Competing interests Authors' contributions Acknowledgments Transparency document References", "Acknowledgement": "Acknowledgments This research was supported by a Grant for \u201cConstruction of Scientific Evidences for Herbal Medicine Formulas (K16250)\u201d from the Korea Institute of Oriental Medicine. Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-SDA-soybean-oil--Results-of-a-28-d_2008_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18804141", "content": {"CoiStatement": "Conflict of interest The toxicology studies that are summarized in this manuscript were sponsored by Monsanto Company. Monsanto contracted with WIL Research Laboratories, LLC, to carry out the toxicology studies, and Covance Laboratories Inc. to analyze SDA, control and menha- den oils and formulated diets. References Conclusions Conflict of interest References", "Compliance with ethical standards": "Safety assessment of SDA soybean oil: Results of a 28-day gavage study and a 90-day/one generation reproduction feeding study in rats Introduction Materials and methods1Studies were conducted in compliance with the United States Food and Drug Administration FDA Good Laboratory Practice Regulations 21 CFR Part 58, Oct 5, 1987; the United States Materials Subchronic toxicity and reproduction studies2The experimental design for the 4 weeks gavage study was adapted from OECD Guideline 407. The experimental design for the 90 day/one generation reproduct Animals Animal treatment 28-day gavage study 90-day/one generation reproduction study"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-Weissella-confusa---A-dire_2019_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31254555", "content": {"CoiStatement": "Conflicts of interest There are no conflicts of interest in this article. There are no conflicts of interest in this article. Acknowledgement Discussion Conclusion Conflicts of interest Acknowledgement Transparency document References", "Compliance with ethical standards": "OECD, 1997. Test No. 471: Bacterial Reverse Mutation Test. OECD, 1998a. OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring. Number 1. OECD Principles on Good Laboratory Practice (As Revised in 1997). ENV/MC/CHEM(98)17. OECD Publishing, Paris.", "Acknowledgement": "Acknowledgement The studies were conducted at different CROs with Novozymes A/S as a sponsor. Novozymes A/S has funded these studies to ensure the safety of the W. confusa strain. Discussion Conclusion Conflicts of interest Acknowledgement Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-a-modified-acetolactate-synthase-p_2009_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19682528", "content": {"Acknowledgement": "320 C.A. Mathesius et al. / Regulatory Toxicology and Pharmacology 55 (2009) 309\u2013320 known allergenic proteins using the step-wise, weight-of-evidence approach. Furthermore, serum screening studies with soy allergic patient serum indicated that the DP-356\u00d843-5 soybean, containing both the GM-HRA and GAT4601 proteins, and non-transgenic soy- bean flours are very similar in protein/allergen profiles without demonstrating significant changes in concentrations of total pro- tein or individual protein/allergen profiles (Delaney et al., 2008a). The GM-HRA protein is not similar in sequence to known protein toxins and no evidence of adverse effects was observed in toxicol- ogy studies following single or repeated dose exposure. Finally, hu- man exposure to the GM-HRA protein is likely to be extremely low because it is present at low concentrations in whole soybeans ob- tained from genetically modified soybean plants where it is ex- pressed and because it is heat labile and has not been identified at measurable concentrations in soybean oil which is the primary component of soybeans that is consumed by humans. In conclu- sion, these data demonstrate the safety of the GM-HRA protein for use in food and feed applications and indicate that this protein presents no risk for adverse health effects when used in the context of agricultural biotechnology. Acknowledgments These studies were funded by Pioneer, A DuPont Company. Hugh Sampson and Luda Bardina from the Mount Sinai School of Medicine assisted in the preparation of the paper. Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-allergic-contact-dermatitis-hazard_2011_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20974208", "content": {"CoiStatement": "This work was supported by the Intramural Research Program of the National Institutes of Health, National Institute of Environ- mental Health Sciences. ILS staff are supported by NIEHS contract N01-Eleni Salicru 35504. The views expressed in this manuscript do not nec- essarily represent the official position of any US Federal agency. Conflict of interest statement The authors declare that there are no conflicts of interest. Acknowledgments The authors declare that there are no conflicts of interest. Acknowledgments We acknowledge the following companies and organizations and their representatives that submitted LLNA data to NICEATM for the evaluation of new applications and modifications of the LLNA: BASF \u2013 The Chemical Company, USA (Mr. Charles Hastings); The German Institute for Occupational Safety and Health, Germany (Ms. Heidi Ott); Dow AgroSciences, USA (Dr. Michael Woolhiser); DuPont, USA (Dr. Fredrick O\u2019Neal); European Crop Protection http://www.danielsoper.com/statcalc/calc49.aspx Discussion Conclusions Funding Conflict of interest statement Acknowledgments Supplementary data References", "Funding": "Based on the updated ICCVAM-recommended LLNA protocol and the analyses reported herein, on July 22, 2010, the OECD adopted revisions to TG 429 that reduced the minimum number of animals per dose group from five to four when lymph nodes from individual mice are processed separately (OECD, 2010). This international adoption of the four-animal group size will now facil- itate the collection of individual animal data in those countries that require that the minimum number of animals be used for testing, and provide for a 20% reduction in the number of animals required for each LLNA test where individual animal data are collected. Reg- ulatory agencies and other data end users can then take full advan- tage of the additional information provided by individual animal data. Funding This work was supported by the Intramural Research Program of the National Institutes of Health, National Institute of Environ- mental Health Sciences. ILS staff are supported by NIEHS contract N01-Eleni Salicru 35504. The views expressed in this manuscript do not nec- essarily represent the official position of any US Federal agency. Conflict of interest statement Discussion Conclusions Funding Conflict of interest statement Acknowledgments Supplementary data References", "Acknowledgement": "The authors declare that there are no conflicts of interest. Acknowledgments We acknowledge the following companies and organizations and their representatives that submitted LLNA data to NICEATM for the evaluation of new applications and modifications of the LLNA: BASF \u2013 The Chemical Company, USA (Mr. Charles Hastings); The German Institute for Occupational Safety and Health, Germany (Ms. Heidi Ott); Dow AgroSciences, USA (Dr. Michael Woolhiser); DuPont, USA (Dr. Fredrick O\u2019Neal); European Crop Protection http://www.danielsoper.com/statcalc/calc49.aspx Discussion Conclusions Funding Conflict of interest statement Acknowledgments Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-astaxanthin-derived-from-engineered-E_2017_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28483713", "content": {"CoiStatement": "Conflict of interest statement Ming-Hsi Chiou and Yin-Ju Lin are employees of Lemnaceae Fermentation Inc., which sponsored the present studies. The remaining author does not have any potential conflicts of interest to report. Ming-Hsi Chiou and Yin-Ju Lin are employees of Lemnaceae Fermentation Inc., which sponsored the present studies. The remaining author does not have any potential conflicts of interest to report. Acknowledgement 4. Discussion 5. Conclusions Conflict of interest statement Acknowledgement Appendix A. Supplementary data Transparency document References", "Acknowledgement": "Acknowledgement The authors wish to thank professor Todd Hsu at National Taiwan Ocean University for critical reading of this manuscript. 4. Discussion 5. Conclusions Conflict of interest statement Acknowledgement Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-astaxanthin-from-Haematococcus-pluvi_2020_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32512118", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. Discussion Funding Declaration of competing interest Acknowledgement Supplementary data References", "Funding": "5. Funding This project was funded by National Key R&D Program of China (2018YFD0901103); NSFC (31872540), Natural Science Foundation of Zhejiang (LY18C190004, LY19H030001), China Agricultural Research System (CARS-50), Ningbo Programs for Science and Technology Development (2017C110026), Medical Science and Technology of Zhejiang Province (2018KY726, 2018KY710), K.C. Wong Magna Fund in Ningbo University. Discussion Funding Declaration of competing interest Acknowledgement Supplementary data References", "Acknowledgement": "Acknowledgement We would like to thank Yuling Song, Lili Hong, Kaiqin Zheng, and Jiaxing Zhang for their assisting in animal experiments. Discussion Funding Declaration of competing interest Acknowledgement Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-boron-by-application-of-new-u_2013_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23137930", "content": {"CoiStatement": "This article presents a new concept for UFs and the subsequent subdivision led to new TDIs, based on the appropriate NOAEL or BMDL05 derived from the reevaluation of available toxicity studies, and measured boron clearance and GFR used to derive them (Ta- ble 6). TDIs calculated from rat or dog studies were very similar, specifically, 0.26 and 0.22 mg B/kg/day, respectively. TDIs for developmental toxicity in mice and rats were also very similar, specifically 0.18 and 0.13 mg B/kg/day, and lower than TDIs for tes- ticular toxicity. At this moment, it is considered that this is the best approach based on the latest scientific concept of uncertainty fac- tors. In conclusion, the overall TDI of boron is 0.13 mg B/kg/day, based on a BMDL05 from rat developmental toxicity and the scien- tifically developed uncertainty factors. Conflict of interest statement The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgments 5 Concept of new uncertainty factors 6 Application of new uncertainty factors and their subdivision 7 Discussion and conclusion Conflict of interest statement Acknowledgments References", "Acknowledgement": "Acknowledgments This work was supported by a Health and Labour Sciences Re- search Grant (H22-Kenki-Ippan-006) from the Ministry of Health, Labour and Welfare, Japan. 5 Concept of new uncertainty factors 6 Application of new uncertainty factors and their subdivision 7 Discussion and conclusion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-coenzyme-Q10--Kaneka-Q10--in-heal_2006_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16431002", "content": {"Acknowledgement": "Acknowledgments We are grateful to Mr. Iizuka and Dr. Yamamoto (TTC Co., Ltd) for supporting this study. Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-dicamba-mono-oxygenases-that-_2016_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27575686", "content": {"Acknowledgement": "Acknowledgments The authors would like to thank Stephen Hill, Adam J. Evans, Dr. Bin Chen and Dr. Chun-Ju Chen for productions of DMO, Dr Dilip Chandu and Dr. Wenze Li for DMO equivalence studies, Chris Dalton, Richard S. Thoma, Jing Berry and Dr. Zhenjiu Liu for protein concentration and identity analyses, Robert Heeren, Ronald Frazier, Dr. Ronald Hernan and Dr. Chun-Ju Chen for DMO heat stability studies, Jamie Burge, Dr. Bin Chen, Dr. Thomas Edrington and Dr. Jennifer Calcaterra for DMO digestibilities, Dr. Chun-Ju Chen, Robert Heeren and Adam J. Evans for DMO formulations for toxicity study, Dr. Eric Park and Dr. Jay Petrick for toxicity studies, Richard Thoma, Dr. Zhenjiu Liu and Susan Elliott for DMO characterization, Andrew E. Deffenbaugh and Iryna Nahirna for DMO Western analyses, Dr. Yanfei Wang for N-terminal analysis of mDMO, Yelena Dudin for DMO monoclonal antibody, Sharie Fitzpatrick, Tracy Laufer, Melinda McCann and Marianne Malven for dicamba tolerance study, Dr. Kathleen S. Crowley, Dr. Thomas C. Lee and John J. Fin- nessy for experiment designs and technical supports, andMarianne Malven for critical reading of the manuscript. 4. Discussion Acknowledgments Abbreviations used Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-essential-oil-from-Minthostachys-ve_2015_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25445298", "content": {"Acknowledgement": "Acknowledgments This work was supported by grants from FONCyT \u2013 PICT \ufffdN: 1606/12 and SeCyT, Resolution #852, years 2012/14, from Univers- idad Nacional de R\u00edo Cuarto. 4 Discussion 5 Conclusions Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-ethanolic-extract-of-Olea-europae_2018_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29678768", "content": {"CoiStatement": "Conflicts of interest The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgements Papoti, V.T., Tsimidou, M.Z., 2009. Impact of sampling parameters on the radical scavenging potential of olive (Olea europaea L. Leaves. J. Agric. Food Chem. 57, 3470\u20133477. Pollier, J., Goossens, A., 2012. Oleanolic acid. Phytochemistry 77, 10\u201315. Rahmanian, N., Jafari, S.M., Wani, T.A., 2015. Bioactive profile, dehydration, extraction and application of the bioactive components of olive leaves. Trends Food Sci. Technol. 42, 150\u2013172. Roy, C.K., Kamath, J.V., Asad, M., 2006. Hepatoprotective activity of Psidium guajava linn. Indian J. Exp. Biol. 44, 305\u2013311. Soni, M.G., Burdock, G.A., Christian, M.S., Bitler, C.M., Crea, R., 2006. Safety assessment of aqueous olive pulp extract as an antioxidante or antimicrobial agent in foods. Food Chem. Toxicol. 44, 903\u2013915. Sporn, M.B., Liby, K.T., Yore, M.M., Fu, L., Lopchuk, J.M., Gribble, G.W., 2011. New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J. Nat. Prod. 74, 537\u2013545. Woisky, R.G., Salatino, A., 1998. Analysis of propolis: some parameters and procedures for chemical quality control. J. Apicult. Res. 37, 99\u2013105. C.G. Guex et al. Regulatory Toxicology and Pharmacology 95 (2018) 395\u2013399 399 http://dx.doi.org/10.1016/j.yrtph.2018.04.013 http://dx.doi.org/10.1016/j.yrtph.2018.04.013 http://dx.doi.org/10.1016/j.yrtph.2018.04.013 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref1 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref1 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref1 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref2 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref2 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref2 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref2 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref3 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref3 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref3 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref4 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref4 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref4 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref6 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref6 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref6 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref6 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref7 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref7 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref7 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref7 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref8 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref8 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref8 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref8 http://dx.doi.org/10.3389/fphar.2013.00177 http://dx.doi.org/10.3389/fphar.2013.00177 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref10 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref10 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref11 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref11 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref11 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref12 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref12 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref12 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref13 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref13 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref13 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref14 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref14 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref15 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref15 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref15 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref16 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref16 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref16 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref17 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref17 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref17 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref17 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref18 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref18 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref18 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref19 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref19 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref19 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref20 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref20 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref20 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref21 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref21 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref21 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref22 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref22 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref22 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref22 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref23 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref23 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref24 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref24 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref24 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref25 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref25 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref26 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref26 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref27 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref27 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref27 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref28 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref28 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref28 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref29 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref30 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref30 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref30 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref31 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref31 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref32 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref32 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref32 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref33 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref33 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref33 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref34 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref34 Safety assessment of ethanolic extract of Olea europaea L. leaves after acute and subacute administration to Wistar rats Introduction Materials and methods Plant material Chemical and reagents Quantitative analysis of nonpolar compounds by HPLC Determination of total phenolics content and total flavonoids content Radical-scavenging activity \u2013 2, 2 diphenyl-2-pricrylhydrazyl (DPPH) assay Experimental animals Acute toxicity Sub-acute toxicity Hematological and biochemical parameters Statistical analysis Results Quantitative analysis of nonpolar compounds by HPLC Total polyphenolics, flavonoids content and DPPH Acute toxicity Sub-acute toxicity Discussion Conclusion Conflicts of interest Acknowledgements Supplementary data Transparency document References", "Acknowledgement": "Acknowledgements The authors thank CAPES, UFSM and Bioclin/Quibasa for the fi- nancial assistance. Papoti, V.T., Tsimidou, M.Z., 2009. Impact of sampling parameters on the radical scavenging potential of olive (Olea europaea L. Leaves. J. Agric. Food Chem. 57, 3470\u20133477. Pollier, J., Goossens, A., 2012. Oleanolic acid. Phytochemistry 77, 10\u201315. Rahmanian, N., Jafari, S.M., Wani, T.A., 2015. Bioactive profile, dehydration, extraction and application of the bioactive components of olive leaves. Trends Food Sci. Technol. 42, 150\u2013172. Roy, C.K., Kamath, J.V., Asad, M., 2006. Hepatoprotective activity of Psidium guajava linn. Indian J. Exp. Biol. 44, 305\u2013311. Soni, M.G., Burdock, G.A., Christian, M.S., Bitler, C.M., Crea, R., 2006. Safety assessment of aqueous olive pulp extract as an antioxidante or antimicrobial agent in foods. Food Chem. Toxicol. 44, 903\u2013915. Sporn, M.B., Liby, K.T., Yore, M.M., Fu, L., Lopchuk, J.M., Gribble, G.W., 2011. New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J. Nat. Prod. 74, 537\u2013545. Woisky, R.G., Salatino, A., 1998. Analysis of propolis: some parameters and procedures for chemical quality control. J. Apicult. Res. 37, 99\u2013105. C.G. Guex et al. Regulatory Toxicology and Pharmacology 95 (2018) 395\u2013399 399 http://dx.doi.org/10.1016/j.yrtph.2018.04.013 http://dx.doi.org/10.1016/j.yrtph.2018.04.013 http://dx.doi.org/10.1016/j.yrtph.2018.04.013 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref1 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref1 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref1 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref2 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref2 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref2 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref2 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref3 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref3 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref3 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref4 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref4 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref4 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref6 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref6 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref6 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref6 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref7 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref7 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref7 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref7 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref8 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref8 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref8 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref8 http://dx.doi.org/10.3389/fphar.2013.00177 http://dx.doi.org/10.3389/fphar.2013.00177 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref10 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref10 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref11 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref11 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref11 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref12 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref12 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref12 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref13 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref13 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref13 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref14 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref14 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref15 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref15 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref15 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref16 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref16 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref16 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref17 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref17 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref17 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref17 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref18 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref18 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref18 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref19 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref19 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref19 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref20 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref20 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref20 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref21 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref21 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref21 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref22 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref22 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref22 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref22 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref23 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref23 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref24 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref24 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref24 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref25 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref25 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref26 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref26 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref27 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref27 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref27 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref28 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref28 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref28 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref29 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref30 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref30 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref30 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref31 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref31 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref32 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref32 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref32 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref33 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref33 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref33 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref34 http://refhub.elsevier.com/S0273-2300(18)30113-2/sref34 Safety assessment of ethanolic extract of Olea europaea L. leaves after acute and subacute administration to Wistar rats Introduction Materials and methods Plant material Chemical and reagents Quantitative analysis of nonpolar compounds by HPLC Determination of total phenolics content and total flavonoids content Radical-scavenging activity \u2013 2, 2 diphenyl-2-pricrylhydrazyl (DPPH) assay Experimental animals Acute toxicity Sub-acute toxicity Hematological and biochemical parameters Statistical analysis Results Quantitative analysis of nonpolar compounds by HPLC Total polyphenolics, flavonoids content and DPPH Acute toxicity Sub-acute toxicity Discussion Conclusion Conflicts of interest Acknowledgements Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-ethanolic-root-extract-of-Za_2021_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33217502", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 3 Results and discussion 4 Conclusion Funding body information Data availability Author contributions Ethics approval Declaration of competing interest References", "Funding": "Funding body information The study was supported by the Department of Science and Tech- nology (DST), India in the form of DST-Inspire fellowship to Ms. D. Malarvizhi. 3 Results and discussion 4 Conclusion Funding body information Data availability Author contributions Ethics approval Declaration of competing interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-food-and-feed-from-biotechnology-der_2013_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23557984", "content": {"CoiStatement": "4 Conclusions Conflict of interest Acknowledgments References", "Acknowledgement": "4 Conclusions Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-freeze-dried-powdered-Tenebrio-molit_2016_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26993751", "content": {"CoiStatement": "Conflicts of interest There are no competing financial interests. 4. Conclusion Conflicts of interest Acknowledgments Appendix A. Supplementary data References", "Acknowledgement": "Acknowledgments This research was supported by a grant (#PJ008969) from the Agenda program, Rural Development Administration, and a grant (#311006-3) from the Bio-industry Technology Development project, Ministry for Food, Agriculture, Forestry and Fisheries, Re- public of Korea. 4. Conclusion Conflicts of interest Acknowledgments Appendix A. Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-gamma-glutamylcystein_2012_Regulatory-Toxicology-and-Ph.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22698997", "content": {"CoiStatement": "No animals died and all animals continued to gain weight when administered 2000 mg/kg of bw GGC (sodium salt) as a single dose. No clinical abnormalities were observed that could be associated with the repeat dose of sodium GGC at 1000 mg/kg of bw. On this basis, the no observed adverse effect level (NOAEL) of GGC (sodium salt) in Wistar rats is at least 2000 mg/kg when administered as a single acute dose, and at least 1000 mg/kg when taken as a repeat dose. As such, sodium GGC (sodium salt) appears safe and further experimentation to explore its potential benefits for glutathione replenishment in animal and human studies is warranted. Conflict of interest statement The studies described herein were performed by the contract research organisation Bioneeds Laboratory Animals & Preclinical Services, and sponsored by Biospecialties International Pty. Ltd., which manufactures GGC. 4 Discussion 5 Conclusions Conflict of interest statement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-medium--and-long-chain-triacylgly_2017_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28212845", "content": {"Acknowledgement": "Acknowledgments This research was supported by a special fund for Agro-scientific Research in the Public Interest (Grant No. 201203069), National High Technology Research and Development Program of China (Grant Nos. 2013AA102202; 2013AA102207), and a Grant from Wilmar (Shanghai) Biotechnology Research & Development Center Co., Ltd. The authors wish to thank the QC group for providing technical support. The authors declare no further conflict of inter- est. The authors wish to thank Dr. J. Jacoby for assistance in manuscript revision. 4. Conclusion Acknowledgments Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-metarrestin-in-dogs--A-clinical-ca_2020_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32619635", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare that they have no known competing interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgments 4 Discussion 5 Conclusion Funding Declaration of competing interest Acknowledgments References", "Funding": "Funding This work was supported by NCI/Leidos, United States; Contract No. HHSN261200800001E, under BrIDGs/NCATS Program. 4 Discussion 5 Conclusion Funding Declaration of competing interest Acknowledgments References", "Acknowledgement": "Acknowledgments The authors thank the Study Director Dr. William Johnson and staff at IIT Research Institute (IITRI), Chicago, IL for conducting the studies. 4 Discussion 5 Conclusion Funding Declaration of competing interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-methanol-extract-of-red-dragon-fr_2012_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22440551", "content": {"CoiStatement": "Conflict of interest statement The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgments 4 Discussion 5 Conclusion Conflict of interest statement Acknowledgments References", "Acknowledgement": "Acknowledgments We appreciate the contribution of all those who participated in this study. Moreover, Sook Yee Hor acknowledges the USM fellow- ship provided by the Universiti Sains Malaysia. 4 Discussion 5 Conclusion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-methanolic-extract-of-Terminalia-cheb_2018_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29288719", "content": {"CoiStatement": "Conflicts of interest The authors declare no conflict of interest. The authors declare no conflict of interest. Acknowledgement Conclusion Conflicts of interest Acknowledgement Transparency document References", "Acknowledgement": "Acknowledgement The authors Dr. N Suganthy wishes to thank UGC, India for the financial support through UGC start up grant [No. F.4-2/2006(BSR)/BL/13-14/ 0345] and Prof. G Archunan acknowledges with thanks to UGC, New Delhi for the award of UGC-BSR Faculty Fellow. The authors gratefully ac- knowledge the authorities of Bharathidasan University, Tiruchirappalli, UGC-SAP-II, DST-FIST and DST-PURSE for providing instrument facil- ities to carry out this work. Conclusion Conflicts of interest Acknowledgement Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Safety-assessment-of-phytase-transgenic-maize-11TPY_2022_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34863905", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 4 Discussion CRediT authorship contribution statement Declaration of competing interest Acknowledgements References", "Funding": "Nana Sun: Methodology, Data curation, Visualization, Writing \u2013 original draft, Writing \u2013 review & editing. Chunlai Liang: Methodology, Data curation, Formal analysis, Visualization. Qiannan Zhang: Meth- odology, Data curation, Visualization. Xue Geng: Data curation, Formal analysis. Haibo Liu: Investigation, Data curation, Formal analysis. Yongquan Feng: Investigation, Formal analysis. Hui Yang: Data curation, Formal analysis. Zhou Yu: Conceptualization, Resources, Investigation, Writing \u2013 review & editing, Funding acquisition. Xudong Jia: Conceptualization, Resources, Investigation, Writing \u2013 review & editing, Funding acquisition. Declaration of competing interest", "Acknowledgement": "Acknowledgements This study was supported by the Chinese National Major Project for the Development of Genetically modified Organisms (2016ZX08011- 005). 4 Discussion CRediT authorship contribution statement Declaration of competing interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-plant-varieties-using-transcr_2014_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25046166", "content": {"CoiStatement": "Conflict of interest RIKILT, Wageninge UR received grants from the Ministry of Eco- nomic Affairs, the Netherlands, and the Federal University of Santa Catarina, Brazil, received grants from the Ministery of Education, Brazil. 5 Discussion Note Conflict of interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-propylparaben-in-juv_2018_Regulatory-Toxicology-and-Pha.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29248488", "content": {"Funding": "Funding The study conducted at CR MTL was co-sponsored by Bristol-Myers Squibb, New Brunswick, NJ, USA and Pfizer, Groton, CT, USA and uterotrophic study was sponsored and conducted at the facilities of Bristol-Myers Squibb New Brunswick, NJ, USA. Discussion Commentary Funding Acknowledgements Transparency document References", "Compliance with ethical standards": "Guidance for industry nonclinical safety evaluation of pediatric drug products. February 2006. US Department of Health and Human Services FDA-CDER. https://www.fda. gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ ucm079247.pdf. US FDA Guidance Document, \u201cNonclinical Safety Evaluation of Pediatric Drug Products\u201d - http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/ guidances/ucm079247.pdf. US FDA Guidance Document, \u201cNonclinical Safety Evaluation of Pediatric Drug Products\u201d - http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/ guidances/ucm079247.pdf. Vo, T.T., Yoo, Y.M., Choi, K.C., Jeung, E.B., 2010. Potential estrogenic effect(s) of para- bens at the prepubertal stage of a postnatal female rat model. Reprod. Toxicol. 29, 306\u2013316. http://refhub.elsevier.com/S0273-2300(17)30398-7/sref14 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref14 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref15 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref15 http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S3A/Step4/S3A_Guideline.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S3A/Step4/S3A_Guideline.pdf http://refhub.elsevier.com/S0273-2300(17)30398-7/sref17 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref17 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref18 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref18 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref19 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref19 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref19 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref20 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref20 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref20 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref21 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref21 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref21 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref22 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref22 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref22 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref23 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref23 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref24 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref24 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref24 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref25 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref25 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref25 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref26 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref26 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref26 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref27 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref27 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref27 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref28 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref28 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref28 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref28 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref29 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref29 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref31 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref31 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref31 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref32 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref32 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref33 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref33 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref33 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref34 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref34 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref34 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref35 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref35 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref35 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref36 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref36 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref36 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref37 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref37 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref37 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref38 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref38 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref40 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref40 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref41 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref41 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref41 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref42 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref42 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref43 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref43 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref43 https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079247.pdf https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079247.pdf https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079247.pdf http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm079247.pdf http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm079247.pdf http://refhub.elsevier.com/S0273-2300(17)30398-7/sref46 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref46 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref46 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref47 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref47 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref47 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref48 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref48 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref49 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref49 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref49 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref50 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref50 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref50 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref50 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref51 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref51 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref51 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref51 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref52 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref52 http://refhub.elsevier.com/S0273-2300(17)30398-7/sref52 Safety assessment of propylparaben in juvenile rats Introduction Experimental materials and methods Ethics statements Test materials Study animal assignments Environmental conditions and husbandry Formulation and formulation analyses Treatment regimen Toxicokinetics Observations and measurements Uterotrophic assay Study design", "Acknowledgement": "Acknowledgements The authors thank Y.Zhao, G. Liu, H. Shen, and C. Parrula for their bioanalytical, toxicokinetic or clinical pathology assessments and S. Rayhon, Reproductive Toxicology, Bristol-Myers Squibb Company, New Brunswick Laboratories for the conduct of the uterotrophic study. Discussion Commentary Funding Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-sanitary-pads-with-a-poly_2015_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26255105", "content": {"Acknowledgement": "Acknowledgments The authors acknowledge Deborah Hutchins, Ph.D., of Hutchins and Associates, LLC. (Cincinnati, Ohio), for technical writing assistance. 5. Post-market surveillance 6. Conclusion Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-the-calcium-binding-protein--_2014_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24768935", "content": {"CoiStatement": "From these data, there is no added concern of safety due to gastrointestinal stability of the protein. Conflict of interest Dr. R. Goodman reports grants from Quincy Bioscience LLC, dur- ing the conduct of the study. Dr. M.Y. Underwood has a patent US No. 7,671,015 issued, a patent US Appl. 12/694,427 pending, and a patent US Appl. 12/672,463 pending and Dr. A. Tetteh has nothing to disclose. Appendix A. Supplementary data 4 Discussion Conflict of interest Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-the-commensal-strain-Bacte_2012_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22085591", "content": {"CoiStatement": "Conflict of interest statement The studies were sponsored by the Glycotope GmbH. All authors except Jost Leuschner are employees of the Glycotope GmbH. 4 Discussion 5 Conclusion Conflict of interest statement Acknowledgments References", "Acknowledgement": "Acknowledgments We thank Professor Arne Rodloff (Institute for Medical Microbi- ology, University of Leipzig, Germany), for kindly providing the strain Bacteroides fragilis RMA 6791, and for his support in the establishment of the intraperitoneal model. We are grateful to Hei- ke Schmidt, Sigrid Wiese, Sabine Schulze and Anja Alfandega for technical assistance and Albert B\u00e4r for critical reading of the man- uscript and helpful discussions. 4 Discussion 5 Conclusion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-transgenic-canola-RF3-with-bar-an_2017_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29074276", "content": {"Acknowledgement": "Acknowledgements The work was supported by the National GMO Cultivation Major Project of New Varieties (2015ZX08013-003-003) and by scholarships from the Chinese Scholarship Council (CSC), 201506355010 awarded to Xiaoyun He. Discussion Conclusion Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-vitacoxib--180-day-chroni_2018_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29601910", "content": {"CoiStatement": "Conflicts of interest The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgements Discussion Conclusion Conflicts of interest Acknowledgements Supplementary data Transparency document References", "Acknowledgement": "Acknowledgements This work was supported by National Natural Science Foundation (No. 31672599), Projects in the National Science & Technology Pillar Program during the Thirteenth Five-Year Plan Period (2016YFD0501309-1) and Quality & Safety Risk Assessment for Animal Products on Chemical Hazards Foundation of China (No. GJFP201800701). We acknowledge Xilong Xiao, Jianping Song, Ruiliang Du, YuZhou and Lu Zhang for their assistance with this project. Discussion Conclusion Conflicts of interest Acknowledgements Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-vitacoxib--Acute-and-90-day_2017_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28238853", "content": {"CoiStatement": "Conflict of interest The authors declare there are no conflicts of interest. The authors declare there are no conflicts of interest. Founding 4. Discussion 5. Conclusion Conflict of interest Founding Acknowledgement Transparency document References", "Acknowledgement": "Acknowledgement We acknowledge Xilong Xiao, Jianping Song, Ruiliang Du, Yu Zhou and Lu Zhang for their assistance with this project. We thank Rui Hua for its linguistic assistance during the preparation of this manuscript. 4. Discussion 5. Conclusion Conflict of interest Founding Acknowledgement Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-widely-used-fermented-virgin-coconut_2016_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27756558", "content": {"Acknowledgement": "Acknowledgement The authors are thankful to the EMAN Lab management, EMAN Biodiscoveries Sdn Bhd. This research was supported by Research University grant (RUT) ref# 1001/PFARMASI/851001. Authors are grateful to USM-APEX fellowship 2014e2015 grant # APEX(1002/ JHEA/ATSG4001. Transparency document Transparency document related to this article can be found online at http://dx.doi.org/10.1016/j.yrtph.2016.10.004. References Asian and Pacific Coconut Community (APCC). Retrieved 30 July 2013. Bruce, 2005. Coconut Cures, Piccadilly Books, Ltd, pp. 184e185. ISBN 978-0-941599- 60-3. Dandekar, P., Dhumal, R., Jain, R., Tiwari, D., Vanage, G., Patravale, V., 2010. Toxi- cological evaluation of pH-sensitive nanoparticles of curcumin: acute, sub- acute and genotoxicity studies. Food Chem. Toxicol. 48, 2073e2089. Dia, V.P., Garcia, V.V., Mabesa, R.C., Tecson-Mendoza, E.M., 2005. Comparative physicochemical characteristics of virgin coconut oil produced by different methods. Philipp. Agric. Sci. 88, 462e475. Giknis, M.L.A., Clifford, C.B., 2008. Clinical Laboratory Parameters for the Crl:WI (Han). Charles River Laboratories. Hainer, V., Kunesova, M., Stich, V., Zak, A., Parizkova, J., 1994. The role of oils con- taining triacylglycerols and medium-chain fatty acids in the dietary treatment of obesity. The effect on resting energy expenditure and serum lipids. Cas. Lek. Cesk. J. 133 (12), 373e375. Hashim, S.A., Roholt, H.B., Babayan, V.K., Van Itallie, T.B., 1964. Treatment of chyluria and chylothorax with medium-chain triglyceride. N. Engl. J. Med. 270 (15), 756e761. Huttenlocher, P.R., Wilbourn, A.J., Signore, J.M., 1971. Medium-chain triglycerides as a therapy for intractable childhood epilepsy. Neurology 21 (11), 1097e1097. Kossoff, E.H., 2004. More fat and fewer seizures: dietary therapies for epilepsy. Lancet Neurol. 3 (7), 415e420. Marina, A.M., Che Man, Y.B., Nazimah, S.A.H., Amin, I., 2009. Antioxidant capacity and phenolic acids of virgin coconut oil. Int. J. Food Sci. Nutr. 60 (2), 114e123. Nevin, K.G., Rajamohan, T., 2006. Virgin coconut oil supplemented diet increases the antioxidant status in rats. Food Chem. 99, 260e266. OECD, 3 October 2008. Guideline for Testing of Chemicals. Acute Oral Toxicity eAcute Oral Toxicity e Up-and-Down-Procedure (UDP). Guideline No. 425. Seneviratne, K.N., Sudarshana Dissanayake, D.M., 2008. Variation of phenolic con- tent in coconut oil extracted by two conventional methods. Int. J. food Sci. Technol. 43 (4), 597e602. Sizer, F.S., Pich\ufffde, L.A., Whitney, E.N., 2012. Nutrition: Concepts and Controversies. Cengage Learning. Controversies, 11 ed. Thomson Wadsworth, United States of America, pp. 221e235. ISBN 0495390658. St-Onge, M.P., Jones, P.J., 2003. Physiological effects of medium-chain triglycerides: potential agents in the prevention of obesity. J. Nutr. 132 (3), 329e332. Stewart, J.W., Wiggers, K.D., Jacobsen, N.L., Berger, P.J., 1978. Effect of various tri- glycerides on blood and tissue cholesterol of calves. J. Nutr. 108, 561e566. Takeuchi, H., Sekine, S., Kojima, K., Aoyama, T., 2008. The application of medium- chain fatty acids: edible oil with a suppressing effect on body fat accumula- tion. Asia Pac. J. Clin. Nutr. 17 (Suppl. 1), 320e323. Tantibhedhyangkul, P., Hashim, S.A., 1971 January. Clinical and physiologic aspects of medium-chain triglycerides: allviation of steatorrhea in premature infants. Bull. N. Y. Acad. Med. 47 (1), 17. Trott, O., Olson, A.J., 2010. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J. Comput. Chem. 31, 455e461. Zbinden, G., Flury-Roversi, M., 1981. Significance of the LD50 test for the toxico- logical evaluation of chemical substances. Arch. Toxicol. 47, 77e99. http://dx.doi.org/10.1016/j.yrtph.2016.10.004 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref2 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref2 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref2 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref3 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref3 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref3 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref3 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref4 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref4 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref4 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref4 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref5 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref5 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref6 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref6 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref6 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref6 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref6 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref7 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref7 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref7 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref7 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref8 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref8 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref8 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref9 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref9 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref9 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref10 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref10 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref10 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref12 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref12 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref12 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref13 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref13 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref13 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref14 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref14 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref14 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref14 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref15 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref15 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref15 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref15 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref15 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref16 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref16 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref16 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref17 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref17 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref17 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref18 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref18 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref18 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref18 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref19 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref19 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref19 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref20 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref20 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref20 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref20 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref21 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref21 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref21 Safety assessment of widely used fermented virgin coconut oil (Cocos nucifera) in Malaysia: Chronic toxicity studies and SA ... 1. Introduction 2. Materials and method 2.1. Preparation of formulation 2.2. Animals 2.3. Acute oral toxicity 2.4. Sub-chronic and chronic toxicity 2.5. Histopathology 2.6. Clinical biochemistry indexes 2.7. Haematology indexes 2.8. Fatty acid composition 2.9. Statistical analysis 3. Results 3.1. Acute, sub-chronic, chronic 3.1.1. Clinical signs 3.1.2. Food, water intake and body weight 3.1.3. Relative organ weight 3.1.4. Haematology parameters 3.1.5. Biochemical parameters 3.1.6. Histology of selected organs 3.2. Fatty acid analysis 3.3. Structure activity relationship 4. Discussion 5. Conclusion Acknowledgement Transparency document References The authors are thankful to the EMAN Lab management, EMAN Biodiscoveries Sdn Bhd. This research was supported by Research University grant (RUT) ref# 1001/PFARMASI/851001. Authors are grateful to USM-APEX fellowship 2014e2015 grant # APEX(1002/ JHEA/ATSG4001. Transparency document Transparency document related to this article can be found online at http://dx.doi.org/10.1016/j.yrtph.2016.10.004. References Asian and Pacific Coconut Community (APCC). Retrieved 30 July 2013. Bruce, 2005. Coconut Cures, Piccadilly Books, Ltd, pp. 184e185. ISBN 978-0-941599- 60-3. Dandekar, P., Dhumal, R., Jain, R., Tiwari, D., Vanage, G., Patravale, V., 2010. Toxi- cological evaluation of pH-sensitive nanoparticles of curcumin: acute, sub- acute and genotoxicity studies. Food Chem. Toxicol. 48, 2073e2089. Dia, V.P., Garcia, V.V., Mabesa, R.C., Tecson-Mendoza, E.M., 2005. Comparative physicochemical characteristics of virgin coconut oil produced by different methods. Philipp. Agric. Sci. 88, 462e475. Giknis, M.L.A., Clifford, C.B., 2008. Clinical Laboratory Parameters for the Crl:WI (Han). Charles River Laboratories. Hainer, V., Kunesova, M., Stich, V., Zak, A., Parizkova, J., 1994. The role of oils con- taining triacylglycerols and medium-chain fatty acids in the dietary treatment of obesity. The effect on resting energy expenditure and serum lipids. Cas. Lek. Cesk. J. 133 (12), 373e375. Hashim, S.A., Roholt, H.B., Babayan, V.K., Van Itallie, T.B., 1964. Treatment of chyluria and chylothorax with medium-chain triglyceride. N. Engl. J. Med. 270 (15), 756e761. Huttenlocher, P.R., Wilbourn, A.J., Signore, J.M., 1971. Medium-chain triglycerides as a therapy for intractable childhood epilepsy. Neurology 21 (11), 1097e1097. Kossoff, E.H., 2004. More fat and fewer seizures: dietary therapies for epilepsy. Lancet Neurol. 3 (7), 415e420. Marina, A.M., Che Man, Y.B., Nazimah, S.A.H., Amin, I., 2009. Antioxidant capacity and phenolic acids of virgin coconut oil. Int. J. Food Sci. Nutr. 60 (2), 114e123. Nevin, K.G., Rajamohan, T., 2006. Virgin coconut oil supplemented diet increases the antioxidant status in rats. Food Chem. 99, 260e266. OECD, 3 October 2008. Guideline for Testing of Chemicals. Acute Oral Toxicity eAcute Oral Toxicity e Up-and-Down-Procedure (UDP). Guideline No. 425. Seneviratne, K.N., Sudarshana Dissanayake, D.M., 2008. Variation of phenolic con- tent in coconut oil extracted by two conventional methods. Int. J. food Sci. Technol. 43 (4), 597e602. Sizer, F.S., Pich\ufffde, L.A., Whitney, E.N., 2012. Nutrition: Concepts and Controversies. Cengage Learning. Controversies, 11 ed. Thomson Wadsworth, United States of America, pp. 221e235. ISBN 0495390658. St-Onge, M.P., Jones, P.J., 2003. Physiological effects of medium-chain triglycerides: potential agents in the prevention of obesity. J. Nutr. 132 (3), 329e332. Stewart, J.W., Wiggers, K.D., Jacobsen, N.L., Berger, P.J., 1978. Effect of various tri- glycerides on blood and tissue cholesterol of calves. J. Nutr. 108, 561e566. Takeuchi, H., Sekine, S., Kojima, K., Aoyama, T., 2008. The application of medium- chain fatty acids: edible oil with a suppressing effect on body fat accumula- tion. Asia Pac. J. Clin. Nutr. 17 (Suppl. 1), 320e323. Tantibhedhyangkul, P., Hashim, S.A., 1971 January. Clinical and physiologic aspects of medium-chain triglycerides: allviation of steatorrhea in premature infants. Bull. N. Y. Acad. Med. 47 (1), 17. Trott, O., Olson, A.J., 2010. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J. Comput. Chem. 31, 455e461. Zbinden, G., Flury-Roversi, M., 1981. Significance of the LD50 test for the toxico- logical evaluation of chemical substances. Arch. Toxicol. 47, 77e99. http://dx.doi.org/10.1016/j.yrtph.2016.10.004 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref2 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref2 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref2 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref3 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref3 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref3 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref3 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref4 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref4 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref4 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref4 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref5 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref5 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref6 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref6 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref6 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref6 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref6 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref7 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref7 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref7 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref7 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref8 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref8 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref8 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref9 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref9 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref9 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref10 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref10 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref10 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref12 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref12 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref12 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref13 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref13 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref13 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref14 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref14 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref14 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref14 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref15 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref15 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref15 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref15 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref15 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref16 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref16 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref16 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref17 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref17 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref17 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref18 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref18 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref18 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref18 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref19 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref19 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref19 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref20 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref20 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref20 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref20 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref21 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref21 http://refhub.elsevier.com/S0273-2300(16)30294-X/sref21 Safety assessment of widely used fermented virgin coconut oil (Cocos nucifera) in Malaysia: Chronic toxicity studies and SA ... 1. Introduction 2. Materials and method 2.1. Preparation of formulation 2.2. Animals 2.3. Acute oral toxicity 2.4. Sub-chronic and chronic toxicity 2.5. Histopathology 2.6. Clinical biochemistry indexes 2.7. Haematology indexes 2.8. Fatty acid composition 2.9. Statistical analysis 3. Results 3.1. Acute, sub-chronic, chronic 3.1.1. Clinical signs 3.1.2. Food, water intake and body weight 3.1.3. Relative organ weight 3.1.4. Haematology parameters 3.1.5. Biochemical parameters 3.1.6. Histology of selected organs 3.2. Fatty acid analysis 3.3. Structure activity relationship 4. Discussion 5. Conclusion Acknowledgement Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-assessment-of-xylan-by-a-90-day-feed_2017_Regulatory-Toxicology-and-P.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28137641", "content": {"CoiStatement": "Conflict of interest The authors declare no conflicts of interest. The authors declare no conflicts of interest. Acknowledgments 4. Discussion 5. Conclusion Conflict of interest Acknowledgments Transparency document References", "Acknowledgement": "Acknowledgments The authors gratefully thank Xiaoxiao Huang, Jieni Liang, Zhi Ruan, Jian Tan, Jiangwei Wang and Shuai Li (Institute of Toxicology, Guangxi CDC) for their excellent technical assistance. This work was supported by the Department of Science and Technology of Guangxi (grant number 13-29-04 and 14-91-04). 4. Discussion 5. Conclusion Conflict of interest Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-and-protective-effects-of-ethanolic-ex_2020_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31884156", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper.", "Funding": "Funding Research reported in the article received no funding or funding from source other than the listed funding bodies. Research reported in the article received no funding or funding from source other than the listed funding bodies. Declaration of competing interest Discussion and conclusions Funding mk:H1_40 Acknowledgments References", "Acknowledgement": "Acknowledgments The authors thank the Analytical and Testing Center of Huazhong University of Science and Technology for the LC\u2212MS analysis of ma- camides. Discussion and conclusions Funding mk:H1_40 Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-for-ingredients-used-in-baby-car_2017_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28916467", "content": {"CoiStatement": "Conflict of interest statement The authors are all employed by Procter & Gamble, which manufactures and markets disposable diapers. 7. Summary Conflict of interest statement Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of---agarase-preparations-from_2019_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30453009", "content": {"CoiStatement": "Conflicts of interest The authors declare no conflict of interest. The authors declare no conflict of interest. S.J. Hong et al. Regulatory Toxicology and Pharmacology 101 (2019) 142\u2013155 Discussion Conclusions Conflicts of interest Acknowledgements Transparency document References", "Acknowledgement": "Acknowledgements This work was supported by a grant from Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries through Technology Commercialization Support Program, funded by Ministry of Agriculture, Food and Rural Affairs (815003-3). Discussion Conclusions Conflicts of interest Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of---lipoic-acid--_2006_Regulatory-Toxicology-and-Pharmaco.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16904799", "content": {"Acknowledgement": "Acknowledgments The 4-week subchronic toxicity study in Wistar rats was conducted at ASTA Medica AG. The study director was Dr. St. Schneider. The Ames assay study was conducted on behalf of ASTA Medica at the Institute of Toxicology, Uni- versity of Mainz. The study director was Dr. J.G. Hengstler. The micronucleus test was also done at ASTA Medica AG. The responsible study director for the latter study was Dr. K. Krauser. Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-3--siallylactose-sodium-salt-supp_2019_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30453008", "content": {"CoiStatement": "Conflicts of interest Marcia H Monaco reports no conflicts of interest. Sharon M Donovan received grant funding from GeneChem. Rit Bahadur Gurung is a full-time employee of GeneChem. Marcia H Monaco reports no conflicts of interest. Sharon M Donovan received grant funding from GeneChem. Rit Bahadur Gurung is a full-time employee of GeneChem. Financial support Discussion Conclusions Conflicts of interest Financial support Supplementary data Transparency document References", "Funding": "Marcia H Monaco reports no conflicts of interest. Sharon M Donovan received grant funding from GeneChem. Rit Bahadur Gurung is a full-time employee of GeneChem. Financial support"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-Angelica-gigas--Genotoxicity-_2015_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26032491", "content": {"CoiStatement": "In conclusion, the 13-week repeat-dose oral toxicity result together with the negative genotoxicity results as seen from the Ames assay, in vitro chromosome aberration assay, and in vivo micronucleus assay clearly support that administration of the AG extract did not promote toxic effects. These results are consistent with the previous findings that evaluated the effects of decursin, the major component of the AG extract, in both genotoxicity (Kim et al., 2009a) and acute toxicity (Kim et al., 2009b). The NOAEL of the AG extract was considered to be greater than 2000 mg/kg in both male and female rats. According to the surface-area-guided dosing adjustment of the US Food and Drug Administration (Reagan-Shaw et al., 2008), the human dose 324 mg/kg converted from the rat dose 2000 mg/kg could be con- sidered for further clinical study. To our knowledge, this study is the first to demonstrate long-term toxicity and genotoxicity of the AG extract. Conflict of Interest The authors declare that they have no conflict of interest. Transparency Document The authors declare that they have no conflict of interest. Transparency Document The Transparency document associated with this article can be found in the online version. Acknowledgments 4 Discussion Conflict of Interest Transparency Document Acknowledgments Appendix A Supplementary data References", "Acknowledgement": "The Transparency document associated with this article can be found in the online version. Acknowledgments This research was supported with a grant (05122MFDS471) from the Ministry of Food and Drug Safety. We thank Dr. Hyeong-Kyu Lee at Korea Research Institute of Bioscience and Biotechnology for kindly providing HPLC data for the AG extract. Appendix A. Supplementary data 4 Discussion Conflict of Interest Transparency Document Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-BPL9K-4-rice-in-a-subchro_2021_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33933548", "content": {"CoiStatement": "Declaration of competing interest The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. References 4 Discussion 5 Conclusions Funding body information CRediT authorship contribution statement Declaration of competing interest References", "Funding": "Funding body information This study was supported by the Chinese National Major Project for the Development of Genetically Modified Organisms [2016ZX08011- 005]. Yuzhe Li: Methodology, Data curation, Writing \u2013 original draft, Writing \u2013 review & editing. Chunlai Liang: Methodology, Data cura- tion, Formal analysis. Jing Hu: Methodology, Data curation, Formal analysis. Xue Geng: Data curation, Formal analysis. Haibo Liu: Inves- tigation, Data curation, Formal analysis. Yongquan Feng: Investigation, Formal analysis. Yuan Zhi: Investigation, Formal analysis. Zhou Yu: Conceptualization, Resources, Investigation, Writing \u2013 review & editing, Funding acquisition. Declaration of competing interest 4 Discussion 5 Conclusions Funding body information CRediT authorship contribution statement Declaration of competing interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-Bacillus-coagulans-SNZ-_2020_Regulatory-Toxicology-and-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31751640", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Authors are bmanufacturer of Bacillus coagulans SNZ 1969 and aem- ployee of the funding source company. The study was however carried out independently with no intervention from manufacturers. Animal toxicity studies were carried out at Sanzyme Bio-Analytical Lab, Hyderabad, India. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Authors are bmanufacturer of Bacillus coagulans SNZ 1969 and aem- ployee of the funding source company. The study was however carried out independently with no intervention from manufacturers. Animal toxicity studies were carried out at Sanzyme Bio-Analytical Lab, Hyderabad, India. Acknowledgement", "Funding": "Funding This work was supported by the Sanzyme Pvt. Ltd., India. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Authors are bmanufacturer of Bacillus coagulans SNZ 1969 and aem- ployee of the funding source company. The study was however carried out independently with no intervention from manufacturers. Animal toxicity studies were carried out at Sanzyme Bio-Analytical Lab, Hyderabad, India. Acknowledgement Discussion Conclusion Funding mk:H1_28 Acknowledgement Supplementary data References", "Acknowledgement": "Acknowledgement The authors would like to acknowledge Sanzyme Bio-Lab, Hyderabad, India for their valuable help in toxicological studies. Discussion Conclusion Funding mk:H1_28 Acknowledgement Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-E12--W8--X17--and-Y9-potatoes--N_2020_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32540328", "content": {"CoiStatement": "Discussion Conclusions Funding body information Declaration of competing interest Acknowledgements Supplementary data References", "Funding": "Discussion Conclusions Funding body information Declaration of competing interest Acknowledgements Supplementary data References", "Compliance with ethical standards": "FDA, 2005. Compliance program guidance manual 7371.003. https://www.fda.gov/ media/74766/download accessed 03.04.20. FDA, 1992. FDA Federal Register. Foods Derived from New Plant Varieties; Policy Statement [WWW Document]. Food Drug Adm. https://www.fda.gov/regulatory- information/search-fda-guidance-documents/statement-policy-foods-derived-new- plant-varieties accessed 3.3.20.", "Acknowledgement": "Discussion Conclusions Funding body information Declaration of competing interest Acknowledgements Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-Eucommia-ulmoides-_2020_Regulatory-Toxicology-and-Pharm.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33122045", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Conflicts of interest All the authors declare that there are no conflicts of interest. All the authors declare that there are no conflicts of interest. Author agreement 4 Discussion 5 Conclusion Declaration of competing interest Acknowledgments Abbreviations Appendix A Supplementary data Conflicts of interest Author agreement Funding body information References", "Funding": "Funding body information This work was financially supported by Traditional Chinese Medi- cine Industry Special Project (grant No. 201507004). 4 Discussion 5 Conclusion Declaration of competing interest Acknowledgments Abbreviations Appendix A Supplementary data Conflicts of interest Author agreement Funding body information References", "Acknowledgement": "Acknowledgments This work was financially supported by Traditional Chinese Medi- cine Industry Special Project (grant No. 201507004). 4 Discussion 5 Conclusion Declaration of competing interest Acknowledgments Abbreviations Appendix A Supplementary data Conflicts of interest Author agreement Funding body information References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-Mucor-rouxii-CFR-G15-biomass_2012_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22024236", "content": {"CoiStatement": "Dried biomass of M. rouxii CFR-G15 was well tolerated even at higher dosages as evidenced by the absence of any adverse effect on growth, relative organ weights, histology, hematological param- eters and serum enzyme levels. The highest dosage level of 20,000 mg/kg of diet for 13 weeks shall be regarded as no- observed-adverse-effect-level (NOAEL) for supplementation of GLA rich M. rouxii CFR-G15 biomass. The present study also re- vealed the significant reduction in triglycerides and cholesterol levels in serum lipids. In conclusion, the whole biomass of M. rouxii CFR-G15 containing GLA could be a safe source of essential fatty acids in feed and food formulations. Conflict of interest statement The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgments 4 Discussion 5 Conclusion Conflict of interest statement Acknowledgments References", "Acknowledgement": "Acknowledgments Mamatha S.S. thanks CSIR, for providing the fellowship to carry out this work. The authors acknowledge Dr. S. Umesh Kumar, Head, Food Microbiology Department, Dr. P. Saibaba for their valuable suggestions and encouragement. Authors also thank Dr. Girija Bai for language presentation and reviewers for their comments for improvement of this manuscript. 4 Discussion 5 Conclusion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-Ochratoxin-A-and-Citrinin-after_2020_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32525063", "content": {"CoiStatement": "Discussion Conclusion Declaration of competing interest Acknowledgment Abbreviations Funding References", "Funding": "Discussion Conclusion Declaration of competing interest Acknowledgment Abbreviations Funding References", "Acknowledgement": "Discussion Conclusion Declaration of competing interest Acknowledgment Abbreviations Funding References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-Propionibacterium-freude_2011_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21406207", "content": {"CoiStatement": "Conflict of interest statement The authors of this publication have declared that they have no conflicts of interest. The authors of this publication have declared that they have no conflicts of interest. Funding sources statement Discussion Conflict of interest statement Funding sources statement References", "Funding": "Funding sources statement Funding for the research and preparation of this publication was provided by Meiji Dairies Corporation. Funding for the research and preparation of this publication was provided by Meiji Dairies Corporation. References Discussion Conflict of interest statement Funding sources statement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-Se-methylselenocysteine-as-nutriti_2014_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25444999", "content": {"Compliance with ethical standards": "All aspects in this project involving animal care, use, and wel- fare were performed in compliance with the Food and Drug Administration (FDA) principles of GLP and in accordance with the FDA Guidance for Industry and Other Stakeholders, \u2018\u2018Toxicolog- ical Principles for the Safety Assessment of Food Ingredients Redbook 2000\u2019\u2019 (FDA, 2000). All animal study protocols have been approved by the Office of Laboratory Animal Welfare, National Institute for Nutrition and Food Safety (Beijing, China). 2.1. Test substance"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-a-high-lipid-Whole-Algalin-Fl_2012_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22480966", "content": {"CoiStatement": "Conflict of interest All authors have a financial relationship with the sponsor of the studies and manuscript, Solazyme Roquette Nutritionals LLC., South San Francisco, CA. 4 Discussion Conflict of interest Acknowledgments References", "Compliance with ethical standards": "OECD, 1998. OECD Principles of Good Laboratory Practice (as Revised in 1997). Organisation for Economic Co-Operation & Development (OECD), Environment Directorate, Chemicals Group and Management Committee, OECD Environmental Health and Safety Publications, Paris, France. Series on Principles of Good Laboratory Practice and Compliance Monitoring, No. 1 [ENV/MC/CHEM(98)17]. Peron, A., Tenconi, R., Leone, M., Macellaro, P., Ceriani, E., D\u2019Arcais, A.F., 2011. Negative atopy patch test and negative skin prick test reduce the need for oral food challenge in children with atopic dermatitis. Pediatr. Allergy Immunol. Pulmonol. 24, 107\u2013112.", "Acknowledgement": "Acknowledgments The 13-wk subchronic toxicity study for WAF in rats was con- ducted at Product Safety Labs in Dayton, New Jersey, US. The muta- genic and clastogenic assays testing WAF were conducted at BSL Bioservice in Planegg, Germany. The human repeat-insult patch test was conducted at Thomas J. Stephens and Associates, Inc., Car- rollton, Texas, US. 4 Discussion Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-a-high-lipid-algal-biomass_2009_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19580838", "content": {"Compliance with ethical standards": "OECD, 1998. OECD Principles of Good Laboratory Practice (as Revised in 1997). Organisation for Economic Co-Operation & Development (OECD), Environment Directorate, Chemicals Group and Management Committee, OECD Environmental Health and Safety Publications, Paris, France. Series on Principles of Good Laboratory Practice and Compliance Monitoring, No. 1 [ENV/MC/CHEM(98)17]. PDRNS, 2001. Chlorella. In: PDR\ufffd for Nutritional Supplementsm, first ed. Physicians\u2019 Desk Reference (PDR), Demoines, Iowa/Medical Economics Data Production Company, Montvale, New Jersey, pp. 86\u201388."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-a-lipase-enzyme--BD29241-Palmitase--_2012_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22706145", "content": {"CoiStatement": "Conflict of interest statement Roxanna Halich, Katie Kline, and Diane Shanahan are employed by Verenium Corporation, the study sponsor. Vince Ciofalo is a paid consultant by Verenium Corporation in matters of toxicology. Verenium Corporation and Bunge Global Innovation, LLC finan- cially supported this project including the writing of the manu- script and paying third party costs. Third party toxicology labs were paid to execute the toxicology studies, collect, analyze, and interpret data. 4 Discussion 5 Conclusion Conflict of interest statement References", "Compliance with ethical standards": "FDA, 2003. Toxicology Principles for the Sadety Assessment of Food Ingredients, Redbook 2000: IVince Ciofalo.4.a Subchronic Toxicity Studies with Rodents. Available at: <http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/ GuidanceDocuments/FoodIngredientsandPackaging/Redbook/ ucm078345.htm>. Gad, S.C. (Ed.), 1995. Safety Assessment for Pharmaceuticals. Van Nostrand Rheinhold, New York, pp. 111\u2013116. http://www.anses.fr/Documents/BIOT2006sa0058.pdf http://www.anses.fr/Documents/BIOT2006sa0058.pdf http://www.fao.org/ag/agn/jecfa-additives/docs/enzymes_en.htm http://www.fao.org/ag/agn/jecfa-additives/docs/enzymes_en.htm http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodIngredientsandPackaging/Redbook/ucm078345.htm http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodIngredientsandPackaging/Redbook/ucm078345.htm http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodIngredientsandPackaging/Redbook/ucm078345.htm http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=OCDE/GD(97)22&amp;docLanguage=En http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=OCDE/GD(97)22&amp;docLanguage=En http://www.ers.usda.gov/Data/FoodConsumption/FoodAvailSpreadsheets.htm#fats http://www.ers.usda.gov/Data/FoodConsumption/FoodAvailSpreadsheets.htm#fats Safety evaluation of a lipase enzyme (BD29241 Palmitase) preparation, expressed in Pseudomonas fluorescens, intended for removing palmitic acid from triacylglycerol 1 Introduction 2 Materials and methods 2.1 Test article preparation"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-a-natural-tomato-oleoresin-ex_2004_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15135216", "content": {"Compliance with ethical standards": "The individual safety studies for determination of the safety evaluation of NTOE were carried out by inde- pendent and experienced contractor(s). All study pro- tocols were in compliance with Good Laboratory Practice (GLP) standards."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-a-novel-muramidase-for_2017_Regulatory-Toxicology-and-P.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28720348", "content": {"CoiStatement": "J. Lichtenberg et al. / Regulatory Toxicology and Pharmacology 89 (2017) 57e6968 Conflict of interest None of the authors has any conflicts of interest concerning this paper. None of the authors has any conflicts of interest concerning this paper. Transparency document 4. Conclusion Conflict of interest Transparency document References", "Compliance with ethical standards": "OECD (Organisation for Economic Co-operation and Development), 1998a. Princi- ples of Good Laboratory Practice (As Revised in 1997). OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring. ENV/MC/CHEM(98)17. OECD Publishing, Paris. OECD (Organisation for Economic Co-operation and Development), 2011. Fresh- water Alga and Cyanobacteria, Growth Inhibition Test. OECD Guidelines for the Testing of Chemicals/Section 2: Effects on Biotic Systems. Guideline No. 201. OECD Publishing, Paris."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-a-triazine-compound-nitromezuril-by-_2015_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25645284", "content": {"Acknowledgement": "Acknowledgments This work was financially supported by the National Natural Science Foundation of China (31272607), the Special Fund for Agro-Scientific Research in the Public Interest (201303038-1) and the National High Technology Research and Development Program of China (863 program) (2011AA10A214). The authors express their gratitude to Dr. Shijin Pu of Yangzhou University for support in conducting the chromosomal aberration tests. 3 Results 4 Discussion 5 Conclusions Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-a-whey-protein-fraction-contain_2014_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24842704", "content": {"CoiStatement": "Based on the studies performed, namely a 13-week oral toxicity study and a 6-week juvenile toxicity study in rats and in vitro bac- terial reverse mutation and micronucleus tests, we can conclude that these studies, which covered a wide variety of endpoints (including clinical well being, hematology, blood biochemistry, histopathology, juvenile developmental landmarks, pubertal development, cognitive and memory functions, and behavioral changes), support the safety of Takashi Mikogami0601p, a whey protein isolate concentrated in TGF-b2. Conflict of interest statement Authors Roy Forster, J\u00e9r\u00e9my Silvano, Guillaume Sire and Fran\u00e7ois Sp\u00e9zia are employees of CiToxLAB France, which received financial support for the conduct of this research from Armor Prot\u00e9ines and Nestec. Authors Michel Bourtourault, Caroline Puel and Takashi Mikogami are employees of Armor Prot\u00e9ines. Author Yong Joo Chung is an employee of Nestec. Author Jacques Descotes is an independent consultant. 4 Discussion and conclusions Conflict of interest statement Acknowledgments Appendix A Supplementary material References", "Compliance with ethical standards": "Safety evaluation of a whey protein fraction con 1 Introduction 2 Materials and methods 2.1 Test material 2.2 Experimental design: 13-week rat toxicity study by gavage 2.3 Experimental design: 6-week juvenile toxicity study in rats 2.4 Experimental design: bacterial reverse mutation test 2.5 Experimental design: in vitro micronucleus test 2.6 Guidelines and regulatory compliance 3 Results 3.1 13-week rat toxicity study by gavage 3.2 6-week juvenile toxicity study in rats 3.3 Bacterial reverse mutation test 3.4 In vitro micronucleus test", "Acknowledgement": "Acknowledgments Our thanks to Joanna Moore (CiToxLab France) for assistance in drafting the manuscript, to Barbara Danielewska-Nikiel (Intertek Cantox) for review of the manuscript and to Bernard Palate (CiToxLAB France) for many helpful comments. Appendix A. Supplementary material 4 Discussion and conclusions Conflict of interest statement Acknowledgments Appendix A Supplementary material References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-amylomaltase-from-The_2010_Regulatory-Toxicology-and-Ph.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20043969", "content": {"CoiStatement": "Conflict of interest statement The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. References Discussion Conflict of interest statement References", "Compliance with ethical standards": "OECD, 1998. OECD Principles of Good Laboratory Practice (as Revised in 1997). Organisation for Economic Co-Operation & Development (OECD), Environment Directorate, Chemicals Group and Management Committee, OECD Environmental Health and Safety Publications, Paris, France. OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring, no. 1, ENV/ MC/CHEM(98)17. Available from: <http://www.olis.oecd.org/olis/1998doc.nsf/ LinkTo/env-mc-chem(98)17/>. Olempska-Beer, Z.S., Merker, R.I., Ditto, M.D., DiNovi, M.J., 2006. Food-processing enzymes from recombinant microorganisms\u2014a review. Regul. Toxicol. Pharmacol. 45, 144\u2013158."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-an---cyclodextrin-glycosy_2004_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15265615", "content": {"Acknowledgement": "In conclusion, the use of an a-CGTase preparation fromE. coli for the production ofa-CD is considered to be safe based on the non-toxigenicity and non-pathogenicity of theE. coliK12 strain fromwhich the source organism is derived, and the K. oxytoca strain from which the a- CGTase gene was obtained. Direct evidence for the safety of the a-CGTase preparation is provided by a 13-week subchronic toxicity study in rats and in vitro genotoxicity tests (Ames test, chromosome aberration test). Acknowledgment This work was funded by Wacker-Chemie GmbH, Munich, Germany. References Discussion Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-an-enzymatically-synthe_2010_Regulatory-Toxicology-and-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20197075", "content": {"CoiStatement": "In summary, an acute toxicity study indicated that ESG exhibits a very low order of acute toxicity in experimental rats by the oral route of exposure. ESG also did not display any mutagenic proper- ties in an in vitro bacterial mutagenic assay. The effects noted in the 13-week subchronic study were not considered to be of toxicolog- ical concern, and therefore the NOAEL was established to be the highest concentration tested. Taken together, these data indicate that ESG would not pose a safety concern when used as a food ingredient. Conflict of Interest statement The authors declare that there are no conflicts of interest. References The authors declare that there are no conflicts of interest. References Adam, A., Levrat-Verny, M.A., Lopez, H.W., Leuillet, M., Demign\u00e9, C., R\u00e9m\u00e9sy, C.M., 2001. Whole wheat and triticale flours with differing viscosities stimulate cecal fermentations and lower plasma and hepatic lipids in rats. J. Nutr. 131, 1770\u2013 1776. Discussion Conflict of Interest statement References", "Compliance with ethical standards": "Ministry of Health, Labor and Welfare, Japan, 1999. Guideline for Genotoxicity Studies of Drugs. Ministry of Health and Welfare, Japan, Director of Evaluation and Licensing Division, Pharmaceutical and Medical Safety Bureau, Tokyo, Japan. Notification No. 1604, November 1, 1999. OECD, 1998. OECD Principles of Good Laboratory Practice (as Revised in 1997). Organisation for Economic Co-Operation & Development (OECD), Environment Directorate, Chemicals Group and Management Committee, OECD Environmental Health and Safety Publications, Paris, France. OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring, No 1, ENV/ MC/CHEM(98)17. Available from: <http://www.olis.oecd.org/olis/1998doc.nsf/ LinkTo/env-mc-chem(98)17>. Ohdan, K., Fujii, K., Yanase, M., Takaha, T., Kuriki, T., 2006. Enzymatic synthesis of amylose. Biocat. Biotransform. 24, 77\u201381."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-arachidonic-acid-rich-Mortierel_2009_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19545514", "content": {"Acknowledgement": "Acknowledgments The authors acknowledge Prof. Donald A. Mackenzie for provid- ing M. alpina culture. A. Nisha thanks the Council of Scientific and Industrial Research (CSIR) for the junior and senior research fel- lowships, The authors are grateful to Dr. V. Prakash, Director CFTRI, Dr. S. Umesh Kumar, Head, Food Microbiology Department and Dr. P. Saibaba, In charge, Animal house, B&N Department for providing all facilities to carry out this experiment successfully. References Blond, J.P., Bezard, J., 1991. D5 desaturation of dihomogammalinoleic acid (20:3(n \ufffd 6) by rat liver microsomes and incorporation of fatty acids in microsome phospholipids. Biochim. Biophys. Acta 1084, 255\u2013260. Bougle, D., Denise, P., Uimard, F., Nourelet, A., Penniello, M.J., Guillois, B., 1999. Early neurological and neurophysiological development of the preterm infant and polyunsaturated fatty acid supply. Clin. Neurophysiol. 110, 1363\u20131370. Brick, E.E., Garfield, S., Hoffman, D.R., Uauy, R., Birch, D.G., 2000. A randomized controlled trial of early dietary supply of long-chain polyunsaturated fatty acids and mental development in term infants. Dev. Med. Child Neurol. 42, 174\u2013181. Burns, R.A., Wibert, G.J., Diersen-Schade, D.A., Kelly, C.M., 1999. Evaluation of single cell sources of docosahexaenoic acid and arachidoinc acid: 3 month rat oral safety study with an in utero phase. Fd. Chem. Toxicol. 37, 23\u201336. Carlson, S.E., Werkman, S.H., Peeples, J.M., Cooke, R.J., Tolley, E.A., 1993. Arachidonic acid status correlates with first year growth in preterm infants. Proc. Natl. Acad. Sci. USA 90, 1073\u20131077. Gomez, De, Dumm, I.N.T., Alainz, M.J.T., Brenner, R.R., 1983. Effect of dietary fatty acids on delta-5 desaturase activity and biosynthesis of arachidonic acid in rat liver microsomes. Lipids 18 (11), 781\u2013788. Harris, W.S., 1989. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J. Lipid Res. 30, 785\u2013807. Hempenius, R.A., van Delft, J.M.H., Prinsen, M., Lina, B.A.R., 1997. Preliminary safety assessment of an arachidonic acid-enriched oil derived from Mortierella alpina: summary of toxicological data. Fd. Chem. Toxicol. 35, 573\u2013581. Hempenius, R.A., Lina, B.A.R., Haggit, R.C., 2000. Evaluation of a subchronic (13 week) oral toxicity study, preceded by an in utero exposure phase with 194 A. Nisha et al. / Regulatory Toxicology and Pharmacology 53 (2009) 186\u2013194 arachidonic acid oil derived from Mortierella alpina in rats. Fd. Chem. Toxicol. 38, 127\u2013139. Herzberg, G.R., 1989. The mechanism of triacylglycerol lowering by dietary fish oil. In: Chandra, R.K. (Ed.), Health Benefits of Fish and Fish Oils. ARTS Biomedical publishers & distributors, St. John\u2019s. Huang, Y., Pereira, S.L., Leonard, A.E., 2004. Enzymes for transgenic biosynthesis of long chain polyunsaturated fatty acids. Biochimie 86, 793\u2013798. Innis, S.M., 1991. Essential fatty acids in growth and development. Prog. Lipid Res. 30, 39\u2013103. Jong, S.C., Birmingham, J.M., Ma, G., 1994. ATCC Names of Industrial Fungi. ATCC, Rockville, Maryland, USA. Kendrick, A., Ratledge, C., 1992. Lipids of selected molds grown for production of n \ufffd 3 and n \ufffd 6 polyunsaturated fatty acids. Lipids 27, 15\u201320. Koletzko, B., Braun, M., 1991. Arachidonic acid and early human growth: is there a relation? Ann. Nutr. Metab. 35, 128\u2013131. Kroes, R., Schaefer, E.J., Squire, R.A., Williams, G.M., 2003. A review of the safety of DHA oil. Fd. Chem. Toxicol. 41, 1433\u20131446. Lina, B.A.R., Wolterbeek, A.P.M., Suwa, Y., Fujikawa, S., Ishikura, Y., Tsuda, S., Dohnalek, M., 2006. Sub chronic (13 week) oral toxicity study preceded by an in utero exposure phase with arachidonate enriched triglyceride oil (SUNTGA40S) in rats. Fd. Chem. Toxicol. 44, 326\u2013335. Merritt, R.J., Auestad, N., Kruger, C., Buchanan, S., 2003. Safety evaluation of sources of docosahexaenoic acid and archidonic acid for use in infant formulas in newborn piglets. Fd. Chem. Toxicol. 41, 897\u2013904. Mills, E.P., Murthy, M., Galey, W.R., 1995. Dietary fatty acids, membrane transport and oxidative sensitivity in human erythrocytes. Lipids 30, 657\u2013663. Nakano, D., Ishii, F., Fujii, K., Ishikura, Y., Akimoto, K., Kontani, M., Kawashima, H., Kiso, Y., Matsumura, Y., 2007. Effects of dietary arachidonic acid supplementation on age related changes in the endothelium dependent vascular responses. J. Nutr. Sci. Vitaminol. 53, 75\u201381. Needleman, P., Turk, J., Jackshik, R.A., Morrison, A.R., Lefkowi, J.B., 1986. Arachidonic acid metabolism. Annu. Rev. Biochem. 55, 69\u2013102. Nisha, A., Venkateswaran, G., in press. Effect of culture variables on mycelial arachidonic acid production by Mortierella alpina. Food Bioprocess Technol. doi:10.1007/s11947-008-0146-y. Okaichi, Y., Ishikura, Y., Akimoto, K., Kawashima, H., Toyoda-Ono, Y., Kiso, Y., Okaichi, H., 2005. Arachidonic acid improves aged rats spatial cognition. Physiol. Behav. 84, 617\u2013623. Peters, J.M., Boyd, E.M., 1966. Organ weights and water levels of the rat following reduced food intake. J. Nutr. 90, 354\u2013360. Pfeiffer, C.J., 1968. A mathematical evaluation of the thymic weight parameter. Toxicol. Appl. Pharmacol. 13, 220\u2013227. Rodr\u00edguez-Cruz, M., Tovar, A.R., del Prado, M., Torres, N., 2005. Molecular mechanisms of action and health benefits of poly unsaturated fatty acids. Rev. Invest. Clin. 57 (3), 457\u2013472. Roy, R., Singh, S., Pujari, S., 2008. Dietary role of omega\u20143 polyunsaturated fatty acid (PUFA): a study with growing chicks, Gallus domesticus. Int. J. Poul. Sci. 7 (4), 360\u2013367. Sakuradani, E., Shimizu, S., 2003. Gene cloning and functional analysis of a second D6 fatty acid desaturase from an arachidonic acid producing Mortierella fungus. Biosci. Biotechnol. Biochem. 67, 704\u2013771. Sampath, H., Ntambi, J.M., 2004. Poly unsaturated fatty acid regulation of genes of lipid metabolism. Nutr. Rev. 62, 333\u2013339. Sampath, H., Ntambi, J.M., 2005. Polyunsaturated fatty acid regulation of genes of lipid metabolism. Annu. Rev. Nutr. 25, 317\u2013340. Saynor, R., Gillot, T., 1992. Changes in blood lipids and fibrogen with a note of safety in along term study on the effects of n \ufffd 3 fatty acids in subjects receiving fish oil supplements and followed for seven years. Lipids 27, 533\u2013 538. SPSS Inc., 1998. SPSS base 8.0 for Windows User\u2019s Guide. SPSS Inc. Chicago IL. Streekstra, H., 1997. On the safety of Mortierella alpina for the production of food ingredients such as arachidonic acid. J. Biotechnol. 56, 153\u2013165. Wang, J., Leung, P.C., 1989. Arachidonic acid as a stimulatory mediator of luteinizing hormone releasing hormone action in the rat ovary. Endocrinology 124, 1973\u2013 1979. Weiler, H.A., 2000. Dietary supplementation of arachidonic acid is associated with higher whole body weight and bone mineral density in growing pigs. Pediatr. Res. 47, 692\u2013697. Xiang, M., Zetterstrom, R., 1999. Relation between poly unsaturated fatty acids and growth. Acta Paediatr. 88, 78\u201382. http://dx.doi.org/10.1007/s11947-008-0146-y Safety evaluation of arachidonic acid rich Mortierella alpina biomass in albino rats\u2014A subchronic study Introduction Materials and methods Chemicals and reagent kits Test material Animals and treatment design Acute oral exposure in rats Subchronic oral exposure study Diet preparation Viability test Hematology and serum biochemical indices Relative organ weights Histopathology Statistical analysis Results Acute oral exposure Subchronic oral exposure study Viability test Clinical signs Feed intake and body weight Relative organ weights and histopathology Hematological and serum biochemical indices Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-auraptene-in-rats-in-acute_2017_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29080847", "content": {"CoiStatement": "Conflict of interest The authors declared no conflict of interest. The authors declared no conflict of interest. Acknowledgments Discussion Conflict of interest Acknowledgments Transparency document References", "Acknowledgement": "Acknowledgments The authors appreciate Mashhad University of Medical Sciences, for financial support. This study was part of Ph.D thesis of Tooraj Vakili. Discussion Conflict of interest Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-biological-drugs--What-are-to_2011_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20937341", "content": {"CoiStatement": "In conclusion, the answer to the question posed earlier on whether aspects of the standard design approach of toxicology studies for biological drugs, especially the use of three drug-treated and non-dose recovery groups currently used to support initial clinical entry, needs to be revisited is yes. The review of study results for 26 such drugs has indicated, especially for MAbs and related drugs, that a robust toxicological assessment could be achieved in many cases with one control and one or two drug-trea- ted groups and with non-dose recovery groups only for the control and highest level used. Study findings when seen, were largely of an expected pharmacological nature, with no necessity to establish a dose response, if indeed possible. Such a conclusion is supported from a review of published literature for other drugs in develop- ment or, on the market, which again showed no study findings or changes due to exaggerated pharmacology. However, despite strong evidence for a reduced study design approach, it should be pointed out that movement away from the established three drug-treated group approach, allowing establishment of a dose\u2013re- sponse and calculation of a study NOAEL, may not be ideal for some biologicals, especially some rh human proteins which may have many potential targets, which could result in off-target toxicity as seen with chemically synthesised small molecules. Exaggerated pharmacology in an animal model can, of course, be a pointer for adverse effects in the clinic. A clear understanding of the drug\u2019s mechanism of action, especially if novel, for determination of potential adverse effects is therefore key. Conflict of interest and funding sources statement None. References Conclusion Conflict of interest and funding sources statement References", "Funding": "In conclusion, the answer to the question posed earlier on whether aspects of the standard design approach of toxicology studies for biological drugs, especially the use of three drug-treated and non-dose recovery groups currently used to support initial clinical entry, needs to be revisited is yes. The review of study results for 26 such drugs has indicated, especially for MAbs and related drugs, that a robust toxicological assessment could be achieved in many cases with one control and one or two drug-trea- ted groups and with non-dose recovery groups only for the control and highest level used. Study findings when seen, were largely of an expected pharmacological nature, with no necessity to establish a dose response, if indeed possible. Such a conclusion is supported from a review of published literature for other drugs in develop- ment or, on the market, which again showed no study findings or changes due to exaggerated pharmacology. However, despite strong evidence for a reduced study design approach, it should be pointed out that movement away from the established three drug-treated group approach, allowing establishment of a dose\u2013re- sponse and calculation of a study NOAEL, may not be ideal for some biologicals, especially some rh human proteins which may have many potential targets, which could result in off-target toxicity as seen with chemically synthesised small molecules. Exaggerated pharmacology in an animal model can, of course, be a pointer for adverse effects in the clinic. A clear understanding of the drug\u2019s mechanism of action, especially if novel, for determination of potential adverse effects is therefore key. Conflict of interest and funding sources statement None. References Conclusion Conflict of interest and funding sources statement References", "Compliance with ethical standards": "http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/03/WC500079536.pdf http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/03/WC500079536.pdf http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/03/WC500079536.pdf http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&amp;murl=menus/medicines/medicines.jsp&amp;mid=WC0b01ac058001d125 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&amp;murl=menus/medicines/medicines.jsp&amp;mid=WC0b01ac058001d125 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&amp;murl=menus/medicines/medicines.jsp&amp;mid=WC0b01ac058001d125 http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodIngredientsandPackaging/Redbook/ucm078315.htm http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodIngredientsandPackaging/Redbook/ucm078315.htm http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodIngredientsandPackaging/Redbook/ucm078315.htm http://www.ich.org/LOB/media/MEDIA5544.pdf http://www.ich.org/LOB/media/MEDIA503.pdf http://www.ich.org/LOB/media/MEDIA5784.pdf http://www.ich.org/LOB/media/MEDIA5784.pdf http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Scientific_Discussion/human/000395/WC500039192.pdf http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Scientific_Discussion/human/000395/WC500039192.pdf Safety evaluation of biological drugs: What are toxicology studies in primates telling us? Introduction Materials and methods Results Study design Study findings Clinical signs Bodyweight and food consumption Ophthalmoscopy ECG and heart rate+blood pressure Toxicokinetics Clinical pathology (haematology/clinical chemistry and urinalysis) Organ weights Macroscopic examination Histopathological examination Antibody analysis Immunophenotyping and cytokine release Other parameters"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-collagenase-from-Strept_2020_Regulatory-Toxicology-and-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32278234", "content": {"CoiStatement": "Discussion Declaration of competing interest Acknowledgments References", "Funding": "Nagase ChemteX Corporation. Nagase ChemteX Corporation provided the funding for this study. Acknowledgments", "Compliance with ethical standards": "All of the studies were conducted at the Bozo Research Center Inc., Gotemba Laboratory, 1284, Kamado, Gotemba, Shizuoka, 412\u20130039, Japan. The laboratory is a GLP-compliant testing facility. All of the studies were in compliance with the Organization of Economic Co-op- eration and Development (OECD) Principles of Good Laboratory Practice (GLP) and approved by the Institutional Animal Care and Use Committee (IACUC) of the testing facility. References OECD, 1998. OECD Principles of Good Laboratory Practice (As Revised in 1997). Organisation for Economic Co-Operation & Development (OECD), Environment Directorate, Chemicals Group and Management Committee, OECD Environmental Health and Safety Publications, Paris OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring, no 1, ENV/MC/CHEM(98)17. OECD, 1998. Test No. 408: repeated dose 90-day oral toxicity study in rodents. In: OECD Guidelines for the Testing of Chemicals, Section 4. OECD Publishing, Paris.", "Acknowledgement": "Acknowledgments All of the studies were conducted at the Bozo Research Center Inc., Gotemba Laboratory, 1284, Kamado, Gotemba, Shizuoka, 412\u20130039, Japan. The laboratory is a GLP-compliant testing facility. All of the studies were in compliance with the Organization of Economic Co-op- eration and Development (OECD) Principles of Good Laboratory Practice (GLP) and approved by the Institutional Animal Care and Use Committee (IACUC) of the testing facility. Discussion Declaration of competing interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-fish-protein-hydrolysate-sup_2014_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24569051", "content": {"CoiStatement": "6. Conflicts of interests Knut Olav Nesse is a consultant retained by Zymtech Production As. A.P. Nagalakshmi is an employee of the Consortium Clinical Re- search Pvt. Ltd. Manki Ho and Ryan Simon are employees of Inter- tek Scientific & Regulatory Consultancy; Intertek Scientific & Regulatory Consultancy has provided scientific consulting services to the Zymtech within the past 3 years. 4 Discussion 6 Conflicts of interests Acknowledgments References", "Funding": "The authors\u2019 responsibilities were as follows\u2014Knut Olav Nesse: study design, oversight, funding and carry the primary responsibil- ity for final content; A.P. Nagalakshmi: study design, conduct of the experiments and data collection; P. Marimuthu: statistical analy- sis; and Manki Ho and Ryan Simon: writing and critical review of 6 K.O. Nesse et al. / Regulatory Toxicology and Pharmacology 69 (2014) 1\u20136 the manuscript. All authors read and approved the final manu- script. Research work has been funded by Zymtech AS, Norway. The guidance and help for this study provided by Dr. P. Usha Sar- ma, Emeritus Scientist, Indian Agricultural Research Institute, New Delhi, India, is gratefully acknowledged. We are also thankful to Dr. Taruna Madan, Scientist D, National Institute for Research in Reproductive Health, Mumbai India, for her valuable comments during the preparation of the manuscript. References", "Acknowledgement": "Acknowledgments The authors\u2019 responsibilities were as follows\u2014Knut Olav Nesse: study design, oversight, funding and carry the primary responsibil- ity for final content; A.P. Nagalakshmi: study design, conduct of the experiments and data collection; P. Marimuthu: statistical analy- sis; and Manki Ho and Ryan Simon: writing and critical review of 6 K.O. Nesse et al. / Regulatory Toxicology and Pharmacology 69 (2014) 1\u20136 the manuscript. All authors read and approved the final manu- script. Research work has been funded by Zymtech AS, Norway. The guidance and help for this study provided by Dr. P. Usha Sar- ma, Emeritus Scientist, Indian Agricultural Research Institute, New Delhi, India, is gratefully acknowledged. We are also thankful to Dr. Taruna Madan, Scientist D, National Institute for Research in Reproductive Health, Mumbai India, for her valuable comments during the preparation of the manuscript. 4 Discussion 6 Conflicts of interests Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Safety-evaluation-of-food-enzymes-produced-by-a-s_2021_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34455008", "content": {"CoiStatement": "6 Discussion and conclusion CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data Funding References", "Funding": "Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. References 6 Discussion and conclusion CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data Funding References", "Compliance with ethical standards": "U.S. FDA Center for Veterinary Medicine, 2015. Compliance Policy Guide (CPG) Sec. 689.100, Direct-Fed Microbial Products. https://www.fda.gov/regulatory-informa tion/search-fda-guidance-documents/cpg-sec-689100-direct-fed-microbial-products. van Dijl, J.M., Hecker, M., 2013. Bacillus subtilis: from soil bacterium to super-secreting cell factory. Microb. Cell Factories 12, 3. https://doi.org/10.1186/1475-2859-12-3.", "Acknowledgement": "6 Discussion and conclusion CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data Funding References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-genetically-modified-DAS-40278_2018_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29763631", "content": {"Acknowledgement": "Acknowledgements We are grateful to Dow AgroSciences and Corteva Agriscience\u2122 Agriculture Division of DowDuPont\u2122 for their critical review of the manuscript. Discussion and conclusions Acknowledgements Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-glucose-oxidase-from-Pen_2013_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23454104", "content": {"CoiStatement": "In summary, PGO was not associated with any adverse effects in Crl:CD (SD) rats at doses of up to 15,600 U/kg bw/day (equivalent to 193 mg TOS/kg bw/day) in a 90-day oral toxicity study. The en- zyme preparation also was demonstrated to be non-genotoxic in a series of in vitro and in vivo genotoxicity tests. The results of the toxicological tests, together with the history of safe use of the pro- duction strain P. chrysogenum in food processing, support the safety of PGO for use in food for human consumption. Conflict of interest The authors of this publication have declared that they have no conflicts of interest. Funding sources The authors of this publication have declared that they have no conflicts of interest. Funding sources Funding for the research and preparation of this publication was provided by Shin Nihon Chemical Co., Ltd. OECD, 1998a. OECD series on application of principles of good laboratory practice and compliance monitoring. OECD principles on good laboratory practice (as revised in 1997). Document: ENV/MC/CHEM (98)17. OECD, Paris, France. (accessed March, 2012. Available from: <http://www.oecd.org/official documents/displaydocumentpdf/?cote=env/mc/chem(98)17&doclanguage=en>. OECD, 1998b. Repeated dose 90-day oral toxicity study in rodents. OECD guideline for testing of chemicals. Guideline 408. OECD, Paris, France. (Updated & Adopted 21st September 1998, accessed November, 2012). Available from: <http://www.oecd-ilibrary.org/environment/test-no-408-repeated-dose-90- day-oral-toxicity-study-in-rodents_9789264070707-en>. Rasiah, I.A. et al., 2005. Crosslinking of wheat dough proteins by glucoseoxidase and the resulting effects on bread and croissants. Food Chem. 89, 325\u2013332. Sisak, C. et al., 2006. Elimination of glucose in egg white using immobilized glucose oxidase. Enzyme Microb. Technol. 39, 1002\u20131007. Sunesen, L.O., Stahnke, L.H., 2003. Mould starter cultures for dry sausages-selection, application and effects. Meat Sci. 65, 935\u2013948. Vemulapalli, V., Hoseney, R.C., 1998. Glucose oxidase effects on gluten and water soluble. Cereal Chem. 75, 859\u2013862. Vemulapalli, V., Miller, K.A., Hoseney, R.C., 1998. Glucose oxidase in breadmaking systems. Cereal Chem. 75, 439\u2013442. Wong, C.M., Wong, K.H., Chen, X.D., 2008. Glucose oxidase: natural occurrence, function, properties and industrial applications. Appl. Microbiol. Biotechnol. 78, 927\u2013938. http://www.oecd-ilibrary.org/environment/test-no-471-bacterial-reverse-mutation-test_9789264071247-en http://www.oecd-ilibrary.org/environment/test-no-471-bacterial-reverse-mutation-test_9789264071247-en http://www.oecd-ilibrary.org/environment/test-no-471-bacterial-reverse-mutation-test_9789264071247-en http://www.oecd-ilibrary.org/environment/test-no-473-in-vitro-mammalian-chromosome-aberration-test_9789264071261-en http://www.oecd-ilibrary.org/environment/test-no-473-in-vitro-mammalian-chromosome-aberration-test_9789264071261-en http://www.oecd-ilibrary.org/environment/test-no-473-in-vitro-mammalian-chromosome-aberration-test_9789264071261-en http://www.oecd-ilibrary.org/environment/test-no-474-mammalian-erythrocyte-micronucleus-test_9789264071285-en http://www.oecd-ilibrary.org/environment/test-no-474-mammalian-erythrocyte-micronucleus-test_9789264071285-en http://www.oecd-ilibrary.org/environment/test-no-474-mammalian-erythrocyte-micronucleus-test_9789264071285-en http://www.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/mc/chem(98)17&amp;doclanguage=en http://www.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/mc/chem(98)17&amp;doclanguage=en http://www.oecd-ilibrary.org/environment/test-no-408-repeated-dose-90-day-oral-toxicity-study-in-rodents_9789264070707-en http://www.oecd-ilibrary.org/environment/test-no-408-repeated-dose-90-day-oral-toxicity-study-in-rodents_9789264070707-en Safety evaluation of glucose oxidase from Penicillium chrysogenum 1 Introduction 2 Materials and methods 2.1 Enzyme preparation 2.2 Repeated dose 90-day oral toxicity study 2.2.1 Preparation of dosing formulations 2.2.2 Animals and treatment 2.2.3 Clinical observations, body weights, food consumption, and opthalmology 2.2.4 Clinical pathology and urinalysis 2.2.5 Pathology 2.2.6 Statistical analysis 2.3 Genotoxicity studies 2.3.1 Bacterial reverse mutation test (Ames test) 2.3.2 In vitro mammalian chromosome aberration test 2.3.3 Combined in vivo mammalian erythrocyte micronucleus test and comet assay 3 Results 3.1 Repeated dose 90-day oral toxicity study 3.1.1 Clinical observations, body weights, food consumption, and opthalmology 3.1.2 Clinical pathology and urinalysis 3.1.3 Pathology 3.2 Genotoxicity studies 3.2.1 Bacterial reverse mutation test (Ames test) 3.2.2 In vitro mammalian chromosome aberration test 3.2.3 Combined in vivo mammalian erythrocyte micronucleus test and comet assay 4 Discussion Conflict of interest Funding sources References", "Funding": "The authors of this publication have declared that they have no conflicts of interest. Funding sources Funding for the research and preparation of this publication was provided by Shin Nihon Chemical Co., Ltd. Funding for the research and preparation of this publication was provided by Shin Nihon Chemical Co., Ltd. References OECD, 1998a. OECD series on application of principles of good laboratory practice and compliance monitoring. OECD principles on good laboratory practice (as revised in 1997). Document: ENV/MC/CHEM (98)17. OECD, Paris, France. (accessed March, 2012. Available from: <http://www.oecd.org/official documents/displaydocumentpdf/?cote=env/mc/chem(98)17&doclanguage=en>. OECD, 1998b. Repeated dose 90-day oral toxicity study in rodents. OECD guideline for testing of chemicals. Guideline 408. OECD, Paris, France. (Updated & Adopted 21st September 1998, accessed November, 2012). Available from: <http://www.oecd-ilibrary.org/environment/test-no-408-repeated-dose-90- day-oral-toxicity-study-in-rodents_9789264070707-en>. Rasiah, I.A. et al., 2005. Crosslinking of wheat dough proteins by glucoseoxidase and the resulting effects on bread and croissants. Food Chem. 89, 325\u2013332. Sisak, C. et al., 2006. Elimination of glucose in egg white using immobilized glucose oxidase. Enzyme Microb. Technol. 39, 1002\u20131007. Sunesen, L.O., Stahnke, L.H., 2003. Mould starter cultures for dry sausages-selection, application and effects. Meat Sci. 65, 935\u2013948. Vemulapalli, V., Hoseney, R.C., 1998. Glucose oxidase effects on gluten and water soluble. Cereal Chem. 75, 859\u2013862. Vemulapalli, V., Miller, K.A., Hoseney, R.C., 1998. Glucose oxidase in breadmaking systems. Cereal Chem. 75, 439\u2013442. Wong, C.M., Wong, K.H., Chen, X.D., 2008. Glucose oxidase: natural occurrence, function, properties and industrial applications. Appl. Microbiol. Biotechnol. 78, 927\u2013938. http://www.oecd-ilibrary.org/environment/test-no-471-bacterial-reverse-mutation-test_9789264071247-en http://www.oecd-ilibrary.org/environment/test-no-471-bacterial-reverse-mutation-test_9789264071247-en http://www.oecd-ilibrary.org/environment/test-no-471-bacterial-reverse-mutation-test_9789264071247-en http://www.oecd-ilibrary.org/environment/test-no-473-in-vitro-mammalian-chromosome-aberration-test_9789264071261-en http://www.oecd-ilibrary.org/environment/test-no-473-in-vitro-mammalian-chromosome-aberration-test_9789264071261-en http://www.oecd-ilibrary.org/environment/test-no-473-in-vitro-mammalian-chromosome-aberration-test_9789264071261-en http://www.oecd-ilibrary.org/environment/test-no-474-mammalian-erythrocyte-micronucleus-test_9789264071285-en http://www.oecd-ilibrary.org/environment/test-no-474-mammalian-erythrocyte-micronucleus-test_9789264071285-en http://www.oecd-ilibrary.org/environment/test-no-474-mammalian-erythrocyte-micronucleus-test_9789264071285-en http://www.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/mc/chem(98)17&amp;doclanguage=en http://www.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/mc/chem(98)17&amp;doclanguage=en http://www.oecd-ilibrary.org/environment/test-no-408-repeated-dose-90-day-oral-toxicity-study-in-rodents_9789264070707-en http://www.oecd-ilibrary.org/environment/test-no-408-repeated-dose-90-day-oral-toxicity-study-in-rodents_9789264070707-en Safety evaluation of glucose oxidase from Penicillium chrysogenum 1 Introduction 2 Materials and methods 2.1 Enzyme preparation 2.2 Repeated dose 90-day oral toxicity study 2.2.1 Preparation of dosing formulations 2.2.2 Animals and treatment 2.2.3 Clinical observations, body weights, food consumption, and opthalmology 2.2.4 Clinical pathology and urinalysis 2.2.5 Pathology 2.2.6 Statistical analysis 2.3 Genotoxicity studies 2.3.1 Bacterial reverse mutation test (Ames test) 2.3.2 In vitro mammalian chromosome aberration test 2.3.3 Combined in vivo mammalian erythrocyte micronucleus test and comet assay 3 Results 3.1 Repeated dose 90-day oral toxicity study 3.1.1 Clinical observations, body weights, food consumption, and opthalmology 3.1.2 Clinical pathology and urinalysis 3.1.3 Pathology 3.2 Genotoxicity studies 3.2.1 Bacterial reverse mutation test (Ames test) 3.2.2 In vitro mammalian chromosome aberration test 3.2.3 Combined in vivo mammalian erythrocyte micronucleus test and comet assay 4 Discussion Conflict of interest Funding sources References", "Compliance with ethical standards": "OECD, 1998a. OECD series on application of principles of good laboratory practice and compliance monitoring. OECD principles on good laboratory practice (as revised in 1997). Document: ENV/MC/CHEM (98)17. OECD, Paris, France. (accessed March, 2012. Available from: <http://www.oecd.org/official documents/displaydocumentpdf/?cote=env/mc/chem(98)17&doclanguage=en>. OECD, 1998b. Repeated dose 90-day oral toxicity study in rodents. OECD guideline for testing of chemicals. Guideline 408. OECD, Paris, France. (Updated & Adopted 21st September 1998, accessed November, 2012). Available from: <http://www.oecd-ilibrary.org/environment/test-no-408-repeated-dose-90- day-oral-toxicity-study-in-rodents_9789264070707-en>. Rasiah, I.A. et al., 2005. Crosslinking of wheat dough proteins by glucoseoxidase and the resulting effects on bread and croissants. Food Chem. 89, 325\u2013332. Sisak, C. et al., 2006. Elimination of glucose in egg white using immobilized glucose oxidase. Enzyme Microb. Technol. 39, 1002\u20131007. Sunesen, L.O., Stahnke, L.H., 2003. Mould starter cultures for dry sausages-selection, application and effects. Meat Sci. 65, 935\u2013948. Vemulapalli, V., Hoseney, R.C., 1998. Glucose oxidase effects on gluten and water soluble. Cereal Chem. 75, 859\u2013862. Vemulapalli, V., Miller, K.A., Hoseney, R.C., 1998. Glucose oxidase in breadmaking systems. Cereal Chem. 75, 439\u2013442. Wong, C.M., Wong, K.H., Chen, X.D., 2008. Glucose oxidase: natural occurrence, function, properties and industrial applications. Appl. Microbiol. Biotechnol. 78, 927\u2013938. http://www.oecd-ilibrary.org/environment/test-no-471-bacterial-reverse-mutation-test_9789264071247-en http://www.oecd-ilibrary.org/environment/test-no-471-bacterial-reverse-mutation-test_9789264071247-en http://www.oecd-ilibrary.org/environment/test-no-471-bacterial-reverse-mutation-test_9789264071247-en http://www.oecd-ilibrary.org/environment/test-no-473-in-vitro-mammalian-chromosome-aberration-test_9789264071261-en http://www.oecd-ilibrary.org/environment/test-no-473-in-vitro-mammalian-chromosome-aberration-test_9789264071261-en http://www.oecd-ilibrary.org/environment/test-no-473-in-vitro-mammalian-chromosome-aberration-test_9789264071261-en http://www.oecd-ilibrary.org/environment/test-no-474-mammalian-erythrocyte-micronucleus-test_9789264071285-en http://www.oecd-ilibrary.org/environment/test-no-474-mammalian-erythrocyte-micronucleus-test_9789264071285-en http://www.oecd-ilibrary.org/environment/test-no-474-mammalian-erythrocyte-micronucleus-test_9789264071285-en http://www.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/mc/chem(98)17&amp;doclanguage=en http://www.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/mc/chem(98)17&amp;doclanguage=en http://www.oecd-ilibrary.org/environment/test-no-408-repeated-dose-90-day-oral-toxicity-study-in-rodents_9789264070707-en http://www.oecd-ilibrary.org/environment/test-no-408-repeated-dose-90-day-oral-toxicity-study-in-rodents_9789264070707-en Safety evaluation of glucose oxidase from Penicillium chrysogenum 1 Introduction 2 Materials and methods 2.1 Enzyme preparation 2.2 Repeated dose 90-day oral toxicity study 2.2.1 Preparation of dosing formulations 2.2.2 Animals and treatment 2.2.3 Clinical observations, body weights, food consumption, and opthalmology 2.2.4 Clinical pathology and urinalysis 2.2.5 Pathology 2.2.6 Statistical analysis 2.3 Genotoxicity studies 2.3.1 Bacterial reverse mutation test (Ames test) 2.3.2 In vitro mammalian chromosome aberration test 2.3.3 Combined in vivo mammalian erythrocyte micronucleus test and comet assay 3 Results 3.1 Repeated dose 90-day oral toxicity study 3.1.1 Clinical observations, body weights, food consumption, and opthalmology 3.1.2 Clinical pathology and urinalysis 3.1.3 Pathology 3.2 Genotoxicity studies 3.2.1 Bacterial reverse mutation test (Ames test) 3.2.2 In vitro mammalian chromosome aberration test 3.2.3 Combined in vivo mammalian erythrocyte micronucleus test and comet assay 4 Discussion Conflict of interest Funding sources References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-highly-branched-cyclic-dextrin-an_2009_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19651182", "content": {"Compliance with ethical standards": "OECD, 1998. OECD Principles of Good Laboratory Practice (as Revised in 1997). Organisation for Economic Co-Operation & Development (OECD), Environment Directorate, Chemicals Group and Management Committee, OECD Environmental Health and Safety Publications, Paris, France. OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring, no 1, ENV/ MC/CHEM(98)17. Ohdan, K., Kuriki, T., Kaneko, H., Shimada, J., Takada, T., Fujimoto, Z., Mizuno, H., Okada, S., 1999. Characteristics of two forms of a-amylases and structural implication. Appl. Environ. Microbiol. 65 (10), 4652\u20134658."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-metal-exposure-from-commonly-us_2015_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25667956", "content": {"CoiStatement": "The results of the present study indicate that Pb and Cd were detected in these body creams at concentrations below the speci- fied limit or maximal limit as impurities in colour additives in cos- metics for external use by the Canadian authority. The concentrations of Ni and Co were below the suggested limit of 5 lg/g as \u2018\u2018good manufacturing practice\u2019\u2019, while Cr was found at concentrations that can induce allergenic contact dermatitis in pre-sensitized individuals. The results also showed that skin-light- ening creams contained higher concentrations of the studied met- als than the moisturizing creams except for Ni, which indicates that persons who use skin-lightening creams in preference to moisturizing creams are potentially exposed to higher concentra- tions of metals. The results of the present study demonstrate the urgent need for the establishment of regulatory limits for metals in cosmetic products in Nigeria. Conflicts of interest Dr. Iwegbue has nothing to disclose. Acknowledgements 3 Results and discussion 4 Conclusions Conflicts of interest Acknowledgements References", "Acknowledgement": "Dr. Iwegbue has nothing to disclose. Acknowledgements Chukwujindu M A Iwegbue thanks the University of KwaZulu-Natal College of Agri- culture, Engineering and Science for the award of a Post-Doctoral Scholarship. References 3 Results and discussion 4 Conclusions Conflicts of interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-mulberry-leaf-extract--Acute-_2018_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29530616", "content": {"CoiStatement": "Conflicts of interest The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgement Discussion Conflicts of interest Acknowledgement Transparency document References", "Acknowledgement": "Acknowledgement This work was supported by the National Key Research and Development Program of China (No. 2016YFD0400601). Discussion Conflicts of interest Acknowledgement Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-pectin-derived-acidic-oligosacc_2010_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20026148", "content": {"Acknowledgement": "Acknowledgments The authors thank Guenther Boehm, Niels Kildemark and Ald- win Vriesema for their input and critical comments on the manuscript. Discussion Conclusion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-phytase-50104-enzyme-preparation--als_2014_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24945743", "content": {"CoiStatement": "Therefore, we conclude that the documented safety record of P. fluorescens and the results of the toxicology studies described for VR003 test article and in the published literature for phytases in general indicate that phytase 50104 enzyme is safe for the intended use as an animal feed additive to improve digestibility of phosphorus. Conflict of interest Scott Krygier, Arne Solbak, and Diane Shanahan are or were employed by Verenium Corporation, the study Sponsor. Vince Ciofalo is a paid consultant by Verenium Corporation in matters of toxicology. Verenium Corporation and Novus International, Inc. financially supported this project including the writing of this manuscript and paying third party costs. Third party toxicology labs were paid to execute the toxicology studies, collect, analyze, and interpret data. References 4 Discussion 5 Conclusion Conflict of interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-proanthocyanidin-polymer-rich-fracti_2010_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20655967", "content": {"CoiStatement": "Our study showed that the proanthocyanidin polymer-rich frac- tion (F2) obtained from stem bark of S. adstringens had no geno- toxic activity in the assays performed, and indicates that F2 probably protected against damage caused by cyclophosphamide. Thus, the use of F2 seems to be safe with respect to genotoxicity, and this fraction has potential as a pharmacological agent, mainly for antifungal treatment. 6. Conflict of interest The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgements Discussion Conclusions Conflict of interest Acknowledgements References Glossary", "Acknowledgement": "Acknowledgements This study was supported by the Coordena\u00e7\u00e3o de Aperfei\u00e7oa- mento de Pessoal de N\u00edvel Superior (CAPES), Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico (CNPq), INCT_if, Financiadora de Estudos e Projetos (FINEP), PRONEX/Funda\u00e7\u00e3o Arauc\u00e1ria, and Programa de P\u00f3s-Gradua\u00e7\u00e3o em Ci\u00eancias Farm- ac\u00eauticas da Universidade Estadual de Maring\u00e1. Discussion Conclusions Conflict of interest Acknowledgements References Glossary"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-recycling-process-used-to-pro_2021_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33652038", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 5 Conclusions Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgements References", "Funding": "Funding body information This research did not receive any specific grant from any funding agencies in the public, commercial, or not-for-profit sectors. This research did not receive any specific grant from any funding agencies in the public, commercial, or not-for-profit sectors. CRediT authorship contribution statement This research did not receive any specific grant from any funding agencies in the public, commercial, or not-for-profit sectors. References 5 Conclusions Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgements References", "Acknowledgement": "Acknowledgements This research did not receive any specific grant from any funding agencies in the public, commercial, or not-for-profit sectors. 5 Conclusions Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-standardized-allergen-extract-o_2015_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25701184", "content": {"Acknowledgement": "Acknowledgments The authors gratefully acknowledge to Messrs. Hidehiro Ogata, Tomonari Miyazaki (LSI Medience Corporation, formerly Mitsubishi Chemical Medience Corporation), Yoshihisa Miwa, 540 Y. Mitobe et al. / Regulatory Toxicology and Pharmacology 71 (2015) 529\u2013540 Dr. Yasushi Hirasawa (Nihon Bioresearch Center) and Mrs. Chiharu Fukano (Torii Pharmaceutical Co. Ltd) for expert technical assis- tance, and Mr. Goro Ito (Torii Pharmaceutical Co. Ltd) for useful discussion. The authors also express gratitude to Professor Akiyoshi Fukamizu (University of Tsukuba) for his critical reading of the manuscript. 4 Discussion 5 Conclusion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-superabsorbent-baby_2009_Regulatory-Toxicology-and-Phar.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18992296", "content": {"CoiStatement": "88 K. Kosemund et al. / Regulatory Toxicology and Pharmacology 53 (2009) 81\u201389 Conflict of interest statement The authors are employees of Procter & Gamble. New Material Testing material testing and Clinical Studiesclinical studies Accidental Ingestioningestion Scientific review In-Market MonitoringIn-market monitoring Conclusion Conflict of Interest Statementinterest statement Acknowledgments References", "Acknowledgement": "Acknowledgments The authors thank Dr. Ralf Adam for his contributions to the safety assessment program. Lisa Bosch assisted in the preparation of this manuscript. New Material Testing material testing and Clinical Studiesclinical studies Accidental Ingestioningestion Scientific review In-Market MonitoringIn-market monitoring Conclusion Conflict of Interest Statementinterest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-supratherapeutic-dose-of-Maytenus-il_2017_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28889966", "content": {"CoiStatement": "Conflict of interest The authors have declared that there is no conflict of interest associated with this publication. The authors have declared that there is no conflict of interest associated with this publication. Transparency document 4. Discussion Acknowledgments Conflict of interest Transparency document References", "Acknowledgement": "Acknowledgments The financial supports from PIIC/URI, CAPES and CNPq are gratefully acknowledged. 4. Discussion Acknowledgments Conflict of interest Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-the-double-mutant-5-enol-pyruvylshiki_2009_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19303906", "content": {"Acknowledgement": "Risk is defined as hazard (or inherent toxicity) of a product and exposure to the product. By using the step-wise, evidence- based and weight of evidence approach, the hazard is near zero in the case of the 2mEPSPS protein. Zea mays, source of the gene, has a good history of safe use. The 2mEPSPS protein is not toxic for mammals and do not possess any of the characteristics asso- ciated with food allergens. Therefore, it can be concluded that there is no expected risk associated with 2mEPSPS protein consumption. Acknowledgments The authors would like to thank Agn\u00e8s Arnaud, Nadine Bautso- ens, Chuck Haas, B\u00e9n\u00e9dicte Labory-Carcenac, St\u00e9phane Lebas, Dim- itri Tack, Robert-Jan van der Klis, and Ann Vanhooren for their excellent technical assistance. The authors would like to extend their gratitude to Dr. Bernhard Weingaertner and his team for the assistance in the production of the 2mEPSPS protein. They also thank Dr. Regina Oberd\u00f6rfer for her scientific support with regard to the nutritional data used for calculating the safety factor. Discussion Conclusion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-the-human-identical-milk-_2015_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25728407", "content": {"CoiStatement": "4 Discussion Conflict of interest Appendix A Supplementary data References", "Compliance with ethical standards": "OECD, 1998a. OECD Series on principles of good laboratory practice and compliance monitoring. Number 1. Organization for Economic Co-operation and Development (OECD). <http://search.oecd.org/officialdocuments/ displaydocumentpdf/?cote=env/mc/chem(98)17&doclanguage=en>. OECD, 1998b. Repeated dose 90-day oral toxicity study in rodents. In: OECD Guidelines for the Testing of Chemicals. Organisation for Economic Co- operation and Development (OECD), Paris, France. OECD Guideline no 408 [Adopted 21st September 1998]. <http://www.oecd-ilibrary.org/environment/test- no-408-repeated-dose-90-day-oral-toxicity-study-in-rodents_9789264070707-en; jsessionid=1m6bvwspup322.delta>."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-the-human-identical-milk-monosacc_2014_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25111575", "content": {"CoiStatement": "In conclusion, the results of the 13-week dietary toxicity study with an in utero phase, together with the negative mutagenicity and genotoxicity results, would support the safety of HiMM Neu5Ac for addition to infant formula and for dietary consumption in humans, at levels representing natural intake from human breast milk in infants. Conflict of interest The authors Sharon S.H. Choi, Nigel Baldwin, Jennifer Rose, Bjorn A. Thorsrud, Phoukham Phothirath have nothing to disclose. Valentine Wagner reports other from BioReliance Corporation, dur- ing the conduct of the study. Shambhu Roy reports other from BioReliance Corporation, during the conduct of the study. Chris- toph H. R\u00f6hrig has no relevant interests to declare other than his affiliation with Glycom A/S. Glycom A/S produces human-identical milk saccharides. Appendix A. Supplementary data 4 Discussion Conflict of interest Appendix A Supplementary data References", "Compliance with ethical standards": "OECD, 1998a. OECD Series on principles of good laboratory practice and compliance monitoring. Number 1. Organization for Economic Co-operation and Development (OECD). <http://search.oecd.org/officialdocuments/ displaydocumentpdf/?cote=env/mc/chem(98)17&doclanguage=en>. OECD, 1998b. Repeated dose 90-day oral toxicity study in rodents. In: OECD Guidelines for the Testing of Chemicals. Organisation for Economic Co- operation and Development (OECD). Paris, France. OECD Guideline No. 408. <http://www.oecd-ilibrary.org/environment/test-no-408-repeated-dose-90- day-oral-toxicity-study-in-rodents_9789264070707-en;jsessionid=1m6bvwspup 322.delta> (adopted 21.09.1998)"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-the-oils-extracted-from-edible-in_2019_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30611818", "content": {"Funding": "Funding sources This work was supported by the Funda\u00e7\u00e3o de Apoio ao Desenvolvimento do Ensino, Ci\u00eancia e Tecnologia do Estado de Mato Grosso do Sul (FUNDECT) for the scholarship assistance; the Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico (CNPq); the Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior (CAPES); and the Federal University of Grande Dourados (UFGD). Conclusions Funding sources Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-the-phosphinothricin-acetyltransferas_2005_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15698537", "content": {"Compliance with ethical standards": "FDA (Food and Drug Administration), 1987. Guideline on validation of the Limulus Amebocyte Lysate as an end-product endotoxin test for human and animal parenteral drugs, biological products, and medical devices. Division of manufacturing and product quality (HFN-320), OYce of Compliance, Center for Drug Evaluation and Research, Rockville. FDA, 1992. Statement of policy: foods derived from new plant varie- ties. Federal Register, 57, 22984."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-traces-of-nickel-and-chrome-_2015_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26496819", "content": {"Acknowledgement": "Acknowledgments Geological Survey: Dr. Moshe Shirav, Dr. Olga Yoffe, Yevgeni Zakon. 4. Discussion 5. Conclusions Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-two---amylase-enzyme-preparations-d_2018_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30048706", "content": {"Acknowledgement": "Our inclusion of the WB enzyme preparation in the toxicological studies in parallel to the classic food-grade UFC enzyme preparation was to rule out any safety concerns regarding whole-broth enzyme preparations that contain cell debris and rDNA from the production organism. It is widely known that whole-broth enzyme preparations are used in enzyme applications where the finished food product is sub- jected to further processing that will remove the cell debris, such as it is the case in the distillation process to produce potable alcohol. However, there is nothing inherently unsafe about using WB enzyme preparations (containing dell debris and rDNA) in food, as there is nothing inherently unsafe about rDNA unless it encodes for a harmful substance or would easily transfer resistance to an antibiotic of clinical relevance to humans or animals. \u03b1-Amylase is not a harmful substance and the chlor- amphenicol resistance marker (endogenous to B. licheniformis) has been used safely for decades; it is used only in initial strain selection and does not reside on a plasmid that is easily mobilized or transferred. The safety of the resulting enzyme preparation is further illustrated by the current toxicology results. Obviously, such generalization is predicated upon both UFC and WB enzyme preparations being manufactured using the same appropriate raw materials of suitable purity for the intended use per Good Manufacturing Practices, i.e.minimum amounts needed to achieve desired effect (Sewalt et al., 2016). In addition, once the manufacturing process is completed, an evaluation for microbial and chemical contaminants is performed (per the Food Chemical Codex (US Pharmacopeia, 2018) and FAO/WHO's Joint Evaluation Committee for Food Additives (JECFA, 2006), and only then is the final enzyme pre- paration product (WB or UFC) released. Furthermore, for both Quality and Intellectual Property (IP) protection reasons, enzyme manu- facturers further evaluate the final enzyme product to make sure that they are free of the active production organism. In addition to the food applications previously mentioned, the C16F \u03b1-amylase enzyme preparation (WB and UFC) is also intended for use in fermentables e.g., potable alcohol with resulting distillers' grains (DG) and organic/amino acids for use in animal feed. Similarly, use in wet milling (WM) results in WM co-products, corn gluten feed and corn gluten meal, both of which are used in animal feed as well at inclusion rates no higher than DG. Using the NOAEL derived from the 90-day oral toxicity test with C16F alpha amylase (either UFC or WB), it was cal- culated that exposure to animals via DG or WM co-products is of no safety concern as the safety margin is greater than 100 (see Tables 3 and 4). The proposed uses of C16F \u03b1-amylase in potable alcohol at the proposed application rate of 6.2 mg protein/kg starch for UFC and 27mg protein/kg starch for WB, respectively, are not a human health concern and are supported by existing toxicological data. Finally, even under the worst-case scenario that C16F \u03b1-amylase is applied at the maximum rate for both UFC and WB and the enzyme is not destroyed and/or removed during processing, the use of C16F \u03b1-amylase in the manufacture of lysine to be used as a feed additive is toxicologically insignificant. We conclude C16F synthetic variant Cytophaga sp. \u03b1-amylase ex- pressed in B. licheniformis in either clarified or whole-broth format is safe in the manufacture of ethanol or wet milling co-products and amino acids, without health concern to animals consuming the co- products or amino acids and to humans consuming the potable alcohol, as substantiated by existing toxicology data. Acknowledgement We thank Gregory Ladics and Kees Broekhuizen for their critical review of toxicology conclusions and strain details, respectively. In addition, we thank Sanusha Bijj for her skillful assistance in preparing the Supplemental Data Tables. Appendix A. Supplementary data Supplementary data related to this article can be found at https:// doi.org/10.1016/j.yrtph.2018.07.015. Transparency document Transparency document related to this article can be found online at https://doi.org/10.1016/j.yrtph.2018.07.015. References Ames, B.N., McCann, J., Yamasaki, E., 1975. Methods for detecting carcinogens and mutagens with the Salmonella/Mammalian microsome mutagenicity test. Mutat. Res. 31, 347\u2013364. Association of American Feed Control Officials (AAFCO), 2018. 2018 AAFCO Official Publication, pp. 373\u2013378. Aunstrup, K., 1979. Production, isolation, and economics of extracellular enzymes. In: In: Wingard, L.B., Katchalski-Katzir, E., Golsdstein, L. (Eds.), Applied Biochemistry and Bioengineering, vol. 2. Enzyme Technology, pp. 28\u201368. Aunstrup, K., Andersen, O., Falch, E.A., Nielsen, T.K., 1979. In: second ed. In: Peppler, H.J., Perlman, D. (Eds.), Production of Microbial Enzymes in Microbial Technologypp. 282\u2013309 Chapter 9, 1. BioReliance, 2014a. H-30928: Bacterial Reverse Mutation Assay. Report No. AD84GN.507001.BTL. BioReliance, 2014b. H-30929: Bacterial Reverse Mutation Assay. Report No. AD84GP.507001.BTL. Carson, J., Schmidtke, L.M., Munday, B.L., 1993. Cytophaga johnsonae: a putative skin Table 6 Margin of Safety Calculation for C16F \u03b1-amylase WB via DGa. Cattle Pigs Poultry Maximum enzyme use rate (mg TOS/kg DM) 42.4 42.4 42.4 Fold-concentration in DG, DM basis (process dependent) 3 3 3 Maximum Enzyme TOS concentration in DG (mg/kg DM) 127 127 127 Maximum Inclusion rate of DG in complete animal ration 0.6 0.5 0.3 Maximum Enzyme TOS concentration in feed (mg/kg DM) 76 64 38 Maximum Daily feed intake (kg DM/kg BW) 0.03 0.045 0.065 Maximum intake of enzyme TOS (mg/kg BW) 2.3 2.8 2.5 NOAEL (mg TOS/kg bw/day) 500 500 500 Margin of safety 219 175 202 a Same calculations apply to WM-coproducts. V.J. Sewalt et al. Regulatory Toxicology and Pharmacology 98 (2018) 140\u2013150 149 https://doi.org/10.1016/j.yrtph.2018.07.015 https://doi.org/10.1016/j.yrtph.2018.07.015 https://doi.org/10.1016/j.yrtph.2018.07.015 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref1 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref1 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref1 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref3 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref3 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref3 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref4 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref4 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref4 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref5 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref5 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref6 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref6 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref7 pathogen of juvenile farmed barramundi. Lates calcarifer Bloch. J. Fish Dis 16, 209\u2013218. Codex Alimentarius Commission, 2009. Joint FAO/WHO Food Standards Programme. Codex Alimentarius Commission, Rome, Italy. Cooney, R.P., Pantos, O., Le Tissier, M.D.A., Barer, M.R., O'Donnell, A.G., Bythell, J.C., 2002. Characterization of the bacterial consortium associated with black band dis- ease in coral using molecular microbiological techniques. Environ. Microbiol. 7, 401\u2013413. Dalsgaard, I., 1993. Virulence mechanisms in Cytophaga psychrophila and other Cytophaga-like bacteria pathogenic for fish. Annu. Rev. Fish Dis. 3, 127\u2013144. De Boer, A.S., Diderichsen, B., 1994. On the industrial use of B. licheniformis: a Review. Appl. Microbiol. Biotechol 40, 595\u2013598. Douglass, J.S., Barraj, L.M., Tennant, D.R., Long, W.R., Chaisson, C.F., 1997. Evaluation of the budget method for screening food additive intakes. Food Addit. Contam 14, 791\u2013802. DuPont Haskell Global Centers, 2014a. H-30928: Level 10 C16F Whole Broth: in Vitro Mammalian Chromosome Aberration Test in Human Peripheral Blood Lymphocytes. Report No. 20557\u2013544. Dupont Haskell Global Centers, 2014b. H-30929: Level 10 C16F Clarified: in Vitro Mammalian Chromosome Aberration Test in Human Peripheral Blood Lymphocytes. Report No. 20558\u2013544. Durborow, R.M., Thune, R., Hawke, J.P., Camus, C., 1998. Columnaris Disease, a Bacterial Infection Caused by Flavobacterium Columnare. Southern Regional Aquaculture Center, USA Publication No. 479. https://appliedecology.cals.ncsu.edu/ wp-content/uploads/479.pdf. Environmental Protection Agency (EPA), 1997. Attachment I\u2014final Risk Assessment of Bacillus Licheniformis. https://www.epa.gov/sites/production/files/2015-09/ documents/fra005.pdf. Fisher, R.A., 1985. Statistical Methods for Research Workers, thirteenth ed. Haffner, New York. Green, M.H.L., Muriel, W.J., 1976. Mutagen testing using trp+ reversion in Escherichia coli. Mutat. Res. 38, 3\u201332. Gryczan, T., Shivakumar, A.G., Dubnau, D., 1980. Characterization of chimeric plasmid cloning vehicles in Bacillus subtilis. J. Bacteriol. 141, 246\u2013253. Gupta, R., Gigras, P., Mohapatra, H., Goswami, V.K., Chauhan, B., 2003. Microbial \u03b1- amylase s: a biotechnological perspective. Process Biochem. 38, 1599\u20131616. Guzman-Maldonado, H., Paredes-Lopez, O., 1995. Amylolytic enzymes and products derived from starch: a review. Crit. Rev. Food Sci. Nutr. 35, 373\u2013403. International Food Biotechnology Council (IFBC), 1990. Safety evaluation of foods and food ingredients derived from microorganisms. Biotechnologies and Food: Assuring the Safety of Foods Produced by Genetic Modification. Regul. Toxicol. Pharmacol, vol. 12. pp. S114\u2013S128. Jane\u010dek, S., 1994. Sequence similarities and evolutionary relationships of microbial, plant and animal \u03b1-amylases. Eur. J. Biochem. 2, 519\u2013524. Jane\u010dek, S., 1997. \u03b1-amylase family: molecular biology and evolution. Prog. Biophys. Mol. Biol. 67, 67\u201397. JECFA, 2006. General specifications and considerations for enzyme preparations used in food processing. In: Compendium of Food Additive Specifications, Volume 4. Analytical Methods, Test Procedures and Laboratory Solutions Used by and Referenced in the Food Additive Specifications. FAO/WHO JECFA, Monographs 1. Rome pp. xxi-xxv. Jeang, C.L., Lee, Y.H., Chang, L.W., 1995. Purification and characterization of a raw- starch digesting amylase from a soil bacterium Cytophaga sp. Biochem. Mol. Biol. Int. 35, 549\u2013551. Jeang, C.L., Chen, L.S., Chen, M.Y., Shiau, R.J., 2002. Cloning of a gene encoding raw- starch-digesting amylase from a Cytophaga sp. and its expression in Escherichia coli. Appl. Environ. Microbiol. 68, 3651\u20133654. Jonas, D.A., Antignac, E., Antoine, J.M., Classen, H.G., Huggett, A., Knudsen, I., Mahler, J., Ockhuizen, T., Smith, M., Teuber, M., Walker, R., de Vogel, P., 1996. The safety assessment of novel foods. Guidelines prepared by ILSI Europe Novel Food Task Force. Food Chem. Toxicol. 34, 931\u2013940. Kirchman, D.L., 2002. The ecology of Cytophaga\u2013Flavobacteria in aquatic environments. FEMS Microbiol. Ecol. 39, 91\u2013100. Kroschwitz, J.I., 1994. fourth ed. Enzyme Applications in Encyclopedia of Chemical Technology, vol. 9. pp. 567\u2013620. Ladics, G.S., Cressman, R.F., Herouet-Guicheney, C., Herman, R.A., Privalle, L., Song, P., Ward, J.M., McLain, S., 2011. Bioinformatics and the allergy assessment of agri- cultural biotechnology products: industry practices and recommendations. Regul. Toxicol. Pharmacol. 60, 46\u201353. Lee, S., Mouri, Y., Minoda, M., Oneda, H., Inouye, K., 2006. Comparison of the wild-type \u03b1-amylase and its variant enzymes in Bacillus amyloliquefaciens in activity and thermal stability, and insights into engineering the thermal stability of Bacillus \u03b1- amylase. J. Biochem. 139, 1007\u20131015. Li, Y., Fang, Z., Dai, J., Partridge, G., Ruc, Y., Penga, J., 2010. Corn extrusion and enzyme addition improves digestibility of corn/soy based diets by pigs: In vitro and in vivo studies. Anim. Feed Sci. Technol. 158, 146\u2013154. Mayberger, J.M., 2011. Studies of genera Cytophaga-Flavobacterium in context of the soil carbon cycle. Diss. Abstr. Int. 73, 1\u2013115. Magrane, M., the UniProt consortium, 2011. UniProt Knowledgebase: a Hub of Integrated Protein Data. Database, 2011: bar009 2011. https://doi.org/10.1093/database/ bar009. MPI Research, 2014a. H-30928: Level 10 C16F Whole Broth: Sub-chronic Toxicity 90 Day Oral Gavage Study in Rats. Report No. 125\u2013181. MPI Research, 2014b. H-30929: Subchronic Toxicity 90 Day Oral Gavage Study in Rats. Report No. 125\u2013180. NRC (National Research Council), 1994. Nutrient Requirements of Poultry, 9th Revised Edition. National Academy Press. NRC, 1998. Nutrient Requirements of Swine, 10th Revised Edition. National Academy Press. OECD, 1998. Test No. 408: repeated dose 90-day oral toxicity study in rodents. In: OECD Guidelines for the Testing of Chemicals, Section 4. OECD Publishing, Paris. OECD, 1997a. Test No. 471: bacterial reverse mutation test. In: OECD Guidelines for the Testing of Chemicals, Section 4. OECD Publishing, Paris. OECD, 1997b. Test No. 473: in vitro mammalian chromosome aberration test. In: OECD Guidelines for the Testing of Chemicals, Section 4. OECD Publishing, Paris. Olempska-Beer, Z.S., Merker, R.I., Ditto, M.D., DiNovi, M.J., 2006. Food-processing en- zymes from recombinant microorganisms\u2014a review. Regul. Toxicol. Pharmacol. 45, 144\u2013158. Pandey, A., Poonam, N., Soccol, C.R., Soccol, V.T., Singh, D., Radjiskumar, M., 2000. Advances in microbial amylases. Biotechnol. Appl. Biochem. 31, 135\u2013152. Pariza, M.W., Johnson, E.A., 2001. Evaluating the safety of microbial enzyme prepara- tions used in food processing: update for a new century. Regul. Toxicol. Pharmacol. 33, 173\u2013186. Pariza, M.W., Foster, E.M., 1983. Determining the safety of enzymes used in food pro- cessing. J. Food Prot 46, 453\u2013468. Pariza, M.W., Cook, M., 2010. Determining the safety of enzymes used in animal feed. Regul. Toxicol. Pharmacol. 3, 332\u2013342. Romero, L.F., Parsons, C.M., Utterback, P.L., Plumstead, P.W., Ravindran, V., 2013. Comparative effects of dietary carbohydrases without or with protease on the ileal digestibility of energy and amino acids and AMEn in young broilers. Anim. Feed Sci. Technol. 181, 35\u201344. Rottman, R.W., Francis-Floyd, R., Durborow, R., 1992. The Role of Stress in Fish Disease. Southern Regional Aquaculture Center Publication 474, Mississippi State Univ. MS. Snedecor, G.W., Cochran, W.G., 1967. Statistical Methods. pp. 246\u2013248 and 349-352. sixth ed. The Iowa State University Press, Ames, Iowa. Scientific Committee for Food (SCF), 1992. Guidelines for the Presentation of Data on Food Enzymes, 27th Series. pp. 13\u201322 Ref. No. EUR 14181 EN. Sewalt, V., Shanahan, D., Gregg, L., La Marta, J., Carrillo, R., 2016. The generally re- cognized as safe (GRAS) process for industrial microbial enzymes. Ind. Biotechnol. 12 (5), 295\u2013302. Sewalt, V., LaMarta, J., Shanahan, D., Gregg, L., Carrillo, R., 2017. Letter to the editor regarding \u201cGRAS from the ground up: review of the Interim Pilot Program for GRAS notification\u201d by Hanlon et al., 2017. Food Chem. Toxicol. 105, 140\u2013150. Soltani, M., Shanker, S., Munday, B.L., 1995. Chemotherapy of Cytophaga/Flexibacter-like bacteria (CFLB) infections in fish: studies validating clinical efficacies of selected antimicrobials. J. Fish. Dis. 18, 555\u2013565. U.S. Pharmacopeia, 2018. Enzyme preparations. In: Food Chemicals Codex, eleventh ed. pp. 413\u2013419 Washington, D.C. van der Kaaij, R.M., Jane\u010dek, M.J., van der Maarel, E.C., Dijkhuizen, L., 2007. Phylogenetic and biochemical characterization of a novel cluster of intracellular fungal a-amylase enzymes. Microbiol. 153, 4003\u20134015. Wang, C., Liu, Y.M., Wang, Z.Q., Yang, J.X., Liu, Y.M., Wu, T., Yan, Ye, H.W., 2010. Effects of dietary supplementation of methionine and lysine on milk production and nitrogen utilization in dairy cows. J. Dairy Sci. 93, 3661\u20133670. Yuuki, T., Nomura, T., Tezuka, H., Tsuboi, A., Yamagata, H., Tsukagoshi, N., Udaka, S., 1985. Complete nucleotide sequence of a gene coding for heat- and pH-stable \u03b1- amylase of Bacillus licheniformis: comparison of the amino acid sequences of three bacterial liquefying \u03b1-amylase s deduced from the DNA sequences. J. Biochem. 98, 1147\u20131156. V.J. Sewalt et al. Regulatory Toxicology and Pharmacology 98 (2018) 140\u2013150 150 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref7 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref7 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref8 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref8 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref9 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref9 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref9 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref9 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref10 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref10 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref11 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref11 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref12 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref12 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref12 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref13 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref13 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref13 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref14 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref14 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref14 https://appliedecology.cals.ncsu.edu/wp-content/uploads/479.pdf https://appliedecology.cals.ncsu.edu/wp-content/uploads/479.pdf https://www.epa.gov/sites/production/files/2015-09/documents/fra005.pdf https://www.epa.gov/sites/production/files/2015-09/documents/fra005.pdf http://refhub.elsevier.com/S0273-2300(18)30199-5/sref17 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref17 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref18 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref18 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref19 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref19 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref20 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref20 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref21 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref21 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref22 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref22 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref22 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref22 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref23 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref23 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref24 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref24 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref25 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref25 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref25 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref25 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref25 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref26 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref26 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref26 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref27 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref27 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref27 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref28 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref28 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref28 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref28 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref29 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref29 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref30 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref30 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref31 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref31 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref31 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref31 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref32 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref32 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref32 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref32 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref33 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref33 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref33 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref34 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref34 https://doi.org/10.1093/database/bar009 https://doi.org/10.1093/database/bar009 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref36 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref36 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref37 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref37 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref38 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref38 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref39 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref39 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref40 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref40 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref41 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref41 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref42 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref42 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref43 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref43 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref43 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref44 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref44 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref45 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref45 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref45 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref46 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref46 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref47 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref47 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref48 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref48 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref48 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref48 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref49 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref49 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref50 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref50 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref51 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref51 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref52 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref52 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref52 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref53 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref53 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref53 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref54 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref54 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref54 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref55 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref55 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref56 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref56 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref56 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref57 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref57 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref57 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref58 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref58 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref58 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref58 http://refhub.elsevier.com/S0273-2300(18)30199-5/sref58 Safety evaluation of two \u03b1-amylase enzyme preparations derived from Bacillus licheniformis expressing an \u03b1-amylase gene from Cytophaga species Introduction Development of the production strain of Bacillus licheniformis (C16F) Materials and methods Test material preparation and characterization Experimental design Oral administration test (90-day oral gavage study) Statistical analysis In vitro mammalian chromosomal aberration test performed with human lymphocytes Statistical analysis Bacterial reverse mutation assays Data analysis Sequence screening for food allergy potential and homology to protein toxins Food allergens Toxins Results Oral administration tests (90-day oral gavage study) Genetic toxicology studies Bacterial reverse mutation assay In-vitro chromosomal aberration assay-human lymphocytes Chromosomal aberration assay - WB test material UFC test material Sequence-based assessment of food allergenicity potential and similarity to toxin proteins Discussion Safety of the production organism Safe strain lineage- use of B. licheniformis and Cytophaga \u2013 Pariza decision tree Uses and applications Human exposure to C16F amylase &#x200B;&&#x200B; margin of safety Animal exposure to C16F \u03b1-amylase C16F \u03b1-amylase in the production of lysine for use in animal feed Conclusions Acknowledgement Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-water-extract-of-Gastrodia-elat_2020_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32278877", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. Conclusion Funding body information Declaration of competing interest Acknowledgements Supplementary data References", "Funding": "Funding body information This study was supported in part by grants from the Ministry of Science and Technology (MOST 104-2320-B-002-036-MY3 and 107- 2320-B-002-022-MY3) and the Taipei City Hospital (10701-62-068), Taiwan. The funding sources were not involved in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. This study was supported in part by grants from the Ministry of Science and Technology (MOST 104-2320-B-002-036-MY3 and 107- 2320-B-002-022-MY3) and the Taipei City Hospital (10701-62-068), Taiwan. The funding sources were not involved in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. Declaration of competing interest Conclusion Funding body information Declaration of competing interest Acknowledgements Supplementary data References", "Acknowledgement": "Acknowledgements The authors would like to thank Prof. Fu-Chuo Peng for the tech- nical support on genotoxicity study and Prof. Jiunn-Wang Liao for the histopathological analysis. Conclusion Funding body information Declaration of competing interest Acknowledgements Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-water-soluble-palm-fr_2017_Regulatory-Toxicology-and-Ph.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28583666", "content": {"Compliance with ethical standards": "OECD, 1998a. OECD Series on principles of good laboratory practice and compliance monitoring. Number 1. Organ. Econ. Co-operation Dev. (OECD). http://search. oecd.org/officialdocuments/displaydocumentpdf/?cote\u00bcenv/mc/chem(98) 17&doclanguage\u00bcen. OECD, 1998b. Repeated dose 90-day oral toxicity study in rodents. In: OECD Guidelines for the Testing of Chemicals. Organisation for Economic Co- operation and Development (OECD). Paris, France. OECD Guideline no 408 [Adopted 21st September 1998]. http://www.oecd-ilibrary.org/environment/ test-no-408-repeated-dose-90-day-oral-toxicity-study-in-rodents_ 9789264070707-en;jsessionid\u00bc1m6bvwspup322.delta."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-of-xylanase-50316-enzyme-preparation--_2018_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29857114", "content": {"CoiStatement": "Conflicts of interest Roxanna Van Dorn and Diane Shanahan are employed by BASF Enzymes LLC, the study Sponsor. Vince Ciofalo is a paid consultant by BASF Enzymes LLC in matters of toxicology. BASF Enzymes LLC and Novus International, Inc. financially supported this project including the writing of this manuscript and paying third party costs. Third party toxicology labs were paid to execute the toxicology studies, collect, analyze, and interpret data. Discussion Conclusion Conflicts of interest Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-to-support-First-In-Man-investiga_2008_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18501489", "content": {"Compliance with ethical standards": "From examination of information in the IBs reviewed, study compliance was variable for kinetic studies. Thus, the range of in vitro and in vivo studies performed were either Good Laboratory Practice (GLP) certified or not, or were a mixture of GLP and non-GLP studies. Some studies were performed in GLP laboratories but the study report did not undergo full quality assurance review and sign-off. In con- trast, and in line with regulatory guidance (ICH, S7A; ICH, S7B), all key safety phar- macology studies were performed to GLP. 3. Results"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-evaluation-to-support-first-in-man-invest_2008_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18501490", "content": {"Compliance with ethical standards": "Other than with the 2 proteins (which would not be expected to be genotoxic), all study packages had 2 in vitro assays (a reverse mutation bacteria and either a chromosome aberration or mouse lymphoma assay) to support FIM work which is in compliance with current guidance (ICH, S2A; ICH, S2B). For these latter studies, the chromosome aberration assay using cultured human peripheral blood lymphocytes was the most common option. The majority of studies gave a negative result, although a positive finding was found in 7 of the mammalian cell assays. Interestingly, although not needed for human volunteer studies (ICH, S2B), the majority of study packages had an in vivo bone marrow micronucleus test (most commonly in the rat) as well as the 2 in vitro studies (even when both these studies were negative). Presumably, companies wish to perform this study early to avoid any delay in starting studies in patients, as required under current regulatory guidance (ICH, S2B). In cases in which a positive in vitro result was seen, a second in vivo study was performed (usually the rat liver micronu- cleus or unscheduled DNA synthesis test) in compliance with cur- rent guidance (ICH, S2A). In recent years, the approach of backing up equivocal or real genotoxicity results with appropriate studies and a human risk assessment before commencing with clinical trial investigations has been further clarified (CDER, 2006b). Such an approach is important as positive genotoxicity results do occur but do not necessarily \u2018\u2018kill\u201d a drug. In the present evaluation, 2/7 positive mammalian cell assay results were not surprising given that drugs in question were nucleoside anti-virals, which are known to be clastogenic. Indeed, the hepatitis B drug entecavir has been shown to be clastogenic to human lymphocyte cultures (at concentrations substantially higher than those achieved clini- cally) but was negative in other in vitro and in vivo genotoxicity as- says (SPC, 2008). In a review of 352 drugs marketed in the USA, 29% had a least one positive finding (Snyder and Green, 2001). How- ever, there is a current worry about the number of false-positive results (e.g., due to solubility or cytotoxicity issues) seen with in vitro mammalian cell assays. In a recent interrogation of pub- lished data (using a database of over 700 chemicals), sensitivity to predict rodent carcinogenicity responses of 59%, 66% and 73% for the Ames, chromosome aberration and mouse lymphoma as- says, respectively, were shown compared to specificity of 74, 45% and 39%, respectively (Kirkland et al., 2005). The study authors sta- ted that specificity levels of <50% are unacceptable for prediction of carcinogenic profiles for new drugs. Indeed, a reassessment of the conditions and criteria for positive results and/or the development and use of new in vitro tests were proposed. Thus in the future, a different pattern of genotoxicity may occur compared to that found in the present evaluation (a new set of in vitro assays or even an Ames test only plus 2 in vivo tests?). 5. Conclusion A review of study packages to support 34 FIM clinical trials over a period from 1997 to 2006 showed similarity among general and genotoxicity studies performed. Thus for toxicology, packages had single dose studies in the rodent as well as range-finding and key 2\u20134 week repeat dose studies in the rodent and non-rodent. Over the years, there has been a gradual reduction in the number of sin- gle dose toxicity studies performed and recent packages reviewed commonly had such studies only in the rat by an oral and paren- teral route or by the oral route only. A recent drive has been to re- move these studies out of early development altogether. Range- finding studies have often had a similar design among packages for the rodent but a number of different study designs have been used for the non-rodent. A surprising finding in the dataset exam- ined was that dogs and monkeys were equally common as the non- rodent species (probably an unfortunate result from the packages reviewed as the dog is the usual non-rodent); a common feature has been low numbers of animals used in these studies. A great deal of consistency was seen in the pivotal repeat dose toxicity study designs with the establishment of NOAELs for both species in the majority of packages. The rodent was shown to be less sen- sitive to target organ toxicity than the non-rodent. It was found that a range of target organ toxicities (at higher dose levels) did not prevent the 34 drugs examined entering the clinic; the liver and then the kidney were seen as the most common target organs. Genotoxicity assessment included 2 in vitro assays (a reverse mutation bacteria and either a chromosome aberration or mouse lymphoma assay). Although not needed for human volunteer stud- ies when in vitro data are negative, the majority of study packages had an in vivo rodent bone marrow micronucleus test) as well as the 2 in vitro studies perhaps to avoid any delay in starting studies in patients for which this study is needed. A second in vivo study was performed if a positive result was seen in the miconucleus study. Although the genotoxicity battery has not changed much over the period reviewed in the present evaluation, the robustness and utility of the current package as it stands (especially due to in vitro false-positives) is being questioned and may alter in the near future."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-investigation-on-total-steroid-saponins-extracts-_2017_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29066336", "content": {"CoiStatement": "Conflicts of interest The authors confirm that there are no known conflicts of interest associated with this publication and there has been no significant fi- nancial support for this work that could have influenced its outcome. The authors confirm that there are no known conflicts of interest associated with this publication and there has been no significant fi- nancial support for this work that could have influenced its outcome. Acknowledgements Discussion Conclusions Conflicts of interest Acknowledgements Transparency document References", "Acknowledgement": "Acknowledgements This study was financially supported by the National Natural Science Foundation of China (No. 81603267), the Fundamental Research Funds for the Central Universities, China Postdoctoral Science Foundation (First-class, No. 2016M590958), Scientific Research Supporting Project for New Teacher of Xi'an Jiaotong University (No. 1191320023), Natural Science Foundation of Shaanxi Province (No. 2015JQ2048, No. 2016JM8075 and No. 2017JQ8017), the Open Projects Program of the Key Laboratory of Tibetan Medicine Research, Chinese Academy of Sciences, Qinghai Province (No. 2017-002), and Shaanxi Health and Family Planning Commission (No. 2016D089). Discussion Conclusions Conflicts of interest Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-of-high-doses-of-Propionibacterium-freudenr_2011_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21172397", "content": {"CoiStatement": "Conflict of interest statement The authors of this publication have declared that they have no conflicts of interest. Funding sources statement The authors of this publication have declared that they have no conflicts of interest. Funding sources statement Funding for the research and preparation of this publication was provided by Meiji Dairies Corporation. Discussion Conflict of interest statement Funding sources statement References", "Funding": "The authors of this publication have declared that they have no conflicts of interest. Funding sources statement Funding for the research and preparation of this publication was provided by Meiji Dairies Corporation. Funding for the research and preparation of this publication was provided by Meiji Dairies Corporation. References Discussion Conflict of interest statement Funding sources statement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-of-medicinal-comfrey-cream-preparations--Symphytum_2020_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32941922", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Mathias Schmidt has in the past provided scientific and regulatory consultancy to the manufacturer of the comfrey cream. Kenny Kuchta has no competing interests. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Mathias Schmidt has in the past provided scientific and regulatory consultancy to the manufacturer of the comfrey cream. Kenny Kuchta has no competing interests. Acknowledgements 3 Results 4 Discussion and conclusions Funding Declaration of competing interest Acknowledgements References", "Funding": "Funding The study was funded by Gehrlicher Pharmazeutische Extrakte GmbH. The work in Go\u0308ttingen is supported by the \u201cFo\u0308rderkreis der Forschungsstelle f\u00fcr Ferno\u0308stliche Medizin\". 3 Results 4 Discussion and conclusions Funding Declaration of competing interest Acknowledgements References", "Acknowledgement": "Acknowledgements The experimental part of the study was performed by ENVIGO, Alconbury, UK. 3 Results 4 Discussion and conclusions Funding Declaration of competing interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-of-the-Bacillus-thuringiensis-derived-Cry1A-105-_2018_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30196079", "content": {"Acknowledgement": "Acknowledgments The authors would like to thank Dr. Bin Chen and Geoffrey M. Mueller for equivalence study, Richard S. Thoma and Jing Berry for protein concentration and identity analyses, Dr. Ronald Hernan for heat stability studies, Robert Barlow and Brian E. Goertz for digestibilities, Dr. Bin Li, Janguo Tan and Debbie Mahadeo for critical reading of the manuscript. Conclusions Acknowledgments Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-profiling-of-pioglitazone-and-telmisartan-co_2016_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27569202", "content": {"Acknowledgement": "Acknowledgement We are grateful to the Ministry of Higher Education, Govt. of Malaysia for providing the financial support through their Funda- mental Research Grant Scheme (Ref: FRGS/2/2014/SKK02/LINCOLN/ 02/1). We are also grateful to Lincoln University College, Malaysia and International Islamic University Malaysia, Malaysia for providing the necessary facilities required for this research work. 4. Conclusion Acknowledgement Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-studies-conducted-on-a-proprietary-high-purit_2010_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20096744", "content": {"Compliance with ethical standards": "The disparate and incongruous results of previous studies led the authors to believe the problem may lie with test substances that included these pharmacologically potent anthraquinones. Therefore, we conducted a 90-day repeated dose study, as well as in vitro and in vivo genotoxicity studies, to investigate the poten- tial toxicity of a well-characterized and highly-purified inner leaf fillet preparation derived from A. vera (L.), derived from the muci- laginous fluid of parenchymal cells found in the inner central area of the aloe vera leaf (commonly referred to as aloe vera gel, inner leaf gel or inner leaf fillet), which has a very low level of anthraqui- nones. These studies were conducted in compliance with GLP and OECD guidelines. 2. Materials and methods 2.1. Test material"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-studies-of-LP20-powder-produced-from-heat-_2009_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19328216", "content": {"Compliance with ethical standards": "The study was conducted at Biosafety Research Center Foods, Drugs and Pesticides (Shizuoka, Japan) under non-Good Laboratory Practice (GLP) conditions, but in compliance with the Revised Guidelines for Single and Repeated Dose Toxicity Studies (Notifica- tion No. 88 of the Pharmaceuticals and Cosmetics Division, PAD da- ted August 10, 1993). 2.3. Genotoxicity studies All studies were conducted in compliance with \u2018\u2018Ordinance on Standards for Conduct of Nonclinical Studies on the Safety of Drugs\u201d.1 The genotoxicity studies comply with US Food and Drug Administration (2000) Redbook guidelines, which state that the \u2018\u2018recommended genetic toxicity test battery for food ingredients whose cumulative estimated daily intake exceeds 50 ppb in the diet (150 lg per person per day) generally includes: (a) a test for gene mutations in bacteria and (b) an in vitro test with cytogenetic evalu- ation of chromosomal damage using mammalian cells or an in vitro mouse lymphoma thymidine kinase+/\ufffd gene mutation assay. . . and (c) an in vivo test for chromosomal damage using mammalian hema- topoietic cells\u201d. All studies were conducted in compliance with \u2018\u2018Ordinance on Standards for Conduct of Nonclinical Studies on the Safety of Drugs\u201d.1 The genotoxicity studies comply with US Food and Drug Administration (2000) Redbook guidelines, which state that the \u2018\u2018recommended genetic toxicity test battery for food ingredients whose cumulative estimated daily intake exceeds 50 ppb in the diet (150 lg per person per day) generally includes: (a) a test for gene mutations in bacteria and (b) an in vitro test with cytogenetic evalu- ation of chromosomal damage using mammalian cells or an in vitro mouse lymphoma thymidine kinase+/\ufffd gene mutation assay. . . and (c) an in vivo test for chromosomal damage using mammalian hema- topoietic cells\u201d. All of the studies were conducted at Hashima Laboratory, Nihon Bioresearch, Inc., Japan. The study was conducted in general accor- dance with the principles of GLP; however, stability tests, confir- 1 \u2018\u2018Ordinance on Standards for Conduct of Nonclinical Studies on the Safety of Drugs\u201d Ministry of Health and Welfare Ordinance No. 21, Japan, March 26, 1997; \u2018\u2018Implementation of Ordinance on Standard for Conduct of Nonclinical Studies on the Safety of Drugs\u201d, Notification No. 424 of the Pharmaceutical Affairs Bureau, Ministry of Health and Welfare, Japan, March 27, 1997, and partial Amendment No. 0909001 of the Pharmaceutical and Food Safety Bureau, Ministry of Health, Labor and Welfare, Japan, September 9, 2005; \u2018\u2018On Guideline for Genotoxicity Studies on Drugs\u201d, Notification No. 1604 of the Pharmaceutical Affairs Bureau, Ministry of Health and Welfare, Japan, November 1, 1999. mation of concentration analyses, and characterization of the test article were either not to GLP standards or were not conducted."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-studies-of-l-alanyl-l-glutamine_2008_Regulatory-Toxicology-and-Pharma.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18082299", "content": {"Compliance with ethical standards": "The study was conducted in compliance with GLP (Japanese Ministry of Health and Welfare, 1997), study design and conduct (Japanese Minis- try of Health and Welfare, 1996, 1998, 1999), and animal welfare guidelines. 2.4. Ames test The Ames test was conducted in compliance with the UK and OECD GLP principles. 2.5. In vitro chromosome aberration assay The chromosome aberration test was conducted in compliance with the UK and OECD GLP principles. 3. Results"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-study-of-Ciprofloxacin-in-newbo_2016_Regulatory-Toxicology-and-Pharma.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26627140", "content": {"CoiStatement": "Conflicts of interest Boris Matrot, Estelle Durand and Jorge Gallego own or owned stocks of PhenoPups SAS at the time this work was conducted. Thomas Bourgeois, Anne-Lise Delezoide, Wei Zhao, Fabien Guimiot, Homa Adle-Biassette, Maud Ringot, Thomas Storme, Chantal Le Guellec, Behrouz Kassa\u00ef, Mark Turner and Evelyne Jacqz-Aigrain declare no conflict of interest related to this work. Boris Matrot, Estelle Durand and Jorge Gallego own or owned stocks of PhenoPups SAS at the time this work was conducted. Thomas Bourgeois, Anne-Lise Delezoide, Wei Zhao, Fabien Guimiot, Homa Adle-Biassette, Maud Ringot, Thomas Storme, Chantal Le Guellec, Behrouz Kassa\u00ef, Mark Turner and Evelyne Jacqz-Aigrain declare no conflict of interest related to this work. Funding sources statement 5. Conclusion Conflicts of interest Funding sources statement Appendix A. Supplementary data Transparency document References", "Funding": "Funding sources statement This work was supported by a grant from the Commission of the European Union 7th Framework Programme: TINN (Treat In- fections in Neonates), FP7-HEALTH-2007-B, N\ufffd 223614. Jacqz-Aigrain, E., 2011. Drug policy in Europe Research and funding in neonates: current challenges, future perspectives, new opportunities. Early Hum. Dev. 1 (87 Suppl. l), S27eS30. Kaguelidou, F., et al., 2011. Ciprofloxacin use in neonates: a systematic review of the literature. Pediatr. Infect. Dis. J. 30, e29e37. 5. Conclusion Conflicts of interest Funding sources statement Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Safety-testing-of-adult-novelties-using-in_2020_Regulatory-Toxicology-and-Ph.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32898621", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 3 Results 4 Discussion 5 Conclusion Declaration of competing interest Acknowledgement Appendix A Supplementary data References", "Acknowledgement": "Acknowledgement This work was supported by ERDF/ESF project \u201cInternational competitiveness of NIPH in research, development and education in alternative toxicological methods\u201d [CZ.02.1.01/0.0/0.0/16_019/ 0000860]. 3 Results 4 Discussion 5 Conclusion Declaration of competing interest Acknowledgement Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Saline-extract-of-Pilosocereus-gounellei-stem-has-antino_2018_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29626561", "content": {"CoiStatement": "Conflicts of interest The authors declare no conflict of interest. The authors declare no conflict of interest. References Results and discussion Conclusion Acknowledgments Supplementary data Conflicts of interest References", "Acknowledgement": "Acknowledgments The authors express their gratitude to the Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico (CNPq) for financial support (446902/2014-4) and investigator research grants (Patr\u00edcia Maria Guedes Paiva, Thiago Henrique Napole\u00e3o). We are also grateful to the Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior (CAPES) and the Funda\u00e7\u00e3o de Amparo \u00e0 Ci\u00eancia e Tecnologia do Estado de Pernambuco (FACEPE; APQ-0108-2.08/14; APQ- 0493-4.03/14; APQ-0661-2.08/15) for financial support. AMO would like to thank FACEPE (IBPG-0467-2.08/15) for graduate scholarship. Results and discussion Conclusion Acknowledgments Supplementary data Conflicts of interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Sameness--The-regulatory-crux-with-nanomaterial-ide_2015_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26049104", "content": {"CoiStatement": "In order to enrich the clouds with test strategies, research on MOA and AOP should have high priority. MOA and AOP explain the toxicity of nanomaterials and the interplay of physico-chemical properties with kinetics and toxicities. As a con- sequence, the concept of the clouds can lead to targeted quantita- tive assessments of human toxicity and in parallel allows saving resources \u2013 or investing them at the right places, i.e., at the MOAs and AOPs of concern. Therefore, the suggested framework of entities and clouds will enable us to develop more efficient and reliable strategies for risk assessment of nanomaterials, and as a further consequence, to make regulatory decisions more rele- vant to the objective quantitative assessment of potential nanospecific human risks. Conflict of Interest There is no conflict of interest. Transparency Document There is no conflict of interest. Transparency Document The Transparency document associated with this article can be found in the online version. Acknowledgment Sameness: The regulatory crux with nanomaterial identity and grouping schemes for hazard assessment Conflict of Interest Transparency Document Acknowledgment References", "Acknowledgement": "The Transparency document associated with this article can be found in the online version. Acknowledgment Barbara Rothen-Rutishauser (Adolphe Merkle Institute), Heinrich Hofmann (Ecole Polyt\u00e9chnique Federale Lausanne), Wendelin Stark (Eidgen\u00f6ssische Technische Hochschule Z\u00fcrich) for their review. Sameness: The regulatory crux with nanomaterial identity and grouping schemes for hazard assessment Conflict of Interest Transparency Document Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Science--politics--and-the-GM-debate-in_2006_Regulatory-Toxicology-and-Pharm.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16188360", "content": {"Funding": "Historically, Europe has played a leading role in bio- technology and genomics research, with European scien- tists involved in critical steps ranging from the unraveling of the structure of DNA at Cambridge\u2019s Cavendish Labo- ratory 50 years ago (Watson and Crick, 1953) to the assembly of a practical system for the genetic engineering of plants at the University of Ghent in Belgium (Schell et al., 1983). Nevertheless, the situation in Europe with regard to plant biotechnology is currently anything but positive. Europe does not have a single shared vision for biotechnology but an assemblage of various sector-spe- ciWc, EU, Member State, and local policies. In 2000, although the number of biotechnology companies in the EU was higher than in the US (many SMEs versus fewer larger US companies), employment, expenditure on R&D, and the importance of the sector in terms of % GDP were all lower (Table 2). Probably the most pressing issue fac- ing biotechnology companies is funding. The average total public and private research eVort in the EU today amounts to 1.8% of GDP, against 2.7% in the US and 3.1% in Japan. Despite its larger economy, the EU\u2019s indus- trial biotechnology R&D has remained at only half the levels of the US over the last 25 years; in 2000, the EU bio- technology sector raised D6 billion for investments, com- pared to the D13 billion mentioned above for the US (Ernst and Young, 2001). Table 2 Comparison of the biotechnology sectors in the EU and the US (2000)"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Science-and-norms-in-policies-for-sustainable-development-_2006_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16213076", "content": {"Acknowledgement": "M. Karlsson / Regulatory Toxicology and Pharmacology 44 (2006) 49\u201356 55 Acknowledgment The author thanks Hanna Karlsson for valuable com- ments on earlier drafts of this article. Science and norms in policies for sustainable development: Assessing and managing risks of chemical substances and genetically modified organisms in the European Union Introduction Chemical substances, genetically modified organisms, and complex risks Operational principles for sustainable development Present and emerging risk policies for chemical substances in the European Union Risk policies for genetically modified organisms in the European Union Concluding remarks Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Science-and-politics--From-science-to-dec_2006_Regulatory-Toxicology-and-Pha.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16198034", "content": {"Compliance with ethical standards": "The last block of this special issue, deals with Regulato- ry Impact Analysis (RIA) as a tool and technique to eval- uate and improve the quality of the regulatory process and the consideration of science in an international trade con- text. Ballantine and Devonald describe and evaluate the new approach of the RIA process adopted by the Europe- an Commission, in theory and practice, and make a num- ber of recommendations for further improvements to the quality of the regulatory process in the European Union. Barnett contends that the classical approach to RIA, based on compliance costs, is inappropriate to fully understand the aggregate impact of legislation. The final paper by Lu- gard provides some legal views on the use of science in International Trade Law. Lugard argues that science and risk assessment is anchored in WTO agreements and non- science based regulations that affect trade without proper scientific justification, can be legally challenged. Overall, this Special Issue aims at discussing, on the ba- sis of experiences and case studies, the use and consider- ation of science in existing EU environmental policies and those in the pipeline; additional non-science factors that play a role in policy making; and tools to evaluate the quality of regulations. We are perfectly aware that we did not cover all issues that deserve attention. But in com- bining the view from different stakeholder scientists, it is our express hope that this Special Issue of Regulatory Tox- icology and Pharmacology will foster further discussion and debate among scientists. Encouraged by the lively de- bates that the presentations created at the SETAC Special Symposia \ufffdScience and Politics\ufffd in the last three years, we are confident that this will happen.", "Acknowledgement": "Acknowledgments We thank Ruth Knowles from the Weinberg Group and Jamie Wardman from the Centre of Risk Management of King\ufffds College of London for their help in organising this Special Topics Issue of Regulatory Toxicology and Phar- macology. We are also grateful to the various reviewers for their review of the enclosed publications."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Science-based-guidance-for-the-assessment-of-endoc_2011_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20858523", "content": {"CoiStatement": "The ECETOC proposal provides a structured, science based pro- cess to evaluate results from a variety of apical, mechanistic and screening toxicity studies. It integrates knowledge of adverse effects and mode of action from these studies to reach a conclusion regarding the endocrine disrupting properties of substances, in accordance with the Weybridge and other related definitions. A workshop discussing the proposal considered it to be scientifically sound and viewed it as a valuable contribution to the definition of criteria required for the determination of endocrine disrupting properties. ECETOC hopes that the criteria proposed in this paper will contribute to the development of regulatory guidance under the relevant pieces of legislation. 7. Conflict of interest statement The authors declare that there are no conflicts of interest. Mel- anie Gross\u2019 involvement in the production of the manuscript was supported by ECETOC. The authors declare that there are no conflicts of interest. Mel- anie Gross\u2019 involvement in the production of the manuscript was supported by ECETOC. Acknowledgments Commentary Conclusions Conflict of interest statement Acknowledgments Supplementary data References", "Acknowledgement": "Acknowledgments The ECETOC task force is grateful for the expert input received from the invited participants at a workshop held in Barcelona on June 29\u201330, 2009, which the task force has used to refine its origi- nal guidance. Commentary Conclusions Conflict of interest statement Acknowledgments Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Science-peer-review-for-the-21st-century--Assessing-scien_2019_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30634024", "content": {"CoiStatement": "Science peer review for the 21st century_ Assessing scientific consensus for decision-making while managing conflict of interests, reviewer and process bias representative of a subset of the population of scientists), to designing a follow-up study designed around the demographic parameters of the outlier reviewer (e.g., assess their representativeness, prevalence of their positions). Identification of hidden sources of bias can assist sci- ence panel managers to ensure that underlying factors are considered in the design of future peer reviews. Additional analyses are also possible based upon the structured format of peer reviewer input, including: (1) for Delphi-formatted reviews, changes in favorability and consensus metrics can be tracked across rounds (i.e., are panelists moving towards or away from consensus as a result of comment and debate); and (2) assessment of level of effort/engagement metrics (e.g., number of comments, number of characters/text response, total time spent online, comment ratings from fellow panel members) to assess whether or not panelists are sufficiently engaged in the review. In this peer review, the degree of consensus among peer reviewers was defined with precision using the consensus metric of Tastle and Wierman (2007). This contrasts with the definition of consensus ap- plied to science panels, which varies from agency to agency, but is generally less precise, optionally illuminated, and often presented in an unstructured manner. For example: (1) IARC states, \u201cConsensus reflects broad agreement among Working Group Members, but not necessarily unanimity. The chair may elect to poll Working Group Members to determine the diversity of scientific opinion on issues where consensus is not readily apparent.\u201d (IARC, 2015); WHO states, \u201cWhen consensus has been reached, it generally means that every committee member finds the proposed resolu- tion acceptable \u2013 or at least lends it support, even if less than whole- heartedly.\u201d (WHO, 2014); USEPA states, \u201cConsensus recommendations and conclusions are most helpful to the agency. However, when there is disagreement among experts, that information is also valuable to note. In most cases, different views can be accommodated within the committee's report. On rare occasions, a member may request that a minority report be appended to the report.\u201d (USEPA, 2012); and OMB states, \u201cConsensus is defined as general agreement, but not necessarily unanimity. During the development of consensus, comments and objections are considered using fair, impartial, open, and transparent processes.\u201d (OMB, 2016; OMB Cir- cular A-119). In most cases, the recommendations of regulatory science panels consist of a report that may span tens to hundreds of pages, but rarely is degree of consensus among reviewers on key issues of the assessment presented in a clear manner. This is an important omission since the degree of consensus within a voting group imparts a degree of confidence that a decision maker can have in moving forward with the group recommendation. For example, a decision maker can have greater confidence in a recommendation that is unanimously supported by 12/12 reviewers, than in a recommendation that is supported fully by 6/12 reviewers and only partially by the other 6/12. Presenting both of these hypothetical panel outcomes as consensus recommendations represents a loss of information, information that would otherwise be very useful to decision makers. The desire for a consensus re- commendation from a panel is understandable, but conflating con- sensus and apparent unanimity is neither reasonable nor helpful. Dis- agreement and debate among scientists is healthy, and should not be concealed. The consensus metric of Tastle and Wierman (2007) used herein is just one possible option by which consensus could be defined with greater precision and illumination than typically adopted for sci- ence panel deliberations. Claxton, L.D., 2007. A review of conflict of interest, competing interest, and bias for toxicologists. Toxicol. Ind. Health 23, 557\u2013571. Cole, S., et al., 1981. Chance and consensus in peer review. Science (New York, N.Y.). 214, 881\u2013886. ERG, 2007. Measuring Conflict of Interest and Expertise on FDA Advisory Committees. Eastern Research Group Task Order No. 14 Contract No. 223-03-8500. ERG, 2009. Financial Conflict-Of-Interest Disclosure and Voting Patterns at FDA Advisory Committee Meetings. Eastern Research Group Task Order No. 6 Contract No. HHSF 223200810017I. Gasparyan, 2015. Conflicts of interest in biomedical publications: considerations for au- thors, peer reviewers, and editors. Croat. Med. J. 54, 600\u2013608. Glaze, W.H., 1988. Editorial: peer review: a foundation of science. Environ. Sci. Technol. 22, 235. GM, 2015. FDA Advisory Committees: Conflicts of Interest and Voting Relative to Benchmarks. George Mason University School of Law. Hsu, C.-C., Sandford, B.A., 2007. The Delphi technique: making sense of concensus. Practical Assess. Res. Eval. 12 (10), 1\u20138. public health policy. A systematic review. PLoS One 8 e77404. Lurie, P., Almeida, C.M., Stine, N., Stine, A.R., Wolfe, S.M., 2006. Financial conflict of interest disclosure and voting patterns at food and drug administration drug advisory committee meetings. J. Am. Med. Assoc. 295 (16), 1921\u20131928. Manchikanti, L., Kaye, A.D., Boswell, M.V., Hirsch, J.A., 2015. Medical journal peer re- view: process and bias. Pain Physician 18 (1), E1\u2013E14 2015 Jan-Feb. Science peer review for the 21st century: Assessing scientific consensus for decision-making while managing conflict of interests, reviewer and process bias Introduction Methods Peer review structure Peer review process Panel recruitment Panel expertise verification Panel selection Charge questions Panel engagement Analyses Results Panel composition Analyses of peer reviewer input", "Disclosure": "ERG, 2009. Financial Conflict-Of-Interest Disclosure and Voting Patterns at FDA Advisory Committee Meetings. Eastern Research Group Task Order No. 6 Contract No. HHSF 223200810017I. Gad, S.C., Sullivan Jr., D.W., 2016. Ninth triennial Toxicology salary survey. Int. J. Toxicol. 35 (2), 243\u2013251. public health policy. A systematic review. PLoS One 8 e77404. Lurie, P., Almeida, C.M., Stine, N., Stine, A.R., Wolfe, S.M., 2006. Financial conflict of interest disclosure and voting patterns at food and drug administration drug advisory committee meetings. J. Am. Med. Assoc. 295 (16), 1921\u20131928. Manchikanti, L., Kaye, A.D., Boswell, M.V., Hirsch, J.A., 2015. Medical journal peer re- view: process and bias. Pain Physician 18 (1), E1\u2013E14 2015 Jan-Feb.", "Acknowledgement": "Acknowledgements and Disclaimers The peer reviews presented in this manuscript were sponsored by Philip Morris International PMI (Peer Review Sponsor). The science that was peer reviewed included studies conducted by PMI and their contractors to assess safety of an MRTP (THS2.2), and were included as part of their product registration package submitted to FDA. Please see Boue (2018) for additional details on the science package for THS2.2. The authors of this paper had complete control of the conduct of the peer reviews. The Sponsor did not have access to the selection of peer reviewers, and remains blinded to their identities. The authors C R Kirman and S M Hays are owners of SciPinion, and thus have a financial interest in the content of this manuscript. Acknowledgements and Disclaimers Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Scientific-Criteria-Used-for-the-Development-of-Occupa_2002_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/12473411", "content": {"Acknowledgement": "APPENDIX A. CALCULATION OF THE HUMAN EQUIVALENT CONCENTRATION ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Scientific-advances-and-challenges-in-safety-evaluat_2018_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30048703", "content": {"CoiStatement": "Conflicts of interest The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Ron Osborn is an employee of Mars Wrigley Confectionery. The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Ron Osborn is an employee of Mars Wrigley Confectionery. Acknowledgments https://doi.org/10.1016/j.yrtph.2018.07.017 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref1 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref1 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref2 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref2 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref2 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref3 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref3 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref3 http://expofacts.jrc.ec.europa.eu/facet/ http://expofacts.jrc.ec.europa.eu/facet/ http://www.europarl.europa.eu/RegData/etudes/STUD/2016/581411/EPRS_STU(2016 http://www.europarl.europa.eu/RegData/etudes/STUD/2016/581411/EPRS_STU(2016 https://www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/FederalFoodDrugandCosmeticActFDCAct/default.htm https://www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/FederalFoodDrugandCosmeticActFDCAct/default.htm https://www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/FederalFoodDrugandCosmeticActFDCAct/default.htm https://www.fda.gov/Food/GuidanceRegulation/ucm081818.htm https://www.fda.gov/Food/GuidanceRegulation/ucm081818.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm081825.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm081825.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm081825.htm https://www.fda.gov/RegulatoryInformation/Guidances/ucm081833.htm https://www.fda.gov/RegulatoryInformation/Guidances/ucm081833.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm081049.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm081049.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm081049.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm120762.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm120762.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm120762.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm081818.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm081818.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm081818.htm https://www.accessdata.fda.gov/scripts/fdcc/?set=fcn&id=1135 https://www.accessdata.fda.gov/scripts/fdcc/?set=fcn&id=1135 https://www.fda.gov/downloads/ScienceResearch/FieldScience/UCM491328.pdf https://www.fda.gov/downloads/ScienceResearch/FieldScience/UCM491328.pdf http://refhub.elsevier.com/S0273-2300(18)30202-2/sref15 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref15 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref16 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref16 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=174.5 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=174.5 https://www.fda.gov/Food/IngredientsPackagingLabeling/PackagingFCS/Notifications/ucm308462.htm https://www.fda.gov/Food/IngredientsPackagingLabeling/PackagingFCS/Notifications/ucm308462.htm https://www.fda.gov/Food/IngredientsPackagingLabeling/Definitions/default.htm https://www.fda.gov/Food/IngredientsPackagingLabeling/Definitions/default.htm http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/default.htm http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/default.htm http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/default.htm http://refhub.elsevier.com/S0273-2300(18)30202-2/sref21 https://www.iso.org/standard/23152.html https://www.iso.org/standard/23152.html http://refhub.elsevier.com/S0273-2300(18)30202-2/sref23 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref23 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref24 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref24 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref24 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref25 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref25 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref26 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref26 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref26 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref26 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref27 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref27 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref27 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref28 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref28 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref28 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref29 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref29 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref29 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref30 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref30 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref31 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref31 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref31 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref31 https://www.epa.gov/sites/production/files/2014-01/documents/computer_display_lca.pdf https://www.epa.gov/sites/production/files/2014-01/documents/computer_display_lca.pdf https://sustainablepackaging.org/wp-content/uploads/2017/09/Definition-of-Sustainable-Packaging.pdf https://sustainablepackaging.org/wp-content/uploads/2017/09/Definition-of-Sustainable-Packaging.pdf https://sustainablepackaging.org/wp-content/uploads/2017/09/Definition-of-Sustainable-Packaging.pdf Scientific advances and challenges in safety evaluation of food packaging materials: Workshop proceedings Introduction and purpose of the workshop Defining food packaging materials and identification of potential migration contaminants Defining substances that migrate from food packaging Analytical approaches for identifying substances that migrate from food packaging Advances in exposure assessments Advances in the generation of new packaging materials Regulatory framework for food packaging substances The US regulatory approach for food packaging Global perspectives on food packaging regulation Food packaging sustainability and recycling Considerations for sustainability and recycling of food packaging FDA's regulatory approach for recycling Conclusions and key workshop outcomes Funding Conflicts of interest Acknowledgments Transparency document References", "Funding": "Funding The workshop was developed and supported by the ILSI North America Food and Chemical Safety Committee. Agnes Karmaus re- ceived funds from the ILSI North America Food and Chemical Safety Committee for her work on this article. https://doi.org/10.1016/j.yrtph.2018.07.017 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref1 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref1 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref2 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref2 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref2 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref3 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref3 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref3 http://expofacts.jrc.ec.europa.eu/facet/ http://expofacts.jrc.ec.europa.eu/facet/ http://www.europarl.europa.eu/RegData/etudes/STUD/2016/581411/EPRS_STU(2016 http://www.europarl.europa.eu/RegData/etudes/STUD/2016/581411/EPRS_STU(2016 https://www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/FederalFoodDrugandCosmeticActFDCAct/default.htm https://www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/FederalFoodDrugandCosmeticActFDCAct/default.htm https://www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/FederalFoodDrugandCosmeticActFDCAct/default.htm https://www.fda.gov/Food/GuidanceRegulation/ucm081818.htm https://www.fda.gov/Food/GuidanceRegulation/ucm081818.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm081825.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm081825.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm081825.htm https://www.fda.gov/RegulatoryInformation/Guidances/ucm081833.htm https://www.fda.gov/RegulatoryInformation/Guidances/ucm081833.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm081049.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm081049.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm081049.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm120762.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm120762.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm120762.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm081818.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm081818.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm081818.htm https://www.accessdata.fda.gov/scripts/fdcc/?set=fcn&id=1135 https://www.accessdata.fda.gov/scripts/fdcc/?set=fcn&id=1135 https://www.fda.gov/downloads/ScienceResearch/FieldScience/UCM491328.pdf https://www.fda.gov/downloads/ScienceResearch/FieldScience/UCM491328.pdf http://refhub.elsevier.com/S0273-2300(18)30202-2/sref15 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref15 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref16 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref16 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=174.5 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=174.5 https://www.fda.gov/Food/IngredientsPackagingLabeling/PackagingFCS/Notifications/ucm308462.htm https://www.fda.gov/Food/IngredientsPackagingLabeling/PackagingFCS/Notifications/ucm308462.htm https://www.fda.gov/Food/IngredientsPackagingLabeling/Definitions/default.htm https://www.fda.gov/Food/IngredientsPackagingLabeling/Definitions/default.htm http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/default.htm http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/default.htm http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/default.htm http://refhub.elsevier.com/S0273-2300(18)30202-2/sref21 https://www.iso.org/standard/23152.html https://www.iso.org/standard/23152.html http://refhub.elsevier.com/S0273-2300(18)30202-2/sref23 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref23 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref24 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref24 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref24 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref25 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref25 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref26 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref26 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref26 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref26 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref27 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref27 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref27 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref28 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref28 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref28 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref29 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref29 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref29 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref30 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref30 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref31 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref31 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref31 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref31 https://www.epa.gov/sites/production/files/2014-01/documents/computer_display_lca.pdf https://www.epa.gov/sites/production/files/2014-01/documents/computer_display_lca.pdf https://sustainablepackaging.org/wp-content/uploads/2017/09/Definition-of-Sustainable-Packaging.pdf https://sustainablepackaging.org/wp-content/uploads/2017/09/Definition-of-Sustainable-Packaging.pdf https://sustainablepackaging.org/wp-content/uploads/2017/09/Definition-of-Sustainable-Packaging.pdf Scientific advances and challenges in safety evaluation of food packaging materials: Workshop proceedings Introduction and purpose of the workshop Defining food packaging materials and identification of potential migration contaminants Defining substances that migrate from food packaging Analytical approaches for identifying substances that migrate from food packaging Advances in exposure assessments Advances in the generation of new packaging materials Regulatory framework for food packaging substances The US regulatory approach for food packaging Global perspectives on food packaging regulation Food packaging sustainability and recycling Considerations for sustainability and recycling of food packaging FDA's regulatory approach for recycling Conclusions and key workshop outcomes Funding Conflicts of interest Acknowledgments Transparency document References", "Acknowledgement": "Acknowledgments The authors thank the speakers for reviewing the manuscript. https://doi.org/10.1016/j.yrtph.2018.07.017 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref1 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref1 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref2 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref2 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref2 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref3 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref3 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref3 http://expofacts.jrc.ec.europa.eu/facet/ http://expofacts.jrc.ec.europa.eu/facet/ http://www.europarl.europa.eu/RegData/etudes/STUD/2016/581411/EPRS_STU(2016 http://www.europarl.europa.eu/RegData/etudes/STUD/2016/581411/EPRS_STU(2016 https://www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/FederalFoodDrugandCosmeticActFDCAct/default.htm https://www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/FederalFoodDrugandCosmeticActFDCAct/default.htm https://www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/FederalFoodDrugandCosmeticActFDCAct/default.htm https://www.fda.gov/Food/GuidanceRegulation/ucm081818.htm https://www.fda.gov/Food/GuidanceRegulation/ucm081818.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm081825.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm081825.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm081825.htm https://www.fda.gov/RegulatoryInformation/Guidances/ucm081833.htm https://www.fda.gov/RegulatoryInformation/Guidances/ucm081833.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm081049.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm081049.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm081049.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm120762.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm120762.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm120762.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm081818.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm081818.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm081818.htm https://www.accessdata.fda.gov/scripts/fdcc/?set=fcn&id=1135 https://www.accessdata.fda.gov/scripts/fdcc/?set=fcn&id=1135 https://www.fda.gov/downloads/ScienceResearch/FieldScience/UCM491328.pdf https://www.fda.gov/downloads/ScienceResearch/FieldScience/UCM491328.pdf http://refhub.elsevier.com/S0273-2300(18)30202-2/sref15 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref15 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref16 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref16 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=174.5 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=174.5 https://www.fda.gov/Food/IngredientsPackagingLabeling/PackagingFCS/Notifications/ucm308462.htm https://www.fda.gov/Food/IngredientsPackagingLabeling/PackagingFCS/Notifications/ucm308462.htm https://www.fda.gov/Food/IngredientsPackagingLabeling/Definitions/default.htm https://www.fda.gov/Food/IngredientsPackagingLabeling/Definitions/default.htm http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/default.htm http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/default.htm http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/default.htm http://refhub.elsevier.com/S0273-2300(18)30202-2/sref21 https://www.iso.org/standard/23152.html https://www.iso.org/standard/23152.html http://refhub.elsevier.com/S0273-2300(18)30202-2/sref23 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref23 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref24 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref24 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref24 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref25 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref25 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref26 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref26 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref26 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref26 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref27 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref27 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref27 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref28 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref28 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref28 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref29 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref29 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref29 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref30 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref30 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref31 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref31 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref31 http://refhub.elsevier.com/S0273-2300(18)30202-2/sref31 https://www.epa.gov/sites/production/files/2014-01/documents/computer_display_lca.pdf https://www.epa.gov/sites/production/files/2014-01/documents/computer_display_lca.pdf https://sustainablepackaging.org/wp-content/uploads/2017/09/Definition-of-Sustainable-Packaging.pdf https://sustainablepackaging.org/wp-content/uploads/2017/09/Definition-of-Sustainable-Packaging.pdf https://sustainablepackaging.org/wp-content/uploads/2017/09/Definition-of-Sustainable-Packaging.pdf Scientific advances and challenges in safety evaluation of food packaging materials: Workshop proceedings Introduction and purpose of the workshop Defining food packaging materials and identification of potential migration contaminants Defining substances that migrate from food packaging Analytical approaches for identifying substances that migrate from food packaging Advances in exposure assessments Advances in the generation of new packaging materials Regulatory framework for food packaging substances The US regulatory approach for food packaging Global perspectives on food packaging regulation Food packaging sustainability and recycling Considerations for sustainability and recycling of food packaging FDA's regulatory approach for recycling Conclusions and key workshop outcomes Funding Conflicts of interest Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Scientific-assessments-in-European-food-law--_2019_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31386882", "content": {"CoiStatement": "Conflicts of interest The author declares that she has no conflict of interest. The author declares that she has no conflict of interest. Funding body information European Commission, 2000. White Paper on Food Safety (COM (1999). European Commission, 2012. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions - EU Regulatory Fitness (COM(2012) 746 Final). European Commission, 2013. Commission Staff Working Document: A Fitness Check of the Food Chain - State of Play and Next Steps (SWD(2013) 516 Final). European Commission, 2018a. Commission StaffWorking Document: the Refit Evaluation of the General Food Law (Regulation (EC) No 178/2002) (SWD(2018) 37 Final). European Commission, 2018b. Proposal for a Regulation of the European Parliament and of the Council on the Transparency and Sustainability of the EU Risk Assessment in the Food Chain Amending Amending Regulation (EC) No 178/2002 No 178/2002 [on General Food Law], Directive 2001/18/EC [on the Deliberate Release into the Environment of GMOs], Regulation (EC) No 1829/2003 [on GM Food and Feed], Regulation (EC) No 1831/2003 [on Feed Additives], Regulation (EC) No 2065/2003 [on Smoke Flavourings], Regulation (EC) No 1935/2004 [on Food Contact Materials], Regulation (EC) No 1331/2008 [on the Common Authorisation Procedure for Food Additives, Food Enzymes and Food Flavourings], Regulation (EC) No 1107/ 2009 [on Plant Protection Products] and Regulation (EU) No 2015/2283 [on Novel Foods] (COM(2018) 179). European Commission, 2018c. Commission Staff Working Document: Synopsis Report Accompanying the Document Regulation of the European Parliament and of the Council on the Transparency and Sustainability of the EU Risk Assessment in the Food Chain (SWD(2018) 97 Final). European Commission, 2018d. Public Consultation on the Transparency and Sustainability of the EU Risk Assessment in the Food Chain. European Commission DG Sanco, 2014. DG SANCO REFIT Mandate. Brussels. European Food Safety Authority, 2010. Application of systematic review methodology to food and feed safety assessments to support decision making. EFSA J 8, 1637. European Parliament and Council, 2002. Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general principles and requirements of food law, establishing the European Food Safety Authority and A. de Boer Regulatory Toxicology and Pharmacology 108 (2019) 104437 5 https://doi.org/10.1016/j.yrtph.2019.104437 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref1 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref1 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref1 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref1 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref1 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref2 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref2 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref3 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref3 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref3 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref3 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref4 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref4 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref5 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref5 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref5 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref6 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref6 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref6 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref6 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref6 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref7 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref7 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref7 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref7 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref8 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref8 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref8 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref9 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref9 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref9 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref10 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref10 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref11 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref11 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref11 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref11 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref12 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref12 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref13 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref13 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref14 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref14 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref15 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref15 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref16 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref18 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref18 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref19 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref19 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref20 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref20 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref21 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref21 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref22 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref23 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref23 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref23 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref24 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref24 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref27 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref27 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref27 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref27 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref28 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref28 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref29 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref30 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref30 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref31 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref31 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref31 laying down procedures in matters of food safety. Off J Eur Communities L 31 45, 1\u201324. European Parliament and Council of the European Union, 2006. Regulation (EC) No 1924/2006 of the European Parliament and of the council of 20 December 2006 on nutrition and health claims made on foods. Off J Eur Union L 404 (49), 9\u201325. European Parliament and Council of the European Union, 2010. Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. Off J Eur Union L 276, 33\u201379. European Parliament and Council of the European Union, 2015. Regulation (EU) 2015/ 2283 of the european parliament and of the council of 25 November 2015 on novel foods. Off J Eur Union L 327, 1\u201322. European Parliament and the Council, 2019. Regulation on the Transparency and Sustainability of the EU Risk Assessment in the Food Chain and Amending Regulations (EC) No 178/2002, (EC) No 1829/2003, (EC) No 1831/2003, (EC) No 2065/2003, (EC) No 1935/2004, (EC) No 1331/2008, (EC) No 1107/2009, (EU) 2015/2283 and Directive 2001/18/EC. PE-CONS 41/1/19, Rev 1. FAO/WHO, 2006. Food Safety Risk Analysis - A Guide for National Food Safety Authorities. (Rome). Glanville, J., King, S., Guarner, F., Hill, C., Sanders, M.E., 2015. A review of the sys- tematic review process and its applicability for use in evaluating evidence for health claims on probiotic foods in the European Union. Nutr. J. 14, 16. Graham, J.D., Hsia, S., 2002. Europe's precautionary principle: promise and pitfalls. J. Risk Res. 5, 371\u2013390. Hackam, D.G., Redelmeier, D.A., 2006. Translation of research evidence from animals to humans. J. Am. Med. Assoc. 296, 1727. EFSA Scientific Committee, Hardy, A., Benford, D., Halldorsson, T., Jeger, M.J., Knutsen, H.K., More, S., Naegeli, H., Noteborn, H., Ockleford, C., Ricci, A., Rychen, G., Schlatter, J.R., Silano, V., Solecki, R., Turck, D., Benfenati, E., Chaudhry, Q.M., Craig, P., Frampton, G., Greiner, M., Hart, A., Hogstrand, C., Lambre, C., Luttik, R., Makowski, D., Siani, A., Wahlstroem, H., Aguilera, J., Dorne, J., Fernandez Dumont, A., Hempen, M., Valtue\u00f1a Mart\u00ednez, S., Martino, L., Smeraldi, C., Terron, A., Georgiadis, N., Younes, M., 2017. Guidance on the use of the weight of evidence approach in scientific assessments. EFSA J 15. Hart, A., Maxim, L., Siegrist, M., Von Goetz, N., da Cruz, C., Merten, C., Mosbach\u2010Schulz, O., Lahaniatis, M., Smith, A., Hardy, A., 2019. Guidance on communication of un- certainty in scientific assessments. EFSA J 17, 1\u201373. Healy, A., Hardy, A., Kleiner, J., Robinson, T., Verhagen, H., 2016. Editorial: review of authorship principles. EFSA J 14, e14091. Higgins, J.P.T., Altman, D.G., G\u00f8tzsche, P.C., J\u00fcni, P., Moher, D., Oxman, A.D., Savovic, J., Schulz, K.F., Weeks, L., Sterne, J.A.C., Cochrane Bias Methods Group, Cochrane Statistical Methods Group, 2011. the cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ 343, d5928. Hook, E.B., 2002. Prematurity in Scientific Discovery: on Resistance and Neglect. University of California Press, Berkeley. IPCS, 2010. Harmonization Project Document No. 8 WHO Human Health Risk Assessment Toolkit: Chemical Hazards. Khedkar, S., Ciliberti, S., Br\u00f6ring, S., 2016. The EU health claims regulation: implications for innovation in the EU food sector. Br. Food J. 118, 2647\u20132665. Khedkar, S., Br\u00f6ring, S., Ciliberti, S., 2017. Exploring the Nutrition and Health Claims Regulation (EC) No. 1924/2006: what is the impact on innovation in the EU food sector? Int. J. Food Sci. Nutr. 68, 10\u201317. Lenssen, K.G.M., Bast, A., de Boer, A., 2018. Clarifying the health claim assessment procedure of EFSA will benefit functional food innovation. J Funct Foods 47, 386\u2013396. Lofstedt, R.E., 2007. The \u2018Plateau\u2010ing\u2019 of the european better regulation agenda: an analysis of activities carried out by the Barroso commission. J. Risk Res. 423\u2013447. Martini, D., Rossi, S., Biasini, B., Zavaroni, I., Bedogni, G., Musci, M., Pruneti, C., Passeri, G., Ventura, M., Di Nuzzo, S., Galli, D., Mirandola, P., Vitale, M., Dei Cas, A., Bonadonna, R.C., Del Rio, D., 2017. Claimed effects, outcome variables and methods of measurement for health claims proposed under European Community Regulation 1924/2006 in the framework of protection against oxidative damage and cardio- vascular health. Nutr. Metab. Cardiovasc. Dis. 27, 473\u2013503. Martini, D., Galli, C., Guareschi, C., Angelino, D., Bedogni, G., Biasini, B., Zavaroni, I., Pruneti, C., Ventura, M., Galli, D., Mirandola, P., Vitale, M., Dei Cas, A., Bonadonna, R.C., Passeri, G., Del Rio, D., 2018a. Claimed effects, outcome variables and methods of measurement for health claims on foods proposed under Regulation (EC) 1924/ 2006 in the area of oral health. NFS J 10, 10\u201325. Martini, D., Guareschi, C., Biasini, B., Bedogni, G., Galli, C., Angelino, D., Marchi, L., Zavaroni, I., Pruneti, C., Ventura, M., Galli, D., Mirandola, P., Vitale, M., Dei Cas, A., Bonadonna, R.C., Passeri, G., Del Rio, D., 2018b. Claimed effects, outcome variables and methods of measurement for health claims proposed under Regulation (EC) 1924/2006 in the framework of bone health. PharmaNutrition 6, 17\u201336. Meyer, A.H., 2006. Risk analysis in accordance with article 6, regulation (EC) No. 178/ 2002. Eur Food Feed Law Rev 3, 146\u2013153. Moher, D., Tricco, A.C., 2008. Issues related to the conduct of systematic reviews: a focus on the nutrition field. Am. J. Clin. Nutr. 88, 1191\u20131199. Nauta, M.J., Andersen, R., Pilegaard, K., Pires, S.M., Ravn-Haren, G., Tetens, I., Poulsen, M., 2018. Meeting the challenges in the development of risk-benefit assessment of foods. Trends Food Sci. Technol. 76, 90\u2013100. O'Connor, A.M., Lovei, G.L., Eales, J., Frampton, G.K., Glanville, J., Pullin, A.S., Sargeant, J., 2012. Implementation of systematic reviews in EFSA scientific outputs workflow. EFSA Support Publ 9. Pelkmans, J., Renda, A., 2014. Does EU Regulation Hinder or Stimulate Innovation? (Brussels). Petticrew, M., Roberts, H., 2006. Systematic Reviews in the Social Sciences: a Practical Guide. Blackwell Publishing, Malden, MA. Post, D.L., 2006. The precautionary principle and risk assessment in international food safety: how the world trade organization influences standards. Risk Anal. 26, 1259\u20131273. Pravst, I., Ku\u0161ar, A., \u017dmitek, K., Miklavec, K., Lavri\u0161a, \u017d., L\u00e4hteenm\u00e4ki, L., Kulikovskaja, V., Malcolm, R.N., Hodgkins, C., Raats, M.M., 2018. Recommendations for successful substantiation of new health claims in the European Union. Trends Food Sci. Technol. 71, 259\u2013263. Schilter, B., Benigni, R., Boobis, A., Chiodini, A., Cockburn, A., Cronin, M.T.D., Lo Piparo, E., Modi, S., Thiel, A., Worth, A., 2014. Establishing the level of safety concern for chemicals in food without the need for toxicity testing. Regul. Toxicol. Pharmacol. 68, 275\u2013296. Shanks, N., Greek, R., Greek, J., 2009. Are animal models predictive for humans? Philos. Ethics Humanit. Med. 4, 2. Silano, V., 2009. Science, risk assessment and decision-making to ensure food and feed safety in the European Union. Eur Food Feed Law Rev 4, 400\u2013405. Smith, A., Terry, S., Detken, D., 2012. 10 years of the european food safety authority (EFSA) and the EU food safety system. Eur Food Feed Law Rev 7. Stibernitz, B., 2012. A brief comment on science-based risk regulation within the European Union. Eur J Risk Regul 3, 86\u201391. Szajkowska, A., 2009. From mutual recognition to mutual scientific opinion? Constitutional framework for risk analysis in EU food safety law. Food Policy 34, 529\u2013538. Szawlowska, K., 2004. Risk assessment in the european food safety regulation: who is to decide whose science is better - commission v. France and beyond. Ger Law J 5. Uman, L.S., 2011. Systematic reviews and meta-analyses. J Can Acad Child Adolesc Psychiatry 20, 57\u201359. van der Meulen, B.M.J., 2009. Science based food law. Eur Food Feed Law Rev 4, 58\u201371. van Lunteren, A., Chheng Ly, S., van Hoorn, R., Eeuwij, J., Vonk Noordegraaf-Schouten, M., Renkema, M., Melse, A., 2019. Extensive literature search as preparatory work for a systematic review on health outcomes related to the age of introduction of com- plementary food for the scientific assessment of the appropriate age of introduction of complementary feeding into an infant's diet. EFSA Support Publ 16. Verhagen, H., Loveren, H. van, 2016. Status of nutrition and health claims in Europe by mid 2015. Trends Food Sci. Technol. 56, 39\u201345. Vos, E., 2000. EU food safety regulation in the aftermath of the BSE crisis. J. Consum. Policy 23, 227\u2013255. Wiener, J.B., 2006. Better regulation in Europe. Curr. Leg. Probl. 59, 447\u2013518. Wiener, J.B., Rogers, M.D., 2002. Comparing precaution in the United States and Europe. J. Risk Res. 5, 317\u2013349. Zwietering, M.H., 2015. Risk assessment and risk management for safe foods: assessment needs inclusion of variability and uncertainty, management needs discrete decisions. Int. J. Food Microbiol. 213, 118\u2013123. A. de Boer Regulatory Toxicology and Pharmacology 108 (2019) 104437 6 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref31 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref31 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref32 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref32 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref32 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref33 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref33 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref33 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref34 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref34 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref34 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref35 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref35 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref35 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref35 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref35 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref36 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref36 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref37 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref37 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref37 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref38 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref38 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref39 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref39 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref40 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref40 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref40 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref40 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref40 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref40 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref40 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref40 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref41 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref41 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref41 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref42 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref42 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref43 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref43 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref43 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref43 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref44 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref44 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref45 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref45 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref46 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref46 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref47 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref47 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref47 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref48 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref48 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref48 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref49 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref49 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref51 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref51 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref51 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref51 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref51 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref52 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref52 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref52 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref52 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref52 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref53 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref53 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref54 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref54 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref55 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref55 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref55 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref56 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref56 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref56 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref57 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref57 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref58 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref58 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref59 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref59 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref59 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref60 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref60 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref60 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref60 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref61 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref61 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref61 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref61 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref62 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref62 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref63 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref63 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref64 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref64 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref65 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref65 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref66 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref66 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref66 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref67 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref67 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref68 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref68 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref69 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref70 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref70 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref70 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref70 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref70 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref71 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref71 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref72 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref72 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref73 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref74 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref74 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref75 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref75 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref75 Scientific assessments in European food law: Making it future-proof Introduction Legal basis of risk assessment Risk analysis Risk assessment versus scientific assessment Evaluating EU food law Improving the link between nutrition &#x200B;&&#x200B; law Conclusion and future perspectives Conflicts of interest Funding body information Acknowledgements Transparency document References", "Funding": "Funding body information Not applicable: this research has not been funded by a specific grant or institution. The author is employed by Maastricht University, the Netherlands. European Commission, 2000. White Paper on Food Safety (COM (1999). European Commission, 2012. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions - EU Regulatory Fitness (COM(2012) 746 Final). European Commission, 2013. Commission Staff Working Document: A Fitness Check of the Food Chain - State of Play and Next Steps (SWD(2013) 516 Final). European Commission, 2018a. Commission StaffWorking Document: the Refit Evaluation of the General Food Law (Regulation (EC) No 178/2002) (SWD(2018) 37 Final). European Commission, 2018b. Proposal for a Regulation of the European Parliament and of the Council on the Transparency and Sustainability of the EU Risk Assessment in the Food Chain Amending Amending Regulation (EC) No 178/2002 No 178/2002 [on General Food Law], Directive 2001/18/EC [on the Deliberate Release into the Environment of GMOs], Regulation (EC) No 1829/2003 [on GM Food and Feed], Regulation (EC) No 1831/2003 [on Feed Additives], Regulation (EC) No 2065/2003 [on Smoke Flavourings], Regulation (EC) No 1935/2004 [on Food Contact Materials], Regulation (EC) No 1331/2008 [on the Common Authorisation Procedure for Food Additives, Food Enzymes and Food Flavourings], Regulation (EC) No 1107/ 2009 [on Plant Protection Products] and Regulation (EU) No 2015/2283 [on Novel Foods] (COM(2018) 179). European Commission, 2018c. Commission Staff Working Document: Synopsis Report Accompanying the Document Regulation of the European Parliament and of the Council on the Transparency and Sustainability of the EU Risk Assessment in the Food Chain (SWD(2018) 97 Final). European Commission, 2018d. Public Consultation on the Transparency and Sustainability of the EU Risk Assessment in the Food Chain. European Commission DG Sanco, 2014. DG SANCO REFIT Mandate. Brussels. European Food Safety Authority, 2010. Application of systematic review methodology to food and feed safety assessments to support decision making. EFSA J 8, 1637. European Parliament and Council, 2002. Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general principles and requirements of food law, establishing the European Food Safety Authority and A. de Boer Regulatory Toxicology and Pharmacology 108 (2019) 104437 5 https://doi.org/10.1016/j.yrtph.2019.104437 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref1 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref1 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref1 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref1 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref1 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref2 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref2 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref3 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref3 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref3 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref3 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref4 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref4 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref5 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref5 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref5 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref6 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref6 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref6 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref6 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref6 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref7 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref7 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref7 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref7 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref8 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref8 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref8 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref9 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref9 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref9 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref10 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref10 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref11 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref11 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref11 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref11 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref12 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref12 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref13 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref13 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref14 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref14 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref15 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref15 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref16 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref18 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref18 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref19 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref19 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref20 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref20 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref21 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref21 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref22 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref23 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref23 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref23 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref24 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref24 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref27 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref27 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref27 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref27 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref28 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref28 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref29 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref30 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref30 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref31 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref31 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref31 laying down procedures in matters of food safety. Off J Eur Communities L 31 45, 1\u201324. European Parliament and Council of the European Union, 2006. Regulation (EC) No 1924/2006 of the European Parliament and of the council of 20 December 2006 on nutrition and health claims made on foods. Off J Eur Union L 404 (49), 9\u201325. European Parliament and Council of the European Union, 2010. Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. Off J Eur Union L 276, 33\u201379. European Parliament and Council of the European Union, 2015. Regulation (EU) 2015/ 2283 of the european parliament and of the council of 25 November 2015 on novel foods. Off J Eur Union L 327, 1\u201322. European Parliament and the Council, 2019. Regulation on the Transparency and Sustainability of the EU Risk Assessment in the Food Chain and Amending Regulations (EC) No 178/2002, (EC) No 1829/2003, (EC) No 1831/2003, (EC) No 2065/2003, (EC) No 1935/2004, (EC) No 1331/2008, (EC) No 1107/2009, (EU) 2015/2283 and Directive 2001/18/EC. PE-CONS 41/1/19, Rev 1. FAO/WHO, 2006. Food Safety Risk Analysis - A Guide for National Food Safety Authorities. (Rome). Glanville, J., King, S., Guarner, F., Hill, C., Sanders, M.E., 2015. A review of the sys- tematic review process and its applicability for use in evaluating evidence for health claims on probiotic foods in the European Union. Nutr. J. 14, 16. Graham, J.D., Hsia, S., 2002. Europe's precautionary principle: promise and pitfalls. J. Risk Res. 5, 371\u2013390. Hackam, D.G., Redelmeier, D.A., 2006. Translation of research evidence from animals to humans. J. Am. Med. Assoc. 296, 1727. EFSA Scientific Committee, Hardy, A., Benford, D., Halldorsson, T., Jeger, M.J., Knutsen, H.K., More, S., Naegeli, H., Noteborn, H., Ockleford, C., Ricci, A., Rychen, G., Schlatter, J.R., Silano, V., Solecki, R., Turck, D., Benfenati, E., Chaudhry, Q.M., Craig, P., Frampton, G., Greiner, M., Hart, A., Hogstrand, C., Lambre, C., Luttik, R., Makowski, D., Siani, A., Wahlstroem, H., Aguilera, J., Dorne, J., Fernandez Dumont, A., Hempen, M., Valtue\u00f1a Mart\u00ednez, S., Martino, L., Smeraldi, C., Terron, A., Georgiadis, N., Younes, M., 2017. Guidance on the use of the weight of evidence approach in scientific assessments. EFSA J 15. Hart, A., Maxim, L., Siegrist, M., Von Goetz, N., da Cruz, C., Merten, C., Mosbach\u2010Schulz, O., Lahaniatis, M., Smith, A., Hardy, A., 2019. Guidance on communication of un- certainty in scientific assessments. EFSA J 17, 1\u201373. Healy, A., Hardy, A., Kleiner, J., Robinson, T., Verhagen, H., 2016. Editorial: review of authorship principles. EFSA J 14, e14091. Higgins, J.P.T., Altman, D.G., G\u00f8tzsche, P.C., J\u00fcni, P., Moher, D., Oxman, A.D., Savovic, J., Schulz, K.F., Weeks, L., Sterne, J.A.C., Cochrane Bias Methods Group, Cochrane Statistical Methods Group, 2011. the cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ 343, d5928. Hook, E.B., 2002. Prematurity in Scientific Discovery: on Resistance and Neglect. University of California Press, Berkeley. IPCS, 2010. Harmonization Project Document No. 8 WHO Human Health Risk Assessment Toolkit: Chemical Hazards. Khedkar, S., Ciliberti, S., Br\u00f6ring, S., 2016. The EU health claims regulation: implications for innovation in the EU food sector. Br. Food J. 118, 2647\u20132665. Khedkar, S., Br\u00f6ring, S., Ciliberti, S., 2017. Exploring the Nutrition and Health Claims Regulation (EC) No. 1924/2006: what is the impact on innovation in the EU food sector? Int. J. Food Sci. Nutr. 68, 10\u201317. Lenssen, K.G.M., Bast, A., de Boer, A., 2018. Clarifying the health claim assessment procedure of EFSA will benefit functional food innovation. J Funct Foods 47, 386\u2013396. Lofstedt, R.E., 2007. The \u2018Plateau\u2010ing\u2019 of the european better regulation agenda: an analysis of activities carried out by the Barroso commission. J. Risk Res. 423\u2013447. Martini, D., Rossi, S., Biasini, B., Zavaroni, I., Bedogni, G., Musci, M., Pruneti, C., Passeri, G., Ventura, M., Di Nuzzo, S., Galli, D., Mirandola, P., Vitale, M., Dei Cas, A., Bonadonna, R.C., Del Rio, D., 2017. Claimed effects, outcome variables and methods of measurement for health claims proposed under European Community Regulation 1924/2006 in the framework of protection against oxidative damage and cardio- vascular health. Nutr. Metab. Cardiovasc. Dis. 27, 473\u2013503. Martini, D., Galli, C., Guareschi, C., Angelino, D., Bedogni, G., Biasini, B., Zavaroni, I., Pruneti, C., Ventura, M., Galli, D., Mirandola, P., Vitale, M., Dei Cas, A., Bonadonna, R.C., Passeri, G., Del Rio, D., 2018a. Claimed effects, outcome variables and methods of measurement for health claims on foods proposed under Regulation (EC) 1924/ 2006 in the area of oral health. NFS J 10, 10\u201325. Martini, D., Guareschi, C., Biasini, B., Bedogni, G., Galli, C., Angelino, D., Marchi, L., Zavaroni, I., Pruneti, C., Ventura, M., Galli, D., Mirandola, P., Vitale, M., Dei Cas, A., Bonadonna, R.C., Passeri, G., Del Rio, D., 2018b. Claimed effects, outcome variables and methods of measurement for health claims proposed under Regulation (EC) 1924/2006 in the framework of bone health. PharmaNutrition 6, 17\u201336. Meyer, A.H., 2006. Risk analysis in accordance with article 6, regulation (EC) No. 178/ 2002. Eur Food Feed Law Rev 3, 146\u2013153. Moher, D., Tricco, A.C., 2008. Issues related to the conduct of systematic reviews: a focus on the nutrition field. Am. J. Clin. Nutr. 88, 1191\u20131199. Nauta, M.J., Andersen, R., Pilegaard, K., Pires, S.M., Ravn-Haren, G., Tetens, I., Poulsen, M., 2018. Meeting the challenges in the development of risk-benefit assessment of foods. Trends Food Sci. Technol. 76, 90\u2013100. O'Connor, A.M., Lovei, G.L., Eales, J., Frampton, G.K., Glanville, J., Pullin, A.S., Sargeant, J., 2012. Implementation of systematic reviews in EFSA scientific outputs workflow. EFSA Support Publ 9. Pelkmans, J., Renda, A., 2014. Does EU Regulation Hinder or Stimulate Innovation? (Brussels). Petticrew, M., Roberts, H., 2006. Systematic Reviews in the Social Sciences: a Practical Guide. Blackwell Publishing, Malden, MA. Post, D.L., 2006. The precautionary principle and risk assessment in international food safety: how the world trade organization influences standards. Risk Anal. 26, 1259\u20131273. Pravst, I., Ku\u0161ar, A., \u017dmitek, K., Miklavec, K., Lavri\u0161a, \u017d., L\u00e4hteenm\u00e4ki, L., Kulikovskaja, V., Malcolm, R.N., Hodgkins, C., Raats, M.M., 2018. Recommendations for successful substantiation of new health claims in the European Union. Trends Food Sci. Technol. 71, 259\u2013263. Schilter, B., Benigni, R., Boobis, A., Chiodini, A., Cockburn, A., Cronin, M.T.D., Lo Piparo, E., Modi, S., Thiel, A., Worth, A., 2014. Establishing the level of safety concern for chemicals in food without the need for toxicity testing. Regul. Toxicol. Pharmacol. 68, 275\u2013296. Shanks, N., Greek, R., Greek, J., 2009. Are animal models predictive for humans? Philos. Ethics Humanit. Med. 4, 2. Silano, V., 2009. Science, risk assessment and decision-making to ensure food and feed safety in the European Union. Eur Food Feed Law Rev 4, 400\u2013405. Smith, A., Terry, S., Detken, D., 2012. 10 years of the european food safety authority (EFSA) and the EU food safety system. Eur Food Feed Law Rev 7. Stibernitz, B., 2012. A brief comment on science-based risk regulation within the European Union. Eur J Risk Regul 3, 86\u201391. Szajkowska, A., 2009. From mutual recognition to mutual scientific opinion? Constitutional framework for risk analysis in EU food safety law. Food Policy 34, 529\u2013538. Szawlowska, K., 2004. Risk assessment in the european food safety regulation: who is to decide whose science is better - commission v. France and beyond. Ger Law J 5. Uman, L.S., 2011. Systematic reviews and meta-analyses. J Can Acad Child Adolesc Psychiatry 20, 57\u201359. van der Meulen, B.M.J., 2009. Science based food law. Eur Food Feed Law Rev 4, 58\u201371. van Lunteren, A., Chheng Ly, S., van Hoorn, R., Eeuwij, J., Vonk Noordegraaf-Schouten, M., Renkema, M., Melse, A., 2019. Extensive literature search as preparatory work for a systematic review on health outcomes related to the age of introduction of com- plementary food for the scientific assessment of the appropriate age of introduction of complementary feeding into an infant's diet. EFSA Support Publ 16. Verhagen, H., Loveren, H. van, 2016. Status of nutrition and health claims in Europe by mid 2015. Trends Food Sci. Technol. 56, 39\u201345. Vos, E., 2000. EU food safety regulation in the aftermath of the BSE crisis. J. Consum. Policy 23, 227\u2013255. Wiener, J.B., 2006. Better regulation in Europe. Curr. Leg. Probl. 59, 447\u2013518. Wiener, J.B., Rogers, M.D., 2002. Comparing precaution in the United States and Europe. J. Risk Res. 5, 317\u2013349. Zwietering, M.H., 2015. Risk assessment and risk management for safe foods: assessment needs inclusion of variability and uncertainty, management needs discrete decisions. Int. J. Food Microbiol. 213, 118\u2013123. A. de Boer Regulatory Toxicology and Pharmacology 108 (2019) 104437 6 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref31 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref31 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref32 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref32 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref32 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref33 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref33 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref33 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref34 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref34 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref34 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref35 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref35 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref35 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref35 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref35 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref36 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref36 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref37 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref37 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref37 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref38 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref38 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref39 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref39 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref40 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref40 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref40 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref40 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref40 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref40 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref40 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref40 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref41 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref41 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref41 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref42 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref42 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref43 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref43 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref43 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref43 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref44 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref44 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref45 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref45 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref46 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref46 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref47 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref47 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref47 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref48 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref48 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref48 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref49 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref49 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref51 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref51 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref51 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref51 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref51 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref52 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref52 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref52 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref52 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref52 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref53 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref53 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref54 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref54 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref55 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref55 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref55 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref56 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref56 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref56 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref57 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref57 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref58 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref58 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref59 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref59 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref59 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref60 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref60 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref60 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref60 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref61 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref61 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref61 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref61 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref62 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref62 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref63 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref63 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref64 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref64 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref65 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref65 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref66 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref66 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref66 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref67 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref67 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref68 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref68 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref69 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref70 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref70 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref70 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref70 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref70 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref71 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref71 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref72 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref72 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref73 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref74 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref74 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref75 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref75 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref75 Scientific assessments in European food law: Making it future-proof Introduction Legal basis of risk assessment Risk analysis Risk assessment versus scientific assessment Evaluating EU food law Improving the link between nutrition &#x200B;&&#x200B; law Conclusion and future perspectives Conflicts of interest Funding body information Acknowledgements Transparency document References", "Acknowledgement": "Acknowledgements The author thanks Prof. dr. Aalt Bast (Maastricht University), Annemiek Canjels (Province of Limburg) and Edwin Teurlinx (Regio Venlo) for their valuable insights and discussion. This research has been made possible with the support of the Dutch Province of Limburg. European Commission, 2000. White Paper on Food Safety (COM (1999). European Commission, 2012. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions - EU Regulatory Fitness (COM(2012) 746 Final). European Commission, 2013. Commission Staff Working Document: A Fitness Check of the Food Chain - State of Play and Next Steps (SWD(2013) 516 Final). European Commission, 2018a. Commission StaffWorking Document: the Refit Evaluation of the General Food Law (Regulation (EC) No 178/2002) (SWD(2018) 37 Final). European Commission, 2018b. Proposal for a Regulation of the European Parliament and of the Council on the Transparency and Sustainability of the EU Risk Assessment in the Food Chain Amending Amending Regulation (EC) No 178/2002 No 178/2002 [on General Food Law], Directive 2001/18/EC [on the Deliberate Release into the Environment of GMOs], Regulation (EC) No 1829/2003 [on GM Food and Feed], Regulation (EC) No 1831/2003 [on Feed Additives], Regulation (EC) No 2065/2003 [on Smoke Flavourings], Regulation (EC) No 1935/2004 [on Food Contact Materials], Regulation (EC) No 1331/2008 [on the Common Authorisation Procedure for Food Additives, Food Enzymes and Food Flavourings], Regulation (EC) No 1107/ 2009 [on Plant Protection Products] and Regulation (EU) No 2015/2283 [on Novel Foods] (COM(2018) 179). European Commission, 2018c. Commission Staff Working Document: Synopsis Report Accompanying the Document Regulation of the European Parliament and of the Council on the Transparency and Sustainability of the EU Risk Assessment in the Food Chain (SWD(2018) 97 Final). European Commission, 2018d. Public Consultation on the Transparency and Sustainability of the EU Risk Assessment in the Food Chain. European Commission DG Sanco, 2014. DG SANCO REFIT Mandate. Brussels. European Food Safety Authority, 2010. Application of systematic review methodology to food and feed safety assessments to support decision making. EFSA J 8, 1637. European Parliament and Council, 2002. Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general principles and requirements of food law, establishing the European Food Safety Authority and A. de Boer Regulatory Toxicology and Pharmacology 108 (2019) 104437 5 https://doi.org/10.1016/j.yrtph.2019.104437 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref1 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref1 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref1 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref1 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref1 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref2 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref2 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref3 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref3 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref3 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref3 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref4 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref4 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref5 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref5 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref5 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref6 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref6 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref6 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref6 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref6 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref7 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref7 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref7 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref7 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref8 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref8 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref8 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref9 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref9 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref9 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref10 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref10 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref11 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref11 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref11 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref11 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref12 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref12 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref13 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref13 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref14 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref14 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref15 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref15 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref16 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref18 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref18 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref19 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref19 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref20 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref20 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref21 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref21 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref22 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref23 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref23 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref23 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref24 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref24 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref27 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref27 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref27 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref27 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref28 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref28 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref29 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref30 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref30 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref31 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref31 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref31 laying down procedures in matters of food safety. Off J Eur Communities L 31 45, 1\u201324. European Parliament and Council of the European Union, 2006. Regulation (EC) No 1924/2006 of the European Parliament and of the council of 20 December 2006 on nutrition and health claims made on foods. Off J Eur Union L 404 (49), 9\u201325. European Parliament and Council of the European Union, 2010. Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. Off J Eur Union L 276, 33\u201379. European Parliament and Council of the European Union, 2015. Regulation (EU) 2015/ 2283 of the european parliament and of the council of 25 November 2015 on novel foods. Off J Eur Union L 327, 1\u201322. European Parliament and the Council, 2019. Regulation on the Transparency and Sustainability of the EU Risk Assessment in the Food Chain and Amending Regulations (EC) No 178/2002, (EC) No 1829/2003, (EC) No 1831/2003, (EC) No 2065/2003, (EC) No 1935/2004, (EC) No 1331/2008, (EC) No 1107/2009, (EU) 2015/2283 and Directive 2001/18/EC. PE-CONS 41/1/19, Rev 1. FAO/WHO, 2006. Food Safety Risk Analysis - A Guide for National Food Safety Authorities. (Rome). Glanville, J., King, S., Guarner, F., Hill, C., Sanders, M.E., 2015. A review of the sys- tematic review process and its applicability for use in evaluating evidence for health claims on probiotic foods in the European Union. Nutr. J. 14, 16. Graham, J.D., Hsia, S., 2002. Europe's precautionary principle: promise and pitfalls. J. Risk Res. 5, 371\u2013390. Hackam, D.G., Redelmeier, D.A., 2006. Translation of research evidence from animals to humans. J. Am. Med. Assoc. 296, 1727. EFSA Scientific Committee, Hardy, A., Benford, D., Halldorsson, T., Jeger, M.J., Knutsen, H.K., More, S., Naegeli, H., Noteborn, H., Ockleford, C., Ricci, A., Rychen, G., Schlatter, J.R., Silano, V., Solecki, R., Turck, D., Benfenati, E., Chaudhry, Q.M., Craig, P., Frampton, G., Greiner, M., Hart, A., Hogstrand, C., Lambre, C., Luttik, R., Makowski, D., Siani, A., Wahlstroem, H., Aguilera, J., Dorne, J., Fernandez Dumont, A., Hempen, M., Valtue\u00f1a Mart\u00ednez, S., Martino, L., Smeraldi, C., Terron, A., Georgiadis, N., Younes, M., 2017. Guidance on the use of the weight of evidence approach in scientific assessments. EFSA J 15. Hart, A., Maxim, L., Siegrist, M., Von Goetz, N., da Cruz, C., Merten, C., Mosbach\u2010Schulz, O., Lahaniatis, M., Smith, A., Hardy, A., 2019. Guidance on communication of un- certainty in scientific assessments. EFSA J 17, 1\u201373. Healy, A., Hardy, A., Kleiner, J., Robinson, T., Verhagen, H., 2016. Editorial: review of authorship principles. EFSA J 14, e14091. Higgins, J.P.T., Altman, D.G., G\u00f8tzsche, P.C., J\u00fcni, P., Moher, D., Oxman, A.D., Savovic, J., Schulz, K.F., Weeks, L., Sterne, J.A.C., Cochrane Bias Methods Group, Cochrane Statistical Methods Group, 2011. the cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ 343, d5928. Hook, E.B., 2002. Prematurity in Scientific Discovery: on Resistance and Neglect. University of California Press, Berkeley. IPCS, 2010. Harmonization Project Document No. 8 WHO Human Health Risk Assessment Toolkit: Chemical Hazards. Khedkar, S., Ciliberti, S., Br\u00f6ring, S., 2016. The EU health claims regulation: implications for innovation in the EU food sector. Br. Food J. 118, 2647\u20132665. Khedkar, S., Br\u00f6ring, S., Ciliberti, S., 2017. Exploring the Nutrition and Health Claims Regulation (EC) No. 1924/2006: what is the impact on innovation in the EU food sector? Int. J. Food Sci. Nutr. 68, 10\u201317. Lenssen, K.G.M., Bast, A., de Boer, A., 2018. Clarifying the health claim assessment procedure of EFSA will benefit functional food innovation. J Funct Foods 47, 386\u2013396. Lofstedt, R.E., 2007. The \u2018Plateau\u2010ing\u2019 of the european better regulation agenda: an analysis of activities carried out by the Barroso commission. J. Risk Res. 423\u2013447. Martini, D., Rossi, S., Biasini, B., Zavaroni, I., Bedogni, G., Musci, M., Pruneti, C., Passeri, G., Ventura, M., Di Nuzzo, S., Galli, D., Mirandola, P., Vitale, M., Dei Cas, A., Bonadonna, R.C., Del Rio, D., 2017. Claimed effects, outcome variables and methods of measurement for health claims proposed under European Community Regulation 1924/2006 in the framework of protection against oxidative damage and cardio- vascular health. Nutr. Metab. Cardiovasc. Dis. 27, 473\u2013503. Martini, D., Galli, C., Guareschi, C., Angelino, D., Bedogni, G., Biasini, B., Zavaroni, I., Pruneti, C., Ventura, M., Galli, D., Mirandola, P., Vitale, M., Dei Cas, A., Bonadonna, R.C., Passeri, G., Del Rio, D., 2018a. Claimed effects, outcome variables and methods of measurement for health claims on foods proposed under Regulation (EC) 1924/ 2006 in the area of oral health. NFS J 10, 10\u201325. Martini, D., Guareschi, C., Biasini, B., Bedogni, G., Galli, C., Angelino, D., Marchi, L., Zavaroni, I., Pruneti, C., Ventura, M., Galli, D., Mirandola, P., Vitale, M., Dei Cas, A., Bonadonna, R.C., Passeri, G., Del Rio, D., 2018b. Claimed effects, outcome variables and methods of measurement for health claims proposed under Regulation (EC) 1924/2006 in the framework of bone health. PharmaNutrition 6, 17\u201336. Meyer, A.H., 2006. Risk analysis in accordance with article 6, regulation (EC) No. 178/ 2002. Eur Food Feed Law Rev 3, 146\u2013153. Moher, D., Tricco, A.C., 2008. Issues related to the conduct of systematic reviews: a focus on the nutrition field. Am. J. Clin. Nutr. 88, 1191\u20131199. Nauta, M.J., Andersen, R., Pilegaard, K., Pires, S.M., Ravn-Haren, G., Tetens, I., Poulsen, M., 2018. Meeting the challenges in the development of risk-benefit assessment of foods. Trends Food Sci. Technol. 76, 90\u2013100. O'Connor, A.M., Lovei, G.L., Eales, J., Frampton, G.K., Glanville, J., Pullin, A.S., Sargeant, J., 2012. Implementation of systematic reviews in EFSA scientific outputs workflow. EFSA Support Publ 9. Pelkmans, J., Renda, A., 2014. Does EU Regulation Hinder or Stimulate Innovation? (Brussels). Petticrew, M., Roberts, H., 2006. Systematic Reviews in the Social Sciences: a Practical Guide. Blackwell Publishing, Malden, MA. Post, D.L., 2006. The precautionary principle and risk assessment in international food safety: how the world trade organization influences standards. Risk Anal. 26, 1259\u20131273. Pravst, I., Ku\u0161ar, A., \u017dmitek, K., Miklavec, K., Lavri\u0161a, \u017d., L\u00e4hteenm\u00e4ki, L., Kulikovskaja, V., Malcolm, R.N., Hodgkins, C., Raats, M.M., 2018. Recommendations for successful substantiation of new health claims in the European Union. Trends Food Sci. Technol. 71, 259\u2013263. Schilter, B., Benigni, R., Boobis, A., Chiodini, A., Cockburn, A., Cronin, M.T.D., Lo Piparo, E., Modi, S., Thiel, A., Worth, A., 2014. Establishing the level of safety concern for chemicals in food without the need for toxicity testing. Regul. Toxicol. Pharmacol. 68, 275\u2013296. Shanks, N., Greek, R., Greek, J., 2009. Are animal models predictive for humans? Philos. Ethics Humanit. Med. 4, 2. Silano, V., 2009. Science, risk assessment and decision-making to ensure food and feed safety in the European Union. Eur Food Feed Law Rev 4, 400\u2013405. Smith, A., Terry, S., Detken, D., 2012. 10 years of the european food safety authority (EFSA) and the EU food safety system. Eur Food Feed Law Rev 7. Stibernitz, B., 2012. A brief comment on science-based risk regulation within the European Union. Eur J Risk Regul 3, 86\u201391. Szajkowska, A., 2009. From mutual recognition to mutual scientific opinion? Constitutional framework for risk analysis in EU food safety law. Food Policy 34, 529\u2013538. Szawlowska, K., 2004. Risk assessment in the european food safety regulation: who is to decide whose science is better - commission v. France and beyond. Ger Law J 5. Uman, L.S., 2011. Systematic reviews and meta-analyses. J Can Acad Child Adolesc Psychiatry 20, 57\u201359. van der Meulen, B.M.J., 2009. Science based food law. Eur Food Feed Law Rev 4, 58\u201371. van Lunteren, A., Chheng Ly, S., van Hoorn, R., Eeuwij, J., Vonk Noordegraaf-Schouten, M., Renkema, M., Melse, A., 2019. Extensive literature search as preparatory work for a systematic review on health outcomes related to the age of introduction of com- plementary food for the scientific assessment of the appropriate age of introduction of complementary feeding into an infant's diet. EFSA Support Publ 16. Verhagen, H., Loveren, H. van, 2016. Status of nutrition and health claims in Europe by mid 2015. Trends Food Sci. Technol. 56, 39\u201345. Vos, E., 2000. EU food safety regulation in the aftermath of the BSE crisis. J. Consum. Policy 23, 227\u2013255. Wiener, J.B., 2006. Better regulation in Europe. Curr. Leg. Probl. 59, 447\u2013518. Wiener, J.B., Rogers, M.D., 2002. Comparing precaution in the United States and Europe. J. Risk Res. 5, 317\u2013349. Zwietering, M.H., 2015. Risk assessment and risk management for safe foods: assessment needs inclusion of variability and uncertainty, management needs discrete decisions. Int. J. Food Microbiol. 213, 118\u2013123. A. de Boer Regulatory Toxicology and Pharmacology 108 (2019) 104437 6 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref31 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref31 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref32 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref32 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref32 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref33 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref33 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref33 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref34 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref34 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref34 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref35 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref35 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref35 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref35 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref35 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref36 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref36 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref37 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref37 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref37 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref38 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref38 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref39 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref39 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref40 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref40 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref40 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref40 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref40 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref40 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref40 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref40 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref41 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref41 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref41 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref42 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref42 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref43 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref43 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref43 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref43 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref44 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref44 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref45 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref45 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref46 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref46 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref47 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref47 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref47 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref48 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref48 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref48 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref49 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref49 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref51 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref51 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref51 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref51 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref51 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref52 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref52 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref52 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref52 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref52 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref53 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref53 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref54 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref54 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref55 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref55 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref55 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref56 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref56 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref56 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref57 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref57 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref58 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref58 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref59 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref59 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref59 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref60 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref60 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref60 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref60 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref61 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref61 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref61 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref61 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref62 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref62 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref63 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref63 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref64 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref64 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref65 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref65 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref66 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref66 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref66 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref67 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref67 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref68 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref68 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref69 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref70 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref70 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref70 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref70 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref70 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref71 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref71 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref72 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref72 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref73 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref74 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref74 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref75 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref75 http://refhub.elsevier.com/S0273-2300(19)30201-6/sref75 Scientific assessments in European food law: Making it future-proof Introduction Legal basis of risk assessment Risk analysis Risk assessment versus scientific assessment Evaluating EU food law Improving the link between nutrition &#x200B;&&#x200B; law Conclusion and future perspectives Conflicts of interest Funding body information Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Scientific-issues-related-to-Codex-Alimentarius-go_2011_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21382429", "content": {"CoiStatement": "History of safe use is a major factor in Codex food safety policies, and appropriate practical application of the concept is essential to assist the safety evaluation and regulation of conventional foods, novel foods, and foods derived from genetically modified organ- isms. Although some reference is made in government legislation to the history of safe use concept, definitions are variable, and the information required to establish such a history is not always spec- ified (EU 2003; Food and Drug Administration, 1997; FSANZ; Health Canada, 2003; OECD, 1999). The global regulatory system would benefit from an internationally recognized definition for history of safe use and an agreed set of criteria to establish such a history. Conflict of interest statement Somogyi\u2014none; Hathcock\u2014employed by Council for Responsi- ble Nutrition; Biesalski\u2014none; Blumberg\u2014none; Antoine\u2014employed by Danone; Edwards\u2014none; Prock\u2014none. Scientific issues related to Codex Alimentarius goals: A review of principles, with examples Policy background General principles Evidence for benefits Evidence on safety Conflict of interest statement Role of the funding source References", "Funding": "164 A. Somogyi et al. / Regulatory Toxicology and Pharmacology 60 (2011) 161\u2013164 Role of the funding source All authors had salaries paid by their employers; no other fund- ing was involved. References Scientific issues related to Codex Alimentarius goals: A review of principles, with examples Policy background General principles Evidence for benefits Evidence on safety Conflict of interest statement Role of the funding source References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Screening-for-in-Vivo--Anti-estrogenic-and--Anti-andr_2002_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/12202052", "content": {"Acknowledgement": "ACKNOWLEDGMENTS This work was supported in part by grants from CNPq, CAPES, and FUNPAR. DISCUSSION CONCLUSIONS ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Screening-level-Biomonitoring-Equivalents-for-tiered-in_2018_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29113940", "content": {"CoiStatement": "Conflict of interest statements The authors declare no conflict of interest. The authors declare no conflict of interest. Acknowledgements Conflict of interest statements Acknowledgements Transparency document References", "Acknowledgement": "Acknowledgements This analysis was performed and funded under Health Canada contract number 4500276415. Conflict of interest statements Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Screening-level-population-risk-assessment-of-nasal_2010_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20156512", "content": {"CoiStatement": "Discussion Conflict of interest Acknowledgments References", "Acknowledgement": "Acknowledgments We gratefully acknowledge support and editorial suggestions from Dr. Anne LeHuray (Naphthalene Coalition), Dr. R. Jeffery Lewis (ExxonMobil Biomedical Sciences, Inc.), LtCol Stephanie McCor- mack-Brown (US Air Force), LtCol Wade Weisman (US Air Force), and Mr. G. Cornell Long (US Air Force Center for Engineering and the Environment). Discussion Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Screening-of-acute-and-sub-chronic-dermal-toxicity_2018_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30075180", "content": {"CoiStatement": "Conflicts of interest The authors report no conflict of interest. The authors report no conflict of interest. Acknowledgements Discussion Conclusions Conflicts of interest Acknowledgements References", "Acknowledgement": "Acknowledgements Authors are thankful to Management of IFTM University, Moradabad for motivation and facilities provided to conduct this work. Discussion Conclusions Conflicts of interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Screening-of-different-cytotoxicity-methods-for-the-a_2021_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34314750", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Riccardo Polosa is full tenured professor of Internal Medicine at the University of Catania (Italy) and Medical Director of the Institute for Internal Medicine and Clinical Immunology at the same University. In relation to his recent work in the area of respiratory diseases, clinical immunology, and tobacco control, Roberta Pulvirenti has received lecture fees and research funding from Pfizer, GlaxoSmithKline, CV Therapeutics, Neu- roSearch A/S, Sandoz, MSD, Boehringer Ingelheim, Novartis, Duska Therapeutics, and Forest Laboratories. Lecture fees from a number of European EC industry and trade associations (including FIVAPE in France and FIESEL in Italy) were directly donated to vaper advocacy no- profit organizations. Roberta Pulvirenti has also received grants from European Com- mission initiatives (U-BIOPRosalia EmmaD and AIRoberta PulvirentiROM) and from the Integral Rheumatology & Immunology Specialists Network (IRIS) initiative. He has also served as a consultant for Pfizer, Global Health Alliance for treatment of tobacco dependence, CV Therapeutics, Boehringer Ingel- heim, Novartis, Duska Therapeutics, ECITA (Electronic Cigarette In- dustry Trade Association, in the UK), Arbi Group Srl., and Health Diplomats. Roberta Pulvirenti has served on the Medical and Scientific Advisory Board of Cordex Pharma, Inc., CV Therapeutics, Duska Therapeutics Inc, Pfizer, and PharmaCielo. Roberta Pulvirenti is also founder of the Center for Tobacco prevention and treatment (CPCT) at the University of Catania and of the Center of Excellence for the acceleration of HArm Reduction (CoEHAR) at the same University, which has received support from Foundation for a Smoke Free World to conduct 8 independent investigator-initiated research projects on harm reduction. Roberta Pulvirenti is also currently involved in the following pro bono activities: scientific advisor for LIAF, Lega Ital- iana Anti Fumo (Italian acronym for Italian Anti-Smoking League), the Consumer Advocates for Smoke-free Alternatives (CASAA) and the In- ternational Network of Nicotine Consumers Organizations (INNCO); Chair of the European Technical Committee for standardization on \u201cRequirements and test methods for emissions of electronic cigarettes\u201d (CEN/TC 437; WG4). Giovanni Li Volti is currently elected Director of the Center of Excellence for the acceleration of HArm Reduction and principal investigator with Massimo Caruso of the Rosalia EmmaPLICA project funded by ECLAT srl. The contents, selection, and presentation of facts, as well as any opinions expressed herein are the sole responsibility of the authors and under no circumstances shall be regarded as reflecting the positions of the Foundation for a Smoke-Free World, Inc. All the other authors declare no conflicts of interest. Appendix A. Supplementary data The National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), 2003. A Test for Basal Cytotoxicity for an In Vitro Validation Study Phase III (National Institute of Environmental Health Sciences (NIEHS)- National Institutes of Health (NIH). U.S. Public Health Service - Department of Health and Human Services. Issue. OECD/OCDE, 2004. OECD Guideline for testing of chemicalsGuideline - 432 in vitro 3T3 nru phototoxicity test. OECD Better Pol. Better Lives. http://www.oecd.org/env/eh s/testing/TG432-TC-4dec-clean.pdf. Putnam, K.P., et al., 2002. Evaluation of eight in vitro assays for assessing the cytotoxicity of cigarette smoke condensate. Toxicol. Vitro 16, 599\u2013607. M. Caruso et al. https://doi.org/10.1016/j.yrtph.2021.105018 https://doi.org/10.1016/j.yrtph.2021.105018 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref1 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref1 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref3 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref3 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref3 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref5 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref5 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref7 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref7 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref9 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref9 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref11 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref11 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref13 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref13 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref13 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref15 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref15 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref17 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref17 https://ctrp.uky.edu/assets/pdf/webdocs/CoA18_1R6F.pdf https://ctrp.uky.edu/assets/pdf/webdocs/CoA18_1R6F.pdf http://refhub.elsevier.com/S0273-2300(21)00159-8/sref20 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref20 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref23 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref23 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref25 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref25 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref27 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref27 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref29 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref29 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref31 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref31 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref31 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref21 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref21 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref21 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref21 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref21 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref34 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref34 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref34 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref36 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref36 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref38 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref38 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref40 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref40 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref40 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref42 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref42 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref42 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref44 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref44 https://doi.org/10.1016/j.tiv.2016.07.019 https://doi.org/10.1016/j.tiv.2016.07.019 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref47 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref47 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref49 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref49 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref51 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref51 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref51 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref51 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref51 http://www.oecd.org/env/ehs/testing/TG432-TC-4dec-clean.pdf http://www.oecd.org/env/ehs/testing/TG432-TC-4dec-clean.pdf http://refhub.elsevier.com/S0273-2300(21)00159-8/sref54 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref54 Regulatory Toxicology and Pharmacology 125 (2021) 105018 10 Repetto, G., et al., 2008. Neutral red uptake assay for the estimation of cell viability/ cytotoxicity. Nat. Protoc. 3, 1125\u20131131. Sohal, S.S., et al., 2019. IQOS exposure impairs human airway cell homeostasis: direct comparison with traditional cigarette and e-cigarette. ERJ Open Res. 5. Stockert, J.C., et al., 2018. Tetrazolium salts and formazan products in Cell Biology: viability assessment, fluorescence imaging, and labeling perspectives. Acta Histochem. 120, 159\u2013167. Winikoff, S.E., et al., 2005. Chapter 29 - Cytolytic Assays. In: Lotze, M.T., Thomson, A.W. (Eds.), Measuring Immunity. Academic Press, pp. 343\u2013349. Yan, G., et al., 2018. Application of real-time cell electronic analysis system in modern pharmaceutical evaluation and analysis. Molecules 23. M. Caruso et al. http://refhub.elsevier.com/S0273-2300(21)00159-8/sref56 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref56 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref58 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref58 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref60 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref60 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref60 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref62 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref62 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref65 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref65 Screening of different cytotoxicity methods for the assessment of ENDS toxicity relative to tobacco cigarettes 1 Introduction 2 Methods 2.1 Test products and exposure regimes 2.2 Cell culture and air-liquid interface (ALI) exposure methods 2.3 Neutral Red Uptake (NRU) assay 2.4 MTT assay 2.5 Annexin V apoptosis assay 2.6 Neutral Red Uptake (NRU) assay in live imaging 2.7 xCELLigence real-time cell analysis 2.8 Statistics 3 Results 3.1 Cell viability by NRU assay 3.2 Cell viability by MTT assay 3.3 Evaluation of apoptosis and necrosis after smoke/vapor exposure 3.4 Cell viability by NRU assay in live imaging 3.5 Real-time analysis of toxicity 3.6 Comparison of cytotoxicity assays 4 Discussion 5 Conclusion Funding CRediT authorship contribution statement Declaration of competing interest Appendix A Supplementary data References", "Funding": "Massimo Caruso: Conceptualization, Validation, Supervision, Writing-Reviewing and Editing. Rosalia Emma: Data curation, Writing- Original draft preparation, Formal analysis. Sonja Rust: Project administration, Review manuscript. Alfio Distefano: Methodology, Formal analysis, Investigation. Giuseppe Carota: Methodology, Formal analysis, Investigation. Roberta Pulvirenti: Formal analysis, Data curation. Riccardo Polosa: Funding acquisition, supervision. Giovanni Li Volti: Conceptualization, Validation, Reviewing manuscript, supervision. Declaration of competing interest Riccardo Polosa is full tenured professor of Internal Medicine at the University of Catania (Italy) and Medical Director of the Institute for Internal Medicine and Clinical Immunology at the same University. In relation to his recent work in the area of respiratory diseases, clinical immunology, and tobacco control, RP has received lecture fees and research funding from Pfizer, GlaxoSmithKline, CV Therapeutics, Neu- roSearch A/S, Sandoz, MSD, Boehringer Ingelheim, Novartis, Duska Therapeutics, and Forest Laboratories. Lecture fees from a number of European EC industry and trade associations (including FIVAPE in France and FIESEL in Italy) were directly donated to vaper advocacy no- profit organizations. RP has also received grants from European Com- mission initiatives (U-BIOPRED and AIRPROM) and from the Integral Rheumatology & Immunology Specialists Network (IRIS) initiative. He has also served as a consultant for Pfizer, Global Health Alliance for treatment of tobacco dependence, CV Therapeutics, Boehringer Ingel- heim, Novartis, Duska Therapeutics, ECITA (Electronic Cigarette In- dustry Trade Association, in the UK), Arbi Group Srl., and Health Diplomats. RP has served on the Medical and Scientific Advisory Board of Cordex Pharma, Inc., CV Therapeutics, Duska Therapeutics Inc, Pfizer, and PharmaCielo. RP is also founder of the Center for Tobacco prevention and treatment (CPCT) at the University of Catania and of the Center of Excellence for the acceleration of HArm Reduction (CoEHAR) at the same University, which has received support from Foundation for a Smoke Free World to conduct 8 independent investigator-initiated research projects on harm reduction. RP is also currently involved in the following pro bono activities: scientific advisor for LIAF, Lega Ital- iana Anti Fumo (Italian acronym for Italian Anti-Smoking League), the Consumer Advocates for Smoke-free Alternatives (CASAA) and the In- ternational Network of Nicotine Consumers Organizations (INNCO); Chair of the European Technical Committee for standardization on \u201cRequirements and test methods for emissions of electronic cigarettes\u201d (CEN/TC 437; WG4). Giovanni Li Volti is currently elected Director of the Center of Excellence for the acceleration of HArm Reduction and principal investigator with Massimo Caruso of the REPLICA project funded by ECLAT srl. The contents, selection, and presentation of facts, as well as any opinions expressed herein are the sole responsibility of the authors and under no circumstances shall be regarded as reflecting the positions of the Foundation for a Smoke-Free World, Inc. All the other authors declare no conflicts of interest. The National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), 2003. A Test for Basal Cytotoxicity for an In Vitro Validation Study Phase III (National Institute of Environmental Health Sciences (NIEHS)- National Institutes of Health (NIH). U.S. Public Health Service - Department of Health and Human Services. Issue. OECD/OCDE, 2004. OECD Guideline for testing of chemicalsGuideline - 432 in vitro 3T3 nru phototoxicity test. OECD Better Pol. Better Lives. http://www.oecd.org/env/eh s/testing/TG432-TC-4dec-clean.pdf. Putnam, K.P., et al., 2002. Evaluation of eight in vitro assays for assessing the cytotoxicity of cigarette smoke condensate. Toxicol. Vitro 16, 599\u2013607. M. Caruso et al. https://doi.org/10.1016/j.yrtph.2021.105018 https://doi.org/10.1016/j.yrtph.2021.105018 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref1 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref1 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref3 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref3 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref3 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref5 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref5 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref7 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref7 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref9 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref9 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref11 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref11 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref13 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref13 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref13 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref15 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref15 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref17 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref17 https://ctrp.uky.edu/assets/pdf/webdocs/CoA18_1R6F.pdf https://ctrp.uky.edu/assets/pdf/webdocs/CoA18_1R6F.pdf http://refhub.elsevier.com/S0273-2300(21)00159-8/sref20 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref20 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref23 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref23 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref25 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref25 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref27 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref27 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref29 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref29 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref31 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref31 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref31 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref21 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref21 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref21 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref21 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref21 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref34 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref34 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref34 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref36 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref36 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref38 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref38 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref40 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref40 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref40 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref42 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref42 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref42 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref44 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref44 https://doi.org/10.1016/j.tiv.2016.07.019 https://doi.org/10.1016/j.tiv.2016.07.019 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref47 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref47 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref49 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref49 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref51 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref51 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref51 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref51 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref51 http://www.oecd.org/env/ehs/testing/TG432-TC-4dec-clean.pdf http://www.oecd.org/env/ehs/testing/TG432-TC-4dec-clean.pdf http://refhub.elsevier.com/S0273-2300(21)00159-8/sref54 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref54 Regulatory Toxicology and Pharmacology 125 (2021) 105018 10 Repetto, G., et al., 2008. Neutral red uptake assay for the estimation of cell viability/ cytotoxicity. Nat. Protoc. 3, 1125\u20131131. Sohal, S.S., et al., 2019. IQOS exposure impairs human airway cell homeostasis: direct comparison with traditional cigarette and e-cigarette. ERJ Open Res. 5. Stockert, J.C., et al., 2018. Tetrazolium salts and formazan products in Cell Biology: viability assessment, fluorescence imaging, and labeling perspectives. Acta Histochem. 120, 159\u2013167. Winikoff, S.E., et al., 2005. Chapter 29 - Cytolytic Assays. In: Lotze, M.T., Thomson, A.W. (Eds.), Measuring Immunity. Academic Press, pp. 343\u2013349. Yan, G., et al., 2018. Application of real-time cell electronic analysis system in modern pharmaceutical evaluation and analysis. Molecules 23. M. Caruso et al. http://refhub.elsevier.com/S0273-2300(21)00159-8/sref56 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref56 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref58 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref58 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref60 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref60 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref60 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref62 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref62 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref65 http://refhub.elsevier.com/S0273-2300(21)00159-8/sref65 Screening of different cytotoxicity methods for the assessment of ENDS toxicity relative to tobacco cigarettes 1 Introduction 2 Methods 2.1 Test products and exposure regimes 2.2 Cell culture and air-liquid interface (ALI) exposure methods 2.3 Neutral Red Uptake (NRU) assay 2.4 MTT assay 2.5 Annexin V apoptosis assay 2.6 Neutral Red Uptake (NRU) assay in live imaging 2.7 xCELLigence real-time cell analysis 2.8 Statistics 3 Results 3.1 Cell viability by NRU assay 3.2 Cell viability by MTT assay 3.3 Evaluation of apoptosis and necrosis after smoke/vapor exposure 3.4 Cell viability by NRU assay in live imaging 3.5 Real-time analysis of toxicity 3.6 Comparison of cytotoxicity assays 4 Discussion 5 Conclusion Funding CRediT authorship contribution statement Declaration of competing interest Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Seafood-arsenic--Implications-for-human-ri_2007_Regulatory-Toxicology-and-Ph.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/17092619", "content": {"Compliance with ethical standards": "US Environmental Protection Agency, 2001. National Primary Drinking Water Regulations: Arsenic and clariWcations to compliance and new source contaminants monitoring. US Environmental Protection Agency, Washington, DC. US Environmental Protection Agency, 2005. Integrated Risk Information System: Arsenic, inorganic (CASRN 7440-38-2); <http://www.epa.gov/ iris/subst/0278.htm/>. US Environmental Protection Agency, Wash- ington, DC. (accessed 09.2006.).", "Acknowledgement": "Implications for risk assessment Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Selecting-a-minimal-set-of-androgen-receptor-as_2020_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32798611", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 3 Results 4 Discussion Disclaimer Funding information Declaration of competing interest Appendix A Supplementary data References", "Funding": "Funding information This work was wholly funded by the US Environmental Protection Agency. 3 Results 4 Discussion Disclaimer Funding information Declaration of competing interest Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Selective-inhibition-of-butyrylcholinesterase-in-viv_2008_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18166255", "content": {"Acknowledgement": "Any neurobehavioral changes elicited by Equitrol\ufffd dos- ing, such as those reported by Berger and coworkers (2007), would apparently have to be initiated through a mechanism other than acetylcholinesterase inhibition. While butyrylcholinesterase has traditionally been thought to have essentially no role in neurotransmission, more recent studies suggest that it may be involved in cholinergic physiology and pathology (Greig et al., 2002; Mesulam et al., 2002a,b). Recent studies (Duysen et al., 2007) using butyrylcholinesterase knockout mice challenged with anticholinesterases provide further evidence that butyrylch- olinesterase may indeed have a role in the hydrolysis of ace- tylcholine at cholinergic terminals. The data herein suggest that when orally administered at the recommended dosing rate to horses, Equitrol\ufffd is absorbed and can markedly inhibit butyrylcholinesterase in the plasma, but has no sig- nificant effect on acetylcholinesterase in either erythrocytes or target tissues. Whether butyrylcholinesterase inhibition in tissues outside the circulation occurs with Equitrol\ufffd feeding and, if so, whether this inhibition could lead to neu- robehavioral or other adverse changes remains unclear. Acknowledgments This research was supported in part by the Oklahoma State University Board of Regents and NIH (NCRR T32 Training Grant for Veterinary Students in Research). We appreciate the technical assistance Carl Gedon, Larae Ma- son and Nikita Mirajkar. The corresponding author (Carey N Pope.) previously served as a paid consultant for Far- nam, the producer of Equitrol\ufffd. Results Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Sensitivity-of-Radioluminography-using-14C-Labeled_2000_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/10806056", "content": {"Acknowledgement": "TABLE 3 Mean, Standard Deviation (SD), and Coefficient of Variation (CV) of Measured Signals (PSL/mm2 S26 BINDER AND ARCHIMBAUD DISCUSSION The limit of detection and quantitation were deter- mined with fixed parameters as the section thickness (30 or 40 mm) and variable parameters (as area inte- rated and exposure time). The limit of quantitation as lower when the exposure time increase from 1 to 7 ays and was independent of the area integrated from .5 to 66 mm2. Therefore, to have the highest sensitiv- ty a long exposure time (e.g., 7 days) and an integrated rea larger than 3.5 mm2 is recommended. Whatever method was selected to determine the limit of quantitation (defined as 10 times the standard deviation of background values or as the radioactivity concentration for which the coefficient of variation is less than 20%), the results were similar (60, 50, 26, and 20 Bq/g or 74, 65, 33, and 24 Bq/g after 1, 3, 4, and 7 days of exposure, respectively). Nevertheless, to deter- mine the limit of quantitation using the radioactivity concentration for which the coefficient of variation was less than 20%, several exposures of the same imaging plates containing the blood standard sections, with a wide range of concentrations, should be performed. A LOQ, obtained for one imaging plate after several ex- posures, varied with the blood standard sections used. On the other hand, when using the standard deviation of background values, the LOQ is obtained for each imaging plate after each exposure. Therefore, the lat- ter method to determine the LOQ can be used as an in process control. Different Blood Standard Sections of Various Regio Activity (Bq/g) Region size 42 mm2 Re Mean (PSL/mm2) SD (PSL/mm2) CV (%) Mean (PSL/mm2) 17.3 1.4 0.3 22.1 1.5 60.1 3.9 0.2 6.0 4.5 186.1 11.3 0.4 3.4 11.8 264.9 15.2 0.7 4.8 16.0 2041.3 116.4 5.9 5.1 125.1 6683.7 395.9 10.3 2.6 405.8 20246.9 1066 39.7 3.7 1047 CONCLUSION The sensitivity of RLG is influenced by a large num- ber of factors, some of which like exposure time or temperature can be controlled by standardizing the procedure; others like contamination and flair effect must be carefully estimated for each individual mea- surement. Under routine conditions of whole-body ra- dioluminography reliable quantification can be per- formed at least down to 60 Bq/g wet tissue or even below. Concentrations of 6 Bq/g wet tissue can be well detected. ACKNOWLEDGMENTS The authors acknowledge the excellent technical assistance of Mr. Christophe Gros and Ms. Ina Mairhofer. REFERENCES Hamaoka, T. (1990). Autoradiography of new era replacing tradi- tional X-ray film. Cell Technol. 9, 456\u2013462. Klein, O., Binder, R., and Steinke, W. (2000). Quantification of tissue self-absorption of weak b-radiation in lyophilized whole-body sec- tions of rats. Regul. Toxicol. Pharmacol. 31, S27\u2013S31. Maas, J., Binder, R., and Steinke, W. (2000). Quantitative whole- body autoradiography: Recommendations for the standardization of the method. Regul. Toxicol. Pharmacol. 31, S15\u2013S21. Ullberg, S. (1954). Studies on the distribution and fate of 35S-labelled benzylpenicillin in the body. Acta Radiol. Suppl. 118, 1\u2013110. ) of Sizes Exposed Several Times for 4 Days below 8\u00b0C n size 3.5 mm2 Region size 1.3 mm2 SD (PSL/mm2) DISCUSSION CONCLUSION ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Sensory-irritation-of-vapours-of-formic--acetic_2018_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30223073", "content": {"Funding": "Funding and association The experimental part of the study was possible due to a grant from Arbejdsmilj\u00f8fondet [The Danish Occupational Environment Fond], which is a governmental foundation for conducting occupational re- levant research. Gunnar Damgaard Nielsen was a member of the EU Scientific Committee on Occupational Exposure Limits (SCOEL). Funding and association Acknowledgement Supplementary data References", "Acknowledgement": "Acknowledgement I am grateful to Lea Frimann Hansen, PhD, and to chief technician Maria Hammer for conducting the experiments. Also, I have to thank the librarians, Elizabeth Bengtsen and Rikke Nilsson for assistance by the literature search and collection of references. Furthermore, I have to thank the National Research Centre for the Working Environment for offering me an emeritus position, allowing me to report this study. Funding and association Acknowledgement Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Serial-blood-sampling-effects-in-rat-embryo-fetal_2021_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33891998", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 4 Discussion and conclusion CRediT authorship contribution statement Declaration of competing interest Acknowledgments References", "Acknowledgement": "Acknowledgments This work was supported by the Korea Institute of Toxicology, Republic of Korea (grant no. KK-1909-08 and KK-2005). The authors would like to especially thank to the technical staff of the Korea Institute of Toxicology for their technical support. 4 Discussion and conclusion CRediT authorship contribution statement Declaration of competing interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Setting-an-indoor-air-exposure-limit-for-formal_2008_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18786592", "content": {"Acknowledgement": "Acknowledgments The authors thank Mark Kean, AkzoNobel T&E, Arnhem, the Netherlands, for editing the paper and the FormaCare sector group of CEFIC, Brussels, Belgium for the financial contribution to per- form this evaluation. The views in this paper, however, are those of the authors and do not necessarily reflect the views of the indus- tries presented by the FormaCare sector group. Discussion and conclusion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Seventy-day-safety-assessment-of-an-orally-ingested--_2014_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25042359", "content": {"CoiStatement": "Conflicts of interest Scott C Anderson is a consultant to Freedom Health LLC. Michael I Lindinger is a consultant to the nutraceuticals industry in general, and to Freedom Health LLC specifically. 4 Discussion 5 Conclusion Conflicts of interest Acknowledgments References", "Acknowledgement": "Acknowledgments The study was conducted at Texas A&M University by Dr. Brett Scott. The study was funded by Freedom Health, LLC. 4 Discussion 5 Conclusion Conflicts of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Sex-differences-in-subacute-manganese-intoxication--Oxi_2019_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30878574", "content": {"CoiStatement": "Declaration of interest The authors report no conflicts of interest. The authors are re- sponsible for the content and writing of the manuscript. The authors report no conflicts of interest. The authors are re- sponsible for the content and writing of the manuscript. References Results Discussion Conclusions Acknowledgement Supplementary data Declaration of interest References", "Acknowledgement": "Results Discussion Conclusions Acknowledgement Supplementary data Declaration of interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Short-Term-Oral-Toxicity-Study-of-FAVOR-P_2000_Regulatory-Toxicology-and-Pha.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/11162724", "content": {"Compliance with ethical standards": "Testing was performed by Research Toxicology Cen- tre SpA (RTC) in Rome, Italy, on behalf of Stockhausen GmbH & Co KG in compliance with OECD Test Guide- line 407 and Good Laboratory Practice (GLP) regula- tions established by the U.S. Food and Drug Adminis- tration (FDA) under Part 58 of Title 21 of the Code of Federal Regulations (CFR). Three experimental groups were employed in this study (control, low dose, and high dose). In the dosed animals, the test article was administered to 10 rats/group/sex at 2 dose levels, 1 and 5% in the diet. Treatment was offered orally via the test diet 7 days a week for up to 32 days. The 10 rats/sex in the control group received an untreated diet for the same time period. Animals were allocated to the three experimental groups by computerized stratified randomization to give approximately equal initial group mean body weights. All animals were checked for viability twice daily Monday through Friday, and once daily on Saturdays, Sundays, and holidays. Clinical observations were made daily for signs of toxicity. Body weights were recorded the day prior to treatment allocation, the day treatment commenced, and weekly thereafter, as well as just prior to necropsy. Food consumption was re- corded weekly throughout the test period for all three experimental groups, along with the group mean achieved intake of the test article for the two dosed groups. Measurements of drinking water consumption for each animal were performed over a 3-day period during weeks 1 and 4/5 of treatment. Once before treat- ment commenced and once during week 4 of the study, animals in the control and high-dose groups were given a functional observational battery (FOB) to test for any potential neurotoxic effects of the test substance. Prior to study initiation, both eyes of all animals were sub- jected to an opthalmoscopic examination, and during the final week of the study, an opthalmoscopic re-ex- amination was performed on animals in the control and high-dose groups."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Short-term-clinical-exposure-evaluation-of-a-third-gene_2008_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18640172", "content": {"Acknowledgement": "Acknowledgments The authors thank MDS Pharma Services for clinical conduct and bioanalytical and statistical analyses. The authors also thank Analytisch-Biologisches Forschungslabor GmbH for bioanalyses of urinary aromatic amines and HMPMA. References Discussion AcknowledgementsAcknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Short-term-effects-of-reduced-exposure-to-cigarette-smo_2010_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20394790", "content": {"CoiStatement": "Conflict of interest All authors are or were employees of Philip Morris USA, Inc./Al- tria Client Services Inc. during conduct of the study. Results Discussion Conflict of interest Acknowledgments References", "Acknowledgement": "Acknowledgments The authors thank Lonnie Rimmer and Qiwei Liang for their technical assistance. Financial support and test products provided by Philip Morris USA, Inc. Results Discussion Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Short-term-toxicogenomics-as-an-alternative-approach-to-ch_2020_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32268158", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. Short-term toxicogenomics as an alternative approach to chronic in vivo studies for derivation of points of departure: A case study in the rat with a triazole fungicide Introduction Materials and methods Results Discussion Conclusions Funding information Declaration of competing interest Acknowledgements Supplementary data References", "Funding": "Funding information This work was supported by research and development funds of Corteva Agriscience, (Indianapolis, Indiana, USA). Short-term toxicogenomics as an alternative approach to chronic in vivo studies for derivation of points of departure: A case study in the rat with a triazole fungicide Introduction Materials and methods Results Discussion Conclusions Funding information Declaration of competing interest Acknowledgements Supplementary data References", "Acknowledgement": "Acknowledgements The authors would like to thank the animal handling, pathology, and genomics lab technicians for their assistance in this study. Short-term toxicogenomics as an alternative approach to chronic in vivo studies for derivation of points of departure: A case study in the rat with a triazole fungicide Introduction Materials and methods Results Discussion Conclusions Funding information Declaration of competing interest Acknowledgements Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Signal-detection-for-Thai-traditional-medicine--Examinati_2014_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24945744", "content": {"CoiStatement": "Additionally our findings of serious ADRs from TTMs indicate the need to reduce unnecessary use among patients and the need for intensive surveillance among pharmaco-epidemiologists. This report will be proposed to the signal detection working group of the drug safety advisory subcommittee under the drug committee of the Thai-FDA for qualitative investigation, further study or regulatory measurement. Conflict of interest The authors have no conflict of interest. Acknowledgments The authors have no conflict of interest. Acknowledgments We would like to thank all health facilities which sent ADR reports to the Thai-FDA. We also thank Stephen Pinder, from Sec- tion for Clinical Epidemiology and Biostatistics, Faculty of Medicine 3 Results 4 Discussions and conclusions Conflict of interest Acknowledgments References", "Acknowledgement": "The authors have no conflict of interest. Acknowledgments We would like to thank all health facilities which sent ADR reports to the Thai-FDA. We also thank Stephen Pinder, from Sec- tion for Clinical Epidemiology and Biostatistics, Faculty of Medicine 3 Results 4 Discussions and conclusions Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Signal-detection-of-methylphenidate-by-comparing-a-s_2011_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21510997", "content": {"CoiStatement": "Conflict of Interest. No conflict of interest to declare. References", "Acknowledgement": "We compared signals generated by different data sources. In Korea, the spontaneous reporting rate and amount of data are rel- atively low, so ethnic-specific signals are barely detected. Signal comparison with spontaneous and claims database can be a com- plementary method for generating such signals and can provide basic data for implementing appropriate regulatory control. Acknowledgements This research was supported by a grant (08181KFDA495) from the Korea Food & Drug Administration in 2008 and the views pre- sented in this article do not necessarily reflect those of the KFDA. 3 Results 4 Discussion 5 Conclusions Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Silica-dioxide-nanoparticles-aggravate-airway-inflamma_2020_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32087352", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper.", "Funding": "Funding sources This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education [NRF-2016R1D1A2B04936124]. Discussion Funding sources mk:H1_25 Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Silver-nanoparticles-protect-acetaminophen-induced-ac_2017_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28827191", "content": {"CoiStatement": "Conflict of interest Authors declare that there are no conflicts of interest. Authors declare that there are no conflicts of interest. Acknowledgement 4. Discussion 5. Conclusion Conflict of interest Acknowledgement Transparency document References", "Acknowledgement": "Acknowledgement Authors thank Jiwaji University for providing laboratory facil- ities and UGC, SAP-II for financial support (F.4-1/2006(BSR)/7-97/ 2007(BSR), 26, June, 2012). 4. Discussion 5. Conclusion Conflict of interest Acknowledgement Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Simple-methodology-for-ensuring-the-precision-of-measurin_2021_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33227363", "content": {"CoiStatement": "Conflicts of interest This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. There are no conflicts of interest to declare. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. There are no conflicts of interest to declare. Funding body information Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Conflicts of interest Funding body information Declaration of competing interest Acknowledgments Appendix A Supplementary data References", "Funding": "This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. There are no conflicts of interest to declare. Funding body information Funding body information This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Declaration of competing interest Conflicts of interest Funding body information Declaration of competing interest Acknowledgments Appendix A Supplementary data References", "Compliance with ethical standards": "Solon, G.E., Kraus, L., 2002. Quantitative whole-body autoradiography in the pharmaceutical industry Survey results on the study design, methods, and regulatory compliance. J. Pharmacol. Toxicol. Methods 46, 73\u201381. Solon, G.E., Lee, F., 2002. Methods determining phosphor imaging limits of quantitation in whole-body autoradiography rodent tissue distribution studies affect predictions of 14C human dosimetry. J. Pharmacol. Toxicol. Methods 46, 83\u201391.", "Acknowledgement": "Acknowledgments We thank Mr. Shuhei Matsumoto (Shionogi & Co., Ltd., Toyonaka, Japan), Mr. Shiro Miyazaki, and Dr. Ken-ichi Nezasa (Shionogi TechnoAdvance Research Co., Ltd., Toyonaka, Japan) for support progress of our work. We are also grateful to Editage (www.editage. com) for English language editing. Conflicts of interest Funding body information Declaration of competing interest Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Simulation-of-consumer-exposure-to-deoxynivalenol-accordi_2005_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15964117", "content": {"Acknowledgement": "Acknowledgments This research was funded by the DGAL (French Ministry of Agriculture) and by INRA. We also thank Alex Edelman and Associates for editorial advice. Results and discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Simulation-to-aid-in-interpreting-biological-relevance-_2017_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28716578", "content": {"Acknowledgement": "Acknowledgements The development of scenarios was undertaken as part of the project \u201dUdvikling af et v\u00e6rkt\u00f8j til risikovurdering af pesticider, der tager h\u00f8jde for rumlige og tidsm\u00e6ssige processer, som eksisterende metoder ikke kan h\u00e5ndtere\u201d funded by the Danish EPA Ref: 667- 00176. 5. Conclusions Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Single-dose-acute-toxicity-testing-for-N-N-bis-2-mer_2014_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24721389", "content": {"CoiStatement": "In sum, BMEDA was not associated with any adverse effects in beagles at doses of up to 2 mg/kg in a 14-day systemic toxicity study, and the results of the toxicological tests support the safety of BMEDA for use in the preparation of the 188Re-BMEDA-liposome for clinical trials. Conflict of interest The authors of this publication have declared that they have no conflicts of interest. Appendix A. Supplementary data The authors of this publication have declared that they have no conflicts of interest. Appendix A. Supplementary data Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.yrtph.2014.04. 001. References Single dose acute toxicity testing for N,N-bis(2 1 Introduction 2 Materials and methods 2.1 Animals 2.2 Reagents 2.3 Exposure to BMEDA 2.4 Clinical pathology 2.5 Ophthalmoscopy and electrocardiography 2.6 Urinalysis 2.7 Clinical observations, body weighs, and food consumption 2.8 Examining tissue histology 2.9 Statistical analysis 3 Results 3.1 Clinical observations, body weights, and food consumption 3.2 Clinical pathology 3.3 Urinalysis 3.4 Ophthalmology, pathology, and cardiology 4 Discussion Conflict of interest Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Site-specific-cancer-risk-following-cobalt-exposure-via-_2022_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34896478", "content": {"CoiStatement": "Site-specific cancer risk following cobalt exposure via orthopedic implants or in occupational settings: A systematic revie ... 1 Introduction 2 Methods 3 Results 4 Discussion 5 Conclusion Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgement Appendix A Supplementary data References", "Disclosure": "Bartels, R.H., Delye, H., Boogaarts, J., 2012. Financial disclosures of authors involved in spine research: an underestimated source of bias. Eur. Spine J. 21 (7), 1229\u20131233. Behl, M., Stout, M.D., Herbert, R.A., et al., 2015. Comparative toxicity and carcinogenicity of soluble and insoluble cobalt compounds. Toxicology 333, 195\u2013205.", "Funding": "Site-specific cancer risk following cobalt exposure via orthopedic implants or in occupational settings: A systematic revie ... 1 Introduction 2 Methods 3 Results 4 Discussion 5 Conclusion Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgement Appendix A Supplementary data References", "Acknowledgement": "Acknowledgement The following individuals are acknowledged for their diligent review of the manuscript: Stephen Hope (LifeScan Scotland Inc.); Marek Kolendo (Waldemar Link GmbH & Co. KG); John Wright, Edward Reverdy, and Robert Hastings (Johnson & Johnson); Anna Moeke- Knizhnik (Biotronik); Bola Taiwo (Zimmer Biomet). Site-specific cancer risk following cobalt exposure via orthopedic implants or in occupational settings: A systematic revie ... 1 Introduction 2 Methods 3 Results 4 Discussion 5 Conclusion Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgement Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Six-well-plate-based-colony-forming-efficacy-assay-and_2022_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34800565", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 4 Discussion 5 Conclusion Funding CRediT authorship contribution statement Declaration of competing interest Appendix A Supplementary data References", "Funding": "Funding This work was supported by the Ministry of Food and Drug Safety of Korea (grant number: 20181MFDS401). 4 Discussion 5 Conclusion Funding CRediT authorship contribution statement Declaration of competing interest Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Six-years-after-the-NRC-review-of-EPA-s-Draft-IRIS-Toxicol_2018_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29158043", "content": {"Funding": "Conclusions Funding Acknowledgements Transparency document References", "Acknowledgement": "Conclusions Funding Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Skin-contact-transfer-of-three-fragrance-residu_2007_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/17560701", "content": {"Acknowledgement": "Acknowledgment The measurement of transfer of cinnamic aldehyde, d-limonene and eugenol residues from candles to human hands was carried out at Golden Pacific Laboratories un- der the supervision of Sami Selim, Ph.D. Discussion Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Skin-immune-cell-characterization-in-juvenile-a_2021_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33417970", "content": {"CoiStatement": "4 Discussion 5 Conclusion Declaration of competing interest Acknowledgement Appendix A Supplementary data References", "Acknowledgement": "4 Discussion 5 Conclusion Declaration of competing interest Acknowledgement Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Skin-irritation--false-positives-and-the-local-ly_2011_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21803111", "content": {"CoiStatement": "Conflict of interest The authors declare no conflicts of interest. The authors declare no conflicts of interest. Funding source Skin irritation, false positives and the local lymph node assay: A guideline issue? 1 Introduction 2 SLS \u2013 The classic irritant false positive 3 Published examples of claimed false positives 4 Are all skin sensitisers irritants? 5 Commentary on current sensitisation test guidelines 6 Conclusions and recommendations Conflict of interest Funding source References", "Funding": "Funding source None. Skin irritation, false positives and the local lymph node assay: A guideline issue? 1 Introduction 2 SLS \u2013 The classic irritant false positive 3 Published examples of claimed false positives 4 Are all skin sensitisers irritants? 5 Commentary on current sensitisation test guidelines 6 Conclusions and recommendations Conflict of interest Funding source References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Skin-irritation--prevalence--variability--and-regulato_2005_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15748793", "content": {"Acknowledgement": "Acknowledgments We thank Joseph Haseman whose earlier analysis of the ECETOC Database prompted our study. We are also grateful to Joaquin Baraibar Fentanes (ECB) for the data extraction from the ECB New Chemicals Data- base and Ray Tice (NICEATM) for critical review of the manuscript. Discussion Conclusion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Skin-lightening-products--violations-in-Europe--An-ana_2019_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31029853", "content": {"CoiStatement": "Conflicts of interest None declared. Declaration of interests \u2612The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. \u2610The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests. References Conclusions Supplementary data Sources of funding Conflicts of interest Declaration of interests References", "Funding": "Sources of funding This research was supported, in part, by a Transdisciplinary Center on Health Effects of Early Environmental Exposures P30 Core Center pilot grant (P30ES023515) at the Icahn School of Medicine at Mount Sinai. Conclusions Supplementary data Sources of funding Conflicts of interest Declaration of interests References", "Compliance with ethical standards": "violations\u2019 detection rate in the countries contributing to the Rapex database. Hence, the extent of underreporting bias and its variation in countries contributing to Rapex remains unexplored. Monitoring of the compliance of products with safety requirements is the responsibility of either respective national market surveillance authorities or authorities in charge of external border controls. It may be possible that market surveillance authorities in some countries comply with the law more rigorously than in others. Therefore, data from Rapex represent only an approximate overview of all dangerous products available on the European market. Besides, in some cases, there is no information on the content of the prohibited compound in the notified product. In the majority of cases, in which such information exists, it is unclear if the concentration of the compound indicated in the database is determined based on manu- facturers declaration only, or if it was confirmed by a reference la- boratory."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Skin-sensitisation---Moving-forward-with-non-animal-_2013_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24140884", "content": {"CoiStatement": "Finally, one of the most significant aspects of this workshop is it paved the way for, and perhaps even set the model for, future col- laborations between CEFIC-LRI, EPAA, ECHA and the national authorities in charge of implementing alternative approaches to animal testing. The positive atmosphere of the event and the valu- able progress made, was surprising to some, but in reality a neces- sity for the prompt adoption of skin sensitisation in vitro alternatives that can deliver the same degree of human health pro- tection currently afforded by the in vivo methods. Thus, it is felt that this Skin Sensitisation training workshop was a breakthrough in international collaboration on 3Rs which will promote their adoption and use in regulatory toxicology. Conflicts of interest DAB was paid by the EPAA for the preparation of this workshop report. The remaining authors are paid employees of their respec- tive organisations. Funding source None other than that reflected in the conflict of interest statement. References Adler, S., Basketter, D.A., Creton, S., Pelkonen, O., van Benthem, J., Zuang, V., et al., 2011. Alternative (non-animal) methods for cosmetics testing: current status and future prospects\u20142010. Arch. Toxicol. 85, 367\u2013485. 2 Regulatory requirements for the acceptance of non-animal test methods under REACH 3 Requirements for a non-animal Integrated Testing Strategy (ITS) 4 Acceptance of non-animal test methods pre-validation 5 How to facilitate acceptance 6 Concluding remarks Conflicts of interest Funding source References", "Funding": "DAB was paid by the EPAA for the preparation of this workshop report. The remaining authors are paid employees of their respec- tive organisations. Funding source None other than that reflected in the conflict of interest statement. References 2 Regulatory requirements for the acceptance of non-animal test methods under REACH 3 Requirements for a non-animal Integrated Testing Strategy (ITS) 4 Acceptance of non-animal test methods pre-validation 5 How to facilitate acceptance 6 Concluding remarks Conflicts of interest Funding source References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Skin-sensitization-and-possible-groupings-for--re_2009_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19409440", "content": {"Acknowledgement": "The current single criterion line for labelling requires that chemically modified rosins of very different sensitization potential are labelled similarly and chemically modified rosins of similar sensitization potential are labelled differently. Both the current and the proposed potency based regulatory classification criteria for skin sensitization use boundary criteria that would bisect the groupings that emerge as scientifically sound. However, the flexi- bility in one proposal, that for revising GHS Chapter 3.4, if it was accepted, would allow distinction between strong and weak sensi- tizers and is sufficiently flexible to permit more scientifically satisfying classifications. The presently reported studies illustrate the difficulties that can occur when reconciling science and regulation. Acknowledgments We thank the individual members of HARRPA for synthesising the chemically modified rosins, A Saunders and Safepharm (now Harlan) Laboratories for undertaking the mouse LLNA studies and Syngenta Central Toxicology Laboratory, Scantox and Eurofins/ Product Safety Laboratories for performing the remaining studies. Conclusions Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Skin-sensitization-in-chemical-risk-assessment--Report_2008_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18237832", "content": {"Acknowledgement": "Acknowledgments References Appendix A. Abstracts Introduction Main points Conclusions and future directions References Background Main points Dermal LLNA and hazard identification Respiratory LLNA Results Discussion and conclusions Future directions Acknowledgments References Introduction Main points Test sensitivity False positives False negatives Results Discussion and conclusions Future directions Acknowledgments References Introduction Main points Test sensitivity False positives False negatives Conclusions and future directions References Introduction Main points Hazard assessment Human data Animal studies"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Skin-sensitization-in-silico-protoc_2020_Regulatory-Toxicology-and-Pharmacol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32621976", "content": {"CoiStatement": "Reporting Conclusion Declaration of Competing Interest Acknowledgements Supplementary data Funding References Glossary", "Funding": "Reporting Conclusion Declaration of Competing Interest Acknowledgements Supplementary data Funding References Glossary", "Acknowledgement": "Reporting Conclusion Declaration of Competing Interest Acknowledgements Supplementary data Funding References Glossary"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Skin-sensitization-quantitative-risk-assessment-for-o_2018_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29530615", "content": {"CoiStatement": "Conflict of interest statement Carsten Goebel, Anne Fuchs, Kordula Schlotmann and Maya Krasteva are employees of companies selling cosmetic products in- cluding hair colorants. The hair dye ingredients studied in this paper are currently used in commercial products marketed by these compa- nies. A one day workshop was organized and sponsored by these companies and Thomas Diepgen, Brunhilde Bl\u00f6meke, Anthony Gaspari, Axel Schnuch and Ian Kimber were invited as consultants. The authors alone are responsible for the content and writing of the paper. Discussion Conflict of interest statement Acknowledgments Transparency document References", "Funding": "Schwensen, J.F., Johansen, J.D., Veien, N.K., Funding, A.T., Avnstorp, C., Osterballe, M., Andersen, K.E., Paulsen, E., Mortz, Carsten Goebel., Sommerlund, M., Danielsen, A., Andersen, B.L., Thormann, J., Kristensen, O., Kristensen, B., Vissing, S., Nielsen, N.H., Thyssen, J.P., Sosted, H., 2014. Occupational contact dermatitis in hairdressers: an analysis of patch test data from the Danish contact dermatitis group, 2002-2011. Contact Dermatitis 70 (4), 233\u2013237. Simon, G.A., Maibach, H.I., 2000. The pig as an experimental animal model of percuta- neous permeation in man: qualitative and quantitative observations\u2013an overview. Skin Pharmacol. Appl. Skin Physiol. 13 (5), 229\u2013234.", "Acknowledgement": "Acknowledgments All authors of this paper participated as active members in a workshop that was held in January 2016. As a follow-up of this workshop, the manuscript was composed based on the individual contributions. The manuscript is the joint work of the authors. Discussion Conflict of interest statement Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Slow-infusion-rate-of-doxorubicin-induces-higher-_2016_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27494949", "content": {"CoiStatement": "Conflicts of interest statement The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgments This study was supported, in part, by grants from the National Science Counsel (NSC 101-2314-B-320-002), Tzu Chi University (TCRPP103017), and Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation (TCRD-TPE-103-54). The authors declare that they have no competing interests. We are grateful to Mr. S.J. Ko for the excellent technical advice on the animal experiment. Transparency document 4. Discussion Conflicts of interest statement Acknowledgments Transparency document References", "Acknowledgement": "Acknowledgments This study was supported, in part, by grants from the National Science Counsel (NSC 101-2314-B-320-002), Tzu Chi University (TCRPP103017), and Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation (TCRD-TPE-103-54). The authors declare that they have no competing interests. We are grateful to Mr. S.J. Ko for the excellent technical advice on the animal experiment. 4. Discussion Conflicts of interest statement Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Smoking-bans-and-the-reduction-in-heart-diseas_2012_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22120437", "content": {"CoiStatement": "Smoking bans and the reduction in heart diseases: The emerging scenario Source of funding Conflict of interest statement References", "Funding": "Smoking bans and the reduction in heart diseases: The emerging scenario Source of funding Conflict of interest statement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Smoking-behaviour-and-compensation--A-review-of-_2014_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25277253", "content": {"CoiStatement": "4 Conclusions Conflict of interest Acknowledgments Appendix A Supplementary data References", "Acknowledgement": "4 Conclusions Conflict of interest Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Smoking-intensity-before-and-after-introduction-of_2011_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20347910", "content": {"CoiStatement": "5. Conflict of interest statement The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgments Discussion Conflict of interest statement Acknowledgments References", "Compliance with ethical standards": "This study demonstrated good compliance with the public place smoking ban, as no cigarettes were reportedly smoked indoors at the study locations seven months after the ban. There was a corre- sponding increase in outdoor smoking, but total cigarette con- sumption was unchanged over the study period. Self-reported consumption is an imprecise measure that can be affected by bias and under-reporting (Warner, 1978), in addition, recent data sug- gest that self-reported cigarette consumption on recruitment to a study tends to be higher than cigarette consumption \u2018in the last 24 h\u2019 (Mariner et al., this issue). However, in this study design the same subjects were used in all three waves. Therefore, if one reasonably assumes that individuals consistently under or over re- port smoking habits, then the across wave comparisons in this case are a valid tool for assessing changes in consumption. Also, the pat- tern is consistent with the combined monthly sales volume figures for the selected cigarette products in Scotland compiled by ACNiel- sen Retail Audit which reported total sales by retailers to consum- ers for cigarettes A\u2013D in Scotland in 2006 as follows: millions of cigarettes for February: 152.21; April: 153.76; October: 162.00. In summary, smoking outdoors at public venues, as a result of the PPam Saunders ban in Scotland, did not increase smoking intensity. Any changes in smoking behaviour that may have occurred had little effect on estimated mainstream smoke exposure or cigarette con- sumption for those that continued to smoke. We suggest that filter analysis can provide a valuable tool for measuring changes in smoke exposure as a consequence of, e.g., environmental factors that affect smoking behaviour or differences in cigarette design.", "Acknowledgement": "Acknowledgments The authors thank Ulf Boderius, Michael Weiss and Michael Baer (BAT Regional Product Centre, Bayreuth, Germany) for analyt- ical support and Graham Errington (GR&D, BAT) for advice on sta- tistical analysis. Discussion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Socio-economic-analysis-for-the-authorisation-of-ch_2014_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25220186", "content": {"Acknowledgement": "Acknowledgments We wish to thank Karen Thiele for helpful comments to an earlier draft of our paper. Financial support from Luxemburg Envi- ronment Agency is gratefully acknowledged. 5 Conclusions Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Some-consequences-of-using-cigarette-machine-smoking-r_2011_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21074590", "content": {"CoiStatement": "Further collaborative investigations need to be carried out to bet- ter understand the causes of variability under the CI smoking regime. Before proposing smoking regimes as tools to evaluate smoke emis- sions, it is essential to understand the various interacting factors that smoking regimes can generate, the limitations of their use and the requirement for adequate measurement tolerances. Conflicts of interest The authors are employees of and the study was funded by the Imperial Tobacco Group. Conclusions Conflicts of interest Acknowledgments References", "Acknowledgement": "Acknowledgments The authors would like to thank Sandra Kudszus, Christian Mueller and Fiona Miller for their contributions to this work programme. Conclusions Conflicts of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/South-African-experience-with-asbestos-related-envir_2008_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18023951", "content": {"CoiStatement": "Conflict of Interest The authors declare that they have no conflicts of interest. The authors declare that they have no conflicts of interest. S96 N. White et al. / Regulatory Toxicology and Pharmacology 52 (2008) S92\u2013S96 References aufn1 South African experience with asbestos related environmental mesothelioma: Is asbestos fiber type important? Introduction History of mesothelioma in South Africa Review of the literature Discussion Conclusion Conflict of Interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Special-endpoint-and-product-specific-considerations_2016_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27233924", "content": {"Acknowledgement": "8. Conclusion Acknowledgements Appendix A. Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Species-selection-for-nonclinical-safety-assessment-_2021_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34455009", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. CRediT authorship contribution statement Declaration of competing interest Acknowledgements References", "Acknowledgement": "Acknowledgements The author(s) received no financial support for the research, authorship, and/or publication of this article. The Open Access publi- cation fees have been covered by contributions from the following companies: Roche. CRediT authorship contribution statement Declaration of competing interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Species-specific-inhalable-exposures-in-the-nickel-ind_2007_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/17270331", "content": {"Acknowledgement": "Concluding remarks Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Spontaneous-reports-of-primarily-suspected-herbal-hepa_2012_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22381150", "content": {"CoiStatement": "In conclusion, the present analysis of spontaneous reports of 15 patients reveals little if any evidence for a hepatotoxicity of PS. Problems included poor data quality, lack of efforts to exclude even common liver diseases, and numerous PS unrelated diagnoses. Moreover, assessments of these cases do not fulfill essential crite- ria required to propose the existence of PS hepatotoxicity. Conflict of interest The authors declare that they do not have any conflict of interest. The authors declare that they do not have any conflict of interest. References 4 Discussion Conflict of interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Spontaneous-reports-of-primarily-suspected-herbal-hepato_2012_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22728685", "content": {"CoiStatement": "Spontaneous reports of primarily suspected herbal hepatotoxicity by Pelargonium sidoides: Was causality adequately ascertained? Teschke et al. (2012) Conflict of interest statement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Spontaneously-occurring-fundus-findings-observed-using_2016_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26873774", "content": {"Acknowledgement": "Acknowledgments This study was funded by the Natural Science and Engineering Council (NSERC) of Canada, 2020 Network for the Development of Ophthalmic Biomaterials, and by Translatum Medicus Inc., Canada. 3. Results 4. Discussion Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Standardization--in-silico-and-in-vivo-safety-assessm_2022_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/35218873", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 4 Discussion 5 Conclusion Authors\u2019 contributions Consent for publication Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgement Appendix A Supplementary data References", "Funding": "Funding body information The authors kindly acknowledge the support received from Depart- ment of Science and Technology, New Delhi, Govt. of India supported National Facility for Drug Development (NFDD) for academia, phar- maceutical and allied industries (VI-D&P/349/10\u201311/TDT/1 Dt. October 21, 2010) at Bharathidasan Institute of Technology, Anna University, Tiruchirappalli, providing the necessary facilities and con- stant support to carry out the proposed work. 4 Discussion 5 Conclusion Authors\u2019 contributions Consent for publication Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgement Appendix A Supplementary data References", "Acknowledgement": "Acknowledgement The authors kindly acknowledge the support received from the Department of Science and Technology, New Delhi, Govt. of India sup- ported National Facility for Drug Development (NFDD) for academia, pharmaceutical, and allied industries (VI-D&P/349/10\u201311/TDT/1 Dt. October 21, 2010) at Bharathidasan Institute of Technology, Anna University, Tiruchirappalli, providing the necessary facilities and con- stant support to carry out the proposed work. 4 Discussion 5 Conclusion Authors\u2019 contributions Consent for publication Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgement Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Standardization-of-the-perchlorate-discharge-assa_2007_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/17573170", "content": {"Acknowledgement": "As PB and PTU as representatives of the indirect and direct mechanism respectively yielded reproducible results after a 2- and 4-week treatment interval we propose to include these compounds as positive control substances in any PDA. The duration of treatment in the PDA can be limited to 2 weeks. The effects of direct acting compounds on the thyroid and thyroid hormones will be notable within this time span and most compounds that act through an indirect (liver enzyme induction) mechanism will also be seen after this time. Only compounds with are weak liver enzyme inducers and which have a significant accumula- tion potential may need a 4-week treatment period before the PDA can demonstrate clear effects. The advantages of the PDA are several fold: (1) a single study is sufficient to distinguish between the direct and indirect mechanism, (2) high reproducibility (particularly when compared to hormone assays) and (3) high sensitivity. Acknowledgment The authors thank Dr. Henk Tennekes (ETS\u2014Nether- lands) for his help in the preparation of the manuscript. References Discussion Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Standardized-UV-vis-spectra-as-the-foundation-for-a_2014_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24269723", "content": {"CoiStatement": "Conflict of interest The author declares that there are no conflicts of interest. The author declares that there are no conflicts of interest. Acknowledgments 4 Conclusion Conflict of interest Acknowledgments References", "Compliance with ethical standards": "FDA, Center for Drug Evaluation and Research(CDER), 2003. FDA Guidance for industry\u2013photosafety testing (<http://www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ucm079252.pdf>). Ferguson, J., 2002. Photosensitivity due to drugs. Photodermatol. Photoimmunol. Photomed. 18, 262\u2013269. http://refhub.elsevier.com/S0273-2300(13)00208-0/h0005 http://refhub.elsevier.com/S0273-2300(13)00208-0/h0005 http://refhub.elsevier.com/S0273-2300(13)00208-0/h0005 http://refhub.elsevier.com/S0273-2300(13)00208-0/h0005 http://www.ema.europa.eu/pdfs/human/swp/039801en.pdf http://www.ema.europa.eu/pdfs/human/swp/039801en.pdf http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm079252.pdf http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm079252.pdf http://refhub.elsevier.com/S0273-2300(13)00208-0/h0020 http://refhub.elsevier.com/S0273-2300(13)00208-0/h0020 http://refhub.elsevier.com/S0273-2300(13)00208-0/h0025 http://refhub.elsevier.com/S0273-2300(13)00208-0/h0025 http://refhub.elsevier.com/S0273-2300(13)00208-0/h0025 http://www.ich.org/products/guidelines/multidisciplinary/article/multidisciplinary-guidelines.html http://www.ich.org/products/guidelines/multidisciplinary/article/multidisciplinary-guidelines.html http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html http://refhub.elsevier.com/S0273-2300(13)00208-0/h0040 http://refhub.elsevier.com/S0273-2300(13)00208-0/h0040 http://refhub.elsevier.com/S0273-2300(13)00208-0/h0040 http://refhub.elsevier.com/S0273-2300(13)00208-0/h0045 http://refhub.elsevier.com/S0273-2300(13)00208-0/h0045 http://www.oecd.org/env/testguidelines http://www.oecd.org/env/testguidelines http://www.oecd.org/env/testguidelines http://www.oecd.org/env/testguidelines http://refhub.elsevier.com/S0273-2300(13)00208-0/h0060 http://refhub.elsevier.com/S0273-2300(13)00208-0/h0060 http://refhub.elsevier.com/S0273-2300(13)00208-0/h0060 http://refhub.elsevier.com/S0273-2300(13)00208-0/h0065 http://refhub.elsevier.com/S0273-2300(13)00208-0/h0065 http://refhub.elsevier.com/S0273-2300(13)00208-0/h0065 http://refhub.elsevier.com/S0273-2300(13)00208-0/h0070 http://refhub.elsevier.com/S0273-2300(13)00208-0/h0070 http://refhub.elsevier.com/S0273-2300(13)00208-0/h0075 http://refhub.elsevier.com/S0273-2300(13)00208-0/h0075 http://refhub.elsevier.com/S0273-2300(13)00208-0/h0075 http://refhub.elsevier.com/S0273-2300(13)00208-0/h0080 http://refhub.elsevier.com/S0273-2300(13)00208-0/h0080 http://refhub.elsevier.com/S0273-2300(13)00208-0/h0080 http://refhub.elsevier.com/S0273-2300(13)00208-0/h0085 http://refhub.elsevier.com/S0273-2300(13)00208-0/h0085 http://refhub.elsevier.com/S0273-2300(13)00208-0/h0085 Standardized UV\u2013vis spectra as the foundation for a threshold-based, integrated photosafety evaluation 1 Introduction 1.1 Background: photosafety evaluation during drug development 1.2 \u201cSunlight\u201d, \u201csimulated sunlight\u201d and its absorption by drug substance molecules 1.3 Objective of the study: demonstrate sufficient evidence to support an empirical threshold for relevant light absorption and to enable a tiered photosafety assessment strategy", "Acknowledgement": "Acknowledgments Phil Wilcox (GlaxoSmithKline) for providing input and review- ing the manuscript. Xiao Feng for supporting data selection at Johnson & Johnson/Janssen. 4 Conclusion Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/State-of-the-science-on-alternatives-to-animal-testing-a_2020_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31705943", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Co-author, Agnes Karmaus, received funds from the ILSI North America Food and Chemical Safety Committee for her work on this article. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Co-author, Agnes Karmaus, received funds from the ILSI North America Food and Chemical Safety Committee for her work on this article. Transparency document", "Funding": "Funding The author(s) disclosed the receipt of the following financial sup- port for the research, authorship, and/or publication of this article: The workshop was co-sponsored by the US Food and Drug Administration Center for Food Safety and Applied Nutrition and the ILSI North America Food and Chemical Safety Committee. ILSI North America is a public, nonprofit foundation that provides a forum to advance the un- derstanding of scientific issues related to the nutritional quality and safety of the food supply by sponsoring research programs, educational seminars and workshops, and publications. ILSI North America receives support primarily from its industry membership. The views expressed in this study are those of the authors. Co-author, Agnes Karmaus, sup- ported the development of this article and received funds from the ILSI North America Food and Chemical Safety Committee for her work on this article. The authors thank the speakers for reviewing the manu- script. State of the science on alternatives to animal testing and integration of testing strategies for food safety assessments: Workshop proceedings Introduction and purpose of the workshop Emerging testing strategies in food safety: from traditional toxicity testing to 21st century toxicology New approaches for safety assessment: lessons learned and the path forward Read-across approaches Panel discussion and key takeaways Authors\u2019 note Funding mk:H1_8 Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Statistical-analysis-of-in-vivo-alkaline-comet-assay-d_2020_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33127357", "content": {"CoiStatement": "4 Discussion 5 Conclusion Funding Declaration of competing interest Acknowledgement Appendix A Acknowledgement Appendix B Appendix C References", "Funding": "4 Discussion 5 Conclusion Funding Declaration of competing interest Acknowledgement Appendix A Acknowledgement Appendix B Appendix C References", "Acknowledgement": "4 Discussion 5 Conclusion Funding Declaration of competing interest Acknowledgement Appendix A Acknowledgement Appendix B Appendix C References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Statistical-analysis-of-the-reproducibility-and-predict_2019_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31325533", "content": {"CoiStatement": "Conflicts of interest None. Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Acknowledgment Conclusion Conflicts of interest Funding sources Declaration of interests Acknowledgment Supplementary data References", "Funding": "Funding sources This work was supported by grants from the Ministry of Food and Drug Safety, Korea (16182MFDS522) and the National Research Foundation of Korea (MSIT; 2018R1A5A2025286). Conclusion Conflicts of interest Funding sources Declaration of interests Acknowledgment Supplementary data References", "Acknowledgement": "Acknowledgment This work was supported by grants from the Ministry of Food and Drug Safety, Korea (16182MFDS522 and 18182MFDS463) and the National Research Foundation of Korea (MSIT; 2018R1A5A2025286). Conclusion Conflicts of interest Funding sources Declaration of interests Acknowledgment Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Statistical-analysis-used-in-the-nutritional-asses_2006_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16298467", "content": {"Acknowledgement": "Acknowledgment We thank Msc G. Dilba, University of Hannover, for programming the Fieller interval using the R-package nlme. Hothorn, L.A., 2003. Statistics of interlaboratory in vitro toxicological studies. ATLA (Altern. Lab Anim. 31 (Suppl. 1), 43\u201363. Hothorn, T., Hornik, K., 2002. Exact nonparametric inference in R. In: Ha\u0308rdle, W., Ro\u0308nz, B. (Eds.), Proceedings in Computational Statistics: COMPSTAT2002. Physica-Verlag, Heidelberg, pp. 355\u2013360. Hothorn, T., Munzel, U., 2002. Non-parametric confidence interval for the ratio. Report University of Erlangen, Department Medical Statistics. <http://www.uni-erlangen.de>. ICH, 1996. Guideline for industry: Specific aspects of regulatory genotoxicity tests for pharmaceuticals. In: International Conference on Harmonization ICH S2A. (<http://www.fda.gov/cder/guidance/ ichs2a.pdf>). Kirkland, D.J., Hayashi, M., MacGregor, J.T., 2000. Summary of major conclusions from the international workshop on genotoxicity test procedure. Environ. Mol. Mutagen. 35, 162\u2013166. Liu, J.P., Weng, C.S., 1994. Evaluation of log-transformation in assessing bioequivalence. Commun. Stat. A23, 421\u2013434. McBride, G.B., 2003. Statistical methods helping and hindering environ- mental science and management. J. Agric. Biol. Environ. Stat. 7, 300\u2013305. Metha, C., Patel, N., 2001. StatXact 5. Cytel Corp., Cambridge. Nordic Council, 2000. Safety Assessment of Novel Food Plants. Chemical analytical approaches to the establishment of substantial equivalence. TemaNord 1998: 591. Nordic Council of Ministers, Copenhagen. Oberdoerfer, R.B., 2003. Example dataset from composition analyses of genetically modified oilseed rape seeds. BCS GmbH. Obert, J.C., Ridley, W.P., Schneider, R.W., 2004. The composition of grain and forage from glyphosate tolerant wheat MON 71800 is equivalent to that of conventional wheat (Triticum aestivum L.). J. Agric. Food Chem. 52, 1375\u20131384. OECD, 2001. Consensus Document on Key Nutrients and Key Toxicants in Low Euric Acid Rapeseed (Canola). ENV/JM/MONO(2001)13. Series on Harmonization of Regulatory Oversight in Biotechnology, 134 L.A. Hothorn, R. Oberdoerfer / Regulatory Toxicology and Pharmacology 44 (2006) 125\u2013135 13; Organization of Economic Cooperation and Development: Paris, France, 1999. Available at: <http://www.oecd.org>. O\ufffdGorman, T.W., 2001. A comparison of the F-test, Friedman\ufffds test, and several aligned rank tests for the analysis of randomized complete blocks. J. Agric. Biol. Environ. Stat. 6, 367\u2013378. Quan, H., Bolognese, J., Yuan, W., 2001. Assessment of equivalence on multiple endpoints. Stat. Med. 20, 3159\u20133173. Roehmel, J., 1998. Therapeutic equivalence investigations: statistical considerations. Stat. Med. 17, 1703\u20131714. Sasabuchi, S., 1988. A multivariate one-sided test with composite hypotheses determined by linear inequalities when the covariance matrix has an unknown scale factor, Memoirs Faculty Sci., Kyushu University A42, 9\u201319. Schuirmann, D.J., 1987. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J. Pharmacokin. Biopharm. 15, 657\u2013680. Sidhu, R.S., Hammond, B.G., Fuchs, R.L., 2000. Glyphosate-tolerant corn: The composition and feeding value of grain from glyphosate- tolerant corn is equivalent to that of conventional corn (Zea mays L.). J. Agric. Food Chem. 48, 2305\u20132312. Tempelman, R.J., 2004. Experimental design and statistical methods for classical and bioequivalence hypothesis testing with an appli- cation to dairy nutrition studies. J. Anim. Sci. 82 (E. Suppl.), E162\u2013E172. Van Dongen, S., 2000. Statistical analysis of amounts and ratios in pheromone composition: a mixed model approach. Entomol. Exp. Appl. 94, 269\u2013282. Westfall, P.H., Tobias, R.D., Rom, D., Wolfinger, R.D., Hochberg, Y., 1999. Multiple Comparisons and Multiple Tests Using the SAS System. SAS Institute Inc., Cary. Young, D.A., Zerbe, G.O., Hay, W.W., 1997. Fieller\ufffds theorem, Scheffe simultaneous confidence intervals, and ratios of parameters of linear and nonlinear mixed-effects models. Biometrics 53, 838\u2013847. L.A. Hothorn, R. Oberdoerfer / Regulatory Toxicology and Pharmacology 44 (2006) 125\u2013135 135 Statistical analysis used in the nutritional assessment of novel food using the proof of safety Introduction Methods Discussion and conclusion Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Statistical-considerations-for-a-chronic-bioassay-study--Ex_2016_Regulatory-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26772617", "content": {"CoiStatement": "Conflicts of interest The work was funded by the American Chemistry Council (ACC, http://www.americanchemistry.com/). Evonik Industries applies D5 in the production of special chemicals (http://www.evonik. com). 2. Discussion Conflicts of interest Acknowledgment References", "Acknowledgement": "Acknowledgment Data for both treated and control rats were provided by Dow Corning. The methods presented here build upon the work of George Casella and his co-workers, AndrewWomack and Luis Leon Novelo. Andrew Womack provided all programs the group had used and corrected the probit analysis program. 2. Discussion Conflicts of interest Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Statistical-evaluation-of-mortality-in-long-term-car_2012_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22749913", "content": {"CoiStatement": "The presented Williams-type procedure can also be used to evaluate mortality, observable and fatal tumor data in long-term carcinogenicity studies. An example of the analysis of fatal tumor data is given in the Supplementary material. If the cause-of-death is unknown, a related poly-k approach is recommended (Schaarschmidt et al., 2008). For the common analysis of crude mortality or tumor rates, a related Williams-type approach is avail- able, which is particularly suitable for medium to small sample sizes (Hothorn et al., 2010). The related software is freely available, and real example data can be easily analyzed by these new ap- proaches using the R packages survival, coxme, multcomp, MCPAN, and nparcomp. Conflict of interest statement The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgement 7 Software 8 Discussion Conflict of interest statement Acknowledgement Appendix A Supplementary data References", "Acknowledgement": "Acknowledgement This work was supported in part by HO 1687/9-1 to the second author. Appendix A. Supplementary data 7 Software 8 Discussion Conflict of interest statement Acknowledgement Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Statistical-evaluation-of-the-Local-Lymph_2010_Regulatory-Toxicology-and-Pha.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19922754", "content": {"Acknowledgement": "Acknowledgments The authors would like to thank the three anonymous referees for their valuable comments which helps to improve the readabil- ity for non-statisticians substantially. A proof of safety approach for ratios-to-control comparisons A proposal for routine evaluation Software Conclusions Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Statistical-methodology-to-determine-kinetically-deri_2012_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22487418", "content": {"CoiStatement": "Conflict of interest The authors work for the company at which the substances used as examples are produced. Conflict of interest Acknowledgments Appendix A Supplementary data References", "Acknowledgement": "Acknowledgments The authors wish to thank the Industrial Task Force II on 2,4-D Research Data for allowing the data collected in the extended one- generation dietary toxicity study to be analyzed in this manner. Conflict of interest Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Statistical-methodology-to-evaluate-food-exposure-to-a_2004_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15546679", "content": {"Acknowledgement": "J. Tressou et al. / Regulatory Toxicology and Pharmacology 40 (2004) 252\u2013263 263 but the proposed codex ML on cereals would not signif- icantly reduce the probability to exceed the PTWI. How- ever, the risk to exceed the PTWI is significantly reduced for adults when applying a ML of 5 lg/kg on cereals. On the other hand, the currently proposed ML on wine does not have a significant impact neither on adults nor on wine consumers. Acknowledgments Authors thanks the National Office of wine (ONIV- INS) and French administrations in charge of the Na- tional Food Control (DGCCRF, DGAL) for providing contamination data. References Conclusions Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Statistical-power-in-the-analyses-of-brain-weight-measur_2010_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20226222", "content": {"CoiStatement": "In summary, we examined statistical power in studies of pesti- cide exposure effects on rat brain weight and compared these val- ues within and between commercial laboratories conducting these studies. Our analyses were based on an assumed sample size of 10 animals per group as this was the most common size used in the studies available. In addition, we assumed equal brain weight var- iance between control and treatment groups; therefore, our values may overestimate true probabilities of detecting statistically \u2018\u2018sig- nificant\u201d differences in brain weight in cases where brain weight variance is increased among animals treated with a given pesticide. Likewise, as it was not possible to account for within-litter correla- tions in brain weight (i.e. the fact that brain weights among ani- mals from the same litter are expected to be more similar than brain weights between animals from different litters), the values presented may overestimate power values in full DNT studies if treating all values as independent resulted in an underestimation of between-litter brain weight variance. In general, our findings suggest that biological significance as determined by toxicological expertise should take precedence over statistical \u2018\u2018significance\u201d in studies of pesticide exposure effects on rat brain weight as the power to detect these differences may be low and may vary consid- erably across studies and between laboratories. Conflict of interest statement The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. References Discussion Conflict of interest statement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Status-of-acute-systemic-toxicity-testing-requireme_2018_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29408321", "content": {"Funding": "https://www.gpo.gov/fdsys/search/pagedetails.action?collectionCode=PLAW\ufffd&\ufffdbrowsePath=114%2FPUBLIC%2F[100+XHYPHENXX+XCLOSEBRACKETXX\ufffd&\ufffdgranuleId=\ufffd&\ufffdpackageId=PLAW-114publ182\ufffd&\ufffdfromBrowse=true https://www.gpo.gov/fdsys/search/pagedetails.action?collectionCode=PLAW\ufffd&\ufffdbrowsePath=114%2FPUBLIC%2F[100+XHYPHENXX+XCLOSEBRACKETXX\ufffd&\ufffdgranuleId=\ufffd&\ufffdpackageId=PLAW-114publ182\ufffd&\ufffdfromBrowse=true http://refhub.elsevier.com/S0273-2300(18)30038-2/sref23 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref58 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref92 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref92 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref94 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref94 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref95 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref95 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref2 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref96 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref96 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref3 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref3 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref4 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref4 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref4 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref6 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref6 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref6 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref6 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref6 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref7 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref7 http://dx.doi.org/10.1016/j.tiv.2017.12.011 http://dx.doi.org/10.1016/j.yrtph.2016.10.007 http://dx.doi.org/10.1016/j.yrtph.2016.10.007 http://www.cpsc.gov/en/Business%5fManufacturing/Testing-Certification/Recommended-Procedures-Regarding-the-CPSCs-Policy-on-Animal-Testing/ http://www.cpsc.gov/en/Business%5fManufacturing/Testing-Certification/Recommended-Procedures-Regarding-the-CPSCs-Policy-on-Animal-Testing/ http://www.cpsc.gov/en/Business%5fManufacturing/Testing-Certification/Recommended-Procedures-Regarding-the-CPSCs-Policy-on-Animal-Testing/ http://www.cpsc.gov/en/Business%5fManufacturing/Testing-Certification/Recommended-Procedures-Regarding-the-CPSCs-Policy-on-Animal-Testing/ http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-sec1500-3.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-sec1500-3.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-sec1500-40.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-sec1500-40.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-sec1500-40.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-part1702.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-part1702.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-sec1500-232.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-sec1500-232.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-sec1500-232.pdf http://www.phmsa.dot.gov/pv_obj_cache/pv_obj_id_FC1B48D1EA0BE29F97429EC9David Allen321602AD970000/filename/SP10904_2006050025.pdf http://www.phmsa.dot.gov/pv_obj_cache/pv_obj_id_FC1B48D1EA0BE29F97429EC9David Allen321602AD970000/filename/SP10904_2006050025.pdf http://www.phmsa.dot.gov/pv_obj_cache/pv_obj_id_FC1B48D1EA0BE29F97429EC9David Allen321602AD970000/filename/SP10904_2006050025.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title49-vol2/pdf/CFR-2015-title49-vol2-sec173-133.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title49-vol2/pdf/CFR-2015-title49-vol2-sec173-133.pdf http://www.ecfr.gov/cgi-bin/text-idx?SID=516261bee7784b6aa6b2fe828f61a636\ufffd&\ufffdmc=true\ufffd&\ufffdnode=se49.2.173_1132\ufffd&\ufffdrgn=div8 http://www.ecfr.gov/cgi-bin/text-idx?SID=516261bee7784b6aa6b2fe828f61a636\ufffd&\ufffdmc=true\ufffd&\ufffdnode=se49.2.173_1132\ufffd&\ufffdrgn=div8 http://www.ecfr.gov/cgi-bin/text-idx?SID=516261bee7784b6aa6b2fe828f61a636\ufffd&\ufffdmc=true\ufffd&\ufffdnode=se49.2.173_1132\ufffd&\ufffdrgn=div8 http://www.gpo.gov/fdsys/pkg/CFR-2015-title49-vol2/pdf/CFR-2015-title49-vol2-sec173-137.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title49-vol2/pdf/CFR-2015-title49-vol2-sec173-137.pdf https://eurl-ecvam.jrc.ec.europa.eu/eurl-ecvam-recommendations/3t3-nru-recommendation https://eurl-ecvam.jrc.ec.europa.eu/eurl-ecvam-recommendations/3t3-nru-recommendation https://eurl-ecvam.jrc.ec.europa.eu/eurl-ecvam-strategy-papers/strategy-acute-mammalian-systemic-toxicity https://eurl-ecvam.jrc.ec.europa.eu/eurl-ecvam-strategy-papers/strategy-acute-mammalian-systemic-toxicity https://eurl-ecvam.jrc.ec.europa.eu/eurl-ecvam-strategy-papers/strategy-acute-mammalian-systemic-toxicity http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02006R1907-20140410 http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02006R1907-20140410 http://dx.doi.org/10.1016/j.tiv.2017.01.004 http://dx.doi.org/10.1016/j.tiv.2017.01.004 http://dx.doi.org/10.1126/science.1188302 https://ntp.niehs.nih.gov/pubhealth/evalatm/test-method-evaluations/acute-systemic-tox/oral-udp/peer-review-rpt/index.html#Complete-Report https://ntp.niehs.nih.gov/pubhealth/evalatm/test-method-evaluations/acute-systemic-tox/oral-udp/peer-review-rpt/index.html#Complete-Report https://ntp.niehs.nih.gov/iccvam/docs/acutetox_docs/brd_tmer/at-tmer-complete.pdf https://ntp.niehs.nih.gov/iccvam/docs/acutetox_docs/brd_tmer/at-tmer-complete.pdf https://ntp.niehs.nih.gov/go/natl-strategy https://ntp.niehs.nih.gov/go/natl-strategy http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step4/S6_R1_Guideline.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step4/S6_R1_Guideline.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2__Guideline.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2__Guideline.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2__Guideline.pdf http://refhub.elsevier.com/S0273-2300(18)30038-2/sref30 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref30 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref32 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref32 http://dx.doi.org/10.3791/54344 https://ntp.niehs.nih.gov/iccvam/meetings/iccvam-forum-2016/1-iccvam-508.pdf https://ntp.niehs.nih.gov/iccvam/meetings/iccvam-forum-2016/1-iccvam-508.pdf http://ntp.niehs.nih.gov/ntp/about_ntp/sacatm/2016/september/update20160927_508.pdf http://ntp.niehs.nih.gov/ntp/about_ntp/sacatm/2016/september/update20160927_508.pdf http://ntp.niehs.nih.gov/ntp/about_ntp/sacatm/2016/september/update20160927_508.pdf http://dx.doi.org/10.1016/j.ejpb.2015.03.002 https://www.nap.edu/catalog/10122/standing-operating-procedures-for-developing-acute-exposure-guideline-levels-for-hazardous-chemicals https://www.nap.edu/catalog/10122/standing-operating-procedures-for-developing-acute-exposure-guideline-levels-for-hazardous-chemicals https://www.nap.edu/catalog/10122/standing-operating-procedures-for-developing-acute-exposure-guideline-levels-for-hazardous-chemicals http://www.nap.edu/catalog.php?record_id=11970 https://www.nap.edu/catalog/21775/application-of-modern-toxicology-approaches-for-predicting-acute-toxicity-for-chemical-defense https://www.nap.edu/catalog/21775/application-of-modern-toxicology-approaches-for-predicting-acute-toxicity-for-chemical-defense https://www.nap.edu/catalog/21775/application-of-modern-toxicology-approaches-for-predicting-acute-toxicity-for-chemical-defense http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2001 http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2001 http://www.oecd-ilibrary.org/environment/test-no-420-acute-oral-toxicity-fixed-dose-procedure_9789264070943-en http://www.oecd-ilibrary.org/environment/test-no-420-acute-oral-toxicity-fixed-dose-procedure_9789264070943-en http://www.oecd-ilibrary.org/environment/test-no-420-acute-oral-toxicity-fixed-dose-procedure_9789264070943-en http://www.oecd-ilibrary.org/environment/test-no-423-acute-oral-toxicity-acute-toxic-class-method_9789264071001-en http://www.oecd-ilibrary.org/environment/test-no-423-acute-oral-toxicity-acute-toxic-class-method_9789264071001-en http://www.oecd-ilibrary.org/environment/test-no-423-acute-oral-toxicity-acute-toxic-class-method_9789264071001-en http://www.oecd-ilibrary.org/environment/test-no-425-acute-oral-toxicity-up-and-down-procedure_9789264071049-en http://www.oecd-ilibrary.org/environment/test-no-425-acute-oral-toxicity-up-and-down-procedure_9789264071049-en http://www.oecd-ilibrary.org/environment/test-no-425-acute-oral-toxicity-up-and-down-procedure_9789264071049-en http://refhub.elsevier.com/S0273-2300(18)30038-2/sref46 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref46 http://www.oecd-ilibrary.org/environment/test-no-403-acute-inhalation-toxicity_9789264070608-en http://www.oecd-ilibrary.org/environment/test-no-403-acute-inhalation-toxicity_9789264070608-en http://www.oecd-ilibrary.org/environment/test-no-436-acute-inhalation-toxicity-acute-toxic-class-method_9789264076037-en http://www.oecd-ilibrary.org/environment/test-no-436-acute-inhalation-toxicity-acute-toxic-class-method_9789264076037-en http://www.oecd-ilibrary.org/environment/test-no-436-acute-inhalation-toxicity-acute-toxic-class-method_9789264076037-en http://www.oecd.org/env/ehs/testing/seriesontestingandassessmenttestingforhumanhealth.htm http://www.oecd.org/env/ehs/testing/seriesontestingandassessmenttestingforhumanhealth.htm http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2010)20\ufffd&\ufffddoclanguage=en http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2010)20\ufffd&\ufffddoclanguage=en http://www.oecd.org/env/ehs/testing/mono%202016%2032.pdf http://refhub.elsevier.com/S0273-2300(18)30038-2/sref52 Mammalian Acute Toxicity Tests Series on Testing & Assessment. OECD, 2017a. Test No. 402: Acute Dermal Toxicity. OECD Guidelines for the Testing of Chemicals, Section 4, from. http://www.oecd-ilibrary.org/environment/test-no-402- acute-dermal-toxicity_9789264070585-en. OECD, 2017b. Test No. 433: Acute Inhalation Toxicity - Fixed Concentration Procedure. OECD Guidelines for the Testing of Chemicals, Section 4, from. http://www.oecd- ilibrary.org/environment/test-no-433-acute-inhalation-toxicity-fixed-concentration- procedure_9789264284166-en. OSHA, 2012. Hazard Communication final rule. Fed. Regist. 77 (58), 17574\u201317896. from. www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=FEDERAnna Lowit_ REGISTER&p_id=22607. Pampaloni, F., Reynaud, E.G., Stelzer, E.H., 2007. The third dimension bridges the gap between cell culture and live tissue. Nat. Rev. Mol. Cell Biol. 8 (10), 839\u2013845. http:// dx.doi.org/10.1038/nrm2236. Peck, Y., Wang, David Allen., 2013. Three-dimensionally engineered biomimetic tissue models for in vitro drug evaluation: delivery, efficacy and toxicity. [Research Support, Non-U.S. Gov't Review]. Expert. Opin. Drug. Deliv. 10 (3), 369\u2013383. http://dx.doi.org/10. 1517/17425247.2013.751096. Robinson, S., Delongeas, J., Donald, E., Dreher, D., Festag, M., Kervyn, S., Chapman, K., 2008. A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development. Regul. Toxicol. Pharmacol. 50 (3), 345\u2013352. Scarano, L., 2015. Requirements and Evaluation of Toxicity Testing in the TSCA New Chemicals Program (Presentation at Alternative Approaches for Identifying Acute Systemic Toxicity: Moving from Research to Regulatory Testing). Scarano, L., 2016. Application of QSurender AhirR Principles in the Regulatory Environment. The US EPA New Chemicals Program (Presentation at ICCVAM Communities of Practice Webinar), from. http://ntp.niehs.nih.gov/go/commprac-2016. The Technical Cooperation Program, 2014. Assessing the Potential Environmental and Human Health Consequences of Energetic Materials: a Phased Approach. Phased Evaluation of Energetic Materials. The Technical Cooperation Program Technical Report CP 4\u201342. United Nations, 2009. Globally Harmonized System of Classification and Labelling of Chemicals (GHS), third ed. from. http://www.unece.org/trans/danger/publi/ghs/ ghs_rev03/03files_e.html. United Nations, 2015. Globally Harmonized System of Classification and Labelling of Chemicals 6th Revised Edition. from. http://www.unece.org/fileadmin/David AllenM/ trans/danger/publi/ghs/ghs_rev06/English/ST-SG-AC10-30-Rev6e.pdf. US EPA, 1998a. Health Effects Test Guidelines OPPTS 870.1200 Acute Dermal Toxicity. EPA 712-C-98-192, from. https://www.regulations.gov/document?D=EPA-HQ- OPPT-2009-0156-0005. US EPA, 1998b. Health Effects Test Guidelines OPPTS 870.1300 Acute Inhalation Toxicity. EPA 712-C-98\u2013193. Office of Prevention, Pesticides, and Toxic Substances, Washington, DC. US EPA, 2002a. Health Effects Test Guidelines OPPTS 870.1000 Acute Oral Toxicity Testing\u2013background. EPA 712\u2013C\u201302\u2013189, from. https://www.regulations.gov/ document?D=EPA-HQ-OPPT-2009-0156-0002. US EPA, 2002b. Health Effects Test Guidelines OPPTS 870.1100 Acute Oral Toxicity. EPA 712\u2013C\u201302\u2013190, from. https://www.regulations.gov/document?D=EPA-HQ-OPPT- 2009-0156-0003. US EPA, 2010. TSCA New Chemicals Program (NCP) Chemical Categories. from. https:// www.epa.gov/sites/production/files/2014-10/documents/ncp_chemical_categories_ august_2010_version_0.pdf. US EPA, 2012. Guidance for Waiving or Bridging of Mammalian Acute Toxicity Tests for Pesticides and Pesticide Products (Acute Oral, Acute Dermal, Acute Inhalation, Primary Eye, Primary Dermal, and Dermal Sensitization). from. http://www.epa. gov/sites/production/files/documents/acute-data-waiver-guidance.pdf. US EPA, 2013. Guiding Principles for Data Requirements. from. http://www.epa.gov/ sites/production/files/2015-04/documents/data-require-guide-principle.pdf. US EPA, 2015a. Acute Exposure Guideline Levels for Airborne Chemicals. from. http:// www.epa.gov/aegl. US EPA, 2015b. Microbial Pesticides Toxicology Data Requirements Table. 40 CFR 158.2140, from. www.gpo.gov/fdsys/pkg/CFR-2015-title40-vol24/pdf/CFR-2015- title40-vol24-part158.pdf. US EPA, 2015c. Summary of the Federal Food, Drug, and Cosmetic Act. from. http:// www.epa.gov/laws-regulations/summary-federal-food-drug-and-cosmetic-act. US EPA, 2015d. Summary of the Federal Insecticide, Fungicide, and Rodenticide Act. from. www.epa.gov/laws-regulations/summary-federal-insecticide-fungicide-and- rodenticide-act. US EPA, 2015e. Toxicology Data Requirement Table. 40 CFR 158.500, from. www.gpo. gov/fdsys/pkg/CFR-2015-title40-vol24/pdf/CFR-2015-title40-vol24-part158.pdf. US EPA, 2015f. Toxicology. 40 CFR 158.2230, from. www.gpo.gov/fdsys/pkg/CFR- 2015-title40-vol24/pdf/CFR-2015-title40-vol24-part158.pdf. US EPA, 2016a. The Frank R. Lautenberg Chemical Safety for the 21st Century Act. from. www.epa.gov/assessing-and-managing-chemicals-under-tsca/frank-r-lautenberg- chemical-safety-21st-century-act. US EPA, 2016b. Guidance for Waiving Acute Dermal Toxicity Tests for Pesticide Formulations & Supporting Retrospective Analysis. from. https://www.epa.gov/ sites/production/files/2016-11/documents/acute-dermal-toxicity-pesticide- formulations_0.pdf. US EPA, 2016c. Label Review Manual. from. https://www.epa.gov/sites/production/ files/2016-12/documents/lrmcomplete.pdf. US EPA, 2016d. Mixtures Equation Pilot Program to Reduce Animal Testing. from. https://www.epa.gov/pesticide-registration/mixtures-equation-pilot-program- reduce-animal-testing. US EPA, 2016e. Process for Establishing and Implementing Alternative Approaches to Traditional in Vivo Acute Toxicity Studies for FIFRA Regulatory Use. from. https:// www.epa.gov/pesticide-science-and-assessing-pesticide-risks/process-establishing- implementing-alternative. US EPA, 2016f. Strategic Vision for Adopting 21st Century Science Methodologies. from. https://www.epa.gov/pesticide-science-and-assessing-pesticide-risks/strategic- vision-adopting-21st-century-science. US FDavid Allen, 1988. LD 50 Test Policy [Docket No. 86P-0224], 53. from. https://cdn.loc.gov/ service/ll/fedreg/fr053/fr053196/fr053196.pdf. US FDavid Allen, 1996. Guidance for Industry: Single Dose Acute Toxicity Testing for Pharmaceuticals. from. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm079270.pdf. US FDavid Allen, 2005. General Biological Products Standards: Equivalent Methods and Processes. 21 CFR 610.9, from. http://www.ecfr.gov/cgi-bin/text-idx?SID= 0fe7ae5ae5d0af1a60a09e9b4a770a4b&mc=true&node=se21.7.610_19&rgn=div8. US FDavid Allen, 2007. Guidance for Industry and Other Stakeholders: Toxicological Principles for the Safety Assessment of Food Ingredients. from. http://www.fda.gov/Food/ GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/ IngredientsAdditivesGRASPackaging/ucm2006826.htm. US FDavid Allen, 2013. Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products. from. www.fda.gov/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ ucm376136.htm. US FDavid Allen, 2014. Requests for feedback on medical device submissions. In: The Pre-sub- mission Program and Meetings with Food and Drug Administration Staff. US FDavid Allen, 2016. Use of International Standard ISO 10993-1, \u201cBiological Evaluation of Medical Devices - Part 1: Evaluation and Testing within a Risk Management Process. from. https://www.fda.gov/downloads/MedicalDevices/ DeviceRegulationandGuidance/GuidanceDocuments/ucm348890.pdf. J. Strickland et al. Regulatory Toxicology and Pharmacology 94 (2018) 183\u2013196 196 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref52 http://www.oecd-ilibrary.org/environment/test-no-402-acute-dermal-toxicity_9789264070585-en http://www.oecd-ilibrary.org/environment/test-no-402-acute-dermal-toxicity_9789264070585-en http://www.oecd-ilibrary.org/environment/test-no-433-acute-inhalation-toxicity-fixed-concentration-procedure_9789264284166-en http://www.oecd-ilibrary.org/environment/test-no-433-acute-inhalation-toxicity-fixed-concentration-procedure_9789264284166-en http://www.oecd-ilibrary.org/environment/test-no-433-acute-inhalation-toxicity-fixed-concentration-procedure_9789264284166-en http://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=FEDERAnna Lowit_REGISTER\ufffd&\ufffdp_id=22607 http://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=FEDERAnna Lowit_REGISTER\ufffd&\ufffdp_id=22607 http://dx.doi.org/10.1038/nrm2236 http://dx.doi.org/10.1038/nrm2236 http://dx.doi.org/10.1517/17425247.2013.751096 http://dx.doi.org/10.1517/17425247.2013.751096 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref59 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref59 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref59 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref59 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref60 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref60 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref60 http://ntp.niehs.nih.gov/go/commprac-2016 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref62 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref62 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref62 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref62 http://www.unece.org/trans/danger/publi/ghs/ghs_rev03/03files_e.html http://www.unece.org/trans/danger/publi/ghs/ghs_rev03/03files_e.html http://www.unece.org/fileadmin/David AllenM/trans/danger/publi/ghs/ghs_rev06/English/ST-SG-AC10-30-Rev6e.pdf http://www.unece.org/fileadmin/David AllenM/trans/danger/publi/ghs/ghs_rev06/English/ST-SG-AC10-30-Rev6e.pdf https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0005 https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0005 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref66 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref66 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref66 https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0002 https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0002 https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0003 https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0003 https://www.epa.gov/sites/production/files/2014-10/documents/ncp_chemical_categories_august_2010_version_0.pdf https://www.epa.gov/sites/production/files/2014-10/documents/ncp_chemical_categories_august_2010_version_0.pdf https://www.epa.gov/sites/production/files/2014-10/documents/ncp_chemical_categories_august_2010_version_0.pdf http://www.epa.gov/sites/production/files/documents/acute-data-waiver-guidance.pdf http://www.epa.gov/sites/production/files/documents/acute-data-waiver-guidance.pdf http://www.epa.gov/sites/production/files/2015-04/documents/data-require-guide-principle.pdf http://www.epa.gov/sites/production/files/2015-04/documents/data-require-guide-principle.pdf http://www.epa.gov/aegl http://www.epa.gov/aegl http://www.gpo.gov/fdsys/pkg/CFR-2015-title40-vol24/pdf/CFR-2015-title40-vol24-part158.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title40-vol24/pdf/CFR-2015-title40-vol24-part158.pdf http://www.epa.gov/laws-regulations/summary-federal-food-drug-and-cosmetic-act http://www.epa.gov/laws-regulations/summary-federal-food-drug-and-cosmetic-act http://www.epa.gov/laws-regulations/summary-federal-insecticide-fungicide-and-rodenticide-act http://www.epa.gov/laws-regulations/summary-federal-insecticide-fungicide-and-rodenticide-act http://www.gpo.gov/fdsys/pkg/CFR-2015-title40-vol24/pdf/CFR-2015-title40-vol24-part158.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title40-vol24/pdf/CFR-2015-title40-vol24-part158.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title40-vol24/pdf/CFR-2015-title40-vol24-part158.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title40-vol24/pdf/CFR-2015-title40-vol24-part158.pdf http://www.epa.gov/assessing-and-managing-chemicals-under-tsca/frank-r-lautenberg-chemical-safety-21st-century-act http://www.epa.gov/assessing-and-managing-chemicals-under-tsca/frank-r-lautenberg-chemical-safety-21st-century-act https://www.epa.gov/sites/production/files/2016-11/documents/acute-dermal-toxicity-pesticide-formulations_0.pdf https://www.epa.gov/sites/production/files/2016-11/documents/acute-dermal-toxicity-pesticide-formulations_0.pdf https://www.epa.gov/sites/production/files/2016-11/documents/acute-dermal-toxicity-pesticide-formulations_0.pdf https://www.epa.gov/sites/production/files/2016-12/documents/lrmcomplete.pdf https://www.epa.gov/sites/production/files/2016-12/documents/lrmcomplete.pdf https://www.epa.gov/pesticide-registration/mixtures-equation-pilot-program-reduce-animal-testing https://www.epa.gov/pesticide-registration/mixtures-equation-pilot-program-reduce-animal-testing https://www.epa.gov/pesticide-science-and-assessing-pesticide-risks/process-establishing-implementing-alternative https://www.epa.gov/pesticide-science-and-assessing-pesticide-risks/process-establishing-implementing-alternative https://www.epa.gov/pesticide-science-and-assessing-pesticide-risks/process-establishing-implementing-alternative https://www.epa.gov/pesticide-science-and-assessing-pesticide-risks/strategic-vision-adopting-21st-century-science https://www.epa.gov/pesticide-science-and-assessing-pesticide-risks/strategic-vision-adopting-21st-century-science https://cdn.loc.gov/service/ll/fedreg/fr053/fr053196/fr053196.pdf https://cdn.loc.gov/service/ll/fedreg/fr053/fr053196/fr053196.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079270.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079270.pdf http://www.ecfr.gov/cgi-bin/text-idx?SID=0fe7ae5ae5d0af1a60a09e9b4a770a4b\ufffd&\ufffdmc=true\ufffd&\ufffdnode=se21.7.610_19\ufffd&\ufffdrgn=div8 http://www.ecfr.gov/cgi-bin/text-idx?SID=0fe7ae5ae5d0af1a60a09e9b4a770a4b\ufffd&\ufffdmc=true\ufffd&\ufffdnode=se21.7.610_19\ufffd&\ufffdrgn=div8 http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm2006826.htm http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm2006826.htm http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm2006826.htm http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm376136.htm http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm376136.htm http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm376136.htm http://refhub.elsevier.com/S0273-2300(18)30038-2/sref89 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref89 https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm348890.pdf https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm348890.pdf Status of acute systemic toxicity testing requirements and data uses by U.S. regulatory agencies Introduction Overview of U.S. regulatory testing requirements for acute systemic toxicity Regulatory uses of acute systemic toxicity data by agency Consumer Product Safety Commission Standards, guidelines, and guidance for acute systemic toxicity testing Current requirements for animal testing and flexibility for the use of alternatives Information needed from alternative tests to fulfill the needs for acute toxicity data Acceptance of alternative methods and approaches to determine acute toxicity Department of Defense Standards, guidelines, and guidance for acute systemic toxicity testing Current requirements for animal testing and flexibility for the use of alternatives Information needed from alternative tests to fulfill the needs for acute toxicity data Acceptance of alternative methods and approaches to determine acute toxicity Department of Transportation Standards, guidelines, and guidance for acute systemic toxicity testing Current requirements for animal testing and flexibility for the use of alternatives Information needed from alternative tests to fulfill the needs for acute toxicity data Acceptance of alternative methods and approaches to determine acute toxicity Environmental Protection Agency Office of Pesticide Programs Standards, guidelines, and guidance for acute systemic toxicity testing Current requirements for animal testing and flexibility for the use of alternatives Information needed from alternative tests to fulfill the needs for acute toxicity data Acceptance of alternative methods and approaches to determine acute toxicity EPA Office of Pollution Prevention and Toxics Standards, guidelines, and guidance for acute systemic toxicity testing Current requirements for animal testing and flexibility for the use of alternatives Information needed from alternative tests to fulfill the needs for acute toxicity data Acceptance of alternative methods and approaches to determine acute toxicity FDavid Allen Center for Biologics Evaluation and Research Standards, guidelines, and guidance for acute systemic toxicity testing Current requirements for animal testing and flexibility for the use of alternatives Information needed from alternative tests to fulfill the needs for acute toxicity data Acceptance of alternative methods and approaches to determine acute toxicity FDavid Allen Center for Devices and Radiological Health Standards, guidelines, and guidance for acute systemic toxicity testing Current requirements for animal testing and flexibility in the use of alternatives Information needed from alternative tests to fulfill the needs for acute toxicity data Acceptance of alternative methods and approaches to determine acute toxicity FDavid Allen Center for Food Safety and Nutrition Standards, guidelines, and guidance for acute systemic toxicity testing Current requirements for animal testing and flexibility for the use of alternatives Information needed from alternative tests to fulfill the needs for acute toxicity data Acceptance of alternative methods and approaches to determine acute toxicity Occupational Safety and Health Administration Standards, guidelines, and guidance for acute systemic toxicity testing Current requirements for animal testing and flexibility for the use of alternatives Information needed from alternative tests to fulfill the needs for acute toxicity data Acceptance of alternative methods and approaches to determine acute toxicity Discussion Funding Disclaimer Acknowledgements Transparency document References", "Compliance with ethical standards": "https://www.gpo.gov/fdsys/search/pagedetails.action?collectionCode=PLAW\ufffd&\ufffdbrowsePath=114%2FPUBLIC%2F[100+XHYPHENXX+XCLOSEBRACKETXX\ufffd&\ufffdgranuleId=\ufffd&\ufffdpackageId=PLAW-114publ182\ufffd&\ufffdfromBrowse=true https://www.gpo.gov/fdsys/search/pagedetails.action?collectionCode=PLAW\ufffd&\ufffdbrowsePath=114%2FPUBLIC%2F[100+XHYPHENXX+XCLOSEBRACKETXX\ufffd&\ufffdgranuleId=\ufffd&\ufffdpackageId=PLAW-114publ182\ufffd&\ufffdfromBrowse=true http://refhub.elsevier.com/S0273-2300(18)30038-2/sref23 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref58 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref92 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref92 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref94 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref94 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref95 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref95 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref2 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref96 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref96 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref3 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref3 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref4 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref4 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref4 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref6 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref6 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref6 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref6 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref6 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref7 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref7 http://dx.doi.org/10.1016/j.tiv.2017.12.011 http://dx.doi.org/10.1016/j.yrtph.2016.10.007 http://dx.doi.org/10.1016/j.yrtph.2016.10.007 http://www.cpsc.gov/en/Business%5fManufacturing/Testing-Certification/Recommended-Procedures-Regarding-the-CPSCs-Policy-on-Animal-Testing/ http://www.cpsc.gov/en/Business%5fManufacturing/Testing-Certification/Recommended-Procedures-Regarding-the-CPSCs-Policy-on-Animal-Testing/ http://www.cpsc.gov/en/Business%5fManufacturing/Testing-Certification/Recommended-Procedures-Regarding-the-CPSCs-Policy-on-Animal-Testing/ http://www.cpsc.gov/en/Business%5fManufacturing/Testing-Certification/Recommended-Procedures-Regarding-the-CPSCs-Policy-on-Animal-Testing/ http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-sec1500-3.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-sec1500-3.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-sec1500-40.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-sec1500-40.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-sec1500-40.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-part1702.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-part1702.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-sec1500-232.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-sec1500-232.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-sec1500-232.pdf http://www.phmsa.dot.gov/pv_obj_cache/pv_obj_id_FC1B48D1EA0BE29F97429EC9David Allen321602AD970000/filename/SP10904_2006050025.pdf http://www.phmsa.dot.gov/pv_obj_cache/pv_obj_id_FC1B48D1EA0BE29F97429EC9David Allen321602AD970000/filename/SP10904_2006050025.pdf http://www.phmsa.dot.gov/pv_obj_cache/pv_obj_id_FC1B48D1EA0BE29F97429EC9David Allen321602AD970000/filename/SP10904_2006050025.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title49-vol2/pdf/CFR-2015-title49-vol2-sec173-133.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title49-vol2/pdf/CFR-2015-title49-vol2-sec173-133.pdf http://www.ecfr.gov/cgi-bin/text-idx?SID=516261bee7784b6aa6b2fe828f61a636\ufffd&\ufffdmc=true\ufffd&\ufffdnode=se49.2.173_1132\ufffd&\ufffdrgn=div8 http://www.ecfr.gov/cgi-bin/text-idx?SID=516261bee7784b6aa6b2fe828f61a636\ufffd&\ufffdmc=true\ufffd&\ufffdnode=se49.2.173_1132\ufffd&\ufffdrgn=div8 http://www.ecfr.gov/cgi-bin/text-idx?SID=516261bee7784b6aa6b2fe828f61a636\ufffd&\ufffdmc=true\ufffd&\ufffdnode=se49.2.173_1132\ufffd&\ufffdrgn=div8 http://www.gpo.gov/fdsys/pkg/CFR-2015-title49-vol2/pdf/CFR-2015-title49-vol2-sec173-137.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title49-vol2/pdf/CFR-2015-title49-vol2-sec173-137.pdf https://eurl-ecvam.jrc.ec.europa.eu/eurl-ecvam-recommendations/3t3-nru-recommendation https://eurl-ecvam.jrc.ec.europa.eu/eurl-ecvam-recommendations/3t3-nru-recommendation https://eurl-ecvam.jrc.ec.europa.eu/eurl-ecvam-strategy-papers/strategy-acute-mammalian-systemic-toxicity https://eurl-ecvam.jrc.ec.europa.eu/eurl-ecvam-strategy-papers/strategy-acute-mammalian-systemic-toxicity https://eurl-ecvam.jrc.ec.europa.eu/eurl-ecvam-strategy-papers/strategy-acute-mammalian-systemic-toxicity http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02006R1907-20140410 http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02006R1907-20140410 http://dx.doi.org/10.1016/j.tiv.2017.01.004 http://dx.doi.org/10.1016/j.tiv.2017.01.004 http://dx.doi.org/10.1126/science.1188302 https://ntp.niehs.nih.gov/pubhealth/evalatm/test-method-evaluations/acute-systemic-tox/oral-udp/peer-review-rpt/index.html#Complete-Report https://ntp.niehs.nih.gov/pubhealth/evalatm/test-method-evaluations/acute-systemic-tox/oral-udp/peer-review-rpt/index.html#Complete-Report https://ntp.niehs.nih.gov/iccvam/docs/acutetox_docs/brd_tmer/at-tmer-complete.pdf https://ntp.niehs.nih.gov/iccvam/docs/acutetox_docs/brd_tmer/at-tmer-complete.pdf https://ntp.niehs.nih.gov/go/natl-strategy https://ntp.niehs.nih.gov/go/natl-strategy http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step4/S6_R1_Guideline.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step4/S6_R1_Guideline.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2__Guideline.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2__Guideline.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2__Guideline.pdf http://refhub.elsevier.com/S0273-2300(18)30038-2/sref30 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref30 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref32 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref32 http://dx.doi.org/10.3791/54344 https://ntp.niehs.nih.gov/iccvam/meetings/iccvam-forum-2016/1-iccvam-508.pdf https://ntp.niehs.nih.gov/iccvam/meetings/iccvam-forum-2016/1-iccvam-508.pdf http://ntp.niehs.nih.gov/ntp/about_ntp/sacatm/2016/september/update20160927_508.pdf http://ntp.niehs.nih.gov/ntp/about_ntp/sacatm/2016/september/update20160927_508.pdf http://ntp.niehs.nih.gov/ntp/about_ntp/sacatm/2016/september/update20160927_508.pdf http://dx.doi.org/10.1016/j.ejpb.2015.03.002 https://www.nap.edu/catalog/10122/standing-operating-procedures-for-developing-acute-exposure-guideline-levels-for-hazardous-chemicals https://www.nap.edu/catalog/10122/standing-operating-procedures-for-developing-acute-exposure-guideline-levels-for-hazardous-chemicals https://www.nap.edu/catalog/10122/standing-operating-procedures-for-developing-acute-exposure-guideline-levels-for-hazardous-chemicals http://www.nap.edu/catalog.php?record_id=11970 https://www.nap.edu/catalog/21775/application-of-modern-toxicology-approaches-for-predicting-acute-toxicity-for-chemical-defense https://www.nap.edu/catalog/21775/application-of-modern-toxicology-approaches-for-predicting-acute-toxicity-for-chemical-defense https://www.nap.edu/catalog/21775/application-of-modern-toxicology-approaches-for-predicting-acute-toxicity-for-chemical-defense http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2001 http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2001 http://www.oecd-ilibrary.org/environment/test-no-420-acute-oral-toxicity-fixed-dose-procedure_9789264070943-en http://www.oecd-ilibrary.org/environment/test-no-420-acute-oral-toxicity-fixed-dose-procedure_9789264070943-en http://www.oecd-ilibrary.org/environment/test-no-420-acute-oral-toxicity-fixed-dose-procedure_9789264070943-en http://www.oecd-ilibrary.org/environment/test-no-423-acute-oral-toxicity-acute-toxic-class-method_9789264071001-en http://www.oecd-ilibrary.org/environment/test-no-423-acute-oral-toxicity-acute-toxic-class-method_9789264071001-en http://www.oecd-ilibrary.org/environment/test-no-423-acute-oral-toxicity-acute-toxic-class-method_9789264071001-en http://www.oecd-ilibrary.org/environment/test-no-425-acute-oral-toxicity-up-and-down-procedure_9789264071049-en http://www.oecd-ilibrary.org/environment/test-no-425-acute-oral-toxicity-up-and-down-procedure_9789264071049-en http://www.oecd-ilibrary.org/environment/test-no-425-acute-oral-toxicity-up-and-down-procedure_9789264071049-en http://refhub.elsevier.com/S0273-2300(18)30038-2/sref46 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref46 http://www.oecd-ilibrary.org/environment/test-no-403-acute-inhalation-toxicity_9789264070608-en http://www.oecd-ilibrary.org/environment/test-no-403-acute-inhalation-toxicity_9789264070608-en http://www.oecd-ilibrary.org/environment/test-no-436-acute-inhalation-toxicity-acute-toxic-class-method_9789264076037-en http://www.oecd-ilibrary.org/environment/test-no-436-acute-inhalation-toxicity-acute-toxic-class-method_9789264076037-en http://www.oecd-ilibrary.org/environment/test-no-436-acute-inhalation-toxicity-acute-toxic-class-method_9789264076037-en http://www.oecd.org/env/ehs/testing/seriesontestingandassessmenttestingforhumanhealth.htm http://www.oecd.org/env/ehs/testing/seriesontestingandassessmenttestingforhumanhealth.htm http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2010)20\ufffd&\ufffddoclanguage=en http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2010)20\ufffd&\ufffddoclanguage=en http://www.oecd.org/env/ehs/testing/mono%202016%2032.pdf http://refhub.elsevier.com/S0273-2300(18)30038-2/sref52 Mammalian Acute Toxicity Tests Series on Testing & Assessment. OECD, 2017a. Test No. 402: Acute Dermal Toxicity. OECD Guidelines for the Testing of Chemicals, Section 4, from. http://www.oecd-ilibrary.org/environment/test-no-402- acute-dermal-toxicity_9789264070585-en. OECD, 2017b. Test No. 433: Acute Inhalation Toxicity - Fixed Concentration Procedure. OECD Guidelines for the Testing of Chemicals, Section 4, from. http://www.oecd- ilibrary.org/environment/test-no-433-acute-inhalation-toxicity-fixed-concentration- procedure_9789264284166-en. OSHA, 2012. Hazard Communication final rule. Fed. Regist. 77 (58), 17574\u201317896. from. www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=FEDERAnna Lowit_ REGISTER&p_id=22607. Pampaloni, F., Reynaud, E.G., Stelzer, E.H., 2007. The third dimension bridges the gap between cell culture and live tissue. Nat. Rev. Mol. Cell Biol. 8 (10), 839\u2013845. http:// dx.doi.org/10.1038/nrm2236. Peck, Y., Wang, David Allen., 2013. Three-dimensionally engineered biomimetic tissue models for in vitro drug evaluation: delivery, efficacy and toxicity. [Research Support, Non-U.S. Gov't Review]. Expert. Opin. Drug. Deliv. 10 (3), 369\u2013383. http://dx.doi.org/10. 1517/17425247.2013.751096. Robinson, S., Delongeas, J., Donald, E., Dreher, D., Festag, M., Kervyn, S., Chapman, K., 2008. A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development. Regul. Toxicol. Pharmacol. 50 (3), 345\u2013352. Scarano, L., 2015. Requirements and Evaluation of Toxicity Testing in the TSCA New Chemicals Program (Presentation at Alternative Approaches for Identifying Acute Systemic Toxicity: Moving from Research to Regulatory Testing). Scarano, L., 2016. Application of QSurender AhirR Principles in the Regulatory Environment. The US EPA New Chemicals Program (Presentation at ICCVAM Communities of Practice Webinar), from. http://ntp.niehs.nih.gov/go/commprac-2016. The Technical Cooperation Program, 2014. Assessing the Potential Environmental and Human Health Consequences of Energetic Materials: a Phased Approach. Phased Evaluation of Energetic Materials. The Technical Cooperation Program Technical Report CP 4\u201342. United Nations, 2009. Globally Harmonized System of Classification and Labelling of Chemicals (GHS), third ed. from. http://www.unece.org/trans/danger/publi/ghs/ ghs_rev03/03files_e.html. United Nations, 2015. Globally Harmonized System of Classification and Labelling of Chemicals 6th Revised Edition. from. http://www.unece.org/fileadmin/David AllenM/ trans/danger/publi/ghs/ghs_rev06/English/ST-SG-AC10-30-Rev6e.pdf. US EPA, 1998a. Health Effects Test Guidelines OPPTS 870.1200 Acute Dermal Toxicity. EPA 712-C-98-192, from. https://www.regulations.gov/document?D=EPA-HQ- OPPT-2009-0156-0005. US EPA, 1998b. Health Effects Test Guidelines OPPTS 870.1300 Acute Inhalation Toxicity. EPA 712-C-98\u2013193. Office of Prevention, Pesticides, and Toxic Substances, Washington, DC. US EPA, 2002a. Health Effects Test Guidelines OPPTS 870.1000 Acute Oral Toxicity Testing\u2013background. EPA 712\u2013C\u201302\u2013189, from. https://www.regulations.gov/ document?D=EPA-HQ-OPPT-2009-0156-0002. US EPA, 2002b. Health Effects Test Guidelines OPPTS 870.1100 Acute Oral Toxicity. EPA 712\u2013C\u201302\u2013190, from. https://www.regulations.gov/document?D=EPA-HQ-OPPT- 2009-0156-0003. US EPA, 2010. TSCA New Chemicals Program (NCP) Chemical Categories. from. https:// www.epa.gov/sites/production/files/2014-10/documents/ncp_chemical_categories_ august_2010_version_0.pdf. US EPA, 2012. Guidance for Waiving or Bridging of Mammalian Acute Toxicity Tests for Pesticides and Pesticide Products (Acute Oral, Acute Dermal, Acute Inhalation, Primary Eye, Primary Dermal, and Dermal Sensitization). from. http://www.epa. gov/sites/production/files/documents/acute-data-waiver-guidance.pdf. US EPA, 2013. Guiding Principles for Data Requirements. from. http://www.epa.gov/ sites/production/files/2015-04/documents/data-require-guide-principle.pdf. US EPA, 2015a. Acute Exposure Guideline Levels for Airborne Chemicals. from. http:// www.epa.gov/aegl. US EPA, 2015b. Microbial Pesticides Toxicology Data Requirements Table. 40 CFR 158.2140, from. www.gpo.gov/fdsys/pkg/CFR-2015-title40-vol24/pdf/CFR-2015- title40-vol24-part158.pdf. US EPA, 2015c. Summary of the Federal Food, Drug, and Cosmetic Act. from. http:// www.epa.gov/laws-regulations/summary-federal-food-drug-and-cosmetic-act. US EPA, 2015d. Summary of the Federal Insecticide, Fungicide, and Rodenticide Act. from. www.epa.gov/laws-regulations/summary-federal-insecticide-fungicide-and- rodenticide-act. US EPA, 2015e. Toxicology Data Requirement Table. 40 CFR 158.500, from. www.gpo. gov/fdsys/pkg/CFR-2015-title40-vol24/pdf/CFR-2015-title40-vol24-part158.pdf. US EPA, 2015f. Toxicology. 40 CFR 158.2230, from. www.gpo.gov/fdsys/pkg/CFR- 2015-title40-vol24/pdf/CFR-2015-title40-vol24-part158.pdf. US EPA, 2016a. The Frank R. Lautenberg Chemical Safety for the 21st Century Act. from. www.epa.gov/assessing-and-managing-chemicals-under-tsca/frank-r-lautenberg- chemical-safety-21st-century-act. US EPA, 2016b. Guidance for Waiving Acute Dermal Toxicity Tests for Pesticide Formulations & Supporting Retrospective Analysis. from. https://www.epa.gov/ sites/production/files/2016-11/documents/acute-dermal-toxicity-pesticide- formulations_0.pdf. US EPA, 2016c. Label Review Manual. from. https://www.epa.gov/sites/production/ files/2016-12/documents/lrmcomplete.pdf. US EPA, 2016d. Mixtures Equation Pilot Program to Reduce Animal Testing. from. https://www.epa.gov/pesticide-registration/mixtures-equation-pilot-program- reduce-animal-testing. US EPA, 2016e. Process for Establishing and Implementing Alternative Approaches to Traditional in Vivo Acute Toxicity Studies for FIFRA Regulatory Use. from. https:// www.epa.gov/pesticide-science-and-assessing-pesticide-risks/process-establishing- implementing-alternative. US EPA, 2016f. Strategic Vision for Adopting 21st Century Science Methodologies. from. https://www.epa.gov/pesticide-science-and-assessing-pesticide-risks/strategic- vision-adopting-21st-century-science. US FDavid Allen, 1988. LD 50 Test Policy [Docket No. 86P-0224], 53. from. https://cdn.loc.gov/ service/ll/fedreg/fr053/fr053196/fr053196.pdf. US FDavid Allen, 1996. Guidance for Industry: Single Dose Acute Toxicity Testing for Pharmaceuticals. from. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm079270.pdf. US FDavid Allen, 2005. General Biological Products Standards: Equivalent Methods and Processes. 21 CFR 610.9, from. http://www.ecfr.gov/cgi-bin/text-idx?SID= 0fe7ae5ae5d0af1a60a09e9b4a770a4b&mc=true&node=se21.7.610_19&rgn=div8. US FDavid Allen, 2007. Guidance for Industry and Other Stakeholders: Toxicological Principles for the Safety Assessment of Food Ingredients. from. http://www.fda.gov/Food/ GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/ IngredientsAdditivesGRASPackaging/ucm2006826.htm. US FDavid Allen, 2013. Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products. from. www.fda.gov/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ ucm376136.htm. US FDavid Allen, 2014. Requests for feedback on medical device submissions. In: The Pre-sub- mission Program and Meetings with Food and Drug Administration Staff. US FDavid Allen, 2016. Use of International Standard ISO 10993-1, \u201cBiological Evaluation of Medical Devices - Part 1: Evaluation and Testing within a Risk Management Process. from. https://www.fda.gov/downloads/MedicalDevices/ DeviceRegulationandGuidance/GuidanceDocuments/ucm348890.pdf. J. Strickland et al. Regulatory Toxicology and Pharmacology 94 (2018) 183\u2013196 196 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref52 http://www.oecd-ilibrary.org/environment/test-no-402-acute-dermal-toxicity_9789264070585-en http://www.oecd-ilibrary.org/environment/test-no-402-acute-dermal-toxicity_9789264070585-en http://www.oecd-ilibrary.org/environment/test-no-433-acute-inhalation-toxicity-fixed-concentration-procedure_9789264284166-en http://www.oecd-ilibrary.org/environment/test-no-433-acute-inhalation-toxicity-fixed-concentration-procedure_9789264284166-en http://www.oecd-ilibrary.org/environment/test-no-433-acute-inhalation-toxicity-fixed-concentration-procedure_9789264284166-en http://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=FEDERAnna Lowit_REGISTER\ufffd&\ufffdp_id=22607 http://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=FEDERAnna Lowit_REGISTER\ufffd&\ufffdp_id=22607 http://dx.doi.org/10.1038/nrm2236 http://dx.doi.org/10.1038/nrm2236 http://dx.doi.org/10.1517/17425247.2013.751096 http://dx.doi.org/10.1517/17425247.2013.751096 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref59 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref59 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref59 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref59 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref60 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref60 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref60 http://ntp.niehs.nih.gov/go/commprac-2016 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref62 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref62 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref62 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref62 http://www.unece.org/trans/danger/publi/ghs/ghs_rev03/03files_e.html http://www.unece.org/trans/danger/publi/ghs/ghs_rev03/03files_e.html http://www.unece.org/fileadmin/David AllenM/trans/danger/publi/ghs/ghs_rev06/English/ST-SG-AC10-30-Rev6e.pdf http://www.unece.org/fileadmin/David AllenM/trans/danger/publi/ghs/ghs_rev06/English/ST-SG-AC10-30-Rev6e.pdf https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0005 https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0005 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref66 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref66 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref66 https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0002 https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0002 https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0003 https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0003 https://www.epa.gov/sites/production/files/2014-10/documents/ncp_chemical_categories_august_2010_version_0.pdf https://www.epa.gov/sites/production/files/2014-10/documents/ncp_chemical_categories_august_2010_version_0.pdf https://www.epa.gov/sites/production/files/2014-10/documents/ncp_chemical_categories_august_2010_version_0.pdf http://www.epa.gov/sites/production/files/documents/acute-data-waiver-guidance.pdf http://www.epa.gov/sites/production/files/documents/acute-data-waiver-guidance.pdf http://www.epa.gov/sites/production/files/2015-04/documents/data-require-guide-principle.pdf http://www.epa.gov/sites/production/files/2015-04/documents/data-require-guide-principle.pdf http://www.epa.gov/aegl http://www.epa.gov/aegl http://www.gpo.gov/fdsys/pkg/CFR-2015-title40-vol24/pdf/CFR-2015-title40-vol24-part158.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title40-vol24/pdf/CFR-2015-title40-vol24-part158.pdf http://www.epa.gov/laws-regulations/summary-federal-food-drug-and-cosmetic-act http://www.epa.gov/laws-regulations/summary-federal-food-drug-and-cosmetic-act http://www.epa.gov/laws-regulations/summary-federal-insecticide-fungicide-and-rodenticide-act http://www.epa.gov/laws-regulations/summary-federal-insecticide-fungicide-and-rodenticide-act http://www.gpo.gov/fdsys/pkg/CFR-2015-title40-vol24/pdf/CFR-2015-title40-vol24-part158.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title40-vol24/pdf/CFR-2015-title40-vol24-part158.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title40-vol24/pdf/CFR-2015-title40-vol24-part158.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title40-vol24/pdf/CFR-2015-title40-vol24-part158.pdf http://www.epa.gov/assessing-and-managing-chemicals-under-tsca/frank-r-lautenberg-chemical-safety-21st-century-act http://www.epa.gov/assessing-and-managing-chemicals-under-tsca/frank-r-lautenberg-chemical-safety-21st-century-act https://www.epa.gov/sites/production/files/2016-11/documents/acute-dermal-toxicity-pesticide-formulations_0.pdf https://www.epa.gov/sites/production/files/2016-11/documents/acute-dermal-toxicity-pesticide-formulations_0.pdf https://www.epa.gov/sites/production/files/2016-11/documents/acute-dermal-toxicity-pesticide-formulations_0.pdf https://www.epa.gov/sites/production/files/2016-12/documents/lrmcomplete.pdf https://www.epa.gov/sites/production/files/2016-12/documents/lrmcomplete.pdf https://www.epa.gov/pesticide-registration/mixtures-equation-pilot-program-reduce-animal-testing https://www.epa.gov/pesticide-registration/mixtures-equation-pilot-program-reduce-animal-testing https://www.epa.gov/pesticide-science-and-assessing-pesticide-risks/process-establishing-implementing-alternative https://www.epa.gov/pesticide-science-and-assessing-pesticide-risks/process-establishing-implementing-alternative https://www.epa.gov/pesticide-science-and-assessing-pesticide-risks/process-establishing-implementing-alternative https://www.epa.gov/pesticide-science-and-assessing-pesticide-risks/strategic-vision-adopting-21st-century-science https://www.epa.gov/pesticide-science-and-assessing-pesticide-risks/strategic-vision-adopting-21st-century-science https://cdn.loc.gov/service/ll/fedreg/fr053/fr053196/fr053196.pdf https://cdn.loc.gov/service/ll/fedreg/fr053/fr053196/fr053196.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079270.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079270.pdf http://www.ecfr.gov/cgi-bin/text-idx?SID=0fe7ae5ae5d0af1a60a09e9b4a770a4b\ufffd&\ufffdmc=true\ufffd&\ufffdnode=se21.7.610_19\ufffd&\ufffdrgn=div8 http://www.ecfr.gov/cgi-bin/text-idx?SID=0fe7ae5ae5d0af1a60a09e9b4a770a4b\ufffd&\ufffdmc=true\ufffd&\ufffdnode=se21.7.610_19\ufffd&\ufffdrgn=div8 http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm2006826.htm http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm2006826.htm http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm2006826.htm http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm376136.htm http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm376136.htm http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm376136.htm http://refhub.elsevier.com/S0273-2300(18)30038-2/sref89 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref89 https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm348890.pdf https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm348890.pdf Status of acute systemic toxicity testing requirements and data uses by U.S. regulatory agencies Introduction Overview of U.S. regulatory testing requirements for acute systemic toxicity Regulatory uses of acute systemic toxicity data by agency Consumer Product Safety Commission Standards, guidelines, and guidance for acute systemic toxicity testing Current requirements for animal testing and flexibility for the use of alternatives Information needed from alternative tests to fulfill the needs for acute toxicity data Acceptance of alternative methods and approaches to determine acute toxicity Department of Defense Standards, guidelines, and guidance for acute systemic toxicity testing Current requirements for animal testing and flexibility for the use of alternatives Information needed from alternative tests to fulfill the needs for acute toxicity data Acceptance of alternative methods and approaches to determine acute toxicity Department of Transportation Standards, guidelines, and guidance for acute systemic toxicity testing Current requirements for animal testing and flexibility for the use of alternatives Information needed from alternative tests to fulfill the needs for acute toxicity data Acceptance of alternative methods and approaches to determine acute toxicity Environmental Protection Agency Office of Pesticide Programs Standards, guidelines, and guidance for acute systemic toxicity testing Current requirements for animal testing and flexibility for the use of alternatives Information needed from alternative tests to fulfill the needs for acute toxicity data Acceptance of alternative methods and approaches to determine acute toxicity EPA Office of Pollution Prevention and Toxics Standards, guidelines, and guidance for acute systemic toxicity testing Current requirements for animal testing and flexibility for the use of alternatives Information needed from alternative tests to fulfill the needs for acute toxicity data Acceptance of alternative methods and approaches to determine acute toxicity FDavid Allen Center for Biologics Evaluation and Research Standards, guidelines, and guidance for acute systemic toxicity testing Current requirements for animal testing and flexibility for the use of alternatives Information needed from alternative tests to fulfill the needs for acute toxicity data Acceptance of alternative methods and approaches to determine acute toxicity FDavid Allen Center for Devices and Radiological Health Standards, guidelines, and guidance for acute systemic toxicity testing Current requirements for animal testing and flexibility in the use of alternatives Information needed from alternative tests to fulfill the needs for acute toxicity data Acceptance of alternative methods and approaches to determine acute toxicity FDavid Allen Center for Food Safety and Nutrition Standards, guidelines, and guidance for acute systemic toxicity testing Current requirements for animal testing and flexibility for the use of alternatives Information needed from alternative tests to fulfill the needs for acute toxicity data Acceptance of alternative methods and approaches to determine acute toxicity Occupational Safety and Health Administration Standards, guidelines, and guidance for acute systemic toxicity testing Current requirements for animal testing and flexibility for the use of alternatives Information needed from alternative tests to fulfill the needs for acute toxicity data Acceptance of alternative methods and approaches to determine acute toxicity Discussion Funding Disclaimer Acknowledgements Transparency document References", "Acknowledgement": "https://www.gpo.gov/fdsys/search/pagedetails.action?collectionCode=PLAW\ufffd&\ufffdbrowsePath=114%2FPUBLIC%2F[100+XHYPHENXX+XCLOSEBRACKETXX\ufffd&\ufffdgranuleId=\ufffd&\ufffdpackageId=PLAW-114publ182\ufffd&\ufffdfromBrowse=true https://www.gpo.gov/fdsys/search/pagedetails.action?collectionCode=PLAW\ufffd&\ufffdbrowsePath=114%2FPUBLIC%2F[100+XHYPHENXX+XCLOSEBRACKETXX\ufffd&\ufffdgranuleId=\ufffd&\ufffdpackageId=PLAW-114publ182\ufffd&\ufffdfromBrowse=true http://refhub.elsevier.com/S0273-2300(18)30038-2/sref23 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref58 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref92 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref92 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref94 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref94 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref95 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref95 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref2 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref96 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref96 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref3 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref3 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref4 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref4 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref4 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref5 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref6 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref6 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref6 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref6 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref6 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref7 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref7 http://dx.doi.org/10.1016/j.tiv.2017.12.011 http://dx.doi.org/10.1016/j.yrtph.2016.10.007 http://dx.doi.org/10.1016/j.yrtph.2016.10.007 http://www.cpsc.gov/en/Business%5fManufacturing/Testing-Certification/Recommended-Procedures-Regarding-the-CPSCs-Policy-on-Animal-Testing/ http://www.cpsc.gov/en/Business%5fManufacturing/Testing-Certification/Recommended-Procedures-Regarding-the-CPSCs-Policy-on-Animal-Testing/ http://www.cpsc.gov/en/Business%5fManufacturing/Testing-Certification/Recommended-Procedures-Regarding-the-CPSCs-Policy-on-Animal-Testing/ http://www.cpsc.gov/en/Business%5fManufacturing/Testing-Certification/Recommended-Procedures-Regarding-the-CPSCs-Policy-on-Animal-Testing/ http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-sec1500-3.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-sec1500-3.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-sec1500-40.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-sec1500-40.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-sec1500-40.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-part1702.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-part1702.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-sec1500-232.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-sec1500-232.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title16-vol2/pdf/CFR-2015-title16-vol2-sec1500-232.pdf http://www.phmsa.dot.gov/pv_obj_cache/pv_obj_id_FC1B48D1EA0BE29F97429EC9David Allen321602AD970000/filename/SP10904_2006050025.pdf http://www.phmsa.dot.gov/pv_obj_cache/pv_obj_id_FC1B48D1EA0BE29F97429EC9David Allen321602AD970000/filename/SP10904_2006050025.pdf http://www.phmsa.dot.gov/pv_obj_cache/pv_obj_id_FC1B48D1EA0BE29F97429EC9David Allen321602AD970000/filename/SP10904_2006050025.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title49-vol2/pdf/CFR-2015-title49-vol2-sec173-133.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title49-vol2/pdf/CFR-2015-title49-vol2-sec173-133.pdf http://www.ecfr.gov/cgi-bin/text-idx?SID=516261bee7784b6aa6b2fe828f61a636\ufffd&\ufffdmc=true\ufffd&\ufffdnode=se49.2.173_1132\ufffd&\ufffdrgn=div8 http://www.ecfr.gov/cgi-bin/text-idx?SID=516261bee7784b6aa6b2fe828f61a636\ufffd&\ufffdmc=true\ufffd&\ufffdnode=se49.2.173_1132\ufffd&\ufffdrgn=div8 http://www.ecfr.gov/cgi-bin/text-idx?SID=516261bee7784b6aa6b2fe828f61a636\ufffd&\ufffdmc=true\ufffd&\ufffdnode=se49.2.173_1132\ufffd&\ufffdrgn=div8 http://www.gpo.gov/fdsys/pkg/CFR-2015-title49-vol2/pdf/CFR-2015-title49-vol2-sec173-137.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title49-vol2/pdf/CFR-2015-title49-vol2-sec173-137.pdf https://eurl-ecvam.jrc.ec.europa.eu/eurl-ecvam-recommendations/3t3-nru-recommendation https://eurl-ecvam.jrc.ec.europa.eu/eurl-ecvam-recommendations/3t3-nru-recommendation https://eurl-ecvam.jrc.ec.europa.eu/eurl-ecvam-strategy-papers/strategy-acute-mammalian-systemic-toxicity https://eurl-ecvam.jrc.ec.europa.eu/eurl-ecvam-strategy-papers/strategy-acute-mammalian-systemic-toxicity https://eurl-ecvam.jrc.ec.europa.eu/eurl-ecvam-strategy-papers/strategy-acute-mammalian-systemic-toxicity http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02006R1907-20140410 http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02006R1907-20140410 http://dx.doi.org/10.1016/j.tiv.2017.01.004 http://dx.doi.org/10.1016/j.tiv.2017.01.004 http://dx.doi.org/10.1126/science.1188302 https://ntp.niehs.nih.gov/pubhealth/evalatm/test-method-evaluations/acute-systemic-tox/oral-udp/peer-review-rpt/index.html#Complete-Report https://ntp.niehs.nih.gov/pubhealth/evalatm/test-method-evaluations/acute-systemic-tox/oral-udp/peer-review-rpt/index.html#Complete-Report https://ntp.niehs.nih.gov/iccvam/docs/acutetox_docs/brd_tmer/at-tmer-complete.pdf https://ntp.niehs.nih.gov/iccvam/docs/acutetox_docs/brd_tmer/at-tmer-complete.pdf https://ntp.niehs.nih.gov/go/natl-strategy https://ntp.niehs.nih.gov/go/natl-strategy http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step4/S6_R1_Guideline.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step4/S6_R1_Guideline.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2__Guideline.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2__Guideline.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2__Guideline.pdf http://refhub.elsevier.com/S0273-2300(18)30038-2/sref30 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref30 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref32 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref32 http://dx.doi.org/10.3791/54344 https://ntp.niehs.nih.gov/iccvam/meetings/iccvam-forum-2016/1-iccvam-508.pdf https://ntp.niehs.nih.gov/iccvam/meetings/iccvam-forum-2016/1-iccvam-508.pdf http://ntp.niehs.nih.gov/ntp/about_ntp/sacatm/2016/september/update20160927_508.pdf http://ntp.niehs.nih.gov/ntp/about_ntp/sacatm/2016/september/update20160927_508.pdf http://ntp.niehs.nih.gov/ntp/about_ntp/sacatm/2016/september/update20160927_508.pdf http://dx.doi.org/10.1016/j.ejpb.2015.03.002 https://www.nap.edu/catalog/10122/standing-operating-procedures-for-developing-acute-exposure-guideline-levels-for-hazardous-chemicals https://www.nap.edu/catalog/10122/standing-operating-procedures-for-developing-acute-exposure-guideline-levels-for-hazardous-chemicals https://www.nap.edu/catalog/10122/standing-operating-procedures-for-developing-acute-exposure-guideline-levels-for-hazardous-chemicals http://www.nap.edu/catalog.php?record_id=11970 https://www.nap.edu/catalog/21775/application-of-modern-toxicology-approaches-for-predicting-acute-toxicity-for-chemical-defense https://www.nap.edu/catalog/21775/application-of-modern-toxicology-approaches-for-predicting-acute-toxicity-for-chemical-defense https://www.nap.edu/catalog/21775/application-of-modern-toxicology-approaches-for-predicting-acute-toxicity-for-chemical-defense http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2001 http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2001 http://www.oecd-ilibrary.org/environment/test-no-420-acute-oral-toxicity-fixed-dose-procedure_9789264070943-en http://www.oecd-ilibrary.org/environment/test-no-420-acute-oral-toxicity-fixed-dose-procedure_9789264070943-en http://www.oecd-ilibrary.org/environment/test-no-420-acute-oral-toxicity-fixed-dose-procedure_9789264070943-en http://www.oecd-ilibrary.org/environment/test-no-423-acute-oral-toxicity-acute-toxic-class-method_9789264071001-en http://www.oecd-ilibrary.org/environment/test-no-423-acute-oral-toxicity-acute-toxic-class-method_9789264071001-en http://www.oecd-ilibrary.org/environment/test-no-423-acute-oral-toxicity-acute-toxic-class-method_9789264071001-en http://www.oecd-ilibrary.org/environment/test-no-425-acute-oral-toxicity-up-and-down-procedure_9789264071049-en http://www.oecd-ilibrary.org/environment/test-no-425-acute-oral-toxicity-up-and-down-procedure_9789264071049-en http://www.oecd-ilibrary.org/environment/test-no-425-acute-oral-toxicity-up-and-down-procedure_9789264071049-en http://refhub.elsevier.com/S0273-2300(18)30038-2/sref46 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref46 http://www.oecd-ilibrary.org/environment/test-no-403-acute-inhalation-toxicity_9789264070608-en http://www.oecd-ilibrary.org/environment/test-no-403-acute-inhalation-toxicity_9789264070608-en http://www.oecd-ilibrary.org/environment/test-no-436-acute-inhalation-toxicity-acute-toxic-class-method_9789264076037-en http://www.oecd-ilibrary.org/environment/test-no-436-acute-inhalation-toxicity-acute-toxic-class-method_9789264076037-en http://www.oecd-ilibrary.org/environment/test-no-436-acute-inhalation-toxicity-acute-toxic-class-method_9789264076037-en http://www.oecd.org/env/ehs/testing/seriesontestingandassessmenttestingforhumanhealth.htm http://www.oecd.org/env/ehs/testing/seriesontestingandassessmenttestingforhumanhealth.htm http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2010)20\ufffd&\ufffddoclanguage=en http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2010)20\ufffd&\ufffddoclanguage=en http://www.oecd.org/env/ehs/testing/mono%202016%2032.pdf http://refhub.elsevier.com/S0273-2300(18)30038-2/sref52 Mammalian Acute Toxicity Tests Series on Testing & Assessment. OECD, 2017a. Test No. 402: Acute Dermal Toxicity. OECD Guidelines for the Testing of Chemicals, Section 4, from. http://www.oecd-ilibrary.org/environment/test-no-402- acute-dermal-toxicity_9789264070585-en. OECD, 2017b. Test No. 433: Acute Inhalation Toxicity - Fixed Concentration Procedure. OECD Guidelines for the Testing of Chemicals, Section 4, from. http://www.oecd- ilibrary.org/environment/test-no-433-acute-inhalation-toxicity-fixed-concentration- procedure_9789264284166-en. OSHA, 2012. Hazard Communication final rule. Fed. Regist. 77 (58), 17574\u201317896. from. www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=FEDERAnna Lowit_ REGISTER&p_id=22607. Pampaloni, F., Reynaud, E.G., Stelzer, E.H., 2007. The third dimension bridges the gap between cell culture and live tissue. Nat. Rev. Mol. Cell Biol. 8 (10), 839\u2013845. http:// dx.doi.org/10.1038/nrm2236. Peck, Y., Wang, David Allen., 2013. Three-dimensionally engineered biomimetic tissue models for in vitro drug evaluation: delivery, efficacy and toxicity. [Research Support, Non-U.S. Gov't Review]. Expert. Opin. Drug. Deliv. 10 (3), 369\u2013383. http://dx.doi.org/10. 1517/17425247.2013.751096. Robinson, S., Delongeas, J., Donald, E., Dreher, D., Festag, M., Kervyn, S., Chapman, K., 2008. A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development. Regul. Toxicol. Pharmacol. 50 (3), 345\u2013352. Scarano, L., 2015. Requirements and Evaluation of Toxicity Testing in the TSCA New Chemicals Program (Presentation at Alternative Approaches for Identifying Acute Systemic Toxicity: Moving from Research to Regulatory Testing). Scarano, L., 2016. Application of QSurender AhirR Principles in the Regulatory Environment. The US EPA New Chemicals Program (Presentation at ICCVAM Communities of Practice Webinar), from. http://ntp.niehs.nih.gov/go/commprac-2016. The Technical Cooperation Program, 2014. Assessing the Potential Environmental and Human Health Consequences of Energetic Materials: a Phased Approach. Phased Evaluation of Energetic Materials. The Technical Cooperation Program Technical Report CP 4\u201342. United Nations, 2009. Globally Harmonized System of Classification and Labelling of Chemicals (GHS), third ed. from. http://www.unece.org/trans/danger/publi/ghs/ ghs_rev03/03files_e.html. United Nations, 2015. Globally Harmonized System of Classification and Labelling of Chemicals 6th Revised Edition. from. http://www.unece.org/fileadmin/David AllenM/ trans/danger/publi/ghs/ghs_rev06/English/ST-SG-AC10-30-Rev6e.pdf. US EPA, 1998a. Health Effects Test Guidelines OPPTS 870.1200 Acute Dermal Toxicity. EPA 712-C-98-192, from. https://www.regulations.gov/document?D=EPA-HQ- OPPT-2009-0156-0005. US EPA, 1998b. Health Effects Test Guidelines OPPTS 870.1300 Acute Inhalation Toxicity. EPA 712-C-98\u2013193. Office of Prevention, Pesticides, and Toxic Substances, Washington, DC. US EPA, 2002a. Health Effects Test Guidelines OPPTS 870.1000 Acute Oral Toxicity Testing\u2013background. EPA 712\u2013C\u201302\u2013189, from. https://www.regulations.gov/ document?D=EPA-HQ-OPPT-2009-0156-0002. US EPA, 2002b. Health Effects Test Guidelines OPPTS 870.1100 Acute Oral Toxicity. EPA 712\u2013C\u201302\u2013190, from. https://www.regulations.gov/document?D=EPA-HQ-OPPT- 2009-0156-0003. US EPA, 2010. TSCA New Chemicals Program (NCP) Chemical Categories. from. https:// www.epa.gov/sites/production/files/2014-10/documents/ncp_chemical_categories_ august_2010_version_0.pdf. US EPA, 2012. Guidance for Waiving or Bridging of Mammalian Acute Toxicity Tests for Pesticides and Pesticide Products (Acute Oral, Acute Dermal, Acute Inhalation, Primary Eye, Primary Dermal, and Dermal Sensitization). from. http://www.epa. gov/sites/production/files/documents/acute-data-waiver-guidance.pdf. US EPA, 2013. Guiding Principles for Data Requirements. from. http://www.epa.gov/ sites/production/files/2015-04/documents/data-require-guide-principle.pdf. US EPA, 2015a. Acute Exposure Guideline Levels for Airborne Chemicals. from. http:// www.epa.gov/aegl. US EPA, 2015b. Microbial Pesticides Toxicology Data Requirements Table. 40 CFR 158.2140, from. www.gpo.gov/fdsys/pkg/CFR-2015-title40-vol24/pdf/CFR-2015- title40-vol24-part158.pdf. US EPA, 2015c. Summary of the Federal Food, Drug, and Cosmetic Act. from. http:// www.epa.gov/laws-regulations/summary-federal-food-drug-and-cosmetic-act. US EPA, 2015d. Summary of the Federal Insecticide, Fungicide, and Rodenticide Act. from. www.epa.gov/laws-regulations/summary-federal-insecticide-fungicide-and- rodenticide-act. US EPA, 2015e. Toxicology Data Requirement Table. 40 CFR 158.500, from. www.gpo. gov/fdsys/pkg/CFR-2015-title40-vol24/pdf/CFR-2015-title40-vol24-part158.pdf. US EPA, 2015f. Toxicology. 40 CFR 158.2230, from. www.gpo.gov/fdsys/pkg/CFR- 2015-title40-vol24/pdf/CFR-2015-title40-vol24-part158.pdf. US EPA, 2016a. The Frank R. Lautenberg Chemical Safety for the 21st Century Act. from. www.epa.gov/assessing-and-managing-chemicals-under-tsca/frank-r-lautenberg- chemical-safety-21st-century-act. US EPA, 2016b. Guidance for Waiving Acute Dermal Toxicity Tests for Pesticide Formulations & Supporting Retrospective Analysis. from. https://www.epa.gov/ sites/production/files/2016-11/documents/acute-dermal-toxicity-pesticide- formulations_0.pdf. US EPA, 2016c. Label Review Manual. from. https://www.epa.gov/sites/production/ files/2016-12/documents/lrmcomplete.pdf. US EPA, 2016d. Mixtures Equation Pilot Program to Reduce Animal Testing. from. https://www.epa.gov/pesticide-registration/mixtures-equation-pilot-program- reduce-animal-testing. US EPA, 2016e. Process for Establishing and Implementing Alternative Approaches to Traditional in Vivo Acute Toxicity Studies for FIFRA Regulatory Use. from. https:// www.epa.gov/pesticide-science-and-assessing-pesticide-risks/process-establishing- implementing-alternative. US EPA, 2016f. Strategic Vision for Adopting 21st Century Science Methodologies. from. https://www.epa.gov/pesticide-science-and-assessing-pesticide-risks/strategic- vision-adopting-21st-century-science. US FDavid Allen, 1988. LD 50 Test Policy [Docket No. 86P-0224], 53. from. https://cdn.loc.gov/ service/ll/fedreg/fr053/fr053196/fr053196.pdf. US FDavid Allen, 1996. Guidance for Industry: Single Dose Acute Toxicity Testing for Pharmaceuticals. from. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm079270.pdf. US FDavid Allen, 2005. General Biological Products Standards: Equivalent Methods and Processes. 21 CFR 610.9, from. http://www.ecfr.gov/cgi-bin/text-idx?SID= 0fe7ae5ae5d0af1a60a09e9b4a770a4b&mc=true&node=se21.7.610_19&rgn=div8. US FDavid Allen, 2007. Guidance for Industry and Other Stakeholders: Toxicological Principles for the Safety Assessment of Food Ingredients. from. http://www.fda.gov/Food/ GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/ IngredientsAdditivesGRASPackaging/ucm2006826.htm. US FDavid Allen, 2013. Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products. from. www.fda.gov/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ ucm376136.htm. US FDavid Allen, 2014. Requests for feedback on medical device submissions. In: The Pre-sub- mission Program and Meetings with Food and Drug Administration Staff. US FDavid Allen, 2016. Use of International Standard ISO 10993-1, \u201cBiological Evaluation of Medical Devices - Part 1: Evaluation and Testing within a Risk Management Process. from. https://www.fda.gov/downloads/MedicalDevices/ DeviceRegulationandGuidance/GuidanceDocuments/ucm348890.pdf. J. Strickland et al. Regulatory Toxicology and Pharmacology 94 (2018) 183\u2013196 196 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref52 http://www.oecd-ilibrary.org/environment/test-no-402-acute-dermal-toxicity_9789264070585-en http://www.oecd-ilibrary.org/environment/test-no-402-acute-dermal-toxicity_9789264070585-en http://www.oecd-ilibrary.org/environment/test-no-433-acute-inhalation-toxicity-fixed-concentration-procedure_9789264284166-en http://www.oecd-ilibrary.org/environment/test-no-433-acute-inhalation-toxicity-fixed-concentration-procedure_9789264284166-en http://www.oecd-ilibrary.org/environment/test-no-433-acute-inhalation-toxicity-fixed-concentration-procedure_9789264284166-en http://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=FEDERAnna Lowit_REGISTER\ufffd&\ufffdp_id=22607 http://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=FEDERAnna Lowit_REGISTER\ufffd&\ufffdp_id=22607 http://dx.doi.org/10.1038/nrm2236 http://dx.doi.org/10.1038/nrm2236 http://dx.doi.org/10.1517/17425247.2013.751096 http://dx.doi.org/10.1517/17425247.2013.751096 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref59 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref59 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref59 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref59 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref60 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref60 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref60 http://ntp.niehs.nih.gov/go/commprac-2016 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref62 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref62 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref62 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref62 http://www.unece.org/trans/danger/publi/ghs/ghs_rev03/03files_e.html http://www.unece.org/trans/danger/publi/ghs/ghs_rev03/03files_e.html http://www.unece.org/fileadmin/David AllenM/trans/danger/publi/ghs/ghs_rev06/English/ST-SG-AC10-30-Rev6e.pdf http://www.unece.org/fileadmin/David AllenM/trans/danger/publi/ghs/ghs_rev06/English/ST-SG-AC10-30-Rev6e.pdf https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0005 https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0005 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref66 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref66 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref66 https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0002 https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0002 https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0003 https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0003 https://www.epa.gov/sites/production/files/2014-10/documents/ncp_chemical_categories_august_2010_version_0.pdf https://www.epa.gov/sites/production/files/2014-10/documents/ncp_chemical_categories_august_2010_version_0.pdf https://www.epa.gov/sites/production/files/2014-10/documents/ncp_chemical_categories_august_2010_version_0.pdf http://www.epa.gov/sites/production/files/documents/acute-data-waiver-guidance.pdf http://www.epa.gov/sites/production/files/documents/acute-data-waiver-guidance.pdf http://www.epa.gov/sites/production/files/2015-04/documents/data-require-guide-principle.pdf http://www.epa.gov/sites/production/files/2015-04/documents/data-require-guide-principle.pdf http://www.epa.gov/aegl http://www.epa.gov/aegl http://www.gpo.gov/fdsys/pkg/CFR-2015-title40-vol24/pdf/CFR-2015-title40-vol24-part158.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title40-vol24/pdf/CFR-2015-title40-vol24-part158.pdf http://www.epa.gov/laws-regulations/summary-federal-food-drug-and-cosmetic-act http://www.epa.gov/laws-regulations/summary-federal-food-drug-and-cosmetic-act http://www.epa.gov/laws-regulations/summary-federal-insecticide-fungicide-and-rodenticide-act http://www.epa.gov/laws-regulations/summary-federal-insecticide-fungicide-and-rodenticide-act http://www.gpo.gov/fdsys/pkg/CFR-2015-title40-vol24/pdf/CFR-2015-title40-vol24-part158.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title40-vol24/pdf/CFR-2015-title40-vol24-part158.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title40-vol24/pdf/CFR-2015-title40-vol24-part158.pdf http://www.gpo.gov/fdsys/pkg/CFR-2015-title40-vol24/pdf/CFR-2015-title40-vol24-part158.pdf http://www.epa.gov/assessing-and-managing-chemicals-under-tsca/frank-r-lautenberg-chemical-safety-21st-century-act http://www.epa.gov/assessing-and-managing-chemicals-under-tsca/frank-r-lautenberg-chemical-safety-21st-century-act https://www.epa.gov/sites/production/files/2016-11/documents/acute-dermal-toxicity-pesticide-formulations_0.pdf https://www.epa.gov/sites/production/files/2016-11/documents/acute-dermal-toxicity-pesticide-formulations_0.pdf https://www.epa.gov/sites/production/files/2016-11/documents/acute-dermal-toxicity-pesticide-formulations_0.pdf https://www.epa.gov/sites/production/files/2016-12/documents/lrmcomplete.pdf https://www.epa.gov/sites/production/files/2016-12/documents/lrmcomplete.pdf https://www.epa.gov/pesticide-registration/mixtures-equation-pilot-program-reduce-animal-testing https://www.epa.gov/pesticide-registration/mixtures-equation-pilot-program-reduce-animal-testing https://www.epa.gov/pesticide-science-and-assessing-pesticide-risks/process-establishing-implementing-alternative https://www.epa.gov/pesticide-science-and-assessing-pesticide-risks/process-establishing-implementing-alternative https://www.epa.gov/pesticide-science-and-assessing-pesticide-risks/process-establishing-implementing-alternative https://www.epa.gov/pesticide-science-and-assessing-pesticide-risks/strategic-vision-adopting-21st-century-science https://www.epa.gov/pesticide-science-and-assessing-pesticide-risks/strategic-vision-adopting-21st-century-science https://cdn.loc.gov/service/ll/fedreg/fr053/fr053196/fr053196.pdf https://cdn.loc.gov/service/ll/fedreg/fr053/fr053196/fr053196.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079270.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079270.pdf http://www.ecfr.gov/cgi-bin/text-idx?SID=0fe7ae5ae5d0af1a60a09e9b4a770a4b\ufffd&\ufffdmc=true\ufffd&\ufffdnode=se21.7.610_19\ufffd&\ufffdrgn=div8 http://www.ecfr.gov/cgi-bin/text-idx?SID=0fe7ae5ae5d0af1a60a09e9b4a770a4b\ufffd&\ufffdmc=true\ufffd&\ufffdnode=se21.7.610_19\ufffd&\ufffdrgn=div8 http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm2006826.htm http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm2006826.htm http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm2006826.htm http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm376136.htm http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm376136.htm http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm376136.htm http://refhub.elsevier.com/S0273-2300(18)30038-2/sref89 http://refhub.elsevier.com/S0273-2300(18)30038-2/sref89 https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm348890.pdf https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm348890.pdf Status of acute systemic toxicity testing requirements and data uses by U.S. regulatory agencies Introduction Overview of U.S. regulatory testing requirements for acute systemic toxicity Regulatory uses of acute systemic toxicity data by agency Consumer Product Safety Commission Standards, guidelines, and guidance for acute systemic toxicity testing Current requirements for animal testing and flexibility for the use of alternatives Information needed from alternative tests to fulfill the needs for acute toxicity data Acceptance of alternative methods and approaches to determine acute toxicity Department of Defense Standards, guidelines, and guidance for acute systemic toxicity testing Current requirements for animal testing and flexibility for the use of alternatives Information needed from alternative tests to fulfill the needs for acute toxicity data Acceptance of alternative methods and approaches to determine acute toxicity Department of Transportation Standards, guidelines, and guidance for acute systemic toxicity testing Current requirements for animal testing and flexibility for the use of alternatives Information needed from alternative tests to fulfill the needs for acute toxicity data Acceptance of alternative methods and approaches to determine acute toxicity Environmental Protection Agency Office of Pesticide Programs Standards, guidelines, and guidance for acute systemic toxicity testing Current requirements for animal testing and flexibility for the use of alternatives Information needed from alternative tests to fulfill the needs for acute toxicity data Acceptance of alternative methods and approaches to determine acute toxicity EPA Office of Pollution Prevention and Toxics Standards, guidelines, and guidance for acute systemic toxicity testing Current requirements for animal testing and flexibility for the use of alternatives Information needed from alternative tests to fulfill the needs for acute toxicity data Acceptance of alternative methods and approaches to determine acute toxicity FDavid Allen Center for Biologics Evaluation and Research Standards, guidelines, and guidance for acute systemic toxicity testing Current requirements for animal testing and flexibility for the use of alternatives Information needed from alternative tests to fulfill the needs for acute toxicity data Acceptance of alternative methods and approaches to determine acute toxicity FDavid Allen Center for Devices and Radiological Health Standards, guidelines, and guidance for acute systemic toxicity testing Current requirements for animal testing and flexibility in the use of alternatives Information needed from alternative tests to fulfill the needs for acute toxicity data Acceptance of alternative methods and approaches to determine acute toxicity FDavid Allen Center for Food Safety and Nutrition Standards, guidelines, and guidance for acute systemic toxicity testing Current requirements for animal testing and flexibility for the use of alternatives Information needed from alternative tests to fulfill the needs for acute toxicity data Acceptance of alternative methods and approaches to determine acute toxicity Occupational Safety and Health Administration Standards, guidelines, and guidance for acute systemic toxicity testing Current requirements for animal testing and flexibility for the use of alternatives Information needed from alternative tests to fulfill the needs for acute toxicity data Acceptance of alternative methods and approaches to determine acute toxicity Discussion Funding Disclaimer Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Steviol-glycosides-in-purified-stevia-leaf-extra_2016_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26924787", "content": {"CoiStatement": "Conflicts of interest The authors declare no conflicts of interest. Intertek Scientific & Regulatory Consultancy has provided con- sultancy services to each of PureCircle Ltd. and The Coca-Cola Company Ltd. The authors declare no conflicts of interest. Intertek Scientific & Regulatory Consultancy has provided con- sultancy services to each of PureCircle Ltd. and The Coca-Cola Company Ltd. Funding sources statement 2. Discussion and conclusion Conflicts of interest Funding sources statement Acknowledgments Transparency document References", "Funding": "Funding sources statement The funding for the research was provided by PureCircle Ltd. (USA) and The Coca-Cola Company, Ltd. (USA). The funding for the research was provided by PureCircle Ltd. (USA) and The Coca-Cola Company, Ltd. (USA). Acknowledgments 2. Discussion and conclusion Conflicts of interest Funding sources statement Acknowledgments Transparency document References", "Acknowledgement": "Acknowledgments The authors would like to acknowledge Dr. David Kwok of BRI Biopharmaceutical Research Inc. (Vancouver, Canada) and his team members for their diligent work in conducting all in-vitro studies and for reviewing the manuscript for publication. 2. Discussion and conclusion Conflicts of interest Funding sources statement Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Strain-related-differences-in-mouse-lung-gene-expression_2018_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29777725", "content": {"Funding": "Collection and analysis of the gene expression data was supported by a series of contracts with the Styrene Information & Research Center (SIRC). Funding for development of the bioinformatics tools to evaluate patterns of gene expression and TF networks was provided by support from the American Chemistry Council Long-Range Research Initiative (ACC-LRI) as part of a program at ScitoVation LLC to develop compu- tational tools to assess and better visualize modes of action of com- pounds in vivo and in vitro. Appendix A. Supplementary data", "Acknowledgement": "Acknowledgements Collection and analysis of the gene expression data was supported by a series of contracts with the Styrene Information & Research Center (SIRC). Funding for development of the bioinformatics tools to evaluate patterns of gene expression and TF networks was provided by support from the American Chemistry Council Long-Range Research Initiative (ACC-LRI) as part of a program at ScitoVation LLC to develop compu- tational tools to assess and better visualize modes of action of com- pounds in vivo and in vitro. Acknowledgements Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Strategies-for-the-optimisation-of-in-vivo-experim_2012_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22446816", "content": {"CoiStatement": "Conflict of interest statement The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgments 3 Conclusions and recommendations Conflict of interest statement Acknowledgments References", "Funding": "The funding of the EU FP6 OSIRIS Project (GOCE-CT-2007- 037017) and the contributions from Theo Vermeire (on technical content) and Katy Taylor (on application of 3Rs) are also gratefully acknowledged. References", "Acknowledgement": "Acknowledgments The funding of the EU FP6 OSIRIS Project (GOCE-CT-2007- 037017) and the contributions from Theo Vermeire (on technical content) and Katy Taylor (on application of 3Rs) are also gratefully acknowledged. 3 Conclusions and recommendations Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Strengthening-the-foundation-of-next-generat_2014_Regulatory-Toxicology-and-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24342233", "content": {"CoiStatement": "Conflict of interest Preparation of this manuscript was funded in part by the Texas Commission on Environmental Quality (TCEQ). The authors have sole responsibility for the writing and contents of this paper. This paper represents the professional opinions of the authors and not necessarily those of TCEQ. 5 Conclusions Conflict of interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Strengths-and-limitations-of-using-repeat-dose-tox_2007_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/17512650", "content": {"Acknowledgement": "Discussion Conclusion Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Stroke-risk-among-menthol-versus-non-menthol-cigarette-sm_2017_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28163170", "content": {"CoiStatement": "Declaration of interest Dr. Sulsky, Ms. Van Landingham, Dr. Fuller and Mr. Mariano are all employees of Ramboll Environ where they have multiple pro- jects with multiple clients including other tobacco companies and projects with RAIS that are outside the scope of this collaborative work. Dr. Curtin and Dr. Marano are employees of RAIS. Stroke risk among menthol versus non-menthol cigarette smokers in the United States: Analysis of the National Health and Nu ... 1. Introduction 2. Methods 3. Results 4. Discussion Funding Declaration of interest Acknowledgments Transparency document References", "Disclosure": "Clarity and reproducibility of methods is considered a hallmark of good science, and is particularly important in carrying out research that is intended to influence public policies and regula- tions. These goals are more easily achieved when using publically available data, like the NHANES, whose accessibility facilitates replication of published results. Each researcher must correctly and accurately report the data used (e.g., combination of survey cycles), any calculations used to create variables or categories in the ana- lyses, and the methods by which the data were analyzed. The an- alyses reported here show that replication of results can be difficult to achieve if the methods used and adjustments made to the data are not completely or clearly reported. The results of these direct replication and cross-model validation efforts serve to highlight the importance of full and accurate disclosure of methods, including equations for key calculations, as well as the value of including descriptive results, such as the unweighted sample counts, to show the true sample sizes in survey data sets. Overall, the results from the three models were consistent with each other when applied to the same data sets. The analyses employing the largest, most robust data sets (i.e., combining NHANES cycles 1999e2010 or 1999e2012) were consistent with each other and with the literature in suggesting no substantial in- creases in the risk of stroke among smokers of menthol compared with non-menthol cigarettes. Analyses of individual cycles of the NHANES survey show that the 2007e2008 cycle was different from the other cycles in the 1999e2012 period (Fig. 1). Only in this cycle", "Funding": "Funding All work was completed by Ramboll Environ (RE) as a work product for hire, funded by a contract between RE and RAI Services Company (RAIS). None of the authors received separate funding (i.e., apart from their regular salaries) to complete the work. All work was completed by Ramboll Environ (RE) as a work product for hire, funded by a contract between RE and RAI Services Company (RAIS). None of the authors received separate funding (i.e., apart from their regular salaries) to complete the work. Declaration of interest Stroke risk among menthol versus non-menthol cigarette smokers in the United States: Analysis of the National Health and Nu ... 1. Introduction 2. Methods 3. Results 4. Discussion Funding Declaration of interest Acknowledgments Transparency document References", "Acknowledgement": "Acknowledgments The authors are grateful to Dr. Vozoris for discussing the analytical methods used, and graciously confirming the reporting error in the previously published paper. In addition, we thank Allison Franzen and Sara Oglesbee for their assistance in formatting the tables and text for submission. The editor of Regulatory Toxi- cology and Pharmacology, and the reviewers assigned to this paper, provided highly useful recommendations; our paper was greatly improved by following their suggestions. Stroke risk among menthol versus non-menthol cigarette smokers in the United States: Analysis of the National Health and Nu ... 1. Introduction 2. Methods 3. Results 4. Discussion Funding Declaration of interest Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Structural-analysis-of-linear-and-conformation_2009_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19121639", "content": {"Acknowledgement": "We regard our studies important in providing a solid scientific foundation in the general discussion on the potential risk of genet- ically modified (GM) foods. The statistical results and the novel bioinformatics tools can help regulatory agencies in the US and other countries that grow GM plants to find more specific bioinfor- matics guidelines for these crops. Since food allergies can result in fatal reactions, the allergenic potential of genetically-engineered food products needs to be carefully assessed prior to their entry into the market. There is a vital need for faster and reliable meth- ods to evaluate the potential allergenicity of proteins that have not previously been part of the food supply. Our novel approaches can reduce some uncertainty for those crops that may be potentially allergenic for some sensitive sub-population. Acknowledgments This work was supported by a contract from the US Food and Drug Administration (HHSF223200710011I) and grants from the National Institute of Health (R01 AI 064913), and the US Environ- mental Protection Agency under a STAR Research Assistance Agreement (No. RD 833137). References Conclusions Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Structural-and-functional-pharmacokinetic-analogs-for_2018_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30201539", "content": {"CoiStatement": "Conflicts of interest None. Discussion Conflicts of interest Funding Acknowledgments Supplementary data Transparency document References", "Funding": "Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Acknowledgments Discussion Conflicts of interest Funding Acknowledgments Supplementary data Transparency document References", "Acknowledgement": "Acknowledgments The author would like to acknowledge and thank several individuals for their help, guidance and support with this work. Cathy Lester pro- vided Tanimoto scores. Shendge Wu provided expert review of che- mical structures for structural PK analogs. Christopher Ruark, George Discussion Conflicts of interest Funding Acknowledgments Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Structure-activity-relationship--SAR--toxicologica_2018_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29305951", "content": {"Acknowledgement": "Acknowledgments The authors gratefully acknowledge SAllison Reis specialist Greg Dameron for help in understanding the analog searching workflow and for pro- viding the analogs used for computing similarity coefficients. Conclusion Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Structure-activity-relationship-analysis-tools--Val_2008_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18023949", "content": {"Acknowledgement": "Future validation experiments should examine other available SAR software programs, e.g. MDL-QSAR (Else- vier MDL, 2007) and DEREK (Lhasa Limited, 2005), and more recent versions of MCASE (Multicase Inc., 2006). New QSAR modules are constantly being developed; these modules should be tested and refined for use in further val- idation experiments. In addition to any future versions of the CPDB, there are also other datasets that could be used in validation experiments, such as publicly releasable data on compounds submitted to FDA and various other regu- latory agencies. As SAR software programs are becoming more and more refined, growing to encompass metabolic pathways and mechanisms of action, validation studies should be continually used to assess the capabilities of these new/refined programs. Acknowledgments The authors thank Drs. Ron Chanderbhan, Kirk Arvid- son, Rene Sotomayor, and Chihae Yang for their insightful comments and technical contributions to this manuscript. The authors also thank Ms. Luciann Bracero and Mr. Nizar Dowla for technical assistance. References Results and discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Studies-of-styrene--styrene-oxide-and-4-hydroxystyrene-to_2013_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23454103", "content": {"CoiStatement": "G. Cruzan et al. / Regulatory Toxicology and Pharmacology 66 (2013) 24\u201329 29 Conflict of interest statement The Styrene Information and Research Center (SIRC) was the sponsor of this research, conducted at the Dow laboratory (J Hotchkiss study director; R Sura pathology). G Yost and C Moore metabolism work sup- ported in part by a grant from SIRC. G Cruzan is a consultant to SIRC. J Bus, M Banton, and S Sarang are employed by companies that are members of SIRC. 4 Discussion Conflict of interest statement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Studies-on-the-environmental-fate--ecotoxicology-a_2017_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29097239", "content": {"Funding": "Funding for this paper and the studies that are described herein was provided by LyondellBasell Industries. Transparency document", "Acknowledgement": "Acknowledgements Funding for this paper and the studies that are described herein was provided by LyondellBasell Industries. Discussion Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Study-on-safety-and-bioavailability-of-ubiquinol--Kanek_2007_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16919858", "content": {"Compliance with ethical standards": "In order to assess the safety of Kaneka QH\u2122 (ubiqui- nol), a series of preclinical safety studies were performed in compliance with relevant Good Laboratory Practice (GLP) Standards with ubiquinol bulk, including an acute toxicity study and subchronic toxicity studies in rats and dogs, as well as in vitro and in vivo genotoxicity studies. 1.1. Review of previously unpublished studies"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Study-on-the-developmental-toxicity-of---io_2018_Regulatory-Toxicology-and-P.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29928934", "content": {"Acknowledgement": "Acknowledgments This study was supported in part by grants from the National Research Council and the Rio de Janeiro State Agency for Supporting Research (FAPERJ). Isabella F Delgado and Francisco J R Paumgartten were recipients of research fellow- ships from CNPq. IPCS-WHO (International Programme on Chemical Safety \u2013 World health Organization, 1999. Safety evaluation of certain food additives. Ionones and structurally related substances. WHO Food Addit. Ser. 42. http://www.inchem.org/documents/jecfa/ jecmono/v042je19.htm. Jeong, T.C., Kim, H.J., Yun, C.H., Lee, S.S., Yang, K.H., Han, S.S., Roh, J.K., 1995. Induction of liver cytochrome P450 2B1 by beta-ionone in Sprague Dawley rats. Biochem. Biophys. Res. Commun. 216 (1), 198\u2013202. Jeong, T.C., Gu, H.K., Chun, Y.J., Yun, C.H., Han, S.S., Roh, J.K., 1998. Effects of beta- ionone on the expression of cytochrome P450s and NADPH-cytochrome P450 re- ductase in Sprague Dawley rats. Chem. Biol. Interact. 114 (1\u20132), 97\u2013107. Jeong, H.G., Chun, Y.J., Yun, C.H., Moon, C.K., Lee, H.S., Han, S.S., Lee, E.S., Jeong, T.C., 2002. Induction of cytochrome P450 1A and 2B by alpha- and beta-ionone in Sprague Dawley rats. Arch Pharm. Res. (Seoul) 25 (2), 197\u2013201. Leone, V.G., 1977. Comparative aspects of developmental stages in mammals used for teratogenic tests. In: Neubert, D., Merker, J.-H., Kwasigroch, T.E. (Eds.), Methods in Prenatal Toxicology. Georg Thieme Publishers, Stuttgart, pp. 11\u201324. Makris, S.L., Solomon, H.M., Clark, R., Shiota, K., Barbellion, S., Buschmann, J., Ema M,Fujiwara, M., Grote, K., Hazelden, K.P., Hew, K.W., Horimoto, M., Ooshima, Y., Parkinson, M., Wise, L.D., 2009. Terminology of developmental abnormalities in common laboratory mammals (version 2). Reprod. Toxicol. 28 (3), 371\u2013434. National Research Council of the National Academies (NRC), 2008. Recognition and Alleviation of Distress in Laboratory Animals. Committee on Recognition and Alleviation of Distress in Laboratory Animals - Institute for Laboratory Animal Research. The National Academies Press, Washington, D.C, pp. 132. http://www.nap. edu/catalog/11931.html. OECD, 2004. Screening Information Data Set (SIDS) High Production Volume Chemicals. \u0392-ionone [(E)-4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-buten-2-one] CAS N\u02da79-77-6. Paris, France, 19-22 April. 30p. http://www.inchem.org/pages/ sids.html. Salewski, E., 1964. F\u00e4rbemethoden zum makrokospischen Nachweis von Implantationsstellem am Uterus der Ratte Naunyn-Schmiedeberg's Arch Exp Pathol Pharmakol, vol. 281. pp. 367. Simkin, A.J., Underwood, B.A., Auldridge, M., Loucas, H.M., Shibuya, K., Schmelz, E., Clark, D.G., Klee, H.J., 2004. Circadian regulation of the PhCCD1 carotenoid cleavage dioxygenase controls emission of beta-ionone, a fragrance volatile of petunia flowers. Plant Physiol. (Wash. D C) 136 (3), 3504\u20133514. Simpson, K.L., Chichester, C.O., 1981. Metabolism and nutritional significance of car- otenoids. Annu. Rev. Nutr. 1, 351\u2013374. Solecki, R., B\u00fcrgin, H., Buschmann, J., Clark, R., Duverger, M., Fialkowski, O., et al., 2001. Harmonisation of Rat Fetal Skeletal Terminology and Classification. Report of the Third Workshop on the Terminology in Developmental Toxicology. Berlin, 14-16 September 2000. Reprod. Toxicol. (15), 713\u2013721. Solecki, R., Rauch, M., Gall, A., Buschmann, J., Clark, R., Fuchs, A., et al., 2003. Continuing harmonization of terminology and innovations for methodologies in de- velopmental toxicology: report of the 8th Berlin Workshop on Developmental Toxicity. 14-16 May 2014. Reprod. Toxicol. (57), 140\u2013146. Sterz, H., 1977. Routine examination of rat and rabbit fetuses for malformations of in- ternal organs: combination of Barrow's and Wilson's methods. In: Neubert, D., Merker, J.-H., Kwasigroch, T.E. (Eds.), Methods in Prenatal Toxicology. Georg Thieme Publishers, Stuttgart, pp. 113\u2013122. Verrett, M.J., Scott, W.F., Reynaldo, E.F., Alterman, E.K., Thomas, C.A., 1980. Toxicity and teratogenicity of food additive chemicals in the developing chicken embryo. Toxicol. Appl. Pharmacol. 56 (2), 265\u2013273. Willhite, C.C., 1986. Structure-activity relationships of retinoids in developmental tox- icology. II. Influence of the polyene chain of the vitamin A molecule. Toxicol. Appl. Pharmacol. 83 (3), 563\u2013575. F.C.M. Pinto et al. Regulatory Toxicology and Pharmacology 97 (2018) 110\u2013119 119 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref4 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref4 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref5 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref5 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref5 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref6 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref6 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref6 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref7 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref7 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref7 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref8 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref8 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref9 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref9 http://www.inchem.org/documents/jecfa/jecmono/v042je19.htm http://www.inchem.org/documents/jecfa/jecmono/v042je19.htm http://refhub.elsevier.com/S0273-2300(18)30165-X/sref11 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref11 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref11 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref12 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref12 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref12 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref13 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref13 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref13 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref14 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref14 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref14 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref15 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref15 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref15 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref15 http://www.nap.edu/catalog/11931.html http://www.nap.edu/catalog/11931.html http://www.inchem.org/pages/%20sids.html http://refhub.elsevier.com/S0273-2300(18)30165-X/sref18 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref18 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref18 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref19 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref19 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref19 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref19 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref20 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref20 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref21 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref21 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref21 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref21 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref22 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref22 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref22 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref22 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref23 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref23 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref23 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref23 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref24 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref24 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref24 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref25 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref25 http://refhub.elsevier.com/S0273-2300(18)30165-X/sref25 Study on the developmental toxicity of \u03b2-ionone in the rat Introduction Material and methods Animals Mating procedure Treatment Cesarean section Statistical analysis Results Pregnancy weight gain and maternal toxicity Developmental toxicity Embryotoxicity of a single dose of \u03b2-ionone administered on GD11 Discussion Conclusions Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Study-parameters-influencing-NOAEL-and-LOAEL-in-toxicity-f_2011_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21875639", "content": {"CoiStatement": "Conflict of interest statement The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Funding sources statement 4 Significance for dietary risk assessment 5 Conclusion Conflict of interest statement Funding sources statement Acknowledgments References", "Funding": "Funding sources statement The authors declare that this work was not funded by any sources. 4 Significance for dietary risk assessment 5 Conclusion Conflict of interest statement Funding sources statement Acknowledgments References", "Acknowledgement": "Acknowledgments The critical comments of Max Haldimann were very helpful. 4 Significance for dietary risk assessment 5 Conclusion Conflict of interest statement Funding sources statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Styrene-Respiratory-Tract-Toxicity-and-Mouse-Lung-T_2002_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/12202046", "content": {"Acknowledgement": "DNA ADDUCT FORMATION IN VIVO AFTER STYRENE INHALATION EXPOSURE IN THE MOUSE AND RAT EVALUATION OF POSSIBLE MODES OF ACTION RESPONSIBLE FOR THE LUNG TUMOR FORMATION IN THE MOUSE CONCLUSIONS ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Sub-acute-toxicological-study-of-artemisinin-pip_2019_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31580888", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper.", "Funding": "Funding body information The manuscript entitled \u201cSub-acute toxicological study of arte- misinin-piperaquine tablets in rhesus monkeys\u201d was supported by National natural science foundation (Grant Number: 81873218); YangFan Innovative and Entrepreneurial Research Team Project (No.2014YT02S008); National Science and Technology Major Project \u201cMajor new drug development\u201d (Grant Number: 2018Zhiyong Xu09303008); Science and technology program of Guangzhou city (Grant Number: 201807010007); Science and technology program of Guangdong pro- vince (Grant Number: 2015A040404042). Discussion Conclusion Funding body information mk:H1_23 Acknowledgments Transparency document References", "Acknowledgement": "Acknowledgments The authors would like to thank all technicians who conducted the studies. Discussion Conclusion Funding body information mk:H1_23 Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Sub-chronic-oral-toxicity-of-Cuminum-cyminum-L--s_2017_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28634146", "content": {"CoiStatement": "Supplementary data related to this article can be found at http:// dx.doi.org/10.1016/j.yrtph.2017.06.007. Conflict of interest statement The authors have no conflicts of interest to declare. References The authors have no conflicts of interest to declare. References Bettaieb, I., Bourgou, S., Wannes, W.A., Hamrouni, I., Limam, F., Marzouk, B., 2010. Essential oils, phenolics, and antioxidant activities of different parts of cumin (Cuminum cyminum L.). J. Agric. Food Chem. 58, 10410e10418. 4. Discussion 5. Conclusion Author contribution Acknowledgments Transparency document Appendix A. Supplementary data Conflict of interest statement References", "Acknowledgement": "Acknowledgments This study was funded by the Research and Development Divi- sion of Barij Essence Company, Kashan, Iran (Grant Number: 8970). The study protocol was approved by ethics committee of Tehran University of Medical Sciences. 4. Discussion 5. Conclusion Author contribution Acknowledgments Transparency document Appendix A. Supplementary data Conflict of interest statement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Sub-chronic-safety-evaluation-of-the-ethanol-extra_2016_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27156779", "content": {"CoiStatement": "The results provided evidence that oral administration of ELE at dose of 100 mg/kg/d has no toxic effects in Beagle dogs. The find- ings in this study provided a vital reference for selecting a safe application dosage of ELE for human consumption. Conflicts of interest The authors declare no conflict of interest. Acknowledgment The authors declare no conflict of interest. Acknowledgment This study was funded by the National Key New Drug Creation Program (No. 2011ZX11102). Transparency document 4. Discussion 5. Conclusion Conflicts of interest Acknowledgment Transparency document References", "Acknowledgement": "The authors declare no conflict of interest. Acknowledgment This study was funded by the National Key New Drug Creation Program (No. 2011ZX11102). Transparency document 4. Discussion 5. Conclusion Conflicts of interest Acknowledgment Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Sub-structure-based-category-formation-for-the-prioriti_2022_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/35017022", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 4 Conclusions Funding body CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Funding": "Funding body Crop Life Europe are gratefully acknowledged for funding this research. Crop Life Europe are gratefully acknowledged for funding this research. Zuzana Hasarova reports financial support was provided by Crop Life Europe. S.J. Enoch: Conceptualization, Writing \u2013 original draft, Writing \u2013 review & editing. Z. Hasarova: Formal analysis, Data curation. M.T.D. Cronin: Funding acquisition, Writing \u2013 review & editing. K. Bridg- wood: Writing \u2013 review & editing. S. Rao: Writing \u2013 review & editing. F. M. Kluxen: Writing \u2013 review & editing. M. Frericks: Conceptualization, Writing \u2013 review & editing. Declaration of competing interest This research received funding from CropLife Europe. Appendix A. Supplementary data 4 Conclusions Funding body CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Acknowledgement": "Acknowledgements This research received funding from CropLife Europe. 4 Conclusions Funding body CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subacute-toxicity-and-toxicokinetics-study-of-DHP107-_2019_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30738088", "content": {"CoiStatement": "Declaration of conflicting interests The author(s) declared no conflicts of interest with respect to the authorship and/or publication of this article. The author(s) declared no conflicts of interest with respect to the authorship and/or publication of this article. Acknowledgments Discussion Conclusion Declaration of conflicting interests Acknowledgments Supplementary data Transparency document References", "Compliance with ethical standards": "Organisation for Economic Co-operation and Development, 1998. OECD Principles on Good Laboratory Practice (as revised in 1997). OECD, Paris OECD Series on Principles of GLP and Compliance Monitoring, No. 1, ENV/MC/CHEM(98)17). http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/ mc/chem(98)17&doclanguage=en. Poirier, V.J., et al., 2004. Efficacy and toxicity of paclitaxel (Taxol) for the treatment of canine malignant tumors. J. Vet. Intern. Med. 18 (2), 219\u2013222 PMID: 15058774.", "Acknowledgement": "Acknowledgments This work was supported by the Ministry of Education of the Republic of Korea and the National Research Foundation of Korea (2016R1A2B4008382). Discussion Conclusion Declaration of conflicting interests Acknowledgments Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subacute-toxicity-assessment-of-carotenoids-extracted_2012_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22197624", "content": {"CoiStatement": "In conclusion, under the experimental condition of this re- search, No-Observed-Adverse-Effect Level for the mixture of carotenoids extracted from citrus (Nanfengmiju, C. reticulata Blan- co) peel was at least 2000 mg/kg body weight/day. Conflict of interest statement The authors declare that there are no conflicts of interest. Acknowledgments The authors declare that there are no conflicts of interest. Acknowledgments This work is financially supported by the National Natural Sci- ence Foundation of China (Grant No. 30972044). The authors thank Mr. Bing Tian for the technical assistance. 4 Discussion Conflict of interest statement Acknowledgments References", "Acknowledgement": "The authors declare that there are no conflicts of interest. Acknowledgments This work is financially supported by the National Natural Sci- ence Foundation of China (Grant No. 30972044). The authors thank Mr. Bing Tian for the technical assistance. 4 Discussion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subacute-toxicity-evaluation-of-KR-33493--FAF1-inhibitor_2016_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27664323", "content": {"Acknowledgement": "KR33493 did not show adverse effects in repeated administra- tion for four weeks in rats and for two weeks in dog, which is possibly associated with the FAF-1 protein which is masked with Hsp70/Hsc70 at normal state (Kim et al., 2005). Thus, NOAEL can be appointed as 500 mg/kg/day for rats by 4-week repeated admin- istration and 1000 mg/kg/day for dogs by 2-week repeated dosing. Based on the repeated toxicity, we calculated the NOAEL and sug- gested a 480 mg Maximum Safe Starting Dose (FDA, 2005). Consequently, the Phase 1 clinical trial was approved by MFDS for KR33493 starting from 100 mg as the Maximum Safe Starting Dose and effective dose. Acknowledgement This work was financially supported by the by the research fund of Chungnam National University. 4. Discussion 5. Conclusion Acknowledgement Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subacute-toxicity-evaluation-of-a-new-camptothecin-ant_2004_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15546689", "content": {"Acknowledgement": "Acknowledgments The authors would like to thank Mr. Jeong-Doo Heo and Ms Young-Hee Kim for skillful assistance and Ms. Jeong-Eun Suh for statistical analysis. Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subchronic--13-week--oral-toxicity-study-of--_2004_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15265612", "content": {"Acknowledgement": "9.8 and 10.4 g a-CD/kg bw/d, represents a NOAEL. Acknowledgment This work was funded by Wacker\u2013Chemie GmbH, Munich, Germany. References Results Discussion Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subchronic--13-week--toxicity-and-prenatal-developme_2015_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26493001", "content": {"CoiStatement": "Conflicts of interest J Edwards and P Beilstein are employees of DSM Nutritional Products Ltd. The remaining author is unaware of any conflicts of interest. J Edwards and P Beilstein are employees of DSM Nutritional Products Ltd. The remaining author is unaware of any conflicts of interest. Funding sources statement 4. Discussion 5. Conclusion Conflicts of interest Funding sources statement Transparency document References", "Funding": "Funding sources statement These studies were sponsored and conducted during 1980e1981 by F. Hoffmann-La Roche Ltd. (Basel, Switzerland), who developed the specific astaxanthin formulation later acquired by DSM Nutritional Products Ltd. DSM Nutritional Products Ltd. employed Intertek Scientific & Regulatory Consultancy (Somerset, NJ, USA) to prepare this manuscript. 4. Discussion 5. Conclusion Conflicts of interest Funding sources statement Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subchronic--90-Day--repeated-dose-toxicity-study-o_2020_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32771599", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: J. C. Fuller, Jr. is employed by Metabolic Technologies, LLC which is a part of the TSI USA, LLC group which markets PEAK ATP\u00ae. R. Ja\u0308ger and M. Purpura are employed by Increnovo and perform consulting work with TSI USA, LLC. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: J. C. Fuller, Jr. is employed by Metabolic Technologies, LLC which is a part of the TSI USA, LLC group which markets PEAK ATP\u00ae. R. Ja\u0308ger and M. Purpura are employed by Increnovo and perform consulting work with TSI USA, LLC. Appendix A. Supplementary data 4 Discussion Funding Declaration of competing interest Appendix A Supplementary data References", "Funding": "Funding We are grateful for the support from TSI USA, LLC, Missoula, MT, for funding this study. We are grateful for the support from TSI USA, LLC, Missoula, MT, for funding this study. Declaration of competing interest 4 Discussion Funding Declaration of competing interest Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subchronic--90-day--repeated-dose-oral-toxicity-st_2018_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30359704", "content": {"CoiStatement": "Conflicts of interest J. C. Fuller, Jr., L.M. Pitchford, and J. A. Rathmacher are employed by Metabolic Technologies Inc. N. N. Abumrad is co-founder and part owner of Metabolic Technologies, Inc. Metabolic Technologies, Inc. is developing 2-HOBA as a nutritional supplement. Conclusions Funding Conflicts of interest Acknowledgements Transparency document References", "Funding": "Funding This research was funded by Metabolic Technologies, Inc., Ames, IA, USA. Conclusions Funding Conflicts of interest Acknowledgements Transparency document References", "Acknowledgement": "Acknowledgements We would like to acknowledge the study director, Sanju Tiwari, and the entire research team at Vedic Life Sciences for their data collection and analyses. Conclusions Funding Conflicts of interest Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subchronic--90-day--repeated-dose-toxicity-study-_2018_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30266239", "content": {"CoiStatement": "Conflicts of interest J. C. Fuller, Jr., L.M. Pitchford, and J. A. Rathmacher are employed by Metabolic Technologies, Inc., Ames, IA. N. N. Abumrad is co-founder and part owner of Metabolic Technologies, Inc. Conclusions Funding Conflicts of interest Transparency document References", "Funding": "Funding This research was funded by Metabolic Technologies, Inc., Ames, IA. Conclusions Funding Conflicts of interest Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subchronic--91-day--oral-toxicity-study-of-c_2020_Regulatory-Toxicology-and-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31704258", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper.", "Funding": "Funding body information The execution and reporting of the here presented genotoxicity tests was commissioned by Pfeifer & Langen (K\u00f6ln, Germany), i.e. the company producing cellobiose, the subject substance of this work. However, none of the authors is or was employed by this company or has received a direct remuneration for the present work. Discussion Funding body information mk:H1_19 References", "Compliance with ethical standards": "Subchronic (91\u2013day) oral toxicity study of cellobiose in rats Introduction Materials and methods Compliance with ethical and procedural standards Animals Test substance and dosing solution Diet Experimental designs 28-Day pilot study 91-Day oral toxicity study Statistical analyses"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subchronic--reproductive--and-maternal-toxicity-st_2014_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24486531", "content": {"CoiStatement": "In conclusion, repeated inhalation exposure of P400 ppm TBAC for thirteen weeks caused clinical observations of hyperactivity in mice immediately post-exposure. These reversible clinical signs could not be confirmed when the mice were examined by a tech- nician unaware of treatment status conducting a modified FOB. An increase in motor activity counts in male rats during the last 15-min of 1-h session following 13 weeks of exposure to 1600 ppm TBAC suggests a slight behavioral response in male rats. Repeated exposure to TBAC for 13 weeks did not affect body weight, feed consumption, and immunopathology endpoints. TBAC caused a2u-globulin accumulation within the male rat kidney. In- creased liver and adrenal weights in rats were not accompanied by histopathological changes in those organs. Thyroid endpoints were not affected in male and female rats while male mice had de- creased concentrations of T4 at study week 4 but not week 13. There was no evidence that TBAC caused reproductive toxicity fol- lowing repeated inhalation exposures throughout premating, mat- ing, gestation and lactation. Oral gavage dose administration of TBAC to pregnant rats at dose levels of P 800 mg/kg/d caused sig- nificant signs of acute neurotoxicity and transient decreases in feed consumption and body weight gain in pregnant dams. Limited fetal evaluations indicated that exposure to maternally toxic dose levels of TBAC did not affect fetal viability. Conflict of interest Lyondell Chemical Company was the sponsor of the studies, conducted at WIL Research Laboratory (Daniel Kirkpatrick, Pragati Coder) and Integrated Lab- oratory Systems (Susan Borghoff). Willem Faber. and Abby Li. are consultants to Lyondell Chemical Company. Marcy Banton is employed by Lyondell Chemical 4 Discussion Conflict of interest Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subchronic-bisphenol-S-exposure-affects-liver-func_2018_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29199064", "content": {"Acknowledgement": "Acknowledgments This work was supported by the Science and Technology Projects of Xiamen City, Fujian, China (Public Service Platform of Food Safety; Grant No. 3502Z20151005). Discussion Conclusions Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subchronic-oral-toxicity-studies-with---cyc_2004_Regulatory-Toxicology-and-P.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15265611", "content": {"Acknowledgement": "cepted to be physiological phenomena that lack toxi- cological relevance. Acknowledgments This work was funded by Wacker-Chemie GmbH, Munich, Germany. References Discussion Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subchronic-oral-toxicity-study-of-Korean-red-ginseng-_2018_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29155077", "content": {"Acknowledgement": "Acknowledgments This work was supported by a research fund from the Korea Ginseng Corp Korea Ginseng Corp. Discussion Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subchronic-oral-toxicity-study-of-rhubarb-extr_2021_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33894279", "content": {"CoiStatement": "Fig. 3. Ultrastructural observation of kidneys in high-dose group and control group at the end of treatment period. A (Renal tubules \u00d7 500 times, control group normal renal tubules),B(Renal tubules\u00a3500 times, high dose group, the blue arrow shows a large number of vacuoles of varying sizes in the cytoplasm, and the red arrow shows a small amount of irregular dense deposits),C(Renal tubules \u00d7 2000 times, high dose group, enlarged view of Figure B, as shown by the blue arrow,a large number of vacuoles of varying sizes can be seen in the cytoplasm, and phagocytic vesicles can be seen in the vacuoles),D (Renal tubules \u00d7 2000 times, high dose group, as shown by the red arrow, a large number of irregular dense deposits can be seen in the cytoplas. C. Liu et al. Regulatory Toxicology and Pharmacology 123 (2021) 104921 6 Pharmacopoeia. Funding The study was supported by the special scientific research project for Traditional Chinese Medicine of National Administration of Traditional Chinese Medicine of China (No. 201307012). CRediT authorship contribution statement Chunxia Liu: Investigation, Data curation, Writing \u2013 original draft. Ji Liu: Project administration. Yanhua Zheng: Investigation. Jingjing Qu: Data curation. Wenxiang Yang: Investigation. Xiaoqiao Tang: Writing \u2013 review & editing. Hong Bai: Project administration. Bolin Fan: Supervision. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Appendix A. Supplementary data Supplementary data to this article can be found online at https://doi. org/10.1016/j.yrtph.2021.104921. References Bao, Jingjing Qu., Li, F., Zhang, W.S., Wang, H.M., Liu, Q., Han, H., Liang, L., Du, Y.P., 2008. Effects of total anthraquinone in rheum on aquaporin 2,4 expression in rat kindney. J. Chinese Journal of Nephrology. 24 (8), 581\u2013585. NTP Toxicology, Carcinogenesis Studies of Emodin (CAS No, 2001. 518-82-1) feed studies in F344/N rats and B6C3F1 mice. J. Natl Toxicol Program Tech Rep Ser 493, 1\u2013278. Chai, B.J., Li, X., Chen, J.W., 2011. Subacute toxicity of total extract of rhubarb in rats. J. Pharmaceutical and Clinical Research. 19 (4). Chinese Pharmacopoeia Commission, 2015. Pharmacopoeia of the People\u2019s Republic of China. China Medical Science Press, p. 23. Deng, N., Yi, Y., Liang, A.H., 2018. Mechanism of nephrotoxicity of rhubarb in rats. J. China Journal of Chinese Materia Medica 43 (13), 2777\u20132783. Kon, R., Ikarashi, N., Nagoya, C., Takayama, T., Kusunoki, Y., Ishii, M., Ueda, H., Ochiai, W., Machida, Y., Sugita, K., Sugiyama, K., 2014. Rheinanthrone, a metabolite of sennoside A, triggers macrophage activation to decrease aquaporin-3 expression in the colon, causing the laxative effect of rhubarb extract. J.J Ethnopharmacol 152 (1), 190\u2013200. Lei, R.H., Wang, Q.X., Yan, X.Z., Wu, C.Q., Liao, MinY., Xiao, X.H., Wang, Q.J., 2015. Changes of endogenous metabolites in rats administered with emodin by 1H-NMR technology. J. Drug Evaluation Research 38 (1), 29\u201335. Li, X., 2015. Properties and clinical application of rhubarb. J. Chinese Journal of Clinical Rational Drug Use 13, 67\u201368. Wang, Q.X., 2007. Study on the toxicity and its mechanisms of rhubarb and its major constituents. D. Academy of Military Medical Sciences. Wang, M., Lu, B., Fan, Y.H., Xu, Y., 2005. Effects of stimulant laxatives on intestinal transit function of rats. J. Zhejiang Medical Journal. 27 (4), 261\u2013262. Wang, Z., Ma, P., Xu, L.j., He, C.N., Peng, Y., Xiao, P.G., 2013. Evaluation of the content variation of anthraquinone glycosides in rhubarb by UPLC-PDA. J. Chem Cent J 7 (1), 170. Wang, Y.H., Zhao, H.P., Wang, J.B., Zhao, Y.L., Xiao, X.H., 2014. Study on dosage- toxicity/efficacy relationship of prepared rhubarb on basis of symptom-based prescription theory. J. China Journal of Chinese Materia Medica 39 (15), 2918\u20132923. Wang, Y.J., Feng, S.H., Cheng, J.T., Chen, S., 2018. Research Progress on Chemical Constituents and Pharmacological Action of Anthraquinone in Rhei Radix et Rhizoma. J.Chinese Journal of Experimental Traditional Medical Formulae 24 (13), 227\u2013234. Wang, Y., Yang, X., Xia, P.F., Ma, X., Yang, R.J., Hu, J.R., Fan, Q., Jin, X.J., Wu, X.Y., Peng, X.J., Zhao, L., 2019. Research progress on chemical composition and pharmacological effects of Rhei Radix et Rhizoma and predictive analysis on quality markers. J.Chinese Traditional and Herbal Drugs 50 (19), 4821\u20134837. Wu, X.A., 2002. Opinion of colon-targeting delivery about rhubarb extract as a purgative. J. China Journal of Chinese Materia Medica 27 (1), 72\u201374. Ye, B.G., Feng, Y., Wang, S., 2014. Scientific evaluation of the acute toxicity and 13-week subchronic toxicity of Rheum emodi rhizome extracts in Sprague Dawley rats. J. Food Chem. Toxicol. 66, 278\u2013285. Zeng, L.N., Ma, Z.J., Zhao, Y.L., 2013. The protective and toxic effects of rhubarb tannins and anthraquinones in treating hexavalent chromium-injured rats: the Yin/Yang actions of rhubarb. J. J Hazard Mater 246\u2013247, 1\u20139. Zhang, L.Y., Jiang, Z.Z., Pu, C.H., Yan, M., 2004. Six-month oral toxicity study of total anthraquinone in radix et rhizoma rhei in SD rats. J .Chinese Journal of Biochemical Pharmaceutics. 25, 206\u2013209. Zhang, T., Tong, J.M., Liang, C., Wang, H.J., Zhang, S.F., 2016. Study on toxicity and reversibility of rhubarb on rats\u2019 kidney. J. Journal of Chengde Medical College 33 (1), 5\u20137. Zhang, L., Pan, J., Wu, H., 2019. Research progress on chemical constituents, antioxidant activity, and enzyme inhibitory characteristics of rhubarb. J. Hainan Medical Journal. 30 (20), 2683\u20132686. Zhao, P., Luo, J.Y., Dong, L., Guan, H.T., Guo, X.D., 2006. Establishment of rhubarb- induced melanosis coli model in Guinea pig. J. Chinese Journal of Integrated Traditional and Western Medicine on Digestion 14 (5), 308\u2013311. Zheng, Q.X., Wu, H.F., Guo, J., Nan, H.J., Chen, S.L., Yang, J.S., Xu, X.D., 2013. Review of rhubarbs: chemistry and pharmacology. J. Chinese Herbal Medicines 1, 9\u201332. C. Liu et al. https://doi.org/10.1016/j.yrtph.2021.104921 https://doi.org/10.1016/j.yrtph.2021.104921 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref1 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref1 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref1 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref2 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref2 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref2 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref3 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref3 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref4 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref4 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref5 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref5 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref6 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref6 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref6 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref6 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref6 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref7 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref7 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref7 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref8 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref8 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref9 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref9 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref10 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref10 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref11 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref11 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref11 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref12 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref12 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref12 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref12 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref13 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref13 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref13 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref13 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref14 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref14 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref14 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref14 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref15 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref15 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref16 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref16 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref16 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref17 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref17 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref17 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref18 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref18 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref18 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref19 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref19 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref19 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref20 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref20 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref20 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref21 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref21 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref21 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref22 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref22 Subchronic oral toxicity study of rhubarb extract in Sprague-Dawley rats 1 Introduction 2 Test material 2.1 Preparation and characterization of the test substance 2.2 Experimental animals 2.3 Experimental design 2.3.1 Animal grouping and treatment period 2.3.2 Clinical observations 2.3.3 Clinical investigations 2.3.4 Pathology 2.4 Statistical analysis 3 Result 3.1 Characterization of rhubarb extract 3.2 General observation 3.3 Body weight and food consumption 3.4 Hematological parameters 3.5 Serum biochemistry 3.6 Urinalysis 3.7 Organs 3.8 Gross anatomy, histopathology and TEM 4 Discussion 5 Conclusions Funding CRediT authorship contribution statement Declaration of competing interest Appendix A Supplementary data References", "Funding": "Fig. 3. Ultrastructural observation of kidneys in high-dose group and control group at the end of treatment period. A (Renal tubules \u00d7 500 times, control group normal renal tubules),B(Renal tubules\u00a3500 times, high dose group, the blue arrow shows a large number of vacuoles of varying sizes in the cytoplasm, and the red arrow shows a small amount of irregular dense deposits),C(Renal tubules \u00d7 2000 times, high dose group, enlarged view of Figure B, as shown by the blue arrow,a large number of vacuoles of varying sizes can be seen in the cytoplasm, and phagocytic vesicles can be seen in the vacuoles),D (Renal tubules \u00d7 2000 times, high dose group, as shown by the red arrow, a large number of irregular dense deposits can be seen in the cytoplas. C. Liu et al. Regulatory Toxicology and Pharmacology 123 (2021) 104921 6 Pharmacopoeia. Funding The study was supported by the special scientific research project for Traditional Chinese Medicine of National Administration of Traditional Chinese Medicine of China (No. 201307012). CRediT authorship contribution statement Chunxia Liu: Investigation, Data curation, Writing \u2013 original draft. Ji Liu: Project administration. Yanhua Zheng: Investigation. Jingjing Qu: Data curation. Wenxiang Yang: Investigation. Xiaoqiao Tang: Writing \u2013 review & editing. Hong Bai: Project administration. Bolin Fan: Supervision. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Appendix A. Supplementary data Supplementary data to this article can be found online at https://doi. org/10.1016/j.yrtph.2021.104921. References Bao, Jingjing Qu., Li, F., Zhang, W.S., Wang, H.M., Liu, Q., Han, H., Liang, L., Du, Y.P., 2008. Effects of total anthraquinone in rheum on aquaporin 2,4 expression in rat kindney. J. Chinese Journal of Nephrology. 24 (8), 581\u2013585. NTP Toxicology, Carcinogenesis Studies of Emodin (CAS No, 2001. 518-82-1) feed studies in F344/N rats and B6C3F1 mice. J. Natl Toxicol Program Tech Rep Ser 493, 1\u2013278. Chai, B.J., Li, X., Chen, J.W., 2011. Subacute toxicity of total extract of rhubarb in rats. J. Pharmaceutical and Clinical Research. 19 (4). Chinese Pharmacopoeia Commission, 2015. Pharmacopoeia of the People\u2019s Republic of China. China Medical Science Press, p. 23. Deng, N., Yi, Y., Liang, A.H., 2018. Mechanism of nephrotoxicity of rhubarb in rats. J. China Journal of Chinese Materia Medica 43 (13), 2777\u20132783. Kon, R., Ikarashi, N., Nagoya, C., Takayama, T., Kusunoki, Y., Ishii, M., Ueda, H., Ochiai, W., Machida, Y., Sugita, K., Sugiyama, K., 2014. Rheinanthrone, a metabolite of sennoside A, triggers macrophage activation to decrease aquaporin-3 expression in the colon, causing the laxative effect of rhubarb extract. J.J Ethnopharmacol 152 (1), 190\u2013200. Lei, R.H., Wang, Q.X., Yan, X.Z., Wu, C.Q., Liao, MinY., Xiao, X.H., Wang, Q.J., 2015. Changes of endogenous metabolites in rats administered with emodin by 1H-NMR technology. J. Drug Evaluation Research 38 (1), 29\u201335. Li, X., 2015. Properties and clinical application of rhubarb. J. Chinese Journal of Clinical Rational Drug Use 13, 67\u201368. Wang, Q.X., 2007. Study on the toxicity and its mechanisms of rhubarb and its major constituents. D. Academy of Military Medical Sciences. Wang, M., Lu, B., Fan, Y.H., Xu, Y., 2005. Effects of stimulant laxatives on intestinal transit function of rats. J. Zhejiang Medical Journal. 27 (4), 261\u2013262. Wang, Z., Ma, P., Xu, L.j., He, C.N., Peng, Y., Xiao, P.G., 2013. Evaluation of the content variation of anthraquinone glycosides in rhubarb by UPLC-PDA. J. Chem Cent J 7 (1), 170. Wang, Y.H., Zhao, H.P., Wang, J.B., Zhao, Y.L., Xiao, X.H., 2014. Study on dosage- toxicity/efficacy relationship of prepared rhubarb on basis of symptom-based prescription theory. J. China Journal of Chinese Materia Medica 39 (15), 2918\u20132923. Wang, Y.J., Feng, S.H., Cheng, J.T., Chen, S., 2018. Research Progress on Chemical Constituents and Pharmacological Action of Anthraquinone in Rhei Radix et Rhizoma. J.Chinese Journal of Experimental Traditional Medical Formulae 24 (13), 227\u2013234. Wang, Y., Yang, X., Xia, P.F., Ma, X., Yang, R.J., Hu, J.R., Fan, Q., Jin, X.J., Wu, X.Y., Peng, X.J., Zhao, L., 2019. Research progress on chemical composition and pharmacological effects of Rhei Radix et Rhizoma and predictive analysis on quality markers. J.Chinese Traditional and Herbal Drugs 50 (19), 4821\u20134837. Wu, X.A., 2002. Opinion of colon-targeting delivery about rhubarb extract as a purgative. J. China Journal of Chinese Materia Medica 27 (1), 72\u201374. Ye, B.G., Feng, Y., Wang, S., 2014. Scientific evaluation of the acute toxicity and 13-week subchronic toxicity of Rheum emodi rhizome extracts in Sprague Dawley rats. J. Food Chem. Toxicol. 66, 278\u2013285. Zeng, L.N., Ma, Z.J., Zhao, Y.L., 2013. The protective and toxic effects of rhubarb tannins and anthraquinones in treating hexavalent chromium-injured rats: the Yin/Yang actions of rhubarb. J. J Hazard Mater 246\u2013247, 1\u20139. Zhang, L.Y., Jiang, Z.Z., Pu, C.H., Yan, M., 2004. Six-month oral toxicity study of total anthraquinone in radix et rhizoma rhei in SD rats. J .Chinese Journal of Biochemical Pharmaceutics. 25, 206\u2013209. Zhang, T., Tong, J.M., Liang, C., Wang, H.J., Zhang, S.F., 2016. Study on toxicity and reversibility of rhubarb on rats\u2019 kidney. J. Journal of Chengde Medical College 33 (1), 5\u20137. Zhang, L., Pan, J., Wu, H., 2019. Research progress on chemical constituents, antioxidant activity, and enzyme inhibitory characteristics of rhubarb. J. Hainan Medical Journal. 30 (20), 2683\u20132686. Zhao, P., Luo, J.Y., Dong, L., Guan, H.T., Guo, X.D., 2006. Establishment of rhubarb- induced melanosis coli model in Guinea pig. J. Chinese Journal of Integrated Traditional and Western Medicine on Digestion 14 (5), 308\u2013311. Zheng, Q.X., Wu, H.F., Guo, J., Nan, H.J., Chen, S.L., Yang, J.S., Xu, X.D., 2013. Review of rhubarbs: chemistry and pharmacology. J. Chinese Herbal Medicines 1, 9\u201332. C. Liu et al. https://doi.org/10.1016/j.yrtph.2021.104921 https://doi.org/10.1016/j.yrtph.2021.104921 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref1 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref1 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref1 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref2 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref2 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref2 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref3 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref3 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref4 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref4 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref5 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref5 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref6 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref6 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref6 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref6 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref6 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref7 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref7 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref7 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref8 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref8 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref9 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref9 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref10 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref10 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref11 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref11 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref11 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref12 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref12 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref12 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref12 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref13 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref13 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref13 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref13 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref14 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref14 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref14 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref14 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref15 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref15 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref16 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref16 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref16 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref17 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref17 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref17 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref18 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref18 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref18 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref19 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref19 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref19 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref20 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref20 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref20 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref21 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref21 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref21 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref22 http://refhub.elsevier.com/S0273-2300(21)00061-1/sref22 Subchronic oral toxicity study of rhubarb extract in Sprague-Dawley rats 1 Introduction 2 Test material 2.1 Preparation and characterization of the test substance 2.2 Experimental animals 2.3 Experimental design 2.3.1 Animal grouping and treatment period 2.3.2 Clinical observations 2.3.3 Clinical investigations 2.3.4 Pathology 2.4 Statistical analysis 3 Result 3.1 Characterization of rhubarb extract 3.2 General observation 3.3 Body weight and food consumption 3.4 Hematological parameters 3.5 Serum biochemistry 3.6 Urinalysis 3.7 Organs 3.8 Gross anatomy, histopathology and TEM 4 Discussion 5 Conclusions Funding CRediT authorship contribution statement Declaration of competing interest Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subchronic-safety-evaluation-of-CMS-1--a-botanical-antih_2014_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24928566", "content": {"Funding": "Based on our results, the NOAEL is at least 100 mg/kg/day, the primary toxic dose is between 100 mg/kg/day and 300 mg/kg/ day, and the severe toxic dose is greater than 900 mg/kg/day for rats. For dogs, the NOAEL is at least 50 mg/kg/day, the primary toxic dose is between 50 mg/kg/day and 150 mg/kg/day, and the severe toxic dose is greater than 300 mg/kg/day. The main target organs are the digestive system, including the gastrointestinal tract and liver, the immune system, including the thymus, the cardio- vascular system and blood. However, the majority of CMS-1 toxic- ity was transient and reversible. Previously, phellopterin isolated from Radix Angelicae dahurica was shown to be a potent inhibitor of diazepam binding to the central nervous system benzodiazepine receptor in vitro (Bergendorff et al., 1997). In this study, we did not find any central nervous system toxicity with CMS-1, so we consid- ered that most of the toxic effects of CMS-1 are derived from imperatorin. Our data from the non-clinical studies in dogs and rats suggest that the clinical safety monitoring of CMS-1 should focus on the gastrointestinal system, blood chemistry for liver functions and electrolytes, blood homeostasis, cardiovascular functions, and immune functions. Funding This work was supported by the National Natural Science Foun- dation of China (30901322), the morning program of the Shanghai Municipal Education Commission (09CG34), the National Scientific and Technological Major Special Project for \u2018\u2018Significant Creation of New Drugs\u2019\u2019 (2008Zhen-Na XiaJ 09014-0095 and 2010Zhen-Na Xiaue-Lian Gong0900X-005) and the Shanghai Public Health Priority Disciplines (12GWZhen-Na Xia0501). References 4 Discussion Funding References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subchronic-toxicity--toxicity-to-reproduction-and-p_2014_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24956586", "content": {"CoiStatement": "In a study on testicular effects of VAc in mice, a significantly decreased relative testes weight and an increased frequency of sperm abnormalities were observed 5 weeks after i.p. administra- tion of VAc at 500 mg/kg bw/d for 5 consecutive days. Lower doses were ineffective (L\u00e4hdetie, 1988). In contrast, testicular effects of the VL treatment were not observed in the here reported TG 422 study, although VL was administered at a higher nominal dose (1000 mg/kg bw/d) and for a longer period of time (14 days). Most likely, the internal availability of acetaldehyde reached higher lev- els in testicular tissue after i.p. administration of VAc than after p.o. administration of VL, despite the fact that the p.o. administered dose of vinyl moiety (as acetaldehyde precursor) was not much dif- ferent between the two studies (about 200 and 230 mg/kg bw/d for the VAc and VL treatment, respectively). The main reasons for a lower internal availability of acetaldehyde from p.o. VAc are that (a) the systemic availability of ingested VAc \u2013 and thus, by analogy, VL \u2013 is likely to be incomplete (650%) because of a presystemic metabolization in the upper GI tract epithelium (BAuA, 2008) while i.p. administered VAc is fully available and b) most of intes- tinally absorbed VAc and VL will be metabolized on first passage in the liver which disposes of carboxylesterase (releasing acetalde- hyde from vinyl esters) and which also has the highest concentra- tion of mitochondrial aldehyde dehydrogenase (ALDH2) oxidizing acetaldehyde to acetic acid (Simon et al., 1985; Strong et al., 1980 as cited in BAuA, 2008; ECHA, 2014 and INRS, 2013). Conflict of interest The preparation of this publication has been commissioned by Wacker Chemie AG, Munich, Germany. However, the sponsor was not involved in any way in the execution of this work. 5 Discussion Conflict of interest Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subchronic-toxicity-and-anti-HSV-1-activity-in-experim_2017_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28284712", "content": {"CoiStatement": "5. Declaration of interest The authors report that there are no conflicts of interest. The authors report that there are no conflicts of interest. Acknowledgments 4. Conclusions 5. Declaration of interest Acknowledgments Transparency document References", "Acknowledgement": "Acknowledgments The studied algae were collected and identified by Dr. Roberto Villa\u00e7a (Departamento de Biologia Marinha, Instituto de Biologia, UFF). This work was supported by the Conselho Nacional do Desenvolvimento Cient\u00edfico e Tecnol\ufffdogico (CNPq) number 443911/ 2014-2, the Coordena\u00e7~ao de Aperfei\u00e7oamento d e Pessoal de N\u00edvel Superior (CAPES), and the Funda\u00e7~ao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ). We also thank the Laboratory of Pathology of Afra\u0302nio Peixoto Legal Medical Institute of Rio de Janeiro (IMLAP) for the histology used in experiments and to Dr. Carlos Augusto de Martino Campos in the handling of experimental animals. 4. Conclusions 5. Declaration of interest Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subchronic-toxicity-and-genotoxicity-of-diiodomethy_2012_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22210449", "content": {"CoiStatement": "Conflict of interest statement The authors work for the company at which the substance is produced. Acknowledgments 4 Discussion Conflict of interest statement Acknowledgments References", "Acknowledgement": "The authors work for the company at which the substance is produced. Acknowledgments The authors gratefully acknowledge Amanda Andrus, Kim An- klam, Debbie Beuthin, Laura Daniels, Rebecca Drury, Kathy Galla- gher, Rachel Golden, Patrick Goodwin, Steve Hansen, Lori Ito, Jane Lacher, Marie Lawson, Dean Louch, Lindsay McNalley, Julie Passage, Joyce Wachner, Bernadette West, histology support, and animal care staff for their help in different parts of the study. 4 Discussion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subchronic-toxicity-and-genotoxicity-studies-of-A_2018_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29287801", "content": {"CoiStatement": "Conflicts of interest S. N. Chen and C. S. Chang work as independent Consulting Biologists for the studies. S. Chen is currently employed by Glytheron Inc. (Irvine, CA, USA) that funded these studies. Madhu G. Soni works as an independent Consulting Toxicologist and assisted in the pre- paration of this manuscript. Discussion Conflicts of interest Acknowledgement Transparency document References", "Acknowledgement": "Acknowledgement Glytheron Inc (Irvine, CA, USA) for supplying standardized Antrodia mushroom \u03b2-glucan for use in these studies. Discussion Conflicts of interest Acknowledgement Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subchronic-toxicity-and-toxicokinetics-of-LZB--a-new-p_2008_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18039554", "content": {"Compliance with ethical standards": "This nonclinical laboratory study was carried out in compliance with the Testing Guidelines for Safety Evaluation of Drugs (Notification [H] GPT2-1 issued by China Food and Drug Administration on March 2005) and the Organization for Economic Cooperation and Development under the Good Laboratory Practice Regulations for Nonclinical Labora- tory Studies. This experiment was conducted in facilities approved by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAA LAC), and animals were maintained in accordance with the Guide for the Care and Use of Laboratory Animals (NRC, 1996). 2.5. Clinical observations"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subchronic-toxicity-and-toxicokinetics-of-long-term-in_2011_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21130130", "content": {"CoiStatement": "Conflict of interest statement Dr. Xiaoping Chen is the director of Beijing Shiqiao Biological & Pharmaceutical Co. Ltd. The opinions expressed in this article are those of the authors, and not necessarily represent the views of the sponsors. Discussion Conflict of interest statement Acknowledgments References", "Acknowledgement": "Acknowledgments This work was supported by the Innovation Fund for Technol- ogy Based Firms of China\u2019s Science and Technology Ministry (06C26211100623), and was partly funded by Beijing Shiqiao Biological & Pharmaceutical Co. Ltd. The authors express their gratitude to Mannie M.Y. Fan (Ph.D., Celator Pharmaceuticals Corp., Vancouver, Canada) for editorial assistance with the paper. Discussion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subchronic-toxicity-evaluation-of-alo_2011_Regulatory-Toxicology-and-Pharmac.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21784118", "content": {"CoiStatement": "Conflict of interest statement Ashley Roberts, Ryan Simon, and Barry Lynch are employees of Cantox Health Sciences Interna- tional, an Intertek company, and has provided consulting services to UNIGEN, Inc. over the past year. 4 Discussion Conflict of interest statement Funding sources statement Acknowledgments References", "Funding": "Funding sources statement Funding for the research was provided by Univera Korea and preparation of this publication was provided by UNIGEN, Inc. Funding for the research was provided by Univera Korea and preparation of this publication was provided by UNIGEN, Inc. Acknowledgments 4 Discussion Conflict of interest statement Funding sources statement Acknowledgments References", "Acknowledgement": "Acknowledgments The authors would like to acknowledge that the research presented in this publication was conducted at ChemOn in South Korea. Also, the authors would like to thank Univera for initiating this research. 4 Discussion Conflict of interest statement Funding sources statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subchronic-toxicity-evaluation-of-ethanol-extrac_2019_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31585136", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper.", "Acknowledgement": "Acknowledgments This study was part of a project (Safety of the Korean Herbal Medicine, N18001) funded by the Division of Tradition Korean Medicine Research of the National Institute for Korean Medicine Development. This work was also supported by a grant (16182MFDS384) from Ministry of Food and Drug Safety in 2018. Discussion Author's contribution mk:H1_28 Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subchronic-toxicity-evaluation-of-isoeugenyl-methyl-_2019_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30529462", "content": {"Acknowledgement": "Acknowledgements We thank Ms. Yoshimi Komatsu and Ms. Ayako Saikawa (Division of Pathology, National Institute of Health Sciences) for expert technical assistance. This study was supported by the Ministry of Health, Labour and Welfare of Japan. Conclusion Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subchronic-toxicity-of-Citrus-aurantium-L---Rutac_2009_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19275924", "content": {"Acknowledgement": "Acknowledgments We would like to thank Farm\u00e1cia Cal\u00eandula for C. aurantium commercial extract donation and the technical assistance of Msc. Viviane de Moura Linck and Ana Paula Herrmann. This work was supported by CNPQ (Processo 478054/2006-8). Results Discussion Conclusions Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subchronic-toxicity-of-Sipjeondaebo-tang--SDT-_2011_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20937344", "content": {"CoiStatement": "In conclusion, oral administration of SDT to SD rats for 13-weeks did not cause any adverse effects at doses of 62000 mg/kg/day. Under these experimental conditions, the NOAEL of SDT was determined to be more than 2000 mg/kg/day in both genders. Additionally, in human, the single dose of SDT is about 45 g dried herb, which is equivalent to 10.53 g of the SDT ex- tract (yield = 23.4%). Considering an average body weight of an adult of 60 kg (van Miert, 1986; Manimaran et al., 2010), this dose for a 60 kg human is equal to 175.5 mg of SDT extract/kg. This dos- age is about 10-fold lower than the NOAEL of SDT. Therefore, the results of present study provide an important reference for the safety of SDT as herbal medicine for humans. Conflicts of interest No competing financial interests exist. Acknowledgments Discussion Conflicts of interest Acknowledgments References", "Acknowledgement": "No competing financial interests exist. Acknowledgments This research was part of a project (The Evidence Based Medi- cine for Herbal Formula, K10030) funded by the Herbal Medicine EBM Research Center of Korea Institute of Oriental Medicine. References Discussion Conflicts of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subchronic-toxicity-of-cerium-nitrate-by-90-day_2019_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31494192", "content": {"CoiStatement": "Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. Discussion Conclusion Funding Declaration of interests Acknowledgement References", "Funding": "Funding Not applicable. My paper has received no funding from any in- stitution. Not applicable. My paper has received no funding from any in- stitution. Declaration of interests This project was surpported by the funding of the Key Laboratory of Food Safety Risk Assessment, Ministry of Health, PRC. References Discussion Conclusion Funding Declaration of interests Acknowledgement References", "Acknowledgement": "Acknowledgement This project was surpported by the funding of the Key Laboratory of Food Safety Risk Assessment, Ministry of Health, PRC. Discussion Conclusion Funding Declaration of interests Acknowledgement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subchronic-toxicity-study-in-rats-evaluating-herb_2021_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33259869", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 3 Discussion The statement of funding sources Declaration of competing interest References", "Funding": "The statement of funding sources Respected Editor-in-Chief: There are no funding agencies to provide fund support for this study. Respected Editor-in-Chief: There are no funding agencies to provide fund support for this study. Declaration of competing interest 3 Discussion The statement of funding sources Declaration of competing interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subchronic-toxicity-study-of-the-total-flavonoids-_2012_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22226919", "content": {"CoiStatement": "Conflict of interest statement The authors declared that there are no conflicts of interest. Acknowledgments The authors declared that there are no conflicts of interest. Acknowledgments This work was supported by funds of Science Foundation of Sci- ence & Technology Bureau of Liaoning Province (No. 2009225009- 2) and the Science and Technology Foundation of Dalian, China (No. 2008E11SF223). References 4 Discussion 5 Conclusion Conflict of interest statement Acknowledgments References", "Acknowledgement": "The authors declared that there are no conflicts of interest. Acknowledgments This work was supported by funds of Science Foundation of Sci- ence & Technology Bureau of Liaoning Province (No. 2009225009- 2) and the Science and Technology Foundation of Dalian, China (No. 2008E11SF223). References 4 Discussion 5 Conclusion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subchronic-toxicity-study-of-yttrium-nitrate-by-9_2017_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28866266", "content": {"CoiStatement": "Conflict of interest The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Transparency document 4. Discussion 5. Conclusion Conflict of interest Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Subretinal-transplantation-of-human-embryonic-stem-cell-d_2019_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31009651", "content": {"CoiStatement": "Conflict of interest The authors declare no conflict of interest. The authors declare no conflict of interest. Acknowledgments Discussion Conclusion Conflict of interest Acknowledgments Transparency document References", "Acknowledgement": "Acknowledgments This study was supported by the Ministry of Trade, Industry & Energy (Korea, grant number: 10067737) and the Korea Health Industry Development Institute (grant number: HI12C1794). Discussion Conclusion Conflict of interest Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Substance-tailored-testing-strategies-in-toxicology--An-in_2010_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19766156", "content": {"Acknowledgement": "Acknowledgment This work was supported by the National French Agency for Scientific Research (ANR) in the framework of the CP2D program (Chimie et Proc\u00e8des pour le D\u00e9veloppement Durable). Contract ANR-07-CP2D-03. Discussion Acknowledgment Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Successful-regulatory-agency-interaction---A-noncl_2022_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/35131340", "content": {"CoiStatement": "Declaration of competing interest The author declares that he has no known competing financial in- terests or personal relationships that could have appeared to influence the work reported in this paper. Successful regulatory agency interaction \u2013 A nonclinical regulatory strategist\u2019s perspective 1 Introduction 2 Successful regulatory agency meetings 3 Successful regulatory submissions 4 Successful marketing applications 5 Successful post-marketing strategy 6 Conclusion Funding body information CRediT authorship contribution statement Declaration of competing interest References", "Funding": "Funding body information No funding body was involved in supporting this work. No funding body was involved in supporting this work. CRediT authorship contribution statement Successful regulatory agency interaction \u2013 A nonclinical regulatory strategist\u2019s perspective 1 Introduction 2 Successful regulatory agency meetings 3 Successful regulatory submissions 4 Successful marketing applications 5 Successful post-marketing strategy 6 Conclusion Funding body information CRediT authorship contribution statement Declaration of competing interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Sucralose-revisited--Rebuttal-of-two-papers-_2012_Regulatory-Toxicology-and-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22579627", "content": {"CoiStatement": "Our response: The \u2018\u2018Expert Panel\u2019\u2019 assembled by McNeil Nutri- tionals (Brusick et al., 2009) included individuals who (1) had pre- viously participated as a joint author with McNeil on sucralose, (2) have declared that they are consultants for McNeil (in one case for 13 years), and (3) had published previously in a special issue on sucralose sponsored by McNeil. No acknowledgments of these con- flicts of interest or financial support were given in this critique. This does not conform to the policy and guidance on conflict of interest established by the National Institutes of Health (NIH, 2011) or by Elsevier as described on their website. Furthermore, the claims expressed by the \u2018\u2018Expert Panel\u2019\u2019 (Brusick et al., 2009) closely mirror the positions expressed directly by McNeil (Grotz and Munro, 2009). The first time that we saw these critiques of our findings was when they appeared in print in Regulatory Toxicology and Phar- macology. Standard procedure for critiques of scientific published works is to submit a letter to the same journal in which the article was published, which in our case was Journal of Toxicology and Environmental Health, Part A (Abou-Donia et al., 2008). The \u2018\u2018Ex- pert Panel\u2019\u2019 did not follow standard scientific protocol but rather chose to publish its critique simultaneously in a different journal \u2018\u2018back to back\u2019\u2019 along with one directly from McNeil Nutritionals. The conclusions in our peer-reviewed study are supported by our data, and the critiques by Grotz and Munro (2009) and the Bru- sick et al. (2009) are without merit. Additional safety studies must be performed to determine the full impact of sucralose on drug bioavailability and to evaluate the biological effects of chronic sucralose usage particularly for special populations (e.g., children, elderly, nursing mothers, persons with diabetes, cancer patients). Disclosure of conflict of interest We declare that there are no conflicts of interest for this rebuttal. We noted on the first page in our original paper that \u2018\u2018the research was supported in part by a grant from the Sugar Association, Inc., Washington, DC\u2019\u2019. References We declare that there are no conflicts of interest for this rebuttal. We noted on the first page in our original paper that \u2018\u2018the research was supported in part by a grant from the Sugar Association, Inc., Washington, DC\u2019\u2019. References Abou-Donia, M.B., El-Masry, E.M., Abdel-Rahman, A.A., McLendon, R.E., Schiffman, S.S., 2008. Splenda alters gut microflora and increases intestinal P-glycoprotein and cytochrome P-450 in male rats. J. Toxicol. Environ. Health A 71, 1415\u20131429. NIH (National Institutes of Health), 2011. Financial Conflicts of Interest. <http:// grants.nih.gov/grants/policy/coi/index.htm>. O\u2019Flaherty, S., Klaenhammer, T.R., 2010. The role and potential of probiotic bacteria in the gut, and the communication between gut microflora and gut/host. Int. Dairy J. 20, 262\u2013268. Sucralose revisited: Rebuttal of two papers about Splenda safety Critique 1: Sucralose \u201cis stable in vivo\u201d and \u201celiminated unchanged in the feces\u201d Critique 2: Sucralose does not induce cytochrome P450 family of enzymes Critique 3: Increases in Cytochrome P450 levels were only normal biological variations Critique 4: CYP3A4 and CYP2D1 protein expression was measured in the colon Critique 5: P-gp is not involved in the disposition of sucralose because the response was not dose-dependent Critique 6: P-gp expression has no effect on nutrients Critique 7: Sucralose is a small molecule with low potential for chemical reactivity Critique 8: Sucralose is stable at elevated temperatures Critique 9: Sucralose is highly water-soluble and not expected to be bioaccumulative Critique 10: Decreases in bacterial counts were normal variation Critique 11: Statistical analysis of pH changes was not provided Critique 12: No weight gain associated with approved sucralose doses Critique 13: Sucralose has no effect on therapeutic management of Type 2 diabetics Critique 14: Critical safety studies were conducted according to the standards required by FDA Critique 15: Members of \u201cExpert Panel\u201d were independent reviewers Conclusions Disclosure of conflict of interest References", "Disclosure": "The conclusions in our peer-reviewed study are supported by our data, and the critiques by Grotz and Munro (2009) and the Bru- sick et al. (2009) are without merit. Additional safety studies must be performed to determine the full impact of sucralose on drug bioavailability and to evaluate the biological effects of chronic sucralose usage particularly for special populations (e.g., children, elderly, nursing mothers, persons with diabetes, cancer patients). Disclosure of conflict of interest We declare that there are no conflicts of interest for this rebuttal. We noted on the first page in our original paper that \u2018\u2018the research was supported in part by a grant from the Sugar Association, Inc., Washington, DC\u2019\u2019. References Sucralose revisited: Rebuttal of two papers about Splenda safety Critique 1: Sucralose \u201cis stable in vivo\u201d and \u201celiminated unchanged in the feces\u201d Critique 2: Sucralose does not induce cytochrome P450 family of enzymes Critique 3: Increases in Cytochrome P450 levels were only normal biological variations Critique 4: CYP3A4 and CYP2D1 protein expression was measured in the colon Critique 5: P-gp is not involved in the disposition of sucralose because the response was not dose-dependent Critique 6: P-gp expression has no effect on nutrients Critique 7: Sucralose is a small molecule with low potential for chemical reactivity Critique 8: Sucralose is stable at elevated temperatures Critique 9: Sucralose is highly water-soluble and not expected to be bioaccumulative Critique 10: Decreases in bacterial counts were normal variation Critique 11: Statistical analysis of pH changes was not provided Critique 12: No weight gain associated with approved sucralose doses Critique 13: Sucralose has no effect on therapeutic management of Type 2 diabetics Critique 14: Critical safety studies were conducted according to the standards required by FDA Critique 15: Members of \u201cExpert Panel\u201d were independent reviewers Conclusions Disclosure of conflict of interest References", "Acknowledgement": "Our response: The \u2018\u2018Expert Panel\u2019\u2019 assembled by McNeil Nutri- tionals (Brusick et al., 2009) included individuals who (1) had pre- viously participated as a joint author with McNeil on sucralose, (2) have declared that they are consultants for McNeil (in one case for 13 years), and (3) had published previously in a special issue on sucralose sponsored by McNeil. No acknowledgments of these con- flicts of interest or financial support were given in this critique. This does not conform to the policy and guidance on conflict of interest established by the National Institutes of Health (NIH, 2011) or by Elsevier as described on their website. Furthermore, the claims expressed by the \u2018\u2018Expert Panel\u2019\u2019 (Brusick et al., 2009) closely mirror the positions expressed directly by McNeil (Grotz and Munro, 2009). The first time that we saw these critiques of our findings was when they appeared in print in Regulatory Toxicology and Phar- macology. Standard procedure for critiques of scientific published works is to submit a letter to the same journal in which the article was published, which in our case was Journal of Toxicology and Environmental Health, Part A (Abou-Donia et al., 2008). The \u2018\u2018Ex- pert Panel\u2019\u2019 did not follow standard scientific protocol but rather chose to publish its critique simultaneously in a different journal \u2018\u2018back to back\u2019\u2019 along with one directly from McNeil Nutritionals."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Suggesting-a-testing-strategy-for-possible-endoc_2012_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22342601", "content": {"CoiStatement": "5. Conflict of interest statement The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. References 5 Conflict of interest statement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Suitability-of-biomarkers-of-biological-effects--BOBEs--for_2018_Regulatory-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29428304", "content": {"CoiStatement": "Conflicts of interest Acknowledgments Supplementary data Transparency document References", "Acknowledgement": "Conflicts of interest Acknowledgments Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Summary-of-the-epidemiological-evidence-rela_2011_Regulatory-Toxicology-and-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21163315", "content": {"CoiStatement": "Conclusions Conflict of interest Acknowledgments Appendix References", "Acknowledgement": "Conclusions Conflict of interest Acknowledgments Appendix References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Support-vector-machine-based-model-for-toxicity-_2021_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33940084", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Support vector machine-based model for toxicity of organic compounds against fish 1 Introduction 2 Materials and methods 3 Results and discussion 4 Conclusions Funding CRediT authorship contribution statement Declaration of competing interest Appendix A Supplementary data References", "Funding": "Funding This work was supported by the Scientific Research Fund of Hunan Provincial Education Department (No. 16A047), and the Open Project Program of Hunan Provincial Key Laboratory of Environmental Catal- ysis & Waste Regeneration (Hunan Institute of Engineering) (No. 2018KF11). Support vector machine-based model for toxicity of organic compounds against fish 1 Introduction 2 Materials and methods 3 Results and discussion 4 Conclusions Funding CRediT authorship contribution statement Declaration of competing interest Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Suppressive-effect-of-astaxanthin-on-retinal-injur_2010_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20457203", "content": {"Acknowledgement": "Acknowledgment This study was supported by a Grant (No.: 2006.02.0122.013) from Akdeniz University Research Foundation. Discussion Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Surface-passivity-largely-governs-the-bioaccessibilit_2016_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27575685", "content": {"Acknowledgement": "Acknowledgements The International Chromium Development Association, ICDA, the Swedish Research Council (VR, 2013-5621, and 2015-04177), and the Swedish Research Council Formas (216-2010-968) are highly acknowledged for financial support. Neda Mazinanian, Maria-Elisa Karlsson, and Dr. Jonas Hedberg, all at KTH, and Oskar Karlsson, Swerea Kimab, are highly acknowledged for experimental help. The authors are very grateful to Dr. Grant Darrie and Dr. Tony Newson for long-term collaboration related to aspects of relevance for metals and alloys. 4. Conclusions Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Survey-results-on-the-use-of-the-tissue-cross-rea_2011_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20951178", "content": {"Acknowledgement": "Acknowledgements The authors would like to acknowledge Ron Tyler, Carol John- son (Amgen Inc.), Anthony Ndifor (Johnson and Johnson), Elizabeth Galbreath (Eli Lilly), and other authors from the industry white pa- per (Leach et al., 2010) for assistance with the structure and/or content of certain survey questions. Special thanks to Paul Zamora for the design, conduct and data management of the survey and CVENT Event Management and Web Survey Solutions (8180 Greensboro Drive, Suite 450, McLean, VA, 22102) for the survey tool. Discussion Conclusions Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Survival-of-Escherichia-coli-harboring-nucleic-acid_2018_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29486271", "content": {"Acknowledgement": "Acknowledgments We thank Dr. Munjin Kwon for critical reading of this manuscript. This study was supported by the 2015\u20132019 RDA Fellowship Program of the National Institute of Animal Science, Rural Development Administration, Republic of Korea. This work also received support from the Cooperative Research Program for Agriculture Science & Technology Development (Project No. PJ01094401) of the Rural Development Administration, Republic of Korea. Discussion Acknowledgments Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Suspected-herbal-hepatotoxicity--The-pharmacovigilan_2012_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32595044", "content": {"CoiStatement": "Conflict of interest statement The authors declare no conflicts of interest. The authors declare no conflicts of interest. References Suspected herbal hepatotoxicity: The pharmacovigilance dilemma with disputed and obsolete evaluation methods Conflict of interest statement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Synergetic-toxicity-of-DATR--a-recombinant-soluble-hum_2012_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23000416", "content": {"CoiStatement": "Conflict of interest There is no conflict of interest. There is no conflict of interest. Acknowledgments 4 Discussion Conflict of interest Acknowledgments References", "Acknowledgement": "Acknowledgments This work was supported by grants from Chengdu Diao Pharma- ceutical Group Co., Ltd. (Chengdu, China). We would like to thank Professor Yimin Dai for his excellent technical assistance with the histopathology analysis. 4 Discussion Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Systematic-analysis-of-the-relationship-between-standardiz_2013_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23524270", "content": {"CoiStatement": "4 Overall assessment of the concentration\u2013response relationship between prenatal PCB exposure and development based on the standardized approach Conflicts of interest statement Acknowledgments References", "Acknowledgement": "4 Overall assessment of the concentration\u2013response relationship between prenatal PCB exposure and development based on the standardized approach Conflicts of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Systematic-comparison-of-study-quality-_2016_Regulatory-Toxicology-and-Pharm.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26743741", "content": {"Acknowledgement": "Acknowledgments This paper was produced with support to Gradient from the American Chemistry Council's the Center for Advancing Risk Assessment Science and Policy. Scientific input and peer review from Drs. Dale Strother and Christopher Bevan are gratefully acknowledged. The authors retain sole responsibility for the content. Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Systematic-review-and-evaluation-of-aspartame-carc_2019_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29339245", "content": {"CoiStatement": "Declaration of interest The authors are from Intertek Scientific & Regulatory Consultancy (Intertek). Intertek is a scientific consulting firm which provides sci- entific and regulatory advice, including safety and efficacy evaluations, to companies in food, pharmaceutical and chemical industries. https://echa.europa.eu/documents/10162/13643/information_requirements_r4_en.pdf https://echa.europa.eu/documents/10162/13643/information_requirements_r4_en.pdf https://doi.org/10.2903/j.efsa.2006.356 https://doi.org/10.2903/j.efsa.2006.356 https://doi.org/10.2903/j.efsa.2009.945 https://doi.org/10.2903/j.efsa.2009.1015 https://doi.org/10.2903/j.efsa.2009.1015 https://doi.org/10.2903/j.efsa.2013.3496 https://doi.org/10.2903/j.efsa.2013.3496 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref15 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref15 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref15 https://doi.org/10.20772/cancersci1959.75.9_763 https://doi.org/10.20772/cancersci1959.75.9_763 https://doi.org/10.1016/0273-2300(86)90031-0 https://doi.org/10.1016/0273-2300(86)90031-0 https://doi.org/10.1016/j.yrtph.2010.10.002 https://doi.org/10.1016/0378-4274(81)90089-8 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref20 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref20 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref20 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref21 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref21 https://doi.org/10.1371/journal.pbio.1000412 https://doi.org/10.1006/rtph.1996.1076 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref24 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref24 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref24 https://doi.org/10.1016/0278-6915(86)90348-0 https://doi.org/10.1016/j.yrtph.2015.12.017 https://doi.org/10.1016/j.yrtph.2015.12.017 https://doi.org/10.1080/10408440701516184 https://doi.org/10.1080/10408440701516184 https://doi.org/10.1080/19338244.2013.828674 https://doi.org/10.1080/19338244.2013.828674 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref29 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref29 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref29 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref29 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref29 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref29 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref29 http://ntp.niehs.nih.gov/ntp/htdocs/GMM_rpts/GMM1.pdf https://ntp.niehs.nih.gov/ntp/about_ntp/partnerships/international/summarypwg_report_ri_bioassays.pdf https://ntp.niehs.nih.gov/ntp/about_ntp/partnerships/international/summarypwg_report_ri_bioassays.pdf http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?doclanguage=en\ufffd&\ufffdcote=env/jm/mono(2005 http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?doclanguage=en\ufffd&\ufffdcote=env/jm/mono(2005 https://doi.org/10.1787/9789264071186-en https://doi.org/10.1787/9789264071223-en https://doi.org/10.1787/9789264071223-en http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/MONO(2011 http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/MONO(2011 http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/MONO(2011 https://doi.org/10.1016/j.toxlet.2009.05.013 https://doi.org/10.1016/j.toxlet.2009.05.013 https://doi.org/10.1354/vp.08-VP-0240-S-COM http://refhub.elsevier.com/S0273-2300(18)30009-6/sref38 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref38 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref38 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref38 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref39 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref39 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref39 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref39 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref40 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref40 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref40 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref40 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref41 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref41 https://doi.org/10.1289/ehp.8711 https://doi.org/10.1289/ehp.10271 https://doi.org/10.1289/ehp.10271 https://doi.org/10.1111/j.1742-7843.2007.00200.x https://doi.org/10.1002/ajim.20896 https://doi.org/10.1002/ajim.2229 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref47 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref47 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref48 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref48 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref49 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref49 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref49 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref49 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref49 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref50 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref50 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref50 https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm2006826.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm2006826.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm2006826.htm http://refhub.elsevier.com/S0273-2300(18)30009-6/sref52 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref52 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref52 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=172.804 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=172.804 https://doi.org/10.1354/vp.09-VP-0059-W-COM Systematic review and evaluation of aspartame carcinogenicity bioassays using quality criteria Introduction Methodology Literature searches Quality appraisal tools Results Carcinogenicity studies Overview Searle Studies in mice NTP studies in transgenic mice Searle Studies in rats Brain tumor study in rats Ramazzini Institute rat studies Quality evaluation Discussion and conclusions Acknowledgements Transparency document Declaration of interest References", "Funding": "The Calorie Control Council provided funding for this evaluation. The Calorie Control Council is an international association representing the low- and reduced-calorie food and beverage industry. References", "Acknowledgement": "Acknowledgements The authors acknowledge Sylvia P. Poulos, Director of Nutrition & Scientific Affairs of the Calorie Control Council who reviewed the drafts of the manuscript and provided editorial corrections. The authors also acknowledge our Intertek colleague, Julie James, who conducted the literature searches. https://echa.europa.eu/documents/10162/13643/information_requirements_r4_en.pdf https://echa.europa.eu/documents/10162/13643/information_requirements_r4_en.pdf https://doi.org/10.2903/j.efsa.2006.356 https://doi.org/10.2903/j.efsa.2006.356 https://doi.org/10.2903/j.efsa.2009.945 https://doi.org/10.2903/j.efsa.2009.1015 https://doi.org/10.2903/j.efsa.2009.1015 https://doi.org/10.2903/j.efsa.2013.3496 https://doi.org/10.2903/j.efsa.2013.3496 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref15 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref15 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref15 https://doi.org/10.20772/cancersci1959.75.9_763 https://doi.org/10.20772/cancersci1959.75.9_763 https://doi.org/10.1016/0273-2300(86)90031-0 https://doi.org/10.1016/0273-2300(86)90031-0 https://doi.org/10.1016/j.yrtph.2010.10.002 https://doi.org/10.1016/0378-4274(81)90089-8 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref20 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref20 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref20 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref21 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref21 https://doi.org/10.1371/journal.pbio.1000412 https://doi.org/10.1006/rtph.1996.1076 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref24 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref24 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref24 https://doi.org/10.1016/0278-6915(86)90348-0 https://doi.org/10.1016/j.yrtph.2015.12.017 https://doi.org/10.1016/j.yrtph.2015.12.017 https://doi.org/10.1080/10408440701516184 https://doi.org/10.1080/10408440701516184 https://doi.org/10.1080/19338244.2013.828674 https://doi.org/10.1080/19338244.2013.828674 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref29 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref29 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref29 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref29 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref29 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref29 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref29 http://ntp.niehs.nih.gov/ntp/htdocs/GMM_rpts/GMM1.pdf https://ntp.niehs.nih.gov/ntp/about_ntp/partnerships/international/summarypwg_report_ri_bioassays.pdf https://ntp.niehs.nih.gov/ntp/about_ntp/partnerships/international/summarypwg_report_ri_bioassays.pdf http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?doclanguage=en\ufffd&\ufffdcote=env/jm/mono(2005 http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?doclanguage=en\ufffd&\ufffdcote=env/jm/mono(2005 https://doi.org/10.1787/9789264071186-en https://doi.org/10.1787/9789264071223-en https://doi.org/10.1787/9789264071223-en http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/MONO(2011 http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/MONO(2011 http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/MONO(2011 https://doi.org/10.1016/j.toxlet.2009.05.013 https://doi.org/10.1016/j.toxlet.2009.05.013 https://doi.org/10.1354/vp.08-VP-0240-S-COM http://refhub.elsevier.com/S0273-2300(18)30009-6/sref38 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref38 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref38 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref38 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref39 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref39 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref39 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref39 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref40 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref40 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref40 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref40 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref41 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref41 https://doi.org/10.1289/ehp.8711 https://doi.org/10.1289/ehp.10271 https://doi.org/10.1289/ehp.10271 https://doi.org/10.1111/j.1742-7843.2007.00200.x https://doi.org/10.1002/ajim.20896 https://doi.org/10.1002/ajim.2229 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref47 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref47 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref48 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref48 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref49 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref49 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref49 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref49 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref49 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref50 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref50 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref50 https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm2006826.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm2006826.htm https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm2006826.htm http://refhub.elsevier.com/S0273-2300(18)30009-6/sref52 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref52 http://refhub.elsevier.com/S0273-2300(18)30009-6/sref52 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=172.804 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=172.804 https://doi.org/10.1354/vp.09-VP-0059-W-COM Systematic review and evaluation of aspartame carcinogenicity bioassays using quality criteria Introduction Methodology Literature searches Quality appraisal tools Results Carcinogenicity studies Overview Searle Studies in mice NTP studies in transgenic mice Searle Studies in rats Brain tumor study in rats Ramazzini Institute rat studies Quality evaluation Discussion and conclusions Acknowledgements Transparency document Declaration of interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Systematic-review-and-meta-analysis-of-epidemiological-lit_2020_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31991162", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: All the authors are employed by Cardno ChemRisk, a consulting firm that provides scientific advice to the government, corporations, law firms and various scientific/professional organizations. GM is also Professor of Biostatistics and Director and Founder of the Center for Occupational Biostatistics and Epidemiology at the University of Pittsburgh Graduate School of Public Health. Financial support for the research described in the manuscript was provided by the North American Insulation Manufacturers Association (NAIMA). The funding association had no involvement or influence in the analysis, writing or conclusions of this review. This article was prepared and written ex- clusively by the authors without review or comment by any outside entity. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: All the authors are employed by Cardno ChemRisk, a consulting firm that provides scientific advice to the government, corporations, law firms and various scientific/professional organizations. GM is also Professor of Biostatistics and Director and Founder of the Center for Occupational Biostatistics and Epidemiology at the University of Pittsburgh Graduate School of Public Health. Financial support for the research described in the manuscript was provided by the North American Insulation Manufacturers Association (NAIMA). The funding association had no involvement or influence in the analysis, writing or conclusions of this review. This article was prepared and written ex- clusively by the authors without review or comment by any outside entity. References", "Funding": "Funding source Financial support for the research described in the manuscript was provided by the North American Insulation Manufacturers Association (NAIMA). The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: All the authors are employed by Cardno ChemRisk, a consulting firm that provides scientific advice to the government, corporations, law firms and various scientific/professional organizations. GM is also Professor of Biostatistics and Director and Founder of the Center for Occupational Biostatistics and Epidemiology at the University of Pittsburgh Graduate School of Public Health. Financial support for the research described in the manuscript was provided by the North American Insulation Manufacturers Association (NAIMA). The funding association had no involvement or influence in the analysis, writing or conclusions of this review. This article was prepared and written ex- clusively by the authors without review or comment by any outside entity. References Discussion Conclusions Funding source mk:H1_14 References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Systematically-evaluating-read-across-prediction-and-perf_2016_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27174420", "content": {"CoiStatement": "Conflict of interest The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article. Acknowledgement 4. Discussion 5. Conclusions Disclaimer Conflict of interest Acknowledgement Appendix A. Supplementary data Transparency document References", "Acknowledgement": "Acknowledgement This work was supported in part by an appointment to the Research Participation Program at the Office of Research and Development, U.S. Environmental Protection Agency, administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and EPA. 4. Discussion 5. Conclusions Disclaimer Conflict of interest Acknowledgement Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Systemic-absorption-of-benzalkonium-chloride-after-_2021_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34174381", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Lonza, Inc., a manufacturer of benzalkonium chloride, funded this work. Paul DeLeo, is employed by Integral Consulting Inc., and received consulting fees from Lonza, Inc. during the preparation of the manu- script. One study author, Victoria Tu, is employed by Lonza, Inc., and contributed to the preparation and review of this manuscript. One author, Janice Fuls, is employed by Henkel Corporation, Inc., a company that manufactures antiseptic hand soap containing benzalkonium chlo- ride. All study authors contributed to the preparation and review of this manuscript. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Lonza, Inc., a manufacturer of benzalkonium chloride, funded this work. Paul DeLeo, is employed by Integral Consulting Inc., and received consulting fees from Lonza, Inc. during the preparation of the manu- script. One study author, Victoria Tu, is employed by Lonza, Inc., and contributed to the preparation and review of this manuscript. One author, Janice Fuls, is employed by Henkel Corporation, Inc., a company that manufactures antiseptic hand soap containing benzalkonium chlo- ride. All study authors contributed to the preparation and review of this manuscript. Acknowledgements 4 Discussion and conclusion Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Funding": "Funding body information Systemic Absorption of Benzalkonium Chloride after Exaggerated Use of a Consumer Antiseptic Wash Product Paul C. DeLeo: Writing \u2013 original draft, preparation, Writing \u2013 review & editing, Project administration. Victoria Tu: Conceptualiza- tion, Methodology, Formal analysis, Writing \u2013 review & editing, Su- pervision, Project administration, Funding acquisition. Janice Fuls: Conceptualization, Methodology, Formal analysis, Writing \u2013 review & editing. Declaration of competing interest 4 Discussion and conclusion Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Acknowledgement": "Acknowledgements The authors wish to extend their thanks to Monica Carstens of Inte- gral Consulting Inc. for her rigorous editorial support during the development of this manuscript. 4 Discussion and conclusion Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Systemic-toxicity-of-di--2-ethylhexyl--adipate--DEH_2019_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30826316", "content": {"CoiStatement": "Conflicts of interest The authors have no conflicts of interest that affect their scientific analysis or conclusions. There are no contractual relations or proprie- tary considerations that restrict the authors\u2019 publication or dissemina- tion of their findings. The authors have no conflicts of interest that affect their scientific analysis or conclusions. There are no contractual relations or proprie- tary considerations that restrict the authors\u2019 publication or dissemina- tion of their findings. Acknowledgements Results Discussion and conclusion Submission declaration Statement Ethical approval Conflicts of interest Acknowledgements Transparency document References", "Acknowledgement": "Acknowledgements The authors thank Matteo Manfredini for his help with DEHA shipment, Bin Luo for her help with dosing formulation preparation, Yijun Cheng and Jinsong Zhao for their help with analytical method development, and all personnel at participating institutions involved in this study. Without their contribution, the compilation of data for this report would not have been possible. The study is sponsored by Baxter and conducted at WuXi AppTec Co., Ltd. Publication permission has been obtained from Baxter. Results Discussion and conclusion Submission declaration Statement Ethical approval Conflicts of interest Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/TDCPP-protects-cardiomyocytes-from-hypoxia-reoxygenation-_2018_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29129621", "content": {"CoiStatement": "ii) Yanhong Liao, Xiju He, Shoutian Li and Xiaoxia Fang are in agreement with the manuscript, There has no conflict of interest of all the authors in the manuscript. References", "Acknowledgement": "Acknowledgments This research was supported by Education Department of Hubei Province Foundation B2014053 (to X.J.), and National Natural Science Foundation of China Grants 30970662 (to Y.H.). Discussion Acknowledgments Transparency document Authorship declaration References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/TIMES-SS-A-promising-tool-for-the-assessment-of-skin-sensit_2007_Regulatory-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/17467128", "content": {"Funding": "TIMES-SS can be termed a hybrid expert system since it has been developed in principle to make predictions for a wide range of chemicals using a framework of intercon- nected models. It was developed by the Laboratory of Mathematical Chemistry (LMC) (University \u2018\u2018Prof. As. Zlatarov,\u2019\u2019 Bourgas, Bulgaria) using funding and data from a Consortium comprising Industry (ExxonMobil, P&G, Unilever) and a Regulatory Agency (DK-EPA). TIMES-SS was developed to incorporate structure\u2013toxic- ity and structure\u2013metabolism relationships through a number of transformations simulating skin metabolism and interaction of the generated reactive metabolites with skin proteins. The skin metabolism simulator mimics metabolism using 2D structural information. Metabolic pathways are generated based on a set of 236 hierarchi- cally ordered principal transformations including sponta- neous reactions and enzyme catalyzed biotransformation reactions (phase I and II). The covalent reactions with proteins are described by 47 alerting groups. The associ- ated mechanisms are in accordance with the existing knowledge on electrophilic interaction mechanisms of var- ious structural functionalities. The integral model is essen- tially based on a set of submodels, associated with each of the reactive groups. Some of these reactions are addition- ally underpinned by mechanistically based 3D QSARs to predict the intrinsic reactivity of compounds that have substructural features associated with reactivity. These 3D-QSAR models depend on both the structural alert and the rate of skin sensitization. Steric effects around the active site, molecular size, shape, solubility, lipophilic- ity and electronic properties are all taken into account. These models may involve combinations of molecular descriptors which trigger the alerting group. The TIMES-SS model has already been described previously (Dimitrov et al., 2005a). The primary objective of this article is to describe the scientific validity of TIMES-SS with reference to the OECD principles for (Q)SAR validation (OECD, 2004) and with particular emphasis on the external evaluation study that was recently conducted. In addition, we present TIMES-SS as a promising model that could be employed as part of an \u2018\u2018integrated testing strategy\u2019\u2019 to provide information to evaluate skin sensitization under legislative programs such as REACH. 1.1. Regulatory use of (Q)SARs and the OECD principles for (Q)SAR validation"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/TK-Modeler-version-1-0--a-Microsoft--Excel--based-modeli_2012_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22504463", "content": {"CoiStatement": "Conflict of interest Some of the substances used as examples are produced and the program was developed at the facility where all of the authors work. The contents of this paper describe the practices used by the authors\u2019 employer, and statements contained herein do not constitute war- ranties upon which readers should rely. Neither the authors nor their employers shall be liable for any losses or damages arising out of the use of the information contained in this paper. 4 Discussion and conclusions Conflict of interest Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/TSCA-risk-evaluation-directed-characterization-of-occupati_2022_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/35483541", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: James H. Sherman reports financial support and equipment, drugs, or supplies were provided by Celanese Corporation. J. Tyler Tanniehill reports financial support and equipment, drugs, or supplies were pro- vided by Celanese Corporation. Gary M. Rowen reports financial support and equipment, drugs, or supplies were provided by Celanese Corpo- ration. James H. Sherman reports a relationship with Celanese Corpo- ration that includes: employment, equity or stocks, and travel reimbursement. J. Tyler Tanniehill reports a relationship with Celanese Corporation that includes: employment and travel reimbursement. Gary The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: James H. Sherman reports financial support and equipment, drugs, or supplies were provided by Celanese Corporation. J. Tyler Tanniehill reports financial support and equipment, drugs, or supplies were pro- vided by Celanese Corporation. Gary M. Rowen reports financial support and equipment, drugs, or supplies were provided by Celanese Corpo- ration. James H. Sherman reports a relationship with Celanese Corpo- ration that includes: employment, equity or stocks, and travel reimbursement. J. Tyler Tanniehill reports a relationship with Celanese Corporation that includes: employment and travel reimbursement. Gary M. Rowen reports a relationship with Celanese Corporation that in- cludes: consulting or advisory and equity or stocks. 6 Conclusions Funding CRediT authorship contribution statement Declaration of competing interest Abbreviations References", "Funding": "Funding Funding for this manuscript was provided by Celanese Corporation and was limited to normal employee compensation for James Sherman and Jordan TannieHill. Gary Rowen is a retiree from Celanese and was paid a consulting fee for his participation. Celanese also paid for the monitoring badges that were used to quantify worker exposures. Funding for this manuscript was provided by Celanese Corporation and was limited to normal employee compensation for James Sherman and Jordan TannieHill. Gary Rowen is a retiree from Celanese and was paid a consulting fee for his participation. Celanese also paid for the monitoring badges that were used to quantify worker exposures. CRediT authorship contribution statement James H. Sherman: Conceptualization, Methodology, Validation, Formal analysis, Data curation, Writing \u2013 original draft, Writing \u2013 re- view & editing, Visualization, Supervision, Project administration, Funding acquisition. Gary M. Rowen: Conceptualization, Validation, Writing \u2013 original draft, Writing \u2013 review & editing. J. Tyler Tanniehill: Conceptualization, Methodology, Software, Validation, Formal analysis, Investigation, Resources, Data curation, Writing \u2013 original draft, Writing \u2013 review & editing. Declaration of competing interest 6 Conclusions Funding CRediT authorship contribution statement Declaration of competing interest Abbreviations References", "Compliance with ethical standards": "Responding to the challenges presented by the emerging dual OSHA and EPA regulatory approach triggered by TSCA as amended by the Lautenberg Act will require manufacturers to focus on ensuring their worker exposure monitoring programs are fit for risk assessment pur- poses, in addition to complying with OSHA regulatory requirements. Doing so will ensure that accurate information is available to OSHA and EPA during their respective compliance and risk assessments, as well as when evaluating the potential need for, and type of, additional exposure controls in a dynamic manufacturing environment. Additionally, reporting of the exposure data should include a discussion of the strengths and limitations of the exposure evidence, and that the dis- cussion of uncertainties, variability and underlying assumptions sup- porting the exposure estimates are clear and documented. In this way, industry can help ensure accurate exposure data, which is a precondition for the best science-based decisions required by TSCA. Such data would replace worst-case default exposure assumptions or the use of unvali- dated exposure models, which generally lead to highly uncertain risk assessments and present less than optimal risk characterizations to risk managers. Lastly, EPA and OSHA have a continuing need to better co- ordinate their workplace chemical assessments to reduce the regulatory burden of overlapping and sometimes conflicting regulations and in order to ensure limited resources are directed toward protecting worker health and making real-time decisions for numerous chemicals across a wide diversity of industries. Funding"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/TSNA-exposure-from-cigarette-smoking--18Years-o_2014_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23920111", "content": {"Funding": "In conclusion, an analysis of total urinary NNAL excretion data among 3941 study participants reported in 35 studies published over 18 years suggests that exposure to TSNAs has declined among cigarette smokers over that time period. These findings are consis- tent with various efforts to reduce TSNA levels in tobacco products as well as observed reductions in TSNA levels in cigarette tobacco and smoke over the same time period. 5. Funding sources None. Acknowledgment TSNA exposure from cigarette smoking: 18Years of urinary NNAL excretion data 1 Introduction 2 Methods 3 Results 4 Discussion 5 Funding sources Acknowledgment References", "Compliance with ethical standards": "USDHHS, 2012. US Food and Drug Administration. Harmful and potentially harmful constituents in tobacco products and tobacco smoke: established list. <http:// www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ ucm297786.htm> (accessed July 2013). http://refhub.elsevier.com/S0273-2300(13)00115-3/h0180 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0180 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0180 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0185 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0185 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0185 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0185 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0190 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0190 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0195 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0195 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0195 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0195 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0200 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0200 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0200 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0200 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0205 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0205 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0205 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0210 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0210 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0210 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0210 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0210 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0215 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0215 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0215 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0220 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0220 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0225 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0225 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0225 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0225 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0230 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0230 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0230 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0235 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0235 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0235 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0240 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0240 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0240 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0245 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0245 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0245 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0250 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0250 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0250 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0250 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0255 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0255 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0255 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0255 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0260 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0260 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0260 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0265 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0265 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0265 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0265 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0270 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0270 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0270 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0270 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0275 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0275 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0275 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0275 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0275 http://www.surgeongeneral.gov/library/reports/tobaccosmoke/report-index.html http://www.surgeongeneral.gov/library/reports/tobaccosmoke/report-index.html http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm http://refhub.elsevier.com/S0273-2300(13)00115-3/h0180 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0180 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0180 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0185 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0185 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0185 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0185 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0190 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0190 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0195 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0195 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0195 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0195 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0200 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0200 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0200 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0200 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0205 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0205 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0205 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0210 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0210 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0210 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0210 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0210 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0215 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0215 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0215 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0220 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0220 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0225 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0225 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0225 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0225 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0230 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0230 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0230 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0235 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0235 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0235 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0240 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0240 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0240 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0245 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0245 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0245 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0250 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0250 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0250 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0250 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0255 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0255 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0255 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0255 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0260 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0260 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0260 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0265 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0265 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0265 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0265 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0270 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0270 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0270 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0270 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0275 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0275 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0275 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0275 http://refhub.elsevier.com/S0273-2300(13)00115-3/h0275 http://www.surgeongeneral.gov/library/reports/tobaccosmoke/report-index.html http://www.surgeongeneral.gov/library/reports/tobaccosmoke/report-index.html http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm TSNA exposure from cigarette smoking: 18Years of urinary NNAL excretion data 1 Introduction 2 Methods 3 Results 4 Discussion 5 Funding sources Acknowledgment References", "Acknowledgement": "None. Acknowledgment The authors acknowledge the editorial assistance of Eileen Y. Ivasauskas of Accuwrit Inc. TSNA exposure from cigarette smoking: 18Years of urinary NNAL excretion data 1 Introduction 2 Methods 3 Results 4 Discussion 5 Funding sources Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/TSNA-levels-in-machine-generated-mainstream-cig_2013_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23557986", "content": {"CoiStatement": "In conclusion, this review of data collected over the past 35 years does not support the suggestion that TSNA levels in MS smoke of US commercial cigarettes have increased over time. On the contrary, the general impression of this data set is that TSNA levels in MS cigarette smoke appear to be generally decreasing. The statistical analyses are consistent with this impression. This trend is particularly evident over the past 10 years. The apparent downward trend in TSNA levels in MS smoke of US commercial cig- arettes is consistent with efforts implemented by the tobacco industry and the agricultural community to reduce levels of TSNAs in tobacco and cigarette smoke. Conflict of interest The authors are employees of Altria Client Services Inc. Funding sources 4 Discussion Conflict of interest ack15 References", "Funding": "The authors are employees of Altria Client Services Inc. Funding sources None. Acknowledgment", "Compliance with ethical standards": "USDHHS, 2012. US Food and Drug Administration. Harmful and potentially harmful constituents in tobacco products and tobacco smoke: established list. <http:// www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ ucm297786.htm> (accessed December 2012). Virginia Cooperative Extension and Virginia Polytechnic Institute and Virginia State University, 2011. 2012 Flue-cured tobacco production guide. Publication 436- 048. <http://pubs.ext.vt.edu/AREC/AREC-14/AREC-14-pdf.pdf> (accessed December 2012). http://www.coresta.org/Meetings/Past_Abstracts/Sapporo2012-PlenarySessions.pdf http://www.coresta.org/Meetings/Past_Abstracts/Sapporo2012-PlenarySessions.pdf http://monographs.iarc.fr/ENG/Monographs/vol89/mono89.pdf http://ipm.ncsu.edu/Production_Guides/Flue-cured/flue_cured.pdf http://ipm.ncsu.edu/Production_Guides/Flue-cured/flue_cured.pdf http://www.ca.uky.edu/agc/pubs/id/id160/id160.pdf http://www.surgeongeneral.gov/library/reports/tobaccosmoke/report-index.html http://www.surgeongeneral.gov/library/reports/tobaccosmoke/report-index.html http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm http://pubs.ext.vt.edu/AREC/AREC-14/AREC-14-pdf.pdf TSNA levels in machine-generated mainstream cigarette smoke: 35years of data 1 Introduction 2 Methods 2.1 Published literature values 2.2 Monitoring data 2.3 Control cigarette data 2.4 Data analyses", "Acknowledgement": "None. Acknowledgment The authors acknowledge the editorial assistance of Eileen Y. Ivasauskas of Accuwrit Inc. References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/TTC-based-risk-assessment-of-tetrachlorobutadienes-and-p_2010_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20688124", "content": {"Acknowledgement": "Risk reduction measures have been taken by suppliers of drink- ing water in Basel to reduce the water concentrations of polychlo- rinated butadienes since April 2008. The total drinking water of Basel (mixture of groundwater from Lange Erlen and Muttenzer Hard) has been filtrated through granular activated carbon (GAC) resulting in concentrations of polychlorinated butadienes below the corresponding detection limits (10 ng/L for 1,1,2,3-TetraCBD, 1,1,2,3,4-PentaCBD and HexaCBD; 20 ng/L for the other measured TetraCBDs and PentaCBDs) (IWB, 2009). The measured concentra- tions of TetraCBDs and PentaCBDs are clearly below the TTC-based target value of 75 ng/L (sum value of both substance groups). Acknowledgments The in vitro genotoxicity tests were financed by Hardwasser AG (Pratteln, CH), a drinking water supplier near Basel. The author wants to thank Josef Schlatter (Federal Office of Public Health, Z\u00fcrich, CH) and Richard W\u00fclser (IWB, Quality Assurance DW, Basel, CH) for valuable comments on the manuscript. References Results Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Target-animal-safety-testing-of-an-oral-salicylanilide-_2019_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30634022", "content": {"CoiStatement": "Conflicts of interest Funding: This work was supported by the Research on the key Technologies of the creation and industrialization of New Special Chemical drugs for Animals [grant numbers 2015BAD11B01-01] and Drug Development and Clinical Drug use posts of National Beef Yak Industry Technical system [grant numbers CARS-37]. Discussion Conflicts of interest Acknowledgements Transparency document References", "Funding": "Funding: This work was supported by the Research on the key Technologies of the creation and industrialization of New Special Chemical drugs for Animals [grant numbers 2015BAD11B01-01] and Drug Development and Clinical Drug use posts of National Beef Yak Industry Technical system [grant numbers CARS-37]. Acknowledgements", "Acknowledgement": "Acknowledgements The author sincerely thanks the veterinarians and staff of the farm for their selfless and patient help and participation. Discussion Conflicts of interest Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Target-organ-profiles-in-toxicity-studies-supporting-_2014_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25020275", "content": {"CoiStatement": "Conflict of interest Steve Horner., Sally Robinson., David Lees., Richard Callander. and Ruth Roberts. are all current employees of AstraZeneca. References 5 Conclusion Conflict of interest References", "Compliance with ethical standards": "ICM M3 (R2) Q&A, 2013. Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. Questions and Answers (R2). Feb 2013. <http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292340.pdf>. Lanning, L., Creasy, D., Chapin, R., Mann, P., Barlow, N., Regan, K., Goodman, D., 2002. Recommended approaches for the evaluation of testicular and epididymal toxicity. Toxicol. Pathol. 30, 507\u2013520. NC3Rs, 2012: National Centre for the Replacement, Refinement & Reduction of Animals in Research, 2012. Reducing the use of recovery animals in pharmaceutical development. <http://www.nc3rs.org.uk/news.asp?id=1814> (last accessed 11 November 2013). http://refhub.elsevier.com/S0273-2300(14)00162-7/h0020 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0020 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0025 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0025 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0025 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0030 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0035 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0035 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0035 http://www.ich.org/products/guidelines/multidisciplinary/article/multidisciplinary-guidelines.html http://www.ich.org/products/guidelines/multidisciplinary/article/multidisciplinary-guidelines.html http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292340.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292340.pdf http://refhub.elsevier.com/S0273-2300(14)00162-7/h0060 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0060 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0060 http://www.nc3rs.org.uk/news.asp?id=1814 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0070 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0070 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0070 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0070 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0075 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0075 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0075 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0080 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0080 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0080 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0085 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0085 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0090 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0090 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0090 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0090 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0095 http://refhub.elsevier.com/S0273-2300(14)00162-7/h0095 Target organ profiles in toxicity studies supporting human dosing: An assessment of recovery and chronic dosing 1 Introduction 2 Materials and methods 3 Results 3.1 Recovery of target organs in the rodent and non-rodent 3.2 Recovery of target organs in the rodent and non-rodent by intended therapy area 3.3 Recovery of target organ toxicity for CDs that progressed into humans compared with those that did not 3.4 Additional target organs identified in chron"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Target-organ-profiles-in-toxicity-studies-supporting-h_2015_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26517939", "content": {"CoiStatement": "Conflict of interest statement Richard Callander, Paul Duffy, Matt Jacobsen, Richard Knight are current employees of AstraZeneca. Ruth Roberts was an employee of AstraZeneca at the time the analysis was conducted. 5. Conclusions Conflict of interest statement Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Target-organ-toxicities-in-studies-conducted-to-suppor_2013_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23422911", "content": {"CoiStatement": "Conflict of interest statement Steve Horner, David Ryan, Richard Callander, Sally Robinson, and RR are all current employees of AstraZeneca. Katie Stamp was an employee of AstraZeneca at the time the analysis was performed. 5 Conclusion Conflict of interest statement References", "Compliance with ethical standards": "FDA Guidance for Industry, 2005. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. <www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM078932.pdf> (last accessed 09 November 2012). Greaves, P., Williams, A., Eve, M., 2004. First dose of potential new medicines to humans: how animals help. Nat. Rev. Drug Discovery 3, 226\u2013236. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078932.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078932.pdf http://www.ich.org/products/guidelines/multidisciplinary/article/multidisciplinary-guidelines.html http://www.ich.org/products/guidelines/multidisciplinary/article/multidisciplinary-guidelines.html http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html http://www.nc3rs.org.uk/downloaddoc.asp?id=1108&amp;page=1428&amp;skin=0 http://www.nc3rs.org.uk/downloaddoc.asp?id=1108&amp;page=1428&amp;skin=0 Target organ toxicities in studies conducted to support first time in man dosing: An analysis across species and therapy areas 1 Introduction 2 Materials and methods 3 Results 3.1 Target organ profiles in the rodent and non-rodent 3.2 Target organ profiles in the rodent and non-rodent by intended therapy area 3.3 Target organ profiles for CDs that progressed into humans compared with those that did not"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Target-specific-micronucleus-induction-by-colon-carcino_2020_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31935482", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper.", "Funding": "Funding body information The authors received no financial support for the research, author- ship, and/or publication of this article. Discussion Conclusions Funding body information mk:H1_14 Acknowledgements References", "Acknowledgement": "Acknowledgements We would like to thank Tomoko Ishii, Chihiro Matsuura, Tomoaki Sunahara, and Reiko Yoshino for their dedicated assistance with these experiments. Discussion Conclusions Funding body information mk:H1_14 Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Targeted-inhibition-of-tumor-survival--metastasis-and-angiog_2018_Regulatory.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29678767", "content": {"CoiStatement": "Competing interests The authors have declared that no competing interests exists. The authors have declared that no competing interests exists. Acknowledgements Discussion Competing interests Acknowledgements Transparency document References", "Funding": "Source of Funding: This study was funded by Indian Council of Medical Research, Government of India, New Delhi (Ref No: 45/68/ 2013/BMS/TRM) in the form of ICMR-Senior Research Fellowship (SRF). The authors wish to thank Origin Laboratories, Coimbatore for assisting in pathology studies. Transparency document", "Acknowledgement": "Acknowledgements Source of Funding: This study was funded by Indian Council of Medical Research, Government of India, New Delhi (Ref No: 45/68/ 2013/BMS/TRM) in the form of ICMR-Senior Research Fellowship (SRF). The authors wish to thank Origin Laboratories, Coimbatore for assisting in pathology studies. Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Taurine-treatment-decreases-inflammation-and-oxidativ_2018_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30026134", "content": {"Acknowledgement": "Acknowledgments The authors would like to express their gratitude to the Federal University of Ouro Preto and this work was supported by the Federal University of Ouro Preto (# 23109.003267/2017-01 and # 23109.003268/2017\u201347) and Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior [Bolsista CAPES - Process # 88881.172437/ 2018\u201301] to Frank Silva Bezerra. Andr\u00e9 Talvani credits CNPq for the fellowship of research pro- ductivity. Frank Silva Bezerra is doing a Post-Doctoral Fellow in Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada. Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Technical-Validation-of-Radioluminograph_2000_Regulatory-Toxicology-and-Phar.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/10806054", "content": {"Acknowledgement": "ACKNOWLEDGMENTS The help of A. Wagner and T. So\u0308rensen in many discussions is gratefully acknowledged. We thank L. Keck and S. Weisel ments. ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Technical-guide-for-applications-of-gene-expression-pr_2015_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25944780", "content": {"CoiStatement": "5 Overview of applications of toxicogenomics in human health risk assessment 6 Concluding remarks Disclaimer Conflict of Interest Transparency Document Acknowledgments References", "Acknowledgement": "5 Overview of applications of toxicogenomics in human health risk assessment 6 Concluding remarks Disclaimer Conflict of Interest Transparency Document Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Template-based-peptide-modeling-for-celiac-risk-ass_2020_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32619636", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: The authors are employed by a company that develops and markets transgenic seeds. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: The authors are employed by a company that develops and markets transgenic seeds. Appendix A. Supplementary data Vartdal, F., Johansen, B.H., Friede, T., Thorpe, C.J., Stevanovi\ufffdc, S., Eriksen, J.E., Sletten, K., Thorsby, E., Rammensee, H.G., SollidLudvig, L.M., Sollid, M., 1996. The peptide binding motif of the disease associated HLA-DQ (\u03b11*0501, (\u03b2 1*0201) molecule. Eur. J. Immunol. 26, 2764\u20132772. Zhou, P., Jin, B., Li, H., Huang, S.Y., 2018. HPEPDOCK: a web server for bling peptide- protein docking based on a hierarchical algorithm. Nucleic Acids Res. 46, W443\u2013W450. P. Song et al. https://doi.org/10.1016/j.yrtph.2020.104715 https://doi.org/10.1016/j.yrtph.2020.104715 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref1 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref1 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref1 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref1 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref1 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref1 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref2 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref2 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref2 http://refhub.elsevier.com/S0273-2300(20)30141-0/optLqlfIbSX5i http://refhub.elsevier.com/S0273-2300(20)30141-0/optLqlfIbSX5i http://refhub.elsevier.com/S0273-2300(20)30141-0/sref3 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref3 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref3 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref3 http://refhub.elsevier.com/S0273-2300(20)30141-0/optl60MairRrZ http://refhub.elsevier.com/S0273-2300(20)30141-0/optl60MairRrZ http://refhub.elsevier.com/S0273-2300(20)30141-0/optl60MairRrZ http://refhub.elsevier.com/S0273-2300(20)30141-0/optl60MairRrZ http://refhub.elsevier.com/S0273-2300(20)30141-0/sref4 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref4 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref4 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref5 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref6 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref6 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref6 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref6 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref6 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref7 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref7 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref7 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref8 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref9 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref9 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref10 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref10 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref11 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref11 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref11 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref12 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref12 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref12 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref12 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref13 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref13 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref13 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref14 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref14 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref14 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref14 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref14 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref14 https://doi.org/10.17226/23395 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref16 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref16 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref16 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref16 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref16 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref17 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref17 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref17 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref17 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref18 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref18 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref18 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref18 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref19 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref19 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref19 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref20 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref20 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref20 https://doi.org/10.1007/s00251-019-01141-w https://doi.org/10.1007/s00251-019-01141-w http://refhub.elsevier.com/S0273-2300(20)30141-0/sref22 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref22 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref22 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref23 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref23 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref23 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref23 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref24 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref24 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref24 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref24 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref25 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref25 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref25 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref26 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref26 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref26 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref27 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref27 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref27 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref27 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref28 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref28 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref28 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref28 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref29 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref29 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref29 Template-based peptide modeling for celiac risk assessment of newly expressed proteins in GM crops 1 Introduction 2 Material and method 2.1 Characterization of the structure surrounding the peptide binding site in the HLA-DQ2/peptide/TCR complex 2.2 Software packages used for template-based peptide docking 2.3 HLA-DQ2/peptide/TCR complexes used for evaluation of peptide docking software 2.4 Peptides for testing 3 Results 3.1 Structure surrounding the peptide binding site in the HLA-DQ/peptide/TCR complex 3.2 Performance of the two peptide-docking software packages 3.3 Predicted binding models of various peptides using GalaxyPepDock 4 Discussion Funding statement Declaration of competing interest Appendix A Supplementary data References", "Funding": "Funding statement The research work presented in this manuscript received no funding from external sources outside Corteva AgriscienceTM, Inc. The research work presented in this manuscript received no funding from external sources outside Corteva AgriscienceTM, Inc. Declaration of competing interest Vartdal, F., Johansen, B.H., Friede, T., Thorpe, C.J., Stevanovi\ufffdc, S., Eriksen, J.E., Sletten, K., Thorsby, E., Rammensee, H.G., SollidLudvig, L.M., Sollid, M., 1996. The peptide binding motif of the disease associated HLA-DQ (\u03b11*0501, (\u03b2 1*0201) molecule. Eur. J. Immunol. 26, 2764\u20132772. Zhou, P., Jin, B., Li, H., Huang, S.Y., 2018. HPEPDOCK: a web server for bling peptide- protein docking based on a hierarchical algorithm. Nucleic Acids Res. 46, W443\u2013W450. P. Song et al. https://doi.org/10.1016/j.yrtph.2020.104715 https://doi.org/10.1016/j.yrtph.2020.104715 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref1 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref1 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref1 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref1 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref1 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref1 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref2 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref2 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref2 http://refhub.elsevier.com/S0273-2300(20)30141-0/optLqlfIbSX5i http://refhub.elsevier.com/S0273-2300(20)30141-0/optLqlfIbSX5i http://refhub.elsevier.com/S0273-2300(20)30141-0/sref3 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref3 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref3 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref3 http://refhub.elsevier.com/S0273-2300(20)30141-0/optl60MairRrZ http://refhub.elsevier.com/S0273-2300(20)30141-0/optl60MairRrZ http://refhub.elsevier.com/S0273-2300(20)30141-0/optl60MairRrZ http://refhub.elsevier.com/S0273-2300(20)30141-0/optl60MairRrZ http://refhub.elsevier.com/S0273-2300(20)30141-0/sref4 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref4 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref4 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref5 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref6 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref6 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref6 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref6 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref6 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref7 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref7 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref7 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref8 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref9 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref9 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref10 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref10 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref11 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref11 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref11 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref12 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref12 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref12 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref12 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref13 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref13 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref13 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref14 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref14 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref14 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref14 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref14 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref14 https://doi.org/10.17226/23395 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref16 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref16 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref16 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref16 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref16 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref17 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref17 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref17 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref17 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref18 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref18 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref18 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref18 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref19 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref19 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref19 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref20 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref20 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref20 https://doi.org/10.1007/s00251-019-01141-w https://doi.org/10.1007/s00251-019-01141-w http://refhub.elsevier.com/S0273-2300(20)30141-0/sref22 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref22 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref22 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref23 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref23 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref23 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref23 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref24 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref24 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref24 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref24 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref25 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref25 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref25 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref26 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref26 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref26 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref27 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref27 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref27 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref27 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref28 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref28 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref28 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref28 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref29 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref29 http://refhub.elsevier.com/S0273-2300(20)30141-0/sref29 Template-based peptide modeling for celiac risk assessment of newly expressed proteins in GM crops 1 Introduction 2 Material and method 2.1 Characterization of the structure surrounding the peptide binding site in the HLA-DQ2/peptide/TCR complex 2.2 Software packages used for template-based peptide docking 2.3 HLA-DQ2/peptide/TCR complexes used for evaluation of peptide docking software 2.4 Peptides for testing 3 Results 3.1 Structure surrounding the peptide binding site in the HLA-DQ/peptide/TCR complex 3.2 Performance of the two peptide-docking software packages 3.3 Predicted binding models of various peptides using GalaxyPepDock 4 Discussion Funding statement Declaration of competing interest Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Temporal-kinetics-of-organ-damage-in-copper-toxicit_2016_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27670080", "content": {"CoiStatement": "A conflict of interest On behalf of all authors, the corresponding author states that there is no conflicts of interest. On behalf of all authors, the corresponding author states that there is no conflicts of interest. Ethics approval 4. Discussion A conflict of interest Ethics approval Funding Acknowledgement: Transparency document Appendix A. Supplementary data References", "Funding": "Funding This work was funded by Intramural grant from the Sanjay Gandhi Post Graduate Medical Sciences, Lucknow, India (PGI/39/ 287) andMr. Vijay Kumar received a fellowship from Indian Council of Medical research, Government of India (ICMR-JRF, 3/1/3/JRF- 2009/MPD 31381). 4. Discussion A conflict of interest Ethics approval Funding Acknowledgement: Transparency document Appendix A. Supplementary data References", "Acknowledgement": "Acknowledgement: We gratefully acknowledge the help of Dr. G. Palit, Central Drug and Research Institute, Lucknow for providing facilities for neuro- behavioral studies and Dr. R.C. Murthy, Indian Institute of Toxi- cology Research, Lucknow for providing facilities for Cu estimation. 4. Discussion A conflict of interest Ethics approval Funding Acknowledgement: Transparency document Appendix A. Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Testing-REACH-draft-technical-guidance-notes-for-conduct_2008_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18479796", "content": {"Acknowledgement": "Acknowledgments The project is funded by the Norwegian Council of Research (Contract No. 176723/i40) (Innochem, 2006) and the Occupational Health Fund of the Norwegian Industry Association, as well as by the companies that participated. Acknowledgements are given to the persons developing the exposure scenarios in Dow, repre- sented by Mr. Jan Twisk, Global Industrial Hygiene Expertise Cen- ter/Global Regulatory Affairs Expertise Centre, Arbodienst Dow Benelux Nederland B.V., Dow Benelux (NV), and to three anony- mous reviewers for valuable input. The project is funded by the Norwegian Council of Research (Contract No. 176723/i40) (Innochem, 2006) and the Occupational Health Fund of the Norwegian Industry Association, as well as by the companies that participated. Acknowledgements are given to the persons developing the exposure scenarios in Dow, repre- sented by Mr. Jan Twisk, Global Industrial Hygiene Expertise Cen- ter/Global Regulatory Affairs Expertise Centre, Arbodienst Dow Benelux Nederland B.V., Dow Benelux (NV), and to three anony- mous reviewers for valuable input. References Conclusions Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Testing-Therapeutic-Potency-of-Anticancer-Drugs-_2002_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/12052010", "content": {"Acknowledgement": "3. Clear guidelines from regulatory authorities could prevent costly, useless animal experiments, costly clin- ical trials, and unnecessary suffering of cancer patients and animals. ACKNOWLEDGMENTS We thank GLAXO-Wellcome (Zeist, The Netherlands) for providing the old references on the old anticancer drugs and Dr. Jan-Willem Koten for editing the manuscript. COMPARISON OF THE THERAPEUTIC EFFECTS OF DRUGS ACCORDING TO THE PRECLINICAL EVALUATION AND ADMITTANCE TO THE MARKET WOULD WE HAVE DETECTED WELL-KNOWN CYTOSTATIC COMPOUNDS? FINAL REMARKS CONCLUSIONS ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Testing-developmental-toxicity-in-a-second-species--_2019_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31226390", "content": {"CoiStatement": "ICH, 2005. ICH Harmonized Tripartite Guideline: Detection of Toxicity to Reproduction for Medicinal Products & Toxicity to Male Fertility S5(R2. ICH, 2017. Draft ICH Harmonised Guideline: Detection of Toxicity to Reproduction for Human Pharmaceuticals S5. R3. IPCS, 2017. In: WHO (Ed.), Hazard Project document 11: guidance document on evalu- ating and expressing uncertaintyin hazard characterization. WHO, Switzerland. Janer, G., Slob, W., Hakkert, B.C., Vermeire, T., Piersma, A.H., 2008. A retrospective analysis of developmental toxicity studies in rat and rabbit: what is the added value of the rabbit as an additional test species? Regul. Toxicol. Pharmacol. 50, 206\u2013217. Knudsen, T.B., Martin, M.T., Kavlock, R.J., Judson, R.S., Dix, D.J., Singh, A.V., 2009. Profiling the activity of environmental chemicals in prenatal developmental toxicity studies using the U.S. EPA's ToxRefDB. Reprod. Toxicol. 28, 209\u2013219. OECD, 2001. Test No. 414: Prenatal Development Toxicity Study. OECD Publishing. Rovida, C., Hartung, T., 2009. Re-evaluation of animal numbers and costs for in vivo tests to accomplish REACH legislation requirements for chemicals - a report by the transatlantic think tank for toxicology (t(4)). ALTEX 26, 187\u2013208. Slob, W., 1994. Uncertainty analysis in multiplicative models. Risk Anal. 14. Slob, W., 2014. Benchmark dose and the three Rs. Part II. Consequences for study design and animal use. Crit. Rev. Toxicol. 44, 568\u2013580. Slob, W., Setzer, R.W., 2014. Shape and steepness of toxicological dose-response re- lationships of continuous endpoints. Crit. Rev. Toxicol. 44, 270\u2013297. Theunissen, P.T., Beken, S., Beyer, B., Breslin, W.J., Cappon, G.D., Chen, C.L., Chmielewski, G., De Schaepdrijver, L., Enright, B., Foreman, J.E., Harrouk, W., Hew, K.W., Hoberman, A.M., J, Y.H., Knudsen, T.B., Laffan, S.B., Makris, S.L., Martin, M., Mcnerney, M.E., Siezen, C.L., Stanislaus, D.J., Stewart, J., Thompson, K.E., Tornesi, B., Van Der laan, J.W., Weinbauer, G.F., Wood, S., Piersma, A.H., 2017. Comparing rat and rabbit embryo-fetal developmental toxicity data for 379 pharmaceuticals: on systemic dose and developmental effects. Crit. Rev. Toxicol. 47, 402\u2013414. Theunissen, P.T., Beken, S., Beyer, B.K., Breslin, W.J., Cappon, G.D., Chen, C.L., Chmielewski, G., DE Schaepdrijver, L., Enright, B., Foreman, J.E., Harrouk, W., Hew, K.W., Hoberman, A.M., Hui, J.Y., Knudsen, T.B., Laffan, S.B., Makris, S.L., Martin, M., Mcnerney, M.E., Siezen, C.L., Stanislaus, D.J., Stewart, J., Thompson, K.E., TORNESI, B., Van Der laan, J.W., Weinbauer, G.F., Wood, S., Piersma, A.H., 2016. Comparison of rat and rabbit embryo-fetal developmental toxicity data for 379 pharmaceuticals: on the nature and severity of developmental effects. Crit. Rev. Toxicol. 46, 900\u2013910. Theunissen, P.T., Beken, S., Cappon, G.D., Chen, C., Hoberman, A.M., Van Der Laan, J.W., Stewart, J., Piersma, A.H., 2014. Toward a comparative retrospective analysis of rat and rabbit developmental toxicity studies for pharmaceutical compounds. Reprod. Toxicol. 47, 27\u201332. Van Der Jagt, K., Munn, S., T\u00f6rsl\u00f6v, J., De Bruijn, J., 2004. Alternative approaches can reduce the use of test animals under Reach. In: Commission, E. (Ed.), European Commission Report. European Commission. H.M. Braakhuis, et al. Regulatory Toxicology and Pharmacology 107 (2019) 104410 10 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref1 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref1 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref1 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref2 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref2 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref3 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref3 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref3 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref3 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref4 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref4 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref4 https://doi.org/10.2903/j.efsa.2017.4658 https://doi.org/10.2903/j.efsa.2017.4658 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref5 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref5 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref5 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref6 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref6 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref7 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref7 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref8 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref8 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref9 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref9 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref9 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref10 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref10 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref10 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref11 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref12 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref12 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref12 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref13 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref14 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref14 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref15 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref15 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref16 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref16 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref16 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref16 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref16 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref16 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref16 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref18 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref18 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref18 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref18 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref19 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref19 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref19 Testing developmental toxicity in a second species: are the differences due to species or replication error? Introduction Methods Data sources Database characteristics Data analysis Results Difference between rat and rabbit, on average Compound-specific differences between rat and rabbit Discussion Declaration of interest Funding Declaration of interests Acknowledgements Supplementary data Annex. R-script for back-estimating possible interspecies differences. References", "Funding": "ICH, 2005. ICH Harmonized Tripartite Guideline: Detection of Toxicity to Reproduction for Medicinal Products & Toxicity to Male Fertility S5(R2. ICH, 2017. Draft ICH Harmonised Guideline: Detection of Toxicity to Reproduction for Human Pharmaceuticals S5. R3. IPCS, 2017. In: WHO (Ed.), Hazard Project document 11: guidance document on evalu- ating and expressing uncertaintyin hazard characterization. WHO, Switzerland. Janer, G., Slob, W., Hakkert, B.C., Vermeire, T., Piersma, A.H., 2008. A retrospective analysis of developmental toxicity studies in rat and rabbit: what is the added value of the rabbit as an additional test species? Regul. Toxicol. Pharmacol. 50, 206\u2013217. Knudsen, T.B., Martin, M.T., Kavlock, R.J., Judson, R.S., Dix, D.J., Singh, A.V., 2009. Profiling the activity of environmental chemicals in prenatal developmental toxicity studies using the U.S. EPA's ToxRefDB. Reprod. Toxicol. 28, 209\u2013219. OECD, 2001. Test No. 414: Prenatal Development Toxicity Study. OECD Publishing. Rovida, C., Hartung, T., 2009. Re-evaluation of animal numbers and costs for in vivo tests to accomplish REACH legislation requirements for chemicals - a report by the transatlantic think tank for toxicology (t(4)). ALTEX 26, 187\u2013208. Slob, W., 1994. Uncertainty analysis in multiplicative models. Risk Anal. 14. Slob, W., 2014. Benchmark dose and the three Rs. Part II. Consequences for study design and animal use. Crit. Rev. Toxicol. 44, 568\u2013580. Slob, W., Setzer, R.W., 2014. Shape and steepness of toxicological dose-response re- lationships of continuous endpoints. Crit. Rev. Toxicol. 44, 270\u2013297. Theunissen, P.T., Beken, S., Beyer, B., Breslin, W.J., Cappon, G.D., Chen, C.L., Chmielewski, G., De Schaepdrijver, L., Enright, B., Foreman, J.E., Harrouk, W., Hew, K.W., Hoberman, A.M., J, Y.H., Knudsen, T.B., Laffan, S.B., Makris, S.L., Martin, M., Mcnerney, M.E., Siezen, C.L., Stanislaus, D.J., Stewart, J., Thompson, K.E., Tornesi, B., Van Der laan, J.W., Weinbauer, G.F., Wood, S., Piersma, A.H., 2017. Comparing rat and rabbit embryo-fetal developmental toxicity data for 379 pharmaceuticals: on systemic dose and developmental effects. Crit. Rev. Toxicol. 47, 402\u2013414. Theunissen, P.T., Beken, S., Beyer, B.K., Breslin, W.J., Cappon, G.D., Chen, C.L., Chmielewski, G., DE Schaepdrijver, L., Enright, B., Foreman, J.E., Harrouk, W., Hew, K.W., Hoberman, A.M., Hui, J.Y., Knudsen, T.B., Laffan, S.B., Makris, S.L., Martin, M., Mcnerney, M.E., Siezen, C.L., Stanislaus, D.J., Stewart, J., Thompson, K.E., TORNESI, B., Van Der laan, J.W., Weinbauer, G.F., Wood, S., Piersma, A.H., 2016. Comparison of rat and rabbit embryo-fetal developmental toxicity data for 379 pharmaceuticals: on the nature and severity of developmental effects. Crit. Rev. Toxicol. 46, 900\u2013910. Theunissen, P.T., Beken, S., Cappon, G.D., Chen, C., Hoberman, A.M., Van Der Laan, J.W., Stewart, J., Piersma, A.H., 2014. Toward a comparative retrospective analysis of rat and rabbit developmental toxicity studies for pharmaceutical compounds. Reprod. Toxicol. 47, 27\u201332. Van Der Jagt, K., Munn, S., T\u00f6rsl\u00f6v, J., De Bruijn, J., 2004. Alternative approaches can reduce the use of test animals under Reach. In: Commission, E. (Ed.), European Commission Report. European Commission. H.M. Braakhuis, et al. Regulatory Toxicology and Pharmacology 107 (2019) 104410 10 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref1 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref1 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref1 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref2 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref2 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref3 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref3 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref3 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref3 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref4 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref4 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref4 https://doi.org/10.2903/j.efsa.2017.4658 https://doi.org/10.2903/j.efsa.2017.4658 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref5 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref5 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref5 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref6 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref6 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref7 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref7 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref8 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref8 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref9 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref9 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref9 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref10 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref10 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref10 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref11 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref12 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref12 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref12 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref13 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref14 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref14 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref15 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref15 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref16 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref16 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref16 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref16 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref16 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref16 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref16 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref18 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref18 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref18 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref18 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref19 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref19 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref19 Testing developmental toxicity in a second species: are the differences due to species or replication error? Introduction Methods Data sources Database characteristics Data analysis Results Difference between rat and rabbit, on average Compound-specific differences between rat and rabbit Discussion Declaration of interest Funding Declaration of interests Acknowledgements Supplementary data Annex. R-script for back-estimating possible interspecies differences. References", "Acknowledgement": "ICH, 2005. ICH Harmonized Tripartite Guideline: Detection of Toxicity to Reproduction for Medicinal Products & Toxicity to Male Fertility S5(R2. ICH, 2017. Draft ICH Harmonised Guideline: Detection of Toxicity to Reproduction for Human Pharmaceuticals S5. R3. IPCS, 2017. In: WHO (Ed.), Hazard Project document 11: guidance document on evalu- ating and expressing uncertaintyin hazard characterization. WHO, Switzerland. Janer, G., Slob, W., Hakkert, B.C., Vermeire, T., Piersma, A.H., 2008. A retrospective analysis of developmental toxicity studies in rat and rabbit: what is the added value of the rabbit as an additional test species? Regul. Toxicol. Pharmacol. 50, 206\u2013217. Knudsen, T.B., Martin, M.T., Kavlock, R.J., Judson, R.S., Dix, D.J., Singh, A.V., 2009. Profiling the activity of environmental chemicals in prenatal developmental toxicity studies using the U.S. EPA's ToxRefDB. Reprod. Toxicol. 28, 209\u2013219. OECD, 2001. Test No. 414: Prenatal Development Toxicity Study. OECD Publishing. Rovida, C., Hartung, T., 2009. Re-evaluation of animal numbers and costs for in vivo tests to accomplish REACH legislation requirements for chemicals - a report by the transatlantic think tank for toxicology (t(4)). ALTEX 26, 187\u2013208. Slob, W., 1994. Uncertainty analysis in multiplicative models. Risk Anal. 14. Slob, W., 2014. Benchmark dose and the three Rs. Part II. Consequences for study design and animal use. Crit. Rev. Toxicol. 44, 568\u2013580. Slob, W., Setzer, R.W., 2014. Shape and steepness of toxicological dose-response re- lationships of continuous endpoints. Crit. Rev. Toxicol. 44, 270\u2013297. Theunissen, P.T., Beken, S., Beyer, B., Breslin, W.J., Cappon, G.D., Chen, C.L., Chmielewski, G., De Schaepdrijver, L., Enright, B., Foreman, J.E., Harrouk, W., Hew, K.W., Hoberman, A.M., J, Y.H., Knudsen, T.B., Laffan, S.B., Makris, S.L., Martin, M., Mcnerney, M.E., Siezen, C.L., Stanislaus, D.J., Stewart, J., Thompson, K.E., Tornesi, B., Van Der laan, J.W., Weinbauer, G.F., Wood, S., Piersma, A.H., 2017. Comparing rat and rabbit embryo-fetal developmental toxicity data for 379 pharmaceuticals: on systemic dose and developmental effects. Crit. Rev. Toxicol. 47, 402\u2013414. Theunissen, P.T., Beken, S., Beyer, B.K., Breslin, W.J., Cappon, G.D., Chen, C.L., Chmielewski, G., DE Schaepdrijver, L., Enright, B., Foreman, J.E., Harrouk, W., Hew, K.W., Hoberman, A.M., Hui, J.Y., Knudsen, T.B., Laffan, S.B., Makris, S.L., Martin, M., Mcnerney, M.E., Siezen, C.L., Stanislaus, D.J., Stewart, J., Thompson, K.E., TORNESI, B., Van Der laan, J.W., Weinbauer, G.F., Wood, S., Piersma, A.H., 2016. Comparison of rat and rabbit embryo-fetal developmental toxicity data for 379 pharmaceuticals: on the nature and severity of developmental effects. Crit. Rev. Toxicol. 46, 900\u2013910. Theunissen, P.T., Beken, S., Cappon, G.D., Chen, C., Hoberman, A.M., Van Der Laan, J.W., Stewart, J., Piersma, A.H., 2014. Toward a comparative retrospective analysis of rat and rabbit developmental toxicity studies for pharmaceutical compounds. Reprod. Toxicol. 47, 27\u201332. Van Der Jagt, K., Munn, S., T\u00f6rsl\u00f6v, J., De Bruijn, J., 2004. Alternative approaches can reduce the use of test animals under Reach. In: Commission, E. (Ed.), European Commission Report. European Commission. H.M. Braakhuis, et al. Regulatory Toxicology and Pharmacology 107 (2019) 104410 10 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref1 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref1 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref1 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref2 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref2 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref3 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref3 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref3 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref3 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref4 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref4 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref4 https://doi.org/10.2903/j.efsa.2017.4658 https://doi.org/10.2903/j.efsa.2017.4658 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref5 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref5 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref5 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref6 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref6 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref7 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref7 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref8 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref8 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref9 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref9 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref9 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref10 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref10 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref10 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref11 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref12 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref12 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref12 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref13 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref14 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref14 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref15 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref15 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref16 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref16 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref16 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref16 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref16 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref16 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref16 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref17 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref18 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref18 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref18 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref18 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref19 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref19 http://refhub.elsevier.com/S0273-2300(19)30174-6/sref19 Testing developmental toxicity in a second species: are the differences due to species or replication error? Introduction Methods Data sources Database characteristics Data analysis Results Difference between rat and rabbit, on average Compound-specific differences between rat and rabbit Discussion Declaration of interest Funding Declaration of interests Acknowledgements Supplementary data Annex. R-script for back-estimating possible interspecies differences. References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Testing-in-artificial-sweat---Is-less-more--Compariso_2016_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27664322", "content": {"Compliance with ethical standards": "In conclusion, our results illustrate that a bio-elution test in EN1811 artificial sweat at stagnant conditions can serve its purpose in providing information on the bioaccessible amount of metal that potentially can deposit onto skin. Tests to determine compliance with regulations, and experimental data for risk assessment pur- poses may even benefit from a simpler test procedure that can eliminate potential experimental errors and bias in results. When skin exposure to metals is the study end point, the actual amount of metal that is deposited on skin can be measured directly by, for example, acid wipe sampling technique (Lid\ufffden et al., 2006). The measure of themetal skin dose in context of skin exposure and skin as the target organ for sensitizing metals is in this case advanta- geous over release tests in sweat models. 4. Conclusion The results of metal release from a white gold alloy and some hard metal materials are found to be within the same range after immersion in two different artificial sweat solutions; a compre- hensive sweat model intended for use within research, and the EN1811 artificial sweat solution intended for testing compliance with the nickel restriction in REACH. The endpoint for study of skin exposure to metals is decisive for the experimental design. If direct measurements of metal skin doses or metal absorption are not possible, the metal release in artificial sweat can provide in vitro data on the bioaccessible metal at simulated skin contact. From this study we conclude that a bio- elution test using a simple artificial sweat compositionmay provide results that sufficiently indicate the degree of metal release at skin contact. Less is more, it seems.", "Acknowledgement": "Acknowledgements The authors would like to acknowledge Karin Holm at Stock- holm University for the help with metal analysis. Dr Aleksandr Stefaniak is acknowledged for valuable discussions regarding the laboratory procedure of mixing the comprehensive sweat model with a low vitamin formula. 3. Results and discussion 4. Conclusion Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Testing-strategies-for-embryo-fetal-toxicity-of-human-_2012_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22449444", "content": {"CoiStatement": "Conflict of interest statement Jan Willem van der Laan, Aldert Piersma and Abigail Jacobs de- clare not having a conflict of interest. Bob Chapin is employed by Pfizer, Inc, and Bert Haenen by 3D-PharmXchange. No other con- flicts of interest to be mentioned. Jan Willem van der Laan, Aldert Piersma and Abigail Jacobs de- clare not having a conflict of interest. Bob Chapin is employed by Pfizer, Inc, and Bert Haenen by 3D-PharmXchange. No other con- flicts of interest to be mentioned. Acknowledgments 5 Discussion on further steps Conflict of interest statement Acknowledgments References", "Acknowledgement": "Acknowledgments The authors, program committee of the DIA workshop held in Leiden, wish to thank Beth Donley (Stemina) and Mary Ellen Mcnerney (BMS) for their contributions to this report. 5 Discussion on further steps Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Testing-the-coherence-between-occupational-exposure-limits_2014_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24852492", "content": {"CoiStatement": "Conflict of interest The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Appendix A. Supplementary data Conflict of interest Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Testing-the-validity-of-a-proposed-dermal-cancer_2021_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33359623", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 4 Discussion Funding body information CRediT authorship contribution statement Declaration of competing interest Appendix A Supplementary data References", "Funding": "Funding body information Support for preparation of the manuscript was provided by Arcadis U.S., Inc., the Pavement Coatings Treatment Council, and the American Petroleum Institute. The study sponsors provided editorial comments on the manuscript and participated in the decision to publish the manuscript. 4 Discussion Funding body information CRediT authorship contribution statement Declaration of competing interest Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Testosterone-stimulated-weanlings-as-an-alternative-t_2004_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15041151", "content": {"Acknowledgement": "It is suggested that the present data place the TP- stimulated weanling assay in a position for formal val- idation as an alternative to the Hershberger assay; with the goal of reducing the stressful surgical procedures on the test animals while retaining assay sensitivity. Acknowledgments We thank Dr. Robert Combes of FRAME (Fund for the Replacement of Animals in Medical Experiments) for helpful advice during the course of these studies. References Discussion Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Tetrahydrofuran-induced-tumors-in-rodents-are-not-relevant-t_2019_Regulatory.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31626827", "content": {"CoiStatement": "Tetrahydrofuran-induced tumors in rodents are not relevant to humans_ Quantitative weight of evidence analysis of mode of action information does not support classification of tetrahydrofuran as a possible human carcinogen conflict of interest statement. No competing professional and financial interests. Declaration of competing interest Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper.", "Funding": "Discussion and conclusions Funding body statement mk:H1_18 Acknowledgement Supplementary data References", "Acknowledgement": "Acknowledgement Preparation of this review was supported in part through an hon- orarium to Dr. Dekant from the Tetrahydrofuran Task Force. This re- view represents the individual professional view of the author and not necessarily the views of the Tetrahydrofuran Task Force. The sponsor was not involved in selecting the approach for data evaluation, conduct of the evaluation, and writing of the manuscript. Discussion and conclusions Funding body statement mk:H1_18 Acknowledgement Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-21st-Century-movement-within-the-area-of-skin-sensit_2019_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31430506", "content": {"CoiStatement": "Hazard and potency assessments for skin sensitizers Discussion Conflicts of interest Funding body information References", "Funding": "Hazard and potency assessments for skin sensitizers Discussion Conflicts of interest Funding body information References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-3T3-neutral-red-uptake-phototoxicity-test--Practical_2012_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22687423", "content": {"CoiStatement": "Conflict of interest statement The authors declare that there are no conflict of interest. The authors declare that there are no conflict of interest. References 9 View point from regulators 10 Conclusions Conflict of interest statement References Glossary"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-ADME-profile-of-the-fungicide-tricyclazole-in-roden_2019_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31461669", "content": {"CoiStatement": "Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Dr Corvaro is an employee of Dow Agrociences. Dr. Bartels reports and Dr. Bartels is a former employee of DowDupont (parent company of Dow AgroSciences) and currently a paid consultant for Dow AgroSciences. Funding body information Declaration of interests Funding body information Acknowledgements Supplementary data References", "Funding": "Funding body information This work summaries regulatory studies conducted for the regis- tration of the fungicide tricyclazole, supported by the manufacturer, Dow AgroSciences, under project number 10002533. Declaration of interests Funding body information Acknowledgements Supplementary data References", "Acknowledgement": "Acknowledgements The authors would like to thank Claire Terry for the internal peer- review, Jyotigna Mehta for the scientific conversations, and Mary Challender for the editorial review. Declaration of interests Funding body information Acknowledgements Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/The-Botanical-Safety-Consortium--A-public-private-p_2022_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34863907", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The Botanical Safety Consortium: A public-private partnership to enhance the botanical safety toolkit 1 Introduction 2 Formation and Structure of the Botanical Safety Consortium 3 Strategy 4 Initial steps \u2013 botanical case studies 5 Future steps - assay and approach selection and evaluation 6 Conclusions Cynthia RiderediT authorship contribution statement Declaration of competing interest Acknowledgments References", "Acknowledgement": "Acknowledgments This work was supported in part by the Health and Environmental Sciences Institute Botanical Safety Consortium. It is recognized via a Memorandum of Understanding between the US FDA, NIEHS, and HESI (MOU 225-19-032) that outlines joint commitments to a multisector and multidisciplinary Botanical Safety Consortium. We acknowledge the committee members for their support and helpful feedback on devel- opment of this document. This work is supported by U.S. Food and Drug Administration (FDA); Office of Dietary Supplement Programs and Department of Health and Human Services (HHS); National Institute of Environmental Health Sciences (NIEHS); Division of the National Toxicology Program, Office of Liaison, Policy, and Review; and Health and Environmental Sciences Institute (HESI) via Department of the Interior (DOI) Federal Consulting Group (FCG) under Blanket Purchase Agreement Order 140D0421F0068. This work is also supported in part by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences, Intramural Research project ZIA ES103316-04. The Botanical Safety Consortium: A public-private partnership to enhance the botanical safety toolkit 1 Introduction 2 Formation and Structure of the Botanical Safety Consortium 3 Strategy 4 Initial steps \u2013 botanical case studies 5 Future steps - assay and approach selection and evaluation 6 Conclusions CRediT authorship contribution statement Declaration of competing interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-Costly-Illusion-of-Regulating-Unknow_2001_Regulatory-Toxicology-and-Phar.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/11754525", "content": {"Compliance with ethical standards": "210 GIO BATTA GORI If truth be told, the protection of health, safety, and the environment is no longer the principal goal of the regulatory enterprise, which is often used to restrain international and internal competition. Real and espe- cially imaginary risks are essential to the finances and political clout of the advocacy fringes manning the bar- ricades of class warfare. They inflame public anxieties that build political careers and that fund public agen- cies at the tune of billions of dollars. Legions of regu- lators are mirrored by layers of employment that the regulated industries need to support compliance. Am- biguous statutes and rules empower armies of lawyers, and secure the fortunes of a litigious tort bar. A vast complex of secondary industries toil to execute regula- tory mandates. Supranational agencies coordinate, har- monize, and settle disputes. The careers of millions de- pend on a regulatory Leviathan that has secured for itself not only the power of the law but also that of a gar- gantuan and ominous incumbency. The system provides an anxious public with the comforting illusion that risks are being looked after, while buried in the small print is EPA\u2019s single scrupulous admission that it cannot war- rant that some of its most significant and costly actions are either beneficial or harmful. It might seem quixotic if not dangerous to mount a cri- tique of such a massive enterprise, for it is not an imag- inary windmill and it is positively touchy, aware as it is of its feet of clay. Indeed it would seem wishful think- ing, if it were not for the courts, and signs of momen- tous advances in judicial philosophy. A series of rulings over the past decade began a transformation of what scientific evidence may be admissible at trial, meaning that expert opinion unsupported by credible data from controlled experiments may no longer do. The Supreme Court\u2019s ruling in Daubert v. Merrell Dow of 1993 was followed in 1999 by Kumho v. Carmichael. The rulings essentially supplant the relaxed Frie rule that allowed almost anything when it came to an expert\u2019s opinion. The new prescriptions ask for scientific reliability, and although they need further clarification, the rulings are a major step forward, signaling a radical distinction of independently proven or provable facts versus unsup- ported opinion."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-Dermal-Sensitisation-Threshold-A-TTC-approac_2008_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18406502", "content": {"Acknowledgement": "Acknowledgments The author would like to thank Hannah Bauling for collating the data sets used in this analysis and Nora Aptula, Catherine Clapp, Namali Corea, Carol Courage, Ian Jowsey, Grace Patlewicz and Carl Westmorland for reviewing the manuscript. Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/The-Dilemma-of-perfluorooctanoate--PFOA--h_2021_Regulatory-Toxicology-and-Ph.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34400261", "content": {"CoiStatement": "Appendix Fig. 1. Average volume of distribution (Vd) in liters with weekly dose in mg(developed from Elcombe et al. (2013). References Campbell, J., Allen, B., Olsen, G., Elcombe, C., Doyle, E., Evans, J., Clewell, H., 2016. Evaluation of the short-term clearance of perflourooctanoic acid (PFOA) in a clinical trial using a PBPK model and Markov chain Monte Carlo analysis. In: Poster at the Society of Toxicology Annual Meeting. Alliance for Risk Assessment (ARA), 2021a. Beyond Science and Decisions Workshop XII. Meeting report in preparation. To be available at: https://tera.org/Alliance%20for% 20Risk/ARA_Dose-Response.htm. Alliance for Risk Assessment (ARA), 2021b. Harvey harvey presentation. Beyond science and Decisions. In: WorkshopXII. February 24 & 25. Available at: https://tera.or g/Alliance%20for%20Risk/ARA_Dose-Response.htm. Agency for Toxic Substances and Disease Registry (ATSDR), 2013. Exposure Investigation Report - Perfluorochemical Serum Sampling in the Vicinity of Decatur, AL, Morgan, Lawrence, and Limestone Counties. Division of Community Health Investigation. https://www.atsdr.cdc.gov/hac/pha/Decatur/Perfluorochemical_Se rum%20Sampling.pdf. Balk, F.G.P., Puetz, K.W., Ribbenstedt, A., Gomis, M.I., Filipovic, M., Cousins, I.T., 2019. Children\u2019s exposure to perfluoroalkyl acids\u2014a modelling approach. Environ Sci Process Impacts 21, 1875\u20131886. Bartell, S., 2012. Bias in half-life estimates using log concentration regression in the presence of background exposures, and potential solutions. J. Expo. Sci. Environ. Epidemiol. 22, 299\u2013303, 2012. Bartell, S.M., Calafat, A.M., Lyu, C., Kato, K., Ryan, P.B., Steenland, K., 2010. Rate of decline in serum PFOA concentrations after granular activated carbon filtration at two public water systems in Ohio and West Virginia. Environ. Health Perspect. 118 (2), 222\u2013228. https://doi.org/10.1289/ehp.0901252. PMID: 20123620. Brede, E., Wilhelm, M., Go\u0308en, T., M\u00fcller, J., Rauchfuss, K., Kraft, M., et al., 2010. Two- year follow-up biomonitoring pilot study of residents\u2019 and controls\u2019 PFC plasma levels after PFOA reduction in public water system in Arnsberg, Germany. Int. J. Hyg Environ. Health 213 (3), 217\u2013223. https://doi.org/10.1016/j.ijheh.2010.03.007. PMID: 20488749. Convertino, M., Church, T.R., Olsen, G.W., Liu, Y., Doyle, E., Elcombe, C.R., Barnett, A.L., Samuel, L.M., MacPherson, I.R., Evans, T.R., 2018. Stochastic pharmacokinetic- pharmacodynamic modeling for assessing the systemic health risk of perfluorooctanoate (PFOA). Toxicol. Sci. 163 (1), 293\u2013306. De Silva, Amila O., Armitage, James M., Bruton, Thomas A., Dassuncao, Clifton, Heiger- Bernays, Wendy, Hu, Xindi C., Anna, Ka\u0308rrman, Kelly, Barry, Ng, Carla, Anna, Robuck, Sun, Mei, Webster, Thomas F., Sunderland, Elsie M., 2020. PFAS exposure pathways for humans and wildlife: a synthesis of current knowledge and key gaps in understanding. Environ. Toxicol. Chem. https://doi.org/10.1002/ etc.4935. Dourson, Michael L., Gadagbui, Bernard, Onyema, Chijioke, McGinnis, Patricia M., York, Raymond G., 2019. Data derived Extrapolation Factors for developmental toxicity: a preliminary research case study with perfluorooctanoate (PFOA). Regul. Toxicol. Pharmacol. 108, 104446. Drinking Water Inspectorate, 2021. Guidance on the Water Supply (Water Quality) Regulations 20161 specific to PFOS (perfluorooctane sulphonate) and PFOA (perfluorooctanoic acid) concentrations in drinking water. London, UK. Elcombe, C.R., Wolf, C.R., Westwood, A.L., 2013. US Patent Application Publication. Pub. No.: US 2013/0029928. Available at: https://patentimages.storage.googleapis. com/24/ee/73/f58267c7d70dde/WO2011101643A1.pdf. Emmett, E.A., Shofer, F.S., Zhang, H., Freeman, D., Desai, C., Shaw, L.M., 2006. Community exposure to perfluorooctanoate: relationships between serum concentrations and exposure sources. J. Occup. Environ. Med. 48 (8), 759\u2013770. Fromme, H., Tittlemier, S.A., Vo\u0308lkel, W., Wilhelm, M., Twardella, D., 2009. Perfluorinated compounds\u2014exposure assessment for the general population in western countries. Int. J. Hyg Environ. Health 212, 239\u2013270. Gebbink, W.A., Berger, U., Cousins, I.T., 2015. Estimating human exposure to PFOS isomers and PFCA homologues: the relative importance of direct and indirect (precursor) exposure. Environ. Int. 74, 160\u2013169. Gleason, J.A., Cooper, K.R., Klotz, J.B., Post, G.B., Van Orden, G., 2017. Health-based Maximum Contaminant Level Support Document: Perfluorooctanoic Acid (PFOA) \u2013 Appendix New Jersey Drinking Water Quality Institute. Health Effects Subcommittee. Cited in Gormis et al. Gomis, M.I., Vestergren, R., Nilsson, H., Cousins, I.T., 2016. Contribution of direct and indirect exposure to human serum concentrations of perfluorooctanoic acid in an occupationally exposed group of ski waxers. Environ. Sci. Technol. 50 (13), 7037\u20137046. Gomis, M.I., Vestergren, R., MacLeod, M., Mueller, J.F., Cousins, I.T., 2017. Historical human exposure to perfluoroalkyl acids in the United States and Australia reconstructed from biomonitoring data using population-based pharmacokinetic modelling. Environ. Int. 108, 92\u2013102. https://doi.org/10.1016/j. envint.2017.08.002. Harrad, S., Wemken, N., Drage, D.S., Abdallah, M.A.E., Coggins, A.M., 2019. Perfluoroalkyl substances in drinking water, indoor air and dust from Ireland: implications for human exposure. Environ. Sci. Technol. 53, 13449\u201313457. https:// doi.org/10.1021/acs.est.9b04604. Haug, L.S., Huber, S., Bechera, G., Thomsen, C., 2011. Characterisation of human exposure pathways to perfluorinated compounds - comparing exposure estimates with biomarkers of exposure. Environ. Int. 37 (4), 687\u2013693. https://doi.org/ 10.1016/j.envint.2011.01.011. Health Canada, 2018. Guidelines for Canadian Drinking Water Quality: Guideline Technical Document \u2014 Perfluorooctanoic Acid (PFOA). Water and Air Quality Bureau, Healthy Environments and Consumer Safety Branch. Health Canada, Ottawa, Ontario (Catalogue No. H144-13/8-2018E-PDF). Available at: https://p ublications.gc.ca/collections/collection_2018/sc-hc/H144-13-8-2018-eng.pdf. IPCS (International Programme on Chemical Safety), 2005. Chemical-specific Adjustment Factors for Interspecies Differences and Human Variability: Guidance Document for Use of Data in Dose/concentration-Response Assessment. Geneva Switzerland. https://apps.who.int/iris/bitstream/handle/10665/43294/924154678 6_eng.pdf;jsessionid=B768CD63C4F93BC4F2388483532665D6?sequence=1. Li, Y., Fletcher, T., Mucs, D., Scott, K., Lindh, C.H., Tallving, P., et al., 2018. Half-lives of PFOS, PFHxS and PFOA after end of exposure to contaminated drinking water. Occup. Environ. Med. 75 (1), 46\u201351. https://doi.org/10.1136/oemed-2017-104651. PMID: 29133598. Lorber, M., Egeghy, P.P., 2011. Simple intake and pharmacokinetic modeling to characterize exposure of Americans to perfluoroctanoic acid, PFOA. Environ. Sci. Technol. 45, 8006\u20138014. https://doi.org/10.1021/es103718h. Lou, I., Wambaugh, J.F., Lau, C., Hanson, R.G., Lindstrom, A.B., Strynar, M.J., Zehr, R.D., Setzer, R.W., Barton, H.A., 2009. Modeling single and repeated dose pharmacokinetics of PFOA in mice. Toxicol. Sci. 107 (2), 331\u2013341. Loveless, S.E., Finlay, C., Everds, N.E., Frame, S.R., Gillies, P.J., O\u2019Connor, J.C., et al., 2006. Comparative responses of rats and mice exposed to linear/branched, linear, or branched ammonium perfluorooctanoate (APFO). Toxicology 220 (2\u20133), 203\u2013217. https://doi.org/10.1016/j.tox.2006.01.003. Mikkonen, Antti T., Martin, Jennifer, Dourson, Michael L., Hinwood, Andrea, Johnson, Mark S., 2020. Suggestions for improving the characterisation of risk from exposures to per and polyfluorinated alkyl substances (PFAS). Environ. Toxicol. Chem. 2021, 1\u201316. https://doi.org/10.1002/etc.4931, 01. Olsen, G.W., Burris, J.M., Ehresman, D.J., Froehlich, J.W., Seacat, A.M., Butenhoff, J.L., et al., 2007. Half- life of serum elimination of perfluorooctanesulfonate, M. Dourson and B. Gadagbui http://refhub.elsevier.com/S0273-2300(21)00166-5/sref1 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref1 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref1 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref1 https://tera.org/Alliance%20for%20Risk/ARA_Dose-Response.htm https://tera.org/Alliance%20for%20Risk/ARA_Dose-Response.htm https://tera.org/Alliance%20for%20Risk/ARA_Dose-Response.htm https://tera.org/Alliance%20for%20Risk/ARA_Dose-Response.htm https://www.atsdr.cdc.gov/hac/pha/Decatur/Perfluorochemical_Serum%20Sampling.pdf https://www.atsdr.cdc.gov/hac/pha/Decatur/Perfluorochemical_Serum%20Sampling.pdf http://refhub.elsevier.com/S0273-2300(21)00166-5/sref6 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref6 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref6 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref7 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref7 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref7 https://doi.org/10.1289/ehp.0901252 https://doi.org/10.1016/j.ijheh.2010.03.007 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref11 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref11 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref11 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref11 https://doi.org/10.1002/etc.4935 https://doi.org/10.1002/etc.4935 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref13 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref13 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref13 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref13 http://refhub.elsevier.com/S0273-2300(21)00166-5/optA83sms1blj http://refhub.elsevier.com/S0273-2300(21)00166-5/optA83sms1blj http://refhub.elsevier.com/S0273-2300(21)00166-5/optA83sms1blj https://patentimages.storage.googleapis.com/24/ee/73/f58267c7d70dde/WO2011101643A1.pdf https://patentimages.storage.googleapis.com/24/ee/73/f58267c7d70dde/WO2011101643A1.pdf http://refhub.elsevier.com/S0273-2300(21)00166-5/sref15 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref15 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref15 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref16 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref16 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref16 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref17 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref17 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref17 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref18 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref18 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref18 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref18 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref19 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref19 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref19 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref19 https://doi.org/10.1016/j.envint.2017.08.002 https://doi.org/10.1016/j.envint.2017.08.002 https://doi.org/10.1021/acs.est.9b04604 https://doi.org/10.1021/acs.est.9b04604 https://doi.org/10.1016/j.envint.2011.01.011 https://doi.org/10.1016/j.envint.2011.01.011 https://publications.gc.ca/collections/collection_2018/sc-hc/H144-13-8-2018-eng.pdf https://publications.gc.ca/collections/collection_2018/sc-hc/H144-13-8-2018-eng.pdf https://apps.who.int/iris/bitstream/handle/10665/43294/9241546786_eng.pdf;jsessionid=B768CD63C4F93BC4F2388483532665D6?sequence=1 https://apps.who.int/iris/bitstream/handle/10665/43294/9241546786_eng.pdf;jsessionid=B768CD63C4F93BC4F2388483532665D6?sequence=1 https://doi.org/10.1136/oemed-2017-104651 https://doi.org/10.1021/es103718h http://refhub.elsevier.com/S0273-2300(21)00166-5/sref27 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref27 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref27 https://doi.org/10.1016/j.tox.2006.01.003 https://doi.org/10.1002/etc.4931 Regulatory Toxicology and Pharmacology 126 (2021) 105025 14 perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ. Health Perspect. 115 (9), 1298\u20131305. https://doi.org/ 10.1289/ehp.10009. PMID: 17805419. Pizzurro, D.M., Seeley, M., Kerper, L.E., Beck, B.D., 2019. Interspecies differences in perfluoroalkyl substances (PFAS) toxicokinetics and application to health-based criteria. Regul. Toxicol. Pharmacol. 106, 239\u2013250. Poothong, S., Papadopoulou, E., Padilla-Sa\u0301nchez, J.A., Thomsen, C., Haug, L.S., 2020. Multiple pathways of human exposure to poly- and perfluoroalkyl substances (PFASs): from external exposure to human blood. Environ. Int. 134, 105244. https:// doi.org/10.1016/j.envint.2019.105244. Russell, M.H., Waterland, R.L., Wong, F., 2015. Calculation of chemical elimination halflife from blood with an ongoing exposure source: the example of perfluorooctanoic acid (PFOA). Chemosphere 129, 210\u2013216. https://doi.org/ 10.1016/j.chemosphere.2014.07.061. PMID: 25149361. Schultes, L., Vestergren, R., Volkova, K., Westberg, E., Jacobson, T., Benskin, J.P., 2018. Per- and polyfluoroalkyl substances and fluorine mass balance in cosmetic products from the Swedish market: implications for environmental emissions and human exposure. Environ Sci-Process Impacts 20, 1680\u20131690. https://doi.org/10.1039/ c8em00368h. Seals, R., Bartell, S.M., Steenland, K., 2011. Accumulation and clearance of perfluorooctanoic acid (PFOA) in current and former residents of an exposed community. Environ. Health Perspect. 119 (1), 119\u2013124. Shin, H., Vieira, V., Ryan, P., Detwiler, R., Sanders, B., Steenland, K., Bartell, S., 2011a. Environmental fate and transport modeling for perfluorooctanoic acid emitted from the Washington Works Facility in West Virginia. Environ. Sci. Technol. 45, 1435\u20131442. Shin, H.M., Vieira, V.M., Ryan, P.B., Steenland, K., Bartell, S.M., 2011b. Retrospective exposure estimation and predicted versus observed serum perfluorooctanoic acid concentrations for participants in the C8 Health Project. Environ. Health Perspect. 119, 1760\u20131765. https://doi.org/10.1289/ehp.1103729. Thompson, J., Lorber, M., Toms, L.M.L., Kato, K., Calafat, A.M., Mueller, J.F., 2010. Use of simple pharmacokinetic modeling to characterize exposure of Australians to perfluorooctanoic acid and perfluorooctane sulfonic acid. Environ. Int. 36, 390\u2013397. Tittlemier, S.A., Pepper, K., Seymour, C., Moisey, J., Bronson, R., Cao, X.L., Dabeka, R. W., 2007. Dietary exposure of Canadians to perfluorinated carboxylates and perfluorooctane sulfonate via consump[1]tion of meat, fish, fast foods, and food items prepared in their packaging. J. Agric. Food Chem. 55, 3203\u20133210. Trudel, D., Horowitz, L., Wormuth, M., Scheringer, M., Cousins, I.T., Hungerbuhler, K., 2008. Estimating consumer exposure to PFOS and PFOA. Risk Anal. 28, 251\u2013269. United States Environmental Protection Agency (U.S. EPA), 2014. Guidance for Applying Quantitative Data to Develop Data-Derived Extrapolation Factors for Interspecies and Intraspecies Extrapolation. EPA/100/R-14/002F. September. https://www.epa. gov/sites/production/files/2015-01/documents/ddef-final.pdf. United States Environmental Protection Agency (U.S. EPA), 2016. Health Effects Support Document for Perfluorooctanoic Acid (PFOA). EPA 822-R-16-003. Office of Water (4304T) Health and Ecological Criteria Division Washington, DC 20460. May 2016. https://www.epa.gov/sites/production/files/2016-05/documents/pfoa_hesd_finalpl ain.pdf. U.S. Environmental Protection Agency (U.S. EPA), 2021. Human Health Toxicity Values for Perfluorobutane Sulfonic Acid and Related Compound Potassium Perfluorobutane Sulfonate. Washington, DC, EPA/600/R-20/345F. Vestergren, R., Cousins, I.T., 2009. Tracking the pathways of human exposure to perfluorocarboxylates. Environ. Sci. Technol. 43, 5565\u20135575. Vestergren, R., Berger, U., Glynn, A., Cousins, I.T., 2012. Dietary exposure to perfluoroalkyl acids for the Swedish population in 1999, 2005 and 2010. Environ. Int. 49, 120\u2013127. Cited in Gormis et al. (2017). Worley, R.R., Moore, S.M., Tierney, B.C., Ye, X., Calafat, A.M., Campbell, S., et al., 2017. Perand polyfluoroalkyl substances in human serum and urine samples from a residentially exposed community. Environ. Int. 106, 135\u2013143. https://doi.org/ 10.1016/j.envint.2017.06.007. PMID: 28645013. Xu, Y., Fletcher, T., Pineda, D., Lindh, C.H., Nilsson, C., Glynn, A., Vogs, C., Norstro\u0308m, K., Lilja, K., Jakobsson, K., Li, Y., 2020. Serum half-lives for short- and long-chain perfluoroalkyl acids after ceasing exposure from drinking water contaminated by firefighting foam. Environ. Health Perspect. 28, 7. https://doi.org/10.1289/ EHP6785. CID: 077004. Yeung, L.W.Y., Robinson, S.J., Koschorreck, J., Mabury, S.A., 2013a. Part I. A temporal study of PFCAs and their precursors in human plasma from two German cities 1982\u20132009. Environ. Sci. Technol. 47, 3865\u20133874. Yeung, L.W.Y., Robinson, S.J., Koschorreck, J., Mabury, S.A., 2013b. Part II. A temporal study of PFOS and its precursors in human plasma from two German cities in 1982\u20132009. Environ. Sci. Technol. 47, 3875\u20133882. Zhang, Y., Beesoon, S., Zhu, L., Martin, J.W., 2013. Biomonitoring of perfluoroalkyl acids in human urine and estimates of biological half-life. Environ. Sci. Technol. 47 (18), 10619\u201310627. https://doi.org/10.1021/es401905e. PMID: 23980546. M. Dourson and B. Gadagbui https://doi.org/10.1289/ehp.10009 https://doi.org/10.1289/ehp.10009 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref31 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref31 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref31 https://doi.org/10.1016/j.envint.2019.105244 https://doi.org/10.1016/j.envint.2019.105244 https://doi.org/10.1016/j.chemosphere.2014.07.061 https://doi.org/10.1016/j.chemosphere.2014.07.061 https://doi.org/10.1039/c8em00368h https://doi.org/10.1039/c8em00368h http://refhub.elsevier.com/S0273-2300(21)00166-5/sref35 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref35 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref35 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref36 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref36 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref36 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref36 https://doi.org/10.1289/ehp.1103729 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref38 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref38 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref38 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref39 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref39 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref39 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref39 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref40 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref40 https://www.epa.gov/sites/production/files/2015-01/documents/ddef-final.pdf https://www.epa.gov/sites/production/files/2015-01/documents/ddef-final.pdf https://www.epa.gov/sites/production/files/2016-05/documents/pfoa_hesd_finalplain.pdf https://www.epa.gov/sites/production/files/2016-05/documents/pfoa_hesd_finalplain.pdf http://refhub.elsevier.com/S0273-2300(21)00166-5/sref43 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref43 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref43 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref44 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref44 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref45 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref45 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref45 https://doi.org/10.1016/j.envint.2017.06.007 https://doi.org/10.1016/j.envint.2017.06.007 https://doi.org/10.1289/EHP6785 https://doi.org/10.1289/EHP6785 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref48 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref48 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref48 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref49 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref49 http://refhub.elsevier.com/S0273-2300(21)00166-5/sref49 https://doi.org/10.1021/es401905e The Dilemma of perfluorooctanoate (PFOA) human half-life 1 Introduction 2 Methods 3 Results 3.1 Relevant exposure information 3.2 Human observational studies of PFOA half life 3.3 Human clinical findings 3.4 Integration of findings 4 Discussion 5 Conclusion CRediT authorship contribution statement Declaration of competing interest Appendix References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-Effect-of-Different-Tumor-Groupings-on-Findings-o_2002_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/12460748", "content": {"Acknowledgement": "ACKNOWLEDGMENTS We are grateful to the staff of NIEHS for making the CBDS data available to us (in 1986 and 1989) and to Dr. Haseman for the crit- icisms of our earlier work that prompted this paper. This work was partially funded by grants from the Elsa U. Pardee Foundation, Pfizer Inc., and Zeneca Inc. APPENDIX APPENDIX\u2014Continued ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-Effects-of-Atrazine-on-the-Sexual-Matura_2002_Regulatory-Toxicology-and-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/12202059", "content": {"Acknowledgement": "ACKNOWLEDGMENT We are grateful to I. Pate for all statistical analyses. DISCUSSION ACKNOWLEDGMENT REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-Evolution-of-SEND-at-AstraZenec_2021_Regulatory-Toxicology-and-Pharmacol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33974947", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The Evolution of SEND at AstraZeneca 1 Introduction 2 Regulatory submission impact 3 SEND data fitness 4 Current and future data visualisation perspective 5 Ongoing SEND development Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgements References", "Funding": "Funding This work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. CRediT authorship contribution statement The Evolution of SEND at AstraZeneca 1 Introduction 2 Regulatory submission impact 3 SEND data fitness 4 Current and future data visualisation perspective 5 Ongoing SEND development Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgements References", "Acknowledgement": "Acknowledgements The authors gratefully acknowledge input from Joanne Phillips, Giles Ratcliffe, Shaun Maguire, Lindsey Schofield and other members of the AZ SEND Project Team. The Evolution of SEND at AstraZeneca 1 Introduction 2 Regulatory submission impact 3 SEND data fitness 4 Current and future data visualisation perspective 5 Ongoing SEND development Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-FQPA--A-Challenge-for-Science-Policy-and-_2000_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/10915584", "content": {"Disclosure": "FQPA is a potentially data-rich statute. It empha- sizes data about use, residues on food and the full range of exposures to retain tolerances. Apparently, the law is inadequate to bring about the availability and reporting of such data. As Dr. Starr pointed out, even EPA\u2019s models depend on the size of the supporting data sets. EPA has yet to define relevant exposure data. EPA has not asked, and the stakeholders have not told. In the past 3 years, FQPA has not successfully forced the definition of \u201cnecessary\u201d data, caused EPA or registrants to gather the data, caused third parties to come forward with data, protected submitters from onerous requirements, protected those who voluntarily have come forward with data from the disclosure of sensitive data, nor provided assurances that EPA will use the data. EPA has not asked about actual harm. We cannot know everything and we cannot know what we do not know to ask. Yet, our actual knowledge about pesti- cides has increased dramatically. This information shows safety of pesticides and lack of exposure to them. The standards in the law are \u201creasonable certainty of no harm\u201d and \u201cno unreasonable adverse effects.\u201d \u201cRea- sonable\u201d does not require or even contemplate zero risk. The concept of reasonableness is well-steeped in common law. It means that the burden of avoidance outweighs the risk of harm and, thus, requires a bal- ancing of risk and burden. In this context, the burden is the loss of products necessary to maintain a health- ful and abundant food supply.", "Acknowledgement": "ACKNOWLEDGMENTS ISTRP and CAST thank the following contributors: AgrEvo U.S.A. Company; American Bar Association, Section of Natural Resources, Energy, and Environmental Law; American Crop Protection Associ- ation; American Cyanamid Company, Ag Products Research Divi- sion; Bayer Corporation; Dow AgroSciences; Farm Foundation; Gowan Company; Monsanto Company; Novartis Crop Protection; Valent U.S.A. Corporation; Zeneca Inc. SESSION ONE: THE FOOD QUALITY PROTECTION ACT OF 1996 (FQPA) SESSION TWO: HAZARD EVALUATION UNDER FQPA AND THE EXTRA 10-FOLD SAFETY FACTOR SESSION THREE: DIETARY EXPOSURE ASSESSMENT UNDER FQPA SESSION FOUR: CUMULATIVE RISK AND COMMON MECHANISM OF ACTION SESSION FIVE: CLINTON ADMINISTRATION POLICY ABOUT FQPA SESSION SIX: AGRICULTURAL, INTERNATIONAL, AND LEGAL IMPACTS OF FQPA ACKNOWLEDGMENTS"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-French-approach-to-deriving-toxicity-reference_2009_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19703506", "content": {"CoiStatement": "Methodological developments should focus, first and foremost, on the definition of the critical dose. They should include the def- inition and standardisation of toxicology protocols suited to estab- lishing TRVs (especially TRVs based on reprotoxic effects). Rules for determining a BMD should be outlined and allometric and tempo- ral adjustments taken into account. Thus, to address the issue of the critical dose better, we need to analyse and exploit data more efficiently. This would probably lead to a reduction in uncertainty factor values. Conflict of interest statement The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgments Discussion Conclusion Conflict of interest statement Acknowledgments References", "Acknowledgement": "Acknowledgments The work described in this article was coordinated by AFSSET. The authors thank all the members of the workgroup and the ex- pert committee on \u2018\u2018Assessing the risks associated with chemical substances\u201d, whose advice was key to the success of this project. The French Ministry of Health funded this work, as part of the Na- tional Health and Environment Action Plan. Discussion Conclusion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-Grouping-and-Assessment-Strategy-for-Organic-Pigme_2019_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31629781", "content": {"Funding": "Conclusions Funding mk:H1_31 Acknowledgements Supplementary data References", "Compliance with ethical standards": "Bercaru, O., 2019. Taking action to ensure compliance. Presentation by ECHA at: safer chemicals - ECHA conference. 22 may 2019. https://echa.europa.eu/documents/ 10162/27594883/03_bercaru.pdf/3e12c71a-dbd0-3250-8541-7a99a7e8027f. Bevan, R.J., Kreiling, R., Levy, L.S., Warheit, D.B., 2018. Toxicity testing of poorly soluble particles, lung overload and lung cancer. Regul. Toxicol. Pharmacol. 100, 80\u201391.", "Acknowledgement": "Conclusions Funding mk:H1_31 Acknowledgements Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-High-Production-Volume-Chemical-Challenge-Progr_2000_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/10854124", "content": {"Acknowledgement": "Williams, G. M. (1980). Batteries of short-term tests for carcinogen Zeiger, E., Ashby, J., Bakale, G., Enslein, K., Klopman, G., and 189RELEVANCE OF IN VIVO MICRONUCLEASE ASSAY screening. In The Predictive Value of Short-Term Screening Tests in Carcinogenicity Valuation. (G. M. Williams et al., (Eds.), pp. 327\u2013346. Elsevier/North Holland, Amsterdam. Yamasaki, H. (1996). Role of disrupted gap junctional intercellular communication in detection and characterization of carcinogens. Mutat. Res. 365, 91\u2013105. Yamasaki, H., Mesnil, M., Omori, Y., Mironov, N., and Krutovskikh, V. (1995). Intercellular communication and carcinogenesis. Mutat. Res. 333, 181\u2013188. Yang, W.-L., Klopman, G., and Rosenkranz, H. S. (1992). Structural basis of the in vivo induction of micronuclei. Mutat. Res. 272, 111\u2013124. Rosenkranz, H. S. (1996). Prediction of Salmonella mutagenicity. Mutagenesis 11, 471\u2013484. Zhang, Y. P., van Praagh, A., Klopman, G., and Rosenkranz, H. S. (1994). Structural basis of the induction of unscheduled DNA synthesis in rat hepatocytes. Mutagenesis 9, 141\u2013149. Zhang, Y. P., Sussman, N., Macina, O. T., Rosenkranz, H. S., and Klopman, G. (1996). Prediction of the carcinogenicity of a second group of chemicals undergoing carcinogenicity testing. Environ. Hlth. Perspect. 104, Suppl. 5: 1045\u20131050. Zhu, X., Klopman, G., and Rosenkranz, H. S. (1999). Evaluating the cytotoxicity of 181 chemicals to HeLa cells using SAR expert sys- tem. The Toxicologist 48, 373. INTRODUCTION MATERIALS AND METHODS RESULTS AND DISCUSSION TABLE 1 TABLE 2 TABLE 3 ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-Isolated-Chicken-Eye-test-to-replace-the-_2017_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28192172", "content": {"CoiStatement": "3. 2D or 3D human corneal epithelium reconstruction models, which have as major disadvantage the lack of the different membranes of the cornea, corneal stroma and corneal endothelium. Conflict of interest statement The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Transparency document 4. ICE OECD test guideline 438 5. Lessons learned and considerations 6. Conclusions Conflict of interest statement Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-JRC-Nanomaterials-Repository--A-unique-facility-p_2016_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27670079", "content": {"Compliance with ethical standards": "Currently, there are apparently only few documents detailing how the handling of NMs should be done in order to ensure a high level of safety for the operator(s)/workers, as well as for the envi- ronment (NIOSH 2012, ISO12901, EC 2014]. Projects such as the EU- funded NanoValid have also addressed this topic (Baron et al., 2015). The JRC Nanomaterials Repository has been set up in compliance with the highest standards of safety for both the operators and the environment. A series of measures have been put in place to eliminate the operator (and environmental) exposure. If elimina- tionwas not possible, then the risk of exposure has been reduced to a negligible level. The preventivemeasures adoptedwere guided by good health and safety practices, common sense and precaution, with considerations from a risk assessment perspective. The possible \u201chazardousness\u201d of the materials is intrinsic and, thus, any Table 1 List of representative NMs hosted in the JRC Nanomaterials Repository (starred [*] NMs are the batches used also in the OECDWPMN Testing Programme). Detailed list available at: https://ec.europa.eu/jrc/sites/default/files/JRC%20Nanomaterials% 20Repository-List%20of%20Representative%20Nanomaterials-201606.pdf. JRC ID Substance JRC ID Substance JRCNM01001a * Titanium Dioxide JRCNM04000a * MWCNTs JRCNM01005a * JRCNM04001a * JRCNM10202a JRCNM04002a * JRCNM10200a JRCNM04003a * JRCNM62001a JRCNM40001a JRCNM62002a JRCNM40002a JRCNM02101a * Cerium Dioxide JRCNM40003a JRCNM01101a * Zinc Oxide JRCNM40004a JRCNM62101a JRCNM40005a JRCNM06000a * Nanoclay JRCNM40006a JRCNM03300a Au dispersion JRCNM40007a JRCPD03301a Au dispersant JRCNM40008a JRCNM02000a * Silicon Dioxide JRCNM40009a JRCNM02001a * JRCNM40010a JRCNM02002a * JRCNM46000a SWCNT JRCNM02004a * JRCNM48001a graphene JRCNM10404a S. Totaro et al. / Regulatory Toxicology and Pharmacology 81 (2016) 334e340338 risk reduction can only be achieved acting on the exposure and reducing it to the lowest level possible. Moreover, in the absence of precise guidelines/regulations, given the large amount of NMs that are handled and the uncertainty still associated to the toxicological effects of many NMs, a strict control of exposure was applied without any discrimination of the type of NM actually handled. The laboratory is equipped with state-of-the-art glove boxes, explicitly designed for the treatment of nanoscale powders, i.e. including two HEPA filters working in cascade with wet traps and glove bags (see section 2.2.3 for further details), as also recom- mended by NIOSH (NIOSH, 2012). Regarding the personnel safety and the reduction of exposure, the ALARA principle (as low as reasonably achievable) has been implemented in the design of both the facility and the working procedures. In practice, through the whole workflow, the nano- materials are treated in such a way that there is no direct contact between the powder and the laboratory atmosphere. The operators involved in any stage of the process are regularly trained on risks and hazards related to a laboratory environment and specifically to NMs. The use of Personal Protective Equipment (PPE) is mandatory and depends on the operation to be carried out. For example, during Phase 1, which as explained is the one where large amount of NMs are handled, and therefore there is the highest risk for the operator, disposable laboratory complete coverall (Tyvek), nitrile gloves, full facial masks with filters, lab-dedicated protective shoes and covers are normally worn. During Phase 2 and during the preparation of the shipment, disposable laboratory coats (Tyvek), gloves (nitrile), masks (disposable masks FFFrancesca Pianella3), protective shoes and safety goggles are used. As described in detail in previous sections 2.2.1 and 2.2.2, the most relevant measure put in place to contain accidental spills into the environment (to reduce environmental exposure) is the establishment of a pressure gradient within the JRC Repository and to the environment. This helps keeping the different areas of the repository separated, avoiding cross-contamination between the different rooms of the facility. Furthermore, as an accidental contamination from NMs might take place in the facility, specific decontamination measures have been planned at any point in the workflow, for which operators are duly trained. A complete safety cleaning set for intervention is available in the rooms, and for example, the laboratory is equipped with a HEPA-filtered vacuum cleaner and dedicated washing material (mobs, etc.). Finally, the level of particulate matter in the laboratory atmo- sphere is constantly monitored using a portable Condensation Particle Counter (CPC, TSI). Any sudden increase of airborne parti- cles during each step of the workflow can be tracked, thus allowing corrective measures to be taken almost immediately. The evalua- tion of background particulate matter is still under discussion. Indeed, any operator movement, even if not directly involving the handling of powders, might generate alterations in the 'background level' of airborne particulate matter. This level is furthermore highly dependent on the atmospheric conditions (season, weather, wind etc.). Thus, in order to have good benchmark background data, an on-going sampling campaign was started once the labo- ratory was operational to register and evaluate the overall trend of the background level, both in presence and absence of operators, and with or without on-going operator movement. 3. Hosted nanomaterials The nanomaterials that are included in the Repository are either industrial, commercially available NMs that have been supplied to JRC directly by the producers, or are supplied via projects for which they have been synthesized or supplied by industry. They are representative of a portion of the 'nanomaterial' market across Europe, and beyond. The intended uses of these NMs are, according to the suppliers, varied and range from cosmetics to food additives, from photo catalytic materials to chemical polishing and to fuel additives. Most of them have been tested in the OECD WPMN Testing Programme (mentioned above) and many research projects, both EU-funded, such as ENPRA, MARINA, NANoREG and NANOGENTOX, as well as national (e.g. Austrian, Norwegian, USA, German and Singaporean projects) and industry-led initiatives (e.g. BASF, Uni- lever) have been supported by the JRC Repository supplying them the test materials. The wide distribution of NMs from JRC to the scientific com- munity led to a thorough physico-chemical characterisation of those NMs. The main results have been included in JRC Scientific Reports (Singh et al., 2011; 2014; Rasmussen et al., 2013, 2014a, 2014b). In addition to these reports, the testing activities per- formed under the umbrella of the OECD Testing Programme have enabled the publication of the OECD dossiers (see OECD website, OECD, 2007). The list of nanomaterials included in and available from the JRC Repository can be found in Table 1. More detailed information about their physico-chemical characteristics can be found at the JRC Nanomaterials Repository website (Repository URL https://ec. europa.eu/jrc/en/scientific-tool/jrc-nanomaterials-repository). Some vials remaining from the batches used for the OECD Testing Programme are still available (and indicated in Table 1 with a star). Once older batches of materials (e.g. those used during the OECD Testing Programme) are depleted, they are substituted, where possible, with new ones that are obtained from the same producer. The new batches of materials are subjected to a basic characterisation in the JRC laboratories. Normally, to have the ma- terials available for customers, size and particle size distribution (electron microscopy), centrifuge liquid sedimentation, crystallite size and crystalline phase are determined, with themain purpose of confirming (with in relation to the specifications declared by the supplier) their size. If relevant, other properties can be investi- gated/confirmed, e.g. hydrophobicity with Raman spectroscopy. The NMs currently hosted belong to 7 different classes of chemistry and these are: TiO2, SiO2, CeO2, ZnO, Au, Nanoclay and C- based materials (Multi Wall Carbon Nanotubes e MWCNT, Single Wall Carbon Nanotubes e SWCNT, Graphene). Some of these ma- terials are coated, but most are not. The JRC representative https://ec.europa.eu/jrc/en/scientific-tool/jrc-nanomaterials-repository https://ec.europa.eu/jrc/en/scientific-tool/jrc-nanomaterials-repository https://ec.europa.eu/jrc/sites/default/files/JRC%20Nanomaterials%20Repository-List%20of%20Representative%20Nanomaterials-201606.pdf https://ec.europa.eu/jrc/sites/default/files/JRC%20Nanomaterials%20Repository-List%20of%20Representative%20Nanomaterials-201606.pdf S. Totaro et al. / Regulatory Toxicology and Pharmacology 81 (2016) 334e340 339 nanomaterials have also been thoroughly tested for (eco) toxico- logical endpoints by the scientific community and Farcal et al., 2015, Peijnenburg et al., 2015, Van der Zande et al., 2014, Louro et al., 2014 are just some examples of such work. Each chemistry class is represented by different types of NMs, which differ in one or more of their characteristics. Normally, each class is composed of NMs that not only have a different particle size, but also differ in other physico-chemical properties, such as surface functionalization (coating or not) or type of crystallinity. For some of the classes, the 'non-nano' size material (according to the EC Recommendation on the definition of nanomaterial, EC, 2011/696/ EU) is also available. This allows for a better comparability and evaluation of possible nano-size effects for a given endpoint. For example, 7 different types of TiO2 are available, with size ranging roughly from 5e6 to 115 nm nm (Rasmussen et al., 2014b and Repository URL). Furthermore, different crystalline phases are available: pure anatase or rutile, or a mix of both. Due to their low stability, the JRC Repository no longer stores NMs in suspension, but, as mentioned also in section 2.2.1, it is equipped to properly handle them and, if needed, to subsample them automatically. 4. Representative test materials as benchmark materials for the harmonisation of test methods Roebben et al. defined representative test materials as follows: \u201cRepresentative Test Material (RTM) is a material from a single batch, which is sufficiently homogeneous and stable with respect to one or more specified properties, and which implicitly is assumed to be fit for its intended use in the development of test methods which target properties other than the properties for which homogeneity and sta- bility have been demonstrated\u201d (Roebben et al., 2013). Since each set of subsampled RTM originates from the same batch, all the subsamples can, in principle, be assumed to be identical. The NMs can therefore serve as international benchmarks with the aim of fostering the harmonisation in nanoEHS assess- ment, by creating a common and unique nanomaterial source for all stakeholders. RTMs are assumed to be sufficiently stable and homogeneous with respect to one or more specified properties. They are expected to be fit for their intended use in the development of test methods that target properties other than the properties for which homo- geneity and stability have been demonstrated (Roebben et al., 2013). The NMs hosted in the JRC Nanomaterials Repository represent the first collection of thoroughly characterised NMs available for benchmarking in research and regulatory studies. Indeed, due to the considerable amount of resources and time needed to produce Reference Materials (RMs) and Certified RMs (CRMs), only few,, nano-sized (C)RMs have been produced so far (e.g. by NISara Totaroand JRC). In this framework, RTMs can actually act as benchmark materials to enable pre-normative work and to develop new (updated) tests, thus promoting faster innovation. It has been shown for instance that when starting from powder NMs, themethod used to create a liquid-based dispersion influences toxicity outcomes. Therefore, the harmonisation of methods e in this particular case of the dispersionprotocolewould allowa better consistency in the generation of data. There is still a considerable harmonisation gap here, since the laboratories performing testing on NMs tend to adhere to their in-house procedures applied to facilitate their own intra-lab comparability, but not facilitating suf- ficiently the inter-lab comparability. This practice is however counterbalanced by regulatory requirements, where the needs of harmonisationandstandardisationareofparamount importance for the e.g. evaluation of the repeatability and comparability of results. In recent years and based on the above considerations, several projects have attempted to harmonise as much as possible the dispersion protocols, thus setting a first baseline to ensure the comparability of data. The same approach has been also followed by OECD, where a long process of evaluation of the available regulatory test guide- lines (TGs) started, with the aim of understanding to which extent these TGs, developed for the regulatory testing of chemicals in general, would be applicable to NMs. The experimental part of this evaluationmade use of the NMs provided by the JRC Repository and has resulted in the OECD Test Guidelines Programme working on nano-specific adaptation of some OECD TGs, for example Guide- lines for Inhalation Toxicity and a number of the environmental end-points. H. Krug (Krug, 2014) stated: \u201cthe unification of criteria and standardisation of methods are absolutely necessary in order that we arrive at a situation where investigations may be effectively compared and provide reliable data\u201d. The on-going harmonisation of test methods for NMs is thus essential to allow the comparability of research results. Furthermore, the applicability and acceptance of OECD TGs for nanomaterials is essential in a global regulatory context, and the investigation of this has been supported by the material supply from the JRC Nanomaterials Repository. In addition, the use of RTMs as control substances in performing nanotoxicity-related experiments would allow the creation of more and better sets of comparable data. Such experimental results in (regulatory) research are the basis to build and consolidate the nanoEHS knowledge. 5. Conclusions The Joint Research Centre of the European Commission hosts a Repository for representative nanomaterials. This is a unique fa- cility that serves the European and global scientific community active in the nanoEHS (regulatory) research well. The JRC Nanomaterials repository is a unique facility providing state-of the-art design and equipment for sub-sampling of indus- trial nanomaterials under the safest possible conditions, with traceable final samples distributed world-wide for research pur- poses. This paper provides information on considerations and ac- tions undertaken by the JRC to guarantee the safety of the operators of the JRC Repository, and environmental protection, during each NM handling phase. The Paper also describes the automation of the subsampling procedure, which offers an unrivalled degree of flex- ibility and precision in the preparation of NM vials for customers. The JRC nanomaterials are representative for part of the world NM market. Given the scarcity of (certified) reference nano- materials on the market, the possibility for the scientific commu- nity to use well-characterised NMs is of utmost importance for the generation of comparable and reliable experimental results and datasets in support to regulatory research. The publication of the physical chemical properties of these materials (ref EUR reports) is an important support to the further use of these materials. The further development and use of the RTMs could eventually lead to the generation of additional scientific results of high quality that can help to consolidate the nano-related knowledge with the ultimate and very important purpose of supporting regulation. Transparency document Transparency document related to this article can be found online at http://dx.doi.org/10.1016/j.yrtph.2016.08.008. References Baron, M., et al., 2015. Safe Handling of Nanomaterials and Other Advanced Materials at Workplaces e Final Product of the Project NanoValid available http://dx.doi.org/10.1016/j.yrtph.2016.08.008 S. Totaro et al. / Regulatory Toxicology and Pharmacology 81 (2016) 334e340340 at: URL: http://www.nanovalid.eu/nanoToGo/Brochure/Safe%20handling%20of %20nanomaterials%20and%20other%20advanced%20materials%20at%20workplaces_ v1-0.pdf. EC 2011/696/EU. Commission Recommendation on the definition of nanomaterial e 2011/696/EU. Official Journal of the European Union. L275/38e40. EC, 2014. European Commission e Working Safely with Manufactured Nano- materials e Guidance for Workers e 2014. Available at: URL: ec.europa.eu/so- cial/BlobServlet?docId\u00bc13088&langId\u00bcen. ECHA, 2016. Usage of (eco)toxicological data for bridging data gaps between and grouping of nanoforms of the same substance. Elem. consider. http://dx.doi.org/ 10.2823/982046. Available at: URL: https://echa.europa.eu/documents/10162/ 13630/eco_toxicological_for_bridging_grouping_nanoforms_en.pdf. Farcal, L., Torres, F.A., Di Cristo, L., Rotoli, B.M., Bussolati, O., Bergamaschi, E., Mech, A., Hartmann, N.B., Rasmussen, K., Riego-Sintes, J., Ponti, J., Kinsner- Ovaskainen, A., Rossi, F., Omen, A., Bos, P., Chen, R., Bai, R., Chen, C., Rocks, L., Fulton, N., Ross, B., Hutchinson, G., Tran, L., Mues, S., Ossig, R., Schnekenburger, J., Campagnolo, L., Pietroiusti, A., Fadel, B., 2015. Comprehen- sive In vitro toxicity testing of a panel of representative oxide nanomaterials: first steps towards an intelligent testing strategy. PLOS One. http://dx.doi.org/ 10.1371/journal.pone.0127174. Gottardo, S., Quiros Pesudo, L., Totaro, S., Riego Sintes, J., Crutzen, H., 2016. NANo- REG Harmonised Terminology for Environmental Health and Safety Assessment of Nanomaterials. http://dx.doi.org/10.2788/71213. European Commission. EUR 27808. ISO 12901. ISO/TS 12901-1 and 12901-2. Nanotechnologies e Occupational risk management applied to engineered nanomaterials e Part1: principle and ap- proaches e Part 2: Use of the control banding approach. Krug, H., 2014. Nanosafety research e are we on the right track? Angew. Chem. Int. Ed. 53, 2e18. http://dx.doi.org/10.1002/anie.201403367. Louro, H., Tavares, A., Vital, N., Costa, P.M., Alverca, E., Zwart, E., de Jong, W.H., Fessard,V., Lavinha, J., Silva,M.J., 2014. Integratedapproach to the invivogenotoxic effects of a titanium dioxide nanomaterial using LacZ plasmid-based transgenic mice. Environ. Mol. Mutagen 55, 500e509. http://dx.doi.org/10.1002/em.21864. NIOSH, 2012. General Safe Practive for Working with Engineered Nanomaterials in Research Laboratories. National Institute for Occupational Safety and Health (NIOSH). DHHS(NIOSH) Publication No. 2012e147. OECD, 2007. OECD Testing Programme of Manufactured Nanomaterials available at: URL: http://www.oecd.org/chemicalsafety/nanosafety/dossiers-and-endpoints- testing-programme-manufactured-nanomaterials.htm. Peijnenburg, W.J.G.M., Baalousha, M., Chen, J., Chaudry, Q., Von der Kammer, F., Kuhlbusch, T.A.J., Lead, J., Nickel, C., Quik, J.T.K., Renker, M., Wang, Z., Koelmans, A.A., 2015. A review of the properties and processes determining the fate of engineered nanomaterials in the aquatic environment. Crit. Rev. Environ. Sci. Technol. 45, 2084e2134. http://dx.doi.org/10.1080/10643389.2015.1010430. Rasmussen, K., Mech, A., Mast, J., de Temmerman, P.-J., Waegeneers, N., Van Steen, F., Pizzolon, J.C., de Temmerman, L., Van Doren, E., Jensen, K.A., Birkedal, R., Levin, M., Nielsen, S.H., Koponen, I.K., Clausen, P.A., Kembouche, Y., Thieriet, N., Spalla, O., Guiot, C., Rousset, D., Witschger, O., Bau, S., Bianchi, B., Shivachev, B., Gilliland, D., Pianella, F., Ceccone, G., Cotogno, G., Rauscher, H., Gibson, N., Stamm, H., EUR-Scientific and Technical Research Reports, 2013. Synthetic Amorphous Silicon Dioxide (NM-200, NM-201, NM-202, NM-203, NM-204): Characterisation and Physico-chemical Properties. Available at: URL: http://publications.jrc.ec.europa.eu/repository/handle/JRC83506. Rasmussen, K., Mast, J., De Temmerman, P.-.J., Verleysen, E., Waegeneers, N., Van Steen, F., Pizzolon, J.C., De Temmerman, L., Van Doren, E., Jensen, K.A., Birkedal, R., Clausen, P.A., Kembouche, Y., Thieriet, N., Spalla, O., Giuot, C., Rousset, D., Witschger, O., Bau, S., Bianchi, B., Shivachev, B., Dimowa, L., Nikolova, R., Nihtianova, D., Tarassov, M., Petrov, O., Bakardjieva, S., Motzkus, C., Labarraque, G., Oster, C., Cotogno, G., Gaillard, C., 2014a. EUR e Scientific and Technical Research Reports e 2014 e Multi-walled Carbon Nanotubes, NM-400, NM-401, NM-402, NM-403: Characterisation and Physico-chemical Properties. Available at: URL: http://publications.jrc.ec.europa.eu/repository/handle/ JRC91205. Rasmussen, K., Mast, J., De Temmerman, P.J., Verleysen, E., Waegeneers, N., Van Steen, F., Pizzolon, J.C., De Temmerman, L., Van Doren, E., Jensen, K., Birkedal, R., Levin, M., Nielsen, S.H., Koponen, I.K., Clausen, P.A., Kofoed-S\u00f8rensen, V., Kembouche, Y., Thieriet, N., Spalla, O., Giuot, C., Rousset, D., Witschger, O., Bau, S., Bianchi, B., Motzkus, C., Shivachev, B., Dimowa, L., Nikolova, R., Nihtianova, D., Tarassov, M., Petrov, O., Bakardjieva, S., Gilliland, D., Pianella, F., Ceccone, G., Spampinato, V., Cotogno, G., Gibson, P., Gaillard, C., Mech, A., 2014b. EUR e Scientific and Technical Research Reports e Titanium Dioxide, NM-100, NM-101, NM-102, NM-103, NM-104, NM-105: Characterisation and Physico- chemical Properties. http://publications.jrc.ec.europa.eu/repository/handle/ JRC86291. Rasmussen, K., Gonzalez, M., Kearns, P., Riego Sintes, J., Rossi, F., Sayre, P., 2016. Review of achievements of the OECD working party on manufactured nano- materials' testing and assessment programme. From exploratory testing to test guidelines. Regul. Toxicol. Pharmacol. 74, 147e160. http://dx.doi.org/10.1016/ j.yrtph.2015.11.004. Repository URL https://ec.europa.eu/jrc/en/scientific-tool/jrc-nanomaterials- repository. Roebben, G., Rasmussen, K., Kestens, V., Linsinger, T.P.-J., Rauscher, H., Emons, H., Stamm, H., 2013. Reference materials and representative test materials: the nanotechnology case. J. Nanopart. Res. 15, 1455. http://dx.doi.org/10.1007/ s11051-013-1455-2. Singh, C., Friedrich, S., Levin, M., Birkedal, R., Jensen, K.A., Pojana, G., Wohllben, W., Schulte, S., Wiench, K., Tuney, T., Koulaeva, D., Mashall, D., Hund-Rinke, K., Koeredl, W., Van Doren, E., De Temmerman, P.-J., Abi Daoud, F., Mast, J., Gibson, P., Koeber, R., Linsinger, T., Kelin, C., 2011. EUR e Scientific and Technical Reports eM-series of Representative Manufactured Nanomaterials - Zinc Oxide NM-110, NM-111, NM-112, NM-113: Characterisation and Test Item Preparation. Available at: URL: http://publications.jrc.ec.europa.eu/repository/handle/ JRC64075. Singh, C., Friedrich, S., Ceccone, G., Gibson, P., Jensen, K.A., Levin, M., Goenaga, H.I., Carlander, D., Rasmussen, K., 2014. EUR e Scientific and Technical Research Reports e 2014 e Cerium Dioxide, NM-211, NM-212, NM-213. Characterisation and Test Item Preparation. Available at: URL: http://publications.jrc.ec.europa. eu/repository/handle/JRC89825. Van der Zande, M., Vandebriel, R.J., Groot, M.J., Kramer, E., Rivera, Z.E.H., Rasmussen, K., Ossenkoppele, J.S., Tromp, P., Gremmer, E.R., Peters, R.J.B., Hendriksen, P.J., Marvin, H.J.P., Hoogenboom, R.L.A.P., Peijnenburg, A.A.C.M., Bouwmeester, H., 2014. Sub-chronic toxicity study in rats orally exposed to nanostructured silica. Part. Fibre Toxicol. http://dx.doi.org/10.1186/1743-8977- 11-8. http://www.nanovalid.eu/nanoToGo/Brochure/Safe%20handling%20of%20nanomaterials%20and%20other%20advanced%20materials%20at%20workplaces_v1-0.pdf http://www.nanovalid.eu/nanoToGo/Brochure/Safe%20handling%20of%20nanomaterials%20and%20other%20advanced%20materials%20at%20workplaces_v1-0.pdf http://www.nanovalid.eu/nanoToGo/Brochure/Safe%20handling%20of%20nanomaterials%20and%20other%20advanced%20materials%20at%20workplaces_v1-0.pdf http://refhub.elsevier.com/S0273-2300(16)30229-X/sref3 http://refhub.elsevier.com/S0273-2300(16)30229-X/sref3 http://refhub.elsevier.com/S0273-2300(16)30229-X/sref3 http://refhub.elsevier.com/S0273-2300(16)30229-X/sref3 http://refhub.elsevier.com/S0273-2300(16)30229-X/sref3 http://refhub.elsevier.com/S0273-2300(16)30229-X/sref3 http://refhub.elsevier.com/S0273-2300(16)30229-X/sref3 http://refhub.elsevier.com/S0273-2300(16)30229-X/sref3 http://refhub.elsevier.com/S0273-2300(16)30229-X/sref3 http://dx.doi.org/10.2823/982046 http://dx.doi.org/10.2823/982046 https://echa.europa.eu/documents/10162/13630/eco_toxicological_for_bridging_grouping_nanoforms_en.pdf https://echa.europa.eu/documents/10162/13630/eco_toxicological_for_bridging_grouping_nanoforms_en.pdf http://dx.doi.org/10.1371/journal.pone.0127174 http://dx.doi.org/10.1371/journal.pone.0127174 http://dx.doi.org/10.2788/71213 http://dx.doi.org/10.1002/anie.201403367 http://dx.doi.org/10.1002/em.21864 http://refhub.elsevier.com/S0273-2300(16)30229-X/sref10 http://refhub.elsevier.com/S0273-2300(16)30229-X/sref10 http://refhub.elsevier.com/S0273-2300(16)30229-X/sref10 http://refhub.elsevier.com/S0273-2300(16)30229-X/sref10 http://www.oecd.org/chemicalsafety/nanosafety/dossiers-and-endpoints-testing-programme-manufactured-nanomaterials.htm http://www.oecd.org/chemicalsafety/nanosafety/dossiers-and-endpoints-testing-programme-manufactured-nanomaterials.htm http://dx.doi.org/10.1080/10643389.2015.1010430 http://publications.jrc.ec.europa.eu/repository/handle/JRC83506 http://publications.jrc.ec.europa.eu/repository/handle/JRC91205 http://publications.jrc.ec.europa.eu/repository/handle/JRC91205 http://publications.jrc.ec.europa.eu/repository/handle/JRC86291 http://publications.jrc.ec.europa.eu/repository/handle/JRC86291 http://dx.doi.org/10.1016/j.yrtph.2015.11.004 http://dx.doi.org/10.1016/j.yrtph.2015.11.004 https://ec.europa.eu/jrc/en/scientific-tool/jrc-nanomaterials-repository https://ec.europa.eu/jrc/en/scientific-tool/jrc-nanomaterials-repository http://dx.doi.org/10.1007/s11051-013-1455-2 http://dx.doi.org/10.1007/s11051-013-1455-2 http://publications.jrc.ec.europa.eu/repository/handle/JRC64075 http://publications.jrc.ec.europa.eu/repository/handle/JRC64075 http://publications.jrc.ec.europa.eu/repository/handle/JRC89825 http://publications.jrc.ec.europa.eu/repository/handle/JRC89825 http://dx.doi.org/10.1186/1743-8977-11-8 http://dx.doi.org/10.1186/1743-8977-11-8 The JRC Nanomaterials Repository: A unique facility providing representative test materials for nanoEHS research 1. Introduction and background 2. A unique facility 2.1. Aims of the JRC Nanomaterials Repository 2.2. The JRC Nanomaterials Repository: setup and material flow 2.2.1. The structural set up of the JRC repository and the material flow 2.2.2. Ventilation system 2.2.3. The JRC Nanomaterials Repository: equipment 2.3. Safety measures 3. Hosted nanomaterials 4. Representative test materials as benchmark materials for the harmonisation of test methods 5. Conclusions Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-OSIRIS-Weight-of-Evidence-approach--ITS-f_2013_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23792263", "content": {"CoiStatement": "Quantifying and subsequently combining the (general) predic- tive performance of (alternative) methods using a pre-set algorithm (Bayesian inference) gives an objective, transparent, and reproduc- ible way to perform a WoE procedure. The definition of a clear threshold of reliability, as indicated by the acceptance of different test results within the regulatory framework REACH, gives an objective measure of the reliability considered sufficient for Weight of Evidence. Transparency of the proposed WoE procedure is increased by the use of this objective threshold value. Any devi- ations from the procedure will require documentation of these deviations, giving both motivation and quantification. Finally, the use of the proposed procedures and algorithms to calculate a quan- titative measure for WoE makes this procedure fully reproducible. This can not be said from qualitative procedures, where judgement of sufficiency of the Weight of Evidence is often made using subjec- tive, case-by-case arguments. The lack of a quantifiable threshold will also hamper reproducibility, as it is up to the user to decide when WoE is considered sufficient. The proposed quantitative WoE procedure will therefore facilitate a harmonized evaluation of the WoE, and allow discussion on the choices made for specific cases. As such, it is preferable to a qualitative approach, which is often termed \u2018\u2018expert judgement\u2019\u2019, and which might sometimes lead to (selectively) ignoring pieces of information that do not fit the desired WoE puzzle. Conflict of interest statement The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgments Conflict of interest statement Acknowledgments Appendix A Supplementary data References", "Funding": "Support is gratefully acknowledged from the Sixth EU Research Framework Programme for funding Project no. GOCE-CT-2007- 037017 OSIRIS; the Dutch Ministry of Infrastructure and the Envi- ronment within the scope of Project M/601353 Development of Methodology for REACH; and Directorate General RIVM within the scope of the Strategic Research Project S/601001. We thank Rob Vandebriel for his contributions to the manuscript, and we thank Ralph K\u00fchne and Eduard Paun\u00e9 for their feedback on the methodology and their efforts for the implementation of the ITS in the OSIRIS webtool. Appendix A. Supplementary data Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.yrtph.2013.06. 003.", "Acknowledgement": "Acknowledgments Support is gratefully acknowledged from the Sixth EU Research Framework Programme for funding Project no. GOCE-CT-2007- 037017 OSIRIS; the Dutch Ministry of Infrastructure and the Envi- ronment within the scope of Project M/601353 Development of Methodology for REACH; and Directorate General RIVM within the scope of the Strategic Research Project S/601001. We thank Rob Vandebriel for his contributions to the manuscript, and we thank Ralph K\u00fchne and Eduard Paun\u00e9 for their feedback on the methodology and their efforts for the implementation of the ITS in the OSIRIS webtool. Appendix A. Supplementary data Conflict of interest statement Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-OSIRIS-Weight-of-Evidence-approach--ITS-for-the_2013_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23439429", "content": {"CoiStatement": "Up to now the RepDose Inga TluczkiewiczS is applicable to only two study types: oral subacute and subchronic repeated-dose toxicity studies in rats. A statistical evaluation of the coverage of other typical re- peated-dose study types such as chronic studies, studies testing other species (e.g. mice) and other routes of exposure (dermal, inhalation exposure) was not possible because of limited data. The developed RepDose Inga TluczkiewiczS concept, however, accounts for all types of repeated-dose toxicity studies. Conflict of interest statement The authors declare that there are no conflicts of interest. Acknowledgments The authors declare that there are no conflicts of interest. Acknowledgments This work has been founded by the European Union project OSI- RIS (Optimized Strategies for Risk Assessment of Industrial Chem- icals through Integration of Non-Test and Test Information) project no. 037017, an integrated project within the sixth EU research framework programme. References", "Acknowledgement": "The authors declare that there are no conflicts of interest. Acknowledgments This work has been founded by the European Union project OSI- RIS (Optimized Strategies for Risk Assessment of Industrial Chem- icals through Integration of Non-Test and Test Information) project no. 037017, an integrated project within the sixth EU research framework programme. References The OSIRIS Weight of Evidence approach: Inga TluczkiewiczS for the endpointsrepeated-dose toxicity (RepDose Inga TluczkiewiczS) 1. Introduction 2. Overview of the RepDose Inga TluczkiewiczS 3. Quality assessment of non-guideline studies 4. Influence of the scope of examination on the LOELs of studies(Coverage approach) 5. Alternative methods 6. Case study 7. Implementation of the RepDose Inga TluczkiewiczS in the OSIRIS webtool 8. Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-OSIRIS-Weight-of-Evidence-approach--ITS-muta_2013_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23357514", "content": {"CoiStatement": "The use and implementation of ITS for regulatory purposes lar- gely depend on their acceptance by various stakeholders. The OSI- RIS project has organised five stakeholder workshops during its 4.5 year existence to promote stakeholder involvement in the elab- oration of the ITS. As part of the fourth stakeholder workshop, held in March 2011, stakeholder perceptions with respect to ITS and their characterisation, application and acceptance were investi- gated. The results of these investigations were published by Gab- bert and Benighaus (2012). Although the number of participants was low (19 divided over 4 stakeholder categories), the results do provide an important insight in the problems surrounding acceptance. The core theme with respect to ITS identified by all stakeholders groups was \u2018\u2018uncertainty\u2019\u2019, but each group had a dif- ferent view on which was the most relevant uncertainty. NGOs fo- cused on reliability, private enterprises on regulatory acceptance, researchers and regulators on polyinterpretability of ITS, which the former linked to specific toxicological endpoints and the latter to methods and sources of information. To improve the acceptance of ITS, private enterprises stated they should provide higher reduc- tions in costs than until date, regulatory authorities needed more precise guidance on how to perform ITS, researchers wanted more hands-on experience in its application and NGOs pleaded for more stakeholder involvement. From this all emanate the characteristics of a Catch 22 situation, in which one stakeholder waits for the other to move and vice versa. Within the OSIRIS project, there was close cooperation between research organisations and private enterprises, but key regulatory players were absent. In order to fur- ther develop the ITS framework laid down by OSIRIS and promote its acceptance, it would be best to have all stakeholders actively participate in a follow-up project. Conflict of interest statement The research was funded by the Sixth EU Research Framework Programme. The study sponsor had no involvement sponsors in the study design nor in the collection, analysis and interpretation of data nor in the writing of the manuscript nor in the decision to submit the manuscript for publication. Appendix A. Supplementary data The OSIRIS Weight of Evidence approach: ITS mutagenicityand ITS carcinogenicity 1. Introduction 2. Description ITS 3. Weight of evidence 4. Further development needed Conflict of interest statement Appendix A. Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-Power-of-the-European-Union-Protocol-to-Test-_2001_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/11407937", "content": {"Acknowledgement": "ACKNOWLEDGMENT Research supported by The Morgan Crucible Co., PLC. DISCUSSION ACKNOWLEDGMENT REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-Proportions-of-Mutagens-among-Chemical_2000_Regulatory-Toxicology-and-Ph.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/11067778", "content": {"Acknowledgement": "5. Chemicals in commerce (.1 million lb/year) 52-52-8 2 1-Aminocyclopentanecarboxylic acid 80-63-7 1 2-Propenoic acid, 2-chloro-, methyl ester [methyl 2-chloroacrylate] 91-21-4 2 Isoquinoline, 1,2,3,4-tetrahydro- [1,2,3,4-tetrahydroisoquinoline] 100-03-8 2 4-Chlorobenzenesulfinic acid 125-31-5 2 Phenol, 4,49-(3H-2,1-benzoxathiol-3-ylidine)-bis(2,5-dimethyl-, S,S-dioxide [p-xylenol blue] 527-53-7 2 1,2,3,5-Tetramethylbenzene 574-06-1 2 Ethanone, 2-(acetyloxy)-1,2-diphenyl [benzoin acetate] 622-20-8 2,2 1,19-[1,2-Ethanediylbis(thio)]bis-benzene [1,2-bis(phenylthio)ethane] 1193-24-4 2 4(1H)-Pyrimidinone, 6-hydroxy- [6-hydroxy-4(1H)-pyrimidinone] 3173-53-3 ? Cyclohexane, isocyanato- [isocyanatocyclohexane] 3582-17-0 2 Stannane, difluorodimethyl- [dimethyltin difluoride] 4584-49-0 1 1-Propanamine, 2-chloro-N,N-dimethyl-, hydrochloride [2-chloro-N,N-dimethyl-1-propanamine HCl] 6225-06-5 2 Pentanamide, N,N-dimethyl- [N,N-dimethylvaleramide] 17376-04-4 2 2-Iodoethyl benzene 18640-74-9 1 2-(2-Methylpropyl) thiazole 25148-68-9 1 1,2-Benzenediamine, N-methyl-, dihydrochloride [N-methyl-o-phenylenediamine 2HCl] 35250-53-4 2 Pyrazineethanethiol 63213-29-6 ? 1-(2,4,5-Triethoxyphenyl)ethanone [2,4,5-triethoxyacetophenone] 68608-36-6 2 Terpenes and terpenoids, Litsea cubeba oil, hydrogenated [68855-99-2] 68915-66-2 2 Fatty acids, C5-10, esters with polypentaerythritol 6. Chemicals in commerce (,1 million lb/year) 77-47-4 2,2 1,3-Cyclopentadiene, 1,2,3,4,5,5-hexachloro- [hexachlorocyclopentadiene] 100-52-7 2,2 Benzaldehyde 119-36-8 2,1w Benzoic acid, 2-hydroxy-, methyl ester [methyl salicylate] 143-18-0 2 9-Octadecenoic acid, (Z)-, potassium salt [potassium oleate] 462-06-6 1 Benzene, fluoro [fluorobenzene] 473-55-2 2 Bicyclo[3.1.1]heptane, 2,6,6-trimethyl- [pinane] 1064-48-8 1 2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-3-[(4-nitrophenyl)azo]-6-(phenylazo)-, disodium salt [C.I. acid black 1] 1174-72-7 2 Silicic acid (H4SiO4), tetraphenyl ester [tetraphenoxysilane] 1552-42-7 2 1(3H)-Isobenzofuranone, 6-(dimethylamino)-3,3-bis[4-(dimethylamino)-phenyl]- [crystal violet lactone] 1941-30-6 2,1w 1-Propanaminium, N,N,N-tripropyl-, bromide [tetrapropylammonium Br] 2288-13-3 2 2,8,9-Trioxa-5-aza-1-silabicyclo[3.3.3]undecane, 1-methyl [methylsilatrane] 2598-99-4 2 Hexadecanoic acid, octadecyl ester [stearyl palmitate] 2818-69-1 1 1H-Benzimidazole, 5-chloro-2-methyl- [5-chloro-2-methyl-1H-benzimidazole] 3318-43-2 ?,1 Indol-3-ol, dihydrogen phosphate (ester), disodium salt [indol-3-yl sodium phosphate] 4861-85-2 2 Benzeneacetic acid, 1-methylethyl ester [isopropyl phenylacetate] 8029-68-3 2 Ichthammol 8030-28-2 2 Orange flower water 8046-19-3 2 Styrax balsam 17928-28-8 2 Trisiloxane, 1,1,1,3,5,5,5-heptamethyl-3-[(trimethylsilyl)oxy]- [methyltris (trimethylsiloxy)silane] 25703-79-1 2 2-Propenoic acid, 2-methyl-, 2-hydroxypropyl ester, homopolymer [poly(2-hydroxypropyl methacrylate)] 57166-92-4 1 Methanediamine, dihydrochloride . Chemicals in commerce (production unknown or inaccessible) 75-33-2 2 2-Propanethiol [isopropyl mercaptan] 78-84-2 2,? Propanal, 2-methyl- [isobutyraldehyde] 87-44-5 2 Bicyclo[7.2.0]undec-4-ene, 4,11,11-trimethyl-8-methylene- [1R(1R*,4E,9S*)]-[b-caryophyllene] 97-23-4 1,1w Phenol, 2,29-methylenebis[4-chloro- [2,29-methylenebis(4-chlorophenol)] 102-54-5 ?,2,2 Ferrocene 104-49-4 2 1,4-Diisocyanatobenzene [p-phenylene diisocyanate] 105-11-3 1,1 2,5-Cyclohexadiene-1,4-dione, dioxime [p-quinone dioxime] 107-20-0 1 Acetaldehyde, chloro- [chloroacetaldehyde] 111-02-4 2 2,6,10,14,18,22-Tetracosahexaene, 2,6,10,15,19,23-hexamethyl-, (all-E)- [trans-squalene] 483-84-1 1 2-Naphthalenesulfonic acid, 8-hydroxy-5,7-dinitro- [2,4-dinitro-1-naphtho-7-sulfonic acid] 505-32-8 ? 1-Hexadecen-3-ol, 3,7,11,15-tetramethyl- [isophytol] 539-48-0 2 1,4-Benzenedimethanamine 557-61-9 2 1-Octacosanol 821-06-7 1 2-Butene, 1,4-dibromo-, (E)- [(E)-1,4-dibromo-2-butene] 1163-19-5 2 Benzene, 1,19-oxybis[2,3,4,5,6-pentabromo- [decabromodiphenyl oxide] 1328-53-6 1 C.I. pigment green 7 1718-34-9 1 Benzoic acid, 2-hydroxy-5-[(4-nitrophenyl)azo]-, Na salt [alizarin yellow R, Na salt] 3333-67-3 ? Carbonic acid, nickel (21) salt (1:1) [nickel carbonate] 10039-54-0 2 Hydroxylamine, sulfate (2:1) 15217-42-2 1w 1H-Benzotriazole, sodium salt [95-14-7; 1H-benzotriazole] 16323-43-6 2 2-Propenoic acid, 3,39-(1,4-phenylene)bis- 17409-47-1 1 Benzenediazonium, 4-(diethylamino)-, chloride, compound with zinc chloride [6217-19-2; p-(diethylamino)benzenediazonium zinc chloride] 25103-58-6 2,2 tert-Dodecanethiol [tert-dodecylmercaptan] 25155-30-0 2 Benzenesulfonic acid, dodecyl-, sodium salt [dodecylbenzenesulfonic acid, sodium salt] 25956-17-6 2 2-Naphthalenesulfonic acid, 6-hydroxy-5-[(2-methoxy-5-methyl-4-sulfophenyl)azo]-, disodium salt [allura red; C.I. 16035] 61789-19-3 2 Amides, coco [8051-30-7] 61789-81-9 2 Quaternary ammonium compounds, bis(hydrogenated tallow alkyl)dimethyl, methyl sulfates [bis(hydrogenated tallow alkyl)dimethylammonium methyl sulfates] 66070-63-1 ? Soybean oil, polymer with isophthalic acid and trimethylolethane [isophthalic acid trimethylolethane soybean oil polymer] 67634-00-8 2 Acetic acid, (3-methylbutoxy)-, 2-propenyl ester 67828-17-5 ? Phosphoramidic acid, dibutyl-, diethyl ester [diethylibutyl phosphoramidate] 68015-41-8 2 Fatty acids, tall oil, polymers with glycerol, maleic anhydride, phthalic anhydride, and soybean oil 70955-34-9 2 Fatty acids, tall oil, reaction products with 2-[(2-aminoethyl)amino]ethanol, quaternized with sulfate diethyl 72276-00-7 2 Benzene, trichloro-, polymer with 1,4-dichlorobenzene and sodium sulfide [trichlorobenzene, polymer with 1,4-dichlorobenzene and Na2S] a Salmonella test results of individual, independent tests; 1, mutagenic; 1w, weakly mutagenic; ?, equivocal response; 2, not mutagenic. b NTP name and/or CASRN, where different from the NAS designation. Dr. Bhajat Qaqish, UNC Department of Biostatistics, for his helpful comments and discussions. Portions of this work were performed G G J K M N T U U Z Z Z APPENDIX 2 Mutagenicity and Carcinogenicity of the Highest- P M S M X F T E p C E A P P B I A V A B C A N C 1 I A M M o P P E M M P D d t a 225MUTAGENS IN COMMERCE ACKNOWLEDGMENTS We appreciate the help provided by Dr. William Kalsbeek, UNC Department of Biostatistics, who performed the stratifications, and Production Organic Chemicals of 1995a Chemical CASRN Salmonella test result Rodent carcinogenicity ropylene 115-07-1 1 2 ethyl tert-butyl ether 1634-04-4 2 1 Ethylene dichloride 107-06-2 1 1 Benzene 71-43-2 2 1 Urea 57-13-6 2 2 Vinyl chloride 75-01-4 1b 1b Ethylbenzene 100-41-1 2 1 tyrene 100-42-5 2 ? ethanol 67-56-1 ? ylene 1330-20-7 2 2 ormaldehyde 50-00-0 1 1 erephthalic acid 100-21-0 2 thylene oxide 75-21-8 1b 1b Toluene 108-88-3 2 2 -Xylene 106-42-3 2 2 umene 98-82-8 2 thylene glycol 107-21-1 2 2 cetic acid 64-19-7 2 henol 108-95-2 2 2 ropylene oxide 75-56-9 1 1 utadiene 106-99-0 1 1 sobutylene 115-11-7 2 1 crylonitrile 107-13-1 1 1 inyl acetate 108-05-4 2 1 cetone 67-64-1 2 utyraldehyde 123-72-8 2 yclohexane 110-82-7 2 dipic acid 124-04-9 2 itrobenzene 98-95-3 2 1b Bisphenol A 80-05-7 2 2 aprolactam 105-60-2 2 2 -Butanol 71-36-3 2 sopropyl alcohol 67-63-0 2 niline 62-53-3 2 1 ethyl methacrylate 80-62-6 2 2 ethyl chloride 74-87-3 1 -Xylene 95-47-6 2 2 ropylene glycol 57-55-6 2 2 hthalic anhydride 85-44-9 2 2 thanolamines \u2014c 2 1c 2-Ethoxyethanol 110-80-5 2 Ethanol (synthetic) 64-17-5 2 ? ethyl ethyl ketone 78-93-3 2 aleic anhydride 108-31-6 2 erchloroethylene 127-18-4 2 1 ioctyl phthalate 117-84-0 2 Note. Blank, no test data found. a From \u201cTop 50 Chemicals\u201d C&EN, June 24, 1996, p. 41 (listed in ecreasing order of production volume). Polymers are not included. b Non-NTP results (from published studies). c Monoethanolamine (141-43-5); diethanolamine (111-42-2); and riethanolamine (102-71-6) are all nonmutagenic; diethanolamine nd triethanolamine are rodent carcinogens. under NIEHS Contract 273-92-C-0013 with the UNC Department of Biostatistics. REFERENCES Chemical and Engineering News (C&EN) (1996). Top 50 chemicals. Chem. Eng. News June 24, 41. old, L. S., Slone, T. H., and Ames, B. N. (1997). Overview and update of analyses of the carcinogenic potency database. In Hand- book of Carcinogenic Potency and Genotoxicity Databases (L. S. Gold and E. Zeiger, Eds.), pp. 661\u2013685. CRC Press, Boca Raton, FL. old, L. S., Slone, T. H., and Bernstein, L. (1989). Summary of carcinogenic potency and positivity for 492 rodent carcinogens in the carcinogenic potency database. Environ. Health Perspect. 79, 259\u2013272. apan Chemical Industry Ecology\u2013Toxicology & Information Center (JETOC) (1996). Mutagenicity Test Data of Existing Chemical Sub- stances, Based on the Toxicity Investigation System of the Indus- trial Safety and Health Law, Bacterial Mutagenicity Test, p. 80\u2013 406. ier, L. D., Brusick, D. J., Auletta, A. E., Von Halle, E. S., Simmon, V. F., Brown, M. M., Dunkel, V. C., McCann, J., Mortelmans, K., Prival, M. J., Rao, T. K., and Ray, V. A. (1986). The Salmonella typhimurium/mammalian microsome mutagenicity assay: A re- port of the U. S. Environmental Protection Agency Gene-Tox Pro- gram. Mutat. Res. 168, 67\u2013238. orita, T., Asano, N., Awogi, T., Sasaki, Yu. F., Sato, S-i., Shimada, H., Sutou, S., Suzuki, T., Wakata, A., Sofuni, T., and Hayashi, M. (1997). Evaluation of the rodent micronucleus assay in the screen- ing of IARC carcinogens (Groups 1, 2A and 2B): The summary report of the 6th collaborative study by CSGMT/JEMS. MMS. Mutat. Res. 389, 3\u2013122. ational Academy of Sciences (NAS) (1984). Toxicity Testing, Strat- egies to Determine Needs and Priorities. National Research Coun- cil, Natl. Acad. Press, Washington, DC. enenbein, A. (1970). A double sampling scheme for estimating from binomial data with misclassifications. J. Am. Stat. Assoc. 65, 1350\u20131361. .S. Environmental Protection Agency (U.S. EPA) (1982). Toxic Substances Control Act Chemical Substances Inventory, Cumu- lative Supplement II. U.S. Govt. Printing Office, Washington, DC. .S. Environmental Protection Agency (U.S. EPA) (1988). Office of Pollution Prevention and Toxics, High Production Volume Chemical List, at URL http://www.epa.gov/opptintr/chemtest/ hpv.htm. eiger, E. (1997). Genotoxicity database. In Handbook of Carcino- genic Potency and Genotoxicity Databases (L. S. Gold and E. Zeiger, Eds.), pp. 687\u2013729. CRC Press, Boca Raton, FL. eiger, E. (1998). Identification of rodent carcinogens and noncar- cinogens using genetic toxicity tests: Premises, promises, and per- formance. Regul. Toxicol. Pharmacol. 28, 85\u201395. eiger, E., Anderson, B., Haworth, S., Lawlor, T., and Mortelmans, K. (1992). Salmonella mutagenicity tests. V. Results from the testing of 311 chemicals. Environ. Mol. Mutagen. 19(Suppl. 21), 1\u2013141. Zeiger, E., Haseman, J. K., Shelby, M. D., Margolin, B. H., and Tennant, R. W. (1990). Evaluation of four in vitro genetic toxicity tests for predicting rodent carcinogenicity: Confirmation of earlier results with 41 additional chemicals. Environ. Mol. Mutagen. 16(Suppl. 18), 1\u201314. INTRODUCTION METHODS TABLE 1 RESULTS AND DISCUSSION TABLE 2 TABLE 3 SUMMARY APPENDIX 1 APPENDIX 2 ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-Random-Effects-Model-Applied-to-Refractor_2000_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/11067775", "content": {"Compliance with ethical standards": "FIG. 8. Relation between CV of TWA workplace concentration easurements and true mean (as ratio to OEL) to provide 95% uarantee of compliance no overexposure. tial 0.5 f/cc or 0.1 f/cc Permissible Exposure Limit (PEL) for Re- fractory Ceramic Fiber (RCF). Everest Consulting Associates, Cranbury, NJ. [Sponsored by the Refractory Ceramic Fibers Coa- lition (RCFC), Washington, DC] Everest Consulting Associates (ECA) (1992). Report to the Occupa- tional Safety and Health Administration (OSHA): An Analysis of the Economic Feasibility of a 1 f/cc Permissible Exposure Limit (PEL) for the Refractory Ceramic Fiber (RCF) Industry. Everest Consulting Associates, Cranbury, NJ. [Sponsored by Refractory Ceramic Fibers Coalition (RCFC), Washington, DC] Hewett, P. (1998). Letter to the editor\u2014Comments on relating to Tornero-Velez et al.: Compliance versus risk in assessing occupa- tional exposures. Risk Anal. 18(6), 665\u2013667. Johnson, N. L., and Kotz, S. (1970). Continuous Univariate Distri- butions\u20141. Wiley, New York. Rappaport, S. M., Tornero-Velez, R., Symanski, E., Kromhout, H., and Yu, R. C. (1998). Letter to the editor\u2014Response to Paul Hewett\u2019s comments relating to Tornero-Velez et al.: Compliance versus risk in assessing occupational exposures. Risk Anal. 18(6), 669\u2013671. Rappaport, S. M., Lyles, R. H., and Kupper, L. L. (1995). An expo- sure-assessment strategy accounting for within- and between- worker sources of variability. Ann. Occup. Hyg. 39(4), 459\u2013495. pear, R. C., and Selvin, S. (1989). OSHA\u2019s permissible exposure limits: regulatory compliance versus health risk. Risk Anal. 9(4), 579\u2013586. Tornero-Velez, R., Symanski, E., Kromhout, H., Yu, R. C., and Rap- paport, S. M. (1997). Compliance versus risk in assessing occupa- tional exposures. Risk Anal. 17(3), 279\u2013292. Tornero-Velez, R., Symanski, E., Kromhout, H., Yu, R. C., and Rap- paport, S. M. (1997). Compliance versus risk in assessing occupa- tional exposures. Risk Anal. 17(3), 279\u2013292. U.S. Department of Labor, Occupational Safety and Health Admin- istration (1996). Section 1\u2014Sampling, Measurement Methods, and Instruments: Chapter 1\u2014Personal Sampling for Air Contami- nants. Issued by OSHA Instruction TED 1.15, Sept. 22, 1995; Amended by OSHA Instruction TED 1.15 CH-1, May 24, 1996.", "Acknowledgement": "ACKNOWLEDGMENTS The overall monitoring program was sponsored by RCFC. Unifrax Corporation supported this particular analysis. The constructive comments of the referees have improved the clarity of this paper. CONCLUDING COMMENTS ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-Research-Institute-for-Fragrance-Materials--hu_2008_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18177987", "content": {"CoiStatement": "Other responses/recording characteristics S Spreading\u2014evidence of the reaction beyond the pad area (does not include obvious signs of leakage of test material away from pad W Weeping\u2014evidence of release of fluid from a vesicular or bullous reaction A Marked reaction to adhesive (patch relocated) X Succeeding patch not applied and succeeding grade is for residual reaction L Patch lost (came off) during first 12 h V.T. Politano, A.M. Api / Regulatory Toxicology and Pharmacology 52 (2008) 35\u201338 37 both an occlusive and semi-occlusive 24-h back patches of the test article, vehicle control, and saline control to na\u0131\u0308ve sites with readings of the patch test sites at 24, 48, 72, and 96 h post-patch applications. If the reactivity is still inconclusive, the test subject undergoes a use test, in which an open application of the test article to the antecubital fossa of either the left or right arm is repeated 3 times per day for 5 days, with the first application performed at the Testing Facility. 3. Discussion The results of the HRIPT protocol are presented as the number of induced sensitization reactions observed out of the total number of volunteers who completed the study. The results of the individual patch sites are presented in tabular format. The induction of dermal sensitization is determined by enhancement of the skin reaction observed at Challenge greater than that observed during Induction. Low grade reactions observed during Induction but which are not observed at Challenge are considered to be irritant in nat- ure. If a volunteer has an erythematous and edematous reaction during the early part of the Induction phase that is confirmed at Challenge, the subject is considered to be presensitized and the reaction is not considered having been induced during the Induction phase. If a test subject reacted during the earliest part of the Induction phase and returns to confirm the reactivity at Challenge, the subject is considered to have exhibited 38 V.T. Politano, A.M. Api / Regulatory Toxicology and Pharmacology 52 (2008) 35\u201338 reactions indicative of presensitization to the test material. This subject is considered to have completed that study but is not included in the number of induced sensitization reactions. An erythematous and edematous reaction to the test arti- cle (and none to the vehicle or negative control) during Chal- lenge that is confirmed at Rechallenge is indicative of induction of dermal sensitization. If no dermal sensitization is induced, then the concentration of test article tested is determined to be a NOEL for the induction of dermal sensi- tization. Since the HRIPT is used to confirm a NOEL, it will determine the negative or the lack of a sensitization reaction. As such, \u2018a\u2019 NOEL for the induction of sensitization may be determined, not necessarily \u2018the\u2019 NOEL, since the method is not used to define a Lowest-Observed-Effect-Level (LOEL) or NOEL on the dose response curve. The NOEL may be determined if there are historical data in humans which pro- vide a known LOEL. To ensure an adequate safety evaluation, approximately 100 subjects must complete the entire HRIPT protocol. Henderson and Riley (1945) investigated statistical calcula- tions of patch tests adapted for the detection and evalua- tion of chemical agents. If no reactions were observed in a group of 100 test subjects, then the rate of positive reac- tions in a larger population is not likely to exceed 2.9%, based on a confidence level of 95%, under identical condi- tions (Henderson and Riley, 1945). The likely maximum rate of 2.9% positive reactions is often misinterpreted to mean that there would be an expected rate of 2.9% in the marketplace. The test conditions in the HRIPT are not identical to real life scenarios. To increase the sensitivity of the test whilst using such numbers of subjects, if appro- priate one generally tests a higher concentration of test material and usually more exaggerated exposure conditions than would actually be encountered in intended and fore- seeable use situations among the general population. Other factors that further increase the sensitivity and reliability of the test, in some HRIPT protocols, are exaggerated through possible minor skin irritation of a test material, use of occluded patches, and vehicle effects from the test conditions (Basketter et al., 2006; McNamee et al., 2008). The induction of human dermal sensitization from the HRIPT is rare. Hall (2006) estimated the rate of dermal sensitization induction to be 0.09% of volunteers in tests on cosmetic products. In addition, Hall (2006) identified there has been no evidence of adverse sequelae from these tests. Conflict of Interest Valerie T. Politano is an employee of the Research Insti- tute for Fragrance Materials an independent research insti- tute supported by the manufacturers of fragrances and consumer products containing fragrances. Funding Source This research was supported by the Research Institute for Fragrance Materials, an independent research institute that is funded by the manufacturers of fragrances and con- sumer\u2019 products containing fragrances. References Api, A.M., Basketter, D.A., Cadby, P.A., Cano, M.-F., Ellis, G., Gerberick, G.F., Griem, P., McNamee, P.M., Ryan, C.A., Safford, B., 2008. Dermal sensitization quantitative risk assessment (QRA) for fragrance ingredients. Reg. Toxicol. Pharmacol. 52, 3\u201323. Basketter, D.A., Jefferies, D., Safford, B.J., Gilmour, N.J., Jowsey, I.R., McFadden, J., Chansinghakul, W., Duangdeeden, I., Kullavanijaya, P., 2006. The impact of exposure variables on the induction of skin sensitization. Contact Dermatitis 55, 178\u2013185. Draize, J.H., Woodard, G., Calvery, H.O., 1944. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J. Pharmacol. Exp. Ther. 82, 377\u2013390. Draize, J.H., 1959. Appraisal of the safety of chemicals in foods, drugs and cosmetics. Dermal toxicity. Association of Food and Drug Officials of the United States, 46\u201359. Hall, B., 2006. Prevention of contact allergy to cosmetics safety of consumer confirmed by the human repeat insult patch test (HRIPT). 8th Congress of the European Society of Contact Dermatitis, 13\u201316 September, Berlin, Germany. Henderson, C.R., Riley, E.C., 1945. Certain statistical considerations in patch testing. J. Invest. Dermatol. 6, 227\u2013232. Kligman, A.M., 1966. The identification of contact allergens by human assay. II. Factors influencing the induction and measurement of allergic contact dermatitis. J. Invest. Dermatol. 47, 375\u2013392. Lalko, J., Isola, D., Api, A.M., 2004. Ethanol and diethyl phthalate: vehicle effects in the local lymph node assay. Int. J. Toxicol. 23, 171\u2013177. Marzulli, F.N., Maibach, H.I., 1976. Contact allergy: predictive testing in man. Contact Dermatitis 2, 1\u201317. McNamee, P.M., Api, A.M., Basketter, D.A., Gerberick, G.F., Gilpin, D.A., Hall, B.M., Jowsey, I., Robinson, M.K., 2008. A review of critical factors in the conduct and interpretation of the human repeat insult patch test. Reg. Toxicol. Pharmacol. 52, 24\u201334. Phillips 2nd, L., Steinberg, M., Maibach, H.I., Akers, W.A., 1972. A comparison of rabbit and human skin response to certain irritants. Toxicol. Appl. Pharmacol. 21, 369\u2013382. Stotts, J., Ely, W.J., 1977. Induction of human skin sensitization to ethanol. J. Invest. Dermatol. 69, 219\u2013222. The Research Institute for Fragrance Materials \" human repeated insult patch test protocol Introduction Protocol Test subjects Test articles Experimental design Induction phase Challenge phase Rechallenge Discussion Conflict of Interest Funding Source References", "Funding": "Other responses/recording characteristics S Spreading\u2014evidence of the reaction beyond the pad area (does not include obvious signs of leakage of test material away from pad W Weeping\u2014evidence of release of fluid from a vesicular or bullous reaction A Marked reaction to adhesive (patch relocated) X Succeeding patch not applied and succeeding grade is for residual reaction L Patch lost (came off) during first 12 h V.T. Politano, A.M. Api / Regulatory Toxicology and Pharmacology 52 (2008) 35\u201338 37 both an occlusive and semi-occlusive 24-h back patches of the test article, vehicle control, and saline control to na\u0131\u0308ve sites with readings of the patch test sites at 24, 48, 72, and 96 h post-patch applications. If the reactivity is still inconclusive, the test subject undergoes a use test, in which an open application of the test article to the antecubital fossa of either the left or right arm is repeated 3 times per day for 5 days, with the first application performed at the Testing Facility. 3. Discussion The results of the HRIPT protocol are presented as the number of induced sensitization reactions observed out of the total number of volunteers who completed the study. The results of the individual patch sites are presented in tabular format. The induction of dermal sensitization is determined by enhancement of the skin reaction observed at Challenge greater than that observed during Induction. Low grade reactions observed during Induction but which are not observed at Challenge are considered to be irritant in nat- ure. If a volunteer has an erythematous and edematous reaction during the early part of the Induction phase that is confirmed at Challenge, the subject is considered to be presensitized and the reaction is not considered having been induced during the Induction phase. If a test subject reacted during the earliest part of the Induction phase and returns to confirm the reactivity at Challenge, the subject is considered to have exhibited 38 V.T. Politano, A.M. Api / Regulatory Toxicology and Pharmacology 52 (2008) 35\u201338 reactions indicative of presensitization to the test material. This subject is considered to have completed that study but is not included in the number of induced sensitization reactions. An erythematous and edematous reaction to the test arti- cle (and none to the vehicle or negative control) during Chal- lenge that is confirmed at Rechallenge is indicative of induction of dermal sensitization. If no dermal sensitization is induced, then the concentration of test article tested is determined to be a NOEL for the induction of dermal sensi- tization. Since the HRIPT is used to confirm a NOEL, it will determine the negative or the lack of a sensitization reaction. As such, \u2018a\u2019 NOEL for the induction of sensitization may be determined, not necessarily \u2018the\u2019 NOEL, since the method is not used to define a Lowest-Observed-Effect-Level (LOEL) or NOEL on the dose response curve. The NOEL may be determined if there are historical data in humans which pro- vide a known LOEL. To ensure an adequate safety evaluation, approximately 100 subjects must complete the entire HRIPT protocol. Henderson and Riley (1945) investigated statistical calcula- tions of patch tests adapted for the detection and evalua- tion of chemical agents. If no reactions were observed in a group of 100 test subjects, then the rate of positive reac- tions in a larger population is not likely to exceed 2.9%, based on a confidence level of 95%, under identical condi- tions (Henderson and Riley, 1945). The likely maximum rate of 2.9% positive reactions is often misinterpreted to mean that there would be an expected rate of 2.9% in the marketplace. The test conditions in the HRIPT are not identical to real life scenarios. To increase the sensitivity of the test whilst using such numbers of subjects, if appro- priate one generally tests a higher concentration of test material and usually more exaggerated exposure conditions than would actually be encountered in intended and fore- seeable use situations among the general population. Other factors that further increase the sensitivity and reliability of the test, in some HRIPT protocols, are exaggerated through possible minor skin irritation of a test material, use of occluded patches, and vehicle effects from the test conditions (Basketter et al., 2006; McNamee et al., 2008). The induction of human dermal sensitization from the HRIPT is rare. Hall (2006) estimated the rate of dermal sensitization induction to be 0.09% of volunteers in tests on cosmetic products. In addition, Hall (2006) identified there has been no evidence of adverse sequelae from these tests. Conflict of Interest Valerie T. Politano is an employee of the Research Insti- tute for Fragrance Materials an independent research insti- tute supported by the manufacturers of fragrances and consumer products containing fragrances. Funding Source This research was supported by the Research Institute for Fragrance Materials, an independent research institute that is funded by the manufacturers of fragrances and con- sumer\u2019 products containing fragrances. References Api, A.M., Basketter, D.A., Cadby, P.A., Cano, M.-F., Ellis, G., Gerberick, G.F., Griem, P., McNamee, P.M., Ryan, C.A., Safford, B., 2008. Dermal sensitization quantitative risk assessment (QRA) for fragrance ingredients. Reg. Toxicol. Pharmacol. 52, 3\u201323. Basketter, D.A., Jefferies, D., Safford, B.J., Gilmour, N.J., Jowsey, I.R., McFadden, J., Chansinghakul, W., Duangdeeden, I., Kullavanijaya, P., 2006. The impact of exposure variables on the induction of skin sensitization. Contact Dermatitis 55, 178\u2013185. Draize, J.H., Woodard, G., Calvery, H.O., 1944. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J. Pharmacol. Exp. Ther. 82, 377\u2013390. Draize, J.H., 1959. Appraisal of the safety of chemicals in foods, drugs and cosmetics. Dermal toxicity. Association of Food and Drug Officials of the United States, 46\u201359. Hall, B., 2006. Prevention of contact allergy to cosmetics safety of consumer confirmed by the human repeat insult patch test (HRIPT). 8th Congress of the European Society of Contact Dermatitis, 13\u201316 September, Berlin, Germany. Henderson, C.R., Riley, E.C., 1945. Certain statistical considerations in patch testing. J. Invest. Dermatol. 6, 227\u2013232. Kligman, A.M., 1966. The identification of contact allergens by human assay. II. Factors influencing the induction and measurement of allergic contact dermatitis. J. Invest. Dermatol. 47, 375\u2013392. Lalko, J., Isola, D., Api, A.M., 2004. Ethanol and diethyl phthalate: vehicle effects in the local lymph node assay. Int. J. Toxicol. 23, 171\u2013177. Marzulli, F.N., Maibach, H.I., 1976. Contact allergy: predictive testing in man. Contact Dermatitis 2, 1\u201317. McNamee, P.M., Api, A.M., Basketter, D.A., Gerberick, G.F., Gilpin, D.A., Hall, B.M., Jowsey, I., Robinson, M.K., 2008. A review of critical factors in the conduct and interpretation of the human repeat insult patch test. Reg. Toxicol. Pharmacol. 52, 24\u201334. Phillips 2nd, L., Steinberg, M., Maibach, H.I., Akers, W.A., 1972. A comparison of rabbit and human skin response to certain irritants. Toxicol. Appl. Pharmacol. 21, 369\u2013382. Stotts, J., Ely, W.J., 1977. Induction of human skin sensitization to ethanol. J. Invest. Dermatol. 69, 219\u2013222. The Research Institute for Fragrance Materials \" human repeated insult patch test protocol Introduction Protocol Test subjects Test articles Experimental design Induction phase Challenge phase Rechallenge Discussion Conflict of Interest Funding Source References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-Role-of-Inhibition-of-Gap-Junctional-Intercellular-Comm_2000_Regulatory-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/11029268", "content": {"Acknowledgement": "ACKNOWLEDGMENTS The author thanks Drs. J. Smith and M. Penman for making available data from manuscripts in preparation and for critical re- view and particularly G. Pugh, for assistance in preparing the fig- ures. The author also thanks Ms. Rusch for editorial assistance. SUMMARY AND CONCLUSIONS ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/The-SCCS-Notes-of-Guidance-for-the-testing-of-cosmetic-i_2021_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34653552", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The SCCS Notes of Guidance for the testing of cosmetic ingredients and their safety evaluation, 11th revision, 30\u201331 March ... Funding body information CRediT authorship contribution statement Declaration of competing interest Reference", "Funding": "Funding body information None. The SCCS Notes of Guidance for the testing of cosmetic ingredients and their safety evaluation, 11th revision, 30\u201331 March ... Funding body information CRediT authorship contribution statement Declaration of competing interest Reference"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-SCCS-guidance-on-the-safety-assessment-of-_2020_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32061657", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper.", "Funding": "Funding body information None. The SCCS guidance on the safety assessment of nanomaterials in cosmetics Funding body information mk:H1_2 Further reading mk:H2_4"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/The-SCCS-scientific-advice-on-the-safety-of-na_2021_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34560169", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The SCCS scientific advice on the safety of nanomaterials in cosmetics Scientific Advice to be cited as Funding body information Christophe RousselleediT authors contribution statement Declaration of competing interest Transparency document References", "Funding": "The SCCS scientific advice on the safety of nanomaterials in cosmetics Scientific Advice to be cited as Funding body information CRediT authors contribution statement Declaration of competing interest Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-T-cell-dependent-antibody-response-assay-in-nonclini_2014_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24566336", "content": {"CoiStatement": "7 Conclusions 8 Disclaimer Conflict of interest Acknowledgments References", "Acknowledgement": "7 Conclusions 8 Disclaimer Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-Threshold-of-Toxicological-Concern--TTC--is-a-pragmat_2021_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34023455", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 3 Conclusions Funding body information CRediT authorship contribution statement Declaration of competing interest References", "Funding": "Funding body information This work was funded through the Long Range Science Strategy (LRSS) programme of Cosmetics Europe (https://www.lrsscosmetics europe.eu). 3 Conclusions Funding body information CRediT authorship contribution statement Declaration of competing interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-Threshold-of-Toxicological-Concern-for-prenata_2017_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28645885", "content": {"CoiStatement": "B. van Ravenzwaay et al. / Regulatory Toxicology and Pharmacology 88 (2017) 157e172 171 Luechtefeld are consulting Underwriter Laboratories (UL) in their efforts to develop computational tools and services for the safety assessments of chemicals and receive shares of revenue for their efforts. TTC approaches are not currently involved in these efforts. The other authors declare that there are no conflicts of interest. If the end point specific TTC concept gains eventually regulatory acceptance, chemical industry, including BASF SE, employing Ben- nard van Ravenzwaay, may be able to reduce animal testing and reduce financial resources allocated to such tests. 4. Discussion Acknowledgements Conflict of interest statement Funding sources statement Appendix A. Supplementary data Transparency document References", "Funding": "Funding sources statement The work was not funded by any sources. 4. Discussion Acknowledgements Conflict of interest statement Funding sources statement Appendix A. Supplementary data Transparency document References", "Acknowledgement": "4. Discussion Acknowledgements Conflict of interest statement Funding sources statement Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-Tibetan-medicine-Zuotai-differs-from-HgCl2-and_2016_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27032305", "content": {"Acknowledgement": "Acknowledgment This study is supported by Key Laboratory Special Development Program of Qinghai Province (2014-Z-Y02) and Chinese National Science Foundation (81374063; 81560682). 4. Discussion Acknowledgment Appendix A. Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-Use-and-Evaluation-of-Primary-Data-in-29-Trich_2001_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/11502152", "content": {"Acknowledgement": "ACKNOWLEDGMENTS I thank professor Sven Ove Hansson; associate professori Katarina Victorin; and professor Harri Vainio for excellent supervision and support during the work with this paper. 5. SUMMARY AND CONCLUSIONS ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-Use-of-Mechanistic-Data-and-the-Handling-of-Scienti_2002_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/11846638", "content": {"Acknowledgement": "5. SUMMARY 6. CONCLUSIONS AND RECOMMENDATIONS ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-ability-of-animal-studies-to-detect-serious-p_2012_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22982732", "content": {"CoiStatement": "A safety related regulatory action was taken after reports of sudden onset of sleep which was associated with the use of a drug. In non-clinical studies, increased yawning was seen in drug treated rats. In both cats and rats REM sleep depression was observed in drug treated animals. Clearly, these observed effects indicate that the central nervous sys- tem, and in particular sleep, is affected but sudden onset of sleep was not observed. The effects were considered target organ related, but not predictive. Conflict of interest This work was supported by Top Institute Pharma [Project T6- 301]. The views expressed in this article are the personal views of the authors and are not to be understood or quoted as being made on behalf of or reflecting the position of the Medicines Evaluation Board or any other regulatory agency, or one of its com- mittees or working parties. PvM, Marlous Kooijman, CGdW and EM declare no P.J.K. van Meer et al. / Regulatory Toxicology and Pharmacology 64 (2012) 345\u2013349 349 conflict of interest. Huub Schellekens participated in meetings and publications sponsored by Amgen, Johnson & Johnson, Roche, Sandoz and Hospira. Part of his research is directly or indirectly sponsored by Roche and Amgen. Acknowledgments The authors wish to thank Gerard Mulder and Jan-Willem van der Laan for their expert contributions in the evaluation of non- clinical data. We are also grateful to Jane Sykes for her editorial support. References The ability of animal studies to detect serious post marketing adverse events is limited 1 Introduction 2 Methods 3 Results 4 Discussion 5 Conclusion Conflict of interest Acknowledgments References", "Acknowledgement": "P.J.K. van Meer et al. / Regulatory Toxicology and Pharmacology 64 (2012) 345\u2013349 349 conflict of interest. Huub Schellekens participated in meetings and publications sponsored by Amgen, Johnson & Johnson, Roche, Sandoz and Hospira. Part of his research is directly or indirectly sponsored by Roche and Amgen. Acknowledgments The authors wish to thank Gerard Mulder and Jan-Willem van der Laan for their expert contributions in the evaluation of non- clinical data. We are also grateful to Jane Sykes for her editorial support. References The ability of animal studies to detect serious post marketing adverse events is limited 1 Introduction 2 Methods 3 Results 4 Discussion 5 Conclusion Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-absence-of-genotoxicity-of-a-novel-fatty-acid_2020_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31866344", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests. The study was funded by Bial Portela & Companhia S.A. (S\u00e3o Mamede do Coronado, Portugal). Stephen B. Harris, Jerry F. Hardisty, A. Wallace Hayes, and Klaus Weber were paid consultants of Bial. Furthermore, one of the authors (Klaus Weber) was the study pathologist on all of the studies. The manuscript was written by the authors and reviewed by Bial; however, the work product and conclusions are those of the authors. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests. The study was funded by Bial Portela & Companhia S.A. (S\u00e3o Mamede do Coronado, Portugal). Stephen B. Harris, Jerry F. Hardisty, A. Wallace Hayes, and Klaus Weber were paid consultants of Bial. Furthermore, one of the authors (Klaus Weber) was the study pathologist on all of the studies. The manuscript was written by the authors and reviewed by Bial; however, the work product and conclusions are those of the authors. Acknowledgments", "Funding": "Funding The study was funded by Bial Portela & Companhia S.A. (S\u00e3o Mamede do Coronado, Portugal). Stephen B. Harris, Jerry F. Hardisty, A. Wallace Hayes, R\u00fcdiger H\u00e4cker and Klaus Weber were paid con- sultants of Bial. Discussion Funding mk:H1_12 Acknowledgments References", "Acknowledgement": "Acknowledgments The authors would like to acknowledge the contributions of the study directors, Colin G. Riach, Craig MacMillan and Dawn C. Innes, Charles River, Edinburgh, EH33 2NE, UK. Discussion Funding mk:H1_12 Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-accessibility-of-data-on-environmental-risk-assessment-o_2020_Regulatory.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31893528", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. Competing interests The author declare that she has no competing interests. The author declare that she has no competing interests. Funding Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code Relating to Medicinal Products for Human Use (OJ L 311, 28.11.2001, P. 67\u2013128), Last Amended by Article 2 of Amending Regulation (EU) 2019/5 of 11.12.2018 (OJ 2019 No. L 4, 24. European Parliament, Council of the European Union, 2010. Directive 2010/75/EU of the European Parliament and of the Council of 24 November 2010 on industrial emis- sions (integrated pollution prevention and control) Text with EEA relevance (OJ L 334, 17.12.2010, p. 17\u2013119)-. Ferrari, B., Mons, R., Vollat, B., Fraysse, B., Pax\u00e9us, N., Lo Giudice, R., Pollio, A., Garric, J., 2004. Environmental risk assessment of six human pharmaceuticals: are the cur- rent environmental risk assessment procedures sufficient for the protection of the aquatic environment? Environ. Toxicol. Chem. 23, 1344\u20131354. https://doi.org/10. 1897/03-246. Gawel, E., K\u00f6ck, W., Fischer, H., M\u00f6ckel, S., 2017. Arzneimittelabgabe \u2013 inpflichtnahme des Arz-neimittelsektors f\u00fcr Ma\u00dfnahmen zur Reduktion von Mikroschadstoffen in Gew\u00e4ssern TEXTE 115/2017. 91 pp. https://www.umweltbundesamt.de/sites/ default/files/medien/1410/publikationen/2017-12-19_texte_15-2017_ arzneimittelabgabe.pdf Accessed 10 February 2018. German Environment Agency, 2019. Database \"Pharmaceuticals in the environment\". https://www.umweltbundesamt.de/en/database-pharmaceuticals-in-the- environment-1, Accessed date: 12 November 2019. Gunnarsson, L., Snape, J.R., Verbruggen, B., Owen, S.F., Kristiansson, E., Margiotta- Casaluci, L., \u00d6sterlund, T., Hutchinson, K., Leverett, D., Marks, B., Tyler, C.R., 2019. Pharmacology beyond the patient - the environmental risks of human drugs. Environ. Int. 129, 320\u2013332. https://doi.org/10.1016/j.envint.2019.04.075. Halling-S\u00f8rensen, B., Nors Nielsen, S., Lanzky, P.F., Ingerslev, F., Holten L\u00fctzh\u00f8ft, H.C., J\u00f8rgensen, S.E., 1998. Occurrence, fate and effects of pharmaceutical substances in the environment\u2013a review. Chemosphere 36, 357\u2013393. https://doi.org/10.1016/ S0045-6535(97)00354-8. Holtz, S., 2006. There is No away: pharmaceuticals, personal care products, and endo- crine-disrupting substances: emerging contaminants detected in water, toronto. http://www.cielap.org/pub/pub_noaway.php Accessed 7 August 2019. Jones, O.A.H., Voulvoulis, N., Lester, J.N., 2002. Aquatic environmental assessment of the top 25 English prescription pharmaceuticals. Water Res. 36, 5013\u20135022. https://doi. org/10.1016/S0043-1354(02)00227-0. Karthikeyan, K.G., Meyer, M.T., 2006. Occurrence of antibiotics in wastewater treatment facilities in Wisconsin, USA. Sci. Total Environ. 361, 196\u2013207. https://doi.org/10. 1016/j.scitotenv.2005.06.030. K\u00f6ck, W., 2005. Die Entwicklung des Vorsorgeprinzips im Recht \u2014 ein Hemmnis f\u00fcr Innovationen zum nachhaltigen Wirtschaften? In: Hansj\u00fcrgens, B., Nordbeck, R. (Eds.), Chemikalienregulierung und Innovationen zum nachhaltigen Wirtschaften. Physika Verl., Heidelberg, pp. 85\u2013120. Kokott, J., 2016. Opinion of Advocate General Kokott: case C-442/14.Bayer CropScience SA-NV Stichting De Bijenstichting v College voor de toelating van ge- wasbeschermingsmiddelen en biociden. Reports of Cases. 20 pp. https://eur-lex. europa.eu/legal-content/GA/TXT/?uri=CELEX%3A62014CC0442 Accessed 4 February 2019. K\u00fcmmerer, K., 2008. Pharmaceuticals in the Environment: Sources, Fate, Effects and Risks. Springer Berlin Heidelberg. Moermond, C., 2019. The chain approach on pharmaceuticals in The Netherlands: a wicked problem. In: SETAC Europe 29th Annual Meeting, 29 May 2019, Helsinki. Nakata, H., Kannan, K., Jones, P.D., Giesy, J.P., 2005. Determination of fluoroquinolone antibiotics in wastewater effluents by liquid chromatography-mass spectrometry and fluorescence detection. Chemosphere 58, 759\u2013766. https://doi.org/10.1016/j. chemosphere.2004.08.097. Oelkers, K., Floeter, C., 2019. The accessibility of data on environmental risk assessment of pharmaceuticals: is the marketing authorisation procedure in conflict with the international right of access to environmental information? Environ. Sci. Eur. https:// doi.org/10.1186/s12302-019-0256-3. Pereira, A.M.P.T., Silva, L.J.G., Lino, C.M., Meisel, L.M., Pena, A., 2016. Assessing en- vironmental risk of pharmaceuticals in Portugal: an approach for the selection of the Portuguese monitoring stations in line with Directive 2013/39/EU. Chemosphere 144, 2507\u20132515. https://doi.org/10.1016/j.chemosphere.2015.10.100. Rang, H.P., Dale, M.M., 2003. Pharmacology, fifth ed. Churchill Livingstone, Edinburgh, pp. 797. R\u00f6nnefahrt, I., 2014. Monograph system of active pharmaceutical substances: necessity, challenges and perspectives. In: Federal Environment Agency, Germany. Workshop \u201eMonograph System on Active Pharmaceutcial Substances\u201c, 26 November 2014, Brussels. Schwarz, S., Bachmann, J., Brandt, U., 2018. Environmental Risk Assessment of Human Pharmaceuticals - what Can We Learn from Regulatory Effect So Far? SETAC Europe 28th Annual Meeting. German Environment Agency. Touraud, E., Roig, B., 2008. KNAPPE knowledge and need assessment on pharmaceutical products in environmental waters: D6.6 KNAPPE final report. 43 pp. https://cordis. europa.eu/project/rcn/81276/reporting/en Accessed 8 March 2019. The United Nations Economic Commission for Europe, 1998. Convention on Access to Information, Public Participation in Decision-Making and Access to Justice in Environmental Matters, Done at Aarhus, Denmark, on 25 June 1998: Aarhus Convention. United Nations, Economic Commission for Europe, 2014. The Aarhus convention: an implementation guide. 282 pp. http://www.unece.org/fileadmin/DAM/env/pp/ Publications/Aarhus_Implementation_Guide_interactive_eng.pdf Accessed 25 June 2018. Voulvoulis, N., Barc\u00e9lo, D., Verlicchi, P., 2016. Pharmaceutical residues in sewage treatment works. In: Hester, R.E., Harrison, R.M. (Eds.), Pharmaceuticals in the Environment, pp. 120\u2013179. Wegener, B.W., 2017. Kein \u201eMund auf \u2013 Augen zu\u201c \u2013 Der freie Zugang zu Informationen \u00fcber Emissionen in die Umwelt. Z. Umweltrecht: ZUR 28, 146\u2013152. K. Oelkers Regulatory Toxicology and Pharmacology 111 (2020) 104571 8 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref26 https://doi.org/10.1897/03-246 https://doi.org/10.1897/03-246 https://www.umweltbundesamt.de/sites/default/files/medien/1410/publikationen/2017-12-19_texte_15-2017_arzneimittelabgabe.pdf https://www.umweltbundesamt.de/sites/default/files/medien/1410/publikationen/2017-12-19_texte_15-2017_arzneimittelabgabe.pdf https://www.umweltbundesamt.de/sites/default/files/medien/1410/publikationen/2017-12-19_texte_15-2017_arzneimittelabgabe.pdf https://www.umweltbundesamt.de/en/database-pharmaceuticals-in-the-environment-1 https://www.umweltbundesamt.de/en/database-pharmaceuticals-in-the-environment-1 https://doi.org/10.1016/j.envint.2019.04.075 https://doi.org/10.1016/S0045-6535(97)00354-8 https://doi.org/10.1016/S0045-6535(97)00354-8 http://www.cielap.org/pub/pub_noaway.php https://doi.org/10.1016/S0043-1354(02)00227-0 https://doi.org/10.1016/S0043-1354(02)00227-0 https://doi.org/10.1016/j.scitotenv.2005.06.030 https://doi.org/10.1016/j.scitotenv.2005.06.030 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref42 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref42 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref42 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref42 https://eur-lex.europa.eu/legal-content/GA/TXT/?uri=CELEX%3A62014CC0442 https://eur-lex.europa.eu/legal-content/GA/TXT/?uri=CELEX%3A62014CC0442 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref44 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref44 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref45 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref45 https://doi.org/10.1016/j.chemosphere.2004.08.097 https://doi.org/10.1016/j.chemosphere.2004.08.097 https://doi.org/10.1186/s12302-019-0256-3 https://doi.org/10.1186/s12302-019-0256-3 https://doi.org/10.1016/j.chemosphere.2015.10.100 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref49 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref49 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref51 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref51 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref51 https://cordis.europa.eu/project/rcn/81276/reporting/en https://cordis.europa.eu/project/rcn/81276/reporting/en http://refhub.elsevier.com/S0273-2300(19)30335-6/sref52 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref52 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref52 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref52 http://www.unece.org/fileadmin/DAM/env/pp/Publications/Aarhus_Implementation_Guide_interactive_eng.pdf http://www.unece.org/fileadmin/DAM/env/pp/Publications/Aarhus_Implementation_Guide_interactive_eng.pdf http://refhub.elsevier.com/S0273-2300(19)30335-6/sref55 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref55 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref55 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref56 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref56 The accessibility of data on environmental risk assessment of pharmaceuticals \u2013 are environmental risk assessments information on emissions with respect to international and European environmental information law? Introduction Methods Results Emissions into the environment The distinction between emissions, discharges and other releases Definition of emissions in other European Union acts Limitation to predictable emissions European Court of Justice Calculation of the predicted environmental concentration as part of the pharmaceutical authorisation process Differentiation from purely hypothetical emissions Actually present in the environment Comparison with plant protection products and biocides whose release is recognized as an emission by the European Court of Justice Jurisprudence Result Information on emissions into the environment Information on emissions as such and on their fate and effects Ecotoxicity of the foreseeable emission Scope of information Result Discussion Conclusions mk:H1_21 Acknowledgements Abbreviations Ethics approval and consent to participate Consent for publication Availability of data and material Competing interests Funding Authors\u2019 contributions References", "Funding": "The author would also like to thank the law office Teppe Hamburg for its funding and the Hamburg University of Applied Sciences for supporting the PharmCycle project. Abbreviations Funding The Hamburg University of Applied Sciences funds the PharmCycle project in which this legal project is integrated. The legal subproject is funded by the law office Teppe Hamburg. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code Relating to Medicinal Products for Human Use (OJ L 311, 28.11.2001, P. 67\u2013128), Last Amended by Article 2 of Amending Regulation (EU) 2019/5 of 11.12.2018 (OJ 2019 No. L 4, 24. European Parliament, Council of the European Union, 2010. Directive 2010/75/EU of the European Parliament and of the Council of 24 November 2010 on industrial emis- sions (integrated pollution prevention and control) Text with EEA relevance (OJ L 334, 17.12.2010, p. 17\u2013119)-. Ferrari, B., Mons, R., Vollat, B., Fraysse, B., Pax\u00e9us, N., Lo Giudice, R., Pollio, A., Garric, J., 2004. Environmental risk assessment of six human pharmaceuticals: are the cur- rent environmental risk assessment procedures sufficient for the protection of the aquatic environment? Environ. Toxicol. Chem. 23, 1344\u20131354. https://doi.org/10. 1897/03-246. Gawel, E., K\u00f6ck, W., Fischer, H., M\u00f6ckel, S., 2017. Arzneimittelabgabe \u2013 inpflichtnahme des Arz-neimittelsektors f\u00fcr Ma\u00dfnahmen zur Reduktion von Mikroschadstoffen in Gew\u00e4ssern TEXTE 115/2017. 91 pp. https://www.umweltbundesamt.de/sites/ default/files/medien/1410/publikationen/2017-12-19_texte_15-2017_ arzneimittelabgabe.pdf Accessed 10 February 2018. German Environment Agency, 2019. Database \"Pharmaceuticals in the environment\". https://www.umweltbundesamt.de/en/database-pharmaceuticals-in-the- environment-1, Accessed date: 12 November 2019. Gunnarsson, L., Snape, J.R., Verbruggen, B., Owen, S.F., Kristiansson, E., Margiotta- Casaluci, L., \u00d6sterlund, T., Hutchinson, K., Leverett, D., Marks, B., Tyler, C.R., 2019. Pharmacology beyond the patient - the environmental risks of human drugs. Environ. Int. 129, 320\u2013332. https://doi.org/10.1016/j.envint.2019.04.075. Halling-S\u00f8rensen, B., Nors Nielsen, S., Lanzky, P.F., Ingerslev, F., Holten L\u00fctzh\u00f8ft, H.C., J\u00f8rgensen, S.E., 1998. Occurrence, fate and effects of pharmaceutical substances in the environment\u2013a review. Chemosphere 36, 357\u2013393. https://doi.org/10.1016/ S0045-6535(97)00354-8. Holtz, S., 2006. There is No away: pharmaceuticals, personal care products, and endo- crine-disrupting substances: emerging contaminants detected in water, toronto. http://www.cielap.org/pub/pub_noaway.php Accessed 7 August 2019. Jones, O.A.H., Voulvoulis, N., Lester, J.N., 2002. Aquatic environmental assessment of the top 25 English prescription pharmaceuticals. Water Res. 36, 5013\u20135022. https://doi. org/10.1016/S0043-1354(02)00227-0. Karthikeyan, K.G., Meyer, M.T., 2006. Occurrence of antibiotics in wastewater treatment facilities in Wisconsin, USA. Sci. Total Environ. 361, 196\u2013207. https://doi.org/10. 1016/j.scitotenv.2005.06.030. K\u00f6ck, W., 2005. Die Entwicklung des Vorsorgeprinzips im Recht \u2014 ein Hemmnis f\u00fcr Innovationen zum nachhaltigen Wirtschaften? In: Hansj\u00fcrgens, B., Nordbeck, R. (Eds.), Chemikalienregulierung und Innovationen zum nachhaltigen Wirtschaften. Physika Verl., Heidelberg, pp. 85\u2013120. Kokott, J., 2016. Opinion of Advocate General Kokott: case C-442/14.Bayer CropScience SA-NV Stichting De Bijenstichting v College voor de toelating van ge- wasbeschermingsmiddelen en biociden. Reports of Cases. 20 pp. https://eur-lex. europa.eu/legal-content/GA/TXT/?uri=CELEX%3A62014CC0442 Accessed 4 February 2019. K\u00fcmmerer, K., 2008. Pharmaceuticals in the Environment: Sources, Fate, Effects and Risks. Springer Berlin Heidelberg. Moermond, C., 2019. The chain approach on pharmaceuticals in The Netherlands: a wicked problem. In: SETAC Europe 29th Annual Meeting, 29 May 2019, Helsinki. Nakata, H., Kannan, K., Jones, P.D., Giesy, J.P., 2005. Determination of fluoroquinolone antibiotics in wastewater effluents by liquid chromatography-mass spectrometry and fluorescence detection. Chemosphere 58, 759\u2013766. https://doi.org/10.1016/j. chemosphere.2004.08.097. Oelkers, K., Floeter, C., 2019. The accessibility of data on environmental risk assessment of pharmaceuticals: is the marketing authorisation procedure in conflict with the international right of access to environmental information? Environ. Sci. Eur. https:// doi.org/10.1186/s12302-019-0256-3. Pereira, A.M.P.T., Silva, L.J.G., Lino, C.M., Meisel, L.M., Pena, A., 2016. Assessing en- vironmental risk of pharmaceuticals in Portugal: an approach for the selection of the Portuguese monitoring stations in line with Directive 2013/39/EU. Chemosphere 144, 2507\u20132515. https://doi.org/10.1016/j.chemosphere.2015.10.100. Rang, H.P., Dale, M.M., 2003. Pharmacology, fifth ed. Churchill Livingstone, Edinburgh, pp. 797. R\u00f6nnefahrt, I., 2014. Monograph system of active pharmaceutical substances: necessity, challenges and perspectives. In: Federal Environment Agency, Germany. Workshop \u201eMonograph System on Active Pharmaceutcial Substances\u201c, 26 November 2014, Brussels. Schwarz, S., Bachmann, J., Brandt, U., 2018. Environmental Risk Assessment of Human Pharmaceuticals - what Can We Learn from Regulatory Effect So Far? SETAC Europe 28th Annual Meeting. German Environment Agency. Touraud, E., Roig, B., 2008. KNAPPE knowledge and need assessment on pharmaceutical products in environmental waters: D6.6 KNAPPE final report. 43 pp. https://cordis. europa.eu/project/rcn/81276/reporting/en Accessed 8 March 2019. The United Nations Economic Commission for Europe, 1998. Convention on Access to Information, Public Participation in Decision-Making and Access to Justice in Environmental Matters, Done at Aarhus, Denmark, on 25 June 1998: Aarhus Convention. United Nations, Economic Commission for Europe, 2014. The Aarhus convention: an implementation guide. 282 pp. http://www.unece.org/fileadmin/DAM/env/pp/ Publications/Aarhus_Implementation_Guide_interactive_eng.pdf Accessed 25 June 2018. Voulvoulis, N., Barc\u00e9lo, D., Verlicchi, P., 2016. Pharmaceutical residues in sewage treatment works. In: Hester, R.E., Harrison, R.M. (Eds.), Pharmaceuticals in the Environment, pp. 120\u2013179. Wegener, B.W., 2017. Kein \u201eMund auf \u2013 Augen zu\u201c \u2013 Der freie Zugang zu Informationen \u00fcber Emissionen in die Umwelt. Z. Umweltrecht: ZUR 28, 146\u2013152. K. Oelkers Regulatory Toxicology and Pharmacology 111 (2020) 104571 8 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref26 https://doi.org/10.1897/03-246 https://doi.org/10.1897/03-246 https://www.umweltbundesamt.de/sites/default/files/medien/1410/publikationen/2017-12-19_texte_15-2017_arzneimittelabgabe.pdf https://www.umweltbundesamt.de/sites/default/files/medien/1410/publikationen/2017-12-19_texte_15-2017_arzneimittelabgabe.pdf https://www.umweltbundesamt.de/sites/default/files/medien/1410/publikationen/2017-12-19_texte_15-2017_arzneimittelabgabe.pdf https://www.umweltbundesamt.de/en/database-pharmaceuticals-in-the-environment-1 https://www.umweltbundesamt.de/en/database-pharmaceuticals-in-the-environment-1 https://doi.org/10.1016/j.envint.2019.04.075 https://doi.org/10.1016/S0045-6535(97)00354-8 https://doi.org/10.1016/S0045-6535(97)00354-8 http://www.cielap.org/pub/pub_noaway.php https://doi.org/10.1016/S0043-1354(02)00227-0 https://doi.org/10.1016/S0043-1354(02)00227-0 https://doi.org/10.1016/j.scitotenv.2005.06.030 https://doi.org/10.1016/j.scitotenv.2005.06.030 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref42 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref42 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref42 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref42 https://eur-lex.europa.eu/legal-content/GA/TXT/?uri=CELEX%3A62014CC0442 https://eur-lex.europa.eu/legal-content/GA/TXT/?uri=CELEX%3A62014CC0442 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref44 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref44 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref45 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref45 https://doi.org/10.1016/j.chemosphere.2004.08.097 https://doi.org/10.1016/j.chemosphere.2004.08.097 https://doi.org/10.1186/s12302-019-0256-3 https://doi.org/10.1186/s12302-019-0256-3 https://doi.org/10.1016/j.chemosphere.2015.10.100 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref49 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref49 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref51 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref51 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref51 https://cordis.europa.eu/project/rcn/81276/reporting/en https://cordis.europa.eu/project/rcn/81276/reporting/en http://refhub.elsevier.com/S0273-2300(19)30335-6/sref52 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref52 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref52 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref52 http://www.unece.org/fileadmin/DAM/env/pp/Publications/Aarhus_Implementation_Guide_interactive_eng.pdf http://www.unece.org/fileadmin/DAM/env/pp/Publications/Aarhus_Implementation_Guide_interactive_eng.pdf http://refhub.elsevier.com/S0273-2300(19)30335-6/sref55 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref55 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref55 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref56 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref56 The accessibility of data on environmental risk assessment of pharmaceuticals \u2013 are environmental risk assessments information on emissions with respect to international and European environmental information law? Introduction Methods Results Emissions into the environment The distinction between emissions, discharges and other releases Definition of emissions in other European Union acts Limitation to predictable emissions European Court of Justice Calculation of the predicted environmental concentration as part of the pharmaceutical authorisation process Differentiation from purely hypothetical emissions Actually present in the environment Comparison with plant protection products and biocides whose release is recognized as an emission by the European Court of Justice Jurisprudence Result Information on emissions into the environment Information on emissions as such and on their fate and effects Ecotoxicity of the foreseeable emission Scope of information Result Discussion Conclusions mk:H1_21 Acknowledgements Abbreviations Ethics approval and consent to participate Consent for publication Availability of data and material Competing interests Funding Authors\u2019 contributions References", "Acknowledgement": "Acknowledgements The author would like to thank Prof. Dr. Carolin Floeter for the helpful and constructive remarks. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code Relating to Medicinal Products for Human Use (OJ L 311, 28.11.2001, P. 67\u2013128), Last Amended by Article 2 of Amending Regulation (EU) 2019/5 of 11.12.2018 (OJ 2019 No. L 4, 24. European Parliament, Council of the European Union, 2010. Directive 2010/75/EU of the European Parliament and of the Council of 24 November 2010 on industrial emis- sions (integrated pollution prevention and control) Text with EEA relevance (OJ L 334, 17.12.2010, p. 17\u2013119)-. Ferrari, B., Mons, R., Vollat, B., Fraysse, B., Pax\u00e9us, N., Lo Giudice, R., Pollio, A., Garric, J., 2004. Environmental risk assessment of six human pharmaceuticals: are the cur- rent environmental risk assessment procedures sufficient for the protection of the aquatic environment? Environ. Toxicol. Chem. 23, 1344\u20131354. https://doi.org/10. 1897/03-246. Gawel, E., K\u00f6ck, W., Fischer, H., M\u00f6ckel, S., 2017. Arzneimittelabgabe \u2013 inpflichtnahme des Arz-neimittelsektors f\u00fcr Ma\u00dfnahmen zur Reduktion von Mikroschadstoffen in Gew\u00e4ssern TEXTE 115/2017. 91 pp. https://www.umweltbundesamt.de/sites/ default/files/medien/1410/publikationen/2017-12-19_texte_15-2017_ arzneimittelabgabe.pdf Accessed 10 February 2018. German Environment Agency, 2019. Database \"Pharmaceuticals in the environment\". https://www.umweltbundesamt.de/en/database-pharmaceuticals-in-the- environment-1, Accessed date: 12 November 2019. Gunnarsson, L., Snape, J.R., Verbruggen, B., Owen, S.F., Kristiansson, E., Margiotta- Casaluci, L., \u00d6sterlund, T., Hutchinson, K., Leverett, D., Marks, B., Tyler, C.R., 2019. Pharmacology beyond the patient - the environmental risks of human drugs. Environ. Int. 129, 320\u2013332. https://doi.org/10.1016/j.envint.2019.04.075. Halling-S\u00f8rensen, B., Nors Nielsen, S., Lanzky, P.F., Ingerslev, F., Holten L\u00fctzh\u00f8ft, H.C., J\u00f8rgensen, S.E., 1998. Occurrence, fate and effects of pharmaceutical substances in the environment\u2013a review. Chemosphere 36, 357\u2013393. https://doi.org/10.1016/ S0045-6535(97)00354-8. Holtz, S., 2006. There is No away: pharmaceuticals, personal care products, and endo- crine-disrupting substances: emerging contaminants detected in water, toronto. http://www.cielap.org/pub/pub_noaway.php Accessed 7 August 2019. Jones, O.A.H., Voulvoulis, N., Lester, J.N., 2002. Aquatic environmental assessment of the top 25 English prescription pharmaceuticals. Water Res. 36, 5013\u20135022. https://doi. org/10.1016/S0043-1354(02)00227-0. Karthikeyan, K.G., Meyer, M.T., 2006. Occurrence of antibiotics in wastewater treatment facilities in Wisconsin, USA. Sci. Total Environ. 361, 196\u2013207. https://doi.org/10. 1016/j.scitotenv.2005.06.030. K\u00f6ck, W., 2005. Die Entwicklung des Vorsorgeprinzips im Recht \u2014 ein Hemmnis f\u00fcr Innovationen zum nachhaltigen Wirtschaften? In: Hansj\u00fcrgens, B., Nordbeck, R. (Eds.), Chemikalienregulierung und Innovationen zum nachhaltigen Wirtschaften. Physika Verl., Heidelberg, pp. 85\u2013120. Kokott, J., 2016. Opinion of Advocate General Kokott: case C-442/14.Bayer CropScience SA-NV Stichting De Bijenstichting v College voor de toelating van ge- wasbeschermingsmiddelen en biociden. Reports of Cases. 20 pp. https://eur-lex. europa.eu/legal-content/GA/TXT/?uri=CELEX%3A62014CC0442 Accessed 4 February 2019. K\u00fcmmerer, K., 2008. Pharmaceuticals in the Environment: Sources, Fate, Effects and Risks. Springer Berlin Heidelberg. Moermond, C., 2019. The chain approach on pharmaceuticals in The Netherlands: a wicked problem. In: SETAC Europe 29th Annual Meeting, 29 May 2019, Helsinki. Nakata, H., Kannan, K., Jones, P.D., Giesy, J.P., 2005. Determination of fluoroquinolone antibiotics in wastewater effluents by liquid chromatography-mass spectrometry and fluorescence detection. Chemosphere 58, 759\u2013766. https://doi.org/10.1016/j. chemosphere.2004.08.097. Oelkers, K., Floeter, C., 2019. The accessibility of data on environmental risk assessment of pharmaceuticals: is the marketing authorisation procedure in conflict with the international right of access to environmental information? Environ. Sci. Eur. https:// doi.org/10.1186/s12302-019-0256-3. Pereira, A.M.P.T., Silva, L.J.G., Lino, C.M., Meisel, L.M., Pena, A., 2016. Assessing en- vironmental risk of pharmaceuticals in Portugal: an approach for the selection of the Portuguese monitoring stations in line with Directive 2013/39/EU. Chemosphere 144, 2507\u20132515. https://doi.org/10.1016/j.chemosphere.2015.10.100. Rang, H.P., Dale, M.M., 2003. Pharmacology, fifth ed. Churchill Livingstone, Edinburgh, pp. 797. R\u00f6nnefahrt, I., 2014. Monograph system of active pharmaceutical substances: necessity, challenges and perspectives. In: Federal Environment Agency, Germany. Workshop \u201eMonograph System on Active Pharmaceutcial Substances\u201c, 26 November 2014, Brussels. Schwarz, S., Bachmann, J., Brandt, U., 2018. Environmental Risk Assessment of Human Pharmaceuticals - what Can We Learn from Regulatory Effect So Far? SETAC Europe 28th Annual Meeting. German Environment Agency. Touraud, E., Roig, B., 2008. KNAPPE knowledge and need assessment on pharmaceutical products in environmental waters: D6.6 KNAPPE final report. 43 pp. https://cordis. europa.eu/project/rcn/81276/reporting/en Accessed 8 March 2019. The United Nations Economic Commission for Europe, 1998. Convention on Access to Information, Public Participation in Decision-Making and Access to Justice in Environmental Matters, Done at Aarhus, Denmark, on 25 June 1998: Aarhus Convention. United Nations, Economic Commission for Europe, 2014. The Aarhus convention: an implementation guide. 282 pp. http://www.unece.org/fileadmin/DAM/env/pp/ Publications/Aarhus_Implementation_Guide_interactive_eng.pdf Accessed 25 June 2018. Voulvoulis, N., Barc\u00e9lo, D., Verlicchi, P., 2016. Pharmaceutical residues in sewage treatment works. In: Hester, R.E., Harrison, R.M. (Eds.), Pharmaceuticals in the Environment, pp. 120\u2013179. Wegener, B.W., 2017. Kein \u201eMund auf \u2013 Augen zu\u201c \u2013 Der freie Zugang zu Informationen \u00fcber Emissionen in die Umwelt. Z. Umweltrecht: ZUR 28, 146\u2013152. K. Oelkers Regulatory Toxicology and Pharmacology 111 (2020) 104571 8 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref25 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref26 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref26 https://doi.org/10.1897/03-246 https://doi.org/10.1897/03-246 https://www.umweltbundesamt.de/sites/default/files/medien/1410/publikationen/2017-12-19_texte_15-2017_arzneimittelabgabe.pdf https://www.umweltbundesamt.de/sites/default/files/medien/1410/publikationen/2017-12-19_texte_15-2017_arzneimittelabgabe.pdf https://www.umweltbundesamt.de/sites/default/files/medien/1410/publikationen/2017-12-19_texte_15-2017_arzneimittelabgabe.pdf https://www.umweltbundesamt.de/en/database-pharmaceuticals-in-the-environment-1 https://www.umweltbundesamt.de/en/database-pharmaceuticals-in-the-environment-1 https://doi.org/10.1016/j.envint.2019.04.075 https://doi.org/10.1016/S0045-6535(97)00354-8 https://doi.org/10.1016/S0045-6535(97)00354-8 http://www.cielap.org/pub/pub_noaway.php https://doi.org/10.1016/S0043-1354(02)00227-0 https://doi.org/10.1016/S0043-1354(02)00227-0 https://doi.org/10.1016/j.scitotenv.2005.06.030 https://doi.org/10.1016/j.scitotenv.2005.06.030 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref42 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref42 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref42 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref42 https://eur-lex.europa.eu/legal-content/GA/TXT/?uri=CELEX%3A62014CC0442 https://eur-lex.europa.eu/legal-content/GA/TXT/?uri=CELEX%3A62014CC0442 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref44 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref44 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref45 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref45 https://doi.org/10.1016/j.chemosphere.2004.08.097 https://doi.org/10.1016/j.chemosphere.2004.08.097 https://doi.org/10.1186/s12302-019-0256-3 https://doi.org/10.1186/s12302-019-0256-3 https://doi.org/10.1016/j.chemosphere.2015.10.100 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref49 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref49 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref50 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref51 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref51 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref51 https://cordis.europa.eu/project/rcn/81276/reporting/en https://cordis.europa.eu/project/rcn/81276/reporting/en http://refhub.elsevier.com/S0273-2300(19)30335-6/sref52 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref52 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref52 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref52 http://www.unece.org/fileadmin/DAM/env/pp/Publications/Aarhus_Implementation_Guide_interactive_eng.pdf http://www.unece.org/fileadmin/DAM/env/pp/Publications/Aarhus_Implementation_Guide_interactive_eng.pdf http://refhub.elsevier.com/S0273-2300(19)30335-6/sref55 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref55 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref55 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref56 http://refhub.elsevier.com/S0273-2300(19)30335-6/sref56 The accessibility of data on environmental risk assessment of pharmaceuticals \u2013 are environmental risk assessments information on emissions with respect to international and European environmental information law? Introduction Methods Results Emissions into the environment The distinction between emissions, discharges and other releases Definition of emissions in other European Union acts Limitation to predictable emissions European Court of Justice Calculation of the predicted environmental concentration as part of the pharmaceutical authorisation process Differentiation from purely hypothetical emissions Actually present in the environment Comparison with plant protection products and biocides whose release is recognized as an emission by the European Court of Justice Jurisprudence Result Information on emissions into the environment Information on emissions as such and on their fate and effects Ecotoxicity of the foreseeable emission Scope of information Result Discussion Conclusions mk:H1_21 Acknowledgements Abbreviations Ethics approval and consent to participate Consent for publication Availability of data and material Competing interests Funding Authors\u2019 contributions References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-activity-of-methacrylate-esters-in-skin-sens_2019_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30826317", "content": {"Acknowledgement": "Discussion Conclusions Acknowledgement Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-activity-of-methacrylate-esters-in-skin-sensitisat_2021_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33186628", "content": {"CoiStatement": "3 Discussion 4 Concluding comments Declaration of competing interest Acknowledgement References", "Acknowledgement": "3 Discussion 4 Concluding comments Declaration of competing interest Acknowledgement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-acute-effects-of-daily-nicotine-intake-on-heart-_2014_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25066669", "content": {"CoiStatement": "4 Discussion 5 Conclusions Conflicts of interest Acknowledgments Appendix A.1 References", "Acknowledgement": "4 Discussion 5 Conclusions Conflicts of interest Acknowledgments Appendix A.1 References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-acute-lethal-dose-50--LD50--of-caffeine_2016_Regulatory-Toxicology-and-P.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27461039", "content": {"CoiStatement": "Conflict of interest information The funding for the literature review of this article was provided by the American Beverage Association. The acute lethal dose 50 (LD50) of caffeine in albino rats 1. Summary Conflict of interest information References", "Funding": "The funding for the literature review of this article was provided by the American Beverage Association. Richard H. Adamson is a consultant for the American Beverage Association."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-added-value-of-the-90-day-repeated-dose-oral-toxicity_2014_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24768988", "content": {"CoiStatement": "Conflict of interest None declared. 5 Conclusion Conflict of interest Acknowledgments References", "Funding": "The authors are grateful to Ian Indans, Sarah Dutton and Gary Dougherty of the UK Health and Safety Executive for initiating the NONS study, for sharing their findings and providing advice on this analysis. The authors are also grateful to members of the Member State Committee for providing comments on the study at the 29th meeting in April 2013. Authors Taylor and Rego were supported by funding from the BUAV Charitable Trust. Finally, the authors are very grateful to the holders of the eChemPortal and the ECHA CHEM database for these valuable, free resources. References", "Acknowledgement": "Acknowledgments The authors are grateful to Ian Indans, Sarah Dutton and Gary Dougherty of the UK Health and Safety Executive for initiating the NONS study, for sharing their findings and providing advice on this analysis. The authors are also grateful to members of the Member State Committee for providing comments on the study at the 29th meeting in April 2013. Authors Taylor and Rego were supported by funding from the BUAV Charitable Trust. Finally, the authors are very grateful to the holders of the eChemPortal and the ECHA CHEM database for these valuable, free resources. 5 Conclusion Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-added-value-of-the-90-day-repeated-dose-oral-toxicity_2017_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28919391", "content": {"Funding": "Author Taylor was supported by funding from the Cruelty Free International Charitable Trust during the drafting of this manuscript. Transparency document Transparency document related to this article can be found online at https://doi.org/10.1016/j.yrtph.2017.09.018. References", "Acknowledgement": "It should be noted that relatively few substanceswillfit this kind of chemical space; only approximately 10% of substances so far regis- tered on the various databases appear to fit this profile. Nonetheless, any opportunity to avoid unnecessary animal testing should be taken where possible. Therewill be more substances for which there is now 90-day study data available (see for example, Luechtefeld et al., 2016), including more substances for which testing proposals have been submitted since our cut-off date of 1 September 2012, so it is possible to further test our hypothesis with more substances. Acknowledgments Author Taylor was supported by funding from the Cruelty Free International Charitable Trust during the drafting of this manuscript. Transparency document The added value of the 90-day repeated dose oral toxicity test for industrial chemicals with a low (sub)acute toxicity prof ... 1. Introduction 2. Results 3. Conclusion Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-adverse-outcome-pathway-for-rodent-liver-tumor-pr_2015_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26145830", "content": {"Acknowledgement": "9. Conclusions Acknowledgments Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-antipsychotics-haloperidol-and-chlorpromazine-inc_2010_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20709132", "content": {"CoiStatement": "Conflict of interest statement Takeshi Kunimatsu, Juki Kimura, Hitoshi Funabashi, Tadashi Inoue and Takaki Seki are all full-time employees of Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan. Discussion Conclusion Conflict of interest statement Acknowledgment References", "Funding": "Funding for this research was provided by Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan. Acknowledgment", "Acknowledgement": "Acknowledgment A preliminary summary of the data in this manuscript appeared previously in a Japanese language industry magazine. Discussion Conclusion Conflict of interest statement Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-antithrombotic--anticoagulant-activity-and-toxicity-_2018_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29524465", "content": {"CoiStatement": "Conflicts of interest The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgements Discussion Conclusion Conflicts of interest Acknowledgements Transparency document References", "Acknowledgement": "Acknowledgements This work was supported by the Science and Technology Planning Project from Liaoning Provincial Department of Education (Grant No. L2014381), the Key Laboratory Program from Liaoning Province Science and Technology office, China [serial number: 2011(20)] and Liaoning Institute for Drug Control of China. Discussion Conclusion Conflicts of interest Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-application-of-structure-based-assessment-to-support-s_2006_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16464524", "content": {"Acknowledgement": "Acknowledgments The authors acknowledge the eVorts of Christopher Smith in compiling compounds for the retrospective analy- sis, as well as Roger Nosal, David De Antonis, and Russell Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-bottom-up-approach-to-bounding-potential-low-d_2016_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26851508", "content": {"CoiStatement": "Conflict of interest statement Thomas B Starr has served as a consultant on risk assessment issues related to formaldehyde for the American Chemistry Council. The formal- dehyde research conducted by James A Swenberg has been funded in part by the NIEHS, the American Chemistry Council, Formacare, and the Texas Commission for Environmental Quality. The sponsors do not have access to research results until they have been accepted for publi- cation. James A Swenberg has also served as a formaldehyde consultant to ENVI- RON International. Conflict of interest statement Acknowledgments Transparency document References", "Acknowledgement": "Acknowledgments Dr. Robinan Gentry provided invaluable comments on a previ- ous draft of this manuscript. Thomas B Starr received partial financial support for this work under Agreement R0069 from the American Chem- istry Council's Research Foundation for Health and Environmental Effects, Washington DC. Conflict of interest statement Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-challenge-of-reproductive-and-developmenta_2008_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18490093", "content": {"Compliance with ethical standards": "The cost of compliance Alternatives to whole-animal testing Quantitative structure-activity relationship and related analyses In vitro testing Grouping or read-across Classification and labeling Integrated testing strategy Conclusions Acknowledgments References", "Acknowledgement": "Acknowledgments The author appreciates the invaluable input of Dr. Herman Gibb and A.J. Guikema. Classification and labeling Integrated testing strategy Conclusions Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-challenge-of-the-application-of--omics-technolog_2017_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28927750", "content": {"CoiStatement": "5. Discussion towards facilitating the regulatory acceptance and use of transcriptomics microarray methodologies Conflict of interest Disclaimer Acknowledgements Appendix A. Supplementary data Transparency document References", "Acknowledgement": "5. Discussion towards facilitating the regulatory acceptance and use of transcriptomics microarray methodologies Conflict of interest Disclaimer Acknowledgements Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-challenge-of-using-read-across-within-the-EU-REACH-reg_2014_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24378700", "content": {"Compliance with ethical standards": "N. Ball et al. / Regulatory Toxicology and Pharmacology 68 (2014) 212\u2013221 221 compliance with the regulation. However given this situation where a potentially unnecessary study is performed, it is critical that the issues highlighted in this case study are addressed so that read-across can reach its full potential under regulatory pro- grammes such as EU REACH as a means of avoiding unnecessary animal testing. References Andreasen, M.F. et al., 2001. Esterase activity able to hydrolyze dietary antioxidant hydroxycinnamates is distributed along the intestine of mammals. J. Agric. Food Chem. 49, 5679\u20135684."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-changing-face-of-nanomaterials--Risk-assessme_2017_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27998719", "content": {"Funding": "This work has been partly supported by grants from the EU FP7 Programme to the projects SIINN (Project #265799) and NANOREG (Project #310584). The funding agencies had no influence on any part of the process leading to the writing and submission of this manuscript. Parts of the content in this paper has been used in internal re- ports in the above mentioned projects.", "Acknowledgement": "M.-O. Mattsson, M. Simk\ufffdo / Regulatory Toxicology and Pharmacology 84 (2017) 105e115114 Acknowledgements This work has been partly supported by grants from the EU FP7 Programme to the projects SIINN (Project #265799) and NANOREG (Project #310584). The funding agencies had no influence on any part of the process leading to the writing and submission of this manuscript. 6. Discussion and conclusions Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-chronic-hepatotoxicity-assessment-of-the-he_2017_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27916537", "content": {"CoiStatement": "Conflict of interest No competing financial interests declared. 4. Discussion 5. Conclusions Conflict of interest Acknowledgements Transparency document References", "Acknowledgement": "Acknowledgements This work is supported by Special Research Project of TCMs by State Administration of Traditional Chinese Medicine of China (2015468004-2). 4. Discussion 5. Conclusions Conflict of interest Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-combination-of-two-novel-tobacco-blends-and-filter-t_2015_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25584437", "content": {"CoiStatement": "Conflicts of interest statement This work was funded by British American Tobacco (BAT) and all authors are employees of BAT. 4 Discussion Conflicts of interest statement Acknowledgments References", "Acknowledgement": "Acknowledgments The authors thank Research Support Services, BAT for producing the particulate matter and Covance Laboratories, UK for conduct- ing the in vitro testing and providing the statistical analysis. References 4 Discussion Conflicts of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-comparative-toxicology-of-4-chloro-2-methylphenoxya_2005_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15896442", "content": {"Compliance with ethical standards": "OECD, 1981. Decision of the council concerning the mutual accep- tance of data in the assessment of chemicals. In: OECD Series on the Principles of Good Laboratory Practice and Compliance Moni- toring, No. 1, Monograph 45. OECD, Paris. OECD, 1995. OECD Guideline No. 407. OECD Test Guidelines for testing of chemicals, Section 4, Health EVects (updated 27 July, 1995). OECD, Paris.", "Acknowledgement": "A further point that needs to be addressed is the structure (activity) relationship. Clearly in case of CCPA there is a signiWcant structural relationship with the ref- erence compound MCPA. For general read-across crite- ria structural relationship should play an important role in the considerations. However, as biotransformation may radically alter the chemical structure of a molecule, this aspect should also be considered. In those cases where the main metabolite of the chemical for which read across is to be performed is structurally similar to the reference chemical, or may be formed in the metabo- lism of this chemical read across can be justiWed. How- ever, if the metabolite is signiWcantly dissimilar and this metabolite (or a close structural analog) is not a meta- bolic product of the reference chemical the use of read across must be approached with caution. In contrast read across could be justiWed if a complex molecule is rapidly and completely metabolized to one or more chemicals with a suitable information base. Under such circumstances minimal data on the toxicological poten- tial of the complex molecule may suYce. Acknowledgments The studies were sponsored by the MCPA Task Force Three. We thank Dr. Tennekes for the initial preparation of the manuscript. Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-comparison-of-animal-models-for-premature-ovarian_2016_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27612992", "content": {"CoiStatement": "4. Discussion 5. Conclusion Conflict of interest statement Funding sources Transparency document References", "Funding": "4. Discussion 5. Conclusion Conflict of interest statement Funding sources Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-design-of-chronic-toxicology-studies-of-monoclonal_2012_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22100994", "content": {"CoiStatement": "Conflict of interest statement In accordance with the ABPI Code of Practice regulating the pharmaceutical industry, the following companies have provided financial funding to the NC3Rs; AstraZeneca plc, Covance Laborato- ries Ltd., GlaxoSmithKline plc, Huntingdon Life Sciences Ltd., Eli- Lilly and Company Ltd., Pfizer Ltd. and Novartis Pharmaceuticals Ltd. 6 Summary and recommendations Conflict of interest statement Acknowledgments References", "Funding": "In accordance with the ABPI Code of Practice regulating the pharmaceutical industry, the following companies have provided financial funding to the NC3Rs; AstraZeneca plc, Covance Laborato- ries Ltd., GlaxoSmithKline plc, Huntingdon Life Sciences Ltd., Eli- Lilly and Company Ltd., Pfizer Ltd. and Novartis Pharmaceuticals Ltd. Acknowledgments", "Acknowledgement": "Acknowledgments The authors thank Dr. J. McBlane and Dr. R. Hawkins of the Medicines and Healthcare products Regulatory Agency and Dr. Abigail Jacobs from the US Food and Drug Administration, for their input into the working group discussions and comments on the manuscript. 6 Summary and recommendations Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-development-and-implementation-of-occupation_2006_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16530314", "content": {"Compliance with ethical standards": "The voluntary Codes and Guides published in the early days were mainly for the guidance of local industries for good practice in the control of hazardous substances to safeguard the health of persons employed. The booklet \u2018\u2018A Reference Note on occupational exposure limits for Chemical Substances in the Work Environment\u2019\u2019 was a comprehensive list of standards for reference. It was first published in 1993. The application of limit for exposure levels, although they were not mandatory in local legisla- tion, formed part of the criteria for workplace air monitor- ing. They could be used in assessing compliance with the statutory duty of the employer to ensure that his employees were not exposed to occupational disease hazard. Where the atmosphere of a workplace was likely to be contaminat- ed, sampling of the atmosphere and subsequent analysis should be carried out on a periodic basis with a frequency determined by conditions. By then, advice on monitoring methods or other aspects of the prevention of occupational health hazard could be available from the former Occupa- tional Health Division of the Labour Department. The Reference Note was widely accepted by the industries, and had been used by the safety and health professionals as a reference guide for assessing the risks to health of workers for almost 10 years. The publication of the Code of Practice on the Control of Air Impurities has however replaced the Reference Note since April 2002. The listing of occupational exposure lim- its has been revised and formed based on the previous Ref- erence Note. The data are incorporated into the new publication to provide practical guidance to the propri- etors/employers to take adequate measures for the safe- guard of the workers against air impurities or airborne chemicals that are released from use, handling, storage, and transport of the substances. The maintenance of air impurities in the workplace well below the exposure limits of the chemicals listed in the Code of Practice shall demon- strate the discharge of the general duties under Section 6A of the Factories and Industrial Undertakings Ordinance (Chapter 59) and compliance with the relevant require- ments of the subsidiary regulations under the same Ordi- nance. For some management of establishments not included under the definition of industrial undertakings, they may make reference to the Code of Practice for the control of chemical exposure in their workplace environ- ment. The Code of Practice is issued by the Commissioner for Labour under Section 7A(1) of the Factories and Industrial Undertakings Ordinance and has a special legal status. Although failure to observe the provisions of the Code of Practice is not itself an offence, that failure may be taken by a court in criminal proceedings as a factor in determining whether or not a person has breached the rel- evant safety and health provisions under the legislation. The publication of the Code of Practice on the Control of Air Impurities has however replaced the Reference Note since April 2002. The listing of occupational exposure lim- its has been revised and formed based on the previous Ref- erence Note. The data are incorporated into the new publication to provide practical guidance to the propri- etors/employers to take adequate measures for the safe- guard of the workers against air impurities or airborne chemicals that are released from use, handling, storage, and transport of the substances. The maintenance of air impurities in the workplace well below the exposure limits of the chemicals listed in the Code of Practice shall demon- strate the discharge of the general duties under Section 6A of the Factories and Industrial Undertakings Ordinance (Chapter 59) and compliance with the relevant require- ments of the subsidiary regulations under the same Ordi- nance. For some management of establishments not included under the definition of industrial undertakings, they may make reference to the Code of Practice for the control of chemical exposure in their workplace environ- ment. The Code of Practice is issued by the Commissioner for Labour under Section 7A(1) of the Factories and Industrial Undertakings Ordinance and has a special legal status. Although failure to observe the provisions of the Code of Practice is not itself an offence, that failure may be taken by a court in criminal proceedings as a factor in determining whether or not a person has breached the rel- evant safety and health provisions under the legislation. In Hong Kong, the breach of the safety and health law is a criminal offence. An employer who contravenes the pro- visions commits an offence and is liable to a maximum fine of HK$500,000, and in case, it is a willful act and without reasonable excuse, the person is liable to a fine of HK$500,000 as well as to imprisonment for 6 months (Government of HKSAR, 1998). There are penalties to employees too but the fines are relatively lower being HK$50,000 if it is willfully and to imprisonment of 6 months. In short, under the general duties, proprietors are required to ensure, so far as is reasonably practicable, the health at work of all persons employed by him, or the maintenance of the safe system of work, or arrange- ments for ensuring the absence of health risk in connection with the use and handling of substances, or the mainte- nance of a safe working environment and without risks to health. Monitoring of workplace environment may be required in the above-mentioned situations to assist in risk assessment for ensuring the protection of employees\u2019 health."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-development-and-regulation-of-occupational_2006_Regulatory-Toxicology-a1.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16701932", "content": {"Acknowledgement": "Acknowledgment The authors are grateful to Dr. Otto Wong for his kind invitation of this paper and his assistance in editing the manuscript. Conclusion Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-development-and-regulation-of-occupational_2006_Regulatory-Toxicology-a3.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16564609", "content": {"Compliance with ethical standards": "OEL in Korea is a recommendation rather than a legally binding limit in the sense that not all the substances with OELs are required to be measured at the workplace. For 516 out of 698 chemicals, for which OELs have been cur- rently established, the aforementioned mandatory measure- ment requirements do not apply. As there are no reporting requirements, these OEL-listed substances but outside the legal requirement category are not measured by the techni- cal service agencies, and they are left up to the voluntary compliance eVorts of employers. At present, the workplace environment measurement program is focused on monitoring of production line main- tenance rather than assessment of potential risks. Repeated one-day-per-every-6-months measurements of limited but the same problems, rather than progressive investigation of full-scale but the diVerent problems, have been imple- mented. Under this strategy, obvious changes or malfunc- tioning in a regular production line or process can be easily detected and reported, but investigation of rare events or irregular tasks could be a problem. Also, determination of the exact exposure level is limited since daily variations can- not be encountered."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-development-and-regulation-of-occupational_2006_Regulatory-Toxicology-a4.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32595044", "content": {"Compliance with ethical standards": "(2 ppm) as 8-h TWA, revised downward from the previous OEL of 40 mg/m3. At the same time, the new legislature pro- vides more authority to regulatory agencies in its enforce- ment. Non-compliance will result in mandatory remedial actions, stiff fines, and even criminal prosecutions. The effec- tiveness of the new regulation, however, is not measured by the fines collected or punishments imposed but ultimately measured by the reduction of workers\u2019 exposures. The last two papers in this special issue provide the readers with the first insights into the initial impact of the new ODPCAct 2002 on workers\u2019 exposures to benzene and lead in China and the results may surprise many readers. I hope the readers will find the reports in this special issue of Regulatory Toxicology and Pharmacology both interesting and informative. At the same time, I hope these reports will stimulate discussion and collaboration among regulators internationally. Finally, I sincerely thank the authors of these reports for their valuable contributions."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-development-of-statistical-models-to-determine-the-rela_2013_Regulatory-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23247261", "content": {"CoiStatement": "Conflict of interest Four of the coauthors (Randy N Roth, Barry J Simpson, Mark J Nicolich, F Jay Murray) are paid consultants to the Petroleum High Production Volume Testing Group Three (Randy N Roth, Barry J Simpson, Mark J Nicolich) are former employees of companies that manufac- ture petroleum products. One co-author (Thomas M Gray) is employed by the American Petroleum Institute. Simpson, B., Dalbey, W., Fetzer, J., Gray, T., Murray, J., Nicolich, M., Roth, R., Saperstein, M., White, R., 2008. The relationship between the aromatic ring class content and selected endpoints of repeat-dose and developmental toxicity of high-boiling petroleum substances. Report of the PAC Analysis Task Group, Sponsored by the Petroleum HPV Testing Group, March 31, 2008. <http:// www.petroleumhpv.org/pages/publications.html> (accessed 16 January 2012. Simpson, B.J., Murray, F.J., Roth, R.N., Nicolich, M.J., Gray, T.M., this issue. Application of statistical models to characterize the repeat-dose and developmental toxicity of high-boiling petroleum substances. Regul. Toxicol. Pharmacol. Shapiro, S.S., Wilk, M.B., 1965. An analysis of variance test for normality (complete samples). Biometrika 52, 591\u2013611. http://dx.doi.org/10.1016/j.yrtph.2012.11.015 http://dx.doi.org/10.1016/j.yrtph.2012.11.015 http://www.cds.caltech.edu/~prajna/papers_pdf/modinv.pdf http://www.tera.org/peer/API/APIWelcome.htm http://www.tera.org/peer/API/APIWelcome.htm http://www.petroleumhpv.org/pages/publications.html http://www.petroleumhpv.org/pages/publications.html M.J. Nicolich et al. / Regulatory Toxicology and Pharmacology 67 (2013) S10\u2013S29 S29 Speight, J., 2007. The Chemistry and Technology of Petroleum, fourth ed. CRC Press, Taylor & Francis Group, Boca Raton. US EPA (US Environmental Protection Agency), 2000. Data collection and development on high production volume (HPV) chemicals. Federal Register 65(248), 81686\u201381698. US EPA (US Environmental Protection Agency), 2009. Guidance on the Development, Evaluation, and Application of Environmental Models, EPA/100/ K-09/003. <http://www.epa.gov/crem/library/cred_guidance_0309.pdf> (accessed 21 April 2012). http://www.epa.gov/crem/library/cred_guidance_0309.pdf The development of statistical models to determine the relationship between aromatic-ring class profile and repeat-dose and developmental toxicities of high-boiling petroleum substances 1 Introduction 2 Background 3 Materials and methods 3.1 Terminology 3.2 Data sources 3.3 Data selection 3.4 Data integration 4 Statistical model development 4.1 Modeling methods 4.2 Choice of dependent variables 4.3 Choice of independent variables 4.3.1 Analytical variables (PAC measures) 4.3.2 Individual ARC terms 4.3.3 Toxicity study design variables 4.4 Models 4.5 Model equations 4.6 Model fit 5 Model testing and corroboration 5.1 Interpolation and extrapolation 5.2 Model testing 5.2.1 Using holdout sample data 5.2.2 Using \u2018nonsense\u2019 data 5.2.3 Using new data 5.2.3.1 Direct corroboration 5.2.3.2 Indirect corroboration \u2013 repeat-dose model 5.2.3.3 Indirect corroboration \u2013 developmental toxicity model 5.2.4 Sensitivity analyses 5.2.4.1 Screening analyses 5.2.4.2 Global analyses 6 Model comparisons 7 Discussion 8 Conclusions Conflict of interest Role of the funding source Acknowledgments Appendix A Supplementary data References", "Disclosure": "This project was sponsored and funded by the Petroleum HPV Testing Group (PHPVTG), an unincorporated group of manufactur- ers and importers affiliated by contractual obligation to fund a vol- untary data disclosure and toxicity testing program on certain petroleum-related chemical substances in response to the US EPA HPV Challenge Program. The American Petroleum Institute (API) manages the PHPVTG\u2019s activities. Appendix A. Supplementary data", "Funding": "Role of the funding source The authors received financial support for the research, author- ing and publication of this article from the Petroleum High Produc- tion Volume Testing Group. Simpson, B., Dalbey, W., Fetzer, J., Gray, T., Murray, J., Nicolich, M., Roth, R., Saperstein, M., White, R., 2008. The relationship between the aromatic ring class content and selected endpoints of repeat-dose and developmental toxicity of high-boiling petroleum substances. Report of the PAC Analysis Task Group, Sponsored by the Petroleum HPV Testing Group, March 31, 2008. <http:// www.petroleumhpv.org/pages/publications.html> (accessed 16 January 2012. Simpson, B.J., Murray, F.J., Roth, R.N., Nicolich, M.J., Gray, T.M., this issue. Application of statistical models to characterize the repeat-dose and developmental toxicity of high-boiling petroleum substances. Regul. Toxicol. Pharmacol. Shapiro, S.S., Wilk, M.B., 1965. An analysis of variance test for normality (complete samples). Biometrika 52, 591\u2013611. http://dx.doi.org/10.1016/j.yrtph.2012.11.015 http://dx.doi.org/10.1016/j.yrtph.2012.11.015 http://www.cds.caltech.edu/~prajna/papers_pdf/modinv.pdf http://www.tera.org/peer/API/APIWelcome.htm http://www.tera.org/peer/API/APIWelcome.htm http://www.petroleumhpv.org/pages/publications.html http://www.petroleumhpv.org/pages/publications.html M.J. Nicolich et al. / Regulatory Toxicology and Pharmacology 67 (2013) S10\u2013S29 S29 Speight, J., 2007. The Chemistry and Technology of Petroleum, fourth ed. CRC Press, Taylor & Francis Group, Boca Raton. US EPA (US Environmental Protection Agency), 2000. Data collection and development on high production volume (HPV) chemicals. Federal Register 65(248), 81686\u201381698. US EPA (US Environmental Protection Agency), 2009. Guidance on the Development, Evaluation, and Application of Environmental Models, EPA/100/ K-09/003. <http://www.epa.gov/crem/library/cred_guidance_0309.pdf> (accessed 21 April 2012). http://www.epa.gov/crem/library/cred_guidance_0309.pdf The development of statistical models to determine the relationship between aromatic-ring class profile and repeat-dose and developmental toxicities of high-boiling petroleum substances 1 Introduction 2 Background 3 Materials and methods 3.1 Terminology 3.2 Data sources 3.3 Data selection 3.4 Data integration 4 Statistical model development 4.1 Modeling methods 4.2 Choice of dependent variables 4.3 Choice of independent variables 4.3.1 Analytical variables (PAC measures) 4.3.2 Individual ARC terms 4.3.3 Toxicity study design variables 4.4 Models 4.5 Model equations 4.6 Model fit 5 Model testing and corroboration 5.1 Interpolation and extrapolation 5.2 Model testing 5.2.1 Using holdout sample data 5.2.2 Using \u2018nonsense\u2019 data 5.2.3 Using new data 5.2.3.1 Direct corroboration 5.2.3.2 Indirect corroboration \u2013 repeat-dose model 5.2.3.3 Indirect corroboration \u2013 developmental toxicity model 5.2.4 Sensitivity analyses 5.2.4.1 Screening analyses 5.2.4.2 Global analyses 6 Model comparisons 7 Discussion 8 Conclusions Conflict of interest Role of the funding source Acknowledgments Appendix A Supplementary data References", "Acknowledgement": "Acknowledgments This project was sponsored and funded by the Petroleum HPV Testing Group (PHPVTG), an unincorporated group of manufactur- ers and importers affiliated by contractual obligation to fund a vol- untary data disclosure and toxicity testing program on certain petroleum-related chemical substances in response to the US EPA HPV Challenge Program. The American Petroleum Institute (API) manages the PHPVTG\u2019s activities. Simpson, B., Dalbey, W., Fetzer, J., Gray, T., Murray, J., Nicolich, M., Roth, R., Saperstein, M., White, R., 2008. The relationship between the aromatic ring class content and selected endpoints of repeat-dose and developmental toxicity of high-boiling petroleum substances. Report of the PAC Analysis Task Group, Sponsored by the Petroleum HPV Testing Group, March 31, 2008. <http:// www.petroleumhpv.org/pages/publications.html> (accessed 16 January 2012. Simpson, B.J., Murray, F.J., Roth, R.N., Nicolich, M.J., Gray, T.M., this issue. Application of statistical models to characterize the repeat-dose and developmental toxicity of high-boiling petroleum substances. Regul. Toxicol. Pharmacol. Shapiro, S.S., Wilk, M.B., 1965. An analysis of variance test for normality (complete samples). Biometrika 52, 591\u2013611. http://dx.doi.org/10.1016/j.yrtph.2012.11.015 http://dx.doi.org/10.1016/j.yrtph.2012.11.015 http://www.cds.caltech.edu/~prajna/papers_pdf/modinv.pdf http://www.tera.org/peer/API/APIWelcome.htm http://www.tera.org/peer/API/APIWelcome.htm http://www.petroleumhpv.org/pages/publications.html http://www.petroleumhpv.org/pages/publications.html M.J. Nicolich et al. / Regulatory Toxicology and Pharmacology 67 (2013) S10\u2013S29 S29 Speight, J., 2007. The Chemistry and Technology of Petroleum, fourth ed. CRC Press, Taylor & Francis Group, Boca Raton. US EPA (US Environmental Protection Agency), 2000. Data collection and development on high production volume (HPV) chemicals. Federal Register 65(248), 81686\u201381698. US EPA (US Environmental Protection Agency), 2009. Guidance on the Development, Evaluation, and Application of Environmental Models, EPA/100/ K-09/003. <http://www.epa.gov/crem/library/cred_guidance_0309.pdf> (accessed 21 April 2012). http://www.epa.gov/crem/library/cred_guidance_0309.pdf The development of statistical models to determine the relationship between aromatic-ring class profile and repeat-dose and developmental toxicities of high-boiling petroleum substances 1 Introduction 2 Background 3 Materials and methods 3.1 Terminology 3.2 Data sources 3.3 Data selection 3.4 Data integration 4 Statistical model development 4.1 Modeling methods 4.2 Choice of dependent variables 4.3 Choice of independent variables 4.3.1 Analytical variables (PAC measures) 4.3.2 Individual ARC terms 4.3.3 Toxicity study design variables 4.4 Models 4.5 Model equations 4.6 Model fit 5 Model testing and corroboration 5.1 Interpolation and extrapolation 5.2 Model testing 5.2.1 Using holdout sample data 5.2.2 Using \u2018nonsense\u2019 data 5.2.3 Using new data 5.2.3.1 Direct corroboration 5.2.3.2 Indirect corroboration \u2013 repeat-dose model 5.2.3.3 Indirect corroboration \u2013 developmental toxicity model 5.2.4 Sensitivity analyses 5.2.4.1 Screening analyses 5.2.4.2 Global analyses 6 Model comparisons 7 Discussion 8 Conclusions Conflict of interest Role of the funding source Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-effect-of-Cynara-scolymus--artichoke--on-materna_2019_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30611817", "content": {"Funding": "Funding This work was supported by: Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico (CNPq). Results Discussion Funding Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-effect-of-cigarette-burn-time-on-exposure-to-n_2008_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/17931761", "content": {"Acknowledgement": "Acknowledgements We would like to thank Jane Lewis, Mary Ellen Counts, and Bill Dwyer for reviewing the manuscript and their helpful comments. Discussion Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-effect-of-long-term-storage-on-tobacco-smoke-part_2013_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23220485", "content": {"CoiStatement": "200 I. Crooks et al. / Regulatory Toxicology and Pharmacology 65 (2013) 196\u2013200 Conflicts of interest statement This work was funded by British American Tobacco (BAT) and all authors, with the exception of M. Ballantyne, are employees of BAT. M. Ballantyne\u2019s involvement was in the capacity of Study Director. 4 Conclusion Conflicts of interest statement Acknowledgments References", "Compliance with ethical standards": "OECD (Organisation for Economic Co-operation and Development), 1998. OECD series on principles of good laboratory practice and compliance monitoring. In: Guidelines for Testing of Chemicals. OECD Publishing, Paris, France. OECD (Organisation for Economic Co-operation and Development), 2010. In vitro mammalian cell micronucleus test. In: Guidelines for Testing of Chemicals. OECD Publishing, Paris, France.", "Acknowledgement": "Acknowledgments The authors are grateful to Mel Lloyd and Victoria Stone of Cov- ance Laboratories for their vital role as Study Directors, and Jim Saul of Covance Laboratories for his contribution to the statistical analysis. 4 Conclusion Conflicts of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-effect-of-menthol-containing-cigarettes-on-adul_2010_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20025920", "content": {"Acknowledgement": "Acknowledgments The authors thank Management Science Associates, Pittsburgh, Pennsylvania for data analysis, Dr. Qiwei Liang for statistical re- view and Dr. Mohamadi Sarkar for his review and helpful suggestions. Results Discussions Acknowledgments Reference"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-effect-of-reducing-the-number-of-cigarettes-smoked_2013_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24013038", "content": {"CoiStatement": "To obtain better evidence on effects of cutting down consump- tion on the risk of smoking-related disease more evidence is needed, particularly from large cohort studies which collect data at regular intervals on amount smoked. 6. Conflict of interest statement The author is a long-term consultant to the tobacco industry. However, this is an independent scientific assessment, the views expressed being those of the author alone. 4 Discussion 5 Conclusion 6 Conflict of interest statement Acknowledgments References", "Acknowledgement": "Acknowledgments This review was supported by Altria Client Services Inc. The study sponsor had no involvement in the planning, execution or writing of this manuscript or the decision to submit it for publica- tion. Thanks are due to Pauline Wassell, Diana Morris and Yvonne Cooper for typing, and obtaining relevant literature, and to Barbara Forey and John Fry for commenting on drafts. 4 Discussion 5 Conclusion 6 Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-effect-of-time-changes-in-diagnosing-lung-cancer-ty_2016_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27664320", "content": {"CoiStatement": "Evidence from 16 studies examining time trends in the pro- portion of AdC using standard diagnostic criteria, six considering a period of at least 30 years, did not find consistent evidence of any increase. Where an increase was seen, it may be due to an increase in BalC. Conflict of interest Peter N Lee is a long-term consultant to various tobacco organizations, including the study sponsors. John R Gosney has no competing financial interests. Authors' contributions 4. Discussion 5. Conclusions Conflict of interest Authors' contributions Acknowledgements Transparency document References", "Acknowledgement": "Acknowledgements We thank Barbara Forey and Katharine Coombs for assistance with identifying the literature, and Diana Morris, Pauline Wassell and Yvonne Cooper with manuscript preparation. We also thank British American Tobacco (Investments) Limited and Altria Client Services who provided financial support to Peter N Lee. 4. Discussion 5. Conclusions Conflict of interest Authors' contributions Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-effect-on-health-of-switching-from-cigare_2013_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23454227", "content": {"CoiStatement": "Though based on a somewhat limited database, the findings consistently demonstrate that switching from cigarettes to snus is associated with a clearly lower risk of CVD and cancer than is continuing to smoke. The risk in switchers is no different from that in smokers who quit smoking. The findings are consistent with other evidence that adverse health effects of snus are at most minimal. Conflict of Interest statement The author is a long-term consultant to the tobacco industry. However, this is an independent scientific assessment, the views expressed being those of the author alone. The effect on health of switching from cigarettes to snus \u2013 A review 1 Introduction 2 Materials and methods 3 Results 4 Discussion 5 Conclusion Conflict of Interest statement Acknowledgments References", "Acknowledgement": "Acknowledgments This update was supported by Altria Client Services Inc. with some of the earlier work underpinning it supported by Philip Mor- ris Products, the European Smokeless Tobacco Council and Swedish Match. The study sponsor had no involvement in the planning or execution of the project, the interpretation of the findings pre- sented in this manuscript, or the decision to submit the manuscript for publication. Thanks are due to Pauline Wassell, Diana Morris and Yvonne Cooper for typing, and obtaining relevant literature, and to Barbara Forey and John Fry for commenting on drafts. The effect on health of switching from cigarettes to snus \u2013 A review 1 Introduction 2 Materials and methods 3 Results 4 Discussion 5 Conclusion Conflict of Interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-environmental-risk-assessment-of-human-pharmaceu_2006_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16716476", "content": {"Compliance with ethical standards": "Although there is no monitoring of the compliance of users with the recommendations, this example gives an indi- cation how the EU Directive could be implemented in a case-speciWc manner. In general, the present draft of the EMEA guideline pro- poses labelling, information on environmental risks in SPC, and package leaXets as an appropriate way to deal with environmental risk mitigation issues. There is no published review yet available, how far any medication, use or waste disposal patterns have been inXuenced by respective label- ling, use or waste disposal patterns. We suggest that after adoption of the environmental risk assessment guideline, the compliance of hospitals, doctors and, if possible, patients with labelling statements should be monitored. In general, the present draft of the EMEA guideline pro- poses labelling, information on environmental risks in SPC, and package leaXets as an appropriate way to deal with environmental risk mitigation issues. There is no published review yet available, how far any medication, use or waste disposal patterns have been inXuenced by respective label- ling, use or waste disposal patterns. We suggest that after adoption of the environmental risk assessment guideline, the compliance of hospitals, doctors and, if possible, patients with labelling statements should be monitored. 5. Bottlenecks in the authorization process"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-evaluation-of-drug-rechallenge--The-casop_2010_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20932869", "content": {"CoiStatement": "Analysis of controlled clinical trial events reveals positive rechallenge occurring at a similar rate in those receiving casopitant or placebo in two Phase III studies, with no serious clinical out- comes or Grade 4 ALT elevations. In contrast, review of published case series suggest that drugs causing mitochondrial, immunoal- lergic and hepatocellular injury are associated with a higher rate of clinically important and even fatal positive rechallenge reac- tions. Cumulative mitochondrial dysfunction may particularly in- crease the risk of positive rechallenge when a suspect drug is restarted within weeks of the primary injury. So, drug rechallenge should generally be avoided and considered only if the benefit ex- ceeds the risk (e.g. life-saving drug). Publication of drug-specific rechallenge information from controlled clinical trials and liver in- jury registries will further elucidate risk factors for positive rechal- lenge. Understanding risk factors and mechanisms of primary and rechallenge liver injury, as well as clinical outcomes, through an expanded evidence base, will advance drug safety. Conflict of interest statement All authors are fully employed by GSK. Discussion Conclusions Conflict of interest statement Acknowledgments References", "Acknowledgement": "Acknowledgments The authors wish to thank the Casopitant Project Team, Steve Lane, Jon Lyon, and the GSK Hepatotoxicity Board for their expert input and Cynthia Traynham for her administrative assistance. The corresponding author affirms that she has listed everyone who contributed significantly to the work. References Discussion Conclusions Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-evolution-and-challenges-for-the-international-har_2015_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26387930", "content": {"Acknowledgement": "Acknowledgements The authors thank TFDA (grants 102-TFDA-P-033, 103-TFDA-P- 034, 104-TFDA-P-034), the expert committee, and their colleagues who participate in the review and discussion of regulatory re- quirements for excipients. 4. Conclusions Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-evolution-of-juvenile-animal-testing-for-s_2013_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23896345", "content": {"CoiStatement": "134 P. Baldrick / Regulatory Toxicology and Pharmacology 67 (2013) 125\u2013135 described earlier from evaluation of European PIP decisions over the last few years, a particular concern is that a large number of juvenile animal studies are being requested with the vast majority appearing to be toxicology studies, presumably using standard endpoints and/or with additional add-on measurements (such as developmental/reproductive or behavioural endpoints) on occa- sion. Undoubtedly, more juvenile animal data are appearing in drug labels. However, it is still unclear to what extent juvenile ani- mal work is identifying new toxicities/safety concerns not already available from adult data or predictable from exposure/maturation differences. What would be useful is publication of the rationale with details of why juvenile animal work is being proposed by a drug company or requested by the regulators (as in the example discussed earlier for combination of two antifungal drugs). If full information is made available, it is possible that the need to exam- ine a particular maturation concern (as in the example discussed earlier with SGLT2 inhibitors) for further new drugs will not be needed, greatly reducing the number of studies. The case for fur- ther evolution of juvenile animal testing continues! Conflict of interest The author declares that there are no conflicts of interest. The author declares that there are no conflicts of interest. References 5 Testing of biological drugs 6 Conclusions Conflict of interest References", "Compliance with ethical standards": "FDA, 2006: United States Food and Drug Administration (FDA): Guidance for Industry: Nonclinical Safety Evaluation of Pediatric Drug Products. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm079247.pdf. FDA, 2013. Fact Sheet: Pediatric provisions in the Food and Drug Administration (FDA) Safety and Innovation Act (FDASIA). http://www.fda.gov/ RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/ SignificantAmendmentstotheFDCAct/FDASIA/ucm311038.htm. http://refhub.elsevier.com/S0273-2300(13)00111-6/h0005 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0005 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0005 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0010 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0010 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0015 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0015 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0020 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0020 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0020 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0020 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0020 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0025 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0025 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002098/WC500108357.pdf http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002098/WC500108357.pdf http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002098/WC500108357.pdf http://refhub.elsevier.com/S0273-2300(13)00111-6/h0030 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0030 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0030 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0035 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0035 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0040 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0040 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0045 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0045 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0045 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0045 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0045 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0050 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0050 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0050 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0050 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0050 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0055 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0055 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0055 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0055 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0060 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0060 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0060 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0060 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0065 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0065 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0065 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0070 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0070 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0070 http://www.emea.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000293.jsp&amp;mid=WC0b01ac0580025b91 http://www.emea.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000293.jsp&amp;mid=WC0b01ac0580025b91 http://www.emea.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000293.jsp&amp;mid=WC0b01ac0580025b91 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/pip_search.jsp http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/pip_search.jsp http://www.ema.europa.eu/pdfs/human/swp/16921505en08.pdf http://www.ema.europa.eu/pdfs/human/swp/16921505en08.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079247.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079247.pdf http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDASIA/ucm311038.htm http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDASIA/ucm311038.htm http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDASIA/ucm311038.htm http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002322/WC500136024.pdf http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002322/WC500136024.pdf http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002322/WC500136024.pdf http://refhub.elsevier.com/S0273-2300(13)00111-6/h0075 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0075 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0080 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0080 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0080 http://www.emea.europa.eu/pdfs/human/ich/028695en.pdf http://www.emea.europa.eu/pdfs/human/ich/028695en.pdf http://www.ema.europa.eu/docs/en_GB/document_library/Other/2011/07/WC500109298.pdf http://www.ema.europa.eu/docs/en_GB/document_library/Other/2011/07/WC500109298.pdf http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/001109/WC500140964.pdf http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/001109/WC500140964.pdf http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/001109/WC500140964.pdf http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204042s000lbl.pdf http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204042s000lbl.pdf http://wwwhourei.mhlw.go.jp/hourei/doc/tsuchi/T121018I0010.pdf http://wwwhourei.mhlw.go.jp/hourei/doc/tsuchi/T121018I0010.pdf http://refhub.elsevier.com/S0273-2300(13)00111-6/h0085 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0085 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0085 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0085 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0090 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0090 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0090 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0095 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0095 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0095 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0095 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0100 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0100 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0100 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0105 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0105 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0105 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0110 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0110 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0110 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0115 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0115 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0115 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0120 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0120 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0120 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0120 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0125 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0125 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0125 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0130 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0130 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0130 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0130 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0135 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0135 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0140 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0140 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0140 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0145 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0145 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0150 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0150 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0150 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0150 http://refhub.elsevier.com/S0273-2300(13)00111-6/h0150 P. Baldrick / Regulatory Toxicology and Pharmacology 67 (2013) 125\u2013135 135 Soellner, L., Olejniczak, K., 2013. The need for juvenile animal studies \u2013 a critical review. Regul. Toxicol. Pharmacol. 65, 87\u201399."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-evolution-of-skin-notations-for-occupational-_2011_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21689711", "content": {"CoiStatement": "5 Discussion and conclusion Conflict of interest statement and funding sources Acknowledgments and Disclaimer Appendix A Calculation of the SI ratio for acrylamide References", "Funding": "5 Discussion and conclusion Conflict of interest statement and funding sources Acknowledgments and Disclaimer Appendix A Calculation of the SI ratio for acrylamide References", "Acknowledgement": "5 Discussion and conclusion Conflict of interest statement and funding sources Acknowledgments and Disclaimer Appendix A Calculation of the SI ratio for acrylamide References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-ex-vivo-intestinal-absorption-rate-of-uranium_2014_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24793262", "content": {"CoiStatement": "For regulatory purposes, the World Health Organisation and other authors assumed relatively low in-vivo absorption rates ranging from 0.3% to 1.5% (WHO, 2012; Konietzka, 2014; Konietzka et al., 2005). However, for the purposes of risk quantifi- cation our results indicate that absorption rates could be signifi- cantly higher for uranium concentrations above 20 lg/l than at lower concentrations. The resulting higher internal exposures appear relevant for the setting of Guideline values in this concen- tration range because higher absorptions rates will cause higher levels in the target organ (kidneys). A lower Guideline value would be appropriate to account for this mechanism. Conflicts of interest None. 4 Discussion and conclusions Conflicts of interest Acknowledgments References", "Acknowledgement": "Acknowledgments We thank Mr. Matthias Skerswetat for his experimental work and Mr. Ulrich Lippold for the uranium analyses. We are grateful to Dr. Ingrid Chorus and Dr. Tamara Grummt for helpful comments. 4 Discussion and conclusions Conflicts of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-expressions-of-protooncogenes-and-CYP1A-in-lungs_2006_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16616405", "content": {"Acknowledgement": "Acknowledgments This research was supported by Grants 30230310 and 20477023 from the National Natural Science Foundation of China and by Grant 20031092 from the Natural Science Foundation of Shanxi Province. Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-food-contaminant-acetamide-is-not-an-in-vivo-clas_2019_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31470077", "content": {"CoiStatement": "Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. Funding Declaration of interests Author contributions Acknowledgments Supplementary data References", "Funding": "Funding The work described in this paper was supported by a grant from the Bill and Melinda Gates Foundation [OPP1142801] to Michigan State University and its technology development affiliate, the Michigan Biotechnology Institute (MBI). Funding Declaration of interests Author contributions Acknowledgments Supplementary data References", "Acknowledgement": "Acknowledgments The work described in this paper was supported by a grant from the Bill and Melinda Gates Foundation [OPP1142801] to Michigan State University and its technology development affiliate, the Michigan Biotechnology Institute (MBI). Under this grant, ammoniation-based technologies are being investigated for increasing the digestibility of agricultural residues as ruminant feeds. Earlier in this investigation, acetamide was detected in common foods, including milk and beef. The widespread adoption of ammoniation technologies for ruminant feeds could result in an increased level of acetamide in selected foods. Martha M Moore and Bryan Balshaskar Gollapudi acted as consultants to MBI. We would like to thank Prof. Dan Jones (MSU) and Diane Haddad (MBI) for assisting with validating the analytical approach for detecting acetamide/metabolites, as well as Dr. Jeffrey Bemis (Litron laboratories) for assistance with the statistical analysis of the Pig-a gene mutation assay data. We would also like to acknowledge Dr. Duncan Turnbull (Ramboll) for his assistance in in- terpreting historical acetamide cancer studies. Funding Declaration of interests Author contributions Acknowledgments Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-food-safety-of-DP-356-43-soybeans-on-SD-rats-reflec_2018_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29940211", "content": {"CoiStatement": "Conflict of interest statement The authors declare no conflict of interest. The authors declare no conflict of interest. Acknowledgement Conclusion Conflict of interest statement Acknowledgement Supplementary data Transparency document References", "Acknowledgement": "Acknowledgement This work was supported by Genetically Modified Organisms Breeding Major Projects of P.R. China grant 2011ZX08011-005 and 2009ZX08011-001B. Conclusion Conflict of interest statement Acknowledgement Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-genotoxicity-of-an-organic-solvent-mixture--A-human_2020_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32659246", "content": {"CoiStatement": "4 Discussion Financial support Declaration of competing interest Acknowledgments References", "Acknowledgement": "4 Discussion Financial support Declaration of competing interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-hormesis-database--The-occurrence-of-hormetic-d_2011_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21699952", "content": {"CoiStatement": "Conflict of interest statement The authors declare that there are no conflicts of interest. This manuscript has not been published previously and is not under consideration for publication elsewhere. The authors declare that there are no conflicts of interest. This manuscript has not been published previously and is not under consideration for publication elsewhere. Acknowledgments 3 Discussion Conflict of interest statement Acknowledgments References", "Funding": "Effort sponsored by the Air Force Office of Scientific Research, Air Force Material Command, USAF, under Grant number FA9550-07-1-0248. The US Government is authorized to reproduce and distribute for governmental purposes notwithstanding any copyright notation thereon. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsement, either expressed or implied, of the Air Force Office of Scientific Research or the US Government. The funding source had no involvement in study design, collection, analysis and interpretation of data; in writing the report and in the decision to submit the manuscript for publication. References", "Acknowledgement": "Acknowledgments Effort sponsored by the Air Force Office of Scientific Research, Air Force Material Command, USAF, under Grant number FA9550-07-1-0248. The US Government is authorized to reproduce and distribute for governmental purposes notwithstanding any copyright notation thereon. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsement, either expressed or implied, of the Air Force Office of Scientific Research or the US Government. The funding source had no involvement in study design, collection, analysis and interpretation of data; in writing the report and in the decision to submit the manuscript for publication. 3 Discussion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-human-relevant-potency-threshold--Reducing-uncert_2012_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22057094", "content": {"CoiStatement": "3 The Human-Relevant Potency-Threshold (HRPT) 4 Application of the HRPT approach to potential anti-androgens 5 Conclusions 6 Conflict of interest statement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-impact-of-CYP2E1-genetic-variability-on-ris_2011_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21295098", "content": {"CoiStatement": "Effect on risk assessment Conclusions Funding sources statement Conflict of interest References", "Funding": "Effect on risk assessment Conclusions Funding sources statement Conflict of interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-impact-of-REACH-on-classification-for-hu_2014_Regulatory-Toxicology-and-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25128672", "content": {"CoiStatement": "Similar analyses could be extended to effects on the environ- ment and/or to other sets of chemicals. Since we observed a sub- stantial impact of REAC Heidorn on comparatively well studied high production volume substances, it would be interesting to evaluate data for substances of lower tonnage bands with potentially fewer data. It may be assumed that the information requirements under REAC Heidorn will ultimately trigger an even more pronounced increase in classification than we observed for our set of substances. How- ever, the tonnage-dependence of the information requirements can be expected to counteract this trend and such an increase may only be expected for endpoints, for which information is required at the lower tonnage levels. Conflict of interest Mr. Oltmanns reports grants from European Commission, Direc- torate-General EUROSTAT (Luxembourg), during the conduct of the study for parts of the work. Acknowledgments 4 Discussion and conclusions Conflict of interest Acknowledgments Appendix A Supplementary data References", "Funding": "J. Oltmanns et al. / Regulatory Toxicology and Pharmacology 70 (2014) 474\u2013481 481 2012.578. The additional analyses presented in this paper were not part of the work under this contract and received no additional funding from other sources. Appendix A. Supplementary data", "Acknowledgement": "Mr. Oltmanns reports grants from European Commission, Direc- torate-General EUROSTAT (Luxembourg), during the conduct of the study for parts of the work. Acknowledgments The initial retrieval of the classification information for the Sus- tainable Development Indicator \u2018\u2018Production of toxic chemicals\u2019\u2019 was sponsored by the European Commission, Directorate General EUROSTAT (Luxembourg), under contract 50302.2012.001- 4 Discussion and conclusions Conflict of interest Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-impact-of-recent-advances-in-research-on-ar_2014_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24534001", "content": {"CoiStatement": "3 Risk assessment approach for arsenic 4 Remaining uncertainties/recommendations Conflict of interest Acknowledgment References", "Compliance with ethical standards": "US Environmental Protection Agency, 2001. National primary drinking water regulations: arsenic and clarifications to compliance and new source contaminants monitoring. Final Rule. 40 CFR Parts 141 and 142. Fed. Reg. 66 (14), 6976\u20137066. US Environmental Protection Agency, 2005. Toxicological Review of Ingested Inorganic Arsenic. Review Draft for the Science Advisory Board, July 2005.", "Acknowledgement": "3 Risk assessment approach for arsenic 4 Remaining uncertainties/recommendations Conflict of interest Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-impact-on-classifications-for-carcinogenicity--mutagen_2019_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31085250", "content": {"CoiStatement": "Conflicts of interest The authors have no conflict of interest to declare. The authors have no conflict of interest to declare. Appendix A. Supplementary data Discussion and conclusions Conflicts of interest Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-implementation-of-RAAF-in-the-OECD-QS_2019_Regulatory-Toxicology-and-Pha.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30970268", "content": {"Acknowledgement": "Acknowledgements The authors would like to thank the OECD secretariat from the Environment, Health and Safety Division for efficient management of the OECD QSAR Toolbox project and the members of the QSAR Toolbox Management group for the discussions and valuable input during the development phase of the software. Summary and conclusions Acknowledgements Supplementary data Transparency document Disclaimer References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-importance-of-problem-formulations-in-risk-asses_2013_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23545073", "content": {"CoiStatement": "Funding for the symposium and subsequent work has been pro- vided by a number of organizations including the Dow Chemical Company, Toxicology Excellence for Risk Assessment (TERA), U.S. Environmental Protection Agency (EPA), and the Kita City Admin- istrative Office in Tokyo, Japan. Conflict of interest statement Several authors, Michael L Dourson, Bernard Gadagbui, Laurie C Haws, and CRK, currently provide or have provided consulting services to the Dow Chemical Company. Another author, David H Garabrant, is the principal investigator of a grant at the University of Michigan which is funded by the Dow Chemical Com- pany. The funder had no role in the study design, data collection, analysis and interpretation, decision to publish or preparation of the manuscript. The scientific conclusions derived from this re- search solely represent the opinions of the individual authors. Acknowledgements The importance of problem formulations in risk assessment: A case study involving dioxin-contaminated soil 1 Introduction 2 The range of theoretical risk assessment approaches for characterizing exposure and risks from dioxin-contaminated soil 3 Using toxicokinetics to improve soil exposure and risk assessment 4 Regulatory approach to characterizing and mitigating exposure and risk at dioxin contaminated sites 5 Dioxins and related compounds in the blood of children and adults in a dioxin-contaminated area in Tokyo 6 Dioxin exposure in Michigan residents exposed to contaminated soils 7 Discussion 8 Disclaimer 9 Funding source Conflict of interest statement Acknowledgements References", "Funding": "The research described in this article has been reviewed by US EPA, Region 8, and approved for publication. Approval does not sig- nify that the contents necessarily reflect the views and policies of the Agency nor does mention of trade names or commercial prod- ucts constitute endorsement or recommendation for use. 9. Funding source Funding for the symposium and subsequent work has been pro- vided by a number of organizations including the Dow Chemical Company, Toxicology Excellence for Risk Assessment (TERA), U.S. Environmental Protection Agency (EPA), and the Kita City Admin- istrative Office in Tokyo, Japan. Conflict of interest statement Funding for the symposium and subsequent work has been pro- vided by a number of organizations including the Dow Chemical Company, Toxicology Excellence for Risk Assessment (TERA), U.S. Environmental Protection Agency (EPA), and the Kita City Admin- istrative Office in Tokyo, Japan. Conflict of interest statement Several authors, Michael L Dourson, Bernard Gadagbui, Laurie C Haws, and CRK, currently provide or have provided consulting services to the Dow Chemical Company. Another author, David H Garabrant, is the principal investigator of a grant at the University of Michigan which is funded by the Dow Chemical Com- pany. The funder had no role in the study design, data collection, analysis and interpretation, decision to publish or preparation of the manuscript. The scientific conclusions derived from this re- search solely represent the opinions of the individual authors. Acknowledgements The importance of problem formulations in risk assessment: A case study involving dioxin-contaminated soil 1 Introduction 2 The range of theoretical risk assessment approaches for characterizing exposure and risks from dioxin-contaminated soil 3 Using toxicokinetics to improve soil exposure and risk assessment 4 Regulatory approach to characterizing and mitigating exposure and risk at dioxin contaminated sites 5 Dioxins and related compounds in the blood of children and adults in a dioxin-contaminated area in Tokyo 6 Dioxin exposure in Michigan residents exposed to contaminated soils 7 Discussion 8 Disclaimer 9 Funding source Conflict of interest statement Acknowledgements References", "Acknowledgement": "Several authors, Michael L Dourson, Bernard Gadagbui, Laurie C Haws, and CRK, currently provide or have provided consulting services to the Dow Chemical Company. Another author, David H Garabrant, is the principal investigator of a grant at the University of Michigan which is funded by the Dow Chemical Com- pany. The funder had no role in the study design, data collection, analysis and interpretation, decision to publish or preparation of the manuscript. The scientific conclusions derived from this re- search solely represent the opinions of the individual authors. Acknowledgements The authors wish to thank Robert Budinsky of the Dow Chemi- cal Company for his thoughtful comments on early drafts and Mrs. Ann Parker for her technical edit of the manuscript. The importance of problem formulations in risk assessment: A case study involving dioxin-contaminated soil 1 Introduction 2 The range of theoretical risk assessment approaches for characterizing exposure and risks from dioxin-contaminated soil 3 Using toxicokinetics to improve soil exposure and risk assessment 4 Regulatory approach to characterizing and mitigating exposure and risk at dioxin contaminated sites 5 Dioxins and related compounds in the blood of children and adults in a dioxin-contaminated area in Tokyo 6 Dioxin exposure in Michigan residents exposed to contaminated soils 7 Discussion 8 Disclaimer 9 Funding source Conflict of interest statement Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-in-Vivo-Rodent-Test-Systems-for-Assessment_2002_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/11846641", "content": {"Acknowledgement": "ACKNOWLEDGMENTS We greatly appreciate the contributions from the workshop partici- pants for constructive discussions and critical comments. We also thank the members of the program committee: D. Robinson (ILSI- HESI, U.S.A.), P. McAnulty (Ferring International, Denmark), G. Bode (Byk Gulden GmbH, Germany), R. Forster (CIT, France), J. MacDonald (Schering Plough Corporation, U.S.A.), and C. van Kreyl (RIVM, The Netherlands) for contributions to the success of the workshop. In addition we are very grateful to J. Ashby (Synthega, UK) for a critical appraisal during the workshop stimulating the discussions. DISCUSSIONS ON THE USE OF THE SHORT- AND MEDIUM-TERM RODENT MODELS BIOTECHNOLOGY PRODUCTS ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-interpretation-of-occupational-epidemiologic-data-i_2006_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16464525", "content": {"Acknowledgement": "Acknowledgment The author has served as an expert/consultant in matters involving friction products and petrochemicals. The prepa- ration of this commentary was not funded by any group. Concluding remarks Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-limitations-of-using-the-NTP-chronic-bioassay-_2020_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32246946", "content": {"CoiStatement": "The limitations of using the NTP chronic bioassay on vanadium pentoxide in risk assessments Introduction Initial studies Dose selection for the chronic 2-year study Adverse effects from chronic whole-body exposure to respirable particulate of V2O5 limited to the site of contact, the respiratory system Lack of an oncogenic response in the rat Challenges in assessing risk Future research needs Conclusion Declaration of competing interest Acknowledgements Supplementary data References", "Acknowledgement": "The limitations of using the NTP chronic bioassay on vanadium pentoxide in risk assessments Introduction Initial studies Dose selection for the chronic 2-year study Adverse effects from chronic whole-body exposure to respirable particulate of V2O5 limited to the site of contact, the respiratory system Lack of an oncogenic response in the rat Challenges in assessing risk Future research needs Conclusion Declaration of competing interest Acknowledgements Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-linear-relationship-between-cigarette-tar-and-nico_2011_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21216263", "content": {"Disclosure": "While broader tests will be required for a generalization of these findings to other blend styles, (e.g. all flue-cured blends typ- ical of Canada, England, or Australia), the data indicate that the cor- relations of analytical yields of tar and nicotine, and possibly of other smoke components, obtained under different machine smok- ing conditions yield linear regressions, whose slopes can be used as invariant characterizations of the corresponding cigarettes. The slopes increase with an increase in the concentration of alkaloids in the tobacco blend, and thus in the smoke, and as such they pro- vide the basis for an index analogous to the TNR. Unlike the vari- able ratio, however, the slope is unaffected by different puffing/ smoking parameters or even cigarette designs. With further testing of different blend-styles, the relationship of such slopes to the con- centration of nicotine in the blends of cigarettes could extend and further simplify the ranking of cigarettes based simply on the nic- otine concentration of their blends. Disclosure statement Generation of the original data set was funded by Brown and Williamson Tobacco Corporation prior to merger with R.J. Reynolds Tobacco Company. Preparation of the manuscript and the sham smoking experiments were funded by British American Tobacco (Investments) Ltd. F.K. St.Charles currently consults for British American Tobacco (Investments) Ltd. and R.J. Reynolds Tobacco Company. C.J. Cook currently is an employee of R.J. Reynolds To- bacco Company. P.M. Clayton is an employee of British American Tobacco (Investments) Ltd. Results and discussion Conclusions Disclosure statement Acknowledgments References", "Acknowledgement": "148 F.K. St.Charles et al. / Regulatory Toxicology and Pharmacology 59 (2011) 143\u2013148 Acknowledgments The authors thank Drs. M. Borgerding, M. Dixon, D.C. Mariner, A. Norman, and A. Williams for their helpful comments and L. Lobendhan and K. Nother for their assistance with the sham smok- ing experiments. Results and discussion Conclusions Disclosure statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-lower-alkyl-methacrylates--Genotoxic-profile_2017_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28087335", "content": {"Compliance with ethical standards": "HEMA, n-BMA, and i-BMA were each evaluated for MN induc- tion in BM cells in vivo in single studies. Male rats exposed to HEMA orally at doses of 500, 1000 or 2000 mg/kg \ufffd2 were sacrificed 24 h post exposure and BM MN (MN-PCE) were measured in 2000 PCE per dose (MHW Japan 2001; (Mitsubishi_Rayon_Co.L, 2001). PCE/ NCE ratios determined cytotoxicity. The authors report compliance with OECD 474 and GLP standards. There were no increases in MN- PCE in any treatment group compared with the negative control while the positive control (cyclophosphamide) gave the expected significant increase. n-BMA at concentrations of 500, 1000 and R.J. Albertini / Regulatory Toxicology and Pharmacology 84 (2017) 77e9388 2000 mg/kg was administered i.p. to male and female mice with sacrifice 24 and 48 h post exposure for determination of BM MN (MN-PCE) induction in 2000 PCE (Ciliutti, 1999). Five animals per sex per dose were scored. There was no significant increase in MN- PCE in either sex at any dose at any time point, with mild toxicity seen by PCE/MNC ratio. The authors state compliance with GLP standards. i-BMAwas administered orally to male and female mice as a single one-time dose of 5000 mg/kg with sacrifice 24, 48 or 72 h later for determination of MN-PCE in 1000 BM cells (V\u20acolkner, 1989). Five animals per sex per group were scored. There was no significant increase in MN-PCE in either sex at any dose level with mild toxicity as measured by PCE/NCE ratios. 3.2.1.6.2. Study in male germ cells. MMA's in vivo germ cell mutagenicity was determined in a Dominant Lethal Test in mice (Anderson and Hodge, 1976). This test evaluates mutation induc- tion, usually at the chromosome level, in sperm by assessing viability of embryos in subsequentmatings. In this study, malemice were exposed by inhalation to MMA to doses of 100, 1000, or 9000 ppm six hours/day for five days, after which they were mated to females for five days. Following removal, the females were sacrificed 15 days later and products of conception analyzed. No effects were seen as regards number of early embryo deaths, mean number of early deaths per pregnancy or pre-implantation egg loss. This test result was negative indicating no in vivo germ cell muta- genesis. The cyclophosphamide control gave clearly positive results under the conditions of this test. 3.2.2. Human studies Studies in humans may detect genotoxic events resulting from adverse environmental exposures. Although humans are the most relevant species for assessing genotoxicity as it relates to health risks, human studies are observational rather than experimental. The potential pitfall of observational studies is uncertainty as to exposure. Co-exposure to other chemicals, which are often not characterized, can confound interpretation. The inclusion of spe- cific exposure biomarkers in a study modifies this concern. Three studies in humans exposed to a methacrylate in industry or dental practice were identified (Marez et al., 1991; Seiji et al., 1994; Lamberti et al., 1998; Azhar et al., 2013). Additional studies in the dental literature that report in vivo genotoxic events in humans attributed to dental restorative materials (amalgam or resin based restoratives) or bone cements are not reviewed here as these materials contain a variety of substances, some of which are genotoxic (Lamberti et al., 1998; Rogalewicz et al., 2006; Di Pietro, Visalli et al., 2008; Visalli et al., 2013). Thirty-one workers in four French industries engaged in pro- duction of MMA or poly-methyl methacrylate products were studied for SCE frequencies in PBLs (Marez et al., 1991). MMA concentrations, measured as workplace levels in air differed among the industries ranging from 2.71 to 21.6 ppm means over an 8-h period. However, six workers were exposed to short term \u201cpeak\u201d MMA levels, measured over one hour at 114e165 ppm means (two workers) or 360e400 ppm means (four workers) in two different plants. Overall ages were similar between controls and exposed workers. Overall, there was no increase in mean frequencies of SCE between the exposed and control groups. However, when comparing values for the six workers with high level peak MMA exposures, mean SCE frequencies and numbers of high frequency cells (HFCs) in this group were significantly higher than for either the control group or the remainder of the exposed workers. HFCs, defined as cells with a number of SCE greater than expected from the distribution of SCEs among cells for the group, may represent either exceptionally sensitive cells or long-lived cells with greater accumulation of SCEs over time. HFCs accounted for the increase in mean SCE frequencies in the peak worker group. Unfortunately, although the mean ages of groups studied were similar, nothing is said of the six workers with the greater SCE and HFC frequencies. SCE values increase with age in some studies. Somewhat later, 38 workers engaged in poly-methyl methac- rylate glass production in Japan were studied for CAs (100 cells per subject) and SCEs (20 cells per subject) in PBLs, with results compared to those in 11 age and sex matched controls (Seiji et al., 1994). MMA vapor levels ranged from 0.9 to 71.9 ppm as measured by personal monitors; worker blood and urine methanol concen- trations were consistent with levels of exposure. Overall, there was no difference in mean CA frequencies between the exposed and controls while SCE levels were higher in the exposed. This was attributed by the authors to higher ages in the exposed group. A nested study of non-smoking control and exposed workers, with the latter dichotomized into low and high exposure subgroups, showed no differences in either CA or SCE frequencies among the groups. In the most recent human study, MN frequencies were assessed in buccal mucosa cells of 13 technicians working in a dental pros- thesis laboratory for one year or more (10 males; 3 females) and compared with those from 14 non-workers (students and doctors, all male) (Azhar et al., 2013). The age range of the entire study populationwas 21e40 years. Subjects were excluded from study for mouth wash use, oral lesions or dental prostheses. Exposures of technicians were said to be to MMA although no measurements were made. There was no significant difference in MN mean fre- quencies between the two groups. The authors state that this may be due to the protective measures taken by the technicians, i.e. face masks and gloves. 3.2.3. Summary of genotoxicity The several genotoxicity studies reviewed here have evaluated responses in naked DNA, bacteria, eukaryotic micro-organisms and mammalian cells in vitro and in sub-mammalian and mammalian species in vivo, including human studies. Two general observations can be made from this data set. First, when directly applied to test organisms in vitro, the lower methacrylates (and presumably MAA) can damage the DNA, inducing DNA SSB, DNA DSB, and gene and chromosome level mutations, the latter manifest as CA or MN. The DNA strand breaks are the likely molecular substrates of the gene and chromosome level mutations. Indications that the induced genetic changes are due to large scale alterations in the DNA is reflected at the gene level by results being almost universally negative for reverse mu- tations in bacteria but positive for Tk\ufffd/\ufffd mutations in L5178Y mouse lymphoma cells detected primarily as slow growing mu- tants - a phenotype associated with the mutations being due large scale alterations. These in vitromutational changes are usually seen only at high dose toxic concentrations of the agents e higher than those achieved in vivo. As noted above, several of the mutation studies do not meet current guidelines due to excessive toxicity. Second, despite the findings in vitro, there is no convincing ev- idence that the lower methacrylates (or presumably MAA) can produce genotoxic effects in vivo in any test organism. All results in sub-mammalian species were reported as negative. The weight of evidence in mammals is also negative, with the scattering of equivocal/positive claims by authors of early studies likely resulting from scoring chromosome changes that are no longer thought to reflect aberrations. Furthermore, few of the early studies would be considered valid by OECD guidelines. Although only fragmentary, results of human studies do not suggest in vivo mutagenicity. These observations may be reconciled by considering the po- tential genotoxic intermediates generated by metabolism of the lowermethacrylates and themutagenicmechanisms bywhich they damage DNA. R.J. Albertini / Regulatory Toxicology and Pharmacology 84 (2017) 77e93 89 4. Discussion and conclusions 4.1. Potential genotoxic intermediates/mechanisms Metabolic detoxification of the lower methacrylates generates several potentially genotoxic intermediates. The requirement for metabolism to produce genotoxicity is illustrated by the studies reviewed above in which neither MMA nor HEMA had an effect in vitro on naked plasmid DNA (Pawlowska et al., 2010; Szczepanska et al., 2012). 4.1.1. Acidity MAA per se and as an intermediate resulting from the primary carboxylesterase mediated detoxification metabolism of the lower methacrylates is a weak organic acid with pKa of 4.66 at 20 \ufffdC. Its direct application to cells in vitro or at sites of contact in vivo may result in significant reduction of pH. A study of Tk mutations in MMA exposed L5178Y mouse lymphoma cells reviewed above commented that the culture medium turned yellow at a concen- tration of 4.7 mM and above, clearly indicating acidity (Cifone, 1985). Many of the in vitro mutagenicity studies reviewed here employed concentrations in this range for the various methacry- lates. As MAA is a metabolic intermediate produced in a one to one ratio by detoxification metabolism of all the lower methacrylates, the resulting acidity should be the same for all. Genotoxic effects of low pH in cultured mammalian cells were reported three decades ago (Brusick, 1986; Cifone et al., 1987). These effects include chromosome changes and genemutations, i.e. Tk mutations in L5178Y mouse lymphoma cells. More recently, the issue of acidity induced chromosome aberrations has been studied in greater deal, demonstrating that it is a real phenomenon and differs from cell type to cell type (Morita et al., 1989; Morita et al., 1990; Meinti\ufffderes and Marzin, 2004). Low pH is a well-documented cause of disparity between in vitro and in vivo genotoxicity test results. 4.1.2. Epoxides: 2,3-EpoxyMAA and 2,3-EpodioxyMMA As reviewed above, MAA and some methacrylates themselves may undergo mono- or di-oxygenase mediated oxidation to form epoxides. Epoxides are well known DNA reactive chemicals and form DNA adducts. Some DNA adducts by their very presence may cause errors of DNA replication resulting in a mutation unless efficiently repaired. These include those that alter DNA structure, prevent replication, or form at coding sites, i.e., O6, N1 and N2 of guanine (G) [superscript indicates exo-cyclic oxygen or nitrogen], N1 and N6 of adenine (A), O2, N3 and N4 of cytosine (C) and O4 and N3 of thymine (T) and are termed pro-mutagenic adducts. On the other hand, some adducts occurring on cyclic nitrogens in purines that are non-coding sites, e.g., N7G and N3A, usually do not produce mutations unless they distort DNA structure or convert to cyclic or ring-open structures (Singer and Grunberger, 1983). These are termed non-pro-mutagenic adducts. Simple epoxides preferentially react at the N7 position of gua- nine (N7G adducts). The next most frequent site of adduction of these epoxides is at the N3 position of adenine (N3A adducts). It is estimated that 75e90% of adducts formed by these epoxides are N7Gwhile an additional 4e8% are N3A adducts (Koskinen and Plna, 2000). Both are non-pro-mutagenic adducts. In addition, N7G and N3A adducts are unstable and are usually removed by spontaneous depurination, leaving behind apurinic (AP) sites that are efficiently repaired (Boysen et al., 2009). It has been estimated that there are approximately 30,000 abasic sites per mammalian cell at steady state, making them the most abundant kind of endogenous, back- ground DNA damage (Swenberg et al., 2011). The standard alkaline Comet assay reflects these lesions as well as DNA SSB. Although DNA synthesis across an abasic sitemay result in amutation if there is insufficient time for closure of the site, this is not usually observed except at high and toxic concentrations of the offending agent (Boysen et al., 2009). Simple epoxides may produce other mutations at any of the base pairs, although these are in the minority. Some are pro- mutagenic adducts inducing base-change mutations at either GC or AT base pairs. However, in the aggregate, all of the Salmonella reverse mutation assays reviewed above gave negative results for base change mutations. This was true also for tester strain YG7108pin3ERb5 which contains p450 enzymes capable of metabolizing test compounds (Emmert et al., 2006). In the aggre- gate, the bacterial studies e all of which were negative - have evaluated base-changes at both base pairs. 4.1.3. Alcohols, formaldehyde As discussed above, both alcohols and formaldehyde are pro- duced by detoxification metabolism of the methacrylates, with formaldehyde itself being produced by MAA metabolism through the epoxidation pathway. These compounds are or may be further metabolized to potentially genotoxic agents. However, as regards formaldehyde, endogenous production provides a ubiquitous source in vivo under normal conditions. Endogenous blood con- centrations of formaldehyde are in the range of 0.1 mM in rats, monkeys, and humans (Heck et al., 1982; Heck et al., 1985; Casanova et al., 1988). Physiological intra-cellular formaldehyde concentrations are generally about half the blood concentrations (~0.050 mM); levels in nasal mucosa and liver are two-to four-fold blood levels (Heck and Casanova, 2004). However, as noted above, the systemic distribution of HEMA in mice studied after either sub- cutaneous or gastric tube administration of 20 mM/kg radio-labeled material was rapid to all tissues, with tissue concentrations in the nM range after 24 h (Durner et al., 2009). Furthermore, blood levels of MMA in patients exposed internally to contaminant monomers from the implanted prosthesis have shown the highest concen- trations (~1.5 mg/ml \u00bc 15 mM) in the first 10 min post-surgery, with rapid fall-off thereafter (Pfaffli and Svartling, 1985). The internal levels of these methacrylates, which approximate internal formal- dehyde levels resulting from further metabolism, are well below normal background levels. Presumably this applies to in- termediates resulting from metabolism of the alcohols. On purely quantitative grounds therefore, concentrations of formaldehyde or alcohols derived from the methacrylates that are below the endogenous background level are unlikely to induce any additional systemic mutational events. Theoretically however, this may not apply to high concentration direct applications to local tissues at sites of contact in vivo. 4.1.4. Oxidative stress: reactive oxygen species (ROS) The lower methacrylates have been shown to induce oxidative stress with attendant production of ROS and DNA damage in vitro (Walther et al., 2004; Chang et al., 2005; Spagnuolo, D'Anto et al., 2006; Paranjpe et al., 2007; Samuelsen et al., 2007; Paranjpe et al., 2008; Paranjpe et al., 2009; Szczepanska et al., 2012); ROS are clearly mutagenic chemicals. A great many DNA adducts affecting all four nucleobases are known to characterize oxidative DNA damage (reviewed in (Wallace, 2002; Cooke et al., 2003; Marnett et al., 2003). Many are pro-mutagenic. Oxidative lesions in DNA are continually being produced from endogenous sources in vivo, with estimates of the number of such lesions produced per cell per day ranging up to 1.5 \ufffd 105 (Beckman and Ames, 1997). Highly reactive carbonyls arising from lipid peroxidation resulting from oxidative stress also produce a variety of mutagenic DNA adducts (De Bont and van Larebeke, 2004; Bolt, 2012). However, despite the genotoxicity shown by R.J. Albertini / Regulatory Toxicology and Pharmacology 84 (2017) 77e9390 the lower methacrylates in the studies referenced above, and the potential mutagenicity of the products of oxidative stress, all of the methacrylate studies on oxidative DNA damage reviewed were in vitro and employed relatively high concentrations of the methacrylate tested (usually HEMA in the mM range). As noted for the alcohols/formaldehyde potential mutagenicity, these methac- rylate concentrations are much higher than those that have been achieved in vivo. Again, on quantitative grounds, the lower methacrylates are unlikely to induce systemic mutations over background in vivo. 4.2. Conclusions The genotoxicity profile of MAA and the lower methacrylates shows these compounds to be genotoxic in vitro where they have the capacity to induce DNA damage, gene level mutations asso- ciated with gross changes in the DNA as well as chromosome level mutations, i.e. CA and MN. Some of the positive results however, especially the mutations, have been seen in studies that do not meet current guidelines for chemical testing. Specifically, these events have been demonstrated on applications of high and usu- ally toxic doses of the agent of concern. Despite this in vitro ca- pacity, there is no convincing evidence that the lower methacrylates induce mutagenic events in vivo in any species tested. This dichotomy of genotoxic effects may be explained by consideration of the potentially genotoxic agents responsible for the in vitro effects, all of which derive from detoxification meta- bolism. One, acidity, will be only an in vitro phenomenon seenwith direct application to cells. Others are unlikely to be produced in sufficient amounts at systemic sites in vivo to induce genotoxicity. Formaldehyde, some of the organic acids and ROS are normally endogenously produced, with systemic levels achievable by expo- sures to the lower methacrylates being only a fraction of the levels already present. The genotoxicity profile of the lower alkyl methacrylates can be viewed in the context of the carcinogenicity of these compounds as determined by studies of MMA. MMA and presumably the other methacrylates reviewed here are non-carcinogens in either animals or humans. Might this have been inferred from the genotoxicity test results of these compounds? The value of short term genotoxicity test results has been discussed and evaluated since the land-mark report of McCann et al. (1975) demonstrating that many carcino- gens are mutagens. Schemes for using these tests have been debated ever since, with most agreeing that in vitro testing cannot fully predict carcinogenicity and that it is the mutational end- points, i.e. gene or chromosome, that are of most value in pre- dicting carcinogenicity (MacGregor et al., 2000; Bajpayee et al., 2005) and references therein. It can be concluded that MAA and the group of lower methac- rylates have all been evaluated for genotoxicity, even though every assay has not been performed on every agent. The similarities of structure, detoxification metabolic pathways and performance in the several tests in which several members of the group have been tested, indicate that the read-across approach to evaluating group genotoxicity is adequate for this appraisal. The genotoxicity profile for the lower methacrylates is consis- tent with the earlier findings of long term carcinogenicity bioassays in animals, i.e. MMA as example of the group is not carcinogenic. Even though this group of agents has been termed high dose clastogens in vitro, they are not in vivo mutagens. The genotoxicity profile of the lower alkyl methacrylates predicts therefore, what has been concluded by the several agencies that have offered cancer classifications) (NTP, 1986; IARC, 1994; ECETOC, 1995; EPA, 1998; EU, 2002). Transparency document Transparency document related to this article can be found online at http://dx.doi.org/10.1016/j.yrtph.2017.01.001. References Alexander, P., 1961. Mouse lymphoma cells with different radiosensitivities. Nature 192, 572e573. Amtower, A., Brock, K., Doerr, C., Dearfield, K., Moore, M., 1986. Genotoxicity of 3 acrylate compounds in l5178y mouse lymphoma-cells. Environmental Muta- genesis. WILEY-LISS DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012. Anderson, B.E., Zeiger, E., Shelby, M.D., Resnick, M.A., Gulati, D., Ivett, J.L., Loveday, K., 1990. Chromosome aberration and sister chromatid exchange test results with 42 chemicals. Environ. Mol. Mutagen. 16 (S18), 55e137. Anderson, D., Hodge, M.C.E., 1976. Methylmethacrylate Monomer: Dominant Lethal Study in the Mouse. Testing Laboratory: ICI, Central Toxicology Laboratory. Report no.: CTL/P/295. Owner company: Imperial Chemical Industries, limited/ Zeneca, Alderley Park, Macclesfield, Cheshire. Anderson, D., Richardson, C.R., 1976. Methyl Methacrylate Monomer: Cytogenetic Study in the Rat. Report CTL/P/292. ICI, Macclesfield, Cheshire. Anderson, D., Richardson, C.R., Weight, T.M., 1979. Methylmethacrylate Monomer: a Second Cytogenetic Study in the Rat. Testing Laboratory: ICI, Central Toxicology Laboratory. Report no.: CTL/P/449. Owner company: Imperial Chemical In- dustries, limited/Zeneca, Alderley Park, Macclesfield, Cheshire. Anonymous, 1989. An Ames Salmonella/mammalian Microsome Mutagenesis Pre- incubation Assay for Determination of Potential Mutagenicity of Butyl- methacrylate with Cover Letter Dated 020890. Study No.: 86e890000850. DuPont Haskell Laboratories. Anonymous, 1990. An Ames Salmonella/mammalian Microsome Mutagenesis Pre- incubation Assay for Determination of Potential Mutagenicity of Butyl- methacrylate with Cover Letter Dated 020890. Study No.: 63736ZC, Mobil's Environmental Health and Safety Laboratory. Mobile Oil Corp, Princeton. Anonymous, 1991. An Ames Salmonella/mammalian Microsome Mutagenesis Pre- incubation Assay for Determination of Potential Mutagenicity of Butyl- methacrylate with Cover Letter (Sanitized). Study No.: 63915, Mobil's Envi- ronmental Health and Safety Laboratory. Mobile Oil Corp, Princeton. Ansteinsson, V., Solhaug, A., Samuelsen, J.T., Holme, J.A., Dahl, J.E., 2011. DNA- damage, cell-cycle arrest and apoptosis induced in BEAS-2B cells by 2- hydroxyethyl methacrylate (HEMA). Mutat. Res. 723 (2), 158e164. Ara\u00fajo, A.M., Alves, d.,G.R., Avan\u00e7o, G.T., Parizi, J.L.S., Nai, G.A., 2013. Assessment of methyl methacrylate genotoxicity by the micronucleus test. Braz. oral Res. 27 (1), 31e36. Arossi, G.A., Lehmann, M., Dihl, R.R., Reguly, M.L., de Andrade, H.H., 2010. Induced DNA damage by dental resin monomers in somatic cells. Basic Clin. Pharmacol. Toxicol. 106 (2), 124e129. Azhar, D.A., Syed, S., Luqman, M., Ali, A.A., 2013. Evaluation of methyl methacrylate monomer cytotoxicity in dental lab technicians using buccal micronucleus cytome assay. Dent. Mater. J. 32 (3), 519e521. Bajpayee, M., Pandey, A.K., Parmar, D., Dhawan, A., 2005. Current status of short- term tests for evaluation of genotoxicity, mutagenicity, and carcinogenicity of environmental chemicals and NCEs. Toxicol. Mech. Methods 15 (3), 155e180. Barsky, F., 1975. In Vitro Microbiological Mutagenicity Studies of Methyl Methac- rylate Monomer. Testing Laboratory: DuPont Haskell Laboratory, Newark, Delaware, Report No. 136-75; H-9430-mr-2093. Owner company: Lucite In- ternational UK Limited, Cumberland House, 15e17 Cumberland Place, South- ampton, SO15 2BG, United Kingdom. Beckman, K.B., Ames, B.N., 1997. \"Oxidative decay of DNA.\". J. Biol. Chem. 272 (32), 19633e19636. Bigatti, M.P., Lamberti, L., Cannas, M., Rossi, E., 1989. Lack of sister-chromatid ex- change induction by polymethyl methacrylate bone cement in human lym- phocytes cultured in vitro. Mutat. Res. 227 (1), 21e24. Bigatti, M.P., Lamberti, L., Rizzi, F.P., Cannas, M., Allasia, G., 1994. In vitro micronu- cleus induction by polymethyl methacrylate bone cement in cultured human lymphocytes. Mutat. Res. 321 (3), 133e137. Blanco, M., Urios, A., Martinez, A., 1998. \"New Escherichia coli WP2 tester strains highly sensitive to reversion by oxidative mutagens.\". Mutat. Res. 413 (2), 95e101. Bolt, H.M., 2012. Enzymic detoxification of endogenously produced mutagenic carcinogens maintaining cellular homeostasis. In: The Cellular Response to the Genotoxic Insult: the Question of Threshold for Genotoxic Carcinogens Ch. 2.1. H. Greim and R. J. Albertini. The Royal Society of Chemistry, Cambridge, UK. Bonassi, S., Lando, C., Ceppi, M., Landi, S., Rossi, A.M., Barale, R., 2004. No association between increased levels of high-frequency sister chromatid exchange cells (HFCs) and the risk of cancer in healthy individuals. Environ. Mol. Mutagen 43 (2), 134e136. Bouzyk, E., Gradzka, I., Iwanenko, T., Kruszewski, M., Sochanowicz, B., Szumiel, I., 2000. The response of L5178Y lymphoma sublines to oxidative stress: antioxi- dant defence, iron content and nuclear translocation of the p65 subunit of NF- kappaB. Acta Biochim. Pol. 47 (4), 881e888. Boysen, G., Pachkowski, B.F., Nakamura, J., Swenberg, J.A., 2009. The formation and biological significance of N7-guanine adducts. Mutat. Research/Genetic Toxicol. http://dx.doi.org/10.1016/j.yrtph.2017.01.001 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref1 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref1 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref1 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref2 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref2 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref2 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref2 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref2 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref3 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref3 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref3 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref3 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref4 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref4 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref4 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref4 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref5 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref5 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref6 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref6 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref6 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref6 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref7 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref7 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref7 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref7 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref7 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref8 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref8 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref8 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref8 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref9 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref9 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref9 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref9 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref10 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref10 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref10 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref10 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref11 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref11 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref11 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref11 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref12 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref12 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref12 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref12 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref13 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref13 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref13 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref13 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref14 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref14 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref14 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref14 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref15 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref15 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref15 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref15 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref15 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref15 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref16 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref16 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref16 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref17 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref17 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref17 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref17 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref18 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref18 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref18 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref18 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref19 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref19 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref19 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref19 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref20 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref20 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref20 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref20 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref21 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref21 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref21 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref21 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref21 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref22 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref22 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref22 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref22 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref22 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref23 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref23 R.J. Albertini / Regulatory Toxicology and Pharmacology 84 (2017) 77e93 91 Environ. Mutagen. 678 (2), 76e94. Bratt, H., Hathway, D., 1977. Fate of methyl methacrylate in rats. Br. J. cancer 36 (1), 114. Brusick, D., 1986. Genotoxic effects in cultured mammalian cells produced by low pH treatment conditions and increased ion concentrations. Environ. Mutagen 8 (6), 879e886. Cannas, M., Bigatti, P., Rossi, E., Rossi, P., 1987. In vitro research on the possibility of chromosomal damage caused by polymethyl methacrylate in orthopaedics. A preliminary report. Italian J. Orthop. traumatology 13 (3), 387e391. Carpanini_FMB, 1981. Toxicity Studies with HEMA (Hydroxyethyl Methacrylate) and Related Studies; BP Chemicals Inc. Report No. 25-90-0044 Dated March 10, 1981. Owner: BP Chemicals Inc. Casanova, M., Heck, H.D., Everitt, J.I., Harrington Jr., W.W., Popp, J.A., 1988. Form- aldehyde concentrations in the blood of rhesus monkeys after inhalation exposure. Food Chem. Toxicol. 26 (8), 715e716. Chan, P.C., Eustis, S.L., Huff, J.E., Haseman, J.K., Ragan, H., 1988. Two-year inhalation carcinogenesis studies of methyl methacrylate in rats and mice: inflammation and degeneration of nasal epithelium. Toxicology 52 (3), 237e252. Chang, H.H., Guo, M.K., Kasten, F.H., Chang, M.C., Huang, G.F., Wang, Y.L., Wang, R.S., Jeng, J.H., 2005. Stimulation of glutathione depletion, ROS production and cell cycle arrest of dental pulp cells and gingival epithelial cells by HEMA. Bio- materials 26 (7), 745e753. Chou, L.S., Chao, S.M., Bian, S.S., Cherng, S.H., Chou, M.Y., Lee, H., 1996. Suppressive effects of methyl methacrylate on the mutagenicity and DNA adduct formation induced by 1-nitropyrene and benzo[a]pyrene. Mutagenesis 11 (2), 177e181. Cifone, M.A., 1985. Mutagenicity Evaluation of TD-80-254 in the Mouse Lymphoma Forward Mutation Assay and Cover Letter Dated 081089.; EPA/OTS; Doc #FYI- ots-0785-0367, NTIS/OTS 0000367-1 Rohm & Haas Report No. 81RC-136. Cifone, M.A., Myhr, B., Eiche, A., Bolcsfoldi, G., 1987. Effect of pH shifts on the mutant frequency at the thymidine kinase locus in mouse lymphoma L5178Y TK\u00fe/- cells. Mutat. Res. 189 (1), 39e46. Ciliutti, P., 1999. n-Butyl Methacrylate Micronucleus Test. RTC, Pomezia, Italy. Un- published Report No. 6418-M-01599 on behalf of CEFIC Methacrylate Toxi- cology Committee. Clark, L.S., Hart, D.W., Vojta, P.J., Harrington-Brock, K., Barrett, J.C., Moore, M.M., Tindall, K.R., 1998. Identification and chromosomal assignment of two hetero- zygous mutations in the Trp53 gene in L5178Y/Tk(\u00fe/-)-3.7.2C mouse lymphoma cells. Mutagenesis 13 (5), 427e434. Collins, A.R., 2009. Investigating oxidative DNA damage and its repair using the comet assay. Mutat. Res. 681 (1), 24e32. Cooke, M.S., Evans, M.D., Dizdaroglu, M., Lunec, J., 2003. Oxidative DNA damage: mechanisms, mutation, and disease. Faseb J. 17 (10), 1195e1214. Corkill, J.A., Lloyd, E.J., Hoyle, P., Crout, D.H., Ling, R.S., James, M.L., Piper, R.J., 1976. Toxicology of methyl methacrylate: the rate of disappearance of methyl methacrylate in human blood in vitro. Clin. Chim. Acta 68 (2), 141e146. Covance, 1997. 2-Ethylhexyl Methacrylate: Induction of Chromosome Aberrations in Cultured Human Peripheral Blood Lymphocytes. Covance Laboratories Ltd report no. 514/33-1052. Darre, E., Jorgensen, L.G., Vedel, P., Jensen, J.S., 1992. Breathing zone concentrations of methylmethacrylate monomer during joint replacement operations. Phar- macol. Toxicol. 71 (3 Pt 1), 198e200. De Bont, R., van Larebeke, N., 2004. Endogenous DNA damage in humans: a review of quantitative data. Mutagenesis 19 (3), 169e185. Dearfield, K.L., Millis, C.S., Harrington-Brock, K., Doerr, C.L., Moore, M.M., 1989. Analysis of the genotoxicity of nine acrylate/methacrylate compounds in L5178Y mouse lymphoma cells. Mutagenesis 4 (5), 381e393. Di Pietro, A., Visalli, G., La Maestra, S., Micale, R., Baluce, B., Matarese, G., Cingano, L., Scoglio, M.E., 2008. Biomonitoring of DNA damage in peripheral blood lym- phocytes of subjects with dental restorative fillings. Mutat. Res. 650 (2), 115e122. Doerr, C.L., Harrington-Brock, K., Moore, M.M., 1989. Micronucleus, chromosome aberration, and small-colony TK mutant analysis to quantitate chromosomal damage in L5178Y mouse lymphoma cells. Mutat. Research/Genetic Toxicol. 222 (3), 191e203. Durner, J., Kreppel, H., Zaspel, J., Schweikl, H., Hickel, R., Reichl, F.X., 2009. The toxicokinetics and distribution of 2-hydroxyethyl methacrylate in mice. Bio- materials 30 (11), 2066e2071. Durner, J., Walther, U.I., Zaspel, J., Hickel, R., Reichl, F.X., 2010. Metabolism of TEGDMA and HEMA in human cells. Biomaterials 31 (5), 818e823. ECETOC, 1995. Joint Assessment of Commodity Chemicals No. 30, Methyl Methac- rylate. CAS No. 80-62-6. February 1995. ISSN-0773-6339-30. Brussels, February 1995. ECHA. Butyl Methacrylate. Retrieved 09-29-2016, from. https://echa.europa.eu/ registration-dossier/-/registered-dossier/15151. EFSA, 2010. EFSA panel on food contact materials, enzymes, flavourings and pro- cessing aids (cef). European food safety authority (EFSA), parma, Italy. EFSA J. 8 (2), 1401. Emmert, B., Bunger, J., Keuch, K., Muller, M., Emmert, S., Hallier, E., Westphal, G.A., 2006. Mutagenicity of cytochrome P450 2E1 substrates in the Ames test with the metabolic competent S. typhimurium strain YG7108pin3ERb5. Toxicology 228 (1), 66e76. EPA, 1998. Toxicological Review of Methyl Methacrylate (CAS No. 80-62-6): in Support of Summary Information on the Integrated Risk Information System (IRIS). EU, R.A.R., 2002. European Commission, Joint Research Centre. European Union Risk Assessment Report, Methyl Methacrylate, 1st Priority List, vol. 22. EU, R.A.R., 2002b. European Commission, Joint Research Centre. European Union Risk Assessment Report, Methyl Methacrylate Nos. 80-62-6/201-297-1, vol. 22. EU, R.A.R., 2002a. European Commission, Joint Research Centre. European Union Risk Assessment Report, Methacrylic Acid, 1st Priority List, vol. 25. Fedyukovich, L.V., Ergova, A.B., 1991. Genotoxic effects of acrylates. Gig. Sanit. 12, 62e64. Fedyukovich, L.V., Kotlovshy, Yu, V., Sviderskaya, L.N., Borisov, Yu, 1988. Genet. (Mosco) 24 (6), 1132e1133. Fenech, M., 1998. Important variables that influence base-line micronucleus fre- quency in cytokinesis-blocked lymphocytes-a biomarker for DNA damage in human populations. Mutat. Res. 404 (1e2), 155e165. Fenech, M., 2000. The in vitro micronucleus technique. Mutat. Res. 455 (1e2), 81e95. Foureman, P., Mason, J.M., Valencia, R., Zimmering, S., 1994. Chemical mutagenesis testing in Drosophila. IX. Results of 50 coded compounds tested for the National Toxicology Program. Environ. Mol. Mutagen 23 (1), 51e63. Gerzina, T.M., Hume, W.R., 1996. Diffusion of monomers from bonding resin-resin composite combinations through dentine in vitro. J. Dent. 24 (1e2), 125e128. Hachitani, N., Takeya, A., Takazawa, Y., 1981. Mutagenicity study on environmental substances. 3. Ames test and mouse bone marrow micronucleus test on acrylic resin monomer and other additives. Nippon. Koshu Eisei Zasshi 29, 236e392. Hachiya, N., Taketani, A., Takizawa, Y., 1982. Research relating to the mutagenicity of substances in the living environment. Report 3. Ames tests and mouse bone marrow micronucleus test for acrylic resin monomers and their main additives. Nippon. Koshu Eisei Zasshi 29, 236e239. Harlan, 2008. Gene mutation assay in Chinese Hamster V79 cells in vitro (V79/ HPRT) with 2-ethylhexyl methacrylate. Harlan Cytotest Cell Res. GmbH (Harlan CCR), study number 1175901. Hatano_Research_Institute, 1997. Toxicity Testing Reports of Environmental Chemicals 5: 525-552. Toxicity Testing Reports of Environmental Chemicals, vol. 5. Testing laboratory: Hatano Research Institute, Kanagawa, Japan, pp. 525e552. Haworth, S., Lawlor, T., Mortelmans, K., Speck, W., Zeiger, E., 1983. Salmonella mutagenicity test results for 250 chemicals. Environ. Mutagen 5 (Suppl. 1), 1e142. Heck, H.D., Casanova, M., 2004. The implausibility of leukemia induction by form- aldehyde: a critical review of the biological evidence for distal site toxicity. Reg. Tox. Pharm. 40, 92e106. Heck, H.D., Casanova-Schmitz, M., Dodd, P.B., Schachter, E.N., Witek, T.J., Tosun, T., 1985. \"Formaldehyde (CH2O) concentrations in the blood of humans and Fischer-344 rats exposed to CH2O under controlled conditions. Am. Ind. Hyg. Assoc. J. 46 (1), 1e3. Heck, H.D., White, E.L., Casanova-Schmitz, M., 1982. Determination of formaldehyde in biological tissues by gas chromatography/mass spectrometry. Biomed. Mass Spectrom. 9 (8), 347e353. Heddle, J.A., Fenech, M., Hayashi, M., MacGregor, J.T., 2011. Reflections on the development of micronucleus assays. Mutagenesis 26 (1), 3e10. Heil, J., Reifferscheid, G., Waldmann, P., Leyhausen, G., Geurtsen, W., 1996. Geno- toxicity of dental materials. Mutat. Res. 368 (3e4), 181e194. IARC, 1994. Methyl methacrylate. In: ARC Monographs on the Evaluation of Carci- nogenic Risks to Humans. Vol. 60: Some Industrial Chemicals. IARC, Lyon, pp. 445e474. Jensen, J.S., Sylvest, A., Trap, B., Jensen, J.C., 1991. Genotoxicity of acrylic bone ce- ments. Pharmacol. Toxicol. 69 (5), 386e389. Jiang, Z., et al., 1989. Genotoxicity of 23 chemicals to S. Cerevisiae. Environ. Mol. Mutagen. 14 (Suppl. ment), 95. Johannsen, F., Vogt, B., Waite, M., Deskin, R., 2008. Mutagenicity assessment of acrylate and methacrylate compounds and implications for regulatory toxi- cology requirements. Regul. Toxicol. Pharmacol. 50 (3), 322e335. Jones, O., 2002. Using Physiologically Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Toxicity of Methacrylate Esters Doctor of Philosophy. University of Manchester. Kleinsasser, N.H., Schmid, K., Sassen, A.W., Harreus, U.A., Staudenmaier, R., Folwaczny, M., Glas, J., Reichl, F.X., 2006. Cytotoxic and genotoxic effects of resin monomers in human salivary gland tissue and lymphocytes as assessed by the single cell microgel electrophoresis (Comet) assay. Biomaterials 27 (9), 1762e1770. Kleinsasser, N.H., Wallner, B.C., Harreus, U.A., Kleinjung, T., Folwaczny, M., Hickel, R., Kehe, K., Reichl, F.X., 2004. Genotoxicity and cytotoxicity of dental materials in human lymphocytes as assessed by the single cell microgel electrophoresis (comet) assay. J. Dent. 32 (3), 229e234. Koskinen, M., Plna, K., 2000. Specific DNA adducts induced by some mono- substituted epoxides in vitro and in vivo. Chem. Biol. Interact. 129 (3), 209e229. Kubinski, H., Gutzke, G.E., Kubinski, Z.O., 1981. DNA-cell-binding (DCB) assay for suspected carcinogens and mutagens. Mutat. Res. 89 (2), 95e136. Kushida, H., Fujita, K., Suzuki, A., Yamada, M., Nohmi, T., Kamataki, T., 2000. Development of a Salmonella tester strain sensitive to promutagenic N-nitro- samines: expression of recombinant CYP2A6 and human NADPH-cytochrome P450 reductase in S. typhimurium YG7108. Mutat. Res. 471 (1e2), 135e143. Lamberti, L., Bigatti, P., Rizzi, P., Marchisio, S., Rizzo, E., Cannas, M., 1998. In vivo cytogenetic studies of the genotoxic effects of polymethyl methacrylate employed in orthopaedics. J. Mater Sci. Mater Med. 9 (4), 239e242. Lee, D.H., Lim, B.S., Lee, Y.K., Ahn, S.J., Yang, H.C., 2006. Involvement of oxidative stress in mutagenicity and apoptosis caused by dental resin monomers in cell http://refhub.elsevier.com/S0273-2300(17)30001-6/sref23 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref23 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref24 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref24 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref25 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref25 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref25 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref25 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref26 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref26 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref26 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref26 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref27 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref27 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref27 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref28 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref28 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref28 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref28 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref29 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref29 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref29 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref29 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref30 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref30 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref30 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref30 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref30 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref31 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref31 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref31 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref31 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref32 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref32 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref32 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref32 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref33 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref33 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref33 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref33 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref33 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref34 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref34 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref34 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref35 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref35 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref35 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref35 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref35 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref35 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref36 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref36 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref36 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref37 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref37 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref37 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref38 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref38 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref38 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref38 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref39 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref39 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref39 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref40 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref40 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref40 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref40 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref41 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref41 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref41 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref42 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref42 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref42 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref42 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref43 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref43 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref43 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref43 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref43 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref44 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref44 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref44 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref44 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref44 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref45 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref45 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref45 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref45 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref46 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref46 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref46 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref47 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref47 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref47 https://echa.europa.eu/registration-dossier/-/registered-dossier/15151 https://echa.europa.eu/registration-dossier/-/registered-dossier/15151 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref49 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref49 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref49 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref50 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref50 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref50 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref50 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref50 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref51 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref51 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref51 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref52 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref52 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref53 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref53 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref54 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref54 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref55 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref55 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref55 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref56 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref56 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref56 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref57 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref57 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref57 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref57 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref57 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref58 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref58 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref58 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref58 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref59 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref59 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref59 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref59 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref60 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref60 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref60 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref60 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref61 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref61 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref61 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref61 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref62 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref62 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref62 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref62 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref62 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref63 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref63 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref63 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref64 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref64 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref64 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref64 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref64 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref65 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref65 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref65 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref65 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref164 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref164 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref164 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref164 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref66 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref66 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref66 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref66 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref66 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref67 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref67 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref67 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref67 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref68 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref68 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref68 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref69 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref69 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref69 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref69 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref70 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref70 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref70 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref70 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref71 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref71 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref71 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref72 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref72 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref73 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref73 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref73 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref73 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref74 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref74 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref74 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref75 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref75 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref75 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref75 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref75 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref75 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref76 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref76 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref76 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref76 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref76 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref77 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref77 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref77 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref78 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref78 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref78 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref79 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref79 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref79 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref79 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref79 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref79 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref80 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref80 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref80 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref80 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref81 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref81 R.J. Albertini / Regulatory Toxicology and Pharmacology 84 (2017) 77e9392 cultures. Dent. Mater 22 (12), 1086e1092. Lijinsky, W., Andrews, A.W., 1980. Mutagenicity of vinyl compounds in Salmonella typhimurium. Teratog. Carcinog. Mutagen 1 (3), 259e267. Lomax, L., Krivanek, N., Frame, S., 1997. Chronic inhalation toxicity and oncogenicity of methyl methacrylate in rats and hamsters. Food Chem. Toxicol. 35 (3), 393e407. MacGregor, J.T., Casciano, D., Muller, L., 2000. Strategies and testing methods for identifying mutagenic risks. Mutat. Res. 455 (1e2), 3e20. Maher, DeFonso, 1984. Unpublished data, rohm haas. March, 1984 in: Collins JJ, page LC, Caporossi JC, Uitdjian HM, saipher in (1989). Mortality patterns among men exposed to methyl methacrylate. 1. Occup. Med. 31, 41e46. Mainwaring, G., Foster, J.R., Lund, V., Green, T., 2001. Methyl methacrylate toxicity in rat nasal epithelium: studies of the mechanism of action and comparisons between species. Toxicology 158 (3), 109e118. Marez, T., Shirali, P., Hildebrand, H.F., Haguenoer, J.M., 1991. Increased frequency of sister chromatid exchange in workers exposed to high doses of methyl- methacrylate. Mutagenesis 6 (2), 127e129. Marnett, L.J., Riggins, J.N., West, J.D., 2003. Endogenous generation of reactive ox- idants and electrophiles and their reactions with DNA and protein. J. Clin. Invest. 111 (5), 583e593. Matsui, M., Sofuni, T., Nohmi, T., 1996. Regionally-targeted mutagenesis by metabolically-activated steviol: DNA sequence analysis of steviol-induced mutants of guanine phosphoribosyltransferase (gpt) gene of Salmonella typhimurium TM677. Mutagenesis 11 (6), 565e572. McCann, J., Choi, E., Yamasaki, E., Ames, B.N., 1975. Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemicals. Proc. Natl. Acad. Sci. U. S. A. 72 (12), 5135e5139. McCarthy, T.J., Hayes, E.P., Schwartz, C.S., Witz, G., 1994. The reactivity of selected acrylate esters toward glutathione and deoxyribonucleosides in vitro: structure-activity relationships. Toxicol. Sci. 22 (4), 543e548. McCarthy, T.J., Witz, G., 1991. Structure-activity relationships of acrylate esters: reactivity towards glutathione and hydrolysis by carboxylesterase in vitro. Adv. Exp. Med. Biol. 283, 333e335. McCarthy, T.J., Witz, G., 1997. Structure-activity relationships in the hydrolysis of acrylate and methacrylate esters by carboxylesterase in vitro. Toxicology 116 (1e3), 153e158. Meinti\ufffderes, S., Marzin, D., 2004. Apoptosis may contribute to false-positive results in the in vitro micronucleus test performed in extreme osmolality, ionic strength and pH conditions. Mutat. Research/Genetic Toxicol. Environ. Mutagen. 560 (2), 101e118. MHW, 1998a. Toxicity testing reports of environmental chemicals, 6. ministry of health and welfare, Japan, pp. 77e100. MHW, 1998b. Toxicity testing reports of environmental chemicals, 6. ministry of health and welfare, Japan, pp. 339e430. Michelsen, V.B., Kopperud, H.B., Lygre, G.B., Bjorkman, L., Jensen, E., Kleven, I.S., Svahn, J., Lygre, H., 2012. Detection and quantification of monomers in unsti- mulated whole saliva after treatment with resin-based composite fillings in vivo. Eur. J. Oral Sci. 120 (1), 89e95. Mitsubishi_Rayon_Co, L, 2001. SIDS Initial Assessment Profile Robust Summary for Distribution. Owner company: Mitsubishi Rayon Co., Ltd. Study number: SIAR 868-77-9. Report date: 2001-08-22. Molinier, B., 1994. 2-ethylhexyl Methacrylate. Reverse Mutation Assay on Bacteria Salmonella typhimurium. Testing laboratory: CIT (Centre International de Toxicologie), Miserey, 27005 Evreux, France. Report no.: 10656 MMO. Owner company: Arkema France. Report date: 1994-01-14. Moore, M.M., Amtower, A., Doerr, C.L., Brock, K.H., Dearfield, K.L., 1988. Genotoxicity of acrylic acid, methyl acrylate, ethyl acrylate, methyl methacrylate, and ethyl methacrylate in L5178Y mouse lymphoma cells. Environ. Mol. Mutagen. 11 (1), 49e63. Moore, M.M., Doerr, C.L., 1990. Comparison of chromosome aberration frequency and small-colony TK-deficient mutant frequency in L5178Y/TK(\u00fe/-)-3.7.2C mouse lymphoma cells. Mutagenesis 5 (6), 609e614. Morita, T., Takeda, K., Okumura, K., 1990. Evaluation of clastogenicity of formic acid, acetic acid and lactic acid on cultured mammalian cells. Mutat. Research/Ge- netic Toxicol. 240 (3), 195e202. Morita, T., Watanabe, Y., Takeda, K., Okumura, K., 1989. Effects of pH in the in vitro chromosomal aberration test. Mutat. Res. Lett. 225 (1), 55e60. Mortelmans, K., Zeiger, E., 2000. The Ames Salmonella/microsome mutagenicity assay. Mutat. Res. 455 (1e2), 29e60. MPA_(Methacrylate_Producers_Association), 1999. Initial submission: letter from Methacrylates Producers Association Incorporation to USEPA RE summaries of methacrylate toxicity studies conducted in Japan, with attachments and dated 8/2/1999, Ministry Hlth, OTS0559766. Myhr, B., McGregor, D., Bowers, L., Riach, C., Brown, A.G., Edwards, I., McBride, D., Martin, R., Caspary, W.J., 1990. L5178Y mouse lymphoma cell mutation assay results with 41 compounds. Environ. Mol. Mutagen 16 (Suppl. 18), 138e167. Nocca, G., Ragno, R., Carbone, V., Martorana, G.E., Rossetti, D.V., Gambarini, G., Giardina, B., Lupi, A., 2011. Identification of glutathione-methacrylates adducts in gingival fibroblasts and erythrocytes by HPLC-MS and capillary electropho- resis. Dent. Mater 27 (5), e87e98. Noda, M., Wataha, J.C., Lewis, J.B., Kaga, M., Lockwood, P.E., Messer, R.L., Sano, H., 2005. Dental adhesive compounds alter glutathione levels but not glutathione redox balance in human THP-1 monocytic cells. J. Biomed. Mater Res. B Appl. Biomater. 73 (2), 308e314. NTP, 1985. Unpublished Results of Genotoxicity Studies of Ethyl Methacrylate (Chromosome Aberrations, SCE). NTP, 1986. Toxicology and Carcinogenesis Studies of Methyl Methacrylate (CAS-no.: 80-62-6) in F344/N Rats and B6C3F1 Mice (Inhalation Studies). NTP TR 314, NIH 87-2570. Reseach Triangle Park, NC, US Department of Health and Human Services. Public Health Service, National Institutes of Health. Oda, Y., Nakamura, S., Oki, I., Kato, T., Shinagawa, H., 1985. Evaluation of the new system (umu-test) for the detection of environmental mutagens and carcino- gens. Mutat. Res. 147 (5), 219e229. OECD, 1984. OECD Guideline for the Testing of Chemicals Mammalian Bone Marrow Chromosomal Aberration Test TG 475. OECD, 1997; 2010. OECD Guidelines for the Testing of Chemicals, Section 4 Health Effects; Test No. 487: in Vitro Mammalian Cell Micronucleus Test. OECD, 2001. n-butyl alcohol, SIDS initial assessment profile. SIAM 13, 6e9. November 2001. OECD, 2004. SIDS initial assessment profile. SIAM 18, 20e23. April 2004. OECD, 2007. Series on Testing and Assessment No. 80; Guidance on Grouping of Chemicals, 26-Sep-2007, ENV/JM/MONO(2007)28. OECD, 2014. OECD Guidelines for the Testing of Chemicals, Section 4 Health Effects; Test No. 475: Mammalian Bone Marrow Chromosomal Aberration Test. OECD, 2016a. OECD Guidelines for the Testing of Chemicals, Section 4 Health Ef- fects; Test No. 476: in Vitro Mammalian Cell Gene Mutation Tests Using the Hprt and Xprt Genes. http://dx.doi.org/10.1787/9789264264809-en. OECD, 2016b. OECD Guidelines for the Testing of Chemicals, Section 4 Health Ef- fects; Test No. 490: in Vitro Mammalian Cell Gene Mutation Tests Using the Thymidine Kinnase Gene. http://dx.doi.org/10.1787/9789264264908-en. OECD, 2016c. OECD Guidelines for the Testing of Chemicals, Section 4 Health Ef- fects; Test No. 473: in Vitro Mammalian Chromosomal Aberration Test. http:// dx.doi.org/10.1787/9789264264649-en. OECD, 2016d. OECD Guidelines for the Testing of Chemicals, Section 4 Health Ef- fects; Test No. 487: in Vitro Mammalian Cell Micronucleus Test. http:// dx.doi.org/10.1787/9789264264861-en. OECD, 2016e. OECD Guidelines for the Testing of Chemicals, Section 4 Health Ef- fects; Test No. 475: Mammalian Bone Marrow Chromosomal Aberration Test. http://dx.doi.org/10.1787/20745788. Osman, R., Clark, W.J., Mazurek, A.P., Weinstein, H., 1989. Theoretical studies of molecular mechanisms of DNA damage induced by hydroxyl radicals. Free Radic. Res. Commun. 6 (2e3), 131e132. Ouyang, G., Hao, A., Fan, Z., Lui, R., Wang, Y., Xie, D., Xu, G., Wang, Y., Wu, Y., 1989. Subacute toxicity, mutagenesis, and teratogenesis of methyl methacrylate. Zhonghua Laodong Weisheng Zhiyebing Zazhi 7, 80e81 [chinese; Chem. Abstr. 111, 91946n]. Rem.: paper not available, only abstract. Paranjpe, A., Cacalano, N.A., Hume, W.R., Jewett, A., 2007. N-acetylcysteine protects dental pulp stromal cells from HEMA-induced apoptosis by inducing differen- tiation of the cells. Free Radic. Biol. Med. 43 (10), 1394e1408. Paranjpe, A., Cacalano, N.A., Hume, W.R., Jewett, A., 2008. Mechanisms of N-acetyl cysteine-mediated protection from 2-hydroxyethyl methacrylate-induced apoptosis. J. Endod. 34 (10), 1191e1197. Paranjpe, A., Cacalano, N.A., Hume, W.R., Jewett, A., 2009. N-acetyl cysteine medi- ates protection from 2-hydroxyethyl methacrylate induced apoptosis via nu- clear factor kappa B-dependent and independent pathways: potential involvement of JNK. Toxicol. Sci. 108 (2), 356e366. Patlewicz, G., Ball, N., Booth, E.D., Hulzebos, E., Zvinavashe, E., Hennes, C., 2013. Use of category approaches, read-across and (Q) SAR: general considerations. Regul. Toxicol. Pharmacol. 67 (1), 1e12. Pawlowska, E., Poplawski, T., Ksiazek, D., Szczepanska, J., Blasiak, J., 2010. Geno- toxicity and cytotoxicity of 2-hydroxyethyl methacrylate. Mutat. Res. 696 (2), 122e129. Pfaffli, P., Svartling, N., 1985. Assay of methyl methacrylate in blood samples by headspace capillary gas chromatography. J. Chromatogr. 345 (2), 386e389. Poss, R., Thilly, W.G., Kaden, D.A., 1979. Methylmethacrylate is a mutagen for Sal- monella typhimurium. J. Bone Jt. Surg. Am. 61 (8), 1203e1207. Querens, A., Murray, M., Rawls, H., 1981. Mutagenic potential of residual monomers in dental resins. J. Dent. Res. 60 (A), 550. Amer Assoc Dental Research 1619 Duke St, Alexandria, VA 22314. Rogakou, E.P., Boon, C., Redon, C., Bonner, W.M., 1999. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J. Cell Biol. 146 (5), 905e916. Rogalewicz, R., Voelkel, A., Kownacki, I., 2006. Application of HS-SPME in the determination of potentially toxic organic compounds emitted from resin- based dental materials. J. Environ. Monit. 8 (3), 377e383. Samuelsen, J.T., Dahl, J.E., Karlsson, S., Morisbak, E., Becher, R., 2007. Apoptosis induced by the monomers HEMA and TEGDMA involves formation of ROS and differential activation of the MAP-kinases p38, JNK and ERK. Dent. Mater 23 (1), 34e39. Schweikl, H., Hartmann, A., Hiller, K.A., Spagnuolo, G., Bolay, C., Brockhoff, G., Schmalz, G., 2007. Inhibition of TEGDMA and HEMA-induced genotoxicity and cell cycle arrest by N-acetylcysteine. Dent. Mater 23 (6), 688e695. Schweikl, H., Schmalz, G., Bey, B., 1994. Mutagenicity of dentin bonding agents. J. Biomed. Mater Res. 28 (9), 1061e1067. Schweikl, H., Schmalz, G., Rackebrandt, K., 1998. The mutagenic activity of unpo- lymerized resin monomers in Salmonella typhimurium and V79 cells. Mutat. Research/Genetic Toxicol. Environ. Mutagen. 415 (1), 119e130. Schweikl, H., Schmalz, G., Spruss, T., 2001. The induction of micronuclei in vitro by unpolymerized resin monomers. J. Dent. Res. 80 (7), 1615e1620. Seiji, K., Inoue, O., Kawai, T., Mizunuma, K., Yasugi, T., Moon, C.S., Takeda, S., Ikeda, M., 1994. Absence of mutagenicity in peripheral lymphocytes of workers http://refhub.elsevier.com/S0273-2300(17)30001-6/sref81 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref81 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref82 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref82 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref82 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref83 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref83 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref83 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref83 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref84 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref84 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref84 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref84 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref85 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref85 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref85 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref85 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref86 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref86 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref86 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref86 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref87 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref87 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref87 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref87 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref88 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref88 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref88 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref88 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref89 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref89 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref89 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref89 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref89 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref90 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref90 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref90 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref90 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref91 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref91 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref91 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref91 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref92 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref92 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref92 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref92 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref93 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref93 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref93 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref93 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref93 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref94 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref94 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref94 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref94 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref94 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref94 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref95 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref95 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref95 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref96 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref96 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref96 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref97 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref97 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref97 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref97 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref97 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref98 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref98 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref98 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref99 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref99 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref99 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref99 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref100 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref100 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref100 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref100 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref100 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref101 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref101 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref101 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref101 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref101 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref102 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref102 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref102 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref102 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref103 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref103 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref103 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref104 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref104 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref104 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref104 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref105 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref105 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref105 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref105 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref106 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref106 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref106 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref106 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref107 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref107 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref107 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref107 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref107 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref108 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref108 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref108 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref108 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref108 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref109 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref109 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref110 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref110 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref110 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref110 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref111 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref111 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref111 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref111 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref112 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref112 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref113 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref113 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref114 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref114 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref114 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref115 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref115 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref116 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref116 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref117 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref117 http://dx.doi.org/10.1787/9789264264809-en http://dx.doi.org/10.1787/9789264264908-en http://dx.doi.org/10.1787/9789264264649-en http://dx.doi.org/10.1787/9789264264649-en http://dx.doi.org/10.1787/9789264264861-en http://dx.doi.org/10.1787/9789264264861-en http://dx.doi.org/10.1787/20745788 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref123 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref123 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref123 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref123 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref123 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref124 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref124 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref124 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref124 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref124 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref125 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref125 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref125 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref125 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref126 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref126 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref126 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref126 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref127 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref127 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref127 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref127 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref127 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref128 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref128 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref128 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref128 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref129 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref129 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref129 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref129 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref130 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref130 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref130 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref131 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref131 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref131 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref132 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref132 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref132 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref133 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref133 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref133 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref134 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref134 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref134 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref134 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref135 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref135 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref135 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref135 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref135 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref136 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref136 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref136 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref136 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref137 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref137 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref137 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref138 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref138 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref138 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref138 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref139 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref139 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref139 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref140 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref140 R.J. Albertini / Regulatory Toxicology and Pharmacology 84 (2017) 77e93 93 occupationally exposed to methyl methacrylate. Ind. Health 32 (2), 97e105. Seiss, M., Track, N., Hickel, R., Reichl, F.X., 2009. In vitro stability of methyl- methacrylic acid, TEGDMA and HEMA exposed to esterases. Dent. Mater 25 (8), 1044e1049. Singer, B., Grunberger, D., 1983. Metabolic activation of carcinogens and mutagens. In: Molecular Biology of Mutagens and Carcinogens. Springer, pp. 97e141. Sippel, M., 1979. Methyl Methacrylate; Mutagenic Activity in the Salmonella/ microsome Assay. Testing Laboratory: DuPont Haskell Laboratory, Newark, Delaware, report no. 91-79. Owner company: Lucite International UK Limited, Cumberland House, 15e17 Cumberland Place, Southampton, SO15 2BG, United Kingdom. Skopek, T.R., Liber, H.L., Krolewski, J.J., Thilly, W.G., 1978. \"Quantitative forward mutation assay in Salmonella typhimurium using 8-azaguanine resistance as a genetic marker.\". Proc. Natl. Acad. Sci. U. S. A. 75 (1), 410e414. Smith, C.C., O'Donovan, M.R., Martin, E.A., 2006. hOGG1 recognizes oxidative damage using the comet assay with greater specificity than FPG or ENDOIII. Mutagenesis 21 (3), 185e190. Smith, J.M., 1980. Letter on Review of Toxicology of Methyl Methacrylate. Rohm and Haas Co., Philadelphia, PA, FYI-AX-0380e0063. Spagnuolo, G., D'Anto, V., Cosentino, C., Schmalz, G., Schweikl, H., Rengo, S., 2006. Effect of N-acetyl-L-cysteine on ROS production and cell death caused by HEMA in human primary gingival fibroblasts. Biomaterials 27 (9), 1803e1809. Speit, G., Hartmann, A., 2006. The comet assay: a sensitive genotoxicity test for the detection of DNA damage and repair. Methods Mol. Biol. 314, 275e286. Swenberg, J.A., Lu, K., Moeller, B.C., Gao, L., Upton, P.B., Nakamura, J., Starr, T.B., 2011. Endogenous versus exogenous DNA adducts: their role in carcinogenesis, epidemiology and risk assessment. kfq371 Toxicol. Sci. 120 (S1), S130eS145. Szczepanska, J., Poplawski, T., Synowiec, E., Pawlowska, E., Chojnacki, C.J., Chojnacki, J., Blasiak, J., 2012. 2-hydroxylethyl methacrylate (HEMA), a tooth restoration component, exerts its genotoxic effects in human gingival fibro- blasts trough methacrylic acid, an immediate product of its degradation. Mol. Biol. Rep. 39 (2), 1561e1574. Szumiel, I., 2005. L5178Y sublines: a look back from 40 years. Part 1: general characteristics. Int. J. Radiat. Biol. 81 (5), 339e352. Tomenson, J.A., Carpenter, A.V., Pemberton, M.A., 2005. Critical review of the epidemiology literature on the potential cancer risks of methyl methacrylate. Int. Arch. Occup. Environ. Health 78 (8), 603e612. Urcan, E., Scherthan, H., Styllou, M., Haertel, U., Hickel, R., Reichl, F.X., 2010. In- duction of DNA double-strand breaks in primary gingival fibroblasts by expo- sure to dental resin composites. Biomaterials 31 (8), 2010e2014. Visalli, G., Baluce, B., La Maestra, S., Micale, R.T., Cingano, L., De Flora, S., Di Pietro, A., 2013. Genotoxic damage in the oral mucosa cells of subjects carrying restorative dental fillings. Arch. Toxicol. 87 (1), 179e187. V\u20acolkner, W., 1989. Micronucleus Assay in Bone Marrow Cells of the Mouse with Isobutylmethacrylate. CCR Project 153303. A test report of Cytotest Cell Research GmbH & Co. KG. Sponsor: R\u20acohm GmbH Chemische Fabrik. Waegemaekers, T.H., Bensink, M.P., 1984. Non-mutagenicity of 27 aliphatic acrylate esters in the Salmonella-microsome test. Mutat. Res. 137 (2e3), 95e102. Wallace, S.S., 2002. Biological consequences of free radical-damaged DNA bases. Free Radic. Biol. Med. 33 (1), 1e14. Walther, U.I., Siagian II, Walther, S.C., Reichl, F.X., Hickel, R., 2004. Antioxidative vitamins decrease cytotoxicity of HEMA and TEGDMA in cultured cell lines. Arch. Oral Biol. 49 (2), 125e131. Wang, L., Jiang, Z., 1990. Genetic effects of methyl methacrylate on Saccharomyces cerevisiae. J. Toxicol. 112, 247. Wilson 3rd, D.M., Thompson, L.H., 2007. Molecular mechanisms of sister-chromatid exchange. Mutat. Res. 616 (1e2), 11e23. Yoshii, E., 1997. Cytotoxic effects of acrylates and methacrylates: relationships of monomer structures and cytotoxicity. J. Biomed. Mater Res. 37 (4), 517e524. Zeiger, E., 1990. Mutagenicity of 42 chemicals in Salmonella. Environ. Mol. Mutagen 16 (Suppl. 18), 32e54. Zeiger, E., Anderson, B., Haworth, S., Lawlor, T., Mortelmans, K., Speck, W., 1987. Salmonella mutagenicity tests: III. Results from the testing of 255 chemicals. Environ. Mutagen. 9 (Suppl. 9), 1e110. http://refhub.elsevier.com/S0273-2300(17)30001-6/sref140 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref140 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref141 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref141 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref141 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref141 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref142 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref142 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref142 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref143 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref143 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref143 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref143 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref143 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref143 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref144 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref144 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref144 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref144 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref145 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref145 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref145 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref145 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref146 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref146 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref146 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref147 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref147 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref147 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref147 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref148 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref148 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref148 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref149 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref149 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref149 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref149 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref150 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref150 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref150 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref150 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref150 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref150 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref151 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref151 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref151 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref152 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref152 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref152 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref152 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref153 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref153 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref153 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref153 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref154 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref154 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref154 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref154 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref155 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref155 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref155 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref155 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref155 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref155 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref156 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref156 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref156 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref156 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref157 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref157 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref157 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref158 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref158 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref158 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref158 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref159 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref159 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref160 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref160 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref160 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref160 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref161 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref161 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref161 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref162 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref162 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref162 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref163 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref163 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref163 http://refhub.elsevier.com/S0273-2300(17)30001-6/sref163 The lower alkyl methacrylates: Genotoxic profile of non-carcinogenic compounds 1. Introduction 1.1. Human exposures 1.2. Absorption, distribution and metabolic detoxification 1.3. Genotoxicity versus mutagenicity 1.4. Scope of review 2. Material and methods 2.1. Literature review 2.2. Order of presentation 3. Results 3.1. Carcinogenicity 3.2. Genotoxicity 3.2.1. Experimental studies 3.2.1.1. DNA adducts \u2013 due to direct reaction with DNA or to secondary oxidative DNA damage 3.2.1.2. In vitro studies: DNA damage endpoints reflecting changes resulting from DNA interactions with methacrylates or oxidative s ... 3.2.1.2.1. Bacterial or cellular responses 3.2.1.2.2. DNA strand breaks 3.2.1.2.3. SCE as indicators of DNA damage 3.2.1.3. In vitro studies: mutations 3.2.1.3.1. Mutations in bacteria 3.2.1.3.2. Mutations in eukaryotic microorganisms 3.2.1.3.3. Mutations in mammalian cells 3.2.1.3.3.1. Gene mutations 3.2.1.3.3.2. Chromosome mutations 3.2.1.4. In vivo studies: non mammalian species 3.2.1.4.1. Studies in non-mammalian somatic cells 3.2.1.4.2. Studies in non-mammalian germ cells 3.2.1.5. In vivo studies in mammals: DNA damage 3.2.1.6. In vivo studies in mammals: mutations 3.2.1.6.1. Studies in bone marrow cells 3.2.1.6.2. Study in male germ cells 3.2.2. Human studies 3.2.3. Summary of genotoxicity 4. Discussion and conclusions 4.1. Potential genotoxic intermediates/mechanisms 4.1.1. Acidity 4.1.2. Epoxides: 2,3-EpoxyMAA and 2,3-EpodioxyMMA 4.1.3. Alcohols, formaldehyde 4.1.4. Oxidative stress: reactive oxygen species (ROS) 4.2. Conclusions Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-metrics-of-MWCNT-induced-pulmonary-inflammation_2014_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24486532", "content": {"CoiStatement": "In summary, two independent 13-week inhalation studies with morphologically complex nano materials (MWCNT) were com- pared based on their empirical and modeled outcomes. Despite dif- ferences in dust generation and equipment/methods to characterize the aerodynamic particle size and apparent densities, the modeled prediction provided invaluable information to better understand the involved etiopathologies as well as the potential limitations of any chosen study protocol or method to generate and characterize exposure atmospheres. The comparison of studies support the conclusion that there is an urgent need for novel meth- odologies that can be used to determine the apparent density of dispersed agglomerates in inhalation chambers and workplace environments. Bearing in mind the low concentrations that work- ers may be exposed to chronically, studies focused exclusively on MoAI-related outcomes (high dose using short post-exposure dura- tions) need to be interpreted with caution. Computational study design aimed at well rationalized levels of lung overload make future inhalation studies from different laboratories more comparable as previously emphasized by experts (OECD, 2012). Thus, general principles of toxicity and mechanisms may be more readily identified and understood with less usage of experimental animals and costly resources. 5. Declaration of conflict of interest There is no conflict of interests. Bayer Material Science was a former producer of Baytubes. References There is no conflict of interests. Bayer Material Science was a former producer of Baytubes. References Aiso, S., Yamazaki, K., Umeda, Y., Asakura, M., Kasai, T., Takaya, M., Toya, T., Koda, S., Nagano, K., Arito, H., Fukushima, S., 2010. Pulmonary toxicity of intratracheally instilled multiwall carbon nanotubes in male Fischer 344 rats. Ind. Health. 48, 783\u2013795. 4 Discussion 5 Declaration of conflict of interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-mineral-nature-of-asbestos_2008_Regulatory-Toxicology-and-Pharmacology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18423957", "content": {"CoiStatement": "S30 M. Ross et al. / Regulatory Toxicology and Pharmacology 52 (2008) S26\u2013S30 chains, whereas in chrysotile asbestos growth extends in two directions to follow an effectively infinite sheet. The octahedral sheet is formed by magnesium octahedrally coordinated with oxygen and hydroxyl groups and is simi- lar to that found in brucite. The dimensions of the two sheets differ. Attention is generally focused on the b axis of the octahedral sheet, which is larger than the same axial direction in the tetrahedral sheet (9.45 A\u030a compared with 9.15 A\u030a). The dimensional mismatch of the octahedral and tetrahedral sheets can cause the double sheets to roll up into cylindrical tubes with the layer octahedral portion of the double layer forming to exterior of the curved surface. These fibrils are the ultimate minimum diameter that can be found in chrysotile and generally have a diameter around 25 nm. Usually, polygonal forms of chrysotile also occur rarely. The outer octahedral layer of chrysotile is readily leached of magnesium, even under mildly acid con- ditions (Hume and Rimstidt, 1992), and indeed chrysotile is now known to have a lower chemical durability than the amphibole asbestos minerals for this reason. Conflict of Interest The authors declare that they have no conflicts of interest. The authors declare that they have no conflicts of interest. Funding Source The mineral nature of asbestos Conflict of Interest Funding Source References", "Funding": "Funding Source Support is acknowledged from the Center for Applied Studies of the Environment, CUNY. The mineral nature of asbestos Conflict of Interest Funding Source References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-molecular-basis-for-induction-of-human-cancer_2011_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21382430", "content": {"CoiStatement": "Comparison of rodent and human adduct data Relevance of the molecular biology data The origin of methylated and POB\u2013DNA adducts in \u201cunexposed\u201d humans Conclusions Conflict of interest statement Acknowledgment References", "Acknowledgement": "Comparison of rodent and human adduct data Relevance of the molecular biology data The origin of methylated and POB\u2013DNA adducts in \u201cunexposed\u201d humans Conclusions Conflict of interest statement Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-molecular-mechanisms-of-sodium-metabisulfite-on-_2015_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26015265", "content": {"CoiStatement": "6. Conflict of interest The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Transparency Document 4 Discussion 5 Conclusions 6 Conflict of interest Transparency Document Acknowledgments References", "Acknowledgement": "The Transparency document associated with this article can be found in the online version. Acknowledgments This research was supported by Grants 21107064 and 20677035 from the National Natural Science Foundation of China and by Grant 2012021033-4 from the Natural Science Foundation of Shanxi Province. References 4 Discussion 5 Conclusions 6 Conflict of interest Transparency Document Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-naphthalene-state-of-the-science-symposium--Ob_2008_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18243454", "content": {"CoiStatement": "Conflict of interest disclosure statement The authors declare that they have no conflicts of interest. The authors declare that they have no conflicts of interest. Acknowledgments The naphthalene state of the science symposium: Objectives, organization, structure, and charge Introduction Objectives Organization Structure Selection and compensation Charge Sponsorship funding Conflict of interest disclosure statement Acknowledgments References", "Disclosure": "Conflict of interest disclosure statement The authors declare that they have no conflicts of interest. The naphthalene state of the science symposium: Objectives, organization, structure, and charge Introduction Objectives Organization Structure Selection and compensation Charge Sponsorship funding Conflict of interest disclosure statement Acknowledgments References", "Funding": "An expert in decision sciences facilitated each expert panel. In addition to moderating discussion and debate, they had substantive responsibility for assisting the subject matter experts in distinguishing among types of uncertainty so that quintessential uncertainties could be identified and research projects devised. A commonly used strategy was to ask experts to explain how the data would resolve uncer- tainty assuming that they had it in hand today. Fig. 1. The NS3 model for identifying In many cases, the expert panels struggled to orient their thinking along these lines. As research scientists, all had a great deal of experience proposing and evaluating research projects, but the criteria normally used to evaluate intellec- tual merit are different from those which the Planning Com- mittee asked be applied. Few expert panelists had prior experience with the application of value-of-information principles for ranking such proposals. The NS3 process yielded many valuable insights on specific research. Never- theless, there remains considerable room for improvement in devising more effective strategies for eliciting expert scien- tific judgment in ways that target scarce research resources to resolve the most pressing scientific uncertainties. 7. Sponsorship funding Sponsorship NS3 was funded in part by grants to the University of Nebraska Medical Center by the U.S. Envi- ronmental Protection Agency (Grant No. 83330401-0) and the Electric Power Research Institute; to Regulatory Checkbook by the Naphthalene Council, Inc., and the American Petroleum Institute on behalf of an ad hoc industry coalition consisting of the Association of Rail- roads, the American Coke and Coal Chemicals Institute, the American Petroleum Institute, the Asphalt Institute, and the National Petrochemical Refiners Association; and by unrestricted grants to Regulatory Checkbook, a and resolving scientific uncertainty. Finally, Regulatory Checkbook, the 501(c) (3) nonprofit organization that coordinated the project, also provided funding from unrestricted support and retained earnings. References The naphthalene state of the science symposium: Objectives, organization, structure, and charge Introduction Objectives Organization Structure Selection and compensation Charge Sponsorship funding Conflict of interest disclosure statement Acknowledgments References", "Acknowledgement": "Acknowledgments This article was developed in part under EPA Assistance Agreement No. 83330401-0 awarded by the U.S. Environ- mental Protection Agency. It has not been formally re- viewed by the EPA. The views expressed in this document are solely those of the authors and the EPA does not endorse any products or commercial services men- tioned in this publication. The naphthalene state of the science symposium: Objectives, organization, structure, and charge Introduction Objectives Organization Structure Selection and compensation Charge Sponsorship funding Conflict of interest disclosure statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-need-for-juvenile-animal-studies---A-c_2013_Regulatory-Toxicology-and-Ph.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23108189", "content": {"CoiStatement": "Conflict of interest The authors confirm that they have no conflicts of interests that could inappropriately influence, or be perceived to influence, their work. The authors confirm that they have no conflicts of interests that could inappropriately influence, or be perceived to influence, their work. References 3 Conclusions Conflict of interest References", "Compliance with ethical standards": "EU, 2008. Communication from the commission \u2013 Guideline on the format and content of applications for agreement or modification of a paediatric investigation plan and requests for waivers or deferrals and concerning the operation of the compliance check and on criteria for assessing significant studies. 2008/C 243/01. EU, 2010. Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. OJ L 276, 20.10.2010, p. 33."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-need-for-transparency-and-reproducibility-in-document_2016_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27771342", "content": {"Funding": "This project was supported by funding provided by the Research Foundation for Health and Environmental Effects (Contract number R0072). RFHEE is a 501(c) (3) tax-exempt organization established by the American Chemistry Council (ACC). Established in 1995, RFHEE works to address uncertainties and answer questions on health and environmental issues related to the production and use of chemistry. RFHEE works with industry, public agencies, academia and other foundations on projects that will furnish crucial information, peer-reviewed scientific research, expert panels, and workshops that will provide information for public policy. RFHEE receives contributions from government, industry (companies and trade organizations), and other industry partners who share its commitment to improving the factual and scientific understanding about critical questions associated with and/or impacting chemistry. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of any manuscript. The funders were given the opportunity to review draft manuscripts at the time of external peer review. The purpose of such review was to allow input on the clarity of the science pre- sented but not on interpretation of the research findings. The re- searchers' scientific conclusions and professional judgments were not subject to the funders' control. C. Van Landingham et al. / Regulatory Toxicology and Pharmacology 81 (2016) 512e521 521 Most of the authors (Gentry, Van Landingham, and Mundt) are employees of Ramboll Environ US Corporation, and performed this work as part of their normal employment. Ramboll Environ US Corporation is a consulting firm providing services in environ- mental and health sciences matters to private firms, trade organi- zations, and government agencies. Mr. Allen provided senior technical review on the manuscript and its content as an inde- pendent consultant with fee for service. The authors had sole re- sponsibility for the analyses performed, the interpretations made, conclusions drawn and the writing of the paper, which may not necessarily reflect the views of RFHEE. None of the authors have appeared as experts in any litigation related to formaldehyde.", "Acknowledgement": "Acknowledgements This project was supported by funding provided by the Research Foundation for Health and Environmental Effects (Contract number R0072). RFHEE is a 501(c) (3) tax-exempt organization established by the American Chemistry Council (ACC). Established in 1995, RFHEE works to address uncertainties and answer questions on health and environmental issues related to the production and use of chemistry. RFHEE works with industry, public agencies, academia and other foundations on projects that will furnish crucial information, peer-reviewed scientific research, expert panels, and workshops that will provide information for public policy. RFHEE receives contributions from government, industry (companies and trade organizations), and other industry partners who share its commitment to improving the factual and scientific understanding about critical questions associated with and/or impacting chemistry. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of any manuscript. The funders were given the opportunity to review draft manuscripts at the time of external peer review. The purpose of such review was to allow input on the clarity of the science pre- sented but not on interpretation of the research findings. The re- searchers' scientific conclusions and professional judgments were not subject to the funders' control. 4. Discussion Acknowledgements Appendix A.. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-origins-of-public-concern-with-taconite-and-hum_2008_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18055081", "content": {"CoiStatement": "Answers to these questions and others are imperative for state agency decision-makers to manage current permits and to make future permitting decisions. Improved scien- tific understanding of the health concerns associated with taconite tailings can have wide ranging effects on the char- acter, extent and frequency of required monitoring, opera- tion efficiency of tailings disposal facilities, and may open the possibility of alternative uses for tailings. Conflict of Interest The authors declare that they have no conflicts of interest. Funding Source The authors declare that they have no conflicts of interest. Funding Source Funded by the state of Minnesota. Aftermath Conclusions Conflict of Interest Funding Source Acknowledgments References", "Funding": "The authors declare that they have no conflicts of interest. Funding Source Funded by the state of Minnesota. Aftermath Conclusions Conflict of Interest Funding Source Acknowledgments References", "Acknowledgement": "M.E. Berndt, W.C. Brice / Regulatory Toxicology and Pharmacology 52 (2008) S31\u2013S39 S39 Acknowledgments The authors thank Robert Bartlett and two anonymous peer reviewers who provided helpful comments and Eldon Kaul of the Minnesota Attorney General\u2019s office for his assistance and thoughtful inputs to this paper. Aftermath Conclusions Conflict of Interest Funding Source Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-performance--reliability-and-potential-application-o_2021_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33166621", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 5 Conclusion Funding Research ethics Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Funding": "Funding This research was funded by Bristol Myers Squibb. 5 Conclusion Funding Research ethics Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Acknowledgement": "Acknowledgements The authors would like to thank Anjali Prasad for assistance in compiling the historical AOT data, Dr. Glenn Myatt for providing the opportunity to evaluate the Leadscope AOT suite, Dr. Kamel Mansouri for assistance with the CATMoS AOT suite, Carol Gleason for assistance with the statistical analysis and Dr. Raja Mangipudy for his support, input and review of the manuscript. 5 Conclusion Funding Research ethics Declaration of competing interest Acknowledgements Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-potential-protective-effect-of-green--black--red-and-_2015_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26472100", "content": {"CoiStatement": "Conflicts of interest None declared. Conflicts of interest Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-presence-of-drug-in-control-samples-during-toxi_2005_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15885865", "content": {"Compliance with ethical standards": "Can a study containing positive control specimens still be characterized as a good laboratory practice (GLP) study? According to the OECD guidelines (OECD, 1998), good laboratory practice is \u201ca quality system concerned with the organizational process and the conditions under which studies are planned, per- formed, monitored, recorded, archived, and reported.\u201d GLP neither assures that the scientiWc design of a study is sound nor that standard operating procedures (SOPs) or analyses are scientiWcally adequate. It will not decide whether the occurrence of positive control specimens invalidates a study since this is a scientiWc judgment. In other words, a study can be in compliance with GLP even when positive control specimens are found. The Study Director should, however, identify and fully dis- cuss any issues in the Wnal report. Can compliance with good laboratory practice pre- vent contamination of control specimens? GLP provides Can compliance with good laboratory practice pre- vent contamination of control specimens? GLP provides I. Nicholls et al. / Regulatory Toxicology and Pharmacology 42 (2005) 172\u2013178 177 a full set of basic principles, such as SOPs for all major standard activities, a detailed study plan for each study, training records for all involved individuals, direct and prompt records for all activities, archives that contain all study information, and a Quality Assurance Unit super- vising the GLP compliance of each study. All these requirements serve in the reconstruction of the study at a later date and give accountability for each procedure. Despite such procedures it is not always possible to pre- vent positive control specimens. Consider the situation when a mix-up of two animals occurs in a rat toxicology study and a control animal unintentionally receives the low dose treatment. In all other respects, procedures were followed. Nevertheless, one control was exposed to the drug as shown after the bio-analyses. Based on the results, the Study Director could identify what happened and address the issue in the Wnal report. This example of an incorrect dosing of a control animal is easy to under- stand but what about ex vivo contamination? There are many possibilities why this may happen during the han- dling of animals, blood collection, during processing, storage, shipment of specimens or analyses, and due to the speciWc substance properties. Usually it is not easy to identify the reasons but examination of the procedures laid down in the GLP documentation might identify weak points. In addition, the support of Quality Assur- ance personnel is helpful as they oversee a large variety of procedures and may Wnd possible sources of the con- tamination. One can therefore state that GLPs do not necessarily prevent contamination of control specimens but they may reduce the potential for contamination and help to Wnd reasons for any occurrences during study conduct. I. Nicholls et al. / Regulatory Toxicology and Pharmacology 42 (2005) 172\u2013178 177 a full set of basic principles, such as SOPs for all major standard activities, a detailed study plan for each study, training records for all involved individuals, direct and prompt records for all activities, archives that contain all study information, and a Quality Assurance Unit super- vising the GLP compliance of each study. All these requirements serve in the reconstruction of the study at a later date and give accountability for each procedure. Despite such procedures it is not always possible to pre- vent positive control specimens. Consider the situation when a mix-up of two animals occurs in a rat toxicology study and a control animal unintentionally receives the low dose treatment. In all other respects, procedures were followed. Nevertheless, one control was exposed to the drug as shown after the bio-analyses. Based on the results, the Study Director could identify what happened and address the issue in the Wnal report. This example of an incorrect dosing of a control animal is easy to under- stand but what about ex vivo contamination? There are many possibilities why this may happen during the han- dling of animals, blood collection, during processing, storage, shipment of specimens or analyses, and due to the speciWc substance properties. Usually it is not easy to identify the reasons but examination of the procedures laid down in the GLP documentation might identify weak points. In addition, the support of Quality Assur- ance personnel is helpful as they oversee a large variety of procedures and may Wnd possible sources of the con- tamination. One can therefore state that GLPs do not necessarily prevent contamination of control specimens but they may reduce the potential for contamination and help to Wnd reasons for any occurrences during study conduct. 6. General discussion and conclusions"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-problem-of-maternal-toxicity-in-developme_2012_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22178772", "content": {"CoiStatement": "Conflict of interest statement The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. References The problem of maternal toxicity in developmental toxicity studies Conflict of interest statement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-prooxidant-effect-of-sodium-metabisulfite-_2005_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15896446", "content": {"Acknowledgement": "In summary, the presented data confirm the proox- idant activity of sulfites and suggests that increased GPx activity and plasma uric acid levels may par- tially reduce the observed renal and hepatocellular oxidative damage caused via the ingestion of sulfites. These findings are also relevant in the context of hu- man exposure to sulfites, especially in patients receiv- ing TPN solutions, in subjects undergoing peritoneal dialysis and in patients with congenital sulfite oxidase deficiency. Acknowledgment This study was supported by a grant from Akdeniz University Research Foundation, Turkey (21.01.0122.09). References Discussion Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/The-purity-of-tattoo-inks--screening-substan_2022_Regulatory-Toxicology-and-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/35065093", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 4 Conclusion Funding body information CRediT authorship contribution statement Declaration of competing interest References", "Funding": "Funding body information No external funds were acquired for this research project. B. Desmedt: Conceptualization, Methodology, Investigation, Vali- dation, Writing \u2013 original draft, Supervision. M. Vanhamme: Investi- gation. E. Deconinck: Writing \u2013 review & editing, Funding acquisition. Declaration of competing interest 4 Conclusion Funding body information CRediT authorship contribution statement Declaration of competing interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-rat-bone-marrow-micronucleus-test--Statistical-_2019_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30572081", "content": {"CoiStatement": "Funding and conflict of interest statement This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The au- thors state no conflict of interest. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The au- thors state no conflict of interest. Acknowledgements Discussion Conclusions Funding and conflict of interest statement Acknowledgements Transparency document mk:H1_20 One-sided parametric tolerance intervals References", "Funding": "Funding and conflict of interest statement This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The au- thors state no conflict of interest. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The au- thors state no conflict of interest. Acknowledgements Discussion Conclusions Funding and conflict of interest statement Acknowledgements Transparency document mk:H1_20 One-sided parametric tolerance intervals References", "Acknowledgement": "Acknowledgements We would like to thank all laboratories/institutions that performed the rat bone marrow micronucleus test experiments and provided the negative control data and secondary information as a profound basis for the current study. Their professionalism and expertise are gratefully acknowledged. The authors also thank Karin Schlemminger (Fraunhofer ITEM) for her careful proofreading of the manuscript, and finally the \u201cGesellschaft f\u00fcr Umwelt-Mutationsforschung e.V.\u201d (GUM) for providing the opportunity and framework for the interdisciplinary activities of the working group \u201cStatistics\u201d. Discussion Conclusions Funding and conflict of interest statement Acknowledgements Transparency document mk:H1_20 One-sided parametric tolerance intervals References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-regulatory-challenge-of-chemicals-in-the-environme_2018_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30291878", "content": {"Funding": "The key to improvement is plain: recognize the needs of ERA de- cision support and use more rigorous scientific methods in the design and application of models used in ecotoxicity testing/interpretation and regulatory decision-making. Also, carefully consider the DIKW process to ensure that experimental data collection addresses immediate model design requirements as well as data quality and validity requirements for other models that are used to facilitate information and knowledge development for use in decision-making models. Avoid reification ex- cesses in research funding (i.e., working hypotheses must relate to factual phenomena, not derived concepts) and both design and inter- pretation of results from investigative studies. Prior to use in trans- parent decision-making support, do not assume data quality based on conduct and reporting of standard methods and models; rather, routi- nely subject results to thorough primary data validity evaluation prior to a tertiary (i.e., case-specific) relevance assessment. Above all, and in line with a conclusion from a risk historian (Bernstein, 1996), check meanings rather than just comparing numbers to quantitatively estab- lish when, why, and how toxicity occurs so testing information can better inform environmental risk decision-making. Funding Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Transparency document The key ERA problem Discussion Conclusion Funding Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-regulatory-framework-for-preventing-cross-contamina_2016_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27230736", "content": {"Funding": "The statements and conclusions in this paper reflect the opin- ions of the authors and do not necessarily represent official policies of the organizations as listed on the title page. The authors would like to acknowledge Patricia Weideman, Andrew Maier, and Alison Pecquet for organizing and facilitating the workshop that served as the basis for developing this manuscript. The authors would also like to thank all of the participants of the workshop for their con- tributions at the workshop and subsequent reviews of this manu- script, including: Joel Bercu, Courtney Callis, Dave Dolan, Ellen Faria, Janet Gould, Eileen Hayes, Robert Jolly, Andrew Maier, Eric Morinello, Bruce Naumann, Michael Olson, Alison Pecquet, Thomas Pfister, Christopher Seaman, Claudia Sehner, Bryan Shipp, Brad Stanard, Anthony Streeter, Robert Sussman, and AndrewWalsh. The manuscript was developed in part with funding from Genentech Inc. for organizational and editorial staff activities. Transparency document", "Compliance with ethical standards": "US FDA, 2013a. Guidance for Industry Process Validation: General Principles and Practices. U.S. Food and Drug Administration (FDA), Silver Spring, MD. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInfor mation/Guidances/ucm079250.pdf. US FDA, 2013b. Guidance for Industry Non-penicillin Beta Lactam Drugs: a CGMP Framework for Preventing Cross-contamination. U.S. Food and Drug Adminis- tration (FDA), Center for Drug Evaluation and Research, Silver Spring, MD. Available at: http://www.fda.gov/downloads/Drugs/.../Guidances/UCM078932. pdf. US FDA, 2008. Guidance for Industry: Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches. U.S. Food and Drug Administration (FDA), Silver Spring, MD. Available at: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM347725.pdf. US FDA, 2005a. Guidance for Industry PAT: a Framework for Innovative Pharma- ceutical Development, Manufacturing, and Quality Assurance. U.S. Food and Drug Administration (FDA), Silver Spring, MD. Available at: http://www.fda.gov/ downloads/Drugs/Guidances/ucm070305.pdf. US FDA, 2005b. Guidance for Industry Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients. U.S. Food and Drug Administration (FDA), Silver Spring, MD. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm079250.pdf. US FDA, 2005c. Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research, Silver Spring, MD. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm078932.pdf. US FDA, 2005c. Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research, Silver Spring, MD. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm078932.pdf. US FDA, 1993. FDA Guide to Inspections: Validation of Cleaning Processes. U.S. Food and Drug Administration (FDA), Silver Spring, MD. Available at: http://www.fda. gov/ICECI/Inspections/InspectionGuides/ucm074922.htm. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3A_R2/Step4/Q3A_R2__Guideline.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3A_R2/Step4/Q3A_R2__Guideline.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3B_R2/Step4/Q3B_R2__Guideline.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3B_R2/Step4/Q3B_R2__Guideline.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3B_R2/Step4/Q3B_R2__Guideline.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q7/Step4/Q7_Guideline.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q7/Step4/Q7_Guideline.pdf http://www.who.int/ipcs/methods/en/ http://ipecamericas.org/system/files/Instructions_for_PDE%20Calculator.pdf http://ipecamericas.org/system/files/Instructions_for_PDE%20Calculator.pdf http://ipecamericas.org/sites/default/files/ExcipientQualificationGuide.pdf http://ipecamericas.org/sites/default/files/ExcipientQualificationGuide.pdf http://www.ispe.org/baseline-guides/risk-mapp http://refhub.elsevier.com/S0273-2300(16)30142-8/sref41 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref41 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref41 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref41 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref41 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref41 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref41 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref42 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref42 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref42 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref43 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref43 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref43 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref44 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref44 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref44 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref44 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref44 http://www.picscheme.org http://www.picscheme.org http://refhub.elsevier.com/S0273-2300(16)30142-8/sref46 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref46 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref46 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref46 http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM420445.pdf http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM420445.pdf http://refhub.elsevier.com/S0273-2300(16)30142-8/sref48 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref48 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref48 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref49 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref49 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref49 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref49 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref50 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref50 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref50 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref51 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref51 http://www.epa.gov/risk/guidance.htm http://www.epa.gov/risk/guidance.htm http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079250.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079250.pdf http://www.fda.gov/downloads/Drugs/.../Guidances/UCM078932.pdf http://www.fda.gov/downloads/Drugs/.../Guidances/UCM078932.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM347725.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM347725.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM347725.pdf http://www.fda.gov/downloads/Drugs/Guidances/ucm070305.pdf http://www.fda.gov/downloads/Drugs/Guidances/ucm070305.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079250.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079250.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078932.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078932.pdf http://www.fda.gov/ICECI/Inspections/InspectionGuides/ucm074922.htm http://www.fda.gov/ICECI/Inspections/InspectionGuides/ucm074922.htm http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Manufacturing/ucm206756.htm http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Manufacturing/ucm206756.htm http://refhub.elsevier.com/S0273-2300(16)30142-8/sref61 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref61 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref61 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref62 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref62 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref62 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref63 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref63 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref63 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref64 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref64 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref64 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref64 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref64 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref64 http://refhub.elsevier.com/S0273-2300(16)30142-8/sref64 http://www.who.int/water_sanitation_health/publications/dwq_guidelines/en/ http://www.who.int/water_sanitation_health/publications/dwq_guidelines/en/ http://www.who.int/medicines/services/expertcommittees/pharmprep/CleanRev-290709-GMPHazardous_QAS08_256.pdf http://www.who.int/medicines/services/expertcommittees/pharmprep/CleanRev-290709-GMPHazardous_QAS08_256.pdf http://www.who.int/medicines/services/expertcommittees/pharmprep/CleanRev-290709-GMPHazardous_QAS08_256.pdf The regulatory framework for preventing cross-contamination of pharmaceutical products: History and considerations for the ... 1. Introduction 2. Historical review of regulatory approaches for GMPs as they pertain to cross-contamination in multi-product facilities 3. Historical review of approaches for establishing cleaning limits 4. Approaches to further harmonization of GMPs 5. Summary and conclusions Acknowledgements Transparency document References", "Acknowledgement": "Acknowledgements The statements and conclusions in this paper reflect the opin- ions of the authors and do not necessarily represent official policies of the organizations as listed on the title page. The authors would like to acknowledge Patricia Weideman, Andrew Maier, and Alison Pecquet for organizing and facilitating the workshop that served as the basis for developing this manuscript. The authors would also like to thank all of the participants of the workshop for their con- tributions at the workshop and subsequent reviews of this manu- script, including: Joel Bercu, Courtney Callis, Dave Dolan, Ellen Faria, Janet Gould, Eileen Hayes, Robert Jolly, Andrew Maier, Eric Morinello, Bruce Naumann, Michael Olson, Alison Pecquet, Thomas Pfister, Christopher Seaman, Claudia Sehner, Bryan Shipp, Brad Stanard, Anthony Streeter, Robert Sussman, and AndrewWalsh. The manuscript was developed in part with funding from Genentech Inc. for organizational and editorial staff activities. The regulatory framework for preventing cross-contamination of pharmaceutical products: History and considerations for the ... 1. Introduction 2. Historical review of regulatory approaches for GMPs as they pertain to cross-contamination in multi-product facilities 3. Historical review of approaches for establishing cleaning limits 4. Approaches to further harmonization of GMPs 5. Summary and conclusions Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-regulatory-use-of-the-Local-Lymph-Node-Assay-fo_2011_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21539884", "content": {"CoiStatement": "The most important information derived from our evaluation is the performance of the test in identifying potential sensitisers amongst new chemicals when only the highest dose is taken into consideration, confirming the finding of previous evaluations. The use of the reduced-LLNA is already foreseen in the REACH imple- mentation program and has now been adopted in the revised OECD TG 429 as a tool to be employed in those regulatory situations where dose\u2013response information is not needed, or as a confirma- tory test to complement additional information in a weight-of-evi- dence context. With our larger sample size and despite the generally complex structure of the chemicals found in the NCD, A. Angers-Loustau et al. / Regulatory Toxicology and Pharmacology 60 (2011) 300\u2013307 307 the accuracy of the reduced LLNA compared to the standard LLNA is comparable to the results obtained in previous evaluations. Conflict of interest statement The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgments Conflict of interest statement Acknowledgments References", "Compliance with ethical standards": "In compliance with OECD 429, both approaches have been used, although time analyses show a positive trend over the years in the use of the individual approach. This might be a reflection of the intensive debates surrounding the merits of using one versus the other approach. These include the possibility of identifying po- tential outlier responses when individual lymph node data are col- lected which may help to avoid labelling weak sensitisers as negative and identify potential false positives and the fact that pooling lymph nodes minimises the inevitable loss of material associated with the handling of small amounts of tissues, resulting in a higher sensitivity of the test. Recent analyses that investigated and compared these two approaches show that both approaches are of equal value in identifying potential skin sensitisers as well as for the assessment of their relative potency (Basketter et al., 2009). This is confirmed in our evaluation where the results for the positive control are comparable between the two (see Sec- tion 3.8), and by the fact that the prevalence of skin sensitisers amongst the notification performed with the pooled approach and the individual approach is similar (see Section 3.4). In the revised version of the OECD TG 429, the minimal number of animals to be used in the individual approach has been de- creased from 5 to 4, following statistical studies that showed that this decrease did not affect the test performance (Haseman et al., 2011). Considering the rising popularity of the individual approach we have observed in the time frame of the NCD submissions, this change will be of particular importance in Europe, where all efforts are being made to decrease the number of test animals used to the minimum.", "Acknowledgement": "Acknowledgments We are grateful to Joaquin Baraibar Fentanes for performing the data extraction from the New Chemicals Database. Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-relationship-between-developmental-toxicity-and-a_2013_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23680405", "content": {"CoiStatement": "A relationship between sensitive endpoints of developmental toxicity and the substance\u2019s weight percent of each of the 1\u20137 and larger aromatic-ring compounds (the \u2018\u2018ARC profile\u2019\u2019) was dem- onstrated for HBPS. Predictive ARC models based on these associa- tions were developed for effects on three developmental toxicity endpoints (percent resorptions, live fetuses per litter, and fetal body weight). Such associations provide a promising approach for predicting the developmental toxicity of untested HBPS. How- ever, further development and refinement of the ARC models is recommended before they can be reliably applied to all HBPS. Conflict of interest Four of the coauthors (Randy N Roth, Barry J Simpson, Mark J Nicolich, F Jay Murray) are paid consultants to the Petroleum High Production Volume Testing Group. Three (Randy N Roth, Barry J Simpson, Mark J Nicolich) are former employees of companies that manufac- ture petroleum products. One co-author (Thomas M Gray) is employed by the American Petroleum Institute. Role of the funding source US EPA (U.S. Environmental Protection Agency), 2012. Glossary of terms. (http:// www.epa.gov/radon/glossary.html> (last updated 02.08.12; accessed 29.01.13). http://refhub.elsevier.com/S0273-2300(13)00070-6/h0190 http://refhub.elsevier.com/S0273-2300(13)00070-6/h0190 http://refhub.elsevier.com/S0273-2300(13)00070-6/h0190 http://refhub.elsevier.com/S0273-2300(13)00070-6/h0135 http://refhub.elsevier.com/S0273-2300(13)00070-6/h0135 http://refhub.elsevier.com/S0273-2300(13)00070-6/h0135 http://refhub.elsevier.com/S0273-2300(13)00070-6/h0140 http://refhub.elsevier.com/S0273-2300(13)00070-6/h0140 http://refhub.elsevier.com/S0273-2300(13)00070-6/h0150 http://refhub.elsevier.com/S0273-2300(13)00070-6/h0150 http://www.epa.gov/crem/library/cred_guidance_0309.pdf http://www.epa.gov/radon/glossary.html http://www.epa.gov/radon/glossary.html The relationship between developmental toxicity and aromatic-ring class profile of high-boiling petroleum substances 1 Introduction 2 Materials and methods 2.1 Terminology 2.2 Developmental toxicity data 2.3 Identification of toxicity endpoints and studies for modeling 2.4 Compositional analysis of petroleum substances evaluated for developmental toxicity 2.5 Identification of developmental toxicity endpoints for mathematical modeling 2.6 Model development and evaluation 2.7 Comparison of predicted values with estimates of observed toxicity 2.8 Methods to corroborate the models with samples not used to build the final models 3 Results 3.1 Identification of sensitive endpoints of developmental toxicity 3.1.1 Type I developmental toxicity studies 3.1.1.1 Fetal loss and resorptions 3.1.1.2 Live fetuses per litter 3.1.1.3 Fetal body weight 3.1.1.4 Fetal malformations 3.1.1.5 Skeletal variants and delayed ossification 3.1.2 Type II developmental toxicity studies 3.1.3 Maternal toxicity 3.2 Preliminary modeling of developmental toxicity 3.3 Final modeling of developmental toxicity 3.4 Use of the models to predict developmental toxicity 3.5 Comparison with existing predictive methods for samples used to build the ARC models 3.6 Comparison with existing predictive methods for samples not used in building the ARC models 4 Discussion 5 Conclusion Conflict of interest Role of the funding source Acknowledgments Appendix A Supplementary data References", "Disclosure": "This project was sponsored and funded by the Petroleum HPV Testing Group (PHPVTG), an unincorporated group of manufactur- ers and importers affiliated by contractual obligation to fund a vol- untary data disclosure and toxicity testing program on certain petroleum-related chemical substances in response to the US EPA HPV Challenge Program. The American Petroleum Institute (API) manages the PHPVTG\u2019s activities. Appendix A. Supplementary data Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.yrtph.2013. 05.003.", "Funding": "Four of the coauthors (Randy N Roth, Barry J Simpson, Mark J Nicolich, F Jay Murray) are paid consultants to the Petroleum High Production Volume Testing Group. Three (Randy N Roth, Barry J Simpson, Mark J Nicolich) are former employees of companies that manufac- ture petroleum products. One co-author (Thomas M Gray) is employed by the American Petroleum Institute. Role of the funding source The authors received financial support for the research, author- ing and publication of this article from the Petroleum High Produc- tion Volume Testing Group. Acknowledgments US EPA (U.S. Environmental Protection Agency), 2012. Glossary of terms. (http:// www.epa.gov/radon/glossary.html> (last updated 02.08.12; accessed 29.01.13). http://refhub.elsevier.com/S0273-2300(13)00070-6/h0190 http://refhub.elsevier.com/S0273-2300(13)00070-6/h0190 http://refhub.elsevier.com/S0273-2300(13)00070-6/h0190 http://refhub.elsevier.com/S0273-2300(13)00070-6/h0135 http://refhub.elsevier.com/S0273-2300(13)00070-6/h0135 http://refhub.elsevier.com/S0273-2300(13)00070-6/h0135 http://refhub.elsevier.com/S0273-2300(13)00070-6/h0140 http://refhub.elsevier.com/S0273-2300(13)00070-6/h0140 http://refhub.elsevier.com/S0273-2300(13)00070-6/h0150 http://refhub.elsevier.com/S0273-2300(13)00070-6/h0150 http://www.epa.gov/crem/library/cred_guidance_0309.pdf http://www.epa.gov/radon/glossary.html http://www.epa.gov/radon/glossary.html The relationship between developmental toxicity and aromatic-ring class profile of high-boiling petroleum substances 1 Introduction 2 Materials and methods 2.1 Terminology 2.2 Developmental toxicity data 2.3 Identification of toxicity endpoints and studies for modeling 2.4 Compositional analysis of petroleum substances evaluated for developmental toxicity 2.5 Identification of developmental toxicity endpoints for mathematical modeling 2.6 Model development and evaluation 2.7 Comparison of predicted values with estimates of observed toxicity 2.8 Methods to corroborate the models with samples not used to build the final models 3 Results 3.1 Identification of sensitive endpoints of developmental toxicity 3.1.1 Type I developmental toxicity studies 3.1.1.1 Fetal loss and resorptions 3.1.1.2 Live fetuses per litter 3.1.1.3 Fetal body weight 3.1.1.4 Fetal malformations 3.1.1.5 Skeletal variants and delayed ossification 3.1.2 Type II developmental toxicity studies 3.1.3 Maternal toxicity 3.2 Preliminary modeling of developmental toxicity 3.3 Final modeling of developmental toxicity 3.4 Use of the models to predict developmental toxicity 3.5 Comparison with existing predictive methods for samples used to build the ARC models 3.6 Comparison with existing predictive methods for samples not used in building the ARC models 4 Discussion 5 Conclusion Conflict of interest Role of the funding source Acknowledgments Appendix A Supplementary data References", "Acknowledgement": "The authors received financial support for the research, author- ing and publication of this article from the Petroleum High Produc- tion Volume Testing Group. Acknowledgments This project was sponsored and funded by the Petroleum HPV Testing Group (PHPVTG), an unincorporated group of manufactur- ers and importers affiliated by contractual obligation to fund a vol- untary data disclosure and toxicity testing program on certain petroleum-related chemical substances in response to the US EPA HPV Challenge Program. The American Petroleum Institute (API) manages the PHPVTG\u2019s activities. Appendix A. Supplementary data US EPA (U.S. Environmental Protection Agency), 2012. Glossary of terms. (http:// www.epa.gov/radon/glossary.html> (last updated 02.08.12; accessed 29.01.13). http://refhub.elsevier.com/S0273-2300(13)00070-6/h0190 http://refhub.elsevier.com/S0273-2300(13)00070-6/h0190 http://refhub.elsevier.com/S0273-2300(13)00070-6/h0190 http://refhub.elsevier.com/S0273-2300(13)00070-6/h0135 http://refhub.elsevier.com/S0273-2300(13)00070-6/h0135 http://refhub.elsevier.com/S0273-2300(13)00070-6/h0135 http://refhub.elsevier.com/S0273-2300(13)00070-6/h0140 http://refhub.elsevier.com/S0273-2300(13)00070-6/h0140 http://refhub.elsevier.com/S0273-2300(13)00070-6/h0150 http://refhub.elsevier.com/S0273-2300(13)00070-6/h0150 http://www.epa.gov/crem/library/cred_guidance_0309.pdf http://www.epa.gov/radon/glossary.html http://www.epa.gov/radon/glossary.html The relationship between developmental toxicity and aromatic-ring class profile of high-boiling petroleum substances 1 Introduction 2 Materials and methods 2.1 Terminology 2.2 Developmental toxicity data 2.3 Identification of toxicity endpoints and studies for modeling 2.4 Compositional analysis of petroleum substances evaluated for developmental toxicity 2.5 Identification of developmental toxicity endpoints for mathematical modeling 2.6 Model development and evaluation 2.7 Comparison of predicted values with estimates of observed toxicity 2.8 Methods to corroborate the models with samples not used to build the final models 3 Results 3.1 Identification of sensitive endpoints of developmental toxicity 3.1.1 Type I developmental toxicity studies 3.1.1.1 Fetal loss and resorptions 3.1.1.2 Live fetuses per litter 3.1.1.3 Fetal body weight 3.1.1.4 Fetal malformations 3.1.1.5 Skeletal variants and delayed ossification 3.1.2 Type II developmental toxicity studies 3.1.3 Maternal toxicity 3.2 Preliminary modeling of developmental toxicity 3.3 Final modeling of developmental toxicity 3.4 Use of the models to predict developmental toxicity 3.5 Comparison with existing predictive methods for samples used to build the ARC models 3.6 Comparison with existing predictive methods for samples not used in building the ARC models 4 Discussion 5 Conclusion Conflict of interest Role of the funding source Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-relationship-between-nicotine-dependence-scores-_2011_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21342662", "content": {"CoiStatement": "Competing interest All authors are or were employees of Philip Morris USA Inc./Al- tria Client Services Inc. Results Discussion Funding Competing interest Acknowledgments References", "Funding": "Funding Philip Morris USA Inc. Results Discussion Funding Competing interest Acknowledgments References", "Compliance with ethical standards": "Guidance for Industry. Bioanalytical Method Validation, 2001. U.S. Department of Health and Human Services and U.S. Food and Drug Administration. Available online at: http://www.fda.gov/downloads/Drugs/Guidance Compliance Regulatory Information/Guidances/UCM070107.pdf. Last accessed September 30, 2009. Heatherton, T.F., Kozlowski, L.T., Frecker, R.C., Fagerstr\u00f6m, K.O., 1991. Fagerstr\u00f6m test for nicotine dependence. A revision of the Fagerstr\u00f6m tolerance questionnaire. British Journal of Addiction 86, 1119\u20131127. Hudmon, K.S., Marks, J.L., Pomerleau, C.S., Bolt, D.M., Brigham, J., Swan, G.E., 2003. A multidimentional model for characterizing tobacco dependence. Nicotine and Tobacco Research 5, 655\u2013664.", "Acknowledgement": "Acknowledgments The authors thank Dr. Hans J. Roethig for his technical assis- tance and Yan Jin for the data management and technical support while writing and editing the manuscript. Results Discussion Funding Competing interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-relationship-between-repeat-dose-toxicity-and-aro_2013_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23751816", "content": {"CoiStatement": "5 Conclusions Conflict of interest Role of the funding source Acknowledgments References", "Funding": "5 Conclusions Conflict of interest Role of the funding source Acknowledgments References", "Acknowledgement": "5 Conclusions Conflict of interest Role of the funding source Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-relationship-between-smoking-machine-derived-tar-y_2009_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19481578", "content": {"Compliance with ethical standards": "The NE per cigarette by tar category in the current study was higher than what Byrd et al. (1998) found for urine nicotine and 8 metabolites in 72 smokers in approximately comparable catego- ries (0.65 (T1), 0.63 (T2), 0.67 (T3), and 0.89 mg/cigarette (T4) and very similar to those of St. Charles et al. (2006) except for T1, which was much lower as compared to this study. The higher NE per cig- arette values in our study may be due to the combination of using complete urine collections (based on the plausibility checks) and using butt collection (instead of self-reports) for number of ciga- rettes smoked per day. The lower NE per cigarette in T1 in the St. Charles et al. (2006) study may be due to the difficulty in recruiting subjects in this category (some subjects may have said they smoked this category of cigarettes to be recruited) or to greater non-compliance in the T1 group in our ambulatory setting. The validity of our data, which covered more than 300 brand styles, is supported by NE per cigarette data reported in other highly con- trolled clinical studies (Roethig et al., 2005; Roethig et al., 2007; St. Charles et al., 2006; Mendes et al., 2008; Sarkar et al., 2008). How- ever, as noted above, the validity for T1 is not as strong. The ciga- rette butt collection method for more accurate determination of number of cigarettes smoked, together with the 24 h urine collec- tion with the creatinine plausibility checks, may help eliminate some of the shortcomings encountered in ambulatory exposure studies. In conclusion, the study data indicate that in adult smokers most measured PP and GVP biomarkers generally tended to be lower in lower tar yield categories (T4 to T1) for all tobacco specific and most non-tobacco specific biomarkers. The differences in to- bacco specific biomarkers (NE, NNAL and serum cotinine) were sta- tistically significant in most of the pair-wise comparisons; the differences for the non tobacco-specific biomarkers were smaller, due to other nonsmoking related exposure, metabolic variability or other factors. Acknowledgements The authors thank Lonnie Rimmer and Yan Jin for data manage- ment support and Denise Mawyer for her technical assistance in writing and editing the manuscript. References Andersson, G., Vala, E.K., Curvall, M., 1997. The influence of cigarette consumption and smoking machine yields of tar and nicotine on the nicotine uptake and oral mucosal lesions in smokers. Journal of Oral Pathology and Medicine 26, 117\u2013 123. Benowitz, N.L., Kuyt, F., Jacob III, P., 1982. Circadian blood nicotine concentrations during cigarette smoking. Clinical Pharmacology and Therapeutics 32, 758\u2013764. Benowitz, N.L., Hall, Sagar Munjal., Herning, R.I., et al., 1983. Smokers of low-yield cigarettes do not consume less nicotine. The New England Journal of Medicine 309, 139\u2013 142. Benowitz, N.L., Jacob III, P., 1984. Daily intake of nicotine during cigarette smoking. Clinical Pharmacology and Therapeutics 35, 499\u2013504. Benowitz, N.L., Jacob III, P., Yu, L., et al., 1986. Reduced tar, nicotine, and carbon monoxide exposure while smoking ultralow- but not low-yield cigarettes. Journal of the American Medical Association 256, 241\u2013246. Blackford, A.L., Yang, G., Hernandez-Avila, M., et al., 2006. Cotinine concentration in smokers from different countries: relationship with amount smoked and cigarette type. Cancer Epidemiology Biomarkers and Prevention 15, 1799\u20131804. Bridges, R.B., Combs, J.G., Humble, J.W., et al., 1990. Population characteristics and cigarette yield as determinants of smoke exposure. Pharmacology Biochemistry and Behavior 37, 17\u201328. Burtis, C.A., Ashwood, E.R. (Eds.), 1999. Tietz Textbook of Clinical Chemistry. W.B. Saunders Company, Philadelphia. Byrd, G.D., Robinson, J.H., Caldwell, W.S., Debethizy, J.D., 1995. Comparison of measured and FTC-predicted nicotine uptake in smokers. Psychopharmacology 122, 95\u2013103. Byrd, G.D., Davis, R.A., Caldwell, W.S., Robinson, J.H., Debethizy, J.D., 1998. A further study of FTC yield and nicotine absorption in smokers. Psychopharmacology 139, 291\u2013299. Caraballo, R.S., Giovino, G.A., Pechacek, T.F., et al., 1998. Racial and ethnic differences in serum cotinine levels of cigarette smokers: Third National Health and Nutrition Examination Survey, 1988\u20131991. Journal of the American Medical Association 280, 135\u2013139. Clinical Laboratory Improvement Amendments. U.S. Department of Health and Human Services. Available from: <http://wwwn.cdc.gov/clia/regs/toc.aspx>. Counts, M.E., Hsu, F.S., Tewes, F.J., 2006. Development of a cigarette \u2018\u2018market map\u201d comparison methodology for evaluating new or non-conventional cigarettes. Regulatory Toxicology and Pharmacology 46, 225\u2013242. Djordjevic, M.V., Stellman, S.D., Zang, E., 2000. Doses of nicotine and lung carcinogens delivered to cigarette smokers. Journal of the National Cancer Institute 92, 106\u2013111. Federal Trade Commission, 1967. Statement of Considerations. Press release. August 1, 1967, pp. 2. Feng, S., Plunkett, S.E., Lam, K., Kapur, S., Muhammad, R., Jin, Y., Zimmermann, M., Mendes, P., Kinser, R., Roethig, H.J., 2007a. A new method for estimating the retention of selected smoke constituents in the respiratory tract of smokers during cigarette smoking. Inhalation Toxicology 19, 169\u2013179. Feng, S., Kapur, S., Sarkar, M., Muhammad, R., Mendes, P., Newland, K., Roethig, H.J., 2007b. Respiratory retention of nicotine and urinary excretion of nicotine and its five major metabolites in adult male smokers. Toxicology Letters 173 (2), 101\u2013106. Gori, G.B., Lynch, C.J., 1983. Smoker intake from cigarettes in the 1-mg Federal Trade Commission tar class. Regulatory Toxicology and Pharmacology 3 (2), 110\u2013120. Gori, G.B., Lynch, C.J., 1985. Analytical cigarette yields as predictors of smoke bioavailability. Regulatory Toxicology and Pharmacology 5, 314\u2013326. Guidance for Industry, 2001. Bioanalytical Method Validation. U.S.Department of Health and Human Services and U.S.Food and Drug Administration. Accessed on August 14, 7 A.D. Available from: <http://www.fda.gov/cder/guidance/ 4252fnl.htm>. Guidance for data quality assessment, 2007. Guidance for Data Quality Assessment: Practical Methods of Data Analysis. Office of Environmental Information, U.S. Environmental Protection Agency, Washington, DC. Accessed on April 2, 2007. Available from: <http://www.epa.gov/quality/qs-docs/g9-final.pdf>. Hart, C.L., Smith, G.D., Hole, D.J., Hawthorne, V.M., 2006. Carboxyhaemoglobin concentration, smoking habit, and mortality in 25 years in the Renfrew/Paisley prospective cohort study. Biochemistry 92, 321\u2013324. Hawkins, L.H., Cole, P.V., Harris, J.R., 1976. Smoking habits and blood carbon monoxide levels. Environmental Research 11, 310\u2013318. Institute of Medicine, 2001. Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction. National Academy Press, Washington, DC. Jarvis, M.J., Boreham, R., Primatesta, P., Feyerabend, C., Bryant, A., 2001. Nicotine yield from machine-smoked cigarettes and nicotine intakes in smokers: evidence from a representative population survey. Journal of the National Cancer Institute 93, 134\u2013138. Lawrence, T., Aveyard, P., Croghan, E., 2003. What happens to women\u2019s self- reported cigarette consumption and urinary cotinine levels in pregnancy? Addiction 98, 1315\u20131320. Lee, P.N., 2001. Lung cancer and type of cigarette smoked. Inhalation Toxicology 13, 951\u2013976. Lewis, S.J., Cherry, N.M., Niven, R.M., Barber, P.V., Wilde, K., Povey, A.C., 2003. Cotinine levels and self-reported smoking status in patients attending a bronchoscopy clinic. Biomarkers 8 (3\u20134), 218\u2013228. Maron, D.J., Fortmann, S.P., 1987. Nicotine yield and measures of cigarette smoke exposure in a large population: are lower-yield cigarettes safer. American Journal of Public Health 77, 546\u2013549. Mendes, P., Kapur, S., Wang, J., Feng, S.F., Roethig, H.J., 2008. A randomized, controlled exposure study in adult smokers of full flavor Marlboro cigarettes switching to Marlboro Lights or Marlboro Ultra Lights cigarettes. Regulatory Toxicology and Pharmacology 51, 295\u2013305. Murray, R.P., Connett, J.E., Lauger, G.G., Voelker, H.T., 1993. Error in smoking measures: effects of intervention on relations of cotinine and carbon monoxide to self-reported smoking. American Journal of Pubic Health 83 (9), 1251\u20131257. National Center for Health Statistics United States, 2004. With Chartbook on Trends in the Health of Americans. (PDF\u2013116KB). U.S. Department of Health and Human Services, Hyattsville, MD. CDC, 2004 (cited 2006 October 30). O\u2019Connor, R.J., Giovino, G.A., Kozlowski, L.T., et al., 2006. Changes in nicotine intake and cigarette use over time in two nationally representative cross-sectional samples of smokers. American Journal of Epidemiology 164, 750\u2013759. Office of Solid Waste Permits and State Programs Division, 2007. Statistical analysis of groundwater monitoring data at RCRA facilities: addendum to interim final guidance. United States Environmental Protection Agency Office of Solid Waste Permits and State Programs Division, Washington, DC. Accessed on April 2, 2007. Available from: <http://dqo.pnl.gov/VSP/Addendum%20to%20interim%20 final%20guidance.pdf>. Roethig, H.J., Kinser, R.D., Lau, Ruediger-A Walk., Walk, R.A., Wang, N., 2005. Short-term exposure evaluation of adult smokers switching from conventional to first-generation electrically heated cigarettes during controlled smoking. Journal of Clinical Pharmacology 45, 133\u2013145. http://wwwn.cdc.gov/clia/regs/toc.aspx http://www.fda.gov/cder/guidance/4252fnl.htm http://www.fda.gov/cder/guidance/4252fnl.htm http://www.epa.gov/quality/qs-docs/g9-final.pdf http://dqo.pnl.gov/VSP/Addendum%20to%20interim%20final%20guidance.pdf http://dqo.pnl.gov/VSP/Addendum%20to%20interim%20final%20guidance.pdf P. Mendes et al. / Regulatory Toxicology and Pharmacology 55 (2009) 17\u201327 27 Roethig, H.J., Zedler, B.K., Kinser, R.D., Feng, S., Nelson, B.L., Liang, Q., 2007. Short-term clinical exposure evaluation of second-generation electrically heated cigarette smoking system. The Journal of Clinical Pharmacology 47, 518\u2013530. Rosa, M., Pacifici, R., Altieri, I., Pichini, S., Ottaviani, G., Zuccaro, P., 1992. How the steady-state cotinine concentration in cigarette smokers is directly related to nicotine intake. Clinical Pharmacology and Therapeutics 52, 324\u2013 329. Sarkar, M., Stabbert, R., Kinser, R.D., Oey, J., Rustemeier, K., von Holt, K., Schepers, G., Walk, R.A., Roethig, H.J., 2006. CYP1A2 and NAT2 phenotyping and 3- aminobiphenyl and 4-aminobiphenyl hemoglobin adduct levels in smokers and non-smokers. Toxicology and Applied Pharmacology 213, 198\u2013206. Sarkar, M., Kapur, S., Frost-Pineda, K., Feng, S., Wang, J., Liang, Q., Roethig, H.J., 2008. Evaluation of biomarkers of exposure to selected cigarette smoke constituent in adult smokers switched to carbon-filtered cigarettes in short-term and long- term studies. Nicotine and Tobacco Research 10, 1761\u20131772. Scherer, G., 1999. Smoking behavior and compensation: a review of the literature. Psychopharmacology 145, 1\u201320. Scherer, G., 2006. Carboxyhemoglobin and thiocyanate as biomarkers of exposure to carbon monoxide and hydrogen cyanide in tobacco smoke. Experimental and Toxicologic Pathology 58, 101\u2013124. St. Charles, F.K., Krautter, G.R., Dixon, M., Mariner, D.C., 2006. A comparison of nicotine dose estimates in smokers between filter analysis, salivary cotinine, and urinary excretion of nicotine metabolites. Psychopharmacology (Berl.) 189 (3), 345\u2013354. Tobacco Institute Testing Laboratory, 2001. Testing Laboratory Market Sample #43. Report Tar, nicotine, and carbon monoxide values, 2001. Tobacco Institute Testing Laboratory, Rockville, MD. Tobacco Institute Testing Laboratory, 2002. Testing Laboratory Market Sample #44 Report. Tar, nicotine, and carbon monoxide values, 2002. Tobacco Institute Testing Laboratory, Rockville, MD. Tobacco in the United States, 2005. Cigarette Retail Sales: Tar Levels (Table 19), vol. 31. Euromonitor International, Plc., London, p. 31. Ueda, K., Kawachi, I., Nakamura, M., et al., 2002. Cigarette nicotine yields and nicotine intake among Japanese male workers. Tobacco Control 11, 55\u201360. United States Federal Trade Commission, 2000. Tar, nicotine, and carbon monoxide of the smoke of 1294 varieties of domestic cigarettes for the year 1998. U.S.Federal Trade Commission. Accessed on April 10, 2007. Available from: <http://www.ftc.gov/reports/tobacco/1998tar&nicotinereport.pdf>. Urban, M., Gilch, G., Schepers, G., van Miert, E., Scherer, G., 2003. Determination of the major mercapturic acids of 1,3-butadiene in human and rat urine using liquid chromatography with tandem mass spectrometry. Journal of Chromatography B 796, 131\u2013140. Woodward, M., Tunstall-Pedoe, H., Smith, W.C., Tavendale, R., 1991. Smoking characteristics and inhalation biochemistry in the Scottish population. Journal of Clinical Epidemiology 44, 1405\u20131410. Woodward, M., Tunstall-Pedoe, H., 1992. Do smokers of lower tar cigarettes consume lower amounts of smoke components? Results from the Scottish Heart Health Study. British Journal of Addiction 87, 921\u2013928. World Medical Association, 2000. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. 52nd World Medical Association General Assembly, Edinburgh, Scotland, 2000. Accessed on April 10, 2007. Available from: <http://www.wma.net/e/policy/pdf/17c.pdf>. Zedler, B.K., Kinser, R., Oey, J., et al., 2006. Biomarkers of exposure and potential harm in adult smokers of 3\u20137 mg tar yield (Federal Trade Commission) cigarettes and in adult non-smokers. Biomarkers 11, 201\u2013220. http://www.ftc.gov/reports/tobacco/1998tar&amp;nicotinereport.pdf http://www.wma.net/e/policy/pdf/17c.pdf The relationship between smoking machine derived tar yields and biomarkers of exposure in adult cigarette smokers in the US Introduction Materials and methods Study design Subjects Study conduct Biomarker sampling and analytical methods Biomarkers of exposure Nicotine equivalents (NE) Carboxyhemoglobin (COHb) 4-ABP-Hb adducts and serum cotinine Total NNAL Total 1-OHP and 3-HPaul MendesA MHBMA and DHBMA Statistical methods Results Subjects Cigarette consumption Biomarkers of exposure Particulate phase biomarkers Nicotine equivalents per day Nicotine equivalents per cigarette Serum cotinine Total NNAL per day Total NNAL per cigarette Total 1-OHP per day 4-ABP-Hb Gas phase biomarkers COHb 3-HPaul MendesA per day MHBMA and DHBMA per day Discussion Acknowledgements References", "Acknowledgement": "The NE per cigarette by tar category in the current study was higher than what Byrd et al. (1998) found for urine nicotine and 8 metabolites in 72 smokers in approximately comparable catego- ries (0.65 (T1), 0.63 (T2), 0.67 (T3), and 0.89 mg/cigarette (T4) and very similar to those of St. Charles et al. (2006) except for T1, which was much lower as compared to this study. The higher NE per cig- arette values in our study may be due to the combination of using complete urine collections (based on the plausibility checks) and using butt collection (instead of self-reports) for number of ciga- rettes smoked per day. The lower NE per cigarette in T1 in the St. Charles et al. (2006) study may be due to the difficulty in recruiting subjects in this category (some subjects may have said they smoked this category of cigarettes to be recruited) or to greater non-compliance in the T1 group in our ambulatory setting. The validity of our data, which covered more than 300 brand styles, is supported by NE per cigarette data reported in other highly con- trolled clinical studies (Roethig et al., 2005; Roethig et al., 2007; St. Charles et al., 2006; Mendes et al., 2008; Sarkar et al., 2008). How- ever, as noted above, the validity for T1 is not as strong. The ciga- rette butt collection method for more accurate determination of number of cigarettes smoked, together with the 24 h urine collec- tion with the creatinine plausibility checks, may help eliminate some of the shortcomings encountered in ambulatory exposure studies. In conclusion, the study data indicate that in adult smokers most measured PP and GVP biomarkers generally tended to be lower in lower tar yield categories (T4 to T1) for all tobacco specific and most non-tobacco specific biomarkers. The differences in to- bacco specific biomarkers (NE, NNAL and serum cotinine) were sta- tistically significant in most of the pair-wise comparisons; the differences for the non tobacco-specific biomarkers were smaller, due to other nonsmoking related exposure, metabolic variability or other factors. Acknowledgements The authors thank Lonnie Rimmer and Yan Jin for data manage- ment support and Denise Mawyer for her technical assistance in writing and editing the manuscript. References Andersson, G., Vala, E.K., Curvall, M., 1997. The influence of cigarette consumption and smoking machine yields of tar and nicotine on the nicotine uptake and oral mucosal lesions in smokers. Journal of Oral Pathology and Medicine 26, 117\u2013 123. Benowitz, N.L., Kuyt, F., Jacob III, P., 1982. Circadian blood nicotine concentrations during cigarette smoking. Clinical Pharmacology and Therapeutics 32, 758\u2013764. Benowitz, N.L., Hall, Sagar Munjal., Herning, R.I., et al., 1983. Smokers of low-yield cigarettes do not consume less nicotine. The New England Journal of Medicine 309, 139\u2013 142. Benowitz, N.L., Jacob III, P., 1984. Daily intake of nicotine during cigarette smoking. Clinical Pharmacology and Therapeutics 35, 499\u2013504. Benowitz, N.L., Jacob III, P., Yu, L., et al., 1986. Reduced tar, nicotine, and carbon monoxide exposure while smoking ultralow- but not low-yield cigarettes. Journal of the American Medical Association 256, 241\u2013246. Blackford, A.L., Yang, G., Hernandez-Avila, M., et al., 2006. Cotinine concentration in smokers from different countries: relationship with amount smoked and cigarette type. Cancer Epidemiology Biomarkers and Prevention 15, 1799\u20131804. Bridges, R.B., Combs, J.G., Humble, J.W., et al., 1990. Population characteristics and cigarette yield as determinants of smoke exposure. Pharmacology Biochemistry and Behavior 37, 17\u201328. Burtis, C.A., Ashwood, E.R. (Eds.), 1999. Tietz Textbook of Clinical Chemistry. W.B. Saunders Company, Philadelphia. Byrd, G.D., Robinson, J.H., Caldwell, W.S., Debethizy, J.D., 1995. Comparison of measured and FTC-predicted nicotine uptake in smokers. Psychopharmacology 122, 95\u2013103. Byrd, G.D., Davis, R.A., Caldwell, W.S., Robinson, J.H., Debethizy, J.D., 1998. A further study of FTC yield and nicotine absorption in smokers. Psychopharmacology 139, 291\u2013299. Caraballo, R.S., Giovino, G.A., Pechacek, T.F., et al., 1998. Racial and ethnic differences in serum cotinine levels of cigarette smokers: Third National Health and Nutrition Examination Survey, 1988\u20131991. Journal of the American Medical Association 280, 135\u2013139. Clinical Laboratory Improvement Amendments. U.S. Department of Health and Human Services. Available from: <http://wwwn.cdc.gov/clia/regs/toc.aspx>. Counts, M.E., Hsu, F.S., Tewes, F.J., 2006. Development of a cigarette \u2018\u2018market map\u201d comparison methodology for evaluating new or non-conventional cigarettes. Regulatory Toxicology and Pharmacology 46, 225\u2013242. Djordjevic, M.V., Stellman, S.D., Zang, E., 2000. Doses of nicotine and lung carcinogens delivered to cigarette smokers. Journal of the National Cancer Institute 92, 106\u2013111. Federal Trade Commission, 1967. Statement of Considerations. Press release. August 1, 1967, pp. 2. Feng, S., Plunkett, S.E., Lam, K., Kapur, S., Muhammad, R., Jin, Y., Zimmermann, M., Mendes, P., Kinser, R., Roethig, H.J., 2007a. A new method for estimating the retention of selected smoke constituents in the respiratory tract of smokers during cigarette smoking. Inhalation Toxicology 19, 169\u2013179. Feng, S., Kapur, S., Sarkar, M., Muhammad, R., Mendes, P., Newland, K., Roethig, H.J., 2007b. Respiratory retention of nicotine and urinary excretion of nicotine and its five major metabolites in adult male smokers. Toxicology Letters 173 (2), 101\u2013106. Gori, G.B., Lynch, C.J., 1983. Smoker intake from cigarettes in the 1-mg Federal Trade Commission tar class. Regulatory Toxicology and Pharmacology 3 (2), 110\u2013120. Gori, G.B., Lynch, C.J., 1985. Analytical cigarette yields as predictors of smoke bioavailability. Regulatory Toxicology and Pharmacology 5, 314\u2013326. Guidance for Industry, 2001. Bioanalytical Method Validation. U.S.Department of Health and Human Services and U.S.Food and Drug Administration. Accessed on August 14, 7 A.D. Available from: <http://www.fda.gov/cder/guidance/ 4252fnl.htm>. Guidance for data quality assessment, 2007. Guidance for Data Quality Assessment: Practical Methods of Data Analysis. Office of Environmental Information, U.S. Environmental Protection Agency, Washington, DC. Accessed on April 2, 2007. Available from: <http://www.epa.gov/quality/qs-docs/g9-final.pdf>. Hart, C.L., Smith, G.D., Hole, D.J., Hawthorne, V.M., 2006. Carboxyhaemoglobin concentration, smoking habit, and mortality in 25 years in the Renfrew/Paisley prospective cohort study. Biochemistry 92, 321\u2013324. Hawkins, L.H., Cole, P.V., Harris, J.R., 1976. Smoking habits and blood carbon monoxide levels. Environmental Research 11, 310\u2013318. Institute of Medicine, 2001. Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction. National Academy Press, Washington, DC. Jarvis, M.J., Boreham, R., Primatesta, P., Feyerabend, C., Bryant, A., 2001. Nicotine yield from machine-smoked cigarettes and nicotine intakes in smokers: evidence from a representative population survey. Journal of the National Cancer Institute 93, 134\u2013138. Lawrence, T., Aveyard, P., Croghan, E., 2003. What happens to women\u2019s self- reported cigarette consumption and urinary cotinine levels in pregnancy? Addiction 98, 1315\u20131320. Lee, P.N., 2001. Lung cancer and type of cigarette smoked. Inhalation Toxicology 13, 951\u2013976. Lewis, S.J., Cherry, N.M., Niven, R.M., Barber, P.V., Wilde, K., Povey, A.C., 2003. Cotinine levels and self-reported smoking status in patients attending a bronchoscopy clinic. Biomarkers 8 (3\u20134), 218\u2013228. Maron, D.J., Fortmann, S.P., 1987. Nicotine yield and measures of cigarette smoke exposure in a large population: are lower-yield cigarettes safer. American Journal of Public Health 77, 546\u2013549. Mendes, P., Kapur, S., Wang, J., Feng, S.F., Roethig, H.J., 2008. A randomized, controlled exposure study in adult smokers of full flavor Marlboro cigarettes switching to Marlboro Lights or Marlboro Ultra Lights cigarettes. Regulatory Toxicology and Pharmacology 51, 295\u2013305. Murray, R.P., Connett, J.E., Lauger, G.G., Voelker, H.T., 1993. Error in smoking measures: effects of intervention on relations of cotinine and carbon monoxide to self-reported smoking. American Journal of Pubic Health 83 (9), 1251\u20131257. National Center for Health Statistics United States, 2004. With Chartbook on Trends in the Health of Americans. (PDF\u2013116KB). U.S. Department of Health and Human Services, Hyattsville, MD. CDC, 2004 (cited 2006 October 30). O\u2019Connor, R.J., Giovino, G.A., Kozlowski, L.T., et al., 2006. Changes in nicotine intake and cigarette use over time in two nationally representative cross-sectional samples of smokers. American Journal of Epidemiology 164, 750\u2013759. Office of Solid Waste Permits and State Programs Division, 2007. Statistical analysis of groundwater monitoring data at RCRA facilities: addendum to interim final guidance. United States Environmental Protection Agency Office of Solid Waste Permits and State Programs Division, Washington, DC. Accessed on April 2, 2007. Available from: <http://dqo.pnl.gov/VSP/Addendum%20to%20interim%20 final%20guidance.pdf>. Roethig, H.J., Kinser, R.D., Lau, Ruediger-A Walk., Walk, R.A., Wang, N., 2005. Short-term exposure evaluation of adult smokers switching from conventional to first-generation electrically heated cigarettes during controlled smoking. Journal of Clinical Pharmacology 45, 133\u2013145. http://wwwn.cdc.gov/clia/regs/toc.aspx http://www.fda.gov/cder/guidance/4252fnl.htm http://www.fda.gov/cder/guidance/4252fnl.htm http://www.epa.gov/quality/qs-docs/g9-final.pdf http://dqo.pnl.gov/VSP/Addendum%20to%20interim%20final%20guidance.pdf http://dqo.pnl.gov/VSP/Addendum%20to%20interim%20final%20guidance.pdf P. Mendes et al. / Regulatory Toxicology and Pharmacology 55 (2009) 17\u201327 27 Roethig, H.J., Zedler, B.K., Kinser, R.D., Feng, S., Nelson, B.L., Liang, Q., 2007. Short-term clinical exposure evaluation of second-generation electrically heated cigarette smoking system. The Journal of Clinical Pharmacology 47, 518\u2013530. Rosa, M., Pacifici, R., Altieri, I., Pichini, S., Ottaviani, G., Zuccaro, P., 1992. How the steady-state cotinine concentration in cigarette smokers is directly related to nicotine intake. Clinical Pharmacology and Therapeutics 52, 324\u2013 329. Sarkar, M., Stabbert, R., Kinser, R.D., Oey, J., Rustemeier, K., von Holt, K., Schepers, G., Walk, R.A., Roethig, H.J., 2006. CYP1A2 and NAT2 phenotyping and 3- aminobiphenyl and 4-aminobiphenyl hemoglobin adduct levels in smokers and non-smokers. Toxicology and Applied Pharmacology 213, 198\u2013206. Sarkar, M., Kapur, S., Frost-Pineda, K., Feng, S., Wang, J., Liang, Q., Roethig, H.J., 2008. Evaluation of biomarkers of exposure to selected cigarette smoke constituent in adult smokers switched to carbon-filtered cigarettes in short-term and long- term studies. Nicotine and Tobacco Research 10, 1761\u20131772. Scherer, G., 1999. Smoking behavior and compensation: a review of the literature. Psychopharmacology 145, 1\u201320. Scherer, G., 2006. Carboxyhemoglobin and thiocyanate as biomarkers of exposure to carbon monoxide and hydrogen cyanide in tobacco smoke. Experimental and Toxicologic Pathology 58, 101\u2013124. St. Charles, F.K., Krautter, G.R., Dixon, M., Mariner, D.C., 2006. A comparison of nicotine dose estimates in smokers between filter analysis, salivary cotinine, and urinary excretion of nicotine metabolites. Psychopharmacology (Berl.) 189 (3), 345\u2013354. Tobacco Institute Testing Laboratory, 2001. Testing Laboratory Market Sample #43. Report Tar, nicotine, and carbon monoxide values, 2001. Tobacco Institute Testing Laboratory, Rockville, MD. Tobacco Institute Testing Laboratory, 2002. Testing Laboratory Market Sample #44 Report. Tar, nicotine, and carbon monoxide values, 2002. Tobacco Institute Testing Laboratory, Rockville, MD. Tobacco in the United States, 2005. Cigarette Retail Sales: Tar Levels (Table 19), vol. 31. Euromonitor International, Plc., London, p. 31. Ueda, K., Kawachi, I., Nakamura, M., et al., 2002. Cigarette nicotine yields and nicotine intake among Japanese male workers. Tobacco Control 11, 55\u201360. United States Federal Trade Commission, 2000. Tar, nicotine, and carbon monoxide of the smoke of 1294 varieties of domestic cigarettes for the year 1998. U.S.Federal Trade Commission. Accessed on April 10, 2007. Available from: <http://www.ftc.gov/reports/tobacco/1998tar&nicotinereport.pdf>. Urban, M., Gilch, G., Schepers, G., van Miert, E., Scherer, G., 2003. Determination of the major mercapturic acids of 1,3-butadiene in human and rat urine using liquid chromatography with tandem mass spectrometry. Journal of Chromatography B 796, 131\u2013140. Woodward, M., Tunstall-Pedoe, H., Smith, W.C., Tavendale, R., 1991. Smoking characteristics and inhalation biochemistry in the Scottish population. Journal of Clinical Epidemiology 44, 1405\u20131410. Woodward, M., Tunstall-Pedoe, H., 1992. Do smokers of lower tar cigarettes consume lower amounts of smoke components? Results from the Scottish Heart Health Study. British Journal of Addiction 87, 921\u2013928. World Medical Association, 2000. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. 52nd World Medical Association General Assembly, Edinburgh, Scotland, 2000. Accessed on April 10, 2007. Available from: <http://www.wma.net/e/policy/pdf/17c.pdf>. Zedler, B.K., Kinser, R., Oey, J., et al., 2006. Biomarkers of exposure and potential harm in adult smokers of 3\u20137 mg tar yield (Federal Trade Commission) cigarettes and in adult non-smokers. Biomarkers 11, 201\u2013220. http://www.ftc.gov/reports/tobacco/1998tar&amp;nicotinereport.pdf http://www.wma.net/e/policy/pdf/17c.pdf The relationship between smoking machine derived tar yields and biomarkers of exposure in adult cigarette smokers in the US Introduction Materials and methods Study design Subjects Study conduct Biomarker sampling and analytical methods Biomarkers of exposure Nicotine equivalents (NE) Carboxyhemoglobin (COHb) 4-ABP-Hb adducts and serum cotinine Total NNAL Total 1-OHP and 3-HPaul MendesA MHBMA and DHBMA Statistical methods Results Subjects Cigarette consumption Biomarkers of exposure Particulate phase biomarkers Nicotine equivalents per day Nicotine equivalents per cigarette Serum cotinine Total NNAL per day Total NNAL per cigarette Total 1-OHP per day 4-ABP-Hb Gas phase biomarkers COHb 3-HPaul MendesA per day MHBMA and DHBMA per day Discussion Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-relationship-between-the-IC50--toxic-threshold--and_2009_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19393280", "content": {"Acknowledgement": "Acknowledgments Effort sponsored by the Air Force Office of Scientific Research, Air Force Material Command, USAF, under Grant No. FA9550-07- 1-0248. The US Government is authorized to reproduce and dis- tribute for governmental purposes notwithstanding any copyright notation thereon. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsement, either expressed or implied, of the Air Force Office of Scientific Research or the US Government. Results Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-relationship-of-snus-use-to-diabetes-and_2017_Regulatory-Toxicology-and-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29061372", "content": {"CoiStatement": "Conflict of interest P N Lee is a long-term consultant to the tobacco industry and A J Thornton is a consultant to P N Lee's company, P N Lee Statistics and Computing Ltd. However, this is an independent scientific assessment, the views expressed being those of the authors alone. Discussion Conclusions Conflict of interest Acknowledgements Supplementary data Transparency document References", "Acknowledgement": "Acknowledgements We thank Mrs. Y. Cooper and Mrs. D. Morris for their assistance in typing the various drafts of this report, and their help in assembling the relevant literature. We also thank colleagues for providing helpful comments, and Swedish Match for financial support. Discussion Conclusions Conflict of interest Acknowledgements Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-relevance-of--non-relevant-metabolites--from-plan_2010_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19706317", "content": {"Compliance with ethical standards": "The German Drinking Water Ordinance 2001 already lists this kind of precautionary limit values, but their selection and quantity is non-systematic (Dieter, 1998a,b, 2004). Some of its limit values could even be considered higher than a health based guide value but only (with nitrate as an important exception) if the 10% default allocation of a TDI on 2 l of daily drinking water is too low (compare health based limit values in Table 3 in Melching-Kollmu\u00df et al. with those in Dieter, 1999). Legally binding precautionary threshold val- ues for \u2018\u2018non-relevant metabolites\u201d and other groups of environ- mental contaminants relevant for drinking water would only be reasonably feasible if compliance with such values in regard to drinking water production could be managed in such a way that it would not lead to technical treatment procedures at waterworks as an obligatory regulation. What we need is cooperation to pre- vent discharges according to generally acknowledged standards of (agricultural) technology and according to the state of the art in science and technology, e.g., integrated pest management. 6. Conclusion From the point of view of regulatory (human) toxicologists (Dieter et al., 2007), the present situation in regard to \u2018\u2018non-rele- vant metabolites\u201d cannot be yet satisfactory. Data sets are more or less insufficient. Partially missing analytical methods to trace back their fate only in a few cases enables a complete hygienic assessment of \u2018\u2018non-relevant metabolites\u201d and their transformation products in the water cycle. This should be an incentive to employ existing instruments for minimization of emissions."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-relevance-of-international-assessments-to_2016_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27318100", "content": {"CoiStatement": "Many times, GRAS determinations rely on evaluations by Expert Panels who opine on basis for the consensus of safety that is derived from the risk assessment. The use of Expert Panels for evaluating the safety of ingredients in our food supply has a long history. European Food Standards Agency (EFSA) is an example of an expert panel that opines on the safety of foods. Flavor Extracts Manufacturing Association (FEMA) has used expert panels for de- cades to evaluate the GRAS status of flavors. It is very important that panel members do not have conflicts of interest, that they represent the expertise needed, and that there is a balance of bias, because no one comes to a discussion completely neutral on any particular subject. JECFA has articulated useful guidance on some of the key elements of how expert panel members should be selected to avoid conflict of interest and assure effective communication and deliberation. This guidance is useful to embrace in selecting Expert panels for GRAS deliberations (see Table 1). 1. Conclusion In summary, GRAS is not unregulated. It relies on established scientific principles articulated by regulatory and authoritative agencies around the world for risk assessment. There is a way that every stakeholder can check the results of this process because pivotal information is published. Most critical is the knowledge that the risk assessments applied to the GRAS process are not static. Both science and regulation are never static, nor should they be.We must constantly question old paradigms, test new methodologies, and incorporate better strategies. But we must do this is a thoughtful, deliberate and unbiased fashion. The process must allow us to keep the processes that work well while incorporating innovations that add to their value. Eliminating processes that have served us well for 50 years with no evidence that there is a compromise in the assurance that we are protecting public health is unconscionable. The GRAS process is a robust, rigorous, peer review process. It is a process that can satisfy consumer concerns about food ingredient safety that articulates what was done, how it was done, and why we can conclude that the ingredient is safe. Transparency document"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-reliability-of-an-environmental-epidemiolog_2019_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30590082", "content": {"Funding": "Funding The work of Young was partially funded by the American Petroleum Institute. The other researchers are unfunded. The reliability of an environmental epidemiology meta-analysis, a case study Introduction Methods Results Discussion Funding Supplementary data References References: references numbers from Nawrot et al. Lancet 377: 732\u2013740."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-risk-based-approach-to-ATMP-development---General_2013_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23933031", "content": {"CoiStatement": "Conflicts of interest M. Kooijman, P.J.K. van Meer, E.H.M. Moors, M.P. Hekkert and C.C. Gispen-de Wied declare no conflicts of interest. H. Schellekens participated in meetings and publications sponsored by Amgen, Johnson & Johnson, Roche, Sandoz and Hospira. Some of his re- search is directly or indirectly sponsored by Roche and Amgen. M. Kooijman, P.J.K. van Meer, E.H.M. Moors, M.P. Hekkert and C.C. Gispen-de Wied declare no conflicts of interest. H. Schellekens participated in meetings and publications sponsored by Amgen, Johnson & Johnson, Roche, Sandoz and Hospira. Some of his re- search is directly or indirectly sponsored by Roche and Amgen. Acknowledgments 4 Discussion 5 Conclusion Conflicts of interest Acknowledgments References", "Acknowledgement": "Acknowledgments This research was performed under the framework of Top Insti- tute Pharma (project T6-301), which includes the Medicines Eval- uation Board, the Organization of Innovative Pharmaceutical Industries in the Netherlands (Nefarma), the Life Science and Health Initiative and Utrecht University. PvM and M Kooijman performed this work with the TI Pharma grant. The views expressed in this article are the personal views of the authors and are not to be understood or quoted as being made on behalf of or reflecting the position of the Medicines Evaluation Board or any other regu- latory agency, or one of its committees or working parties. The authors would like to thank Spiros Vamvakas for his help in refin- ing the manuscripts. References 4 Discussion 5 Conclusion Conflicts of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-role-of-ammonia-in-the-transfer-of-nicotine-_2006_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16875767", "content": {"Acknowledgement": "Summary, conclusions and implications Acknowledgments Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-role-of-developmental-toxicity-studies-in-acute-exp_2009_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19306903", "content": {"CoiStatement": "Conflict of interest The authors declare that there are no conflicts of interest. References The authors declare that there are no conflicts of interest. References Akaike, H., 1973. Information theory and an extension of the maximum likelihood principle. In: Petrov, B.N., Csaki, F. (Eds.), Proceedings of the Second International Symposium on Information Theory. Akademiai Kiado, Budapest, pp. 267\u2013281. Discussion Disclaimer Conflict of interest References", "Funding": "Partial funding was provided by the NCEA-ORISE Interagency Agreement. The information in this document has been subjected to review by the National Center for Environmental Assessment, U.S. Environmental Protection Agency, and approved for publica- tion. Approval does not signify that the contents reflect the views of the Agency, nor does mention of trade names or commercial products constitute endorsement or recommendation for use. The research presented in this document was funded in part by the U.S. Environmental Protection Agency. Conflict of interest"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-role-of-ethyl-acrylate-induced-GSH-depletion-in-the-ro_2018_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29183839", "content": {"Acknowledgement": "Acknowledgements This research was sponsored by the Basic Acrylate Monomer Manufacturers member companies: Arkema Inc., BASF SE, The Dow Chemical Company. The authors gratefully acknowledge the support of D. DeLine, V.A. Marshall, L.G. McFadden, and F. Zhang in the conduct and analysis of this work. Discussion Conclusions Acknowledgements Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-role-of-fiber-durability-biopersistence-of-silica-_2006_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16837114", "content": {"Acknowledgement": "Future directions Acknowledgments blank References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-role-of-professional-judgment-in-chemical-ha_2006_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16843576", "content": {"Disclosure": "Recent insight was oVered by OSHA (Fairfax, 2005) regarding the need to report compounds present in mix- tures below the stated limits of disclosure of 1% and 0.1%. SpeciWcally, the question related to MSDS reporting of fra- grance materials in cosmetic products that may act as skin sensitizers, even at levels less than 0.1%. OSHA contended that the HCS requires reporting of all components on the MSDSs which pose a health risk to employees: \u201c\u0192regard- less of the percentage amounts of the chemical present in their products, provided there is scientiWc evidence that the particular chemical poses a health risk to employees.\u201d Their logic was based upon chemicals that are sensitizers may be present in very low concentrations in mixtures, yet still present a health risk to exposed workers. Hence, an assessor that strictly abides by the threshold limits of disclosure under the HCS, without expert consid- eration of health risk, may not be serving the intent of the law. To the extent possible, hazard assessments should aug- ment the threshold limits of reporting with statements that convey the net properties of the mixture or preparation. Hence, an assessor that strictly abides by the threshold limits of disclosure under the HCS, without expert consid- eration of health risk, may not be serving the intent of the law. To the extent possible, hazard assessments should aug- ment the threshold limits of reporting with statements that convey the net properties of the mixture or preparation. 4.6. Coherent hazard communication Health Canada, 1997. WHMIS Information Bulletin No. 12: Guidelines for the Disclosure of Toxicological Information on a Material Safety Data Sheet. Intergovernmental WHMIS Coordinating Committee, Product Safety Bureau, Health Canada, 1000 Wing, Statistics Canada Main Bldg., Tunney\u2019s Pasture, Otawa, Ontario K1A 0LZ. IARC, 1999. Monographs on the evaluation of carcinogenic risks to humans 73: 307. International Agency for Research on Cancer. <http:/ /monographs.iarc.fr/>. Accessed March 21, 2005.", "Acknowledgement": "Acknowledgment The authors thank Laura Fell of ToxLink, LLC, for her contributions to the paper. Summary and conclusions Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-role-of-science-in-international-tr_2006_Regulatory-Toxicology-and-Pharm.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16213075", "content": {"Compliance with ethical standards": "But even if the home government of an aVected stake- holder brings an oYcial WTO complaint challenging the non-science based regulations, the underlying dispute is often settled before the claim is heard and decided by a WTO panel. Each claim begins with a \u201crequest for consul- tations,\u201d which provides a period of at least 60 days for the complainant and the respondent to seek information and consider possible resolutions to the dispute. Indeed, although more than 300 complaints have oYcially been Wled, WTO panels issued fewer than half that number of reports. In many cases, setting forth the factual and legal basis for a claim has been suYcient to convince the defend- ing government to bring its measures into compliance with WTO rules, thereby underscoring the importance of these rules and the inXuence of the WTO dispute settlement sys- tem. Stakeholders are increasingly using the option of invoking WTO rules if they object to foreign regulations that obstruct trade and are not based on credible science. 5. WTO disputes 74 M. Lugard, M. Smart / Regulatory Toxicology and Pharmacology 44 (2006) 69\u201374 Japanese apples from the Wre blight bacterium (Erwinia amylovora). Fire blight was Wrst reported in the United States in 1793 and over time spread to much of Europe and the Mediterranean region. Japan, however, is still free of Wre blight free and the Japanese government had imposed a trade restrictive measure to keep the bacteria from entering its territory. The Panel and Appellate Body agreed that the Japanese measure violated Article 2.2 of the SPS Agree- ment, because it was \u201cmaintained without scientiWc evi- dence.\u201d16 In addition, they found that the measure was not imposed in respect of a situation where relevant scientiWc evidence is \u201cinsuYcient,\u201d and, therefore, the Panel and Appellate Body concluded that it was not a provisional measure that could be justiWed under Article 5.7 of the SPS Agreement.17 Finally, the Appellate Body upheld the Panel\u2019s conclusion that the measure was \u201cnot based on a risk assessment as required by Article 5.1 of the SPS Agree- ment.\u201d18 Since the Appellate Body\u2019s ruling, Japan claims to have brought its regime into compliance with its WTO commitments. The United States disagrees, however, and on July 30, 2004, it initiated another WTO case against Japan, challenging the new measure. 5.2. TBT agreement The Appellate Body aYrmed that the EC measure is a \u201ctechnical regulation\u201d under the TBT Agreement because it is a document which lays down product characteristics with which compliance is mandatory.21 The Appellate Body then upheld the Panel\u2019s Wnding that the regulation was inconsis- tent with Article 2.4 because of the existence of an interna- tional standard for labeling sardines (i.e., a Codex Alimentarius Commission standard),22 which the European Communities did not use as the basis for its regulation,23 and Peru, the complainant, demonstrated that this interna- tional standard was \u201cnot \u2018ineVective or inappropriate\u2019 to full the \u2018legitimate objectives\u2019 of the EC regulation.\u201d24 EC\u2014Sardines is noteworthy, therefore, for the central role that international standards played in deciding the out- come of this dispute."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-role-of-the-benchmark-dose-in-a-regula_2005_Regulatory-Toxicology-and-Ph.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16143439", "content": {"Acknowledgement": "It is time to recognise the conventional NOAEL approach as a valuable tool that provides a simple, repeatable, and checkable summary of effects in toxi- cology studies. Each study is just conducted in one laboratory, with one animal strain, under one set of conditions, so the danger of over-interpretation is real. More labour- and discussion-intensive methods such as the BMD can be used to best advantage as a high- er tier approach, once the critical studies and end- points have been identified across the entire data package. Acknowledgments Financial support for this work from the UK Depart- ment of Food and Rural Affairs (DEFRA) is acknowl- edged. The authors are grateful to John Doe for helpful discussions concerning the work reported here. References Overall benefits evaluation Concluding remarks Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/The-safety-of-a-Kluyveromyces-lactis-strain-lin_2021_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34428516", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 7 Discussion 8 Conclusion CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data Funding sources References", "Funding": "Funding sources This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. References 7 Discussion 8 Conclusion CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data Funding sources References", "Acknowledgement": "Acknowledgements We are grateful to Noe\u0308l van Peij for his contribution and critical comments throughout the process of writing the paper. We would like to thank Markus Wyss for his critical review of this paper. Sandra Bouter is kindly acknowledged for preparing the figure overview of the enzyme production process. 7 Discussion 8 Conclusion CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data Funding sources References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-safety-of-a-dry-spearmint-extract-in-vi_2015_Regulatory-Toxicology-and-P.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25527048", "content": {"CoiStatement": "J.A. Lasrado et al. / Regulatory Toxicology and Pharmacology 71 (2015) 213\u2013224 223 (1948 mg/kg bw/day) when tested in vivo by gavage administra- tion for 90 days in male and female Sprague\u2013Dawley rats. Based on the findings, the NOAEL for orally administered dry spearmint extract is 1948 mg/kg bw/day, the highest dose tested, which is equivalent to 300 mg rosmarinic acid/kg bw/day. The dry spear- mint extract also showed no mutagenic activity in the Ames assay and did not induce chromosomal aberrations in human peripheral blood lymphocytes in the presence or absence of metabolic activation. Conflict of interest Kemin Foods, L.C. was the sponsor of the studies, conducted at Vanta Bioscience, Gummipundi, India. Vanta Bioscience is owned by Kemin Industries, Des Moines, USA. Joanne Lasrado, Debbie Trinker and Kelli Herrlinger are current employees and Michael Ceddia is a former employee of Kemin Foods, the manufacturer of dry spearmint extract standardized to rosmarinic acid. Acknowledgments 4 Discussion Conflict of interest Acknowledgments References", "Compliance with ethical standards": "OECD, 1998. Principles of Good Laboratory Practice. OECD Environmental Health and Safety Publications, Series on Principles of Good Laboratory Practice and Compliance Monitoring No. 1. ENV/MC/CHEM (98)17. Organisation for Economic Cooperation and Development (OECD). Pearson, W., Fletcher, R.S., Kott, L.S., 2011. Oral Rosmarinic Acid-Enhanced Mentha spicata modulated Synovial Fluid Biomarkers of Inflammation in Horses Challenged with Intra-Articular LPS. J. vet. Pharmacol. Therap. 35, 495.", "Acknowledgement": "Kemin Foods, L.C. was the sponsor of the studies, conducted at Vanta Bioscience, Gummipundi, India. Vanta Bioscience is owned by Kemin Industries, Des Moines, USA. Joanne Lasrado, Debbie Trinker and Kelli Herrlinger are current employees and Michael Ceddia is a former employee of Kemin Foods, the manufacturer of dry spearmint extract standardized to rosmarinic acid. Acknowledgments We would like to thank Elke Kennepohl, Equinox Scientific Ser- vices, and Dr. Joseph Borzelleca, Professor Emeritus at VCU School of Medicine and President of Toxicology and Pharmacology, Inc., for their valuable help with the critique of the above safety studies, and the development and writing of the manuscript. We would also like to thank Daniele Del Rio and his team at The Laboratory of Phytochemicals in Physiology, Department of Food Science, Uni- versity of Parma, Parma, Italy for characterizing the phenolic con- stituents in the dry spearmint extract. References 4 Discussion Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-safety-of-ethyl-oleate-is-supported-by-a-91_2004_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15041149", "content": {"Acknowledgement": "In conclusion, the data generated in this study show that consumption of EO in the diet of rats at up to 10% of the diet for 91 days (consumption generally ranged between 4 and 8 g EO/kg body weight/day) was well- tolerated and devoid of any toxic effects. The No Ob- servable Effect Level was determined to be 6.7% EO in the diet (based on the small decreases in calcium and phosphorous in the high-dose males). The No Ob- servable Adverse Effect Level was determined to be 10% EO in the diet based on the lack of any clear adverse effects seen in this study. Acknowledgments The authors would like to thank John A. Discussion Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-safety-of-whey-protein-concentrate-derived-from-_2007_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/17293018", "content": {"Compliance with ethical standards": "To examine the safety of the product for consumption by patients with CDAD, a prospective, uncontrolled open-label cohort study was conducted at the Department of Infectious Diseases, Leiden University Medical Center (LUMC), The Netherlands, while concurrently a pro- spective, unblinded randomized controlled study was conducted at the University of Pittsburgh Medical Center (UPMC), U.S., from November 2004 to December 2005. Of note, the trial protocols (inclusion and exclu- sion criteria, follow-up and laboratory assessment of safety) used in The Netherlands and Pittsburgh were identical, with the exception of the inclusion of a control group (not receiving an intervention) in Pitts- burgh. For the present safety assessment of anti-CD WPC, the results of all study participants from LUMC (n D 68) and the results of partici- pants assigned to receive the anti-CD WPC treatment at UPMC (n D 9) are presented herein. Within 3 days of each study participant\u2019s last day of standard antibiotic treatment for CDAD (i.e., metronidazole and/or vancomycin) and following a minimum of 10 days of treatment, study participants were given 5 g anti-CD WPC three times daily for 14 days, which was stirred into 60\u201380 mL of lukewarm water and consumed 1 h before meals. This dose is consistent with that used in a pilot study that showed that this is likely an eYcacious and safe dose in patients with CDAD (van Dissel et al., 2005). Study participants were provided sequentially numbered sachets of anti-CD WPC for the 14-day course, which were counted at follow-up visits to assess compliance. Study par- ticipants were monitored for an additional 46 days during a follow-up period. 2.5. Participants"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-screening-of-everyday-life-chemicals-in-validat_2013_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23590819", "content": {"CoiStatement": "Our ELC database, although at present small, is nonetheless a pertinent contribution to the intense deliberations concerning endocrine disruption, its causal agents and their regulation for three main reasons. First, it infers that the range of chemicals that can interfere with and as a consequence potentially cause adverse effects on the endocrine system may be more significant in terms of numbers and diversity than first imagined. Second, at present the focus is the elimination or further regulation of synthetic chemicals but our data highlight an as yet unexplored source of unregulated substances that may also have endocrine disrupting properties, which must be investigated if we are to fully under- stand the relative contribution of all causal agents to the putative endocrine disorders in man (and wildlife). Third, as discussed by Bars et al. (2011, 2012 and as highlighted by the data for caffeine, other factors, such as potency, severity of adverse effects and margin of exposure, need to be considered before deciding whether a substance(natural or man-made) merits regulatory intervention. Funding information This work was partly funded by the BioIntelligence Consortium, France. Conflict of interest statement The authors declare that there are no conflicts of interest. Acknowledgments The authors would like to thank B\u00e9n\u00e9dicte Labory, Daisy Ces- pedes and Dominique Debarbeyrac for technical expertise and Da- vid Rouqui\u00e9 for useful discussions. Appendix A. Supplementary data Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.yrtph.2013.04. 002. References Ashby, J., Tinwell, H., 1998. Oestrogenic activity of burgen bread to female rats. Hum. Exp. Toxicol. 17, 598\u2013599. Bars, R., Broeckaert, F., Fegert, I., Gross, M., Hallmark, N., Kedwards, T., Lewis, D., O\u2019Hagan, S., Panter, G.H., Weltje, L., Weyers, A., Wheeler, J.R., Galay-Burgos, M., 2011. Science based guidance for the assessment of endocrine disrupting properties of chemicals. Regul. Toxicol. Pharmacol. 59 (1), 37\u201346Bars, R., Broeckaert, F., Fegert, I., Gross, M., Hallmark, N., Kedwards, T., Lewis, D., O\u2019Hagan, S., Panter, G.H., Weltje, L., Weyers, A., Wheeler, J.R., Galay-Burgos, M., . Science based guidance for the assessment of endocrine disrupting properties of chemicals. Regul. Toxicol. Pharmacol. 60 (3), 411\u2013412. Bars, R., Fegert, I., Gross, M., Lewis, D., Weltje, L., Weyers, A., Wheeler, J.R., Galay- Burgos, M., 2012. Risk assessment of endocrine active chemicals: identifying chemicals of regulatory concern. Regul. Toxicol. Pharmacol. 64 (1), 143\u2013154. Behr, M., Oehlmannn, J., Wagner, M., 2011. Estrogens in the daily diet: In vitro analysis indicates that estrogenic activity is omnipresent in foodstuff and infant formula. Food Chem. Toxicol. 49, 2681\u20132688. BfR (Bundesinstitut f\u00fcr Risikobewertung), 2011. Final Joint DE-UK position. Regulatory definition of an endocrine disrupter in relation to potential threat to human health. Available at: <http://www.bfr.bund.de/cm/349/regulatory_ definition_of_an_endocrine_disrupter_in_relation_to_potential_threat_to_ human_health.pdf>. Christiansen, S., Kortenkamp, A., Axelstad, M., Boberg, J., Scholze, M., Jacobsen, P.R., Faust, M., Lichtensteiger, W., Schlumpf, M., Burdorf, A., Hass, U., 2012. Mixtures of endocrine disrupting contaminants modelled on human high end exposures: an exploratory study in rats. Int. J. Androl. 35, 303\u2013316. COT statement on the reproductive effects of caffeine, 2001. Available at <http:// www.food.gov.uk/science/ouradvisors/toxicity/statements/cotstatements2001/ caffeine>. EC, 2006. Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18th December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 000/21/EC. Official J. Europ. Union L396/1. EC, 2009a. Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placing of plant protection products on the market and repealing Council Directives 79/117/EEC and 91/414/EEC. Official J. Europ. Commun. L 309/1. EC, 2009b. Regulation (COM 2009/267) of the European Parliament and of the Council of 12th June 2009 replacing Directive 98/8/EC concerning the placing of biocidal products on the market. Official J. Europ. Commun. L276. EU, 2010. The Directive 2010/63/EU of the European Parliament and the Council of 22 September 2010 on the protection of animals used for scientific purposes. Official Journal of the European Community, L276/34. Ezzat, A.R., el-Gohary, Z.M., 1994. Hormonal and histological effects of chronic caffeine administration on the pituitary\u2013gonadal and pituitary-adrenocortical axes in male rabbits. Funct. Dev. Morphol. 4, 45\u201350. Fernandes, G.S., Fernandez, C.D., Campos, K.E., Damasceno, D.C., Anselmo-Franci, J.A., Kempinas, W.D., 2011. Vitamin C partially attenuates male reproductive deficits in hyperglycemic rats. Reprod. Biol. Endocrinol. 9, 100. Flynn, D.L., Rafferty, M.F., Boctor, A.M., 1986. Inhibition of human neutrophil 5- lipoxygenase activity by gingerdione, shogaol, capsaicin and related pungent compounds. Prostaglandins Leukot Med. 24, 195\u2013198. http://dx.doi.org/10.1016/j.yrtph.2013.04.002 http://dx.doi.org/10.1016/j.yrtph.2013.04.002 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0005 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0005 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0175 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0175 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0175 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0180 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0180 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0180 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0180 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0180 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0010 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0010 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0010 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0015 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0015 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0015 http://www.bfr.bund.de/cm/349/regulatory_definition_of_an_endocrine_disrupter_in_relation_to_potential_threat_to_human_health.pdf http://www.bfr.bund.de/cm/349/regulatory_definition_of_an_endocrine_disrupter_in_relation_to_potential_threat_to_human_health.pdf http://www.bfr.bund.de/cm/349/regulatory_definition_of_an_endocrine_disrupter_in_relation_to_potential_threat_to_human_health.pdf http://refhub.elsevier.com/S0273-2300(13)00054-8/h0020 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0020 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0020 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0020 http://www.food.gov.uk/science/ouradvisors/toxicity/statements/cotstatements2001/caffeine http://www.food.gov.uk/science/ouradvisors/toxicity/statements/cotstatements2001/caffeine http://www.food.gov.uk/science/ouradvisors/toxicity/statements/cotstatements2001/caffeine http://refhub.elsevier.com/S0273-2300(13)00054-8/h0025 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0025 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0025 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0030 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0030 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0030 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0035 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0035 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0035 196 H. Tinwell et al. / Regulatory Toxicology and Pharmacology 66 (2013) 184\u2013196 Friedman, L., Weinberger, M.A., Farber, T.M., Moreland, F.M., Peters, E.L., Gilmore, C.E., Khan, M.A., 1979. Testicular atrophy and impaired spermatogenesis in rats fed high levels of the methylxanthines caffeine, theobromine, or theophylline. J. Environ. Pathol. Toxicol. 2, 687\u2013706. Frye, C.A., Bo, E., Calamandrei, G., Calza, L., Dess\u0131\u2018-Fulgheri, F., Fernandez, M., Fusani, L., Kah, O., Kajta, M., Le Page, Y., Patisaul, H.B., Venerosi, A., Wojtowicz, A.K., Panzica, G.C., 2011. Endocrine disrupters: a review of some sources, effects, and mechanisms of actions on behaviour and neuroendocrine systems. J. Neuroendocrinol. 24, 144\u2013159. Gupta, C., 1989. The role of prostaglandins in masculine differentiation: modulation of prostaglandin levels in the differentiating genital tract of the fetal mouse. Endocrinology 124, 129\u2013133. Gupta, C., Goldman, A.S., 1986. The arachidonic acid cascade is involved in the masculinizing action of testosterone on embryonic external genitalia in mice. Proc. Natl. Acad. Sci. USA 83, 4346\u20134349. Jefferson, W.N., Patisaul, H.B., Williams, C.J., 2012. Reproductive consequences of developmental phytoestrogen exposure. Reproduction 143, 247\u2013260. Kamtchouing, P., Mbongue Fandio, G.Y., Dimo, T., Jatsa, H.B., 2002. Evaluation of androgenic activity of Zingiber officinale and Pentadiplandra brazzeana in male rats. Asian J. Androl. 4, 299\u2013301. Khaki, A., Fathiazad, F., Nouri, M., Khaki, A.A., Ozanci, C.C., Ghafari-Novin, M., Hamadeh, M., 2009. The effects of ginger on spermatogenesis and sperm parameters of rat. Iranian J. Reproduct. Med. 7, 7\u201312. Kim, P., Park, Y., Ji, K., Seo, J., Lee, S., Choi, K., Kho, Y., Park, J., Choi, K., 2012. Effect of chronic exposure to acetaminophen and lincomycin on Japanese medaka (Oryzias latipes) and freshwater cladocerans Daphnia magna and Moina macrocopa, and potential mechanisms of endocrine disruption. Chemosphere 89, 10\u201318. Kiuchi, F., Shibuya, M., Sankawa, U., 1982. Inhibitors of prostaglandin biosynthesis from ginger. Chem. Pharm. Bull. 30, 754\u2013757. Kiuchi, F., Iwakami, S., Shibuya, M., Hanaoka, F., Sakawa, U., 1992. Inhibition of prostaglandin and leukotriene biosynthesis by gingerols and diarylheptanoids. Chem. Pharm. Bull. 40, 387\u2013391. Kristensen, D.M., Skalkam, M.L., Audouze, K., Lesn\u00e9, L., Desdoits-Lethimonier, C., Frederiksen, H., Brunak, S., Skakkeb\u00e6k, N.E., J\u00e9gou, B., Hansen, J.B., Junker, S., Leffers, H., 2011. Many putative endocrine disruptors inhibit prostaglandin synthesis. Environ. Health Perspect. 119 (4), 534\u2013541. Kristensen, D.M., Lesn\u00e9, L., Le Fol, V., Desdoits-Lethimonier, C., Dejucq-Rainsford, N., Leffers, H., J\u00e9gou, B., 2012. Paracetamol (acetaminophen), aspirin (acetylsalicylic acid) and indomethacin are anti-androgenic in the rat foetal testis. Int. J. Androl. 35, 377\u2013384. Ludwig, S., Tinwell, H., Rouqui\u00e9, D., Schorsch, F., Pallardy, M., Bars, R., 2012. Potential new targets involved in 1,3-dinitrobenzene induced testicular toxicity. Toxicol. Lett. 213, 275\u2013284. National Research Council, 2011. The Guide for the Care and Use of Laboratory Animals (8th edition) for the Institute for Laboratory Animal Research (ILAR) by the National Research Council of the National Academies Washington D.C., National Academies Press. Ndebele, K., Graham, B., Tchounwou, P.B., 2010. Estrogenic Activity of Coumestrol, DDT, and TCDD in Human Cervical Cancer Cells. Int. J. Environ. Res. Public Health 7, 2045\u20132056. Nielsen, T.S., N\u00f8rgaard, J.V., Purup, S., Frett\u00e9, X.C., Bonefeld-J\u00f8rgensen, E.C., 2009. Estrogenic activity of bovine milk high or low in equol using immature mouse uterotrophic responses and an estrogen receptor transactivation assay. Cancer Epidemiol. 33, 61\u201368. Pollard, I., Williamson, S., Magre, S., 1990. Influence of caffeine administered during pregnancy on the early differentiation of fetal rat ovaries and testes. J. Dev. Physiol. 13, 59\u201365. Sakamoto, T., Horiguchi, H., Oguma, E., Kayama, F., 2010. Effects of diverse dietary phytoestrogens on cell growth, cell cycle and apoptosis in estrogen-receptor- positive breast cancer cells. J. Nutr. Biochem. 21, 856\u2013864. Sanderson, J.T., Hordijk, J., Denison, M.S., Springsteel, M.F., Nantz, M.H., Van den Berg, M., 2004. Induction and inhibition of aromatase (Cyp 19) activity by natural and synthetic flavonoid compounds in H295R human adrenocortical carcinoma cells. Toxicol. Sci. 82, 70\u201379. S\u00f6nmez, M., T\u00fcrk, G., Y\u00fcce, A., 2005. The effect of ascorbic acid supplementation on sperm quality, lipid peroxidation and testosterone levels of male Wistar rats. Theriogenology. 63, 2063\u20132072. Sotoca, A.M., Ratman, D., van der Saag, P., Strom, A., Gustafsson, J.A., Vervoot, J., Rietjens, I.M., Murk, A.J., 2008. Phytoestrogen-mediated inhibition of proliferation of the human T47D breast cancer cells depends on the ERalpha/ ERbeta ratio. J. Steroid Biochem. Mol. Biol. 112, 171\u2013178. Taxvig, C., Elleby, A., Sonne-Hansen, K., Bonefeld-J\u00f8rgensen, E.C., Vinggaard, A.M., Lykkesfeldt, A.E., Nellemann, C., 2010. Effects of nutrition relevant mixtures of phytoestrogens on steroidogenesis, aromatase, estrogen, and androgen activity. Nutr. Cancer 62, 122\u2013131. US-EPA, OPPTS Series 890, 2009. Endocrine disruptor screening program test guidelines, no. 890.1550: steroidogenesis (Human Cell Line \u2013 H295R) (October 2009). US-EPA OPPTS Series 890, 2009a. Endocrine Disruptor Screening Program Test Guidelines, No. 890.1300: Estrogen Receptor Transcriptional Activation (Human Cell Line (HeLa-9903)) (October 2009). US-EPA OPPTS Series 890, 2009b. Endocrine Disruptor Screening Program Test Guidelines, No. 890.1450: pubertal development and thyroid function in intact juvenile/peripubertal female rats (October 2009). US-EPA OPPTS Series 890, 2009c. Endocrine Disruptor Screening Program Test Guidelines, 890.1500: pubertal development and thyroid function in intact juvenile/peripubertal male rats (October 2009). VanderPloeg, L.C., Wolfrom, D.M., Rao, A.R., Braselton, W.E., Welsch, C.W., 1992. Caffeine, theophylline, theobromine, and developmental growth of the mouse mammary gland. J. Environ. Pathol. Toxicol. Oncol. 11 (3), 177\u2013189. Wagner, M., Oehlmann, J., 2011. Endocrine disruptors in bottled mineral water estrogenic activity in the E-Screen. J. Steroid Biochem. Mol. Biol. 127, 128\u2013135. Welsch, C.W., DeHoog, J.V., O\u2019Connor, D.H., 1988. Influence of caffeine consumption on carcinomatous and normal mammary gland development in mice. Cancer Res. 48 (8), 2078\u20132082. West, G.L., Sobotka, T.J., Brodie, R.E., Beier, J.M., O\u2019Donnell Jr., M.W., 1986. Postnatal neurobehavioral development in rats exposed in utero to caffeine. Neurobehav. Toxicol. Teratol. 8, 29\u201343. Yamagami, T., Handa, H., Takeuchi, J., Munemitsu, H., Aoki, M., Kato, Y., 1983. Rat pituitary adenoma and hyperplasia induced by caffeine administration. Surg. Neurol. 20, 323\u2013331. http://refhub.elsevier.com/S0273-2300(13)00054-8/h0045 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0045 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0045 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0045 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0040 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0040 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0040 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0040 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0040 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0040 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0060 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0060 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0060 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0055 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0055 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0055 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0065 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0065 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0070 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0070 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0070 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0075 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0075 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0075 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0080 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0080 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0080 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0080 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0080 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0090 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0090 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0085 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0085 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0085 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0095 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0095 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0095 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0095 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0100 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0100 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0100 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0100 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0105 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0105 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0105 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0115 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0115 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0115 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0110 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0110 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0110 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0110 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0120 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0120 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0120 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0125 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0125 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0125 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0130 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0130 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0130 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0130 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0140 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0140 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0140 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0135 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0135 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0135 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0135 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0145 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0145 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0145 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0145 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0150 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0150 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0150 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0155 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0155 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0160 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0160 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0160 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0165 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0165 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0165 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0170 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0170 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0170 The screening of everyday life chemicals in validated assays targeting the pituitary\u2013gonadal axis 1 Introduction 2 Materials and methods 2.1 Chemicals 2.2 In vitro Assessment 2.2.1 hERTa assay 2.2.2 H295R steroidogenesis assay 2.2.3 Leydig cell steroidogenesis assay 2.3 In Vivo Assessment 2.3.1 Animals and housing 2.3.2 Dose selection 2.3.3 Male pubertal study 2.3.4 Female pubertal study 2.4 Hormone measurements 2.5 Gene transcript measurements 2.5.1 Total RNA isolation 2.5.2 RT-qPCR analysis 2.6 Statistical analyses 3 Results 3.1 In vitro assessment 3.1.1 hER transcriptional activation assay (Fig. 2; Table 1) 3.1.2 H295R steroidogenesis assay (Figs. 2 and 3; Table 2) 3.1.3 Leydig cell steroidogenesis assay (Fig. 3) 3.2 In vivo assessment of caffeine 3.2.1 Male pubertal study 3.2.1.1 In-life parameters and organ weights (Fig. 4; Table 3a) 3.2.1.2 Preputial separation (Table 3b) 3.2.1.3 Hormone measurements (Fig. 4c; Table 3a) 3.2.1.4 Gene transcript changes (Table 5a) 3.2.2 Female pubertal study 3.2.2.1 In-life parameters and organ weights (Table 4a) 3.2.2.2 Vaginal opening and estrus cyclicity (Fig. 5; Table 4b and c) 3.2.2.3 Hormone measurements (Table 4a) 3.2.2.4 Gene transcript changes (Table 5b) 4 Discussion Funding information Conflict of interest statement Acknowledgments Appendix A Supplementary data References", "Funding": "Our ELC database, although at present small, is nonetheless a pertinent contribution to the intense deliberations concerning endocrine disruption, its causal agents and their regulation for three main reasons. First, it infers that the range of chemicals that can interfere with and as a consequence potentially cause adverse effects on the endocrine system may be more significant in terms of numbers and diversity than first imagined. Second, at present the focus is the elimination or further regulation of synthetic chemicals but our data highlight an as yet unexplored source of unregulated substances that may also have endocrine disrupting properties, which must be investigated if we are to fully under- stand the relative contribution of all causal agents to the putative endocrine disorders in man (and wildlife). Third, as discussed by Bars et al. (2011, 2012 and as highlighted by the data for caffeine, other factors, such as potency, severity of adverse effects and margin of exposure, need to be considered before deciding whether a substance(natural or man-made) merits regulatory intervention. Funding information This work was partly funded by the BioIntelligence Consortium, France. Conflict of interest statement The authors declare that there are no conflicts of interest. Acknowledgments The authors would like to thank B\u00e9n\u00e9dicte Labory, Daisy Ces- pedes and Dominique Debarbeyrac for technical expertise and Da- vid Rouqui\u00e9 for useful discussions. Appendix A. Supplementary data Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.yrtph.2013.04. 002. References Ashby, J., Tinwell, H., 1998. Oestrogenic activity of burgen bread to female rats. Hum. Exp. Toxicol. 17, 598\u2013599. Bars, R., Broeckaert, F., Fegert, I., Gross, M., Hallmark, N., Kedwards, T., Lewis, D., O\u2019Hagan, S., Panter, G.H., Weltje, L., Weyers, A., Wheeler, J.R., Galay-Burgos, M., 2011. Science based guidance for the assessment of endocrine disrupting properties of chemicals. Regul. Toxicol. Pharmacol. 59 (1), 37\u201346Bars, R., Broeckaert, F., Fegert, I., Gross, M., Hallmark, N., Kedwards, T., Lewis, D., O\u2019Hagan, S., Panter, G.H., Weltje, L., Weyers, A., Wheeler, J.R., Galay-Burgos, M., . Science based guidance for the assessment of endocrine disrupting properties of chemicals. Regul. Toxicol. Pharmacol. 60 (3), 411\u2013412. Bars, R., Fegert, I., Gross, M., Lewis, D., Weltje, L., Weyers, A., Wheeler, J.R., Galay- Burgos, M., 2012. Risk assessment of endocrine active chemicals: identifying chemicals of regulatory concern. Regul. Toxicol. Pharmacol. 64 (1), 143\u2013154. Behr, M., Oehlmannn, J., Wagner, M., 2011. Estrogens in the daily diet: In vitro analysis indicates that estrogenic activity is omnipresent in foodstuff and infant formula. Food Chem. Toxicol. 49, 2681\u20132688. BfR (Bundesinstitut f\u00fcr Risikobewertung), 2011. Final Joint DE-UK position. Regulatory definition of an endocrine disrupter in relation to potential threat to human health. Available at: <http://www.bfr.bund.de/cm/349/regulatory_ definition_of_an_endocrine_disrupter_in_relation_to_potential_threat_to_ human_health.pdf>. Christiansen, S., Kortenkamp, A., Axelstad, M., Boberg, J., Scholze, M., Jacobsen, P.R., Faust, M., Lichtensteiger, W., Schlumpf, M., Burdorf, A., Hass, U., 2012. Mixtures of endocrine disrupting contaminants modelled on human high end exposures: an exploratory study in rats. Int. J. Androl. 35, 303\u2013316. COT statement on the reproductive effects of caffeine, 2001. Available at <http:// www.food.gov.uk/science/ouradvisors/toxicity/statements/cotstatements2001/ caffeine>. EC, 2006. Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18th December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 000/21/EC. Official J. Europ. Union L396/1. EC, 2009a. Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placing of plant protection products on the market and repealing Council Directives 79/117/EEC and 91/414/EEC. Official J. Europ. Commun. L 309/1. EC, 2009b. Regulation (COM 2009/267) of the European Parliament and of the Council of 12th June 2009 replacing Directive 98/8/EC concerning the placing of biocidal products on the market. Official J. Europ. Commun. L276. EU, 2010. The Directive 2010/63/EU of the European Parliament and the Council of 22 September 2010 on the protection of animals used for scientific purposes. Official Journal of the European Community, L276/34. Ezzat, A.R., el-Gohary, Z.M., 1994. Hormonal and histological effects of chronic caffeine administration on the pituitary\u2013gonadal and pituitary-adrenocortical axes in male rabbits. Funct. Dev. Morphol. 4, 45\u201350. Fernandes, G.S., Fernandez, C.D., Campos, K.E., Damasceno, D.C., Anselmo-Franci, J.A., Kempinas, W.D., 2011. Vitamin C partially attenuates male reproductive deficits in hyperglycemic rats. Reprod. Biol. Endocrinol. 9, 100. Flynn, D.L., Rafferty, M.F., Boctor, A.M., 1986. Inhibition of human neutrophil 5- lipoxygenase activity by gingerdione, shogaol, capsaicin and related pungent compounds. Prostaglandins Leukot Med. 24, 195\u2013198. http://dx.doi.org/10.1016/j.yrtph.2013.04.002 http://dx.doi.org/10.1016/j.yrtph.2013.04.002 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0005 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0005 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0175 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0175 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0175 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0180 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0180 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0180 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0180 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0180 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0010 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0010 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0010 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0015 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0015 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0015 http://www.bfr.bund.de/cm/349/regulatory_definition_of_an_endocrine_disrupter_in_relation_to_potential_threat_to_human_health.pdf http://www.bfr.bund.de/cm/349/regulatory_definition_of_an_endocrine_disrupter_in_relation_to_potential_threat_to_human_health.pdf http://www.bfr.bund.de/cm/349/regulatory_definition_of_an_endocrine_disrupter_in_relation_to_potential_threat_to_human_health.pdf http://refhub.elsevier.com/S0273-2300(13)00054-8/h0020 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0020 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0020 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0020 http://www.food.gov.uk/science/ouradvisors/toxicity/statements/cotstatements2001/caffeine http://www.food.gov.uk/science/ouradvisors/toxicity/statements/cotstatements2001/caffeine http://www.food.gov.uk/science/ouradvisors/toxicity/statements/cotstatements2001/caffeine http://refhub.elsevier.com/S0273-2300(13)00054-8/h0025 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0025 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0025 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0030 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0030 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0030 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0035 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0035 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0035 196 H. Tinwell et al. / Regulatory Toxicology and Pharmacology 66 (2013) 184\u2013196 Friedman, L., Weinberger, M.A., Farber, T.M., Moreland, F.M., Peters, E.L., Gilmore, C.E., Khan, M.A., 1979. Testicular atrophy and impaired spermatogenesis in rats fed high levels of the methylxanthines caffeine, theobromine, or theophylline. J. Environ. Pathol. Toxicol. 2, 687\u2013706. Frye, C.A., Bo, E., Calamandrei, G., Calza, L., Dess\u0131\u2018-Fulgheri, F., Fernandez, M., Fusani, L., Kah, O., Kajta, M., Le Page, Y., Patisaul, H.B., Venerosi, A., Wojtowicz, A.K., Panzica, G.C., 2011. Endocrine disrupters: a review of some sources, effects, and mechanisms of actions on behaviour and neuroendocrine systems. J. Neuroendocrinol. 24, 144\u2013159. Gupta, C., 1989. The role of prostaglandins in masculine differentiation: modulation of prostaglandin levels in the differentiating genital tract of the fetal mouse. Endocrinology 124, 129\u2013133. Gupta, C., Goldman, A.S., 1986. The arachidonic acid cascade is involved in the masculinizing action of testosterone on embryonic external genitalia in mice. Proc. Natl. Acad. Sci. USA 83, 4346\u20134349. Jefferson, W.N., Patisaul, H.B., Williams, C.J., 2012. Reproductive consequences of developmental phytoestrogen exposure. Reproduction 143, 247\u2013260. Kamtchouing, P., Mbongue Fandio, G.Y., Dimo, T., Jatsa, H.B., 2002. Evaluation of androgenic activity of Zingiber officinale and Pentadiplandra brazzeana in male rats. Asian J. Androl. 4, 299\u2013301. Khaki, A., Fathiazad, F., Nouri, M., Khaki, A.A., Ozanci, C.C., Ghafari-Novin, M., Hamadeh, M., 2009. The effects of ginger on spermatogenesis and sperm parameters of rat. Iranian J. Reproduct. Med. 7, 7\u201312. Kim, P., Park, Y., Ji, K., Seo, J., Lee, S., Choi, K., Kho, Y., Park, J., Choi, K., 2012. Effect of chronic exposure to acetaminophen and lincomycin on Japanese medaka (Oryzias latipes) and freshwater cladocerans Daphnia magna and Moina macrocopa, and potential mechanisms of endocrine disruption. Chemosphere 89, 10\u201318. Kiuchi, F., Shibuya, M., Sankawa, U., 1982. Inhibitors of prostaglandin biosynthesis from ginger. Chem. Pharm. Bull. 30, 754\u2013757. Kiuchi, F., Iwakami, S., Shibuya, M., Hanaoka, F., Sakawa, U., 1992. Inhibition of prostaglandin and leukotriene biosynthesis by gingerols and diarylheptanoids. Chem. Pharm. Bull. 40, 387\u2013391. Kristensen, D.M., Skalkam, M.L., Audouze, K., Lesn\u00e9, L., Desdoits-Lethimonier, C., Frederiksen, H., Brunak, S., Skakkeb\u00e6k, N.E., J\u00e9gou, B., Hansen, J.B., Junker, S., Leffers, H., 2011. Many putative endocrine disruptors inhibit prostaglandin synthesis. Environ. Health Perspect. 119 (4), 534\u2013541. Kristensen, D.M., Lesn\u00e9, L., Le Fol, V., Desdoits-Lethimonier, C., Dejucq-Rainsford, N., Leffers, H., J\u00e9gou, B., 2012. Paracetamol (acetaminophen), aspirin (acetylsalicylic acid) and indomethacin are anti-androgenic in the rat foetal testis. Int. J. Androl. 35, 377\u2013384. Ludwig, S., Tinwell, H., Rouqui\u00e9, D., Schorsch, F., Pallardy, M., Bars, R., 2012. Potential new targets involved in 1,3-dinitrobenzene induced testicular toxicity. Toxicol. Lett. 213, 275\u2013284. National Research Council, 2011. The Guide for the Care and Use of Laboratory Animals (8th edition) for the Institute for Laboratory Animal Research (ILAR) by the National Research Council of the National Academies Washington D.C., National Academies Press. Ndebele, K., Graham, B., Tchounwou, P.B., 2010. Estrogenic Activity of Coumestrol, DDT, and TCDD in Human Cervical Cancer Cells. Int. J. Environ. Res. Public Health 7, 2045\u20132056. Nielsen, T.S., N\u00f8rgaard, J.V., Purup, S., Frett\u00e9, X.C., Bonefeld-J\u00f8rgensen, E.C., 2009. Estrogenic activity of bovine milk high or low in equol using immature mouse uterotrophic responses and an estrogen receptor transactivation assay. Cancer Epidemiol. 33, 61\u201368. Pollard, I., Williamson, S., Magre, S., 1990. Influence of caffeine administered during pregnancy on the early differentiation of fetal rat ovaries and testes. J. Dev. Physiol. 13, 59\u201365. Sakamoto, T., Horiguchi, H., Oguma, E., Kayama, F., 2010. Effects of diverse dietary phytoestrogens on cell growth, cell cycle and apoptosis in estrogen-receptor- positive breast cancer cells. J. Nutr. Biochem. 21, 856\u2013864. Sanderson, J.T., Hordijk, J., Denison, M.S., Springsteel, M.F., Nantz, M.H., Van den Berg, M., 2004. Induction and inhibition of aromatase (Cyp 19) activity by natural and synthetic flavonoid compounds in H295R human adrenocortical carcinoma cells. Toxicol. Sci. 82, 70\u201379. S\u00f6nmez, M., T\u00fcrk, G., Y\u00fcce, A., 2005. The effect of ascorbic acid supplementation on sperm quality, lipid peroxidation and testosterone levels of male Wistar rats. Theriogenology. 63, 2063\u20132072. Sotoca, A.M., Ratman, D., van der Saag, P., Strom, A., Gustafsson, J.A., Vervoot, J., Rietjens, I.M., Murk, A.J., 2008. Phytoestrogen-mediated inhibition of proliferation of the human T47D breast cancer cells depends on the ERalpha/ ERbeta ratio. J. Steroid Biochem. Mol. Biol. 112, 171\u2013178. Taxvig, C., Elleby, A., Sonne-Hansen, K., Bonefeld-J\u00f8rgensen, E.C., Vinggaard, A.M., Lykkesfeldt, A.E., Nellemann, C., 2010. Effects of nutrition relevant mixtures of phytoestrogens on steroidogenesis, aromatase, estrogen, and androgen activity. Nutr. Cancer 62, 122\u2013131. US-EPA, OPPTS Series 890, 2009. Endocrine disruptor screening program test guidelines, no. 890.1550: steroidogenesis (Human Cell Line \u2013 H295R) (October 2009). US-EPA OPPTS Series 890, 2009a. Endocrine Disruptor Screening Program Test Guidelines, No. 890.1300: Estrogen Receptor Transcriptional Activation (Human Cell Line (HeLa-9903)) (October 2009). US-EPA OPPTS Series 890, 2009b. Endocrine Disruptor Screening Program Test Guidelines, No. 890.1450: pubertal development and thyroid function in intact juvenile/peripubertal female rats (October 2009). US-EPA OPPTS Series 890, 2009c. Endocrine Disruptor Screening Program Test Guidelines, 890.1500: pubertal development and thyroid function in intact juvenile/peripubertal male rats (October 2009). VanderPloeg, L.C., Wolfrom, D.M., Rao, A.R., Braselton, W.E., Welsch, C.W., 1992. Caffeine, theophylline, theobromine, and developmental growth of the mouse mammary gland. J. Environ. Pathol. Toxicol. Oncol. 11 (3), 177\u2013189. Wagner, M., Oehlmann, J., 2011. Endocrine disruptors in bottled mineral water estrogenic activity in the E-Screen. J. Steroid Biochem. Mol. Biol. 127, 128\u2013135. Welsch, C.W., DeHoog, J.V., O\u2019Connor, D.H., 1988. Influence of caffeine consumption on carcinomatous and normal mammary gland development in mice. Cancer Res. 48 (8), 2078\u20132082. West, G.L., Sobotka, T.J., Brodie, R.E., Beier, J.M., O\u2019Donnell Jr., M.W., 1986. Postnatal neurobehavioral development in rats exposed in utero to caffeine. Neurobehav. Toxicol. Teratol. 8, 29\u201343. Yamagami, T., Handa, H., Takeuchi, J., Munemitsu, H., Aoki, M., Kato, Y., 1983. Rat pituitary adenoma and hyperplasia induced by caffeine administration. Surg. Neurol. 20, 323\u2013331. http://refhub.elsevier.com/S0273-2300(13)00054-8/h0045 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0045 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0045 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0045 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0040 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0040 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0040 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0040 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0040 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0040 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0060 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0060 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0060 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0055 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0055 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0055 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0065 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0065 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0070 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0070 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0070 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0075 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0075 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0075 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0080 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0080 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0080 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0080 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0080 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0090 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0090 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0085 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0085 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0085 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0095 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0095 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0095 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0095 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0100 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0100 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0100 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0100 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0105 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0105 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0105 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0115 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0115 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0115 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0110 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0110 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0110 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0110 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0120 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0120 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0120 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0125 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0125 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0125 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0130 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0130 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0130 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0130 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0140 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0140 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0140 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0135 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0135 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0135 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0135 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0145 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0145 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0145 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0145 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0150 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0150 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0150 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0155 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0155 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0160 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0160 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0160 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0165 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0165 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0165 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0170 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0170 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0170 The screening of everyday life chemicals in validated assays targeting the pituitary\u2013gonadal axis 1 Introduction 2 Materials and methods 2.1 Chemicals 2.2 In vitro Assessment 2.2.1 hERTa assay 2.2.2 H295R steroidogenesis assay 2.2.3 Leydig cell steroidogenesis assay 2.3 In Vivo Assessment 2.3.1 Animals and housing 2.3.2 Dose selection 2.3.3 Male pubertal study 2.3.4 Female pubertal study 2.4 Hormone measurements 2.5 Gene transcript measurements 2.5.1 Total RNA isolation 2.5.2 RT-qPCR analysis 2.6 Statistical analyses 3 Results 3.1 In vitro assessment 3.1.1 hER transcriptional activation assay (Fig. 2; Table 1) 3.1.2 H295R steroidogenesis assay (Figs. 2 and 3; Table 2) 3.1.3 Leydig cell steroidogenesis assay (Fig. 3) 3.2 In vivo assessment of caffeine 3.2.1 Male pubertal study 3.2.1.1 In-life parameters and organ weights (Fig. 4; Table 3a) 3.2.1.2 Preputial separation (Table 3b) 3.2.1.3 Hormone measurements (Fig. 4c; Table 3a) 3.2.1.4 Gene transcript changes (Table 5a) 3.2.2 Female pubertal study 3.2.2.1 In-life parameters and organ weights (Table 4a) 3.2.2.2 Vaginal opening and estrus cyclicity (Fig. 5; Table 4b and c) 3.2.2.3 Hormone measurements (Table 4a) 3.2.2.4 Gene transcript changes (Table 5b) 4 Discussion Funding information Conflict of interest statement Acknowledgments Appendix A Supplementary data References", "Acknowledgement": "Our ELC database, although at present small, is nonetheless a pertinent contribution to the intense deliberations concerning endocrine disruption, its causal agents and their regulation for three main reasons. First, it infers that the range of chemicals that can interfere with and as a consequence potentially cause adverse effects on the endocrine system may be more significant in terms of numbers and diversity than first imagined. Second, at present the focus is the elimination or further regulation of synthetic chemicals but our data highlight an as yet unexplored source of unregulated substances that may also have endocrine disrupting properties, which must be investigated if we are to fully under- stand the relative contribution of all causal agents to the putative endocrine disorders in man (and wildlife). Third, as discussed by Bars et al. (2011, 2012 and as highlighted by the data for caffeine, other factors, such as potency, severity of adverse effects and margin of exposure, need to be considered before deciding whether a substance(natural or man-made) merits regulatory intervention. Funding information This work was partly funded by the BioIntelligence Consortium, France. Conflict of interest statement The authors declare that there are no conflicts of interest. Acknowledgments The authors would like to thank B\u00e9n\u00e9dicte Labory, Daisy Ces- pedes and Dominique Debarbeyrac for technical expertise and Da- vid Rouqui\u00e9 for useful discussions. Appendix A. Supplementary data Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.yrtph.2013.04. 002. References Ashby, J., Tinwell, H., 1998. Oestrogenic activity of burgen bread to female rats. Hum. Exp. Toxicol. 17, 598\u2013599. Bars, R., Broeckaert, F., Fegert, I., Gross, M., Hallmark, N., Kedwards, T., Lewis, D., O\u2019Hagan, S., Panter, G.H., Weltje, L., Weyers, A., Wheeler, J.R., Galay-Burgos, M., 2011. Science based guidance for the assessment of endocrine disrupting properties of chemicals. Regul. Toxicol. Pharmacol. 59 (1), 37\u201346Bars, R., Broeckaert, F., Fegert, I., Gross, M., Hallmark, N., Kedwards, T., Lewis, D., O\u2019Hagan, S., Panter, G.H., Weltje, L., Weyers, A., Wheeler, J.R., Galay-Burgos, M., . Science based guidance for the assessment of endocrine disrupting properties of chemicals. Regul. Toxicol. Pharmacol. 60 (3), 411\u2013412. Bars, R., Fegert, I., Gross, M., Lewis, D., Weltje, L., Weyers, A., Wheeler, J.R., Galay- Burgos, M., 2012. Risk assessment of endocrine active chemicals: identifying chemicals of regulatory concern. Regul. Toxicol. Pharmacol. 64 (1), 143\u2013154. Behr, M., Oehlmannn, J., Wagner, M., 2011. Estrogens in the daily diet: In vitro analysis indicates that estrogenic activity is omnipresent in foodstuff and infant formula. Food Chem. Toxicol. 49, 2681\u20132688. BfR (Bundesinstitut f\u00fcr Risikobewertung), 2011. Final Joint DE-UK position. Regulatory definition of an endocrine disrupter in relation to potential threat to human health. Available at: <http://www.bfr.bund.de/cm/349/regulatory_ definition_of_an_endocrine_disrupter_in_relation_to_potential_threat_to_ human_health.pdf>. Christiansen, S., Kortenkamp, A., Axelstad, M., Boberg, J., Scholze, M., Jacobsen, P.R., Faust, M., Lichtensteiger, W., Schlumpf, M., Burdorf, A., Hass, U., 2012. Mixtures of endocrine disrupting contaminants modelled on human high end exposures: an exploratory study in rats. Int. J. Androl. 35, 303\u2013316. COT statement on the reproductive effects of caffeine, 2001. Available at <http:// www.food.gov.uk/science/ouradvisors/toxicity/statements/cotstatements2001/ caffeine>. EC, 2006. Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18th December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 000/21/EC. Official J. Europ. Union L396/1. EC, 2009a. Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placing of plant protection products on the market and repealing Council Directives 79/117/EEC and 91/414/EEC. Official J. Europ. Commun. L 309/1. EC, 2009b. Regulation (COM 2009/267) of the European Parliament and of the Council of 12th June 2009 replacing Directive 98/8/EC concerning the placing of biocidal products on the market. Official J. Europ. Commun. L276. EU, 2010. The Directive 2010/63/EU of the European Parliament and the Council of 22 September 2010 on the protection of animals used for scientific purposes. Official Journal of the European Community, L276/34. Ezzat, A.R., el-Gohary, Z.M., 1994. Hormonal and histological effects of chronic caffeine administration on the pituitary\u2013gonadal and pituitary-adrenocortical axes in male rabbits. Funct. Dev. Morphol. 4, 45\u201350. Fernandes, G.S., Fernandez, C.D., Campos, K.E., Damasceno, D.C., Anselmo-Franci, J.A., Kempinas, W.D., 2011. Vitamin C partially attenuates male reproductive deficits in hyperglycemic rats. Reprod. Biol. Endocrinol. 9, 100. Flynn, D.L., Rafferty, M.F., Boctor, A.M., 1986. Inhibition of human neutrophil 5- lipoxygenase activity by gingerdione, shogaol, capsaicin and related pungent compounds. Prostaglandins Leukot Med. 24, 195\u2013198. http://dx.doi.org/10.1016/j.yrtph.2013.04.002 http://dx.doi.org/10.1016/j.yrtph.2013.04.002 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0005 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0005 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0175 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0175 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0175 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0180 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0180 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0180 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0180 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0180 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0010 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0010 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0010 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0015 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0015 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0015 http://www.bfr.bund.de/cm/349/regulatory_definition_of_an_endocrine_disrupter_in_relation_to_potential_threat_to_human_health.pdf http://www.bfr.bund.de/cm/349/regulatory_definition_of_an_endocrine_disrupter_in_relation_to_potential_threat_to_human_health.pdf http://www.bfr.bund.de/cm/349/regulatory_definition_of_an_endocrine_disrupter_in_relation_to_potential_threat_to_human_health.pdf http://refhub.elsevier.com/S0273-2300(13)00054-8/h0020 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0020 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0020 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0020 http://www.food.gov.uk/science/ouradvisors/toxicity/statements/cotstatements2001/caffeine http://www.food.gov.uk/science/ouradvisors/toxicity/statements/cotstatements2001/caffeine http://www.food.gov.uk/science/ouradvisors/toxicity/statements/cotstatements2001/caffeine http://refhub.elsevier.com/S0273-2300(13)00054-8/h0025 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0025 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0025 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0030 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0030 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0030 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0035 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0035 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0035 196 H. Tinwell et al. / Regulatory Toxicology and Pharmacology 66 (2013) 184\u2013196 Friedman, L., Weinberger, M.A., Farber, T.M., Moreland, F.M., Peters, E.L., Gilmore, C.E., Khan, M.A., 1979. Testicular atrophy and impaired spermatogenesis in rats fed high levels of the methylxanthines caffeine, theobromine, or theophylline. J. Environ. Pathol. Toxicol. 2, 687\u2013706. Frye, C.A., Bo, E., Calamandrei, G., Calza, L., Dess\u0131\u2018-Fulgheri, F., Fernandez, M., Fusani, L., Kah, O., Kajta, M., Le Page, Y., Patisaul, H.B., Venerosi, A., Wojtowicz, A.K., Panzica, G.C., 2011. Endocrine disrupters: a review of some sources, effects, and mechanisms of actions on behaviour and neuroendocrine systems. J. Neuroendocrinol. 24, 144\u2013159. Gupta, C., 1989. The role of prostaglandins in masculine differentiation: modulation of prostaglandin levels in the differentiating genital tract of the fetal mouse. Endocrinology 124, 129\u2013133. Gupta, C., Goldman, A.S., 1986. The arachidonic acid cascade is involved in the masculinizing action of testosterone on embryonic external genitalia in mice. Proc. Natl. Acad. Sci. USA 83, 4346\u20134349. Jefferson, W.N., Patisaul, H.B., Williams, C.J., 2012. Reproductive consequences of developmental phytoestrogen exposure. Reproduction 143, 247\u2013260. Kamtchouing, P., Mbongue Fandio, G.Y., Dimo, T., Jatsa, H.B., 2002. Evaluation of androgenic activity of Zingiber officinale and Pentadiplandra brazzeana in male rats. Asian J. Androl. 4, 299\u2013301. Khaki, A., Fathiazad, F., Nouri, M., Khaki, A.A., Ozanci, C.C., Ghafari-Novin, M., Hamadeh, M., 2009. The effects of ginger on spermatogenesis and sperm parameters of rat. Iranian J. Reproduct. Med. 7, 7\u201312. Kim, P., Park, Y., Ji, K., Seo, J., Lee, S., Choi, K., Kho, Y., Park, J., Choi, K., 2012. Effect of chronic exposure to acetaminophen and lincomycin on Japanese medaka (Oryzias latipes) and freshwater cladocerans Daphnia magna and Moina macrocopa, and potential mechanisms of endocrine disruption. Chemosphere 89, 10\u201318. Kiuchi, F., Shibuya, M., Sankawa, U., 1982. Inhibitors of prostaglandin biosynthesis from ginger. Chem. Pharm. Bull. 30, 754\u2013757. Kiuchi, F., Iwakami, S., Shibuya, M., Hanaoka, F., Sakawa, U., 1992. Inhibition of prostaglandin and leukotriene biosynthesis by gingerols and diarylheptanoids. Chem. Pharm. Bull. 40, 387\u2013391. Kristensen, D.M., Skalkam, M.L., Audouze, K., Lesn\u00e9, L., Desdoits-Lethimonier, C., Frederiksen, H., Brunak, S., Skakkeb\u00e6k, N.E., J\u00e9gou, B., Hansen, J.B., Junker, S., Leffers, H., 2011. Many putative endocrine disruptors inhibit prostaglandin synthesis. Environ. Health Perspect. 119 (4), 534\u2013541. Kristensen, D.M., Lesn\u00e9, L., Le Fol, V., Desdoits-Lethimonier, C., Dejucq-Rainsford, N., Leffers, H., J\u00e9gou, B., 2012. Paracetamol (acetaminophen), aspirin (acetylsalicylic acid) and indomethacin are anti-androgenic in the rat foetal testis. Int. J. Androl. 35, 377\u2013384. Ludwig, S., Tinwell, H., Rouqui\u00e9, D., Schorsch, F., Pallardy, M., Bars, R., 2012. Potential new targets involved in 1,3-dinitrobenzene induced testicular toxicity. Toxicol. Lett. 213, 275\u2013284. National Research Council, 2011. The Guide for the Care and Use of Laboratory Animals (8th edition) for the Institute for Laboratory Animal Research (ILAR) by the National Research Council of the National Academies Washington D.C., National Academies Press. Ndebele, K., Graham, B., Tchounwou, P.B., 2010. Estrogenic Activity of Coumestrol, DDT, and TCDD in Human Cervical Cancer Cells. Int. J. Environ. Res. Public Health 7, 2045\u20132056. Nielsen, T.S., N\u00f8rgaard, J.V., Purup, S., Frett\u00e9, X.C., Bonefeld-J\u00f8rgensen, E.C., 2009. Estrogenic activity of bovine milk high or low in equol using immature mouse uterotrophic responses and an estrogen receptor transactivation assay. Cancer Epidemiol. 33, 61\u201368. Pollard, I., Williamson, S., Magre, S., 1990. Influence of caffeine administered during pregnancy on the early differentiation of fetal rat ovaries and testes. J. Dev. Physiol. 13, 59\u201365. Sakamoto, T., Horiguchi, H., Oguma, E., Kayama, F., 2010. Effects of diverse dietary phytoestrogens on cell growth, cell cycle and apoptosis in estrogen-receptor- positive breast cancer cells. J. Nutr. Biochem. 21, 856\u2013864. Sanderson, J.T., Hordijk, J., Denison, M.S., Springsteel, M.F., Nantz, M.H., Van den Berg, M., 2004. Induction and inhibition of aromatase (Cyp 19) activity by natural and synthetic flavonoid compounds in H295R human adrenocortical carcinoma cells. Toxicol. Sci. 82, 70\u201379. S\u00f6nmez, M., T\u00fcrk, G., Y\u00fcce, A., 2005. The effect of ascorbic acid supplementation on sperm quality, lipid peroxidation and testosterone levels of male Wistar rats. Theriogenology. 63, 2063\u20132072. Sotoca, A.M., Ratman, D., van der Saag, P., Strom, A., Gustafsson, J.A., Vervoot, J., Rietjens, I.M., Murk, A.J., 2008. Phytoestrogen-mediated inhibition of proliferation of the human T47D breast cancer cells depends on the ERalpha/ ERbeta ratio. J. Steroid Biochem. Mol. Biol. 112, 171\u2013178. Taxvig, C., Elleby, A., Sonne-Hansen, K., Bonefeld-J\u00f8rgensen, E.C., Vinggaard, A.M., Lykkesfeldt, A.E., Nellemann, C., 2010. Effects of nutrition relevant mixtures of phytoestrogens on steroidogenesis, aromatase, estrogen, and androgen activity. Nutr. Cancer 62, 122\u2013131. US-EPA, OPPTS Series 890, 2009. Endocrine disruptor screening program test guidelines, no. 890.1550: steroidogenesis (Human Cell Line \u2013 H295R) (October 2009). US-EPA OPPTS Series 890, 2009a. Endocrine Disruptor Screening Program Test Guidelines, No. 890.1300: Estrogen Receptor Transcriptional Activation (Human Cell Line (HeLa-9903)) (October 2009). US-EPA OPPTS Series 890, 2009b. Endocrine Disruptor Screening Program Test Guidelines, No. 890.1450: pubertal development and thyroid function in intact juvenile/peripubertal female rats (October 2009). US-EPA OPPTS Series 890, 2009c. Endocrine Disruptor Screening Program Test Guidelines, 890.1500: pubertal development and thyroid function in intact juvenile/peripubertal male rats (October 2009). VanderPloeg, L.C., Wolfrom, D.M., Rao, A.R., Braselton, W.E., Welsch, C.W., 1992. Caffeine, theophylline, theobromine, and developmental growth of the mouse mammary gland. J. Environ. Pathol. Toxicol. Oncol. 11 (3), 177\u2013189. Wagner, M., Oehlmann, J., 2011. Endocrine disruptors in bottled mineral water estrogenic activity in the E-Screen. J. Steroid Biochem. Mol. Biol. 127, 128\u2013135. Welsch, C.W., DeHoog, J.V., O\u2019Connor, D.H., 1988. Influence of caffeine consumption on carcinomatous and normal mammary gland development in mice. Cancer Res. 48 (8), 2078\u20132082. West, G.L., Sobotka, T.J., Brodie, R.E., Beier, J.M., O\u2019Donnell Jr., M.W., 1986. Postnatal neurobehavioral development in rats exposed in utero to caffeine. Neurobehav. Toxicol. Teratol. 8, 29\u201343. Yamagami, T., Handa, H., Takeuchi, J., Munemitsu, H., Aoki, M., Kato, Y., 1983. Rat pituitary adenoma and hyperplasia induced by caffeine administration. Surg. Neurol. 20, 323\u2013331. http://refhub.elsevier.com/S0273-2300(13)00054-8/h0045 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0045 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0045 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0045 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0040 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0040 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0040 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0040 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0040 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0040 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0060 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0060 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0060 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0055 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0055 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0055 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0065 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0065 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0070 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0070 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0070 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0075 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0075 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0075 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0080 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0080 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0080 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0080 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0080 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0090 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0090 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0085 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0085 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0085 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0095 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0095 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0095 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0095 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0100 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0100 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0100 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0100 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0105 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0105 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0105 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0115 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0115 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0115 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0110 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0110 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0110 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0110 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0120 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0120 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0120 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0125 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0125 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0125 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0130 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0130 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0130 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0130 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0140 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0140 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0140 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0135 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0135 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0135 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0135 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0145 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0145 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0145 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0145 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0150 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0150 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0150 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0155 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0155 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0160 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0160 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0160 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0165 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0165 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0165 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0170 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0170 http://refhub.elsevier.com/S0273-2300(13)00054-8/h0170 The screening of everyday life chemicals in validated assays targeting the pituitary\u2013gonadal axis 1 Introduction 2 Materials and methods 2.1 Chemicals 2.2 In vitro Assessment 2.2.1 hERTa assay 2.2.2 H295R steroidogenesis assay 2.2.3 Leydig cell steroidogenesis assay 2.3 In Vivo Assessment 2.3.1 Animals and housing 2.3.2 Dose selection 2.3.3 Male pubertal study 2.3.4 Female pubertal study 2.4 Hormone measurements 2.5 Gene transcript measurements 2.5.1 Total RNA isolation 2.5.2 RT-qPCR analysis 2.6 Statistical analyses 3 Results 3.1 In vitro assessment 3.1.1 hER transcriptional activation assay (Fig. 2; Table 1) 3.1.2 H295R steroidogenesis assay (Figs. 2 and 3; Table 2) 3.1.3 Leydig cell steroidogenesis assay (Fig. 3) 3.2 In vivo assessment of caffeine 3.2.1 Male pubertal study 3.2.1.1 In-life parameters and organ weights (Fig. 4; Table 3a) 3.2.1.2 Preputial separation (Table 3b) 3.2.1.3 Hormone measurements (Fig. 4c; Table 3a) 3.2.1.4 Gene transcript changes (Table 5a) 3.2.2 Female pubertal study 3.2.2.1 In-life parameters and organ weights (Table 4a) 3.2.2.2 Vaginal opening and estrus cyclicity (Fig. 5; Table 4b and c) 3.2.2.3 Hormone measurements (Table 4a) 3.2.2.4 Gene transcript changes (Table 5b) 4 Discussion Funding information Conflict of interest statement Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-search-for-asbestos-within-the-Peter-Mitchell-T_2008_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18060674", "content": {"CoiStatement": "Conflict of Interest The authors declare that they have no conflicts of interest. The authors declare that they have no conflicts of interest. Fig. 11. SEM X-ray spectra analysis of ferroactinolite taken in area X of Fig. 10 and of grunerite/ferrian sepiolite taken in area Y of Fig. 10. Conclusions Conflict of Interest Acknowledgments References", "Acknowledgement": "S50 M. Ross et al. / Regulatory Toxicology and Pharmacology 52 (2008) S43\u2013S50 Acknowledgments We thank Dr. Ronald G. Graber, Dennis M. Wagner and Dennis Wagner for their help with the geological sur- vey. We acknowledge support from a Higher Education Advance Technology grant from New York State and the International Environmental Research Foundation (www.ierfinc.org) of New York, New York and assistance from Cleveland-Cliffs, Cleveland, Ohio. Conclusions Conflict of Interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-selective-determination-of-potentially-carcinogenic-poly_2019_Regulatory.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31103638", "content": {"CoiStatement": "Conflicts of interest The authors work for companies or associations of the oil industry that manufacture or market mineral oil related products. Writing of scientific publications is part of their regular job. Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: The authors work for industry associations or oil companies that manufacture mineral oils and related materials referenced in this pub- lication. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: The authors work for industry associations or oil companies that manufacture mineral oils and related materials referenced in this pub- lication. The authors have not received any funding or material compensa- tion for writing this paper. The time devoted to produce the manuscript is part of their day to day job activities. Correlation of DMSO extractible fraction with the mouse skin painting assay Applicability of the IP346 and regulatory status in Europe Discussion Conflicts of interest Declaration of interests Acknowledgments Transparency document References", "Funding": "The authors have not received any funding or material compensa- tion for writing this paper. The time devoted to produce the manuscript is part of their day to day job activities. Den Haag, 30 April 2018.", "Acknowledgement": "Acknowledgments The original studies of the DMSO selectivity that lead to the estab- lishment of the IP346, were conducted at the Koninklijke Shell Laboratorium Amsterdam (KSLA) by the team of Arnold van der Wiel in 1979, who is acknowledged as the person behind this data. Correlation of DMSO extractible fraction with the mouse skin painting assay Applicability of the IP346 and regulatory status in Europe Discussion Conflicts of interest Declaration of interests Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-significance-of-the-subchronic-toxicity-in-th_2010_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20406660", "content": {"CoiStatement": "Conflict of interest statement The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. References Conclusions Conflict of interest statement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-simultaneous-analysis-of-discrete-and-continuous-_2007_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/17331631", "content": {"Acknowledgement": "Discussion Acknowledgments Appendix A Appendix B References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-stability-of-historical-control-data-for-common-neo_2004_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15546683", "content": {"Acknowledgement": "H. Tennekes et al. / Regulatory Toxicology and Pharmacology 40 (2004) 293\u2013304 303 and strains where they are well known to occur spon- taneously with a high incidence, with good evidence that this sensitivity cannot be extrapolated to man and the mechanism of experimental tumor formation does not involve genotoxicity and shows a clear no ob- served effect level. Acknowledgment This survey was financed by the Verband der Chemis- chen Industrie e.V. (Chemical Industry Association) of Germany, which is gratefully acknowledged by the authors. References Discussion Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-stability-of-historical-control-data-for-common-neopla_2004_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15265603", "content": {"Acknowledgement": "In conclusion, the results of this analysis indicate that indiscriminate use of historical control data is inappro- priate. Likewise, restricted use of historical control data is counterproductive when time-related trends are ab- sent. We propose that the use of historical control data should be based on organ- and strain-specific statistical analysis of tumor data over time. Acknowledgment This survey was financed by the Verband der Chem- ischen Industrie e.V. (Chemical Industry Association) of Germany, which is gratefully acknowledged by the authors. References Conclusions Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-state-of-adverse-event-reporting-and-signal-ge_2010_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20074608", "content": {"CoiStatement": "The authors declare that there are no conflicts of interest. Acknowledgments This work was funded by grants from KFDA (07061-109 and 08081-093). The authors are responsible for its content. The views expressed in this article are those of the authors and do not neces- sarily reflect the views or policies of the KFDA. References", "Acknowledgement": "The authors declare that there are no conflicts of interest. Acknowledgments This work was funded by grants from KFDA (07061-109 and 08081-093). The authors are responsible for its content. The views expressed in this article are those of the authors and do not neces- sarily reflect the views or policies of the KFDA. References Conclusion Conflict of statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-sub-chronic-oral-toxicity-of-1-3-5-trimethyl_2014_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24704044", "content": {"CoiStatement": "4 Discussion 5 Conclusion Conflict of interest Acknowledgments Appendix A.1 Provisional reference dose calculations for 1,3,5-trimethylbenzene (default uncertainty factor approach) Appendix A.2 General population derived no effect levels (DNEL) for 1,3,5-trimethylbenzene (ECETOC approach) Appendix A.3 Comparisons with other provisional reference dose calculations References", "Acknowledgement": "4 Discussion 5 Conclusion Conflict of interest Acknowledgments Appendix A.1 Provisional reference dose calculations for 1,3,5-trimethylbenzene (default uncertainty factor approach) Appendix A.2 General population derived no effect levels (DNEL) for 1,3,5-trimethylbenzene (ECETOC approach) Appendix A.3 Comparisons with other provisional reference dose calculations References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-sub-chronic-oral-toxicity-of-dearomatized-hydr_2014_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25455222", "content": {"CoiStatement": "Apart from its use in deriving regulatory safe limits, NOAEL or BMDL values are also used as a means of determining the potential for regulatory hazard classification. Under existing UN GHS guid- ance for hazard classification, chemical classification for Specific Target Organ Toxicity/Repeated Exposure (STOT/RE) are based on the significant health effects seen in a standard 90-day repeated dose toxicity study conducted in rats, similar to the study described herein. Two STOT/RE classification categories are avail- able; a category 1 classification is applied when significant toxic effects in a 90-day repeated-dose study are seen to occur at or below 10 mg/kg bw/day. On the other hand, a category 2 classifica- tion is applicable when significant toxic effects are seen to occur at doses between 10 and 100 mg/kg bw/day. In this study, the NOAEL value of 500 mg/kg bw/day was 5-fold higher than the upper limit for a category 2 STOT/RE classification. For the complex C11\u2013C14 mixed aliphatic solvent and the C11\u2013C15 isoalkanes, the NOAELs of 1000 mg/kg bw/day are 10-fold higher than the upper limit for a category 2 STOT/RE classification, indicating that with regard to repeated-dose oral exposure, a STOT/RE classification is not war- ranted for category 8 solvents in general. Conflict of interest statement The authors are employed by companies that manufacture dearomatized hydrocarbon solvents. This manuscript was written as part of their normal employment. The toxicological studies were funded by ExxonMobil Chemical Company, Houston, Texas. 4 C11\u2013C14. mixed aliphatic (dearomatized) solvent 5 C11\u2013C15 isoalkanes 6 Discussion 7 Conclusion Conflict of interest statement Acknowledgments Appendix A Supplementary data References", "Acknowledgement": "Acknowledgments The 90-day repeated oral toxicity test was conducted by the Tox- icology laboratory of Exxon Biomedical Sciences, Inc. (East Millstone, NJ). David Adenuga and Richard H Mckee were funded by the Hydrocarbon Solvents Panel of the American Chemistry Council which comprise of the ExxonMobil Chemical Company, Chevron Phillips Chemical Company LLC, CITGO Petroleum Corporation and Sasol North America Inc. Appendix A. Supplementary data 4 C11\u2013C14. mixed aliphatic (dearomatized) solvent 5 C11\u2013C15 isoalkanes 6 Discussion 7 Conclusion Conflict of interest statement Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-sub-chronic-toxicity-in-rats-of-isopara_2013_Regulatory-Toxicology-and-P.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24044944", "content": {"CoiStatement": "Conflict of interest statement The authors are employed by companies that manufacture hydrocarbon solvents or consultants paid by the companies for their assistance in preparing this publication. The studies and the cost of manuscript preparation were funded by the manufacturers of the substances tested. 5 Discussion 6 Conclusions Conflict of interest statement Acknowledgments References", "Acknowledgement": "Acknowledgments The 13 week inhalation toxicity study of the C10\u2013C12 isoparaf- finic solvent was conducted by D. Blair, D.G. Clark and S.T.G. But- terworth of the former Experimental Toxicology and Pathology Divisions of the Shell Toxicology Laboratory, Tunstall, U.K. 5 Discussion 6 Conclusions Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-sub-chronic-toxicity-of-a-naphthenic-hydr_2018_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29630908", "content": {"CoiStatement": "Conflicts of interest The authors are employed by companies that manufacture hydro- carbon solvents and/or petroleum substances that contain naphthenic hydrocarbons. This manuscript was written as part of their normal employment. Conclusions Conflicts of interest Acknowledgments Transparency document References", "Acknowledgement": "Acknowledgments The 13 week inhalation toxicity study of Naphthenic Solvent, C9- C11< 2% aromatics (TLER.79.143) was performed at the former Experimental Toxicology and Pathology Divisions of the Shell Toxicology Laboratory, Tunstall, U.K. Special thanks to Hans Turfboer at the Shell Technology Center Amsterdam for his historical and tech- nical knowledge about this sample and to Kim van Brie and Jill Ledder at Shell Health for their assistance in the manuscript preparation. Conclusions Conflicts of interest Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-sub-chronic-toxicity-of-regular-White-_2014_Regulatory-Toxicology-and-Ph.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25013991", "content": {"CoiStatement": "The data summarized herein provide evidence that repeated exposure of rats to regular White Spirit at levels of up to 7500 mg/m3, approximately the maximally attainable vapor con- centration for this substance, exhibited minimal systemic toxicity. The only clear systemic effect was a renal effect in male rats con- sistent with an a2u-globulin-mediated process which is not con- sidered relevant to humans. The NOAEC was 4000 mg/m3 based on reduced body weights at the highest exposure level. These data are supported by other inhalation toxicity studies in rats and other species in which the NOAECs ranged from approximately 1300 to 4000 mg/m3 and were the highest concentrations tested in each case. The only exception to this was one study in which it was found that guinea pigs were more sensitive than other species, but this was later found to have been due to the lack of sufficient levels of ascorbic acid in the diets of these animals. These results were also supported by similar findings in oral and dermal studies of kerosene and jet fuel which are compositionally similar to the solvent discussed in this study. Conflict of interest statement The authors are employed by companies that manufacture hydrocarbon solvents including White Spirit. The costs of the stud- ies and manuscript preparation were paid by the manufacturers of the substance tested. Manuscript preparation was part of the nor- mal job responsibilities of the authors. Acknowledgments 4 Discussion 5 Conclusions Conflict of interest statement Acknowledgments References", "Acknowledgement": "The authors are employed by companies that manufacture hydrocarbon solvents including White Spirit. The costs of the stud- ies and manuscript preparation were paid by the manufacturers of the substance tested. Manuscript preparation was part of the nor- mal job responsibilities of the authors. Acknowledgments The 13 week inhalation toxicity study of LAWS was conducted and originally reported as TLER.79.141 by D. Blair, D.G. Clark and S.L. Linnett, scientists at the former Experimental Toxicology and Pathology Divisions of the Shell Toxicology Laboratory, Tunstall, U.K. DA and Richard H Mckee were funded by the Hydrocarbon Solvents Panel of the American Chemistry Council, the members of which are ExxonMobil Chemical Company, Chevron Phillips Chemical Com- pany LLC, CITGO Petroleum Corporation and Sasol North America Inc. 4 Discussion 5 Conclusions Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-substitution-principle_2011_Regulatory-Toxicology-and-Pharmacology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21295097", "content": {"CoiStatement": "5. Conflict of Interest The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgments Legislative approaches Choosing how to promote substitution Conflict of Interest Acknowledgments References", "Acknowledgement": "Acknowledgments This work was performed within the ChEmiTecs (Organic Chemicals Emitted from Technosphere Articles) research pro- gramme, which is funded by the Swedish Environmental Protec- tion Agency. Legislative approaches Choosing how to promote substitution Conflict of Interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-therapeutic-equivalence-of-complex_2011_Regulatory-Toxicology-and-Pharma.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20951177", "content": {"Acknowledgement": "Acknowledgments The authors of the paper want to acknowledge the contribu- tions of the participants of the TI Pharma consensus meeting: Bio- equivalence of Complex Drugs 7 October 2009, Leiden, the Netherlands. The meeting was sponsored by Teva, Sanofi-Aventis and Vifor-Pharma. The therapeutic equivalence of complex drugs Introduction The generic paradigm Therapeutic proteins Low molecular weight heparins (LMWH) Liposomal drugs Complex iron\u2013carbohydrate (\u201ciron\u2013sugar\u201d) drugs Glatiramoids A regulatory framework for complex products Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-threshold-of-toxicological-concern-for-pren_2011_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20875834", "content": {"CoiStatement": "Results Discussion Concluding remarks Conflict of interest statement Funding sources statement Acknowledgements Supplementary data References", "Funding": "Results Discussion Concluding remarks Conflict of interest statement Funding sources statement Acknowledgements Supplementary data References", "Acknowledgement": "B. van Ravenzwaay et al. / Regulatory Toxicology and Pharmacology 59 (2011) 81\u201390 89 Acknowledgements The authors would like to thank Mrs Meyasse Bugay for her help in the preparation of the manuscript. Results Discussion Concluding remarks Conflict of interest statement Funding sources statement Acknowledgements Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-threshold-of-toxicological-concern-for-prenatal-de_2012_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22705707", "content": {"CoiStatement": "The calculation of a TTC value is normally done by taking the 5th percentile of the relevant NOAEL values and dividing this fac- tor by 100 (Meek et al., 2011). In our previous work on 111 rat pre- natal developmental toxicity studies (van Ravenzwaay et al., 2011) we have used an increased safety factor of 500 to account for a possible underrepresentation of chemical classes on the 5th per- centile of the NOAEL values to calculate a TTC value for develop- mental toxicity in rats of 8 lg/kg bw/d. The selection of the additional safety factor of 5 could be regarded as somewhat arbi- trary, but this generally cannot be avoided irrespective of the value of the additional safety factor (be it 5 or e.g. 10). We have used the additional factor of 5 because it was in line with a previous paper (van Ravenzwaay et al., 2011) and because with more than 100 studies evaluated, this data base is not small. Although changes can be expected with the extension of the data base it is not very likely that this will include a factor of more than 5. Most impor- tantly, however, most of the compounds used for this evaluation consisted of active ingredients (either pesticides or biocides (>70% of BASF\u2019s data base, or veterinary products \u2013 literature data). Even for the industrial chemicals tested a certain bias towards po- sitive effects for developmental toxicity can be expected, as such studies were often triggered because there was some suspicion of effects (e.g. for glycol ethers and solvents). Thus, the compounds which formed the basis of the evaluation presented here are gen- erally considered to represent a worst-case situation, relative to industrial chemicals (or impurities formed in production pro- cesses). This will be the major category for which a TTC concept can be applied. With the extension of the data base for develop- mental toxicity it may be possible to perform an analysis with re- spect to chemical classes. This may be as informative as using the Cramer class concept, and could also confirm the indication that (biologically) active ingredients generally have lower NOAEL and LOAEL values then non-active (industrial) chemicals. It is of inter- est to note that in a recent paper exactly this issue has been tack- led. Laufersweiler et al. (2012) have analyzed a total of 283 compounds with data on reproductive and developmental toxicity and have derived a TTC value for this end point. Given the size of the data base (with close to 300 compounds) and the fact that 3 species were taken into account, the authors concluded that a safety factor of 100 would be appropriate. The overall TTC value derived in the Laufersweiler paper was actually very close (5.7 lg/kg bw/d) to the values that we have derived for the rabbit (4 lg/kg bw/d) and rat (8 lg/kg bw/d). As indicated above the authors of the paper have used a safety factor of 100 for a data base consisting of close to 300 chemicals. Therefore, we believe that our choice to use an additional safety factor of 5 (with a data base containing slightly over 100 compounds) is appropriate and possibly conservative as most of the compounds analyzed were active ingredients. Finally, in the Laufersweiler paper an attempt was made to sub- divide the overall TTC value into the three different Cramer classes. As the data base was dominated by Cramer class 3 compounds (a total of 203) it is not surprising that the value for class 3 com- pounds (3.1 lg/kg bw/d) was close to the overall value. For Cramer class 1 compounds the TTC value was significantly higher, i.e. 131 lg/kg bw/d. The fact that there appears to be a relation between chemical structure (Cramer class) and TTC values indi- cates that the TTC value derived for rabbit developmental toxicity in this paper is likely to be conservative as it is based mainly on the analysis of biologically active ingredients (class 3 compounds). Applying the safe safety factor of 500 on the 5th percentile of the NOAEL values for developmental toxicity for 104 rabbit studies we calculate a TTC value of 4 lg/kg bw/d. Using the lowest of both TTC values, i.e. 4 lg/kg bw/d, would seem to be an appropriate guidance value for a decision to request more data and perform an animal experiment or to rely on a TTC value if exposure is sufficiently low. We hope that this paper will stimulate others to publish NOAEL and LOAEL values for developmental toxicity to strengthen the robustness of TTC values for reproduction toxicity. Conflict of interest statement The authors declare that there are no conflicts of interest. Funding sources statement The work was not funded by any sources. Acknowledgements The authors would like to acknowledge the assistance of Nicole Str\u00e4ssner and Sandra Michel in the preparation of this manuscript Appendix A. Supplementary data Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.yrtph.2012.06. 004. References Barlow, S.M., Kozianowski, G., Wurtzen, G., Schlatter, J., 2001. Threshold of toxicological concern for chemical substances present in the diet. Food Chem. Toxicol. 39, 893\u2013905. Bernauer, U., Heinemeyer, G., Heinrich-Hirsch, B., Ulbrich, B., Gundert-Remy, U., 2008. Exposure-triggered reproductive toxicity testing under the REACH legislation: a proposal to define significant/relevant exposure. Toxicol. Lett. 176, 68\u201376. Blackburn, K., Stickney, J.A., Carlson-Lynch, H.L., McGinnis, P.M., Chappell, L., Felter, S.P., 2005. Application of the threshold of toxicological concern approach to ingredients in personal and household care products. Regul. Toxicol. Pharmacol. 43, 249\u2013259. Cramer, G.M., Ford, R.A., Hall, R.L., 1978. Estimation of toxic hazard \u2013 a decision tree approach. Food Cosmet. Toxicol. 16, 255\u2013276. De Wolf, W., Sieber-Sauer, A., Lecloux, A., Koch, A., Holt, M., Feytel, T., Comber, M., Boeije, G., 2005. Mode of action and aquatic exposure thresholds of no concern. Environ. Tox. Chem. 24, 479\u2013485. Dolan, D.G., Nauman, B.D., Sargent, E.V., Maier, A., Dourson, M., 2005. Application of the threshold of toxicological concern concept to pharmaceutica manufacturing operations. Regul. Toxicol. Pharmacol. 43, 1\u20139. ECHA, 2008. Guidance on information requirements and chemical safety assess- ment, Chapter R.7c: Endpoint specific guidance. Available at: <http://echa. europa.eu/documents/10162/13632/information_requirements_r7c_en.pdf>. http://dx.doi.org/10.1016/j.yrtph.2012.06.004 http://dx.doi.org/10.1016/j.yrtph.2012.06.004 http://www.echa.europa.eu/documents/10162/13632/information_requirements_r7c_en.pdf http://www.echa.europa.eu/documents/10162/13632/information_requirements_r7c_en.pdf 8 B. van Ravenzwaay et al. / Regulatory Toxicology and Pharmacology 64 (2012) 1\u20138 EFSA, 2004. European Food Safety Authority. Scientific Panel on Food Additives, Flavorings, Processing Aids and Materials in Contact with Food. Opinion on Flavoring Group FGE.03 Acetals of branched- and straight-chain aliphatic saturated primary alcohols and branched- and straight-chain saturated aldehydes, and an orthoester of formic acid, from chemical groups 1 and 2. Opinion expressed on 7 October 2004. Available at: <www.efsa.eu.int/science/ afc/catindex_en.html>. EFSA, 2011. European Food Safety Authority. EFSA Scientific Committee. DRAFT Scientific Opinion on Exploring options for providing preliminary advice about possible human health risks based on the concept of Threshold of Toxicological Concern (TTC) Endorsed for Public Consultation 2011. Available at: <http:// www.efsa.europa.eu/en/consultationsclosed/call/110712a.pdf>. EMEA, 2003. The European Medical Control Agency. Committee for Medicinal Products for Human Use. Guideline on the limits of genotoxic impurities. London, 23 June 2003. <http://eudra.org/emea.html>. EMEA, 2004. European Medicines Evaluation Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on the limits of genotoxic impurities. CPMP/SWP/5199/02. London, 23 June 2004. <http:// www.emeaeu.int/pdfs/human/swp/519902en.pdf>. EPA Health Effects Test Guidelines, 1988. OPPTS 870.3700: Prenatal Developmental Toxicity Study (Aug 1998). Escher, S.E., Tluczkiewicz, I., Batke, M., Bitsch, A., Melber, C., Kroese, E.D., Buist, H.E., Mangelsdorf, I., 2010. Evaluation of inhalation TTC values with the data base RepDose. Regul. Toxicol. Pharmacol. 58, 259\u2013274. Federal Register, 1995. Food additives; threshold of regulation for substances used in food-contact articles. Final rule. Fed. Regist. 60 (136), 36582\u201336594. Food and Drug Administration, 1983. Toxicological Principles for the Safety Assessment of Direct Food Additives and Color Additives Used in Food, Redbook, US Food and Drug Administration, Bureau of Foods, Washington, DC. Food and Drug Administration, 1993. Toxicological Principles for the Safety Assessment of Direct Food Additives and Color Additives Used in Food, Redbook. Food and Drug Administration, 1995. US Food and Drug Administration, Department of Health and Human Services. Food Additives; Threshold of Regulation for Substances Used in Food-Contact Articles 21 CFR Parts 5, 25 170, 171, 174. Frawley, J.P., 1967. Scientific evidence and common sense as a basis for food- packaging regulations. Food Cosmet. Toxicol. 5, 293\u2013308. Hartung, T., Rovida, C., 2009. Chemical regulators have overreached. Nature 460, 1080\u20131081. Hurtt, M.E., Cappon, G.D., Browning, A., 2003. Proposal for a tiered approach to developemtal toxicity testing for veterinary pharmaceutical products for food producing animals. Food Chem. Toxicol. 41, 611\u2013619. IPCS, 1998. International Program on Chemical Safety, World Health Organisation, WHO Food Additives Series 35, WHO, Geneva, Switzerland. Janer, G., Slob, W., Hakkert, B.C., Vermeire, T., Piersma, A.H., 2008. A retrospective analysis of developmental toxicity studies in rats and rabbits: what is the added value of the rabbit as an additional test species. Regul. Toxicol. Pharmacol. 50, 206\u2013207. JECFA, 1993. Evaluation of Certain Food Additives and Contaminants. Safety evaluation of flavoring agents. Forty-first Report of the Joint FAO/WHO Expert Committee on Food Additives, WHO Technical Report Series 837. World Health Organization, Geneva. JECFA, 1995. Evaluation of Certain Food Additives and Contaminants. Safety evaluation of flavoring agents. In: Forty-fourth Report of the Joint FAO/WHO Expert Committee on Food Additives, WHO Technical Report Series 859. World Health Organization, Geneva. pp. 2\u20133. JECFA, 1999. Evaluation of Certain Food Additives and Contaminants. Procedure for the safety evaluation of flavoring agents. In: Forty-ninth Report of the Joint FAO/ WHO Expert Committee on Food Additives, WHO Technical Report Series 884. World Health Organization, Geneva. pp. 3\u20136. JECFA, 2003. Summary of Evaluations Performed by the Joint FAO/WHO Expert Committee on Food Additives (JECFA 1956-2003). In: First through sixty-first meetings. <http://jecfa.ilsi.org/>. JECFA, 2005. Joint FAO/WHO Expert Committee on Food Additives Sixty-Fifth Meeting: Summary and Conclusions, June 7-16, 2005. Food and Agriculture Organization of the United Nations (FAO)/World Health Organization (WHO); Geneva, Switz., [JECFA/65/SC]. Available from: <ftp://ftp.fao.org/es/esn/jecfa/ jecfa65_summary.pdf>. JECFA, 2006. Evaluation of Certain Food Additives and Contaminants. Sixty-Fifth Report of the joint FAO/WHO Expert Committee on Food Additives, June 7-16, 2005, Geneva. World Health Organization (WHO); Geneva, Switz., WHO Technical Report Series, No. 934. Available from: <http://whqlibdoc.who.int/ trs/WHO_TRS_934.pdf>. Kimmel, C.A., Trammell, C., 1981. A rapid procedure for routine double staining of cartilage and bone in fetal and adult animals. Stain Technol. 56, 271\u2013273. Koster, S., Boobis, A.R., Cubberley, R., Hollnagel, H.M., Richling, E., Wildemann, T., W\u00fcrtzen, G., Galli, C.L., 2011. Application of the TTC concept to unknown substance found in food analysis. Food Chem. Toxicol. 49, 1643\u20131660. Kroes, R., Galli, C.L., Munro, I., Schilter, B., Tran, L.-A., Walker, R., Wurtzen, G., 2000. Threshold of toxicological concern for chemical substances present in the diet: a practical tool for assessing the need for toxicity testing. Food Chem. Toxicol. 38, 255\u2013312. Kroes, R., Renwick, A.G., Cheeseman, M., Kleiner, J., Mangelsdorf, I., Piersma, A., Schilter, B., Schlatter, J., van Schothorst, F., Vos, J.G., Wurtzen, G., 2004. Structure-based thresholds of toxicological concern (TTC): guidance for application to substances present at low levels in the diet. Food Chem. Toxicol. 42, 65\u201383. Kroes, R., Renwick, A.G., Feron, V., Galli, C.L., Gibney, M., Greim, H., Guy, R.H., Lhuguenot, J.C., van de Sandt, J.J., 2007. Applications of the threshold of toxicological concern (TTC) to the safety evaluation of cosmetic ingredients. Food Chem. Toxicol. 45, 2533\u20132562. Laufersweiler, M.C., Gadagbui, B., Baskerville-Abraham, I.M., Maier, A., Willis, A., Scialli, A.R., Carr, G.J., Felter, S.P., Blackburn, K., Daston, G., 2012. Correlation of chemical structure with reproductive and developmental toxicity as it relates to the use of the threshold of toxicological concern. Regul. Toxicol. Pharmacol. 62, 160\u2013182. Meek, M.E., Boobis, A.R., Crofton, K.M., Heinemeyer, G., van Raaij, M., Vickers, C., 2011. Risk assessment of combined exposure to multiple chemicals: a WHI/IPCS framework. Regul. Toxicol. Pharmacol. 60, 1\u201314. Melching-Kollmu\u00df, S., Dekant, W., Kalberlah, F., 2010. Application of the \u2018\u2018threshold of toxicological concern\u2018\u2018 to derive tolerable concentrations of \u2018\u2018non relevant metabolites\u2019\u2019 formed from plant protection products in ground and drinking water. Regul. Toxicol. Pharmacol. 56, 126\u2013134. M\u00fcller, L., Mauthe, R.J., Riley, C.M., Andino, M.M., De Antonis, D., Beels, C., DeGeorge, J., De Knaep, A.G.M., Ellison, D., Fagerland, J.A., Frank, R., Fritschel, B., Galloway, S., Harpur, E., Humfrey, C.D.N., Jacks, A.S., Jagota, N., Mackinnon, J., Mohan, G., Ness, D.K., O\u0301Donovan, M.R., Smith, M Dammann., Vudathala, G., Yotti, L., 2006. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. Regul. Toxicol. Pharmacol. 44, 198\u2013211. Munro, I.C., 1990. Safety assessment procedures for indirect food additives: an overview. Report of a Workshop. Regul. Toxicol. Pharmacol. 12, 2\u201312. Munro, I.C., Ford, R.A., Kennepohl, E., Sprenger, J.G., 1996. Correlation of structural class with no-observed effect levels: a proposal for establishing a threshold of concern. Food Chem. Toxicol. 34, 829\u2013867. Munro, I.C., Kennepohl, E., Kroes, R., 1999. A procedure for the safety evaluation of flavoring substances. Food Chem. Toxicol. 37, 207\u2013232. OECD Guideline for Testing of Chemicals, Proposal for updating Guideline 414: Prenatal Developmental Toxicity Study (22 Jan 2001). Renwick, A.G., 2004. Toxicology databases and the concept of thresholds of toxicological concern as used by the JECFA for the safety evaluation of flavoring agents. Toxicol. Lett. 149, 223\u2013234. Rowbotham, A.L., Gibson, R.M., 2011. Exposure driven risk assessment: applying exposure based waiving of toxicity tests under REACH. Food Chem. Toxicol. 49, 1661\u20131673. Rulis, A.M., 1986. De minimis and the threshold of regulation. In: Felix, C.W. (Ed.), Food Protection Technology. Lewis Publishers, Chelsea, MI, pp. 29\u201337. Scientific Committee on Consumer Products (SCCP) \u2013 Scientific Committee on Health and Environmental Risks (SCHER) \u2013 Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR), 2008. Draft Opinion on Use of the Threshold of Toxicological Concern (TTC) Approach for the Safety Assessment of Chemical Substances. Tluczkiewicz, I., Buist, H.E., Martin, M.T., Mangelsdorf, I., Escher, S.E., 2011. Improvement of the Cramer classification for oral exposure using the database TTC RepDose \u2013 a strategy description. Regul. Toxicol. Pharmacol. 61, 340\u2013350. van Ravenzwaay, B., Dammann, M., Buesen, M., Schneider, S., 2011. The threshold of toxicological concern for prenatal developmental toxicity. Regul. Toxicol. Pharmacol. 59, 81\u201390. Vermeire, T., van de Bovenkamp, M., Bruinen de Bruin, Y., Delmaar, C., van Engelen, J., Escher, S., Marquat, H., Meijster, T., 2010. Exposure based waiving under REACH. Regul. Toxicol. Pharmacol. 58, 408\u2013420. Wilson, J.G., and Warkany, J. 1965, Teratology: Principles and Techniques. The University of Chicago Press. Chicago and London. http://www.efsa.eu.int/science/afc/catindex_en.html http://www.efsa.eu.int/science/afc/catindex_en.html http://www.efsa.europa.eu/en/consultationsclosed/call/110712a.pdf http://www.efsa.europa.eu/en/consultationsclosed/call/110712a.pdf http://www.eudra.org/emea.html http://www.emeaeu.int/pdfs/human/swp/519902en.pdf http://www.emeaeu.int/pdfs/human/swp/519902en.pdf http://www.jecfa.ilsi.org/ http://www.ftp://ftp.fao.org/es/esn/jecfa/jecfa65_summary.pdf http://www.ftp://ftp.fao.org/es/esn/jecfa/jecfa65_summary.pdf http://www.whqlibdoc.who.int/trs/WHO_TRS_934.pdf http://www.whqlibdoc.who.int/trs/WHO_TRS_934.pdf The threshold of toxicological concern for prenatal developmental toxicity in rabbits and a comparison to TTC values in rats 1 Introduction 2 Materials and methods 2.1 General design of developmental toxicity studies 2.2 Statistical analysis 3 Results 3.1 Calculation of a TTC value for oral prenatal developmental toxicity for rabbits 4 Discussion Conflict of interest statement Funding sources statement Acknowledgements Appendix A Supplementary data References", "Funding": "The calculation of a TTC value is normally done by taking the 5th percentile of the relevant NOAEL values and dividing this fac- tor by 100 (Meek et al., 2011). In our previous work on 111 rat pre- natal developmental toxicity studies (van Ravenzwaay et al., 2011) we have used an increased safety factor of 500 to account for a possible underrepresentation of chemical classes on the 5th per- centile of the NOAEL values to calculate a TTC value for develop- mental toxicity in rats of 8 lg/kg bw/d. The selection of the additional safety factor of 5 could be regarded as somewhat arbi- trary, but this generally cannot be avoided irrespective of the value of the additional safety factor (be it 5 or e.g. 10). We have used the additional factor of 5 because it was in line with a previous paper (van Ravenzwaay et al., 2011) and because with more than 100 studies evaluated, this data base is not small. Although changes can be expected with the extension of the data base it is not very likely that this will include a factor of more than 5. Most impor- tantly, however, most of the compounds used for this evaluation consisted of active ingredients (either pesticides or biocides (>70% of BASF\u2019s data base, or veterinary products \u2013 literature data). Even for the industrial chemicals tested a certain bias towards po- sitive effects for developmental toxicity can be expected, as such studies were often triggered because there was some suspicion of effects (e.g. for glycol ethers and solvents). Thus, the compounds which formed the basis of the evaluation presented here are gen- erally considered to represent a worst-case situation, relative to industrial chemicals (or impurities formed in production pro- cesses). This will be the major category for which a TTC concept can be applied. With the extension of the data base for develop- mental toxicity it may be possible to perform an analysis with re- spect to chemical classes. This may be as informative as using the Cramer class concept, and could also confirm the indication that (biologically) active ingredients generally have lower NOAEL and LOAEL values then non-active (industrial) chemicals. It is of inter- est to note that in a recent paper exactly this issue has been tack- led. Laufersweiler et al. (2012) have analyzed a total of 283 compounds with data on reproductive and developmental toxicity and have derived a TTC value for this end point. Given the size of the data base (with close to 300 compounds) and the fact that 3 species were taken into account, the authors concluded that a safety factor of 100 would be appropriate. The overall TTC value derived in the Laufersweiler paper was actually very close (5.7 lg/kg bw/d) to the values that we have derived for the rabbit (4 lg/kg bw/d) and rat (8 lg/kg bw/d). As indicated above the authors of the paper have used a safety factor of 100 for a data base consisting of close to 300 chemicals. Therefore, we believe that our choice to use an additional safety factor of 5 (with a data base containing slightly over 100 compounds) is appropriate and possibly conservative as most of the compounds analyzed were active ingredients. Finally, in the Laufersweiler paper an attempt was made to sub- divide the overall TTC value into the three different Cramer classes. As the data base was dominated by Cramer class 3 compounds (a total of 203) it is not surprising that the value for class 3 com- pounds (3.1 lg/kg bw/d) was close to the overall value. For Cramer class 1 compounds the TTC value was significantly higher, i.e. 131 lg/kg bw/d. The fact that there appears to be a relation between chemical structure (Cramer class) and TTC values indi- cates that the TTC value derived for rabbit developmental toxicity in this paper is likely to be conservative as it is based mainly on the analysis of biologically active ingredients (class 3 compounds). Applying the safe safety factor of 500 on the 5th percentile of the NOAEL values for developmental toxicity for 104 rabbit studies we calculate a TTC value of 4 lg/kg bw/d. Using the lowest of both TTC values, i.e. 4 lg/kg bw/d, would seem to be an appropriate guidance value for a decision to request more data and perform an animal experiment or to rely on a TTC value if exposure is sufficiently low. We hope that this paper will stimulate others to publish NOAEL and LOAEL values for developmental toxicity to strengthen the robustness of TTC values for reproduction toxicity. Conflict of interest statement The authors declare that there are no conflicts of interest. Funding sources statement The work was not funded by any sources. Acknowledgements The authors would like to acknowledge the assistance of Nicole Str\u00e4ssner and Sandra Michel in the preparation of this manuscript Appendix A. Supplementary data Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.yrtph.2012.06. 004. References Barlow, S.M., Kozianowski, G., Wurtzen, G., Schlatter, J., 2001. Threshold of toxicological concern for chemical substances present in the diet. Food Chem. Toxicol. 39, 893\u2013905. Bernauer, U., Heinemeyer, G., Heinrich-Hirsch, B., Ulbrich, B., Gundert-Remy, U., 2008. Exposure-triggered reproductive toxicity testing under the REACH legislation: a proposal to define significant/relevant exposure. Toxicol. Lett. 176, 68\u201376. Blackburn, K., Stickney, J.A., Carlson-Lynch, H.L., McGinnis, P.M., Chappell, L., Felter, S.P., 2005. Application of the threshold of toxicological concern approach to ingredients in personal and household care products. Regul. Toxicol. Pharmacol. 43, 249\u2013259. Cramer, G.M., Ford, R.A., Hall, R.L., 1978. Estimation of toxic hazard \u2013 a decision tree approach. Food Cosmet. Toxicol. 16, 255\u2013276. De Wolf, W., Sieber-Sauer, A., Lecloux, A., Koch, A., Holt, M., Feytel, T., Comber, M., Boeije, G., 2005. Mode of action and aquatic exposure thresholds of no concern. Environ. Tox. Chem. 24, 479\u2013485. Dolan, D.G., Nauman, B.D., Sargent, E.V., Maier, A., Dourson, M., 2005. Application of the threshold of toxicological concern concept to pharmaceutica manufacturing operations. Regul. Toxicol. Pharmacol. 43, 1\u20139. ECHA, 2008. Guidance on information requirements and chemical safety assess- ment, Chapter R.7c: Endpoint specific guidance. Available at: <http://echa. europa.eu/documents/10162/13632/information_requirements_r7c_en.pdf>. http://dx.doi.org/10.1016/j.yrtph.2012.06.004 http://dx.doi.org/10.1016/j.yrtph.2012.06.004 http://www.echa.europa.eu/documents/10162/13632/information_requirements_r7c_en.pdf http://www.echa.europa.eu/documents/10162/13632/information_requirements_r7c_en.pdf 8 B. van Ravenzwaay et al. / Regulatory Toxicology and Pharmacology 64 (2012) 1\u20138 EFSA, 2004. European Food Safety Authority. Scientific Panel on Food Additives, Flavorings, Processing Aids and Materials in Contact with Food. Opinion on Flavoring Group FGE.03 Acetals of branched- and straight-chain aliphatic saturated primary alcohols and branched- and straight-chain saturated aldehydes, and an orthoester of formic acid, from chemical groups 1 and 2. Opinion expressed on 7 October 2004. Available at: <www.efsa.eu.int/science/ afc/catindex_en.html>. EFSA, 2011. European Food Safety Authority. EFSA Scientific Committee. DRAFT Scientific Opinion on Exploring options for providing preliminary advice about possible human health risks based on the concept of Threshold of Toxicological Concern (TTC) Endorsed for Public Consultation 2011. Available at: <http:// www.efsa.europa.eu/en/consultationsclosed/call/110712a.pdf>. EMEA, 2003. The European Medical Control Agency. Committee for Medicinal Products for Human Use. Guideline on the limits of genotoxic impurities. London, 23 June 2003. <http://eudra.org/emea.html>. EMEA, 2004. European Medicines Evaluation Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on the limits of genotoxic impurities. CPMP/SWP/5199/02. London, 23 June 2004. <http:// www.emeaeu.int/pdfs/human/swp/519902en.pdf>. EPA Health Effects Test Guidelines, 1988. OPPTS 870.3700: Prenatal Developmental Toxicity Study (Aug 1998). Escher, S.E., Tluczkiewicz, I., Batke, M., Bitsch, A., Melber, C., Kroese, E.D., Buist, H.E., Mangelsdorf, I., 2010. Evaluation of inhalation TTC values with the data base RepDose. Regul. Toxicol. Pharmacol. 58, 259\u2013274. Federal Register, 1995. Food additives; threshold of regulation for substances used in food-contact articles. Final rule. Fed. Regist. 60 (136), 36582\u201336594. Food and Drug Administration, 1983. Toxicological Principles for the Safety Assessment of Direct Food Additives and Color Additives Used in Food, Redbook, US Food and Drug Administration, Bureau of Foods, Washington, DC. Food and Drug Administration, 1993. Toxicological Principles for the Safety Assessment of Direct Food Additives and Color Additives Used in Food, Redbook. Food and Drug Administration, 1995. US Food and Drug Administration, Department of Health and Human Services. Food Additives; Threshold of Regulation for Substances Used in Food-Contact Articles 21 CFR Parts 5, 25 170, 171, 174. Frawley, J.P., 1967. Scientific evidence and common sense as a basis for food- packaging regulations. Food Cosmet. Toxicol. 5, 293\u2013308. Hartung, T., Rovida, C., 2009. Chemical regulators have overreached. Nature 460, 1080\u20131081. Hurtt, M.E., Cappon, G.D., Browning, A., 2003. Proposal for a tiered approach to developemtal toxicity testing for veterinary pharmaceutical products for food producing animals. Food Chem. Toxicol. 41, 611\u2013619. IPCS, 1998. International Program on Chemical Safety, World Health Organisation, WHO Food Additives Series 35, WHO, Geneva, Switzerland. Janer, G., Slob, W., Hakkert, B.C., Vermeire, T., Piersma, A.H., 2008. A retrospective analysis of developmental toxicity studies in rats and rabbits: what is the added value of the rabbit as an additional test species. Regul. Toxicol. Pharmacol. 50, 206\u2013207. JECFA, 1993. Evaluation of Certain Food Additives and Contaminants. Safety evaluation of flavoring agents. Forty-first Report of the Joint FAO/WHO Expert Committee on Food Additives, WHO Technical Report Series 837. World Health Organization, Geneva. JECFA, 1995. Evaluation of Certain Food Additives and Contaminants. Safety evaluation of flavoring agents. In: Forty-fourth Report of the Joint FAO/WHO Expert Committee on Food Additives, WHO Technical Report Series 859. World Health Organization, Geneva. pp. 2\u20133. JECFA, 1999. Evaluation of Certain Food Additives and Contaminants. Procedure for the safety evaluation of flavoring agents. In: Forty-ninth Report of the Joint FAO/ WHO Expert Committee on Food Additives, WHO Technical Report Series 884. World Health Organization, Geneva. pp. 3\u20136. JECFA, 2003. Summary of Evaluations Performed by the Joint FAO/WHO Expert Committee on Food Additives (JECFA 1956-2003). In: First through sixty-first meetings. <http://jecfa.ilsi.org/>. JECFA, 2005. Joint FAO/WHO Expert Committee on Food Additives Sixty-Fifth Meeting: Summary and Conclusions, June 7-16, 2005. Food and Agriculture Organization of the United Nations (FAO)/World Health Organization (WHO); Geneva, Switz., [JECFA/65/SC]. Available from: <ftp://ftp.fao.org/es/esn/jecfa/ jecfa65_summary.pdf>. JECFA, 2006. Evaluation of Certain Food Additives and Contaminants. Sixty-Fifth Report of the joint FAO/WHO Expert Committee on Food Additives, June 7-16, 2005, Geneva. World Health Organization (WHO); Geneva, Switz., WHO Technical Report Series, No. 934. Available from: <http://whqlibdoc.who.int/ trs/WHO_TRS_934.pdf>. Kimmel, C.A., Trammell, C., 1981. A rapid procedure for routine double staining of cartilage and bone in fetal and adult animals. Stain Technol. 56, 271\u2013273. Koster, S., Boobis, A.R., Cubberley, R., Hollnagel, H.M., Richling, E., Wildemann, T., W\u00fcrtzen, G., Galli, C.L., 2011. Application of the TTC concept to unknown substance found in food analysis. Food Chem. Toxicol. 49, 1643\u20131660. Kroes, R., Galli, C.L., Munro, I., Schilter, B., Tran, L.-A., Walker, R., Wurtzen, G., 2000. Threshold of toxicological concern for chemical substances present in the diet: a practical tool for assessing the need for toxicity testing. Food Chem. Toxicol. 38, 255\u2013312. Kroes, R., Renwick, A.G., Cheeseman, M., Kleiner, J., Mangelsdorf, I., Piersma, A., Schilter, B., Schlatter, J., van Schothorst, F., Vos, J.G., Wurtzen, G., 2004. Structure-based thresholds of toxicological concern (TTC): guidance for application to substances present at low levels in the diet. Food Chem. Toxicol. 42, 65\u201383. Kroes, R., Renwick, A.G., Feron, V., Galli, C.L., Gibney, M., Greim, H., Guy, R.H., Lhuguenot, J.C., van de Sandt, J.J., 2007. Applications of the threshold of toxicological concern (TTC) to the safety evaluation of cosmetic ingredients. Food Chem. Toxicol. 45, 2533\u20132562. Laufersweiler, M.C., Gadagbui, B., Baskerville-Abraham, I.M., Maier, A., Willis, A., Scialli, A.R., Carr, G.J., Felter, S.P., Blackburn, K., Daston, G., 2012. Correlation of chemical structure with reproductive and developmental toxicity as it relates to the use of the threshold of toxicological concern. Regul. Toxicol. Pharmacol. 62, 160\u2013182. Meek, M.E., Boobis, A.R., Crofton, K.M., Heinemeyer, G., van Raaij, M., Vickers, C., 2011. Risk assessment of combined exposure to multiple chemicals: a WHI/IPCS framework. Regul. Toxicol. Pharmacol. 60, 1\u201314. Melching-Kollmu\u00df, S., Dekant, W., Kalberlah, F., 2010. Application of the \u2018\u2018threshold of toxicological concern\u2018\u2018 to derive tolerable concentrations of \u2018\u2018non relevant metabolites\u2019\u2019 formed from plant protection products in ground and drinking water. Regul. Toxicol. Pharmacol. 56, 126\u2013134. M\u00fcller, L., Mauthe, R.J., Riley, C.M., Andino, M.M., De Antonis, D., Beels, C., DeGeorge, J., De Knaep, A.G.M., Ellison, D., Fagerland, J.A., Frank, R., Fritschel, B., Galloway, S., Harpur, E., Humfrey, C.D.N., Jacks, A.S., Jagota, N., Mackinnon, J., Mohan, G., Ness, D.K., O\u0301Donovan, M.R., Smith, M Dammann., Vudathala, G., Yotti, L., 2006. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. Regul. Toxicol. Pharmacol. 44, 198\u2013211. Munro, I.C., 1990. Safety assessment procedures for indirect food additives: an overview. Report of a Workshop. Regul. Toxicol. Pharmacol. 12, 2\u201312. Munro, I.C., Ford, R.A., Kennepohl, E., Sprenger, J.G., 1996. Correlation of structural class with no-observed effect levels: a proposal for establishing a threshold of concern. Food Chem. Toxicol. 34, 829\u2013867. Munro, I.C., Kennepohl, E., Kroes, R., 1999. A procedure for the safety evaluation of flavoring substances. Food Chem. Toxicol. 37, 207\u2013232. OECD Guideline for Testing of Chemicals, Proposal for updating Guideline 414: Prenatal Developmental Toxicity Study (22 Jan 2001). Renwick, A.G., 2004. Toxicology databases and the concept of thresholds of toxicological concern as used by the JECFA for the safety evaluation of flavoring agents. Toxicol. Lett. 149, 223\u2013234. Rowbotham, A.L., Gibson, R.M., 2011. Exposure driven risk assessment: applying exposure based waiving of toxicity tests under REACH. Food Chem. Toxicol. 49, 1661\u20131673. Rulis, A.M., 1986. De minimis and the threshold of regulation. In: Felix, C.W. (Ed.), Food Protection Technology. Lewis Publishers, Chelsea, MI, pp. 29\u201337. Scientific Committee on Consumer Products (SCCP) \u2013 Scientific Committee on Health and Environmental Risks (SCHER) \u2013 Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR), 2008. Draft Opinion on Use of the Threshold of Toxicological Concern (TTC) Approach for the Safety Assessment of Chemical Substances. Tluczkiewicz, I., Buist, H.E., Martin, M.T., Mangelsdorf, I., Escher, S.E., 2011. Improvement of the Cramer classification for oral exposure using the database TTC RepDose \u2013 a strategy description. Regul. Toxicol. Pharmacol. 61, 340\u2013350. van Ravenzwaay, B., Dammann, M., Buesen, M., Schneider, S., 2011. The threshold of toxicological concern for prenatal developmental toxicity. Regul. Toxicol. Pharmacol. 59, 81\u201390. Vermeire, T., van de Bovenkamp, M., Bruinen de Bruin, Y., Delmaar, C., van Engelen, J., Escher, S., Marquat, H., Meijster, T., 2010. Exposure based waiving under REACH. Regul. Toxicol. Pharmacol. 58, 408\u2013420. Wilson, J.G., and Warkany, J. 1965, Teratology: Principles and Techniques. The University of Chicago Press. Chicago and London. http://www.efsa.eu.int/science/afc/catindex_en.html http://www.efsa.eu.int/science/afc/catindex_en.html http://www.efsa.europa.eu/en/consultationsclosed/call/110712a.pdf http://www.efsa.europa.eu/en/consultationsclosed/call/110712a.pdf http://www.eudra.org/emea.html http://www.emeaeu.int/pdfs/human/swp/519902en.pdf http://www.emeaeu.int/pdfs/human/swp/519902en.pdf http://www.jecfa.ilsi.org/ http://www.ftp://ftp.fao.org/es/esn/jecfa/jecfa65_summary.pdf http://www.ftp://ftp.fao.org/es/esn/jecfa/jecfa65_summary.pdf http://www.whqlibdoc.who.int/trs/WHO_TRS_934.pdf http://www.whqlibdoc.who.int/trs/WHO_TRS_934.pdf The threshold of toxicological concern for prenatal developmental toxicity in rabbits and a comparison to TTC values in rats 1 Introduction 2 Materials and methods 2.1 General design of developmental toxicity studies 2.2 Statistical analysis 3 Results 3.1 Calculation of a TTC value for oral prenatal developmental toxicity for rabbits 4 Discussion Conflict of interest statement Funding sources statement Acknowledgements Appendix A Supplementary data References", "Acknowledgement": "The calculation of a TTC value is normally done by taking the 5th percentile of the relevant NOAEL values and dividing this fac- tor by 100 (Meek et al., 2011). In our previous work on 111 rat pre- natal developmental toxicity studies (van Ravenzwaay et al., 2011) we have used an increased safety factor of 500 to account for a possible underrepresentation of chemical classes on the 5th per- centile of the NOAEL values to calculate a TTC value for develop- mental toxicity in rats of 8 lg/kg bw/d. The selection of the additional safety factor of 5 could be regarded as somewhat arbi- trary, but this generally cannot be avoided irrespective of the value of the additional safety factor (be it 5 or e.g. 10). We have used the additional factor of 5 because it was in line with a previous paper (van Ravenzwaay et al., 2011) and because with more than 100 studies evaluated, this data base is not small. Although changes can be expected with the extension of the data base it is not very likely that this will include a factor of more than 5. Most impor- tantly, however, most of the compounds used for this evaluation consisted of active ingredients (either pesticides or biocides (>70% of BASF\u2019s data base, or veterinary products \u2013 literature data). Even for the industrial chemicals tested a certain bias towards po- sitive effects for developmental toxicity can be expected, as such studies were often triggered because there was some suspicion of effects (e.g. for glycol ethers and solvents). Thus, the compounds which formed the basis of the evaluation presented here are gen- erally considered to represent a worst-case situation, relative to industrial chemicals (or impurities formed in production pro- cesses). This will be the major category for which a TTC concept can be applied. With the extension of the data base for develop- mental toxicity it may be possible to perform an analysis with re- spect to chemical classes. This may be as informative as using the Cramer class concept, and could also confirm the indication that (biologically) active ingredients generally have lower NOAEL and LOAEL values then non-active (industrial) chemicals. It is of inter- est to note that in a recent paper exactly this issue has been tack- led. Laufersweiler et al. (2012) have analyzed a total of 283 compounds with data on reproductive and developmental toxicity and have derived a TTC value for this end point. Given the size of the data base (with close to 300 compounds) and the fact that 3 species were taken into account, the authors concluded that a safety factor of 100 would be appropriate. The overall TTC value derived in the Laufersweiler paper was actually very close (5.7 lg/kg bw/d) to the values that we have derived for the rabbit (4 lg/kg bw/d) and rat (8 lg/kg bw/d). As indicated above the authors of the paper have used a safety factor of 100 for a data base consisting of close to 300 chemicals. Therefore, we believe that our choice to use an additional safety factor of 5 (with a data base containing slightly over 100 compounds) is appropriate and possibly conservative as most of the compounds analyzed were active ingredients. Finally, in the Laufersweiler paper an attempt was made to sub- divide the overall TTC value into the three different Cramer classes. As the data base was dominated by Cramer class 3 compounds (a total of 203) it is not surprising that the value for class 3 com- pounds (3.1 lg/kg bw/d) was close to the overall value. For Cramer class 1 compounds the TTC value was significantly higher, i.e. 131 lg/kg bw/d. The fact that there appears to be a relation between chemical structure (Cramer class) and TTC values indi- cates that the TTC value derived for rabbit developmental toxicity in this paper is likely to be conservative as it is based mainly on the analysis of biologically active ingredients (class 3 compounds). Applying the safe safety factor of 500 on the 5th percentile of the NOAEL values for developmental toxicity for 104 rabbit studies we calculate a TTC value of 4 lg/kg bw/d. Using the lowest of both TTC values, i.e. 4 lg/kg bw/d, would seem to be an appropriate guidance value for a decision to request more data and perform an animal experiment or to rely on a TTC value if exposure is sufficiently low. We hope that this paper will stimulate others to publish NOAEL and LOAEL values for developmental toxicity to strengthen the robustness of TTC values for reproduction toxicity. Conflict of interest statement The authors declare that there are no conflicts of interest. Funding sources statement The work was not funded by any sources. Acknowledgements The authors would like to acknowledge the assistance of Nicole Str\u00e4ssner and Sandra Michel in the preparation of this manuscript Appendix A. Supplementary data Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.yrtph.2012.06. 004. References Barlow, S.M., Kozianowski, G., Wurtzen, G., Schlatter, J., 2001. Threshold of toxicological concern for chemical substances present in the diet. Food Chem. Toxicol. 39, 893\u2013905. Bernauer, U., Heinemeyer, G., Heinrich-Hirsch, B., Ulbrich, B., Gundert-Remy, U., 2008. Exposure-triggered reproductive toxicity testing under the REACH legislation: a proposal to define significant/relevant exposure. Toxicol. Lett. 176, 68\u201376. Blackburn, K., Stickney, J.A., Carlson-Lynch, H.L., McGinnis, P.M., Chappell, L., Felter, S.P., 2005. Application of the threshold of toxicological concern approach to ingredients in personal and household care products. Regul. Toxicol. Pharmacol. 43, 249\u2013259. Cramer, G.M., Ford, R.A., Hall, R.L., 1978. Estimation of toxic hazard \u2013 a decision tree approach. Food Cosmet. Toxicol. 16, 255\u2013276. De Wolf, W., Sieber-Sauer, A., Lecloux, A., Koch, A., Holt, M., Feytel, T., Comber, M., Boeije, G., 2005. Mode of action and aquatic exposure thresholds of no concern. Environ. Tox. Chem. 24, 479\u2013485. Dolan, D.G., Nauman, B.D., Sargent, E.V., Maier, A., Dourson, M., 2005. Application of the threshold of toxicological concern concept to pharmaceutica manufacturing operations. Regul. Toxicol. Pharmacol. 43, 1\u20139. ECHA, 2008. Guidance on information requirements and chemical safety assess- ment, Chapter R.7c: Endpoint specific guidance. Available at: <http://echa. europa.eu/documents/10162/13632/information_requirements_r7c_en.pdf>. http://dx.doi.org/10.1016/j.yrtph.2012.06.004 http://dx.doi.org/10.1016/j.yrtph.2012.06.004 http://www.echa.europa.eu/documents/10162/13632/information_requirements_r7c_en.pdf http://www.echa.europa.eu/documents/10162/13632/information_requirements_r7c_en.pdf 8 B. van Ravenzwaay et al. / Regulatory Toxicology and Pharmacology 64 (2012) 1\u20138 EFSA, 2004. European Food Safety Authority. Scientific Panel on Food Additives, Flavorings, Processing Aids and Materials in Contact with Food. Opinion on Flavoring Group FGE.03 Acetals of branched- and straight-chain aliphatic saturated primary alcohols and branched- and straight-chain saturated aldehydes, and an orthoester of formic acid, from chemical groups 1 and 2. Opinion expressed on 7 October 2004. Available at: <www.efsa.eu.int/science/ afc/catindex_en.html>. EFSA, 2011. European Food Safety Authority. EFSA Scientific Committee. DRAFT Scientific Opinion on Exploring options for providing preliminary advice about possible human health risks based on the concept of Threshold of Toxicological Concern (TTC) Endorsed for Public Consultation 2011. Available at: <http:// www.efsa.europa.eu/en/consultationsclosed/call/110712a.pdf>. EMEA, 2003. The European Medical Control Agency. Committee for Medicinal Products for Human Use. Guideline on the limits of genotoxic impurities. London, 23 June 2003. <http://eudra.org/emea.html>. EMEA, 2004. European Medicines Evaluation Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on the limits of genotoxic impurities. CPMP/SWP/5199/02. London, 23 June 2004. <http:// www.emeaeu.int/pdfs/human/swp/519902en.pdf>. EPA Health Effects Test Guidelines, 1988. OPPTS 870.3700: Prenatal Developmental Toxicity Study (Aug 1998). Escher, S.E., Tluczkiewicz, I., Batke, M., Bitsch, A., Melber, C., Kroese, E.D., Buist, H.E., Mangelsdorf, I., 2010. Evaluation of inhalation TTC values with the data base RepDose. Regul. Toxicol. Pharmacol. 58, 259\u2013274. Federal Register, 1995. Food additives; threshold of regulation for substances used in food-contact articles. Final rule. Fed. Regist. 60 (136), 36582\u201336594. Food and Drug Administration, 1983. Toxicological Principles for the Safety Assessment of Direct Food Additives and Color Additives Used in Food, Redbook, US Food and Drug Administration, Bureau of Foods, Washington, DC. Food and Drug Administration, 1993. Toxicological Principles for the Safety Assessment of Direct Food Additives and Color Additives Used in Food, Redbook. Food and Drug Administration, 1995. US Food and Drug Administration, Department of Health and Human Services. Food Additives; Threshold of Regulation for Substances Used in Food-Contact Articles 21 CFR Parts 5, 25 170, 171, 174. Frawley, J.P., 1967. Scientific evidence and common sense as a basis for food- packaging regulations. Food Cosmet. Toxicol. 5, 293\u2013308. Hartung, T., Rovida, C., 2009. Chemical regulators have overreached. Nature 460, 1080\u20131081. Hurtt, M.E., Cappon, G.D., Browning, A., 2003. Proposal for a tiered approach to developemtal toxicity testing for veterinary pharmaceutical products for food producing animals. Food Chem. Toxicol. 41, 611\u2013619. IPCS, 1998. International Program on Chemical Safety, World Health Organisation, WHO Food Additives Series 35, WHO, Geneva, Switzerland. Janer, G., Slob, W., Hakkert, B.C., Vermeire, T., Piersma, A.H., 2008. A retrospective analysis of developmental toxicity studies in rats and rabbits: what is the added value of the rabbit as an additional test species. Regul. Toxicol. Pharmacol. 50, 206\u2013207. JECFA, 1993. Evaluation of Certain Food Additives and Contaminants. Safety evaluation of flavoring agents. Forty-first Report of the Joint FAO/WHO Expert Committee on Food Additives, WHO Technical Report Series 837. World Health Organization, Geneva. JECFA, 1995. Evaluation of Certain Food Additives and Contaminants. Safety evaluation of flavoring agents. In: Forty-fourth Report of the Joint FAO/WHO Expert Committee on Food Additives, WHO Technical Report Series 859. World Health Organization, Geneva. pp. 2\u20133. JECFA, 1999. Evaluation of Certain Food Additives and Contaminants. Procedure for the safety evaluation of flavoring agents. In: Forty-ninth Report of the Joint FAO/ WHO Expert Committee on Food Additives, WHO Technical Report Series 884. World Health Organization, Geneva. pp. 3\u20136. JECFA, 2003. Summary of Evaluations Performed by the Joint FAO/WHO Expert Committee on Food Additives (JECFA 1956-2003). In: First through sixty-first meetings. <http://jecfa.ilsi.org/>. JECFA, 2005. Joint FAO/WHO Expert Committee on Food Additives Sixty-Fifth Meeting: Summary and Conclusions, June 7-16, 2005. Food and Agriculture Organization of the United Nations (FAO)/World Health Organization (WHO); Geneva, Switz., [JECFA/65/SC]. Available from: <ftp://ftp.fao.org/es/esn/jecfa/ jecfa65_summary.pdf>. JECFA, 2006. Evaluation of Certain Food Additives and Contaminants. Sixty-Fifth Report of the joint FAO/WHO Expert Committee on Food Additives, June 7-16, 2005, Geneva. World Health Organization (WHO); Geneva, Switz., WHO Technical Report Series, No. 934. Available from: <http://whqlibdoc.who.int/ trs/WHO_TRS_934.pdf>. Kimmel, C.A., Trammell, C., 1981. A rapid procedure for routine double staining of cartilage and bone in fetal and adult animals. Stain Technol. 56, 271\u2013273. Koster, S., Boobis, A.R., Cubberley, R., Hollnagel, H.M., Richling, E., Wildemann, T., W\u00fcrtzen, G., Galli, C.L., 2011. Application of the TTC concept to unknown substance found in food analysis. Food Chem. Toxicol. 49, 1643\u20131660. Kroes, R., Galli, C.L., Munro, I., Schilter, B., Tran, L.-A., Walker, R., Wurtzen, G., 2000. Threshold of toxicological concern for chemical substances present in the diet: a practical tool for assessing the need for toxicity testing. Food Chem. Toxicol. 38, 255\u2013312. Kroes, R., Renwick, A.G., Cheeseman, M., Kleiner, J., Mangelsdorf, I., Piersma, A., Schilter, B., Schlatter, J., van Schothorst, F., Vos, J.G., Wurtzen, G., 2004. Structure-based thresholds of toxicological concern (TTC): guidance for application to substances present at low levels in the diet. Food Chem. Toxicol. 42, 65\u201383. Kroes, R., Renwick, A.G., Feron, V., Galli, C.L., Gibney, M., Greim, H., Guy, R.H., Lhuguenot, J.C., van de Sandt, J.J., 2007. Applications of the threshold of toxicological concern (TTC) to the safety evaluation of cosmetic ingredients. Food Chem. Toxicol. 45, 2533\u20132562. Laufersweiler, M.C., Gadagbui, B., Baskerville-Abraham, I.M., Maier, A., Willis, A., Scialli, A.R., Carr, G.J., Felter, S.P., Blackburn, K., Daston, G., 2012. Correlation of chemical structure with reproductive and developmental toxicity as it relates to the use of the threshold of toxicological concern. Regul. Toxicol. Pharmacol. 62, 160\u2013182. Meek, M.E., Boobis, A.R., Crofton, K.M., Heinemeyer, G., van Raaij, M., Vickers, C., 2011. Risk assessment of combined exposure to multiple chemicals: a WHI/IPCS framework. Regul. Toxicol. Pharmacol. 60, 1\u201314. Melching-Kollmu\u00df, S., Dekant, W., Kalberlah, F., 2010. Application of the \u2018\u2018threshold of toxicological concern\u2018\u2018 to derive tolerable concentrations of \u2018\u2018non relevant metabolites\u2019\u2019 formed from plant protection products in ground and drinking water. Regul. Toxicol. Pharmacol. 56, 126\u2013134. M\u00fcller, L., Mauthe, R.J., Riley, C.M., Andino, M.M., De Antonis, D., Beels, C., DeGeorge, J., De Knaep, A.G.M., Ellison, D., Fagerland, J.A., Frank, R., Fritschel, B., Galloway, S., Harpur, E., Humfrey, C.D.N., Jacks, A.S., Jagota, N., Mackinnon, J., Mohan, G., Ness, D.K., O\u0301Donovan, M.R., Smith, M Dammann., Vudathala, G., Yotti, L., 2006. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. Regul. Toxicol. Pharmacol. 44, 198\u2013211. Munro, I.C., 1990. Safety assessment procedures for indirect food additives: an overview. Report of a Workshop. Regul. Toxicol. Pharmacol. 12, 2\u201312. Munro, I.C., Ford, R.A., Kennepohl, E., Sprenger, J.G., 1996. Correlation of structural class with no-observed effect levels: a proposal for establishing a threshold of concern. Food Chem. Toxicol. 34, 829\u2013867. Munro, I.C., Kennepohl, E., Kroes, R., 1999. A procedure for the safety evaluation of flavoring substances. Food Chem. Toxicol. 37, 207\u2013232. OECD Guideline for Testing of Chemicals, Proposal for updating Guideline 414: Prenatal Developmental Toxicity Study (22 Jan 2001). Renwick, A.G., 2004. Toxicology databases and the concept of thresholds of toxicological concern as used by the JECFA for the safety evaluation of flavoring agents. Toxicol. Lett. 149, 223\u2013234. Rowbotham, A.L., Gibson, R.M., 2011. Exposure driven risk assessment: applying exposure based waiving of toxicity tests under REACH. Food Chem. Toxicol. 49, 1661\u20131673. Rulis, A.M., 1986. De minimis and the threshold of regulation. In: Felix, C.W. (Ed.), Food Protection Technology. Lewis Publishers, Chelsea, MI, pp. 29\u201337. Scientific Committee on Consumer Products (SCCP) \u2013 Scientific Committee on Health and Environmental Risks (SCHER) \u2013 Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR), 2008. Draft Opinion on Use of the Threshold of Toxicological Concern (TTC) Approach for the Safety Assessment of Chemical Substances. Tluczkiewicz, I., Buist, H.E., Martin, M.T., Mangelsdorf, I., Escher, S.E., 2011. Improvement of the Cramer classification for oral exposure using the database TTC RepDose \u2013 a strategy description. Regul. Toxicol. Pharmacol. 61, 340\u2013350. van Ravenzwaay, B., Dammann, M., Buesen, M., Schneider, S., 2011. The threshold of toxicological concern for prenatal developmental toxicity. Regul. Toxicol. Pharmacol. 59, 81\u201390. Vermeire, T., van de Bovenkamp, M., Bruinen de Bruin, Y., Delmaar, C., van Engelen, J., Escher, S., Marquat, H., Meijster, T., 2010. Exposure based waiving under REACH. Regul. Toxicol. Pharmacol. 58, 408\u2013420. Wilson, J.G., and Warkany, J. 1965, Teratology: Principles and Techniques. The University of Chicago Press. Chicago and London. http://www.efsa.eu.int/science/afc/catindex_en.html http://www.efsa.eu.int/science/afc/catindex_en.html http://www.efsa.europa.eu/en/consultationsclosed/call/110712a.pdf http://www.efsa.europa.eu/en/consultationsclosed/call/110712a.pdf http://www.eudra.org/emea.html http://www.emeaeu.int/pdfs/human/swp/519902en.pdf http://www.emeaeu.int/pdfs/human/swp/519902en.pdf http://www.jecfa.ilsi.org/ http://www.ftp://ftp.fao.org/es/esn/jecfa/jecfa65_summary.pdf http://www.ftp://ftp.fao.org/es/esn/jecfa/jecfa65_summary.pdf http://www.whqlibdoc.who.int/trs/WHO_TRS_934.pdf http://www.whqlibdoc.who.int/trs/WHO_TRS_934.pdf The threshold of toxicological concern for prenatal developmental toxicity in rabbits and a comparison to TTC values in rats 1 Introduction 2 Materials and methods 2.1 General design of developmental toxicity studies 2.2 Statistical analysis 3 Results 3.1 Calculation of a TTC value for oral prenatal developmental toxicity for rabbits 4 Discussion Conflict of interest statement Funding sources statement Acknowledgements Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-toxicokinetic-profile-of-curdione-in-pregnant-SD-ra_2015_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25527910", "content": {"CoiStatement": "Conflict of interest statement The authors declare that they have no conflicts of interest. The authors declare that they have no conflicts of interest. Acknowledgments 4 Discussion 5 Conclusion Conflict of interest statement Acknowledgments References", "Acknowledgement": "Acknowledgments The National Science and Technology Major Project of Original New Drug Research of China (2011ZX09301-005) supported this study. 4 Discussion 5 Conclusion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-toxicological-evaluation-of-repetitive-2--and-4-we_2015_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26107293", "content": {"CoiStatement": "B.-H. Yoon et al. / Regulatory Toxicology and Pharmacology 73 (2015) 1e88 Conflicts of interest All authors disclose here that there are no conflicts of interest that could inappropriately have influenced the outcome of the present study. All authors disclose here that there are no conflicts of interest that could inappropriately have influenced the outcome of the present study. Funding sources statement 4. Discussion Conflicts of interest Funding sources statement Transparency document References", "Funding": "Funding sources statement This work was supported by a Grant-in-aid from the Korean Health Industry Development Institute (#HI12C0006). 4. Discussion Conflicts of interest Funding sources statement Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-transgenic-mouse-assay-as-an-alternative-test-met_2009_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19126422", "content": {"CoiStatement": "It is also worth noting that the information derived from the alternatives indicated in the Integrated Testing Strategy for carcin- ogenicity does not appear to be adequate for use in human health risk characterization (a key goal of safety assessment), at least with regard to establishment of a safe exposure level (i.e., Derived No Effect Level [DNEL] and Derived Minimal Effect Level [DMEL] values, with DNEL values being set for threshold effects and DMEL values being set for non-threshold effects (ECHA-2, 2008). Certainly, bioassays conducted in in vitro systems or in transgenic animals in the absence of additional in vivo carcinogenicity data cannot directly inform the derivation of DNELs or DMELs. Thus, the use of these techniques can at best be expected to influence future courses of action or, as discussed above, supplement under- standing of traditional toxicology studies. It is doubtful that the results of such studies will frequently or consistently obviate the need for a traditional two-year carcinogenicity bioassay. In conclusion, based on the comprehensive analyses conducted by NTP, HESI, ICCVAM, and EMEA, the use of transgenic animals as a replacement for the second, traditional carcinogenicity test per- formed in mice can greatly enhance the accuracy of such testing, reducing the numbers of false positives and false negatives. Therefore, the use of transgenic animals can increase the level of http://ecvam.jrc.it M.Y. Wells, E.S. Williams / Regulatory Toxicology and Pharmacology 53 (2009) 150\u2013155 155 certainty about potential carcinogenicity of chemicals in the mar- ketplace while minimizing the use of laboratory animals. These goals are entirely compatible with the philosophy of REACH. Yet, the REACH Regulation and Guidance on IR/CSA do not make firm recommendations on the course of testing or decision-making with regard to carcinogenicity. The language of these documents strongly implies that the Agency may find a single traditional ani- mal test acceptable (in accordance with the goal of reducing the use of laboratory animals), despite the demonstrated added value to human risk assessment provided by the transgenic mouse assay. As written, the current regulatory policy does not acknowledge that a requirement for a second, alternative carcinogenicity assay would reduce the possibility that human carcinogens would go undetected. Conflict of interest statement The authors declare that there are no conflicts of interest. References Allanou, R., Hansen, B.G., van der Bilt, Y., 2003. Public availability of data on EU high production volume chemicals\u2014Part 2. Chimica Oggi, 59\u201364. Ashby, J., 2001. Expectations for transgenic rodent cancer bioassay models. Toxicol. Pathol. 29, 177\u2013181. Bucher, J.R., 1998. Update on national toxicology program (NTP) assays with genetically altered or \u2018\u2018transgenic\u201d mice. Environ. Health Perspect. 106, 619\u2013 621. Cohen, S.M., Robinson, D., MacDonald, J., 2001. Alternative models for carcinogenicity testing. Toxicol. Sci. 64, 14\u201319. Combes, R., Grindon, C., Cronin, M.T.D., Roberts, D.W., Garrod, J., 2007. Proposed integrated decision-tree testing strategies for mutagenicity and carcinogenicity in relation to the EU REACH legislation. ATLA 35, 267\u2013287. Doe, J.E., Boobis, A.R., Blacker, A., Dellarco, V., Doerrer, N.G., Franklin, C., Goodman, J.I., Kronenberg, J.M., Lewis, R., Mcconnell, E.E., Mercier, T., Moretto, A., Nolan, C., Padilla, S., Phang, W., Solecki, R., Tilbury, L., van Ravenzwaay, B., Wolf, D.C., 2006a. A tiered approach to systemic toxicity testing for agricultural chemical safety assessment. Crit. Rev. Toxicol. 36, 37\u201368. Doe, J.E., Lewis, R.W., Botham, P.A., 2006b. Comments on a scientific and animal welfare assessment of the OECD health effects test guidelines for the safety testing of chemicals under the European Union REACH system. Altern. Lab Anim. 34, 111\u2013114. ECHA-1, 2008. Guidance on information requirements and chemical safety assessment. Chapter R.7a: Endpoint specific guidance. Available from: <http:// reach.jrc.it/docs/guidance_document/information_requirements_r7a_en.pdf? vers=30_07_08>. Accessed on 8 October 2008. ECHA-2, 2008. Guidance on information requirements and chemical safety assessment. Chapter R.8: Characterisation of dose [concentration]-response for human health. Available from: <http://reach.jrc.it/docs/guidance_ document/information_requirements_r8_en.pdf?vers=20_08_08>. Accessed on 6 November 2008. European Centre for the Validation of Alternative Methods, 2008. Available from: <http://ecvam.jrc.it>. Accessed on 8 October 2008. European Medicines Agency, 2004. CHMP SWP Conclusions and Recommendations on the Use of Genetically Modified Animal Models for Carcinogenicity Assessment. CPMP/SWP/2592/02 Rev 1. 12 p. European Medicines Agency, 2008. Guidelines for Human Medicinal Products. Available from: <http://www.emea.europa.eu/htms/human/humanguidelines/ nonclinical.htm>. Accessed on 8 October 2008. European Research Center, 2008. European Chemical Substances Information System\u2014HPV-LPV. Available from: <http://ecb.jrc.ec.europa.eu/esis/index. php?PGM=hpv>. Accessed on 8 October 2008. European Union, 2007. Regulation (EC) 1907/2006 of the European Parliament and of the Council of 18 December 2006 Concerning the Registration, Evaluation, Authorization and Restriction of Chemicals (REACH). Official Journal of the European Union, L 136/3\u2014L 136/280. European Union, 2008. Council Regulation (EC) 440/2008 of 31 May 2008 laying down test methods pursuant to Regulation (EC) 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorization and Restriction of Chemicals (REACH). Official Journal of the European Union, L 142/1\u2014L 142/739. Forster, R., 1998. A global collaboration on carcinogenicity screening in transgenic mouse models. Transgenic Anim. 7, 1\u20133. H\u00f6fer, T., Gerner, I., Gundert-Remy, U., Liebsch, M., Schulte, A., Spielmann, H., Vogel, R., Wettig, K., 2004. Animal testing and alternative approaches for the human health risk assessment under the proposed new european chemicals regulation. Arch. Toxicol. 78, 549\u2013564. International Conference on Harmonisation, 1997. S1B: Testing for Carcinogenicity of Pharmaceuticals. Available from: <http://www.ich.org/LOB/media/ MEDIA490.pdf>. Accessed on 8 October 2008. Jacobsen-Kram, D., Sistare, F.D., Jacobs, A.C., 2004. Use of transgenic mice in carcinogenicity hazard assessment. Toxicol. Pathol. 32 (Suppl. 1), 49\u201352. Koch, L., Ashford, N.A., 2006. Rethinking the role of information in chemicals policy: implications for TSCA and REACH. J. Clean. Prod. 14, 31\u201336. Lilienblum, W., Dekant, W., Foth, H., Gebel, T., Hengstler, J.G., Kahl, R., Kramer, P.- J., Schweinfurth, H., Wollin, K.-M., 2008. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European chemicals legislation (REACH). Arch. Toxicol. 82, 211\u2013236. Mephem, T.B., Combes, R.D., Balls, M., Barbieri, O., Blokhuis, H.J., Costa, P., Crilly, R.E., Buning, T.dC., Delpire, V.C., O\u2019Hare, M.J., Houdebine, L.-M., van Kreijl, C.F., van der Meer, M., Reinhardt, C.A., Wolf, E., van Zeller, A.-M., 1998. The use of transgenic animals in the european union. The report and recommendations of ECVAM workshop 28. ATLA 26, 21\u201343. National Institutes of Health, 2008. The NICEATM-ICCVAM Five-Year Plan (2008\u2013 2012). NIH Publication 08-6410. National Toxicology Program. Basis of Transgenic Model Studies. Available from: <http://ntp-server.niehs.nih.gov/?objectid=1EF2F674-F1F6-975E-751EAA7191 13D6ED>. Accessed 8 October 2008. National Toxicology Program. Summary of NIEHS/NTP Alternative Test System Development and Validation. Available from: <http://ntp-server.niehs.nih.gov/ ?objectid=05742678-F1F6-975E-71A9C5E73E2B6E93>. Accessed 8 October 2008. OECD 451, 1981. OECD Guideline for Testing of Chemicals: \u2018\u2018Carcinogenicity Studies\u201d. 17 p. Pederson, F., de Bruijn, J., Munn, S., van Leeuwen, K., 2003. Assessment of additional testing needs under REACH\u2014Effects of (Q)SARs, risk based testing and voluntary industry initiatives. JRC Report EUR 20863, 33 p. Pritchard, J.B., French, J.E., Davis, B.J., Haseman, J.K., 2003. The role of transgenic mouse models in carcinogen identification. Environ. Health Perspect. 111, 444\u2013 454. Thompson, K.L., Rosenzweig, B., Sistare, F.D., 1998. An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals ii. genotyping that predicts tumorigenic responsiveness. Toxicol. Pathol. 26, 548\u2013555. US Food and Drug Administration Guidance Documents: International Conference on Harmonisation\u2014Safety, 2008. Available from: <http://www.fda.gov/cder/ guidance/index.htm#International%20Conference%20on%20Harmonisation% 20-%20Safety>. Accessed on 8 October 2008. US Environmental Protection Agency Risk Assessment Forum, 2005. Guideline for Carcinogen Risk Assessment. EPA/630/P-03/001B. 166 p. van der Jagt, K., Munn, S., T\u00f8rsl\u00f8v, J., de Bruijn, J., 2004. Alternative Approaches Can Reduce the Use of Test Animals Under REACH. JRC Report EUR 24105. 31 p. http://reach.jrc.it/docs/guidance_document/information_requirements_r7a_en.pdf?vers=30_07_08 http://reach.jrc.it/docs/guidance_document/information_requirements_r7a_en.pdf?vers=30_07_08 http://reach.jrc.it/docs/guidance_document/information_requirements_r7a_en.pdf?vers=30_07_08 http://reach.jrc.it/docs/guidance_document/information_requirements_r8_en.pdf?vers=20_08_08 http://reach.jrc.it/docs/guidance_document/information_requirements_r8_en.pdf?vers=20_08_08 http://ecvam.jrc.it http://www.emea.europa.eu/htms/human/humanguidelines/nonclinical.htm http://www.emea.europa.eu/htms/human/humanguidelines/nonclinical.htm http://ecb.jrc.ec.europa.eu/esis/index.php?PGM=hpv http://ecb.jrc.ec.europa.eu/esis/index.php?PGM=hpv http://www.ich.org/LOB/media/MEDIA490.pdf http://www.ich.org/LOB/media/MEDIA490.pdf http://ntp-server.niehs.nih.gov/?objectid=1EF2F674-F1F6-975E-751EAA719113D6ED http://ntp-server.niehs.nih.gov/?objectid=1EF2F674-F1F6-975E-751EAA719113D6ED http://ntp-server.niehs.nih.gov/?objectid=05742678-F1F6-975E-71A9C5E73E2B6E93 http://ntp-server.niehs.nih.gov/?objectid=05742678-F1F6-975E-71A9C5E73E2B6E93 http://www.fda.gov/cder/guidance/index.htm#International%20Conference%20on%20Harmonisation%20-%20Safety http://www.fda.gov/cder/guidance/index.htm#International%20Conference%20on%20Harmonisation%20-%20Safety http://www.fda.gov/cder/guidance/index.htm#International%20Conference%20on%20Harmonisation%20-%20Safety The transgenic mouse assay as an alternative test method for regulatory carcinogenicity studies\u2014Implications for REACH Introduction The two-year rodent carcinogenicity bioassay Transgenic mouse models as alternatives to the two-year carcinogenicity bioassay HESI initiative (See Table 1) NTP initiative (See Table 1) Current state of the science Conflict of interest statement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-translational-value-of-animal-models-in-orphan-me_2020_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33122047", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The translational value of animal models in orphan medicines designations for rare paediatric neurological diseases 1 Introduction 2 Scope of the review 3 Orphan designations: Future therapies for rare paediatric neurologic diseases 4 Relevance of nonclinical models to support medical plausibility 5 Animal models of centronuclear myopathy (CNM) 6 Animal models of Aicardi\u2013Gouti\u00e8res syndrome (AGS) 7 Overall conclusions Disclaimer Funding sources Declaration of competing interest References", "Funding": "Funding sources This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Declaration of competing interest The translational value of animal models in orphan medicines designations for rare paediatric neurological diseases 1 Introduction 2 Scope of the review 3 Orphan designations: Future therapies for rare paediatric neurologic diseases 4 Relevance of nonclinical models to support medical plausibility 5 Animal models of centronuclear myopathy (CNM) 6 Animal models of Aicardi\u2013Gouti\u00e8res syndrome (AGS) 7 Overall conclusions Disclaimer Funding sources Declaration of competing interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/The-underlying-mode-of-action-for-lung-tumors-in-a-ti_2022_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/35158000", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Ruth Danzeisen reports financial support and administrative support were provided by Cobalt Institute. Ruth Danzeisen reports financial support and administrative support were provided by Cobalt REACH Consortium. Ruth Danzeisen reports a relationship with Cobalt Institute that includes: employment. Ruth Danzeisen reports a relationship with Cobalt REACH Consortium that includes: employment. 9 Uncertainties, inconsistencies and data gaps 10 Assessment of postulated mode of action Summary and conclusion Funding statement and COI CRediT authorship contribution statement Declaration of competing interest References", "Funding": "Funding statement and COI The experimental work discussed in this manuscript and presented in the companion papers of this special issue was funded by the Cobalt REACH Consortium (CoRC, https://www.cobaltreachconsortium.org/) and Cobalt Institute (CI, https://www.cobaltinstitute.org). The authors V Viegas and R Danzeisen are employees of the CI. G-R Ja\u0308nig, A Burzlaff, and J Adam have been providing scientific and regulatory consulting to the CI and CoRC. The author S Verberckmoes is working on behalf of BeTechnic Studios. All authors declare that the Cobalt REACH Con- sortium and Cobalt Institute did at no time interfere with the interpre- tation of data and preparation and content of the manuscript. 9 Uncertainties, inconsistencies and data gaps 10 Assessment of postulated mode of action Summary and conclusion Funding statement and COI CRediT authorship contribution statement Declaration of competing interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-urinary-metabolic-profile-of-diethylene-glycol-methyl-e_2020_Regulatory-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31704259", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: J R Kelsey is a paid consultant to REACHCentrum SA and the glycol ethers REACH consortium. He is also a paid consultant to the CEFIC Glycol Ethers Sector Group for the monitoring of literature on glycol ethers. N Cnubben was responsible for the conduct of the study at Triskelion and was an employee of Triskelion at the time. J Bogaards, L van Stee and R Braakman were members of the team that conducted the study at Triskelion and all were employees of Triskelion at the time. Karen Smet is an employee of INEOS nv who manufacture glycol ethers and was responsible for monitoring the study. The study was sponsored by the glycol ethers REACH consortium. The CEFIC Glycol Ethers sector group sponsored the preparation of the manuscript for publication. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: J R Kelsey is a paid consultant to REACHCentrum SA and the glycol ethers REACH consortium. He is also a paid consultant to the CEFIC Glycol Ethers Sector Group for the monitoring of literature on glycol ethers. N Cnubben was responsible for the conduct of the study at Triskelion and was an employee of Triskelion at the time. J Bogaards, L van Stee and R Braakman were members of the team that conducted the study at Triskelion and all were employees of Triskelion at the time. Karen Smet is an employee of INEOS nv who manufacture glycol ethers and was responsible for monitoring the study. The study was sponsored by the glycol ethers REACH consortium. The CEFIC Glycol Ethers sector group sponsored the preparation of the manuscript for publication. Acknowledgements", "Funding": "Funding This work was supported by REACH Centrum S.A., acting on its own behalf and for account of the interested individual members of the GLYCOL ETHERS REACH CONSORTIUM. Funding for publication of the work was provided by the Oxygenated Solvents Producers Association, a sector group of CEFIC, the European Chemicals Producers Association. J. R. Kelsey is a paid consultant to both REACH Centrum S.A. (Glycol Ethers Reach Consortium) and the Glycol Ethers sector group of CEFIC). This work was supported by REACH Centrum S.A., acting on its own behalf and for account of the interested individual members of the GLYCOL ETHERS REACH CONSORTIUM. Funding for publication of the work was provided by the Oxygenated Solvents Producers Association, a sector group of CEFIC, the European Chemicals Producers Association. J. R. Kelsey is a paid consultant to both REACH Centrum S.A. (Glycol Ethers Reach Consortium) and the Glycol Ethers sector group of CEFIC). Declaration of competing interest Conclusions Funding mk:H1_27 Acknowledgements References", "Acknowledgement": "Acknowledgements The authors acknowledge Dr. A. Wolterbeek for scientific discus- sions and providing data on zebrafish toxicity. (ECHA, 2018a). Conclusions Funding mk:H1_27 Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-use-of-Cav-rather-than-AUC-in-safety-_2010_Regulatory-Toxicology-and-Pha.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20074607", "content": {"CoiStatement": "1-PP 25 (single) 1250 420 50 (divided) 2290 510 100 (divided 6100 1600 Buspirone 25 (single) 15 1.4 50 (divided) 105 6.75 100 (divided 503 27.25 D.A. Smith et al. / Regulatory Toxicology and Pharmacology 57 (2010) 70\u201373 73 trast the affinity of 1-PP for a2 adrenoceptors means that there is high receptor occupancy at all dose levels suggesting that its ef- fects are relatively benign. The low receptor occupancy will be partly offset by the fact another active metabolite 6-hydroxybuspi- rone has not been measured. This metabolite (Wong et al., 2007) contributes considerably more to the 5HT1A actions of the drug than 1-PP. Moreover overall receptor occupancy (drug plus metab- olites) in the clinic is very low (approximately 5%) at therapeutic doses and concentrations to achieve this (around 1\u20132 nM) indicat- ing that only a small degree of receptor activation is required (Vis et al., 2001). This low level of occupancy, which may be a factor of agonist activity, is therefore similar to the average occupancy achieved by buspirone at the 25 mg/kg dose level The higher doses that cause side effects (particularly CNS) achieve much more marked 5HT1A receptor occupancies throughout the dosing period. 5. Conclusion We suggest Cav represents a more useful expression of time/ concentration relationships than AUC. It allows similar compari- sons of linearity but its units are directly comparable with the measures of affinity of the drug (and its metabolites) for primary and secondary pharmacology targets. Thus it allows simple PKPD relationships to be immediately investigated. When subdivided Cav gives a numerical representation of the concentration time curve. Ideally time courses of pharmacodynamic and pharmacoki- netic effects should be sampled and modelled in a comprehensive way. Indeed PKPD modelling is being increasingly used to good ef- fect in safety pharmacology studies to better understand transla- tion of cardiovascular safety signals between animals and humans (Cavero, 2007; van der Graaf et al., 2008). However, for chronic toxicology studies, where observations and sampling are sparse and certain toxicological findings can only be obtained at the end of a study (e.g. histopathology), it remains to be deter- mined if PKPD modelling and study design can be fully deployed. Nevertheless we do believe that attempts should always be made to broadly understand the concentrations at which toxicological ef- fects occur and compare these to the known potency of the com- pound against receptors associated with primary and secondary pharmacology. Such potency information is becoming much more comprehensive as broad ligand binding screens are continually en- riched. In this way basic PKPD principles can be applied to all tox- icology studies. Conflict of interest There are no conflicts of interest although all authors are employees of Pfizer. References Abbott, D., Comby, P., Charuel, C., Graepel, P., Hanton, G., Leblancc, B., Ladola, A., Longeart, L., Paulus, G., Peters, C., Stadler, J., 2004. Preclinical safety profile of sildenafil. Int. J. Impot. Res. 16, 498\u2013504. Bendele, A., Means, J., Shoufler, J., Schmalz, C., Hanasono, G., Symanowski, J., Adams, E., 1995. Chronic toxicity of zatosetron, a 5 HT3 receptor antagonist, in rhesus monkeys. Drug Chem. Toxicol. 18, 61\u201382. Cavero, I., 2007. Using pharmacokinetic/pharmacodynamic modelling in safety pharmacology to better define safety margins: a regional workshop of the Safety Pharmacology Society. Expert Opin. Drug Saf. 6, 465\u2013471. Celio, L., Denaro, A., Canova, S., Gevorgyan, A., Bajetta, E., 2008. Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting. Tumori 94, 447\u2013452. Cohen, M.L., Bloomquist, W., Schmid, C.R., Robertson, D.W., Wong, D.T., 1993. Zatosetron, a selective 5-HT3 receptor antagonist: pharmacological activities of human and animal metabolites. Drug Dev. Res. 29, 209\u2013215. Danielsson, B., Skold, A.C., Azarbayjani, F., Ohman, I., Webster, W., 2000. Pharmacokinetic data support pharmacologically induced embryonic dysrhythmia as explanation to fetal hydantoin syndrome in rats. Toxicol. Appl. Pharmacol. 163, 164\u2013175. Danielsson, B.R., Skold, A.C., Azarbayjani, F., 2001. Class III antiarrhythmics and phenytoin: teratogenicity due to embryonic cardiac dysrhythmia and reoxygenation damage. Curr. Pharm. Des. 7, 787\u2013802. Danielsson, B.R., Landsell, K., Patmore, L., Tomson, T., 2003. Phenytoin and phenobarbitol inhibit human HERG potassium channels. Epilepsy Res. 55, 147\u2013157. Franz, P Morgan., Mattiuz, E.L., Hatcher, B.L., Desante, K.A., Breau, A.P., Occolowitz, J.L., Dorman, D.E., Schmid, C.R., Goldberg, M.J., Rubin, A., 1993. Disposition of zatosetron, a serotonin (5-HT3) receptor antagonist, in humans. Drug Metab. Dispos. 21, 249\u2013254. Goodin, S., Cunningham, R., 2002. 5-HT3-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile. Oncologist 7, 424\u2013436. Kuryshev, Y.A., Brown, A.M., Wang, L., Benedict, C.R., Rampe, D., 2000. Interactions of 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J. Pharmacol. Exp. Ther. 295, 614\u2013620. Marathe, P.H., Shen, F., Markham, P., Greene, D.S., 1999. Pharmacokinetics of buspirone following oral administration to rhesus monkeys. J. Pharm. Pharmacol. 51, 601\u2013607. Sanger, G.J., 2008. 5-Hydroxytryptamine and the gastrointestinal tract: where next? Trends Pharmacol. Sci. 29, 465\u2013471. Smith, W.T., Londborg, P.D., Blomgren, S.L., Tollefson, G.D., Sayler, M.E., 1999. Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety. J. Clin. Psychopharmacol. 19, 125\u2013131. van der Graaf, P., Holbrook, M., Wallis, R., 2008. Application of translational pharmacokinetic\u2013pharmacodynamic (PKPD) modelling and simulation to preclinical safety testing. Preclinical World 2008, pp. 10\u201312. Available from: <http://www.sovereign-publications.com/pcw.htm>. Vis, P., Pasqua, O.D., Kruk, M., Martin, D., Mocaer, E., Danhof, M., Jochemsen, R., 2001. Population pharmacokinetic\u2013pharmacodynamic modelling of S15535, a 5HT1A receptor antagonist, using a behavioural model in rats. Eur. J. Pharmacol. 414, 233\u2013343. Wallis, R.M., 1999. The pharmacology of sildenafil, a novel and selective inhibitor of phosphodiesterase (PDE) type 5. Nippon Yakurigaku Zasshi 114, 22P\u201326P. Williams, P.D., Cohen, M.L., Turk, J.A., 1991. Electrocardiographic effects of zatosetron and ondansetron, two 5HT3 receptor antagonists, in anesthetised dogs. Drug Dev. Res. 24, 277\u2013284. Wong, H., Dockens, R.C., Pajor, L., Yeola, S., Grace Jr., J.E., Stark, A.D., Taub, R.A., Yocca, F.D., Zaczek, R.C., Li, Y.W., 2007. 6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5HT1A receptor occupancy in rats. Drug Metab. Dispos. 35, 1387\u20131392. http://www.sovereign-publications.com/pcw.htm The use of Cav rather than AUC in safety assessment Background The rationale for Cav To allow interpretation of dose\u2013response within a study To allow comparison across species Conclusion Conflict of interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-use-of-Genomic-Allergen-Rapid-Detection--GARD--ass_2019_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30629970", "content": {"Funding": "Funding This work was funded and supported by Fontem Ventures B.V. Imperial Brands Group PLukasz Czekala is the parent company of Fontem Ventures B.V., the manufacturer of one of the commercial e-liquids used in this study. Discussion Conclusion Funding Acknowledgments Supplementary data Transparency document References", "Acknowledgement": "Acknowledgments We would like to thank SenzaGen for conducting the study and statistical evaluation. We would also like to thank Dr Anne May and Claire Martin for their contributions to manuscript writing. Discussion Conclusion Funding Acknowledgments Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-use-of-MRI-to-assist-the-section-selections-for_2014_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25265367", "content": {"CoiStatement": "The use of MRI in the living animal can be utilized to target spe- cific brain areas to be examined for classical neuropathology. This approach offers a dramatic improvement over the current practice of selecting three to five routine arbitrary brain sections for tradi- tional analyses. Here, the basic assumption is made that these MRI- targeted areas will include whatever neuropathology a new or unknown compound or drug may produce. The longitudinal inves- tigation of the onset of toxicity in the living animal, its apex and regression, allows each experimental subject to serve as its own control. This advantage should improve the statistical power of J. Hanig et al. / Regulatory Toxicology and Pharmacology 70 (2014) 641\u2013647 647 the resulting data and decrease animal usage in routine toxicolog- ical studies. This approach also allows for the optimization of time of sacrifice and selection of an appropriate stain for definitive neu- ropathology. This is extremely important since a large number of neurodegenerative processes occur within a certain time period after exposure and the evidence can be scavenged away over time. Thus, the use of even an appropriate stain can result in false nega- tive findings if the tissue collection occurs at the wrong time. Importantly, MRI images can inform the selection of appropriate stains. For example, when the MRI signal is concentrated in white matter areas, then myelin stains would be indicated. Finally, utili- zation of whole brain MRI, when used to optimize target location for subsequent neuropathology, accomplishes what would typi- cally require more than 60 sections if only routine neuropathology techniques were employed. While there is significant initial cost associated with the MRI approach, the expenditure can be minis- cule compared to the cost savings realized when toxicity is detected long before a compound enters phase II clinical trials which is where most compounds having CNS side effects fail. In addition to this substantial cost savings there is the ultimate ben- efit of increasing drug safety and decreasing the number of animals used pre-clinically. Conflict of interest The authors, Joseph Hanig., M.P., V.R., Larry Schmued., Tetyana Konak., Srinivasulu Chigurupati., William Slikker., Sumit Sarkar. and Serguei Liachenko. are all employees of the Food and Drug Administration and have no conflicts of interest. Funding The authors, Joseph Hanig., M.P., V.R., Larry Schmued., Tetyana Konak., Srinivasulu Chigurupati., William Slikker., Sumit Sarkar. and Serguei Liachenko. are all employees of the Food and Drug Administration and have no conflicts of interest. Funding FDA \u2013 Center for Drug Evaluation & Research (CDER) Critical Path Program, CDER Office of Research & Testing and National Cen- ter for Toxicological Research/FDA (E0741801) for support. Disclaimer 3 Results 4 Discussion 5 Conclusions Conflict of interest Funding Disclaimer Acknowledgments References", "Funding": "The authors, Joseph Hanig., M.P., V.R., Larry Schmued., Tetyana Konak., Srinivasulu Chigurupati., William Slikker., Sumit Sarkar. and Serguei Liachenko. are all employees of the Food and Drug Administration and have no conflicts of interest. Funding FDA \u2013 Center for Drug Evaluation & Research (CDER) Critical Path Program, CDER Office of Research & Testing and National Cen- ter for Toxicological Research/FDA (E0741801) for support. Disclaimer 3 Results 4 Discussion 5 Conclusions Conflict of interest Funding Disclaimer Acknowledgments References", "Acknowledgement": "The content of this publication represents solely the authors\u2019 views and may not reflect any position of the U.S. Government or the Food and Drug Administration. Acknowledgments Jay Chang, Ph.D. for helpful suggestions and advice. Vincent Vilker, Ph.D. for encouragement and programmatic support. References 3 Results 4 Discussion 5 Conclusions Conflict of interest Funding Disclaimer Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-use-of-Markov-chain-Monte-Carlo-uncertainty-analy_2007_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16901594", "content": {"Acknowledgement": "Acknowledgments The authors wish to thank Bruce Allen and Eric Hack for their helpful advice during the implementation of the MCMC approach. This work was supported by the Dow Chemical Company, E. I. du Pont de Nemours and Com- pany, Hoyt Corporation, Occidental Chemical Corpora- tion, PPG Industries Inc., R.R. Street and Company, Inc., and Vulcan Materials Company. However, the views presented in this paper are strictly those of the authors and do not necessarily reflect the positions of the various sponsors. The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene Introduction Methods Results Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-use-of-charcoal-in-modified-cigarette-filters-_2017_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28238852", "content": {"CoiStatement": "Declaration of interests The authors declare no competing financial interests. Funding Declaration of interests Acknowledgements Appendix A. Supplementary data Transparency document References", "Funding": "Funding This research was funded by the Center for Tobacco Products at the United States Food and Drug Administration (FDA). Funding Declaration of interests Acknowledgements Appendix A. Supplementary data Transparency document References", "Acknowledgement": "Acknowledgements The findings and conclusions of this study are those of the au- thors and do not necessarily represent the position or policy of the FDA. Use of trade names and commercial sources is for identifica- tion only and does not constitute endorsement by the U.S. Department of Health and Human Services or the FDA. The authors thank Jenna DuMond, Ph.D. for her scientific input. Funding Declaration of interests Acknowledgements Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-use-of-emerging-safety-biomarkers-in-nonclinical-and_2021_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33387566", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 4 Conclusion Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Funding": "Funding This work did not receive any specific grant from the funding agencies in the public, commercial, or not-for-profit sectors. The authors of this article are full-time employees of Genentech (T.Z.), Pfizer (John Burkhardt., W.R., Lila Ramaiah.), Sanofi (J. G.), Merck & Co. (W.G.), AbbVie (Magali Guffroy.), Astra- Zeneca (Joanna Harding.), Novartis (Dominique Brees.), Janssen (Eric McDuffie.), Lilly Research Labora- tories (E.S.), Boehringer Ingelheim (J.S.), UCB Biopharma (Alison Wolfreys.), and GlaxoSmithKline (Deidre A Dalmas). Opinions expressed in this article are those of the authors, and not necessarily reflect those of the organization with which the authors are affiliated. This work did not receive any specific grant from the funding agencies in the public, commercial, or not-for-profit sectors. The authors of this article are full-time employees of Genentech (T.Z.), Pfizer (John Burkhardt., W.R., Lila Ramaiah.), Sanofi (J. G.), Merck & Co. (W.G.), AbbVie (Magali Guffroy.), Astra- Zeneca (Joanna Harding.), Novartis (Dominique Brees.), Janssen (Eric McDuffie.), Lilly Research Labora- tories (E.S.), Boehringer Ingelheim (J.S.), UCB Biopharma (Alison Wolfreys.), and GlaxoSmithKline (Deidre A Dalmas). Opinions expressed in this article are those of the authors, and not necessarily reflect those of the organization with which the authors are affiliated. CRediT authorship contribution statement 4 Conclusion Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Acknowledgement": "Acknowledgements The authors wish to thank the contributions from prior members of the IQ DruSafe team, Kristin Barnhart (AbbVie) and Andre da Costa (UCB Biopharma), IQ independent third-party secretariat (Drinker, T.S. Zabka et al. Regulatory Toxicology and Pharmacology 120 (2021) 104857 11 Biddle, & Reath LLP) for helping with the conduct of the survey and blinding of survey results, and Joanne Birkebak (Gilead), Mazin Derzi (Pfizer), Timothy Hart (GlaxoSmithKline), Timothy LaBranche (Blue- print Medicines), and Ian Pyrah (Seattle Genetics) for critical review of the manuscript. 4 Conclusion Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-use-of-human-adipose-derived-stem-cells-based-_2015_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26382612", "content": {"CoiStatement": "In summary, ADSC represent an interesting cell model for alternative assays to animal tests with great relevance for toxicity prediction that represent important potential for industry appli- cations and for regulatory purposes. They can be used to evaluate chemical compound cytotoxicity including products that are already established or are still in development. Therefore, they can bring a new perspective to cytotoxicity tests by reducing or replacing the use of laboratory animals. In summary, ADSC repre- sents an interesting cellular model for alternative tests to animal testing. Such cells show comparable results for the 3T3 cell line, but with the advantage of being of human origin. Thus, it is concluded that this model could be used to complete the data provided by existing models, with great relevance for predicting toxicity. Our results suggest that they can be used to evaluate the cytotoxicity of chemical compounds, including products that are already estab- lished or are under development. Conflicts of interest We report no potential conflicts of interest or financial interests. We report no potential conflicts of interest or financial interests. Acknowledgments 4. Discussion 5. Conclusion Conflicts of interest Acknowledgments Transparency document References", "Acknowledgement": "Acknowledgments The authors would like to thank Dr. Alejandro Correa and Dr. Marco Stimamiglio for review and very useful suggestions and Dr. Rodrigo Re\u0302go Barros Caruso for advice on statistical analysis. 4. Discussion 5. Conclusion Conflicts of interest Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-use-of-myocardial-and-testicular-end-points-as-a-bas_2007_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/17030370", "content": {"Acknowledgement": "An attempt to estimate population threshold for humans is fraught with uncertainty because of poorly stud- ied toxicokinetics and toxicodynamics between the test spe- cies and humans, and because of heterogeneity in these processes among human populations. In addition, the pau- city of information about the toxicokinetics of 1080 in humans indicates the need to carefully limit and monitor occupational and environmental exposures to achieve a better understanding and management of human toxicity (Temple and Edwards, 1985). Acknowledgments The Wnancial support of the New Zealand Ministry of Health is kindly acknowledged. The authors also gratefully acknowledge the helpful comments of Dr. Michael Dour- son and Eric Hack, Toxicology Excellence for Risk Assess- ment (TERA). Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-use-of-structure-activity-relationship-analysi_2005_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15935536", "content": {"Acknowledgement": "Cheeseman et al. (1999) showed that SAs, genotoxi- city test results and short-term toxicity data for a large number of substances may be used to reliably predict whether an untested substance is likely to be a potent carcinogen, if it is a carcinogen at all. This work has since been expanded upon to describe a threshold of tox- icological concern (TTC) (Kroes et al., 2003). As dis- cussed by Cheeseman et al., the inclusion of SAs, genotoxicity test results and short-term toxicity data as criteria for substances proposed for approval under a TOR process was shown to significantly increase the safety assurance margin, both for carcinogenic and non-carcinogenic endpoints, even at DCs >0.5 ppb (Cheeseman et al., 1999). Moreover, the analysis served as the basis for suggesting a possible method for extend- ing FDA\ufffds TOR to a range of DCs between 0.5 and 15 ppb. For example, substances that do not belong to any SA classes, or those testing negative in the Ames as- say, may qualify for a higher TOR, possibly on the order of 5 ppb in the daily diet. On the other hand, it was sug- gested by Cheeseman et al., that even those substances that belong to certain structure classes (e.g., N-nitroso- amine or benzidine) and test positive in the Ames assay may not be appropriate for TOR exemptions even at DCs of 60.5 ppb (Cheeseman et al., 1999). The OFAS is currently exploring the possibility of extending these concepts to the FCN process. As noted earlier, the min- imum recommended genetic toxicity tests for substances with DCs >0.5 ppb include the assessment of gene muta- tions in bacteria, (e.g., Ames assay), and gene mutations in mammalian cells (e.g., in vitro mouse lymphoma tk+/\ufffd assay) or cytogenetic damage in mammalian cells (e.g., in vitro detection of micronuclei or chromosomal aber- rations). For example, the possibility of recommending one assay, an Ames assay, and an SAR analysis for sub- stances with DCs between 0.5 and 5 ppb is currently being examined. This approach is consistent with the observation that the Ames assay is useful as a qualitative predictor of carcinogenicity (Fetterman et al., 1997) and, moreover, many constituents have DC values in the low ppb range. Furthermore, preliminary work paring the results of MCASE-ES, Ames and other mutagenicity tests suggests that inclusion of the other mutagenicity tests do not significantly increase the predictive power at low DCs (Cheeseman, personal communication). Such an approach would significantly increase the effec- tiveness of the existing TOR and FCN processes by effi- ciently utilizing agency resources by providing a level of effort commensurate with the perceived public health risk. Acknowledgments The authors wish to thank Ms. Julie Mayer and Drs. George Pauli, Kirk Arvidson, Andrew McDougal, and Francis Lin for insightful comments and the generation of statistics used in the paper. References Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-utility-of-QSARs-in-predicting-acute-fish-toxicit_2016_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27235557", "content": {"CoiStatement": "Conflict of interest statement None. 5. Conclusions Conflict of interest statement Acknowledgements Transparency document Appendix A. Supplementary data References", "Acknowledgement": "Acknowledgements There was no specific financial support for this paper other than the time invested by the authors. Its conception resulted from discussions within the UK's NC3Rs ecotoxicology working group. 5. Conclusions Conflict of interest statement Acknowledgements Transparency document Appendix A. Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-utility-of-the-K6-ODC-transgenic-mouse-as-an-altern_2008_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18069108", "content": {"Acknowledgement": "96 T.J. Miller et al. / Regulatory Toxicology and Pharmacology 50 (2008) 87\u201397 this model for assessing the carcinogenic potential of pharmaceuticals for regulatory purposes. Age-related, adverse phenotypic changes combined with heightened sensitivity to changing environmental conditions and opportunistic pathogenic organisms would likely prevent use of K6/ODC mice as an alternative carcinogenicity assay, since the ICH recommended minimum time for the in-life portion for those studies is six months (Jacob- son-Kram et al., 2004). In addition, prior to initiation of the study, the large number of animals needed for this study warranted a two-year waiting period before suffi- cient mice could be generated to populate each treatment group. Unique phenotypic changes characteristic of the transgene including toenail hypertrophy, skin hyperplasia, hyperkeratosis, follicular dystrophy, and sebaceous gland hyperplasia appear to be the root cause for many of the degenerative health conditions observed in the latter half of the study (<20 weeks). Despite the demonstrated sus- ceptibility of K6/ODC mice to chemical induced carcino- genesis with established carcinogens, the health and survivability problems observed in this study preclude the use of the K6/ODC mouse as a six month ICH in vivo alternative to the two-year rodent cancer bioassay for evaluating the carcinogenic potential of pharmaceuti- cals. However, the presence of extensive, multi-organ amy- loid deposition in the aged K6/ODC mouse suggests that this transgenic strain might be a useful model to study mechanisms of amyloidosis or to examine eczematous conditions in possible immuno-compromised, transgenic mice, a lesser studied research area. In addition, future studies to address the oncogenic potential of viral cell sub- strate DNA may be evaluated in other proposed alterna- tive transgenic mouse models. Acknowledgments The authors thank Dr. Albert E. New and Dr. Robert Hickman for their insightful advise, support, suggestions, and veterinary care for the animals in this study. The authors also thank Drs. Andrew Lewis, Keith Peden, and Li Sheng from the Division of Viral Products at the Center for Biologics Evaluation and Research (CBER), USFDA for the development and analysis of the p-MSV-T24-H- ras plasmid and MSV expression plasmid used in this study. Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-validation--amp--verification-of-an-LC-MS-method-for_2018_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29577958", "content": {"CoiStatement": "Declaration of conflicting interests The authors declare no competing financial interest. Conclusion Acknowledgments Transparency document Funding Declaration of conflicting interests References", "Funding": "Funding This work was funded by Alltech SARL (France). Conclusion Acknowledgments Transparency document Funding Declaration of conflicting interests References", "Acknowledgement": "Conclusion Acknowledgments Transparency document Funding Declaration of conflicting interests References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-value-of-acute-toxicity-studies-to-support-the-cli_2010_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20627115", "content": {"CoiStatement": "Conflict of interest Dr. Wilks is a shareholder of AstraZeneca and Syngenta. All other authors declare no conflict of interest. Dr. Wilks is a shareholder of AstraZeneca and Syngenta. All other authors declare no conflict of interest. Acknowledgments Conclusions Funding sources Conflict of interest Acknowledgments References", "Funding": "5. Funding sources This workshop was funded by the NC3Rs. Conclusions Funding sources Conflict of interest Acknowledgments References", "Acknowledgement": "Acknowledgments The authors thank Vicky Robinson (NC3Rs) for chairing the acute toxicity workshop and for her helpful comments on this manuscript. The authors are also grateful to the experts who par- ticipated in the NC3Rs workshop, who were from the organisations listed below2: Conclusions Funding sources Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-value-of-acute-toxicity-testing-of-pharmaceut_2012_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22306828", "content": {"CoiStatement": "418 E. Lov\u0161in Barle et al. / Regulatory Toxicology and Pharmacology 62 (2012) 412\u2013418 for potential acute toxicity within the GHS/EU CLP based on human data and disregard classification based on animal oral LD50 values. Conflict of Interest statement The authors do not have any conflicts of interest related to the topic presented in this article. References The authors do not have any conflicts of interest related to the topic presented in this article. References Andrew, D.J., 2009. Acute toxicity. In: Ballantyne, B., Marrs, T.C., Syversen, T. (Eds.), General and Applied Toxicology. Wiley and Sons, Chichester, pp. 58\u201372. 4 Discussion Conflict of Interest statement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/The-value-of-avian-gross-pathology-in-identifyin_2020_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31978447", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Data utilized for evaluation of avian gross pathological findings was obtained from the Eurofins Agroscience Services historical control da- tabase. Funding for the statistical analysis of the historical control data and preparation of this publication was funded by Corteva Agriscience. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Data utilized for evaluation of avian gross pathological findings was obtained from the Eurofins Agroscience Services historical control da- tabase. Funding for the statistical analysis of the historical control data and preparation of this publication was funded by Corteva Agriscience. References", "Funding": "The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Data utilized for evaluation of avian gross pathological findings was obtained from the Eurofins Agroscience Services historical control da- tabase. Funding for the statistical analysis of the historical control data and preparation of this publication was funded by Corteva Agriscience. References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Therapeutic-dose-as-the-point-of-departure-in-assessing-_2011_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20056125", "content": {"Acknowledgement": "Benchmark dose: a model-derived dose, based on actual data, to arrive at a standard response. Most frequently, a statistical lower bound of this dose is used as a point of departure for arriving at a safe exposure level (e.g. LTD10 = the 95% lower bound on the dose that would produce a 10% response in a population. Granular activated carbon (GAC): coal, or other carbon based material that is acti- vated by high heat, to expose absorptive surfaces. Lowest observed adverse effect level (LOAEL): the lowest dose at which a significant adverse response occurs. Frequently used as a point of departure in the absence of a no observed adverse effect level (NOAEL) with the application of an uncertainty factor. http://www.leadscope.com/ http://ntp.niehs.nih.gov/?objectid=D7C7E75B-F1F6-975E-7960632E81DA3E97 http://ntp.niehs.nih.gov/?objectid=D7C7E75B-F1F6-975E-7960632E81DA3E97 http://ntp-server.niehs.nih.gov/ http://www.rxlist.com/script/main/hp.asp http://www.epa.gov/safewater http://www.fda.gov/cder/reports/rtn/2005/rtn2005.pdf http://www.fda.gov/cder/reports/rtn/2005/rtn2005.pdf http://www.fda.gov/cder/Offices/OPS_IO/MRTD.htm http://www.fda.gov/cder/Offices/OPS_IO/MRTD.htm http://www.fda.gov/CDER/DRug/drugReactions/default.htm http://www.fda.gov/CDER/DRug/drugReactions/default.htm http://www.fda.gov/cder/DrugSafety/DrugIndex.htm http://www.fda.gov/cder/offices/OTC/consumer.htm http://www.fda.gov/cder/offices/OTC/consumer.htm http://www.accessdatga.fda.gov/scripts/medwatch http://www.accessdatga.fda.gov/scripts/medwatch R.J. Bull et al. / Regulatory Toxicology and Pharmacology 60 (2011) 1\u201319 19 Margin of exposure (MOE): the ratio of the lowest dose to produce an adverse effect, commonly referred to as a LOAEL, to the dose that is obtained through an environmental exposure. Minimum therapeutic dose (MTD): the lowest therapeutic dose that could be iden- tified for a drug, preferably an oral dose. Membrane bioreactor (MBR): a bioreactor used in the treatment of wastewater from which the processed water is removed through an ultrafiltration membrane. No observed adverse effect level (LOAEL): the highest dose at which an adverse effect is not observed. Point of departure (POD): the dose that is used for establishing a \u2018\u2018safe\u2019\u2019 level or de minimis risk by applying a series of uncertainty factors or by linear extrapola- tion to lower doses. It usually is a LOAEL, NOAEL, or benchmark dose for the adverse effect that is observed at the lowest dose. Reverse Osmosis: a filtration process that uses pressure to force the product water through a semipermeable membrane while retaining salts and most organic solutes in the reject water. Soil Aquifer Treatment: placing water in a basin with permeable sides and bottom with the purpose of recharging underground waters. The passage of the water through the soil removes contaminants through absorptive and biologic processes. Uncertainty factor (UF): a factor applied to a point of departure, such as a NOAEL, LOAEL, or benchmark dose to adjust the dose to allow for inadequate data. For example, UFs are used to adjust data from animals to compensate for the fact the sensitivity of humans is unknown. Other uncertainty factors are used to adjust for variations in senstivity within the human population or the lack of specific experimental datasets. Vadose zone: unsaturated zone in soil and aquifers. Therapeutic dose as the point of departure in assessing potential health hazards from drugs in drinking water and recycled municipal wastewater Introduction Methods Concentrations of drugs in municipal wastewater and following further treatment Identifying pharmaceuticals with low margins of exposure vs. therapeutic doses Results Summary of occurrence of drugs in municipal wastewater following varying degrees of treatment Margins of exposure Consideration of severe adverse effects associated with therapeutic use Differences inherent in assessing drug safety and environmental risk Carcinogenic drugs Genotoxic carcinogens Non-genotoxic carcinogens Severe side effects specific to humans Reproductive and developmental toxicants Adjustment for period of treatment Cumulative toxicity of drugs Interactive toxicities among drugs and other environmental chemicals Potential synergism among hypolipidemic drugs acting by different mechanisms Potential synergy among drugs used in treatment of hypertension Are the existing occurrence data representative? Existing data and how they were gathered Survey designs Trends in the future Veterinary drugs Drugs of abuse Discussion and conclusions Acknowledgments Supplementary data References Glossary"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Thirteen-week-oral-dose-toxicity-study-of-Oligonol-con_2014_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24326174", "content": {"Acknowledgement": "Acknowledgments The authors would like to thank Myoung Kim (pathologist at Biotoxtest Co., Ltd., Korea) who carried out the pathology evalua- tions and provided valuable comments on the study results. 4 Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Thirteen-week-oral-toxicity-study-of-fermented-gi_2020_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33122046", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 4 Discussion 5 Conclusions Funding Authors\u2019 contributions Declaration of competing interest Acknowledgments References", "Funding": "Funding This work was supported by the Ministry of Trade, Industry & Energy (MOTIE), Korea Institute for Advancement of Technology (KIAT) through the Encouragement Program for The Industries of Economic Cooperation Region [grant number R0004537]. 4 Discussion 5 Conclusions Funding Authors\u2019 contributions Declaration of competing interest Acknowledgments References", "Acknowledgement": "Acknowledgments This research was supported by the Ministry of Trade, Industry & Energy (MOTIE), Korea Institute for Advancement of Technology (KIAT) through the Encouragement Program for The Industries of Economic Cooperation Region. 4 Discussion 5 Conclusions Funding Authors\u2019 contributions Declaration of competing interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Threshold-and-non-threshold-chemical-carcinogens--_2017_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28119000", "content": {"CoiStatement": "Conflict of interest statement The named authors all contributed to this paper. Ruth Bevan and Paul Harrison are independent toxicology/risk assessment consul- tants; they are not involved in any legal testimony related to the materials and products discussed and do not have any form of commercial interest in them. Paul Harrison acts as an advisor to ECFIA (an association representing the high temperature insulation wool industry) in matters relating to health and safety. Acknowledgement 6. Discussion and conclusions Conflict of interest statement Acknowledgement Transparency document References", "Acknowledgement": "The named authors all contributed to this paper. Ruth Bevan and Paul Harrison are independent toxicology/risk assessment consul- tants; they are not involved in any legal testimony related to the materials and products discussed and do not have any form of commercial interest in them. Paul Harrison acts as an advisor to ECFIA (an association representing the high temperature insulation wool industry) in matters relating to health and safety. Acknowledgement The authors acknowledge the support provided by ECFIA in the preparation of this paper. 6. Discussion and conclusions Conflict of interest statement Acknowledgement Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Threshold-of-Toxicological-Concern--Extending-the-chemi_2021_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34757112", "content": {"CoiStatement": "5 Conclusions Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgments Appendix A Supplementary data Appendix B Study selection process for 1,6-bis(trimethoxysilyl)hexane (CAS RN #87135-01-1) and isobutylisopropyldimethoxysi ... Appendix C Study Selection and NOAEL setting for the three cyclics D4, D5 and D6 Octamethylcyclotetrasiloxane (D4, CAS RN #556-67-2) Decamethylcyclopentasiloxane (D5, CAS RN #541-02-6) Dodecamethylcyclohexasiloxane (D6, CAS RN #540-97-6) References", "Funding": "5 Conclusions Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgments Appendix A Supplementary data Appendix B Study selection process for 1,6-bis(trimethoxysilyl)hexane (CAS RN #87135-01-1) and isobutylisopropyldimethoxysi ... Appendix C Study Selection and NOAEL setting for the three cyclics D4, D5 and D6 Octamethylcyclotetrasiloxane (D4, CAS RN #556-67-2) Decamethylcyclopentasiloxane (D5, CAS RN #541-02-6) Dodecamethylcyclohexasiloxane (D6, CAS RN #540-97-6) References", "Acknowledgement": "5 Conclusions Funding body information CRediT authorship contribution statement Declaration of competing interest Acknowledgments Appendix A Supplementary data Appendix B Study selection process for 1,6-bis(trimethoxysilyl)hexane (CAS RN #87135-01-1) and isobutylisopropyldimethoxysi ... Appendix C Study Selection and NOAEL setting for the three cyclics D4, D5 and D6 Octamethylcyclotetrasiloxane (D4, CAS RN #556-67-2) Decamethylcyclopentasiloxane (D5, CAS RN #541-02-6) Dodecamethylcyclohexasiloxane (D6, CAS RN #540-97-6) References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Threshold-of-toxicological-concern--TTC--for-develop_2015_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26025210", "content": {"CoiStatement": "B. Stanard et al. / Regulatory Toxicology and Pharmacology 72 (2015) 602\u2013609 609 Conflict of Interest Statement The authors are employees of pharmaceutical companies and Colorado State University. Transparency Document Threshold of toxicological concern (TTC) for developmental and reproductive toxicity of anticancer compounds 1 Introduction 2 Methods 3 Results 4 Discussion 5 Conclusion Conflict of Interest Statement Transparency Document Acknowledgements Appendix A Supplementary data References", "Acknowledgement": "Acknowledgements We thank Helena Hemming and Nicola Powles-Glover for their critical review of this manuscript. We also are thankful for the sup- port from the graduate school at Colorado State University, Environmental and Radiological Health Sciences. Appendix A. Supplementary data Threshold of toxicological concern (TTC) for developmental and reproductive toxicity of anticancer compounds 1 Introduction 2 Methods 3 Results 4 Discussion 5 Conclusion Conflict of Interest Statement Transparency Document Acknowledgements Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Thujone-and-thujone-containing-herbal-medicinal-and_2013_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23201408", "content": {"CoiStatement": "106 O. Pelkonen et al. / Regulatory Toxicology and Pharmacology 65 (2013) 100\u2013107 Regarding the earlier assessments of thujone-containing medic- inal products by EMA/HMPC and thujone-containing botanicals by other authorities, there are a number of discrepant positions and views which should be harmonized. For example, the HMPC should revisit its earlier decisions on two different maximum daily intakes for thujone in Artemisia and Sage preparations. Also, authorities dealing with medicinal products and botanicals containing the same ingredient should align their policies at least regarding the safety considerations. Conflict of Interest The authors declare that there are no conflicts of interest. References The authors declare that there are no conflicts of interest. References Abass, K., Reponen, P., Mattila, S., Pelkonen, O., 2011. Metabolism of alpha-thujone in human hepatic preparations in vitro. Xenobiotica 41, 101\u2013111. 5 Pharmacokinetics of thujone 6 Considerations on acceptable limit exposures 7 Regulatory status of thujone or thujone-containing products 8 Future needs in risk assessment of thujone exposure Conflict of Interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Thyroid-tumor-formation-in-the-male-mouse-induced-by-f_2014_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25455223", "content": {"CoiStatement": "In conclusion, despite the weak thyroid effects induced by fluo- pyram at the end of the mouse cancer bioassay, the early key events implicit in the MOA responsible for the thyroid tumor were identified in short-term studies using a combination of molecular and cellular tools. These key events induced by fluopyram in male mice were identified in a dose and temporal-responsive manner. Compelling evidence for Car/Pxr being the molecular initiating event for these tumors is provided by the absence of the key events in Car/Pxr KO mice when exposed to fluopyram. Finally, NOELs could be identified for each of the key events, which provided evi- dence that fluopyram is a threshold-dependent rodent carcinogen. Conflict of interest None declared. 4 Discussion Conflict of interest Acknowledgments References", "Acknowledgement": "Acknowledgments The authors would like to thank M.P. Come, B. Labory, D. Ces- pedes, and H. Lormeau for their technical expertise and A. Blacker, C. Langrand-Lerche and B. Stahl for their helpful discussions. 4 Discussion Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Tiered-application-of-the-neutral-red-release-and-EpiOcu_2016_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27693708", "content": {"Acknowledgement": "In this manuscript, a retrospectively developed tiered-testing approach relying on the NRR and EpiOcular assays was imple- mented to assess the spectrum of eye irritation potential for 11 types of agrochemical formulations. Results suggested that the NRR assay as a standalone served as an encouraging tool to evaluate UN GHS Cat 1 and NC formulations, while the EpiOcular assay demonstrated encouraging performance for identifying UN GHS Cat NC formulations. Implementation of these assays in a tiered manner further improved performance for identifying UN GHS Cat 1 and NC formulations; however, themodel exhibited limitations to identify UN GHS Cat 2 formulations. Future efforts will focus on expanding the chemical set, including methods to assess tissue repair and refining the tiered-testing approach to improve perfor- mance for UN GHS Cat 2 formulations and extending applicability to additional types of chemistries and complex mixtures. Acknowledgments The authors are grateful to Drs. Pamela Spencer, Daniel Wilson, Matthew LeBaron, Reza Rasoulpour, and Michael Woolhiser of The Dow Chemical Company for critical review of the manuscript. The authors are thankful to Lindsay Sosinski, Mathew Koehler, Coreena Cheney, and Elizabeth Srebinski of The Dow Chemical Company for their contributions. Transparency document 4. Discussion 5. Conclusions Acknowledgments Transparency document Appendix A. Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Tiered-environmental-risk-assessment-of-methyltins_2005_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15649829", "content": {"Acknowledgement": "The use of methyltin mercaptide heat stabilisers for rigid PVC in Sweden results in leaching of the methyltin chlorides MMTTC and DMTDC. When it is assumed that methyltin mercaptide stabilizers are used in all new rigid PVC in Sweden, the predicted environmental concentrations in water, sediment, soil, and air stay well (PEC:PNEC < 1E\ufffd3) below predicted no-effect concen- trations. Therefore, the products are of no concern for aquatic and terrestrial ecosystems, or humans exposed through the environment. Acknowledgments The authors thank Richard Johnson, Phil McKittrick, Mary-Rita Dominic, and Vince Kramer for their contri- butions, and Rohm and Haas for their financial support. References Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Time-extrapolation-in-regulatory-risk-assessment--The_2020_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32006672", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper.", "Acknowledgement": "Acknowledgement This work has been supported financially by ERASM. We thank Dr. Thomas Steger-Hartmann for his support and data provision from the I MangelsdorfI eTOX project, Prof. Dr. Ursula Gundert-Remy for her support and data donation from the ELINCS database and Dr. Matthew Martin for his support and data provision from the ToxRef database. Conclusion mk:H1_19 Acknowledgement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Time-to-first-cigarette-of-the-day-and-4--methylnitrosam_2019_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31470076", "content": {"CoiStatement": "Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. Current cigarette smoking among adults- United States, 2011, morbidity and mortality weekly reports. MMWR (Morb. Mortal. Wkly. Rep. 61 (44), 889\u2013894. Fagerstrom, K., 1978. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict. Behav. (3), 235\u2013241. Gankhuyag, N., Lee, K.-H., Cho, J.-Y., 2017. The role of nitrosamine (NNK) in breast cancer carcinogenesis. J. Mammary Gland Biol. Neoplasia 22 (3), 159\u2013170. https:// doi.org/10.1007/s10911-017-9381-z. S.A. Branstetter, et al. Regulatory Toxicology and Pharmacology 108 (2019) 104454 5 https://doi.org/10.1542/peds.2014-2502 https://doi.org/10.1542/peds.2014-2502 https://doi.org/10.1158/1055-9965.EPI-12-0842 https://doi.org/10.1093/ntr/nts189 https://doi.org/10.1111/add.12515 https://doi.org/10.1093/ntr/ntw179 https://doi.org/10.1093/ntr/ntw179 http://www.cdc.gov/nchs/data/nhanes/nhanes_09_10/lab.pdf http://www.cdc.gov/nchs/nhanes/nhanes2003-2004/analytical_guidelines.htm http://refhub.elsevier.com/S0273-2300(19)30218-1/sref8 http://refhub.elsevier.com/S0273-2300(19)30218-1/sref8 http://refhub.elsevier.com/S0273-2300(19)30218-1/sref9 http://refhub.elsevier.com/S0273-2300(19)30218-1/sref9 https://doi.org/10.1007/s10911-017-9381-z https://doi.org/10.1007/s10911-017-9381-z Hecht, S.S., Kenney, P.M., Wang, M., et al., 1999. Evaluation of butylated hydroxyanisole, myo-inositol, curcumin, esculetin, resveratrol and lycopene as inhibitors of benzo [a] pyrene plus 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumor- igenesis in A/J mice. Cancer Lett. 137 (2), 123\u2013130. Husten, C.G., 2009. How should we define light or intermittent smoking? Does it matter? Nicotine Tob Res Off J Soc Res Nicotine Tob 11 (2), 111\u2013121. https://doi.org/10. 1093/ntr/ntp010. Inoue-Choi, M., Liao, L.M., Reyes-Guzman, C., Hartge, P., Caporaso, N., Freedman, N.D., 2017. Association of long-term, low-intensity smoking with all-cause and cause- specific mortality in the national Institutes of health-AARP diet and health study. JAMA Intern Med 177 (1), 87\u201395. https://doi.org/10.1001/jamainternmed.2016. 7511. Jamal, A., King, B., Neff, L., Whitmill, J., Babb, S., Graffunder, C., 2016. Current cigarette smoking among adults \u2014 United States, 2005\u20132015. MMWR Morb. Mortal. Wkly. Rep. (65), 1205\u20131211. https://doi.org/10.15585/mmwr.mm6544a2. Krebs, N.M., Chen, A., Zhu, J., et al., 2016a. Comparison of puff volume with cigarettes per day in predicting nicotine uptake among daily smokers. Am. J. Epidemiol. 184 (1), 48\u201357. https://doi.org/10.1093/aje/kwv341. Krebs, N.M., Chen, A., Zhu, J., et al., 2016b. Comparison of puff volume with cigarettes per day in predicting nicotine uptake among daily smokers. Am. J. Epidemiol. 184 (1), 48\u201357. https://doi.org/10.1093/aje/kwv341. Mercincavage M, Branstetter SA, Muscat JE, Horn KA. Time to first cigarette predicts cessation outcomes among adolescent smokers. Nicotine Tob. Res.. (in press). Muscat, J.E., Stellman, S.D., Caraballo, R.S., Richie, J.P., 2009. Time to first cigarette after waking predicts cotinine levels. Cancer Epidemiol. Biomark. Prev. 18 (12), 3415\u20133420. https://doi.org/10.1158/1055-9965.EPI-09-0737. Muscat, J.E., Ahn, K., Richie Jr., J.P., Stellman, S.D., 2011. Nicotine dependence phe- notype, time to first cigarette, and risk of head and neck cancer. Cancer 117 (23), 5377\u20135382. https://doi.org/10.1002/cncr.26235. Preacher, K.J., Hayes, A.F., 2004. SPSS and SAS procedures for estimating indirect effects in simple mediation models. Behav Res Methods Instrum Comput J Psychon Soc Inc 36 (4), 717\u2013731. Reyes-Guzman, C.M., Pfeiffer, R.M., Lubin, J., et al., 2017a. Determinants of light and intermittent smoking in the U.S.: results from three pooled national health surveys. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 26 (2), 228\u2013239. https://doi.org/10.1158/1055-9965.EPI-16-0028. Reyes-Guzman, C.M., Pfeiffer, R.M., Lubin, J., et al., 2017b. Determinants of light and intermittent smoking in the United States: results from three pooled national health surveys. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 26 (2), 228\u2013239. https://doi.org/10.1158/1055-9965.EPI-16-0028. Shiffman, S., 2009. Light and intermittent smokers: background and perspective. Nicotine Tob. Res. 11 (2), 122\u2013125. https://doi.org/10.1093/ntr/ntn020. Van Overmeire, I.P.I., De Smedt, T., Dendale, P., et al., 2016. Nicotine dependence and urinary nicotine, cotinine and hydroxycotinine levels in daily smokers. Nicotine Tob. Res. 18 (9), 1813\u20131819. https://doi.org/10.1093/ntr/ntw099. Xue, J., Yang, S., Seng, S., 2014. Mechanisms of cancer induction by tobacco-specific NNK and NNN. Cancers 6 (2), 1138\u20131156. https://doi.org/10.3390/cancers6021138. Yang, S.-H., Lee, T.-Y., Ho, C.A., et al., 2018. Exposure to nicotine-derived nitrosamine ketone and arecoline synergistically facilitates tumor aggressiveness via over- expression of epidermal growth factor receptor and its downstream signaling in head and neck squamous cell carcinoma. PLoS One 13 (8). https://doi.org/10.1371/ journal.pone.0201267. S.A. Branstetter, et al. Regulatory Toxicology and Pharmacology 108 (2019) 104454 6 http://refhub.elsevier.com/S0273-2300(19)30218-1/sref11 http://refhub.elsevier.com/S0273-2300(19)30218-1/sref11 http://refhub.elsevier.com/S0273-2300(19)30218-1/sref11 http://refhub.elsevier.com/S0273-2300(19)30218-1/sref11 https://doi.org/10.1093/ntr/ntp010 https://doi.org/10.1093/ntr/ntp010 https://doi.org/10.1001/jamainternmed.2016.7511 https://doi.org/10.1001/jamainternmed.2016.7511 https://doi.org/10.15585/mmwr.mm6544a2 https://doi.org/10.1093/aje/kwv341 https://doi.org/10.1093/aje/kwv341 https://doi.org/10.1158/1055-9965.EPI-09-0737 https://doi.org/10.1002/cncr.26235 http://refhub.elsevier.com/S0273-2300(19)30218-1/sref20 http://refhub.elsevier.com/S0273-2300(19)30218-1/sref20 http://refhub.elsevier.com/S0273-2300(19)30218-1/sref20 https://doi.org/10.1158/1055-9965.EPI-16-0028 https://doi.org/10.1158/1055-9965.EPI-16-0028 https://doi.org/10.1093/ntr/ntn020 https://doi.org/10.1093/ntr/ntw099 https://doi.org/10.3390/cancers6021138 https://doi.org/10.1371/journal.pone.0201267 https://doi.org/10.1371/journal.pone.0201267 Time to first cigarette of the day and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in adult regular and non-daily smokers: (NHANES) 2007\u201310 Introduction Materials &#x200B;&&#x200B; methods Participants Measures Demographics Smoking behaviors Biomarkers of exposure Smoking subgroups Nondaily smokers (intermittent and non-daily/some days) Daily smokers (light and heavy) Analytic approach Results Intermittent smokers Non-daily/some day smokers Light daily smokers Heavy daily smokers Discussion Funding Funding body information Declaration of interests References", "Funding": "Funding This work was supported by the National Institute on Drug Abuse, National Institutes of Health (R01 DA026815), and National Institutes on Minority Health and Health Disparities, National Institutes of Health (R01 MD013338). Funding body information This work was supported by the National Institute on Drug Abuse, National Institutes of Health (R01 DA026815; Muscat PI), and National Institutes on Minority Health and Health Disparities, National Institutes of Health (R01 MD013338; Branstetter, Co-PI). The work was com- pleted as part of the author's academic roles at Penn State University. The funding agencies had no role in data collection, design, analyses or manuscript preparation. All authors approve of this submission, the work is not under consideration for publication elsewhere, and the authors have no conflicting interests to declare. This work was supported by the National Institute on Drug Abuse, National Institutes of Health (R01 DA026815; Muscat PI), and National Institutes on Minority Health and Health Disparities, National Institutes of Health (R01 MD013338; Branstetter, Co-PI). The work was com- pleted as part of the author's academic roles at Penn State University. The funding agencies had no role in data collection, design, analyses or manuscript preparation. All authors approve of this submission, the work is not under consideration for publication elsewhere, and the authors have no conflicting interests to declare. Declaration of interests Current cigarette smoking among adults- United States, 2011, morbidity and mortality weekly reports. MMWR (Morb. Mortal. Wkly. Rep. 61 (44), 889\u2013894. Fagerstrom, K., 1978. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict. Behav. (3), 235\u2013241. Gankhuyag, N., Lee, K.-H., Cho, J.-Y., 2017. The role of nitrosamine (NNK) in breast cancer carcinogenesis. J. Mammary Gland Biol. Neoplasia 22 (3), 159\u2013170. https:// doi.org/10.1007/s10911-017-9381-z. S.A. Branstetter, et al. Regulatory Toxicology and Pharmacology 108 (2019) 104454 5 https://doi.org/10.1542/peds.2014-2502 https://doi.org/10.1542/peds.2014-2502 https://doi.org/10.1158/1055-9965.EPI-12-0842 https://doi.org/10.1093/ntr/nts189 https://doi.org/10.1111/add.12515 https://doi.org/10.1093/ntr/ntw179 https://doi.org/10.1093/ntr/ntw179 http://www.cdc.gov/nchs/data/nhanes/nhanes_09_10/lab.pdf http://www.cdc.gov/nchs/nhanes/nhanes2003-2004/analytical_guidelines.htm http://refhub.elsevier.com/S0273-2300(19)30218-1/sref8 http://refhub.elsevier.com/S0273-2300(19)30218-1/sref8 http://refhub.elsevier.com/S0273-2300(19)30218-1/sref9 http://refhub.elsevier.com/S0273-2300(19)30218-1/sref9 https://doi.org/10.1007/s10911-017-9381-z https://doi.org/10.1007/s10911-017-9381-z Hecht, S.S., Kenney, P.M., Wang, M., et al., 1999. Evaluation of butylated hydroxyanisole, myo-inositol, curcumin, esculetin, resveratrol and lycopene as inhibitors of benzo [a] pyrene plus 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumor- igenesis in A/J mice. Cancer Lett. 137 (2), 123\u2013130. Husten, C.G., 2009. How should we define light or intermittent smoking? Does it matter? Nicotine Tob Res Off J Soc Res Nicotine Tob 11 (2), 111\u2013121. https://doi.org/10. 1093/ntr/ntp010. Inoue-Choi, M., Liao, L.M., Reyes-Guzman, C., Hartge, P., Caporaso, N., Freedman, N.D., 2017. Association of long-term, low-intensity smoking with all-cause and cause- specific mortality in the national Institutes of health-AARP diet and health study. JAMA Intern Med 177 (1), 87\u201395. https://doi.org/10.1001/jamainternmed.2016. 7511. Jamal, A., King, B., Neff, L., Whitmill, J., Babb, S., Graffunder, C., 2016. Current cigarette smoking among adults \u2014 United States, 2005\u20132015. MMWR Morb. Mortal. Wkly. Rep. (65), 1205\u20131211. https://doi.org/10.15585/mmwr.mm6544a2. Krebs, N.M., Chen, A., Zhu, J., et al., 2016a. Comparison of puff volume with cigarettes per day in predicting nicotine uptake among daily smokers. Am. J. Epidemiol. 184 (1), 48\u201357. https://doi.org/10.1093/aje/kwv341. Krebs, N.M., Chen, A., Zhu, J., et al., 2016b. Comparison of puff volume with cigarettes per day in predicting nicotine uptake among daily smokers. Am. J. Epidemiol. 184 (1), 48\u201357. https://doi.org/10.1093/aje/kwv341. Mercincavage M, Branstetter SA, Muscat JE, Horn KA. Time to first cigarette predicts cessation outcomes among adolescent smokers. Nicotine Tob. Res.. (in press). Muscat, J.E., Stellman, S.D., Caraballo, R.S., Richie, J.P., 2009. Time to first cigarette after waking predicts cotinine levels. Cancer Epidemiol. Biomark. Prev. 18 (12), 3415\u20133420. https://doi.org/10.1158/1055-9965.EPI-09-0737. Muscat, J.E., Ahn, K., Richie Jr., J.P., Stellman, S.D., 2011. Nicotine dependence phe- notype, time to first cigarette, and risk of head and neck cancer. Cancer 117 (23), 5377\u20135382. https://doi.org/10.1002/cncr.26235. Preacher, K.J., Hayes, A.F., 2004. SPSS and SAS procedures for estimating indirect effects in simple mediation models. Behav Res Methods Instrum Comput J Psychon Soc Inc 36 (4), 717\u2013731. Reyes-Guzman, C.M., Pfeiffer, R.M., Lubin, J., et al., 2017a. Determinants of light and intermittent smoking in the U.S.: results from three pooled national health surveys. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 26 (2), 228\u2013239. https://doi.org/10.1158/1055-9965.EPI-16-0028. Reyes-Guzman, C.M., Pfeiffer, R.M., Lubin, J., et al., 2017b. Determinants of light and intermittent smoking in the United States: results from three pooled national health surveys. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 26 (2), 228\u2013239. https://doi.org/10.1158/1055-9965.EPI-16-0028. Shiffman, S., 2009. Light and intermittent smokers: background and perspective. Nicotine Tob. Res. 11 (2), 122\u2013125. https://doi.org/10.1093/ntr/ntn020. Van Overmeire, I.P.I., De Smedt, T., Dendale, P., et al., 2016. Nicotine dependence and urinary nicotine, cotinine and hydroxycotinine levels in daily smokers. Nicotine Tob. Res. 18 (9), 1813\u20131819. https://doi.org/10.1093/ntr/ntw099. Xue, J., Yang, S., Seng, S., 2014. Mechanisms of cancer induction by tobacco-specific NNK and NNN. Cancers 6 (2), 1138\u20131156. https://doi.org/10.3390/cancers6021138. Yang, S.-H., Lee, T.-Y., Ho, C.A., et al., 2018. Exposure to nicotine-derived nitrosamine ketone and arecoline synergistically facilitates tumor aggressiveness via over- expression of epidermal growth factor receptor and its downstream signaling in head and neck squamous cell carcinoma. PLoS One 13 (8). https://doi.org/10.1371/ journal.pone.0201267. S.A. Branstetter, et al. Regulatory Toxicology and Pharmacology 108 (2019) 104454 6 http://refhub.elsevier.com/S0273-2300(19)30218-1/sref11 http://refhub.elsevier.com/S0273-2300(19)30218-1/sref11 http://refhub.elsevier.com/S0273-2300(19)30218-1/sref11 http://refhub.elsevier.com/S0273-2300(19)30218-1/sref11 https://doi.org/10.1093/ntr/ntp010 https://doi.org/10.1093/ntr/ntp010 https://doi.org/10.1001/jamainternmed.2016.7511 https://doi.org/10.1001/jamainternmed.2016.7511 https://doi.org/10.15585/mmwr.mm6544a2 https://doi.org/10.1093/aje/kwv341 https://doi.org/10.1093/aje/kwv341 https://doi.org/10.1158/1055-9965.EPI-09-0737 https://doi.org/10.1002/cncr.26235 http://refhub.elsevier.com/S0273-2300(19)30218-1/sref20 http://refhub.elsevier.com/S0273-2300(19)30218-1/sref20 http://refhub.elsevier.com/S0273-2300(19)30218-1/sref20 https://doi.org/10.1158/1055-9965.EPI-16-0028 https://doi.org/10.1158/1055-9965.EPI-16-0028 https://doi.org/10.1093/ntr/ntn020 https://doi.org/10.1093/ntr/ntw099 https://doi.org/10.3390/cancers6021138 https://doi.org/10.1371/journal.pone.0201267 https://doi.org/10.1371/journal.pone.0201267 Time to first cigarette of the day and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in adult regular and non-daily smokers: (NHANES) 2007\u201310 Introduction Materials &#x200B;&&#x200B; methods Participants Measures Demographics Smoking behaviors Biomarkers of exposure Smoking subgroups Nondaily smokers (intermittent and non-daily/some days) Daily smokers (light and heavy) Analytic approach Results Intermittent smokers Non-daily/some day smokers Light daily smokers Heavy daily smokers Discussion Funding Funding body information Declaration of interests References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Time-trends-in-never-smokers-in-the-relative-frequency-_2016_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26640118", "content": {"CoiStatement": "Conflict of interest Peter N Lee, founder of P N Lee Statistics and Computing Ltd, is an in- dependent consultant in statistics and an advisor in the fields of epidemiology and toxicology to a number of tobacco, pharmaceu- tical and chemical companies. This includes Altria Client Services, the sponsors of this study, for whom Peter J Lipowicz and Scott Appleton are employees. Barbara A Forey and Katharine J Coombs are employees of P N Lee Statistics and Computing Ltd. 4. Discussion 5. Conclusions Conflict of interest Authors\u2019 contributions Acknowledgements Transparency document Appendix A. Supplementary data References", "Acknowledgement": "Acknowledgements The statistical analyses described here were funded by Altria Client Services, whom we thank. They also contributed to the literature searching and data entry costs for the wider project, which were also part funded by British American Tobacco (In- vestments) Limited. However, the opinions and conclusions of the authors are their own, and do not necessarily reflect the position of the sponsors. We also thank Pauline Wassell, Diana Morris and Yvonne Cooper for assistance in typing the various drafts of the paper and in obtaining the relevant literature. 4. Discussion 5. Conclusions Conflict of interest Authors\u2019 contributions Acknowledgements Transparency document Appendix A. Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Tissue-concentrations-of-sulfamethazine-and-tetracycline-_2015_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25707857", "content": {"CoiStatement": "Conflict of interest The authors claim no conflicts of interest at this time or in the past 36 months. All parties have only been employed by their cur- rent employer or North Carolina State University and were not paid by any company that manufactures the products investigated in the manuscript. The authors claim no conflicts of interest at this time or in the past 36 months. All parties have only been employed by their cur- rent employer or North Carolina State University and were not paid by any company that manufactures the products investigated in the manuscript. Acknowledgments 3 Results and discussion 4 Conclusion Conflict of interest Acknowledgments Appendix A Supplementary data References", "Compliance with ethical standards": "FDA, July 25, 2006. U.S. Department of Agriculture, Food and Drug Administration (FDA). Guidance for industry no. 3: General principles for evaluation the safety of compounds used in food producing animals. [online] <http://www. fda.gov/downloads/animalveterinary/guidancecomplianceenforcement/ guidanceforindustry/ucm052180.pdf/>. FDA, 2013. U.S. Department of Health and Human Services. US FDA. Approved Animal Drug Products (Green Book). [online] <www.accessdata.fda.gov/scripts/ animaldrugsatfda/> (accessed on June 2013). http://dx.doi.org/10.1016/j.yrtph.2015.02.013 http://dx.doi.org/10.1016/j.yrtph.2015.02.013 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0005 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0005 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0010 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0010 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0010 http://www.mla.com.au/Meat-safety-and-traceability/On-farm-risk-management/Residues http://www.mla.com.au/Meat-safety-and-traceability/On-farm-risk-management/Residues http://refhub.elsevier.com/S0273-2300(15)00041-0/h0020 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0020 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0020 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0020 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0025 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0025 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0025 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0025 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/vet_mrl_search.jsp http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/vet_mrl_search.jsp http://www.fda.gov/downloads/animalveterinary/guidancecomplianceenforcement/guidanceforindustry/ucm052180.pdf http://www.fda.gov/downloads/animalveterinary/guidancecomplianceenforcement/guidanceforindustry/ucm052180.pdf http://www.fda.gov/downloads/animalveterinary/guidancecomplianceenforcement/guidanceforindustry/ucm052180.pdf http://www.accessdata.fda.gov/scripts/animaldrugsatfda/ http://www.accessdata.fda.gov/scripts/animaldrugsatfda/ http://refhub.elsevier.com/S0273-2300(15)00041-0/h0045 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0045 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0045 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0055 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0055 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0055 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0055 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0060 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0060 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0060 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0060 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0065 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0065 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0065 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0070 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0070 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0070 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0075 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0075 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0075 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0080 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0080 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0085 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0085 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0090 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0090 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0090 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0095 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0095 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0095 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0100 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0100 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0100 http://www.usmef.org/downloads/Pork-2001-to-2010.pdf http://refhub.elsevier.com/S0273-2300(15)00041-0/h0110 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0110 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0110 http://refhub.elsevier.com/S0273-2300(15)00041-0/h0110 Tissue concentrations of sulfamethazine and tetracycline hydrochloride of swine (Sus scrofa domestica) as it relates to withdrawal methods for international export 1 Introduction 2 Materials and methods 2.1 Study design 2.2 Animals 2.3 Water medication administration 2.4 Sample collection 2.5 Chemical analysis and quantification 2.5.1 HPLC conditions 2.5.2 Tetracycline analyses 2.5.2.1 Plasma 2.5.2.2 Tissues: liver 2.5.2.3 Kidney", "Acknowledgement": "Acknowledgments We would like to thank all of the staff at the Swine Education Unit at North Carolina State University for their preparation and maintenance of the facility for this research, and for mixing the antibiotic free food. We would also like to thank Ms. Patty Routh for assistance with animal handling. This research was funded by National Pork Board Grant #09-256 and the Food Animal Residue Avoidance Databank. 3 Results and discussion 4 Conclusion Conflict of interest Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Tobacco-alkaloids-reduction-by-casings-added-enzymat_2016_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26739812", "content": {"CoiStatement": "S. Lin et al. / Regulatory Toxicology and Pharmacology 75 (2016) 27e3434 Conflicts of interest The authors declare no conflicts of interest. The authors declare no conflicts of interest. Transparency document 4. Discussion 5. Conclusion Conflicts of interest Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Tolerance-of-rising-dietary-concentrations-of-esteri_2015_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26255106", "content": {"CoiStatement": "D.H. Bechtel / Regulatory Toxicology and Pharmacology 73 (2015) 413e418 417 Conflicts of interest The author is unaware of any conflicts of interest. Funding sources statement The author is unaware of any conflicts of interest. Funding sources statement This study was sponsored by ARCO Chemical Company (Newton Square, PA, USA) and Best Foods (Somerset, NJ, USA). Choco Finesse, LLC, who has acquired the rights to develop and commercialize EPG, hired Intertek Scientific & Regulatory Consultancy (Bridge- water, NJ, USA) to prepare this manuscript. Transparency document 4. Discussion Conflicts of interest Funding sources statement Transparency document References", "Funding": "The author is unaware of any conflicts of interest. Funding sources statement This study was sponsored by ARCO Chemical Company (Newton Square, PA, USA) and Best Foods (Somerset, NJ, USA). Choco Finesse, LLC, who has acquired the rights to develop and commercialize EPG, hired Intertek Scientific & Regulatory Consultancy (Bridge- water, NJ, USA) to prepare this manuscript. Transparency document 4. Discussion Conflicts of interest Funding sources statement Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Tools-for-the-prioritization-of-substances-on-the-Do_2009_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19766685", "content": {"CoiStatement": "Discussion Conflict of interest disclosure statement Acknowledgments References \u2013 Examples of application of hazard tools", "Disclosure": "Discussion Conflict of interest disclosure statement Acknowledgments References \u2013 Examples of application of hazard tools", "Acknowledgement": "Discussion Conflict of interest disclosure statement Acknowledgments References \u2013 Examples of application of hazard tools"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Total-mercury-concentrations-in-the-general-Ko_2014_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25455224", "content": {"CoiStatement": "Conflict of interest None declared. 4 Discussion 5 Conclusion Conflict of interest Acknowledgement References", "Acknowledgement": "Acknowledgement This research was supported by grants (13161MFDS822 and 14161MFDS658) from the Ministry of Food and Drug Safety in 2013 and 2014. 4 Discussion 5 Conclusion Conflict of interest Acknowledgement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Towards-AOP-application---Implementation-of-an-integrate_2014_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24928565", "content": {"CoiStatement": "4 Conclusions Conflict of interest Acknowledgments References", "Acknowledgement": "4 Conclusions Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Towards-a-nanospecific-approach-for-risk-_2016_Regulatory-Toxicology-and-Pha.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27255696", "content": {"Acknowledgement": "5. Description phase III and further 6. Discussion and conclusions Acknowledgements Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Towards-a-theory-of-tiered-testing_2007_Regulatory-Toxicology-and-Pharmacolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/17289235", "content": {"Acknowledgement": "Acknowledgments We acknowledge the anonymous referees for very valu- able comments to an earlier version of this manuscript. This work was funded by the Swedish Foundation for Stra- tegic Environmental Research (MISTRA). Towards a theory of tiered testing Introduction Characteristics of single tests Combining tests into test systems A decision-theoretical framework Tiered tests without intermediate risk management decisions Tiered tests with intermediate risk management decisions Conclusion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Towards-more-efficient-testing-strategies-Analyzing-the-e_2008_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18334276", "content": {"Acknowledgement": "Moreover, less complex tests usually have less relevance for human health risk assessment which may result in unwanted proportions of either false positive results (and corresponding over-regulation) or false negative results (and corresponding under-regulation). Data generated from regulatory testing are however not just used for the purpose of hazard identification as performed within the classification and labelling system. The data generated in these different tests are also used in more comprehensive risk assessment of chemicals and an additional aspect is therefore what relevance the different tests have for the risk assessment process. Currently more complex tests like the 28-day study are likely to be of more use in these types of evaluations than in the classification and labelling system. Acknowledgments We gratefully acknowledge the kind help we have re- ceived from Joaquin Barabar Fentanes at the European Chemicals Bureau, and from Bengt Melsa\u0308ter, at the Swed- ish Chemicals Agency. References Risk & Policy Analysts Limited (RPA), 2003. \u2018\u2018Revised business impact assessment for the consultation document\u201d, working paper 4, prepared for European Commission Directorate\u2014General Enterprise, Available from: (<http://ec.europa.eu/enterprise/reach/docs/reach/rev_bia-2003_ 10_29.pdf> and <http://ec.europa.eu/enterprise/reach/eia_en.htm>; (accessed 06-13-2007). Rude\u0301n, C., Hansson, S.O., 2003. How accurate are the European Union\u2019s classifications of chemical substances. Tox. Lett. 144, 159\u2013172. Schoemaker, P.J.H., 1982. The expected utility model: its variants, purposes, evidence and limitations. J. Econ. Lit. 20, 529\u2013563. http://ec.europa.eu/enterprise/reach/docs/reach/rev_bia-2003_10_29.pdf http://ec.europa.eu/enterprise/reach/docs/reach/rev_bia-2003_10_29.pdf http://ec.europa.eu/enterprise/reach/eia_en.htm Towards more efficient testing strategies-Analyzing the efficiency of toxicity data requirements in relation to the criteria for classification and labelling Introduction Purpose and methods The classification and labelling system The database Analysis of the cost efficiency of the test systems Results for toxicity tests Single tests Full combinations Negatively coupled tests Further comments on combinations Discussion and conclusion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Towards-optimization-of-chemical-testing-under-REACH-_2010_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20156511", "content": {"Acknowledgement": "Discussion and conclusions Acknowledgments Two-test Bayesian network in a spreadsheet form References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Towards-quantitative-read-across--Prediction-of-A_2019_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31374229", "content": {"CoiStatement": "Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. Conclusions Funding sources Declaration of interests References", "Funding": "Funding sources This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Declaration of interests Conclusions Funding sources Declaration of interests References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Towards-the-development-of-an-omics-data-an_2020_Regulatory-Toxicology-and-P.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32087354", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare that they have no known competing interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgements", "Funding": "Funding body information The current project was funded by the CEFIC LRI C4. The funding source had no involvement in preparation of this article. The current project was funded by the CEFIC LRI C4. The funding source had no involvement in preparation of this article. Maastricht University (the organization of the corresponding au- thor) is affiliated with the VSNU for reimbursement of open access publication fee. Conclusion Disclaimer Funding body information mk:H1_8 Acknowledgements References", "Acknowledgement": "Acknowledgements The current project was funded by the CEFIC LRI C4. Conclusion Disclaimer Funding body information mk:H1_8 Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Towards-toxicokinetic-modelling-of-aluminium-expos_2017_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28237896", "content": {"Acknowledgement": "5. Summary/conclusion Acknowledgements Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxic-metals-contained-in-cosmetics--A-st_2014_Regulatory-Toxicology-and-Pha.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24530804", "content": {"Compliance with ethical standards": "As regards regulatory aspects, the eight metals are all banned from being intentionally added to cosmetics in EU, Canada, and US but also in other countries that uses the EU or US legislations. Anyway they are permitted as impurities according to good manu- facturing practices and if they are safe for human health, but limits have been established only for some metals, for others as Co, Cr and Ni limits are still lacking. The data collected in this review re- vealed three key findings: (i) metals are present in cosmetics at concentrations above what is considered \u2018\u2018technically avoidable\u2019\u2019 and so many cosmetics are not in compliance with legislation on impurities; (ii) there is difference between what level of metal is safe and what is technically avoidable and so the limits suggested for impurities do not necessarily provide a sufficient level of pro- tection for humans and should be lowered; (iii) on the other hand, metals are also detected at concentrations many times lower than the \u2018\u2018technically avoidable limit\u2019\u2019 and so it is feasible for manufac- turers to eliminate these impurities from cosmetics and to produce safer products. Take Pb for example. According to the Canadian guidelines, manufacturers are only considered able to technically avoid Pb lev- els greater than 10 lg/g in cosmetics. On a total of 1300 lip prod- ucts (including lipsticks, lip gloss and lip balm) tested in 13 different studies (see Table 9), the 3.5% of samples contained Pb above 10 lg/g and so they resulted not in compliance with guide- lines on impurities. Instead, the 96.5% of lip products contained concentration lower than 10 lg/g; moreover, the lowest level of Pb detected in lipsticks was ca. 0.1 lg/g and these results show that Pb impurity much lower than 10 lg/g is feasible. Therefore, manufacturers should be able to reduce impurities during the manufacturing process. On the other hand, Pb levels lower than this value are not necessarily safe. In fact, the CDC stated that is no known safe blood Pb level and even the current \u2018\u2018low\u2019\u2019 levels Take Pb for example. According to the Canadian guidelines, manufacturers are only considered able to technically avoid Pb lev- els greater than 10 lg/g in cosmetics. On a total of 1300 lip prod- ucts (including lipsticks, lip gloss and lip balm) tested in 13 different studies (see Table 9), the 3.5% of samples contained Pb above 10 lg/g and so they resulted not in compliance with guide- lines on impurities. Instead, the 96.5% of lip products contained concentration lower than 10 lg/g; moreover, the lowest level of Pb detected in lipsticks was ca. 0.1 lg/g and these results show that Pb impurity much lower than 10 lg/g is feasible. Therefore, manufacturers should be able to reduce impurities during the manufacturing process. On the other hand, Pb levels lower than this value are not necessarily safe. In fact, the CDC stated that is no known safe blood Pb level and even the current \u2018\u2018low\u2019\u2019 levels 464 B. Bocca et al. / Regulatory Toxicology and Pharmacology 68 (2014) 447\u2013467 of exposure in children are associated with neurodevelopmental deficits (Bellinger, 2008; CDC, 2013). It is noteworthy that the 2009 draft Pb, As, Cd, and Sb impurity limits for Canada are more stringent than those of Germany\u2019s limits, which were made in 1985. This suggests that, with time, the ability of manufacturers to technically reduce impurities can and has changed. Another case is the quantity of Hg in skin-weighting creams. On a total of 197 samples investigated in 8 different studies (see Table 8), the 27.9% of samples were well above the 1 lg/g that is the German technically avoidable limit for Hg but the 72.1% of samples con- tained Hg less than 1 lg/g or even under the LoD, so these data suggest that impurities of Hg may be avoidable. Some companies are also moving towards plant-based colorants and away from petroleum or coal tar-based colorants to avoid some raw material contaminants. Others are asking their suppliers to screen for con- taminants and source the least contaminated ingredients possible. In the USA, manufacturers may purchase ingredients certified by an independent organization called United States Pharmacopeia that may contain lower levels of harmful impurities (EWG, 2007)."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicity-and-antioxidant-capacity-of-Frangula-alnu_2015_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26399165", "content": {"CoiStatement": "Conflicts of interest Authors have declared no conflicts of interest. Authors have declared no conflicts of interest. Acknowledgements 4. Discussion Conflicts of interest Acknowledgements Transparency document References", "Acknowledgement": "Acknowledgements We wish to thank the Department of Plant Physiology at the Zagreb University Faculty of Science and the Institute for Medical Research and Occupational Health, Zagreb for financial support for the experimental part of the study. 4. Discussion Conflicts of interest Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicity-assay-in-repeated-doses-of-Dermatophagoi_2012_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22426150", "content": {"CoiStatement": "Results allow us to conclude the test substance did not cause any variation in the animal response, either in parameters such body weight, where response for both groups was similar. Clinical observations reported seem to be close related to the administra- tion site. In hematology and sanguine chemistry determinations, there were not significant differences in any evaluated parameters and all behaved within the normal limits of the pre-established interval. In anatomopathological analysis, there were lesions in the application site, all characteristic of the late response of an allergen by subcutaneous route. We conclude that repeated dosing of 166.6 UB did not cause significant toxic effects in the mouse model. Conflict of interest statement The authors declare that there are no conflicts of interest. Acknowledgments The authors declare that there are no conflicts of interest. Acknowledgments The authors wish to thank Niurka Baez Alayo for her assistance in revision of English language and grammar of this manuscript. 4 Discussion Conflict of interest statement Acknowledgments References", "Compliance with ethical standards": "OECD, 1997. Principles of Good Laboratory Practice, Series on Principles of Good Laboratory Practice and Compliance Monitoring. OECD Environmental Health and Safety Publications. Olfert, E.D., Cross, B.M., McWilliam, A.A., 2004. CCPA Manual sobre el Cuidado y Uso de los Animales de Experimentaci\u00f3n. Consejo Canadiense de Protecci\u00f3n de los Animales, second ed.", "Acknowledgement": "The authors declare that there are no conflicts of interest. Acknowledgments The authors wish to thank Niurka Baez Alayo for her assistance in revision of English language and grammar of this manuscript. 4 Discussion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicity-assessment-of-cypermethrin-nanoparticles-in-Ch_2018_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30393047", "content": {"CoiStatement": "Declaration of interest The authors state no conflicts of interest. The authors state no conflicts of interest. Acknowledgments Conclusion and future perspectives Author's contribution Declaration of interest Acknowledgments Transparency document References", "Acknowledgement": "Acknowledgments The first author thanks the Department of Science and Technology for INSPIRE Fellowship (Code-IF140412). Authors are thankful to the Centre of Excellence in Materials Science (Nanomaterials), Department of Applied Physics, A.M.U., Aligarh, for providing CypNPs, IITR, Lucknow and Dr Abhinav Kumar, Department of Chemistry, University of Lucknow for the characterization facility. Department of Biochemistry, KGMU and Department of Zoology, University of Lucknow, Lucknow are greatly acknowledged for their lab facility. Conclusion and future perspectives Author's contribution Declaration of interest Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicity-assessment-of-pesticide-triclosan-by-aqu_2017_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29111444", "content": {"Acknowledgement": "Acknowledgements Financial support was gratefully acknowledged by the Scientific and Technological Research Council of Turkey (T\u00dcB\u0130TAK) (Grant number 114Y037). The authors also wish to express their gratitude to reviewers for their valuable comments. Discussion Conclusions Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicity-assessment-of-the-extractables-from-multi-layer-_2018_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29360483", "content": {"Acknowledgement": "Acknowledgements We are grateful for the financial support from the General Administration of Quality Supervision, Inspection and Quarantine of the People's Republic of China (No. 201510024). Conclusion Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicity-assessment-strategies--data-requirements--and-ris_2010_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19883711", "content": {"Acknowledgement": "142 W. Dekant et al. / Regulatory Toxicology and Pharmacology 56 (2010) 135\u2013142 Acknowledgments Preparation of this article was supported in part through an honorarium to Drs. Dekant and Kalberlah from BASF Ludwigshafen. This article represents the individual professional views of the authors and not necessarily the views of BASF. References Non-relevant metabolites formed during mammalian biotransformation of the parent AI Non-relevant metabolites not formed during mammalian biotransformation Application of the margin of exposure concept (MOE) to derive safe levels of \u201cnon-relevant metabolites\u201d based on a reduced toxicity testing program Proposed approaches for risk assessment for \u201cnon-relevant metabolites\u201d of AIs Conclusions Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicity-effects-of-a-novel-potent-triple-reuptake-inhib_2018_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30359699", "content": {"CoiStatement": "Conflicts of interest The authors have no conflicts of interest to declare. The authors have no conflicts of interest to declare. Acknowledgments Discussion Conflicts of interest Acknowledgments Supplementary data References", "Acknowledgement": "Acknowledgments The National Natural Science Foundation of China (Grant No. 81473188), the Key Project of Shandong Province (Grant No. 2017GSF218106) as well as \u201cMajor New Drugs Research & Development\u201d special projects of Ministry of Science and Technology of PR China (NO.2018ZX09303015) supported this study. Discussion Conflicts of interest Acknowledgments Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicity-evaluation-of-hydroalcoholic-extract_2016_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26893240", "content": {"CoiStatement": "Conflict of interest The authors declare that they have no conflict of interest. The authors declare that they have no conflict of interest. Acknowledgments 4. Discussion Conflict of interest Acknowledgments Transparency document References", "Acknowledgement": "Acknowledgments This work was supported by a grant (922916) from Vice- Chancellor for Research and Technology, Mashhad University of Medical Sciences (MUMohammad Soukhtanloo), IRAN. 4. Discussion Conflict of interest Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicity-of-boric-acid--borax-and-other-boron-c_2021_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33485927", "content": {"CoiStatement": "7 Hazard characterisation 8 Summary CRediT authorship contribution statement Declaration of competing interest Acknowledgments Appendix A Supplementary data References", "Acknowledgement": "7 Hazard characterisation 8 Summary CRediT authorship contribution statement Declaration of competing interest Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicity-of-orange-peel-originated-hesperidin_2020_Regulatory-Toxicology-an1.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31751641", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper.", "Funding": "Funding body information None. Thanking You. Sincerely. Dr. S. L. Bodhankar, Prof. and Head, Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Erandwane, Pune 411 038, INDIA. Toxicity of orange peel-originated hesperidin in Sprague Dawley rats Responses to reviewers comments Funding body information mk:H1_3 Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicity-of-orange-peel-originated-hesperidin_2020_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31715200", "content": {"Funding": "Toxicity of orange peel-originated hesperidin in Sprague Dawley rats Funding body information mk:H1_2 Acknowledgements References", "Acknowledgement": "Toxicity of orange peel-originated hesperidin in Sprague Dawley rats Funding body information mk:H1_2 Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicity-of-silver-ions--metallic-silver--and-silver-na_2018_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30125612", "content": {"CoiStatement": "Comparison of ionic and nanoparticulate silver Risk characterization Summary Conflicts of interest Acknowledgements Supplementary data Transparency document References", "Acknowledgement": "Comparison of ionic and nanoparticulate silver Risk characterization Summary Conflicts of interest Acknowledgements Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicity-of-so-called-edible-hijiki-seaweed--Sarga_2012_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22561181", "content": {"CoiStatement": "Toxicity of so-called edible hijiki seaweed (Sargassum fusiforme) containing inorganic arsenic 1 Introduction 2 Materials and methods 3 Results 4 Discussion 5 Conclusions Conflict of interest statement Acknowledgments References", "Acknowledgement": "Toxicity of so-called edible hijiki seaweed (Sargassum fusiforme) containing inorganic arsenic 1 Introduction 2 Materials and methods 3 Results 4 Discussion 5 Conclusions Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicity-studies-for-the-use-of-prodrug-of-v_2019_Regulatory-Toxicology-and-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30817970", "content": {"CoiStatement": "Conflicts of interest The authors indicated no potential conflicts of interest. The authors indicated no potential conflicts of interest. Funding Discussion Conflicts of interest Funding Acknowledgements Transparency document Supplementary data References", "Funding": "Funding This research did not receive any specific grant from funding agencies in the public. This research did not receive any specific grant from funding agencies in the public. Acknowledgements Discussion Conflicts of interest Funding Acknowledgements Transparency document Supplementary data References", "Acknowledgement": "Acknowledgements This work was supported by the Jiangsu Center for Safety Evaluation of Drugs. Thanks to Miss. Zhou Bo for her guidance in the writing process. Discussion Conflicts of interest Funding Acknowledgements Transparency document Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicity-testing-of-poorly-soluble-particles--l_2018_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30366008", "content": {"CoiStatement": "Conclusions and recommendations Conflicts of interest Acknowledgement Transparency document References", "Acknowledgement": "Conclusions and recommendations Conflicts of interest Acknowledgement Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicity-value-for-3-monochloropropane-1-2-diol-_2009_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19133308", "content": {"Acknowledgement": "Acknowledgment This research was supported by a grant (01631KFDA380) from Korea Food & Drug Administration in 2006. Toxicity value for 3-monochloropropane-1,2-diol using a benchmark dose methodology Introduction Target tissue and critical endpoint at the 3-MCPD carcinogenicity test Benchmark dose approach Discussion Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicogenomics-and-cancer-risk-assessment--A-framework-_2010_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20801182", "content": {"CoiStatement": "Conflict of Interest None declared. Conclusions Conflict of Interest Funding sources Supplementary data References", "Funding": "Funding sources The studies were conducted at Eli Lilly and Company with no additional sources of funding. The studies were conducted at Eli Lilly and Company with no additional sources of funding. Appendix A. Supplementary data Conclusions Conflict of Interest Funding sources Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicokinetic-and-toxicodynamic-considerations-when-_2016_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27224509", "content": {"Compliance with ethical standards": "US FDA, 2008. Guidance for Industry: Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches. U.S. Food and Drug Administration (FDA), Silver Spring, MD. Available at: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM347725.pdf. US FDA, 2005. Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research, Silver Spring, MD. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm078932.pdf. US FDA, 2005. Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research, Silver Spring, MD. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm078932.pdf. Walsh, A., 2011a. Cleaning validation for the 21st century: acceptance limits for active pharmaceutical ingredients (APIs): Part I. Pharm. Eng. 31, 74e83. http://refhub.elsevier.com/S0273-2300(16)30140-4/sref47 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref47 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref48 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref48 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref49 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref49 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref49 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref50 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref50 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref50 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref50 http://dx.doi.org/10.1080/15298668891379792 http://dx.doi.org/10.1080/15298668891379792 http://dx.doi.org/10.1080/20028091057213 http://dx.doi.org/10.1080/20028091057213 http://dx.doi.org/10.1111/j.1476-5381.2009.00267.x http://dx.doi.org/10.1111/j.1476-5381.2009.00267.x http://refhub.elsevier.com/S0273-2300(16)30140-4/sref54 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref54 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref54 http://dx.doi.org/10.1080/10807039991289347 http://dx.doi.org/10.1016/j.yrtph.2012.03.016 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref57 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref57 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref57 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref57 http://dx.doi.org/10.1021/mp100444g http://dx.doi.org/10.1021/mp100444g http://www2.epa.gov/sites/production/files/2015-01/documents/ddef-final.pdf http://www2.epa.gov/sites/production/files/2015-01/documents/ddef-final.pdf http://www.epa.gov/raf/publications/pdfs/recommended-use-of-bw34.pdf http://www.epa.gov/raf/publications/pdfs/recommended-use-of-bw34.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM347725.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM347725.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM347725.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078932.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078932.pdf http://refhub.elsevier.com/S0273-2300(16)30140-4/sref63 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref63 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref63 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref64 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref64 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref64 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref65 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref65 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref65 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref66 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref66 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref66 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref67 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref67 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref67 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref68 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref68 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref68 http://refhub.elsevier.com/S0273-2300(16)30140-4/sref68 Toxicokinetic and toxicodynamic considerations when deriving health-based exposure limits for pharmaceuticals 1. Introduction 2. Background and history: the move from default adjustment factors to data-derived approaches 3. CSAF values for intra- and interspecies adjustment 3.1. Choosing the appropriate CSAF parameter 3.2. Intraspecies toxicokinetic variability (AFH) 3.3. Interspecies toxicokinetic extrapolation (AFA)", "Acknowledgement": "6. Summary and conclusions Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicokinetic-testing-strategies-to-demonstrate-bone-mar_2020_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31836537", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper.", "Funding": "Funding The presented work did not receive any specific grant from funding agencies in the public or not-for-profit sectors. The examples presented in this paper were obtained from studies conducted on behalf of FMC Corporation. The presented work did not receive any specific grant from funding agencies in the public or not-for-profit sectors. The examples presented in this paper were obtained from studies conducted on behalf of FMC Corporation. Declaration of competing interest Additional considerations Conclusions Funding mk:H1_19 Acknowledgment References Acronyms", "Acknowledgement": "Acknowledgment The authors would like to acknowledge Dr. Li Shen (Frontage Laboratories, Exton, PA); Dr. Manik Desai and Gina Theerman (WuXi AppTec, Plainsboro, NJ) for their contribution to the experiments. Additional considerations Conclusions Funding mk:H1_19 Acknowledgment References Acronyms"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicologic-assessment-of-Paecilomyces-tenuipes-in_2014_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25223566", "content": {"CoiStatement": "534 J.-H. Che et al. / Regulatory Toxicology and Pharmacology 70 (2014) 527\u2013534 (De Groot et al., 1976). Interestingly, this renal karyomegaly induced by free lysinoalanine was a phenomenon unique to the rat, not any other species (quail, mice, hamsters, rabbits, dogs, and monkeys) (De Groot et al., 1976). Hong et al. (2007) previously demonstrated that total free amino acid content of the P. tenuipes was 17.09 mg/g dry weight, and that many amino acids, including glycine, arginine, alanine and lysine, were present in the P. tenuipes (Hong et al., 2007). These previous findings suggest the need for further studies to identify whether the P. tenuipes extract includes lysinoalanine and the renal toxicity of the P. tenuipes extract is spe- cies-specific. Since cultured products with the P. tenuipes, which have anticancer and immune activities, are certified for use in food in South Korea (Nam et al., 2011), it is important to provide accurate information on the safety concern of P. tenuipes to be developed as functional foods and nutritious medicines. Therefore, based on our current results, we suggest that further study is necessary to find no observed adverse effects level associated with karyomegaly using the P. tenuipes extract doses less than 500 mg/ kg and to confirm the P. tenuipes-related renal toxicity in other species. Conflict of interest The authors declare that they have no conflict of interest. References The authors declare that they have no conflict of interest. References Ahn, M.Y., Kang, S.C., Jung, N.J., Koo, H.J., Kwack, S.J., Yoo, E.J., Jung, J.A., Ko, J.K., Ryu, K.S., Jee, S.D., Lee, Y.W., Lee, B.M., 2003. Acute oral toxicity of Paecilomyces sinclairii in beagle dogs. J. Toxicol. Pub. Health 19, 241\u2013245. 4 Discussion Conflict of interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicologic-evaluation-of-repetitive-4-week-intravenou_2019_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30682377", "content": {"CoiStatement": "Conflicts of interest All authors disclose no potential conflicts of interest. All authors disclose no potential conflicts of interest. Acknowledgements Discussion Conflicts of interest Acknowledgements Transparency document References", "Acknowledgement": "Acknowledgements This work was financially supported by the Key Drug Discovery Project of 12th Five-Years Plan (2013ZX09102051), the Ministry of Science and Technology of the People's Republic of China. Discussion Conflicts of interest Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicologic-evaluations-of-recombinant-liver-targeti_2017_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28709686", "content": {"Acknowledgement": "Acknowledgment This workwas financially supported by National Major Scientific and Technological Special Project for \"Significant New Drugs Development\" of China (2013ZX09103003-003); Science and Technology Planning Project of Guangzhou Municipality (No. 201607010272); National Natural Science Foundation of China (No. 31501894 and No. 81274061); Natural Science Foundation of Guangdong Province of China (No. 2015A030310036); Special Foundation of Public Welfare Research and Capacity Building of Guangdong Province (No. 2016A030303060 and No. 2017A010105012); the Joint Natural Sciences Fund of the Depart- ment of Science and Technology and the First Affiliated Hospital of Guangdong Pharmaceutical University (No. GYFYLH201312). 4. Discussion Acknowledgment Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-Studies-on-Laccase-from-Myceliophthor_2002_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/12202045", "content": {"Compliance with ethical standards": "All toxicity studies were carried out in accordance with present guidelines of the Organization for Eco- nomic Cooperation and Development (OECD, 1981b, 1983, 1987, 1992a, 1997a) and selected in accordance with EU guidelines for the presentation of data on food enzymes (EU Scientific Committee for Food, 1991). They were conducted in compliance with the present OECD principles of Good Laboratory Practice (OECD, 1981a, 1997b) or Good Clinical Practice (EU, 1991). The product complies with the Food and Agriculture Organization/World Health Organization (FAO/WHO, 1987), Joint Expert Committee on Food Additives (JECFA, 1992), and Food Chemical Codex (FCC, 1996) recommended purity specifications for food-grade en- zymes, except for copper content, which is higher than recommended because laccase contains copper in the prosthetic group (see Discussion). The high copper con- tent also means that the total heavy metal content in the test substance is higher than that of current purity specifications. MATERIALS AND METHODS"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-analysis-and-anti-inflammatory-effect_2015_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26545326", "content": {"CoiStatement": "Conflict of interest The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. References 3. Results 4. Discussion Acknowledgments Transparency document Conflict of interest References", "Acknowledgement": "Acknowledgments The authors thank CAPES for the financial assistance. 3. Results 4. Discussion Acknowledgments Transparency document Conflict of interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-analysis-points-to-a-lower-tolerabl_2009_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19486917", "content": {"Acknowledgement": "Acknowledgments The authors are grateful to Dr. Chao W. Chen of the US Environ- mental Protection Agency for his advice and insightful discussion on the issues related to melamine toxicity in food safety. The authors also thank Lin Meng-Hung of CMU for running BMD anal- ysis to obtain the results presented in Table 2. Toxicological analysis points to a lower tolerable daily intake of melamine in food Background TDI estimation by FDA Benchmark dose analysis Vulnerability of young children TDI estimation by WHO Issues on uncertainties Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-assessment-compilation-of-selected-exa_2019_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30771368", "content": {"Funding": "Toxicological assessment compilation of selected examples of raw materials for homeopathic medicinal products Introduction Principles and procedures of risk assessment - toxicological considerations Advice for use of the compilation of selected raw materials Summary and outlook Tabular compilation of raw materials Funding Abbreviations Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Toxicological-assessment-method-for-evaluating-the-_2021_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34265403", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 3 Conclusions Funding CRediT authorship contribution statement Declaration of competing interest References", "Funding": "Funding This research received no external funding. This research received no external funding. CRediT authorship contribution statement 3 Conclusions Funding CRediT authorship contribution statement Declaration of competing interest References", "Compliance with ethical standards": "EN 689:2019+AC:2019, 2019. Workplace Exposure - Measurement of Exposure by Inhalation to Chemical Agents - Strategy for Testing Compliance with Occupational Exposure Limit Values - European Standards. European Chemicals Agency, 2012. Guidance on information requirements and chemical safety assessment - Part E: risk characterisation. Eur. Chem. Agency."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-assessment-of-Anionic-Methacrylate-Copo_2016_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27825834", "content": {"Compliance with ethical standards": "Toxicology studies have been performed over a number of years during the development of the product and in line with changing regulatory requirements. All studies were undertaken in compli- ance with the standards in place at the time of their conduct with regard to animal welfare and methodology. Details of methodology have not been provided for those studies conducted in accordance with recognized standard test methods such as the OECD test guidelines. In those cases where non-standard methods have been employed, the methodology has been described in more detail. All tests have been performed in compliance with GLP regulations (Good Laboratory Practices). 3.1. Material and methods"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-assessment-of-Tobacco-Heating-System-_2019_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30878573", "content": {"CoiStatement": "Nat. Rev. Drug Discov. 14, 733\u2013734. Gasparyan, A.Y., et al., 2013. Conflicts of interest in biomedical publications: con- siderations for authors, peer reviewers, and editors. Croat. Med. J. 54, 600\u2013608. Gaudart, J., et al., 2014. Reproducibility issues in science, is P value really the only an- swer? Proc. Natl. Acad. Sci. U. S. A. 111, E1934. Hatsukami, D.K., et al., 2012. Tobacco and nicotine product testing. Nicotine Tob. Res. 14, 7\u201317. Ho, R.C., et al., 2013. Views on the peer review system of biomedical journals: an online Kirman, C.R., et al., 2019. Science peer review for the 21st century: assessing scientific consensus for decision-making while managing conflict of interests, reviewer and process bias. Regul. Toxicol. Pharmacol. 103, 73\u201385. Kozlowski, L.T., Abrams, D.B., 2016. Obsolete tobacco control themes can be hazardous to public health: the need for updating views on absolute product risks and harm reduction. BMC Public Health 16, 432. The National Academies, 2003. Policy on Committee Composition and Balance and Conflicts of Interest for Committees Used in the Development of Reports. National Academies Press. The Royal College of Physicians, 2016. Nicotine without Smoke: Tobacco Harm Reduction. The Royal College of Physicians.", "Funding": "Funding details This work was supported by Philip Morris International. All authors are employees or paid consultants of Philip Morris International. Conclusions Funding details Acknowledgments Supplementary data Transparency document References", "Acknowledgement": "Acknowledgments We would like to thank Sean Hayes and Chris Kirman for the con- duct of the peer reviews, Vincenzo Belcastro, Elena Scotti, Anita Iskandar, Filippo Zanetti, Marja Talikka, and Christelle Haziza for their help with the preparation of material shared for the review of the studies, and Dean Meyer for her help reviewing the manuscript. Conclusions Funding details Acknowledgments Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-assessment-of-cigarette-in_2011_Regulatory-Toxicology-and-Phar.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21771627", "content": {"CoiStatement": "4 Discussion and conclusions Conflict of interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-assessment-of-enzyme-treated-asparagus-ex_2014_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24389363", "content": {"CoiStatement": "T. Ito et al. / Regulatory Toxicology and Pharmacology 68 (2014) 240\u2013249 249 mutagenic activity in the Ames test. These fundamental toxicology data provide critical evidence in support of the safety of ETAtsuya Sato con- sumption and form the basis for a safety study in humans. Conflict of interest Tomohiro Ito., Tomoko Ono., Atsuya Sato., Kazunori Goto., Hiroshi Nishioka. and Takehito Miura. all are employees of Amino Up Chemical Co., Ltd. 4 Discussion Conflict of interest Acknowledgments References", "Acknowledgement": "Acknowledgments We thank Dr. Robert M. Hackman, University of California-Da- vis, for providing greatly valuable suggestions and editorial com- ments. This study was supported by a research grant from Sapporo city and the Northern Advancement Center for Science & Technology (Sapporo, Japan). 4 Discussion Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-assessment-of-kretek-cigarettes--Part-1_2014_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25498000", "content": {"CoiStatement": "Patskan, G.J., Podraza, K.F., Meurrens, K., Coggins, C.R., Friedrichs, B., Gerstenberg, B., Gomm, W., Schnell, P., Stabbert, R., Veltel, D., Weber, S., Terpstra, P., 2008. Toxicological comparisons of three styles of a commercial U.S. cigarette (Marlboro with the 1R4F reference cigarette. Inhal. Toxicol. 20, 695\u2013721. Piad\u00e9, J.-J., Roemer, E., Dempsey, R., Hornig, G., Deger Evans, A., V\u00f6lkel, H., Schramke, H., Trelles-Sticken, E., Wittke, S., Weber, S., Schorp, M.K., 2014a. Toxicological assessment of kretek cigarettes. Part 2: Kreteks and American-blend cigarettes, smoke chemistry and in vitro toxicity. Regul. Toxicol. Pharmacol. 70, S15\u2013S25. Piad\u00e9, J.-J., Roemer, E., Dempsey, R., Weiler, H., Meurrens, K., Vanscheeuwijck, P., Schorp, M.K., 2014b. Toxicological Assessment of Kretek Cigarettes. Part 3: Kreteks and American-blend cigarettes, Inhalation Toxicity. Regul. Toxicol. Pharmacol. 70, S26\u2013S40. Polzin, G.M., Stanfill, S.B., Brown, C.R., Ashley, D.L., Watson, C.H., 2007. Determination of eugenol, anethole, and coumarin in the mainstream cigarette smoke of Indonesian clove cigarettes. Food Chem. Toxicol. 45, 1948\u2013 1953. Pramod, K., Ansari, S.H., Ali, J., 2010. Eugenol: a natural compound with versatile pharmacological actions. Nat. Prod. Commun. 5, 1999\u20132006. Prignot, J.J., Sasco, A.J., Poulet, E., Gupta, P.C., Aditama, T.Y., 2008. Alternative forms of tobacco use. Int. J. Tuberc. Lung Dis. 12, 718\u2013727. Putnam, K.P., Bombick, D.W., Avalos, J.T., Doolittle, D.J., 1999. Comparison of the cytotoxic and mutagenic potential of liquid smoke food flavourings, cigarette smoke condensate and wood smoke condensate. Food Chem. Toxicol. 37, 1113\u2013 1118. Queiroz, A.M., Nelson-Filho, P., Silva, L.A., Assed, S., Silva, R.A., Ito, I.Y., 2009. Antibacterial activity of root canal filling materials for primary teeth: zinc oxide and eugenol cement, Calen paste thickened with zinc oxide, Sealapex and EndoREZ. Braz. Dent. J. 20, 290\u2013296. Radtke, F., Schmickler, M., Ochel, W., Schaffernicht, H., 2007. Pumpenanordnung. In: Office, E.P., (Ed.), Germany. Rickert, W.S., Trivedi, A.H., Momin, R.A., Wagstaff, W.G., Lauterbach, J.H., 2011. Mutagenic, cytotoxic, and genotoxic properties of tobacco smoke produced by cigarillos available on the Canadian market. Regul. Toxicol. Pharmacol. 61, 199\u2013 209. Rickert, W.S., Wright, W.G., Trivedi, A.H., Momin, R.A., Lauterbach, J.H., 2007. A comparative study of the mutagenicity of various types of tobacco products. Regul. Toxicol. Pharmacol. 48, 320\u2013330. Rodrigues, T.G., Fernandes Jr., A., Sousa, J.P., Bastos, J.K., Sforcin, J.M., 2009. In vitro and in vivo effects of clove on pro-inflammatory cytokines production by macrophages. Nat. Prod. Res. 23, 319\u2013326. Roemer, E., Carchman, R.A., 2011. Limitations of cigarette machine smoking regimens. Toxicol. Lett. 203, 20\u201327. Roemer, E., Dempsey, R., Hirter, J., Deger Evans, A., Weber, S., Ode, A., Wittke, S., Schorp, M.K., 2014a. Toxicological assessment of kretek cigarettes. Part 6: The impact of ingredients added to kretek cigarettes on the smoke chemistry and in vitro toxicity. Regul. Toxicol. Pharmacol. 70, S66\u2013S80. Roemer, E., Dempsey, R., Lawless-Pyne, J., Lukman, S., Deger Evans, A., Trelles- Sticken, E., Wittke, S., Schorp, M.K., 2014b. Toxicological assessment of kretek cigarettes. Part 4: mechanistic investigations, smoke chemistry and in vitro toxicity. Regul. Toxicol. Pharmacol. 70, S41\u2013S53. Roemer, E., Ottmueller, T.H., Zenzen, V., Wittke, S., Radtke, F., Blanco, I., Carchman, R.A., 2009. Cytotoxicity, mutagenicity, and tumorigenicity of mainstream smoke from three reference cigarettes machine-smoked to the same yields of total particulate matter per cigarette. Food Chem. Toxicol. 47, 1810\u20131818. Roemer, E., Dempsey, R,, Van Overveld, F.J., Berges, A., Pype, J., Weiler, H., Vanscheeuwijck, P., Schorp, M.K., 2014c. Toxicological Assessment of Kretek Cigarettes. Part 5: Mechanistic investigations, Inhalation Toxicity. Regul. Toxicol. Pharmacol. 70, S54\u2013S65. Roemer, E., Schramke, C., Weiler, H., Buettner, A., Kausche, S., Weber, S., Berges, A., Stueber, M., Muench, M., Trelles-Sticken, E., Pype, J., Kohlgrueber, K., Voelkel, H., Wittke, S., 2012. Mainstream smoke chemistry and in vitro and in vivo toxicity of the reference cigarette 3R4F and 2R4F. Beitr. Tabakforsch. Int. 25, 316\u2013335. Roemer, E., Stabbert, R., Rustemeier, K., Veltel, D.J., Meisgen, T.J., Reininghaus, W., Carchman, R.A., Gaworski, C.L., Podraza, K.F., 2004. Chemical composition, cytotoxicity and mutagenicity of smoke from US commercial and reference http://www.gpo.gov/fdsys/pkg/FR-2009-09-25/html/E9-23144.htm http://refhub.elsevier.com/S0273-2300(14)00290-6/h0175 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0175 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0175 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0180 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0180 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0185 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0185 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0190 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0190 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0190 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0195 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0195 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0195 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0200 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0200 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0205 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0205 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0205 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0210 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0210 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0210 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0215 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0215 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0220 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0220 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0230 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0230 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0235 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0235 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0235 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0240 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0240 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0240 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0245 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0245 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0245 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0250 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0250 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0250 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0255 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0255 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0255 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0260 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0260 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0265 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0265 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0265 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0265 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0270 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0270 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0270 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0275 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0275 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0275 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0275 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0280 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0285 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0285 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0285 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0290 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0290 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0295 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0295 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0295 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0300 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0300 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0305 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0305 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0305 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0305 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0310 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0310 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0310 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0315 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0315 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0315 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0315 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0320 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0320 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0320 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0325 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0325 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0325 http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr223.pdf http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr223.pdf http://refhub.elsevier.com/S0273-2300(14)00290-6/h0335 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0335 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0340 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0340 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0345 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0345 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0350 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0350 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0355 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0355 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0355 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0360 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0360 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0360 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0365 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0365 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0365 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0365 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0380 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0380 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0380 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0380 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0385 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0385 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0390 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0390 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0395 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0395 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0395 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0395 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0400 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0400 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0400 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0400 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0410 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0410 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0410 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0410 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0415 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0415 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0415 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0420 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0420 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0420 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0425 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0425 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0440 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0440 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0440 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0440 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0450 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0450 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0450 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0450 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0455 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0455 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0455 S14 E. Roemer et al. / Regulatory Toxicology and Pharmacology 70 (2014) S2\u2013S14 cigarettes smoked under two sets of machine smoking conditions. Toxicology 195, 31\u201352. Roemer, E., Stabbert, R., Veltel, D., Muller, B.P., Meisgen, T.J., Schramke, H., Anskeit, E., Elves, R.G., Fournier, J.A., 2008. Reduced toxicological activity of cigarette smoke by the addition of ammonium magnesium phosphate to the paper of an electrically heated cigarette: smoke chemistry and in vitro cytotoxicity and genotoxicity. Toxicol. In Vitro 22, 671\u2013681. Roemer, E., Wittke, S., Trelles Sticken, E., Piade, J.-J., Bonk, T., Schorp, M.K., 2010. The addition of cocoa, glycerol, and saccharose to the tobacco of cigarettes: implications for smoke chemistry, in vitro cytotoxicity, mutagenicity, anf further endpoints. Beitr. Tabakforsch. Int. 24, 117\u2013132. Romagna, F., Staniforth, C.D., 1989. The automated bone marrow micronucleus test. Mutat. Res. 213, 91\u2013104. Rustemeier, K., Demetriou, D., Schepers, G., Voncken, P., 1993. High-performance liquid chromatographic determination of nicotine and its urinary metabolites via their 1,3-diethyl-2-thiobarbituric acid derivatives. J. Chromatogr. 613, 95\u2013 103. Sagartz, J.W., Madarasz, A.J., Forsell, M.A., Burger, G.T., Ayres, P.H., Coggins, C.R., 1992. Histological sectioning of the rodent larynx for inhalation toxicity testing. Toxicol. Pathol. 20, 118\u2013121. Schramke, H., Meisgen, T.J., Tewes, F.J., Gomm, W., Roemer, E., 2006. The mouse lymphoma thymidine kinase assay for the assessment and comparison of the mutagenic activity of cigarette mainstream smoke particulate phase. Toxicology 227, 193\u2013210. Schramke, H., Roemer, E., Dempsey, R., Hirter, J., Meurrens, K., Berges, A., Weiler, H., Vanscheeuwijck, P., Schorp, M.K., 2014. Toxicological assessment of kretek cigarettes. Part 7: The impact of ingredients added to kretek cigarettes on inhalation toxicity. Regul. Toxicol. Pharmacol. 70, S81\u2013S89. Sell, A.B., Carlini, E.A., 1976. Anesthetic action of methyleugenol and other eugenol derivatives. Pharmacology 14, 367\u2013377. Stabbert, R., Schafer, K.H., Biefel, C., Rustemeier, K., 2003. Analysis of aromatic amines in cigarette smoke. Rapid Commun. Mass Spectrom. 17, 2125\u20132132. Stanfill, S.B., Calafat, A.M., Brown, C.R., Polzin, G.M., Chiang, J.M., Watson, C.H., Ashley, D.L., 2003. Concentrations of nine alkenylbenzenes, coumarin, piperonal and pulegone in Indian bidi cigarette tobacco. Food Chem. Toxicol. 41, 303\u2013317. Stich, H.F., Rosin, M.P., Wu, C.H., Powrie, W.D., 1981. The action of transition metals on the genotoxicity of simple phenols, phenolic acids and cinnamic acids. Cancer Lett. 14, 251\u2013260. Sukumaran, K., Kuttan, R., 1995. Inhibition of tobacco-induced mutagenesis by eugenol and plant extracts. Mutat. Res. 343, 25\u201330. Tennant, R.W., Margolin, B.H., Shelby, M.D., Zeiger, E., Haseman, J.K., Spalding, J., Caspary, W., Resnick, M., Stasiewicz, S., Anderson, B., et al., 1987. Prediction of chemical carcinogenicity in rodents from in vitro genetic toxicity assays. Science 236, 933\u2013941. US-CPSC, 1993, US Consumer Product Safety Commission: Toxicity Testing Plan for Low Ignition-Potential Cigarettes, vol. 3, Washington DC. Van Miert, E., Vanscheeuwijck, P., Meurrens, K., Gomm, W., Terpstra, P.M., 2008. Evaluation of the micronucleus assay in bone marrow and peripheral blood of rats for the determination of cigarette mainstream-smoke activity. Mutat. Res. 652, 131\u2013138. Vanscheeuwijck, P.M., Teredesai, A., Terpstra, P.M., Verbeeck, J., Kuhl, P., Gerstenberg, B., Gebel, S., Carmines, E.L., 2002. Evaluation of the potential effects of ingredients added to cigarettes. Part 4: subchronic inhalation toxicity. Food Chem. Toxicol. 40, 113\u2013131. Wagner, K.A., Finkel, N.H., Fossett, J.E., Gillman, I.G., 2005. Development of a quantitative method for the analysis of tobacco-specific nitrosamines in mainstream cigarette smoke using isotope dilution liquid chromatography/ electrospray ionization tandem mass spectrometry. Anal. Chem. 77, 1001\u20131006. Werley, M.S., Freelin, S.A., Wrenn, S.E., Gerstenberg, B., Roemer, E., Schramke, H., Van Miert, E., Vanscheeuwijck, P., Weber, S., Coggins, C.R., 2008. Smoke chemistry, in vitro and in vivo toxicology evaluations of the electrically heated cigarette smoking system series K. Regul. Toxicol. Pharmacol. 52, 122\u2013139. WHO, 2009. WHO Indonesia, Tobacco Free Initiative, Country Situation. Available at <http://ino.searo.who.int/EN/Section4/Section22_64.htm>. WHO, 2013. World Health Organization, Report on the global tobacco epidemic, 2013. Available at <http://www.who.int/tobacco/surveillance/policy/country_ profile/idn.pdf>. Yogalakshmi, B., Viswanathan, P., Anuradha, C.V., 2010. Investigation of antioxidant, anti-inflammatory and DNA-protective properties of eugenol in thioacetamide- induced liver injury in rats. Toxicology 268, 204\u2013212. Young, J.T., 1981. Histopathologic examination of the rat nasal cavity. Fundam. Appl. Toxicol. 1, 309\u2013312. Yulisman, L., 2012. Brazil bans sale of clove cigarettes (to be retrieved at <http:// www.thejakartapost.com/news/2012/04/13/brazil-bans-sale-clove-cigarettes. html>) In: The Jakarta Post Jakarta. Zar, J.H., 1999. Biostatistical Analysis. Prentice Hall, New Jersey, USA. Zenzen, V., Diekmann, J., Gerstenberg, B., Weber, S., Wittke, S., Schorp, M.K., 2012. Reduced exposure evaluation of an Electrically Heated Cigarette Smoking System. Part 2: Smoke chemistry and in vitro toxicological evaluation using smoking regimens reflecting human puffing behavior. Regul. Toxicol. Pharmacol. 64, S11\u201334. http://refhub.elsevier.com/S0273-2300(14)00290-6/h0455 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0455 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0460 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0460 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0460 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0460 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0460 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0465 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0465 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0465 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0465 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0470 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0470 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0475 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0475 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0475 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0475 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0480 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0480 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0480 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0485 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0485 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0485 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0485 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0495 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0495 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0500 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0500 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0505 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0505 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0505 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0505 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0510 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0510 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0510 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0515 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0515 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0520 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0520 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0520 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0520 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0530 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0530 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0530 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0530 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0535 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0535 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0535 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0535 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0540 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0540 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0540 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0540 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0545 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0545 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0545 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0545 http://ino.searo.who.int/EN/Section4/Section22_64.htm http://www.who.int/tobacco/surveillance/policy/country_profile/idn.pdf http://www.who.int/tobacco/surveillance/policy/country_profile/idn.pdf http://refhub.elsevier.com/S0273-2300(14)00290-6/h0560 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0560 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0560 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0565 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0565 http://www.thejakartapost.com/news/2012/04/13/brazil-bans-sale-clove-cigarettes.html http://www.thejakartapost.com/news/2012/04/13/brazil-bans-sale-clove-cigarettes.html http://www.thejakartapost.com/news/2012/04/13/brazil-bans-sale-clove-cigarettes.html http://refhub.elsevier.com/S0273-2300(14)00290-6/h0575 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0580 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0580 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0580 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0580 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0580 Toxicological assessment of kretek cigarettes 1 Background 1.1 General 1.2 History of kretek cigarettes 1.3 Product characteristics 1.4 Socioeconomic aspects 2 Existing studies on health risks 3 Results from previously conducted animal inhalation studies 4 General approach 5 Methods 5.1 General 5.2 Cigarettes and MS generation 5.3 MS chemistry 5.4 Basis for normalization 5.5 Mammalian cell cytotoxicity 5.5.1 General 5.5.2 Test substance 5.5.3 Cells and exposure 5.5.4 Evaluation 5.6 Bacterial mutagenicity 5.6.1 General 5.6.2 Test substance 5.6.3 Cells and exposure 5.6.4 Evaluation 5.7 Mammalian cell genotoxicity 5.7.1 General 5.7.2 Test substance 5.7.3 Cells and exposure 5.7.4 Evaluation 5.8 Inhalation toxicity 5.8.1 General 5.8.2 Test substance 5.8.3 Animals and exposure 5.8.4 Evaluation 5.9 In vivo micronucleus assay 5.9.1 General 5.9.2 Test substance 5.9.3 Animals and exposure 5.9.4 Evaluation 5.10 Statistical analyses 6 Summary of results 6.1 Characterization (Part 2 (Piad\u00e9 et al., 2014a) and Part 3 (Piad\u00e9 et al., 2014b)) 6.2 Mechanisms (Part 4 (Roemer et al., 2014b) and Part 5 (Roemer et al., 2014c)) 6.3 Ingredients (Part 6 (Roemer et al., 2014a) and Part 7 (Schramke et al., 2014)) 7 Discussion 7.1 Characterization 7.2 Mechanisms 7.3 Ingredients 8 General conclusion 9 Conflict of interest statement Acknowledgments References", "Acknowledgement": "Patskan, G.J., Podraza, K.F., Meurrens, K., Coggins, C.R., Friedrichs, B., Gerstenberg, B., Gomm, W., Schnell, P., Stabbert, R., Veltel, D., Weber, S., Terpstra, P., 2008. Toxicological comparisons of three styles of a commercial U.S. cigarette (Marlboro with the 1R4F reference cigarette. Inhal. Toxicol. 20, 695\u2013721. Piad\u00e9, J.-J., Roemer, E., Dempsey, R., Hornig, G., Deger Evans, A., V\u00f6lkel, H., Schramke, H., Trelles-Sticken, E., Wittke, S., Weber, S., Schorp, M.K., 2014a. Toxicological assessment of kretek cigarettes. Part 2: Kreteks and American-blend cigarettes, smoke chemistry and in vitro toxicity. Regul. Toxicol. Pharmacol. 70, S15\u2013S25. Piad\u00e9, J.-J., Roemer, E., Dempsey, R., Weiler, H., Meurrens, K., Vanscheeuwijck, P., Schorp, M.K., 2014b. Toxicological Assessment of Kretek Cigarettes. Part 3: Kreteks and American-blend cigarettes, Inhalation Toxicity. Regul. Toxicol. Pharmacol. 70, S26\u2013S40. Polzin, G.M., Stanfill, S.B., Brown, C.R., Ashley, D.L., Watson, C.H., 2007. Determination of eugenol, anethole, and coumarin in the mainstream cigarette smoke of Indonesian clove cigarettes. Food Chem. Toxicol. 45, 1948\u2013 1953. Pramod, K., Ansari, S.H., Ali, J., 2010. Eugenol: a natural compound with versatile pharmacological actions. Nat. Prod. Commun. 5, 1999\u20132006. Prignot, J.J., Sasco, A.J., Poulet, E., Gupta, P.C., Aditama, T.Y., 2008. Alternative forms of tobacco use. Int. J. Tuberc. Lung Dis. 12, 718\u2013727. Putnam, K.P., Bombick, D.W., Avalos, J.T., Doolittle, D.J., 1999. Comparison of the cytotoxic and mutagenic potential of liquid smoke food flavourings, cigarette smoke condensate and wood smoke condensate. Food Chem. Toxicol. 37, 1113\u2013 1118. Queiroz, A.M., Nelson-Filho, P., Silva, L.A., Assed, S., Silva, R.A., Ito, I.Y., 2009. Antibacterial activity of root canal filling materials for primary teeth: zinc oxide and eugenol cement, Calen paste thickened with zinc oxide, Sealapex and EndoREZ. Braz. Dent. J. 20, 290\u2013296. Radtke, F., Schmickler, M., Ochel, W., Schaffernicht, H., 2007. Pumpenanordnung. In: Office, E.P., (Ed.), Germany. Rickert, W.S., Trivedi, A.H., Momin, R.A., Wagstaff, W.G., Lauterbach, J.H., 2011. Mutagenic, cytotoxic, and genotoxic properties of tobacco smoke produced by cigarillos available on the Canadian market. Regul. Toxicol. Pharmacol. 61, 199\u2013 209. Rickert, W.S., Wright, W.G., Trivedi, A.H., Momin, R.A., Lauterbach, J.H., 2007. A comparative study of the mutagenicity of various types of tobacco products. Regul. Toxicol. Pharmacol. 48, 320\u2013330. Rodrigues, T.G., Fernandes Jr., A., Sousa, J.P., Bastos, J.K., Sforcin, J.M., 2009. In vitro and in vivo effects of clove on pro-inflammatory cytokines production by macrophages. Nat. Prod. Res. 23, 319\u2013326. Roemer, E., Carchman, R.A., 2011. Limitations of cigarette machine smoking regimens. Toxicol. Lett. 203, 20\u201327. Roemer, E., Dempsey, R., Hirter, J., Deger Evans, A., Weber, S., Ode, A., Wittke, S., Schorp, M.K., 2014a. Toxicological assessment of kretek cigarettes. Part 6: The impact of ingredients added to kretek cigarettes on the smoke chemistry and in vitro toxicity. Regul. Toxicol. Pharmacol. 70, S66\u2013S80. Roemer, E., Dempsey, R., Lawless-Pyne, J., Lukman, S., Deger Evans, A., Trelles- Sticken, E., Wittke, S., Schorp, M.K., 2014b. Toxicological assessment of kretek cigarettes. Part 4: mechanistic investigations, smoke chemistry and in vitro toxicity. Regul. Toxicol. Pharmacol. 70, S41\u2013S53. Roemer, E., Ottmueller, T.H., Zenzen, V., Wittke, S., Radtke, F., Blanco, I., Carchman, R.A., 2009. Cytotoxicity, mutagenicity, and tumorigenicity of mainstream smoke from three reference cigarettes machine-smoked to the same yields of total particulate matter per cigarette. Food Chem. Toxicol. 47, 1810\u20131818. Roemer, E., Dempsey, R,, Van Overveld, F.J., Berges, A., Pype, J., Weiler, H., Vanscheeuwijck, P., Schorp, M.K., 2014c. Toxicological Assessment of Kretek Cigarettes. Part 5: Mechanistic investigations, Inhalation Toxicity. Regul. Toxicol. Pharmacol. 70, S54\u2013S65. Roemer, E., Schramke, C., Weiler, H., Buettner, A., Kausche, S., Weber, S., Berges, A., Stueber, M., Muench, M., Trelles-Sticken, E., Pype, J., Kohlgrueber, K., Voelkel, H., Wittke, S., 2012. Mainstream smoke chemistry and in vitro and in vivo toxicity of the reference cigarette 3R4F and 2R4F. Beitr. Tabakforsch. Int. 25, 316\u2013335. Roemer, E., Stabbert, R., Rustemeier, K., Veltel, D.J., Meisgen, T.J., Reininghaus, W., Carchman, R.A., Gaworski, C.L., Podraza, K.F., 2004. Chemical composition, cytotoxicity and mutagenicity of smoke from US commercial and reference http://www.gpo.gov/fdsys/pkg/FR-2009-09-25/html/E9-23144.htm http://refhub.elsevier.com/S0273-2300(14)00290-6/h0175 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0175 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0175 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0180 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0180 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0185 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0185 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0190 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0190 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0190 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0195 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0195 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0195 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0200 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0200 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0205 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0205 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0205 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0210 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0210 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0210 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0215 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0215 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0220 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0220 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0230 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0230 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0235 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0235 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0235 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0240 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0240 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0240 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0245 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0245 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0245 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0250 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0250 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0250 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0255 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0255 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0255 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0260 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0260 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0265 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0265 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0265 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0265 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0270 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0270 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0270 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0275 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0275 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0275 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0275 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0280 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0285 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0285 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0285 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0290 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0290 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0295 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0295 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0295 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0300 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0300 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0305 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0305 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0305 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0305 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0310 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0310 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0310 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0315 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0315 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0315 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0315 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0320 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0320 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0320 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0325 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0325 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0325 http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr223.pdf http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr223.pdf http://refhub.elsevier.com/S0273-2300(14)00290-6/h0335 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0335 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0340 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0340 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0345 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0345 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0350 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0350 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0355 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0355 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0355 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0360 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0360 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0360 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0365 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0365 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0365 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0365 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0380 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0380 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0380 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0380 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0385 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0385 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0390 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0390 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0395 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0395 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0395 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0395 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0400 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0400 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0400 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0400 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0410 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0410 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0410 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0410 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0415 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0415 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0415 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0420 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0420 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0420 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0425 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0425 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0440 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0440 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0440 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0440 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0450 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0450 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0450 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0450 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0455 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0455 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0455 S14 E. Roemer et al. / Regulatory Toxicology and Pharmacology 70 (2014) S2\u2013S14 cigarettes smoked under two sets of machine smoking conditions. Toxicology 195, 31\u201352. Roemer, E., Stabbert, R., Veltel, D., Muller, B.P., Meisgen, T.J., Schramke, H., Anskeit, E., Elves, R.G., Fournier, J.A., 2008. Reduced toxicological activity of cigarette smoke by the addition of ammonium magnesium phosphate to the paper of an electrically heated cigarette: smoke chemistry and in vitro cytotoxicity and genotoxicity. Toxicol. In Vitro 22, 671\u2013681. Roemer, E., Wittke, S., Trelles Sticken, E., Piade, J.-J., Bonk, T., Schorp, M.K., 2010. The addition of cocoa, glycerol, and saccharose to the tobacco of cigarettes: implications for smoke chemistry, in vitro cytotoxicity, mutagenicity, anf further endpoints. Beitr. Tabakforsch. Int. 24, 117\u2013132. Romagna, F., Staniforth, C.D., 1989. The automated bone marrow micronucleus test. Mutat. Res. 213, 91\u2013104. Rustemeier, K., Demetriou, D., Schepers, G., Voncken, P., 1993. High-performance liquid chromatographic determination of nicotine and its urinary metabolites via their 1,3-diethyl-2-thiobarbituric acid derivatives. J. Chromatogr. 613, 95\u2013 103. Sagartz, J.W., Madarasz, A.J., Forsell, M.A., Burger, G.T., Ayres, P.H., Coggins, C.R., 1992. Histological sectioning of the rodent larynx for inhalation toxicity testing. Toxicol. Pathol. 20, 118\u2013121. Schramke, H., Meisgen, T.J., Tewes, F.J., Gomm, W., Roemer, E., 2006. The mouse lymphoma thymidine kinase assay for the assessment and comparison of the mutagenic activity of cigarette mainstream smoke particulate phase. Toxicology 227, 193\u2013210. Schramke, H., Roemer, E., Dempsey, R., Hirter, J., Meurrens, K., Berges, A., Weiler, H., Vanscheeuwijck, P., Schorp, M.K., 2014. Toxicological assessment of kretek cigarettes. Part 7: The impact of ingredients added to kretek cigarettes on inhalation toxicity. Regul. Toxicol. Pharmacol. 70, S81\u2013S89. Sell, A.B., Carlini, E.A., 1976. Anesthetic action of methyleugenol and other eugenol derivatives. Pharmacology 14, 367\u2013377. Stabbert, R., Schafer, K.H., Biefel, C., Rustemeier, K., 2003. Analysis of aromatic amines in cigarette smoke. Rapid Commun. Mass Spectrom. 17, 2125\u20132132. Stanfill, S.B., Calafat, A.M., Brown, C.R., Polzin, G.M., Chiang, J.M., Watson, C.H., Ashley, D.L., 2003. Concentrations of nine alkenylbenzenes, coumarin, piperonal and pulegone in Indian bidi cigarette tobacco. Food Chem. Toxicol. 41, 303\u2013317. Stich, H.F., Rosin, M.P., Wu, C.H., Powrie, W.D., 1981. The action of transition metals on the genotoxicity of simple phenols, phenolic acids and cinnamic acids. Cancer Lett. 14, 251\u2013260. Sukumaran, K., Kuttan, R., 1995. Inhibition of tobacco-induced mutagenesis by eugenol and plant extracts. Mutat. Res. 343, 25\u201330. Tennant, R.W., Margolin, B.H., Shelby, M.D., Zeiger, E., Haseman, J.K., Spalding, J., Caspary, W., Resnick, M., Stasiewicz, S., Anderson, B., et al., 1987. Prediction of chemical carcinogenicity in rodents from in vitro genetic toxicity assays. Science 236, 933\u2013941. US-CPSC, 1993, US Consumer Product Safety Commission: Toxicity Testing Plan for Low Ignition-Potential Cigarettes, vol. 3, Washington DC. Van Miert, E., Vanscheeuwijck, P., Meurrens, K., Gomm, W., Terpstra, P.M., 2008. Evaluation of the micronucleus assay in bone marrow and peripheral blood of rats for the determination of cigarette mainstream-smoke activity. Mutat. Res. 652, 131\u2013138. Vanscheeuwijck, P.M., Teredesai, A., Terpstra, P.M., Verbeeck, J., Kuhl, P., Gerstenberg, B., Gebel, S., Carmines, E.L., 2002. Evaluation of the potential effects of ingredients added to cigarettes. Part 4: subchronic inhalation toxicity. Food Chem. Toxicol. 40, 113\u2013131. Wagner, K.A., Finkel, N.H., Fossett, J.E., Gillman, I.G., 2005. Development of a quantitative method for the analysis of tobacco-specific nitrosamines in mainstream cigarette smoke using isotope dilution liquid chromatography/ electrospray ionization tandem mass spectrometry. Anal. Chem. 77, 1001\u20131006. Werley, M.S., Freelin, S.A., Wrenn, S.E., Gerstenberg, B., Roemer, E., Schramke, H., Van Miert, E., Vanscheeuwijck, P., Weber, S., Coggins, C.R., 2008. Smoke chemistry, in vitro and in vivo toxicology evaluations of the electrically heated cigarette smoking system series K. Regul. Toxicol. Pharmacol. 52, 122\u2013139. WHO, 2009. WHO Indonesia, Tobacco Free Initiative, Country Situation. Available at <http://ino.searo.who.int/EN/Section4/Section22_64.htm>. WHO, 2013. World Health Organization, Report on the global tobacco epidemic, 2013. Available at <http://www.who.int/tobacco/surveillance/policy/country_ profile/idn.pdf>. Yogalakshmi, B., Viswanathan, P., Anuradha, C.V., 2010. Investigation of antioxidant, anti-inflammatory and DNA-protective properties of eugenol in thioacetamide- induced liver injury in rats. Toxicology 268, 204\u2013212. Young, J.T., 1981. Histopathologic examination of the rat nasal cavity. Fundam. Appl. Toxicol. 1, 309\u2013312. Yulisman, L., 2012. Brazil bans sale of clove cigarettes (to be retrieved at <http:// www.thejakartapost.com/news/2012/04/13/brazil-bans-sale-clove-cigarettes. html>) In: The Jakarta Post Jakarta. Zar, J.H., 1999. Biostatistical Analysis. Prentice Hall, New Jersey, USA. Zenzen, V., Diekmann, J., Gerstenberg, B., Weber, S., Wittke, S., Schorp, M.K., 2012. Reduced exposure evaluation of an Electrically Heated Cigarette Smoking System. Part 2: Smoke chemistry and in vitro toxicological evaluation using smoking regimens reflecting human puffing behavior. Regul. Toxicol. Pharmacol. 64, S11\u201334. http://refhub.elsevier.com/S0273-2300(14)00290-6/h0455 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0455 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0460 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0460 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0460 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0460 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0460 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0465 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0465 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0465 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0465 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0470 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0470 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0475 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0475 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0475 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0475 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0480 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0480 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0480 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0485 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0485 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0485 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0485 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0495 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0495 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0500 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0500 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0505 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0505 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0505 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0505 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0510 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0510 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0510 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0515 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0515 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0520 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0520 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0520 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0520 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0530 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0530 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0530 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0530 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0535 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0535 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0535 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0535 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0540 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0540 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0540 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0540 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0545 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0545 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0545 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0545 http://ino.searo.who.int/EN/Section4/Section22_64.htm http://www.who.int/tobacco/surveillance/policy/country_profile/idn.pdf http://www.who.int/tobacco/surveillance/policy/country_profile/idn.pdf http://refhub.elsevier.com/S0273-2300(14)00290-6/h0560 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0560 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0560 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0565 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0565 http://www.thejakartapost.com/news/2012/04/13/brazil-bans-sale-clove-cigarettes.html http://www.thejakartapost.com/news/2012/04/13/brazil-bans-sale-clove-cigarettes.html http://www.thejakartapost.com/news/2012/04/13/brazil-bans-sale-clove-cigarettes.html http://refhub.elsevier.com/S0273-2300(14)00290-6/h0575 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0580 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0580 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0580 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0580 http://refhub.elsevier.com/S0273-2300(14)00290-6/h0580 Toxicological assessment of kretek cigarettes 1 Background 1.1 General 1.2 History of kretek cigarettes 1.3 Product characteristics 1.4 Socioeconomic aspects 2 Existing studies on health risks 3 Results from previously conducted animal inhalation studies 4 General approach 5 Methods 5.1 General 5.2 Cigarettes and MS generation 5.3 MS chemistry 5.4 Basis for normalization 5.5 Mammalian cell cytotoxicity 5.5.1 General 5.5.2 Test substance 5.5.3 Cells and exposure 5.5.4 Evaluation 5.6 Bacterial mutagenicity 5.6.1 General 5.6.2 Test substance 5.6.3 Cells and exposure 5.6.4 Evaluation 5.7 Mammalian cell genotoxicity 5.7.1 General 5.7.2 Test substance 5.7.3 Cells and exposure 5.7.4 Evaluation 5.8 Inhalation toxicity 5.8.1 General 5.8.2 Test substance 5.8.3 Animals and exposure 5.8.4 Evaluation 5.9 In vivo micronucleus assay 5.9.1 General 5.9.2 Test substance 5.9.3 Animals and exposure 5.9.4 Evaluation 5.10 Statistical analyses 6 Summary of results 6.1 Characterization (Part 2 (Piad\u00e9 et al., 2014a) and Part 3 (Piad\u00e9 et al., 2014b)) 6.2 Mechanisms (Part 4 (Roemer et al., 2014b) and Part 5 (Roemer et al., 2014c)) 6.3 Ingredients (Part 6 (Roemer et al., 2014a) and Part 7 (Schramke et al., 2014)) 7 Discussion 7.1 Characterization 7.2 Mechanisms 7.3 Ingredients 8 General conclusion 9 Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-assessment-of-kretek-cigarettes--Part-2--_2014_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25497993", "content": {"CoiStatement": "5 Conclusions Conflict of interest Acknowledgments Appendix A. References", "Acknowledgement": "5 Conclusions Conflict of interest Acknowledgments Appendix A. References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-assessment-of-kretek-cigarettes--Part-7--_2014_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25455220", "content": {"CoiStatement": "Conflict of interest statement All authors are or were Philip Morris International (PMI) R&D employees. The work reported here was funded by PMI R&D. 4 Discussion Conflict of interest statement Acknowledgments References", "Acknowledgement": "Acknowledgments The authors are grateful to the staff at Hanjaya Mandala Sampo- erna Tbk Indonesia, who designed and manufactured the experi- mental cigarettes according to demanding specifications. Equally, they thank the involved staffs of Philip Morris Research Laborato- ries, Cologne, Germany, and Leuven, Belgium, for their excellent technical performance. References 4 Discussion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-assessment-of-kretek-cigarettes-Part-6--Th_2014_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25496764", "content": {"CoiStatement": "4 Discussion Conflict of interest statement Acknowledgments Appendix. References", "Acknowledgement": "4 Discussion Conflict of interest statement Acknowledgments Appendix. References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-assessment-of-kretek-cigarettes-part-3-_2014_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25455226", "content": {"CoiStatement": "Conflict of interest All authors are or were Philip Morris International (PMI) R&D employees. The work reported here was funded by PMI R&D. 4 Discussion 5 Conclusions Conflict of interest Acknowledgments Appendix A. References", "Acknowledgement": "Acknowledgments The authors are grateful to the staff at Hanjaya Mandala Sampo- erna Tbk Indonesia who designed and manufactured the experi- mental cigarettes according to demanding specifications. Equally, they thank the involved staffs of Philip Morris Research Laborato- ries Cologne, Germany, and Leuven, Belgium for their excellent technical performance. 4 Discussion 5 Conclusions Conflict of interest Acknowledgments Appendix A. References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-assessment-of-kretek-cigarettes-part-4-_2014_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25455230", "content": {"CoiStatement": "5 Conclusion Conflict of interest statement Acknowledgments Appendix A. References", "Acknowledgement": "S52 E. Roemer et al. / Regulatory Toxicology and Pharmacology 70 (2014) S41\u2013S53 Acknowledgments The authors are grateful to the staff at Hanjaya Mandala Sampo- erna Tbk Indonesia and Philip Morris USA who designed and man- ufactured the experimental cigarettes according to demanding specifications. Equally, they thank the involved staffs of IITRI, Chi- cago, USA, and PMRL, Cologne, Germany, for their excellent techni- cal performance. 5 Conclusion Conflict of interest statement Acknowledgments Appendix A. References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-assessment-of-kretek-cigarettes-part-_2014_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25455231", "content": {"CoiStatement": "Conflict of interest statement All authors are or were Philip Morris International (PMI) R&D employees. The work reported here was funded by PMI R&D. This work was supported in part by Philip Morris USA, Inc. until the spin-off of Philip Morris International, Inc. by Altria Group, Inc. on March 26, 2008. 5 Conclusion Conflict of interest statement Acknowledgments References", "Acknowledgement": "Acknowledgments The authors are grateful to the staff at Hanjaya Mandala Sampoerna Tbk Indonesia who designed and manufactured the experimental cigarettes according to demanding specifications. Equally, they thank the involved staffs of Philip Morris Research Laboratories, Cologne, Germany, and Leuven, Belgium, for their excellent technical performance. References 5 Conclusion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-assessment-of-lower-alkyl-methacry_2018_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29180022", "content": {"CoiStatement": "Conflicts of interest HPG and Mark Pemberton are private consultants working for Mark PembertonA and Lucite International, respectively. Harald M\u00fcllersch\u00f6n is employed by Evonik R\u00f6hm GmbH, Robert Ellis-HutchingsH by The Dow Chemical Company and Sandra Murphy by Arkema Inc., compa- nies producing lower methacrylates. The authors have sole responsi- bility for the content and the writing of the paper. The interpretation and views expressed in the paper are not necessarily those of the au- thor's employers or Mark PembertonA. Summary of results for the different endpoints Discussion and conclusion Conflicts of interest Acknowledgements Supplementary data Transparency document References", "Acknowledgement": "Acknowledgements HPG and Mark Pemberton gratefully acknowledge the financial support of the Methacrylate Producers Association, Inc. (Mark PembertonA) for preparation of the manuscript. Summary of results for the different endpoints Discussion and conclusion Conflicts of interest Acknowledgements Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-comparison-of-cigarette-smoke-and-e-cig_2019_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30721718", "content": {"Funding": "Funding sources This work was funded and supported by Fontem Ventures B.V. Imperial Brands Group PLukasz Czekala is the parent company of Fontem Ventures B.V., the manufacturer of the commercial e-liquid used in this study. Discussion Funding sources Acknowledgements Supplementary data Transparency document References", "Acknowledgement": "Acknowledgements We would like to acknowledge Olivia O'Connell and George R. Jackson for their contribution to conducting these experiments and to the data analysis. In addition, we would like to thank Gary Phillips for his critical review of the manuscript and Ana Maria Cravo for support with the initial study design. Discussion Funding sources Acknowledgements Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-evaluation-of---Galactosidase-enzym_2018_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29233771", "content": {"CoiStatement": "Conflicts of interest The authors declared no conflicts of interest, other than the fore- going. The authors declared no conflicts of interest, other than the fore- going. Acknowledgement Discussion Conclusions Disclosure statement Role of the funding source Conflicts of interest Acknowledgement Transparency document References", "Disclosure": "Disclosure statement Amano Enzyme, Inc. manufactures and produces \u03b2-Galactosidase, that is the subject of this manuscript. Co-author Atsushi Mizutani is an employee of Amano Enzyme, Inc. (Amano) and played a role in the development of \u03b2-Galactosidase. Co-authors Qingdong Ke and Preston Fulmer are scientists employed by Keller and Heckman LLP, and re- ceived financial support from Amano in the preparation of this manu- script. Discussion Conclusions Disclosure statement Role of the funding source Conflicts of interest Acknowledgement Transparency document References", "Funding": "Role of the funding source Amano commissioned and funded the study that is the subject of this manuscript, and provided funding for the writing of the manu- script. Employees of Amano Enzyme, Inc. participated in data analysis and interpretation, assisted with editing the manuscript, and ultimately controlled the decision to submit the manuscript for publication. Amano commissioned and funded the study that is the subject of this manuscript, and provided funding for the writing of the manu- script. Employees of Amano Enzyme, Inc. participated in data analysis and interpretation, assisted with editing the manuscript, and ultimately controlled the decision to submit the manuscript for publication. Conflicts of interest Discussion Conclusions Disclosure statement Role of the funding source Conflicts of interest Acknowledgement Transparency document References", "Acknowledgement": "Acknowledgement The authors thank Mel Drozen and Lisa Alsobrook for their support and helpful comments. The authors also wish to thank Elena Obregon who assisted in proof-reading and submission of the manuscript. Discussion Conclusions Disclosure statement Role of the funding source Conflicts of interest Acknowledgement Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-evaluation-of--red-rice-yeast-extract--_2020_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32278069", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. Discussion Declaration of competing interest Acknowledgments Supplementary data References", "Acknowledgement": "Acknowledgments This work was supported by \u201cMajor New Drugs\u201d special projects of Ministry of Science and Technology of PR China (NO.2013ZX09402201), the \u201cTaishan Industry Leading Talent Laureate\u201d and the \u201cMajor New Drugs Research & Development\u201d special projects of Ministry of Science and Technology of PR China (NO.2018ZX09303015). Discussion Declaration of competing interest Acknowledgments Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-evaluation-of-3--sialyllacto_2018_Regulatory-Toxicology-and-Ph.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29407203", "content": {"CoiStatement": "Conflicts of interest The authors report that Daehee Kim, Rit B. Gurung, Wonmin Seo and Jinsuk Woo are employed by GeneChem, Inc., the sponsor of the study. Other authors declare that there are no conflicts of interest. The authors report that Daehee Kim, Rit B. Gurung, Wonmin Seo and Jinsuk Woo are employed by GeneChem, Inc., the sponsor of the study. Other authors declare that there are no conflicts of interest. Transparency document Discussion Conclusion Acknowledgments Conflicts of interest Transparency document References", "Acknowledgement": "Acknowledgments An acute oral toxicity in rats was conducted by Dr. Yonglin Gao at Yantai University, China. All other studies were conducted at Biotoxtech Co., Ltd, Cheongwon-gun, Chungcheongbuk-do, Republic of Korea. The study Directors were Jae-Sik Hwang, Mi-Yong Lee and Hye- Young Lee. Discussion Conclusion Acknowledgments Conflicts of interest Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-evaluation-of-6--sialyllactose_2018_Regulatory-Toxicology-and-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29555556", "content": {"CoiStatement": "Conflicts of interest The authors report that Rit Bahadur Gurung, Daehee Kim, and Lila Kim are employed by GeneChem, Inc., which provided the 6\u2032-SL sodium salt for the study. Other authors declare that there are no conflicts of interest. The authors report that Rit Bahadur Gurung, Daehee Kim, and Lila Kim are employed by GeneChem, Inc., which provided the 6\u2032-SL sodium salt for the study. Other authors declare that there are no conflicts of interest. Funding Discussion Conflicts of interest Funding Acknowledgements Supplementary data References", "Funding": "Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Acknowledgements Discussion Conflicts of interest Funding Acknowledgements Supplementary data References", "Acknowledgement": "Acknowledgements We acknowledge that Rita Buckley, Buckley/Swartz, Swampscott, Massachusetts, provided professional editing and proofreading of this article. The authors thank Bin Han, Yudong Lv, and Xiaoli Zhang for their histopathology evaluations. Discussion Conflicts of interest Funding Acknowledgements Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-evaluation-of-Gumiganghwaltang-aqueous_2012_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22154825", "content": {"CoiStatement": "6. Conflict of interest statement No competing financial interests exist. 4 Discussion 5 Conclusion 6 Conflict of interest statement Acknowledgments References", "Acknowledgement": "Acknowledgments This research was part of a project (The Evidence Based Medi- cine for Herbal Formula) funded by the Herbal Medicine EBM Re- search Center of the Korea Institute of Oriental Medicine. 4 Discussion 5 Conclusion 6 Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-evaluation-of-Microbacterium-f_2018_Regulatory-Toxicology-and-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30308225", "content": {"CoiStatement": "Conflicts of interest The authors report that Hye-Jung Kim and Chongjin Park are em- ployed by Samyang Corp., the sponsor of the study. Another author declares that he has no conflicts of interest. The authors report that Hye-Jung Kim and Chongjin Park are em- ployed by Samyang Corp., the sponsor of the study. Another author declares that he has no conflicts of interest. Acknowledgments Discussion Conclusion Conflicts of interest Acknowledgments Transparency document References", "Acknowledgement": "Acknowledgments The authors thank Drs. Yeong Park, Ji Sun Lee, Jung-Woo Kim, Minhee Kim, and Hye-Sun Hoe at a GLP contract laboratory for their valuable contributions to animal toxicity and mutagenicity/genotoxi- city studies, without which toxicological evaluations of M. foliorum SYG27B-MF would not have been possible. The authors also thank Dr. Yonghyun Chung for histopathological examinations of test organs. We also acknowledge that Ms. Rita Buckley provided professional editing and proofreading of this article. Discussion Conclusion Conflicts of interest Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Toxicological-evaluation-of-S--involucrata-culture-_2021_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34186141", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 4 Discussion Funding CRediT authorship contribution statement Declaration of competing interest Appendix A Supplementary data References", "Funding": "Funding This study was supported by the National Key R&D Program of China (Grant No. 2018YFC1706100) and the Natural Science Foundation of Shandong Province (No. ZR2020MH411). Lei Han: Conceptualization, Methodology, Writing \u2013 original draft. Kaili Chen: Validation, Formal analysis, Visualization, Software. Ping Liu: Validation, Formal analysis, Visualization. Lintong Yang: Writing \u2013 review & editing, Methodology, Data curation. Yating Kang: Writing \u2013 review & editing, Supervision, Data curation. Yonglin Gao: Funding acquisition, Project administration, Supervision. Chunmei Li: Funding acquisition, Project administration, Supervision. Chengfeng Sun: Investigation, Supervision. Yanshen Li: Writing: Review & Editing. Wenxia Fan: Resources. Hu Hou: Writing: Review & Editing. Declaration of competing interest 4 Discussion Funding CRediT authorship contribution statement Declaration of competing interest Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-evaluation-of-a-dietary-supplement-for_2010_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20043970", "content": {"CoiStatement": "6. Conflict of interest statement The authors from AIBMR Life Sciences were hired as indepen- dent consultants to design and implement safety studies for Life Span labs; none of the authors have any financial interest in the subject matter. Life Span labs LLC, Portland, OR, USA, sponsored the studies. Discussion Conclusions Conflict of interest statement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-evaluation-of-a-glycan-preparation-fro_2021_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33831491", "content": {"CoiStatement": "Declaration of competing interest The authors Gerald P. Dillon, Alexandros Yiannikouris, and Colm A. Moran are employees of Alltech which produces and markets Myco- sorb\u00ae, the commercial yeast glycan preparation evaluated in this study. 4 Discussion CRediT authorship contribution statement Declaration of competing interest Acknowledgments References", "Acknowledgement": "Acknowledgments The authors would like to thank Guillaume Sire (Study Director) and the principle scientists, J.J. Legrand and T. Orsie\u0300re of CiToxLAB (Evreux, France) for conducting the genotoxicity studies and S. Dana Oley (Study Director) the principle scientists, Jacek Ochalski, Cindy Bodnar, Jasbir Bawa, Carolyn Montefusco and Maryann Zakrzewski of Eurofins Product Safety Laboratories (Dayton, NJ, USA) for conducting the acute oral toxicity, acute dermal, acute skin, eye, inhalation and skin sensitization studies. Work was sponsored by Alltech France SARL. 4 Discussion CRediT authorship contribution statement Declaration of competing interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-evaluation-of-advanced-glycation-end-pro_2016_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26921796", "content": {"CoiStatement": "In conclusion, acute oral administration of CML could not cause acute toxicity but repeated intake may have a long-term cumula- tive toxic effect on mice. This study provides the very valuable data on the acute and subacute toxicity profile of CML. However, addi- tional toxicity data (chronic, mutagenicity, reproductive and car- cinogenicity study) of CML are urgent to investigate to confirm the risk of CML for long-term exposure. Conflicts of interest The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. X. Liu et al. / Regulatory Toxicology and Pharmacology 77 (2016) 65e7474 Acknowledgments 4. Discussion Conflicts of interest Acknowledgments Appendix A. Supplementary data References", "Acknowledgement": "X. Liu et al. / Regulatory Toxicology and Pharmacology 77 (2016) 65e7474 Acknowledgments This research was financially supported by National Natural Science Foundation for Young Scholars of China (NO. 31401640), National Basic Research Program of China (NO. 2012CB720804), and the Innovation Foundation for Graduate Students of Wuhan Polytechnic University (NO. 2012cx018). 4. Discussion Conflicts of interest Acknowledgments Appendix A. Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-evaluation-of-ammonium-4-8-dioxa-3H-perfluo_2011_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20875479", "content": {"CoiStatement": "To summarize, ADONA was moderately toxic by single oral administration and practically non-toxic by acute dermal exposure in rats. It was a mild primary skin irritant and a moderate to severe primary eye irritant in rabbits. It was a weak dermal sensitizer in local lymph node assays in mice. ADONA was not genotoxic based on the weight of the evidence from five in vitro and in vivo assays. It was not developmentally toxic in rats except at relatively high, maternally toxic doses. ADONA was a possible PPARa agonist in male rats. The liver was the primary target organ in male rats and the kidney was the primary target organ in female rats in oral repeat-dose studies. NOAELs in 28- and 90-day oral studies in rats were 10 mg/kg/day for males and 100 mg/kg/day for females. Based on these findings, it is concluded that the toxicity profile for ADONA is acceptable for its intended use and is superior to that for APFO. Conflict of interest The author is employed by 3M Company. ADONA is manufac- tured by Dyneon LLC which is a wholly owned subsidiary of 3M. Acknowledgments Discussion Conflict of interest Acknowledgments References", "Compliance with ethical standards": "Toxicological evaluation of ammonium 4,8-dioxa-3H-perfluorononanoate, a new emulsifier to replace ammonium perfluorooctanoate in fluoropolymer manufacturing Introduction Materials and methods Test material Testing facilities and regulatory compliance Acute toxicity studies Primary eye and skin irritation studies Dermal sensitization studies Genotoxicity studies Bacterial reverse mutation assays In vitro mammalian gene mutation assay In vitro chromosome aberration assay in human lymphocytes Micronucleus assay in mice Bone marrow cytogenetic study in rats Repeat-dose toxicity studies 5-Day oral toxicity study in rats 28-Day oral toxicity study in rats 90-Day oral toxicity study in rats", "Acknowledgement": "The author is employed by 3M Company. ADONA is manufac- tured by Dyneon LLC which is a wholly owned subsidiary of 3M. Acknowledgments The author wishes to acknowledge the significant contributions of the following individuals to this project: Dr. C.A.F. Buskens, Dr. M. Stitzinger, Dr. C.G.M. Beerens-Heijnen, Dr. M.S. Teunissen, and C.M. Verspeek-Rip from NOTOX Safety and Environmental Re- search; Dr. Hans-Eric Wollny from RCC Cytotest Cell Research; Dr. Melissa Kirk from MB Research Laboratories; Dr. Alan Hober- man and Jason Smedley from Charles River Laboratories; Dr. Robert Voyksner from LCMS Limited; Dr. Cecilia Tan from CIIT Center for Health Research; Dr. Kendall Wallace and James Bjork from the University of Minnesota Duluth; Trina John from Pace Analytical Services; and Melinda Mitchell, Jay Schulz, David Ehresman, Tho- mas Kestner, Dr. Sue Chang, Jill Hart, Dr. John Butenhoff, Kara An- dres, Michael Falco and Dr. George Millet from 3M. References Discussion Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-evaluation-of-carcinogenicity-of-the_2019_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30905765", "content": {"CoiStatement": "Statement of interest Dr. Lorenz R. Rhomberg, Dr. Joseph K. Haseman, Dr. Peter Greaves, Prof. Helmut Greim, Prof. Colin Berry, and Prof. Samuel M. Cohen consult for Sumitomo Chemical Company, Ltd. The other authors are employed by Sumitomo Chemical Company, Ltd. Summary and conclusions Author contributions Statement of interest Acknowledgments Supplementary data Transparency document Funding References", "Funding": "Funding This work was supported by the Sumitomo Chemical Company, Ltd. Summary and conclusions Author contributions Statement of interest Acknowledgments Supplementary data Transparency document Funding References", "Acknowledgement": "Acknowledgments We would like to thank Dr. Kensuke Kawamoto, Ms. Keiko Maeda and Ms. Yasuko Takamatsu (Sumitomo Chemical Co. Ltd.) and Dr. Xiaobin Liu (Gradient) for technical assistance, and Dr. Kevan Gartland (Sumitomo Chemical [U.K.] Plc.) and Dr. Laura E. Kerper (Gradient) for editorial review of the manuscript and providing helpful suggestions. Summary and conclusions Author contributions Statement of interest Acknowledgments Supplementary data Transparency document Funding References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-evaluation-of-ethanolic-extract-from-Ste_2017_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28351677", "content": {"Compliance with ethical standards": "All aspects in this project involving animal care, use, and welfare were performed in compliance with the Food and Drug Adminis- tration (FDA) principles of Good Laboratory Practice (GLP). Animal studies were conducted in accordance with Chinese National Food Safety Standards: Procedures for Toxicological Assessment on Food Safety (GB15193), which adopts recommendations from Organiza- tion for Economic Cooperation and Development (OECD) Guide- lines for the Testing of Chemicals (OECD, 2009). All animal study protocols have been approved by the Office of Laboratory Animal Welfare, China National Center for Food Safety Risk Assessment (Beijing, China). 2.1. Test substance Stevia rebaudiana Bertoni leaves ethanolic extract in brown powder was provided by Zhucheng HaoTian Pharm Co.,Ltd. (Shandong, China). The ethanolic extract was prepared with 50% ethanol as previously described (Qi et al., 2014). The extract is ho- mogeneous and stable, and can be stored at room temperature. The same batch (No. T6-0903) of the extract was used in all experi- ments in this study. The concentrations of phenolic acids in the extract were determined with High Performance Liquid Table 1 The composition of Stevia rebaudiana Bertoni leaves extract."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-evaluation-of-exosomes-derived-from-hu_2020_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32450131", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Byong Seung Cho and Yong Weon Yi are founders and stockholders of ExoCoBio Inc. Dae Hyun Ha, Jun Ho Lee, Sang Rae Park, Jinkwon Youn, Sang Hee Lee, Ji Eun Kim, Joon Lee, Byong Seung Cho, and Yong Weon Yi are employees of ExoCoBio Inc. SDK and Hyun-Kul Lee are employees of ChemOn Inc. Other authors declare no conflict of interest. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Byong Seung Cho and Yong Weon Yi are founders and stockholders of ExoCoBio Inc. Dae Hyun Ha, Jun Ho Lee, Sang Rae Park, Jinkwon Youn, Sang Hee Lee, Ji Eun Kim, Joon Lee, Byong Seung Cho, and Yong Weon Yi are employees of ExoCoBio Inc. SDK and Hyun-Kul Lee are employees of ChemOn Inc. Other authors declare no conflict of interest. Table 6 Mortalities. Discussion Conclusion Funding statement Declaration of competing interest References", "Funding": "Funding statement This study was partially supported by ExoCoBio Inc. This study was also partially supported by the Korean MOTIE R&D Program of Development of Material & Component Technology Grant Discussion Conclusion Funding statement Declaration of competing interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-evaluation-of-ferrous-N-carbamylglycin_2015_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26364753", "content": {"CoiStatement": "Conflicts of interest The authors declared no conflicts of interest. The authors declared no conflicts of interest. Acknowleagement 4. Disscussion Conflicts of interest Acknowleagement Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-evaluation-of-isopropylparaben-and-isobut_2015_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26359141", "content": {"CoiStatement": "Conflicts of interest The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgments 4. Discussion 5. Conclusion Conflicts of interest Acknowledgments Appendix A. Supplementary data Transparency document References", "Acknowledgement": "Acknowledgments This work was supported by a grant (KFDA2012-17014) from Ministry of Food and Drug Safety (MFDS) in 2012. 4. Discussion 5. Conclusion Conflicts of interest Acknowledgments Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-evaluation-of-l-proline-in-a-90-day_2010_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20447433", "content": {"Acknowledgement": "In conclusion, the no-observed-adverse-effect-level (N OhashiAEL) for L-Pro was determined to be at least a dietary dose of 5.0% (2772.9 mg/kg body weight/day for males and 3009.3 mg/kg body weight/day for females) under the present experimental conditions. Acknowledgments The authors thank Dr. Hideki Wanibuchi (Department of Pathology, Osaka City University Medical School, Osaka, Japan) for helpful suggestions. This work was supported in part by a Health and Labour Sciences Research Grant (awarded to Dai Nakae) from the MHLW. References Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-evaluation-of-naringin--Acute--subch_2020_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31954754", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper.", "Funding": "Funding body information The funding source, Sun Yat-sen University, had no involvement in the collection, analysis, interpretation of data, the writing of the manuscript, and the decision to submit the article for publication. The funding source, Sun Yat-sen University, had no involvement in the collection, analysis, interpretation of data, the writing of the manuscript, and the decision to submit the article for publication. Declaration of competing interest Discussion Conclusion Funding body information mk:H1_31 References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-evaluation-of-neoagarooligosaccharid_2017_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28782575", "content": {"CoiStatement": "This work was supported by a grant from the Next-Generation BioGreen 21 Program (Grant number: PJ01129301), Rural Devel- opment Administration, Republic of Korea. Conflicts of interest The authors declare no conflict of interest. Transparency document The authors declare no conflict of interest. Transparency document Transparency document related to this article can be found online at http://dx.doi.org/10.1016/j.yrtph.2017.08.001. References 4. Discussion 5. Conclusions Acknowledgements Conflicts of interest Transparency document References", "Acknowledgement": "Acknowledgements This work was supported by a grant from the Next-Generation BioGreen 21 Program (Grant number: PJ01129301), Rural Devel- opment Administration, Republic of Korea. Conflicts of interest 4. Discussion 5. Conclusions Acknowledgements Conflicts of interest Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-evaluations-of-colostrum-ul_2019_Regulatory-Toxicology-and-Pha.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30831157", "content": {"CoiStatement": "Declaration of conflicting interest AIBMR Life Sciences, Inc. (Seattle, WA, USA) was contracted by the study sponsor, as an independent third party, to determine appropriate study protocols and dose selections, place the studies, approve the study plans, and monitor the toxicological studies herein described and to analyze and interpret the resulting data and prepare the manuscript. Toxi-Coop Zrt., with test facilities in Budapest, Hungary, was contracted by AIBMR to develop the study plans and conduct, analyze, interpret, and report the results of the toxicological studies herein described. The authors declare no additional conflicts of interest in regard to the re- search, authorship, and/or publication of this article. AIBMR Life Sciences, Inc. (Seattle, WA, USA) was contracted by the study sponsor, as an independent third party, to determine appropriate study protocols and dose selections, place the studies, approve the study plans, and monitor the toxicological studies herein described and to analyze and interpret the resulting data and prepare the manuscript. Toxi-Coop Zrt., with test facilities in Budapest, Hungary, was contracted by AIBMR to develop the study plans and conduct, analyze, interpret, and report the results of the toxicological studies herein described. The authors declare no additional conflicts of interest in regard to the re- search, authorship, and/or publication of this article. Acknowledgements Discussion and conclusions Declaration of conflicting interest Acknowledgements Supplementary data Transparency document References", "Funding": "Source of funding: The authors disclose that financial support for the research described herein was provided by 4Life Research USA, LLC. The authors thank the following individuals for their contributions to the work: participating investigators Vikt\u00f3ria Polg\u00e1r-Balogh, Erika Major Biermann\u00e9, Ibolya Bogd\u00e1n, Tam\u00e1s Buda, T\u00edmea Cs\u00f6rge, Kata Eszter Di\u00f3szegi, J\u00e1nosn\u00e9 D\u00f3zsa, M\u00f3nika Fekete, Stella Fekete, Zsuzsanna Frank, Ir\u00e9n Somogyi H\u00e1rin\u00e9, Ildik\u00f3 Hermann, Brigitta Horv\u00e1th, Istv\u00e1nn\u00e9 Horv\u00e1th, Korn\u00e9lia Sereg Jur\u00e1csikn\u00e9, Vikt\u00f3ria Kocsi, Kl\u00e1ra Fritz Kov\u00e1csn\u00e9, N\u00f3ra Pongr\u00e1cz Kurdin\u00e9, Marcell Mad\u00e1r, M\u00e1t\u00e9 Mad\u00e1r, Vikt\u00f3ria Matina, Anita Mayer, Edit K\u00f6v\u00e1ri Mesterh\u00e1zin\u00e9, \u00c1gota J\u00f3 Sch\u00fcllern\u00e9, J\u00e1nos St\u00e1hl, Beatrix Szil\u00e1gyi, \u00c1kosn\u00e9 Szab\u00f3, Eva L\u00e1ng- Szab\u00f3, Zsuzsanna Szab\u00f3, Mariann Lennert Szab\u00f3n\u00e9, Edit Sz\u00e1m, Olga Sz\u00e1sz, Anett Szegner, M\u00e1rta Tenk, \u00c9va V\u00e1liczk\u00f3, Erzs\u00e9bet Biez\u00f3, Beatrix Havas Dr. Zolt\u00e1nn\u00e9, Csenge Zolt\u00e1n, Dr. Ruth Weimer, and Dr. Levente Zolt\u00e1n for the performance of experimental tasks, collection of data, and/or quality assurance; and Jared Brodin for administrative support in preparation of the manuscript.", "Compliance with ethical standards": "Testing of Chemicals, Section 4. OECD Publishing, Paris. OECD, OECD Principles on Good Laboratory Practice, 1998a. OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring No. 1 OECD Publishing, Paris. OECD, 1998b. Test No. 408: Repeated Dose 90-Day Oral Toxicity Study in Rodents, OECD Guidelines for the Testing of Chemicals, Section 4. OECD Publishing, Paris.", "Acknowledgement": "Acknowledgements Source of funding: The authors disclose that financial support for the research described herein was provided by 4Life Research USA, LLC. Discussion and conclusions Declaration of conflicting interest Acknowledgements Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-profile-of-IQG-607-after-single-and-repeat_2017_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28838610", "content": {"Acknowledgement": "Acknowledgments This work was supported by Banco Nacional de Desenvolvi- mento Econo\u0302mico e Social (BNDES/FUNTEC) and National Institute of Science and Technology on Tuberculosis (Decit/SCTIE/MS-MCT- CNPq-FNDTC-CAPES), Brazil. Di\u00f3genes Santiago Santos. and Luiz Augusto Basso. also acknowledge grants awarded by FINEP and FAPERGS-CNPq-PRONEX-2009. Di\u00f3genes Santiago Santos., Luiz Augusto Basso. and Maria Martha Campos. are research career awardees of the National Council for Scientific and Technological Development of Brazil (CNPq). 4. Discussion Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-profile-of-hydrofluoropol_2005_Regulatory-Toxicology-and-Pharm.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15748797", "content": {"Acknowledgement": "In conclusion, HFPEs have been developed as a novel class of heat exchange fluids and for other specific indus- trial applications. They have physico-chemical proper- ties similar to those of perfluorinated fluids and may replace these a range of applications due to their shorter atmospheric lifetime and favourable toxicological profile. Acknowledgments The authors gratefully acknowledge: G. Spataro (Sol- vay Solexis Bollate IT) for the synthesis of the HFPE samples; B. Schmit (Solvay DCRT/HSE Brussels) for helpful discussions and advice; and J. Bootman (Boot- man Chemical Safety Ltd., UK) for revision of the paper. References Discussion and conclusion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-resources-for-cumulative-risk--an-e_2004_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15546684", "content": {"Acknowledgement": "Cumulative risk assessment approaches show prom- ise and will continue to improve as new sources and types of toxicological data become available. Our anal- ysis shows that available toxicological and human health data can be combined through CRA to identify endpoints of public health concern. There are still major information gaps limiting existing data sources, how- ever, ongoing efforts such as EPA\ufffds High Production Volume testing program will continue to advance our understanding of an increasing range of health end- points. Ultimately the value of refined CRAs depends upon a linkage to prevention. Acknowledgments We thank Tracey Woodruff for contributing data to the project and commenting on the manuscript. Yutaka Toxicological resources for cumulative risk: an example with hazardous air pollutants Introduction and purpose Background Methods Risk screening analysis Results Discussion Conclusion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-risk-assessment-of-bisphenol-a-released-_2020_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33011233", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Authors Melissa A Badding., Jessica R Vargas., and Julian Fortney. are employees of Exponent, Inc., which is an engineering and scientific consulting firm that provides expertise in toxicology and risk assessment, among other areas, and provides such services to manufacturers of medical devices. Authors Qiuqiong J Cheng. and C\u2013H.H. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Authors Melissa A Badding., Jessica R Vargas., and Julian Fortney. are employees of Exponent, Inc., which is an engineering and scientific consulting firm that provides expertise in toxicology and risk assessment, among other areas, and provides such services to manufacturers of medical devices. Authors Qiuqiong J Cheng. and C\u2013H.H. M.A. Badding et al. 4 Discussion Funding Funding body information Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Funding": "Funding This work was supported by Fresenius Medical Care, Ltd. The anal- ysis and conclusions presented herein are those of the authors and not of their employer or the sponsor. Funding body information This work was funded by Fresenius Medical Care (Fresenius) and the work was conducted in a collaborative manner between coauthors employed by both Fresenius and Exponent, Inc. during the authors\u2019 employment. Extractions of dialyzers were performed at a Fresenius facility using Fresenius supplies and equipment and the resulting ex- tracts were subsequently analyzed by Exponent. Fresenius played a role in the study design and manuscript preparation. Exponent performed the chemical analysis and interpretation of the data, along with manu- script preparation. The analysis and conclusions presented in the manuscript are those of the authors and not of their employer or the study sponsor. 4 Discussion Funding Funding body information Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Acknowledgement": "Acknowledgements We would like to thank Dr. Sherry Parker for her contribution to a BPA white paper prepared for internal purposes at Fresenius Medical Care. Some of the background information in the white paper was included in the introduction section of this manuscript. 4 Discussion Funding Funding body information Declaration of competing interest Acknowledgements Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-risk-assessment-of-elemental-gold-follo_2015_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25929617", "content": {"CoiStatement": "Conflict of Interest The authors declare that there are no conflict of interest. The authors declare that there are no conflict of interest. Transparency Document 5 Are the effects of elemental gold due to ions released from its surface? 6 Risk characterization 7 Conclusions Conflict of Interest Transparency Document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-safety-evaluation-of-3-3--diselenodipropi_2018_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30240831", "content": {"CoiStatement": "Conflicts of interest None. Discussion Conclusions Conflicts of interest Transparency document References", "Compliance with ethical standards": "OECD, 1998. OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring. No. 1, \"OECD Principles on Good Laboratory Practice\" ENV/MC/CHEM (98)17 (As Revised in 1997). Plant, N., 2004. Strategies for using in vitro screens in drug metabolism. Drug Discov. Today 9, 328\u2013336."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-significance-of-increased-serum-alkaline-ph_2019_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31568816", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper.", "Funding": "The current analysis was not conducted under any specific grant from any funding agencies in the public, commercial, or non-for-profit sectors. Declaration of competing interest The current analysis was not conducted under any specific grant from any funding agencies in the public, commercial, or non-for-profit sectors. All authors had responsibilities with regard to the writing and contents of this article. The opinions expressed in this article are those of the authors and do not necessarily reflect the views or policies of the author's employers. Appendix A. Supplementary data", "Acknowledgement": "Acknowledgements The current analysis was not conducted under any specific grant from any funding agencies in the public, commercial, or non-for-profit sectors. All authors had responsibilities with regard to the writing and contents of this article. The opinions expressed in this article are those of the authors and do not necessarily reflect the views or policies of the author's employers. Discussion mk:H1_20 Acknowledgements Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-studies-on-Lactose-Oxidase-from-Micro_2004_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15135207", "content": {"Compliance with ethical standards": "Lactose Oxidase was investigated for general toxicity and genotoxicity. All these studies were carried out in accordance with present guidelines of the Organization for Economic Cooperation and Development (OECD, 1981b, 1983, 1987, 1992a,b, 1997b) and selected in ac- cordance with EU guidelines for the presentation of data on food enzymes (SCF, 1992). They were conducted in compliance with the present OECD principles of Good Laboratory Practice (OECD, 1981a, 1997c). The product complies with the Food and Agriculture Organization/"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-studies-on-a-novel-phytase-expressed_2011_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21672596", "content": {"CoiStatement": "410 J. Lichtenberg et al. / Regulatory Toxicology and Pharmacology 60 (2011) 401\u2013410 assays. Based on the toxicological data, the large safety factors cal- culated under common recommended dose assumptions for broi- ler chickens and weaned piglets, and the fact that the A. oryzae is considered a safe strain lineage, it is concluded that there are no reasons for safety concerns when using phytase HP as a feed additive. Conflict of interest None of the authors have any conflicts of interest in regard to this paper. References None of the authors have any conflicts of interest in regard to this paper. References AAFCO (Association of American Feed Control Officials), 2011. Official Publication of the Association of American Feed Control Officials Incorporated, p. 389. 4 Conclusion Conflict of interest References", "Compliance with ethical standards": "Series on principles of good laboratory practice and compliance monitoring, ENV/MC/CHEM (98) 17, OECD Publishing, Paris. OECD, 1998. Repeated Dose 90-Day Oral Toxicity Study in Rodents. OECD Guidelines for the Testing of Chemicals/Section 4: Health Effects. Test No. 408. OECD Publishing, Paris."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicological-testing-of-a-photoactive-phthalocya_2020_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32454236", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests. Acknowledgements Conclusions Declaration of competing interest Acknowledgements References", "Acknowledgement": "Acknowledgements The study was supported by Technological Agency of the Czech Republic, TE02000006 Centre for alternative environment friendly high effective polymer antimicrobial agents for industrial applications (ALTERBIO), and by ERDF/ESF project \u201cInternational competitiveness of NIPH in research, development and education in alternative tox- icological methods\u201d (No. CZ.02.1.01/0.0/0.0/16_019/0000860). Conclusions Declaration of competing interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicology-and-human-health-risk-assessment-of-polyet_2019_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31082430", "content": {"CoiStatement": "Discussion and conclusions Declaration of interest Acknowledgements Supplementary data Transparency document References Further reading mk:H2_2", "Acknowledgement": "Acknowledgements The authors wish to acknowledge Kimberly Hodge-Bell, William Heydens, Michael Koch, Mitch Kurtzweil, David Saltmiras and, Milica Vogt for their thoughtful review of this manuscript. Discussion and conclusions Declaration of interest Acknowledgements Supplementary data Transparency document References Further reading mk:H2_2"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicology-and-the-chemical-foundation-of-p_2014_Regulatory-Toxicology-and-P.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25073109", "content": {"Acknowledgement": "Acknowledgments The work was financially supported by \u2018\u2018Rising-Star Tracking Program\u2019\u2019 from Shanghai Committee of Science and Technology (2011\u20132013, 11QH1402200), \u2018\u2018Youth Fund Program\u2019\u2019 from National Natural Science Foundation of China (NSFC) (2010\u20132012, 30901952) and \u2018\u2018Three-Year Action Plan Project for Development of TCM\u2019\u2019 from Shanghai Health Bureau (2011\u20132013, ZYSNXD-GH- FFYJ). 4 Discussion Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicology-of-decamethylcyclopentasilox_2016_Regulatory-Toxicology-and-Pharm.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26111607", "content": {"CoiStatement": "iii) In the two-year chronic bioassay, D5 inhalation caused a small, but (borderline) statistically significant increase in the incidence of uterine adenocarcinoma at the highest exposure concentration of 160 ppm. A number of mechanistic studies have been performed to elucidate the biological processes which may result in uterine adenocarcinoma induction. Due to the absence of both genotoxicity and estrogenicity of D5 in a variety of test systems, it must be concluded that neither genotoxicity nor a direct estrogen effect produced the slight increase in uterine tumors. Discussed in the detail in the accompanying paper (Klaunig et al., 2015), the likely mech- anism for the induction of uterine adenocarcinoma is an interference with prolactin secretion. While D5 does not appear to be a direct dopamine agonist, the experimental data are suggestive of an indirect interaction of D5 on the dopamine system to alter the pituitary control of the estrus cycle. Like other dopamine receptor agonists, D5 decreases pituitary lactotroph release of prolactin in vitro and decreases circulating prolactin levels in vivo. Further studies in vitro suggest that D5 may interfere with one or more downstream components of the dopamine signal transduction pathway. The observed effects of D5 on estrus cyclicity are consistent with a dopamine-like effect, and further suggest that D5may be accelerating the aging of the reproductive endocrine axis in this strain of rat. Conflicts of interest Dr. Dekant and Dr. Klaunig both report personal fees from the American Chemistry Council. 6. Discussion and conclusions Conflicts of interest Acknowledgment Transparency document References", "Acknowledgement": "Acknowledgment Preparation of this review was supported in part through an honorarium to Drs. Dekant and Klaunig from the American Chemistry Council. This review represents the individual profes- sional views of the authors and not necessarily the views of the American Chemistry Council. 6. Discussion and conclusions Conflicts of interest Acknowledgment Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxicology-study-of-long-term-administration-of-r_2019_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30735698", "content": {"CoiStatement": "Conflicts of interest The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgements Discussion Conclusions Author contributions Conflicts of interest Acknowledgements References", "Acknowledgement": "Acknowledgements This study was funded by a grant from National Science and Technology Major Projects for \u201cMajor New Drugs Innovation and Development (2016ZX09101117), Natural Science Foundation of Zhejiang Province (No.LY17H150002 and No. LY17H300003) and Wenzhou Science and Technology Agency (No.Y20150108). Discussion Conclusions Author contributions Conflicts of interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Toxmatch-A-chemical-classification-and-activity-pr_2008_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18617309", "content": {"Acknowledgement": "Acknowledgments This article reflects the views and understanding of the authors at the time of writing, and does not necessarily reflect the position of the European Commission. Ana Gallegos-Saliner. thanks the support of the Depar- tament d\u2019Universitats, Recerca i Societat de la Informaci\u00f3 (DURSI) of Generalitat de Catalunya for the allocation of a postdoctoral contract. Results and discussion Conclusions Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Trace-elements-in-e-liquids---Development-and-validati_2016_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27058761", "content": {"CoiStatement": "Analytical fees were jointly covered by Universit\ufffde de Lille 2 and INNOVA S AntherieuRL that market the NHOSS\u00ae electronic cigarette brand: the authors themselves received no financial or other consideration from the electronic cigarette or tobacco industry. Conflict of interest The authors declare that they have no conflict of interest. While the study was partially funded by INNOVA, the company had no influence over the study design, the data collection, analysis or interpretation themanuscript preparation or the decision to submit this work for publication. Appendix A. Supplementary data The authors declare that they have no conflict of interest. While the study was partially funded by INNOVA, the company had no influence over the study design, the data collection, analysis or interpretation themanuscript preparation or the decision to submit this work for publication. Appendix A. Supplementary data Supplementary data related to this article can be found at http:// dx.doi.org/10.1016/j.yrtph.2016.03.024. Transparency document 4. Discussion 5. Conclusion Funding Conflict of interest Appendix A. Supplementary data Transparency document References", "Funding": "N. Beauval et al. / Regulatory Toxicology and Pharmacology 79 (2016) 144e148148 rigorous validation of the method informed by the COFRAC and USEPA method guidelines which demonstrated satisfactory line- arity, precision, limits of quantification and robustness. A range of 27 different e-liquids from a single manufacturer, both with nico- tine (16 g/L) or without nicotine and containing different flavorings (or not), was thus analyzed and found to contain very small amounts of some of these 15 elements (<10 ppb or < LLQ for all elements except for Al, Cr, Cu, Sb and Zn, whose maximal concen- trations were 30.7 ppb, 11.5 ppb, 30.6 ppb, 214 ppb and 510 ppb, respectively). All quantifiable concentrations were many times lower than the current AFNOR limits for TE contents of e-liquids in France, which are the first regulations of their kind to be published. This method is transposable in so far as an e-liquid \u201cmatrix\u201d (con- taining only the main constituents) is available, and is timely for laboratories seeking to meet a prospective demand in light of current or future regulations. Funding Analytical fees were jointly covered by Universit\ufffde de Lille 2 and INNOVA S AntherieuRL that market the NHOSS\u00ae electronic cigarette brand: the authors themselves received no financial or other consideration from the electronic cigarette or tobacco industry. Conflict of interest 4. Discussion 5. Conclusion Funding Conflict of interest Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Transcriptional-profiling-of-male-CD-1-mouse-lungs-and-H_2018_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29475067", "content": {"Acknowledgement": "Acknowledgements This work was supported by SNF SAS and Health Canada's Chemicals Management Plan (CMP). We thank ILS animal care, ne- cropsy staff, and Jeffrey Davis, study director, for the in-life portion of this study. We are grateful to Dr. Ivy Moffat and Dr. Mike Wade for their helpful comments on this manuscript. Conclusions Acknowledgements Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Transdermal-nicotine-absorption-handling-e-ci_2016_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26619784", "content": {"CoiStatement": "Declaration of interests The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Transparency document 3. Results 4. Discussion 5. Conclusions Funding Declaration of interests Transparency document References", "Funding": "Funding None declared. 3. Results 4. Discussion 5. Conclusions Funding Declaration of interests Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Transfluthrin--Comparative-efficacy-and-toxicity_2015_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25448443", "content": {"CoiStatement": "In summary, with regard to the generic versions of TFL one may conclude that each batch even from the same alternative producer differed markedly in terms of bioefficacy and the presence of \u2018unusually potent impurities\u2019. These impurities could only be iden- tified analytically with the Tier II-driven knowledge in terms of their identification as such, limit of detection, and specificity. As evidenced in Tables 1 and 4, impurity profile analysis serves an important purpose in determining the quality aspects of any well characterized active substance and critical impurities. This infor- mation may not necessarily apply for alternative source TFLs due to their modified production process-related \u2018new toxicological entities\u2019. This outcome supports the overall conclusion that Tier I and II approaches have to be used in concert rather than in isola- tion. The expert knowledge- and MoA-based Tier II feedback-loop is considered to be an indispensable attribute to demonstrate equivalence of products used as household insecticides. Declaration of conflict of interest There is no conflict of interests. Bayer CropScience is a producer of the innovative Transfluthrin (TFL-R) used in this study. Sumito- mo Chemicals is a distributor of TFL-R in Japan. There is no conflict of interests. Bayer CropScience is a producer of the innovative Transfluthrin (TFL-R) used in this study. Sumito- mo Chemicals is a distributor of TFL-R in Japan. References 4 Discussion Declaration of conflict of interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Transgene-expression-in-sprayed-and-non-sprayed-herb_2020_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31884154", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: The authors work for a company that develops and markets GE seed.", "Acknowledgement": "Acknowledgement DAS-444\u00d86-6 soybean was co-developed by Dow AgroSciences LLC and MS Technologies LLC. Conclusions mk:H1_9 Acknowledgement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Transgenesis-affects-endogenous-soybean-allergen-_2017_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28720347", "content": {"Acknowledgement": "Acknowledgements We thank Jeff Gilbert, Guomin Shan, Nick Storer, Chandra Ara- dhya, Barry Schafer, and Kathryn Clayton from Dow AgroSciences and Kevin Glenn from Monsanto for reviewing a draft of this manuscript. Transparency document 3. Results and discussion 4. Conclusion Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Transgenic-proteins-in-agricultural-biotechnology--_2015_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26493003", "content": {"Acknowledgement": "Acknowledgments Margaret Miller from The Toxicology Forum for helping to plan the session and moderating the discussions. Tim Pastoor from Syngenta for helping to plan the session. 3. Safety assessment of first generation GMOs: evaluation of submissions under FDA's plant biotechnology consultation process 4. Impact of the food wars on agricultural biotechnology: communicating the science 5. Discussion2 Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Transitioning-to-composite-bacterial-mutagenicit_2019_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31586682", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper.", "Funding": "Funding This project was supported by FDA's Safety Research Interest Group and an appointment to the Research Participation Programs at the Oak Ridge Institute for Science and Education through an interagency agreement between the Department of Energy and FDA. Additionally, research reported in this article was partially supported by the National Institute of Environmental Health Sciences of the National Institutes of Health under Award Number 2R44ES026909. Conclusions FDA CDER disclaimer Funding mk:H1_24 Acknowledgements Supplementary data Transparency document References", "Acknowledgement": "Acknowledgements CASE Ultra, Leadscope Enterprise, and Derek Nexus software were used by CDER under Research Collaboration Agreements with MultiCASE Inc., Leadscope Inc., and Lhasa Limited, respectively. Conclusions FDA CDER disclaimer Funding mk:H1_24 Acknowledgements Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Transparency-throughout-the-production-chain-a-way-to_2009_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19545507", "content": {"CoiStatement": "China Daily, 2007. Drug factories ordered to clean up (http:// www.chinadaily.com.cn/language_tips/cdaudio/2007-09/05/ content_6082495.htm. Accessed September 8, 2008. CPA. 2006. Competition in the World APIs Market. Chemical pharmaceutical generic association, Milan, Italy. Report Available at www.cpa-italy.org Cui, C.W., Ji, S.L., Ren, H.Y., 2006. Determination of steroid estrogens in wastewater treatment plant of a contraceptives producing factory. Environ. Monitor. Assess. 121, 409\u2013419. Hoerger, C.C., D\u00f6rr, B., Schlienger, C., Straub, J.O., 2009. Environmental risk assessment for the galenical formulation of solid medicinal products at Roche Basle, Switzerland. Integ. Environ. Assess. Management. doi:10.1897/ IEAM_2008-049.1. Holm, J.V., Rugge, K., Bjerg, P., Christensen, T.H., 1995. Occurrence and distribution of pharmaceutical organic compounds in the groundwater downgradient of a landfill (Grindsted, Denmark). Environ. Sci. Technol. 29, 1415\u20131420. Larsson, D.G.J., De Pedro, C., Pax\u00e9us, N., 2007. Effluent from drug manufactures contains extremely high levels of pharmaceuticals. J. Hazard Mater. 148, 751\u2013 755. Larsson, D.G.J., 2008. Drug production facilities\u2014an overlooked discharge source for pharmaceuticals to the environment. In: K\u00fcmmerer, K. (Ed.), Pharmaceuticals in the Environment. Sources, Fate, Effects and Risks. Springer, Berlin, pp. p 37\u201342. Heidelberg, New York. Li, D., Yang, M., Hu, J., Ren, L., Zhang, Y., Li, K., 2008. Determination and fate of oxytetracycline and related compounds in oxytetracycline production wastewater and the receiving river. Environ. Toxicol. Chem. 27, 80\u201386. Martinez, J.L., 2008. Antibiotics and antibiotic resistance genes in natural environments. Science 321, 365\u2013367. Stenberg, I. LIF vill inf\u00f6ra globala milj\u00f6krav. L\u00e4kemedelsv\u00e4rlden. 2007 (in Swedish) http://www.lakemedelsvarlden.se/zino.aspx?articleID=10963. Accessed September 8, 2008. Z\u00fcehlke, S., Duennbier, U., Heberer, T.H., 2004. Detection and identification of phenazone-type drugs and their microbial metabolites in ground and drinking water applying solid-phase extraction and gas chromatography with mass spectrometric detection. J. Chromatogr. A 1050, 201\u2013209. http://dx.doi.org/10.1897/08-524.1 http://www.chinadaily.com.cn/language_tips/cdaudio/2007-09/05/content_6082495.htm http://www.chinadaily.com.cn/language_tips/cdaudio/2007-09/05/content_6082495.htm http://www.chinadaily.com.cn/language_tips/cdaudio/2007-09/05/content_6082495.htm http://www.cpa-italy.org http://dx.doi.org/10.1897/IEAM_2008-049.1 http://dx.doi.org/10.1897/IEAM_2008-049.1 http://www.lakemedelsvarlden.se/zino.aspx?articleID=10963 Transparency throughout the production chain\u2014a way to reduce pollution from the manufacturing of pharmaceuticals? Conflict of interest Acknowledgments References", "Acknowledgement": "China Daily, 2007. Drug factories ordered to clean up (http:// www.chinadaily.com.cn/language_tips/cdaudio/2007-09/05/ content_6082495.htm. Accessed September 8, 2008. CPA. 2006. Competition in the World APIs Market. Chemical pharmaceutical generic association, Milan, Italy. Report Available at www.cpa-italy.org Cui, C.W., Ji, S.L., Ren, H.Y., 2006. Determination of steroid estrogens in wastewater treatment plant of a contraceptives producing factory. Environ. Monitor. Assess. 121, 409\u2013419. Hoerger, C.C., D\u00f6rr, B., Schlienger, C., Straub, J.O., 2009. Environmental risk assessment for the galenical formulation of solid medicinal products at Roche Basle, Switzerland. Integ. Environ. Assess. Management. doi:10.1897/ IEAM_2008-049.1. Holm, J.V., Rugge, K., Bjerg, P., Christensen, T.H., 1995. Occurrence and distribution of pharmaceutical organic compounds in the groundwater downgradient of a landfill (Grindsted, Denmark). Environ. Sci. Technol. 29, 1415\u20131420. Larsson, D.G.J., De Pedro, C., Pax\u00e9us, N., 2007. Effluent from drug manufactures contains extremely high levels of pharmaceuticals. J. Hazard Mater. 148, 751\u2013 755. Larsson, D.G.J., 2008. Drug production facilities\u2014an overlooked discharge source for pharmaceuticals to the environment. In: K\u00fcmmerer, K. (Ed.), Pharmaceuticals in the Environment. Sources, Fate, Effects and Risks. Springer, Berlin, pp. p 37\u201342. Heidelberg, New York. Li, D., Yang, M., Hu, J., Ren, L., Zhang, Y., Li, K., 2008. Determination and fate of oxytetracycline and related compounds in oxytetracycline production wastewater and the receiving river. Environ. Toxicol. Chem. 27, 80\u201386. Martinez, J.L., 2008. Antibiotics and antibiotic resistance genes in natural environments. Science 321, 365\u2013367. Stenberg, I. LIF vill inf\u00f6ra globala milj\u00f6krav. L\u00e4kemedelsv\u00e4rlden. 2007 (in Swedish) http://www.lakemedelsvarlden.se/zino.aspx?articleID=10963. Accessed September 8, 2008. Z\u00fcehlke, S., Duennbier, U., Heberer, T.H., 2004. Detection and identification of phenazone-type drugs and their microbial metabolites in ground and drinking water applying solid-phase extraction and gas chromatography with mass spectrometric detection. J. Chromatogr. A 1050, 201\u2013209. http://dx.doi.org/10.1897/08-524.1 http://www.chinadaily.com.cn/language_tips/cdaudio/2007-09/05/content_6082495.htm http://www.chinadaily.com.cn/language_tips/cdaudio/2007-09/05/content_6082495.htm http://www.chinadaily.com.cn/language_tips/cdaudio/2007-09/05/content_6082495.htm http://www.cpa-italy.org http://dx.doi.org/10.1897/IEAM_2008-049.1 http://dx.doi.org/10.1897/IEAM_2008-049.1 http://www.lakemedelsvarlden.se/zino.aspx?articleID=10963 Transparency throughout the production chain\u2014a way to reduce pollution from the manufacturing of pharmaceuticals? Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Traumatic-acid-toxicity-mechanisms-in-human-br_2019_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31055047", "content": {"CoiStatement": "Discussion Conclusions Conflicts of interest Compliance with ethical standards Acknowledgements Transparency document References", "Compliance with ethical standards": "Compliance with ethical standards The manuscript does not contain clinical studies or patient data. Discussion Conclusions Conflicts of interest Compliance with ethical standards Acknowledgements Transparency document References", "Acknowledgement": "Acknowledgements The research was carried out as a part of the project No. WZ/WBiI\u015a/ 3/2019 and financed from the funds for education of the Ministry of Science and Higher Education, Poland. Discussion Conclusions Conflicts of interest Compliance with ethical standards Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Treatment-of---thujaplicin-counteracts-di-2-ethylhexyl-ph_2018_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29288721", "content": {"CoiStatement": "Conflicts of interest The authors declare that they have no conflicts of interest with the contents of this article. The authors declare that they have no conflicts of interest with the contents of this article. Acknowledgements Discussion Conclusion Conflicts of interest Acknowledgements References", "Funding": "We are very grateful to the Ministry of Science and Technology of Taiwan for providing funding of this project (MOST 103-2113-M-194- 004). References", "Acknowledgement": "Acknowledgements We are very grateful to the Ministry of Science and Technology of Taiwan for providing funding of this project (MOST 103-2113-M-194- 004). Discussion Conclusion Conflicts of interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Tree-nut-allergy-and-anxiety-related-factors-modulate-f_2018_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30253193", "content": {"CoiStatement": "These results must be analysed considering some limitations. The study population included only the population that consults allergists. This may result in overlooking peanut-allergic individuals with severe allergies, and therefore in an overestimation of the prevalence of severe symptoms and/or of low threshold doses. However, the participation of both office- and hospital-based allergists limits this bias. This recruit- ment strategy also made it possible to recruit a high number of peanut- allergic patients throughout France, Belgium and Luxembourg, and therefore cover peanut allergy and food behaviour variability. Around 11% of the population was diagnosed less than 1 year ago. Given that their food allergy was relatively new, these individuals may not have changed their food habits when the questionnaire had been adminis- tered, or in contrast, they may have changed all their habits before observing that they can consume some products. Moreover, 85% of the patients were younger than 16 years old and thus the questionnaire was filled by the parents. Maybe, the results would change if children had answered, especially for food consumed outside home when parents are not present. Also, even if dietary record is supposed to produce fairly accurate food intake, habitual eating pattern may be influenced by recording process and the reliability of records decrease over time (Biro' et al. (2002). Moreover, it is well known that FFQs usually over- estimated food intake compared to other nutritional assessment methods (Thompson and Byers, 1994). Indeed, as FFQ gives the pos- sibility of choosing several foods in a given category e.g. appetizers, the larger the number of foods in the category the higher the probability of over estimating intake. Moreover, as individuals are surveyed only on a short period, dietary records do not catch the whole consumption, especially products occasionally consumed. Thus, some under- estimation of certain food categories like seasonal or festival products could occur. Finally, this work reflects the difficulty and complexity inherent to the analysis of food consumption. When the project MIRABEL was designed, the French version of the FAQLQ was not available. Therefore, we built a questionnaire with the aim to focus on anxiety linked to food allergy. We translated the four questions of the FAQLQ evaluating emotional impact and related to frightness and apprehension. We added other questions on the anxiety when eating products with the different labels (\u201cguarantee without\u201d, \u201cmay contain peanut\u201d, \u201cmay contain other allergens\u201d) or when products do not have PAL, and also when eating outside home (school canteen, restaurant, family/friends home). We are aware that this questionnaire is not validated and it could impact the measure of anxiety. To conclude, this is the first survey on the consumption of specific food categories by peanut-allergy sufferers. The results showed that food consumption in MIRABEL patients is modulated by factors related to anxiety such as label reading, knowledge of threshold and con- comitant allergies to tree nuts. Factors related to allergy characteristics and diet advice, do not influence food choices. These results must be confirmed by other consumption surveys on allergy sufferers and compared with those of the general population. Waiting for, using the consumption data will directly improve risk assessment of peanut al- lergic individuals and findings will help allergists and risk managers to make diet advices. Contributors Alexandra Papadopoulos: involvement in developing the MIRABEL project, in statistical analysis and interpretation of the data, and in writing the manuscript. Chabi Fabrice El\u00e9gb\u00e9d\u00e9: involvement in data management and substantial involvement in revising the manuscript prior to submission. Sarra Ait-Dahmane: involvement in the data collection and man- agement. Carine Dubuisson: involvement in the data collection and sub- stantial involvement in revising the manuscript prior to submission. Antoine Deschildre: involvement in the data collection, and sub- stantial involvement in writing the manuscript. Am\u00e9lie Cr\u00e9pet: leader in the development and design of the MIRABEL project, involvement in the formulation of hypotheses, and in the acquisition, statistical analysis and interpretation of the data and in writing the manuscript. Conflicts of interest All the authors have approved the final version of the article and declare no conflict of interest. Acknowledgments This study was funded by a French National Research Agency (ANR) grant (no. ANR-10-ALIA-012-01). Transparency document Transparency document related to this article can be found online at https://doi.org/10.1016/j.yrtph.2018.09.020. References Agresti, 1990. Categorical Data Analysis. Avery, N.J., et al., 2003. Assessment of quality of life in children with peanut allergy. Pediatr. Allergy Immunol. 14, 378\u2013382. Biro\u00b4, G., et al., 2002. Selection of methodology to assess food intake. Eur. J. Clin. Nutr. 56. Birdi, G., et al., 2016. Quality of life, stress, and mental health in parents of children with parentally diagnosed food allergy compared to medically diagnosed and healthy controls. J. Allergy 7 2016. Cochrane, Sarra Ait-Dahmane., et al., 2013. Characteristics and purchasing behaviours of food-allergic consumers and those who buy food for them in Great Britain. Clin. Transl. Allergy 3, 31. Cr\u00e9pet, A., et al., 2015. MIRABEL: an integrated project for risk and cost/benefit analysis of peanut allergy. Regul. Toxicol. Pharmacol. 71, 178\u2013183. Crevel, R.W.R., et al., 2014. Development and evolution of risk assessment for food al- lergens. Food Chem. Toxicol. 67, 262\u2013276. Deschildre, A., et al., 2016. Peanut allergic patients in the MIRABEL survey: comorbidities and specificities of eliciting dose in real-life. Clin. Exp. Allergy 4, 610\u2013620. DunnGalvin, A., et al., 2015. Precautionary allergen labelling: perspectives from key stakeholder groups. Allergy 70, 1039\u20131051. Elegbede, C.F., et al., 2015. A Bayesian network to optimise sample size for food allergen monitoring. Food Contr. 47, 212\u2013220. Ferro, M.A., et al., 2016. Condition-specific associations of symptoms of depression and anxiety in adolescents and young adults with asthma and food allergy. J. Asthma 53, 282\u2013288. Flokstra-de Blok, B.M., et al., 2008. Development and validation of the self-administered food allergy quality of life questionnaire for adolescents. J. Allergy Clin. Immunol. 122 (139\u201344) 144 e1-2. Flokstra-de Blok, B.M., et al., 2009a. Development and validation of a self-administered food allergy quality of life questionnaire for children. Clin. Exp. Allergy 39, 127\u2013137. Flokstra-de Blok, B.M., et al., 2009b. Development and validation of the food allergy quality of life questionnaire - adult form. Allergy 64, 1209\u20131217. Hattersley, S., et al., 2014. Advances in the risk management of unintended presence of allergenic foods in manufactured food products \u2013 an overview. Food Chem. Toxicol. A. Papadopoulos et al. Regulatory Toxicology and Pharmacology 99 (2018) 191\u2013199 198 https://doi.org/10.1016/j.yrtph.2018.09.020 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref1 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref2 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref2 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref3 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref3 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref4 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref4 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref4 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref5 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref5 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref5 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref6 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref6 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref7 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref7 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref8 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref8 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref9 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref9 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref10 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref10 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref11 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref11 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref11 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref12 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref12 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref12 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref13 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref13 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref14 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref14 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref15 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref15 67, 255\u2013261. Hefle, S.L., et al., 2007. Consumer attitudes and risks associated with packaged foods having advisory labeling regarding the presence of peanuts. J. Allergy Clin. Immunol. 120, 171\u2013176. Just, J., et al., 2016. Two severe peanut-allergy phenotypes with gender difference: evi- dence from the MIRABEL survey. Clin. Exp. Allergy 46, 1596\u20131604. Kruizinga, A.G., et al., 2008. Probabilistic risk assessment model for allergens in food: sensitivity analysis of the minimum eliciting dose and food consumption. Food Chem. Toxicol. 46, 1437\u20131443. Madsen, C.B., et al., 2009. Approaches to risk assessment in food allergy: report from a workshop ''developing a framework for assessing the risk from allergenic foods. Food Chem. Toxicol. 47, 480\u2013489. Maloney, J.M., et al., 2008. The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy. J. Allergy Clin. Immunol. 122, 145\u2013151. Marchisotto, M.J., et al., 2017. Food allergen labeling and purchasing habits in the United States and Canada. J. Allergy Clin. Immunol.: In Pract. 5, 345\u2013351.e2. Marette, S., et al., Submitted. The Impact of New Allergen Labels on Food Choices by Peanut Allergic Individuals from MIRABEL Survey. McHorney, C.A., et al., 1994. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 32, 40\u201366. Menard, C., et al., 2011. OQALI: a French database on processed foods. J. Food Compos. Anal. 24, 744\u2013749. Nwaru, B.I., et al., 2014. Prevalence of common food allergies in Europe: a systematic review and meta-analysis. Allergy 69, 992\u20131007. Pieretti, M.M., et al., 2009. Audit of manufactured products: use of allergen advisory labels and identification of labeling ambiguities. J. Allergy Clin. Immunol. 124, 337\u2013341. Ranc\u00e9, F., et al., 2005. Prevalence and main characteristics of schoolchildren diagnosed with food allergies in France. Clin. Exp. Allergy 35, 167\u2013172. Rimbaud, L., et al., 2013. Quantitative risk assessment relating to the inadvertent pre- sence of peanut allergens in various food products. Int. Food Risk Anal. J. 3, 1\u201311. Saleh-Langenberg, J., et al., 2015. Predictors of health-related quality of life of European food-allergic patients. Allergy 70, 616\u2013624. Sasaki, M., et al., 2018. Prevalence of clinic-defined food allergy in early adolescence: the SchoolNuts study. J. Allergy Clin. Immunol. 141, 391\u2013398 e4. Sicherer, S.H., et al., 2001. The impact of childhood food allergy on quality of life. Ann. Allergy Asthma Immunol. 87, 461\u2013464. Spanjersberg, M.Q.I., et al., 2007. Risk assessment and food allergy: the probabilistic model applied to allergens. Food Chem. Toxicol. 45, 49\u201354. Spanjersberg, M.Q., et al., 2010. Concentrations of undeclared allergens in food products can reach levels that are relevant for public health. Food Addit. Contam. 27, 169\u2013174. Thompson, F.E., Byers, T., 1994. Dietary assessment resource manual. J. Nutr. 124. Ware Jr., J.E., Sherbourne, Carine Dubuisson., 1992. The MOS 36-item short-form health survey (SF- 36). I. Conceptual framework and item selection. Med Care 30, 473\u2013483. Wassenberg, J., et al., 2012. Parent perceived quality of life is age-dependent in children with food allergy. Pediatr. Allergy Immunol. 23, 412\u2013419. Zagon, J., et al., 2015. Peanut traces in packaged food products consumed by allergic individuals: results of the MIRABEL project. J. Food Compos. Anal. 44, 196\u2013204. Zurzolo, G.A., et al., 2016. Is advising food allergic patients to avoid food with precau- tionary allergen labelling out of date? Curr. Opin. Allergy Clin. Immunol. 16, 272\u2013277. A. Papadopoulos et al. Regulatory Toxicology and Pharmacology 99 (2018) 191\u2013199 199 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref15 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref16 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref16 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref16 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref17 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref17 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref18 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref18 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref18 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref19 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref19 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref19 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref20 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref20 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref21 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref21 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref23 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref23 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref23 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref24 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref24 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref25 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref25 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref26 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref26 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref26 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref27 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref27 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref28 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref28 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref29 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref29 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref30 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref30 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref31 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref31 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref32 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref32 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref33 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref33 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref33 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref34 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref35 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref35 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref36 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref36 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref37 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref37 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref38 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref38 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref38 Tree nut allergy and anxiety related factors modulate food consumption behaviour in peanut-allergic patients: Results of the MIRABEL survey Introduction Materials and methods Study population Data collection Study variables Method of analysis Statistical analysis Results Study population Consumption in MIRABEL patients Associations between food consumption and medical characteristics, label reading, diet advice and anxiety score Discussion Medical characteristics and consumption of specific products Consumption of peanut-allergic patients: most affected products Limitations Contributors Conflicts of interest Acknowledgments Transparency document References", "Acknowledgement": "These results must be analysed considering some limitations. The study population included only the population that consults allergists. This may result in overlooking peanut-allergic individuals with severe allergies, and therefore in an overestimation of the prevalence of severe symptoms and/or of low threshold doses. However, the participation of both office- and hospital-based allergists limits this bias. This recruit- ment strategy also made it possible to recruit a high number of peanut- allergic patients throughout France, Belgium and Luxembourg, and therefore cover peanut allergy and food behaviour variability. Around 11% of the population was diagnosed less than 1 year ago. Given that their food allergy was relatively new, these individuals may not have changed their food habits when the questionnaire had been adminis- tered, or in contrast, they may have changed all their habits before observing that they can consume some products. Moreover, 85% of the patients were younger than 16 years old and thus the questionnaire was filled by the parents. Maybe, the results would change if children had answered, especially for food consumed outside home when parents are not present. Also, even if dietary record is supposed to produce fairly accurate food intake, habitual eating pattern may be influenced by recording process and the reliability of records decrease over time (Biro' et al. (2002). Moreover, it is well known that FFQs usually over- estimated food intake compared to other nutritional assessment methods (Thompson and Byers, 1994). Indeed, as FFQ gives the pos- sibility of choosing several foods in a given category e.g. appetizers, the larger the number of foods in the category the higher the probability of over estimating intake. Moreover, as individuals are surveyed only on a short period, dietary records do not catch the whole consumption, especially products occasionally consumed. Thus, some under- estimation of certain food categories like seasonal or festival products could occur. Finally, this work reflects the difficulty and complexity inherent to the analysis of food consumption. When the project MIRABEL was designed, the French version of the FAQLQ was not available. Therefore, we built a questionnaire with the aim to focus on anxiety linked to food allergy. We translated the four questions of the FAQLQ evaluating emotional impact and related to frightness and apprehension. We added other questions on the anxiety when eating products with the different labels (\u201cguarantee without\u201d, \u201cmay contain peanut\u201d, \u201cmay contain other allergens\u201d) or when products do not have PAL, and also when eating outside home (school canteen, restaurant, family/friends home). We are aware that this questionnaire is not validated and it could impact the measure of anxiety. To conclude, this is the first survey on the consumption of specific food categories by peanut-allergy sufferers. The results showed that food consumption in MIRABEL patients is modulated by factors related to anxiety such as label reading, knowledge of threshold and con- comitant allergies to tree nuts. Factors related to allergy characteristics and diet advice, do not influence food choices. These results must be confirmed by other consumption surveys on allergy sufferers and compared with those of the general population. Waiting for, using the consumption data will directly improve risk assessment of peanut al- lergic individuals and findings will help allergists and risk managers to make diet advices. Contributors Alexandra Papadopoulos: involvement in developing the MIRABEL project, in statistical analysis and interpretation of the data, and in writing the manuscript. Chabi Fabrice El\u00e9gb\u00e9d\u00e9: involvement in data management and substantial involvement in revising the manuscript prior to submission. Sarra Ait-Dahmane: involvement in the data collection and man- agement. Carine Dubuisson: involvement in the data collection and sub- stantial involvement in revising the manuscript prior to submission. Antoine Deschildre: involvement in the data collection, and sub- stantial involvement in writing the manuscript. Am\u00e9lie Cr\u00e9pet: leader in the development and design of the MIRABEL project, involvement in the formulation of hypotheses, and in the acquisition, statistical analysis and interpretation of the data and in writing the manuscript. Conflicts of interest All the authors have approved the final version of the article and declare no conflict of interest. Acknowledgments This study was funded by a French National Research Agency (ANR) grant (no. ANR-10-ALIA-012-01). Transparency document Transparency document related to this article can be found online at https://doi.org/10.1016/j.yrtph.2018.09.020. References Agresti, 1990. Categorical Data Analysis. Avery, N.J., et al., 2003. Assessment of quality of life in children with peanut allergy. Pediatr. Allergy Immunol. 14, 378\u2013382. Biro\u00b4, G., et al., 2002. Selection of methodology to assess food intake. Eur. J. Clin. Nutr. 56. Birdi, G., et al., 2016. Quality of life, stress, and mental health in parents of children with parentally diagnosed food allergy compared to medically diagnosed and healthy controls. J. Allergy 7 2016. Cochrane, Sarra Ait-Dahmane., et al., 2013. Characteristics and purchasing behaviours of food-allergic consumers and those who buy food for them in Great Britain. Clin. Transl. Allergy 3, 31. Cr\u00e9pet, A., et al., 2015. MIRABEL: an integrated project for risk and cost/benefit analysis of peanut allergy. Regul. Toxicol. Pharmacol. 71, 178\u2013183. Crevel, R.W.R., et al., 2014. Development and evolution of risk assessment for food al- lergens. Food Chem. Toxicol. 67, 262\u2013276. Deschildre, A., et al., 2016. Peanut allergic patients in the MIRABEL survey: comorbidities and specificities of eliciting dose in real-life. Clin. Exp. Allergy 4, 610\u2013620. DunnGalvin, A., et al., 2015. Precautionary allergen labelling: perspectives from key stakeholder groups. Allergy 70, 1039\u20131051. Elegbede, C.F., et al., 2015. A Bayesian network to optimise sample size for food allergen monitoring. Food Contr. 47, 212\u2013220. Ferro, M.A., et al., 2016. Condition-specific associations of symptoms of depression and anxiety in adolescents and young adults with asthma and food allergy. J. Asthma 53, 282\u2013288. Flokstra-de Blok, B.M., et al., 2008. Development and validation of the self-administered food allergy quality of life questionnaire for adolescents. J. Allergy Clin. Immunol. 122 (139\u201344) 144 e1-2. Flokstra-de Blok, B.M., et al., 2009a. Development and validation of a self-administered food allergy quality of life questionnaire for children. Clin. Exp. Allergy 39, 127\u2013137. Flokstra-de Blok, B.M., et al., 2009b. Development and validation of the food allergy quality of life questionnaire - adult form. Allergy 64, 1209\u20131217. Hattersley, S., et al., 2014. Advances in the risk management of unintended presence of allergenic foods in manufactured food products \u2013 an overview. Food Chem. Toxicol. A. Papadopoulos et al. Regulatory Toxicology and Pharmacology 99 (2018) 191\u2013199 198 https://doi.org/10.1016/j.yrtph.2018.09.020 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref1 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref2 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref2 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref3 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref3 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref4 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref4 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref4 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref5 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref5 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref5 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref6 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref6 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref7 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref7 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref8 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref8 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref9 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref9 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref10 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref10 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref11 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref11 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref11 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref12 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref12 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref12 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref13 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref13 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref14 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref14 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref15 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref15 67, 255\u2013261. Hefle, S.L., et al., 2007. Consumer attitudes and risks associated with packaged foods having advisory labeling regarding the presence of peanuts. J. Allergy Clin. Immunol. 120, 171\u2013176. Just, J., et al., 2016. Two severe peanut-allergy phenotypes with gender difference: evi- dence from the MIRABEL survey. Clin. Exp. Allergy 46, 1596\u20131604. Kruizinga, A.G., et al., 2008. Probabilistic risk assessment model for allergens in food: sensitivity analysis of the minimum eliciting dose and food consumption. Food Chem. Toxicol. 46, 1437\u20131443. Madsen, C.B., et al., 2009. Approaches to risk assessment in food allergy: report from a workshop ''developing a framework for assessing the risk from allergenic foods. Food Chem. Toxicol. 47, 480\u2013489. Maloney, J.M., et al., 2008. The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy. J. Allergy Clin. Immunol. 122, 145\u2013151. Marchisotto, M.J., et al., 2017. Food allergen labeling and purchasing habits in the United States and Canada. J. Allergy Clin. Immunol.: In Pract. 5, 345\u2013351.e2. Marette, S., et al., Submitted. The Impact of New Allergen Labels on Food Choices by Peanut Allergic Individuals from MIRABEL Survey. McHorney, C.A., et al., 1994. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 32, 40\u201366. Menard, C., et al., 2011. OQALI: a French database on processed foods. J. Food Compos. Anal. 24, 744\u2013749. Nwaru, B.I., et al., 2014. Prevalence of common food allergies in Europe: a systematic review and meta-analysis. Allergy 69, 992\u20131007. Pieretti, M.M., et al., 2009. Audit of manufactured products: use of allergen advisory labels and identification of labeling ambiguities. J. Allergy Clin. Immunol. 124, 337\u2013341. Ranc\u00e9, F., et al., 2005. Prevalence and main characteristics of schoolchildren diagnosed with food allergies in France. Clin. Exp. Allergy 35, 167\u2013172. Rimbaud, L., et al., 2013. Quantitative risk assessment relating to the inadvertent pre- sence of peanut allergens in various food products. Int. Food Risk Anal. J. 3, 1\u201311. Saleh-Langenberg, J., et al., 2015. Predictors of health-related quality of life of European food-allergic patients. Allergy 70, 616\u2013624. Sasaki, M., et al., 2018. Prevalence of clinic-defined food allergy in early adolescence: the SchoolNuts study. J. Allergy Clin. Immunol. 141, 391\u2013398 e4. Sicherer, S.H., et al., 2001. The impact of childhood food allergy on quality of life. Ann. Allergy Asthma Immunol. 87, 461\u2013464. Spanjersberg, M.Q.I., et al., 2007. Risk assessment and food allergy: the probabilistic model applied to allergens. Food Chem. Toxicol. 45, 49\u201354. Spanjersberg, M.Q., et al., 2010. Concentrations of undeclared allergens in food products can reach levels that are relevant for public health. Food Addit. Contam. 27, 169\u2013174. Thompson, F.E., Byers, T., 1994. Dietary assessment resource manual. J. Nutr. 124. Ware Jr., J.E., Sherbourne, Carine Dubuisson., 1992. The MOS 36-item short-form health survey (SF- 36). I. Conceptual framework and item selection. Med Care 30, 473\u2013483. Wassenberg, J., et al., 2012. Parent perceived quality of life is age-dependent in children with food allergy. Pediatr. Allergy Immunol. 23, 412\u2013419. Zagon, J., et al., 2015. Peanut traces in packaged food products consumed by allergic individuals: results of the MIRABEL project. J. Food Compos. Anal. 44, 196\u2013204. Zurzolo, G.A., et al., 2016. Is advising food allergic patients to avoid food with precau- tionary allergen labelling out of date? Curr. Opin. Allergy Clin. Immunol. 16, 272\u2013277. A. Papadopoulos et al. Regulatory Toxicology and Pharmacology 99 (2018) 191\u2013199 199 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref15 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref16 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref16 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref16 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref17 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref17 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref18 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref18 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref18 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref19 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref19 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref19 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref20 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref20 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref21 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref21 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref23 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref23 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref23 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref24 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref24 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref25 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref25 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref26 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref26 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref26 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref27 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref27 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref28 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref28 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref29 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref29 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref30 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref30 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref31 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref31 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref32 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref32 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref33 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref33 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref33 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref34 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref35 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref35 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref36 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref36 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref37 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref37 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref38 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref38 http://refhub.elsevier.com/S0273-2300(18)30242-3/sref38 Tree nut allergy and anxiety related factors modulate food consumption behaviour in peanut-allergic patients: Results of the MIRABEL survey Introduction Materials and methods Study population Data collection Study variables Method of analysis Statistical analysis Results Study population Consumption in MIRABEL patients Associations between food consumption and medical characteristics, label reading, diet advice and anxiety score Discussion Medical characteristics and consumption of specific products Consumption of peanut-allergic patients: most affected products Limitations Contributors Conflicts of interest Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Trends-in-prescription-of-pregnancy-contraindic_2016_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26721338", "content": {"CoiStatement": "3. Results 4. Discussion 5. Conclusion Conflicts of interest Contribution to authorship Appendix A. List of study drugs Appendix B. Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Trichloroethylene-exposure-aggravates-behavioral-abno_2016_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27166294", "content": {"Acknowledgement": "N. Otsuki et al. / Regulatory Toxicology and Pharmacology 79 (2016) 83e90 89 Acknowledgments This work was supported, in part, by the Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circu- lation from the Japan Society for the Promotion of Sciences (S2402). 4. Discussion Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Twenty-eight-day-oral-toxicity-study-of-lycopene-f_2008_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18789998", "content": {"Acknowledgement": "In conclusion, no toxic effects were observed in SD rats that were orally administered 2000 mg/kg/day lycopene for 28 days; therefore, the NOAEL in lycopene derived from metabolically engi- neered E. coli in this study was 2000 mg/kg/day in male and female SD rats. Acknowledgment The authors thank the editorial assistance in this study by Mr. Ted Kony. Discussion and conclusion Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Twenty-eight-days-repeated-oral-dose-toxicity-stud_2010_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20580917", "content": {"Acknowledgement": "In this study, the phototoxic potentials of gemifloxacin were determined systemically. At 200 mg/kg oral dose of gemifloxacin produce severe erythema in rat ear even after 7 day treatment. Phototoxic potentials of gemifloxacin related to the cyclopropane substitution at position 1 (Hayashi et al., 2004). In conclusion, the 28-days repeated oral dose of gemifloxacin produced increases in the liver weight, serum WBC count, serum lymphocyte count, serum T-BIL, serum UA and serum ALT values, and significant decreases in the serum TP value in both sexes at the 200 mg/kg/day dose levels, increases serum platelet counts and dysphoria in males of higher dose level. It was also concluded that gemifloxacin produced erosion of the articular surface of joint, degenerative changes in tendinocytes in Achilles tendon, inflam- mation in joint, increase joint damage related biochemical param- eters (Uric acid content, LDH level), produce pseudogout or gout, some infection in joint and erythema in ear (phototoxic effect) in both sexes at the 200 mg/kg/day dose levels. The target organs were determined to be talar joint, synovial fluid, Achilles tendon, liver, WBC, and gastrointestinal tract in rats (in both sexes). Gem- ifloxacin also had toxic effect in the CNS (in males). These toxic ef- fects of gemifloxacin were transient and reversible. Acknowledgments We would like to thank Assistant Professor Anjan Das for his excellent technical cooperation with the histopathology analysis. We are very thankful to the University Grants Commission (UGC), New Delhi, India for providing the necessary fund for this research. We are very grateful to the M/S Akums Drugs & Pharma- ceuticals Limited, Delhi, India for getting gemifloxacin mesylate as a gift sample. We are also grateful to the Department of Science and Technology (DST), New Delhi, India for providing the necessary instrumental facilities. Appendix A. Supplementary data Discussion Acknowledgments Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Twenty-six-week-repeat-dose-oral-rat-toxicity-study-of-_2021_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33711392", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: The authors declare they were full time employees of Esteve Pharmaceuticals. 3 Results 4 Discussion Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgments References", "Funding": "Funding This research was funded by Esteve Pharmaceuticals. 3 Results 4 Discussion Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgments References", "Acknowledgement": "Acknowledgments The authors would like to acknowledge the contributions by the contract research organizations that supported these studies: Hunting- don Life Science Ltd (now part of Covance Laboratories Ltd), MCC Anal\u00edtica and AnaPath GmbH. 3 Results 4 Discussion Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Two-new-nontoxic--non-pathogenic-strains-of-Sphing_2016_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27079414", "content": {"CoiStatement": "Conflicts of interest All authors have a financial relationship with the sponsor of the studies and manuscript. 4. Discussion and conclusions Conflicts of interest Acknowledgements Transparency document References", "Acknowledgement": "Acknowledgements The authors thank Silvia Ulm and Lu Zhao for assistance in preparing the manuscript. 4. Discussion and conclusions Conflicts of interest Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/U-S--Food-and-Drug-Administration-s-interim-reference-_2020_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31707132", "content": {"Funding": "Conclusion Funding source mk:H1_25 Acknowledgements Supplementary data References", "Acknowledgement": "Conclusion Funding source mk:H1_25 Acknowledgements Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Uncertainties-related-to-the-assignment-of-a-toxic-eq_2006_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16460856", "content": {"Acknowledgement": "Finally, TEF values are based on concentrations at which dioxins will cause enzyme induction. Because the mechanism of dioxin-mediated cancer is unknown, it is uncertain whether these concentration\u2013response character- istics reflect those for cancer causation. Current knowledge of the mode of action of dioxin and dioxin-like compounds indicates that TEFs are useful in considerations of margin of exposure, as a TEQ calculation provides insight into the potential significance of current background exposures rel- ative to the expected early and sensitive response of enzyme induction. However, without identification and measure- ments of the key steps in cancer causation, there is not a strong scientific basis for cancer classifications based on TEFs. Because this class of compounds is an important example of how regulatory agencies can deal with the char- acterization of structurally related chemicals in the envi- ronment, studies to directly demonstrate that OCDD can promote tumors in animals seem warranted. Acknowledgment This project was sponsored by the Pentachlorophenol Task Force, Washington, DC. References Uncertainties related to the assignment of a toxic equivalency factor for 1,2,3,4,6,7,8,9-octachlorodibenzo-p-dioxin Introduction Uncertain ability of rat models to predict human sensitivity TEFs for weaker congeners are even less predictive of sensitivity in both rodent and human models than more potent congeners OCDD exhibits characteristics of a partial agonist in rat models, and in human models, it may be an antagonist In vivo studies of the effects of OCDD do not demonstrate toxicity Effect of OCDD binding to CYP1A2 TEFs and cancer classification Conclusions Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Under-the-law--FDA-must-grant-different-standards-f_2012_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22310217", "content": {"CoiStatement": "458 S. Mister, J. Hathcock / Regulatory Toxicology and Pharmacology 62 (2012) 456\u2013458 It is time for FDA to reconsider its efforts to redistribute the safety burdens allocated by Congress in DSHEA, and to recognize that the pre-market paradigm of food additives is not what Congress intended for dietary supplements, especially in view of their outstanding safety record. 2. Conflict of Interest statement The authors are employees of the Council for Responsible Nutrition, a trade association that represents manufacturers of dietary supplement ingredients and products. Under the law, FDA must grant different standards for new dietary ingredients and food additives 1 Commentary 2 Conflict of Interest statement"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Uniform-assessment-and-ranking-of-opioid-Mu-recepto_2011_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21215785", "content": {"CoiStatement": "The comparative opioid pharmacology at the MOR lies at the base of hazard knowledge for opioids and is an important part of identifying risk mitigation strategies to help support the most appropriate uses of opioids and their safe disposal. Considering the wide range of binding affinities found in the study, this infor- mation can help delineate what other factors are important in driv- ing risk. For instance, a drug that has a high affinity for MOR with a comparatively low incidence and severity of adverse events can be compared to a drug with opposite findings to determine what fac- tors (e.g., drug formulation, labeling, packaging and disposal direc- tions) might enhance the safe use of opioid drugs. In addition to the MOR binding data, specific recommendations for disposal may be improved by also weighing the contributions of drug phar- macokinetics, pharmacodynamics, patterns of use, emergency room admissions, and the potential for abuse. This class of drugs provides important therapeutic benefits for millions, and it is essential that FDA continues to work to understand the scientific basis for their appropriate use. Conflict of Interest Statement The authors declare no conflicts of interest. Acknowledgements The authors declare no conflicts of interest. Acknowledgements The authors wish to acknowledge Vincent Vilker and Joseph Hanig for their thoughtful discussions during this study. References Discussion Conclusions Conflict of Interest Statement Acknowledgements References", "Acknowledgement": "The authors declare no conflicts of interest. Acknowledgements The authors wish to acknowledge Vincent Vilker and Joseph Hanig for their thoughtful discussions during this study. References Discussion Conclusions Conflict of Interest Statement Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Update--Mode-of-action--MOA--for-liver-tumors-ind_2017_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28366800", "content": {"Funding": "The authors wish to thank the Steering Committee of the Alli- ance for Risk Assessment (http://allianceforrisk.org/steering- committee/) for their review and endorsement of this collabora- tive effort, and for the endorsement of the Texas Commission on Environmental Quality, the Commonwealth of Kentucky, ERM, the University of Cincinnati, and Waste Management (see also http:// allianceforrisk.org/14-dioxane-analysis/). We also wish to acknowledge our many colleagues who supported this activity through active participation on technical conference calls, and specifically: Chris Prucha, Satish Deshpande, Jonathan D. Garoutte, Sarah Labib, Nadine Weinberg, Shawn Sager, Barbara Sassi, Shan- non Ethridge and Dennis Wambuguh. Sources of funding for this activity at the TERA Center at the University of Cincinnati include Hamp, Mathews & Associates, Inc., PPG Corporation, Waste Man- agement, and the University of Cincinnati, College of Medicine. Appendix A. Supplementary data", "Acknowledgement": "Acknowledgements The authors wish to thank the Steering Committee of the Alli- ance for Risk Assessment (http://allianceforrisk.org/steering- committee/) for their review and endorsement of this collabora- tive effort, and for the endorsement of the Texas Commission on Environmental Quality, the Commonwealth of Kentucky, ERM, the University of Cincinnati, and Waste Management (see also http:// allianceforrisk.org/14-dioxane-analysis/). We also wish to acknowledge our many colleagues who supported this activity through active participation on technical conference calls, and specifically: Chris Prucha, Satish Deshpande, Jonathan D. Garoutte, Sarah Labib, Nadine Weinberg, Shawn Sager, Barbara Sassi, Shan- non Ethridge and Dennis Wambuguh. Sources of funding for this activity at the TERA Center at the University of Cincinnati include Hamp, Mathews & Associates, Inc., PPG Corporation, Waste Man- agement, and the University of Cincinnati, College of Medicine. 4. Discussion Acknowledgements Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Updated-weight-of-evidence-for-an-association-between-ad_2006_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16624462", "content": {"Acknowledgement": "Acknowledgments Partial Wnancial support was supplied by the Chlorine Chemistry Council. The authors thank Dr. Carol Graves for her contributions to this paper. Spontaneous abortion or miscarriage Stillbirth or fetal death Neonatal death Conclusions Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Updating-exposure-assessment-for-skin-sensitization-_2020_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33075411", "content": {"CoiStatement": "4 Example of application of QRA2 to a fragrance material: methyl octine carbonate 5 Remaining uncertainties 6 Discussion Funding body information Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Funding": "4 Example of application of QRA2 to a fragrance material: methyl octine carbonate 5 Remaining uncertainties 6 Discussion Funding body information Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Acknowledgement": "4 Example of application of QRA2 to a fragrance material: methyl octine carbonate 5 Remaining uncertainties 6 Discussion Funding body information Declaration of competing interest Acknowledgements Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Updating-the-evidence-relating-smoking-bans-to-_2019_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30500390", "content": {"CoiStatement": "Discussion Conclusions Conflict of interest Acknowledgements Supplementary data Transparency document References", "Acknowledgement": "Discussion Conclusions Conflict of interest Acknowledgements Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Urinary-NNAL-in-hookah-smokers-and-non-smokers-after-a_2017_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28716579", "content": {"CoiStatement": "Conflict of interest disclosure Dr. Benowitz is a consultant to several pharmaceutical com- panies that market medications to aid smoking cessation and has served as a paid expert witness in litigation against tobacco com- panies. The other authors declare no competing interests associ- ated with this study. Dr. Benowitz is a consultant to several pharmaceutical com- panies that market medications to aid smoking cessation and has served as a paid expert witness in litigation against tobacco com- panies. The other authors declare no competing interests associ- ated with this study. Role of the funder/sponsor 5. Conclusions Funding/support Author contributions Conflict of interest disclosure Role of the funder/sponsor Acknowledgments Transparency document Appendix A. Supplementary data References", "Disclosure": "Conflict of interest disclosure Dr. Benowitz is a consultant to several pharmaceutical com- panies that market medications to aid smoking cessation and has served as a paid expert witness in litigation against tobacco com- panies. The other authors declare no competing interests associ- ated with this study. 5. Conclusions Funding/support Author contributions Conflict of interest disclosure Role of the funder/sponsor Acknowledgments Transparency document Appendix A. Supplementary data References", "Funding": "Funding/support This research was supported by the American Cancer Society 116623-RSG-09-098-01-CNE (Nada Kassem, DrPH, PI); National Institutes of Health 5R01HL103684 and 5R01CA138192 (Melbourne Hovell, PhD, PI), National Institute on Drug Abuse P30 DA012393 (Reese T Jones, MD, PI), and the National Center for Research Re- sources S10 RR026437 (Peyton Jacob, III, PhD, PI). 5. Conclusions Funding/support Author contributions Conflict of interest disclosure Role of the funder/sponsor Acknowledgments Transparency document Appendix A. Supplementary data References", "Compliance with ethical standards": "U.S. Food and Drug Administration (FDA), 2012. Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke: Established List. http:// www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ ucm297786.htm (Accessed 1 July 2017). Waziry, R., Jawad, M., Ballout, R.A., Al Akel, M., Akl, E.A., 2017. The effects of waterpipe tobacco smoking on health outcomes: an updated systematic review and meta-analysis. Int. J. Epidemiol. 46 (1) , 32e43. http://dx.doi.10.1093/ije/ dyw021. http://dx.doi.10.1158/1055-9965.EPI-12-1422 http://dx.doi.10.1158/1055-9965.EPI-12-1422 http://dx.doi.10.1158/1055-9965.EPI-14-0576 http://dx.doi.10.1158/1055-9965.EPI-14-0576 http://dx.doi.10.1093/ntr/ntu016 http://dx.doi.10.5993/AJHB.39.6.11 http://dx.doi.10.5993/AJHB.39.5.10 http://dx.doi.10.1093/ntr/ntx133 http://refhub.elsevier.com/S0273-2300(17)30193-9/sref23 http://refhub.elsevier.com/S0273-2300(17)30193-9/sref23 http://refhub.elsevier.com/S0273-2300(17)30193-9/sref23 http://dx.doi.10.1016/j.jenvrad.2008.07.005 http://dx.doi.10.1016/j.jenvrad.2008.07.005 http://dx.doi.10.1136/tobaccocontrol-2014-052038 http://dx.doi.10.1136/tobaccocontrol-2014-052038 http://dx.doi.10.1158/1055-9965.EPI-07-0189 http://dx.doi.10.1158/1055-9965.EPI-07-0189 http://www.testcountry.com/products.html?product=1823 http://www.testcountry.com/products.html?product=1823 http://dx.doi.10.1177/003335491613100114 http://dx.doi.10.1093/ntr/nts099 http://dx.doi.10.1093/ntr/nts099 http://dx.doi.10.1016/j.toxlet.2011.06.017 http://dx.doi.10.1016/j.toxlet.2011.06.017 http://dx.doi.10.1136/tobaccocontrol-2014-051907 http://dx.doi.10.1136/tobaccocontrol-2014-051907 http://dx.doi.10.1289/ehp.1104413 http://dx.doi.10.1289/ehp.1104413 http://dx.doi.10.1136/tc.2010.042192 http://dx.doi.10.1136/tc.2010.042192 https://www.ncbi.nlm.nih.gov/books/NBK44324/ https://www.ncbi.nlm.nih.gov/books/NBK44324/ http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm http://dx.doi.10.1093/ije/dyw021 http://dx.doi.10.1093/ije/dyw021 http://dx.doi.10.1038/jes.2014.88 http://dx.doi.10.1038/jes.2014.88 http://www.who.int/mediacentre/factsheets/fs339/en/index.html http://www.who.int/mediacentre/factsheets/fs339/en/index.html http://dx.doi.10.1158/0008-5472.CAN-13-3178 Urinary NNAL in hookah smokers and non-smokers after attending a hookah social event in a hookah lounge or a private home 1. Introduction 2. Methods 2.1. Statistical analyses", "Acknowledgement": "Funders had no further role in the collection, analysis and interpretation of data; in the writing of the report; or in the deci- sion to submit the paper for publication. Acknowledgments We thank our participants, the staff at SDSU laboratory, the Clinical Pharmacology Laboratory, UCSF, and the Center for Behavioral Epidemiology and Community Health (CBEACH). 5. Conclusions Funding/support Author contributions Conflict of interest disclosure Role of the funder/sponsor Acknowledgments Transparency document Appendix A. Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-and-handling-safety-of-Mini-Spike-2--chemo-and-pu_2018_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30296468", "content": {"CoiStatement": "Competing interests Any author nor co-authors declare conflict of interest. Any author nor co-authors declare conflict of interest. Funding Discussion Conclusions Competing interests Funding Acknowledgments Supplementary data Transparency document References", "Funding": "Funding B. Braun covered the costs associated with the study through a non- restrictive research grant. Discussion Conclusions Competing interests Funding Acknowledgments Supplementary data Transparency document References", "Acknowledgement": "Acknowledgments Compounding personnel of University and Polytechnic La Fe Hospital Pharmacy Department, for their collaboration. B. Braun for the grant. Discussion Conclusions Competing interests Funding Acknowledgments Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-and-validation-of-HT-HC-assays-to-support-21_2013_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23291301", "content": {"CoiStatement": "The activities of the Tox21 program, a collaboration of EPA, the Food and Drug Administration, the National Institutes of Environ- mental Health Sciences/National Toxicology Program, and the Na- tional Institutes of Health Chemical Genomics Center (http:// epa.gov/ncct/Tox21/) expand test methods, to increase the number of chemicals evaluated, to develop and evaluate new and improved prediction models, to collaborate and to publish in peer reviewed journals and EPA\u2019s leadership in disseminating data via the web1 and through communities of practice2 are commendable. This open exchange, coupled with the OECD work program for AOPs (OECD, 2011) and the International QSAR Foundation\u2019s development of Effectopedia3 will enable HT/HC methods, AOPs and prediction mod- els to be developed, evaluated, refined and updated as part of a glo- bal scientific community collaboration. As these activities proceed, application of the approaches discussed in this paper can be used to enhance scientific confidence in the assays and their prediction models. To move forward, several actions are recommended: (1) the MIE term should be replaced with IME; (2) drawing from the IOM methodology and/or the OECD QSAR principles, a specific vali- dation strategy should be developed and implemented for HT/HC as- says and their prediction models, focused on the specific biological response of interest and anchored to an adverse effect/response; (3) analytical validation of HT/HC estrogen and androgen assays should include all, or at least a substantial sub-set, of the ICCVAM recommended positive and negative reference compounds; and (4) to build scientific confidence, data should be publicly disseminated and assay results and prediction models should to be subjected to independent scientific peer review. Conflict of interest The employment affiliations of the authors are as shown on the cover page. Ted Simon is principal of Ted Simon LLC, a private firm that offers scientific consultation and research in human and envi- ronmental health. The American Chemistry Council (ACC) provided funding to Ted Simon LLC to support preparation of this manu- script. The authors have sole responsibility for the content and the writing of the paper, and\u2014the interpretations and views ex- pressed in the paper are not necessarily those of the ACC or the authors\u2019 employers or clients. Acknowledgments 4 Applying the OECD, 2007 (Q)SAR Validation Strategy to Develop Scientific Confidence in HT/HC Assays and Prediction Models 5 Review, endorsement and communication of validation results 6 The path ahead Conflict of interest Acknowledgments References", "Funding": "The employment affiliations of the authors are as shown on the cover page. Ted Simon is principal of Ted Simon LLC, a private firm that offers scientific consultation and research in human and envi- ronmental health. The American Chemistry Council (ACC) provided funding to Ted Simon LLC to support preparation of this manu- script. The authors have sole responsibility for the content and the writing of the paper, and\u2014the interpretations and views ex- pressed in the paper are not necessarily those of the ACC or the authors\u2019 employers or clients. Acknowledgments The perspectives and discussion in this manuscript are a prod- uct of the ACC Computational Profiling Workgroup chaired by 1 See http://actor.epa.gov/actor/faces/ACToRHome.jsp. 2 See http://www.epa.gov/ncct/communities_of_practice.html. 3 Effectopedia is a wikipedia type software tool which provides the means to store", "Acknowledgement": "The employment affiliations of the authors are as shown on the cover page. Ted Simon is principal of Ted Simon LLC, a private firm that offers scientific consultation and research in human and envi- ronmental health. The American Chemistry Council (ACC) provided funding to Ted Simon LLC to support preparation of this manu- script. The authors have sole responsibility for the content and the writing of the paper, and\u2014the interpretations and views ex- pressed in the paper are not necessarily those of the ACC or the authors\u2019 employers or clients. Acknowledgments The perspectives and discussion in this manuscript are a prod- uct of the ACC Computational Profiling Workgroup chaired by 1 See http://actor.epa.gov/actor/faces/ACToRHome.jsp. 2 See http://www.epa.gov/ncct/communities_of_practice.html. 3 Effectopedia is a wikipedia type software tool which provides the means to store 4 Applying the OECD, 2007 (Q)SAR Validation Strategy to Develop Scientific Confidence in HT/HC Assays and Prediction Models 5 Review, endorsement and communication of validation results 6 The path ahead Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-compatibility-intervals-in-regulatory_2020_Regulatory-Toxicology-and-Pha.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32645430", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. National Toxicology Program. 13 Weeks Gavage Study on Female F344 Rats Administered with Sodium Dichromate Dihydrate (VI) (CASRN: 7789-12-0, Study Number: C20114,TDMS Number:2011402. National Toxicology Program, 2019. Statistical Procedures. Expanded Overview. htt p://ntp-server.niehs.nih.gov/. Pallmann, P., Hothorn, L.A., 2016. Boxplots for grouped and clustered data in toxicology. Arch. Toxicol. 90 (7), 1631\u20131638. Pfuhler, S., Pirow, R., Downs, T., Haase, A., Hewitt, N., Luch, A., Merkel, M., Petrick, C., Said, A., Schaefer-Korting, M., Reisinger, K., 2020. Validation of the 3D reconstructed human skin Comet assay, an animal-free alternative for following-up positive results from standard in vitro genotoxicity assays. Mutagenesis. https://doi. org/10.1093/mutage/geaa009. Reisinger, K., Blatz, V., Brinkmann, J., Downs, T.R., Fischer, A., Henkler, F., Hoffmann, S., Krul, C., Liebsch, M., Luch, A., Pirow, R., Reus, A.A., Schulz, M., Pfuhler, S., 2018. Validation of the 3d skin comet assay using full thickness skin models: transferability and reproducibility. Mutat. Res. Genet. Toxicol. Environ. Mutagen 827, 27\u201341. Schmidt, S., Brannath, W., 2015. Informative simultaneous confidence intervals for the fallback procedure. Biom. J. 57 (4), 712\u2013719. Shirley, E., 1977. A nonparametric equivalent of Williams\u2019 test for contrasting increasing dose levels of a treatment. Biometrics 33 (2), 386\u2013389. L.A. Hothorn and Ralph Pirow http://refhub.elsevier.com/S0273-2300(20)30146-X/sref11 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref12 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref12 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref12 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref14 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref14 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref15 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref15 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref16 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref16 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref17 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref17 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref18 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref18 https://ntp.niehs.nih.gov/ntp/htdocs/st%20rpts/tox072.pdf https://ntp.niehs.nih.gov/ntp/htdocs/st%20rpts/tox072.pdf http://ntp-server.niehs.nih.gov/ http://ntp-server.niehs.nih.gov/ http://refhub.elsevier.com/S0273-2300(20)30146-X/sref22 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref22 https://doi.org/10.1093/mutage/geaa009 https://doi.org/10.1093/mutage/geaa009 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref24 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref24 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref24 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref24 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref24 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref25 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref25 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref26 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref26 Use compatibility intervals in regulatory toxicology 1 The problem 2 Principles for a new approach 3 Case studies 3.1 Multiple clinical chemistry endpoints in a repeated-dose toxicity study 3.2 Compatibility with multiple models 3.3 Comparing intervals with historical controls 4 Conclusions Declaration of competing interest Acknowledgment References", "Acknowledgement": "Acknowledgment The authors would like thank the both reviewers for targeted notices and Blair Johnston for his helpful comments for improving the manuscript. National Toxicology Program. 13 Weeks Gavage Study on Female F344 Rats Administered with Sodium Dichromate Dihydrate (VI) (CASRN: 7789-12-0, Study Number: C20114,TDMS Number:2011402. National Toxicology Program, 2019. Statistical Procedures. Expanded Overview. htt p://ntp-server.niehs.nih.gov/. Pallmann, P., Hothorn, L.A., 2016. Boxplots for grouped and clustered data in toxicology. Arch. Toxicol. 90 (7), 1631\u20131638. Pfuhler, S., Pirow, R., Downs, T., Haase, A., Hewitt, N., Luch, A., Merkel, M., Petrick, C., Said, A., Schaefer-Korting, M., Reisinger, K., 2020. Validation of the 3D reconstructed human skin Comet assay, an animal-free alternative for following-up positive results from standard in vitro genotoxicity assays. Mutagenesis. https://doi. org/10.1093/mutage/geaa009. Reisinger, K., Blatz, V., Brinkmann, J., Downs, T.R., Fischer, A., Henkler, F., Hoffmann, S., Krul, C., Liebsch, M., Luch, A., Pirow, R., Reus, A.A., Schulz, M., Pfuhler, S., 2018. Validation of the 3d skin comet assay using full thickness skin models: transferability and reproducibility. Mutat. Res. Genet. Toxicol. Environ. Mutagen 827, 27\u201341. Schmidt, S., Brannath, W., 2015. Informative simultaneous confidence intervals for the fallback procedure. Biom. J. 57 (4), 712\u2013719. Shirley, E., 1977. A nonparametric equivalent of Williams\u2019 test for contrasting increasing dose levels of a treatment. Biometrics 33 (2), 386\u2013389. L.A. Hothorn and Ralph Pirow http://refhub.elsevier.com/S0273-2300(20)30146-X/sref11 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref12 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref12 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref12 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref14 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref14 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref15 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref15 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref16 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref16 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref17 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref17 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref18 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref18 https://ntp.niehs.nih.gov/ntp/htdocs/st%20rpts/tox072.pdf https://ntp.niehs.nih.gov/ntp/htdocs/st%20rpts/tox072.pdf http://ntp-server.niehs.nih.gov/ http://ntp-server.niehs.nih.gov/ http://refhub.elsevier.com/S0273-2300(20)30146-X/sref22 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref22 https://doi.org/10.1093/mutage/geaa009 https://doi.org/10.1093/mutage/geaa009 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref24 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref24 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref24 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref24 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref24 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref25 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref25 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref26 http://refhub.elsevier.com/S0273-2300(20)30146-X/sref26 Use compatibility intervals in regulatory toxicology 1 The problem 2 Principles for a new approach 3 Case studies 3.1 Multiple clinical chemistry endpoints in a repeated-dose toxicity study 3.2 Compatibility with multiple models 3.3 Comparing intervals with historical controls 4 Conclusions Declaration of competing interest Acknowledgment References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-Health-Hazard-Criteria-for-Estimating-the-Haz_2000_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/10715219", "content": {"Acknowledgement": "CONCLUSIONS ACKNOWLEDGMENT REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-a-probabilistic-PBPK-PD-model-to-calculate-D_2017_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28238854", "content": {"Acknowledgement": "4. Discussion Acknowledgements Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Use-of-alternative-test-methods-in-a-tiered-testing-ap_2022_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34953932", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 4 Discussion 5 Conclusion Role of the funding source CRediT authorship contribution statement Declaration of competing interest Acknowledgements References", "Funding": "For those materials that demonstrated significant absorbance and lacked available photoirritation data, the 3T3 NRU Phototoxicity Test was conducted. The current data set indicated that about 81% of the 108 materials tested in the 3T3 NRU Phototoxicity Test were predicted not to be photoirritants, again eliminating the need for further testing for photoirritation. Materials that were predicted to be photoirritants or probable photoirritants in the 3T3 NRU Phototoxicity Test were then evaluated in the RhE phototoxicity test. Three concentrations were chosen based on maximum dermal concentration data from the Creme RIFM Aggregate Exposure Model. The concentrations typically flanked the maximum dermal concentration in finished consumer products where UV exposure was likely; applications or finished products where consumers would be unlikely to be exposed to UV irradiation, for example, fragranced candles, were not included. If photoirritation was not observed in the RhE phototoxicity assay, i.e., increased cytotoxicity in light exposed tissues compared to dark-exposed tissues did not exceed 30%, the same concentrations were investigated in a human photo- irritation test, to confirm a no-effect level for photoirritation. In all cases, the NOEL for photoirritation was the highest concentration tested, and there were no adverse events in any of our human photoirritation tests. Of course, this process evolved, and refinements were made along the way. One refinement made was analyzing all available dermal data, such as skin irritation and skin sensitization data, before conducting human photoirritation testing. Another refinement made to the process is to have data to support each of the doses used in the human photoirritation test. Again, we observed no effects in our human photoirritation tests, but these measures added another layer of safety to the testing. We also employed the use of read-across to eliminate the need for testing in a few cases, keeping costs down while at the same time ensuring consumer safety. Typically read-across used at this stage of the tiered process was for the purpose of preventing duplicative testing of materials that were structurally very similar, for example, Vanillin and Ethyl vanillin. Finally, it should be noted that once a maximum acceptable concen- tration level was determined for photoirritation, a local skin effect, other endpoints including systemic endpoints, skin sensitization, and any other endpoint evaluated in the RIFM Fragrance Material Safety Assessment were considered. The maximum acceptable concentration for each product category was based on the lowest maximum acceptable concentration across the endpoints, thus ensuring the safe use of fragrance materials for consumer enjoyment. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Role of the funding source Role of the funding source There were no outside funding sources for the research nor the preparation of the submitted article. Likewise, there was no outside influence or involvement in the study design, data collection, analysis or interpretation of data or in the writing of the report. There was no outside influence in the decision to submit the article for publication. There were no outside funding sources for the research nor the preparation of the submitted article. Likewise, there was no outside influence or involvement in the study design, data collection, analysis or interpretation of data or in the writing of the report. There was no outside influence in the decision to submit the article for publication. CRediT authorship contribution statement 4 Discussion 5 Conclusion Role of the funding source CRediT authorship contribution statement Declaration of competing interest Acknowledgements References", "Acknowledgement": "Acknowledgements Georgia Price, IIVS. 4 Discussion 5 Conclusion Role of the funding source CRediT authorship contribution statement Declaration of competing interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-an-aggregate-exposure-model-to-estimate-consume_2015_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26071898", "content": {"CoiStatement": "The results viewer in the model allows visualisation of the exposure results through various chart types (pie charts (Fig. 3), box-and-whisker plots (see Figs. 1, 2, 4). Moreover, for dermal exposure it is possible to investigate which products contributed to the aggregate exposure to each application site. Currently the Creme RIFM model provides estimates of aggre- gate exposure to fragrance ingredients by combining individual product exposures from dermal and oral personal care and cosmet- ics in populations in Europe and the USA. Recognising that there is a limited understanding of levels of fragrance ingredients currently used in fragrance mixtures, and levels of incorporation of these fra- grance mixtures in products, RIFM has now completed a wide- spread industry survey to collect more accurate and representative data which will be used in the model. This, along with measured skin penetration data of the fragrances, including the effect that volatility may have on this, will make the output more robust. Further expansion of the model to include further personal care products (such as hand soap), household care prod- ucts, in-house (and in-car) fragrance products, and foods (where fragrance ingredients may also be used as flavour components) is ongoing and will provide more accurate determinations of aggre- gate consumer exposure. Given the diversity of the products, routes of exposure are also being expanded to cover oral and inhalation as appropriate. A further publication will follow which will describe the enhancements to the model currently being made. Where consumer data are available, it is also planned to extend the model to other areas of the world such as Asia. The model may be used for other types of ingredients that are used in multiple products, such as preservatives, extending its useful- ness to wider industry and regulators. Conflict of interest This research was supported entirely by the Research Institute for Fragrance Materials, Inc. Transparency Document The Transparency document associated with this article can be found in the online version. References Cadby, P.A., Troy, W.R., Vey, M.G., 2002. Consumer exposure to fragrance ingredients: providing estimates for safety evaluation. Regul. Toxicol. Pharmacol. 36 (3), 246\u2013252. Comiskey, D., Safford, B., Api, A.M., Clapp, C., Ellis, G., Daly, E.J., McNamara, C., O\u2019Mahony, C., Robison, S., Smith, B., Tozer, S., 2015. Novel database for exposure to cosmetics and personal care products. Regul. Toxicol. Pharmacol. http:// dx.doi.org/10.1016/j.yrtph.2015.05.012, in press. Cowan-Ellsberry, C.E., Robison, S.H., 2009. Refining aggregate exposure: example using parabens. Regul. Toxicol. Pharmacol. 55 (3), 321\u2013329. European Commission Cosmetic Ingredient Database, CosIng. http://ec.europa. eu/consumers/consumers_safety/cosmetics/cosing/index_en.htm. Hall, B., Tozer, S., Safford, B., Coroama, M., Steiling, W., Leneveu-Duchemin, M.C., McNamara, C., Gibney, M., 2007. European consumer exposure to cosmetic products, a framework for conducting population exposure assessments. Food Chem. Toxicol. 45 (11), 2097\u20132108. Hall, B., Steiling, W., Safford, B., Coroama, M., Tozer, S., Firmani, C., McNamara, C., Gibney, M., 2011. European consumer exposure to cosmetic products, a http://dx.doi.org/10.1016/j.yrtph.2015.05.017 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0010 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0010 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0010 http://dx.doi.org/10.1016/j.yrtph.2015.05.012 http://dx.doi.org/10.1016/j.yrtph.2015.05.012 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0020 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0020 http://ec.europa.eu/consumers/consumers_safety/cosmetics/cosing/index_en.htm http://ec.europa.eu/consumers/consumers_safety/cosmetics/cosing/index_en.htm http://refhub.elsevier.com/S0273-2300(15)00123-3/h0035 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0035 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0035 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0035 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0040 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0040 682 B. Safford et al. / Regulatory Toxicology and Pharmacology 72 (2015) 673\u2013682 framework for conducting population exposure assessments Part 2. Food Chem. Toxicol. 49 (2), 408\u2013422. Loretz, L.J., Api, A.M., Barraj, L.M., Burdick, J., Dressler, W.E., Gettings, S.D., Han Hsu, H., Pan, Y.H., Re, T.A., Renskers, K.J., Rothenstein, A., Scrafford, C.G., Sewall, C., 2005. Exposure data for cosmetic products: lipstick, body lotion, and face cream. Food Chem. Toxicol. 43 (2), 279\u2013291. Loretz, L., Api, A.M., Barraj, L., Burdick, J., Davis de, A., Dressler, W., Gilberti, E., Jarrett, G., Mann, S., Laurie Pan, Y.H., Re, T., Renskers, K., Scrafford, C., Vater, S., 2006. Exposure data for personal care products: hairspray, spray perfume, liquid foundation, shampoo, body wash, and solid antiperspirant. Food Chem. Toxicol. 44 (12), 2008\u20132018. Loretz, L.J., Api, A.M., Babcock, L., Barraj, L.M., Burdick, J., Cater, K.C., Jarrett, G., Mann, S., Pan, Y.H., Re, T.A., Renskers, K.J., Scrafford, C.G., 2008. Exposure data for cosmetic products: facial cleanser, hair conditioner, and eye shadow. Food Chem. Toxicol. 46 (5), 1516\u20131524. McNamara, C., Rohan, D., Golden, D., Gibney, M., Hall, B., Tozer, S., Safford, B., Coroama, M., Leneveu-Duchemin, M.C., Steiling, W., 2007. Probabilistic modelling of European consumer exposure to cosmetic products. Food Chem. Toxicol. 45 (11), 2086\u20132096. Nohynek, G.J., Antignac, E., Re, T., Toutain, H., 2010. Safety assessment of personal care products/cosmetics and their ingredients. Toxicol. Appl. Pharmacol. 243 (2), 239\u2013259. Pauwels, M., Rogiers, V., 2010. Human health safety evaluation of cosmetics in the EU: A legally imposed challenge to science. Toxicol. Appl. Pharmacol. 243, 260\u2013 274. Politano, V.T., Diener, R.M., Christian, M.S., Hoberman, A.M., Palmer, A., Ritacco, G., Adams, T.B., Api, A.M., 2013. Oral and dermal developmental toxicity studies of phenylethyl alcohol in rats. Int. J. Toxicol. 32 (1), 32\u201338. SCCS (2012). The SCCS\u2019s notes of guidance for the testing of cosmetic substances and their safety evaluation (8th Revision), Available at: http://ec.europa.eu/ health/scientific_committees/consumer_safety/docs/sccs_s_006.pdf. Tozer, S.A., O\u2019Keefe, L., Cowan-Ellsberry, C.E., Rich, K., 2004. Use of probabilistic analysis in the refinement of exposure data for hydroalcoholic perfume products. Toxicology 202 (1\u20132), 123\u2013124. Ye, X., Bishop, A.M., Reidy, J.A., Needham, L.L., Calafat, A.M., 2006. Parabens as urinary biomarkers of exposure in humans. Environ. Health Perspect. 114, 1843\u20131846. http://refhub.elsevier.com/S0273-2300(15)00123-3/h0040 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0040 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0050 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0050 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0050 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0050 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0055 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0055 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0055 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0055 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0055 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0060 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0060 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0060 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0060 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0070 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0070 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0070 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0070 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0080 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0080 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0080 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0085 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0085 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0085 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0090 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0090 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0090 http://refhub.elsevier.com/S0273-2300(15)00123-3/h9000 http://refhub.elsevier.com/S0273-2300(15)00123-3/h9000 http://refhub.elsevier.com/S0273-2300(15)00123-3/h9000 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0100 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0100 http://refhub.elsevier.com/S0273-2300(15)00123-3/h0100 Use of an aggregate exposure model to estimate consumer exposure to fragrance ingredients in personal care and cosmetic products 1 Introduction 2 Materials and methods 2.1 The Creme RIFM aggregate exposure model 2.2 Fragrance ingredient investigated 2.3 Comparison of model results for aggregate systemic exposure with deterministic aggregate exposure calculations 3 Results 3.1 Applied product exposure from individual products 3.2 Aggregate product exposure from all assessed products 3.3 Aggregate exposure to individual application sites 3.4 Systemic exposure to PEA 3.5 Dermal exposure to PEA 3.6 Comparison of model results for aggregate systemic exposure with deterministic aggregate exposure calculations 4 Discussion Conflict of interest Transparency Document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-an-animal-model-of-disease-for-toxicology-enables-i_2021_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33961952", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Minh-Ha Thi Do and John C. McKew are employees of Lumos Pharma and have equity interests in Lumos Pharma. Joy Cavagnaro and Mark Butt are paid consultants of Lumos Pharma. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Minh-Ha Thi Do and John C. McKew are employees of Lumos Pharma and have equity interests in Lumos Pharma. Joy Cavagnaro and Mark Butt are paid consultants of Lumos Pharma. M.-H.T. Do et al. Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Funding": "Funding This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors. This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors. CRediT authorship contribution statement Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Acknowledgement": "The use of animal models of disease for toxicology is therefore not without its challenges. Yet, normal, healthy animals that are typically utilized for pre-clinical safety evaluation may not predict human risk in all instances. The use of animal models of disease is increasing, due in part to acknowledgement in regulatory guidance (US FDA CDER CBER, 2019; US FDA CDER, 2019; ICH, 2011). For example, utilization of a disease model for toxicology led to identification of an appropriate dosing regimen and safety biomarkers to enable the development of recombinant enzyme replacement therapy in sphingomyelinase deficiency (Murray et al., 2015). Advantages of disease model use include improved prediction of exposure, activity and toxicity, direct estimation of therapeutic index, and identification of findings with increased sensitivity in disease state (Cavagnaro and Lima, 2015) \u2013 all of which may have been identified in the cyclocreatine studies. Prior to conducting the toxicology study in CT KO mice, studies of cyclocreatine in conventional, WT animals resulted in severe toxicity and precluded defining a NOAEL in, notably, the juvenile rat; CTD is a progressive disease where intervening early would likely be crucial. Transitioning the program to the CT KO mice revealed a markedly different toxicity profile and enabled definition of a NOAEL in juvenile animals. Together with defining an MED in a similar ubiquitous KO model (Cacciante et al., 2020), a positive benefit:risk ratio was identified and the therapeutic index could be directly calculated. The program was also successful in identification of hazards that appear to be specific to or more sensitive in the disease model (e.g., bone mineral density increases and brain vacuolation). Unfortunately, while the brain vacuolation in CT KO mice did not have functional correlates, it does pose a drug development challenge, as monitoring for vacuoles in patients may not be clinically feasible. Prior to embarking on the studies described herein, FDA\u2019s Division of Gastroenterology and Inborn Errors Products agreed that the hypothesis regarding toxicity was plausible and that the pro- posed study designs (the biodistribution and 3-month toxicology studies described here as well as a 6-month study in CT KO mice should the 3-month be successful), would meet the juvenile and chronic general toxicology requirements to support chronic dosing of cyclocreatine in pediatric CTD patients. However, the Agency stated that the final determination for this question would be based on review of all toxi- cology studies, including those in WT animals. At the end of the 3-month study in CT KO mice, despite the scientific successes described, the vacuolation findings were considered by Lumos Pharma to present a challenging development path which might involve exceedingly slow dose escalation and therefore an internal decision was made to halt development. The FDA was informed of the final study data and decision but no further regulatory discussions were pursued. Acknowledgements The authors acknowledge Cincinnati Children\u2019s Hospital Medical Center and Dr. Matthew Skelton (Cincinnati, OH) for licensure of the CT KO mouse strain. We acknowledge from the National Institutes of Health Dr. Xin Xu and Dr. Amy Q. Wang for the early mouse PK method development work and Dr. Elizabeth A. Ottinger for discussions about the toxicology findings, under the Therapeutics for Rare and Neglected Diseases program. For execution of the studies, we acknowledge Cova- nce (Greenfield, IN) for overall study conduct, Taconic Biosciences (Germantown, NY) for the CT KO mice breeding program, and Charles River Laboratories/MPI Research (Mattawan, MI) for bioanalytical and PK analysis. Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-an-in-vitro-human-skin-permeation-assay-to-assess_2016_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27816671", "content": {"Compliance with ethical standards": "McNeely, W., Spencer, C.M., 1998. Butenafine. Drugs 55, 405e412. Median, V.M., Roper, C.S., 2008. Inter- and intra-individual variability in human skin barrier function: a large scale retrospective study. Toxicol. Vitro 22, 1062e1069. Narkar, Y., 2010. Bioequivalence for topical products e an update. Pharm. Res. 27, 2590e2601. OECD series on principles of Good Laboratory Practice (GLP) and compliance monitoring. http://www.oecd.org/chemicalsafety/testing/ oecdseriesonprinciplesofgoodlaboratorypracticeglpandcompliancemonitoring. htm. monitoring. http://www.oecd.org/chemicalsafety/testing/ oecdseriesonprinciplesofgoodlaboratorypracticeglpandcompliancemonitoring. htm. OECD Guideline 428.http://www.oecd-ilibrary.org/environment/test-no-428-skin- absorption-in-vitro-method_9789264071087-en. http://dx.doi.org/10.1016/j.yrtph.2016.11.008 https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21408lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21408lbl.pdf http://refhub.elsevier.com/S0273-2300(16)30334-8/sref2 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref2 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref2 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref2 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref3 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref4 https://www.epa.gov/sites/production/files/2016-09/documents/triethylamine.pdf https://www.epa.gov/sites/production/files/2016-09/documents/triethylamine.pdf http://refhub.elsevier.com/S0273-2300(16)30334-8/sref6 http://www.accessdata.fda.gov/scripts/cder/iig/getiigWEB.cfm http://www.accessdata.fda.gov/scripts/cder/iig/getiigWEB.cfm http://refhub.elsevier.com/S0273-2300(16)30334-8/sref8 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref8 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref9 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref9 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref9 http://www.iarc.fr/ http://www.iarc.fr/ http://refhub.elsevier.com/S0273-2300(16)30334-8/sref11 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref11 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref11 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref12 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref12 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref12 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref13 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref13 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref13 http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails http://refhub.elsevier.com/S0273-2300(16)30334-8/sref15 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref15 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref16 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref16 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref16 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref17 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref17 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref17 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref17 http://www.oecd.org/chemicalsafety/testing/oecdseriesonprinciplesofgoodlaboratorypracticeglpandcompliancemonitoring.htm http://www.oecd.org/chemicalsafety/testing/oecdseriesonprinciplesofgoodlaboratorypracticeglpandcompliancemonitoring.htm http://www.oecd.org/chemicalsafety/testing/oecdseriesonprinciplesofgoodlaboratorypracticeglpandcompliancemonitoring.htm http://www.oecd-ilibrary.org/environment/test-no-428-skin-absorption-in-vitro-method_9789264071087-en http://www.oecd-ilibrary.org/environment/test-no-428-skin-absorption-in-vitro-method_9789264071087-en http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2004)2&amp;doclanguage=en http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2004)2&amp;doclanguage=en http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2004)2&amp;doclanguage=en http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2004)2&amp;doclanguage=en http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2004)2&amp;doclanguage=en http://refhub.elsevier.com/S0273-2300(16)30334-8/sref21 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref21 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref21 http://oehha.ca.gov/prop65/prop65_list/files/P65single062212.pdf http://oehha.ca.gov/prop65/prop65_list/files/P65single062212.pdf http://refhub.elsevier.com/S0273-2300(16)30334-8/sref23 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref23 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref23 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref23 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref23 http://refhub.elsevier.com/S0273-2300(16)30334-8/sref23 Use of an in vitro human skin permeation assay to assess bioequivalence of two topical cream formulations containing butena ... 1. Introduction 2. Materials & methods 2.1. Materials and reagents 2.2. Preparation of calibration standards and quality control samples 2.3. Sample preparation 2.3.1. Receptor fluid and skin wash 2.3.2. Skin, tape, tissue swabs, cling film and pipette tips (methanol extracts)"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-animals-for-toxicology-testing-is-necessary-t_2014_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25058855", "content": {"Acknowledgement": "Use of animals for toxicology testing is necessary to ensure patient safety in pharmaceutical development Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-background-inorganic-arsenic-exposures-to-p_2007_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/17346867", "content": {"Compliance with ethical standards": "60 J.S. Tsuji et al. / Regulatory Toxicology and Pharmacology 48 (2007) 59\u201368 Background inorganic arsenic intake in the U.S. has been investigated recently for children exposed through diet (Yost et al., 2004), and previously for all ages exposed through diet (Schoof et al., 1999b), and for diet, water, soil, and air (Meacher et al., 2002). This paper builds on that earlier work to conduct probabilistic analyses of back- ground inorganic arsenic intake for children (ages 1\u20136 years) and the general U.S. population (all ages) from the primary background sources, diet and water (Meacher et al., 2002). In comparison to the dietary intake modeling of Meacher et al. (2002), the more comprehensive dietary modeling reported by Yost et al. (2004) is used to estimate dietary and water intakes for the general U.S. population and for children ages 1\u20136 years. Our modeling also incor- porated reduction in arsenic drinking water concentrations in the U.S. as a result of the compliance with the arsenic standard reduction from 50 to 10 lg/L. As risk comparison examples, the results of this analysis are compared to arsenic intakes from soil exposure based on default EPA risk assessment assumptions and to estimated arsenic exposures from CCA-treated wood used for playsets and residential decks (U.S. EPA, 2005a; Zartarian et al., 2006)."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-benchmark-dose-and-meta-analysis-to-determine-_2005_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16099569", "content": {"Acknowledgement": "This article presents a meta-analysis of several rat tox- icity studies for dimethoate. Compared to the most sen- sitive subpopulation for brain cholinesterase inhibition (dams) for gavage exposure, the points-of-departure for risk assessment for cholinesterase inhibition is more than threefold lower than for pup mortality. Therefore, the use of cholinesterase inhibition as an endpoint for risk assessment is likely to be protective of pup mortality. A comparison of brain cholinesterase inhibition and pup mortality in the dietary studies shows that cholinesterase inhibition is about a 10-fold more sensitive endpoint than pup mortality. By route of exposure, the animals were about 2\u20133-fold more sensitive for brain cholinester- ase inhibition by gavage than by dietary exposure. For pup mortality, the animals were at least sixfold more sen- sitive by gavage exposure compared to dietary exposure. Acknowledgments This work was sponsored by Cheminova A/S. The authors wish to thank Paul Whatling, Diane Allemang, Dorrit S\u00f8ndergaard, Judith Hauswirth, Don O\ufffdShaugh- nessy, and Abby Li for their helpful comments. References Conclusion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-benchmark-dose-models-in-risk-assessment-for-oc_2020_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31655092", "content": {"CoiStatement": "The authors report no conflicts of interest. Funding in support of this analysis was provided by the NIEHS Environmental Toxicology and Pathology training grant T32ES007032 and the CDC/NIOSH Cooperative agreement U54 OH007544. The funding organizations had no influence on the planning, data collection, analysis, or manuscript preparation. Declaration of competing interest Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Dr. Pouzou reports previous consulting engagements with National Cattlemen\u2019s Beef Association and Tillotts Pharmaceuticals which were conducted after this study but prior to this publication, and unrelated to the study. Dr. Pouzou, Dr. Yost, and Dr. Fenske were supported from a grant from NIOSH/CDC cooperative agreement U54 OH007544 during the conduct of the study. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Dr. Pouzou reports previous consulting engagements with National Cattlemen\u2019s Beef Association and Tillotts Pharmaceuticals which were conducted after this study but prior to this publication, and unrelated to the study. Dr. Pouzou, Dr. Yost, and Dr. Fenske were supported from a grant from NIOSH/CDC cooperative agreement U54 OH007544 during the conduct of the study. Appendix A. Supplementary data", "Funding": "Funding The authors report no conflicts of interest. Funding in support of this analysis was provided by the NIEHS Environmental Toxicology and Pathology training grant T32ES007032 and the CDC/NIOSH Cooperative agreement U54 OH007544. The funding organizations had no influence on the planning, data collection, analysis, or manuscript preparation. The authors report no conflicts of interest. Funding in support of this analysis was provided by the NIEHS Environmental Toxicology and Pathology training grant T32ES007032 and the CDC/NIOSH Cooperative agreement U54 OH007544. The funding organizations had no influence on the planning, data collection, analysis, or manuscript preparation. Declaration of competing interest Discussion Funding mk:H1_27 Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-category-approaches--read-across-and--Q-_2013_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23764304", "content": {"CoiStatement": "3 Conclusions Conflict of interest statement Acknowledgments Appendix A Supplementary data References", "Acknowledgement": "3 Conclusions Conflict of interest statement Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-computational-tools-in-the-field-of_2011_Regulatory-Toxicology-and-Ph.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21600952", "content": {"CoiStatement": "Despite this variable situation, (Q)SAR analysis is widely per- ceived as a potential useful tool to support regulatory assessments in the field of food safety, and this justifies further exploration and development. In particular to promote the further use of the meth- ods, there is a need to perform focused substance evaluation stud- ies that better explore the potential of (Q)SAR analysis for application in specific situations, and there is a need to develop guidance documents and tools that will promote the harmonised use of (Q)SAR analysis in the different sectors. In addition, there is a widespread demand for training on the applications of (Q)SAR analysis in human dietary risk assessment. Conflict of interest statement All authors declared that no conflict of interest exist and signed a conflict of interest policy form. All authors declared that no conflict of interest exist and signed a conflict of interest policy form. Acknowledgments 4 Discussion: limitations of computational tools and suggestions for the future 5 Conclusions Conflict of interest statement Acknowledgments References", "Compliance with ethical standards": "FDA/OFAS guidance, 2002. Guidance for Industry \u2013Preparation of Notifications for Substamces: Toxicology Recommendations. Available at: <http://fda.gov/Food/ GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodIngredi- entsandPackaging/ucm081825.htm>. JRC (2010). Applicability of QSAR analysis to the evaluation of the toxicological relevance of metabolites and degradates of pesticide active substances for dietary risk assessment. Report from the European Commission\u2019s Joint Research Centre (JRC) to the European Food Safety Authority (EFSA). Available at: <http:// www.efsa.europa.eu/en/scdocs/scdoc/50e.htm>. http://www.epa.gov/opptintr/exposure/pubs/episuite.htm http://www.epa.gov/opptintr/exposure/pubs/episuite.htm http://fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodIngredientsandPackaging/ucm081825.htm http://fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodIngredientsandPackaging/ucm081825.htm http://fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodIngredientsandPackaging/ucm081825.htm http://www.efsa.europa.eu/en/scdocs/scdoc/50e.htm http://www.efsa.europa.eu/en/scdocs/scdoc/50e.htm http://appli1.oecd.org/olis/2006doc.nsf/linkto/env-jm-mono(2006)31 http://www.oecd.org/ http://www.oecd.org/ http://www.oecd.org/ http://guidance.echa.europa.eu/guidance_en.htm http://guidance.echa.europa.eu/guidance_en.htm http://www.nap.edu/catalog.php?record_id=11970#toc http://www.nap.edu/catalog.php?record_id=11970#toc http://www.epa.gov/fedrgstr/EPA-PEST/2008/October/Day-08/p23127.pdf http://www.epa.gov/fedrgstr/EPA-PEST/2008/October/Day-08/p23127.pdf http://www.epa.gov/spc/toxicitytesting/docs/toxtest_strategy_032309.pdf http://www.epa.gov/spc/toxicitytesting/docs/toxtest_strategy_032309.pdf Use of computational tools in the field of food safety 1 Introduction 2 Methods 3 Results 3.1 Use of computational tools in US EPA OSCPP (Office of Chemical Safety and Pollution Prevention), Office of Pesticide Programs 3.1.1 Long term vision for application of integrated testing and assessment tools 3.1.2 Application of QSAR for hazard assessment for metabolites, environmental degradates and impurities 3.1.3 Application of QSAR in establishing \u201cThreshold of Toxicological Concern\u201d, non-animal eye irritation study and antimicrobial hazard 3.1.4 Application of QSAR in ecological risk assessment", "Acknowledgement": "Acknowledgments This work was carried out under the terms of a Grant awarded by EFSA to the European Commission Joint Research Centre, Insti- tute for Health & Consumer Protection, Ispra, Italy (Contract No.: SLA/EFSA-JRC/2009-01). Chihae Yang thanks the US FDA CFSAN CERES team for allowing description of the CERES system. 4 Discussion: limitations of computational tools and suggestions for the future 5 Conclusions Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-computational-toxicology--CompTox--tools-to_2020_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32640296", "content": {"CoiStatement": "4 Discussion and conclusions Funding Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Funding": "4 Discussion and conclusions Funding Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Acknowledgement": "4 Discussion and conclusions Funding Declaration of competing interest Acknowledgements Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-dose-dependent-absorption-into-target-tissues-to_2015_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25445295", "content": {"CoiStatement": "Conflict of interest Nothing to disclose. Use of dose-dependent absorption into target tissues to more accurately predict cancer risk at low oral doses of hexavalent chromium 1 Introduction 2 Materials and methods 3 Results and discussion 4 Conclusions Conflict of interest Acknowledgements References", "Acknowledgement": "Acknowledgements The author would like to thank the staff and management of the Toxicology Division of the TCEQ as well as the rest of the agency for their support in developing an important manuscript. The views and conclusions expressed herein may be those of the study author and not necessarily those of the TCEQ. Use of dose-dependent absorption into target tissues to more accurately predict cancer risk at low oral doses of hexavalent chromium 1 Introduction 2 Materials and methods 3 Results and discussion 4 Conclusions Conflict of interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-in-silico-systems-and-expert-knowledge-for-str_2013_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23669331", "content": {"CoiStatement": "7. Re-evaluation of synthesis intermediates and impurities of adrug substance during drug development 8. Summary 9. Conclusion Conflict of interest statement Acknowledgements Appendix A. Appendix B. Appendix C. References", "Acknowledgement": "7. Re-evaluation of synthesis intermediates and impurities of adrug substance during drug development 8. Summary 9. Conclusion Conflict of interest statement Acknowledgements Appendix A. Appendix B. Appendix C. References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Use-of-in-vitro-metabolism-and-biokinetics-assays-to-refin_2022_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/35217105", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 4 Discussion 5 Conclusion Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Funding": "Funding This work was funded through the Long Range Science Strategy (LRSS) programme of Cosmetics Europe (available at https://www.lrss cosmeticseurope.eu). 4 Discussion 5 Conclusion Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data References", "Acknowledgement": "Acknowledgements Thanks to Przemyslaw Piechota for providing the Meteor analysis. 4 Discussion 5 Conclusion Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgements Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-less-than-lifetime--LTL--durational-limits-for_2021_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33862169", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Some of the authors are employed by pharmaceutical companies The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Some of the authors are employed by pharmaceutical companies Acknowledgements 3 Results 4 Discussion 5 Conclusions Disclosures Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgements References", "Disclosure": "Disclosures Opinions expressed in this paper do not necessarily reflect the views or policies of the Brazilian Health Regulatory Agency (ANVISA). 3 Results 4 Discussion 5 Conclusions Disclosures Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgements References", "Funding": "Funding The following manuscript was not funded. 3 Results 4 Discussion 5 Conclusions Disclosures Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgements References", "Acknowledgement": "Acknowledgements We acknowledge Joanne Birkebak (Gilead Sciences), Roy Bannister (Gilead Sciences), Eric Dowdy (Gilead Sciences), Krista Dobo (Pfizer), Ron Ogilvie (Pfizer), Olivier Dirat (Pfizer), Jim Harvey (GlaxoSmithK- line), Anthony Lynch (GlaxoSmithKline), and Susanne Stalford (Lhasa) for their review of the manuscript. 3 Results 4 Discussion 5 Conclusions Disclosures Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-low-dose-clinical-pharmacodynamic-and-pharmacokineti_2013_Regulatory-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23851069", "content": {"CoiStatement": "Conflict of interest The authors are all stockholders and/or employees of Bristol- Myers Squibb Co. 4 Discussion 5 Conclusions Funding information Conflict of interest Acknowledgments References", "Funding": "Funding information The clinical study was funded by Bristol-Myers Squibb Co. and AstraZeneca. 4 Discussion 5 Conclusions Funding information Conflict of interest Acknowledgments References", "Compliance with ethical standards": "FDA, 2005. Guidance for industry: estimating the maximum safe dose in initial clinical trials for therapeutics in adult healthy volunteers. Available from: <http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM078932.pdf> J:\\!GUIDANC\\5541fnlcln1.doc U.S. Department of Health and Human Services Food and Drug AdministrationCenter for Drug Evaluation and Research Pharmacology and Toxicology, 2005. Francis, J., Zhang, J., et al., 2004. A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association \u2013 European Renal Association 19 (11), 2893\u20132895. http://refhub.elsevier.com/S0273-2300(13)00104-9/h0005 http://refhub.elsevier.com/S0273-2300(13)00104-9/h0005 http://refhub.elsevier.com/S0273-2300(13)00104-9/h0005 http://refhub.elsevier.com/S0273-2300(13)00104-9/h0005 http://refhub.elsevier.com/S0273-2300(13)00104-9/h0010 http://refhub.elsevier.com/S0273-2300(13)00104-9/h0010 http://refhub.elsevier.com/S0273-2300(13)00104-9/h0010 http://refhub.elsevier.com/S0273-2300(13)00104-9/h0010 http://refhub.elsevier.com/S0273-2300(13)00104-9/h0015 http://refhub.elsevier.com/S0273-2300(13)00104-9/h0015 http://www.epa.gov/raf/publications/pdfs/rfd-final.pdf http://www.epa.gov/raf/publications/pdfs/rfd-final.pdf http://hero.epa.gov/index.cfm?action=reference.download&amp;reference_id=786546 http://hero.epa.gov/index.cfm?action=reference.download&amp;reference_id=786546 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078932.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078932.pdf http://refhub.elsevier.com/S0273-2300(13)00104-9/h0025 http://refhub.elsevier.com/S0273-2300(13)00104-9/h0025 http://refhub.elsevier.com/S0273-2300(13)00104-9/h0025 http://refhub.elsevier.com/S0273-2300(13)00104-9/h0025 http://refhub.elsevier.com/S0273-2300(13)00104-9/h0030 http://refhub.elsevier.com/S0273-2300(13)00104-9/h0030 http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3C/Step4/Q3C_R5_Step4.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3C/Step4/Q3C_R5_Step4.pdf http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3C/Step4/Q3C_R5_Step4.pdf http://refhub.elsevier.com/S0273-2300(13)00104-9/h0035 http://refhub.elsevier.com/S0273-2300(13)00104-9/h0035 http://refhub.elsevier.com/S0273-2300(13)00104-9/h0035 http://refhub.elsevier.com/S0273-2300(13)00104-9/h0040 http://refhub.elsevier.com/S0273-2300(13)00104-9/h0040 http://refhub.elsevier.com/S0273-2300(13)00104-9/h0040 http://refhub.elsevier.com/S0273-2300(13)00104-9/h0045 http://refhub.elsevier.com/S0273-2300(13)00104-9/h0045 http://refhub.elsevier.com/S0273-2300(13)00104-9/h0045 J.C. Gould et al. / Regulatory Toxicology and Pharmacology 67 (2013) 89\u201397 97 Lewis, S.C., Lynch, J.R., et al., 1990. A new approach to deriving community exposure guidelines from \u2018\u2018no-observed-adverse-effect-levels\u2019\u2019. Regulatory Toxicology and Pharmacology 11, 314\u2013330.", "Acknowledgement": "Acknowledgments The invaluable contributions of Thomas L. Hunt, MD, PhD (the Principal Investigator), En-Yi Hsiao, MS, Balasubrahmanyam Bud- da, PhD, all employees of PPD, Inc. at the time the clinical study was conducted, for their contributions to the clinical study con- duct, statistical analyses and analysis of pharmacokinetic and pharmacodynamic data, respectively. The role of the participants in the clinical study is gratefully acknowledged. Special thanks to Anna Marie Gonzalez, Hua Yao, Carlos Aponte, RN, Maria Torres- Riveria, RN, and the operators in the manufacture of dapagliflozin. Also, thanks to Drs. Todd Davidson, Jessica Graham and Mark Tir- menstein, for their thoughtful review and suggestions on the man- uscript. We thank Esther Dodge and Mark Pownall from inScience Communications (a Springer Healthcare business), who provided editorial support funded by Bristol-Myers Squibb Co. and AstraZeneca. 4 Discussion 5 Conclusions Funding information Conflict of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-mechanistic-information-to-derive-chemical-sp_2020_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32871170", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. WHO IPC Smeraldi, 2005. Chemical-specific Adjustment Factors for Interspecies Differences and Human Variability: Guidance Document for Use of Data in Dose/concentration Response Assessment (Harmonization Project Document No. 2. http://wholibdoc. who.int/publications/2005/9241546786_eng.pdf. Walker, K., Hattis, D., Russ, A., Sonawane, B., Ginsberg, G., 2007. Approaches to acrylamide physiologically based toxicokinetic modeling for exploring child\u2013adult dosimetry differences. J. Toxicol. Environ. Health Part A 70 (24), 2033\u20132055. C. Smeraldi et al. http://refhub.elsevier.com/S0273-2300(20)30202-6/sref26 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref26 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref27 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref27 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref28 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref28 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref28 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref30 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref30 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref30 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref31 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref31 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref32 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref32 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref32 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref33 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref33 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref33 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref33 https://www.epa.gov/sites/production/files/2015-01/documents/ddef-final.pdf https://www.epa.gov/sites/production/files/2015-01/documents/ddef-final.pdf http://refhub.elsevier.com/S0273-2300(20)30202-6/sref35 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref35 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref36 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref36 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref37 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref37 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref37 http://wholibdoc.who.int/publications/2005/9241546786_eng.pdf http://wholibdoc.who.int/publications/2005/9241546786_eng.pdf http://refhub.elsevier.com/S0273-2300(20)30202-6/sref39 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref39 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref39 Use of mechanistic information to derive chemical-specific adjustment factors \u2013 Refinement of risk assessment 1 Introduction 2 Material and methods 2.1 Theory 3 Calculations 4 Results 4.1 Interspecies and intraspecies toxicodynamic factor 4.2 Kinetic factor 5 Discussion 6 Conclusion Declaration of competing interest Acknowledgement Appendix A Supplementary data References", "Funding": "The authors would like to express thanks to Olaf Mosbach Schulz, EFSA (Parma, Italy) for his help with the distribution modeling. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Appendix A. Supplementary data", "Acknowledgement": "Acknowledgement The authors would like to express thanks to Olaf Mosbach Schulz, EFSA (Parma, Italy) for his help with the distribution modeling. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. WHO IPC Smeraldi, 2005. Chemical-specific Adjustment Factors for Interspecies Differences and Human Variability: Guidance Document for Use of Data in Dose/concentration Response Assessment (Harmonization Project Document No. 2. http://wholibdoc. who.int/publications/2005/9241546786_eng.pdf. Walker, K., Hattis, D., Russ, A., Sonawane, B., Ginsberg, G., 2007. Approaches to acrylamide physiologically based toxicokinetic modeling for exploring child\u2013adult dosimetry differences. J. Toxicol. Environ. Health Part A 70 (24), 2033\u20132055. C. Smeraldi et al. http://refhub.elsevier.com/S0273-2300(20)30202-6/sref26 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref26 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref27 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref27 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref28 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref28 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref28 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref30 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref30 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref30 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref31 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref31 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref32 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref32 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref32 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref33 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref33 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref33 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref33 https://www.epa.gov/sites/production/files/2015-01/documents/ddef-final.pdf https://www.epa.gov/sites/production/files/2015-01/documents/ddef-final.pdf http://refhub.elsevier.com/S0273-2300(20)30202-6/sref35 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref35 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref36 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref36 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref37 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref37 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref37 http://wholibdoc.who.int/publications/2005/9241546786_eng.pdf http://wholibdoc.who.int/publications/2005/9241546786_eng.pdf http://refhub.elsevier.com/S0273-2300(20)30202-6/sref39 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref39 http://refhub.elsevier.com/S0273-2300(20)30202-6/sref39 Use of mechanistic information to derive chemical-specific adjustment factors \u2013 Refinement of risk assessment 1 Introduction 2 Material and methods 2.1 Theory 3 Calculations 4 Results 4.1 Interspecies and intraspecies toxicodynamic factor 4.2 Kinetic factor 5 Discussion 6 Conclusion Declaration of competing interest Acknowledgement Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-mixed-effect-models-and-tolerance-limits-to-evalua_2011_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21315130", "content": {"CoiStatement": "Conflicts of interest The authors have no conflicts of interest to disclose. The authors have no conflicts of interest to disclose. Acknowledgements Discussion Conclusions Conflicts of interest Acknowledgements References", "Acknowledgement": "Acknowledgements The authors would like to thank the following MPI Research personnel for their collaboration and assistance in compiling body weight data: Gerri Boyd, Frank Bell, Crystal Diabo, and Brenda Frantz. This work was presented at the 2010 Society of Toxicology Annual Meeting. Discussion Conclusions Conflicts of interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-mode-of-action-in-risk-assessment--Pas_2005_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/15896438", "content": {"Compliance with ethical standards": "US Environmental Protection Agency (USEPA), 2001d. National Primary Drinking Water Regulations: Arsenic and ClariWcations to Compliance and New Source Contaminants Monitoring. Final Rule. 40 CFR Parts 141 and 142, Fed. Reg. 66 (14), 6976\u2013 7066. U.S. Environmental Protection Agency (USEPA), 2002a. Guidance on Cumulative Risk Assessment of Pesticide Chemicals That Have a Common Mechanism of Toxicity. OYce of Pesticide Programs, USEPA, Washington, DC.", "Acknowledgement": "Summary Acknowledgments References Further reading"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-nonclinical-toxicity-studies-to-support-b_2021_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33662478", "content": {"CoiStatement": "Declaration of competing interest Herve Lebrec, Monica Ramchandani, Vincent Chow are Amgen employees and stockholders. Beth Hinkle, HM, Lauren Mihalcik were employees of Amgen at the time this work was done. Beth Hinkle and Lauren Mihalcik own Amgen stock. Use of nonclinical toxicity studies to support biosimilar antibody development 1 Commentary 2 Discussion Funding Declaration of competing interest Acknowledgements References", "Funding": "Funding The studies and the writing of this manuscript were funded by Amgen Inc. Use of nonclinical toxicity studies to support biosimilar antibody development 1 Commentary 2 Discussion Funding Declaration of competing interest Acknowledgements References", "Acknowledgement": "Acknowledgements Medical writing support provided by Annette Skorupa, PhD (Inno- vation Communications Group, New York, New York) under the direc- tion of Monica Ramchandani, PhD (Amgen, Inc., California, USA). Medical writing support was funded by Amgen Inc. Use of nonclinical toxicity studies to support biosimilar antibody development 1 Commentary 2 Discussion Funding Declaration of competing interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-read-across-and-computer-based-predictive-an_2015_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25659490", "content": {"Acknowledgement": "Acknowledgments The authors gratefully acknowledge Tanya Fitzgerald, chemical information specialist at Procter & Gamble, for her expertise and attention to detail in reviewing chemical structure/CAS No. designations. Appendix A. Supplementary data 4 Discussion 5 Conclusion Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-read-across-and-tiered-exposure-assessment-in-r_2010_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20394791", "content": {"CoiStatement": "For the safety assessment of chemicals a category level, a mind set change and a revision of the paradigm of traditional risk assess- ment is urgently needed (Schaafsma et al., 2009). Data on individ- ual substances that is insufficient as such may provide useful information in a chemical group approach. In vitro assays, possibly not acceptable as stand-alone tests for systemic toxicity endpoints (SCCNFP, 2004), could provide a mechanistic basis for the use of read-across or substantiate trends observed within a chemical cat- egory. In any case, filling the data gaps for REACH without exten- sive animal testing will require intelligent and efficient use of data regarding the assessment of both hazard and exposure. Conflict of interest statement The authors declare that there are no conflicts of interest. Acknowledgments The authors declare that there are no conflicts of interest. Acknowledgments The authors thank Willem Faber (on behalf of LyondellBasell Industries) for suggestions for the paper. The financial support pro- vided by the Dutch Ministry of Social Affairs and Employment is gratefully acknowledged. Risk characterisation Discussion Conflict of interest statement Acknowledgments References", "Acknowledgement": "The authors declare that there are no conflicts of interest. Acknowledgments The authors thank Willem Faber (on behalf of LyondellBasell Industries) for suggestions for the paper. The financial support pro- vided by the Dutch Ministry of Social Affairs and Employment is gratefully acknowledged. Risk characterisation Discussion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-rodent-data-for-cancer-risk-assessment-of-s_2017_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28625913", "content": {"Compliance with ethical standards": "USFDA, 2015. Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. M7(R1) Addendum to ICH M7. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Silver Springs, MD https://www.fda.gov/downloads/ drugs/guidancecomplianceregulatoryinformation/guidances/ucm347725.pdf. USFDA, 2016. Food and Drug Administration. Survey Data on Acrylamide in Food: Individual Food Products. http://www.fda.gov/Food/ FoodborneIllnessContaminants/ChemicalContaminants/ucm053549.htm. http://refhub.elsevier.com/S0273-2300(17)30174-5/sref95 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref96 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref96 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref96 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref96 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref97 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref97 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref97 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref97 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref98 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref98 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref98 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref99 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref99 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref99 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref100 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref100 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref100 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref100 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref100 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref100 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref101 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref101 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref101 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref101 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref102 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref102 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref102 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref102 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref102 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref102 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref102 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref102 http://www.harmreductionjournal.com/content/8/1/11 http://www.harmreductionjournal.com/content/8/1/11 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref104 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref104 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref104 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref104 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref105 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref105 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref105 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref105 http://ec.europa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_013.pdf http://ec.europa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_013.pdf http://refhub.elsevier.com/S0273-2300(17)30174-5/sref107 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref107 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref107 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref107 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref108 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref108 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref108 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref108 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref109 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref109 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref109 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref109 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref109 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref109 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref110 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref110 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref110 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref110 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref111 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref111 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref111 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref111 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref111 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref112 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref112 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref112 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref112 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref112 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref112 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref112 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref113 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref113 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref113 https://www.folkhalsomyndigheten.se/the-public-health-agency-of-sweden/living-conditions-and-lifestyle/ https://www.folkhalsomyndigheten.se/the-public-health-agency-of-sweden/living-conditions-and-lifestyle/ https://www.folkhalsomyndigheten.se/livsvillkor-levnadsvanor/alkohol-narkotika-dopning-tobak-och-spel-andts/tobak/snusbruk-och-halsorisker/ https://www.folkhalsomyndigheten.se/livsvillkor-levnadsvanor/alkohol-narkotika-dopning-tobak-och-spel-andts/tobak/snusbruk-och-halsorisker/ http://refhub.elsevier.com/S0273-2300(17)30174-5/sref116 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref116 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref116 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref116 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref117 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref117 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref117 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref117 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref118 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref118 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref118 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref118 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref119 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref119 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref119 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref120 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref120 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref120 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref120 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref121 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref121 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref121 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref121 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref122 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref122 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref122 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref122 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref122 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref122 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref122 https://cfpub.epa.gov/ncea/iris/iris_documents/documents/subst/0286_summary.pdf https://cfpub.epa.gov/ncea/iris/iris_documents/documents/subst/0286_summary.pdf http://refhub.elsevier.com/S0273-2300(17)30174-5/sref124 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref124 https://www.fda.gov/downloads/Food/GuidanceRegulation/UCM222779.pdf https://www.fda.gov/downloads/Food/GuidanceRegulation/UCM222779.pdf https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm347725.pdf https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm347725.pdf http://www.fda.gov/Food/FoodborneIllnessContaminants/ChemicalContaminants/ucm053549.htm http://www.fda.gov/Food/FoodborneIllnessContaminants/ChemicalContaminants/ucm053549.htm http://refhub.elsevier.com/S0273-2300(17)30174-5/sref128 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref128 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref128 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref129 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref129 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref130 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref130 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref130 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref130 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref131 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref131 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref131 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref132 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref132 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref132 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref132 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref133 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref133 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref133 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref134 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref134 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref134 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref134 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref135 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref135 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref135 http://www.bat-science.com/groupms/sites/bat_9gvjxs.nsf/vwPagesWebLive/DO7AXL9M/&dollar;FILE/medMD7DTDGU.pdf?openelement http://www.bat-science.com/groupms/sites/bat_9gvjxs.nsf/vwPagesWebLive/DO7AXL9M/&dollar;FILE/medMD7DTDGU.pdf?openelement http://refhub.elsevier.com/S0273-2300(17)30174-5/sref137 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref137 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref137 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref137 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref137 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref138 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref138 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref138 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref138 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref139 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref139 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref139 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref139 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref140 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref140 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref140 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref140 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref141 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref141 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref141 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref142 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref142 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref142 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref142 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref143 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref143 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref143 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref143 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref143 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref144 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref144 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref144 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref144 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref145 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref145 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref145 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref146 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref146 http://refhub.elsevier.com/S0273-2300(17)30174-5/sref146 Use of rodent data for cancer risk assessment of smokeless tobacco in the regulatory context 1. Main objectives 2. Background 3. Historical exposures to swedish snus 4. Rodent bioassays 4.1. Bioassays involving smokeless tobacco 4.2. The use of TD50 4.3. Accumulated lifetime dose"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-social-media-to-establish-vapers-puffing-behavio_2019_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31310846", "content": {"CoiStatement": "Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. Conflicts of interest The study was funded by British American Tobacco (BAT). At the time of the study all authors were employers of BAT. Conclusion Funding Declaration of interests Conflicts of interest Transparency document Supplementary data References", "Funding": "Funding The study was funded by British American Tobacco. Conclusion Funding Declaration of interests Conflicts of interest Transparency document Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-stem-cells-as-alternative-methods-to-animal_2019_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30930176", "content": {"CoiStatement": "Conclusion Conflicts of interest Acknowledgements Transparency document References", "Acknowledgement": "Conclusion Conflicts of interest Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-the-kinetically-derived-maximum-dose--Oppo_2020_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32645428", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Use of the kinetically-derived maximum dose: Opportunities for delivering 3Rs benefits Funding body information Declaration of competing interest References", "Funding": "Funding body information This work was conducted in the course of the authors\u2019 employment (see affiliations). Use of the kinetically-derived maximum dose: Opportunities for delivering 3Rs benefits Funding body information Declaration of competing interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-the-kinetically-derived-maximum-dose-concept-in-s_2020_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32334038", "content": {"CoiStatement": "All in all, the selection of maximum doses in toxicity testing is an important and complicated issue, given that the studies should be performed in a such way that the data generated are adequate to fulfil all regulatory requirements.(see also Woutersen et al. (2020). Con- sideration should be given to the Benchmark Dose (BMD) approach, in which it is possible to use more dose groups with smaller group sizes, and the highest dose can be interrupted if the animals appear to suffer. In the BMD approach, the maximal safe or acceptable dose is derived by fitting a curve through all dose-response data, instead of taking the highest tested dose level that produced no significant adverse response. It may even be considered that a redistribution of the animals from high to low dose groups might reduce their overall distress, without im- pairing or even improving the quality of the BMD estimate compared to designs with equally large dose groups (Kalantari et al., 2017). 4. Conclusion and way forward In conclusion, the KMD concept is not a valid approach for deriving the top dose in toxicity testing, and has serious consequences for hazard assessment and risk management. Therefore, we strongly advise to discontinue its use for this purpose, in order to avoid the conduct of toxicity studies that are not adequate for e.g. hazard (including ED) assessment and subsequent risk management measures to prevent ad- verse effects on human health. This requires the updating of regula- tions, guidance documents and OECD test guidelines where the use of toxicokinetic data (including the KMD) for selecting maximum dose levels has already been implemented. Funding Body Information This work was funded by the Dutch Ministry of Infrastructure and Water Management (I&W). The Work was conducted in the course of the authors\u2019 employment. RIVM asked The Dutch Ministry for approval to submit the current manuscript. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. Acknowledgements The authors would like to thank Joke Herremans, Agnes Oomen and Peter Bos for proof-reading this paper. This work was funded by the Dutch Ministry of Infrastructure and Water Management (I&W). References Baldrick, P., 2003. Toxicokinetics in preclinical evaluation. Drug Discov Today 8 (3), 127\u2013133. Barton, H.A., Pastoor, T.P., Baetcke, K., Chambers, J.A., Diliberto, J., Doerrer, N.G., Driver, J.H., Hastings, C.E., Iyengar, S., Krieger, R., Stahl, B., Timchalk, C., 2006. The Acquisition and application of absorption, distribution, metabolism, and excretion (ADME) data in Agricultural chemical safety assessments. Critical Reviews in Toxicology 36, 9\u201335. Buckley, L.A., Dorato, M.A., 2009. High dose selection in general toxicity studies for drug development: a pharmaceutical industry perspective. Regulatory Toxicology and Pharmacology 54, 301\u2013307. Creton, S., Billington, R., Davies, W., Dent, M.P., Hawksworth, G.M., Parry, S., Travis, K.Z., 2009. Application of toxicokinetics to improve chemical risk assessment: im- plications for the use of animals. Regul. Toxicol. Pharmacol. 55, 291\u2013299. Creton, S., Saghir, S.A., Bartels, M.J., Billington, R., Bus, J.S., Davies, W., Dent, M.P., Hawksworth, G.M., Simon, P., Kim, Z.T., 2012. Use of toxicokinetics to support chemical evaluation: Informing high dose selection and study interpretation. Regul. Toxicol. Pharmacol. 62, 241\u2013247. Dawes, M., Chowienczyk, P.J., 2001. Pharmacokinetics in pregnancy. Best Practice Res. Clin. Obst. Gynaecol. 15, 819\u2013826. Domoradzki, J., Boobis, A., 2018. The Kinetically-Derived Maximum (KMD), a New Dimension to the Maximum Tolerated Dose (MTD), Round Table Discussion, SOT. San Antonio. https://www.toxicology.org/events/am/Andre Muller2018/scientific-sessions. asp. ECHA, 2012. CLH Report for Sulfoxaflor, Version 2, Dated January. Available at: https:// echa.europa.eu/documents/10162/6acb4d37-01ed-484b-981e-7319d9290af3 ac- cessed January 2019. ECHA, reportThe Use of Alternatives to Testing on Animals for the REACH Regulation. Third Report under Article 117(3) of REACH. ECHA Report ECHA-17-B-06-EN. https://echa.europa.eu/documents/10162/13639/alternatives_test_animals_2017_ summary_en.pdf/487e2516-0ad0-90a2-a923-96417ffd6b6b. ECHA, Guidance on Information Requirements and Chemical Safety Assessment. Chapter R.7c: Endpoint Specific Guidance. Part R.7.12 Guidance on Toxicokinetics. Version 3. 0. European Chemicals Agency, Helsinki, Finland. Reference: ECHA-17-G-11-EN. Available at: https://echa.europa.eu/documents/10162/13632/information_re- quirements_r7c_en.pdf/e2e23a98-adb2-4573-b450-cc0dfa7988e5 (Accessed August 16, 2018). ECHA, 2018. Combined Draft Assessment Report Prepared According to Regulation (EC) N\u00b0 1107/2009 and Proposal for Harmonised Classification and Labelling (CLH Report) According to Regulation (EC) N\u00b0 1272/2008. Pydiflumetofen. Volume 1. Rapporteur Member State: France. Available at: https://echa.europa.eu/documents/ 10162/4d8943f7-5028-4c59-7421-8938ff1ef9c3. EFSA Scientific Committee, 2017. Guidance Update: use of the benchmark dose approach in risk assessment. ESFA Journal 15 (1), 4658. Goehl, T.J., 1997. Toxicokinetics in the national toxicology program. In: Rapaka, R.S., Chiang, N., Martin, B.R. (Eds.), Pharmacokinetics, Metabolism, and Pharmaceutics of Drugs of Abuse. National Institute on Drug Abuse Research, Rockville, MD, pp. 273\u2013304 Monograph 173. Kalantari, F., Ringblom, J., Sand, S., \u00d6berg, M., 2017. Influence of distribution of animals between dose groups on estimated benchmark dose and animal distress for Quantal responses. Risk Analysis 37, 1716\u20131728. McFadden, L.G., Bartels, M.J., Rick, D.L., Price, P.S., Fontaine, D.D., Saghir, S.A., 2012. Statistical methodology to determine kinetically derived maximum tolerated dose in repeat dose toxicity studies. Regul. Toxicol. Pharmacol. 63, 344\u2013351. Morgan, D.G., Kelvin, A.S., Kinter, L.B., Fish, C.J., Kerns, W.D., Rhodes, G., 1994. The application of toxicokinetic data to dosage selection in toxicology studies. Toxicologic Pathology 22 (2), 112\u2013123. Guidance Document 116 on the Conduct and Design of Chronic Toxicity and Carcinogenicity Studies Supporting Test Guideline 451, 452 and 453, 2ND Edition, Series on Testing and Assessment No. 116. 47 ENV/JM/MONO (2011). OECD Guideline for testing of chemicals, OECD TG 417, 2010. Toxicokinetics: 22 July. OECD Guideline for testing of chemicals, OECD TG 443, 2018. Extended One-Generation Reproductive Toxicity Study: 25 June. Saghir, S.A., 2015. Rethinking guideline toxicity testing. Toxicology and Applied Pharmacology 72, 423\u2013428. Saghir, S.A., Bartels, M.J., Rick, D.L., McCoy, A.T., Rasoulpour, R.J., Ellis-Hutchings, R.G., Marty, M.S., Terry, C., Bailey, J.P., Billington, R., Bus, J.S., 2012. Assessment of diurnal systemic dose of agrochemicals in regulatory toxicity testing \u2013 an integrated approach without additional animal use. Regulatory Toxicology and Pharmacology 63, 321\u2013332. Saghir, S.A., Dorato, M.A., 2016. Reproductive and developmental toxicity testing: M.B. Heringa, et al. Regulatory Toxicology and Pharmacology 114 (2020) 104659 10 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref1 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref1 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref2 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref2 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref2 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref2 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref2 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref3 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref3 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref3 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref4 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref4 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref4 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref5 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref5 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref5 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref5 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref6 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref6 https://www.toxicology.org/events/am/Andre Muller2018/scientific-sessions.asp https://www.toxicology.org/events/am/Andre Muller2018/scientific-sessions.asp https://echa.europa.eu/documents/10162/6acb4d37-01ed-484b-981e-7319d9290af3 https://echa.europa.eu/documents/10162/6acb4d37-01ed-484b-981e-7319d9290af3 https://echa.europa.eu/documents/10162/4d8943f7-5028-4c59-7421-8938ff1ef9c3 https://echa.europa.eu/documents/10162/4d8943f7-5028-4c59-7421-8938ff1ef9c3 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref12 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref12 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref13 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref13 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref13 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref13 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref14 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref14 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref14 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref15 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref15 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref15 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref16 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref16 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref16 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref17 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref17 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref17 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref18 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref19 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref19 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref20 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref20 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref21 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref21 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref21 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref21 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref21 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref22 Examination of the extended one-generation reproductive toxicity study guideline. Regul. Toxicol. Pharmacol. 79, 110\u2013117. Saghir, S.A., Marty, M.S., Zablotny, C.L., Passage, J.K., Perala, A.W., Neal, B.H., Hammond, L., Bus, J.S., 2013. Life-stage-, Sex-, and dose-Dependent dietary tox- icokinetics and relationship to toxicity of 2,4-dichlorophenoxyacetic acid (2,4-D) in rats: implications for toxicity test dose selection, design, and interpretation. Toxicological Sciences 136, 294\u2013307. Sewell, F., Aggarwal, M., Bachler, G., Broadmeadow, A., Gellatlya, N., Moored, E., Robinson, S., Rooseboom, M., Stevens, A., Terry, C., Burdena, N., 2017. The current status of exposure-driven approaches for chemical safety assessment: a cross-sector perspective. Toxicology 389, 109\u2013117. Shao, K., Small, M.J., 2012. Statistical evaluation of toxicological experimental design for Bayesian model averaged benchmark dose estimation with dichotomous data, Human and Ecological risk assessment. An International Journal 18 (5), 1096\u20131119. Slob, W., 2014. Benchmark dose and the three Rs. Part II. Reduction by getting the same information from fewer animals. Crit Rev Toxicol 44, 568\u2013580. Slob, W., Setzer, R.W., 2014. Shape and steepness of toxicological dose-response re- lationships of continuous endpoints. Crit Rev Toxicol 44, 270\u2013297. Slob W., Zeilmaker S. and Hoogenveen R., The relationship between internal and external dose: some general results based on a generic compartmental model. Terry, C., Hays, S., McCoy, A.T., McFadden, L.G., Aggarwal, M., Rasoulpour, R.J., Juberg, D.R., 2016. Implementing a framework for integrating toxicokinetics into human health risk assessment for agrochemicals. Regul. Toxicol. Pharmacol. 75, 89\u2013104. Wambaugh, J.F., Setzer, R.W., Reif, D.M., Gangwal, S., Mitchell-Blackwood, J., Arnot, J.A., Joliet, O., Frame, A., Rabinowitz, J., Knudsen, T.B., Richard, S., Judson, R.S., Egeghy, P., Vallero, D., 2013. Current issue of regulatory toxicology and Farmacology.ohen Hubal E.A., high-throughput models for exposure-based chemical Prioritization in the ExpoCast project. Environ. Sci. Technol. 47, 8479\u20138488. Woutersen M, Muller A, Pronk M.E.J., Cnubben N.H.P. and Hakkert B.C.; . Regulating human safety: how dose selection in toxicity studies impacts human health hazard assessment and subsequent risk management options. Current Issue of Regulatory Toxicology and Pharmacology. M.B. Heringa, et al. Regulatory Toxicology and Pharmacology 114 (2020) 104659 11 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref22 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref22 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref23 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref23 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref23 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref23 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref23 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref24 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref24 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref24 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref24 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref25 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref25 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref25 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref26 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref26 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref27 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref27 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref29 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref29 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref29 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref30 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref30 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref30 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref30 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref30 Use of the kinetically-derived maximum dose concept in selection of top doses for toxicity studies hampers proper hazard assessment and risk management Introduction The KMD concept Main objections to the KMD concept The inflection point does not exist Information at doses with high levels of saturation is of toxicological relevance Further reservations Lack of appropriate exposure information The KMD concept does not meet the 3Rs principle The absence of saturation in humans at low dose is not a justifiable assumption Similarity of toxicokinetics between animals and humans is hard to determine Absence of effects is not informative The AUC as measure for internal dose might be incorrect Conflict with CLP requirements and ED assessment Examples of KMD application Pydiflumetofen Sulfoxaflor 2,4-Dichlorophenoxyacetic acid (2,4-D) Discussion Conclusion and way forward Funding Body Information Declaration of competing interest Acknowledgements References", "Funding": "All in all, the selection of maximum doses in toxicity testing is an important and complicated issue, given that the studies should be performed in a such way that the data generated are adequate to fulfil all regulatory requirements.(see also Woutersen et al. (2020). Con- sideration should be given to the Benchmark Dose (BMD) approach, in which it is possible to use more dose groups with smaller group sizes, and the highest dose can be interrupted if the animals appear to suffer. In the BMD approach, the maximal safe or acceptable dose is derived by fitting a curve through all dose-response data, instead of taking the highest tested dose level that produced no significant adverse response. It may even be considered that a redistribution of the animals from high to low dose groups might reduce their overall distress, without im- pairing or even improving the quality of the BMD estimate compared to designs with equally large dose groups (Kalantari et al., 2017). 4. Conclusion and way forward In conclusion, the KMD concept is not a valid approach for deriving the top dose in toxicity testing, and has serious consequences for hazard assessment and risk management. Therefore, we strongly advise to discontinue its use for this purpose, in order to avoid the conduct of toxicity studies that are not adequate for e.g. hazard (including ED) assessment and subsequent risk management measures to prevent ad- verse effects on human health. This requires the updating of regula- tions, guidance documents and OECD test guidelines where the use of toxicokinetic data (including the KMD) for selecting maximum dose levels has already been implemented. Funding Body Information This work was funded by the Dutch Ministry of Infrastructure and Water Management (I&W). The Work was conducted in the course of the authors\u2019 employment. RIVM asked The Dutch Ministry for approval to submit the current manuscript. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. Acknowledgements The authors would like to thank Joke Herremans, Agnes Oomen and Peter Bos for proof-reading this paper. This work was funded by the Dutch Ministry of Infrastructure and Water Management (I&W). References Baldrick, P., 2003. Toxicokinetics in preclinical evaluation. Drug Discov Today 8 (3), 127\u2013133. Barton, H.A., Pastoor, T.P., Baetcke, K., Chambers, J.A., Diliberto, J., Doerrer, N.G., Driver, J.H., Hastings, C.E., Iyengar, S., Krieger, R., Stahl, B., Timchalk, C., 2006. The Acquisition and application of absorption, distribution, metabolism, and excretion (ADME) data in Agricultural chemical safety assessments. Critical Reviews in Toxicology 36, 9\u201335. Buckley, L.A., Dorato, M.A., 2009. High dose selection in general toxicity studies for drug development: a pharmaceutical industry perspective. Regulatory Toxicology and Pharmacology 54, 301\u2013307. Creton, S., Billington, R., Davies, W., Dent, M.P., Hawksworth, G.M., Parry, S., Travis, K.Z., 2009. Application of toxicokinetics to improve chemical risk assessment: im- plications for the use of animals. Regul. Toxicol. Pharmacol. 55, 291\u2013299. Creton, S., Saghir, S.A., Bartels, M.J., Billington, R., Bus, J.S., Davies, W., Dent, M.P., Hawksworth, G.M., Simon, P., Kim, Z.T., 2012. Use of toxicokinetics to support chemical evaluation: Informing high dose selection and study interpretation. Regul. Toxicol. Pharmacol. 62, 241\u2013247. Dawes, M., Chowienczyk, P.J., 2001. Pharmacokinetics in pregnancy. Best Practice Res. Clin. Obst. Gynaecol. 15, 819\u2013826. Domoradzki, J., Boobis, A., 2018. The Kinetically-Derived Maximum (KMD), a New Dimension to the Maximum Tolerated Dose (MTD), Round Table Discussion, SOT. San Antonio. https://www.toxicology.org/events/am/Andre Muller2018/scientific-sessions. asp. ECHA, 2012. CLH Report for Sulfoxaflor, Version 2, Dated January. Available at: https:// echa.europa.eu/documents/10162/6acb4d37-01ed-484b-981e-7319d9290af3 ac- cessed January 2019. ECHA, reportThe Use of Alternatives to Testing on Animals for the REACH Regulation. Third Report under Article 117(3) of REACH. ECHA Report ECHA-17-B-06-EN. https://echa.europa.eu/documents/10162/13639/alternatives_test_animals_2017_ summary_en.pdf/487e2516-0ad0-90a2-a923-96417ffd6b6b. ECHA, Guidance on Information Requirements and Chemical Safety Assessment. Chapter R.7c: Endpoint Specific Guidance. Part R.7.12 Guidance on Toxicokinetics. Version 3. 0. European Chemicals Agency, Helsinki, Finland. Reference: ECHA-17-G-11-EN. Available at: https://echa.europa.eu/documents/10162/13632/information_re- quirements_r7c_en.pdf/e2e23a98-adb2-4573-b450-cc0dfa7988e5 (Accessed August 16, 2018). ECHA, 2018. Combined Draft Assessment Report Prepared According to Regulation (EC) N\u00b0 1107/2009 and Proposal for Harmonised Classification and Labelling (CLH Report) According to Regulation (EC) N\u00b0 1272/2008. Pydiflumetofen. Volume 1. Rapporteur Member State: France. Available at: https://echa.europa.eu/documents/ 10162/4d8943f7-5028-4c59-7421-8938ff1ef9c3. EFSA Scientific Committee, 2017. Guidance Update: use of the benchmark dose approach in risk assessment. ESFA Journal 15 (1), 4658. Goehl, T.J., 1997. Toxicokinetics in the national toxicology program. In: Rapaka, R.S., Chiang, N., Martin, B.R. (Eds.), Pharmacokinetics, Metabolism, and Pharmaceutics of Drugs of Abuse. National Institute on Drug Abuse Research, Rockville, MD, pp. 273\u2013304 Monograph 173. Kalantari, F., Ringblom, J., Sand, S., \u00d6berg, M., 2017. Influence of distribution of animals between dose groups on estimated benchmark dose and animal distress for Quantal responses. Risk Analysis 37, 1716\u20131728. McFadden, L.G., Bartels, M.J., Rick, D.L., Price, P.S., Fontaine, D.D., Saghir, S.A., 2012. Statistical methodology to determine kinetically derived maximum tolerated dose in repeat dose toxicity studies. Regul. Toxicol. Pharmacol. 63, 344\u2013351. Morgan, D.G., Kelvin, A.S., Kinter, L.B., Fish, C.J., Kerns, W.D., Rhodes, G., 1994. The application of toxicokinetic data to dosage selection in toxicology studies. Toxicologic Pathology 22 (2), 112\u2013123. Guidance Document 116 on the Conduct and Design of Chronic Toxicity and Carcinogenicity Studies Supporting Test Guideline 451, 452 and 453, 2ND Edition, Series on Testing and Assessment No. 116. 47 ENV/JM/MONO (2011). OECD Guideline for testing of chemicals, OECD TG 417, 2010. Toxicokinetics: 22 July. OECD Guideline for testing of chemicals, OECD TG 443, 2018. Extended One-Generation Reproductive Toxicity Study: 25 June. Saghir, S.A., 2015. Rethinking guideline toxicity testing. Toxicology and Applied Pharmacology 72, 423\u2013428. Saghir, S.A., Bartels, M.J., Rick, D.L., McCoy, A.T., Rasoulpour, R.J., Ellis-Hutchings, R.G., Marty, M.S., Terry, C., Bailey, J.P., Billington, R., Bus, J.S., 2012. Assessment of diurnal systemic dose of agrochemicals in regulatory toxicity testing \u2013 an integrated approach without additional animal use. Regulatory Toxicology and Pharmacology 63, 321\u2013332. Saghir, S.A., Dorato, M.A., 2016. Reproductive and developmental toxicity testing: M.B. Heringa, et al. Regulatory Toxicology and Pharmacology 114 (2020) 104659 10 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref1 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref1 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref2 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref2 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref2 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref2 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref2 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref3 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref3 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref3 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref4 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref4 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref4 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref5 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref5 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref5 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref5 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref6 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref6 https://www.toxicology.org/events/am/Andre Muller2018/scientific-sessions.asp https://www.toxicology.org/events/am/Andre Muller2018/scientific-sessions.asp https://echa.europa.eu/documents/10162/6acb4d37-01ed-484b-981e-7319d9290af3 https://echa.europa.eu/documents/10162/6acb4d37-01ed-484b-981e-7319d9290af3 https://echa.europa.eu/documents/10162/4d8943f7-5028-4c59-7421-8938ff1ef9c3 https://echa.europa.eu/documents/10162/4d8943f7-5028-4c59-7421-8938ff1ef9c3 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref12 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref12 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref13 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref13 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref13 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref13 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref14 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref14 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref14 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref15 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref15 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref15 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref16 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref16 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref16 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref17 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref17 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref17 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref18 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref19 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref19 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref20 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref20 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref21 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref21 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref21 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref21 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref21 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref22 Examination of the extended one-generation reproductive toxicity study guideline. Regul. Toxicol. Pharmacol. 79, 110\u2013117. Saghir, S.A., Marty, M.S., Zablotny, C.L., Passage, J.K., Perala, A.W., Neal, B.H., Hammond, L., Bus, J.S., 2013. Life-stage-, Sex-, and dose-Dependent dietary tox- icokinetics and relationship to toxicity of 2,4-dichlorophenoxyacetic acid (2,4-D) in rats: implications for toxicity test dose selection, design, and interpretation. Toxicological Sciences 136, 294\u2013307. Sewell, F., Aggarwal, M., Bachler, G., Broadmeadow, A., Gellatlya, N., Moored, E., Robinson, S., Rooseboom, M., Stevens, A., Terry, C., Burdena, N., 2017. The current status of exposure-driven approaches for chemical safety assessment: a cross-sector perspective. Toxicology 389, 109\u2013117. Shao, K., Small, M.J., 2012. Statistical evaluation of toxicological experimental design for Bayesian model averaged benchmark dose estimation with dichotomous data, Human and Ecological risk assessment. An International Journal 18 (5), 1096\u20131119. Slob, W., 2014. Benchmark dose and the three Rs. Part II. Reduction by getting the same information from fewer animals. Crit Rev Toxicol 44, 568\u2013580. Slob, W., Setzer, R.W., 2014. Shape and steepness of toxicological dose-response re- lationships of continuous endpoints. Crit Rev Toxicol 44, 270\u2013297. Slob W., Zeilmaker S. and Hoogenveen R., The relationship between internal and external dose: some general results based on a generic compartmental model. Terry, C., Hays, S., McCoy, A.T., McFadden, L.G., Aggarwal, M., Rasoulpour, R.J., Juberg, D.R., 2016. Implementing a framework for integrating toxicokinetics into human health risk assessment for agrochemicals. Regul. Toxicol. Pharmacol. 75, 89\u2013104. Wambaugh, J.F., Setzer, R.W., Reif, D.M., Gangwal, S., Mitchell-Blackwood, J., Arnot, J.A., Joliet, O., Frame, A., Rabinowitz, J., Knudsen, T.B., Richard, S., Judson, R.S., Egeghy, P., Vallero, D., 2013. Current issue of regulatory toxicology and Farmacology.ohen Hubal E.A., high-throughput models for exposure-based chemical Prioritization in the ExpoCast project. Environ. Sci. Technol. 47, 8479\u20138488. Woutersen M, Muller A, Pronk M.E.J., Cnubben N.H.P. and Hakkert B.C.; . Regulating human safety: how dose selection in toxicity studies impacts human health hazard assessment and subsequent risk management options. Current Issue of Regulatory Toxicology and Pharmacology. M.B. Heringa, et al. Regulatory Toxicology and Pharmacology 114 (2020) 104659 11 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref22 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref22 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref23 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref23 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref23 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref23 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref23 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref24 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref24 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref24 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref24 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref25 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref25 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref25 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref26 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref26 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref27 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref27 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref29 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref29 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref29 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref30 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref30 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref30 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref30 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref30 Use of the kinetically-derived maximum dose concept in selection of top doses for toxicity studies hampers proper hazard assessment and risk management Introduction The KMD concept Main objections to the KMD concept The inflection point does not exist Information at doses with high levels of saturation is of toxicological relevance Further reservations Lack of appropriate exposure information The KMD concept does not meet the 3Rs principle The absence of saturation in humans at low dose is not a justifiable assumption Similarity of toxicokinetics between animals and humans is hard to determine Absence of effects is not informative The AUC as measure for internal dose might be incorrect Conflict with CLP requirements and ED assessment Examples of KMD application Pydiflumetofen Sulfoxaflor 2,4-Dichlorophenoxyacetic acid (2,4-D) Discussion Conclusion and way forward Funding Body Information Declaration of competing interest Acknowledgements References", "Acknowledgement": "All in all, the selection of maximum doses in toxicity testing is an important and complicated issue, given that the studies should be performed in a such way that the data generated are adequate to fulfil all regulatory requirements.(see also Woutersen et al. (2020). Con- sideration should be given to the Benchmark Dose (BMD) approach, in which it is possible to use more dose groups with smaller group sizes, and the highest dose can be interrupted if the animals appear to suffer. In the BMD approach, the maximal safe or acceptable dose is derived by fitting a curve through all dose-response data, instead of taking the highest tested dose level that produced no significant adverse response. It may even be considered that a redistribution of the animals from high to low dose groups might reduce their overall distress, without im- pairing or even improving the quality of the BMD estimate compared to designs with equally large dose groups (Kalantari et al., 2017). 4. Conclusion and way forward In conclusion, the KMD concept is not a valid approach for deriving the top dose in toxicity testing, and has serious consequences for hazard assessment and risk management. Therefore, we strongly advise to discontinue its use for this purpose, in order to avoid the conduct of toxicity studies that are not adequate for e.g. hazard (including ED) assessment and subsequent risk management measures to prevent ad- verse effects on human health. This requires the updating of regula- tions, guidance documents and OECD test guidelines where the use of toxicokinetic data (including the KMD) for selecting maximum dose levels has already been implemented. Funding Body Information This work was funded by the Dutch Ministry of Infrastructure and Water Management (I&W). The Work was conducted in the course of the authors\u2019 employment. RIVM asked The Dutch Ministry for approval to submit the current manuscript. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. Acknowledgements The authors would like to thank Joke Herremans, Agnes Oomen and Peter Bos for proof-reading this paper. This work was funded by the Dutch Ministry of Infrastructure and Water Management (I&W). References Baldrick, P., 2003. Toxicokinetics in preclinical evaluation. Drug Discov Today 8 (3), 127\u2013133. Barton, H.A., Pastoor, T.P., Baetcke, K., Chambers, J.A., Diliberto, J., Doerrer, N.G., Driver, J.H., Hastings, C.E., Iyengar, S., Krieger, R., Stahl, B., Timchalk, C., 2006. The Acquisition and application of absorption, distribution, metabolism, and excretion (ADME) data in Agricultural chemical safety assessments. Critical Reviews in Toxicology 36, 9\u201335. Buckley, L.A., Dorato, M.A., 2009. High dose selection in general toxicity studies for drug development: a pharmaceutical industry perspective. Regulatory Toxicology and Pharmacology 54, 301\u2013307. Creton, S., Billington, R., Davies, W., Dent, M.P., Hawksworth, G.M., Parry, S., Travis, K.Z., 2009. Application of toxicokinetics to improve chemical risk assessment: im- plications for the use of animals. Regul. Toxicol. Pharmacol. 55, 291\u2013299. Creton, S., Saghir, S.A., Bartels, M.J., Billington, R., Bus, J.S., Davies, W., Dent, M.P., Hawksworth, G.M., Simon, P., Kim, Z.T., 2012. Use of toxicokinetics to support chemical evaluation: Informing high dose selection and study interpretation. Regul. Toxicol. Pharmacol. 62, 241\u2013247. Dawes, M., Chowienczyk, P.J., 2001. Pharmacokinetics in pregnancy. Best Practice Res. Clin. Obst. Gynaecol. 15, 819\u2013826. Domoradzki, J., Boobis, A., 2018. The Kinetically-Derived Maximum (KMD), a New Dimension to the Maximum Tolerated Dose (MTD), Round Table Discussion, SOT. San Antonio. https://www.toxicology.org/events/am/Andre Muller2018/scientific-sessions. asp. ECHA, 2012. CLH Report for Sulfoxaflor, Version 2, Dated January. Available at: https:// echa.europa.eu/documents/10162/6acb4d37-01ed-484b-981e-7319d9290af3 ac- cessed January 2019. ECHA, reportThe Use of Alternatives to Testing on Animals for the REACH Regulation. Third Report under Article 117(3) of REACH. ECHA Report ECHA-17-B-06-EN. https://echa.europa.eu/documents/10162/13639/alternatives_test_animals_2017_ summary_en.pdf/487e2516-0ad0-90a2-a923-96417ffd6b6b. ECHA, Guidance on Information Requirements and Chemical Safety Assessment. Chapter R.7c: Endpoint Specific Guidance. Part R.7.12 Guidance on Toxicokinetics. Version 3. 0. European Chemicals Agency, Helsinki, Finland. Reference: ECHA-17-G-11-EN. Available at: https://echa.europa.eu/documents/10162/13632/information_re- quirements_r7c_en.pdf/e2e23a98-adb2-4573-b450-cc0dfa7988e5 (Accessed August 16, 2018). ECHA, 2018. Combined Draft Assessment Report Prepared According to Regulation (EC) N\u00b0 1107/2009 and Proposal for Harmonised Classification and Labelling (CLH Report) According to Regulation (EC) N\u00b0 1272/2008. Pydiflumetofen. Volume 1. Rapporteur Member State: France. Available at: https://echa.europa.eu/documents/ 10162/4d8943f7-5028-4c59-7421-8938ff1ef9c3. EFSA Scientific Committee, 2017. Guidance Update: use of the benchmark dose approach in risk assessment. ESFA Journal 15 (1), 4658. Goehl, T.J., 1997. Toxicokinetics in the national toxicology program. In: Rapaka, R.S., Chiang, N., Martin, B.R. (Eds.), Pharmacokinetics, Metabolism, and Pharmaceutics of Drugs of Abuse. National Institute on Drug Abuse Research, Rockville, MD, pp. 273\u2013304 Monograph 173. Kalantari, F., Ringblom, J., Sand, S., \u00d6berg, M., 2017. Influence of distribution of animals between dose groups on estimated benchmark dose and animal distress for Quantal responses. Risk Analysis 37, 1716\u20131728. McFadden, L.G., Bartels, M.J., Rick, D.L., Price, P.S., Fontaine, D.D., Saghir, S.A., 2012. Statistical methodology to determine kinetically derived maximum tolerated dose in repeat dose toxicity studies. Regul. Toxicol. Pharmacol. 63, 344\u2013351. Morgan, D.G., Kelvin, A.S., Kinter, L.B., Fish, C.J., Kerns, W.D., Rhodes, G., 1994. The application of toxicokinetic data to dosage selection in toxicology studies. Toxicologic Pathology 22 (2), 112\u2013123. Guidance Document 116 on the Conduct and Design of Chronic Toxicity and Carcinogenicity Studies Supporting Test Guideline 451, 452 and 453, 2ND Edition, Series on Testing and Assessment No. 116. 47 ENV/JM/MONO (2011). OECD Guideline for testing of chemicals, OECD TG 417, 2010. Toxicokinetics: 22 July. OECD Guideline for testing of chemicals, OECD TG 443, 2018. Extended One-Generation Reproductive Toxicity Study: 25 June. Saghir, S.A., 2015. Rethinking guideline toxicity testing. Toxicology and Applied Pharmacology 72, 423\u2013428. Saghir, S.A., Bartels, M.J., Rick, D.L., McCoy, A.T., Rasoulpour, R.J., Ellis-Hutchings, R.G., Marty, M.S., Terry, C., Bailey, J.P., Billington, R., Bus, J.S., 2012. Assessment of diurnal systemic dose of agrochemicals in regulatory toxicity testing \u2013 an integrated approach without additional animal use. Regulatory Toxicology and Pharmacology 63, 321\u2013332. Saghir, S.A., Dorato, M.A., 2016. Reproductive and developmental toxicity testing: M.B. Heringa, et al. Regulatory Toxicology and Pharmacology 114 (2020) 104659 10 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref1 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref1 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref2 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref2 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref2 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref2 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref2 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref3 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref3 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref3 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref4 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref4 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref4 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref5 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref5 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref5 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref5 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref6 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref6 https://www.toxicology.org/events/am/Andre Muller2018/scientific-sessions.asp https://www.toxicology.org/events/am/Andre Muller2018/scientific-sessions.asp https://echa.europa.eu/documents/10162/6acb4d37-01ed-484b-981e-7319d9290af3 https://echa.europa.eu/documents/10162/6acb4d37-01ed-484b-981e-7319d9290af3 https://echa.europa.eu/documents/10162/4d8943f7-5028-4c59-7421-8938ff1ef9c3 https://echa.europa.eu/documents/10162/4d8943f7-5028-4c59-7421-8938ff1ef9c3 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref12 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref12 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref13 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref13 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref13 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref13 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref14 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref14 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref14 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref15 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref15 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref15 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref16 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref16 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref16 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref17 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref17 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref17 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref18 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref19 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref19 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref20 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref20 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref21 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref21 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref21 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref21 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref21 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref22 Examination of the extended one-generation reproductive toxicity study guideline. Regul. Toxicol. Pharmacol. 79, 110\u2013117. Saghir, S.A., Marty, M.S., Zablotny, C.L., Passage, J.K., Perala, A.W., Neal, B.H., Hammond, L., Bus, J.S., 2013. Life-stage-, Sex-, and dose-Dependent dietary tox- icokinetics and relationship to toxicity of 2,4-dichlorophenoxyacetic acid (2,4-D) in rats: implications for toxicity test dose selection, design, and interpretation. Toxicological Sciences 136, 294\u2013307. Sewell, F., Aggarwal, M., Bachler, G., Broadmeadow, A., Gellatlya, N., Moored, E., Robinson, S., Rooseboom, M., Stevens, A., Terry, C., Burdena, N., 2017. The current status of exposure-driven approaches for chemical safety assessment: a cross-sector perspective. Toxicology 389, 109\u2013117. Shao, K., Small, M.J., 2012. Statistical evaluation of toxicological experimental design for Bayesian model averaged benchmark dose estimation with dichotomous data, Human and Ecological risk assessment. An International Journal 18 (5), 1096\u20131119. Slob, W., 2014. Benchmark dose and the three Rs. Part II. Reduction by getting the same information from fewer animals. Crit Rev Toxicol 44, 568\u2013580. Slob, W., Setzer, R.W., 2014. Shape and steepness of toxicological dose-response re- lationships of continuous endpoints. Crit Rev Toxicol 44, 270\u2013297. Slob W., Zeilmaker S. and Hoogenveen R., The relationship between internal and external dose: some general results based on a generic compartmental model. Terry, C., Hays, S., McCoy, A.T., McFadden, L.G., Aggarwal, M., Rasoulpour, R.J., Juberg, D.R., 2016. Implementing a framework for integrating toxicokinetics into human health risk assessment for agrochemicals. Regul. Toxicol. Pharmacol. 75, 89\u2013104. Wambaugh, J.F., Setzer, R.W., Reif, D.M., Gangwal, S., Mitchell-Blackwood, J., Arnot, J.A., Joliet, O., Frame, A., Rabinowitz, J., Knudsen, T.B., Richard, S., Judson, R.S., Egeghy, P., Vallero, D., 2013. Current issue of regulatory toxicology and Farmacology.ohen Hubal E.A., high-throughput models for exposure-based chemical Prioritization in the ExpoCast project. Environ. Sci. Technol. 47, 8479\u20138488. Woutersen M, Muller A, Pronk M.E.J., Cnubben N.H.P. and Hakkert B.C.; . Regulating human safety: how dose selection in toxicity studies impacts human health hazard assessment and subsequent risk management options. Current Issue of Regulatory Toxicology and Pharmacology. M.B. Heringa, et al. Regulatory Toxicology and Pharmacology 114 (2020) 104659 11 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref22 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref22 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref23 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref23 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref23 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref23 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref23 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref24 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref24 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref24 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref24 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref25 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref25 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref25 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref26 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref26 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref27 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref27 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref29 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref29 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref29 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref30 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref30 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref30 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref30 http://refhub.elsevier.com/S0273-2300(20)30085-4/sref30 Use of the kinetically-derived maximum dose concept in selection of top doses for toxicity studies hampers proper hazard assessment and risk management Introduction The KMD concept Main objections to the KMD concept The inflection point does not exist Information at doses with high levels of saturation is of toxicological relevance Further reservations Lack of appropriate exposure information The KMD concept does not meet the 3Rs principle The absence of saturation in humans at low dose is not a justifiable assumption Similarity of toxicokinetics between animals and humans is hard to determine Absence of effects is not informative The AUC as measure for internal dose might be incorrect Conflict with CLP requirements and ED assessment Examples of KMD application Pydiflumetofen Sulfoxaflor 2,4-Dichlorophenoxyacetic acid (2,4-D) Discussion Conclusion and way forward Funding Body Information Declaration of competing interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-the-permitted-daily-exposure--PDE--concept-for-c_2019_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30367903", "content": {"CoiStatement": "Declaration of interest The authors report no declarations of interest. Case examples comparing the PDEIV/500 approach to a PDEIVT Conclusion Declaration of interest Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-toxicogenomics-in-drug-safety-evaluation--C_2018_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29679677", "content": {"Funding": "Funding This work did not receive any specific grant from the funding agencies in the public, commercial, or not-for-profit sectors. The au- thors of this article are full-time employees of Lilly Research Laboratories (John L Vahle.), AstraZeneca (Ulf Anderson.), AbbVie (Eric A G Blomme.), F Hoffmann La Roche (J.-C.H.) and Novartis Pharma AG (Daniel P Stiehl.). Opinions expressed in this article are those of the authors, and do not necessarily reflect those of the organization with which the authors are affiliated. This work did not receive any specific grant from the funding agencies in the public, commercial, or not-for-profit sectors. The au- thors of this article are full-time employees of Lilly Research Laboratories (John L Vahle.), AstraZeneca (Ulf Anderson.), AbbVie (Eric A G Blomme.), F Hoffmann La Roche (J.-C.H.) and Novartis Pharma AG (Daniel P Stiehl.). Opinions expressed in this article are those of the authors, and do not necessarily reflect those of the organization with which the authors are affiliated. Acknowledgments Funding Acknowledgments Transparency document References", "Compliance with ethical standards": "FDA, 2005. Guidance for Industry: Pharmacogenomic Data Submission. Retrieved December 6, 2017, from https://www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ucm079849.pdf. Fielden, M.R., Eynon, B.P., Natsoulis, G., Jarnagin, K., Banas, D., Kolaja, K.L., 2005. A gene expression signature that predicts the future onset of drug-induced renal tubular toxicity. Toxicol. Pathol. 33 (6), 675\u2013683. http://refhub.elsevier.com/S0273-2300(18)30111-9/sref4 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref4 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref4 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref5 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref5 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref5 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref5 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref6 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref6 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref6 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref6 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref6 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref7 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref7 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref7 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref8 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref8 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref8 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref8 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref8 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref8 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref8 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref8 https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm079849.pdf https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm079849.pdf http://refhub.elsevier.com/S0273-2300(18)30111-9/sref10 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref10 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref10 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref11 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref11 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref11 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref12 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref12 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref12 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref12 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref12 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref12 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref12 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref13 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref13 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref13 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref14 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref14 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref14 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref14 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref14 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref14 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref14 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref15 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref15 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref15 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref15 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref15 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref16 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref16 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref16 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref17 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref17 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref18 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref18 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref18 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref18 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref19 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref19 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref19 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref19 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref20 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref20 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref21 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref21 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref21 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref21 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref21 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref22 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref22 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref22 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref23 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref23 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref24 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref24 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref24 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref25 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref25 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref26 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref26 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref26 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref27 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref27 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref27 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref28 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref28 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref28 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref29 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref29 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref29 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref30 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref30 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref30 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref30 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref31 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref31 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref31 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref31 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref32 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref32 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref32 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref32 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref32 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref33 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref33 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref33 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref34 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref34 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref34 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref35 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref35 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref36 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref36 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref36 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref36 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref36 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref37 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref37 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref37 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref37 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref37 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref37 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref38 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref38 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref38 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref38 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref39 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref39 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref39 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref40 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref40 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref40 http://refhub.elsevier.com/S0273-2300(18)30111-9/sref40 Use of toxicogenomics in drug safety evaluation: Current status and an industry perspective Introduction Survey methodology Survey results Regulatory repeat-dose toxicity studies Mechanistic or investigative studies directly supporting clinical development Screening toxicity studies Mechanistic or investigative studies in early screening safety assessment Toxicogenomic study design elements General comments on toxicogenomic strategy", "Acknowledgement": "Acknowledgments The authors wish to thank Cynthia A. Afshari and James L. Stevens for consultation on the design, conduct, and interpretation of the survey, members of the EFPIA Preclinical Development Expert Group for critical review of the paper and supporting the survey, and EFPIA staff for the conduct of the survey and blinding of survey results. Funding Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-toxicokinetic-data-for-afidopyropen-to-determ_2020_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32194133", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. Results Discussion Funding source Author contributions Declaration of competing interest Supplementary data References", "Funding": "Funding source The work described in this paper was funded by BASF Corporation. Exponent was contracted to write this manuscript. Results Discussion Funding source Author contributions Declaration of competing interest Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Use-of-toxicokinetics-to-support-chemical-evaluation_2012_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22198561", "content": {"CoiStatement": "(lo w er 3 os es r2 = 0 .9 94 (l ow er 3 d os es ) Expected dose- dependent increase Fig. 5. TK analysis of Spinetoram in male and female mouse serum following dietary administration for 28 days. S. Creton et al. / Regulatory Toxicology and Pharmacology 62 (2012) 241\u2013247 247 data are becoming increasingly available for many chemicals, and TK can help place these data into context. Information on systemic and target tissue dose is of greater interpretative value than exter- nal dose (Bus and Becker, 2009), and consideration of TK can thus support the development of a more coherent and scientifically sound safety package. As discussed in this paper, an important area where TK can help ensure data of relevance for risk assessment are generated and also support refinement of animal use is through the selection of KMDs where there is an adequate margin between the dose and antici- pated human exposures. While a relatively new approach to high dose selection compared with the MTD (Saghir et al., 2009, 2006, 2011), the KMD is gaining increasing recognition. The draft OECD guidance on the conduct of chronic toxicity and carcinogenicity studies acknowledges that saturation of TK processes at higher doses results in \u2018systemic exposures to parent compound or metabolite that would not be expected in the real life human expo- sures for which risk assessments are needed\u2019 (OECD, 2010b). Ef- fects occurring at doses exceeding the KMD are thus also not of relevance for hazard classification, which as with risk assessment has the goal of protecting human health. Draft guidance accompa- nying the EU regulation on plant protection products (EC 1107/ 2009 (EC, 2010)) states that dose selection should consider TK data such as saturation of absorption (EC, 2010), while REACH guidance specifically mentions the possibility of setting the highest dose in repeat dose studies as a kinetically derived MTD based on depar- ture from linearity in TK processes (ECHA, 2008). Use of the KMD should therefore be acceptable for satisfying regulatory needs: in- deed, the US Environmental Protection Agency (EPA) and Health Canada have recently accepted the use of TK data for the selection of doses for the extended one-generation reproductive toxicity study for an agrochemical, 2,4-D (EPA, 2010; Saghir et al., 2009, 2011). The present paper has aimed to illustrate some general points on how the science of toxicology testing of chemicals and agro- chemicals can be improved through inclusion of TK. Several of the authors are currently engaged in preparing further papers set- ting out in detail how TK studies and modelling can be used in practice as part of an integrated testing strategy (McCoy et al., sub- mitted for publication; Saghir et al., submitted for publication), including the use of statistics to aid selection of a KMD (McFadden et al., submitted for publication). Further efforts to promote the appropriate use of TK in toxicology studies, such as the introduc- tion of a general OECD guidance document on the conduct and application of TK, would be extremely valuable. Conflict of interest statement Stuart Creton., Matthew P Dent., Gabrielle M Hawksworth., Simon Parry. and Kim Z Travis. declare no conflicts of inter- est. Will Davies. is employed by a contract research organisation that con- ducts toxicokinetics on pharmaceutical candidates, and might in future be asked to conduct toxicokinetic work with agrochemicals and chemicals. James S Bus., Michael J Bartels., Richard Billington. and Shakil A Saghir. are employed by the company that makes some of the chemicals presented in the manuscript. References Barfield, M. et al., 2008. Application of dried blood spots combined with HPLC\u2013MS/ MS for the quantification of acetaminophen in toxicokinetic studies. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 870, 32\u201337. Barton, H.A. et al., 2006. The acquisition and application of absorption, distribution, metabolism, and excretion (ADME) data in agricultural chemical safety assessments. Crit. Rev. Toxicol. 36, 9\u201335. Billington, R. et al., 2010. The mouse carcinogenicity study is no longer a scientifically justifiable core data requirement for the safety assessment of pesticides. Crit. Rev. Toxicol. 40, 35\u201349. Boobis, A.R. et al., 2006. IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit. Rev. Toxicol. 36, 781\u2013792. Boobis, A.R. et al., 2008. IPCS framework for analyzing the relevance of a noncancer mode of action for humans. Crit. Rev. Toxicol. 38, 87\u201396. Buckley, L.A., Dorato, M.A., 2009. High dose selection in general toxicity studies for drug development: a pharmaceutical industry perspective. Regul. Toxicol. Pharmacol. 54, 301\u2013307. Bus, J.S., Becker, R.A., 2009. Toxicity testing in the 21st century: a view from the chemical industry. Toxicol. Sci. 112, 297\u2013302. Chasseaud, L.F., 1992. The importance of pharmacokinetic/toxicokinetic and metabolic information in carcinogenicity study design. Drug Inform. J. 26, 445\u2013455. CHMP, 2005. Guideline on the evaluation of control samples in nonclinical safety studies: checking for contamination with the test substance. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency. Counts, J.L., Goodman, J.I., 1995. Principles underlying dose selection for, and extrapolation from, the carcinogen bioassay: dose influences mechanism. Regul. Toxicol. Pharmacol. 21, 418\u2013421. Creton, S. et al., 2009. Application of toxicokinetics to improve chemical risk assessment: implications for the use of animals. Regul. Toxicol. Pharmacol. 55, 291\u2013299. Devine, H., 2006. Preventing the contamination of control samples by test article during toxicokinetic investigations. Toxicol. Sci. 90, 119. EC, 2010. DG SANCO/11802/1010 Rev.0 Draft guidance to EC 1107/2009. ECHA, 2008. Guidance on information requirements and chemical safety assessment. Chapter R.7.12: Guidance on toxicokinetics. European Chemicals Agency, Helsinki. EPA, 2010. U., Memorandum written by Taylor L and Metzger M on November 30, 2010: 2,4-D: review of extended 1-generation reproduction study and dose- range-finding and pharmacokinetic titration studies. Decision No. 431951. Office of Chemical Safety and Pollution Prevention, US Environmental Protection Agency, Washington, DC. ICH, 1995. CPMP/ICH/384/95. Note for guidance on toxicokinetics: a guidance for assessing systemic exposure in toxicology studies. ICH, 2008. Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3(R2). Draft International Conference on Harmonisation Consensus Guideline. Accessed on November 02, 2011. Available from: <http://www.fda.gov/ RegulatoryInformation/Guidances/ucm129520.htm>. McCoy, A.T., et al., submitted for publication. TK Modeler version 1: a Microsoft\ufffd Excel\ufffd-based modeling software for the prediction of diurnal plasma concentration for toxicokinetic use. Regul. Toxicol. Pharmacol. McFadden, L.G., et al., submitted for publication. Statistical methodology to determine nonlinearity of systemic exposure across doses. Regul. Toxicol. Pharmacol. McGregor, D. et al., 2010. Guidance for the classification of carcinogens under the Globally Harmonised System of Classification and Labelling of Chemicals (GHS). Crit. Rev. Toxicol. 40, 245\u2013285. Morgan, D.G. et al., 1994. The application of toxicokinetic data to dosage selection in toxicology studies. Toxicol. Pathol. 22, 112\u2013123. Nicholls, I. et al., 2005. The presence of drug in control samples during toxicokinetic investigations \u2013 a Novartis perspective. Regul. Toxicol. Pharmacol. 42, 172\u2013178. OECD, 2010a. Test Guideline 417: Toxicokinetics OECD Guidelines for the Testing of Chemicals. OECD, Paris. OECD, 2010b. Draft guidance document No. 116 on the design and conduct of chronic toxicity and carcinogenicity studies, supporting TG 451, 452 and 453. 17 December 2010. Series on Testing and Assessment. OECD, Paris. OECD, 2011a. Test Guideline 443: Extended One Generation Reproductive Toxicity Study. OECD Guidelines for the Testing of Chemicals. OECD, Paris. OECD, 2011b. Draft guidance document 151 in support of OECD test guideline 443 on an extended one generation reproductive toxicity study: November 2011. Series on Testing and Assessment. OECD, Paris. Rhomberg, L.R. et al., 2007. Issues in the design and interpretation of chronic toxicity and carcinogenicity studies in rodents: approaches to dose selection. Crit. Rev. Toxicol. 37, 729\u2013837. Saghir, S.A., et al., submitted for publication. Assessment of diurnal systemic dose (toxicokinetics) of agrochemicals in regulatory toxicity testing \u2013 an integrated approach without additional animals use. Regul. Toxicol. Pharmacol. Saghir, S.A. et al., 2009. A dietary dose range-finding and toxicokinetic (TK) study of 2,4-dichlorophenoxyacetic acid (2,4-D) in adult CRL:CD(SD) rats and their offspring: I. Toxicokinetics. Toxicologist 108, 1161. Saghir, S.A. et al., 2006. Strategies to assess systemic exposure of chemicals in subchronic/chronic diet and drinking water studies. Toxicol. Appl. Pharmacol. 211, 245\u2013260. Saghir, S.A. et al., 2011. Integration of toxicokinetics into guideline studies of a new agrochemical. Toxicologist 120, 2107. Slikker Jr., W. et al., 2004a. Dose-dependent transitions in mechanisms of toxicity: case studies. Toxicol. Appl. Pharmacol. 201, 226\u2013294. Slikker Jr., W. et al., 2004b. Dose-dependent transitions in mechanisms of toxicity. Toxicol. Appl. Pharmacol. 201, 203\u2013225. Timchalk, C., 2004. Comparative inter-species pharmacokinetics of phenoxyacetic acid herbicides and related organic acids. Evidence that the dog is not a relevant species for evaluation of human health risk. Toxicology 200, 1\u201319. Yeary, R.A., 1996. Urinary excretion of 2,4-D in commercial lawn specialists. Appl. Ind. Hyg. 3, 119\u2013121. http://www.fda.gov/RegulatoryInformation/Guidances/ucm129520.htm http://www.fda.gov/RegulatoryInformation/Guidances/ucm129520.htm Use of toxicokinetics to support chemical evaluation: Informing high dose selection and study interpretation 1 Introduction 2 TK in chemical development and safety assessment 3 Dose selection 3.1 Case studies \u2013 dose selection 3.1.1 Case study 1 \u2013 2,4-D: saturation of elimination 3.1.2 Case study 2 \u2013 compound A: saturation of systemic exposure 3.1.3 Case study 3 \u2013 Spinetoram: species-dependent nonlinear kinetics 4 Discussion Conflict of interest statement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/User-oriented-independent-analysis-of-the-toxic-load-mo_2019_Regulatory-Toxi.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/30978368", "content": {"Funding": "Funding This work was supported by the Defense Threat Reduction Agency, USA and the central research program of the Institute for Defense Analyses, USA. Lees, Frank, 2004. 18.3.6 Toxic load and 18.3.7 Toxic load-response relation. In: Frank Lees (Sam Mannan (Ed.), In Lees' Loss Prevention in the Process Industries, third ed. Butterworth-Heineman 18/11. Ostwald, Wo., Dernoscheck, A., 1910. \u00dcber die Bieziehungen zwischen Adsorption und Giftigkeit. In: Zeitschrift f\u00fcr Chemie und Industrie der Kolloide (Kolloid-Zeitschrift), vol. 6. pp. 297\u2013307. Pauluhn, J., 2016a. Acute inhalation toxicity of carbon monoxide and hydrogen cyanide revisted: comparison of models to disentangle the concentration \u00d7 time conundrum of lethality and incapacitation. Regul. Toxicol. Pharmacol. 80, 173\u2013182. Pauluhn, J., 2016b. Risk assessment in combustion toxicology: should carbon dioxide be recognized as a modified of toxicity or separate toxicological entity? Toxicol. Lett. 262, 142\u2013152. Pauluhn, J., 2016c. Time scaling of dose and time to response: the toxic load exponent. In: Salem, H., Katz, S.A. (Eds.), Inhalation Toxicology, third ed. CRC Press, pp. 121\u2013136. Pauluhn, J., 2017. \"Corrigendum to 'Risk assessment in combustion toxicology: should carbon dioxide be recognized as a modified of toxicity or separate toxicological en- tity?' [Toxicol. Lett. 262 (2016) 142\u2013152]. Toxicol. Lett. 275, 27. P\u00e9ry, A.R.R., Troise, A.,, Tissot, S., Vincent, J.M., 2010. An impact-effect mathematical model incorporating the influence of exposures to fluctuating concentrations in a dispersing plume of pollutant in the atmosphere. Regul. Toxicol. Pharmacol. 57, 124\u2013128. Platt, N., Warner, S., Nunes, S.M., 2008. Evaluation plan for comparative investigation of source term estimation algorithms using Fusion Field Trial 2007 data. Croatian Meteorological Journal 43, 224\u2013229. Platt, N., Kimball II, W.R., Urban, J.T., 2014. The use of probabilistic plume predictions for the consequence assessment of atmospheric releases of hazardous materials. Int. J. Environ. Pollut. 55, 3\u201312. Rhomberg, L.R., 2009. Uptake kinetics, species differences, and the determination of equivalent combinations of air concentration and exposure duration for assessment of acute inhalation toxicity. Human and Ecological Risk Assessment 15, 1099\u20131145. Ride, D.J., 1984. An assessment of the effects of fluctuations on the severity of poisoning by toxic vapours. J. Hazard Mater. 9, 235\u2013240. Rusch, G.M., 2006. The development and application of acute exposure guideline levels for hazardous substances. In: Salem, H., Katz, S.A. (Eds.), Inhalation Toxicology, second ed. CRC Press, pp. 39\u201360. Saltzman, B.E., 1996. Assessment of health effects of fluctuating concentrations using simplified pharmacokinetic algorithms. J. Air Waste Manag. Assoc. 46, 1022\u20131034. Saltzman, B.E., Fox, S.H., 1986. Biological significance of fluctuating concentrations of carbon monoxide. Environ. Sci. Technol. 20, 916\u2013923. Sommerville, D.R., Park, K.H., Kierzewski, M.O., Dunkel, M.D., Hutton, M.I., Pinto, N.A., 2006. Toxic load modeling. In: Salem, H., Katz, S.A. (Eds.), Inhalation Toxicology, second ed. CRC Press, pp. 137\u2013157. Sommerville, D.R., Bray, J.J., Reutter-Christy, S.A., Jablonski, R.E., Shelly, E.E., 2009. Review and Assessment of Chlorine Mammalian Lethality Data and the Development of a Human Estimate \u2013 R-1. Department of Homeland Security, Chemical Security Analysis Center. Stage, S.A., 2004. Determination of acute exposure guideline levels in a dispersion model. J. Air Waste Manag. Assoc. 54, 49\u201359. Sweeney, L.M., Sharits, B., Gargas, N.M., Doyle, T., Wong, B.A., James, R.A., 2013. Acute Lethality of Inhaled Hydrogen Cyanide in the Laboratory Rat: Impact of Concentration X Time Profile and Evaluation of the Predictivity of \"Toxic Load\" Models. Wright Patterson Air Force Base. Naval Medical Research Unit Dayton, Ohio. Sweeney, L.M., Sommerville, D.R., Channel, S.R., 2014. Impact of non-constant con- centration exposure on lethality of inhaled hydrogen cyanide. Toxicol. Sci. 138, 205\u2013216. Sweeney, L.M., Sommerville, D.R., Channel, S.R., Sharits, B.C., Gargas, N.M., Gut Jr., C.P., 2015. Evaluating the validity and applicable domain of the toxic load model: impact of concentration vs. time profile on inhalation lethality of hydrogen cyanide. Regul. Toxicol. Pharmacol. 71, 571\u2013584. Sweeney, L.M., Sommerville, D.R., Goodwin, M.R., James, R.A., Channel, S.R., 2016. Acute toxicity when concentration varies with time: a case study with carbon mon- oxide inhalation by rats. Regul. Toxicol. Pharmacol. 80, 102\u2013115. Sykes, R.I., Parker, S.F., Henn, D.S., Chowdhury, B., 2016. SCIPUFF Version 3.0 Technical Documentation. Sage Management, Princeton, New Jersey. ten Berge, W.F., van Heemst, M.V., 1983. Fourth International Symposium on Loss Prevention and Safety Promotion in the Process Industries, vol. 1. Institute of Chemical Engineers, Rugby, United Kingdom, pp. 11. ten Berge, W.F., Zwart, A., Appelman, L.M., 1986. Concentration\u2013time mortality response relationship of irritant and systemically acting vapours and gases. J. Hazard Mater. 13, 301\u2013309. Urban, J.T., Galvin, K.J., Platt, N., Bieringer, P.E., Bierbach, G., Annunzio, A.J., 2014. Comparison of hazard area and casualty predictions of a small-scale chemical attack using various toxic load toxicity models. Int. J. Environ. Pollut. 54, 222\u2013232. U.S. Army Chemical School, 2005. \"Potential Military Chemical/Biological Agents and Compounds.\" Army, Marine Corps, Navy, Air Force Multi-Service Tactics and Procedures, FM 3-11.9/MCRP 3-37.1B/NTRP 3-11.32/AFTTP(I) 3-2.55. U.S. Environmental Protection Agency, 2016. Benchmark Dose Software (BMDS) User Manual. U.S. Environmental Protection Agency, Washington, D.C. U.S. Environmental Protection Agency, 2008. Ten Berge CxT Models (External Draft Version 2.0). U.S. Environmental Protection Agency National Center for Environmental Assessment, Research Triangle Park, North Carolina. Wilson, David J., 1995. Concentration Fluctuations and Averaging Time in Vapor Clouds. Center for Chemical Process Safety of the American Institute of Chemical Engineers, New York, New York. Witschi, H., 1999. Some notes on the history of Haber's Law. Toxicol. Sci. 50, 164\u2013168. Yee, E., 1999. An impact-effect mathematical model incorporating the influence of ex- posures to fluctuating concentrations in a dispersing plume of pollutant in the at- mosphere. J. Expo. Anal. Environ. Epidemiol. 9, 300\u2013311. A. Slawik, et al. Regulatory Toxicology and Pharmacology 106 (2019) 27\u201342 42 https://doi.org/10.1016/j.yrtph.2019.04.003 https://doi.org/10.1016/j.yrtph.2019.04.003 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref1 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref1 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref1 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref1 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref2 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref2 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref3 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref3 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref4 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref4 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref4 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref4 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref4 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref5 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref5 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref5 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref6 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref6 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref7 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref7 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref8 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref8 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref9 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref9 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref10 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref10 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref11 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref11 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref12 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref12 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref13 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref13 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref14 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref14 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref14 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref15 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref15 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref16 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref16 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref16 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref17 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref17 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref17 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref18 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref18 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref18 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref19 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref19 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref19 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref20 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref20 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref21 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref21 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref21 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref200 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref200 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref200 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref200 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref22 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref22 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref22 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref23 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref23 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref23 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref24 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref24 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref24 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref25 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref25 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref26 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref26 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref26 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref27 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref27 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref28 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref28 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref29 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref29 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref29 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref30 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref30 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref30 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref30 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref31 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref31 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref32 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref32 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref32 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref32 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref33 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref33 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref33 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref34 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref34 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref34 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref34 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref35 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref35 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref35 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref36 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref36 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref37 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref37 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref37 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref38 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref38 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref38 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref39 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref39 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref39 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref40 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref40 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref40 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref41 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref41 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref42 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref42 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref42 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref43 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref43 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref43 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref44 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref45 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref45 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref45 User-oriented independent analysis of the toxic load model's ability to predict the effects of time-varying toxic inhalation exposures Introduction Materials and methods The ECBC/NAMRU-D toxicology experiments Extensions of the toxic load model to the case of time-varying exposures Outline of methodology Methodological differences from prior work by Sweeney et al. Results and discussion HCN experiments, fitting the constant-concentration profiles HCN experiments, accuracy of model predictions for time-varying exposures Sensitivity of results to parameter set CO experiments, fitting the constant-concentration profiles CO experiments, accuracy of predictions for time-varying exposures Conclusions Potential approaches to modeling inhalation toxicity Funding Acknowledgements Supplementary data References", "Acknowledgement": "Acknowledgements The authors would like to thank the project monitor for this work, Mr. Richard N. Fry of the Defense Threat Reduction Agency. Lees, Frank, 2004. 18.3.6 Toxic load and 18.3.7 Toxic load-response relation. In: Frank Lees (Sam Mannan (Ed.), In Lees' Loss Prevention in the Process Industries, third ed. Butterworth-Heineman 18/11. Ostwald, Wo., Dernoscheck, A., 1910. \u00dcber die Bieziehungen zwischen Adsorption und Giftigkeit. In: Zeitschrift f\u00fcr Chemie und Industrie der Kolloide (Kolloid-Zeitschrift), vol. 6. pp. 297\u2013307. Pauluhn, J., 2016a. Acute inhalation toxicity of carbon monoxide and hydrogen cyanide revisted: comparison of models to disentangle the concentration \u00d7 time conundrum of lethality and incapacitation. Regul. Toxicol. Pharmacol. 80, 173\u2013182. Pauluhn, J., 2016b. Risk assessment in combustion toxicology: should carbon dioxide be recognized as a modified of toxicity or separate toxicological entity? Toxicol. Lett. 262, 142\u2013152. Pauluhn, J., 2016c. Time scaling of dose and time to response: the toxic load exponent. In: Salem, H., Katz, S.A. (Eds.), Inhalation Toxicology, third ed. CRC Press, pp. 121\u2013136. Pauluhn, J., 2017. \"Corrigendum to 'Risk assessment in combustion toxicology: should carbon dioxide be recognized as a modified of toxicity or separate toxicological en- tity?' [Toxicol. Lett. 262 (2016) 142\u2013152]. Toxicol. Lett. 275, 27. P\u00e9ry, A.R.R., Troise, A.,, Tissot, S., Vincent, J.M., 2010. An impact-effect mathematical model incorporating the influence of exposures to fluctuating concentrations in a dispersing plume of pollutant in the atmosphere. Regul. Toxicol. Pharmacol. 57, 124\u2013128. Platt, N., Warner, S., Nunes, S.M., 2008. Evaluation plan for comparative investigation of source term estimation algorithms using Fusion Field Trial 2007 data. Croatian Meteorological Journal 43, 224\u2013229. Platt, N., Kimball II, W.R., Urban, J.T., 2014. The use of probabilistic plume predictions for the consequence assessment of atmospheric releases of hazardous materials. Int. J. Environ. Pollut. 55, 3\u201312. Rhomberg, L.R., 2009. Uptake kinetics, species differences, and the determination of equivalent combinations of air concentration and exposure duration for assessment of acute inhalation toxicity. Human and Ecological Risk Assessment 15, 1099\u20131145. Ride, D.J., 1984. An assessment of the effects of fluctuations on the severity of poisoning by toxic vapours. J. Hazard Mater. 9, 235\u2013240. Rusch, G.M., 2006. The development and application of acute exposure guideline levels for hazardous substances. In: Salem, H., Katz, S.A. (Eds.), Inhalation Toxicology, second ed. CRC Press, pp. 39\u201360. Saltzman, B.E., 1996. Assessment of health effects of fluctuating concentrations using simplified pharmacokinetic algorithms. J. Air Waste Manag. Assoc. 46, 1022\u20131034. Saltzman, B.E., Fox, S.H., 1986. Biological significance of fluctuating concentrations of carbon monoxide. Environ. Sci. Technol. 20, 916\u2013923. Sommerville, D.R., Park, K.H., Kierzewski, M.O., Dunkel, M.D., Hutton, M.I., Pinto, N.A., 2006. Toxic load modeling. In: Salem, H., Katz, S.A. (Eds.), Inhalation Toxicology, second ed. CRC Press, pp. 137\u2013157. Sommerville, D.R., Bray, J.J., Reutter-Christy, S.A., Jablonski, R.E., Shelly, E.E., 2009. Review and Assessment of Chlorine Mammalian Lethality Data and the Development of a Human Estimate \u2013 R-1. Department of Homeland Security, Chemical Security Analysis Center. Stage, S.A., 2004. Determination of acute exposure guideline levels in a dispersion model. J. Air Waste Manag. Assoc. 54, 49\u201359. Sweeney, L.M., Sharits, B., Gargas, N.M., Doyle, T., Wong, B.A., James, R.A., 2013. Acute Lethality of Inhaled Hydrogen Cyanide in the Laboratory Rat: Impact of Concentration X Time Profile and Evaluation of the Predictivity of \"Toxic Load\" Models. Wright Patterson Air Force Base. Naval Medical Research Unit Dayton, Ohio. Sweeney, L.M., Sommerville, D.R., Channel, S.R., 2014. Impact of non-constant con- centration exposure on lethality of inhaled hydrogen cyanide. Toxicol. Sci. 138, 205\u2013216. Sweeney, L.M., Sommerville, D.R., Channel, S.R., Sharits, B.C., Gargas, N.M., Gut Jr., C.P., 2015. Evaluating the validity and applicable domain of the toxic load model: impact of concentration vs. time profile on inhalation lethality of hydrogen cyanide. Regul. Toxicol. Pharmacol. 71, 571\u2013584. Sweeney, L.M., Sommerville, D.R., Goodwin, M.R., James, R.A., Channel, S.R., 2016. Acute toxicity when concentration varies with time: a case study with carbon mon- oxide inhalation by rats. Regul. Toxicol. Pharmacol. 80, 102\u2013115. Sykes, R.I., Parker, S.F., Henn, D.S., Chowdhury, B., 2016. SCIPUFF Version 3.0 Technical Documentation. Sage Management, Princeton, New Jersey. ten Berge, W.F., van Heemst, M.V., 1983. Fourth International Symposium on Loss Prevention and Safety Promotion in the Process Industries, vol. 1. Institute of Chemical Engineers, Rugby, United Kingdom, pp. 11. ten Berge, W.F., Zwart, A., Appelman, L.M., 1986. Concentration\u2013time mortality response relationship of irritant and systemically acting vapours and gases. J. Hazard Mater. 13, 301\u2013309. Urban, J.T., Galvin, K.J., Platt, N., Bieringer, P.E., Bierbach, G., Annunzio, A.J., 2014. Comparison of hazard area and casualty predictions of a small-scale chemical attack using various toxic load toxicity models. Int. J. Environ. Pollut. 54, 222\u2013232. U.S. Army Chemical School, 2005. \"Potential Military Chemical/Biological Agents and Compounds.\" Army, Marine Corps, Navy, Air Force Multi-Service Tactics and Procedures, FM 3-11.9/MCRP 3-37.1B/NTRP 3-11.32/AFTTP(I) 3-2.55. U.S. Environmental Protection Agency, 2016. Benchmark Dose Software (BMDS) User Manual. U.S. Environmental Protection Agency, Washington, D.C. U.S. Environmental Protection Agency, 2008. Ten Berge CxT Models (External Draft Version 2.0). U.S. Environmental Protection Agency National Center for Environmental Assessment, Research Triangle Park, North Carolina. Wilson, David J., 1995. Concentration Fluctuations and Averaging Time in Vapor Clouds. Center for Chemical Process Safety of the American Institute of Chemical Engineers, New York, New York. Witschi, H., 1999. Some notes on the history of Haber's Law. Toxicol. Sci. 50, 164\u2013168. Yee, E., 1999. An impact-effect mathematical model incorporating the influence of ex- posures to fluctuating concentrations in a dispersing plume of pollutant in the at- mosphere. J. Expo. Anal. Environ. Epidemiol. 9, 300\u2013311. A. Slawik, et al. Regulatory Toxicology and Pharmacology 106 (2019) 27\u201342 42 https://doi.org/10.1016/j.yrtph.2019.04.003 https://doi.org/10.1016/j.yrtph.2019.04.003 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref1 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref1 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref1 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref1 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref2 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref2 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref3 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref3 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref4 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref4 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref4 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref4 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref4 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref5 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref5 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref5 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref6 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref6 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref7 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref7 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref8 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref8 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref9 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref9 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref10 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref10 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref11 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref11 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref12 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref12 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref13 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref13 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref14 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref14 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref14 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref15 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref15 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref16 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref16 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref16 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref17 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref17 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref17 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref18 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref18 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref18 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref19 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref19 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref19 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref20 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref20 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref21 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref21 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref21 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref200 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref200 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref200 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref200 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref22 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref22 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref22 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref23 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref23 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref23 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref24 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref24 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref24 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref25 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref25 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref26 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref26 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref26 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref27 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref27 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref28 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref28 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref29 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref29 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref29 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref30 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref30 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref30 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref30 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref31 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref31 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref32 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref32 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref32 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref32 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref33 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref33 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref33 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref34 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref34 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref34 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref34 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref35 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref35 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref35 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref36 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref36 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref37 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref37 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref37 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref38 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref38 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref38 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref39 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref39 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref39 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref40 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref40 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref40 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref41 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref41 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref42 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref42 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref42 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref43 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref43 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref43 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref44 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref45 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref45 http://refhub.elsevier.com/S0273-2300(19)30094-7/sref45 User-oriented independent analysis of the toxic load model's ability to predict the effects of time-varying toxic inhalation exposures Introduction Materials and methods The ECBC/NAMRU-D toxicology experiments Extensions of the toxic load model to the case of time-varying exposures Outline of methodology Methodological differences from prior work by Sweeney et al. Results and discussion HCN experiments, fitting the constant-concentration profiles HCN experiments, accuracy of model predictions for time-varying exposures Sensitivity of results to parameter set CO experiments, fitting the constant-concentration profiles CO experiments, accuracy of predictions for time-varying exposures Conclusions Potential approaches to modeling inhalation toxicity Funding Acknowledgements Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Using-Carcinogenic-Potency-Ranking-to-Assign-Air_2002_Regulatory-Toxicology-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/12473407", "content": {"Acknowledgement": "CONCLUlrike Schuhmacher-WolzION ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Using-Human-Data-to-Protect-the-Public-_2001_Regulatory-Toxicology-and-Pharm.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/11350206", "content": {"Acknowledgement": "DISCUSSION CONCLUSIONS AND FUTURE DIRECTIONS ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Using-default-methodologies-to-derive-an-accep_2016_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27233926", "content": {"Funding": "The statements and conclusions in this paper reflect the opin- ions of the authors and do not necessarily represent official policies of the organizations as listed on the title page. The authors would like to acknowledge Patricia Weideman, Andrew Maier, and Alison Pecquet for organizing and facilitating the workshop that served as the basis for developing this manuscript. The authors would also like to thank all of the participants of the workshop for their con- tributions at the workshop and subsequent reviews of this manu- script, including: Courtney Callis, Andreas Flueckiger, Janet Gould, Eileen Hayes, Robert Jolly, Ester Lovsin Barle, Wendy Luo, Andrew Maier, Lance Molnar, Bruce Naumann, Michael Olson, Thomas Pfister, Reena Sandhu, Edward Sargent, Bryan Shipp, Brad Stanard, Anthony Streeter, Robert Sussman, and Andrew Walsh. The manuscript was developed in part with funding from Genentech Inc. for organizational and editorial staff activities. Transparency document Transparency document related to this article can be found online at http://dx.doi.org/10.1016/j.yrtph.2016.05.026.", "Acknowledgement": "Acknowledgements The statements and conclusions in this paper reflect the opin- ions of the authors and do not necessarily represent official policies of the organizations as listed on the title page. The authors would like to acknowledge Patricia Weideman, Andrew Maier, and Alison Pecquet for organizing and facilitating the workshop that served as the basis for developing this manuscript. The authors would also like to thank all of the participants of the workshop for their con- tributions at the workshop and subsequent reviews of this manu- script, including: Courtney Callis, Andreas Flueckiger, Janet Gould, Eileen Hayes, Robert Jolly, Ester Lovsin Barle, Wendy Luo, Andrew Maier, Lance Molnar, Bruce Naumann, Michael Olson, Thomas Pfister, Reena Sandhu, Edward Sargent, Bryan Shipp, Brad Stanard, Anthony Streeter, Robert Sussman, and Andrew Walsh. The manuscript was developed in part with funding from Genentech Inc. for organizational and editorial staff activities. Transparency document 3. Empirical comparisons of default approaches versus health-based ADE 4. Conclusions/recommendations Acknowledgements Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Using-fewer-animals-to-identify-chemical-eye-hazards--_2011_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21745525", "content": {"CoiStatement": "Conflict of Interest The authors declare that there are no conflicts of interest. References The authors declare that there are no conflicts of interest. References Animal Welfare Act, 2010 (amended). Public Law 89-544, 7 U.S.C. 2131 et seq. ChemIDplus. Bethesda, MD, National Library of Medicine. Available: <http:// chem.sis.nlm.nih.gov/chemidplus/> (accessed 20.05.11.). CPSC, 2010. Federal Hazardous Substances Act Regulations, 16 CFR 1500. deSilva, O. et al., 1997. Evaluation of eye irritation potential: statistical analysis and tier testing strategies. Food Chem. Toxicol. 35, 159\u2013164. DeSousa, D. et al., 1984. Statistical consequences of reducing the number of rabbits utilized in eye irritation testing: data on 67 petrochemicals. Toxicol. Appl. Pharmacol. 76, 234\u2013242. Using fewer animals to identify chemical eye hazards: Revised criteria necessary to maintain equivalent hazard classification 1 Introduction 2 Testing requirements 3 Optimization of the number of positive animals required for FHSA hazard classification and labeling 4 Comparison of three strategies for reducing animal use for FHSA ocular hazard classification 5 Previous proposals to reduce the number of animals used for ocular safety testing 6 Conclusion Funding Conflict of Interest References", "Funding": "Funding This article may be the work product of an employee or group of employees of the National Institute of Environmental Health Sci- ences (NIEHS), National Institutes of Health (NIH), however, the statements, opinions or conclusions contained therein do not nec- essarily represent the statements, opinions or conclusions of NIEHS, NIH or the United States government. ILS staff are sup- ported by NIEHS contract N01-ES 35504. Using fewer animals to identify chemical eye hazards: Revised criteria necessary to maintain equivalent hazard classification 1 Introduction 2 Testing requirements 3 Optimization of the number of positive animals required for FHSA hazard classification and labeling 4 Comparison of three strategies for reducing animal use for FHSA ocular hazard classification 5 Previous proposals to reduce the number of animals used for ocular safety testing 6 Conclusion Funding Conflict of Interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Using-gene-expression-profiling-to-evaluate-cellular-resp_2015_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26210822", "content": {"CoiStatement": "Conflicts of interest Michael B. Black, Darol E. Dodd, Patrick D. McMullen, Salil Pendse and Melvin E. Andersen each have nothing to disclose. 3. Results 4. Discussion 5. Conclusions Conflicts of interest Acknowledgments Transparency document Appendix A. Supplementary data References", "Funding": "Scientific oversight for this work was funded by the U.S. Department of Defense (DoD) as part of funding opportunity W81XWH-BAA07-1, under a cooperative agreement that is awar- ded and administered by the U.S. Army Medical Research and Materiel Command (USAMRMC) and the Telemedicine & Advanced Technology Research Center (TATRC), Fort Detrick, Maryland 21702, under Contract Number: W81XWH-09-2-006. Primary funding came from the Vanadium Producers & Reclaimers Association. Transparency document", "Acknowledgement": "Acknowledgments Scientific oversight for this work was funded by the U.S. Department of Defense (DoD) as part of funding opportunity W81XWH-BAA07-1, under a cooperative agreement that is awar- ded and administered by the U.S. Army Medical Research and Materiel Command (USAMRMC) and the Telemedicine & Advanced Technology Research Center (TATRC), Fort Detrick, Maryland 21702, under Contract Number: W81XWH-09-2-006. Primary funding came from the Vanadium Producers & Reclaimers Association. 3. Results 4. Discussion 5. Conclusions Conflicts of interest Acknowledgments Transparency document Appendix A. Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/Using-historical-control-data-in-bioassays-fo_2021_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34364928", "content": {"CoiStatement": "6 Discussion 7 Conclusion Funding body information CRediT authorship contribution statement Declaration of competing interest References", "Funding": "6 Discussion 7 Conclusion Funding body information CRediT authorship contribution statement Declaration of competing interest References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Using-in-vitro-in-silico-data-for-consumer-safety-asse_2015_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26107290", "content": {"CoiStatement": "4. Discussion 5. Conclusion Conflicts of interest Acknowledgments Transparency document References", "Acknowledgement": "4. Discussion 5. Conclusion Conflicts of interest Acknowledgments Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Using-physiologically-based-pharmacokinetic-modeling-and_2016_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26776754", "content": {"Funding": "Co-authors T S Poet, D E Rodwell, and C R Kirman are independent consultants who have received funding from the NMP Producers Groups for their work on this manuscript. The funders of this work were given an opportunity to review a draft manuscript for the purposes of improving its clarity, but did not have a role in methods design, data collection and analysis, or results interpretation. Appendix A. Supplementary data", "Acknowledgement": "Acknowledgments Co-authors T S Poet, D E Rodwell, and C R Kirman are independent consultants who have received funding from the NMP Producers Groups for their work on this manuscript. The funders of this work were given an opportunity to review a draft manuscript for the purposes of improving its clarity, but did not have a role in methods design, data collection and analysis, or results interpretation. 4. Discussion/conclusions Acknowledgments Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Using-the-fish-plasma-model-for-comparative-hazard-ident_2011_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21889559", "content": {"CoiStatement": "Conflict of interest All authors declare that they have no competing financial interests. 5 Conclusion Conflict of interest Acknowledgements Appendix A Supplementary data References", "Acknowledgement": "Acknowledgements We gratefully acknowledged the receipt of a grant from the Fed- eral Environmental Agency (UBA), project NutzEn, No. Z 6-97 406/ 576 and would like to thank our colleagues Moustafa Ali Aychech, Kai Uwe Goss, Karen Hanisch and Eberhard K\u00fcster for fruitful dis- cussions. For constructive criticism we would like to thank three anonymous reviewer. Part of this study was financially supported by the HGF programme topic CITE. 5 Conclusion Conflict of interest Acknowledgements Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Using-the-negative-exponential-distribution-to-quantitativ_2012_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22728684", "content": {"CoiStatement": "Conflict of interest statement Peter N Lee, founder of P N Lee Statistics and Computing Ltd., is an independent consultant in statistics and an advisor in the fields of epidemiology and toxicology to a number of tobacco, pharma- ceutical and chemical companies. This includes Philip Morris Prod- ucts S.A., the sponsor of this study. John S Fry and Jan S Hamling are employees of P N Lee Statistics and Computing Ltd. 5 Conclusions Conflict of interest statement Authors\u2019 contributions Acknowledgments Appendix A Supplementary data References", "Acknowledgement": "Acknowledgments This research was funded by Philip Morris Products S.A. We thank them for their support. However the opinions and conclu- sions of the authors are their own, and do not necessarily reflect the position of Philip Morris Products S.A. We thank Pauline Was- sell, Diana Morris and Yvonne Cooper for assistance in typing the various drafts of the paper and obtaining the relevant literature. 5 Conclusions Conflict of interest statement Authors\u2019 contributions Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Using-urinary-solubility-data-to-estimate-the-level-of-saf_2010_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20233599", "content": {"CoiStatement": "The use of solubility values generated with adult human urine to address safety in infants has to be taken into account. Urine of human infants has lower specific gravity and osmolarity (\ufffd680 mOsm) than urine from adults (\ufffd1080 mOsm) and it con- tains a larger fraction of uric acid (Grivna et al., 1997; Manz and Wentz, 2003; Remer et al., 2003). The lower levels of some solutes, such as citrate, phosphate and magnesium, which could potentially compete for binding with MEL (Marchewka and Pietraszko, 2003) and/or CYA, might suggest that infants may be more susceptible to MEL + CYA. In contrast there are higher concentrations of uric acid which might complex with MEL and reduce the potential for MEL + CYA crystallization. However, the fact that uric acid may be elevated in infants, reducing MEL + CYA crystallization, could actually make the infant at increased risk for MEL\u2013uric acid crys- tals and resulting potential adverse effects. In this case the risk is correlated with the complex having the lowest solubility (MEL\u2013 uric acid or MEL\u2013CYA). To allow for these uncertainties the lowest solubility value (15\u201327 mg/L of MEL + CYA each) observed with adult human urine (at pH 5\u20135.5) has been used in the analyses in Table 2: this would be over-conservative for infants because the urinary pH of infants fed infant formula is about 6\u20136.5 (Kalhoff et al., 2007) and the solubility of MEL + CYA is considerably higher (77\u201385 mg/L of MEL + CYA each) at this pH. The use of a \u2018\u2018conserva- tive\u201d pH solubility limit was selected to compensate for the possi- ble impact of the chemical composition differences outlined above. Therefore, the 30-fold margin between the solubility limit and cal- culated urinary concentration resulting from 1 ppm of MEL + 1 ppm of CYA in powder infant formula (Table 2) is likely to be sufficient to provide reassurance of infant safety. Conflict of interest statement The authors herein declare that there are no conflicts of interest. References The authors herein declare that there are no conflicts of interest. References Baynes, R.E. et al., 2008. Pharmacokinetics of melamine in pigs following intravenous administration. Food Chem. Toxicol. 46 (3), 1196\u20131200. Results Discussion Conflict of interest statement References Further reading"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Utilisation-of-parametric-methods-to-improve-percenti_2021_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/33556416", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 3 Estimation of TD50 percentiles 4 Effects of errors on safe limits 5 Application of the method to structural subclasses 6 Conclusions Funding body information CRediT authorship contribution statement Declaration of competing interest Appendix A Supplementary data References", "Funding": "Funding body information This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. CRediT authorship contribution statement 3 Estimation of TD50 percentiles 4 Effects of errors on safe limits 5 Application of the method to structural subclasses 6 Conclusions Funding body information CRediT authorship contribution statement Declaration of competing interest Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Utility-and-importance-of-animal-data-in-dr_2014_Regulatory-Toxicology-and-P.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24928564", "content": {"CoiStatement": "In conclusion, animal data have a vital role in drug product labels giving assurance that an extensive safety assessment for the medicinal product has occurred. Of particular use is informa- tion to help council for reproductive risk during pregnancy. How- ever, although some regulatory guidance is available to help write label information, it can be seen that the current system is not perfect in that there is a lack of consistency in the level of detail and actual information given in labels both within and across regions, sometimes using terms known to toxicologists and/or reg- ulatory affairs staff but not healthcare professionals. Bearing in mind the current regional regulatory guidance requirements, it may be time to revise what animal data appear in drug product labels and provide these in a manner that can be easily under- stood/interpreted by healthcare professional (and indeed with free access to product labels through modern technology) and patients themselves. Conflict of interest The author declares that there are no conflicts of interest. The author declares that there are no conflicts of interest. References Discussion Conclusion Conflict of interest References", "Compliance with ethical standards": "FDA, 2013. Food and Drug Administration Guidance for Industry: Labeling for Human Prescription Drug and Biological Products \u2013 Implementing the PLR Content and Format Requirements. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER), February 2013. <http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/ucm075082.pdf> (accessed March 2014). Lal, R., Kremzner, M., 2007. Introduction to the new prescription drug labeling by the Food and Drug Administration. Am. J. Health Syst. Pharm. 64, 2488\u20132494. http://refhub.elsevier.com/S0273-2300(14)00116-0/h0005 http://refhub.elsevier.com/S0273-2300(14)00116-0/h0005 http://www.dailymed.nlm.nih.gov/dailymed/about.cfm http://refhub.elsevier.com/S0273-2300(14)00116-0/h0020 http://refhub.elsevier.com/S0273-2300(14)00116-0/h0020 http://www.ec.europa.eu/health/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf http://www.ec.europa.eu/health/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003307.pdf http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003307.pdf http://www.emc.medicines.org.uk http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093310.htm http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093310.htm http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/labeling/ucm093307.htm http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/labeling/ucm093307.htm http://www.fda.gov/downloads/Drugs/Guidances/ucm075096.pdf http://www.fda.gov/downloads/Drugs/Guidances/ucm075096.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075082.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075082.pdf http://refhub.elsevier.com/S0273-2300(14)00116-0/h0055 http://refhub.elsevier.com/S0273-2300(14)00116-0/h0055 http://refhub.elsevier.com/S0273-2300(14)00116-0/h0060 http://cpnp.org/resource/mhc/2013/08/fda-pregnancy-categories-help-or-hindrance http://cpnp.org/resource/mhc/2013/08/fda-pregnancy-categories-help-or-hindrance Utility and importance of animal data in drug product labels Introduction and history Animal data requirements in drug product labels Examples of animal data in recently approved drug product labels"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Utility-of-proteomics-techniques-for-assessin_2009_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19133307", "content": {"Funding": "We thank Dr. D. Lakshman for critical review of this manuscript. Funding for this research was provided by ARS Project 1275- 21000-223-00D. References", "Acknowledgement": "Acknowledgments We thank Dr. D. Lakshman for critical review of this manuscript. Funding for this research was provided by ARS Project 1275- 21000-223-00D. Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Utility-of-rodent-models-for-evaluating-prot_2009_Regulatory-Toxicology-and-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/18957311", "content": {"CoiStatement": "Conflict of interest statement The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. References Utility of rodent models for evaluating protein allergenicity Introduction Methods Subcutaneous exposure Oral exposure Digestibility Oral tolerance Conclusions Disclaimer Conflict of interest statement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Utilizing-relative-potency-factors--RPF--and-threshold-of-t_2015_Regulatory-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25584438", "content": {"Acknowledgement": "Firstly, a precautionary principle is taken into account when considering human exposure to environmental metabolites, partic- ularly in Europe. However, the level of exposure in combination with the potential toxicity must be taken into account together in order to perform the appropriate risk assessment; mere pres- ence should not imply human risk. For example, a recent publica- tion entitled \u2018Review of the risk from potential emerging contaminants in UK groundwater\u2019 discusses the common ground- water contaminants in the UK (one type being pesticide metabo- lites) (Stuart et al., 2012), but does not put these concentrations into context or discuss how the concentrations of these metabo- lites in groundwater compare to health-based limits/RfDs/toxico- logical databases. Potential exposure to the sulfoxaflor metabolites was a primary driver for the extent of toxicity testing conducted. For example, the primary metabolite, X11719474, found in soil, crops and, potentially, at low concentrations in groundwater, was the most extensively studied comprising genetic, acute, short-term rat and dog, rodent reproductive and developmental toxicity studies. The inclusion of dog studies, for example, was debated considering dog studies are no longer default EU requirements (Kobel et al., 2010; Dellarco et al., 2010) but it was considered warranted due to the potential need for a stand-alone X11719474 risk assessment. However, it is critical to point out that by comparing key toxicities between the parent and X11719474 metabolite, conducting a complete \u2018active sub- stance\u2019 toxicology package on the metabolite was avoided, thereby utilizing many fewer animals than that option would have. This key \u2018bridging\u2019 data showed X11719474 was significantly less toxic than parent. In contrast, X11519540, a minor soil and animal metabolite, exhibited no genotoxicity and had similar acute oral toxicity to sulfoxaflor but repeat-dose studies in the rat showed that X11519540 had the same primary target organ as the parent molecule (i.e., the liver) but that it caused similar effects at lower doses than parent (i.e., higher potency compared to parent, which was explained by the 28-day rat study where toxicokinetic data show that X11519540 has a much longer half-life than parent (24\u201335 h compared to 4\u20138 h, respectively). Subsequently, the comparative toxicology programme was extended to cover further metabolites of sulfoxaflor. Based on structure (i.e., similarity of metabolite structures to one another), toxic effects in comparison with parent (i.e., consistency of the tox- icity profiles and confidence in terms of ability to read across), res- idue compartment (e.g., crop, soil, water) and predicted level of exposure, fewer studies were undertaken for the other metabolites compared to X11719474 or X11519540. For example, for some metabolites with very low predicted environmental concentrations only genotoxicity screening was required. For some metabolites with low predicted concentrations only in liver, a TTC approach was utilized, for example X11596066 which was found at trace lev- els only in liver, had no structural alerts for genotoxicity, was neg- ative in the Ames test, had levels below the lowest Threshold of Toxicological Concern and was overall of low concern for human health. The second point illustrated here is that, to follow such an approach as described for the environmental metabolites of sulfox- aflor, it is important to have an in-depth understanding of the key toxicities and, critically, the MoA eliciting these toxicities. In the case of sulfoxaflor, this in-depth knowledge of a key toxicity (e.g., developmental toxicity in rat offspring elicited via sustained agon- ism at the rat fetal muscle nAChR) allowed in vitro nAChR agonism studies to be conducted for the key environmental metabolites (i.e., X11719474 and X11519540), allowing the conclusion that these metabolites did not cause agonism at this receptor and would therefore not cause the effect of concern in rats. It is becom- ing much more common for agrochemical active substances to be tested above the \u2018\u2018standard\u2019\u2019 toxicity testing requirements and incorporate higher tier investigative studies such as mode-of- action (MoA) work to enable registration of the new PPPs. This increase in higher tier and customized study testing is driven by a general trend to obtain a mechanistic understanding underlying hazard characteristics of molecules to inform risk management decisions (critically, in Europe, the so-called \u2018CMR\u2019 (Carcinogenic- ity, Mutagenicity, Reproductive toxicity) \u2018cut-offs\u2019 which prevent active substance approval). These additional MoA data can be use- ful to support or refute the human relevance of a toxicity finding, which may lead to cessation of further development of a new agro- chemical molecule or performing further research to elucidate the MoA. In addition, the template by which MoA data can be analyzed exists: the mode of action/human relevance framework developed by the International Programme on Chemical Safety (IPCS) of the World Health Organization (WHO) (Boobis et al., 2006, 2008; Sonich-Mullin et al., 2001) and ILSI (Meek et al., 2003; Seed et al., 2005). A classic example of application of this approach is rodent liver tumors with a clearly demonstrated constitutive androstane receptor (CAR)-mediated MoA and specific evidence that the molecule does not cause hepatocellular proliferation in humanized or human liver. In this case, it would be possible to argue that the resulting rodent liver tumors may be considered not relevant to humans (Elcombe et al., 2013; Holsapple et al., 2006; ECHA, 2014). Therefore, this finding would not be used to derive Reference Doses or to trigger hazard classification. Finally, the TTC has been utilized in this example and the approach is gaining regulatory favor across the agrochemical sec- tor. A recent EFSA Scientific Opinion (2012) has summarized an evaluation scheme for pesticide metabolites for dietary risk assess- ment and identifies the TTC concept as an appropriate screening tool, with three critical steps: (1) estimation of the level of the metabolite, (2) evaluation of genotoxicity alerts and (3) detection of neurotoxic metabolites. Assessment schemes for acute and chronic dietary risk assessment of pesticide metabolites, using the TTC approach and combined (Q)SAR and read across, were pro- posed, with the acknowledgment that \u2018\u2018on many occasions the out- come of the assessment scheme will be that further testing is needed to reach a firm conclusion on the toxicological relevance of the metabolite\u2019\u2019. TTC is considered a suitable tool to provide health-based tolerable concentrations of contaminants in matrices with anticipated oral human exposure, below which there is no concern for human health (Melching-Kollmuss et al., 2010; Dekant et al., 2010). This example of comparative assessment utilizing relative potency, hazard characterization, read-across, predicted exposure and TTC ultimately provided a robust database, which minimized C. Terry et al. / Regulatory Toxicology and Pharmacology 71 (2015) 301\u2013317 317 animal use, and ultimately determined the risk presented by these metabolites. Collectively, the work presented here describes the successful programme developed for sulfoxaflor and its metabo- lites and how it might be used to address similar future challenges aimed at determining the relevance of the metabolites from a human hazard and risk perspective. References Boobis, A.R., Cohen, S.M., Dellarco, V., McGregor, D., Meek, M.E., Vickers, C., Willcocks, D., Farland, W., 2006. IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit. Rev. Toxicol. 36, 781\u2013792. Boobis, A.R., Doe, J.E., Heinrich-Hirsch, B., Meek, M.E., Munn, S., Ruchirawat, M., Schlatter, J., Seed, J., Vickers, C., 2008. IPCS framework for analyzing the relevance of a noncancer mode of action for humans. Crit. Rev. Toxicol. 38, 87\u2013 96. Brown et al., 2009. Scientific/technical report submitted to EFSA. Applicability of thresholds of toxicological concern in the dietary risk assessment of metabolites, degradation and reaction products of pesticides. Richard Brown, Julian Carter, Ian Dewhurst, Claire Stephenson, Sonia Tessier. Chemicals Regulation Directorate, 2012. Data Requirements Handbook, Version 2.2. June 2012. Cramer, G.M., Ford, R.A., Hall, R.L., 1978. Estimation of toxic hazard \u2013 a decision tree approach. Food Cosmet. Toxicol. 16, 255\u2013276. Dekant, W., Melching-Kollmu\u00df, S., Kalberlah, F., 2010. Toxicity assessment strategies, data requirements, and risk assessment approaches to derive health based guidance values for non-relevant metabolites of plant protection products. Regul. Toxicol. Pharmacol. 56, 135\u2013142. Dellarco, V.L., Rowland, J., May, B., 2010. A retrospective analysis of toxicity studies in dogs and impact on the chronic reference dose for conventional pesticide chemicals. Crit. Rev. Toxicol. 40, 16\u201323. European Commission, 2003. Guidance Document on the Assessment of the Relevance of Metabolites in Groundwater of Substances Regulated under Council Directive 91/414/EEC. Sanco/221/2000 \u2013rev.10-final (25 February 2003). European Commission, 2009a. Regulation (EC) No. 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placement of plant protection products on the market and repealing Council Directives 79/ 117/EEC and 91/414/EEC. Official J. Eur. Union L 309, 1\u201350. European Commission, 2009. Guidance to Regulation (EC) No 1272/2008 on Classification, Labelling and Packaging of substances and mixtures. ECHA, 2014. Committee for Risk Assessment RAC Opinion proposing harmonised classification and labelling at EU level of Sulfoxaflor (ISO); [methyl(oxo){1-[6- (trifluoromethyl)-3-pyridyl]- ethyl}-k6-sulfanylidene]cyanamide EC number: \u2013 CAS number: 946578-00-3 CLH-O-0000004794-65-01/F Adopted 5 December 2013. EFSA, 2012. Scientific opinion on evaluation of the toxicological relevance of pesticide metabolites for dietary risk assessment. European food safety authority (EFSA) panel on plant protection products and their residues (PPR). EFSA J. 10 (07), 2799. EFSA, 2012a. EFSA scientific committee; scientific opinion on exploring options for providing advice about possible human health risks based on the concept of threshold of toxicological concern (TTC). EFSA J. 10 (7), 2750. EFSA, 2014. Conclusion on pesticide peer review: conclusion on the peer review of the pesticide risk assessment of the active substance sulfoxaflor. EFSA J. 12 (5), 3692. Elcombe, C.R., Peffer, R.C., Wolf, D.C., Bailey, J., Bars, R., Bell, D., Cattley, R.C., Ferguson, S.S., Geter, D., Goetz, A., Goodman, J.I., Hester, S., Jacobs, A., Omiecinski, C.J., Schoeny, R., Xie, W., Lake, B.G., 2013. Mode of action and human relevance analysis for nuclear receptor-mediated liver toxicity. Crit. Rev. Toxicol. 44 (1), 64\u201382. Ellis-Hutchings, R.G., Rasoulpour, R.J., Terry, C., Carney, E.W., Billington, R., 2014. Human relevance evaluation of a nAChR-medicated fetal muscle contracture mode of action induced by sulfoxaflor. Crit. Rev. Toxicol. 44 (S2), 45\u201362. Felter, S., Lane, R.W., Latulippe, M.E., Llewellyn, G.C., Olin, S.S., Scimeca, J.A., Trautman, T.D., 2009. Refining the threshold of toxicological concern (TTC) for risk prioritization of trace chemicals in food. Food Chem. Toxicol. 47, 2236\u2013 2245. Frawley, J.P., 1967. Scientific evidence and common sense as a basis for food- packaging regulations. Food Cosmet. Toxicol. 5, 293\u2013308. Holsapple, M.P., Pitot, H.C., Cohen, S.M., Boobis, A.R., Klaunig, J.E., Pastoor, T., Dellarco, V.L., Dragan, Y.P., 2006. Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol. Sci. 89, 51\u201356. JMPR, 2011. Joint FAO/WHO meeting on pesticide residues. Geneva, 20\u201329 September 2011. Summary Report Acceptable Daily Intakes, Acute Reference Doses, Short-Term And Long-Term Dietary Intakes, Recommended Maximum Residue Limits And Supervised Trials Median Residue Values Recorded By the 2011 Meeting (Issued October 2011). Kobel, W., Fegert, I., Billington, R., Lewis, R., Bentley, K., Bomann, W., Botham, P., Stahl, B., van Ravenzwaay, B., Spielmann, H., 2010. A 1-year toxicity study in dogs is no longer a scientifically justifiable core data requirement for the safety assessment of pesticides. Crit. Rev. Toxicol. 40, 1\u201315. Kroes, R., Kleiner, J., Renwick, A., 2005. The threshold of toxicological concern concept in risk assessment. Toxicol. Sci. 86, 226\u2013230. LeBaron, M.J., Geter, D.R., Rasoulpour, R.J., Gollapudi, B.B., Thomas, J., Murray, J., Kan, H.L., Wood, A.J., Elcombe, C., Vardy, A., McEwan, J., Terry, C., Billington, R., 2013. An integrated approach for prospectively investigating a mode-of-action for rodent liver effects. Toxicol. Appl. Pharmacol. 270, 164\u2013173. LeBaron, M.J., Gollapudi, B.B., Terry, C., Billington, R., Rasoulpour, R.J., 2014. Human relevance framework for sulfoxaflor-induced rodent liver tumors. Crit. Rev. Toxicol. 44 (S2), 15\u201324. Maron, D.M., Ames, B.N., 1983. Revised methods for the Salmonella mutagenicity test. Mutat. Res. 113, 173\u2013215. Meek, M.E., Bucher, J.R., Cohen, S.M., Dellarco, V., Hill, R.N., Lehman-McKeeman, L.D., Longfellow, D.G., Pastoor, T., Seed, J., Patton, D.E., 2003. A framework for human relevance analysis of information on carcinogenic modes of action. Crit. Rev. Toxicol. 33, 591\u2013653. Melching-Kollmuss, S., Dekant, W., Kalberlah, F., 2010. Application of the \u2018threshold of toxicological concern\u2019 to derive tolerable concentrations of \u2018non-relevant metabolites\u2019 formed from plant protection products in ground and drinking water. Regul. Toxicol. Pharmacol. 56, 126\u2013134. Munro, I.C., Ford, R.A., Kenepohl, E., Sprenger, J.G., 1996. Correlation of structural class with no-observed-effect-levels: a proposal for establishing a threshold of concern. Food Chem. Toxicol. 34, 829\u2013867. Munro, I.C., Renwick, A.G., Danielewska-Nikiel, B., 2008. The Threshold of Toxicological Concern (TTC) in risk assessment. Toxicol. Lett. 180, 151\u2013156. OECD, 2009. Guidance Document on the Definition of Residue. Series on Testing and Assessment No. 63 and Series on Pesticides No. 31. 28th July 2009. Rasoulpour, R.J., Ellis-Hutchings, R.G., Terry, C., Millar, N.S., Zablotny, C.L., Gibb, A., Marshall, V., Collins, T., Carney, E.W., Billington, R., 2012. A novel mode-of- action mediated by the fetal muscle nicotinic acetylcholine receptor resulting in developmental toxicity in rats. Toxicol. Sci. 127, 522\u2013534. Rasoulpour, R.J., Terry, C., LeBaron, M.J., Stebbins, K., Ellis-Hutchings, R.J., Billington, R., 2014. Mode-of-action/human relevance framework for rat leydig cell tumors mediated by sulfoxaflor. Crit. Rev. Toxicol. 44 (S2), 25\u201344. Seed, J., Carney, E.W., Corley, R.A., Crofton, K.M., DeSesso, J.M., Foster, P.M., Kavlock, R., Kimmel, G., Klaunig, J., Meek, M.E., Preston, R.J., Slikker Jr., W., Tabacova, S., Williams, G.M., Wiltse, J., Zoeller, R.T., Fenner-Crisp, P., Patton, D.E., 2005. Overview: using mode of action and life stage information to evaluate the human relevance of animal toxicity data. Crit. Rev. Toxicol. 35, 664\u2013672. Sonich-Mullin C., Fielder R., Wiltse J., Baetcke K., Dempsey J., Fenner-Crisp P., Grant D., Hartley M., Knaap A., Kroese D., Mangelsdorf I., Meek E., Rice J.M., Younes M., International Programme on Chemical Safety, 2001. IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Regul. Toxicol. Pharmacol. 34, 146\u2013152. Stuart, M., Lapworth, D., Crane, E., Hart, A., 2012. Review of risk from potential emerging contaminants in UK groundwater. Sci. Total Environ. 416, 1\u201321. US EPA (2012). EPA\u2019s Points of Departure and Revised Relative Potency Factors for the Cumulative Risk Assessment of the Organophosphate Pesticides. http:// www.epa.gov/pesticides/cumulative/pra-op/rpf_final.htm. Yahagi, T., Degawa, M., Seino, Y., Matsushima, T., Nagao, M., Sugimura, T., Hashimoto, Y., 1975. Mutagenicity of carcinogenic azo dyes and their derivatives. Cancer Letters 1, 91\u201397. Further reading Terry, C., Rasoulpour, R.J., Saghir, S., Marty, S., Gollapudi, B.B., Billington, R., 2014. Application of a novel integrated toxicity testing strategy incorporating \u2018\u20183R\u2019\u2019 principles of animal research to evaluate the safety of a new agrochemical, sulfoxaflor. Crit. Rev. Toxicol. 44 (S2), 1\u201314. http://refhub.elsevier.com/S0273-2300(14)00311-0/h0005 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0005 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0005 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0010 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0010 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0010 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0010 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0030 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0030 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0035 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0035 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0035 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0035 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0040 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0040 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0040 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0060 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0060 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0060 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0060 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0075 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0075 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0075 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0075 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0080 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0080 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0080 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0085 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0085 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0085 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0090 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0090 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0090 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0090 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0090 http://refhub.elsevier.com/S0273-2300(14)00311-0/h9000 http://refhub.elsevier.com/S0273-2300(14)00311-0/h9000 http://refhub.elsevier.com/S0273-2300(14)00311-0/h9000 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0100 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0100 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0100 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0100 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0105 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0105 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0110 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0110 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0110 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0120 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0120 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0120 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0120 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0125 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0125 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0130 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0130 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0130 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0130 http://refhub.elsevier.com/S0273-2300(14)00311-0/h9005 http://refhub.elsevier.com/S0273-2300(14)00311-0/h9005 http://refhub.elsevier.com/S0273-2300(14)00311-0/h9005 http://refhub.elsevier.com/S0273-2300(14)00311-0/h9010 http://refhub.elsevier.com/S0273-2300(14)00311-0/h9010 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0140 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0140 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0140 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0140 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0145 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0145 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0145 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0145 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0150 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0150 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0150 http://refhub.elsevier.com/S0273-2300(14)00311-0/h9015 http://refhub.elsevier.com/S0273-2300(14)00311-0/h9015 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0160 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0160 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0160 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0160 http://refhub.elsevier.com/S0273-2300(14)00311-0/h9020 http://refhub.elsevier.com/S0273-2300(14)00311-0/h9020 http://refhub.elsevier.com/S0273-2300(14)00311-0/h9020 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0170 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0170 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0170 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0170 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0170 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0180 http://refhub.elsevier.com/S0273-2300(14)00311-0/h0180 http://refhub.elsevier.com/S0273-2300(14)00311-0/h9025 http://refhub.elsevier.com/S0273-2300(14)00311-0/h9025 http://refhub.elsevier.com/S0273-2300(14)00311-0/h9025 Utilizing relative potency factors (RPF) and threshold of toxicological concern (TTC) concepts to assess hazard and human risk assessment profiles of environmental metabolites: A case study 1 Introduction 2 Materials and methods 2.1 Metabolite identification 2.2 Conduct of toxicity studies 2.2.1 Test material 2.2.2 Animals 2.2.3 Study design 2.2.3.1 Absorption, distribution, metabolism and elimination (ADME) studies 2.2.3.2 Acute studies 2.2.3.2.1 Acute oral toxicity \u2013 test guidelines: OPPTS 870.1100; OECD 423; OECD 425 2.2.3.2.2 Primary eye irritation \u2013 test guidelines: rabbit; OPPTS 870.2400; OECD 405 2.2.3.2.3 Acute dermal irritation \u2013 test guidelines: rat OPPTS 870.1200; OECD 402; rabbit OPPTS 870.2500: OECD 404 2.2.3.2.4 Dermal sensitization \u2013 test guidelines: mice OPPTS 870.2600; OECD 429 2.2.3.3 Genotoxicity tests 2.2.3.3.1 Ames test \u2013 test guidelines: OPPTS 870.5100; OECD 471 (formerly OECD 471 & 472) 2.2.3.3.2 RLCAT \u2013 test guidelines: OPPTS 870.5375; OECD 473 2.2.3.3.3 HGPRT \u2013 test guidelines: OPPTS 870.5300; OECD 476 2.2.3.3.4 Mouse micronucleus test \u2013 test guidelines: OPPTS 870.5395; OECD 474 2.2.3.4 Repeat dose rat studies 2.2.3.5 Repeat dose dog studies 2.2.3.6 Liver mode-of-action (MoA) studies 2.2.3.7 Developmental and reproductive toxicity studies 3 Results and discussion 3.1 Toxicity profile of the parent molecule 3.1.1 ADME 3.1.2 Genotoxicity 3.1.2 Acute toxicity 3.1.3 Short-term toxicity 3.1.4 Long-term toxicity and carcinogenicity 3.1.4.1 Liver effects 3.1.5 Developmental and reproductive toxicity 3.2 The comparative toxicity of environmental metabolites with parent 3.2.1 The comparative toxicity of the primary metabolite X11719474 with parent 3.2.2 The comparative toxicity of the other metabolites with parent and X11719474 4 Discussion and conclusions References Further reading"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Validation-of-Toxtree-and-SciQSAR-in-silico-predictive-soft_2013_Regulatory-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23969001", "content": {"CoiStatement": "Conflict of interest statement The author has no financial ties to SciMatics Inc. and declares that there are no conflicts of interest. This research was not funded by any outside sources. The author has no financial ties to SciMatics Inc. and declares that there are no conflicts of interest. This research was not funded by any outside sources. Acknowledgments 4 Conclusions Conflict of interest statement Acknowledgments References", "Compliance with ethical standards": "US Food and Drug Administration: Center for Drug Evaluation and Research. 2008. Guidance for Industry: Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches. <http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ ucm079235.pdf>. US Food and Drug Administration: Center for Drug Evaluation and Research. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). M7 (2013): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. <http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM347725.pdf>. US Food and Drug Administration: Center for Drug Evaluation and Research. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). M7 (2013): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. <http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM347725.pdf>. Valerio, L.G., 2009. In silico toxicology for the pharmaceutical sciences. Toxicol. Appl. Pharmacol. 241, 356\u2013370. http://refhub.elsevier.com/S0273-2300(13)00125-6/h0005 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0005 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0005 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0010 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0010 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0010 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0015 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0015 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0015 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0020 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0020 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0020 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0020 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0025 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0025 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0025 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0025 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0030 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0030 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0030 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0030 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0035 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0035 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0040 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0040 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0045 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0045 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0045 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0045 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0050 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0050 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0050 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0050 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0050 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0050 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0055 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0055 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0060 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0060 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0065 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0065 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0065 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0070 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0070 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0075 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0075 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0080 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0080 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0080 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0085 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0085 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0085 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0090 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0090 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0095 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0095 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0100 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0100 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0105 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0105 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0110 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0115 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0115 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0115 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0120 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0120 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0120 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0130 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0130 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0130 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079235.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079235.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079235.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM347725.pdf http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM347725.pdf http://refhub.elsevier.com/S0273-2300(13)00125-6/h01351 http://refhub.elsevier.com/S0273-2300(13)00125-6/h01351 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0135 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0135 http://refhub.elsevier.com/S0273-2300(13)00125-6/h0135 Validation of Toxtree and SciQSAR in silico predictive software using a publicly available benchmark mutagenicity database and their applicability for the qualification of impurities in pharmaceuticals 1 Introduction 2 Materials and methods 2.1 Toxtree 2.2 SciQSAR 2.3 SciQSAR domain of applicability 2.4 The Hansen Salmonella mutagenicity training data set 2.5 The external validation case study data set 2.6 SciQSAR-Hansen Salmonella mutagenicity model internal cross validation 2.7 Statistics", "Acknowledgement": "Acknowledgments I thank Dr. Luis Valerio and Leighna Baxter for their assistance and encouragement in this project. 4 Conclusions Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Vanadium-pentoxide--Risk-assessment-implications-of-a-_2014_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24793260", "content": {"CoiStatement": "T.B. Starr, J.A. MacGregor / Regulatory Toxicology and Pharmacology 69 (2014) 333\u2013337 337 Conflict of interest statement The authors have served as consultants to the Vanadium Pro- ducers and Reclaimers Association. Thomas B Starr. has also served as a con- sultant to the DoD-funded Vanadium Safety Readiness Program. Judith A MacGregor. has also served as a consultant to Vanitec, the American Petroleum Institute, and serves on a scientific review board for the Vanadium Safety Readiness Program, DoD. 4 Discussion Conflict of interest statement Acknowledgments References", "Acknowledgement": "Acknowledgments This research was conducted by the authors and has been funded through the Vanadium Safety Readiness Program by ATI, dba SCRA Applied R&D. ATI, dba SCRA Applied R&D is partnering with the Department of Defense (DoD) under a cooperative agree- ment that is awarded and administered by the U.S. Army Medical Research and Materiel Command (USAMRMC) and the Telemedicine & Advanced Technology Research Center (TATRC), Fort Detrick, Maryland 21702, under Contract Number: W81XWH-09-2-006. The views, opinions and findings contained in this research are those of the authors and do not necessarily reflect the views of the DoD and should not be construed as an official DoD/Army policy unless so designated by other documentation. No official endorsement should be made. 4 Discussion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Vanadium-pentoxide--Use-of-relevant-historical-control_2012_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22749912", "content": {"CoiStatement": "We therefore recommend strongly that the additional informa- tion now available regarding lung tumor incidence in NTP-2000- fed historical control rats be taken fully into account in toxicolog- ical assessments of V2O5 such as the one currently underway at USEPA, particularly when considering which weight of evidence descriptor provides the most appropriate summary characteriza- tion of the carcinogenic potential of this important compound. 5. Conflict of interest statement All authors have all served as consultants to the Vanadium Pro- ducers and Reclaimers Association. Thomas B Starr and Kimberly D Ehman also serve as con- sultants to the DoD-funded Vanadium Safety Readiness Program. Andrey I Nikiforov also serves as Principal Investigator on the Vanadium Com- pound Research Testing Program for the Vanadium Safety Readi- ness Program. Judith A Macgregor has also served as a consultant to Vanitec, the American Petroleum Institute, and also serves on a scientific advi- sory board for the Vanadium Safety Readiness Program. Vanadium pentoxide: Use of relevant historical control data shows no evidence for a carcinogenic response in F344/N rats 1 Introduction 2 Materials and methods 3 Results 4 Discussion 5 Conflict of interest statement Acknowledgments References", "Acknowledgement": "Acknowledgments This research was conducted by the authors and has been funded through the Vanadium Safety Readiness Program by ATI. ATI is an SCRA affiliate partnering with the Department of Defense (DoD) under a cooperative agreement that is awarded and admin- istered by the U.S. Army Medical Research and Materiel Command (USAMRMC) and the Telemedicine & Advanced Technology Re- search Center (TATRC), Fort Detrick, Maryland 21702, under Con- tract Number: W81XWH-09-2-006. The views, opinions and findings contained in this research are those of the authors and do not necessarily reflect the views of the DoD and should not be construed as an official DoD/Army policy unless so designated by other documentation. No official endorsement should be made. Vanadium pentoxide: Use of relevant historical control data shows no evidence for a carcinogenic response in F344/N rats 1 Introduction 2 Materials and methods 3 Results 4 Discussion 5 Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Variability-of-in-vivo-fish-acute-toxic_2009_Regulatory-Toxicology-and-Pharm.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19467285", "content": {"Compliance with ethical standards": "In contrast, in a regulatory context, data variability, regardless if caused by natural or technical factors, is a confounder and should be minimised. The knowledge obtained through retrospective database analysis could provide guidance in establishing criteria for data quality assessments that could help to reduce database- inherent variability. Our results indicate that establishing refer- ence parameters, e.g. use of identical test species and life stages, can result in a reduction of variability, and that better recording of test conditions could help to develop algorithms to account, at least partly, for test data variability. Furthermore, it appears essen- tial to subject entries in databases to a rigid and systematic evalu- ation of data quality. Although this is time-consuming, it is important to have high-quality data available for development of non-testing methodologies as they are increasingly utilized in reg- ulatory risk assessment. An example of how data quality can be ap- proached is provided by the Klimisch criteria (Klimisch et al., 1997) which evaluate test data with respect to their relevance, adequacy and reliability. The latter aspect is of particular relevance for our discussion, as it addresses the validity of the experimental data, i.e. whether the test was conducted in compliance with standard- ised test guidelines and is sufficiently documented. For example, whether substance purity is recorded, whether actual substance concentrations in the water were determined, whether pH, dis- solved oxygen and total organic carbon in the water were analysed, etc. When data from multiple tests are available, a weight-of-evi- dence analysis can be performed, as suggested by Parkerton et al. (2008), with greater weight on data from the most reliable studies. However, even with approaches for data quality evaluation being available and established, two problems remain. Firstly, as already outlined above, for many substances the number of reliable tests is rather small. Secondly, certain differences in test conditions, e.g. the use of different species, are even accepted within the standard- ised test guidelines and thus cannot be eliminated. Again, it would be helpful to have reference conditions defined and to have correc- tion factors or algorithms available to address these sources of var- iation. Finally, we would like to emphasise that the fact that a study was performed according to GLP principles does not neces- sarily implicate that the test is meaningful and relevant in the sense of \u2018\u2018good science\u201d (Myers et al., 2009). 4.1. Recommendations", "Acknowledgement": "Acknowledgments This work was supported by the EU 6th Framework Integrated Project OSIRIS (Contract No. GOCE-ET-2007-037017). We also thank Mark Hewitt for constructive comments. Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Variance-of-body-and-organ-weights-in-28-da_2019_Regulatory-Toxicology-and-P.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/31494191", "content": {"CoiStatement": "Conflicts of interest No conflict of interest is declared by the authors. No conflict of interest is declared by the authors. Appendix A. Supplementary data Discussion Conclusion Funding Conflicts of interest Supplementary data References", "Funding": "Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Conflicts of interest Discussion Conclusion Funding Conflicts of interest Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Variation-in-tobacco-and-mainstream-smoke-toxicant-_2015_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/25620723", "content": {"CoiStatement": "It is important to stress that these values are for a single labora- tory. Repeated measures across more than one laboratory will increase the variability substantially (Gregg et al., 2004. Intorp et al., 2009). Taken together, the present results demonstrate the importance of taking all sources of variation into account when mandating maximum product levels of toxicants and analytical tolerance limits. Conflict of interest All the authors state that the work was funded by British American Tobacco (BAT). Health Canada, 2000. Tobacco Reporting Regulations SOR/2000-273. <http://laws- lois.justice.gc.ca>. Published 2000. (accessed 04.14. Health Canada, 2004. Constituents and Emissions Reported for Cigarettes Sold in Canada. Unpublished data received on request from TRR_RRRT@hc-sc.gc.ca. Horwitz, W., Kamps, L.R., Boyer, K.W., 1980. Quality assurance in the analysis of foods for trace constituents. J. Assoc. Off. Anal. Chem. 63, 1344\u20131354. Hyodo, T., Inoue, O., Katagiri, H., Mikita, A., Fujiwara, M., 2006. Long-term inter- laboratory comparisons of selected analytes in 2R4F mainstream smoke. In: 2006 CORESTA Conference Paper SS7. International Organization for Standardization, 1994. ISO 5725-2:1994. Accuracy (Trueness and Precision) of Measurements Methods and Results \u2013 Part 2. Basic Method for Determination of Repeatability and Reproducibility of a Standard Measurement Method, ISO, Geneva. International Organization for Standardization, 2012. ISO 3308:2012. Routine Analytical Cigarette-Smoking Machine \u2014 Definitions and Standard Conditions, ISO, Geneva. http://dx.doi.org/10.1016/j.yrtph.2015.01.006 http://dx.doi.org/10.1016/j.yrtph.2015.01.006 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0150 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0150 http://www.%20health.gov.au/internet/main/publishing.nsf/Content/tobacco-emis http://www.%20health.gov.au/internet/main/publishing.nsf/Content/tobacco-emis http://legacy.library.ucsf.edu/documentStore/y/e/k/yek21c00/Syek21c00.pdf http://legacy.library.ucsf.edu/documentStore/y/e/k/yek21c00/Syek21c00.pdf http://dx.doi.org/10.1136/tc.2007.024158 http://dx.doi.org/10.1136/tc.2007.024158 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0030 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0030 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0030 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0040 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0040 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0040 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0040 http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297752.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297752.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297752.htm http://refhub.elsevier.com/S0273-2300(15)00007-0/h0155 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0155 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0155 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0070 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0070 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0070 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0070 http://www.laws-lois.justice.gc.ca http://www.laws-lois.justice.gc.ca http://refhub.elsevier.com/S0273-2300(15)00007-0/h0075 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0075 A. Eldridge et al. / Regulatory Toxicology and Pharmacology 71 (2015) 409\u2013427 427 International Organization for Standardization, 2013. ISO 8243:2013. Cigarettes \u2013 Sampling, ISO, Geneva. Intorp, M., Purkiss, S., Whittaker, M., Wright, W., 2009. Determination of \u2018Hoffmann Analytes\u2019 in cigarette mainstream smoke. The CORESTA 2006 joint experiment. Beit. Tabakforsch. Int. 23, 161\u2013202. Minagawa, K., 2012. CORESTA Congress, Sapporo, 2012, Smoke Science/Product Technology Groups, abstr. SSPT36. In: Abstracts of Presentations Made at the 2012 CORESTA Congress in Sapporo, Japan available at <www.coresta.org>. Morton, M.J., Laffoon, S.W., 2008. Cigarette smoke chemistry market maps under Massachusetts Department of Public Health smoking conditions. Regul. Toxicol. Pharm. 51 (1), 1\u201330. Oldham, M.J., Desoi, D.J., Rimmer, L.T., Wagner, K.A., Morton, M.J., 2014. Insights from analysis for harmful abd potentially harmful constituents (HPHCs) in tobacco products. Regul. Toxicol. Pharm. 70, 138\u2013148. Purkis, S., Intorp, M., 2014. Analysis of reference cigarette smoke yield data from 21 laboratories for 28 selected analytes as a guide to selection of new CORESTA Recommended Methods. Beit. Tabakforsch. Int. 26 (2), 57\u201373. Rickert, W.S., Wright, W., 2002. Stability of yields of Canadian mandated analytes from the Kentucky reference cigarette 1R4F: a time series analysis. In: 2002 CORESTA Congress, 22\u201327 Sept 2002, New Orleans, USA. Paper ST26. Teillet, B., Cahours, X., Verron, T., Colard, S., Purkis, S., 2013. Comparison of smoke yield data collected from different laboratories. Beit. Tabakforsch. Int. 25 (8), 662\u2013670. US, 2009. Family Smoking Prevention and Tobacco Control Act. 123 Stat 1776. World Health Organization, 2008. The Scientific Basis of Tobacco Product Regulation. WHO Technical Report Series 951. WHO, Geneva. http://refhub.elsevier.com/S0273-2300(15)00007-0/h0160 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0160 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0160 http://www.coresta.org http://refhub.elsevier.com/S0273-2300(15)00007-0/h0115 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0115 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0115 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0165 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0165 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0165 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0125 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0125 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0125 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0135 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0135 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0135 Variation in tobacco and mainstream smoke toxicant yields from selected commercial cigarette products 1 Introduction 2 Materials and methods 2.1 Materials 2.2 Study protocol 2.3 Analysis methods 2.4 Data analysis 3 Results 3.1 Monthly variation in filler blend components 3.2 Monthly variation in smoke toxicant emission levels 3.3 Monthly variation in toxicant emission levels as a ratio to nicotine 4 Discussion 4.1 Analytical variation including sample preparation 4.1.1 Variation due to smoke sample preparation 4.1.2 Variation due to smoking regime 4.1.3 Variation due to analytical method 4.2 Product variation 4.3 Variation in toxicant emission levels as a ratio to nicotine 4.4 Tolerance levels and indications for product regulation 5 Conclusions Conflict of interest Acknowledgments Appendix A Supplementary data References", "Compliance with ethical standards": "FDA, 2012a. Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke: Established list. US Food and Drug Administration. <http:// www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ ucm297786.htm>. FDA, 2012b. Reporting Harmful and Potentially Harmful Constituents in Tobacco products and Tobacco Smoke under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act, Draft Guidance, US Food and Drug Administration. <http:// www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ ucm297752.htm>. FDA, 2012b. Reporting Harmful and Potentially Harmful Constituents in Tobacco products and Tobacco Smoke under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act, Draft Guidance, US Food and Drug Administration. <http:// www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ ucm297752.htm>. Gregg, E., Hill, C., Hollywood, M., Kearney, M., McAdam, K., Purkis, S., McLaughlin, D., Williams, M., 2004. The UK smoke constituents testing study. Summary of results and comparison with other studies. Beit. Tabakforsch. Int. 21, 117\u2013118. Health Canada, 2000. Tobacco Reporting Regulations SOR/2000-273. <http://laws- lois.justice.gc.ca>. Published 2000. (accessed 04.14. Health Canada, 2004. Constituents and Emissions Reported for Cigarettes Sold in Canada. Unpublished data received on request from TRR_RRRT@hc-sc.gc.ca. Horwitz, W., Kamps, L.R., Boyer, K.W., 1980. Quality assurance in the analysis of foods for trace constituents. J. Assoc. Off. Anal. Chem. 63, 1344\u20131354. Hyodo, T., Inoue, O., Katagiri, H., Mikita, A., Fujiwara, M., 2006. Long-term inter- laboratory comparisons of selected analytes in 2R4F mainstream smoke. In: 2006 CORESTA Conference Paper SS7. International Organization for Standardization, 1994. ISO 5725-2:1994. Accuracy (Trueness and Precision) of Measurements Methods and Results \u2013 Part 2. Basic Method for Determination of Repeatability and Reproducibility of a Standard Measurement Method, ISO, Geneva. International Organization for Standardization, 2012. ISO 3308:2012. Routine Analytical Cigarette-Smoking Machine \u2014 Definitions and Standard Conditions, ISO, Geneva. http://dx.doi.org/10.1016/j.yrtph.2015.01.006 http://dx.doi.org/10.1016/j.yrtph.2015.01.006 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0150 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0150 http://www.%20health.gov.au/internet/main/publishing.nsf/Content/tobacco-emis http://www.%20health.gov.au/internet/main/publishing.nsf/Content/tobacco-emis http://legacy.library.ucsf.edu/documentStore/y/e/k/yek21c00/Syek21c00.pdf http://legacy.library.ucsf.edu/documentStore/y/e/k/yek21c00/Syek21c00.pdf http://dx.doi.org/10.1136/tc.2007.024158 http://dx.doi.org/10.1136/tc.2007.024158 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0030 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0030 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0030 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0040 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0040 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0040 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0040 http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297752.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297752.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297752.htm http://refhub.elsevier.com/S0273-2300(15)00007-0/h0155 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0155 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0155 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0070 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0070 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0070 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0070 http://www.laws-lois.justice.gc.ca http://www.laws-lois.justice.gc.ca http://refhub.elsevier.com/S0273-2300(15)00007-0/h0075 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0075 A. Eldridge et al. / Regulatory Toxicology and Pharmacology 71 (2015) 409\u2013427 427 International Organization for Standardization, 2013. ISO 8243:2013. Cigarettes \u2013 Sampling, ISO, Geneva. Intorp, M., Purkiss, S., Whittaker, M., Wright, W., 2009. Determination of \u2018Hoffmann Analytes\u2019 in cigarette mainstream smoke. The CORESTA 2006 joint experiment. Beit. Tabakforsch. Int. 23, 161\u2013202. Minagawa, K., 2012. CORESTA Congress, Sapporo, 2012, Smoke Science/Product Technology Groups, abstr. SSPT36. In: Abstracts of Presentations Made at the 2012 CORESTA Congress in Sapporo, Japan available at <www.coresta.org>. Morton, M.J., Laffoon, S.W., 2008. Cigarette smoke chemistry market maps under Massachusetts Department of Public Health smoking conditions. Regul. Toxicol. Pharm. 51 (1), 1\u201330. Oldham, M.J., Desoi, D.J., Rimmer, L.T., Wagner, K.A., Morton, M.J., 2014. Insights from analysis for harmful abd potentially harmful constituents (HPHCs) in tobacco products. Regul. Toxicol. Pharm. 70, 138\u2013148. Purkis, S., Intorp, M., 2014. Analysis of reference cigarette smoke yield data from 21 laboratories for 28 selected analytes as a guide to selection of new CORESTA Recommended Methods. Beit. Tabakforsch. Int. 26 (2), 57\u201373. Rickert, W.S., Wright, W., 2002. Stability of yields of Canadian mandated analytes from the Kentucky reference cigarette 1R4F: a time series analysis. In: 2002 CORESTA Congress, 22\u201327 Sept 2002, New Orleans, USA. Paper ST26. Teillet, B., Cahours, X., Verron, T., Colard, S., Purkis, S., 2013. Comparison of smoke yield data collected from different laboratories. Beit. Tabakforsch. Int. 25 (8), 662\u2013670. US, 2009. Family Smoking Prevention and Tobacco Control Act. 123 Stat 1776. World Health Organization, 2008. The Scientific Basis of Tobacco Product Regulation. WHO Technical Report Series 951. WHO, Geneva. http://refhub.elsevier.com/S0273-2300(15)00007-0/h0160 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0160 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0160 http://www.coresta.org http://refhub.elsevier.com/S0273-2300(15)00007-0/h0115 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0115 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0115 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0165 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0165 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0165 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0125 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0125 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0125 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0135 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0135 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0135 Variation in tobacco and mainstream smoke toxicant yields from selected commercial cigarette products 1 Introduction 2 Materials and methods 2.1 Materials 2.2 Study protocol 2.3 Analysis methods 2.4 Data analysis 3 Results 3.1 Monthly variation in filler blend components 3.2 Monthly variation in smoke toxicant emission levels 3.3 Monthly variation in toxicant emission levels as a ratio to nicotine 4 Discussion 4.1 Analytical variation including sample preparation 4.1.1 Variation due to smoke sample preparation 4.1.2 Variation due to smoking regime 4.1.3 Variation due to analytical method 4.2 Product variation 4.3 Variation in toxicant emission levels as a ratio to nicotine 4.4 Tolerance levels and indications for product regulation 5 Conclusions Conflict of interest Acknowledgments Appendix A Supplementary data References", "Acknowledgement": "Acknowledgments The authors would like to thank Lothar Bergter and the team at BAT Product Centre Americas for performing the product analyses and Lucy Evans for editorial assistance. Health Canada, 2000. Tobacco Reporting Regulations SOR/2000-273. <http://laws- lois.justice.gc.ca>. Published 2000. (accessed 04.14. Health Canada, 2004. Constituents and Emissions Reported for Cigarettes Sold in Canada. Unpublished data received on request from TRR_RRRT@hc-sc.gc.ca. Horwitz, W., Kamps, L.R., Boyer, K.W., 1980. Quality assurance in the analysis of foods for trace constituents. J. Assoc. Off. Anal. Chem. 63, 1344\u20131354. Hyodo, T., Inoue, O., Katagiri, H., Mikita, A., Fujiwara, M., 2006. Long-term inter- laboratory comparisons of selected analytes in 2R4F mainstream smoke. In: 2006 CORESTA Conference Paper SS7. International Organization for Standardization, 1994. ISO 5725-2:1994. Accuracy (Trueness and Precision) of Measurements Methods and Results \u2013 Part 2. Basic Method for Determination of Repeatability and Reproducibility of a Standard Measurement Method, ISO, Geneva. International Organization for Standardization, 2012. ISO 3308:2012. Routine Analytical Cigarette-Smoking Machine \u2014 Definitions and Standard Conditions, ISO, Geneva. http://dx.doi.org/10.1016/j.yrtph.2015.01.006 http://dx.doi.org/10.1016/j.yrtph.2015.01.006 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0150 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0150 http://www.%20health.gov.au/internet/main/publishing.nsf/Content/tobacco-emis http://www.%20health.gov.au/internet/main/publishing.nsf/Content/tobacco-emis http://legacy.library.ucsf.edu/documentStore/y/e/k/yek21c00/Syek21c00.pdf http://legacy.library.ucsf.edu/documentStore/y/e/k/yek21c00/Syek21c00.pdf http://dx.doi.org/10.1136/tc.2007.024158 http://dx.doi.org/10.1136/tc.2007.024158 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0030 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0030 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0030 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0040 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0040 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0040 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0040 http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297752.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297752.htm http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297752.htm http://refhub.elsevier.com/S0273-2300(15)00007-0/h0155 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0155 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0155 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0070 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0070 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0070 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0070 http://www.laws-lois.justice.gc.ca http://www.laws-lois.justice.gc.ca http://refhub.elsevier.com/S0273-2300(15)00007-0/h0075 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0075 A. Eldridge et al. / Regulatory Toxicology and Pharmacology 71 (2015) 409\u2013427 427 International Organization for Standardization, 2013. ISO 8243:2013. Cigarettes \u2013 Sampling, ISO, Geneva. Intorp, M., Purkiss, S., Whittaker, M., Wright, W., 2009. Determination of \u2018Hoffmann Analytes\u2019 in cigarette mainstream smoke. The CORESTA 2006 joint experiment. Beit. Tabakforsch. Int. 23, 161\u2013202. Minagawa, K., 2012. CORESTA Congress, Sapporo, 2012, Smoke Science/Product Technology Groups, abstr. SSPT36. In: Abstracts of Presentations Made at the 2012 CORESTA Congress in Sapporo, Japan available at <www.coresta.org>. Morton, M.J., Laffoon, S.W., 2008. Cigarette smoke chemistry market maps under Massachusetts Department of Public Health smoking conditions. Regul. Toxicol. Pharm. 51 (1), 1\u201330. Oldham, M.J., Desoi, D.J., Rimmer, L.T., Wagner, K.A., Morton, M.J., 2014. Insights from analysis for harmful abd potentially harmful constituents (HPHCs) in tobacco products. Regul. Toxicol. Pharm. 70, 138\u2013148. Purkis, S., Intorp, M., 2014. Analysis of reference cigarette smoke yield data from 21 laboratories for 28 selected analytes as a guide to selection of new CORESTA Recommended Methods. Beit. Tabakforsch. Int. 26 (2), 57\u201373. Rickert, W.S., Wright, W., 2002. Stability of yields of Canadian mandated analytes from the Kentucky reference cigarette 1R4F: a time series analysis. In: 2002 CORESTA Congress, 22\u201327 Sept 2002, New Orleans, USA. Paper ST26. Teillet, B., Cahours, X., Verron, T., Colard, S., Purkis, S., 2013. Comparison of smoke yield data collected from different laboratories. Beit. Tabakforsch. Int. 25 (8), 662\u2013670. US, 2009. Family Smoking Prevention and Tobacco Control Act. 123 Stat 1776. World Health Organization, 2008. The Scientific Basis of Tobacco Product Regulation. WHO Technical Report Series 951. WHO, Geneva. http://refhub.elsevier.com/S0273-2300(15)00007-0/h0160 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0160 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0160 http://www.coresta.org http://refhub.elsevier.com/S0273-2300(15)00007-0/h0115 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0115 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0115 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0165 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0165 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0165 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0125 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0125 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0125 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0135 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0135 http://refhub.elsevier.com/S0273-2300(15)00007-0/h0135 Variation in tobacco and mainstream smoke toxicant yields from selected commercial cigarette products 1 Introduction 2 Materials and methods 2.1 Materials 2.2 Study protocol 2.3 Analysis methods 2.4 Data analysis 3 Results 3.1 Monthly variation in filler blend components 3.2 Monthly variation in smoke toxicant emission levels 3.3 Monthly variation in toxicant emission levels as a ratio to nicotine 4 Discussion 4.1 Analytical variation including sample preparation 4.1.1 Variation due to smoke sample preparation 4.1.2 Variation due to smoking regime 4.1.3 Variation due to analytical method 4.2 Product variation 4.3 Variation in toxicant emission levels as a ratio to nicotine 4.4 Tolerance levels and indications for product regulation 5 Conclusions Conflict of interest Acknowledgments Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Veterinary-diclofenac-threatens-Africa-s-enda_2009_Regulatory-Toxicology-and.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19545505", "content": {"Acknowledgement": "Acknowledgments This study was approved by the Animal Use and Care Commit- tee of the University of Pretoria. The birds evaluated for the normal values were obtained from the DeWildt Cheetah and Wildlife Trust. This study was approved by Gauteng Nature Conservation (GDACE) and North West Nature Conservation. The study was funded in part by the National Research Foundation of South Africa and the University of Pretoria. Results Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Vinclozolin--A-feasibility-and-sensitivity-study-of-t_2011_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20875480", "content": {"CoiStatement": "The extended one-generation study is a highly complex, but technically feasible study for laboratories which have sufficient experience in routinely performing two-generation studies and at least some experience in carrying out neurotoxicity and develop- mental neurotoxicity studies. The sensitivity of the extended one-generation study was similar to that of the two-generation studies previously performed with vinclozolin. The present paper represents the first of a series of feasibility/sensitivity studies using this protocol. In this larger effort to validate this protocol, three other compounds are currently being tested (ECPA, 2005). With Vinclozolin the emphasis was on endocrine effects, for the other compounds particular attention will be given to pharmacokinetics, immunotoxicity and neurotoxicity. Following the completion of the other studies a final evaluation of this alternative protocol will need to be accomplished. The extended one-generation study is an attractive alternative to the current data request for agro-chemi- cals because it incorporates evaluations required in the two-gener- ation study, developmental neurotoxicity study and potential other requests. The reduction of the animal number by utilizing the extended one-generation design is impressive; whereas with the full study package for pesticide registration approximately 5000 animals will be needed, the extended one-generation study with its branches could reduce the number of animals on study by a factor of 2 (Cooper et al., 2006). For chemicals the extended one-generations study offers the possibility of an even more effi- cient study design when the respective branches (developmental neuro- and immuno-toxicity, 2nd generation) are triggered based on study results or information about the chemical (ECETOC, 2008). Taking into account the very high number of particularly reproduction toxicity studies which will need to be performed under the REACH legislation (Hartung and Rovida, 2009), the ex- tended one-generation study could significantly reduce the num- ber of animals tested, without a significant loss of information for risk assessment. 10. Conflict of interest statement This study was sponsored by BASF SE, Ludwigshafen, Germany. BASF is a producer of Vinclozolin. Discussion Technical feasibility Sensitivity F1 pre-weaning data F1 post-weaning data Conclusion Conflict of interest statement Acknowledgments References", "Acknowledgement": "100 S. Schneider et al. / Regulatory Toxicology and Pharmacology 59 (2011) 91\u2013100 Acknowledgments Thanks to the reproduction, clinical pathology and pathology labs of BASF SE for expert technical assistance. R. FitzGerald as- sisted with preparation of the paper. Discussion Technical feasibility Sensitivity F1 pre-weaning data F1 post-weaning data Conclusion Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Weighing-the-results-of-differing--low-dose--studies-of-t_2005_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/16140446", "content": {"Acknowledgement": "Third, in the future, statisticians supporting major scientific reviews of experimental results, such as the NTP review, should quantify and document the power of disputed studies for the scientific panels. Several sta- tistical approaches may be used, but the statistical re- sults obtained from the ultimate approach should be fully reported (including quantitative p values regardless of significance). This makes transparent the strength or marginality of the results, negative or positive. The pan- els should then clearly incorporate these power results, statistical approaches, and quantitative statistical values in their deliberations and employ the results as one as- pect in an overall weight of the evidence. Acknowledgments We acknowledge and thank Drs. Joe Haseman and Greg Carr for thoughtful discussions and comments that improved the design and performance of these statistical analyses, and thank Drs. George Daston and Scott Belanger for suggesting improvements to the manuscript. Discussion Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Weight-factors-in-an-Integrated-Testing-Strategy-using-ad_2010_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20470846", "content": {"Acknowledgement": "In conclusion, the present report on the application of the IAS in an ITS cover most evaluation issues for regulatory purpose. Docu- mentation and evaluation of the regulatory need, the validity of methods used for data development, and the results obtained by means of those methods using the key principles for evaluation help to see the strength and limitation of the information. The assessment codes support the evaluation of the adequacy of the information and these codes can give weight to the information when used within an ITS to decide on the absence or presence of skin irritation C&L. The decision making process under REACH has become more challenging and will need good documentation but also more room is provided for using other than guideline methods to replacement, reduce and/or refinement of further ani- mal testing. Acknowledgements We thank Jean-Paul Rila from NOTOX, Kate Langton from LHA- SA (Derek for Windows) and Tien Luu from Accelrys (TOPKAT) for their comments on the manuscript. References Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Weight-of-contribution-of-in-vitro-chromosomal-aberration_2018_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/29486272", "content": {"Funding": "This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Transparency document", "Acknowledgement": "Acknowledgement This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Discussion Acknowledgement Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Weight-of-evidence-analysis-of-human-exposures-to-dioxins_2010_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/20416351", "content": {"Acknowledgement": "In addition to providing insights regarding any potential associ- ations between exposures to dioxins and DLCs and effects on thy- roid function and early development, this analysis exemplifies the usefulness of a weight-of-evidence approach, in that it shows how the results from studies that may be relatively small and more lim- ited when viewed individually can be combined to yield more powerful insights regarding patterns of effect or the lack thereof. It also demonstrates how if the data were reviewed in a study- by-study manner, different conclusions might have been reached. Finally, the weight-of-evidence approach illustrates how the com- plexity inherent in many real world data sets (e.g., due to different approaches for measuring exposure, toxicity, and effect for a multi- component toxin) can be clearly addressed in a way that allows di- rect consideration and acknowledgment of the impacts of study variations on interpretation of the study results. In this case, a sys- tematic review of the multi-faceted data \u2013 separately considering each endpoint and life stage evaluated \u2013 revealed no substantial, consistent effects of dioxins and DLCs on thyroid endpoints in neo- nates, infants, and children. While some statistically significant ef- fects were noted in some studies, these were not generally corroborated in other studies at the same lifestage or with other ef- fects that should have occurred concurrently if dioxins and DLCs were truly causal factors. Because dioxin and DLC body burdens have been decreasing over time, this lack of evidence of substan- tial, consistent effects suggests that ambient exposures in the fu- ture will not lead to adverse effects on thyroid function and early development. References Alcock, R.E., Jones, K.C., 1996. Dioxins in the environment: a review of trend data. Environ. Sci. Technol. 30, 3133\u20133143. Available from: http://pubs.acs.org/doi/ pdf/10.1021/es960306z (accessed 23.01.09)."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Weight-of-evidence-and-human-relevance-evaluation-of-t_2020_Regulatory-Toxic.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32798612", "content": {"CoiStatement": "Declaration of competing interest The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Dr. Christian Strupp is a senior toxicologist employed by Gowan Crop Protection, one of the global registrants of benfluralin, and Dr. Werner Bowmann is a consultant of Gowan Crop Protection. The authors declare the following financial interests/personal re- lationships which may be considered as potential competing interests: Dr. Christian Strupp is a senior toxicologist employed by Gowan Crop Protection, one of the global registrants of benfluralin, and Dr. Werner Bowmann is a consultant of Gowan Crop Protection. Appendix A. Supplementary data 5 Conclusion Funding Declaration of competing interest Appendix A Supplementary data References", "Funding": "Funding There was no government funding of this work. The new studies reported in this paper were funded by Gowan Crop Protection. There was no government funding of this work. The new studies reported in this paper were funded by Gowan Crop Protection. Declaration of competing interest 5 Conclusion Funding Declaration of competing interest Appendix A Supplementary data References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Weight-of-evidence-approaches-for-the-identification-of-e_2017_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/28986177", "content": {"CoiStatement": "In conclusion, the requirement for the WoE evaluation for po- tential ED properties is embedded in European legislation gov- erning PPPs and BPs. The recommendations made in this paper draw on existing, established methods and best practice frame- works, as well as an evaluation of how they have been applied in practice. The implementation of these recommendations will allow transparent and robust WoE evaluations of potential ED properties in a European hazard based regulatory context. However, good regulatory practice should not rely on hazard identification alone. Substances that are identified as endocrine disruptors should also undergo a comprehensive risk assessment. Conflict of interest statement The authors declare that there are no conflicts of interest. Mel- anie Gross\u2019 involvement in the production of the manuscript was supported by ECPA. Acknowledgements The authors declare that there are no conflicts of interest. Mel- anie Gross\u2019 involvement in the production of the manuscript was supported by ECPA. Acknowledgements Funding: This work was supported by the European Crop Pro- tection Agency (ECPA). The authors gratefully acknowledge the comments of five anonymous reviewers, which helped improve the paper. 4. Recommendations Conflict of interest statement Acknowledgements Appendix A. Supplementary data Transparency document References", "Funding": "Funding: This work was supported by the European Crop Pro- tection Agency (ECPA). The authors gratefully acknowledge the comments of five anonymous reviewers, which helped improve the paper. https://echa.europa.eu/documents/.../whoipcs_moa_template_withinstructions.docx https://echa.europa.eu/documents/.../whoipcs_moa_template_withinstructions.docx", "Acknowledgement": "The authors declare that there are no conflicts of interest. Mel- anie Gross\u2019 involvement in the production of the manuscript was supported by ECPA. Acknowledgements Funding: This work was supported by the European Crop Pro- tection Agency (ECPA). The authors gratefully acknowledge the comments of five anonymous reviewers, which helped improve the paper. 4. Recommendations Conflict of interest statement Acknowledgements Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Weight-of-evidence-evaluation-of-associations-between_2016_Regulatory-Toxico.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27765718", "content": {"Compliance with ethical standards": "Organisation for Economic Co-operation and Development (OECD), 1998. OECD Principles on Good Laboratory Practice (Revised). Environment Directorate, Chemicals Group and Management Committee, p. 41. ENV/MC/CHEM(98)17. OECD Series on Principles of Good Laboratory Practice and Compliance Moni- toring No. 1. Oh, S.M., Kim, H.R., Park, Y.J., Lee, S.Y., Chung, K.H., 2011. Organic extracts of urban air pollution particulate matter (PM2.5)-induced genotoxicity and oxidative stress in human lung bronchial epithelial cells (BEAS-2B cells). Mutat. Res. 723 (2), 142e151. http://dx.doi.org/10.1016/j.mrgentox.2011.04.003.", "Acknowledgement": "8. Weight-of-evidence conclusions Acknowledgments Appendix A. Supplementary data Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/What-are-the-best-reference-values-for-a-normal-serum-ala_2011_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21539883", "content": {"CoiStatement": "Conflict of Interest Statement Thierry Poynard is the inventor of liver injury biomarkers Fibro- Test ActiTest with a capital interest in Biopredictive the company marketing the tests. Patents belong to the public organization Assistance Publique H\u00f4pitaux de Paris. 5 Conclusion Conflict of Interest Statement References", "Compliance with ethical standards": "Other limitation to our study includes the fact that we used 2 large populations but without identifying the DILI cases among pa- tients with minimal or severe estimates. The ability to identify cases of DILI would improve the risk assessment but would not change the principle of limiting artificial variability between stud- ies. The prevalence of ALT estimates in our low risk population was similar to that of a placebo group (http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ UCM174090.pdf, 0000). Our two populations were useful to dem- onstrate the impact of an absence of consensus in the definition of ULN for assessing the level of DILI estimates. Starting prospec- tive studies in DILI using ALT ULN without consensus seems haz- ardous. We also acknowledge that there are countries and hospitals that measure ALT in lkat/L, which should transform re- sults ALT expression in IU/L (to convert the alanine aminotransfer- ase thresholds to lkat/L, multiply by 16.667). As a single analytical ALT enzymatic method is not used by all laboratories the reference population used to determine the ULN should be described in any scientific publications on DILI preva- lence. From the evidence based data an agreed consensus on a ref- erence population seems possible (Pratiet al., 2002; Lee et al., 2010; Ozer et al., 2010). A consensus already exists for separating male and female reference values, excluding patients with over- weight, medication uses, and excessive declared alcohol consump- tion. In the context of DILI a consensus also exists on the predictive value of the change in ALT rather than the absolute level itself. <http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/UCM174090.pdf>. http://www.fda.gov http://www.fda.gov"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/What-do-animal-experiments-tell-us-that-in-vitro-s_2016_Regulatory-Toxicolog.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/26409932", "content": {"CoiStatement": "Conflict of interest The authors declare they have no actual, or potential, competing financial interests. Transparency document 5. The need for animal experiments 6. Binding affinity of xenoestrogens compared with that of estradiol 7. Publications resulting from the Human Toxome consortium 8. Government funding of \u201crequest for applications\u201d (RFAs) involving large consortiums 9. Conclusions Conflict of interest slink3 Transparency document References", "Funding": "\u201cStop Vivisection\u201d is the third ECI to reach this stage since this \u201ctool for direct democracy\u201d was first introduced in Europe in 2012. The European Commission had rejected the previous two, including last year's demands to stop using E.U. funding for stem cell research. In response to the \u201cStop Vivisection ECI\u201d, a group of 149 scienti- fic organizations (including 16 Nobel laureates) published an open letter [http://scim.ag/Nobelanimal], warning against repealing the current rulese cautioning that anymisguided repeal would \u201crepre- sent a significant step backwards\u201d e both for animal welfare and all biomedical and toxicological research in Europe. 8. Government funding of \u201crequest for applications\u201d (RFAs) involving large consortiums The governmental initiative to support the Human Toxome Proj- ect is well purposed e based on political urging for alternative toxicity testing procedures, including cutting back on laboratory animal use. However, as discussed above, the Human Toxome Proj- ect is exceedingly simplistic, when one considers the complexity of toxic chemical actions in the human body, and the na\u00efvet\ufffde of pro- posing that clinical responses to toxicants can be mimicked by studies in a single human cancer cell culture line. The two examples, presented above, illustrate this principle. Clearly, such aspects are often overlooked during the political- and society-driven lobbying of governmental funding agencies. As a result, funding decisions might then be made hastily e by decision-makers perhaps unaware of the true mechanistic com- plexities surrounding most phenotypes of \u201ctoxicity\u201d that usually occur with high degrees of cell and tissue/organ specificity. Conse- quently, decision-makers can be deceived by applicants who, on grant applications, are not beyond exaggerating the predictability and usefulness of their cell culture in vitro system e as we suggest has happened in funding of the Human Toxome Project as written. 9. Conclusions 5. The need for animal experiments 6. Binding affinity of xenoestrogens compared with that of estradiol 7. Publications resulting from the Human Toxome consortium 8. Government funding of \u201crequest for applications\u201d (RFAs) involving large consortiums 9. Conclusions Conflict of interest slink3 Transparency document References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/What-do-we--need-to--know-about-the-kinetic-prope_2007_Regulatory-Toxicology.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/17868963", "content": {"Acknowledgement": "Metabolism Excretion Conclusions Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_new_articles/PDF_articles/What-happened-to-quinacrine-non-surgical-fem_2021_Regulatory-Toxicology-and-.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/34062206", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 6 McConnell et al. (2010): An alternative interpretation of, \u201cA lifetime cancer bioassay of quinacrine administered into th ... 7 Haseman et al. (2015): A critical examination of the mode of action of quinacrine in the reproductive tract in a 2-year r ... 8 The FDA permanently ends QS 9 Conclusions Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgements References", "Funding": "Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. CRediT authorship contribution statement 6 McConnell et al. (2010): An alternative interpretation of, \u201cA lifetime cancer bioassay of quinacrine administered into th ... 7 Haseman et al. (2015): A critical examination of the mode of action of quinacrine in the reproductive tract in a 2-year r ... 8 The FDA permanently ends QS 9 Conclusions Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgements References", "Acknowledgement": "Acknowledgements The author is grateful to Dr. Ernest E. McConnell, DVM for serving as an unpaid science advisor from January 2007 to the present. Many thanks to Donald A. Collins, Jr., President of ISAF, for his comments and suggestions which were very useful and gratefully appreciated. 6 McConnell et al. (2010): An alternative interpretation of, \u201cA lifetime cancer bioassay of quinacrine administered into th ... 7 Haseman et al. (2015): A critical examination of the mode of action of quinacrine in the reproductive tract in a 2-year r ... 8 The FDA permanently ends QS 9 Conclusions Funding CRediT authorship contribution statement Declaration of competing interest Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/What-is-a-food-and-what-is-a-medicinal-product-in-the-Eur_2012_Regulatory-To.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22960033", "content": {"CoiStatement": "4 Conclusions Conflict of interest statement Acknowledgments References", "Acknowledgement": "4 Conclusions Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/What-s-Wrong-with-the-National-Ambient-Air-Quality-S_2002_Regulatory-Toxicol.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/12202048", "content": {"Acknowledgement": "INTRODUCTION TOXICOLOGIC CONCERNS EPIDEMIOLOGIC CONCERNS OBSERVATIONAL STUDIES ON AMBIENT PM AND DAILY RATES OF MORTALITY DISCUSSION AND CONCLUSIONS ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Whither-the-impending-european-regulation-of-pr_2016_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/27615676", "content": {"CoiStatement": "The social, civic and moral implications of such regulatory sce- narios should advise restraint while raising some key questions. Remembering how the raison d'e\u0302tre of regulation is to provide pub- lic health benefits, is it reasonable to issue costly regulations for the relief of putative public health problems bereft of clinical epidemi- ologic footprints? If a case ismade for preventive and precautionary regulations, should those be justified by direct or indirect evidence that is factually measurable, or should they be triggered by whim- sical conjectures?More pointedly, are certain regulations becoming a pretext for lucrative debates about angels on pin heads? What special interests stand to benefit from regulation, other than public health at large? Have biases and conflicts of interest of all partici- pants e regulators included - been made transparent and openly perceived by the public? Ethical and rational answers to these questions could put regu- lation on the right course, but it will not be. What inflames contro- versial regulations at the center of public, administrative and legislative attention is not a yearning for public health or a respect for science. Rather, it is the achieving of compromises to balance the open and ulterior interests of advocacies, academicians, regula- tors, advisors, industry, politicians and the media. Public health hardly emerges in those discussions."}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/WikiPharma---A-freely-available--easily-accessible--inte_2009_Regulatory-Tox.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/19720105", "content": {"CoiStatement": "The goal is that the WikiPharma should be an easy accessible, comprehensive, and up-to-date source for information about the environmental toxicity of APIs. If this goal will be reached is up to the scientific community. Conflicts of interest The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Acknowledgments WikiPharma \u2013 A freely available, easily accessible, interactive and comprehensive database for environmental effect data for pharmaceuticals Introduction Scope of the database Identification of data \u2013 search strategy Database structure Searching the database Overview of database contents Database availability, guidance and explanations Turning the database into a \u201cWiki\u201d Conflicts of interest Acknowledgments References", "Acknowledgement": "Acknowledgments The authors thank Anna \u00d6stensson for help with the gathering of data and Katarzyna Malkiewicz and three anonymous reviewers for valuable comments on the paper. The study was funded by Mis- tra, the Foundation for Strategic Environmental Research. WikiPharma \u2013 A freely available, easily accessible, interactive and comprehensive database for environmental effect data for pharmaceuticals Introduction Scope of the database Identification of data \u2013 search strategy Database structure Searching the database Overview of database contents Database availability, guidance and explanations Turning the database into a \u201cWiki\u201d Conflicts of interest Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Work-in-the-metal-industry-and-nasopharyngeal-cance_2007_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/17544557", "content": {"Funding": "This study was supported by funding from Cytec Indus- tries Inc. (Cytec), but the design, conduct, analysis and conclusions are those of the authors. Dr. Marsh, Dr. Youk and Jeanine Buchanich performed this work as consultants to Cytec Industries Inc. We gratefully acknowledge the assistance and cooperation of Dr. Randy Deskin, Debra Dahlmeyer and other Cytec staff who participated in this research effort. We also wish to acknowledge the many fine contributions of Annette Krag-Jensen, Jean Perreault, Katy Nealon, Katie Boyd and Steve Sefcik and thank Drs. David Coggon, James Collins, Robin Leonard, and J. Morel Symons who provided helpful comments on an earlier draft of the paper. The research proposal was ap- proved by the Institutional Review Board (IRB) of the University of Pittsburgh. References", "Acknowledgement": "318 G.M. Marsh et al. / Regulatory Toxicology and Pharmacology 48 (2007) 308\u2013319 the local area that entailed possible exposures to several suspected risk factors for upper respiratory system cancer (e.g., sulfuric acid mists, mineral acid, metal dusts and heat). Our findings may also help to explain why the asso- ciations with formaldehyde and nasopharyngeal cancer reported in the 1994 update of the 10-plant NCI formalde- hyde cohort study were unique to the Wallingford plant (Plant 1 in NCI study). Further updates of the NCI form- aldehyde cohort study should include co-exposure data on silver smithing and other metal work for all study plants to help explain the unique findings for nasopharyngeal cancer in Plant 1 compared with the other nine plants. Acknowledgments This study was supported by funding from Cytec Indus- tries Inc. (Cytec), but the design, conduct, analysis and conclusions are those of the authors. Dr. Marsh, Dr. Youk and Jeanine Buchanich performed this work as consultants to Cytec Industries Inc. We gratefully acknowledge the assistance and cooperation of Dr. Randy Deskin, Debra Dahlmeyer and other Cytec staff who participated in this research effort. We also wish to acknowledge the many fine contributions of Annette Krag-Jensen, Jean Perreault, Katy Nealon, Katie Boyd and Steve Sefcik and thank Drs. David Coggon, James Collins, Robin Leonard, and J. Morel Symons who provided helpful comments on an earlier draft of the paper. The research proposal was ap- proved by the Institutional Review Board (IRB) of the University of Pittsburgh. Discussion Conclusions Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Workplace-Monitoring-of-Refractory-Ceramic-Fib_2000_Regulatory-Toxicology-an.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/11162723", "content": {"Acknowledgement": "ACKNOWLEDGMENTS This work was supported by RCFC and member companies. The findings and conclusions are those of the authors and do not neces- sarily reflect the views of RCFC. The editorial suggestions of the referees are appreciated. CONCLUDING REMARKS ACKNOWLEDGMENTS REFERENCES"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Workshop--Combined-exposure-to-chemi_2012_Regulatory-Toxicology-and-Pharmaco.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/22369871", "content": {"CoiStatement": "Conflict of interest statement None of the authors declares any conflict of interest. The work- shop was financed by the European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC). References None of the authors declares any conflict of interest. The work- shop was financed by the European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC). References ECETOC, 2011. Combined Exposure to Chemicals. Workshop 11\u201312 July 2011. ECETOC Workshop Report No. 22. Workshop: Combined exposure to chemicals Conflict of interest statement References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Workshop--Use-of--read-across--for-chemical-saf_2013_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/23266660", "content": {"CoiStatement": "Workshop: Use of \u201cread-across\u201d for chemical safety assessment under REACH 1 Introduction 2 Results Conflict of interest statement Acknowledgments References", "Acknowledgement": "Workshop: Use of \u201cread-across\u201d for chemical safety assessment under REACH 1 Introduction 2 Results Conflict of interest statement Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Workshop-report--Identifying-key-issues-underpinning-the-s_2011_Regulatory-T.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/21256913", "content": {"CoiStatement": "5. Conflict of Interest None. Note added in proof A detailed review relevant to several of issues raised in the workshop has just been published (Rhomberg et al., 2011). Acknowledgements Conclusions Conflict of Interest Note added in proof Acknowledgements References", "Acknowledgement": "None. Note added in proof A detailed review relevant to several of issues raised in the workshop has just been published (Rhomberg et al., 2011). Acknowledgements The co-authors gratefully acknowledge valuable contributions from Ms. Annie Jarabek and Drs. Michael Dourson and Resha Putzrath to this workshop and its summary. References Conclusions Conflict of Interest Note added in proof Acknowledgements References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Workshop-report--Strategies-for-setting-occupationa_2014_Regulatory-Toxicolo.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/24462629", "content": {"CoiStatement": "Conflict of interest The authors declare that there are no conflicts of interest. The authors declare that there are no conflicts of interest. Disclaimer Conflict of interest Disclaimer Acknowledgments References", "Funding": "disposal/recycling. \ufffd Development of a decision logic for an iterative process of establishing OELs for ENMs which might, for example, involve setting provisional OELs based on in vitro and/or short-term in vivo mode of action data followed by confirmatory longer- term animal studies and revision of the provisional OEL. \ufffd Additional government funding for traditional long-term inha- lation toxicity studies on selected ENMs. \ufffd Collaborations with other international organizations including", "Acknowledgement": "Acknowledgments The authors wish to thank the workshop speakers and partici- pants for their valuable contributions to the discussions and results of the workshop. We also thank the National Institute for Occupa- tional Safety and Health (Grant R13 OH010337) and the American Chemistry Council Nanotechnology Panel for their financial sup- port; The George Washington University School of Public Health and Health Services for hosting the workshop; Mary Butow, Julie Goodnight, Mary Popovech, Eric Saunders, and Chia Thach for serving as note takers; and Jessica Knutson, Andrew MacCachran, and Schubert Fabros of the American Chemistry Council for handling the many logistical details. This material is based upon work supported by the National Science Foundation under Grant Number 123634. References Conflict of interest Disclaimer Acknowledgments References"}},
{"http://tableXtr.pdf/extractedFrom": "file:///Users/theobouganim/Desktop/Inria_work/RTP_PDF/Yellow-colored-extract-from-cashew-byproduct---_2020_Regulatory-Toxicology-a.pdf", "PDF_pmid_URI": "https://pubmed.ncbi.nlm.nih.gov/32562761", "content": {"CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influ- ence the work reported in this paper. Discussion Conclusion Funding Declaration of competing interest Acknowledgements Supplementary data References", "Funding": "Funding This work was supported by the Coordination for the Improvement of Higher Education Personnel (CAPES, Financing Code 001) and the National Council for Scientific and Technological Development (CNPq, grants #447191/2014\u20134, #429463/2018\u20139 and #313440/2019-0). Discussion Conclusion Funding Declaration of competing interest Acknowledgements Supplementary data References", "Acknowledgement": "Acknowledgements This work was supported by the Coordination for the Improvement of Higher Education Personnel (CAPES, Financing Code 001) and the National Council for Scientific and Technological Development (CNPq, grants #447191/2014\u20134, #429463/2018\u20139 and #313440/2019-0). The authors also thank Prof. Dr. Edson Antunes (FCM/Unicamp) for the use of microscopy and the Chemical, Biological and Agricultural Pluridisciplinary Research Center (CPQBA/Unicamp) for the infra- structure. Discussion Conclusion Funding Declaration of competing interest Acknowledgements Supplementary data References"}}]
